"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Simple Family Members,Simple Family Member Jurisdictions,Extended Family Size,Extended Family Members,Extended Family Member Jurisdictions,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A1,EP 4085767 A1,085-526-034-446-482,2022-11-09,2022,EP 22171555 A,2022-05-04,IT 202100011798 A,2021-05-07,PROCESS FOR INCREASING THE INTESTINAL BIOVAILABILITY OF POLYPHENOLS IN A PLANT FOOD MATRIX WITH A HIGH POLYPHENOL CONTENT,"The present invention describes a process for the production of a polyphenol-rich, highly intestinal bioavailability freeze-dried product (BioTech) from a polyphenol-rich plant matrix, preferably PGI Annurca Campana apples, subjected to incubation with a food-grade chemical/enzymatic treatment to promote pectin degradation. The subject of the invention is also a food/nutraceutical supplement comprising the BioTech freeze-dried product and its use as an antioxidant, anti-inflammatory and lipid-lowering agent.",NGN HEALTHCARE NEW GENERATION NUTRACEUTICALS S R L,NOVELLINO ETTORE;;TENORE GIAN CARLO,,https://lens.org/085-526-034-446-482,Patent Application,yes,3,0,2,016-445-088-124-211;;085-526-034-446-482,EP;;IT,2,016-445-088-124-211;;085-526-034-446-482,EP;;IT,0,A23F3/10;;C12Y301/01011;;C12Y302/01004;;C12Y302/01015;;C12Y302/01091;;C12Y402/02002,A23F3/10,,14,13,088-757-169-203-389;;002-462-601-570-463;;007-895-046-080-240;;057-358-056-890-183;;072-672-691-146-037;;044-546-244-444-195;;013-414-183-802-382;;044-861-270-292-703;;011-094-165-941-909;;095-715-883-937-396;;048-047-617-195-654;;091-701-276-033-456;;005-225-594-123-015,10.1016/j.foodres.2016.09.009;;28460948;;10.1021/jf0618168;;17177570;;19445316;;10.1177/1934578x0900400504;;10.1007/s11947-015-1634-5;;10.1016/j.fbp.2010.07.007;;10.1016/j.lwt.2010.06.009;;10770272;;10.1080/10408690091189293;;11559117;;10.1021/jf001410+;;10.1016/j.lwt.2017.09.003;;27542479;;10.1016/j.foodchem.2016.07.166;;10.1016/j.indcrop.2020.112250;;35627023;;pmc9141411;;10.3390/foods11101453;;10.1016/0168-9452(89)90008-3,"MARTINS ISABELA M ET AL: ""Enzymatic biotransformation of polyphenolics increases antioxidant activity of red and white grape pomace"", FOOD RESEARCH INTERNATIONAL, ELSEVIER, AMSTERDAM, NL, vol. 89, no. 11, 7 September 2016 (2016-09-07), pages 533 - 539, XP029792952, ISSN: 0963-9969, DOI: 10.1016/J.FOODRES.2016.09.009;;SABINE SEMBRIES ET AL: ""Physiological Effects of Extraction Juices from Apple, Grape, and Red Beet Pomaces in Rats"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 54, no. 26, 1 December 2006 (2006-12-01), US, pages 10269 - 10280, XP055294332, ISSN: 0021-8561, DOI: 10.1021/jf0618168;;SOLER C ET AL: ""Apple-products phytochemicals and processing: A review"", NATURAL PRODUCT COMMUNICATIONS, NATURAL PRODUCT INC, US, vol. 4, no. 5, 1 May 2009 (2009-05-01), pages 659 - 670, XP009177688, ISSN: 1934-578X;;DAL MAGRO LUCAS ET AL: ""Identification of Bioactive Compounds FromVitis labruscaL. Variety Concord Grape Juice Treated With Commercial Enzymes: Improved Yield and Quality Parameters"", FOOD AND BIOPROCESS TECHNOLOGY ; AN INTERNATIONAL JOURNAL, SPRINGER-VERLAG, NEW YORK, vol. 9, no. 2, 30 October 2015 (2015-10-30), pages 365 - 377, XP035950753, ISSN: 1935-5130, [retrieved on 20151030], DOI: 10.1007/S11947-015-1634-5;;VISHWANATH KHANDARE ET AL: ""Black carrot (ssp.) juice: Processing effects on antioxidant composition and color"", FOOD AND BIOPRODUCTS PROCESSING, INSTITUTION OF CHEMICAL ENGINEERS, RUGBY, GB, vol. 89, no. 4, 27 July 2010 (2010-07-27), pages 482 - 486, XP028322877, ISSN: 0960-3085, [retrieved on 20100806], DOI: 10.1016/J.FBP.2010.07.007;;ARMADA L ET AL: ""Influence of several enzymatic treatments on aromatic composition of white wines"", LWT- FOOD SCIENCE AND TECHNOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 43, no. 10, 1 December 2010 (2010-12-01), pages 1517 - 1525, XP027284484, ISSN: 0023-6438, [retrieved on 20100615];;GIRARD B ET AL: ""Membrane Processing of Fruit Juices and Beverages: A Review"", CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, TAYLOR & FRANCIS, USA, vol. 40, no. 2, 1 January 2000 (2000-01-01), pages 91 - 157, XP009133249, ISSN: 1040-8398, DOI: 10.1080/10408690091189293;;DONGOWSKI GERHARD ET AL: ""Effects of commercial pectolytic and cellulolytic enzyme preparations on the apple cell wall"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 49, no. 9, 1 September 2001 (2001-09-01), pages 4236 - 4242, XP009136328, ISSN: 0021-8561;;KESSY HONEST N E ET AL: ""Enrichment and biotransformation of phenolic compounds from litchi pericarps with angiotensin I-converting enzyme (ACE) inhibition activity"", LWT- FOOD SCIENCE AND TECHNOLOGY, vol. 87, 8 September 2017 (2017-09-08), pages 301 - 309, XP085276588, ISSN: 0023-6438, DOI: 10.1016/J.LWT.2017.09.003;;LEE JIHYUN ET AL: ""Identification/quantification of free and bound phenolic acids in peel and pulp of apples (Malus domestica) using high resolution mass spectrometry (HRMS)"", FOOD CHEMISTRY, ELSEVIER LTD, NL, vol. 215, 29 July 2016 (2016-07-29), pages 301 - 310, XP029687629, ISSN: 0308-8146, DOI: 10.1016/J.FOODCHEM.2016.07.166;;LI WU ET AL: ""Analysis of polyphenols in apple pomace: A comparative study of different extraction and hydrolysis procedures"", INDUSTRIAL CROPS AND PRODUCTS, ELSEVIER, NL, vol. 147, 23 February 2020 (2020-02-23), XP086078860, ISSN: 0926-6690, [retrieved on 20200223], DOI: 10.1016/J.INDCROP.2020.112250;;MAISTO MARIA ET AL: ""Application of a Rapid and Simple Technological Process to Increase Levels and Bioccessibility of Free Phenolic Compounds in Annurca Apple Nutraceutical Product"", FOODS, vol. 11, no. 10, 17 May 2022 (2022-05-17), CH, pages 1453, XP055960883, ISSN: 2304-8158, DOI: 10.3390/foods11101453;;PASTUKH ET AL., SCIENTIFIC RESEARCHES OF NUFT, 2013, pages 109 - 114;;PRESSEY ET AL., PLANT SCIENCE, vol. 59, no. 1, 1989, pages 57 - 62",PENDING
2,US,A1,US 2022/0357341 A1,114-689-801-221-679,2022-11-10,2022,US 202017763863 A,2020-09-28,US 202017763863 A;;US 202063077978 P;;US 202062960031 P;;US 201962908195 P;;US 2020/0053102 W,2019-09-30,COMPOSITIONS AND METHODS FOR AN IL-17 TARGET ENGAGEMENT ASSAY WITH SMALL MOLECULE MODULATORS,Methods to measure free IL-17 in a sample comprising IL-17 and a small molecule modulator of IL-17.,JANSSEN PHARMACEUTICA NV,BLEVITT JONATHAN M;;DE LEON-TABALDO AIMEE ROSE;;DEPRIMO SAMUEL E;;GOLDBERG STEVEN;;LEUNG WAI-PING;;STRASNER AMY;;XUE XIAOHUA,JANSSEN PHARMACEUTICALS INC (2021-06-24);;CILAG AG (2021-06-23);;JANSSEN RESEARCH & DEVELOPMENT LLC (2021-06-23);;JANSSEN PHARMACEUTICA NV (2021-07-14),https://lens.org/114-689-801-221-679,Patent Application,yes,2,0,17,143-507-200-856-312;;183-777-105-206-849;;179-320-945-767-45X;;013-708-240-363-675;;067-412-770-612-09X;;110-239-166-972-487;;036-678-764-638-780;;085-600-920-168-387;;100-035-957-958-289;;027-310-768-329-959;;196-791-131-432-738;;082-608-798-104-159;;013-479-266-871-276;;126-629-038-092-009;;139-610-046-539-300;;065-670-550-446-498;;114-689-801-221-679,AU;;JP;;US;;CA;;MX;;BR;;PH;;KR;;EP;;CN;;ES;;IL;;WO,29,143-507-200-856-312;;021-260-556-379-718;;179-320-945-767-45X;;183-777-105-206-849;;013-708-240-363-675;;067-412-770-612-09X;;100-035-957-958-289;;110-875-952-363-23X;;196-791-131-432-738;;119-451-885-711-289;;181-997-147-294-033;;160-698-899-062-460;;082-608-798-104-159;;139-610-046-539-300;;065-670-550-446-498;;114-689-801-221-679;;058-402-043-503-203;;160-123-990-290-045;;036-678-764-638-780;;085-600-920-168-387;;110-239-166-972-487;;027-310-768-329-959;;085-538-746-914-019;;147-279-696-458-804;;012-275-380-307-424;;013-479-266-871-276;;126-629-038-092-009;;059-913-463-431-817;;134-315-333-846-342,AU;;JP;;US;;CA;;MX;;BR;;PH;;KR;;EP;;CN;;IL;;ES;;WO,39,G01N33/6869;;G01N2333/54;;C07K16/244;;G01N33/6869;;G01N2333/54;;C07K16/244;;G01N33/6869;;C07K16/244;;G01N2333/54;;C07K16/244;;G01N33/6869;;G01N2333/54,G01N33/68;;C07K16/24,,8,8,057-353-330-182-946;;122-295-592-742-045;;027-880-661-246-429;;032-427-821-815-367;;087-523-165-177-47X;;037-080-988-119-306;;095-414-104-917-961;;031-934-122-512-666,25237857;;pmc4179228;;10.1016/j.chembiol.2014.09.001;;pmc7434778;;32811869;;10.1038/s41598-020-70886-2;;14596803;;10.1016/j.jmb.2003.09.054;;18974080;;10.1093/protein/gzn058;;10.4049/jimmunol.173.12.7358;;15585860;;10.4049/jimmunol.1302143;;24790145;;28059445;;10.1002/bit.26244;;pmc5726764;;30666176;;pmc6338232;;10.1016/j.bej.2018.06.003,"Arkin et al. (2014, Chem. Biol. 21(9):1102-1114);;Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969);;Edwards et al. (2003, JMB 334:103-118);;Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168);;Goel et al. (2004, J. Immunol. 173: 7358-7367);;Khan et al. (2014, J. Immunol. 192: 5398-5405);;Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331 -1342);;Rabia, et al. (2018, Biochemical Engineering Journal 137:365-374)",PENDING
3,US,A1,US 2020/0319126 A1,093-933-386-723-015,2020-10-08,2020,US 202016906361 A,2020-06-19,US 202016906361 A;;US 202016746293 A;;US 201815909556 A;;US 201615101661 A;;US 2014/0068866 W;;US 201361912884 P,2013-12-06,SENSOR FITTING FOR BIOTECH PROCESS BAG,"A fluid process application bag includes a flexible film body having an opening, a port plate sealed around the opening of the flexible film body, a sensor fitting and a sensor contained within the sensor fitting. The port plate has a receptacle defining a passage in fluid communication with an interior of the flexible film body and the sensor fitting has a body portion seated within the passage of the receptacle and is coupled to the receptacle. The sensor has at least one probe communicating with the interior of the flexible film body. A collar includes first and second semi-circular members that are connected via a living hinge.",PENDOTECH,FUREY JAMES F;;ANNARELLI DENNIS C;;BENSON JOHN,PENDOTECH (2021-07-16),https://lens.org/093-933-386-723-015,Patent Application,yes,0,0,2,111-720-474-587-043;;093-933-386-723-015,US,17,153-507-301-449-452;;111-720-474-587-043;;093-933-386-723-015;;125-706-051-739-153;;049-209-646-184-845;;067-540-189-472-384;;093-482-423-910-814;;039-369-142-271-70X;;067-277-876-534-959;;117-455-152-978-387;;081-701-652-856-50X;;058-636-599-202-168;;086-804-509-934-265;;164-945-942-461-055;;011-490-179-315-700;;173-534-636-057-337;;088-448-849-498-425,EP;;CN;;WO;;US,0,G01N27/07;;G01N27/07,G01N27/07,,0,0,,,,ACTIVE
4,EP,A1,EP 4166247 A1,158-949-800-118-180,2023-04-19,2023,EP 21315197 A,2021-10-12,EP 21315197 A,2021-10-12,INDUSTRIAL WASHER WITH EXHAUST SYSTEM,"An exhaust system for an industrial washer is proposed. The exhaust system comprises a conduit (101) that can be coupled to an exhaust air outlet (24) of a washer (1). A condenser (107) is coupled to the conduit (101) and configured to cool and to extract humidity from the exhaust air. A filter housing (103) with removable filter is connected to the condenser (107) and configured to filter said exhaust air. A fan (102) with an exhaust outlet is connected to the filter housing (103). A controller (30) is configured to control at least the fan (102) to extract the exhaust air from the washer outlet (24) through the conduit, condenser and filter housing and to eject dried and cooled exhaust air from said exhaust outlet (1021). By reducing the humidity and temperature of the exhaust air, the condenser improves the efficacy and lifetime of the filter. The effective and reliable removal of contamination is thus ensured while the need to further process the waste air is obviated.",GETINGE LANCER SAS,TREMOLIERES CÉDRIC;;DUPRAT JEAN-MICHEL;;GUILLAUD NICOLAS,,https://lens.org/158-949-800-118-180,Patent Application,yes,5,0,3,158-949-800-118-180;;000-857-604-266-487;;166-240-865-325-158,JP;;EP;;US,3,158-949-800-118-180;;000-857-604-266-487;;166-240-865-325-158,JP;;EP;;US,0,B01L13/02;;B01D53/002;;B01D53/75;;B01L2300/0681;;B01L2200/143;;B01L2300/1844;;B01L2300/1894;;B08B3/04;;B01L13/02;;B01D5/0051;;B01D5/0072;;B01D46/0043;;B01D46/0086;;B01D46/44;;B01D53/265;;B01D2273/30;;B01D2279/55;;B08B3/02,B08B3/00;;B01D53/75;;B01L5/04;;C12M1/00,,0,0,,,,PENDING
5,EP,A1,EP 4168788 A1,011-490-179-315-700,2023-04-26,2023,EP 21826062 A,2021-06-18,US 202016906361 A;;US 2021/0038024 W,2020-06-19,SENSOR FITTING FOR BIOTECH PROCESS BAG,,PENDOTECH,FUREY JAMES F;;ANNARELLI DENNIS C;;BENSON JOHN,,https://lens.org/011-490-179-315-700,Patent Application,yes,0,0,4,011-490-179-315-700;;081-701-652-856-50X;;067-277-876-534-959;;088-448-849-498-425,EP;;CN;;WO,17,153-507-301-449-452;;111-720-474-587-043;;093-933-386-723-015;;125-706-051-739-153;;049-209-646-184-845;;067-540-189-472-384;;093-482-423-910-814;;039-369-142-271-70X;;067-277-876-534-959;;117-455-152-978-387;;081-701-652-856-50X;;058-636-599-202-168;;086-804-509-934-265;;164-945-942-461-055;;011-490-179-315-700;;173-534-636-057-337;;088-448-849-498-425,EP;;CN;;WO;;US,0,G01D11/30,G01N27/07,,0,0,,,,PENDING
6,WO,A1,WO 2021/257949 A1,081-701-652-856-50X,2021-12-23,2021,US 2021/0038024 W,2021-06-18,US 202016906361 A,2020-06-19,SENSOR FITTING FOR BIOTECH PROCESS BAG,"A fluid process application bag includes a flexible film body having an opening, a port plate sealed around the opening of the flexible film body, a sensor fitting and a sensor contained within the sensor fitting. The port plate has a receptacle defining a passage in fluid communication with an interior of the flexible film body and the sensor fitting has a body portion seated within the passage of the receptacle and is coupled to the receptacle. The sensor has at least one probe communicating with the interior of the flexible film body. A collar includes first and second semi-circular members that are connected via a living hinge.",PENDOTECH,FUREY JAMES F;;ANNARELLI DENNIS C;;BENSON JOHN,,https://lens.org/081-701-652-856-50X,Patent Application,yes,8,0,4,011-490-179-315-700;;081-701-652-856-50X;;067-277-876-534-959;;088-448-849-498-425,EP;;CN;;WO,17,153-507-301-449-452;;111-720-474-587-043;;093-933-386-723-015;;125-706-051-739-153;;049-209-646-184-845;;067-540-189-472-384;;093-482-423-910-814;;039-369-142-271-70X;;067-277-876-534-959;;117-455-152-978-387;;081-701-652-856-50X;;058-636-599-202-168;;086-804-509-934-265;;164-945-942-461-055;;011-490-179-315-700;;173-534-636-057-337;;088-448-849-498-425,EP;;CN;;WO;;US,0,G01D11/30,G01N27/07,,1,0,,,See also references of EP 4168788A4,PENDING
7,US,A1,US 2024/0066428 A1,166-240-865-325-158,2024-02-29,2024,US 202218046092 A,2022-10-12,EP 21315197 A,2021-10-12,Industrial Washer with Exhaust System,"An exhaust system for an industrial washer is proposed. The exhaust system comprises a conduit that can be coupled to an exhaust air outlet of a washer. A condenser is coupled to the conduit and configured to cool and to extract humidity from the exhaust air. A filter housing with removable filter is connected to the condenser and configured to filter said exhaust air. A fan with an exhaust outlet is connected to the filter housing. A controller is configured to control at least the fan to extract the exhaust air from the washer outlet through the conduit, condenser and filter housing and to eject dried and cooled exhaust air from said exhaust outlet. By reducing the humidity and temperature of the exhaust air, the condenser improves the efficacy and lifetime of the filter. The effective and reliable removal of contamination is thus ensured while the need to further process the waste air is obviated.",GETINGE LIFE SCIENCE FRANCE SAS,TREMOLIERES CÉDRIC;;DUPRAT JEAN-MICHEL;;GUILLAUD NICOLAS,,https://lens.org/166-240-865-325-158,Patent Application,yes,35,0,3,158-949-800-118-180;;000-857-604-266-487;;166-240-865-325-158,JP;;EP;;US,3,158-949-800-118-180;;000-857-604-266-487;;166-240-865-325-158,JP;;EP;;US,0,B01L13/02;;B01D53/002;;B01D53/75;;B01L2300/0681;;B01L2200/143;;B01L2300/1844;;B01L2300/1894;;B08B3/04;;B01L13/02;;B01D5/0051;;B01D5/0072;;B01D46/0043;;B01D46/0086;;B01D46/44;;B01D53/265;;B01D2273/30;;B01D2279/55;;B08B3/02,B01D5/00;;B01D46/00;;B01D46/44;;B01D53/26;;B08B3/02,,0,0,,,,PENDING
8,US,A1,US 2020/0339531 A1,187-470-244-874-184,2020-10-29,2020,US 202016922365 A,2020-07-07,US 202016922365 A;;US 201816227820 A;;US 201715598181 A;;US 201615011377 A;;US 201562110449 P,2015-01-30,CRYSTALLINE FORMS OF C21H22Cl2N4O2,Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.,BIOMED VALLEY DISCOVERIES INC;;VERTEX PHARMA,DECRESCENZO GARY;;WELSCH DEAN;;VLAHOVA PETINKA I;;BOERRIGTER STEPHAN X M;;ARONOV ALEXANDER;;KESHAVARZ-SHOKRI ALI;;SCANGAS ALEXANDER N;;STAVROPOULOS KATHY;;LITTLER BENJAMIN;;KADIYALA IRINA NIKOLAEVNA;;ALARGOVA ROSSITZA GUEORGUIEVA,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2016-01-28);;VERTEX PHARMACEUTICALS INCORPORATED (2016-01-13);;ALBANY MOLECULAR RESEARCH INC (2016-01-28);;BIOMED VALLEY DISCOVERIES INC (2015-04-14),https://lens.org/187-470-244-874-184,Patent Application,yes,0,0,47,116-199-399-313-671;;062-164-339-573-490;;166-794-157-487-249;;095-084-552-677-771;;104-647-261-533-488;;043-850-818-426-595;;011-554-860-079-913;;096-868-254-555-436;;004-332-074-676-545;;153-550-500-828-475;;046-188-654-610-999;;001-893-907-269-372;;174-826-743-101-138;;069-261-997-143-205;;084-727-988-685-091;;130-965-892-238-625;;102-230-351-923-950;;136-204-394-028-125;;176-384-435-693-597;;004-743-936-524-729;;049-676-215-490-456;;093-685-947-670-647;;036-252-612-630-255;;031-754-713-783-793;;041-838-127-758-174;;187-470-244-874-184;;199-861-327-043-603;;110-544-515-197-02X;;030-177-747-660-19X;;112-383-433-305-451;;000-990-971-129-09X;;077-021-145-982-372;;148-269-192-068-850;;187-962-477-269-605;;061-008-601-403-016;;058-529-986-491-445;;187-083-365-942-673;;094-363-903-633-910;;074-343-658-329-005;;034-042-476-677-543;;096-779-492-002-779;;060-478-003-161-627;;135-798-422-549-708;;030-245-434-761-426;;153-111-007-114-386;;016-826-996-244-883;;104-967-288-790-348,JP;;AU;;EP;;CN;;ES;;WO;;HK;;US;;SG;;NZ;;CA;;MX,47,116-199-399-313-671;;062-164-339-573-490;;166-794-157-487-249;;095-084-552-677-771;;104-647-261-533-488;;043-850-818-426-595;;011-554-860-079-913;;001-893-907-269-372;;004-332-074-676-545;;153-550-500-828-475;;046-188-654-610-999;;096-868-254-555-436;;174-826-743-101-138;;069-261-997-143-205;;084-727-988-685-091;;130-965-892-238-625;;102-230-351-923-950;;136-204-394-028-125;;176-384-435-693-597;;004-743-936-524-729;;049-676-215-490-456;;093-685-947-670-647;;036-252-612-630-255;;031-754-713-783-793;;041-838-127-758-174;;187-470-244-874-184;;199-861-327-043-603;;110-544-515-197-02X;;030-177-747-660-19X;;112-383-433-305-451;;000-990-971-129-09X;;077-021-145-982-372;;148-269-192-068-850;;187-962-477-269-605;;061-008-601-403-016;;058-529-986-491-445;;187-083-365-942-673;;094-363-903-633-910;;074-343-658-329-005;;034-042-476-677-543;;096-779-492-002-779;;060-478-003-161-627;;135-798-422-549-708;;030-245-434-761-426;;153-111-007-114-386;;016-826-996-244-883;;104-967-288-790-348,JP;;AU;;EP;;ES;;CN;;WO;;HK;;US;;SG;;NZ;;CA;;MX,0,C07D401/04;;A61P35/00;;C07B2200/07;;C07B2200/13;;A61P35/00;;C07D401/04;;A61K31/4439;;A61K45/06;;C07D401/04;;A61K31/4439;;A61K45/06;;A61P35/00,C07D401/04;;A61K31/4439;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
9,WO,A1,WO 2021/064188 A1,103-683-244-399-813,2021-04-08,2021,EP 2020077686 W,2020-10-02,EP 19201152 A,2019-10-02,"COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT","The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with CTLA-4 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for the treatment of cancer. (Formula)",4SC AG,HAMM SVETLANA;;HERMANN FRANK,,https://lens.org/103-683-244-399-813,Patent Application,yes,6,3,2,197-733-628-711-768;;103-683-244-399-813,WO;;TW,2,197-733-628-711-768;;103-683-244-399-813,WO;;TW,60,A61P35/00;;A61K31/4155;;A61K45/06,A61P35/00;;A61K31/497;;A61K39/00;;A61K45/06,,24,12,029-419-062-348-308;;035-563-577-914-042;;003-669-310-918-030;;070-350-313-687-747;;045-517-169-153-42X;;004-591-488-135-85X;;120-738-288-740-114;;088-426-748-536-122;;019-327-300-335-107;;044-782-728-339-775;;108-649-692-723-51X;;014-767-034-487-42X,10.3389/fonc.2018.00092;;29651407;;pmc5884928;;10.2147/btt.s29965;;23459471;;pmc3584656;;11902574;;10.1038/35106079;;15352027;;10.1002/ijc.20372;;10.1146/annurev.pharmtox.45.120403.095825;;15822187;;25943534;;10.1158/2326-6066.cir-14-0191;;10.1016/j.ejca.2008.10.026;;19097774;;10.1038/nature25501;;pmc6028240;;29443960;;10.1056/nejmc1713444;;pmc6549688;;29262275;;10.1186/1479-5876-10-1;;22214470;;pmc3269368;;10.21037/atm.2017.09.35;;29285501;;pmc5733326;;10.4049/jimmunol.154.9.4685;;7722321;;pmc1976248,"SURAWEERA AMILA ET AL: ""Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi"", FRONTIERS IN ONCOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 8, 29 March 2018 (2018-03-29), pages 1 - 15, XP002792137, ISSN: 2234-943X, DOI: 10.3389/FONC.2018.00092;;ANONYMOUS: ""Study: NCT03565406 A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma"", 13 June 2018 (2018-06-13), XP055760552, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03565406?V_3=View#StudyPageTop> [retrieved on 20201216];;ANONYMOUS: ""Study: NCT03552380 Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma"", 26 July 2018 (2018-07-26), XP055761058, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03552380?V_2=View#StudyPageTop> [retrieved on 20201217];;PARDOLL, NAT REV CANCER, 2012;;BLANK ET AL., CANCER IMMUNOLOGY, IMMUNOTHERAPY, 2005;;LU ET AL., J ONCOL PHARM PRACT, 2015;;VERVERIS K ET AL., BIOLOGIES: TARGETS AND THERAPY, vol. 7, 2013, pages 47 - 60;;VITT D ET AL.: ""RSC Drug Discovery Series No. 48: Epigenetics for Drug Discovery"", 2016, THE ROYAL SOCIETY OF CHEMISTRY, article ""Targeting histone acetylation"";;MARKS ET AL., NATURE REVIEWS CANCER, vol. 1, 2001, pages 194 - 202;;VILLAR-GAREA ET AL., INT. J. CANCER, vol. 112, 2004, pages 171 - 178;;DRUMMOND ET AL., ANNU. REV. PHARMACOL. TOXICOL., vol. 45, 2005, pages 495 - 528;;KELLY ET AL., EXPERT OPIN INVEST DRUGS, vol. 11, no. 12, 2002;;CANCER IMMUNOL RES, vol. 2, no. 9, September 2014 (2014-09-01), pages 846 - 56;;CANCER IMMUNOL RES, vol. 3, no. 9, September 2015 (2015-09-01), pages 1052 - 62;;EISENHAUER ET AL., EUR J CANCER, vol. 45, 2009, pages 228 - 247;;NISHINO M ET AL., CLIN CANCER RES, vol. 19, no. 14, 15 July 2013 (2013-07-15), pages 3936 - 4 3;;ARPITA KABIRAJ ET AL., INT J BIOL MED RES, vol. 6, no. 3, 2015, pages 5204 - 5210;;MARIATHASAN, S. ET AL., NATURE, vol. 554, 2018, pages 544 - 548;;YARCHOAN, M. ET AL., N. ENGL. J. MED., vol. 377, 2017, pages 2500 - 2501;;GALON, J. ET AL., J. TRANSL. MED., vol. 10, 2012, pages 1;;ROUTY, B. ET AL., SCIENCE, vol. 80, 2017, pages 3706;;FRIDMAN, W.H., NAT. REV. CLIN. ONCOL., vol. 5-8, 2017;;ANN TRANSL MED, vol. 5, no. 23, 2017, pages 468;;WANG M. ET AL., J. IMMUNOL., vol. 154, 1995, pages 4685 - 4692",PENDING
10,WO,A1,WO 2023/223303 A1,019-347-377-063-216,2023-11-23,2023,IB 2023055253 W,2023-05-22,US 202263344051 P,2022-05-20,NOVEL CELL LINES AND SYSTEMS AND METHODS FOR A MACHINE LEARNING MANUFACTURING SOFTWARE PLATFORM THAT OPTIMIZE UNIQUE FUNCTIONAL INGREDIENTS AND SOLUTIONS FOR THE BIOTECH AND FOODTECH INDUSTRIES,The present invention provides a method to obtain unique cell lines for various applications and systems and methods for a machine learning/AI/Deep Learning software platform that supports the development and optimization of functional ingredients and solutions for the Biotech and Foodtech industries.,ALT ATLAS LTD,GIAMPAOLI SOFIA;;SIMSEK SENEM,,https://lens.org/019-347-377-063-216,Patent Application,yes,17,0,1,019-347-377-063-216,WO,1,019-347-377-063-216,WO,0,G16B5/00;;A01H4/00;;C12M41/48;;C12N5/00;;C12N2501/72;;G06N20/00;;G06Q10/04;;G06Q10/06;;G06Q50/02;;G06Q50/04;;G06Q50/22;;G16B40/20;;G16B50/10;;G16B50/20;;G16H20/60;;G16H50/20;;G16H50/50;;G16H50/70,G06Q50/04;;A01H4/00;;C12M3/00;;C12N1/00;;C12N5/073;;C12N15/00;;G06N3/045;;G16B5/00;;G16B35/20,,0,0,,,,PENDING
11,US,A1,US 2022/0120537 A1,192-662-776-279-316,2022-04-21,2022,US 202017602974 A,2020-04-13,US 202017602974 A;;US 201962832858 P;;US 2020/0028012 W,2019-04-11,SMART AND BIOTECH JEWELRY AND ACCESSORIES FOR SELF DEFENSE,"The disclosed self defense devices include devices configured to look like everyday clothing or accessories, but which allow a user to respond to potential danger or attack.",UNIV TEXAS,HOOD GOLD DARR;;ANDERSON RACHAEL LYNN,,https://lens.org/192-662-776-279-316,Patent Application,yes,4,0,2,024-116-397-344-560;;192-662-776-279-316,WO;;US,2,024-116-397-344-560;;192-662-776-279-316,WO;;US,0,F41H13/0018;;F41B13/06;;F41B13/08;;F41H9/10;;F41H13/0018;;A44C15/00;;F41B13/06;;F41H9/10,F41H13/00;;A44C15/00;;F41B13/06;;F41H9/10,,0,0,,,,DISCONTINUED
12,WO,A1,WO 2020/210838 A1,024-116-397-344-560,2020-10-15,2020,US 2020/0028012 W,2020-04-13,US 201962832858 P,2019-04-11,SMART AND BIOTECH JEWELRY AND ACCESSORIES FOR SELF DEFENSE,"The disclosed self defense devices include devices configured to look like everyday clothing or accessories, but which allow a user to respond to potential danger or attack.",UNIV TEXAS,HOOD GOLD;;ANDERSON RACHAEL,,https://lens.org/024-116-397-344-560,Patent Application,yes,7,0,2,024-116-397-344-560;;192-662-776-279-316,WO;;US,2,024-116-397-344-560;;192-662-776-279-316,WO;;US,0,F41H13/0018;;F41B13/06;;F41B13/08;;F41H9/10;;F41H13/0018;;A44C15/00;;F41B13/06;;F41H9/10,F41B15/04;;F41B15/06,,4,0,,,"""Personal Emergency Response Device"", TEK SPREE, 31 August 2015 (2015-08-31), XP055749122, Retrieved from the Internet <URL:https://web.archive.org/web/20150831204734/http://www.tekspree.com/personal-emergency-response-device> [retrieved on 20200730];;""F8 Quick-Release-Concealed-Gun-Fanny-Pack-Ambidextrous"", EXPLOERED, 20 July 2015 (2015-07-20), XP055749123, Retrieved from the Internet <URL:https://web.archive.org/web/20150720051558/http://www.explorerbag.com/fanny-packs/f8-quick-release-concealed-gun-fanny-pack-ambidextrous> [retrieved on 20200730];;""DESIGNER DOUBLE Can you tell the difference between these 17.50 'knife' stilettos and the 1,225 Balenciaga pair?"", T HE SUN, 27 August 2018 (2018-08-27), XP055749149, Retrieved from the Internet <URL:https://www.thesun.co.uk/fabulous/7108419/designer-double-knife-stilettos-balenciaga> [retrieved on 20200730];;DANA BRONFMAN: ""Black and Gold Magic"", FACEBOOK, 9 November 2017 (2017-11-09), XP055749153, Retrieved from the Internet <URL:https://www.facebook.com/danabronfmancollections/photos/a.713458455386788/1469434836455809> [retrieved on 20200820]",PENDING
13,US,A1,US 2022/0235150 A1,093-536-613-709-24X,2022-07-28,2022,US 202217581434 A,2022-01-21,US 202217581434 A;;US 202163140342 P,2021-01-22,SYSTEM AND METHOD FOR IMPROVING THE CORN WET MILL AND DRY MILL PROCESS,"A novel dry mill process for producing pure starch, which can be used as a feed stock for bio tech processes. Corn feedstock is sent through a particle size reduction device, such as a hammer mill, to produce corn flour. The corn flour is screened into a small particle portion (which mainly contains “free” starch from the floury endosperm) and a larger particle portion (which mainly comprises the horny endosperm, germ pericarp and tip cap). The small particle potion is sent to a liquefication and a saccharification process to produce high Be corn syrup. A mud phase (mixture of oil, germ, and any light solid) is centrifuged. The light phase is sent to precoat drum filtration to produce clean corn syrup. Further, a novel wet mill process to produce starch and alcohol is disclosed. A three-section paddle screen can be used to separate starch from grit and fiber.",LEE TECH LLC,LEE CHIE YING,LEE TECH LLC (2023-03-04),https://lens.org/093-536-613-709-24X,Patent Application,yes,2,5,6,094-724-464-484-933;;017-492-200-179-545;;127-617-377-925-915;;107-882-447-037-502;;169-089-920-531-158;;093-536-613-709-24X,CN;;WO;;US;;BR,7,185-748-864-805-148;;127-617-377-925-915;;093-536-613-709-24X;;169-089-920-531-158;;094-724-464-484-933;;107-882-447-037-502;;017-492-200-179-545,CN;;WO;;US;;BR,0,C08B30/02;;C08B30/044;;C08B30/06;;Y02E50/10;;C08B30/044;;C08B30/06;;C08B30/02,C08B30/04;;C08B30/02;;C08B30/06,,0,0,,,,ACTIVE
14,WO,A1,WO 2022/159719 A1,094-724-464-484-933,2022-07-28,2022,US 2022/0013332 W,2022-01-21,US 202163140342 P,2021-01-22,SYSTEM AND METHOD FOR IMPROVING THE CORN WET MILL AND DRY MILL PROCESS,"A novel dry mill process for producing pure starch, which can be used as a feed stock for bio tech processes. Corn feedstock is sent through a particle size reduction device, such as a hammer mill, to produce corn flour. The corn flour is screened into a small particle portion (which mainly contains ""free"" starch from the floury endosperm) and a larger particle portion (which mainly comprises the horny endosperm, germ pericarp and tip cap). The small particle potion is sent to a liquefication and a saccharification process to produce high Be corn syrup. A mud phase (mixture of oil, germ, and any light solid) is centrifuged. The light phase is sent to precoat drum filtration to produce clean corn syrup. Further, a novel wet mill process to produce starch and alcohol is disclosed. A three-section paddle screen can be used to separate starch from grit and fiber.",LEE TECH LLC,LEE CHIE YING,,https://lens.org/094-724-464-484-933,Patent Application,yes,6,7,6,094-724-464-484-933;;017-492-200-179-545;;127-617-377-925-915;;107-882-447-037-502;;169-089-920-531-158;;093-536-613-709-24X,CN;;WO;;US;;BR,7,185-748-864-805-148;;127-617-377-925-915;;093-536-613-709-24X;;169-089-920-531-158;;094-724-464-484-933;;107-882-447-037-502;;017-492-200-179-545,CN;;WO;;US;;BR,0,C08B30/02;;C08B30/044;;C08B30/06;;Y02E50/10;;C08B30/044;;C08B30/06;;C08B30/02,A01H5/00;;A23L19/00;;C07H21/04,,0,0,,,,PENDING
15,GB,D0,GB 202305115 D0,064-079-620-175-159,2023-05-24,2023,GB 202305115 A,2023-04-06,GB 202305115 A,2023-04-06,Grey biosphere - a comprehensive platform for biotech collaboration and innovation,,KGENGWENYANE MOTHEO SEGALE KGOSI;;GREYX GROUP,,,https://lens.org/064-079-620-175-159,Patent Application,no,0,0,1,064-079-620-175-159,GB,1,064-079-620-175-159,GB,0,,,,0,0,,,,DISCONTINUED
16,CN,A,CN 114502715 A,045-535-330-155-587,2022-05-13,2022,CN 201980098255 A,2019-05-08,EP 2019061878 W,2019-05-08,Method and apparatus for optimizing biotechnological production,"A new method of automatically generating and validating digital twinning for biotech product production, as well as the use of digital twinning, for the purpose of improving product concentration, productivity, biomass concentration and product quality by optimizing medium composition and/or feeding strategies. Digital twinning may be linked directly to production for online optimization or offline decision support.",IESILIACEAE BIOTECHNOLOGY SHARE COMPANY,NIEBEL BASTIAN;;MACH KLAUS;;SCHMID JOACHIM;;BOHNER MATTHIAS,,https://lens.org/045-535-330-155-587,Patent Application,no,7,4,8,144-264-356-112-355;;188-678-249-399-596;;039-944-294-029-830;;030-195-099-513-069;;099-721-630-990-339;;119-916-459-925-062;;138-407-511-559-631;;045-535-330-155-587,JP;;CN;;EP;;WO;;US;;SG,8,144-264-356-112-355;;188-678-249-399-596;;039-944-294-029-830;;030-195-099-513-069;;099-721-630-990-339;;119-916-459-925-062;;138-407-511-559-631;;045-535-330-155-587,JP;;CN;;EP;;WO;;US;;SG,0,C12M41/48;;G06N3/08;;G05B13/027;;G06N3/048;;G06N3/044;;G06N3/09;;G06N3/0985;;G06N3/0442;;C12M41/48;;G05B13/027;;G06N3/044;;G06N3/048,C12M1/36;;G05B17/00;;G06N3/02,,1,0,,,"CARLOS EDUARDO ROBLES RODRIGUEZ: ""Modeling and optimization of the production of lipids by oleaginous yeasts"", 《THESE》, pages 73 - 77",ACTIVE
17,WO,A1,WO 2021/136882 A1,163-019-679-703-571,2021-07-08,2021,FI 2020050870 W,2020-12-29,FI 20196137 A,2019-12-30,ANIMAL FREE CHITOSAN AND METHODS AND USES RELATED THERETO,"The present invention relates to the fields of life sciences and non-animal polymers. Specifically, the invention relates to a method for extracting a composition comprising chitosan from fungal biomass or a method for producing a purified composition comprising fungal chitosan. Still, the present invention relates to an extracted and/or purified fungal chitosan, an extracted and/or purified composition comprising fungal chitosan, optionally obtained by the method of the present invention, a solution comprising fungal chitosan, or uses of any of the above.",KEMIRA OYJ,AHLGREN JONNI;;RECKTENWALD MICHAEL;;FREY ALEXANDER;;NGUYEN HOANG AN;;USVALAMPI ANNE,,https://lens.org/163-019-679-703-571,Patent Application,yes,4,0,1,163-019-679-703-571,WO,1,163-019-679-703-571,WO,0,C08B37/003;;C08L5/08;;C12P19/26,C08B37/08;;C08L5/08;;C12P19/26,,17,12,013-069-631-576-098;;142-159-177-769-135;;024-846-065-381-730;;150-278-913-292-278;;015-217-325-638-54X;;059-170-032-170-200;;047-173-376-091-619;;071-455-384-756-305;;046-578-581-129-670;;168-268-745-532-731;;101-943-381-084-83X;;051-562-582-604-335,10.1016/j.carbpol.2010.06.023;;10.1002/macp.1976.021771210;;11710030;;10.1021/bm015531+;;10.1016/j.carbpol.2007.07.009;;10.1016/s0141-8130(01)00134-9;;11325422;;10.1016/s0032-3861(00)00713-8;;pmc6272693;;26053488;;10.3390/molecules200610313;;10.1016/j.carbpol.2018.08.125;;30287048;;10.1080/08905439309549843;;10.1016/0141-8130(80)90040-9;;19513810;;10.1007/s11120-009-9439-x;;10.1016/j.proche.2014.05.026,"PILLAI, S. K.RAY, S. S.: ""Natural polymers"", vol. 2, 2012, ROYAL SOCIETY OF CHEMISTRY, article ""Chitosan-based nanocomposites"", pages: 34 - 68;;NWE ET AL., CARBOHYDRATE POLYMERS, vol. 84, 2011, pages 743 - 750;;SUBRAMANIYAMVIMALA, INTERNATIONAL JOURNAL OF SCIENCE AND NATURE, vol. 3, 2012, pages 480 - 486;;SANNAN, T. ET AL., MAKROMOL. CHEM., vol. 177, 1976, pages 3589 - 3600;;SORLIER, P. ET AL., BIOMACROMOLECULES, vol. 2, 2001, pages 765 - 772;;KASAAI, M. R., CARBOHYDRATE POLYMERS, vol. 71, 2008, pages 497 - 508;;DUARTE, M. L. ET AL., INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 28, no. 2, 2001, pages 359 - 363;;BRUGNEROTTO, J, POLYMER, vol. 42, 2001, pages 3569 - 3580;;CZECHOWSKA-BISKUP, R. ET AL., PROGRESS ON CHEMISTRY AND APPLICATION OF CHITIN AND ITS DERIVATIVES, vol. 17, 2012, pages 5 - 20;;OBERLERCHNER, J. T. ET AL., MOLECULES, vol. 20, no. 6, 2015, pages 10313 - 10341;;CHEREMISINOFF, N. P.: ""Polymer characterization Laboratory Techniques and Analysis"", 1996, WILLIAM ANDREW INC., article ""Chromatographic techniques"", pages: 1 - 15;;KANG ET AL., CARBOHYDRATE POLYMERS, vol. 202, 2018, pages 99 - 105;;RANE, K. D.HOOVER, D. G., FOOD BIOTECHNOLOGY, vol. 7, no. 11, 1993, pages 11 - 33;;MOOREROBERTS, INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 2, no. 2, 1980, pages 115 - 116;;BRUGNEROTTO, J. ET AL., POLYMER, vol. 42, pages 3569 - 3580;;BERTHOMIEU, C.HIENERWADEL, R., PHOTOSYNTHESIS RESEARCH, vol. 101, 2009, pages 157 - 170;;PIRES, C. ET AL., PROCEDIA CHEMISTRY, vol. 9, 2014, pages 220 - 225",PENDING
18,WO,A2,WO 2024/192195 A2,181-315-141-216-543,2024-09-19,2024,US 2024/0019833 W,2024-03-14,US 202363490240 P;;US 202363493802 P,2023-03-14,INTERFERON PRODRUGS,This disclosure relates to methods and compositions for treating cancer using an inducible IFNalpha prodrug.,JAZZ PHARMACEUTICALS IRELAND LTD,SALMERON-GARCIA JOSE;;BRODKIN HEATHER;;ECONOMIDES KYRIAKOS;;HICKLIN DANIEL;;SEIDEL-DUGAN CYNTHIA;;STEINER PHILIPP;;WINSTON WILLIAM;;NIRSCHL CHRISTOPHER;;HUMPHREYS ROBIN,,https://lens.org/181-315-141-216-543,Patent Application,yes,0,0,2,098-336-195-986-257;;181-315-141-216-543,WO,2,098-336-195-986-257;;181-315-141-216-543,WO,254,C07K14/555;;A61K45/06;;C07K14/56;;A61K38/212;;C07K16/2818;;A61P35/00;;C07K16/2827;;C07K16/2803;;A61K39/39541;;A61K39/39558;;A61K2039/505;;C07K2319/50,C07K14/555;;A61K38/21,,0,0,,,,PENDING
19,US,A1,US 2022/0143104 A1,168-535-646-037-130,2022-05-12,2022,US 201917416692 A,2019-12-20,EP 18215583 A;;EP 2019086763 W,2018-12-21,NOVEL DOLOSIGRANULUM PIGRUM STRAINS AND USES THEREOF,"The present invention relates to novel isolated bacterial strains of the Dolosigranulum pigrum species and variants thereof having at least 99% sequence identity in its 16S rRNA gene to said novel strains. The present invention further relates to the use of these bacterial strains, and compositions comprising said strains for use as a probiotic, such as for improving or restoring the flora/microbiota of the respiratory tract and skin. The present invention further relates to the use of these bacterial strains as an antibacterial agent; for use in human or veterinary medicine; for use in the treatment of human or veterinary diseases; or for use in personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol applications.",UNIV ANTWERPEN,LEBEER SARAH;;JÖRISSEN JENNIFER;;DE BOECK ILKE,UNIVERSITEIT ANTWERPEN (2020-02-20),https://lens.org/168-535-646-037-130,Patent Application,yes,1,5,8,037-072-850-484-888;;008-225-719-214-56X;;174-628-169-783-682;;060-365-143-407-923;;154-132-043-756-852;;191-966-783-103-307;;168-535-646-037-130;;194-004-605-390-173,JP;;EP;;WO;;US;;CA;;BR,8,037-072-850-484-888;;008-225-719-214-56X;;174-628-169-783-682;;060-365-143-407-923;;154-132-043-756-852;;191-966-783-103-307;;168-535-646-037-130;;194-004-605-390-173,JP;;EP;;WO;;US;;CA;;BR,14,A61K35/66;;A61K35/74;;A61P11/06;;A61P31/04;;A61P11/06;;A61P31/04;;A61K35/74,A61K35/74;;A61P11/06;;A61P31/04,,11,8,016-993-540-438-709;;030-731-000-858-064;;019-733-664-278-362;;009-644-694-699-902;;085-578-916-379-044;;019-104-304-464-039;;126-013-786-816-53X;;136-350-480-632-21X,10.1128/mbio.00245-10;;pmc3031303;;21285435;;34485860;;10.1016/j.isci.2021.102978;;pmc8403741;;10.1016/j.jff.2017.11.050;;21467057;;10.1378/chest.10-1861;;23737654;;10.1155/2013/751068;;pmc3662166;;24071026;;10.1016/j.ijantimicag.2013.08.003;;10.3920/bm2017.0101;;29633637;;pmc8547433;;34546072;;10.1128/msystems.00425-21,"GenBank reference corresponding to accession number X70907.1; deposited in the GenBank on December 31, 1993 (Year: 1993);;Laufer et al. “Microbial Communities of the Upper Respiratory Tract and Otitis Media in Children”, mBio, 2011, Vol. 2, Issue 1, article e00245-10, 7 pages (Year: 2011);;NCBI Reference corresponding to RefSeq GCF_000245815.1, Genome Assembly Dolo_pigr_ATCC_51524_V1, the genome for Dolosigranulum pigrum ATCC 51524, deposited February 7, 2012 (Year: 2012);;De Boeck et al. “The nasal mutualist Dolosigranulum pigrum AMBR11 supports homeostasis via multiple mechanisms”, iScience, 2021, Vol. 24, Issue 9, article 102978, 23 pages (Year: 2021);;Sharma et al. “Role of probiotics in the management of lung cancer and related diseases: An update”, Journal of Functional Foods, 2018, Vol. 40, pp.625-633. Available online December 22, 2017 (Year: 2018);;Tapiovaara et al. “Probiotics and the Upper Respiratory Tract: A Review”, Pediatric Infectious Disease, 2016, Vol. 1, No.3:19, 8 pages. (Year: 2016);;Forsythe “Probiotics and Lung Diseases”, Chest, 2011, Vol 139, Issue 4, pp.901-908. (Year: 2011);;Mortaz et al. “Probiotics in the management of Lung Diseases”, Mediators of Inflammation, Vol. 2013, Article ID 751068, 10 pages. (Year: 2013);;Sikorska et al. “Role of probiotics in the prevention and treatment of methicillin-resistant Staphylococcus aureus infections”, International Journal of Antimicrobial Agents, 2013, Vol. 42, Issue 6, pp.475-481. (Year: 2013);;van den Broek et al. “Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis”, Beneficial Microbes, 2018, Vol. 9, Issue 3, pp.429-439, epub available April 10. 2018. (Year: 2018);;Flores Ramos et al. “Genomic Stability and Genetic Defense Systems in Dolosigranulum pigrum, a Candidate Beneficial Bacterium from the Human Microbiome”, mSystems, 2021, Vol. 6, No.5, article 6:e00425-21, 22 pages. (Year: 2021)",PENDING
20,US,A1,US 2022/0186236 A1,127-315-673-271-027,2022-06-16,2022,US 202217683072 A,2022-02-28,US 202217683072 A;;US 201815878243 A;;US 201314098270 A;;US 201261734499 P,2012-12-07,NANNOCHLOROPSIS SPLICED LEADER SEQUENCES AND USES THEREFOR,"The present invention relates to the culture and manipulation of microorganisms for biotech applications, and is based on the discovery and characterization of spliced leader sequences identified in transcripts from Nannochloropsis species. In particular, the invention provides nucleic acid compositions comprising a SL sequence operably linked to a protein-encoding gene. Further provided are compositions and methods for enhanced gene expression in recombinant microorganisms as well as methods for identification and/or isolation of nucleic acid molecules tagged with a spliced leader sequence.",VIRIDOS INC,SESHADRI REKHA;;SCHWARTZ ARIEL S;;SORIAGA LEAH;;BROWN ROBERT C,,https://lens.org/127-315-673-271-027,Patent Application,yes,0,0,6,008-476-447-240-217;;110-252-586-288-346;;030-783-733-519-179;;153-235-649-739-77X;;162-840-999-033-584;;127-315-673-271-027,WO;;US,6,008-476-447-240-217;;110-252-586-288-346;;030-783-733-519-179;;162-840-999-033-584;;153-235-649-739-77X;;127-315-673-271-027,WO;;US,15,C12N15/79;;C12N15/67;;C12N15/79;;C12N15/67;;C12Q1/6876,C12N15/79;;C12Q1/6876,,0,0,,,,DISCONTINUED
21,US,A1,US 2022/0155672 A1,079-364-023-001-211,2022-05-19,2022,US 202017098971 A,2020-11-16,US 202017098971 A,2020-11-16,"MATERIALS, COMPONENTS, AND METHODS FOR USE WITH EXTREME ULTRAVIOLET RADIATION IN LITHOGRAPHY AND OTHER APPLICATIONS","Nanostructured photonic materials, and associated components for use in devices and systems operating at ultraviolet (UV), extreme ultraviolet (EUV), and/or soft Xray wavelengths are described. Such a material may be fabricated with nanoscale features tailored for a selected wavelength range, such as at particular UV, EUV, or soft Xray wavelengths or wavelength ranges. Such a material may be used to make components such as mirrors, lenses or other optics, panels, lightsources, masks, photoresists, or other components for use in applications such as lithography, wafer patterning, astronomical and space applications, biomedical applications, biotech or other applications.",JAISWAL SUPRIYA,JAISWAL SUPRIYA,,https://lens.org/079-364-023-001-211,Patent Application,yes,0,2,1,079-364-023-001-211,US,1,079-364-023-001-211,US,0,G03F7/0005;;B82Y20/00;;C23C16/45525;;G02B5/0891;;G03F1/24;;G03F1/52;;G03F7/70316;;G03F7/70958;;G21K1/062;;G03F1/24;;B82Y20/00;;B82Y30/00;;B82Y40/00;;C01G33/00;;C01G39/00;;C01G55/00;;C01P2004/03;;C01P2004/30;;C01P2004/64;;C01P2006/60;;C23C16/45525;;G03F1/48;;G03F1/54;;G03F7/2004;;G03F7/30,G03F1/24;;C01G33/00;;C01G39/00;;C01G55/00;;C23C16/455;;G03F1/48;;G03F1/54;;G03F7/20;;G03F7/30,,0,0,,,,DISCONTINUED
22,US,A1,US 2021/0115470 A1,141-108-193-391-383,2021-04-22,2021,US 201816612764 A,2018-09-20,CN 201810735328 A;;CN 2018106586 W,2018-07-06,Method for Creating New Germplasm of Male Sterile Crop by Gene Editing and Application Thereof,"A method for creating a new germplasm of a male sterile crop by gene editing and an application thereof are provided. In this method, the gene editing is performed on an exon region of a Ty-5 gene, and a deletion of DNA sequence is introduced by using a repair mechanism of plants themselves to double-strand breaks (DSBs), causing a loss of function of Ty-5 gene, thereby obtaining a male-sterile character. The method can be applied without being limited by crop categories. After the gene editing is performed on Ty-5 genes of various crops, new germplasms can be quickly obtained. The new germplasms have the same agronomic characters as the previous materials, and only differ in sexual aspect, which effectively solves the problem of the lack of male sterile materials and unstable fertility in natural resources.",JIANGSU ACAD AGRICULTURAL SCI,WANG YINLEI;;ZHAO TONGMIN;;YU WENGUI;;ZHAO LIPING;;ZHOU RONG;;SONG LIUXIA,JIANGSU ACADEMY OF AGRICULTURAL SCIENCES (2019-05-20),https://lens.org/141-108-193-391-383,Patent Application,yes,0,1,7,123-231-303-805-067;;141-108-193-391-383;;075-420-967-295-534;;078-898-556-017-62X;;064-498-787-275-297;;135-141-674-891-968;;027-732-408-408-266,CN;;WO;;US,7,123-231-303-805-067;;141-108-193-391-383;;075-420-967-295-534;;078-898-556-017-62X;;135-141-674-891-968;;064-498-787-275-297;;027-732-408-408-266,CN;;WO;;US,7,C12N9/22;;C12N15/8213;;C12N15/8289;;C12N9/22;;C12N15/8213;;C12N15/8289;;C12N2310/20;;C12N9/22;;C12N15/111;;C12N15/8213;;C12N15/8289,C12N15/82;;C12N9/22;;C12N15/11,,0,0,,,,ACTIVE
23,US,A1,US 2025/0177551 A1,119-511-899-266-448,2025-06-05,2025,US 202318845846 A,2023-03-09,CN 202210238234 A;;CN 2023080590 W,2022-03-11,ENGINEERED RED BLOOD CELLS TARGETING PD-1,"The present invention relates to a type of red blood cell targeting PD-1, specifically an engineered red blood cells loading anti-PD-1 antibodies, preparation methods thereof, and methods and uses of the same in treating cancers, particularly cancers that are insensitive or resistant to anti-PD-1 antibodies.",WESTLAKE THERAPEUTICS SHANGHAI CO LTD;;WESTLAKE LABORATORY OF LIFE SCIENCES AND BIOMEDICINE,GAO XIAOFEI;;HUANG YANJIE;;NIE XIAOQIAN;;LIU XUAN;;YUAN YANG,WESTLAKE LABORATORY OF LIFE SCIENCES AND BIOMEDICINE (2024-09-09);;WESTLAKE THERAPEUTICS (SHANGHAI) CO. LIMITED (2024-08-27),https://lens.org/119-511-899-266-448,Patent Application,yes,0,0,6,141-694-620-022-182;;177-253-350-960-306;;020-944-541-676-198;;180-005-517-271-306;;119-511-899-266-448;;176-978-957-953-876,CN;;WO;;US,6,141-694-620-022-182;;177-253-350-960-306;;180-005-517-271-306;;119-511-899-266-448;;020-944-541-676-198;;176-978-957-953-876,CN;;WO;;US,0,C12N5/06;;A61P35/00;;A61K47/6901;;A61K47/6901;;A61K47/6849;;A61P35/00,A61K47/68;;A61K47/69;;A61P35/00,,0,0,,,,PENDING
24,EP,A1,EP 3865582 A1,044-021-650-631-904,2021-08-18,2021,EP 19856460 A,2019-03-13,CN 201811153259 A;;CN 2019077967 W,2018-09-30,HAFFT1 CELL,"The invention discussed in this paper falls under the biotech field, and it is concerned with a specific specie of HAFFT1 cell and the related preparation procedures. The TCR-T technology is used to modify the cell, and the immunosuppressive target of the modified T cell is knocked out. The specific killing T cells are precisely protected from inhibition in vivo, and the cytotoxicity of T cells to tumor cells is improved. The percentage of specific T cells (TCR+) that can recognize tumor antigens is more than 80% after HAFFT1 modification.",BEIJING DCTY BIOTECH CO LTD,JIAO SHUNCHANG;;ZHANG RONG;;ZHANG TIANFU;;ZHOU ZISHAN;;CHEN XIAOBIN;;LI YINGYING;;PENG GANG,,https://lens.org/044-021-650-631-904,Patent Application,yes,0,0,5,153-428-019-944-884;;120-082-522-695-122;;135-025-373-595-796;;070-007-125-209-758;;044-021-650-631-904,CN;;EP;;WO,5,153-428-019-944-884;;120-082-522-695-122;;135-025-373-595-796;;070-007-125-209-758;;044-021-650-631-904,CN;;EP;;WO,46,C12N5/0636;;C12N15/86;;C12N15/907;;C07K14/7051;;C12N2510/00;;C12N2740/15043;;C12N2800/107;;C12N2810/10;;A61K2239/38;;A61K40/42;;A61K40/11;;C12N9/22;;C07K14/7051;;C12N2510/00;;C12N5/0636;;C12N2740/16043;;C12N15/907;;A61K2239/38;;A61K40/42;;A61K40/11;;C12N5/0636;;A61K2239/38;;A61K40/42;;A61K40/11,C12N15/90;;C12N5/10,,0,0,,,,DISCONTINUED
25,WO,A1,WO 2022/180427 A1,015-461-226-780-326,2022-09-01,2022,IB 2021051614 W,2021-02-26,IB 2021051614 W,2021-02-26,MANUFACTURING METHOD OF A STEEL PRODUCT,"A method to manufacture a steel product in a steelmaking plant comprising several different tools, the method including the definition of at least two manufacturing routes using different tools and the calculation of the expected level of CO2 emissions associated to each of this defined manufacturing routes.",ARCELORMITTAL,DA GAMA CAMPOS HUGO;;VAN DER HOEVEN JEAN-MARTIN,,https://lens.org/015-461-226-780-326,Patent Application,yes,0,0,10,195-942-113-924-172;;016-987-265-843-679;;085-060-624-869-045;;015-461-226-780-326;;063-554-951-255-253;;073-413-217-704-847;;071-536-480-970-365;;153-286-029-348-380;;033-890-279-183-582;;110-403-313-678-694,KR;;JP;;CN;;EP;;WO;;ZA;;US;;CA;;MX,10,195-942-113-924-172;;016-987-265-843-679;;085-060-624-869-045;;033-890-279-183-582;;110-403-313-678-694;;073-413-217-704-847;;071-536-480-970-365;;063-554-951-255-253;;015-461-226-780-326;;153-286-029-348-380,JP;;KR;;CN;;EP;;ZA;;WO;;US;;CA;;MX,0,C21B13/00;;C21B5/006;;C21B5/008;;C21B5/06;;C21B13/0073;;C21B2300/04;;C21C5/00;;C21C5/527;;C21C2300/06;;C21B13/0073;;C21B5/006;;C21B5/008;;C21B5/06;;C21C5/527;;C21B2300/04;;C21C2300/06;;C21C2100/02;;C21B5/006;;C21B5/06;;C21B13/00;;C21B2300/04;;C21C5/52;;C21C2300/06,C21B13/00,,4,4,067-333-288-123-284;;030-548-065-093-335;;020-048-341-062-25X;;108-099-761-886-192,10.3390/met9030364;;10.2355/isijinternational.46.1752;;10.1007/s00501-016-0561-8;;10.1016/j.ijggc.2008.06.005,"SONG JIAYUAN ET AL: ""Comparison of Energy Consumption and CO2 Emission for Three Steel Production Routes-Integrated Steel Plant Equipped with Blast Furnace, Oxygen Blast Furnace or COREX"", METALS, vol. 9, no. 3, 21 March 2019 (2019-03-21), pages 364, XP055840776, DOI: 10.3390/met9030364;;RYMAN CHRISTER ET AL: ""Reduction of CO2 Emissions from Integrated Steelmaking by Optimised Scrap Strategies: Application of Process Integration Models on the BF-BOF System"", 12 December 2006 (2006-12-12), pages 1 - 7, XP055844347, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/isijinternational/46/12/46_12_1752/_article> [retrieved on 20210924];;RAMMER BARBARA ET AL: ""Comparing the CO2Emissions of Different Steelmaking Routes"", BHM. BERG UND HUETTENMAENNISCHE MONATSHEFTE, SPRINGER, VIENNA, AU, vol. 162, no. 1, 5 January 2017 (2017-01-05), pages 7 - 13, XP036140025, ISSN: 0005-8912, [retrieved on 20170105], DOI: 10.1007/S00501-016-0561-8;;WANG C ET AL: ""Potential CO""2 emission reduction for BF-BOF steelmaking based on optimised use of ferrous burden materials"", INTERNATIONAL JOURNAL OF GREENHOUSE GAS CONTROL, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 1, 1 January 2009 (2009-01-01), pages 29 - 38, XP025851048, ISSN: 1750-5836, [retrieved on 20080715], DOI: 10.1016/J.IJGGC.2008.06.005",PENDING
26,WO,A1,WO 2022/251306 A1,121-990-604-533-151,2022-12-01,2022,US 2022/0030843 W,2022-05-25,US 202117330386 A;;US 201862771841 P,2018-11-27,"COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS","The present disclosure provides, inter alia, a compound having the structure of Formula (1): Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.",UNIV COLUMBIA,STOCKWELL BRENT R;;ZASK ARIE;;TAN HUI;;DANIELS JACOB D,,https://lens.org/121-990-604-533-151,Patent Application,yes,4,0,13,121-990-604-533-151;;136-303-601-830-019;;114-705-167-288-522;;131-688-800-577-763;;129-377-716-373-258;;160-185-259-414-954;;019-188-334-730-941;;187-018-394-861-206;;175-525-083-150-248;;033-754-575-774-735;;043-025-737-923-864;;192-090-995-050-609;;102-183-983-840-329,AU;;JP;;CN;;EP;;WO;;US,13,121-990-604-533-151;;136-303-601-830-019;;114-705-167-288-522;;131-688-800-577-763;;129-377-716-373-258;;160-185-259-414-954;;019-188-334-730-941;;187-018-394-861-206;;175-525-083-150-248;;033-754-575-774-735;;043-025-737-923-864;;192-090-995-050-609;;102-183-983-840-329,AU;;JP;;CN;;EP;;WO;;US,0,A61K45/06;;C07C2601/14;;C07C229/60;;C07C2603/74;;C07C237/30;;C07D263/32;;C07D271/06;;C07D295/13;;C07D413/04;;C07D213/80;;C07D213/74;;C07D413/12;;A61P25/28;;A61P39/06;;A61P31/06;;A61K31/166;;A61K31/245;;A61K31/421;;A61K31/4245;;A61K31/44;;A61K31/4439;;A61K31/5375;;C07C229/60;;C07C233/65;;C07D213/74;;C07D213/80;;C07D263/32;;C07D271/10;;C07D295/13;;C07D413/04;;C07D413/12,C07D498/04;;C07D513/04;;C07D519/04,,3,2,088-555-154-379-255;;003-741-038-671-967,pmc7180072;;31899616;;10.1021/acschembio.9b00939.s001;;10.1021/acschembio.9b00939;;pmc8424725;;10.1177/17590914211037505;;34463559,"YE ET AL.: ""Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers"", ACS CHEMICAL BIOLOGY, vol. 15, 3 January 2020 (2020-01-03), pages 469 - 484, XP055786303, DOI: 10.1021/acschembio.9b00939;;BU ZHONG-QI, YU HAI-YANG, WANG JUE, HE XIN, CUI YUE-RAN, FENG JIA-CHUN, FENG JUAN: ""Emerging Role of Ferroptosis in the Pathogenesis of Ischemic Stroke: A New Therapeutic Target?"", ASN NEURO, vol. 13, 1 January 2021 (2021-01-01), pages 175909142110375, XP093013788, ISSN: 1759-0914, DOI: 10.1177/17590914211037505;;See also references of EP 4347605A4",PENDING
27,US,A1,US 2020/0316261 A1,061-193-119-508-220,2020-10-08,2020,US 201816955522 A,2018-12-18,PT 11046317 A;;IB 2018060266 W,2017-12-18,"HYDROGELS BASED ON BLOOD PLASMA COMPONENTS, PROCESS AND USES THEREOF","The present disclosure relates to bioactive hydrogels derived from human blood plasma. More particularly, the disclosure relates to multifunctional materials for cell encapsulation, cell culture platforms, medical treatment apparatus and methods, more particularly, hydrogels derived from human blood components and technologies for use of such materials in research, biomedical treatment, biotech and pharmaceutical industry. The disclosure further relates to 3D printable scaffolds, sponges, foams, fibers, particles, capsules, membranes and injectable systems comprising said hydrogel. Additionally, this disclosure allows for the controlled placement of biologically active components that may be delivered by the hydrogel compositions.",UNIV AVEIRO,COLARDELLE DA LUZ MANO JOÃO FILIPE;;DE ALMEIDA CUSTÓDIO CATARINA;;NUNES DA SILVA SANTOS SARA CATARINA,UNIVERSIDADE DE AVEIRO (2020-06-03),https://lens.org/061-193-119-508-220,Patent Application,yes,3,7,9,142-476-612-237-248;;105-614-345-579-577;;003-595-434-285-723;;099-871-571-394-281;;185-880-912-666-241;;188-361-662-317-157;;117-952-809-841-594;;061-193-119-508-220;;104-983-658-248-928,EP;;WO;;FI;;US;;PT;;DK,9,142-476-612-237-248;;117-952-809-841-594;;003-595-434-285-723;;099-871-571-394-281;;185-880-912-666-241;;188-361-662-317-157;;105-614-345-579-577;;061-193-119-508-220;;104-983-658-248-928,EP;;WO;;FI;;US;;PT;;DK,0,A61L27/52;;A61L27/3616;;A61L27/3616;;A61L27/12;;A61L27/26;;A61L27/3834;;A61L27/52;;A61L27/56;;A61L27/52;;A61L27/10;;A61L27/12;;A61L27/26;;A61L27/3616;;A61L27/3834;;A61L27/56;;A61L2300/414;;A61L2400/06;;C12M25/00,A61L27/52;;A61L27/10;;A61L27/12;;A61L27/26;;A61L27/36;;A61L27/38;;A61L27/56;;C12M1/12,,7,5,029-810-216-722-270;;013-276-421-857-678;;135-033-871-627-359;;007-816-405-318-639;;078-355-756-456-431,pmc5808910;;28699750;;10.1021/acs.chemrev.7b00123;;10.1016/j.biomaterials.2004.06.047;;15585249;;10.1021/bm0701189;;17511500;;10.1161/01.cir.23.4.578;;13696820;;1379889;;10.1007/bf00338052,"Zucker (Touro College and University System, Spring 2011, Volume 4, pages 23-29) (Year: 2011);;Fass et al (Chemical reviews, 2018, volume 118, pages 1169-1198) (Year: 2018);;Samateh et al (Scientific reports, 2018, volume 8, pages 1-8) (Year: 2018);;Almany et al (Biomaterials, 2005, volume 26, pages 2467-2477) (Year: 2005);;Tae et al (Biomacromolecules, 2007, volume 8, pages 1979-1986) (Year: 2007);;Engelberg (Circulation, 1961, volume XXIII, pages 578-581) (Year: 1961);;Sumida et al (Cell and Tissue Research, 1992, volume 268, pages 41-49) (Year: 1992)",ACTIVE
28,US,A1,US 2023/0351226 A1,077-437-825-100-686,2023-11-02,2023,US 202318114936 A,2023-02-27,US 202318114936 A;;US 201916662369 A;;US 201862750153 P;;US 201862750156 P;;US 201962832148 P,2018-10-24,LEVERAGING GENETICS AND FEATURE ENGINEERING TO BOOST PLACEMENT PREDICTABILITY FOR SEED PRODUCT SELECTION AND RECOMMENDATION BY FIELD,"An example computer-implemented method includes receiving agricultural data records comprising a first set of yield properties for a first set of seeds grown in a first set of environments, and receiving genetic feature data related to a second set of seeds. The method further includes generating a second set of yield properties for the second set of seeds associated with a second set of environments by applying a model using the genetic feature data and the agricultural data records. In addition, the method includes determining predicted yield performance for a third set of seeds associated with one or more target environments by applying the second set of yield properties, and generating seed recommendations for the one or more target environments based on the predicted yield performance for the third set of seeds. In the present example, the method also includes causing display of the seed recommendations.",CLIMATE LLC,BULL JASON K;;EHLMANN TONYA S;;JIANG DONGMING;;LUTZ BRIAN;;MOORE III JAMES C;;REICH TIMOTHY;;SSEGANE HERBERT;;WANG GUOMEI;;WANG XUEFEI;;WEN LIWEI;;YANG XIAO,CLIMATE LLC (2019-11-04),https://lens.org/077-437-825-100-686,Patent Application,yes,7,0,12,114-661-274-599-703;;172-527-548-760-936;;189-854-905-050-955;;084-054-390-373-68X;;027-240-023-260-765;;019-595-260-632-385;;082-184-596-295-253;;028-894-318-579-596;;040-273-274-419-699;;158-294-662-824-524;;077-437-825-100-686;;000-134-085-013-939,EP;;CN;;WO;;US;;CA;;MX;;BR,19,084-054-390-373-68X;;000-134-085-013-939;;158-294-662-824-524;;103-671-435-814-997;;160-049-885-895-701;;114-661-274-599-703;;154-642-553-950-292;;189-854-905-050-955;;172-527-548-760-936;;060-625-565-634-198;;027-240-023-260-765;;019-595-260-632-385;;082-184-596-295-253;;072-505-636-949-293;;028-894-318-579-596;;040-273-274-419-699;;155-507-720-895-863;;181-003-986-890-860;;077-437-825-100-686,AR;;CN;;EP;;WO;;US;;CA;;MX;;BR,0,G16B10/00;;G16B20/00;;G16B40/20;;G06N20/10;;G06N20/20;;G16B20/20;;A01C21/005;;G06N5/01;;G06N7/01;;G06N5/04;;G06F30/20;;G16B10/00;;G16B20/00;;G16B40/00;;G06N20/00,G06N5/04;;G06F30/20;;G06N20/00;;G16B10/00;;G16B20/00;;G16B40/00,,0,0,,,,ACTIVE
29,US,A1,US 2024/0156790 A1,131-688-800-577-763,2024-05-16,2024,US 202318518731 A,2023-11-24,US 202318518731 A;;US 2022/0030843 W;;US 202117330386 A;;US 2019/0063640 W;;US 201862771841 P,2018-11-27,"COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS","The present disclosure provides, inter alia, a compound having the structure:Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.",UNIV COLUMBIA,STOCKWELL BRENT R;;ZASK ARIE;;TAN HUI;;DANIELS JACOB D,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2024-10-22),https://lens.org/131-688-800-577-763,Patent Application,yes,0,1,13,121-990-604-533-151;;136-303-601-830-019;;114-705-167-288-522;;131-688-800-577-763;;129-377-716-373-258;;160-185-259-414-954;;019-188-334-730-941;;187-018-394-861-206;;175-525-083-150-248;;033-754-575-774-735;;043-025-737-923-864;;192-090-995-050-609;;102-183-983-840-329,AU;;JP;;CN;;EP;;WO;;US,13,121-990-604-533-151;;136-303-601-830-019;;114-705-167-288-522;;131-688-800-577-763;;129-377-716-373-258;;160-185-259-414-954;;019-188-334-730-941;;187-018-394-861-206;;175-525-083-150-248;;033-754-575-774-735;;043-025-737-923-864;;192-090-995-050-609;;102-183-983-840-329,AU;;JP;;CN;;EP;;WO;;US,0,A61K45/06;;C07C2601/14;;C07C229/60;;C07C2603/74;;C07C237/30;;C07D263/32;;C07D271/06;;C07D295/13;;C07D413/04;;C07D213/80;;C07D213/74;;C07D413/12;;A61P25/28;;A61P39/06;;A61P31/06;;A61K31/166;;A61K31/245;;A61K31/421;;A61K31/4245;;A61K31/44;;A61K31/4439;;A61K31/5375;;C07C229/60;;C07C233/65;;C07D213/74;;C07D213/80;;C07D263/32;;C07D271/10;;C07D295/13;;C07D413/04;;C07D413/12,A61K31/4245;;A61K31/166;;A61K31/245;;A61K31/421;;A61K31/44;;A61K31/4439;;A61K31/5375;;A61P31/06;;A61P39/06;;C07C229/60;;C07C233/65;;C07D213/74;;C07D213/80;;C07D263/32;;C07D271/10;;C07D295/13;;C07D413/04;;C07D413/12,,0,0,,,,PENDING
30,US,A1,US 2021/0335456 A1,038-807-303-451-658,2021-10-28,2021,US 202016857181 A,2020-04-24,US 202016857181 A,2020-04-24,SYSTEMS AND METHODS FOR COLLECTING CLINICAL AND NON-CLINICAL DATA ACROSS MULTIPLE FUNCTIONAL MODULES THROUGH A CENTRAL GATEWAY,"Systems and methods for collecting clinical trial data across multiple functional modules is described. One described method comprises managing clinical and non-clinical data on a client device over a network; the data is linked through a central gateway across a plurality of functional modules; with access control to each functional stake holder; and transmitting the data, for access to sponsors over the network.",PAL AVIK KUMAR;;SUBRAMANIAM YERRAMALLI;;CLINIOPS INC,PAL AVIK KUMAR;;SUBRAMANIAM YERRAMALLI,CLINIOPS INC (2022-07-05),https://lens.org/038-807-303-451-658,Patent Application,yes,4,2,1,038-807-303-451-658,US,3,038-807-303-451-658;;135-082-823-548-489;;007-899-148-028-652,US,0,G16H10/20;;G16H10/60;;G16H10/20;;G06F16/907;;G16H10/60,G16H10/20;;G06F16/907;;G16H10/60,,1,1,066-748-061-274-713,10.1038/nrcardio.2015.33;;25781411,"James, S., Rao, S. V., & Granger, C. B. (2015). Registry-based randomized clinical trials—a new clinical trial paradigm. Nature Reviews Cardiology, 12(5), 312-316. (Year: 2015)",DISCONTINUED
31,WO,A1,WO 2021/255147 A1,153-605-792-320-15X,2021-12-23,2021,EP 2021066355 W,2021-06-17,EP 20180858 A,2020-06-18,PROCESS AND REACTOR FOR HEATING AT LEAST ONE FLUID BY MAGNETIC INDUCTION,"The invention relates to a process for heating at least one fluid by magnetic induction using at least one metal as heat transfer medium, wherein the metal is incorporated into the fluid to be heated as a packed bed, and wherein a high frequency alternating magnetic field (AC-field) of at least 50 kHz is applied for generating heat in at least a (thin) interfacial layer of the metal and the generated heat is subsequently transferred to the fluid to be heated.",ETH ZUERICH,BLATTMANN CHRISTOPH OLIVER;;BUCHMANN LEANDRO SILVANO GUIDO;;MATHYS ALEXANDER;;HUG DOMINIK,,https://lens.org/153-605-792-320-15X,Patent Application,yes,2,1,3,153-605-792-320-15X;;160-636-493-401-465;;004-267-244-709-672,EP;;WO;;US,3,153-605-792-320-15X;;004-267-244-709-672;;160-636-493-401-465,EP;;WO;;US,0,A23B70/35;;A23B2/05;;A23B11/13;;A23B2/05;;A23B70/35;;A23B11/13,A23L3/005;;A23C3/07;;A23L2/48,,9,7,020-552-533-162-83X;;117-795-480-840-345;;027-802-749-801-323;;015-984-504-806-702;;055-208-605-898-828;;020-552-533-162-83X;;084-541-465-882-402,10.1002/anie.200801474;;18924199;;10.1111/j.1365-2621.1996.tb10963.x;;pmc5900422;;10.3389/fnut.2018.00024;;29686990;;10.1051/lait:1992322;;10.1016/s0017-9310(05)80130-9;;10.1002/anie.200801474;;18924199;;10.1016/s0921-4534(03)01042-6,"SASCHA CEYLAN ET AL: ""Inductive Heating for Organic Synthesis by Using Functionalized Magnetic Nanoparticles Inside Microreactors"", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 47, no. 46, 3 November 2008 (2008-11-03), pages 8950 - 8953, XP055089006, ISSN: 1433-7851, DOI: 10.1002/anie.200801474;;KESSLER, H. G.HORAK, F. P., MILCHWISSENSCHAFT, vol. 39, 1984, pages 451 - 454;;KESSLER HG.: ""Food and Bio Process Engineering: Dairy Technology"", 2002, VERLAG A. KESSLER;;MORGAN, A. I.RADEWONUK, E. R.SCULLEN, O. J., J FOOD SCI, vol. 61, 1996, pages 1216 - 1218;;MATHYS, A., FRONT. NUTR., vol. 5, 2018, pages 24;;MARTEL, R.POULIOT, Y.CHARETTE, A., LAIT, vol. 72, 1992, pages 297 - 306;;DUQUENNE, P.DELTOUR, A.LACOSTE, G., INT. J. HEAT MASS TRANSF., vol. 36, 1993, pages 2473 - 2477;;CEYLAN, S.FRIESE, C.LAMMEL, C.MAZAC, K.KIRSCHNING, A., ANGEW. CHEM., vol. 47, 2008, pages 8950 - 8953;;KONDO, T.ITOZAKI, H., PHYSICA C, vol. 392-396, 2003, pages 1401 - 1405",PENDING
32,EP,A1,EP 4094939 A1,105-265-833-971-25X,2022-11-30,2022,EP 22186354 A,2016-03-22,US 201562136691 P;;EP 16713264 A;;US 2016/0023534 W,2015-03-23,ABRASION RESISTANT FILM FOR BIOCONTAINERS,"A biocontainer film enhanced with an abrasion resistant or ""cut-proof"" substrate. Such substrates can be combined with current biocontainer materials, via various techniques of embedding, coextrusion or laminating, to maintain the cleanliness and low extractables already validated for biotech manufacturing. The substrate of choice may be constructed from materials known to be more resistant to abrasion and sharp razor type cuts or from materials oriented in such a way to prevent puncture to occur. The new substrate must also be flexible to allow for typical folding as demonstrated by current packaging practices. The new substrate may be constructed from materials other than polymers such as metal, glass or carbon or in combination with polymers. A non-constrained pressure test is also disclosed.",EMD MILLIPORE CORP,DECOSTE DAVID;;CIANCIOLO JOSEPH;;FURBUSH MICHAEL;;SARAGOSA JOHN,,https://lens.org/105-265-833-971-25X,Patent Application,yes,4,0,29,138-329-204-363-670;;021-335-266-355-877;;107-226-572-894-233;;092-593-522-779-095;;010-030-354-596-631;;132-755-896-474-550;;163-853-248-360-41X;;186-572-945-527-223;;138-174-239-152-132;;031-266-536-349-511;;120-863-782-514-262;;153-348-663-370-164;;078-683-625-625-98X;;024-901-063-358-499;;105-265-833-971-25X;;077-288-320-124-600;;043-322-405-186-280;;186-136-731-665-451;;122-439-974-742-067;;152-264-324-357-366;;120-814-493-536-667;;174-862-702-896-817;;081-312-977-633-428;;122-908-756-035-929;;099-539-883-023-370;;120-401-558-920-016;;130-502-620-679-135;;169-900-304-498-016;;013-591-302-545-858,KR;;JP;;ES;;CN;;EP;;WO;;SG;;US;;CA;;MX;;BR,29,138-329-204-363-670;;021-335-266-355-877;;107-226-572-894-233;;092-593-522-779-095;;010-030-354-596-631;;132-755-896-474-550;;163-853-248-360-41X;;186-572-945-527-223;;138-174-239-152-132;;031-266-536-349-511;;120-863-782-514-262;;153-348-663-370-164;;078-683-625-625-98X;;024-901-063-358-499;;105-265-833-971-25X;;077-288-320-124-600;;043-322-405-186-280;;186-136-731-665-451;;122-439-974-742-067;;152-264-324-357-366;;120-814-493-536-667;;174-862-702-896-817;;081-312-977-633-428;;122-908-756-035-929;;099-539-883-023-370;;120-401-558-920-016;;130-502-620-679-135;;169-900-304-498-016;;013-591-302-545-858,KR;;JP;;ES;;CN;;EP;;WO;;SG;;US;;CA;;MX;;BR,0,B32B5/02;;B32B5/022;;B32B5/024;;B32B27/08;;B32B27/12;;B32B27/32;;B32B27/34;;B32B27/40;;B65D31/04;;B65D33/04;;B65D75/58;;B32B2439/40;;B32B2439/80;;B32B2262/0253;;B32B2262/0276;;B32B2262/0269;;B32B2262/0261;;B32B2307/7242;;B32B2307/554;;B32B2262/106;;B32B2262/103;;B32B5/02;;B32B5/022;;B32B27/08;;B32B27/12;;B32B27/32;;B32B27/34;;B32B27/40;;B32B2262/0253;;B32B2262/0261;;B32B2262/0269;;B32B2262/0276;;B32B2262/103;;B32B2262/106;;B32B2307/554;;B32B2307/7242;;B32B2439/40;;B32B2439/80;;B65D2275/00;;B32B5/024;;B32B2260/046;;B32B2262/101;;B32B2262/0284;;C12M23/14;;C12M23/20;;B32B5/02;;B32B5/024;;B32B7/12;;B32B27/08;;B32B27/12;;B32B27/32;;B65D65/40;;C12M23/00;;B32B2307/7244;;B32B2307/554;;B32B1/00;;B32B5/02;;B32B5/022;;B32B27/08;;B32B27/12;;B32B27/32;;B32B27/34;;B32B27/40;;B32B2262/0253;;B32B2262/0261;;B32B2262/0269;;B32B2262/0276;;B32B2262/103;;B32B2262/106;;B32B2307/554;;B32B2307/7242;;B32B2439/40;;B32B2439/80;;B65D2275/00;;B32B5/024;;B01L3/508;;B01L2300/0887;;B01L2300/16;;B65D65/40;;B65D75/58;;G01M3/3272,B32B27/12;;A01N1/00;;A61J1/00;;A61J1/10;;B32B1/00;;B32B5/02;;B32B27/08;;B32B27/32;;B32B27/34;;B32B27/40;;B65D33/04;;C12M1/00,,0,0,,,,PENDING
33,US,A1,US 2024/0132981 A1,071-536-480-970-365,2024-04-25,2024,US 202118278029 A,2021-02-26,IB 2021051614 W,2021-02-26,Manufacturing method of a steel product,"A method to manufacture a steel product in a steelmaking plant including several different tools, the method including the definition of at least two manufacturing routes using different tools and the calculation of the expected level of CO2 emissions associated to each of this defined manufacturing routes.",ARCELORMITTAL,DA GAMA CAMPOS HUGO;;VAN DER HOEVEN JEAN-MARTIN,ARCELORMITTAL (2023-08-24),https://lens.org/071-536-480-970-365,Patent Application,yes,0,0,10,195-942-113-924-172;;016-987-265-843-679;;085-060-624-869-045;;015-461-226-780-326;;063-554-951-255-253;;073-413-217-704-847;;071-536-480-970-365;;153-286-029-348-380;;033-890-279-183-582;;110-403-313-678-694,KR;;JP;;CN;;EP;;WO;;ZA;;US;;CA;;MX,10,195-942-113-924-172;;016-987-265-843-679;;085-060-624-869-045;;033-890-279-183-582;;110-403-313-678-694;;073-413-217-704-847;;071-536-480-970-365;;063-554-951-255-253;;015-461-226-780-326;;153-286-029-348-380,JP;;KR;;CN;;EP;;ZA;;WO;;US;;CA;;MX,0,C21B13/00;;C21B5/006;;C21B5/008;;C21B5/06;;C21B13/0073;;C21B2300/04;;C21C5/00;;C21C5/527;;C21C2300/06;;C21B13/0073;;C21B5/006;;C21B5/008;;C21B5/06;;C21C5/527;;C21B2300/04;;C21C2300/06;;C21C2100/02;;C21B5/006;;C21B5/06;;C21B13/00;;C21B2300/04;;C21C5/52;;C21C2300/06,C21B5/00;;C21B5/06;;C21B13/00;;C21C5/52,,0,0,,,,PENDING
34,US,A1,US 2022/0186167 A1,181-362-176-578-677,2022-06-16,2022,US 202117561389 A,2021-12-23,US 202117561389 A;;US 2020/0040359 W;;US 201962869050 P,2019-07-01,METHOD FOR CULTIVATION OF ADHERENT CELLS IN A MULTIPARALLEL BIOREACTOR,"Disclosed is a process for growing adherent cells in a containment box of a multi-parallel bioreactor, including: seeding the adherent cells on a carrier held in a culture dish; transferring the adherent cells on the carrier to a containment box of the multi-parallel bioreactor; and growing the adherent cells at a containment box while agitating the media at an impeller speed between 200 rpm to a 1200 rpm.",OLOGY BIOSERVICES INC,VELA ERIC;;GREEN APRIL;;BERRIE DALTON,RESILIENCE GOVERNMENT SERVICES INC (2023-01-09),https://lens.org/181-362-176-578-677,Patent Application,yes,3,1,13,111-197-177-434-59X;;097-334-095-754-306;;035-949-101-629-926;;019-884-235-564-545;;181-362-176-578-677;;193-619-396-756-021;;045-146-158-995-365;;191-809-109-737-499;;183-902-727-219-388;;192-509-405-729-217;;031-869-264-671-306;;043-574-527-828-924;;177-045-564-647-992,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;MX;;BR,13,111-197-177-434-59X;;097-334-095-754-306;;035-949-101-629-926;;019-884-235-564-545;;181-362-176-578-677;;193-619-396-756-021;;045-146-158-995-365;;191-809-109-737-499;;183-902-727-219-388;;192-509-405-729-217;;031-869-264-671-306;;043-574-527-828-924;;177-045-564-647-992,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;MX;;BR,0,C12M25/02;;C12M23/58;;C12M41/42;;C12M25/02;;C12M23/58;;C12M23/58;;C12M25/02;;C12M23/12;;C12M41/42;;C12M23/08;;C12M23/22;;C12M23/44;;C12M25/14;;C12M27/02;;C12M35/08;;C12N5/0603;;C12N5/0686;;C12N2533/30,C12M1/06;;C12M1/00;;C12M1/12;;C12M1/24;;C12M1/42;;C12M3/00;;C12N5/071;;C12N5/073,,4,3,008-151-807-725-782;;000-479-337-255-883;;012-797-379-043-829,10.4161/mabs.2.5.12720;;pmc2958569;;20622510;;10.1128/jvi.00829-11;;21957293;;pmc3233163;;10397838;;10.1002/(sici)1097-0290(19990705)64:1<46::aid-bit5>3.0.co;2-9;;10.1002/(sici)1097-0290(19990705)64:1<46::aid-bit5>3.3.co;2-0,"Li, F., Vijayasankaran, N., Shen, A. (Yijuan), Kiss, R., & Amanullah, A. (2010). Cell culture processes for monoclonal antibody production. mAbs, 2(5), 466–479. (Year: 2010);;Tomaskova J, Oveckova I, Labudova M, Lukacikova L, Laposova K, Kopacek J, Pastorekova S, Pastorek J. 2011. Hypoxia Induces the Gene Expression and Extracellular Transmission of Persistent Lymphocytic Choriomeningitis Virus . J Virol 85:. (Year: 2011);;Anna Sanfeliu, Gregory Stephanopoulos. 2000. Effect of glutamine limitation on the death of attached Chinese hamster ovary cells. Biotechnology and Bioengineering. 64(1), 46-53. (Year: 2000);;Translation of TW-1233449-B application (Year: 2005)",PENDING
35,EP,A1,EP 4218862 A1,039-578-024-407-013,2023-08-02,2023,EP 23157103 A,2012-09-27,EP 11306236 A;;EP 12766092 A;;EP 2012069119 W,2011-09-27,MEDICAL INJECTION DEVICE COMPRISING A LUBRICANT COATING,"The invention relates to a medical injection device (1) comprising:a barrel (2) having an inner surface (21), the barrel being configured to be filled with a pharmaceutical composition; anda stopper (3) in gliding engagement with the barrel;the inner surface (21) of the barrel comprising a coating (5) of plasma treated silicone oil configured to be in contact with the pharmaceutical composition,wherein the plasma treatment of the silicone oil reduces the number of particles present on the surface of the coating and the number of particles released into the pharmaceutical composition contained in the medical injection device as compared to silicone oil that is not plasma treated.",BECTON DICKINSON FRANCE,JANVIER SÉBASTIEN;;MANGIAGALLI PAOLO;;JOUFFRAY SÉBASTIEN;;FOUCHER CÉDRIC;;ENFOUX YVES,,https://lens.org/039-578-024-407-013,Patent Application,yes,12,0,19,192-369-174-441-395;;101-383-137-769-260;;024-658-320-738-365;;081-357-384-450-238;;051-611-561-990-247;;119-190-254-493-673;;179-478-928-861-84X;;120-568-505-122-605;;081-290-354-579-31X;;137-402-306-829-322;;054-953-822-139-506;;105-227-439-599-683;;127-529-488-000-026;;077-325-383-484-304;;039-578-024-407-013;;109-007-127-243-638;;022-764-776-105-984;;171-781-381-507-759;;097-913-898-473-23X,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX,19,192-369-174-441-395;;101-383-137-769-260;;024-658-320-738-365;;081-357-384-450-238;;051-611-561-990-247;;119-190-254-493-673;;179-478-928-861-84X;;120-568-505-122-605;;081-290-354-579-31X;;137-402-306-829-322;;054-953-822-139-506;;105-227-439-599-683;;127-529-488-000-026;;077-325-383-484-304;;039-578-024-407-013;;109-007-127-243-638;;022-764-776-105-984;;171-781-381-507-759;;097-913-898-473-23X,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX,0,A61M2005/3131;;F04C2270/041;;A61M5/3129;;A61M5/3129;;A61J1/05;;A61L31/14;;A61M2205/0222;;A61L2400/10;;A61L2420/02;;F04C2270/041;;A61L31/10;;A61M2005/3131;;A61M2005/3117;;A61M5/3129;;A61L31/10;;A61L31/14;;A61M2005/3131;;F04C2270/041;;A61M5/3129;;A61L31/10;;A61L31/14;;A61L2400/10;;A61L2400/18;;A61L2420/02;;A61M2005/3117,A61M5/31;;A61M5/315,,1,1,113-565-558-689-202,pmc3928042;;10.1002/jps.21530;;18704929,"JOHN F. CARPENTER ET AL.: ""Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 98, no. 4, April 2009 (2009-04-01)",PENDING
36,US,A1,US 2023/0225375 A1,004-267-244-709-672,2023-07-20,2023,US 202118010504 A,2021-06-17,EP 20180858 A;;EP 2021066355 W,2020-06-18,Process and Reactor for Heating at Least One Fluid by Magnetic Induction,Provided is a process for heating at least one fluid by magnetic induction using at least one metal as a heat transfer medium. The metal is incorporated into the fluid to be heated as a packed bed. A high frequency alternating magnetic field (AC-field) of at least 50 kHz is applied for generating heat in at least a (thin) interfacial layer of the metal and the generated heat is subsequently transferred to the fluid to be heated.,ETH ZUERICH,BLATTMANN CHRISTOPH OLIVER;;BUCHMANN LEANDRO SILVANO GUIDO;;MATHYS ALEXANDER;;HUG DOMINIK,ETH ZURICH (2022-11-28),https://lens.org/004-267-244-709-672,Patent Application,yes,0,0,3,153-605-792-320-15X;;160-636-493-401-465;;004-267-244-709-672,EP;;WO;;US,3,153-605-792-320-15X;;004-267-244-709-672;;160-636-493-401-465,EP;;WO;;US,0,A23B70/35;;A23B2/05;;A23B11/13;;A23B2/05;;A23B70/35;;A23B11/13,A23C3/03;;A23L3/005;;A23L2/48,,0,0,,,,PENDING
37,EP,A2,EP 4442749 A2,057-267-469-787-922,2024-10-09,2024,EP 24188210 A,2019-02-13,EP 18158865 A;;EP 19703378 A;;EP 2019053523 W,2018-02-27,BIO-BASED REACTIVE PLASTICIZER AND ADHESIVES AND SEALANTS CONTAINING THEM,"The present invention pertains to novel reactive (moisture curing) plasticizers of formula (I), as described herein, and adhesives and sealants containing them to bond and seal substrates.",HENKEL AG & CO KGAA,BRANDT ADRIAN;;BECK HORST;;KLEIN JOHANN;;DAMKE JAN-ERIK;;SCHMIDT SEBASTIAN;;KUX ALEXANDER;;DE VRIES JOHANNES GERARDUS;;HINZE SANDRA;;VAN HECK RICHARD,,https://lens.org/057-267-469-787-922,Patent Application,yes,2,0,13,155-741-011-549-170;;010-438-277-795-643;;177-657-952-038-619;;080-298-193-782-72X;;014-277-044-002-703;;144-824-875-425-25X;;128-681-417-846-932;;128-459-958-054-316;;057-267-469-787-922;;095-223-071-578-454;;127-291-560-659-275;;013-787-596-017-990;;048-484-351-430-607,KR;;JP;;EP;;CN;;WO;;US;;PL,13,155-741-011-549-170;;010-438-277-795-643;;177-657-952-038-619;;080-298-193-782-72X;;014-277-044-002-703;;144-824-875-425-25X;;128-681-417-846-932;;128-459-958-054-316;;057-267-469-787-922;;095-223-071-578-454;;127-291-560-659-275;;013-787-596-017-990;;048-484-351-430-607,KR;;JP;;EP;;CN;;WO;;US;;PL,0,C07F7/1804;;C07F7/1892;;C08K5/0016;;C08K5/101;;C09J11/06;;C07F7/1892;;C08K5/0016;;C08K5/101;;C09J11/06;;C07F7/1804;;C07F7/1892;;C08G61/04;;C09J171/02,C08K5/101,,1,0,,,no. 034206-40-1,PENDING
38,US,A1,US 2021/0343428 A1,097-906-191-299-295,2021-11-04,2021,US 202016862505 A,2020-04-29,US 202016862505 A,2020-04-29,SYSTEMS AND METHODS FOR COLLECTING LOCATION AGNOSTIC CLINICAL AND NON CLINICAL DATA,"Systems and methods for collecting clinical trial data across multiple locations is described. One described method; decentralized clinical trial design; comprises collecting clinical and non-clinical data on a client device over a network; the data is collected at a hospital, home or an alternate care facility, by either the patient or the healthcare professional; and transmitting the data, for access to sponsors over the network.",PAL AVIK KUMAR;;SUBRAMANIAM YERRAMALLI;;CLINIOPS INC,PAL AVIK KUMAR;;SUBRAMANIAM YERRAMALLI,CLINIOPS INC (2022-07-05),https://lens.org/097-906-191-299-295,Patent Application,yes,1,0,2,097-906-191-299-295;;089-728-789-900-955,US,2,097-906-191-299-295;;089-728-789-900-955,US,0,G16H80/00;;G16H10/20;;G16H10/60;;G16H40/67;;G16H70/60;;H04L63/166;;G16H80/00;;G16H10/60;;H04L63/166,G16H80/00;;G16H10/60;;H04L29/06,,1,0,,,"Hagen, Ryan; The Use of Passive Smartphone Data in the Assessment of Mood; William James College, ProQuest Dissertations Publishing, 2013. 10184556. (Year: 2013)",ACTIVE
39,WO,A1,WO 2025/129360 A1,012-831-427-212-655,2025-06-26,2025,CA 2024051726 W,2024-12-23,US 202363614374 P,2023-12-22,"SYSTEM AND METHOD FOR ANALYSING SUCCESS OF CLINICAL TRIALS, INTERPRETING RISK FACTORS AND FOR MANAGING PHARMACEUTICAL PORTFOLIO USING ARTIFICIAL INTELLIGENCE","Methods, systems, and platform are provided for analyzing the success of clinical trials, interpreting risk factors and for strategic pharmaceutical portfolio management. The methods, systems, and platform enable exploitation of an aggregated, multimodal, structured and relational database, methodically built from a variety of heterogeneous, structured and 5 unstructured external data sources. This unique database comprehensively captures meticulously risk factors affecting the clinical drug development process while it reconstructs the historical drug clinical trials pipeline of a drug, facilitating the tracking of its clinical development. This unique database is the cornerstone for the development of an explainable machine learning systems to support complex decision-making processes for end users such as 0 large pharmaceutical companies, biotech companies, clinical research organizations, life science investment funds, investment banks, hedge funds and consulting firms.",GROUPE SORINTELLIS INC,PIFFO EMMANUEL;;HALIMI INESS;;AVRAMIOTI DIANA;;GIERSCHENDORF JORDAN;;RAYMOND CAMELIA;;SOTIR MARTIN,,https://lens.org/012-831-427-212-655,Patent Application,yes,0,0,1,012-831-427-212-655,WO,1,012-831-427-212-655,WO,0,G16H40/20;;G06N20/00;;G16H10/20;;G06Q10/04;;G16H70/40;;G16H50/20;;G16H50/70,G16H10/20;;G06N20/00;;G06Q10/04;;G16H40/20,,0,0,,,,PENDING
40,WO,A1,WO 2021/003188 A1,019-884-235-564-545,2021-01-07,2021,US 2020/0040359 W,2020-06-30,US 201962869050 P,2019-07-01,METHOD FOR CULTIVATION OF ADHERENT CELLS IN A MULTIPARALLEL BIOREACTOR,"The invention relates to a method of cultivating adherent cells in a multiparallel bioreactor, using PET carrier strips, for the optimization of growth and production parameters of adherent cells. The invention also relates to a method of propagating viruses and vectors from adherent cells in a multiparallel bioreactor for production process optimization.",OLOGY BIOSERVICES INC,VELA ERIC;;GREEN APRIL;;BERRIE DALTON,,https://lens.org/019-884-235-564-545,Patent Application,yes,3,1,13,111-197-177-434-59X;;097-334-095-754-306;;035-949-101-629-926;;019-884-235-564-545;;181-362-176-578-677;;193-619-396-756-021;;045-146-158-995-365;;191-809-109-737-499;;183-902-727-219-388;;192-509-405-729-217;;031-869-264-671-306;;043-574-527-828-924;;177-045-564-647-992,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;MX;;BR,13,111-197-177-434-59X;;097-334-095-754-306;;035-949-101-629-926;;019-884-235-564-545;;181-362-176-578-677;;193-619-396-756-021;;045-146-158-995-365;;191-809-109-737-499;;183-902-727-219-388;;192-509-405-729-217;;031-869-264-671-306;;043-574-527-828-924;;177-045-564-647-992,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;MX;;BR,0,C12M25/02;;C12M23/58;;C12M41/42;;C12M25/02;;C12M23/58;;C12M23/58;;C12M25/02;;C12M23/12;;C12M41/42;;C12M23/08;;C12M23/22;;C12M23/44;;C12M25/14;;C12M27/02;;C12M35/08;;C12N5/0603;;C12N5/0686;;C12N2533/30,C12N5/07,,1,0,,,See also references of EP 3994246A4,PENDING
41,US,A1,US 2021/0312512 A1,090-303-796-811-012,2021-10-07,2021,US 202117228198 A,2021-04-12,US 202117228198 A;;US 201113107322 A;;US 33424210 P,2010-05-13,PROSPECTIVE MANAGEMENT SYSTEM FOR MEDICAL BENEFIT PRESCRIPTIONS,"The present invention provides an interactive, electronic, knowledge-based ordering process for specialty/biotech pharmaceuticals (medically coded drugs) which results in less waste, improved procedural efficiencies, and greater cost savings than the current ordering systems. The knowledge-base of the system is based on the health plan's clinical policies as well as the status of the patient and their entitled benefits with the health plan, and it is applied in an interactive manner through a web-enabled system which provides a real-time, prospective examination and control over requests for authorization to dispense the medically coded drugs. The system also includes a feedback loop from the specialty pharmacies to provide information on the medicines that have actually been dispensed. The system also provides to the patient, educational material and adherence reminders to affect therapeutic outcomes.",AXON HEALTHCARE SERVICES LLC,SAMPSON MELISSA;;CHARLES MOHAN P;;ESCUDER MICHAEL,AXON HEALTHCARE SERVICES LLC (2023-03-24);;EVERSANA LIFE SCIENCE SERVICES LLC (2023-08-07),https://lens.org/090-303-796-811-012,Patent Application,yes,4,0,9,090-303-796-811-012;;062-570-218-711-598;;053-375-603-761-217;;074-250-056-772-496;;070-429-670-838-541;;040-307-512-190-838;;176-004-846-438-569;;098-378-207-420-388;;190-017-930-175-319,WO;;US,9,090-303-796-811-012;;062-570-218-711-598;;053-375-603-761-217;;074-250-056-772-496;;070-429-670-838-541;;040-307-512-190-838;;176-004-846-438-569;;098-378-207-420-388;;190-017-930-175-319,WO;;US,0,G06Q30/0603;;G06Q40/08;;G16H15/00;;G16H20/13;;G06Q30/0603;;G06Q40/08;;G16H10/60;;G16H15/00;;G16H20/13,G06Q30/06;;G06Q40/08;;G16H10/60;;G16H15/00;;G16H20/13,,0,0,,,,ACTIVE
42,EP,A1,EP 3719494 A1,096-774-099-018-835,2020-10-07,2020,EP 20154468 A,2020-01-30,EP 20154468 A,2020-01-30,USING IN-LINE MULTI-ANGLE-LIGHT-SCATTERING (MALS) DETECTORS FOR ESTABLISHING DIGITAL TWINS OF CHROMATOGRAPHY UNIT OPERATIONS,What is described herein relates to the use of In-Line Multi Angle Light Scattering for establishing a digital model of a chromatography unit operation.,BAYER AG,BUYEL JOSCHKA,,https://lens.org/096-774-099-018-835,Patent Application,yes,2,2,1,096-774-099-018-835,EP,1,096-774-099-018-835,EP,0,G01N30/8693;;G01N30/74;;G01N2030/8813;;G01N2030/8831,G01N30/86;;G01N30/74;;G01N30/88,,4,3,058-150-839-379-959;;002-559-920-584-855;;061-919-468-588-281,10.1021/mp300513j;;pmc3573692;;23311475;;8765649;;10.1016/0021-9673(96)00134-3;;10.3168/jds.s0022-0302(03)73909-5;;14594226,"WIKIPEDIA: ""4/07/2020 Multiangle light scattering -Wikipedia Multiangle light scattering"", WIKIPEDIA.ORG, 14 October 2019 (2019-10-14), XP055715909, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Multiangle_light_scattering&oldid=921242598> [retrieved on 20200717];;XIAOYI YANG ET AL: ""Molecular Characterization and Functional Activity of an IL-15 Antagonist MutIL-15/Fc Human Fusion Protein"", MOLECULAR PHARMACEUTICS, vol. 10, no. 2, 22 January 2013 (2013-01-22), US, pages 717 - 727, XP055582655, ISSN: 1543-8384, DOI: 10.1021/mp300513j;;ASTAFIEVA I V ET AL: ""Absolute on-line molecular mass analysis of basic fibroblast growth factor and its multimers by reversed-phase liquid chromatography with multi-angle laser light scattering detection"", JOURNAL OF CHROMATOGRAPHY A, ELSEVIER, AMSTERDAM, NL, vol. 740, no. 2, 2 August 1996 (1996-08-02), pages 215 - 229, XP004020139, ISSN: 0021-9673, DOI: 10.1016/0021-9673(96)00134-3;;T. WANG ET AL: ""Use of Multi-Angle Laser Light Scattering and Size-Exclusion Chromatography to Characterize the Molecular Weight and Types of Aggregates Present in Commercial Whey Protein Products"", JOURNAL OF DAIRY SCIENCE, vol. 86, no. 10, 1 October 2003 (2003-10-01), US, pages 3090 - 3101, XP055715011, ISSN: 0022-0302, DOI: 10.3168/jds.S0022-0302(03)73909-5",DISCONTINUED
43,WO,A1,WO 2022/255867 A1,026-537-179-973-463,2022-12-08,2022,NL 2022050298 W,2022-05-31,EP 21176833 A,2021-05-31,PROTEIN BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD),"The invention relates to methods for typing and analysing blood, serum or plasma samples of subjects for the presence of protein biomarkers for non- alcoholic fatty liver disease (NAFLD), and to methods for classifying and diagnosing subjects on the basis of such protein biomarkers and/or for monitoring treatment of NAFLD.",TNO,HANEMAAIJER JAN ROELAND OCCO;;VAN KOPPEN ARIANNE;;VERSCHUREN LARS,,https://lens.org/026-537-179-973-463,Patent Application,yes,4,0,4,022-724-166-978-503;;026-537-179-973-463;;100-218-620-871-796;;024-650-089-628-684,EP;;WO;;US;;CA,4,022-724-166-978-503;;026-537-179-973-463;;100-218-620-871-796;;024-650-089-628-684,EP;;WO;;US;;CA,0,G01N2800/085;;G01N2800/56;;G01N33/6893;;G01N2800/60;;G01N33/6893;;G01N2800/085;;G01N2800/52;;G01N2800/60,G01N33/68,,8,8,098-551-348-944-587;;028-748-899-262-443;;065-865-791-339-669;;098-551-348-944-587;;057-571-668-004-632;;056-516-614-201-712;;168-834-983-717-321;;067-220-965-320-998,10.1016/j.jcmgh.2017.10.001;;29276754;;pmc5738456;;10.1016/j.jhep.2013.07.042;;23973932;;27102725;;10.1111/liv.13150;;10.1016/j.jcmgh.2017.10.001;;29276754;;pmc5738456;;30448594;;10.1016/j.cgh.2018.11.004;;10.1111/j.1478-3231.2005.01209.x;;16448452;;32439497;;10.1053/j.gastro.2020.05.046;;10.1002/hep.20701;;15915461,"VAN KOPPEN ARIANNE ET AL: ""Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model"", CMGH CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, vol. 5, no. 1, 1 January 2018 (2018-01-01), pages 83 - 98.e10, XP055809966, ISSN: 2352-345X, DOI: 10.1016/j.jcmgh.2017.10.001;;CUSI, K.CHANG, Z.HARRISON, S.LOMONACO, R.BRIL, F.ORSAK, B.ORTIZ-LOPEZ, C.HECHT, J.FELDSTEIN, A.E.WEBB, A. ET AL.: ""Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease"", J. HEPATOL., vol. 60, 2014, pages 167 - 174, XP028801938, DOI: 10.1016/j.jhep.2013.07.042;;KAZANKOV, K.BARRERA, F.JON MOLLER, H.CHIARA ROSSO, C.BUGIANESI, E.DAVID, E.IBRAHIM KAMAL JOUNESS, R.ESMAILI, S.ESLAM, M.MCLEOD, D.: ""The macrophage activation marker sCD163 is associated with morphological disease stages patients with non-alcoholic fatty liver disease"", LIVER INT., vol. 36, 2016, pages 1549 - 1557;;VAN KOPPEN AVERSCHUREN LVAN DEN HOEK AMVERHEIJ JMORRISON MCLI KNAGABUKURO HCOSTESSI ACASPERS MPMVAN DEN BROEK TJ: ""Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model"", CELL MOL GASTROENTEROL HEPATOL, vol. 5, no. 1, 14 October 2017 (2017-10-14), pages 83 - 98;;LOOMBA, R.JAIN, A.DIEHL, A.M.GUY, C.D.PORTENIER, D.SUDAN, R.SINGH, S.FAULKNER, C.RICHARDS, L.HESTER, K.D. ET AL.: ""Validation of Serum Test for Advanced Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis"", CLIN. GASTROENTEROL. HEPATOL., vol. 17, 2019, pages 1867 - 1876;;PALEKAR, N.A.NAUS, R.LARSON, S.P.WARD, J.HARRISON, S.A.: ""Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease"", LIVER INT, vol. 26, 2006, pages 151 - 156, XP055199208, DOI: 10.1111/j.1478-3231.2005.01209.x;;RATZIU V.FRIEDMAN S. L.: ""Why do so many NASH trials fail"", GASTROENTEROLOGY, vol. S0016-5085, no. 20, 18 May 2020 (2020-05-18), pages 30680 - 6;;KLEINER DEBRUNT EMVAN NATTA MBEHLING CCONTOS MJCUMMINGS OWFERRELL LDLIU YCTORBENSON MSUNALP-ARIDA A: ""Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease"", HEPATOLOGY, vol. 41, no. 6, June 2005 (2005-06-01), pages 1313 - 21",PENDING
44,US,A1,US 2023/0377009 A1,074-250-056-772-496,2023-11-23,2023,US 202318137837 A,2023-04-21,US 202318137837 A;;US 202117228198 A;;US 201113107322 A;;US 33424210 P,2010-05-13,PROSPECTIVE MANAGEMENT SYSTEM FOR MEDICAL BENEFIT PRESCRIPTIONS,"The present invention provides an interactive, electronic, knowledge-based ordering process for specialty/biotech pharmaceuticals (medically coded drugs) which results in less waste, improved procedural efficiencies, and greater cost savings than the current ordering systems. The knowledge-base of the system is based on the health plan's clinical policies as well as the status of the patient and their entitled benefits with the health plan, and it is applied in an interactive manner through a web-enabled system which provides a real-time, prospective examination and control over requests for authorization to dispense the medically coded drugs. The system also includes a feedback loop from the specialty pharmacies to provide information on the medicines that have actually been dispensed. The system also provides to the patient, educational material and adherence reminders to affect therapeutic outcomes.",AXON HEALTHCARE SERVICES LLC,SAMPSON MELISSA;;CHARLES MOHAN P;;ESCUDER MICHAEL,AXON HEALTHCARE SERVICES LLC (2023-03-24);;EVERSANA LIFE SCIENCE SERVICES LLC (2023-08-07),https://lens.org/074-250-056-772-496,Patent Application,yes,3,0,9,090-303-796-811-012;;062-570-218-711-598;;053-375-603-761-217;;074-250-056-772-496;;070-429-670-838-541;;040-307-512-190-838;;176-004-846-438-569;;098-378-207-420-388;;190-017-930-175-319,WO;;US,9,090-303-796-811-012;;062-570-218-711-598;;053-375-603-761-217;;074-250-056-772-496;;070-429-670-838-541;;040-307-512-190-838;;176-004-846-438-569;;098-378-207-420-388;;190-017-930-175-319,WO;;US,0,G06Q30/0603;;G16H20/13;;G06Q40/08;;G16H15/00;;G06Q30/0603;;G16H10/60;;G16H15/00;;G16H20/13;;G06Q40/08,G06Q30/0601;;G06Q40/08;;G16H10/60;;G16H15/00;;G16H20/13,,0,0,,,,PENDING
45,WO,A1,WO 2021/067191 A1,100-035-957-958-289,2021-04-08,2021,US 2020/0053102 W,2020-09-28,US 201962908195 P;;US 202062960031 P;;US 202063077978 P,2019-09-30,COMPOSITIONS AND METHODS FOR AN IL-17 TARGET ENGAGEMENT ASSAY WITH SMALL MOLECULE MODULATORS,Methods to measure free IL-17 in a sample comprising IL-17 and a small molecule modulator of IL-17.,JANSSEN BIOTECH INC,BLEVITT JONATHAN;;DEPRIMO SAMUEL;;STRASNER AMY;;LEUNG WAI PING;;DE LEON-TALBADO AIMEE;;XUE XIAOHUA;;GOLDBERG STEVEN,,https://lens.org/100-035-957-958-289,Patent Application,yes,3,0,17,143-507-200-856-312;;183-777-105-206-849;;179-320-945-767-45X;;013-708-240-363-675;;067-412-770-612-09X;;110-239-166-972-487;;036-678-764-638-780;;085-600-920-168-387;;100-035-957-958-289;;027-310-768-329-959;;196-791-131-432-738;;082-608-798-104-159;;013-479-266-871-276;;126-629-038-092-009;;139-610-046-539-300;;065-670-550-446-498;;114-689-801-221-679,AU;;JP;;US;;CA;;MX;;BR;;PH;;KR;;EP;;CN;;ES;;IL;;WO,29,143-507-200-856-312;;021-260-556-379-718;;179-320-945-767-45X;;183-777-105-206-849;;013-708-240-363-675;;067-412-770-612-09X;;100-035-957-958-289;;110-875-952-363-23X;;196-791-131-432-738;;119-451-885-711-289;;181-997-147-294-033;;160-698-899-062-460;;082-608-798-104-159;;139-610-046-539-300;;065-670-550-446-498;;114-689-801-221-679;;058-402-043-503-203;;160-123-990-290-045;;036-678-764-638-780;;085-600-920-168-387;;110-239-166-972-487;;027-310-768-329-959;;085-538-746-914-019;;147-279-696-458-804;;012-275-380-307-424;;013-479-266-871-276;;126-629-038-092-009;;059-913-463-431-817;;134-315-333-846-342,AU;;JP;;US;;CA;;MX;;BR;;PH;;KR;;EP;;CN;;IL;;ES;;WO,39,G01N33/6869;;G01N2333/54;;C07K16/244;;G01N33/6869;;G01N2333/54;;C07K16/244;;G01N33/6869;;C07K16/244;;G01N2333/54;;C07K16/244;;G01N33/6869;;G01N2333/54,G01N33/68;;C07K16/24,,6,5,010-728-776-357-846;;041-959-736-167-67X;;053-400-548-958-106;;028-862-168-091-90X;;180-631-728-571-083,10.1016/j.jim.2010.09.004;;20833179;;10.1208/s12248-018-0280-z;;30547287;;10.2210/pdb5hi4/pdb;;10.2210/pdb5hi3/pdb;;27527709;;pmc4985813;;10.1038/srep30859;;10.2210/pdb5hi5/pdb;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1351/pac197645010011,"DEFORGE L E ET AL: ""Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 362, no. 1-2, 31 October 2010 (2010-10-31), pages 70 - 81, XP027509592, ISSN: 0022-1759, [retrieved on 20100909], DOI: 10.1016/J.JIM.2010.09.004;;PENG KUN ET AL: ""Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A"", THE AAPS JOURNAL, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 21, no. 1, 13 December 2018 (2018-12-13), pages 1 - 9, XP036665454, DOI: 10.1208/S12248-018-0280-Z;;LIU, S. ET AL.: ""Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists"", SCIENTIFIC REPORTS, vol. 6, 2016, pages 30859, XP055625254, DOI: 10.1038/srep30859;;ALTSCHUL SF ET AL., NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 3402;;GENBANK , no. NM_002190.3;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30",PATENTED
46,EP,A2,EP 4120291 A2,173-934-779-040-359,2023-01-18,2023,EP 22189399 A,2016-06-30,US 201562186741 P;;EP 16818776 A;;US 2016/0040342 W,2015-06-30,COATINGS FOR EXTREME ULTRAVIOLET AND SOFT X-RAY OPTICS,"Coatings for use in the extreme ultraviolet / soft X-ray spectrum/DUV from 0.1nm to 250nm include one or more sub-wavelength ""A-layers"" alternating with sub-wavelength ""B-layers."" The A-layers may include Group 1, Group 2 and Group 18 materials. The B-layers may include transition metal, lanthanide, actinide, or one of their combinations. The A-layers and/or the B-layers may include nanostructures with features sized or shaped similarly to expected defects. Additional top layers may include higher-atomic-number A-layer materials, hydrophobic materials, or charged materials. Such a material may be used to make components such as mirrors, lenses or other optics, panels, lightsources, photomasks, photoresists, or other components for use in applications such as lithography, wafer patterning, astronomical and space applications, biomedical, biotech applications, or other applications.",JAISWAL SUPRIYA,JAISWAL SUPRIYA,,https://lens.org/173-934-779-040-359,Patent Application,yes,0,0,15,082-922-106-726-076;;054-043-669-453-474;;081-697-053-439-81X;;170-233-454-398-01X;;120-052-732-469-863;;011-940-677-960-353;;173-934-779-040-359;;005-436-931-083-270;;186-964-501-241-470;;005-617-453-382-526;;106-947-000-557-681;;192-698-587-857-214;;087-977-337-132-435;;124-858-991-780-056;;067-319-955-842-573,JP;;KR;;EP;;CN;;WO;;US;;TW,15,082-922-106-726-076;;054-043-669-453-474;;081-697-053-439-81X;;170-233-454-398-01X;;120-052-732-469-863;;011-940-677-960-353;;173-934-779-040-359;;005-436-931-083-270;;186-964-501-241-470;;005-617-453-382-526;;106-947-000-557-681;;067-319-955-842-573;;087-977-337-132-435;;192-698-587-857-214;;124-858-991-780-056,JP;;KR;;EP;;CN;;WO;;US;;TW,0,G21K2201/067;;G21K1/062;;G21K1/062;;G21K2201/067;;G21K1/062;;G21K2201/067,G21K1/06,,0,0,,,,PENDING
47,EP,A1,EP 4352197 A1,088-220-798-289-576,2024-04-17,2024,EP 22734079 A,2022-06-07,US 202163197665 P;;EP 21193332 A;;US 2022/0032426 W,2021-06-07,CELL CULTURE VESSEL FOR USE IN MANUFACTURING CELL PRODUCTS,,SOTIO BIOTECH INC,SOTIO BIOTECH INC,"HODGE, GEOFFREY L. (2024-08-07)",https://lens.org/088-220-798-289-576,Patent Application,yes,0,0,5,008-113-700-776-566;;088-220-798-289-576;;175-759-108-818-26X;;183-460-128-526-065;;106-996-359-494-470,AU;;EP;;WO;;US;;CA,5,008-113-700-776-566;;088-220-798-289-576;;175-759-108-818-26X;;183-460-128-526-065;;106-996-359-494-470,AU;;EP;;WO;;US;;CA,0,C12M23/14;;C12M23/28;;C12M23/34;;C12M29/00;;C12M23/48;;C12M23/02;;C12M27/02;;C12M23/24;;C12M23/34;;C12M41/14;;C12M41/44,C12M1/00;;C12M1/02;;C12M1/36;;C12M3/00,,0,0,,,,PENDING
48,IL,A,IL 273907 A,133-077-098-663-660,2021-10-31,2021,IL 27390720 A,2020-04-10,IL 27390720 A,2020-04-10,Streaming of substance capable of carrying oxygen and carbon di-oxide through the intestine for gas exchange with blood,,BIOTECH ANATOMY LTD,BIOTECH ANATOMY LTD,,https://lens.org/133-077-098-663-660,Patent Application,no,0,0,1,133-077-098-663-660,IL,1,133-077-098-663-660,IL,0,,,,0,0,,,,PENDING
49,US,A1,US 2024/0247235 A1,071-798-663-537-003,2024-07-25,2024,US 201916972379 A,2019-06-06,IT 201800006076 A;;IB 2019054718 W,2018-06-06,niPSCs DERIVED FROM SOMATIC CELLS,"A method obtains naive induced iPSCs (niPSCs) from mammalian somatic cells. The method includes a transgene cocktail delivery to somatic cells in a microfluidic setting, including a first step of Mesenchymal to Epithelial Transition (MET) and a second step of colonies generation.",UNIV DEGLI STUDI PADOVA;;FOND TELETHON,MARTELLO GRAZIANO;;ELVASSORE NICOLA;;PELLEGRINI MARCO;;GIULITTI STEFANO,UNIVERSITA' DEGLI STUDI DI PADOVA (2020-12-03);;FONDAZIONE TELETHON (2020-12-03),https://lens.org/071-798-663-537-003,Patent Application,yes,1,0,4,015-569-031-180-560;;071-798-663-537-003;;103-781-625-601-543;;140-634-608-784-220,EP;;WO;;US;;IT,4,015-569-031-180-560;;071-798-663-537-003;;103-781-625-601-543;;140-634-608-784-220,EP;;WO;;US;;IT,78,C12N5/0696;;C12N2501/602;;C12N2501/603;;C12N2501/604;;C12N2501/605;;C12N2501/606;;C12N5/0696;;C12N2501/603;;C12N2501/604;;C12N2506/1307;;C12N2501/606;;C12N2501/605;;C12N2501/727;;C12N2501/602,C12N5/074,,18,15,049-229-047-964-389;;094-719-376-909-181;;089-668-489-086-136;;003-999-335-140-642;;095-602-443-738-958;;095-386-043-355-68X;;021-708-180-207-039;;026-856-413-148-065;;060-336-224-383-692;;029-468-211-318-809;;092-090-042-407-597;;002-141-141-656-313;;081-857-576-921-998;;048-038-830-083-390;;060-155-105-951-279,10.1038/nmeth.3832;;27088312;;10.1038/nmeth.1593;;pmc3084903;;21478862;;19716359;;10.1016/j.stem.2009.08.001;;28343983;;10.1016/j.stem.2017.02.014;;pmc5459756;;24374290;;10.1016/j.scr.2013.11.010;;pmc4157340;;10.1126/science.282.5391.1145;;9804556;;10.1038/74447;;10748519;;10.1016/j.diff.2009.03.004;;19398262;;10.1073/pnas.1108595109;;22362888;;pmc3309723;;10.1016/b978-0-12-385942-6.00070-6;;26119873;;pmc4833179;;10.1002/stem.2085;;20569691;;pmc3162213;;10.1016/j.stem.2010.05.003;;10.1016/j.stem.2014.09.004;;25280221;;10.1016/j.gde.2015.07.005;;26291026;;pmc5628950;;pmc4534765;;28903029;;28903030;;10.1016/j.stem.2014.08.002;;10.1016/j.stem.2014.09.003;;25090446;;pmc4184977,"Luni, C., et. al. Nat Methods 13, 446–452 (2016) (Year: 2016);;Zhang, S., et. al. Stem Cell Rev and Rep 11, 24–38 (2015) (Year: 2015);;Chen G, et. al. Nat Methods. 2011 May;8(5):424-9) (Year: 2011);;Gafni, O., et. al. Nature 504, 282–286 (2013) (Year: 2013);;Yoshida, Yoshinori, et al. ""Hypoxia enhances the generation of induced pluripotent stem cells."" Cell stem cell 5.3 (2009): 237-241. (Year: 2009);;Collier AJ, et. al. Cell Stem Cell. 2017 Jun 1;20(6):874-890.e7 (Year: 2017);;Mallon BS, et. al. Stem Cell Res. 2014 Mar;12(2):376-86 (Year: 2014);;Thomson JA, et. al. Science. 1998 Nov 6;282(5391):1145-7 (Year: 1998);;Reubinoff BE, et. al. Nat Biotechnol. 2000 Apr;18(4):399-404 (Year: 2000);;Reijo Pera RA,et. al. Differentiation. 2009 Jul;78(1):18-23 (Year: 2009);;Lai YS, et. al. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3772-7 (Year: 2012);;UK House of Parliaments' Select Committee on Science and Technology, Fifth Report of Session 2006-07, Volume II, pages 76-77, 5 April 2007 (Year: 2007);;Dominiguez-Bendala et al., Handbook of Stem Cells, Chapter 70: Islet Cell Therapy and Pancreatic Stem Cells, pages 835-853, 2013 (Year: 2013);;Dodsworth BT, et. al. Stem Cells, Volume 33, Issue 11, November 2015, Pages 3181–3186 (Year: 2015);;Buecker C, et. al. Cell Stem Cell. 2010 Jun 4;6(6):535-46 (Year: 2010);;Fang R, et. al. Cell Stem Cell. 2014 Oct 2;15(4):488-497 (Year: 2014);;Manor, Yair S., et. al. Current opinion in genetics & development 34 (2015): 35-45 (Year: 2015);;Theunissen TW, et, al. Cell Stem Cell. 2014 Oct 2;15(4):471-487 (Year: 2014)",DISCONTINUED
50,US,A1,US 2023/0248058 A1,141-752-478-601-724,2023-08-10,2023,US 202318301804 A,2023-04-17,US 202318301804 A;;US 201916709555 A,2019-12-10,FLAVOR ELEMENTS AND METHODS OF PROVIDING NONVAPORIZED FLAVOR TO ELECTRONIC VAPORIZERS AND E-CIGARETTES,"The present disclosure describes a flavor element configured for providing flavor to a user of an electronic vaporizer, along with nicotine reduction methods. The flavor element includes a flavor material configured to provide the flavor and is configured to attach to the electronic vaporizer. When attached to the electronic vaporizer and during inhalation by the user using the electronic vaporizer, the flavor element is configured to provide the flavor to the user in parallel with an inhalable aerosol provided by the electronic vaporizer. The inhalable aerosol is provided by the electronic vaporizer by at least partially vaporizing a vaporizable substance via a vapor element. The flavor provided via the flavor material is separate from the vaporizable substance.",RUBIN DARREN,RUBIN DARREN,,https://lens.org/141-752-478-601-724,Patent Application,yes,1,0,5,075-029-253-662-476;;183-534-723-824-373;;184-005-713-487-29X;;141-125-306-835-935;;141-752-478-601-724,WO;;US,6,183-534-723-824-373;;075-029-253-662-476;;184-005-713-487-29X;;141-125-306-835-935;;141-752-478-601-724;;152-608-093-480-127,WO;;US,0,A24B15/167;;A24F40/20;;A24F40/30;;A61K31/05;;A61K31/352;;A24D3/18;;A23G3/48;;A24F40/30;;A24F40/20;;A24B15/167;;A61K31/352;;A61K36/185;;A23G3/34;;A61K31/658,A24F40/30;;A23G3/34;;A24B15/167;;A24F40/20;;A61K31/05;;A61K31/352;;A61K36/185,,0,0,,,,ACTIVE
51,WO,A1,WO 2025/199003 A1,138-190-066-191-239,2025-09-25,2025,US US2025/020181,2025-03-17,"US 63/5/066,687",2024-03-18,METHODS AND COMPOSITIONS FOR REDUCING RESIDUAL HERBICIDES,"The present invention is directed to methods of eluting protoporphyrinogen oxidase inhibitors from agricultural equipment comprising contacting the agricultural equipment with a composition comprising one or more amines. The present invention is further directed to compositions for eluting protoporphyrinogen oxidase inhibitors from agricultural equipment comprising one or more amines. The present invention is further directed to methods of degrading protoporphyrinogen oxidase (""PPO"") inhibitors comprising contacting the PPO inhibitors with an effective amount of a composition comprising one or more amines. The present invention is further directed to compositions for degrading protoporphyrinogen oxidase inhibitors comprising an effective amount of one or more amines.",VALENT U.S.A. LLC,"ARNDT, Timothy, Stuart;;NELSON, Kenneth, Marvin;;PAWLAK, John, Andrew;;MAURER, Joel, Jason;;CLAY, Patrick, Allen;;GOHRE, Kirk;;LANDRY, Randall, Lee;;KOHRT, Jonathon, Ryan;;PARIKH, Lipi, Pradeepkumar;;GRIFFIN, Roy, Matthew;;LIN, Brian",,https://lens.org/138-190-066-191-239,Patent Application,yes,0,0,1,138-190-066-191-239,WO,1,138-190-066-191-239,WO,0,,A01N33/02;;A01N33/04;;A01N47/08,,0,0,,,,UNKNOWN
52,WO,A1,WO 2021/233664 A1,005-707-434-031-084,2021-11-25,2021,EP 2021061518 W,2021-05-03,EP 20175682 A,2020-05-20,DEVICE AND METHOD FOR DETERMINING A VIABILITY AND/OR A CELL COUNT OF BIOLOGICAL CELLS IN A CELL SUSPENSION CULTURE BY MEANS OF COLLIMATED TRANSMISSION,The present invention relates to a device (100) and method for determining a viability and/or a cell count of biological cells in a cell suspension culture by means of collimated transmission. The device (100) comprises: - an illumination source (1) for generating an electromagnetic illumination beam; - beam manipulation means for collimating the illumination beam; and - a detection unit (13) for detecting an electromagnetic transmission beam being a portion of the collimated illumination beam which has been transmitted through a sample (6) of the cell suspension culture.,SARTORIUS STEDIM BIOTECH GMBH;;INST FUER LASERTECHNOLOGIE IN DER MEDIZIN UND MESSTECHNIK STIFTUNG BUERGERLICHES RECHT,NOTHELFER STEFFEN;;KIENLE ALWIN;;FOSCHUM FLORIAN;;HOEHSE MAREK,,https://lens.org/005-707-434-031-084,Patent Application,yes,4,0,4,114-054-025-833-023;;120-248-910-422-166;;048-906-107-982-941;;005-707-434-031-084,EP;;WO;;US,4,114-054-025-833-023;;120-248-910-422-166;;048-906-107-982-941;;005-707-434-031-084,EP;;WO;;US,0,C12M41/46;;C12M41/36;;C12M41/46;;C12M41/36,C12M1/34,,0,0,,,,PENDING
53,US,A1,US 2024/0216505 A1,023-671-837-805-452,2024-07-04,2024,US 202418440816 A,2024-02-13,US 202418440816 A;;US 2022/0040478 W;;US 202163275714 P;;US 202163234001 P,2021-08-17,INDUCIBLE CYTOKINE PRODRUG AND PD-1/PD-L1 COMBINATION THERAPY,"This disclosure relates to methods and compositions for treating cancer including lymphoma using an inducible cytokine prodrug, and to a combination therapy comprising an inducible cytokine prodrug in combination with anti-PD-1 and anti-PD-L1 antibodies.",WEREWOLF THERAPEUTICS INC,WINSTON WILLIAM;;HICKLIN DANIEL;;SALMERON-GARCIA JOSE ANDRES;;SEIDEL-DUGAN CYNTHIA;;BRODKIN HEATHER;;STEINER PHILIPP,WEREWOLF THERAPEUTICS INC (2022-08-31),https://lens.org/023-671-837-805-452,Patent Application,yes,0,0,7,099-216-075-814-004;;005-004-004-505-795;;185-985-118-321-001;;023-671-837-805-452;;003-246-508-329-27X;;097-215-913-565-645;;090-957-070-180-410,AU;;JP;;EP;;WO;;US;;TW;;CA,7,099-216-075-814-004;;005-004-004-505-795;;023-671-837-805-452;;185-985-118-321-001;;003-246-508-329-27X;;097-215-913-565-645;;090-957-070-180-410,AU;;JP;;EP;;WO;;US;;TW;;CA,0,A61K38/21;;A61P35/00;;C07K14/555;;A61K2039/505;;C07K16/2818;;A61K39/3955;;C07K14/55;;C07K14/5434;;C07K2319/31;;C07K2319/30;;C07K2319/50;;A61K38/2013;;A61K38/208;;A61K9/0019;;A61K47/6889;;A61K47/643;;A61K47/65;;A61K47/6813;;A61P35/00;;A61K38/2013;;A61K38/208;;A61K38/212;;A61K38/215;;A61K38/217;;A61K39/3955,A61K39/395;;A61K38/20;;A61K38/21;;A61K47/64;;A61K47/65;;A61K47/68;;A61P35/00,,0,0,,,,PENDING
54,WO,A1,WO 2024/013149 A1,033-580-341-379-524,2024-01-18,2024,EP 2023069146 W,2023-07-11,US 202263388358 P;;US 202263390799 P,2022-07-12,LIPID NANOPARTICLE PRODUCTION SYSTEM AND METHOD OF MONITORING AND CONTROLLING THE SAME,"The present invention relates to automated nanoparticle synthesis systems and computer-implemented methods of monitoring and controlling a process of manufacturing lipid nanoparticles (LNPs) containing nucleic acid cargo. The present invention furthermore relates to a computer program product comprising computer-readable instructions, which, when loaded and executed on a computer system, causes the computer system to perform operations according to said methods.",SARTORIUS STEDIM BIOTECH GMBH,POLLARD DAVID;;OLSZOWY MICHAEL;;DEHGHANI MEHDI;;AKBARI SAMIN;;WANG FUJUN;;TAKEDA YUJI,,https://lens.org/033-580-341-379-524,Patent Application,yes,1,2,5,086-958-312-281-08X;;033-580-341-379-524;;067-698-890-962-904;;167-455-965-104-349;;053-240-724-460-631,JP;;KR;;EP;;CN;;WO,5,067-698-890-962-904;;033-580-341-379-524;;167-455-965-104-349;;086-958-312-281-08X;;053-240-724-460-631,KR;;JP;;EP;;CN;;WO,0,B01J19/0046;;B01J2219/00691;;B01J2219/00734;;B01J2219/00389;;B01J2219/00391;;B01J2219/0036;;B01J2219/00317;;G05D21/02;;B01L2300/0867;;B01J19/0046;;G05D21/02;;B01J2219/00691;;B01J2219/00734;;B01J2219/00389;;B01J2219/00391;;B01J2219/0036;;B01J2219/00317;;B01L2300/0867,B01J19/00;;C40B50/00;;G05D21/00,,1,1,031-242-716-793-55X,33639228;;10.1016/j.ijpharm.2021.120392,"FAN YUCHEN ET AL: ""Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 599, 25 February 2021 (2021-02-25), XP086531592, ISSN: 0378-5173, [retrieved on 20210225], DOI: 10.1016/J.IJPHARM.2021.120392",PENDING
55,US,A1,US 2023/0109208 A1,026-632-286-251-007,2023-04-06,2023,US 202117909377 A,2021-03-08,US 202117909377 A;;US 202063027128 P;;US 2021/0021402 W,2020-05-19,METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY,"The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.",HUMANIGEN INC,DURRANT CAMERON;;CHAPPELL DALE,,https://lens.org/026-632-286-251-007,Patent Application,yes,0,0,1,026-632-286-251-007,US,17,111-915-979-409-664;;144-632-442-132-172;;026-632-286-251-007;;182-108-635-350-915;;178-078-151-728-409;;074-707-913-431-862;;006-336-344-087-750;;163-041-693-578-050;;113-722-365-387-183;;176-849-424-365-229;;002-484-367-491-288;;119-133-139-600-946;;067-605-204-292-547;;074-359-018-107-953;;077-687-908-355-467;;115-889-297-133-372;;028-923-096-621-866,JP;;KR;;AU;;IL;;EP;;CN;;WO;;US;;TW;;CA;;MX;;BR,0,A61P11/00;;A61K9/0019;;A61K9/08;;A61K39/395;;A61K45/06;;A61K2039/505;;A61P29/00;;A61P31/14;;C07K16/243;;C07K2317/76;;A61K39/3955;;A61K9/0019;;A61K45/06;;A61K2039/545;;A61P11/00;;A61P29/00;;A61P31/14,A61K39/395;;A61K9/00;;A61K45/06;;A61P11/00;;A61P29/00;;A61P31/14,,0,0,,,,PENDING
56,WO,A1,WO 2021/183456 A1,002-484-367-491-288,2021-09-16,2021,US 2021/0021402 W,2021-03-08,US 202062986751 P;;US 202063027128 P;;US 202063072716 P;;US 202063088971 P,2020-03-08,METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY,"The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.",HUMANIGEN INC,DURRANT CAMERON;;CHAPPELL DALE,,https://lens.org/002-484-367-491-288,Patent Application,yes,11,9,12,111-915-979-409-664;;144-632-442-132-172;;074-359-018-107-953;;077-687-908-355-467;;182-108-635-350-915;;178-078-151-728-409;;006-336-344-087-750;;074-707-913-431-862;;115-889-297-133-372;;002-484-367-491-288;;067-605-204-292-547;;119-133-139-600-946,JP;;AU;;KR;;IL;;EP;;CN;;WO;;US;;CA;;MX;;BR,17,111-915-979-409-664;;144-632-442-132-172;;026-632-286-251-007;;182-108-635-350-915;;178-078-151-728-409;;074-707-913-431-862;;006-336-344-087-750;;163-041-693-578-050;;113-722-365-387-183;;176-849-424-365-229;;002-484-367-491-288;;119-133-139-600-946;;067-605-204-292-547;;074-359-018-107-953;;077-687-908-355-467;;115-889-297-133-372;;028-923-096-621-866,JP;;KR;;AU;;IL;;EP;;CN;;WO;;US;;TW;;CA;;MX;;BR,0,A61K31/706;;A61P11/00;;A61P29/00;;C07K16/243;;A61K2039/505;;A61K2039/55;;A61K39/3955;;C07K2317/76;;A61K31/706;;C07K2317/76;;A61K39/3955;;A61K2039/505;;A61P29/00;;A61K2039/55;;C07K16/243;;A61P11/00;;C07K16/243;;A61K31/513;;A61K45/06;;A61K31/14;;C07K2317/24;;C07K2317/76;;A61K2039/505;;A61K2039/55;;C07K16/243;;A61K31/706;;A61P29/00;;A61P11/00;;A61K39/3955,C07K16/24,,8,5,036-567-351-721-701;;073-275-405-239-505;;153-203-408-850-761;;001-012-414-042-409;;075-948-805-963-208,10.1101/2020.02.12.945576;;26315600;;10.1038/emm.2015.76;;pmc4558490;;pmc1483912;;16796401;;10.1371/journal.pmed.0030237;;32113510;;pmc7128218;;10.1016/s1473-3099(20)30141-9;;10.1016/j.apsb.2020.02.008;;pmc7102550;;32292689,"ZHOU ET AL.: ""Aberrant pathogenic GM-CSF+ T cells and inflammatory CD 14+ CD 16+ monocytes in severe pulmonary syndrome patients of a new coronavirus"", BIORXIV, 20 February 2020 (2020-02-20), XP055856718, Retrieved from the Internet <URL:http://www.biorxiv.org/content/10.1101/2020.02.12.945576v1> [retrieved on 20210707];;DURAI ET AL.: ""Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control"", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 47, no. 8, 28 August 2015 (2015-08-28), pages 1 - 10, XP055856720;;JAN TER MEULEN, EDWARD N VAN DEN BRINK, LEO L. M POON, WILFRED E MARISSEN, CYNTHIA S. W LEUNG, FREEK COX, CHUNG Y CHEUNG, ARJEN Q : ""Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants"", PLOS MEDICINE, vol. 3, no. 7, pages e237, XP055736906, DOI: 10.1371/journal.pmed.0030237;;""Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine"", 28 February 2020 (2020-02-28), XP055856724, Retrieved from the Internet <URL:https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single> [retrieved on 20210708];;CHEN LONG; XIONG JING; BAO LEI; SHI YUAN: ""Convalescent plasma as a potential therapy for COVID-19"", THE LANCET INFECTIOUS DISEASES, vol. 20, no. 4, 27 February 2020 (2020-02-27), AMSTERDAM, NL , pages 398 - 400, XP086103946, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(20)30141-9;;BIOXYTRAN INC.: ""Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25"", 5 February 2020 (2020-02-05), XP055856725, Retrieved from the Internet <URL:https://www.globenewswire.com/fr/news-release/2020/02/05/1980137/0/en/Bioxytran-Seeking-Partners-for-Late-Stage-Treatment-of-Wuhan-Coronavirus-using-BXT-25.html> [retrieved on 20210506];;WU CANRONG, LIU YANG, YANG YUEYING, ZHANG PENG, ZHONG WU, WANG YALI, WANG QIQI, XU YANG, LI MINGXUE, LI XINGZHOU, ZHENG MENGZHU, C: ""Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods"", ACTA PHARMACEUTICA SINICA B, vol. 10, no. 5, 1 May 2020 (2020-05-01), pages 766 - 788, XP055776753, ISSN: 2211-3835, DOI: 10.1016/j.apsb.2020.02.008;;See also references of EP 4118115A4",PENDING
57,CN,A,CN 115999189 A,193-765-820-054-076,2023-04-25,2023,CN 202310030818 A,2023-01-10,CN 202310030818 A,2023-01-10,Extraction equipment for biotechnological medicine production,"The invention discloses extraction equipment for biotech drug production, which comprises a case, one side of the upper surface of the case is provided with a feeding cavity, the inner wall of one side of the case is provided with a barrier plate, the center position of the upper surface of the case is provided with a U-shaped mounting plate, and the center position of the upper surface of the U-shaped mounting plate is provided with a mixing motor. An output shaft of the mixing motor penetrates through a through hole in the U-shaped mounting plate and is connected with a mixing shaft through a transmission, mixing paddles are arranged on the outer wall of the mixing shaft at intervals through connecting sleeves, and the other end of the mixing shaft penetrates through a through hole in the machine box and is connected with a bearing at the center position of the upper surface of a blocking plate; and a U-shaped main pipeline is arranged on the lower surface of the barrier plate. The device can effectively avoid the emulsification or precipitation phenomenon, improve the extraction quality and the extraction efficiency, take certain anti-shaking measures on the device, prevent the device from being damaged, prolong the service life of the device, and is high in practicability.",HUBEI QIANDE ECOLOGICAL AGRICULTURE DEV CO LTD,LI MINGYI,,https://lens.org/193-765-820-054-076,Patent Application,no,3,0,1,193-765-820-054-076,CN,1,193-765-820-054-076,CN,0,,B01D11/02,,0,0,,,,PENDING
58,US,A1,US 2024/0100174 A1,143-206-900-496-961,2024-03-28,2024,US 202318236078 A,2023-08-21,US 202318236078 A;;US 202263399437 P,2022-08-19,PROTEIN-PEG INTERACTIONS THAT REDIRECT THE THERMAL UNFOLDING PATHWAY OF PEGYLATED HUMAN GALECTIN-3C,"Conjugation of polymers to proteins, including biomedically-relevant PEGylation, is a promising approach to address a central challenge of biologics and biotech: the lack of protein stability in demanding non-native environments. Application of conjugation is hindered by the lack of atomic level understanding of protein-polymerinteractions, preventing design of conjugates with predicted properties. An integrative structural and biophysical approach was used to address this challenge using a polymer-modified carbohydrate recognition domain of human galectin-3 (Gal3C), a lectin essential for cellular adhesion and potential biologic. Modification with PEG and other polymers dramatically increased Gal3C thermal stability and redirected its unfolding pathway through forming a stable intermediate. Distinct polymer properties which increased protein thermal stability were revealed. Structural details of Gal3C-polymer conjugates revealed by NMR pointed to the important role of polymer localization. Residues local to the site of conjugation were perturbed by polymer conjugation and these perturbations remained localized over a wide temperature range. For PEGylated conjugates, replacing key lysine residues within the PEG-perturbed region altered the protein-PEG interface and thermal unfolding behavior, providing mechanistic insight into rational design of conjugates that will expand the benefits of polymer conjugation.",UNIV FLORIDA,EDDY MATTHEW;;HARRIS MICHAEL;;PRITZLAFF AMANDA,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (2023-08-22),https://lens.org/143-206-900-496-961,Patent Application,yes,0,1,1,143-206-900-496-961,US,1,143-206-900-496-961,US,0,A61K47/60;;A61K47/58;;C07K14/4726;;C07K14/7056;;A61K47/60,A61K47/60;;C07K14/705,,0,0,,,,PENDING
59,WO,A1,WO 2022/192093 A1,113-722-365-387-183,2022-09-15,2022,US 2022/0019028 W,2022-03-04,US 2021/0021402 W;;US 202117216660 A;;US 202117306884 A,2021-03-08,METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY,"The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.",HUMANIGEN INC,DURRANT CAMERON;;CHAPPELL DALE,,https://lens.org/113-722-365-387-183,Patent Application,yes,8,0,3,176-849-424-365-229;;163-041-693-578-050;;113-722-365-387-183,WO;;US;;TW,17,111-915-979-409-664;;144-632-442-132-172;;026-632-286-251-007;;182-108-635-350-915;;178-078-151-728-409;;074-707-913-431-862;;006-336-344-087-750;;163-041-693-578-050;;113-722-365-387-183;;176-849-424-365-229;;002-484-367-491-288;;119-133-139-600-946;;067-605-204-292-547;;074-359-018-107-953;;077-687-908-355-467;;115-889-297-133-372;;028-923-096-621-866,JP;;KR;;AU;;IL;;EP;;CN;;WO;;US;;TW;;CA;;MX;;BR,0,A61P31/14;;C07K16/243;;A61K2039/505;;A61K2039/55;;C07K16/2866;;C07K2317/76;;A61K39/39541;;A61K39/3955;;A61P37/06;;A61P31/14;;A61K31/675;;A61K39/3955;;A61K45/06;;A61K2039/505;;A61K2039/545;;C07K16/243,A61K39/395;;A61P31/14;;C07K16/24,,4,3,032-819-835-105-449;;064-151-355-543-881;;021-064-945-803-406,32835256;;10.1016/s2665-9913(20)30170-3;;pmc7430344;;pmc7470718;;10.1016/j.mayocp.2020.08.038;;33153629;;pmc7360763;;10.1038/s41467-020-17189-2;;32665542,"DE LUCA G, CAVALLI G, CAMPOCHIARO C, DELLA-TORRE E, TOMELLERI A, BOFFINI N, FARINA N, DAGNA PROF L, ZANGRILLO A, METTE F, LANDONI : ""GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study"", LANCET RHEUMATOLOGY, 16 June 2020 (2020-06-16), pages e465 - e473, XP055971417, DOI: 10.1016/S2665-9913(20)30170-3;;TEMESGEN ZELALEM, ASSI MARIAM, SHWETA F.N.U., VERGIDIS PASCHALIS, RIZZA STACEY A., BAUER PHILIPPE R., PICKERING BRIAN W., RAZONABL: ""GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia"", MAYO CLINIC PROCEEDINGS, DOWDEN HEALTH MEDIA, INC, US, vol. 95, no. 11, 1 November 2020 (2020-11-01), US , pages 2382 - 2394, XP055971432, ISSN: 0025-6196, DOI: 10.1016/j.mayocp.2020.08.038;;SADEGH SEPIDEH, MATSCHINSKE JULIAN, BLUMENTHAL DAVID B., GALINDEZ GIHANNA, KACPROWSKI TIM, LIST MARKUS, NASIRIGERDEH REZA, OUBOUNY: ""Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing"", NATURE COMMUNICATIONS, vol. 11, no. 1, 1 December 2020 (2020-12-01), XP055971433, DOI: 10.1038/s41467-020-17189-2;;ANONYMOUS: ""Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25"", 5 February 2020 (2020-02-05), XP055856725, Retrieved from the Internet <URL:https://www.globenewswire.com/fr/news-release/2020/02/05/1980137/0/en/Bioxytran-Seeking-Partners-for-Late-Stage-Treatment-of-Wuhan-Coronavirus-using-BXT-25.html> [retrieved on 20211101]",PENDING
60,US,A1,US 2022/0177955 A1,011-592-642-019-995,2022-06-09,2022,US 202117406375 A,2021-08-19,CN 202011431450 A,2020-12-07,FLUORESCENT PCR METHOD FOR DETECTING HLA-B*15:02 ALLELE AND SPECIFIC PRIMER PROBE COMBINATION THEREOF,"Disclosed is a fluorescent PCR method for detecting HLA-B*15:02 allele and a specific primer probe combination. In the present disclosure, a set of primers and probes are designed based on an HLA-B*15:02 specific SNP gene locus by using TaqMan probe technology, combining another set of primers and probes corresponding to the internal reference gene β-Actin, and a set of primer probe for non-HLA-B*15:02 genes are designed to detect whether a DNA sample contains an HLA-B*15:02 gene and whether a sample is homozygous or heterozygous. Compared with the similar detection methods in the past, the technical scheme in the present disclosure inherits the advantages of high specificity, high throughput, high resolution, low cost, simple and convenient operation, process controllability and the like of the fluorescent PCR, and may detect whether a sample is homozygous or heterozygous.",SHAANXI LIFEGEN CO LTD,DAI PENGGAO;;ZHONG ZIHUA;;WANG HAO;;CAI ZHIYE;;MENG LEI;;WANG LE,SHAANXI LIFEGEN CO. LTD (2021-08-18),https://lens.org/011-592-642-019-995,Patent Application,yes,1,0,3,011-592-642-019-995;;089-403-313-108-393;;043-673-198-647-738,CN;;US,3,011-592-642-019-995;;089-403-313-108-393;;043-673-198-647-738,CN;;US,8,C12Q1/6858;;C12Q1/6827;;C12Q1/6858;;C12Q1/6881,C12Q1/6858;;C12Q1/6881,,3,2,007-490-726-370-932;;049-278-823-174-381,10.1093/nar/17.7.2503;;2785681;;pmc317639;;24519268;;10.1007/s12033-014-9734-4,"GenBank Accession No. MG886870.1 (Homo sapiens MHC class I antigen (HLA-B) gene, HLA-B*15var allele, complete cds, 2018. (Year: 2018);;Newton (Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS), Nucleic Acids Research, 17(7): 2503-2516, 1989. (Year: 1989);;Medrano (Guidelines for the Tetra-Primer ARMS-PCR Technique Development, Mol Biotechnol, 56: 599-608, 2014. (Year: 2014)",ACTIVE
61,WO,A1,WO 2023/023065 A1,003-246-508-329-27X,2023-02-23,2023,US 2022/0040478 W,2022-08-16,US 202163234001 P;;US 202163275714 P,2021-08-17,INDUCIBLE CYTOKINE PRODRUG AND PD-1/PD-L1 COMBINATION THERAPY,"Prodrugs typically include a native cytokine polypeptide that is attached to a cytokine blocking domain and typically a half-life extension domain, through a protease cleavable linker. This disclosure relates to methods and compositions for treating cancer including lymphoma using an inducible cytokine prodrug, and to a combination therapy comprising an inducible cytokine prodrug in combination with anti-PD-1 and anti-PD-L1 antibodies.",WEREWOLF THERAPEUTICS INC,WINSTON WILLIAM;;HICKLIN DANIEL;;SALMERON-GARCIA JOSE ANDRES;;SEIDEL-DUGAN CYNTHIA;;BRODKIN HEATHER;;STEINER PHILIPP,,https://lens.org/003-246-508-329-27X,Patent Application,yes,2,2,7,099-216-075-814-004;;005-004-004-505-795;;185-985-118-321-001;;023-671-837-805-452;;003-246-508-329-27X;;097-215-913-565-645;;090-957-070-180-410,AU;;JP;;EP;;WO;;US;;TW;;CA,7,099-216-075-814-004;;005-004-004-505-795;;023-671-837-805-452;;185-985-118-321-001;;003-246-508-329-27X;;097-215-913-565-645;;090-957-070-180-410,AU;;JP;;EP;;WO;;US;;TW;;CA,266,A61K38/21;;A61P35/00;;C07K14/555;;A61K2039/505;;C07K16/2818;;A61K39/3955;;C07K14/55;;C07K14/5434;;C07K2319/31;;C07K2319/30;;C07K2319/50;;A61K38/2013;;A61K38/208;;A61K9/0019;;A61K47/6889;;A61K47/643;;A61K47/65;;A61K47/6813;;A61P35/00;;A61K38/2013;;A61K38/208;;A61K38/212;;A61K38/215;;A61K38/217;;A61K39/3955,A61K38/20;;A61K38/21;;A61K39/395;;A61P35/00;;C07K14/54;;C07K14/555,,0,0,,,,PENDING
62,US,A1,US 2024/0317846 A1,163-041-693-578-050,2024-09-26,2024,US 202218280642 A,2022-03-04,US 202218280642 A;;US 202117306884 A;;US 202117216660 A;;US 2021/0021402 W;;US 2022/0019028 W,2021-03-08,METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY,"The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.",HUMANIGEN INC,DURRANT CAMERON;;CHAPPELL DALE,HUMANIGEN INC (2022-06-15),https://lens.org/163-041-693-578-050,Patent Application,yes,0,1,3,176-849-424-365-229;;163-041-693-578-050;;113-722-365-387-183,WO;;US;;TW,17,111-915-979-409-664;;144-632-442-132-172;;026-632-286-251-007;;182-108-635-350-915;;178-078-151-728-409;;074-707-913-431-862;;006-336-344-087-750;;163-041-693-578-050;;113-722-365-387-183;;176-849-424-365-229;;002-484-367-491-288;;119-133-139-600-946;;067-605-204-292-547;;074-359-018-107-953;;077-687-908-355-467;;115-889-297-133-372;;028-923-096-621-866,JP;;KR;;AU;;IL;;EP;;CN;;WO;;US;;TW;;CA;;MX;;BR,0,A61P31/14;;C07K16/243;;A61K2039/505;;A61K2039/55;;C07K16/2866;;C07K2317/76;;A61K39/39541;;A61K39/3955;;A61P37/06;;A61P31/14;;A61K31/675;;A61K39/3955;;A61K45/06;;A61K2039/505;;A61K2039/545;;C07K16/243,C07K16/24;;A61K31/675;;A61K39/00;;A61K39/395;;A61K45/06;;A61P31/14;;A61P37/06,,0,0,,,,PENDING
63,EP,A1,EP 3791870 A1,127-512-816-520-477,2021-03-17,2021,EP 20196973 A,2014-12-01,US 201361910580 P;;US 201461948242 P;;EP 18168252 A;;EP 14867950 A;;US 2014/0067977 W,2013-12-02,MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS,"The present invention relates to a compound having the structure of formula (III):wherein the C<sub>2</sub>-<sub>4</sub> alkyl is selected from the group consisting of ethyl, isopropyl, n-propyl, butyl, and t-butyl, or an N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof.",UNIV COLUMBIA,STOCKWELL BRENT R;;SKOUTA RACHID;;DIXON SCOTT,,https://lens.org/127-512-816-520-477,Patent Application,yes,5,0,12,189-934-343-589-798;;176-240-691-955-522;;104-527-415-704-889;;107-749-774-781-950;;178-763-070-760-904;;073-938-553-952-403;;124-838-927-713-061;;159-016-815-088-051;;127-512-816-520-477;;030-368-341-124-145;;098-610-482-160-238;;033-608-082-817-156,AU;;EP;;WO;;US,12,176-240-691-955-522;;098-610-482-160-238;;104-527-415-704-889;;107-749-774-781-950;;178-763-070-760-904;;159-016-815-088-051;;124-838-927-713-061;;073-938-553-952-403;;127-512-816-520-477;;033-608-082-817-156;;189-934-343-589-798;;030-368-341-124-145,AU;;EP;;WO;;US,24,A61K31/245;;A61K31/196;;A61K31/505;;A61K45/06;;C07C229/60;;C07C233/54;;C07C237/30;;C07C255/58;;C07C271/16;;C07C271/24;;C07C271/28;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2601/20;;C07C2603/72;;C07C2603/74;;C07D213/38;;C07D239/26;;C07D401/12;;C07C229/56;;A61K31/196;;A61K31/245;;A61K31/505;;A61K45/06;;C07C229/60;;C07C255/58;;C07C271/24;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2601/20;;C07C2603/72;;C07C2603/74;;C07D213/38;;C07D239/26;;C07D401/12,A61K31/245;;A61K31/137;;A61K31/196;;A61K31/505;;A61K45/06;;C07C229/56;;C07C229/60;;C07C233/54;;C07C237/30;;C07C255/58;;C07C271/16;;C07C271/24;;C07C271/28;;C07D213/38;;C07D239/26;;C07D401/12,,107,105,033-429-316-649-447;;090-749-638-658-16X;;093-164-067-371-688;;025-826-004-954-759;;075-639-488-193-131;;013-010-052-225-238;;160-639-404-102-548;;041-084-944-568-540;;094-472-649-877-807;;082-376-682-924-761;;049-323-454-453-421;;017-879-710-962-35X;;033-290-251-340-102;;029-307-497-000-056;;079-810-787-199-210;;025-830-478-947-683;;050-612-905-496-452;;063-154-549-605-355;;131-307-160-748-20X;;074-444-745-707-900;;042-525-879-819-75X;;012-432-586-880-142;;096-819-570-165-463;;063-157-688-160-003;;066-588-440-848-270;;000-485-771-855-364;;021-282-304-079-628;;071-663-007-448-012;;073-734-754-614-73X;;032-909-207-628-432;;066-612-064-242-335;;006-055-610-279-683;;063-769-705-913-984;;151-964-694-438-324;;078-860-967-399-622;;011-083-753-183-477;;039-933-602-505-939;;017-485-320-952-429;;020-119-757-232-596;;157-330-939-558-214;;059-166-793-309-885;;018-919-015-178-803;;080-428-439-651-942;;010-135-263-175-509;;112-217-040-718-438;;012-867-066-261-164;;008-861-019-402-057;;005-588-551-176-080;;044-026-193-143-392;;015-802-146-061-826;;028-352-077-943-943;;059-004-237-241-769;;119-355-153-496-325;;032-944-096-591-721;;015-583-704-199-380;;067-130-572-932-724;;042-708-047-285-988;;000-613-901-403-141;;035-105-940-401-711;;000-703-434-210-760;;000-020-742-133-223;;058-254-103-009-708;;009-208-061-502-873;;003-918-002-681-611;;000-848-985-358-881;;032-094-299-811-175;;010-704-580-653-356;;000-309-422-611-158;;041-683-419-873-541;;094-529-681-010-95X;;057-147-662-910-72X;;054-395-529-031-092;;095-706-974-736-093;;020-678-793-003-361;;052-347-841-491-588;;084-474-484-416-792;;048-774-455-086-674;;079-818-813-070-039;;109-918-041-049-030;;100-721-735-849-255;;006-623-075-628-37X;;047-264-215-421-633;;121-863-260-050-25X;;090-369-862-009-135;;062-653-819-438-324;;031-404-352-424-428;;070-031-709-665-888;;020-496-142-835-925;;171-919-583-460-003;;097-003-233-121-552;;030-406-991-297-579;;021-721-798-000-650;;047-539-348-462-666;;000-514-922-530-963;;135-719-103-269-276;;037-760-857-225-482;;071-423-416-916-910;;044-781-394-745-17X;;003-282-838-950-93X;;029-098-776-011-542;;039-019-531-776-402;;004-119-175-547-58X;;050-971-873-087-260;;020-856-421-759-140;;072-995-275-446-897,7298664;;10.1016/s0021-9258(18)43284-x;;10.1021/jo960057x;;11667239;;20943326;;10.1016/j.mehy.2010.09.003;;17828297;;10.1038/sj.onc.1210796;;10.1001/archneur.56.5.569;;10328252;;10.1055/s-2003-40888;;10096843;;10.1016/s0301-0082(98)00055-0;;10.1038/nrmicro2070;;19148178;;pmc2910423;;10.1038/1811199a0;;17250683;;10.1111/j.1471-4159.2006.04379.x;;9600992;;pmc27817;;10.1073/pnas.95.11.6480;;pmc3150500;;16908409;;10.1016/j.neuron.2006.07.011;;8456699;;pmc8332933;;pmc3795666;;24146952;;10.1371/journal.pone.0077023;;2908446;;10.1016/0896-6273(88)90162-6;;10.1016/j.ceb.2009.12.003;;20045303;;pmc2854308;;10.1177/1087057107312035;;18216396;;11490092;;16408008;;10.1038/nchembio711;;pmc2911955;;10.1002/cne.21667;;18314905;;pmc3366463;;10.1016/j.celrep.2012.03.010;;22675671;;24813850;;10.1016/j.cell.2014.04.018;;pmc4068710;;pmc3367386;;22632970;;10.1016/j.cell.2012.03.042;;12676586;;10.1016/s1535-6108(03)00050-3;;10.1016/s1090-3798(98)80006-8;;10727198;;20817278;;10.1016/j.cell.2010.08.014;;pmc2943017;;10.1016/j.arcmed.2007.11.011;;18279698;;16808630;;10.2350/06-01-0024.1;;10.1523/jneurosci.0477-04.2004;;15128855;;pmc6729451;;22078876;;pmc4511103;;10.1016/j.cell.2011.10.033;;24582829;;10.1016/j.semcdb.2014.02.006;;10.1021/ol202237j;;21894954;;11587223;;10.1038/sj.leu.2402238;;10.1158/0008-5472.can-08-1449;;18794128;;pmc2678915;;10.1517/17460441.2012.712513;;22873630;;16196389;;pmc8095889;;10.1111/j.1750-3639.2005.tb00525.x;;10.1093/jnen/62.5.441;;12769184;;019524512;;10.1016/j.cell.2009.05.021;;19524512;;pmc3018711;;10.1038/nchembio.467;;21079601;;15769103;;10.1021/jf030723c;;10.1016/j.bmcl.2006.01.032;;16455252;;7536895;;10.1038/374814a0;;22138129;;10.1016/j.bbadis.2011.11.014;;pmc3303936;;19493276;;pmc11158854;;10.1111/j.1349-7006.2009.01207.x;;10.2131/jts.28.1;;12696180;;20942471;;10.1021/jm100773e;;22286308;;10.1038/nm.2613;;10.1016/s0896-6273(00)80953-8;;9292733;;22237751;;10.1038/ki.2011.450;;23833261;;pmc3785275;;10.1681/asn.2012121169;;23818611;;10.1073/pnas.1305538110;;pmc3718149;;24476434;;10.1056/nejmra1310050;;pmc4035222;;pmc4243360;;24925726;;10.1681/asn.2014030262;;11259830;;10.1016/s0169-409x(00)00129-0;;pmc2527809;;18648370;;10.1038/sj.bjc.6604485;;19552996;;10.1016/j.pneurobio.2009.01.002;;10.1093/cvr/cvu146;;24920296;;10.1038/nrd3368;;21358738;;pmc4040417;;23974869;;10.1038/ng.2732;;21977007;;10.2217/fnl.10.41;;pmc3184508;;16564017;;10.1016/j.cell.2006.01.040;;8045729;;10.1007/bf02943258;;pmc1573611;;12466235;;10.1038/sj.bjp.0704986;;22101431;;pmc3262117;;10.1038/nature10642;;10.1016/0896-6273(89)90043-3;;2576375;;pmc3280949;;10.1126/science.1206727;;22033517;;16101559;;10.2174/1568007054546108;;10.1016/j.cell.2008.06.016;;18614015;;pmc2778844;;pmc3129895;;21490135;;10.1152/ajprenal.00033.2011;;10.1039/b108728m;;10.1016/j.neuint.2013.02.026;;pmc3653299;;23507328;;10.1126/scitranslmed.3001127;;pmc3734848;;10.1126/scisignal.3001127;;20686179;;10.1081/scc-120034169;;21753854;;10.1038/nature10167;;pmc3316487;;pmc3835913;;10.1155/2013/583438;;24303087;;20080789;;pmc2796909;;10.1073/pnas.0912074106;;7903353;;10.1046/j.1471-4159.1994.62010376.x;;21153060;;10.1007/s12035-010-8153-1;;22982598;;10.1016/j.freeradbiomed.2012.09.004;;10.1016/j.bmc.2009.01.019;;19200745;;19762597;;10.1126/science.1176326;;pmc3582197;;21940823;;10.1182/blood-2011-04-343541;;10.1074/jbc.274.17.11455;;10206947;;10.1073/pnas.1105941108;;pmc3102385;;21555567;;pmc3985476;;24592866;;10.1021/ja411006a;;10.1007/s10557-007-6035-1;;17665295;;10.1038/ki.1996.384;;8872959;;16023058;;10.1016/s1359-6446(05)03502-6;;9628898;;pmc2132785;;10.1083/jcb.141.6.1423;;10.1126/science.7878464;;7878464;;10.1016/j.ccr.2006.08.009;;16959615;;10.1038/nm.1865;;pmc3446847;;18724376;;pmc16675;;10.1073/pnas.110078997;;10869421;;10.1073/pnas.1106149108;;pmc3182736;;21896738;;pmc2929180;;10.1126/science.1176333;;19762596;;pmc3124093;;10.1038/nrc2960;;21102635;;10.1016/j.expneurol.2009.03.020;;pmc2752872;;19332058;;17762044;;10.1194/jlr.m700378-jlr200;;10.1073/pnas.0810199105;;19033189;;pmc2596212;;15055997;;10.1021/jm030528p;;10.1038/nature05859;;18355723;;10.1016/j.chembiol.2008.02.010;;pmc2683762;;8764581;;10.1046/j.1471-4159.1996.67020566.x;;10.1016/s0896-6273(02)00615-3;;11906693;;19498109;;10.1126/science.1172308,"ISHII, T.BANNAI, S.SUGITA, Y.: ""Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine"", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 256, 1981, pages 12387 - 12392;;ABDEL-MAGID, A. F.CARSON, K. G.HARRIS, B. D.MARYANOFF, C. A.SHAH, R. D., J. ORG. CHEM., vol. 61, 1996, pages 3849 - 3862;;ANITHA, M.NANDHU, M. S.ANJU, T. R.JES, P.PAULOSE, C. S.: ""Targeting glutamate mediated excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist--memantine"", MEDICAL HYPOTHESES, vol. 76, 2011, pages 138 - 140, XP027552200;;BANJAC, A.PERISIC, T.SATO, H.SEILER, A.BANNAI, S.WEISS, N.KOLLE, P.TSCHOEP, K.ISSELS, R.D.DANIEL, P.T. ET AL.: ""The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death"", ONCOGENE, vol. 27, 2008, pages 1618 - 1628;;BARTZOKIS, G.CUMMINGS, J.PERLMAN, S.HANCE, D. B.MINTZ, J.: ""Increased basal ganglia iron levels in Huntington disease"", ARCH NEUROL, vol. 56, 1999, pages 569 - 574;;BEAULIEU, P. L.HACHE, B.VON MOOS, E., SYNTHESIS, vol. 11, 2003, pages 1683 - 1692;;BEHL, C.: ""Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches"", PROG NEUROBIOL, vol. 57, 1999, pages 301 - 323;;BERGSBAKEN, T.FINK, S.L.COOKSON, B.T.: ""Pyroptosis: host cell death and inflammation"", NAT REV MICROBIOL, vol. 7, 2009, pages 99 - 109;;BLOIS, M.S.: ""Antioxidant determinations by the use of a stable free radical"", NATURE, vol. 181, 1958, pages 1199 - 1200;;CATER, H.L.GITTERMAN, D.DAVIS, S.M.BENHAM, C.D.MORRISON, B., 3RDSUNDSTROM, L.E.: ""Stretch-induced injury in organotypic hippocampal slice cultures reproduces in vivo post-traumatic neurodegeneration: role of glutamate receptors and voltage-dependent calcium channels"", J NEUROCHEM, vol. 101, 2007, pages 434 - 447;;CHA, J. H. ET AL.: ""Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene"", PROC NATL ACAD SCI U S A, vol. 95, 1998, pages 6480 - 6485;;CHEAH, J.H.KIM, S.F.HESTER, L.D.CLANCY, K.W.PATTERSON, S.E., 3RDPAPADOPOULOS, V.SNYDER, S.H.: ""NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1"", NEURON, vol. 51, 2006, pages 431 - 440;;CHEN, J. C. ET AL.: ""MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease"", AJNR. AMERICAN JOURNAL OF NEURORADIOLOGY, vol. 14, 1993, pages 275 - 281;;CHEN, J. ET AL.: ""Iron accumulates in Huntington's disease neurons: protection by deferoxamine"", PLOS ONE, vol. 8, 2013, pages e77023;;CHOI, D.W.: ""Glutamate neurotoxicity and diseases of the nervous system"", NEURON, vol. 1, 1988, pages 623 - 634, XP024246715, DOI: 10.1016/0896-6273(88)90162-6;;CHRISTOFFERSON, D.E.YUAN, J.: ""Necroptosis as an alternative form of programmed cell death"", CURRENT OPINION IN CELL BIOLOGY, vol. 22, 2010, pages 263 - 268;;CHUNG, N.ZHANG, X.D.KREAMER, A.LOCCO, L.KUAN, P.F.BARTZ, S.LINSLEY, P.S.FERRER, M.STRULOVICI, B.: ""Median absolute deviation to improve hit selection for genome-scale RNAi screens"", J BIOMOL SCREEN, vol. 13, 2008, pages 149 - 158;;CRUZ-AGUADO, R.TURNER, L. F.DIAZ, C. M.PINERO, J.: ""Nerve growth factor and striatal glutathione metabolism in a rat model of Huntington's disease"", RESTORATIVE NEUROLOGY AND NEUROSCIENCE, vol. 17, 2000, pages 217 - 221;;DEGTEREV A ET AL.: ""Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury"", NAT CHEM BIOL, vol. 1, no. 2, 2005, pages 112 - 119, XP002349151, DOI: 10.1038/nchembio711;;DESILVA, T. M. ET AL.: ""Glutamate transporter EAAT2 expression is up-regulated in reactive astrocytes in human periventricular leukomalacia"", J COMP NEUROL, vol. 508, 2008, pages 238 - 248;;DILLON CP ET AL.: ""Survival function of the FADD-CASPASE-8-cFLIP(L) complex"", CELL REPORTS, vol. 1, no. 5, 2012, pages 401 - 407;;DILLON CP ET AL.: ""RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3"", CELL, vol. 157, no. 5, 2014, pages 1189 - 1202, XP029028630, DOI: 10.1016/j.cell.2014.04.018;;DIXON, D.J. ET AL.: ""Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death"", CELL, vol. 149, no. 5, 2012, pages 1060 - 1072, XP055213838, DOI: 10.1016/j.cell.2012.03.042;;DOLMA, S.LESSNICK, S.L.HAHN, W.C.STOCKWELL, B.R.: ""Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells"", CANCER CELL, vol. 3, 2003, pages 285 - 296, XP002392895, DOI: 10.1016/S1535-6108(03)00050-3;;DOMMERGUES, M. A.GALLEGO, J.EVRARD, P.GRESSENS, P.: ""Iron supplementation aggravates periventricular cystic white matter lesions in newborn mice"", EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY : EJPN : OFFICIAL JOURNAL OF THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY, vol. 2, 1998, pages 313 - 318;;DUCE, J.A.TSATSANIS, A.CATER, M.A.JAMES, S.A.ROBB, E.WIKHE, K.LEONG, S.L.PEREZ, K.JOHANSSEN, T.GREENOUGH, M.A. ET AL.: ""Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease"", CELL, vol. 142, 2010, pages 857 - 867;;ESTRADA SANCHEZ, A. M.MEJIA-TOIBER, J.MASSIEU, L.: ""Excitotoxic neuronal death and the pathogenesis of Huntington's disease"", ARCHIVES OF MEDICAL RESEARCH, vol. 39, 2008, pages 265 - 276, XP022476906, DOI: 10.1016/j.arcmed.2007.11.011;;FOLKERTH, R. D.: ""Periventricular leukomalacia: overview and recent findings"", PEDIATRIC AND DEVELOPMENTAL PATHOLOGY : THE OFFICIAL JOURNAL OF THE SOCIETY FOR PEDIATRIC PATHOLOGY AND THE PAEDIATRIC PATHOLOGY SOCIETY, vol. 9, 2006, pages 3 - 13;;FOLLETT, P. L. ET AL.: ""Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate"", J NEUROSCI, vol. 24, 2004, pages 4412 - 4420;;FUCHS, Y.STELLER, H.: ""Programmed cell death in animal development and disease"", CELL, vol. 147, 2011, pages 742 - 758, XP028109262, DOI: 10.1016/j.cell.2011.10.033;;GALLUZZI LKEPP OKRAUTWALD SKROEMER GLINKERMANN A: ""Molecular mechanisms of regulated necrosis"", SEMIN CELL DEV BIOL, vol. 35C, 2014, pages 24 - 32;;GENNA, D. T.POSNER, G. H.: ""Cyanocuprates convert carboxylic acids directly into ketones"", ORG LETT, vol. 13, 2011, pages 5358 - 5361;;GOUT, P.W.BUCKLEY, A.R.SIMMS, C.R.BRUCHOVSKY, N.: ""Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug"", LEUKEMIA, vol. 15, 2001, pages 1633 - 1640, XP002535220, DOI: 10.1038/sj.leu.2402238;;GUO, W.WU, S.LIU, J.FANG, B.: ""Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota"", CANCER RES, vol. 68, pages 7403 - 7408, XP055035559, DOI: 10.1158/0008-5472.CAN-08-1449;;HAMADA, Y.KISO, Y.: ""The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors"", EXPERT OPINION ON DRUG DISCOVERY, vol. 7, 2012, pages 903 - 922;;HAYNES, R. L. ET AL.: ""Oxidative and nitrative injury in periventricular leukomalacia: a review"", BRAIN PATHOLOGY, vol. 15, 2005, pages 225 - 233;;HAYNES, R. L. ET AL.: ""Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia"", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 62, 2003, pages 441 - 450;;HE S ET AL.: ""Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha"", CELL, vol. 137, no. 6, 2009, pages 1100 - 1111, XP029215709, DOI: 10.1016/j.cell.2009.05.021;;HOFFSTROM, B. G. ET AL.: ""Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins"", NAT CHEM BIOL, vol. 6, 2010, pages 900 - 906;;HUANG, D.OU, B.PRIOR, R. L.: ""The chemistry behind antioxidant capacity assays"", J AGRIC FOOD CHEM, vol. 53, 2005, pages 1841 - 1856, XP002413438, DOI: 10.1021/jf030723c;;ISHIDA, T.SUZUKI, T.HIRASHIMA, S.MIZUTANI, K.YOSHIDA, A.ANDO, I.IKEDA, S.ADACHI, T.HASHIMOTO, H.: ""Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole"", BIOORG MED CHEM LETT, vol. 16, 2006, pages 1859 - 1863, XP025106983, DOI: 10.1016/j.bmcl.2006.01.032;;JACOBSON, M.D.RAFF, M.C.: ""Programmed cell death and Bcl-2 protection in very low oxygen"", NATURE, vol. 374, 1995, pages 814 - 816;;JOHRI, A.BEAL, M. F.: ""Antioxidants in Huntington's disease"", BIOCHIM BIOPHYS ACTA, vol. 1822, 2012, pages 664 - 674;;KAMATA, T.: ""Roles of Nox1 and other Nox isoforms in cancer development"", CANCER SCI, vol. 100, 2009, pages 1382 - 1388;;KANAI, Y.ENDOU, H.: ""Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity"", J TOXICOL SCI, vol. 28, 2003, pages 1 - 17;;LALEU, B.GAGGINI, F.ORCHARD, M.FIORASO-CARTIER, L.CAGNON, L.HOUNGNINOU-MOLANGO, S.GRADIA, A.DUBOUX, G.MERLOT, C.HEITZ, F. ET AL.: ""First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, 2010, pages 7715 - 7730, XP002672281, DOI: 10.1021/jm100773e;;LEI, P.AYTON, S.FINKELSTEIN, D.I.SPOERRI, L.CICCOTOSTO, G.D.WRIGHT, D.K.WONG, B.X.ADLARD, P.A.CHERNY, R.A.LAM, L.Q ET AL.: ""Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export"", NATURE MEDICINE, vol. 18, 2012, pages 291 - 295;;LI, Y.MAHER, P.SCHUBERT, D.: ""A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion"", NEURON, vol. 19, 1997, pages 453 - 463;;LINKERMANN A ET AL.: ""Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury"", KIDNEY INT, vol. 81, no. 8, 2012, pages 751 - 761, XP055054099, DOI: 10.1038/ki.2011.450;;LINKERMANN A ET AL.: ""The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice"", J AM SOC NEPHROL, vol. 24, no. 10, 2013, pages 1545 - 1557;;LINKERMANN A ET AL.: ""Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury"", PROC NATL ACAD SCI USA, vol. 110, no. 29, 2013, pages 12024 - 12029;;LINKERMANN AGREEN DR, NECROPTOSIS. N ENGL J MED, vol. 370, no. 5, 2014, pages 455 - 465;;LINKERMANN A ET AL.: ""Regulated Cell Death in AKI"", J AM SOC NEPHROL, 2014;;LIPINSKI, C.A.LOMBARDO, F.DOMINY, B.W.FEENEY, P.J.: ""Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings"", ADVANCED DRUG DELIVERY REVIEWS, vol. 46, 2001, pages 3 - 26, XP001097746, DOI: 10.1016/S0169-409X(00)00129-0;;LO, M.LING, V.WANG, Y.Z.GOUT, P.W.: ""The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance"", BRITISH JOURNAL OF CANCER, vol. 99, 2008, pages 464 - 472;;LOSSI, L.ALASIA, S.SALIO, C.MERIGHI, A.: ""Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS"", PROG NEUROBIOL, vol. 88, 2009, pages 221 - 245, XP026337931, DOI: 10.1016/j.pneurobio.2009.01.002;;LUEDDE M ET AL.: ""RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction"", CARDIOVASC RES, vol. 103, no. 2, 2014, pages 206 - 216;;MACARRON, R.BANKS, M.N.BOJANIC, D.BURNS, D.J.CIROVIC, D.A.GARYANTES, T.GREEN, D.V.HERTZBERG, R.P.JANZEN, W.P.PASLAY, J.W. ET AL.: ""Impact of high-throughput screening in biomedical research"", NATURE REVIEWS DRUG DISCOVERY, vol. 10, 2011, pages 188 - 195;;MASON, R. P. ET AL.: ""Glutathione peroxidase activity is neuroprotective in models of Huntington's disease"", NAT GENET, vol. 45, 2013, pages 1249 - 1254;;MILLER, B. R.BEZPROZVANNY, I: ""Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium"", FUTURE NEUROLOGY, vol. 5, 2010, pages 735 - 756;;MOFFAT, J.GRUENEBERG, D.A.YANG, X.KIM, S.Y.KLOEPFER, A.M.HINKLE, G.PIQANI, B.EISENHAURE, T.M.LUO, B.GRENIER, J.K. ET AL.: ""A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen"", CELL, vol. 124, 2006, pages 1283 - 1298, XP055021141, DOI: 10.1016/j.cell.2006.01.040;;MORRISON, P. J.NEVIN, N. C.: ""Serum iron, total iron binding capacity and ferritin in early Huntington disease patients"", IRISH JOURNAL OF MEDICAL SCIENCE, vol. 163, 1994, pages 236 - 237;;MORRISON, B., 3RDPRINGLE, A.K.MCMANUS, T.ELLARD, J.BRADLEY, M.SIGNORELLI, F.LANNOTTI, F.SUNDSTROM, L.E.: ""L-arginyl-3,4-spermidine is neuroprotective in several in vitro models of neurodegeneration and in vivo ischaemia without suppressing synaptic transmission"", BR J PHARMACOL, vol. 137, 2002, pages 1255 - 1268;;MULAY SR ET AL.: ""Calcium oxalate crystals induce renal inflammation by NLRP3-mediated !L-1 β secretion"", J CLIN INVEST, vol. 123, no. 1, 2013, pages 236 - 246;;MULLEN, A.R.WHEATON, W.W.JIN, E.S.CHEN, P.H.SULLIVAN, L.B.CHENG, T.YANG, Y.LINEHAN, W.M.CHANDEL, N.S.DEBERARDINIS, R.J.: ""Reductive carboxylation supports growth in tumour cells with defective mitochondria"", NATURE, 2011;;MURPHY, T.H.MIYAMOTO, M.SASTRE, A.SCHNAAR, R.L.COYLE, J.T.: ""Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress"", NEURON, vol. 2, 1989, pages 1547 - 1558, XP027463266, DOI: 10.1016/0896-6273(89)90043-3;;""NATIONAL RESEARCH COUNCIL"", 2011, NATIONAL ACADEMIES PRESS, article ""Guide for the Care and Use of Laboratory Animals"";;NI CHONGHAILE, T.SAROSIEK, K.A.VO, T.T.RYAN, J.A.TAMMAREDDI, A.MOORE VDEL, G.DENG, J.ANDERSON, K.C.RICHARDSON, P.TAI, Y.T. ET AL.: ""Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy"", SCIENCE, vol. 334, 2011, pages 1129 - 1133, XP055093976, DOI: 10.1126/science.1206727;;NORABERG, J.POULSEN, F.R.BLAABJERG, M.KRISTENSEN, B.W.BONDE, C.MONTERO, M.MEYER, M.GRAMSBERGEN, J.B.ZIMMER, J.: ""Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair"", CURR DRUG TARGETS CNS NEUROL DISORD, vol. 4, 2005, pages 435 - 452;;PAGLIARINI, D.J.CALVO, S.E.CHANG, B.SHETH, S.A.VAFAI, S.B.ONG, S.E.WALFORD, G.A.SUGIANA, C.BONEH, A.CHEN, W.K. ET AL.: ""A mitochondrial protein compendium elucidates complex I disease biology"", CELL, vol. 134, 2008, pages 112 - 123;;PARK, J. S.PASUPULATI, R.FELDKAMP, T.ROESER, N. F.WEINBERG, J. M.: ""Cyclophilin D and the mitochondrial permeability transition in kidney proximal tubules after hypoxic and ischemic injury"", AMERICAN JOURNAL OF PHYSIOLOGY. RENAL PHYSIOLOGY, vol. 301, 2011, pages F134 - 150;;PASSANITI, P. ET AL.: ""Synthesis, spectroscopic and electrochemical properties of mononuclear and dinuclear bis(bipy)ruthenium() complexes containing dimethoxyphenyl(pyridin-2-yl)-1,2,4-triazole ligands"", J. CHEM. SOC., DALTON TRANSACTIONS, vol. 8, 2002, pages 1740 - 1746;;PETR, G. T. ET AL.: ""Glutamate transporter expression and function in a striatal neuronal model of Huntington's disease"", NEUROCHEM INT, vol. 62, 2013, pages 973 - 981, XP028586609, DOI: 10.1016/j.neuint.2013.02.026;;PINNIX, Z.K.MILLER, L.D.WANG, W.D'AGOSTINO, R., JR.KUTE, T.WILLINGHAM, M.C.HATCHER, H.TESFAY, L.SUI, G.DI, X. ET AL.: ""Ferroportin and iron regulation in breast cancer progression and prognosis"", SCI TRANSL MED, vol. 2, 2010, pages 43ra56;;PIPIK, B.HO, G. J.WILLIAMS, J. M.CONLON, D. A.: ""A preferred synthesis of 1,2,4-oxadiazoles"", SYNTHETIC COMMUNICATIONS, vol. 34, 2004, pages 1863 - 1870;;RAJ, L.IDE, T.GURKAR, A.U.FOLEY, M.SCHENONE, M.LI, X.TOLLIDAY, N.J.GOLUB, T.R.CARR, S.A.SHAMJI, A.F. ET AL.: ""Selective killing of cancer cells by a small molecule targeting the stress response to ROS"", NATURE, vol. 475, 2011, pages 231 - 234, XP055635120, DOI: 10.1038/nature10167;;RAMANA, KOTA V. ET AL.: ""Lipid Peroxidation Products in Human Health and Disease"", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2013, 2013;;RAMANATHAN, A.SCHREIBER, S.L.: ""Direct control of mitochondrial function by mTOR"", PROC NATL ACAD SCI U S A, vol. 106, 2009, pages 22229 - 22232;;RATAN, R.R.MURPHY, T.H.BARABAN, J.M.: ""Oxidative stress induces apoptosis in embryonic cortical neurons"", J NEUROCHEM, vol. 62, 1994, pages 376 - 379;;RIBEIRO, F. M.PIRES, R. G.FERGUSON, S. S.: ""Huntington's disease and Group I metabotropic glutamate receptors"", MOLECULAR NEUROBIOLOGY, vol. 43, 2011, pages 1 - 11;;RIBEIRO, M. ET AL.: ""Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells"", FREE RADIC BIOL MED, vol. 53, 2012, pages 1857 - 1867;;SAITOH, M. ET AL.: ""Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta"", BIOORG MED CHEM, vol. 17, 2009, pages 2017 - 2029;;SALAHUDEEN, A.A.THOMPSON, J.W.RUIZ, J.C.MA, H.W.KINCH, L.N.LI, Q.GRISHIN, N.V.BRUICK, R.K.: ""An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis"", SCIENCE, vol. 326, 2009, pages 722 - 726;;SANCHEZ, M.GALY, B.SCHWANHAEUSSER, B.BLAKE, J.BAHR-IVACEVIC, T.BENES, V.SELBACH, M.MUCKENTHALER, M.U.HENTZE, M.W.: ""Iron regulatory protein-1 and -2: transcriptome-wide definition of binding mRNAs and shaping of the cellular proteome by iron regulatory proteins"", BLOOD, vol. 118, 2011, pages e168 - 179;;SATO, H.TAMBA, M.ISHII, T.BANNAI, S.: ""Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins"", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 11455 - 11458, XP002941607, DOI: 10.1074/jbc.274.17.11455;;SHAW, A.T.WINSLOW, M.M.MAGENDANTZ, M.OUYANG, C.DOWDLE, J.SUBRAMANIAN, A.LEWIS, T.A.MAGLATHIN, R.L.TOLLIDAY, N.JACKS, T.: ""Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress"", PROC NATL ACAD SCI USA., 2011;;SKOUTA R ET AL.: ""Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models"", J AM CHEM SOC, vol. 136, no. 12, 2014, pages 4551 - 4556, XP055648750, DOI: 10.1021/ja411006a;;SMITH CC ET AL.: ""Necrostatin: A potentially novel cardioprotective agent?"", CARDIOVASC DRUGS THER, vol. 21, no. 4, 2007, pages 227 - 233, XP019524679, DOI: 10.1007/s10557-007-6035-1;;SOGABE, K.ROESER, N. F.VENKATACHALAM, M. A.WEINBERG, J. M.: ""Differential cytoprotection by glycine against oxidant damage to proximal tubule cells"", KIDNEY INTERNATIONAL, vol. 50, 1996, pages 845 - 854;;SUNDSTROM, L.MORRISON, B., 3RDBRADLEY, M.PRINGLE, A.: ""Organotypic cultures as tools for functional screening in the CNS"", DRUG DISCOVERY TODAY, vol. 10, 2005, pages 993 - 1000, XP005009824, DOI: 10.1016/S1359-6446(05)03502-6;;TAN, S.SAGARA, Y.LIU, Y.MAHER, P.SCHUBERT, D.: ""The regulation of reactive oxygen species production during programmed cell death"", THE JOURNAL OF CELL BIOLOGY, vol. 141, 1998, pages 1423 - 1432;;THOMPSON, C.B.: ""Apoptosis in the pathogenesis and treatment of disease"", SCIENCE, vol. 267, 1995, pages 1456 - 1462, XP000971548, DOI: 10.1126/science.7878464;;TRACHOOTHAM, D.ZHOU, Y.ZHANG, H.DEMIZU, Y.CHEN, Z.PELICANO, H.CHIAO, P.J.ACHANTA, G.ARLINGHAUS, R.B.LIU, J. ET AL.: ""Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate"", CANCER CELL, vol. 10, 2006, pages 241 - 252;;TRAYKOVA-BRAUCH M ET AL.: ""An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice"", NAT MED, vol. 14, no. 9, 2008, pages 979 - 984;;TURMAINE, M. ET AL.: ""Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease"", PROC NATL ACAD SCI U S A, vol. 97, 2000, pages 8093 - 8097, XP000990139, DOI: 10.1073/pnas.110078997;;WOLPAW, A.J.SHIMADA, K.SKOUTA, R.WELSCH, M.E.AKAVIA, U.D.PE'ER, D.SHAIK, F.BULINSKI, J.C.STOCKWELL, B.R.: ""Modulatory profiling identifies mechanisms of small molecule-induced cell death"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011;;VASHISHT, A.A.ZUMBRENNEN, K.B.HUANG, X.POWERS, D.N.DURAZO, A.SUN, D.BHASKARAN, N.PERSSON, A.UHLEN, M.SANGFELT, O. ET AL.: ""Control of iron homeostasis by an iron-regulated ubiquitin ligase"", SCIENCE, vol. 326, 2009, pages 718 - 721;;VIGIL, D.CHERFILS, J.ROSSMAN, K.L.DER, C.J.: ""Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?"", NAT REV CANCER, vol. 10, 2010, pages 842 - 857;;WANG, Y.DAWSON, V.L.DAWSON, T.M.: ""Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos"", EXP NEUROL, vol. 218, 2009, pages 193 - 202, XP026321615, DOI: 10.1016/j.expneurol.2009.03.020;;WATKINS, P.A.MAIGUEL, D.JIA, Z.PEVSNER, J.: ""Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome"", J LIPID RES, vol. 48, 2007, pages 2736 - 2750, XP055034984, DOI: 10.1194/jlr.M700378-JLR200;;WISE, D.R.DEBERARDINIS, R.J.MANCUSO, A.SAYED, N.ZHANG, X.Y.PFEIFFER, H.K.NISSIM, I.DAIKHIN, E.YUDKOFF, M.MCMAHON, S.B. ET AL.: ""Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, 2008, pages 18782 - 18787;;WU, C. ET AL.: ""Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2 -carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist"", J MED CHEM, vol. 47, 2004, pages 1969 - 1986;;YAGODA, N.VON RECHENBERG, M.ZAGANJOR, E.BAUER, A.J.YANG, W.S.FRIDMAN, D.J.WOLPAW, A.J.SMUKSTE, I.PELTIER, J.M.BONIFACE, J.J. ET AL: ""RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels"", NATURE, vol. 447, 2007, pages 864 - 868;;YANG, W.S.STOCKWELL, B.R.: ""Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells"", CHEMISTRY & BIOLOGY, vol. 15, 2008, pages 234 - 245, XP022680233, DOI: 10.1016/j.chembiol.2008.02.010;;YONEZAWA, M.BACK, S.A.GAN, X.ROSENBERG, P.A.VOLPE, J.J.: ""Cystine deprivation induces oligodendroglial death: rescue by free radical scavengers and by a diffusible glial factor"", J NEUROCHEM, vol. 67, 1996, pages 566 - 573;;ZERON, M. M. ET AL.: ""Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease"", NEURON, vol. 33, 2002, pages 849 - 860;;ZHANG DW ET AL.: ""RIP3, an energy metabolism regulator that switches TNFinduced cell death from apoptosis to necrosis"", SCIENCE, vol. 325, no. 5938, 2009, pages 332 - 336",DISCONTINUED
64,CN,A,CN 119034669 A,003-635-533-661-791,2024-11-29,2024,CN 202411258383 A,2024-09-09,CN 202411258383 A,2024-09-09,DNA synthesizer liquid pumping device and DNA synthesizer,"The invention provides a DNA synthesizer liquid beating device and a DNA synthesizer, and belongs to the technical field of biotech, the DNA synthesizer liquid beating device comprises a liquid beating mechanism, a liquid storage tank is fixedly connected in the liquid beating mechanism, a placing plate is fixed on the outer surface of the top end of the liquid storage tank, a driving motor is fixed on the outer wall of one side of the placing plate, and a linkage shaft is movably connected on the outer surface of one side of the driving motor; a cam is fixedly connected to the outer surface of the linkage shaft, a fixed column is fixed to the outer wall of the cam, a first movable piece is movably connected to the outer wall of the fixed column, a connecting piece is movably connected to the outer wall of the first movable piece, and a second movable piece is movably connected to the outer wall of one side of the connecting piece; the rotary motion of the driving motor is converted into the periodic motion of the fixed column through the linkage shaft and the cam, subsequent parts are pushed to move, the rotary motion of the motor is converted into the linear reciprocating motion of the piston, pulsating type liquid beating is achieved, a chemical reagent flows on the synthetic column in an intermittent mode, and the chemical reagent is driven to rotate. And the reagent is promoted to be fully contacted and mixed with reactants on the synthesis column.",BEIJING DINGGUO CHANGSHENG BIOTECHNOLOGY CO LTD,CHENG YAN;;ZHOU WEIDONG,,https://lens.org/003-635-533-661-791,Patent Application,no,0,0,1,003-635-533-661-791,CN,1,003-635-533-661-791,CN,0,C07H1/00;;C07H21/04;;B01J19/241,B01J19/24;;C07H1/00;;C07H21/04,,0,0,,,,PENDING
65,WO,A1,WO 2025/027138 A1,193-872-889-793-268,2025-02-06,2025,EP 2024071819 W,2024-08-01,US 202363530319 P;;US 202363532252 P;;CA 3233757 A,2023-08-02,COMBINATION OF NIRAPARIB AND ABIRATERONE FOR USE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,"The present disclosure relates to a drug product with at least one approved indication, wherein said drug product comprises niraparib and abiraterone acetate.",JANSSEN PHARMACEUTICA NV,FRANCIS PETER;;WANG GUILIN;;HUTNICK NATALIE A;;GORMLEY MICHAEL P;;URTISHAK KAREN ANN;;THOMAS SHIBU;;DIBAJ SHIVA SEYEDEH;;KIM WON;;LI SUSAN XUEMEI;;ZHANG KE;;LOPEZ-GITLITZ ANGELA MENNICKE;;GUCKERT MARY;;ZHANG JING;;DEL CORRAL ADAM A,,https://lens.org/193-872-889-793-268,Patent Application,yes,5,0,2,193-872-889-793-268;;091-190-889-232-632,WO,2,193-872-889-793-268;;091-190-889-232-632,WO,0,A61K31/454;;A61K31/58;;A61K31/573;;A61P35/04,A61K31/454;;A61K31/573;;A61K31/58;;A61P35/04,,3,2,007-940-487-701-655;;041-327-727-454-807,10.1007/s00280-021-04249-7;;pmc8149334;;33754187;;10.1213/00000539-194101000-00064,"SAAD FRED ET AL: ""Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)"", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG , BERLIN, DE, vol. 88, no. 1, 22 March 2021 (2021-03-22), pages 25 - 37, XP037463617, ISSN: 0344-5704, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149334/> [retrieved on 20210322], DOI: 10.1007/S00280-021-04249-7;;CHI KIM N ET AL: ""Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer"", 23 March 2023 (2023-03-23), pages 1 - 15, XP093071658, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431499/> [retrieved on 20230808], DOI: 10.1200/JCO.22;;GOODMANGILMAN: ""The Pharmacological Basis of Therapeutics"", 2001",PENDING
66,US,A1,US 2022/0324832 A1,110-544-515-197-02X,2022-10-13,2022,US 202217842632 A,2022-06-16,US 202217842632 A;;US 202016922365 A;;US 201816227820 A;;US 201715598181 A;;US 201615011377 A;;US 201562110449 P,2015-01-30,CRYSTALLINE FORMS OF C21H22Cl2N4O2,The present invention provides crystalline forms of a compound of formula (I):Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.,BIOMED VALLEY DISCOVERIES INC;;VERTEX PHARMA,DECRESCENZO GARY;;WELSCH DEAN;;VLAHOVA PETINKA I;;BOERRIGTER STEPHAN X M;;ARONOV ALEXANDER;;KESHAVARZ-SHOKRI ALI;;SCANGAS ALEXANDER N;;STAVROPOULOS KATHY;;LITTLER BENJAMIN;;KADIYALA IRINA NIKOLAEVNA;;ALARGOVA ROSSITZA GUEORGUIEVA,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2016-01-28);;VERTEX PHARMACEUTICALS INCORPORATED (2016-01-13);;ALBANY MOLECULAR RESEARCH INC (2016-01-28);;BIOMED VALLEY DISCOVERIES INC (2015-04-14),https://lens.org/110-544-515-197-02X,Patent Application,yes,2,0,47,116-199-399-313-671;;062-164-339-573-490;;166-794-157-487-249;;095-084-552-677-771;;104-647-261-533-488;;043-850-818-426-595;;011-554-860-079-913;;096-868-254-555-436;;004-332-074-676-545;;153-550-500-828-475;;046-188-654-610-999;;001-893-907-269-372;;174-826-743-101-138;;069-261-997-143-205;;084-727-988-685-091;;130-965-892-238-625;;102-230-351-923-950;;136-204-394-028-125;;176-384-435-693-597;;004-743-936-524-729;;049-676-215-490-456;;093-685-947-670-647;;036-252-612-630-255;;031-754-713-783-793;;041-838-127-758-174;;187-470-244-874-184;;199-861-327-043-603;;110-544-515-197-02X;;030-177-747-660-19X;;112-383-433-305-451;;000-990-971-129-09X;;077-021-145-982-372;;148-269-192-068-850;;187-962-477-269-605;;061-008-601-403-016;;058-529-986-491-445;;187-083-365-942-673;;094-363-903-633-910;;074-343-658-329-005;;034-042-476-677-543;;096-779-492-002-779;;060-478-003-161-627;;135-798-422-549-708;;030-245-434-761-426;;153-111-007-114-386;;016-826-996-244-883;;104-967-288-790-348,JP;;AU;;EP;;CN;;ES;;WO;;HK;;US;;SG;;NZ;;CA;;MX,47,116-199-399-313-671;;062-164-339-573-490;;166-794-157-487-249;;095-084-552-677-771;;104-647-261-533-488;;043-850-818-426-595;;011-554-860-079-913;;001-893-907-269-372;;004-332-074-676-545;;153-550-500-828-475;;046-188-654-610-999;;096-868-254-555-436;;174-826-743-101-138;;069-261-997-143-205;;084-727-988-685-091;;130-965-892-238-625;;102-230-351-923-950;;136-204-394-028-125;;176-384-435-693-597;;004-743-936-524-729;;049-676-215-490-456;;093-685-947-670-647;;036-252-612-630-255;;031-754-713-783-793;;041-838-127-758-174;;187-470-244-874-184;;199-861-327-043-603;;110-544-515-197-02X;;030-177-747-660-19X;;112-383-433-305-451;;000-990-971-129-09X;;077-021-145-982-372;;148-269-192-068-850;;187-962-477-269-605;;061-008-601-403-016;;058-529-986-491-445;;187-083-365-942-673;;094-363-903-633-910;;074-343-658-329-005;;034-042-476-677-543;;096-779-492-002-779;;060-478-003-161-627;;135-798-422-549-708;;030-245-434-761-426;;153-111-007-114-386;;016-826-996-244-883;;104-967-288-790-348,JP;;AU;;EP;;ES;;CN;;WO;;HK;;US;;SG;;NZ;;CA;;MX,0,C07D401/04;;A61P35/00;;C07B2200/07;;C07B2200/13;;A61P35/00;;C07D401/04;;A61K31/4439;;A61K45/06;;C07D401/04;;A61K31/4439;;A61K45/06;;A61P35/00,C07D401/04;;A61K31/4439;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
67,EP,A1,EP 4574844 A1,126-252-595-609-026,2025-06-25,2025,EP 23220069 A,2023-12-22,EP 23220069 A,2023-12-22,MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR CD47 AND PDL1,"The present invention relates to a multispecific antibody comprising one binding domain, which specifically binds to CD47 (CD47-BD), one binding domain, which specifically binds to PDL1 (PDL1-BD), and optionally one or two further binding domains having specificity for an antigen different from CD47 and PDL1. The present invention further relates to nucleic acid sequences encoding said multispecific antibody, vector(s) comprising said nucleic acid sequences, host cell(s) comprising said nucleic acid sequences or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.",NUMAB THERAPEUTICS AG,The designation of the inventor has not yet been filed,,https://lens.org/126-252-595-609-026,Patent Application,yes,9,0,1,126-252-595-609-026,EP,4,036-312-470-125-254;;126-252-595-609-026;;003-281-214-903-938;;101-831-207-925-983,EP;;WO,261,C07K2317/31;;C07K2317/33;;C07K2317/92;;C07K2317/76;;C07K2317/73;;C07K2317/24;;C07K2317/55;;C07K16/2827;;C07K16/2803;;C07K2317/90;;C07K2317/34;;C07K2317/622,C07K16/28,,3,2,096-064-940-485-622;;017-064-225-537-571,10.1172/jci97570;;pmc6264729;;30352428;;28258703;;10.1111/imr.12527,"HUI-MING CHEN ET AL: ""Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity"", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 12, 22 October 2018 (2018-10-22), pages 5647 - 5662, XP055554809, DOI: 10.1172/JCI97570;;THU NGUYEN BAO MINH: ""Blocking 'don't eat me' signals CD47 and LILRB2 to enhance macrophage- and granulocyte-mediated phagocytosis of cancer cells"", UNIVERSITY OF GRONINGEN, 1 July 2019 (2019-07-01), XP055931686, Retrieved from the Internet <URL:https://ucg.studenttheses.ub.rug.nl/32/1/Thesis_BaoMinhThuNguyen_Final.pdf>;;HANKE L. MATLUNG ET AL: ""The CD47-SIRP[alpha] signaling axis as an innate immune checkpoint in cancer"", IMMUNOLOGICAL REVIEWS, vol. 276, no. 1, 1 March 2017 (2017-03-01), US, pages 145 - 164, XP055429046, ISSN: 0105-2896, DOI: 10.1111/imr.12527",PENDING
68,US,A1,US 2022/0193236 A1,139-734-717-438-91X,2022-06-23,2022,US 202217589068 A,2022-01-31,US 202217589068 A;;US 202117558295 A;;US 202163286353 P;;US 202163280953 P;;US 202163253790 P;;US 202163249299 P;;US 202163227803 P;;US 202163223921 P;;US 202163220854 P;;US 202063129401 P,2020-12-22,"METHODS, SYSTEMS, AND APPARATUS FOR ADMINISTERING A MONOCLONAL AND/OR POLYCLONAL ANTIBODY TREATMENT VIA RAPID INFUSION","Presented herein are methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via a rapid infusion device, e.g., for the treatment of a disease, e.g., a disease caused by a pathogen, e.g., for the treatment of COVID-19, caused by the virus SARS-CoV-2, or for the treatment of other conditions/diseases, such as neurological diseases, organ and/or tissue transplants, or certain forms of cancer, that require infusions of monoclonal and/or polyclonal antibodies.",HERZLINGER REGINA E,HERZLINGER REGINA E,,https://lens.org/139-734-717-438-91X,Patent Application,yes,10,4,11,057-241-236-672-424;;121-357-040-430-259;;083-936-204-836-520;;100-483-372-867-049;;179-162-822-917-701;;190-161-187-684-788;;148-930-392-518-296;;139-734-717-438-91X;;111-541-912-114-446;;177-442-240-916-307;;040-371-179-032-33X,KR;;JP;;AU;;EP;;WO;;US;;CA,17,105-429-855-406-583;;083-936-204-836-520;;179-162-822-917-701;;190-161-187-684-788;;148-930-392-518-296;;072-898-357-404-928;;111-541-912-114-446;;144-087-239-619-777;;018-926-101-101-904;;057-241-236-672-424;;121-357-040-430-259;;040-371-179-032-33X;;050-048-949-137-481;;100-483-372-867-049;;139-734-717-438-91X;;177-442-240-916-307;;018-240-540-661-78X,KR;;AU;;JP;;EP;;WO;;US;;CA,0,C07K16/2887;;C07K2317/24;;A61K2039/507;;A61K39/395;;A61K2039/54;;A61K2039/545;;A61K39/3955;;A61M5/1413;;A61M5/152;;A61M5/162;;A61M5/165;;A61M5/16813;;A61M5/16881;;C07K16/1003;;A61M5/14244;;A61M5/148;;A61M5/44;;A61M5/14232;;A61M5/14236;;A61M2039/242;;A61M2205/7545;;A61M5/16877;;A61M5/16881;;A61M5/162;;A61M5/165;;A61M5/152;;A61M5/1413;;A61M5/14244;;A61M5/16813;;A61M5/002;;A61K39/395;;A61K39/3955;;A61P35/00;;A61P25/00;;A61P37/06;;A61P31/14;;C07K16/10;;C07K16/2887;;A61M2205/273;;A61K2039/507;;A61K2039/54;;A61K2039/545;;C07K2317/24;;A61K39/3955;;A61M5/14244;;A61M5/162;;A61M5/1413;;A61M5/16881;;A61M5/152;;A61M5/165;;A61M5/002;;A61M5/16813;;C07K16/2887;;C07K16/1003,A61K39/395;;A61M5/00;;A61M5/14;;A61M5/142;;A61M5/152;;A61M5/162;;A61M5/165;;A61M5/168,,0,0,,,,ACTIVE
69,WO,A1,WO 2025/133391 A1,036-312-470-125-254,2025-06-26,2025,EP 2024088374 W,2024-12-23,EP 23220069 A;;EP 23220027 A,2023-12-22,MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR CD47 AND PDL1,"The present invention relates to a multispecific antibody comprising one binding domain, which specifically binds to CD47 (CD47-BD), one binding domain, which specifically binds to PDL1 (PDL1-BD), and optionally one or two further binding domains having specificity for an antigen different from CD47 and PDL1. The present invention further relates to nucleic acid sequences encoding said multispecific antibody, vector(s) comprising said nucleic acid sequences, host cell(s) comprising said nucleic acid sequences or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.",NUMAB THERAPEUTICS AG,GUNDE TEA;;SNELL DANIEL;;WARMUTH STEFAN;;BROCK MATTHIAS;;HESS CHRISTIAN;;SCHINEIS PHILIPP;;TRÜB MARTA,,https://lens.org/036-312-470-125-254,Patent Application,yes,34,0,2,036-312-470-125-254;;003-281-214-903-938,WO,4,036-312-470-125-254;;126-252-595-609-026;;003-281-214-903-938;;101-831-207-925-983,EP;;WO,264,C07K16/2803;;C07K16/2827;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/73;;C07K2317/76;;C07K2317/90;;C07K2317/92;;A61K2039/505;;A61P35/00;;C07K2317/94,C07K16/28,,67,50,096-064-940-485-622;;017-064-225-537-571;;095-138-110-523-848;;009-227-912-600-601;;084-027-870-747-640;;009-927-165-324-005;;083-811-051-643-47X;;017-318-148-072-156;;100-455-735-400-002;;094-234-563-800-063;;122-644-406-202-233;;115-562-794-324-327;;092-325-088-257-225;;020-553-570-616-428;;076-090-519-318-074;;156-501-805-490-709;;004-529-618-392-612;;173-572-222-412-05X;;078-432-639-041-575;;020-855-322-534-259;;032-720-983-972-675;;039-515-794-348-090;;019-982-436-313-59X;;032-071-991-081-664;;084-388-182-984-099;;170-311-024-328-514;;030-607-398-087-475;;050-019-752-984-887;;045-094-249-115-990;;022-023-983-891-895;;005-405-010-898-254;;123-242-072-533-087;;000-776-112-250-230;;018-413-776-840-867;;049-928-993-608-092;;025-794-567-716-961;;043-654-077-374-418;;042-354-196-879-741;;005-112-559-456-657;;052-219-543-437-800;;027-829-588-585-761;;111-109-974-501-414;;048-183-620-015-85X;;063-469-288-339-138;;014-583-412-527-761;;108-448-445-113-510;;037-009-464-188-261;;007-141-101-622-305;;128-033-626-011-207;;116-384-364-039-398,10.1172/jci97570;;pmc6264729;;30352428;;28258703;;10.1111/imr.12527;;10.1111/j.1476-5381.2012.02099.x;;pmc3514757;;22774848;;10.1016/j.coi.2012.01.010;;pmc3319521;;22310103;;10.1016/j.lungcan.2015.03.003;;25799277;;10.1007/s00262-006-0266-z;;pmc11029839;;17186290;;10.1158/1078-0432.ccr-06-2746;;17404099;;14559843;;19028999;;10.1215/15228517-2008-104;;pmc2743219;;10.1097/00001756-200507130-00010;;15973152;;10.1038/nm730;;12091876;;pmc4990391;;27574444;;10.2147/ott.s105862;;8844834;;10.1093/protein/9.7.617;;pmc3772205;;10.3410/f.718046073.793481009;;10.1074/jbc.m113.480483;;23880771;;9143687;;10.1146/annurev.immunol.15.1.203;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;8069524;;10.1006/immu.1994.1004;;7561440;;16793771;;10.1074/jbc.m604292200;;10.1016/0022-2836(91)90498-u;;1748994;;10.1006/jmbi.1997.1354;;9367782;;12477501;;10.1016/s0145-305x(02)00039-3;;10.1006/jmbi.2001.4662;;11397087;;1404359;;10.1016/0022-2836(92)90894-p;;3936039;;pmc391493;;10.1073/pnas.82.24.8648;;10.1073/pnas.0511285103;;16505368;;pmc1383494;;10.1073/pnas.81.21.6851;;6436822;;pmc392030;;2646862;;10.1016/s0065-2776(08)60640-9;;10.1126/science.2451287;;2451287;;10.1016/0161-5890(91)90163-e;;1905784;;10.1016/0161-5890(94)90001-9;;8114766;;27786600;;pmc5240654;;10.1080/19420862.2016.1248012;;17853878;;10.1038/nprot.2007.321;;10.1002/pro.2992;;27479186;;pmc5029533;;10.1006/jmbi.1999.3444;;10656818;;10.1016/s0378-1097(00)00251-2;;10.1111/j.1574-6968.2000.tb09197.x;;10913857;;6239899;;pmc2187539;;10.1084/jem.160.6.1686;;3833240;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1093/nar/19.18.5081;;1923780;;pmc328820;;3838308;;10.1016/s0021-9258(18)89400-5;;10.1006/mcpr.1994.1013;;7935517;;10.1016/0092-8674(92)90213-v;;1370653;;10.1101/gr.1.1.17;;1842916;;10.1038/ng0497-345;;9090378;;10.1146/annurev.micro.49.1.807;;10.1146/annurev.mi.49.100195.004111;;8561480;;10.1007/978-3-540-48037-2_6;;8036313;;3081432;;10.1111/j.1600-065x.1986.tb01472.x;;10.1016/s0092-8674(00)81843-7;;9008163,"HUI-MING CHEN ET AL: ""Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity"", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 12, 22 October 2018 (2018-10-22), pages 5647 - 5662, XP055554809, DOI: 10.1172/JCI97570;;THU NGUYEN BAO MINH: ""Blocking 'don't eat me' signals CD47 and LILRB2 to enhance macrophage- and granulocyte-mediated phagocytosis of cancer cells"", UNIVERSITY OF GRONINGEN, 1 July 2019 (2019-07-01), XP055931686, Retrieved from the Internet <URL:https://ucg.studenttheses.ub.rug.nl/32/1/Thesis_BaoMinhThuNguyen_Final.pdf>;;HANKE L. MATLUNG ET AL: ""The CD47-SIRP[alpha] signaling axis as an innate immune checkpoint in cancer"", IMMUNOLOGICAL REVIEWS, vol. 276, no. 1, 1 March 2017 (2017-03-01), US, pages 145 - 164, XP055429046, ISSN: 0105-2896, DOI: 10.1111/imr.12527;;SICK E ET AL., BR. J. PHARMACOL., vol. 167, no. 7, 2012, pages 1415 - 1430;;CHAO MP ET AL., CURR. OPIN. IMMUNOL, vol. 24, no. 2, 2012, pages 225 - 232;;KATSUYA Y ET AL., LUNG CANCER, vol. 88, no. 2, 2015, pages 154 - 159;;NAKANISHI J ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 56, no. 8, 2007, pages 1173 - 1182;;NOMI T ET AL., CLIN CANCER RES., vol. 13, no. 7, 2007, pages 2151 - 2157;;FAY AP ET AL., J IMMUNOTHER CANCER, vol. 3, 2015, pages 3;;STROME SE ET AL., CANCER RES., vol. 63, no. 19, 2003, pages 6501 - 6505;;JACOBS JF ET AL., NEURO ONCOL., vol. 11, no. 4, 2009, pages 394 - 402;;WILMOTTE R ET AL., NEUROREPORT., vol. 16, no. 10, 2005, pages 1081 - 1085;;DONG H ET AL., NAT MED., vol. 8, no. 8, 2002, pages 793 - 800;;WANG ET AL., ONCO TARGETS THER., vol. 9, 2016, pages 5023 - 5039;;RIDGWAY ET AL., PROTEIN ENG., vol. 9, 1996, pages 617 - 21;;SPIESS ET AL., J BIOL CHEM., vol. 288, no. 37, 2013, pages 26583 - 93;;WANG ET AL., PROTEIN CELL., vol. 9, no. 1, 2018, pages 63 - 732018;;LIU ET AL., ANTIBODIES (BASEL)., vol. 9, no. 4, 2020, pages 64;;M. DAERON, ANNU. REV. IMMUNOL., vol. 5, 1997, pages 203 - 234;;RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 92;;CAPET ET AL., IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34;;HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41;;DALL'ACQUA ET AL., J BIOL CHEM., vol. 281, 2006, pages 23514 - 23524;;MARKS ET AL., J. MOL. BIOL, vol. 222, 1991, pages 581;;AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948;;LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136;;LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77;;HONEGGERPLUCKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 670;;HOOGENBOOMWINTER, J. MOL. BIOL, vol. 227, 1992, pages 381;;LIU, M A ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648;;BOEMER ET AL., J. IMMUNOL, vol. 147, 1991, pages 86 - 95;;VAN DE WINKEL, CURR. OPIN. PHARMACOL, vol. 5, 2001, pages 368 - 74;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;MORRISONOI, ADV. IMMUNOL., vol. 44, 1988, pages 65 - 92;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;PADLAN, MOLEC. IMMUN., vol. 28, 1991, pages 489 - 498;;PADLAN, MOLEC. IMMUN., vol. 31, 1994, pages 169 - 217;;EGAN ET AL., MABS, vol. 9, no. 1, 2017, pages 68 - 84;;NIESEN ET AL., NATURE PROTOCOLS, vol. 2, no. 9, 2007, pages 2212 - 2221;;WONGRALEIGH, PROTEIN SCIENCE, vol. 25, 2016, pages 1834 - 1840;;KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86;;YOKOYAMA ET AL., CURR. PROTOC. IMMUNOL. CHAPTER, 2006, pages 2;;CHAMESBATY, FEMS MICROBIOL. LETTERS, vol. 189, 2000, pages 1 - 8;;KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686;;PAULUS, BEHRING INS. MITT. NO, vol. 78, 1985, pages 118 - 132;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375;;BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081;;OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608;;ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98;;NARANG ET AL., METH. ENZYMOL., vol. 68, 1979, pages 109;;BEAUCAGE ET AL., TETRA. LETT., vol. 22, 1981, pages 1859;;ROSENFELD ET AL., CELL, vol. 68, 1992, pages 143;;""PCR Protocols: A Guide to Methods and Applications"", 1990, ACADEMIC PRESS;;MATTILA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 967;;ECKERT ET AL., PCR METHODS AND APPLICATIONS, vol. 1, 1991, pages 17;;HARRINGTON ET AL., NAT GENET., vol. 15, 1997, pages 345;;SMITH, ANNU. REV. MICROBIOL., vol. 49, 1995, pages 807;;SCHARF ET AL., RESULTS PROBL. CELL DIFFER., vol. 20, 1994, pages 125;;BITTNER ET AL., METH. ENZYMOL., vol. 153, 1987, pages 516;;WINNACKER: ""FROM GENES TO CLONES"", 1987, VCH PUBLISHERS;;QUEEN ET AL., IMMUNOL. REV., vol. 89, 1986, pages 49 - 68;;GREEN, M. R.SAMBROOK, J.: ""Molecular Cloning: A Laboratory Manual"", 2012, COLD SPRING HARBOR LABORATORY PRESS;;ELLIOTO'HARE, CELL, vol. 88, 1997, pages 223;;""Remington: The Science and Practice of Pharmacy"", 2000, MACK PUBLISHING CO.;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.",PENDING
70,GB,D0,GB 202319484 D0,010-932-822-780-660,2024-01-31,2024,GB 202319484 A,2023-12-19,GB 202319484 A,2023-12-19,AI footwear thermal heat ice thermostat thermometer sensors kinetic energy renewable energy solar power biotech connected health wearable technologies airflow,,ASERIE MARCUS LINVAL;;CREATIVE INVENTORS CITINVENTIT LTD,,,https://lens.org/010-932-822-780-660,Patent Application,no,0,0,1,010-932-822-780-660,GB,1,010-932-822-780-660,GB,0,,,,0,0,,,,DISCONTINUED
71,GB,D0,GB 202319490 D0,161-423-790-690-993,2024-01-31,2024,GB 202319490 A,2023-12-19,GB 202319490 A,2023-12-19,AI dog harness trainer robotics legs waste management container sensors kinetic energy renewable energy solar power biotech connected health immersive,,ASERIE MARCUS;;CREATIVE INVENTORS CITINVENTIT LTD,,,https://lens.org/161-423-790-690-993,Patent Application,no,0,0,1,161-423-790-690-993,GB,1,161-423-790-690-993,GB,0,,,,0,0,,,,DISCONTINUED
72,GB,D0,GB 202401939 D0,165-631-775-723-699,2024-03-27,2024,GB 202401939 A,2024-02-13,GB 202401939 A,2024-02-13,Mobile stand alone emergency sports stretcher multi purpose container injury prevention drone biotech technologies ai immersive mixed reality metaverse pcb,,ASERIE MARCUS LINVAL;;CREATIVE INVENTORS CITINVENTIT LTD,,,https://lens.org/165-631-775-723-699,Patent Application,no,0,0,1,165-631-775-723-699,GB,1,165-631-775-723-699,GB,0,,,,0,0,,,,DISCONTINUED
73,WO,A1,WO 2022/140463 A1,100-483-372-867-049,2022-06-30,2022,US 2021/0064724 W,2021-12-21,US 202063129401 P;;US 202163220854 P;;US 202163223921 P;;US 202163227803 P;;US 202163249299 P;;US 202163253790 P;;US 202163280953 P;;US 202163286353 P,2020-12-22,"METHODS, SYSTEMS, AND APPARATUS FOR ADMINISTERING A MONOCLONAL AND/OR POLYCLONAL ANTIBODY TREATMENT VIA RAPID INFUSION","Presented herein are methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via a rapid infusion device, e.g., for the treatment of a disease, e.g., a disease caused by a pathogen, e.g., for the treatment of COVID-19, caused by the virus SARS-CoV-2, or for the treatment of other conditions/diseases, such as neurological diseases, organ and/or tissue transplants, or certain forms of cancer, that require infusions of monoclonal and/or polyclonal antibodies.",HERZLINGER REGINA E,HERZLINGER REGINA E,,https://lens.org/100-483-372-867-049,Patent Application,yes,2,4,11,057-241-236-672-424;;121-357-040-430-259;;083-936-204-836-520;;100-483-372-867-049;;179-162-822-917-701;;190-161-187-684-788;;148-930-392-518-296;;139-734-717-438-91X;;111-541-912-114-446;;177-442-240-916-307;;040-371-179-032-33X,KR;;JP;;AU;;EP;;WO;;US;;CA,17,105-429-855-406-583;;083-936-204-836-520;;179-162-822-917-701;;190-161-187-684-788;;148-930-392-518-296;;072-898-357-404-928;;111-541-912-114-446;;144-087-239-619-777;;018-926-101-101-904;;057-241-236-672-424;;121-357-040-430-259;;040-371-179-032-33X;;050-048-949-137-481;;100-483-372-867-049;;139-734-717-438-91X;;177-442-240-916-307;;018-240-540-661-78X,KR;;AU;;JP;;EP;;WO;;US;;CA,0,C07K16/2887;;C07K2317/24;;A61K2039/507;;A61K39/395;;A61K2039/54;;A61K2039/545;;A61K39/3955;;A61M5/1413;;A61M5/152;;A61M5/162;;A61M5/165;;A61M5/16813;;A61M5/16881;;C07K16/1003;;A61M5/14244;;A61M5/148;;A61M5/44;;A61M5/14232;;A61M5/14236;;A61M2039/242;;A61M2205/7545;;A61M5/16877;;A61M5/16881;;A61M5/162;;A61M5/165;;A61M5/152;;A61M5/1413;;A61M5/14244;;A61M5/16813;;A61M5/002;;A61K39/395;;A61K39/3955;;A61P35/00;;A61P25/00;;A61P37/06;;A61P31/14;;C07K16/10;;C07K16/2887;;A61M2205/273;;A61K2039/507;;A61K2039/54;;A61K2039/545;;C07K2317/24;;A61K39/3955;;A61M5/14244;;A61M5/162;;A61M5/1413;;A61M5/16881;;A61M5/152;;A61M5/165;;A61M5/002;;A61M5/16813;;C07K16/2887;;C07K16/1003,A61M5/00;;A61M5/14;;A61M5/158;;A61M5/162;;A61M5/168;;A61M5/24,,4,3,009-728-756-873-186;;007-974-039-691-890;;000-140-077-206-766,10.1002/phar.1420;;24706572;;17545535;;10.1158/1078-0432.ccr-06-2496;;pmc8344610;;10.1093/ajhp/zxab270;;34223872,"SWAN JOSHUA T., ZAGHLOUL HANNA A., COX JAMES E., MURILLO JOSE R.: ""Use of a Pharmacy Protocol to Convert Standard Rituximab Infusions to Rapid Infusion Shortens Outpatient Infusion Clinic Visits"", PHARMACOTHERAPY, WILEY-BLACKWELL, US, vol. 34, no. 7, 1 July 2014 (2014-07-01), US , pages 686 - 694, XP055953930, ISSN: 0277-0008, DOI: 10.1002/phar.1420;;MITA ALAIN C., OLSZANSKI ANTHONY J., WALOVITCH RICHARD C., PEREZ RAYMOND P., MACKAY KATHLEEN, TUCK DAVID P., SIMMONS CECILIA, HAMM: ""Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel"", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 11, 1 June 2007 (2007-06-01), US, pages 3293 - 3301, XP055953935, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-2496;;GLORIMAR RIVERA, MARISOL DE LEÓN, BERIL BERNARDELLI , BARBARA BRANNAN , JOSEPH DICUBELLIS , CARLA WILLIAMS: ""Rapid implementation of pharmacy infusion services for emergency use authorization COVID-19 treatments at a field hospital "", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, vol. 78, no. 22, 15 November 2021 (2021-11-15), pages 2015 - 2019, XP055953936;;See also references of EP 4267216A4",PENDING
74,US,A1,US 2022/0380383 A1,115-613-283-354-871,2022-12-01,2022,US 202117332058 A,2021-05-27,US 202117332058 A;;US 2019/0064024 W;;US 201962842038 P;;US 201862773278 P;;US 201862773288 P,2018-11-30,NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF,"The present disclosure provides, inter alia, compounds and compositions having the formula (I):as defined herein. Methods of using and making such compounds and compositions are also provided. The present disclosure further provides screening methods, including detectable probes as well as diagnostic methods and methods for monitoring the progress of a disease, such as a neurodegenerative disease.",UNIV COLUMBIA,STOCKWELL BRENT R;;ZASK ARIE;;KAPLAN ANNA,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2019-05-10),https://lens.org/115-613-283-354-871,Patent Application,yes,0,0,1,115-613-283-354-871,US,2,115-613-283-354-871;;058-781-243-234-522,WO;;US,1,A61K31/496;;A61K31/437;;A61K31/4545;;A61K31/5025;;A61K31/5377;;A61P25/28;;A61P43/00;;C07D513/04;;C07D513/04;;A61K31/437;;A61K31/4545;;A61K31/496;;A61K31/5025;;A61K31/5377;;A61K45/06;;A61P25/28;;A61P43/00,C07D513/04;;A61K31/437;;A61K31/4545;;A61K31/496;;A61K31/5025;;A61K31/5377;;A61K45/06;;A61P25/28;;A61P43/00,,0,0,,,,DISCONTINUED
75,US,A1,US 2022/0193235 A1,111-541-912-114-446,2022-06-23,2022,US 202117558295 A,2021-12-21,US 202117558295 A;;US 202163286353 P;;US 202163280953 P;;US 202163253790 P;;US 202163249299 P;;US 202163227803 P;;US 202163223921 P;;US 202163220854 P;;US 202063129401 P,2020-12-22,"METHODS, SYSTEMS, AND APPARATUS FOR ADMINISTERING A MONOCLONAL AND/OR POLYCLONAL ANTIBODY TREATMENT VIA RAPID INFUSION","Presented herein are methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via a rapid infusion device, e.g., for the treatment of a disease, e.g., a disease caused by a pathogen, e.g., for the treatment of COVID-19, caused by the virus SARS-CoV-2, or for the treatment of other conditions/diseases, such as neurological diseases, organ and/or tissue transplants, or certain forms of cancer, that require infusions of monoclonal and/or polyclonal antibodies.",HERZLINGER REGINA E,HERZLINGER REGINA E,,https://lens.org/111-541-912-114-446,Patent Application,yes,5,6,11,057-241-236-672-424;;121-357-040-430-259;;083-936-204-836-520;;100-483-372-867-049;;179-162-822-917-701;;190-161-187-684-788;;148-930-392-518-296;;139-734-717-438-91X;;111-541-912-114-446;;177-442-240-916-307;;040-371-179-032-33X,KR;;JP;;AU;;EP;;WO;;US;;CA,17,105-429-855-406-583;;083-936-204-836-520;;179-162-822-917-701;;190-161-187-684-788;;148-930-392-518-296;;072-898-357-404-928;;111-541-912-114-446;;144-087-239-619-777;;018-926-101-101-904;;057-241-236-672-424;;121-357-040-430-259;;040-371-179-032-33X;;050-048-949-137-481;;100-483-372-867-049;;139-734-717-438-91X;;177-442-240-916-307;;018-240-540-661-78X,KR;;AU;;JP;;EP;;WO;;US;;CA,0,C07K16/2887;;C07K2317/24;;A61K2039/507;;A61K39/395;;A61K2039/54;;A61K2039/545;;A61K39/3955;;A61M5/1413;;A61M5/152;;A61M5/162;;A61M5/165;;A61M5/16813;;A61M5/16881;;C07K16/1003;;A61M5/14244;;A61M5/148;;A61M5/44;;A61M5/14232;;A61M5/14236;;A61M2039/242;;A61M2205/7545;;A61M5/16877;;A61M5/16881;;A61M5/162;;A61M5/165;;A61M5/152;;A61M5/1413;;A61M5/14244;;A61M5/16813;;A61M5/002;;A61K39/395;;A61K39/3955;;A61P35/00;;A61P25/00;;A61P37/06;;A61P31/14;;C07K16/10;;C07K16/2887;;A61M2205/273;;A61K2039/507;;A61K2039/54;;A61K2039/545;;C07K2317/24;;A61K39/3955;;A61M5/14244;;A61M5/162;;A61M5/1413;;A61M5/16881;;A61M5/152;;A61M5/165;;A61M5/002;;A61M5/16813;;C07K16/2887;;C07K16/1003,A61K39/395;;A61M5/00;;A61M5/14;;A61M5/142;;A61M5/152;;A61M5/162;;A61M5/165;;A61M5/168,,0,0,,,,DISCONTINUED
76,WO,A1,WO 2025/097557 A1,023-541-648-721-377,2025-05-15,2025,CN 2023139787 W,2023-12-19,CN 202311479503 A,2023-11-08,"METHOD FOR PRODUCING LONG-CHAIN DICARBOXYLIC ACID, AND PRODUCT","Provided are a method for producing a long-chain dicarboxylic acid and a long-chain dicarboxylic acid product. The method comprises: inoculating a seed liquid of a fermentation strain into a fermentation tank, where a fermentation substrate comprises any one or more among a fatty acid, a derivative thereof, and an alkane. Eco-friendly raw materials such as a fatty acid, a derivative thereof, and a plant-based alkane are used as substrates, which partially or completely replace fossil fuels such as petroleum alkanes; the product is an eco-friendly long-chain dicarboxylic acid, bio-based contents can be controlled, and the fermentation method retains a relatively high yield and conversion rate.",CATHAY BIOTECH INC;;CIBT AMERICA INC,HAO YINGLI;;BAO JIAWEI;;XU MIN;;LIU XIUCAI,,https://lens.org/023-541-648-721-377,Patent Application,yes,12,0,2,023-541-648-721-377;;025-163-787-830-108,CN;;WO,2,023-541-648-721-377;;025-163-787-830-108,CN;;WO,0,C07C55/02;;C12N1/16;;C07C55/20;;C12R2001/74;;C12P7/6409;;C07C55/21;;C12P7/64;;C07C51/42;;C12R2001/72,C12P7/64;;C12R1/72;;C12R1/74,,0,0,,,,PENDING
77,WO,A1,WO 2025/097559 A1,167-967-339-076-28X,2025-05-15,2025,CN 2023139813 W,2023-12-19,CN 202311479510 A,2023-11-08,"LONG CHAIN DICARBOXYLIC ACID, AND METHOD FOR PRODUCING LONG-CHAIN DICARBOXYLIC ACID BY MEANS OF FERMENTATION",Provided are a long-chain dicarboxylic acid and a method for producing the long-chain dicarboxylic acid by means of fermentation. The method comprises: inoculating a seed solution of a fermentation strain into a fermentation tank; adding a substrate for fermentation; and controlling the fermentation temperature to be 20-40 ℃. The substrate comprises fatty acid ester and alkane.,CATHAY BIOTECH INC;;CIBT AMERICA INC;;CATHAY JINXIANG BIOMATERIAL CO LTD,HAO YINGLI;;LUO SHUAI;;XU MIN;;LIU XIUCAI,,https://lens.org/167-967-339-076-28X,Patent Application,yes,6,0,2,119-940-680-029-849;;167-967-339-076-28X,CN;;WO,2,119-940-680-029-849;;167-967-339-076-28X,CN;;WO,0,C07C55/02;;C12N1/16;;C12P7/44;;C07C55/20;;C12P7/6409;;C07C55/21;;C12P7/64;;C07C51/42;;C12R2001/72,C12P7/44;;C12P7/64,,0,0,,,,PENDING
78,WO,A1,WO 2025/097558 A1,003-729-146-035-464,2025-05-15,2025,CN 2023139802 W,2023-12-19,CN 202311479508 A,2023-11-08,METHOD FOR PRODUCING LONG-CHAIN DICARBOXYLIC ACID AND LONG-CHAIN DICARBOXYLIC ACID,"Provided are a method for producing a long-chain dicarboxylic acid and a long-chain dicarboxylic acid. The method for producing the long-chain dicarboxylic acid comprises: inoculating a seed solution of a fermentation strain into a fermentation culture medium and culturing, and adding a substrate fatty acid ester and fermenting. The fatty acid ester is used as a substrate, which can replace fossil fuels such as petroleum alkanes; a long-chain dicarboxylic acid having 100% bio-based content and 98% or greater purity is synthesized, and the present invention has a high yield and conversion rate.",CATHAY BIOTECH INC;;CIBT AMERICA INC;;CATHAY JINXIANG BIOMATERIAL CO LTD,HAO YINGLI;;LV HUAN;;XU MIN;;LIU XIUCAI,,https://lens.org/003-729-146-035-464,Patent Application,yes,6,0,2,192-308-714-845-843;;003-729-146-035-464,CN;;WO,2,192-308-714-845-843;;003-729-146-035-464,CN;;WO,0,C07C55/02;;C12R2001/725;;C12P7/44;;C12R2001/645;;C07C55/20;;C12R2001/74;;C12P7/6409;;C07C55/21;;C07C51/42;;C12R2001/72,C12P7/44,,0,0,,,,PENDING
79,WO,A1,WO 2023/070051 A1,041-418-535-484-386,2023-04-27,2023,US 2022/0078459 W,2022-10-20,US 202163271110 P;;US 202263305089 P,2021-10-22,ANTIBODIES TO CORONAVIRUS SARS-COV-2,"Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.",ATRECA INC,WILLIAMS KATHERINE L;;ATKINS NGAN NGUYEN,,https://lens.org/041-418-535-484-386,Patent Application,yes,2,0,3,004-377-179-659-249;;041-418-535-484-386;;113-669-240-464-691,EP;;WO;;US,3,004-377-179-659-249;;041-418-535-484-386;;113-669-240-464-691,EP;;WO;;US,149,A61P11/00;;A61P31/14;;C07K2317/21;;C07K2317/33;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/1003;;A61P11/00;;C07K16/1003;;A61P31/14;;A61K2039/505;;C07K2317/565;;C07K2317/76,C07K16/10;;A61K39/215;;A61K47/02;;A61K47/18;;A61K47/26;;A61K47/68;;A61P11/00;;A61P31/14;;C07K14/165;;C12N15/11,,3,0,,,"DATABASE PROTEIN ANONYMOUS : ""anti SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens] "", XP093064730, retrieved from NCBI;;DATABASE PROTEIN ANONYMOUS : ""immunoglobulin heavy chain junction region, partial [Homo sapiens]"", XP093064731, retrieved from NCBI;;DATABASE PROTEIN ANONYMOUS : ""immunoglobulin heavy chain variable region, partial [Homo sapiens] "", XP093064733, retrieved from NCBI",PENDING
80,US,A1,US 2021/0225475 A1,088-983-093-222-254,2021-07-22,2021,US 202117202453 A,2021-03-16,US 202117202453 A;;US 201615360799 A;;US 201662365317 P,2016-07-21,"NOVEL HEALTHCARE DELIVERY, TREATMENT, AND PAYMENT MODEL FOR SPECIALTY DRUGS","The present disclosure provides methods, processes, reagents and kits for novel healthcare delivery, treatment and payment, particularly for achieving better economic outcomes in patients treated with specialty drugs. Methods, processes, and kits provide a number of uses, including, for providing assurance, both efficacy and financial, theragnostic-guidance, for providing therapeutic appropriateness, therapeutic guidance, therapeutic effectiveness, and selection of alternative therapeutic strategies, and providing product differentiation and presumably market enrichment for a specialty drug, for authorizing payment and delivering the drug directly from a pharmaceutical company to a patient or her specialty physician through a novel healthcare delivery platform. Medical records and databases using these strategies are also provided.",KLARITOS INC,RAMAKRISHNAN VIJAY,KLARITOS INC (2021-03-16),https://lens.org/088-983-093-222-254,Patent Application,yes,15,1,2,010-200-892-852-208;;088-983-093-222-254,US,2,010-200-892-852-208;;088-983-093-222-254,US,0,G06Q40/08;;G16H10/60;;G16H50/70;;G16H20/10;;Y02A90/10;;G16H20/10;;G06Q40/08;;G16H10/60;;G16H50/70,G16H20/10;;G06Q40/08;;G16H10/60;;G16H50/70,,10,8,105-329-476-691-443;;118-179-322-896-244;;097-339-289-295-50X;;022-411-144-604-925;;124-586-890-817-124;;008-467-290-257-074;;051-308-578-312-096;;052-443-618-247-988,25002563;;10.1503/cmaj.140151;;pmc4330143;;25859119;;pmc4378517;;pmc4346215;;10.1177/1758834014567469;;25755682;;25584071;;pmc4286944;;10.1177/1756285614564152;;25891174;;10.1056/nejmoa1501824;;10.1056/nejmoa1509388;;pmc4722809;;26639149;;23424360;;pmc3571070;;pmc4699485;;26766890,"Rolland, ""Sofosbuvir for the treatment of hepatitis C virus infection"", CMAJ, 2015 Feb 17 , 187(3): 203–204. (Year: 2015);;Gritsenko, ""Ledipasvir/Sofosbuvir (Harvoni): Improving Options for Hepatitis C Virus Infection"", Pharmacy & Therapeutics, 2015 Apr; 40(4): 256-259, 276. (Year: 2015);;Johnson, ""Nivolumab in melanoma: latest evidence and clinical potential"", Ther Adv Med Oncol. 2015 Mar; 7(2): 97–106. (Year: 2015);;Bomprezzi, ""Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview"", Ther Adv Neurol Disord. 2015 Jan; 8(1): 20–30. (Year: 2015);;Garon, ""Pembrolizumab for the treatment of non-small-cell lung cancer"", N Engl J Med. 2015 May 21;372(21):2018-28 (Year: 2015);;Burger ""Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia"", N Engl J Med. 2015 Dec 17; 373(25): 2425–2437. (Year: 2015);;Anderson, Pauline, ""Clozapine Comes with Money-back Offer"", The Medical Post, May 16, 1995. (Year: 1995);;Renshaw RM. Outcomes-based access: what will it mean for biologics? Biotechnol Healthc. 2006 Jun;3(3):39-44. PMID: 23424360; PMCID: PMC3571070. (Year: 2006);;Anderson, P. ""Clozapine Comes with Money-back Offer"", The Medical Post, May 16, 1995 (Year: 1995);;Barlas, Stephen; ""Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing""; P T, Vol. 41 No. 1, January 2016, pages 39-53 (Year: 2016)",PENDING
81,WO,A1,WO 2024/221494 A1,075-909-963-090-623,2024-10-31,2024,CN 2023093215 W,2023-05-10,CN 202310468093 A,2023-04-27,"CATALYST, PREPARATION METHOD THEREFOR, AND USE THEREOF","Disclosed in the present invention are a catalyst, a preparation method therefor, and a use thereof. The catalyst comprises 2-68 parts by weight of a carrier and 32-98 parts by weight of a metal catalyst. The metal catalyst contains a component (A) and an optional component (B), wherein the component (A) is a nickel metal and/or a nickel oxide, and the component (B) comprises at least one of Li, Na, K, Be, Mg, Ca, Cu, Co, Cr, Zr, Mo, Zn, Cd, Ru, Rh, Pd, Pt, LiO, Na2O, K2O, BeO, MgO, CaO, CuO, CoO, Cr2O3, ZrO2, Mo2O3, ZnO, CdO, RuO2, Rh2O3, PdO, and PtO2. The catalyst has high catalytic efficiency in a deamination cyclization reaction. Aliphatic nitrogen-containing heterocyclic compounds such as piperidine, pyrrolidine, morpholine, and piperazine are rapidly synthesized by means of one-step deamination cyclization reaction. The catalyst has the advantages of wide substrate range, high reaction efficiency, good selectivity, simple operation and small pollution, and has wide industrial application prospects.",CATHAY BIOTECH INC;;CIBT AMERICA INC;;CATHAY TAIYUAN BIOMATERIAL CO LTD,BAI MIAO;;YANG CHEN;;LIU XIUCAI,,https://lens.org/075-909-963-090-623,Patent Application,yes,3,0,2,090-119-647-397-225;;075-909-963-090-623,CN;;WO,2,090-119-647-397-225;;075-909-963-090-623,CN;;WO,0,B01J23/755;;B01J23/78;;B01J23/866;;B01J37/03;;B01J37/035;;C07D295/023;;C07D295/027;;C07D211/12;;C07D487/08;;C07D295/03;;Y02P20/584,B01J23/755,,0,0,,,,PENDING
82,WO,A1,WO 2022/087484 A1,148-276-117-506-967,2022-04-28,2022,US 2021/0056348 W,2021-10-22,US 202063105175 P,2020-10-23,ANTIBODIES TO CORONAVIRUS SARS-COV-2,"Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.",WILLIAMS KATHERINE L;;EMERLING DANIEL ERIC;;LIPPOW SHAUN M;;ATKINS NGAN NGUYEN,WILLIAMS KATHERINE;;EMERLING DANIEL;;LIPPOW SHAUN;;ATKINS NGAN,,https://lens.org/148-276-117-506-967,Patent Application,yes,9,2,5,148-276-117-506-967;;097-876-848-512-317;;061-006-789-683-558;;091-354-172-011-03X;;015-247-141-090-038,EP;;WO;;US,5,148-276-117-506-967;;097-876-848-512-317;;061-006-789-683-558;;091-354-172-011-03X;;015-247-141-090-038,EP;;WO;;US,328,A61P31/14;;C07K2317/76;;C07K2317/565;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/1003;;C07K2317/21;;C07K2317/33;;A61P31/14;;C07K16/1003;;C07K2317/14;;C07K2317/565;;C07K2317/76;;C12N15/63,C07K16/10;;A61K39/00;;A61P31/14,,5,3,059-495-787-541-693;;004-555-922-207-61X;;041-100-808-788-255,pmc7857395;;10.1126/science.abe3354;;32972994;;32668443;;pmc7584396;;10.1038/s41586-020-2548-6;;pmc7457611;;10.1038/s41586-020-2852-1;;33045718;;pmc8092461;;10.1101/2020.08.30.273920;;32869026,"TORTORICI M. ALEJANDRA, BELTRAMELLO MARTINA, LEMPP FLORIAN A., PINTO DORA, DANG HA V., ROSEN LAURA E., MCCALLUM MATTHEW, BOWEN JOH: ""Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms - Supplement"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 370, no. 6519, 20 November 2020 (2020-11-20), US , pages 950 - 957, XP055880643, ISSN: 0036-8075, DOI: 10.1126/science.abe3354;;ZOST SETH J.; GILCHUK PAVLO; CASE JAMES BRETT; BINSHTEIN ELAD; CHEN RITA E.; NKOLOLA JOSEPH P.; SCHäFER ALEXANDRA; REIDY JOSE: ""Potently neutralizing and protective human antibodies against SARS-CoV-2"", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 584, no. 7821, 15 July 2020 (2020-07-15), London, pages 443 - 449, XP037223576, ISSN: 0028-0836, DOI: 10.1038/s41586-020-2548-6;;DATABASE NUCLEOTIDE 8 July 2020 (2020-07-08), ANONYMOUS : ""Homo sapiens clone HbnC3t1p1_C6 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds"", XP055946567, retrieved from NCBI Database accession no. MT658844;;BARNES CHRISTOPHER O.; JETTE CLAUDIA A.; ABERNATHY MORGAN E.; DAM KIM-MARIE A.; ESSWEIN SHANNON R.; GRISTICK HARRY B.; MALYUTIN AN: ""SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies"", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 588, no. 7839, 12 October 2020 (2020-10-12), London, pages 682 - 687, XP037319836, ISSN: 0028-0836, DOI: 10.1038/s41586-020-2852-1;;See also references of EP 4232470A4",PENDING
83,US,A1,US 2021/0299107 A1,187-018-394-861-206,2021-09-30,2021,US 202117330386 A,2021-05-25,US 202117330386 A;;US 2019/0063640 W;;US 201862771841 P,2018-11-27,"COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS","The present disclosure provides, inter alia, a compound having the structure:Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.",UNIV COLUMBIA,STOCKWELL BRENT R;;ZASK ARIE;;TAN HUI;;DANIELS JACOB,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2021-06-02),https://lens.org/187-018-394-861-206,Patent Application,yes,8,2,13,121-990-604-533-151;;136-303-601-830-019;;114-705-167-288-522;;131-688-800-577-763;;129-377-716-373-258;;160-185-259-414-954;;019-188-334-730-941;;187-018-394-861-206;;175-525-083-150-248;;033-754-575-774-735;;043-025-737-923-864;;192-090-995-050-609;;102-183-983-840-329,AU;;JP;;CN;;EP;;WO;;US,13,121-990-604-533-151;;136-303-601-830-019;;114-705-167-288-522;;131-688-800-577-763;;129-377-716-373-258;;160-185-259-414-954;;019-188-334-730-941;;187-018-394-861-206;;175-525-083-150-248;;033-754-575-774-735;;043-025-737-923-864;;192-090-995-050-609;;102-183-983-840-329,AU;;JP;;CN;;EP;;WO;;US,0,A61K45/06;;C07C2601/14;;C07C229/60;;C07C2603/74;;C07C237/30;;C07D263/32;;C07D271/06;;C07D295/13;;C07D413/04;;C07D213/80;;C07D213/74;;C07D413/12;;A61P25/28;;A61P39/06;;A61P31/06;;A61K31/166;;A61K31/245;;A61K31/421;;A61K31/4245;;A61K31/44;;A61K31/4439;;A61K31/5375;;C07C229/60;;C07C233/65;;C07D213/74;;C07D213/80;;C07D263/32;;C07D271/10;;C07D295/13;;C07D413/04;;C07D413/12,A61K31/4245;;A61K31/166;;A61K31/245;;A61K31/421;;A61K31/44;;A61K31/4439;;A61K31/5375;;A61P31/06;;A61P39/06;;C07C229/60;;C07C233/65;;C07D213/74;;C07D213/80;;C07D263/32;;C07D271/10;;C07D295/13;;C07D413/04;;C07D413/12,,2,2,035-230-547-171-641;;008-819-276-274-165,11848856;;10.1021/cr950066q;;27117490;;10.2174/092986732311160420104823,"Patani GA, LaVoie EJ. Bioisosterism: A Rational Approach in Drug Design. Chem Rev. 1996 Dec 19;96(8):3147-3176. (Year: 1996);;Álvarez, R., Aramburu, L., Puebla, P., Caballero, E., González, M., Vicente, A., Medarde, M., & Peláez, R. (2016). Pyridine based antitumour compounds acting at the colchicine site. Current Medicinal Chemistry, 23(11), 1100–1130. (Year: 2016)",DISCONTINUED
84,WO,A1,WO 2025/118346 A1,178-057-534-448-268,2025-06-12,2025,CN 2023139681 W,2023-12-19,CN 202311670086 A,2023-12-07,COMPOSITE ROTATOR CUFF PATCH AND PREPARATION METHOD THEREFOR,"Disclosed in the present application are a composite rotator cuff patch and a preparation method therefor. The composite rotator cuff patch is divided into an electrospun layer and a collagen layer. An electrospun nanofiber membrane is coated with a layer of cross-linked collagen gel, and then composite freeze-drying is carried out to obtain the composite rotator cuff patch of the present application. The rotator cuff patch has good biocompatibility and proper tissue adhesion, does not require sutures for fixation, can be degraded in vivo, and, as the degradation time of the patch is close to the repair time of the rotator cuff, does not require postoperative removal.",GUANHAO BIOTECH CO LTD,MO ZIRU,,https://lens.org/178-057-534-448-268,Patent Application,yes,6,0,2,195-048-546-784-041;;178-057-534-448-268,CN;;WO,2,195-048-546-784-041;;178-057-534-448-268,CN;;WO,0,A61L27/24;;A61L27/18;;A61L27/20;;A61L27/54;;A61L27/58;;D01D5/003;;D04H1/728;;A61L2430/10;;A61L2300/602;;A61L2300/232;;A61L2400/12;;A61L2400/04;;A61L2300/412;;A61L2300/402;;A61L27/18;;A61L27/20;;A61L27/24;;A61L27/54;;A61L27/40;;A61L27/44;;A61L27/58;;A61L31/04;;D01D5/00;;D04H1/728,A61L27/40;;A61L27/24;;A61L27/44;;A61L27/54;;A61L27/58;;A61L31/04;;D04H1/728,,0,0,,,,PENDING
85,US,A1,US 2021/0040091 A1,173-361-861-947-907,2021-02-11,2021,US 202017009450 A,2020-09-01,US 202017009450 A;;US 2019/0020362 W;;US 201862637242 P,2018-03-01,"COMPOUNDS, COMPOSITIONS, AND METHODS FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS","Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present invention. Further provided are methods for treating or ameliorating the effects of a disorder in a subject, methods of suppressing the toxicity of endoplasmic reticulum (ER) stress in a subject, methods of treating or ameliorating the effects of a disease involving axon degeneration in a subject, and methods for treating or ameliorating the effects of a neurodegenerative disease.",UNIV COLUMBIA,STOCKWELL BRENT R;;WICHTERLE HYNEK;;BOS PIETER;;ZASK ARIE;;THAMS SEBASTIAN;;LOWRY EMILY ROHDES,THE TRUSTESS OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2021-07-02);;THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (2020-09-09),https://lens.org/173-361-861-947-907,Patent Application,yes,0,4,12,018-424-632-264-964;;133-566-559-415-051;;126-067-048-306-11X;;188-442-935-567-552;;173-361-861-947-907;;154-481-529-885-49X;;069-839-247-021-282;;097-858-571-620-817;;104-884-579-301-707;;191-731-652-610-900;;000-771-192-605-536;;123-713-822-530-466,JP;;AU;;EP;;WO;;US;;CA,12,097-858-571-620-817;;133-566-559-415-051;;126-067-048-306-11X;;188-442-935-567-552;;173-361-861-947-907;;154-481-529-885-49X;;069-839-247-021-282;;123-713-822-530-466;;191-731-652-610-900;;018-424-632-264-964;;104-884-579-301-707;;000-771-192-605-536,JP;;AU;;EP;;WO;;US;;CA,2,C07D471/04;;C07D519/00;;A61P25/00;;C07D471/04,C07D471/04,,0,0,,,,ACTIVE
86,WO,A1,WO 2025/129383 A1,040-126-238-886-660,2025-06-26,2025,CN 2023139421 W,2023-12-18,CN 2023139421 W,2023-12-18,ADIPOSE-DERIVED MESENCHYMAL STEM CELL SERUM AND PREPARATION METHOD THEREFOR,"An adipose-derived mesenchymal stem cell serum and a preparation method therefor. The adipose-derived mesenchymal stem cell serum, in percentage ratios, comprises the following raw materials: 2-5% of an adipose-derived mesenchymal stem cell concentrate, 0.5-1% sodium pyrrolidone carboxylate, 2-5% glycerin, 1-3% propylene glycol, 0.1-0.5% glutathione, 0.1-0.5% allantoin, 0.2-1% ascorbic acid, and 1-5% sodium hyaluronate. The adipose-derived mesenchymal stem cell concentrate is made, via ultraconcentration, using a culturing solution from adipose-derived stem cells and a protein suspension obtained from lysed stem cells. The present invention is rich in cell growth factors, and once prepared into a serum product, the invention has cosmetic effects such as wrinkle reduction, spot reduction, and skin repair.",GUANHAO BIOTECH CO LTD,CHEN JUNLI,,https://lens.org/040-126-238-886-660,Patent Application,yes,0,0,1,040-126-238-886-660,WO,1,040-126-238-886-660,WO,0,A61K8/67;;A61K8/99;;A61K8/98;;A61Q19/00;;A61Q19/08;;C12N5/06,A61K8/99;;A61K8/67;;A61K8/98;;A61Q19/00;;A61Q19/08;;C12N5/0775,,0,0,,,,PENDING
87,US,A1,US 2024/0025971 A1,097-876-848-512-317,2024-01-25,2024,US 202118032630 A,2021-10-22,US 202118032630 A;;US 202063105175 P;;US 2021/0056348 W,2020-10-23,ANTIBODIES TO CORONAVIRUS SARS-COV-2,"Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.",ATRECA INC,WILLIAMS KATHERINE L;;EMERLING DANIEL ERIC;;LIPPOW SHAUN M;;ATKINS NGAN NGUYEN,UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (2023-09-19);;ATRECA INC (2021-10-14),https://lens.org/097-876-848-512-317,Patent Application,yes,0,0,5,148-276-117-506-967;;097-876-848-512-317;;061-006-789-683-558;;091-354-172-011-03X;;015-247-141-090-038,EP;;WO;;US,5,148-276-117-506-967;;097-876-848-512-317;;061-006-789-683-558;;091-354-172-011-03X;;015-247-141-090-038,EP;;WO;;US,328,A61P31/14;;C07K2317/76;;C07K2317/565;;C07K2317/56;;C07K2317/92;;A61K2039/505;;C07K16/1003;;C07K2317/21;;C07K2317/33;;A61P31/14;;C07K16/1003;;C07K2317/14;;C07K2317/565;;C07K2317/76;;C12N15/63,C07K16/10;;A61P31/14;;C12N15/63,,0,0,,,,PENDING
88,WO,A1,WO 2025/081626 A1,007-519-626-361-314,2025-04-24,2025,CN 2023139690 W,2023-12-19,CN 202311332462 A,2023-10-16,ARTIFICIAL MENISCUS AND PREPARATION METHOD THEREFOR,"An artificial meniscus and a preparation method therefor. The preparation method comprises: uniformly punching an acellular matrix material, and filling the pores with collagen, wherein the acellular matrix material is the skin tissue of pigs, cattle, etc., has a high biomechanical performance, and is filled with collagen after punching, which is beneficial for cell adhesion, proliferation and migration, and can induce meniscus regeneration. In addition, the acellular matrix material and the filled collagen are subjected to a cross-linking treatment, thereby having a controllable biodegradability and being adaptable to the rate of meniscus tissue formation. The artificial meniscus prepared in the present invention has a good biocompatibility, biomechanical performance and biodegradability.",GUANHAO BIOTECH CO LTD,HUANG LIJIE,,https://lens.org/007-519-626-361-314,Patent Application,yes,5,0,1,007-519-626-361-314,WO,1,007-519-626-361-314,WO,0,A61L27/24;;A61L27/56,A61L27/24;;A61L27/56,,0,0,,,,PENDING
89,WO,A1,WO 2022/022603 A1,149-788-379-004-76X,2022-02-03,2022,CN 2021109100 W,2021-07-29,CN 202010760135 A,2020-07-31,"CONTACT LENS CLEANER, AND PROTEIN REMOVAL AND STERILIZATION METHOD BY MEANS OF ELECTROPHORESIS DISSOCIATION","A contact lens cleaner, and a protein removal and sterilization method by means of electrophoresis dissociation. The contact lens cleaner comprises a lens cleaning tank (10), two electrophoresis dissociation probes (20) are arranged in the lens cleaning tank (10) opposite one another, and the electrophoresis dissociation probes (20) are electrically connected to a circuit power supply. The lens cleaning tank (10) is filled with an electrolyte solution; a lens to be cleaned is placed in the lens cleaning tank (10); and a switch is turned on, and the two electrophoresis dissociation probes (20) in the lens cleaning tank (10) form an anode and a cathode. There are lacrimal proteins on the surface of the lens to be cleaned, the lacrimal proteins are charged in the solution, and the charged lacrimal proteins move to the electrode opposite to the electrical property thereof in the cleaning tank (10) according to the phenomenon of electrophoresis. The electrolyte solution reacts chemically in the cleaning tank (10) to produce hypochlorite having a strong oxidizing property, and the hypochlorite can not only degrade lacrimal proteins, but can also sterilize and disinfect.",SUZHOU 3N BIOLOGICAL TECH CO LTD,SUN BIXIA,,https://lens.org/149-788-379-004-76X,Patent Application,yes,7,0,5,196-427-746-150-664;;194-106-115-038-705;;149-788-379-004-76X;;008-019-730-520-747;;012-846-208-572-257,EP;;CN;;WO;;US,5,196-427-746-150-664;;194-106-115-038-705;;149-788-379-004-76X;;008-019-730-520-747;;012-846-208-572-257,EP;;CN;;WO;;US,0,G02C13/008;;A61L2/18;;G02C13/008;;A61L12/023;;A61L2101/06;;A61L12/107;;B08B3/10;;A61L2101/06;;A61L12/02;;A61L12/107;;B08B3/10;;G02C13/008,A61L12/02;;G02C13/00;;A61L12/10,,12,0,,,"NANJING REXIAN: ""Self-cleaning, portable, use it to wear new lenses every day, saving you thousands of dollars a year!"", HTTPS://WWW.163.COM/DY/ARTICLE/FI5RGB1H0545AWG3.HTML, 22 July 2020 (2020-07-22), pages 1 - 13, XP055890662;;""Protein molecular weight standard"", THERMO FISHER, no. 26619;;""SDS-PAGE electrophoresis buffer"", SHANGHAI SANGON BIOTECH, no. C520001-0500;;""SDS-PAGE protein electrophoresis sample loading buffer"", SHANGHAI SANGON BIOTECH, no. C508320-0001;;""SDS-PAGE staining solution"", SHANGHAI SANGON BIOTECH, no. C900300-0100.;;""SDS-PAGE bleaching solution"", SHANGHAI SANGON BIOTECH, no. C900299-0300.;;""SDS-PAGE gel"", SHANGHAI SANGON BIOTECH, no. C661103-0001;;""Protein"", LYSOZYME, SOLARBIO, no. L8120;;""Contact lens"", EYEBRIGHT, no. DS200114030 /DS200114028;;""GenBank"", Database accession no. AAA27721.1;;""The electrophoresis solution is SDS-PAGE 10X Tris-Glycine electrophoresis buffer"", SHANGHAI SANGON BIOTECH, no. C520001-0500;;See also references of EP 4187312A4",PENDING
90,US,A1,US 2024/0002447 A1,127-395-452-468-574,2024-01-04,2024,US 202118254576 A,2021-09-26,CN 202011351390 A;;CN 2021120518 W,2020-11-26,MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF,"The present application relates to a modified human papillomavirus (HPV) type 52 L1 protein and a use thereof. Specifically, the present application relates to a HPV type 52 L1 protein, a nucleotide encoded thereby, a carrier comprising the nucleotide, a cell comprising the carrier, a pentamer or virus-like particle consisting of the HPV-52 L1 protein, a vaccine comprising the pentamer or virus-like particle and a vaccine adjuvant, and a use thereof in the prevention of HPV infections and HPV infection-related diseases.",INST BASIC MEDICAL SCIENCES CAMS,XU XUEMEI;;MA MINGRAO;;HAO YARU;;ZHANG TING;;WANG ZHIRONG,INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (2023-05-22),https://lens.org/127-395-452-468-574,Patent Application,yes,0,0,4,136-226-186-430-061;;192-115-163-367-855;;127-395-452-468-574;;024-270-270-220-697,CN;;WO;;US,4,136-226-186-430-061;;192-115-163-367-855;;127-395-452-468-574;;024-270-270-220-697,CN;;WO;;US,58,C07K14/005;;A61K39/12;;A61P31/20;;A61P35/00;;C12N15/86;;C12N2710/14043;;C12N2710/20022;;C12N2710/20023;;C12N2710/20034;;C12N2800/22;;C07K14/005;;A61K39/12;;A61K2039/5258;;A61K2039/575;;A61P31/20;;A61P35/00;;C07K14/025;;C12N7/00;;C12N7/04;;C12N15/63;;C12N15/866;;C12N2710/20034;;C07K14/005;;A61K39/12;;A61K2039/5258;;C12N2710/20022;;C12N2710/20023;;C12N2710/20034;;C12N2710/20071,C07K14/005;;A61K39/12,,0,0,,,,PENDING
91,WO,A1,WO 2024/250838 A1,088-232-183-161-347,2024-12-12,2024,CN 2024087856 W,2024-04-16,CN 202310652547 A,2023-06-05,"ANTIBODY BINDING TO IL-11, ANTIGEN-BINDING FRAGMENT THEREOF, AND USES THEREOF","The present invention relates to the field of biomedicine, and specifically provides an antibody binding to IL-11 or antigen-binding fragment thereof, comprising three heavy-chain complementarity-determining regions respectively represented by HCDR1, HCDR2, and HCDR3, and three light-chain complementarity-determining regions respectively represented by LCDR1, LCDR2, and LCDR3, the antibody or antigen-binding fragment thereof being selected from A-I, A-II, A-III, or A-IV. The provided antibody or antigen-binding fragment thereof has high binding capacity to the IL-11 antigen and can block the IL-11 antigen from binding to receptors thereof, thus effectively inhibiting the pro-fibrotic effect of IL-11 and inhibiting or preventing the generation or proliferation of fibroblasts, and can be effectively used for treating or preventing human fibrotic diseases, inflammation, cancers, or autoimmune diseases.",BEIJING DONGFANG BIOTECH CO LTD;;BEIJING JINGYITAIXIANG TECH DEVELOPMENT CO LTD,BAI YI,,https://lens.org/088-232-183-161-347,Patent Application,yes,5,1,6,087-422-418-078-603;;088-232-183-161-347;;088-419-870-725-829;;174-749-049-718-676;;177-536-502-313-969;;086-561-202-302-593,CN;;WO;;TW,6,087-422-418-078-603;;088-232-183-161-347;;088-419-870-725-829;;086-561-202-302-593;;177-536-502-313-969;;174-749-049-718-676,CN;;WO;;TW,40,C07K16/244;;G01N33/6869;;A61P29/00;;A61P35/00;;A61P37/02;;C07K2317/565;;C07K2317/56;;C07K2317/52;;A61K2039/505;;A61K39/395;;A61P29/00;;A61P35/00;;A61P37/02;;C07K16/00;;C07K16/24;;G01N33/68,C07K16/24;;A61K39/395;;C12N15/13,,1,1,096-202-412-311-162,33262481;;10.1038/s12276-020-00531-5;;pmc7705429,"NG BENJAMIN, COOK STUART A., SCHAFER SEBASTIAN: ""Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway"", EXPERIMENTAL AND MOLECULAR MEDICINE, SEOUL, KR, vol. 52, no. 12, 1 December 2020 (2020-12-01), KR , pages 1871 - 1878, XP093246130, ISSN: 1226-3613, DOI: 10.1038/s12276-020-00531-5",PENDING
92,US,A1,US 2025/0072433 A1,081-173-456-271-946,2025-03-06,2025,US 202217958747 A,2022-10-03,US 202217958747 A;;US 202163251864 P;;US 202263409507 P,2021-10-04,ORGANIC CONCENTRATED VITAMINE-PHYTOHORMONE WITH NATURAL BIO-STIMULANT PROPERTIES AS FERTILIZER CONCENTRATED EXTRACT OF DUCKWEED ARACEA FAMILY OF PLANTS FORMALY KNOWN AS LEMNACEAE SINGLE OR COMBINED SPECIES THAT CAN INCLUDE ALSO COMPOUNDED MULTIPLE FORMULATED AQUATIC PLANTS EXTRACTS TO NATURALY INCREASE PLANT GROWTH AND CROP YIELDS,"A method is provided for biologically stimulating growth of and/or regulate enhancing performance plant for agricultural and non-agricultural purposes crop plants and non-crop plants like ornamental plants, industrial material plants, energy biomass production plants, pharmaceutical interest plants, spices, algae, kelp, etc. And beneficial productivity use in aquaculture as hydroponic systems, etc. comprising applying to the plants a DuckWeed.Bio Concentrated Products depending on the target crop customized formulation product and products having an a Auxin IAA or IBA or a combination comprised of Auxins to Cytokinins by biological activity measurement approximate concentration ratio of at least 10:1 to 30:1 and up to 100:1 to 500:1 but not limited to as synergistically can reach much higher levels of ration beyond 1000:1 depending on the compounding formulation mixes of Aquatic Plants and or its extracts.",GREENBERG CORDERO EDWARD,GREENBERG CORDERO EDWARD PAUL,,https://lens.org/081-173-456-271-946,Patent Application,yes,0,0,1,081-173-456-271-946,US,1,081-173-456-271-946,US,0,C05F11/10;;A01P21/00;;A01N43/38;;A01N43/90;;A01N43/38;;A01P21/00;;A01N43/90;;C05F11/10;;A01N65/40;;C05G5/23,A01N65/40;;A01N43/38;;A01N43/90;;A01P21/00;;C05F11/10;;C05G5/23,,0,0,,,,PENDING
93,WO,A1,WO 2024/239281 A1,141-620-292-365-626,2024-11-28,2024,CN 2023096066 W,2023-05-24,CN 2023096066 W,2023-05-24,TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE,"Provided herein is an antibody-drug conjugate with a side chain linker containing an affinity ligand for enhancement of targeted treatment of prostate cancers and other tumors. It also relates to preparation of such conjugate, pharmaceutical compositions, and methods in treatment of cancers.",HANGZHOU SEEHE BIOTECHNOLOGY CO LTD;;ZHAO ROBERT YONGXIN;;HANGZHOU DAC BIOTECH CO LTD,ZHAO ROBERT YONGXIN;;YANG QINGLIANG;;HUANG YUANYUAN;;YE HANGBO;;ZHANG LINGLI;;GUO HUIHUI;;JIA JUNXIANG;;WANG JUAN;;LI WENJUN;;BAI LU,,https://lens.org/141-620-292-365-626,Patent Application,yes,7,0,3,147-933-251-661-379;;018-178-349-059-163;;141-620-292-365-626,WO;;TW,3,147-933-251-661-379;;018-178-349-059-163;;141-620-292-365-626,WO;;TW,0,A61P31/00;;A61P35/00;;A61P37/00;;C07K7/08;;C07K2319/10;;A61K9/0019;;A61K47/6889;;A61K47/68037;;A61K47/68031,A61K47/00;;A61K47/50;;A61P31/00;;A61P35/00;;A61P37/00;;C07K7/00,,0,0,,,,PENDING
94,US,A1,US 2024/0094205 A1,122-749-429-779-829,2024-03-21,2024,US 202218264965 A,2022-02-11,FR 2101445 A;;FR 2022050254 W,2021-02-15,IMMUNOLOGICAL TEST FOR THE DETECTION OF VIRAL INFECTIONS,"The invention relates to a method for in vitro diagnosis of a viral infection due to the presence of a vims in a subject,comprising a step of detecting at least one antigen specific for said vims by means of an immunological test carried out on a biologicalsample from said subject, characterized in that said biological sample consists of a combination of saliva and secretions from the anteriornasal vestibule of the subject.",UNIV JEAN MONNET SAINT ETIENNE;;CENTRE HOSPITALIER UNIV DE SAINT ETIENNE;;BIOSPEEDIA,BEGAUD EVELYNE;;GERMANI YVES;;POZZETTO BRUNO;;BOURLET THOMAS;;HADDAR CYRILLE HEDI;;PILLET SYLVIE;;MOUNIER SANDRA,BIOSPEEDIA (2023-10-23);;CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE (2023-10-23);;UNIVERSITE JEAN MONNET SAINT ETIENNE (2023-10-23),https://lens.org/122-749-429-779-829,Patent Application,yes,0,0,5,122-749-429-779-829;;019-462-503-725-967;;190-334-374-318-110;;012-489-619-728-882;;181-776-747-700-569,EP;;WO;;US;;CA;;FR,5,190-334-374-318-110;;019-462-503-725-967;;122-749-429-779-829;;012-489-619-728-882;;181-776-747-700-569,EP;;WO;;US;;CA;;FR,0,G01N33/54388;;G01N33/56983;;G01N2333/165;;G01N2469/10;;G01N33/56983;;G01N2333/165;;G01N2469/10,G01N33/569,,0,0,,,,PENDING
95,EP,A1,EP 4159853 A1,158-962-662-854-118,2023-04-05,2023,EP 20938166 A,2020-11-30,CN 2020092799 W;;CN 2020132759 W,2020-05-28,GENOME EDITING SYSTEM AND METHOD,"Provided is a genome editing system and method for gene editing at least one target sequence in a cell genome. The genome editing system comprises: (1) an expression construct comprising a Cas12f nuclease; and (2) an expression DNA sequence comprising a guide RNA corresponding to the Cas12f nuclease, and an expression construct of the targeting sequence of the target sequence. The gene editing system or method can accurately knock out a target gene from within a cell; in addition, in an in vitro cutting experiment, the target gene can be accurately cut.",UNIV SHANGHAI TECHNOLOGY,JI QUANJIANG;;WU ZHAOWEI;;ZHANG YIFEI;;WANG YUJUE;;WANG YANNAN,,https://lens.org/158-962-662-854-118,Patent Application,yes,0,0,5,158-962-662-854-118;;061-882-844-532-585;;019-817-220-143-983;;006-305-514-804-264;;126-094-332-601-187,EP;;CN;;WO;;US,5,158-962-662-854-118;;061-882-844-532-585;;019-817-220-143-983;;006-305-514-804-264;;126-094-332-601-187,EP;;CN;;WO;;US,152,C12N15/113;;C12N9/22;;C12N9/52;;C12N2310/20;;C12N2310/20;;C12N9/22;;C12N15/11;;C12N15/902;;C12N15/907;;C12N2800/80,C12N9/22;;C07K14/00;;C12N15/113;;C12N15/52,,0,0,,,,DISCONTINUED
96,US,A1,US 2023/0212612 A1,126-094-332-601-187,2023-07-06,2023,US 202017927563 A,2020-11-30,CN 2020092799 W;;CN 2020132759 W,2020-05-28,GENOME EDITING SYSTEM AND METHOD,"Provided is a genome editing system and method for gene editing at least one target sequence in a cell genome. The genome editing system comprises: (1) an expression construct comprising a Cas12f nuclease; and (2) an expression DNA sequence comprising a guide RNA corresponding to the Cas12f nuclease, and an expression construct of the targeting sequence of the target sequence. The gene editing system or method can accurately knock out a target gene from within a cell; in addition, in an in vitro cutting experiment, the target gene can be accurately cut.",UNIV SHANGHAI TECHNOLOGY,JI QUANJIANG;;WU ZHAOWEI;;ZHANG YIFEI;;WANG YUJUE;;WANG YANNAN,SHANGHAITECH UNIVERSITY (2022-10-12),https://lens.org/126-094-332-601-187,Patent Application,yes,0,0,5,158-962-662-854-118;;061-882-844-532-585;;019-817-220-143-983;;006-305-514-804-264;;126-094-332-601-187,EP;;CN;;WO;;US,5,158-962-662-854-118;;061-882-844-532-585;;019-817-220-143-983;;006-305-514-804-264;;126-094-332-601-187,EP;;CN;;WO;;US,130,C12N15/113;;C12N9/22;;C12N9/52;;C12N2310/20;;C12N2310/20;;C12N9/22;;C12N15/11;;C12N15/902;;C12N15/907;;C12N2800/80,C12N15/90;;C12N9/22;;C12N15/11,,2,2,002-044-326-015-382;;090-358-108-298-402,32782413;;pmc7419031;;10.1038/s41573-020-0075-7;;10.3389/fbioe.2021.628137;;pmc8012680;;33816449,"Roberts et al (Nature Reviews: Drug Discovery, Vol. 19, pages 673-694 (2020)) (Year: 2020);;Damase et al (Frontiers in Bioengineering and Biotech., Vol. 9, article 628137, pages 1-24 (2021)) (Year: 2021)",PENDING
97,US,A1,US 2024/0261379 A1,097-708-559-374-648,2024-08-08,2024,US 202218562810 A,2022-05-19,CN 202110545336 A;;CN 2022093687 W,2021-05-19,"COMPOSITION COMPRISING PEDF-DERIVED SHORT PEPTIDE, PREPARATION METHOD THEREOF, AND USE THEREOF","The present invention relates to a composition, a preparation method therefor, and a use thereof. The composition comprises a PEDF-derived short peptide (PDSP), a stabilizer, and a buffer agent. The pH of the composition ranges from 4 to 9. The stabilizer is a copolymer of vinyl pyrrolidone and vinyl acetate. The buffer agent is selected from a citric acid buffer system, a phosphoric acid buffer system, a boric acid buffer system, a histidine buffer system, or a combination thereof. The composition has improved stability, small irritation to eyes, and/or high bioavailability.",GRANDPHARMA CHINA CO LTD;;BRIM BIOTECHNOLOGY INC,LI LEI;;HU YIMIN;;ZHAN HUI;;XIANG CAIYUN;;QU LEI;;LIAW WEI-CHENG;;CHANG HUEI-LING;;CHIEN CHIH-TE;;CHIANG YI-LUN,BRIM BIOTECHNOLOGY INC (2023-11-09);;GRANDPHARMA(CHINA) CO. LTD (2023-11-09),https://lens.org/097-708-559-374-648,Patent Application,yes,0,1,4,034-814-849-233-062;;115-978-131-223-321;;097-708-559-374-648;;114-438-886-737-626,CN;;WO;;US,4,034-814-849-233-062;;115-978-131-223-321;;097-708-559-374-648;;114-438-886-737-626,CN;;WO;;US,9,A61K38/1709;;A61K38/10;;A61K9/08;;A61K47/32;;A61K9/0048;;A61K9/10;;A61K47/12;;A61K47/02;;A61K47/183;;A61P9/00;;A61P21/00;;A61P17/14;;A61P17/00;;A61P19/02;;A61P29/00;;A61P17/18;;A61P1/16;;A61P27/02;;A61P17/00;;A61P19/02;;A61P9/00;;A61K47/12;;A61P17/18;;A61K38/17;;A61P1/16;;A61P17/14;;A61K9/08;;A61P29/00;;A61K38/10;;A61P27/02;;A61P21/00;;A61K47/18;;C07K14/435;;A61K38/57;;A61K9/0048;;A61P27/02;;A61K38/57;;A61K47/12;;A61K47/22;;A61K47/32,A61K38/57;;A61K47/12;;A61K47/22;;A61K47/32;;A61P27/02,,0,0,,,,PENDING
98,EP,A1,EP 3791884 A1,161-708-603-363-030,2021-03-17,2021,EP 19197581 A,2019-09-16,EP 19197581 A,2019-09-16,COMBINATION OF HEPARIN AND MAGNESIUM SALT FOR THE TREATMENT OF VIRAL INFECTIONS,"A pharmaceutical or veterinary composition is disclosed, comprising heparin and one or more pharmaceutically acceptable magnesium salts. Further, the pharmaceutical or veterinary composition or a combination of heparin and one or more pharmaceutically acceptable magnesium salts for use in a prophylactic or therapeutic method for treating virus infections is disclosed. The treatment preferably is a topical treatment or intravenous treatment.",BUNZ OSKAR;;MESE KEMAL;;ERHARDT ANJA,BUNZ OSKAR;;MESE KEMAL;;ERHARDT ANJA,"ERHARDT, ANJA (2025-06-04);;MESE, KEMAL (2025-06-04)",https://lens.org/161-708-603-363-030,Patent Application,yes,8,0,1,161-708-603-363-030,EP,1,161-708-603-363-030,EP,0,A61K31/727;;A61K33/14;;A61P31/12,A61K31/727;;A61K33/14;;A61P31/12,,25,23,029-799-212-242-419;;189-710-166-935-115;;090-484-429-113-832;;033-650-103-525-777;;077-184-061-965-926;;064-503-142-651-973;;018-966-884-362-348;;048-512-049-867-459;;144-281-538-905-078;;011-844-504-360-595;;064-304-340-921-32X;;026-605-000-268-425;;033-889-111-076-347;;082-917-640-941-941;;038-791-310-850-530;;001-673-514-399-235;;001-766-266-622-276;;006-814-089-926-935;;032-720-616-533-830;;011-785-665-944-447;;174-557-474-707-71X;;004-747-996-231-141;;122-724-476-230-184,10.1128/jb.87.5.1060-1066.1964;;4289440;;pmc277146;;10.1039/c4md00516c;;18655013;;10.1002/rmv.589;;10.1182/blood-2009-03-208835;;pmc2721791;;19429866;;10.1128/jvi.72.9.7349-7356.1998;;9696831;;pmc109959;;23015725;;pmc3503077;;10.1128/jvi.01364-12;;pmc115122;;11507222;;10.1128/jvi.75.18.8772-8780.2001;;10.1073/pnas.82.10.3197;;pmc397742;;3858816;;8707165;;10.1159/000217270;;10.1371/journal.pone.0115252;;25521480;;pmc4270745;;10.1128/jvi.74.20.9553-9561.2000;;11000226;;pmc112386;;17967492;;pmc2169429;;10.1016/j.mimet.2007.10.002;;10.1134/s0036023606060106;;10.1586/14787210.2013.836964;;24073835;;10.1093/glycob/10.11.1147;;11087707;;pmc4508384;;pmc4377380;;26236728;;10.1155/2015/297425;;10.1155/2015/549417;;25861358;;11518721;;pmc209412;;10.1172/jci200113799;;10.1172/jci13799;;10.1007/s12013-010-9129-5;;20981507;;18267072;;10.1016/j.cell.2008.01.016;;pmc3255932;;10.1128/jvi.06357-11;;22072779;;6667532;;10.1248/cpb.31.3214;;10.1074/jbc.m111.241562;;21596747;;pmc3137028;;10.3390/ijms221810075;;34576237;;pmc8466540,"NAHMIAS A J ET AL: ""Inhibitory effect of heparin on herpes simplex virus."", JOURNAL OF BACTERIOLOGY MAY 1964, vol. 87, no. 5, May 1964 (1964-05-01), pages 1060 - 1066, XP009519128, ISSN: 0021-9193;;MARK A. SKIDMORE ET AL: ""Inhibition of influenza H5N1 invasion by modified heparin derivatives"", MEDCHEMCOMM, vol. 6, no. 4, 1 January 2015 (2015-01-01), United Kingdom, pages 640 - 646, XP055672513, ISSN: 2040-2503, DOI: 10.1039/C4MD00516C;;LIESBETH LENAERTS ET AL: ""Clinical features and treatment of adenovirus infections"", REVIEWS IN MEDICAL VIROLOGY, vol. 18, no. 6, 1 November 2008 (2008-11-01), GB, pages 357 - 374, XP055672514, ISSN: 1052-9276, DOI: 10.1002/rmv.589;;ALBA, R.BRADSHAW, A. C.PARKER, A. L.BHELLA, D.WADDINGTON, S. N.NICKLIN, S. A.BAKER, A. H.: ""Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer"", BLOOD, vol. 114, no. 5, 2009, pages 965 - 971;;BYRNES, A. P.GRIFFIN, D. E.: ""Binding of Sindbis Virus to Cell Surface Heparan Sulfate"", JOURNAL OF VIROLOGY, vol. 72, no. 9, 1998, pages 7349 - 7356;;BOER, S. M.KORTEKAAS, J.DE HAAN, C. A. M.ROTTIER, P. J. M.MOORMANN, R. J. M.BOSCH, B. J.: ""Heparan Sulfate Facilitates Rift Valley Fever Virus Entry into the Cell"", JOURNAL OF VIROLOGY, vol. 86, no. 24, 2012, pages 13767 - 13771;;DECHECCHI, M. C.MELOTTI, P.BONIZZATO, A.SANTACATTERINA, M.CHILOSI, M.CABRINI, G.: ""Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5"", J VIROL, vol. 75, no. 18, 2001, pages 8772 - 8780, XP002264248, doi:10.1128/JVI.75.18.8772-8780.2001;;ESKO, J. D.STEWART, T. E.TAYLOR, W. H.: ""Animal cell mutants defective in glycosaminoglycan biosynthesis"", PROC NATL ACAD SCI USA, vol. 82, no. 10, 1985, pages 3197 - 3201;;FRYDMAN, A.: ""Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans"", HAEMOSTASIS, vol. 26, no. 2, 1996, pages 24 - 38;;HU, Q. Y.FINK, E.GRANT, C. K.ELDER, J. H.: ""Selective interaction of heparin with the variable region 3 within surface glycoprotein of laboratory-adapted feline immunodeficiency virus"", PLOS ONE, vol. 9, no. 12, 2014, pages e115252;;HULST, M. M.VAN GENNIP, H. G. P.MOORMANN, R. J. M.: ""Passage of Classical Swine Fever Virus in Cultured Swine Kidney Cells Selects Virus Variants That Bind to Heparan Sulfate due to a Single Amino Acid Change in Envelope Protein Erns"", JOURNAL OF VIROLOGY, vol. 74, no. 20, 2000, pages 9553 - 9561;;KANG, J.LEE, M. S.GORENSTEIN, D. G.: ""Magnesium ion is an effective inhibitor of the binding of Escherichia coli to heparin"", J MICROBIOL METHODS, vol. 71, no. 3, 2007, pages 340 - 342, XP022363805, doi:10.1016/j.mimet.2007.10.002;;KAROW, T.LANG-ROTH, R.: ""Allgemeine und spezielle Pharmakologie und Toxikologie"", SELBSTVERLAG, PULHEIM, vol. 21, 2012, pages 681;;KARPUKHIN, L. E.FEOFANOVA, M. A.NIKOLAEVA, L. S.MAMONTOV, M. N.DOBRYNINA, N. A.: ""Complexation of magnesium and calcium ions with heparin"", RUSSIAN JOURNAL OF INORGANIC CHEMISTRY, vol. 51, no. 6, 2006, pages 908 - 914, XP019414514, doi:10.1134/S0036023606060106;;MATTHES-MARTIN, S.BOZTUG, H.LION, T.: ""Diagnosis and treatment of adenovirus infection in immunocompromised patients"", EXPERT REV ANTI INFECT THER, vol. 11, no. 10, 2013, pages 1017 - 1028;;MULLOY, B.FORSTER, M. J.: ""Conformation and dynamics of heparin and heparan sulfate"", GLYCOBIOLOGY, vol. 10, no. 11, 2000, pages 1147 - 1156;;OLCZYK, P.MENCNER, L.KOMOSINSKA-VASSEV, K.: ""Diverse Roles of Heparan Sulfate and Heparin in Wound Repair"", BIOMED RES INT, 2015, pages 549417;;RYU, W.-S.: ""Molecular Virology of Human Pathogenic Viruses"", 2016, ACADEMIC PRESS;;SHUKLA, D.SPEAR, P. G.: ""Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry"", J CLIN INVEST, vol. 108, no. 4, 2001, pages 503 - 510, XP002493479;;STEVIC, I.PARMAR, N.PAREDES, N.BERRY, L. R.CHAN, A. K. C.: ""Binding of Heparin to Metals"", CELL BIOCHEMISTRY AND BIOPHYSICS, vol. 59, no. 3, 2011, pages 171 - 178;;WADDINGTON, S. N.MCVEY, J. H.BHELLA, D.PARKER, A. L.BARKER, K.ATODA, H.BAKER, A. H.: ""Adenovirus serotype 5 hexon mediates liver gene transfer"", CELL, vol. 132, no. 3, 2008, pages 397 - 409, XP009118580, doi:10.1016/j.cell.2008.01.016;;WU, C.WANG, S.: ""A pH-sensitive heparin-binding sequence from Baculovirus gp64 protein is important for binding to mammalian cells but not to Sf9 insect cells"", J VIROL, vol. 86, no. 1, 2012, pages 484 - 491;;YAMANE, Y.SAITO, S.KOIZUMI, T.: ""Effects of calcium and magnesium on the anticoagulant action of heparin"", CHEM PHARM BULL (TOKYO), vol. 31, no. 9, 1983, pages 3214 - 3221;;ZAISS, A. K.LAWRENCE, R.ELASHOFF, D.ESKO, J. D.HERSCHMAN, H. R.: ""Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate"", J BIOL CHEM, vol. 286, no. 28, 2011, pages 24535 - 24543;;MESE KEMAL: ""Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses"", 17 September 2021 (2021-09-17), XP093009169, Retrieved from the Internet <URL:https://pmc.ncbi.nlm.nih.gov/articles/PMC8466540/pdf/ijms-22-10075.pdf> [retrieved on 20221218], DOI: https://doi.org/10.3390/ijms221810075",PENDING
99,US,A1,US 2021/0079329 A1,126-244-117-522-25X,2021-03-18,2021,US 201816630734 A,2018-07-13,US 201816630734 A;;US 201762532031 P;;US 2018/0041995 W,2017-07-13,CULTURE PLATES FOR IMAGING,"Specialized culture plates for imaging cells in a quick, high throughput manner are provided. Ideally the wells of the culture plate have triangular, square, or V-shaped wells or cell sorting walls having a plurality of vertices, and more complicated variations thereof are also possible. The plates are tilted or rotated to collect the cells at the vertex or vertices of the wells, optionally vibrated to speed the collection, then the vibration and tilt or rotation removed for some period of time, whereon the cells are imaged through the flat transparent bottom of the plate.",GREINER BIO ONE NORTH AMERICA INC,SOUZA GLAUCO,GREINER BIO-ONE NORTH AMERICA INC (2020-01-14),https://lens.org/126-244-117-522-25X,Patent Application,yes,8,5,8,083-740-180-208-727;;037-355-295-614-099;;154-919-486-629-886;;002-493-181-739-921;;184-035-932-552-191;;126-244-117-522-25X;;005-427-371-483-158;;092-762-570-255-450,JP;;EP;;WO;;US;;BR,8,083-740-180-208-727;;037-355-295-614-099;;154-919-486-629-886;;002-493-181-739-921;;184-035-932-552-191;;092-762-570-255-450;;005-427-371-483-158;;126-244-117-522-25X,JP;;EP;;WO;;US;;BR,0,C12M23/12;;C12M23/22;;C12M23/38;;C12M23/46;;C12M27/16;;C12M33/22;;C12M23/12;;C12M23/22;;C12M23/38;;C12M23/46,C12M1/32;;C12M1/00;;C12M3/00,,1,0,,,Diversified Biotech. WPST-1000. Well Plate Stand. https://web.archive.org/web/20150512182511/https://www.amazon.com/Diversified-Biotech-WPST-1000-Plate-Stand/dp/B00BR3GXWS published 5/12/15,ACTIVE
100,WO,A1,WO 2025/125266 A1,145-832-605-334-485,2025-06-19,2025,EP 2024085567 W,2024-12-10,US 202363608725 P,2023-12-11,"TABLETS CONTAINING FUCTIONALIZED AGAROSE PARTICLES, METHOD FOR PRODUCING THEM AND USE OF THE TABLETS","Described is a material in form of a tablet as a three-dimensional body with a side length and/or diameter of more than 1 mm, comprising a plurality of agarose microparticles. Furthermore, a method for preparing this material and its use are described.",CUBE BIOTECH GMBH,FABIS ROLAND;;ERKELENZ DANIEL;;MAERTENS BARBARA;;KUBICEK JAN;;HANISCH PHILIPP TIMO;;ERKELENZ MICHAEL,,https://lens.org/145-832-605-334-485,Patent Application,yes,17,0,1,145-832-605-334-485,WO,1,145-832-605-334-485,WO,0,A61K9/205;;A61K9/10;;A61K47/36;;C07K1/22;;G01N33/5434;;B01D15/3828;;B01J20/28009;;B01J20/289;;B01J20/3212;;B01J20/3219;;B01J20/3274;;B01J20/3293,A61K9/20;;A61B5/00;;A61K9/10;;A61K47/36;;B01D15/08;;C07K1/22;;G01N33/50,,13,10,139-623-201-631-725;;055-796-994-390-844;;037-888-526-951-319;;039-044-846-162-987;;148-605-944-853-764;;093-823-009-739-081;;055-796-994-390-844;;000-617-154-308-842;;019-565-087-880-424;;116-919-283-583-090,10.1016/j.chroma.2023.464365;;37696128;;10.1016/0021-9673(93)83084-6;;37233493;;10.3390/md21050299;;pmc10220669;;10.22270/jddt.v8i6.2060;;1678;;10.1038/258598a0;;10.1016/s0021-9673(00)93969-4;;3443622;;10.1016/0021-9673(93)83084-6;;874026;;10.1016/s0021-9673(00)88384-3;;10.1021/acsomega.7b00362;;30023643;;pmc6044777;;10.1101/pdb.top11;;21357153,"ZHAO YA-QI ET AL: ""Synthesis of micron-sized magnetic agarose beads chelated with nickel ions towards the affinity-based separation of histidine-tagged/rich proteins"", JOURNAL OF CHROMATOGRAPHY A, vol. 1708, 9 September 2023 (2023-09-09), AMSTERDAM, NL, pages 464365, XP093246476, ISSN: 0021-9673, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/271409/1-s2.0-S0021967323X0020X/1-s2.0-S0021967323005903/main.pdf?hash=6a6f8b16b9a6dcd7fefd3abc6cc8357f56d48409f9c648b2985f6656c4c2bbf9&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0021967323005903&tid=spdf-ac5c3adf-0934-47e8-8f35-32a> DOI: 10.1016/j.chroma.2023.464365;;CUBE BIOTECH: ""Guide to magnetic beads / MagBeads for protein purification"", 11 September 2019 (2019-09-11), XP093246959, Retrieved from the Internet <URL:https://www.youtube.com/watch?v=4JBWN5G8EBg>;;LIFE TECHNOLOGIES CORPORATION: ""Streptavidin Agarose"", 3 October 2012 (2012-10-03), pages 1 - 16, XP093246670, Retrieved from the Internet <URL:https://tools.thermofisher.com/content/sfs/manuals/streptavidin_agarose_man.pdf>;;VAN SOMMEREN A P G ET AL: ""Comparison of three activated agaroses for use in affinity chromatography: Effects on coupling performance and ligand leakage"", JOURNAL OF CHROMATOGRAPHY A, ELSEVIER, AMSTERDAM, NL, vol. 639, no. 1, 4 June 1993 (1993-06-04), pages 23 - 31, XP026531646, ISSN: 0021-9673, DOI: 10.1016/0021-9673(93)83084-6;;JIANG ET AL.: ""Extraction, Modification and Biomedical Application of Agarose Hydrogels: A Review"", MAR. DRUGS, vol. 21, 2023, pages 299, Retrieved from the Internet <URL:https://doi.org/10.3390/md21050299>;;PRIYANKA, KAPIL KUMARDEEPAK TEOTIA, JOURNAL OF DRUG DELIVERY & THERAPEUTICS, vol. 8, no. 6, 2018, pages 382 - 390;;PORATH, J. ET AL.: ""Metal chelate affinity chromatography, a new approach to protein fractionation"", NATURE, vol. 258, 1975, pages 598 - 599, XP037056307, DOI: 10.1038/258598a0;;HOCHULI, E.DÖBELI, H.SCHACHER, A: ""New metal chelate adsorbent for proteins and peptides containing neighbouring histidine residues"", J CHROMATOGR, vol. 411, 1987, pages 177 - 184, XP026487206, DOI: 10.1016/S0021-9673(00)93969-4;;A.P.G. VAN SOMMERENP.A.G.M. MACHIELSENT.C.J. GRIBNAU: ""Comparison of three activated agaroses for use in affinity chromatography: Effects on coupling performance and ligand leakage"", JOURNAL OF CHROMATOGRAPHY A, vol. 639, 1993, pages 23 - 31, XP026531646, Retrieved from the Internet <URL:https://doi.org/10.1016/0021-9673(93)83084-6> DOI: 10.1016/0021-9673(93)83084-6;;RICHARD F. MURPHYJ.MICHAEL CONLONASHRAF IMAMGREGORY J.C. KELLY: ""Comparison of non-biospecific effects in immunoaffinity chromatography using cyanogen bromide and bifunctional oxirane as immobilising agents"", JOURNAL OF CHROMATOGRAPHY A, vol. 135, 1977, pages 427 - 433, XP026484308, Retrieved from the Internet <URL:https://doi.org/10.1016/S0021-9673(00)88384-3> DOI: 10.1016/S0021-9673(00)88384-3;;ZHANG XDUAN YZENG X: ""Improved Performance of Recombinant Protein A Immobilized on Agarose Beads by Site-Specific Conjugation"", ACS OMEGA, vol. 2, no. 4, 28 April 2017 (2017-04-28), pages 1731 - 1737;;EINARSON MBORLINICK JR: ""Protein-Protein Interactions: A Molecular Cloning Manual"", 2002, COLD SPRING HARBOR LABORATORY PRESS, article ""Identification of Protein-Protein Interactions with Glutathione S-Transferase Fusion Proteins"", pages: 37 - 57;;WHITTEN, KENNETH W.KENNETH D. GAILEYRAYMOND E. DAVIS: ""7-3 Formation of covalent bonds"", GENERAL CHEMISTRY, 1992, pages 264",PENDING
101,US,A1,US 2021/0000122 A1,133-378-615-941-091,2021-01-07,2021,US 201816768590 A,2018-11-23,CN 201711261668 A;;CN 2018117249 W,2017-12-04,"RHIZOBIUM AND USE AND BACTERIAL PREPARATION THEREOF, AND METHOD FOR RESTORING RARE-EARTH TAILING SOIL OR SILICA ORE TAILING WASTE","Provided is a type of rhizobium with the classified nomenclature of Bradyrhizobium sp. KTMS 0001 or Bradyrhizobium sp. KTMS 0002, and the deposit number of CCTCC No. M2017580 or CCTCC No. M2017581. Also provided are a bacterial preparation containing the rhizobium, a method for restoring rare-earth tailings soil and a use of the rhizobium.",BONTECH WELFARE ACADEMY OF ENV SCIENCE BEIJING CO LTD,XIE STAEHELIN ZHIPING;;ZHOU SHAOZHAN;;WANG SUIHUA,BONTECH WELFARE ACADEMY OF ENVIRONMENTAL SCIENCE (BEIJING) CO. LTD (2020-04-08),https://lens.org/133-378-615-941-091,Patent Application,yes,0,1,8,164-653-322-168-697;;056-214-049-484-508;;038-302-591-573-954;;091-161-860-175-90X;;133-378-615-941-091;;141-020-006-499-721;;152-872-804-759-865;;151-455-005-095-018,CN;;WO;;US,8,164-653-322-168-697;;056-214-049-484-508;;038-302-591-573-954;;091-161-860-175-90X;;133-378-615-941-091;;152-872-804-759-865;;141-020-006-499-721;;151-455-005-095-018,CN;;WO;;US,2,C12N1/205;;C12R2001/01;;A01N63/20;;C09K17/14;;C09K2101/00;;C12N1/20;;C12N1/20;;A01N63/20;;C09K2101/00;;C12N1/205;;C12R2001/41;;C12N1/205;;A01N63/20;;C09K17/14;;C09K2101/00;;C12N1/20;;C12R2001/01;;C12R2001/41,A01N63/20;;C09K17/14;;C12N1/20,,0,0,,,,ACTIVE
102,US,A1,US 2021/0079035 A1,059-884-981-690-827,2021-03-18,2021,US 201716772115 A,2017-12-11,IB 2017001759 W,2017-12-11,COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS,"Compounds for treating neurodegenerative disorders The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.",ETHNODYNE;;CENTRE NAT RECH SCIENT,RABHI CHÉRIF;;CARIEL LÉON;;DA COSTA NOBLE CHRISTIAN;;OUAZZANI JAMAL;;ARCILE GUILLAUME;;LE GOFF GÉRALDINE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (2020-06-19);;ETHNODYNE (2020-06-19),https://lens.org/059-884-981-690-827,Patent Application,yes,0,0,3,059-884-981-690-827;;045-784-577-865-035;;113-935-424-003-266,EP;;WO;;US,3,059-884-981-690-827;;045-784-577-865-035;;113-935-424-003-266,EP;;WO;;US,0,C07K5/0205;;C07J71/001;;A61K9/0053;;A61P25/28,C07J71/00;;A61K9/00;;A61P25/28,,0,0,,,,DISCONTINUED
103,WO,A1,WO 2025/023895 A1,085-917-076-692-09X,2025-01-30,2025,SK 2023050023 W,2023-07-26,SK 2023050023 W,2023-07-26,ANTIBODY AGAINST COMPLEMENT COMPONENT C4D,"A specific immunogenic peptide for the production of rabbit antibody against human complement protein C4d. In transplants, rejection of the donor organ by the recipient may occur. Immunohistochemical examination can detect pathological changes in the transplant after its rejection. A part of the tissue is examined for the presence of the C4d component of complement as a marker of organ rejection. A unique immunogenic peptide was designed: CAQETGDNLYWGSVTGSQSNAVSP according the C4 complement protein sequence (P0C0L4 • CO4A_HUMAN), including the C4d fragment sequence. It is located in the interval of 1221 to 1243 amino acids in the original sequence and is part of the alpha chain of the complement C4 protein. The immunogenic peptide contains the selected linear epitope GSVTG for the antibody against C4d in the range of 1231 to 1235 amino acids. Anti-C4d antibody is applicable in clinical diagnosis of organ rejection after transplants.",DB BIOTECH A S,DOBRANSKY TOMAS,,https://lens.org/085-917-076-692-09X,Patent Application,yes,4,0,1,085-917-076-692-09X,WO,1,085-917-076-692-09X,WO,1,C07K16/18;;G01N2333/4716;;G01N33/564;;G01N2800/245,C07K16/18;;G01N33/563;;G01N33/577;;G01N37/00,,8,5,056-988-234-165-612;;006-269-368-383-688;;024-636-126-231-934;;043-126-885-458-880;;099-610-009-077-451,18085389;;10.1007/s10157-007-0496-1;;10.1016/b978-0-323-53186-3.00025-5;;pmc1554190;;10.1111/j.1365-2249.1991.tb02954.x;;1747954;;12352891;;10.1097/00007890-200209150-00021;;12717204;;10.1097/01.tp.0000062835.30165.2c,"SUZUKI TAISEI ET AL: ""C4d Immunohistochemistry in glomerulonephritis with different antibodies"", CLINICAL AND EXPERIMENTAL NEPHROLOGY, JAPANESE SOCIETY OF NEPHROLOGY, TOKYO, JP, vol. 11, no. 4, 1 December 2007 (2007-12-01), pages 287 - 291, XP036418778, ISSN: 1342-1751, [retrieved on 20071201], DOI: 10.1007/S10157-007-0496-1;;FORM ANONYMOUS: ""Anti-C4d antibody, prediluted ab58781, abcam"", 1 January 2014 (2014-01-01), XP055152498, Retrieved from the Internet <URL:http://www.abcam.com/C4d-antibody-prediluted-ab58781.pdf> [retrieved on 20141112];;FARRIS IIIALTON B.LYNN D. CORNELLROBERT B. COLVIN: ""Pathology of Kidney."", KIDNEY TRANSPLANTATION-PRINCIPLES AND PRACTICE E-BOOK, vol. 379, 2019, pages 25;;JANEWAY JRCHARLES A. ET AL.: ""The complement system and innate immunity.'' Immunobiology: The Immune System in Health and Disease. 5th editio"", ARLAND SCIEN;;ABBAS, ABUL K.ANDREW H. LICHTMANSHIV PILLAI, CELLULAR AND MOLECULAR IMMUNOLOGY;;FEUCHT, H. E ET AL.: ""Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection"", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 3, no. 86, 1991, pages 464 - 470;;HAASMARKLLOYD E. RATNERROBERT A. MONTGOMERY.: ""C4d staining of perioperative renal transplant biopsies1"", TRANSPLANTATION, 2002, pages 711 - 717;;SUND, STALE ET AL.: ""Complement activation in early protocol kidney graft biopsies after living-donor transplantation1"", TRANSPLANTATION, vol. 75, no. 8, 2003, pages 204 - 121",PENDING
104,WO,A1,WO 2023/172557 A1,150-473-593-093-109,2023-09-14,2023,US 2023/0014715 W,2023-03-07,US 202263317133 P,2022-03-07,METHODS OF SELECTING TREATMENT FOR CANCER,"A method of assessing responsiveness to gaseous nitric oxide (gNO) treatment in a subject diagnosed with cancer is provided. The method comprising determining in a tissue of a subject an increase in cells of the adaptive humoral immune response and/or innate immune response above a predetermined threshold following local treatment with an effective amount of gNO, the increase being indicative of an efficacious treatment with the gNO. Also provided is a method of determining a likelihood of a subject diagnosed with a primary tumor to develop a secondary tumor.",BEYOND AIR INC,LISI STEVEN A;;AVNIEL AMIR;;CONFINO HILA,,https://lens.org/150-473-593-093-109,Patent Application,yes,3,0,4,150-473-593-093-109;;085-791-531-834-950;;159-113-607-791-548;;052-912-698-823-525,AU;;IL;;EP;;WO,4,150-473-593-093-109;;085-791-531-834-950;;159-113-607-791-548;;052-912-698-823-525,AU;;IL;;EP;;WO,0,A61K33/00;;A61P35/00;;A61K33/00;;A61P35/00,A61K33/00;;A61P35/00,,22,22,077-173-325-921-246;;129-223-659-794-491;;047-905-808-005-296;;034-982-122-564-349;;063-859-335-884-408;;033-451-293-197-37X;;031-508-067-553-753;;051-643-734-085-808;;015-312-706-471-662;;057-743-762-704-895;;088-714-433-433-184;;088-296-876-616-079;;007-716-798-413-160;;094-144-767-492-104;;089-475-122-903-864;;039-368-622-672-081;;019-046-119-534-362;;030-588-179-490-917;;031-269-152-326-98X;;045-217-058-798-749;;001-163-196-019-048;;116-704-180-747-63X,pmc7136167;;10.1038/s41571-018-0134-8;;30514977;;10.1038/nrc.2016.25;;27009393;;pmc7055530;;10.1186/s40880-017-0206-7;;28372569;;pmc5379757;;pmc5380551;;28330928;;10.1158/0008-5472.can-16-1536;;30570109;;10.3892/ijo.2018.4661;;pmc6317661;;10.1158/0008-5472.can-19-1147;;31431464;;pmc6744993;;10.1007/s00018-016-2210-5;;pmc4956569;;27022944;;24238374;;pmc4281168;;10.1053/j.tvir.2013.08.002;;pmc5644150;;29037259;;10.1186/s40425-017-0284-8;;26674766;;10.1159/000367740;;pmc4608649;;10.1007/s00262-013-1462-2;;pmc11029492;;23955682;;pmc11029790;;25326364;;10.1007/s00262-014-1626-8;;27585790;;pmc5281669;;10.1007/s00262-016-1891-9;;25286319;;10.1016/j.bbcan.2014.09.005;;28031862;;pmc5137992;;10.4155/fso.15.44;;26335399;;10.1016/j.redox.2015.08.009;;pmc4565017;;29501865;;10.1016/j.ejphar.2018.02.040;;10.2174/2211738507666190429111306;;pmc6967185;;31595847;;24735538;;10.1016/j.bbrc.2014.04.032;;10.1016/j.niox.2008.04.018;;18477483;;10.1093/carcin/bgt034;;23354310;;10.1016/j.redox.2015.05.002;;26056766;;pmc4473092,"ANDERSON RLBALASAS TCALLAGHAN JCOOMBES RCEVANS JHALL JAKINRADE SJONES DJONES PSJONES R: ""A framework for the development of effective anti-metastatic agents"", NAT REV CLIN ONCOL, vol. 16, no. 3, March 2019 (2019-03-01), pages 185 - 204, XP037085254, DOI: 10.1038/s41571-018-0134-8;;STEEG PS: ""Targeting metastasis"", NAT REV CANCER, vol. 16, no. 4, April 2016 (2016-04-01), pages 201 - 18, XP055689817, Retrieved from the Internet <URL:10.1038/nrc.2016.25.PMID:27009393;PMCID:PMC7055530.> DOI: 10.1038/nrc.2016.25;;QIAN CNMEI YZHANG J: ""Cancer metastasis: issues and challenges"", CHIN J CANCER, vol. 36, no. 1, 3 April 2017 (2017-04-03), pages 38;;TOHME SSIMMONS RLTSUNG A: ""Surgery for Cancer: A Trigger for Metastases"", CANCER RES, vol. 77, no. 7, 22 March 2017 (2017-03-22), pages 1548 - 1552, XP055721715, DOI: 10.1158/0008-5472.CAN-16-1536;;SCHIRRMACHER V.: ""From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review"", INT J ONCOL, vol. 54, no. 2, 10 December 2018 (2018-12-10), pages 407 - 419;;KARAGIANNIS GS, CONDEELIS JS, OKTAY MH: ""Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions"", CANCER RES., vol. 79, no. 18, 20 August 2019 (2019-08-20), pages 4567 - 4576;;VILALTA MRAFAT MGRAVES EE: ""Effects of radiation on metastasis and tumor cell migration"", CELL MOL LIFE SCI, vol. 73, no. 16, 29 March 2016 (2016-03-29), pages 2999 - 3007, XP036009154, DOI: 10.1007/s00018-016-2210-5;;KNAVEL EMBRACE CL: ""Tumor ablation: common modalities and general practices"", TECH VASC INTERV RADIOL, vol. 16, no. 4, December 2013 (2013-12-01), pages 192 - 200;;SLOVAK RLUDWIG JMGETTINGER SNHERBST RSKIM HS: ""Immuno-thermal ablations - boosting the anticancer immune response"", J IMMUNOTHER CANCER, vol. 5, no. 1, 17 October 2017 (2017-10-17), pages 78, XP021249814, DOI: 10.1186/s40425-017-0284-8;;KANG TWRHIM H: ""Recent Advances in Tumor Ablation for Hepatocellular Carcinoma"", LIVER CANCER, vol. 4, no. 3, 17 July 2015 (2015-07-17), pages 176 - 87, XP055503077, DOI: 10.1159/000367740;;KEISARI, Y.HOCHMAN, I.CONFINO, H.KORENSTEIN, R.KELSON, I.: ""Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments"", CANCER IMMUNOL. IMMUNOTHER., vol. 63, 2014, pages 1 - 9;;CONFINO HHOCHMAN IEFRATI MSCHMIDT MUMANSKY VKELSON 1KEISARI Y: ""Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors"", CANCER IMMUNOL IMMUNOTHER, vol. 64, no. 2, 18 October 2014 (2014-10-18), pages 191 - 9, XP035441729, DOI: 10.1007/s00262-014-1626-8;;VAN DEN BIJGAART RJEIKELENBOOM DCHOOGENBOOM MFUTTERER JJDEN BROK MHADEMA GJ: ""Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies"", CANCER IMMUNOL IMMUNOTHER, vol. 66, no. 2, February 2017 (2017-02-01), pages 247 - 258, XP036145808, DOI: 10.1007/s00262-016-1891-9;;O'BRIEN MAPOWER DGCLOVER AJBIRD BSODEN DMFORDE PF: ""Local tumour ablative therapies: opportunities for maximising immune engagement and activation"", BIOCHIM BIOPHYS ACTA, vol. 1846, no. 2, 5 October 2014 (2014-10-05), pages 510 - 23, XP055204945, DOI: 10.1016/j.bbcan.2014.09.005;;HUERTA S: ""Nitric oxide for cancer therapy"", FUTURE SCI OA, vol. 1, no. 1, 1 August 2015 (2015-08-01), pages FSO44;;VANNINI FKASHFI KNATH N: ""The dual role of iNOS in cancer"", REDOX BIOL, vol. 6, 24 August 2015 (2015-08-24), pages 334 - 343;;SEABRA AB, DURAN N: ""Nitric oxide donors for prostate and bladder cancers: Current state and challenges"", EUR J PHARMACOL., vol. 826, 5 May 2018 (2018-05-05), pages 158 - 168;;ALIMORADI HGREISH KGAMBLE ABGILES GI: ""Controlled Delivery of Nitric Oxide for Cancer Therapy"", PHARM NANOTECHNOL, vol. 7, no. 4, 2019, pages 279 - 303;;NING SBEDNARSKI MORONSKY BSCICINSKI JKNOX SJ: ""Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy"", BIOCHEM BIOPHYS RES COMMUN, vol. 447, no. 3, 9 May 2014 (2014-05-09), pages 537 - 42, XP028655292, DOI: 10.1016/j.bbrc.2014.04.032;;BONAVIDA BBARITAKI SHUERTA-YEPEZ SVEGA MICHATTERJEE DYEUNG K: ""Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases"", NITRIC OXIDE, vol. 19, no. 2, 24 April 2008 (2008-04-24), pages 152 - 7, XP022854045, DOI: 10.1016/j.niox.2008.04.018;;BURKE AJSULLIVAN FJGILES FJGLYNN SA: ""The yin and yang of nitric oxide in cancer progression"", CARCINOGENESIS, vol. 34, no. 3, 25 January 2013 (2013-01-25), pages 503 - 12;;THOMAS DD: ""Breathing new life into nitric oxide signaling: A brief overview of the interplay between oxygen and nitric oxide"", REDOX BIOL, vol. 5, August 2015 (2015-08-01), pages 225 - 233",PENDING
105,US,A1,US 2025/0032490 A1,009-110-592-343-730,2025-01-30,2025,US 202418784478 A,2024-07-25,US 202418784478 A;;US 201916700910 A;;US 201816053716 A;;US 201762540451 P;;US 201762593669 P,2017-08-02,THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA,"Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.",ACHILLION PHARMACEUTICALS INC,HUANG MINGJUN;;PATEL DHARABEN;;PODOS STEVEN D,ACHILLION PHARMACEUTICALS INC (2017-11-13),https://lens.org/009-110-592-343-730,Patent Application,yes,0,0,8,135-861-823-828-774;;009-110-592-343-730;;145-685-635-408-820;;187-109-806-580-536;;135-983-676-762-642;;087-118-377-465-466;;156-870-027-462-448;;025-071-926-690-945,EP;;CN;;WO;;US,8,135-861-823-828-774;;009-110-592-343-730;;145-685-635-408-820;;187-109-806-580-536;;135-983-676-762-642;;087-118-377-465-466;;156-870-027-462-448;;025-071-926-690-945,EP;;CN;;WO;;US,0,C07K2317/76;;A61K31/506;;A61K39/3955;;A61P7/00;;C07K16/18;;A61K31/506;;A61K39/3955;;A61K2039/505;;A61P7/00;;C07K16/18;;C07K2317/76,A61K31/506;;A61K39/00;;A61K39/395;;A61P7/00;;C07K16/18,,0,0,,,,PENDING
106,US,A1,US 2025/0177654 A1,119-190-254-493-673,2025-06-05,2025,US 202519045859 A,2025-02-05,US 202519045859 A;;EP 11306236 A;;US 201414347677 A;;EP 2012069119 W,2011-09-27,Medical Injection Device With A Plasma Treated Silicone Oil Coating,"The invention relates to a medical injection device having: a barrel having an inner surface; a stopper in gliding engagement with the barrel; and a pharmaceutical composition within the medical injection device and in contact with the inner surface of the barrel, the inner surface of the barrel comprising a coating of plasma treated silicone oil in contact with the composition, wherein the plasma treatment of silicone oil reduces the number of particles present on the surface of the coating and the number of particles released into the pharmaceutical composition contained in the medical injection device as compared to silicone oil that is not plasma treated.",BECTON DICKINSON FRANCE,JANVIER SEBASTIAN;;MANGIAGALLI PAOLO;;JOUFFRAY SÉBASTIEN;;FOUCHER CÉDRIC;;ENFOUX YVES,BECTON DICKINSON FRANCE (2014-04-09),https://lens.org/119-190-254-493-673,Patent Application,yes,0,0,19,192-369-174-441-395;;101-383-137-769-260;;024-658-320-738-365;;081-357-384-450-238;;051-611-561-990-247;;119-190-254-493-673;;179-478-928-861-84X;;120-568-505-122-605;;081-290-354-579-31X;;137-402-306-829-322;;054-953-822-139-506;;105-227-439-599-683;;127-529-488-000-026;;077-325-383-484-304;;039-578-024-407-013;;109-007-127-243-638;;022-764-776-105-984;;171-781-381-507-759;;097-913-898-473-23X,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX,19,192-369-174-441-395;;101-383-137-769-260;;024-658-320-738-365;;081-357-384-450-238;;051-611-561-990-247;;119-190-254-493-673;;179-478-928-861-84X;;120-568-505-122-605;;081-290-354-579-31X;;137-402-306-829-322;;054-953-822-139-506;;105-227-439-599-683;;127-529-488-000-026;;077-325-383-484-304;;039-578-024-407-013;;109-007-127-243-638;;022-764-776-105-984;;171-781-381-507-759;;097-913-898-473-23X,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX,0,A61M2005/3131;;F04C2270/041;;A61M5/3129;;A61M5/3129;;A61J1/05;;A61L31/14;;A61M2205/0222;;A61L2400/10;;A61L2420/02;;F04C2270/041;;A61L31/10;;A61M2005/3131;;A61M2005/3117;;A61M5/3129;;A61L31/10;;A61L31/14;;A61M2005/3131;;F04C2270/041;;A61M5/3129;;A61L31/10;;A61L31/14;;A61L2400/10;;A61L2400/18;;A61L2420/02;;A61M2005/3117,A61M5/31;;A61L31/10;;A61L31/14,,0,0,,,,PENDING
107,US,A1,US 2023/0321202 A1,146-041-610-197-935,2023-10-12,2023,US 202318185315 A,2023-03-16,US 202318185315 A;;US 202263320627 P,2022-03-16,AMERICAN CHESTNUT LEAF COMPOSITIONS COMPRISING OXALATE OXIDASE AND METHODS FOR TREATMENT OF OXALATE-RELATED DISORDERS,The invention provides American chestnut leaf compositions comprising oxalate oxidase. The compositions reduce oxalate levels in dietary sources of oxalate and are useful in reducing oxalate levels and reducing stone disease in patients. The invention provides methods of extracting and purifying oxalate oxidase from American chestnut leaf. The invention provides methods of extracting oxalate from biological samples.,UNIV FLORIDA;;THE RESEARCH FOUNDATION FOR THE STATE UNIV OF NEW YORK RFSUNY,DOMINGUEZ-GUTIERREZ PAUL R;;DONELAN WILLIAM L;;QUESADA TANIA;;POWELL WILLIAM A,THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (RFSUNY) (2023-03-15);;UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (2022-03-21),https://lens.org/146-041-610-197-935,Patent Application,yes,0,0,1,146-041-610-197-935,US,1,146-041-610-197-935,US,0,A61K38/44;;A23F3/14;;A23F3/166;;A61K36/21;;A61K36/49;;A61K36/82;;A61K36/88;;A61K2236/53;;C12N9/0008;;C12Y102/03004;;A61K38/44;;A23F3/14;;A23F3/166;;A61K9/0095;;A61K36/49;;A61K47/46;;A61K2236/15;;A61K2236/331;;A61K2236/37;;C07C51/43;;C12N9/0008;;C12Y102/03004,A61K38/44;;A23F3/14;;A23F3/16;;A61K9/00;;A61K36/49;;A61K47/46;;C07C51/43;;C12N9/02,,0,0,,,,PENDING
108,EP,A1,EP 4299067 A1,112-485-672-472-211,2024-01-03,2024,EP 22759064 A,2022-02-25,TW 110107064 A;;IB 2022051672 W,2021-02-26,"COMPOSITION FOR IMPROVING ORAL IMMUNOGLOBULIN A CONTENT AND INHIBITING PATHOGENS, AND USE","The invention provides compositions for use in increasing an amount of oral immunoglobulin A (IgA) and/or inhibiting oral pathogens. The compositions include probiotics as an effective ingredient. The probiotics include Lactobacillus plantarum LPL28, which can efficiently increase the amount of oral IgA and/or inhibit the oral pathogens, and thus have a potential to prevent teeth cavities and/or periodontal diseases.",GLAC BIOTECH CO LTD,HO HSIEH-HSUN;;LIN WEN-YANG;;KUO YI-WEI;;HUANG YEN-YU;;LIN JIA-HUNG;;LIN CHI-HUEI;;LIU CHENG-RUEI;;CHEN SHU-HUI,,https://lens.org/112-485-672-472-211,Patent Application,yes,0,0,7,086-451-630-205-100;;162-424-761-033-311;;048-912-170-955-728;;112-485-672-472-211;;091-918-419-760-325;;162-906-438-138-836;;159-338-398-798-870,EP;;WO;;US;;TW,7,086-451-630-205-100;;162-424-761-033-311;;048-912-170-955-728;;112-485-672-472-211;;091-918-419-760-325;;162-906-438-138-836;;159-338-398-798-870,EP;;WO;;US;;TW,5,A61P31/04;;A61K35/747;;A23C9/1234;;A23L33/135;;C12R2001/25;;C12R2001/225;;A23V2400/181;;A23V2400/165;;A23V2400/169;;A61K35/747;;C12R2001/25;;C12N1/20;;A61P31/04,A61K35/747;;A23C9/123;;A23L33/135;;A61K6/00;;A61K39/395,,0,0,,,,PENDING
109,US,A1,US 2024/0018222 A1,074-269-297-932-876,2024-01-18,2024,US 202218256221 A,2022-01-04,CN 202110029677 A;;CN 2022070068 W,2021-01-08,MONOCLONAL ANTIBODY INHIBITING SMIM15 AND APPLICATION THEREOF,"A monoclonal antibody inhibiting an SMIM15 and application thereof; the antibody is secreted by a hybridoma cell strain 1M5. A preparation method includes: preparing mouse immunogen and an antigen for detection; preparing the hybridoma cell strain 1M5 against an SMIM15; screening an SMIM15 positive monoclonal antibody: identifying a subtype of the monoclonal antibody; detecting specificity of the SMIM15 positive monoclonal antibody; producing and purifying the monoclonal antibody in a BALB/c mouse; detecting purity of the antibody by SDS-PAGE; and performing function identification and application on the SMIM15 monoclonal antibody with WB, IHC and ELISA. According to the present application, the antibody secreted by the hybridoma cell strain 1M5 is an immunoglobulin, which is non-toxic, and can be used for Western blot and immunohistochemistry and used as an active ingredient to be made into a reagent or drug for diagnosis and treatment of SMIM15-related diseases.",AFFILIATED HOSPITAL OF NANTONG UNIV,HUANG JIANFEI;;LU BING;;SUN PINGPING;;ZHANG XIAOJING,AFFILIATED HOSPITAL OF NANTONG UNIVERSITY (2023-05-18),https://lens.org/074-269-297-932-876,Patent Application,yes,0,0,4,166-592-421-620-307;;005-848-125-876-621;;181-122-273-290-20X;;074-269-297-932-876,CN;;WO;;US,4,166-592-421-620-307;;181-122-273-290-20X;;005-848-125-876-621;;074-269-297-932-876,CN;;WO;;US,1,C07K16/18;;G01N33/577;;G01N33/57407;;G01N33/57446;;G01N33/57415;;G01N33/57484;;A61P35/00;;C07K2317/92;;C07K2317/35;;A61K2039/505;;G01N33/57415;;G01N33/57407;;G01N33/57446;;C07K16/18;;C07K2317/76;;A61P35/00;;C07K2317/33;;C07K16/18;;C07K2317/35;;C07K2317/76;;G01N33/57407;;G01N33/57415;;G01N33/57446,C07K16/18;;G01N33/574,,0,0,,,,PENDING
110,EP,A1,EP 4613764 A1,009-729-239-232-043,2025-09-10,2025,EP 24829014 A,2024-05-24,CN 202410121405 A;;CN 2024095261 W,2024-01-26,RECOMBINANT TYPE XVII COLLAGEN HAVING TRIPLE HELIX STRUCTURE AND USE THEREOF,"The present disclosure provides a recombinant type XVII collagen with a triple helical structure and use thereof and belongs to the field of protein engineering technology. The recombinant type XVII collagen has the amino acid sequence formed by tandem repeats of n core units, wherein n is an integer of 1 or greater than 1, and the core unit has the amino acid sequence as set forth in SEQ ID NO: 1. The present disclosure also provides methods for constructing multiple expression systems and methods for preparing the recombinant type XVII collagen. The present disclosure also provides practical industrial applications based on the characteristics of the protein. The recombinant type XVII collagen provided in the present disclosure has high purity, good thermal stability, high biological activity, and a much smaller molecular weight than natural collagen, thus reducing obstacles for collagen to pass through the skin barrier to exert its biological function. It is experimentally shown that the recombinant type XVII collagen has multiple biological activities such as promoting cell migration.",SHENZHEN LIYING BIOTECHNOLOGY CO LTD,ZHANG XIAOYAN;;SONG XIAOHUI;;FU JUNCHENG;;XU QIAORAN;;GE JIANJING,,https://lens.org/009-729-239-232-043,Patent Application,yes,0,0,3,133-701-178-202-65X;;009-729-239-232-043;;016-259-430-559-175,KR;;EP;;US,6,133-701-178-202-65X;;009-387-005-655-388;;016-259-430-559-175;;109-790-604-802-066;;015-035-760-604-531;;009-729-239-232-043,KR;;CN;;EP;;WO;;US,0,A61K8/65;;A61L31/044;;A61L31/16;;A61Q5/12;;A61Q7/00;;A61Q19/00;;A61Q19/08;;C07K14/78;;C12N9/0071;;C12N15/70;;C12N15/815;;C12R2001/19;;C12R2001/84;;C12Y114/11002;;C12Y114/11004;;A61K38/39;;C07K14/78;;C12P21/02;;A61K38/39;;C12P21/02;;C07K14/78,C07K14/78;;A61L31/04;;A61L31/16;;A61Q7/00;;C12R1/19,,0,0,,,,PENDING
111,US,A1,US 2021/0070799 A1,113-865-619-639-167,2021-03-11,2021,US 201716772121 A,2017-12-11,IB 2017001757 W,2017-12-11,COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS,"The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.",ETHNODYNE;;CENTRE NAT RECH SCIENT,RABHI CHÉRIF;;CARIEL LÉON;;DA COSTA NOBLE CHRISTIAN;;OUAZZANI JAMAL;;ARCILE GUILLAUME;;LE GOFF GÉRALDINE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (2020-06-12);;ETHNODYNE (2020-06-12),https://lens.org/113-865-619-639-167,Patent Application,yes,0,0,5,113-865-619-639-167;;061-545-655-020-946;;107-688-315-249-467;;146-255-405-733-157;;063-077-204-131-59X,EP;;WO;;US,5,113-865-619-639-167;;063-077-204-131-59X;;107-688-315-249-467;;146-255-405-733-157;;061-545-655-020-946,EP;;WO;;US,0,C07D309/32;;A61P25/28;;C07J41/0088;;A61P25/28;;C07J19/00,C07J41/00;;A61P25/28,,0,0,,,,ACTIVE
112,GB,D0,GB 202012991 D0,198-889-087-238-863,2020-10-07,2020,GB 202012991 A,2020-08-20,GB 202012991 A,2020-08-20,Cell culture processes,,UCB BIOPHARMA SPRL,,,https://lens.org/198-889-087-238-863,Patent Application,no,9,0,13,096-330-934-428-524;;049-550-955-783-736;;182-963-548-212-757;;082-223-987-288-711;;175-987-150-513-392;;073-780-930-839-063;;122-700-589-987-515;;198-889-087-238-863;;096-389-821-024-052;;150-750-234-741-824;;198-372-677-336-445;;072-727-690-073-310;;088-860-829-331-171,JP;;AU;;US;;CA;;MX;;BR;;KR;;AR;;EP;;CN;;IL;;WO;;GB,13,096-330-934-428-524;;049-550-955-783-736;;182-963-548-212-757;;082-223-987-288-711;;175-987-150-513-392;;073-780-930-839-063;;122-700-589-987-515;;198-889-087-238-863;;096-389-821-024-052;;150-750-234-741-824;;198-372-677-336-445;;072-727-690-073-310;;088-860-829-331-171,JP;;AU;;US;;CA;;MX;;BR;;KR;;AR;;EP;;CN;;IL;;WO;;GB,0,C12P21/02;;C07K16/00;;C07K2317/14;;C12N2500/60;;C12N5/0018;;C12P21/02;;C12N2500/60;;C07K16/00;;C07K2317/14;;C12N5/0018;;C12P21/00;;C07K16/00;;C12N5/0018;;C07K2317/14;;C12N2500/60;;C07K16/06;;C07K2317/14;;C12N5/0018;;C12N5/0603,,,3,3,049-521-285-006-66X;;176-442-261-523-717;;058-604-961-968-638,10.1002/bit.24511;;22473825;;26654938;;10.1016/j.jbiotec.2015.11.022;;10.1021/ac2009492;;21627078,"KSHIRSAGAR R. ET AL., BIOTECH. AND BIOENG., vol. 109, no. 10, 2012, pages 2523 - 2532;;HECKLAU C ET AL., J BIOTECH, vol. 218, 2016, pages 53 - 63;;ZANG L. ET AL., ANAL. CHEM, vol. 83, 2011, pages 5422 - 5430",DISCONTINUED
113,WO,A1,WO 2022/208508 A1,040-204-487-939-47X,2022-10-06,2022,IN 2021050458 W,2021-05-13,IN 202121014827 A,2021-03-31,SCALABLE TWO STEP SYNTHESIS OF MOLNUPIRAVIR,"The present invention provides a scalable two-step synthesis of molnupiravir. The reaction sequence involves the use of commercially easily available cytidine (1), and molnupiravir is formed through direct hydroxy amination of the cytidine followed by esterification of the primary alcohol without protecting dihydroxy groups (vicinal diols) i.e. without formation of acetonide.",FERMENTA BIOTECH LTD,DATLA ANUPAMA;;NAGRE PRASHANT;;TAMORE JAGDISH;;PRABHU MANOJKUMAR SADANAND;;TRIVIKRAM SREENATH;;KADAM SACHIN VASANT;;DEGAONKAR GAJANAN SUBHASH;;MURALIDHARAN KRISHNA;;RUPRAJ NARAIN,,https://lens.org/040-204-487-939-47X,Patent Application,yes,0,2,1,040-204-487-939-47X,WO,1,040-204-487-939-47X,WO,0,A61P31/14;;A61K31/7068;;C07H1/00;;C07H19/067,A61P31/14;;A61K31/7068;;C07H1/00;;C07H19/067,,1,1,049-527-829-363-17X,10.1039/d0cc05944g;;10.26434/chemrxiv.12931445;;33030468,"N. VASUDEVAN ET AL.: ""A concise route to MK -4482 (EIDD-2801) from cytidine"", CHEM. COMMUN., vol. 56, 2020, pages 13363 - 13364, XP055950766, DOI: 10.1039/d0cc05944g",PENDING
114,US,A1,US 2025/0241998 A1,016-259-430-559-175,2025-07-31,2025,US 202519028605 A,2025-01-17,CN 202410121405 A;;CN 2024095261 W,2024-01-26,RECOMBINANT TYPE XVII COLLAGEN WITH TRIPLE HELICAL STRUCTURE AND USE THEREOF,"The present disclosure provides a recombinant type XVII collagen with a triple helical structure and use thereof and belongs to the field of protein engineering technology. The recombinant type XVII collagen has an amino acid sequence formed by tandem repeats of n core units, wherein n is an integer of 1 or greater than 1, and the core unit has the amino acid sequence as set forth in SEQ ID NO: 1. The present disclosure also provides methods for constructing multiple expression systems and methods for preparing the recombinant type XVII collagen.",SHENZHEN LIYING BIOTECHNOLOGY CO LTD,ZHANG XIAOYAN;;SONG XIAOHUI;;FU JUNCHENG;;XU QIAORAN;;GE JIANJING,SHENZHEN LIYING BIOTECHNOLOGY CO. LTD (2025-01-07),https://lens.org/016-259-430-559-175,Patent Application,yes,0,0,3,133-701-178-202-65X;;009-729-239-232-043;;016-259-430-559-175,KR;;EP;;US,6,133-701-178-202-65X;;009-387-005-655-388;;016-259-430-559-175;;109-790-604-802-066;;015-035-760-604-531;;009-729-239-232-043,KR;;CN;;EP;;WO;;US,0,A61K8/65;;A61L31/044;;A61L31/16;;A61Q5/12;;A61Q7/00;;A61Q19/00;;A61Q19/08;;C07K14/78;;C12N9/0071;;C12N15/70;;C12N15/815;;C12R2001/19;;C12R2001/84;;C12Y114/11002;;C12Y114/11004;;A61K38/39;;C07K14/78;;C12P21/02;;A61K38/39;;C12P21/02;;C07K14/78,A61K38/39;;C07K14/78;;C12P21/02,,0,0,,,,PENDING
115,WO,A1,WO 2025/190927 A1,035-553-377-410-860,2025-09-18,2025,EP 2025056584 W,2025-03-11,EP 24163514 A,2024-03-14,ACTIVE COMPOUND COMBINATIONS HAVING INSECTICIDAL/ACARICIDAL PROPERTIES,The present invention relates to novel active compound combinations comprising the compound of the formula (I) and at least one further active compound of the group (II) which combinations are highly suitable for controlling animal and microbial pests.,BAYER AG,CANCHO GRANDE YOLANDA;;FISCHER RÜDIGER;;JOHN MARITA;;DAUCK HARTWIG,,https://lens.org/035-553-377-410-860,Patent Application,yes,0,0,1,035-553-377-410-860,WO,1,035-553-377-410-860,WO,0,A01N53/00;;A01P5/00;;A01P7/04;;A01N43/90;;A01P7/02;;A01P1/00,A01N43/90;;A01N53/00;;A01N63/23;;A01P1/00;;A01P5/00;;A01P7/04,,0,0,,,,PENDING
116,EP,A1,EP 4428233 A1,039-812-222-273-928,2024-09-11,2024,EP 22900290 A,2022-11-17,CN 202111445474 A;;CN 2022132596 W,2021-11-30,C2C9 NUCLEASE-BASED NOVEL GENOME EDITING SYSTEM AND APPLICATION THEREOF,"The present invention relates to the field of biomedicine, and disclosed are a use of a C2C9 nuclease as an RNA-guided endonuclease, and an extremely small genome editing system. The genome editing system comprises a C2C9 nuclease and/or a nucleic acid encoding the C2C9 nuclease, and a guide RNA or a nucleic acid encoding the guide RNA. The extremely small genome editing system of the present invention can perform gene editing on at least one target sequence in a genome of prokaryotic bacteria and eukaryotic cells. Also disclosed in the present invention are an application of the genome editing system and an editing method. By means of the genome editing system or method of the present invention, a target gene can be precisely knocked out or cut off, the cutting efficiency is high, and precise editing of the target gene is implemented.",UNIV SHANGHAI TECHNOLOGY,JI QUANJIANG;;CHEN WEIZHONG;;MA JIACHENG,,https://lens.org/039-812-222-273-928,Patent Application,yes,0,0,11,039-432-701-742-192;;077-207-830-782-972;;039-812-222-273-928;;155-381-866-387-166;;108-708-597-252-374;;106-913-897-514-268;;088-158-449-087-226;;192-361-712-373-953;;123-322-059-048-538;;098-547-513-075-636;;143-196-000-064-024,AU;;KR;;JP;;CN;;EP;;WO;;US;;CA,11,039-432-701-742-192;;077-207-830-782-972;;039-812-222-273-928;;155-381-866-387-166;;108-708-597-252-374;;106-913-897-514-268;;088-158-449-087-226;;192-361-712-373-953;;123-322-059-048-538;;098-547-513-075-636;;143-196-000-064-024,AU;;KR;;JP;;CN;;EP;;WO;;US;;CA,318,C12N9/22;;C12N15/113;;C12N15/63;;C12N2310/20;;C12N9/14;;C12N9/22;;C12N15/74;;C12N15/102;;C12N2310/20;;C07K14/195;;C12N15/11;;C12N9/22;;C12N15/113;;C12N15/63;;C12N15/102;;C12N2310/20;;C12N2310/531;;C07K2319/09;;C12N2310/20;;C12N9/22;;C12N15/111;;C12N15/902,C12N9/22;;C12N15/10,,0,0,,,,PENDING
117,US,A1,US 2023/0272417 A1,111-201-691-583-984,2023-08-31,2023,US 202217837248 A,2022-06-10,CN 202210175224 A,2022-02-25,"USE OF CIRCUTRN IN PREPARATION OF DRUG FOR TREATING HEART FAILURE, RECOMBINANT VECTOR, AND DRUG FOR TREATING HEART FAILURE","The present disclosure relates to the technical field of biomedicine, in particular to use of circUTRN in preparation of a drug for treating heart failure, a recombinant vector, and a drug for treating heart failure. It is proved by experiments that the drug for treating heart failure prepared by the circUTRN is capable of treating or ameliorating the heart failure, and especially has a desirable therapeutic effect on the heart failure caused by ischemia-reperfusion injury (IRI). Specifically, the circUTRN is capable of improving cardiac systolic dysfunction induced by myocardial IRI 3 weeks. In addition, the circUTRN is also capable of reducing an infarct size of acute myocardial IRI; and overexpression of the circUTRN can inhibit cardiomyocyte apoptosis induced by oxygen-glucose deprivation/recovery.",UNIV SHANGHAI,XIAO JUNJIE;;WANG LIJUN;;HU YUXUE;;SUN JIANGPENG;;CHEN HONGJIAN,SHANGHAI UNIVERSITY (2022-05-12),https://lens.org/111-201-691-583-984,Patent Application,yes,2,1,3,173-820-136-306-170;;064-772-988-506-441;;111-201-691-583-984,CN;;US,3,173-820-136-306-170;;064-772-988-506-441;;111-201-691-583-984,CN;;US,8,A61K31/7088;;A61P9/04;;C12N15/86;;C12N2740/15043;;C12N2750/14143;;C12N2800/107;;Y02A50/30;;A61K31/713;;C12N2750/14143;;C12N15/86;;C12N2740/16043;;A61P9/00;;A61K31/713;;C12N15/111;;C12N15/86;;C12N2750/14122;;C12N2750/14143;;C12N2830/008,C12N15/86;;A61K31/713;;C12N15/11,,15,9,038-063-544-856-104;;038-063-544-856-104;;073-432-120-951-773;;094-584-824-379-765;;076-836-946-899-430;;075-195-609-039-348;;046-266-717-229-070;;083-579-597-863-737;;096-973-724-512-751,pmc5548848;;10.1007/s40259-017-0234-5;;28669112;;pmc5548848;;10.1007/s40259-017-0234-5;;28669112;;10.1093/jpp/rgab161;;34850057;;10.1038/s41598-021-02980-y;;34887449;;pmc8660871;;17612514;;10.1016/j.cardiores.2007.06.003;;10.3389/fgene.2020.00206;;pmc7081725;;32226441;;pmc8076159;;33928080;;10.3389/fcell.2021.640402;;10.1007/s10557-020-07071-0;;32902739;;pmc7479403;;10.1007/s10741-010-9168-4;;20405319,"Li, Z.; Ningning, H.; Fangmei, X.; SHUIYUN, C.; Liu, M.; and GUANGZHOU GENESEED TECH CO LTD. CN109706172A . 03 May 2019. 1 page. (Year: 2019);;Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017 Aug;31(4):317-334. doi: 10.1007/s40259-017-0234-5. PMID: 28669112; PMCID: PMC5548848. (Year: 2017);;Gearing, M. Lentiviral Vector Uses and Overview. addgene Blog. 19 May, 2016. accessed at https://blog.addgene.org/lentiviral-vector-uses-and-overview#:~:text=Advantages on 21 August 2023., pages 1-4 (Year: 2016);;Li, Z.; Ningning, H.; Fangmei, X.; SHUIYUN, C.; Liu, M.; and GUANGZHOU GENESEED TECH CO LTD. CN109706172A . 03 May 2019. pages 1-39. Partial text English translation by STIC at USPTO (Year: 2019);;Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017 Aug;31(4):317-334. (Year: 2017);;Sun Q, Liang R, Li M, Zhou H. J Pharm Pharmacol. 2022 Jun 9;74(6):861-868. Epub 25 Nov 2021. (Year: 2021);;Patil NS, Feng B, Su Z, Castellani CA, Chakrabarti S. ci Rep. 2021 Dec 9;11(1):23766. (Year: 2021);;Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE. Cardiovasc Res. 2007 Oct 1;76(1):81-90. Epub 2007 Jun 12. (Year: 2007);;Yang Y, Ren J, Huang Q, Wu J, Yuan X, Jiang W, Wen Y, Tang L, Sun H. Front Genet. 2020 Mar 12;11:206. (Year: 2020);;UCSC Genome Browser, GRCm38/mm10 Mouse Assembly, retrieved 26 February 2024 from the Internet: <URL: https://genome.ucsc.edu/cgi-bin/hgc>. (Year: 2011);;Life Science Market (pLCDH-ciR), retrieved on 26 February 2024 from the Internet: <URL: https://lifescience-market.com/plasmid-c-94/plcdhcir-p-138912.html>. (Year: 2024);;Li X, Tian G, Wu J. Front Cell Dev Biol. 2021 Apr 12;9:640402. (Year: 2021);;Promega, 1999, Enzyme Resource Guide Part 2: Cloning Enzymes, 1-38. (Year: 1999);;Hanna 2020, Cardiovasular Drugs and Therapy, Vol. 34, 849-863. (Year: 2020);;Hedayat 2010, Heart Fail. Rev., Vol. 15, 543-562. (Year: 2010)",DISCONTINUED
118,US,A1,US 2022/0204965 A1,021-003-642-487-400,2022-06-30,2022,US 202117525283 A,2021-11-12,CN 202011551143 A,2020-12-24,METHOD FOR CONSTRUCTING TREHALOSE MULTI-ENZYME COMPLEX IN VITRO MEDIATED BY ARTIFICIAL SCAFFOLD PROTEIN,"The present disclosure relates to a method for constructing a trehalose polyenzyme complex in vitro by mediation of an artificial scaffold protein, which mainly comprises the following steps: constructing a recombinant bacterium WB800n-ScafCCR for self-assembled scaffold protein module; constructing a recombinant bacterium WB800n-P43-phoD-treY-Ccdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-treZ-Ctdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-cgt-Rfdoc for self-assembled catalytic module; secretorily expressing the recombinant bacteria and self-assembling in vitro to obtain a recombinant trehalose multi-enzyme complex. The trehalose multi-enzyme complex constructed by the method of the present disclosure has a higher catalytic efficiency in preparing trehalose than that of mixed free enzymes, and the method can be used for production of high quality trehalose after immobilization with cellulose microspheres.",UNIV QILU TECHNOLOGY,LIU HONGLING;;WANG TENGFEI;;WANG RUIMING;;ZHANG XINYI,QILU UNIVERSITY OF TECHNOLOGY (2021-10-13),https://lens.org/021-003-642-487-400,Patent Application,yes,0,2,3,132-924-501-856-015;;182-361-997-273-469;;021-003-642-487-400,CN;;US,3,132-924-501-856-015;;182-361-997-273-469;;021-003-642-487-400,CN;;US,26,C12N15/75;;C12N15/52;;C12N9/90;;C12N9/2408;;C12N9/1051;;C12N11/18;;C12P19/24;;C12P19/18;;C12P19/14;;C12P19/12;;C12Y504/99015;;C12Y302/01141;;C07K2319/735;;C07K2319/02;;C12N9/1051;;C12N9/2408;;C12N9/90;;C12N11/18;;C12N15/75;;C12Y302/01141;;C12Y504/99015;;C12N11/12;;C12N15/52;;C12Y204/01;;C12N9/1051;;C12N9/2408;;C12N9/90;;C12N11/18;;C12N15/75;;C12Y302/01141;;C12Y504/99015;;C12N15/52;;C12N15/03,C12N11/18;;C12N9/10;;C12N9/26;;C12N9/90;;C12N15/75,,1,1,038-539-238-374-79X,pmc6547511;;10.1186/s12934-019-1152-7;;31159804,"Liu, H., Yang, S., Wang, X. and Wang, T., 2019. Production of trehalose with trehalose synthase expressed and displayed on the surface of Bacillus subtilis spores. Microbial cell factories, 18, pp.1-13. (Year: 2019)",ACTIVE
119,US,A1,US 2025/0188451 A1,143-196-000-064-024,2025-06-12,2025,US 202218714577 A,2022-11-17,CN 202111445474 A;;CN 2022132596 W,2021-11-30,C2C9 NUCLEASE-BASED NOVEL GENOME EDITING SYSTEM AND USE THEREOF,"The present invention relates to the field of biomedicine and discloses a use of a C2C9 nuclease as an RNA-guided endonuclease, and a small sized genome editing system. The genome editing system comprises a C2C9 nuclease and/or a nucleic acid encoding the C2C9 nuclease, and a guide RNA or a nucleic acid encoding the guide RNA. The small sized genome editing system of the present invention can perform gene editing on at least one target sequence in a genome of prokaryotic bacteria and eukaryotic cells. The present invention also discloses a use of the genome editing system and an editing method. By using the genome editing system or method of the present invention, a target gene can be precisely knocked out or cut off, the cutting efficiency is high, and precise editing of the target gene is implemented.",UNIV SHANGHAI TECHNOLOGY,JI QUANJIANG;;CHEN WEIZHONG;;MA JIACHENG,,https://lens.org/143-196-000-064-024,Patent Application,yes,0,0,11,039-432-701-742-192;;077-207-830-782-972;;039-812-222-273-928;;155-381-866-387-166;;108-708-597-252-374;;106-913-897-514-268;;088-158-449-087-226;;192-361-712-373-953;;123-322-059-048-538;;098-547-513-075-636;;143-196-000-064-024,AU;;KR;;JP;;CN;;EP;;WO;;US;;CA,11,039-432-701-742-192;;077-207-830-782-972;;039-812-222-273-928;;155-381-866-387-166;;108-708-597-252-374;;106-913-897-514-268;;088-158-449-087-226;;192-361-712-373-953;;123-322-059-048-538;;098-547-513-075-636;;143-196-000-064-024,AU;;KR;;JP;;CN;;EP;;WO;;US;;CA,0,C12N9/22;;C12N15/113;;C12N15/63;;C12N2310/20;;C12N9/14;;C12N9/22;;C12N15/74;;C12N15/102;;C12N2310/20;;C07K14/195;;C12N15/11;;C12N9/22;;C12N15/113;;C12N15/63;;C12N15/102;;C12N2310/20;;C12N2310/531;;C07K2319/09;;C12N2310/20;;C12N9/22;;C12N15/111;;C12N15/902,C12N15/11;;C12N9/22;;C12N15/90,,0,0,,,,PENDING
120,WO,A1,WO 2025/120067 A1,052-092-422-331-860,2025-06-12,2025,EP 2024084892 W,2024-12-05,GB 202318647 A,2023-12-06,CELL CULTURE PROCESSES,"The present invention belongs to the field of the manufacture of recombinant proteins, particularly proteins, such as antibodies.",UCB BIOPHARMA SRL,AERTS LUC LAMBERT JOZEF JAN;;BEN YAHIA BASSEM;;CHEVALLIER VALENTINE;;PIEDNOIR ANTOINE PHILIPPE THOMAS,,https://lens.org/052-092-422-331-860,Patent Application,yes,12,0,2,052-092-422-331-860;;073-030-731-112-790,WO;;GB,2,052-092-422-331-860;;073-030-731-112-790,WO;;GB,0,C12N5/0018;;C07K16/00;;C07K2317/14;;C12N2510/02,C07K16/00;;C12N5/00,,3,3,049-521-285-006-66X;;176-442-261-523-717;;058-604-961-968-638,10.1002/bit.24511;;22473825;;26654938;;10.1016/j.jbiotec.2015.11.022;;10.1021/ac2009492;;21627078,"KSHIRSAGAR R. ET AL., BIOTECH. AND BIOENG., vol. 109, no. 10, 2012, pages 2523 - 2532;;HECKLAU C ET AL., J BIOTECH, vol. 218, 2016, pages 53 - 63;;ZANG L. ET AL., ANAL. CHEM, vol. 83, 2011, pages 5422 - 5430",PENDING
121,KR,A,KR 20210104074 A,084-815-635-409-665,2021-08-24,2021,KR 20217021080 A,2019-12-10,JP 2018233145 A;;JP 2019149422 A;;JP 2019048218 W,2018-12-13,"시클로이소말토테트라오스, 시클로이소말토테트라오스 생성효소, 및 그 제조방법과 용도","D-글루코오스를 구성당으로 하는 신규의 환형 당질, 해당 환형 당질을 생성하는 신규 효소, 그들 제조방법 및 용도를 제공하는 것을 과제로 하며, 4분자의 D-글루코오스가 α-1,6 글루코시드 결합을 통해 환형으로 연결된 구조를 갖는 시클로이소말토테트라오스, 시클로이소말토테트라오스 생성효소, 해당 효소를 코딩하는 DNA, 및 이들 제조방법 및 용도를 제공함으로써 상기 과제를 해결한다.",HAYASHIBARA CO,FUJITA AKIHIRO;;KAWASHIMA AKIRA;;FUJISAWA HIROKI;;MORI TETSUYA;;NISHIMOTO TOMOYUKI,,https://lens.org/084-815-635-409-665,Patent Application,no,6,0,7,095-371-714-602-900;;041-087-565-684-895;;016-105-143-560-77X;;011-670-358-745-245;;197-342-166-711-385;;088-619-482-166-232;;084-815-635-409-665,JP;;KR;;EP;;CN;;WO,7,016-105-143-560-77X;;041-087-565-684-895;;095-371-714-602-900;;011-670-358-745-245;;088-619-482-166-232;;197-342-166-711-385;;084-815-635-409-665,JP;;KR;;EP;;CN;;WO,8,A23K20/163;;A23L33/125;;C12P19/18;;C12R2001/00;;C12N9/24;;C12N9/2451;;A61K47/26;;A61K9/0095;;C07H3/06;;C12N1/205;;A61K8/60;;A61Q19/10;;A61Q19/00;;A61Q11/00;;A61K31/07;;C07H3/06;;C12N9/00;;C07K14/305;;A61K31/702;;A61K8/60;;A61Q19/00;;C12N1/205;;A23K20/163;;A23L29/035;;C07B2200/13;;C12R2001/01,C07H3/06;;A23K20/163;;A23L29/00;;A61K8/60;;A61K31/702;;A61Q19/00;;C07K14/305;;C12N1/20;;C12N9/00;;C12R1/01,,3,0,,,"저널 오브 아메리칸 케미컬 소사이어티(Journal of American Chemical Society), 미국, 1949년, 제71권, 353 내지 358 페이지;;바이오사이언스 바이오테크놀로지 바이오케미스트리(Biosci. Biotech. Biochem.) 제57권, 1225-1227 페이지(1993년);;바이오사이언스 바이오테크놀로지 바이오케미스트리(Biosci. Biotech. Biochem.) 제72권, 3277-3280 페이지(2008년)",DISCONTINUED
122,US,A1,US 2025/0244340 A1,176-553-236-409-455,2025-07-31,2025,US 202318878737 A,2023-06-24,US 202318878737 A;;US 202263355590 P;;IB 2023056537 W,2022-06-25,DIAGNOSING AND TREATING A PATHOLOGICAL CONDITION OF THE INTESTINAL TRACT,"The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).",MAGNOSTICS LTD,LI PENG;;LEE GIL;;CHEVALIER ANNE,MAGNOSTICS LIMITED (2025-04-16),https://lens.org/176-553-236-409-455,Patent Application,yes,0,0,2,096-949-990-453-205;;176-553-236-409-455,WO;;US,2,096-949-990-453-205;;176-553-236-409-455,WO;;US,0,G01N33/6893;;G01N2800/06;;G01N33/54326;;G01N33/54326;;G01N33/6893;;G01N2333/4734;;G01N2333/91177;;G01N2800/06,G01N33/68;;G01N33/543,,0,0,,,,PENDING
123,EP,A1,EP 3933032 A1,098-158-648-381-738,2022-01-05,2022,EP 19912906 A,2019-10-14,CN 201910097650 A;;CN 201910098003 A;;CN 201910101736 A;;CN 201910476110 A;;CN 201910505614 A;;CN 201910812773 A;;CN 2019110956 W,2019-01-31,THREE-DIMENSIONAL CULTURE METHOD FOR LARGE-SCALE PREPARATION OF STEM CELLS,"A three-dimensional culture method for large-scale preparation of stem cells, comprising a three-dimensional microcarrier-based cell resuscitation method, a three-dimensional microcarrier cell culture-based in situ passage method, a three-dimensional microcarrier in situ freeze preservation method for cells, a three-dimensional microcarrier cell adsorption culture method, a method for harvesting cells on a three-dimensional microcarrier, a method for sampling cells cultured on a microcarrier, and a three-dimensional microcarrier-based cell large-scale expansion method.",BEIJING CYTONICHE BIOTECHNOLOGY CO LTD,YAN XIAOJUN;;LIU WEI;;ZHANG KUN,,https://lens.org/098-158-648-381-738,Patent Application,yes,0,0,10,107-547-395-643-253;;098-158-648-381-738;;097-974-513-800-674;;074-584-212-251-319;;157-924-486-203-653;;164-031-545-609-916;;116-344-999-531-136;;002-288-193-941-227;;174-680-495-762-578;;031-130-116-828-978,KR;;JP;;EP;;CN;;WO;;US,21,031-130-116-828-978;;098-158-648-381-738;;097-974-513-800-674;;107-547-395-643-253;;064-193-883-005-169;;177-679-039-638-785;;157-924-486-203-653;;164-031-545-609-916;;095-512-473-159-376;;153-380-558-282-138;;116-344-999-531-136;;002-288-193-941-227;;166-876-903-532-881;;172-613-712-465-463;;074-584-212-251-319;;005-796-352-280-615;;015-554-594-193-558;;088-259-906-993-041;;066-980-919-175-537;;079-979-089-990-148;;174-680-495-762-578,JP;;KR;;EP;;CN;;WO;;US,0,C12Q1/06;;C12M25/16;;C12M33/10;;C12N5/0075;;C12N2513/00;;C12N5/0667;;A01N1/162;;C12N5/0062;;C12N5/0667;;C12N5/0665;;C12M25/14;;C12Q1/06;;C12N2513/00;;C12N2511/00;;A01N1/125;;C12N5/0667;;C12N2511/00;;C12N2513/00;;C12N2523/00;;C12N2527/00;;C12N2531/00;;G01N15/1434;;G01N2015/1006;;G01N2015/1486;;G01N15/01;;A01N1/122;;A01N1/162,C12N5/00;;A01N1/02;;C12M1/34;;C12N5/0775;;C12Q1/06;;G01N15/10,,0,0,,,,PENDING
124,US,A1,US 2024/0011001 A1,131-596-182-612-948,2024-01-11,2024,US 202318341792 A,2023-06-27,US 202318341792 A;;CN 201910199413 A;;US 202117279733 A;;CN 2019114789 W,2019-03-15,"GDSL LIPASE, GENETICALLY-ENGINEERED BACTERIA AND APPLICATION THEREOF","The invention relates to a GDSL lipase, genetically-engineered bacteria and an application thereof. The GDSL lipase is derived from Streptomyces diastaticus CS1801 and its amino acid sequence is as shown in SEQ ID NO.2. After construction of a genetically-engineered bacterium strain, a GDSL lipase is generated through fermentation. Through this enzyme, vitamin A and palmitic acid are converted to produce vitamin A palmitate. The content of the vitamin A palmitate obtained from the conversion is 16.35 mg/L at most. The conversion efficiency is 81.75% at most. This lipase provides a new path to synthesize vitamin A palmitate by the enzymatic method and has an important application prospect.",SUZHOU KEMANDUO BIOTECHNOLOGY CO LTD;;CHANGSHU INST TECH,QI BIN;;QI MANTING;;WANG LIMEI;;WANG YUHUA,SUZHOU KEMANDUO BIOTECHNOLOGY CO. LTD (2023-06-25);;CHANGSHU INSTITUTE OF TECHNOLOGY (2023-06-25),https://lens.org/131-596-182-612-948,Patent Application,yes,0,0,9,065-219-484-056-929;;041-343-501-054-747;;180-752-382-445-362;;036-599-529-543-073;;167-281-347-073-576;;016-082-891-005-035;;085-043-736-701-832;;131-596-182-612-948;;193-147-394-110-021,JP;;CN;;WO;;US;;SG,9,065-219-484-056-929;;041-343-501-054-747;;180-752-382-445-362;;036-599-529-543-073;;167-281-347-073-576;;016-082-891-005-035;;085-043-736-701-832;;131-596-182-612-948;;193-147-394-110-021,JP;;CN;;WO;;US;;SG,0,C12N9/20;;C12N15/70;;C12R2001/19;;C12N1/205;;C12P7/6436;;C12P23/00;;C12N9/20;;C12P7/6436,C12N9/20;;C12P7/6436,,0,0,,,,ACTIVE
125,WO,A1,WO 2023/248207 A1,096-949-990-453-205,2023-12-28,2023,IB 2023056537 W,2023-06-24,US 202263355590 P,2022-06-25,DIAGNOSING AND TREATING A PATHOLOGICAL CONDITION OF THE INTESTINAL TRACT,"The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).",MAGNOSTICS LTD,LI PENG;;LEE GIL;;CHEVALIER ANNE,,https://lens.org/096-949-990-453-205,Patent Application,yes,4,1,2,096-949-990-453-205;;176-553-236-409-455,WO;;US,2,096-949-990-453-205;;176-553-236-409-455,WO;;US,0,G01N33/6893;;G01N2800/06;;G01N33/54326;;G01N33/54326;;G01N33/6893;;G01N2333/4734;;G01N2333/91177;;G01N2800/06,G01N33/543;;G01N33/68,,41,38,073-208-493-782-005;;018-937-953-246-373;;108-957-891-198-919;;049-664-918-681-437;;117-404-710-624-138;;025-361-036-003-520;;014-153-852-880-040;;090-505-519-235-841;;046-114-660-251-96X;;154-360-948-169-681;;091-265-642-818-221;;041-529-673-200-902;;089-441-150-674-768;;064-134-250-653-262;;030-218-721-751-438;;005-626-959-824-285;;106-450-431-561-814;;107-721-490-350-054;;047-948-936-205-348;;074-315-627-679-776;;024-647-621-478-460;;101-712-285-331-855;;069-272-832-678-31X;;016-796-053-401-332;;064-857-728-916-228;;017-702-299-683-348;;059-267-022-643-327;;010-998-073-787-006;;075-145-765-677-581;;020-321-349-368-100;;000-121-138-055-487;;023-487-555-483-301;;019-247-060-011-372;;167-800-709-846-911;;017-449-498-900-273;;052-067-959-488-45X;;067-059-833-527-77X;;070-258-340-320-017,10.1097/01.tp.0000521418.83368.0a;;10.1016/j.bpg.2017.01.004;;28395790;;pmc5041130;;27681959;;10.1038/srep34371;;10540150;;10.1046/j.1365-2168.1999.01260.x;;10576894;;pmc10465895;;37643848;;10.1136/bmjopen-2023-072875;;10.1002/macp.200290052;;10.1006/abio.2000.4844;;11112272;;8681887;;10.1016/s0733-8627(05)70270-4;;12630731;;10.1016/s0733-8627(02)00080-9;;2597964;;10.1002/bjs.1800761105;;18958996;;11992334;;10.1053/ajem.2002.32643;;10.1016/s0196-0644(05)81849-9;;8457097;;10.1093/gerona/60.8.1071;;16127115;;9672450;;10.1016/s0735-6757(98)90127-9;;2240749;;10.1016/s0196-0644(05)82602-2;;7091511;;10.1016/0002-9610(82)90052-6;;10.1007/s00268-009-0074-7;;19424744;;10.1053/j.semvascsurg.2009.12.001;;20298944;;18172675;;10.1007/s00423-007-0263-5;;14716789;;10.1002/bjs.4459;;11877691;;10.1067/mva.2002.120373;;27016159;;10.1016/j.ccc.2015.11.001;;24160929;;10.1016/j.bpg.2013.08.006;;10.1159/000338086;;22699523;;26962730;;10.1056/nejmra1503884;;22081293;;10.1007/s11239-011-0660-z;;27036673;;10.1177/1538574416639151;;10.1007/s00068-016-0634-0;;26820988;;pmc4830881;;287075;;pmc383592;;10.1073/pnas.76.5.2321;;10.1152/ajpgi.00207.2002;;12181160;;10.1016/j.febslet.2008.02.040;;pmc2680319;;18307996;;12022993;;10.1016/s1091-255x(01)00076-2;;2002658;;10763139;;10.1177/172460080001500107;;pmc5426554;;10.1016/j.ajpath.2012.01.006;;22349300;;2440895;;pmc2114929;;10.1083/jcb.105.1.359;;25273875;;10.1039/c4an00774c,"CEULEMANS LAURENS ET AL: ""Villin-1 Is a Novel Serological Biomarker for Intestinal Ischemia and Reperfusion Injury in Rats and Humans"", TRANSPLANTATION, vol. 101, no. 6S2, 1 June 2017 (2017-06-01), GB, pages S91, XP093084570, ISSN: 0041-1337, Retrieved from the Internet <URL:http://dx.doi.org/10.1097/01.tp.0000521418.83368.0a> DOI: 10.1097/01.tp.0000521418.83368.0a;;ANONYMOUS: ""The Detrimental Course of Acute Intestinal Ischemia (TACTIC) | ClinicalTrials.gov"", 18 January 2022 (2022-01-18), XP093084573, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT05194527> [retrieved on 20230921];;DERIKX JOEP P M ET AL: ""Serological markers for human intestinal ischemia: A systematic review"", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, BAILLIERE TINDALL, LONDON, US, vol. 31, no. 1, 7 February 2017 (2017-02-07), pages 69 - 74, XP029973605, ISSN: 1521-6918, DOI: 10.1016/J.BPG.2017.01.004;;SUN DA-LI ET AL: ""Accuracy of the serum intestinal fatty-acid-binding protein for diagnosis of acute intestinal ischemia: a meta-analysis"", SCIENTIFIC REPORTS, vol. 6, no. 1, 14 December 2016 (2016-12-14), XP093084675, DOI: 10.1038/srep34371;;DELANEY C P ET AL: ""Conclusion"", BRITISH JOURNAL OF SURGERY., vol. 86, no. 10, 10 December 2002 (2002-12-10), GB, pages 1349 - 1353, XP055825732, ISSN: 0007-1323, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2168.1999.01245.x> DOI: 10.1046/j.1365-2168.1999.01245.x;;ANONYMOUS: ""Dynabeads(TM) Streptavidin Trial Kit"", 1 March 2016 (2016-03-01), XP093084612, Retrieved from the Internet <URL:https://www.veritastk.co.jp/products/pdf/dynabeads_savtrial_kit_man.pdf> [retrieved on 20230922];;DUIVENVOORDEN ANNET A M ET AL: ""Diagnostic potential of plasma biomarkers and exhaled volatile organic compounds in predicting the different stages of acute mesenteric ischaemia: protocol for a multicentre prospective observational study (TACTIC study)"", BMJ OPEN, vol. 13, no. 8, 29 August 2023 (2023-08-29), London, UK, pages e072875, XP093084571, ISSN: 2044-6055, Retrieved from the Internet <URL:http://dx.doi.org/10.1136/bmjopen-2023-072875> DOI: 10.1136/bmjopen-2023-072875;;""Magnetic Polystyrene Nanoparticles with a High Magnetite Content Obtained by Miniemulsion Processes"", MACROMOLECULAR CHEMISTRY AND PHYSICS, vol. 204, 2003, pages 22 - 31;;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, 2007, pages 6640 - 6646;;G.U LEES.W. METZGERM. NATESANC. YANAVICHY.F. DUFRENE: ""Implementation of Force Differentiation in the Immunoassay"", ANALYTICAL BIOCHEMISTRY, vol. 287, 2000, pages 261 - 271, XP002330095, DOI: 10.1006/abio.2000.4844;;SANSON TGO'KEEFE KP.: ""Evaluation of abdominal pain in the elderly"", EMERG. MED. CLIN. NORTH AM., vol. 14, 1996, pages 615 - 627;;KAMIN RANOWICKI TACOURTNEY DSPOWERS RD.: ""Pearls and pitfalls in the emergency department evaluation of abdominal pain"", EMERG. MED. CLIN. NORTH AM., vol. 21, 2003, pages 61 - 72;;IRVIN TT.: ""Abdominal pain: a surgical audit of 1190 emergency admissions"", BR. J. SURG., vol. 76, 1989, pages 1121 - 1125;;PITTS SRNISKA RWXU JBURT CW.: ""National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary"", NATL. HEALTH STAT. REPORT, 2008, pages 1 - 38;;CORDELL WHKEENE KKGILES BKJONES JBJONES JHBRIZENDINE EJ: ""The high prevalence of pain in emergency medical care"", AM. J. EMERG. MED., vol. 20, 2002, pages 165 - 169;;LUKENS TWEMERMAN CEFFRON D.: ""The natural history and clinical findings in undifferentiated abdominal pain"", ANN. EMERG. MED., vol. 22, 1993, pages 690 - 696;;LEWIS LMBANET GABLANDA MHUSTEY FMMELDON SWGERSON LW.: ""Etiology and clinical course of abdominal pain in senior patients: a prospective, multicenter study"", J. GERONTOL. A BIOL. SCI. MED. SCI., vol. 60, 2005, pages 1071 - 1076;;KIZER KWVASSAR MJ: ""Emergency department diagnosis of abdominal disorders in the elderly"", AM. J. EMERG. MED., vol. 16, 1998, pages 357 - 362;;BUGLIOSI TFMELOY TDVUKOV LF.: ""Acute abdominal pain in the elderly"", ANN. EMERG. MED., vol. 19, 1990, pages 1383 - 1386;;FENYO G.: ""Acute abdominal disease in the elderly: experience from two series in Stockholm"", AM. J. SURG., vol. 143, 1982, pages 751 - 754, XP023228860, DOI: 10.1016/0002-9610(82)90052-6;;EVENNETT NJPETROV MSMITTAL AWINDSOR JA.: ""Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia"", WORLD J. SURG., vol. 33, 2009, pages 1374 - 1383, XP019707232;;ACOSTA S.: ""Epidemiology of mesenteric vascular disease: clinical implications"", SEMIN. VASC. SURG., vol. 23, 2010, pages 4 - 8;;KASSAHUN WTSCHULZ TRICHTER O, HAUSS J.: ""Unchanged high mortality rates from acute occlusive intestinal ischemia: six year review"", LANGENBECKS ARCH. SURG., vol. 393, 2008, pages 163 - 171, XP019590094;;SCHOOTS IGKOFFEMAN GILEGEMATE DALEVI MVAN GULIK TM.: ""Systematic review of survival after acute mesenteric ischemia according to disease aetiology"", BR. J. SURG., vol. 91, 2004, pages 17 - 27;;PARK WMGLOVICZKI PCHERRY KJ, JR.HALLETT JW, JR.BOWER TCPANNETON JM ET AL.: ""Contemporary management of acute mesenteric ischemia: Factors associated with survival"", J. VASC. SURG., vol. 35, 2002, pages 445 - 452, XP027500603, DOI: 10.1067/mva.2002.120373;;CARVER TWVORA RSTANEJA A.: ""Mesenteric Ischemia"", CRIT CARE CLIN., vol. 32, 2016, pages 155 - 171;;CORCOS O, NUZZO A.: ""Gastro-intestinal vascular emergencies"", BEST. PRACT. RES. CLIN. GASTROENTEROL., vol. 27, 2013, pages 709 - 725;;DEMIR IECEYHAN GOFRIESS H.: ""Beyond lactate: is there a role for serum lactate measurement in diagnosing acute mesenteric ischemia?"", DIG. SURG., vol. 29, 2012, pages 226 - 235;;CLAIR DGBEACH JM.: ""Mesenteric Ischemia"", N. ENGL. J. MED., vol. 374, 2016, pages 959 - 968;;ACOSTA S, NILSSON T.: ""Current status on plasma biomarkers for acute mesenteric ischemia"", J. THROMB. THROMBOLYSIS., vol. 33, 2012, pages 355 - 361, XP035047776, DOI: 10.1007/s11239-011-0660-z;;ZHAO YYIN HYAO CDENG JWANG MLI Z ET AL.: ""Management of Acute Mesenteric Ischemia: A Critical Review and Treatment Algorithm"", VASC. ENDOVASCULAR. SURG., vol. 50, 2016, pages 183 - 192;;TILSED JVCASAMASSIMA AKURIHARA HMARIANI DMARTINEZ IPEREIRA J ET AL.: ""ESTES guidelines: acute mesenteric ischaemia. Eur"", J. TRAUMA EMERG. SURG., vol. 42, 2016, pages 253 - 270, XP035803550, DOI: 10.1007/s00068-016-0634-0;;BRETSCHER AWEBER K., PROC. NATL. ACAD. SCI. U. S. A., vol. 76, 1979, pages 2321 - 2325;;ATHMAN RLOUVARD DROBINE S.: ""The epithelial cell cytoskeleton and intracellular trafficking. III. How is Villin involved in the actin cytoskeleton dynamics in intestinal cells?"", AM. J. PHYSIOL GASTROINTEST. LIVER PHYSIOL., vol. 283, 2002, pages G496 - G502;;KHURANA SGEORGE SP.: ""Regulation of cell structure and function by actin-binding proteins: villin's perspective"", FEBS LETT., vol. 582, 2008, pages 2128 - 2139, XP022797839, DOI: 10.1016/j.febslet.2008.02.040;;HINNEBUSCH BFMA QHENDERSON JWSIDDIQUE AARCHER SYHODIN RA.: ""Enterocyte response to ischemia is dependent on differentiation state"", J. GASTROINTEST. SURG., vol. 6, 2002, pages 403 - 409;;BACCHI CEGOWN AM.: ""Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue"", LAB INVEST., vol. 64, 1991, pages 418 - 424;;SALBE CBONNETON CMANET SALMEIDA AMAGDELENAT H ET AL.: ""Illegitimate villin transcripts in normal bone marrow precludes detection of colon cancer micrometastases"", INT. J. BIOL. MARKERS., vol. 15, 2000, pages 41 - 43, XP009093560;;ARANGO DAL-OBAIDI SWILLIAMS DSDOPESO HMAZZOLINI RCORNER G ET AL.: ""Villin expression is frequently lost in poorly differentiated colon cancer"", AM. J. PATHOL., vol. 180, 2012, pages 1509 - 1521;;DUDOUET BROBINE SHUET CSAHUQUILLO-MERINO CBLAIR LCOUDRIER E ET AL.: ""Changes in villin synthesis and subcellular distribution during intestinal differentiation of HT29-18 clones"", J. CELL BIOL., vol. 105, 1987, pages 359 - 369;;RANYFFIELDSCMUZARDJLIAUCHUKVCARRM: ""Rapid, highly sensitive detection of herpes simplex virus-1 using multiple antigenic peptide-coated superparamagnetic beads"", ANALYST, 2014",PENDING
126,US,A1,US 2022/0162560 A1,031-130-116-828-978,2022-05-26,2022,US 201917310418 A,2019-10-14,CN 201910097650 A;;CN 201910098003 A;;CN 201910101736 A;;CN 201910476110 A;;CN 201910505614 A;;CN 201910812773 A;;CN 2019110956 W,2019-01-31,THREE-DIMENSIONAL CULTURE METHOD FOR LARGE-SCALE PREPARATION OF STEM CELLS,"A three-dimensional culture method for large-scale preparation of stem cells, comprising a three-dimensional microcarrier-based cell resuscitation method, a three-dimensional microcarrier cell culture-based in situ passage method, a three-dimensional microcarrier in situ freeze preservation method for cells, a three-dimensional microcarrier cell adsorption culture method, a method for harvesting cells on a three-dimensional microcarrier, a method for sampling cells cultured on a microcarrier, and a three-dimensional microcarrier-based cell large-scale expansion method.",BEIJING CYTONICHE BIOTECHNOLOGY CO LTD,YAN XIAOJUN;;LIU WEI;;ZHANG KUN,BEIJING CYTONICHE BIOTECHNOLOGY CO. LTD (2021-08-07),https://lens.org/031-130-116-828-978,Patent Application,yes,0,2,10,107-547-395-643-253;;098-158-648-381-738;;097-974-513-800-674;;074-584-212-251-319;;157-924-486-203-653;;164-031-545-609-916;;116-344-999-531-136;;002-288-193-941-227;;174-680-495-762-578;;031-130-116-828-978,KR;;JP;;EP;;CN;;WO;;US,21,031-130-116-828-978;;098-158-648-381-738;;097-974-513-800-674;;107-547-395-643-253;;064-193-883-005-169;;177-679-039-638-785;;157-924-486-203-653;;164-031-545-609-916;;095-512-473-159-376;;153-380-558-282-138;;116-344-999-531-136;;002-288-193-941-227;;166-876-903-532-881;;172-613-712-465-463;;074-584-212-251-319;;005-796-352-280-615;;015-554-594-193-558;;088-259-906-993-041;;066-980-919-175-537;;079-979-089-990-148;;174-680-495-762-578,JP;;KR;;EP;;CN;;WO;;US,0,C12Q1/06;;C12M25/16;;C12M33/10;;C12N5/0075;;C12N2513/00;;C12N5/0667;;A01N1/162;;C12N5/0062;;C12N5/0667;;C12N5/0665;;C12M25/14;;C12Q1/06;;C12N2513/00;;C12N2511/00;;A01N1/125;;C12N5/0667;;C12N2511/00;;C12N2513/00;;C12N2523/00;;C12N2527/00;;C12N2531/00;;G01N15/1434;;G01N2015/1006;;G01N2015/1486;;G01N15/01;;A01N1/122;;A01N1/162,C12N5/0775;;A01N1/02;;G01N15/14,,1,1,083-313-844-514-748,17644203;;10.1016/j.jbiotec.2007.05.031,"Fernandes, AM; et al; ""Mouse embryonic stem cell expansion in a microcarrier-based stirred culture system"" Journal of Biotechnology, 132, 227-236, 2007 (Year: 2007)",ACTIVE
127,EP,A1,EP 4613330 A1,109-756-685-214-952,2025-09-10,2025,EP 25153683 A,2025-01-23,CN 202410246021 A,2024-03-05,MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,"An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. The present disclosure further discloses an application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2. Compared to an mRNA vaccine encoding separately corresponding antigens, the mRNA vaccine encoding a fusion antigen provided by the present disclosure can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine only needs to synthesize a single mRNA molecule for the encapsulation within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.",ACAD OF MILITARY MEDICAL SCIENCES AMS PLA,YANG YILONG;;CHEN WEI;;XU JUNJIE;;ZHAO XIAOFAN;;ZHANG JUN;;HOU LIHUA;;ZAI XIAODONG;;LI YU,,https://lens.org/109-756-685-214-952,Patent Application,yes,3,0,4,065-979-752-311-853;;008-558-785-418-259;;118-140-880-972-514;;109-756-685-214-952,CN;;EP;;US,4,109-756-685-214-952;;065-979-752-311-853;;118-140-880-972-514;;008-558-785-418-259,EP;;CN;;US,0,C07K14/005;;C12N15/88;;A61K39/12;;A61K39/385;;A61P31/14;;A61P31/20;;C12N2770/20022;;C12N2710/24122;;C12N2770/20034;;C12N2710/24134;;C07K2319/00;;A61K2039/53;;A61K2039/70;;A61K2039/6018;;C12N2710/24134;;C12N2770/20034;;A61K39/12;;A61K2039/53;;A61K2039/55555;;A61P31/14;;A61P31/20;;A61K2039/70;;A61K9/5015;;A61K39/215;;A61K39/275;;C07K14/005,A61P31/14;;A61K39/12;;A61P31/20,,2,0,,,"HOU FUJUN ET AL: ""mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge"", NATURE COMMUNICATIONS, vol. 14, no. 1, 22 September 2023 (2023-09-22), UK, XP093287374, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-023-41628-5> DOI: 10.1038/s41467-023-41628-5;;JIANG FAN ET AL: ""Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis"", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 115, 11 January 2023 (2023-01-11), XP087259425, ISSN: 1567-5769, [retrieved on 20230111], DOI: 10.1016/J.INTIMP.2023.109728",PENDING
128,US,A1,US 2022/0033789 A1,085-043-736-701-832,2022-02-03,2022,US 201917279733 A,2019-10-31,CN 201910199413 A;;CN 2019114789 W,2019-03-15,"GDSL LIPASE, GENETICALLY-ENGINEERED BACTERIA AND APPLICATION THEREOF","The invention relates to a GDSL lipase, genetically-engineered bacteria and an application thereof. The GDSL lipase is derived from Streptomyces diastaticus CS1801 and its amino acid sequence is as shown in SEQ ID NO.2. After construction of a genetically-engineered bacterium strain, a GDSL lipase is generated through fermentation. Through this enzyme, vitamin A and palmitic acid are converted to produce vitamin A palmitate. The content of the vitamin A palmitate obtained from the conversion is 16.35 mg/L at most. The conversion efficiency is 81.75% at most. This lipase provides a new path to synthesize vitamin A palmitate by the enzymatic method and has an important application prospect.",CHANGSHU INST TECH,WANG LIMEI;;XU TIANTIAN;;JI YAMEI;;QI BIN,CHANGSHU INSTITUTE OF TECHNOLOGY (2021-03-18),https://lens.org/085-043-736-701-832,Patent Application,yes,0,0,9,065-219-484-056-929;;041-343-501-054-747;;180-752-382-445-362;;036-599-529-543-073;;167-281-347-073-576;;016-082-891-005-035;;085-043-736-701-832;;131-596-182-612-948;;193-147-394-110-021,JP;;CN;;WO;;US;;SG,9,065-219-484-056-929;;041-343-501-054-747;;180-752-382-445-362;;036-599-529-543-073;;167-281-347-073-576;;016-082-891-005-035;;085-043-736-701-832;;131-596-182-612-948;;193-147-394-110-021,JP;;CN;;WO;;US;;SG,2,C12N9/20;;C12N15/70;;C12R2001/19;;C12N1/205;;C12P7/6436;;C12P23/00;;C12N9/20;;C12P7/6436,C12N9/20;;C12P7/64,,4,1,023-833-180-269-075,23301657;;10.1042/bj20121221,"Studer. Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes. Biochem. J. (2013) 449, 581–594.;;Badalamenti. A0A126Y261_9ACTN. UnitProtKB Database. June 8, 2016;;Doyle. A0A380MP40_STRGR. UnitProtKB Database. November 7, 2018;;Ichikawa (GFH64141. GenBank Database. February 28, 2020",DISCONTINUED
129,US,A1,US 2024/0033339 A1,063-178-076-139-126,2024-02-01,2024,US 202218272371 A,2022-06-10,CN 202110752883 A;;CN 2022098076 W,2021-07-02,STREPTOCOCCUS SUIS (S. SUIS) VACCINE,"A Streptococcus suis (S. suis) vaccine is provided. For the S. suis vaccine, an antigen is a protein with an amino acid sequence shown in SEQ ID NO: 2. A preparation method of the S. suis vaccine is provided, including the following steps: mixing a white oil and aluminum stearate to obtain a white oil adjuvant; adding poly sorbate 80 to an aqueous solution of the protein with the amino acid sequence shown in SEQ ID NO: 2, and thoroughly mixing to obtain an antigen solution; and mixing the antigen solution with the white oil adjuvant according to a volume ratio of (0.5-1.5):2, and emulsifying to obtain the S. suis vaccine. An animal immunized with the S. suis vaccine of the present disclosure can effectively resist the attack of S. suis serotype 2, 3, and 31, with a vaccine protection rate as high as 100%.",JIANGSU ACAD AGRICULTURAL SCI,XIAO QI;;ZHAO XIALING;;FAN HONGJIE;;HUANG XIAOGUO;;QIAN WENXIAN;;WEN LIBIN;;ZHU HAODAN;;NI YANXIU;;ZHOU JUNMING;;WANG DANDAN;;NIU JIAQIANG;;HE KONGWANG,JIANGSU ACADEMY OF AGRICULTURAL SCIENCES (2023-06-09),https://lens.org/063-178-076-139-126,Patent Application,yes,0,0,7,036-193-584-169-408;;063-178-076-139-126;;111-879-832-333-874;;012-585-510-175-284;;094-173-965-044-41X;;114-119-002-591-169;;012-120-335-432-529,CN;;LU;;WO;;US,7,036-193-584-169-408;;063-178-076-139-126;;111-879-832-333-874;;012-585-510-175-284;;094-173-965-044-41X;;114-119-002-591-169;;012-120-335-432-529,CN;;LU;;WO;;US,16,A61K39/092;;A61P31/04;;A61K39/39;;A61K2039/55511;;A61K2039/552;;A61K39/092;;A61P31/04;;A61K2039/552;;A61K2039/55566;;A61K2039/575;;A61P31/04;;A61K39/092;;A61K39/39;;A61K2039/552;;A61K2039/55511;;A61K2039/55566,A61K39/09;;A61K39/39;;A61P31/04,,2,1,031-906-987-946-537,19016627;;10.1086/594370,Ye et al. The Journal of Infectious Diseases. 2009; 199:97-107;;Uniprot Accession D5AI23 6/15/2020,ACTIVE
130,US,A1,US 2022/0017874 A1,149-951-426-860-321,2022-01-20,2022,US 202117389371 A,2021-07-30,CN 202010571607 A;;CN 2021074681 W,2020-06-22,VIRUS PRESERVATION SOLUTION,"A virus preservation solution is disclosed, including the following components: isopropanol or ethyl alcohol, guanidine hydrochloride, tri (hydroxymethyl) aminomethane hydrochloride, and ethylenediaminetetraacetic acid. Furthermore, a kit including the virus preservation solution, a method for preserving a virus, and a method for extracting a viral nucleic acid are also provided. The virus preservation solution of the present invention has the functions of preserving and lysing virus samples, and it is compatible with lysis buffers, wash buffers, elution buffers, etc. in all kinds of viral nucleic acid extraction kit commonly available in the market.",GUANGZHOU DONGSHENG BIOTECH CO LTD,LIU YUANDONG;;MENG WEI;;CHEN MEIYING;;HUANG QIN;;CHEN QINGQING;;ZHOU NING,GUANGZHOU DONGSHENG BIOTECH CO. LTD (2021-06-21),https://lens.org/149-951-426-860-321,Patent Application,yes,5,3,5,176-957-298-920-559;;163-211-254-515-962;;128-382-028-239-100;;093-274-114-435-013;;149-951-426-860-321,CN;;WO;;US,5,176-957-298-920-559;;163-211-254-515-962;;128-382-028-239-100;;149-951-426-860-321;;093-274-114-435-013,CN;;WO;;US,6,C12N15/1013;;C12N15/1013;;C12N7/00;;C12N7/00;;C12N15/1013,C12N7/00;;C12N15/10,,4,3,009-561-861-822-186;;042-844-361-368-542;;036-471-318-145-750,10.1101/2020.04.05.026435;;29218769;;10.1002/rmv.1963;;pmc7169153;;10.1101/2020.02.22.961268,"Tris-HCl Buffer Recipe. Cold Spring Harbor Protocol (2006). doi:10.1101/pdb.rec8747 (Year: 2006);;Scallan et al (13 April 2020). Validation of a Lysis Buffer Containing 4 M Guanidinium Thiocyanate (GITC)/ Triton X-100 for Extraction of SARS-CoV-2 RNA for COVID-19 ..... Lysis Buffers Containing 4 to 6 M GITC, Roche External Lysis Buffer and Qiagen RTL Lysis Buffer. bioRxi (Year: 2020);;Li et al (2018). Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018;28:e1963. (Year: 2018);;Zhao et al (27 Feb 2020). A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. bioRxiv (2020) pages 1-18. (Year: 2020)",ACTIVE
131,WO,A1,WO 2022/164319 A1,157-302-169-774-157,2022-08-04,2022,NL 2022050042 W,2022-01-28,EP 21154421 A;;EP 21166717 A,2021-01-29,CRISPR-ASSOCIATED BASE-EDITING OF THE COMPLEMENTARY STRAND,"The invention relates to methods for clustered regularly interspaced short palindromic repeat (CRISPR)-mediated A to G and/or C to T editing of the guide- complementary strand of a double stranded target DNA. The invention further relates to a nucleotide molecule encoding said CRISPR-mediated base editing system, to an expression vector comprising the nucleotide molecule, and to a cell comprising the expression vector. The invention further relates to an isolated Cas nuclease that allows A to G and/or C to T editing of the complementary strand of a double stranded target nucleic acid.",UNIV WAGENINGEN,VAN DER OOST JOHN;;WU WEN YING;;VILLEGAS WARREN RICARDO,,https://lens.org/157-302-169-774-157,Patent Application,yes,7,2,3,015-664-466-255-280;;157-302-169-774-157;;045-603-823-211-42X,EP;;WO;;US,3,015-664-466-255-280;;157-302-169-774-157;;045-603-823-211-42X,EP;;WO;;US,229,C12N15/113;;C12N2310/20;;C12N9/22;;C12Y305/04002;;C12Y305/04005;;C07K2319/80;;C12N9/78;;C12N2310/20;;C12N9/22;;C12N9/78;;C12N15/63;;C12Y305/04002;;C12Y305/04005,C12N9/22;;C12N15/113,,46,36,082-042-392-128-724;;002-331-636-341-839;;060-899-777-555-65X;;039-739-565-210-672;;031-443-152-485-383;;049-370-581-226-725;;023-008-904-514-014;;009-050-947-857-887;;036-518-169-995-940;;031-350-791-726-603;;002-193-473-352-839;;018-072-808-240-100;;001-191-489-068-327;;064-908-811-700-011;;088-299-462-256-046;;125-980-003-853-48X;;008-411-750-822-650;;016-246-267-722-477;;036-800-431-719-028;;035-867-544-971-262;;001-640-609-473-45X;;020-865-730-642-047;;069-210-062-763-687;;027-164-683-880-36X;;147-797-785-802-371;;044-883-999-175-138;;084-662-794-457-088;;071-933-409-071-673;;090-471-371-814-464;;142-603-438-056-167;;014-176-399-233-583;;022-178-263-495-25X;;063-760-249-087-699;;088-754-540-145-74X;;023-008-904-514-014;;111-180-530-241-510,10.1038/s41587-020-0453-z;;pmc8598131;;32732424;;10.1126/science.abb1390;;10.1038/s41589-018-0080-x;;29915237;;10.1111/mmi.14218;;30746801;;pmc7062608;;28512351;;10.1038/nrm.2017.48;;pmc4888836;;10.1101/gad.280545.116;;27222516;;pmc6535181;;10.1038/s41576-018-0059-1;;30341440;;30323312;;10.1038/nature17946;;27096365;;pmc4873371;;10.1038/protex.2017.054;;10.1038/nmeth.4327;;28581493;;10.1038/s41564-017-0102-6;;29403014;;10.1126/sciadv.aao4774;;28875174;;pmc5576876;;10.1038/nbt.4261;;30272679;;29160308;;pmc5726555;;10.1038/nature24644;;10.1126/science.1225829;;pmc6286148;;22745249;;pmc3465414;;10.1073/pnas.1208507109;;22949671;;pmc3795411;;10.1126/science.1231143;;23287718;;23907171;;10.1038/nbt.2675;;pmc3818127;;10.1038/nmeth.2600;;pmc3911785;;23892895;;10.1038/nmeth.2857;;24584192;;10.1038/nrmicro.2016.184;;pmc5851899;;28111461;;pmc7229846;;10.1093/nar/gkaa208;;32246713;;20353181;;10.1021/cr8002888;;pmc3368803;;22446836;;10.1038/nchembio.922;;pmc5820651;;29301067;;10.1021/acssynbio.7b00413;;10.1021/sb500291r;;pmc4277767;;25350266;;pmc3059133;;10.1038/nmeth.1524;;21037589;;10.1038/nchembio.2063;;27065233;;pmc4871718;;10.1038/nmeth.2681;;24076762;;pmc3844869;;10.1126/science.1247005;;24336571;;pmc4089965;;10.1038/nature13902;;pmc4270925;;25337876;;7917230;;10.1006/biol.1994.1020;;10.1016/j.copbio.2006.06.003;;16781139;;pmc5836994;;10.1002/yea.3278;;28886218;;10.1016/s0076-6879(02)50957-5;;12073338;;pmc6535181;;10.1038/s41576-018-0059-1;;30341440;;30323312;;31021262;;pmc6694769;;10.1089/crispr.2018.0014,"RICHTER MICHELLE F ET AL: ""Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity"", NATURE BIOTECHNOLOGY, GALE GROUP INC, NEW YORK, vol. 38, no. 7, 16 March 2020 (2020-03-16), pages 883 - 891, XP037187543, ISSN: 1087-0156, [retrieved on 20200316], DOI: 10.1038/S41587-020-0453-Z;;LAPINAITE AUDRONE ET AL: ""DNA capture by a CRISPR-Cas9-guided adenine base editor"", SCIENCE, vol. 369, no. 6503, 31 July 2020 (2020-07-31), US, pages 566 - 571, XP055820393, ISSN: 0036-8075, DOI: 10.1126/science.abb1390;;MOHANRAJU ET AL., SCIENCE, vol. 353, 2016, pages aaf8729 - aaf8729;;WU ET AL., NATURE CHEM BIOL, vol. 14, 2018, pages 642;;ANZALONE ET AL., NATURE BIOTECH, vol. 38, 2020, pages 883 - 891;;BERTRAND ET AL., MOL MICROBIOL, vol. 111, 2019, pages 1139 - 1151;;CHANG ET AL., NATURE REVIEWS MOL CELL BIOL, vol. 18, 2017, pages 495;;VERMAGREENBERG, GENES DEVELOP, vol. 30, 2016, pages 1138 - 1154;;REESLIU, NATURE REV GENET, vol. 19, 2018, pages 770 - 788;;KOMOR ET AL., NATURE, vol. 533, 2016, pages 420 - 424;;KUSCU ET AL., NATURE METHODS, vol. 14, 2017, pages 710;;BANNO ET AL., NATURE MICROBIOL, vol. 3, 2018, pages 423 - 429;;KIM ET AL., NATURE BIOTECH, vol. 35, 2017, pages 371 - 376;;KOMOR ET AL., SCIENCE ADVANCES, vol. 3, 2017, pages eaao4774;;KLEINSTIVER ET AL., NATURE BIOTECH, vol. 37, 2019, pages 1070 - 1079;;ZONG ET AL., NATURE BIOTECH, vol. 36, 2018, pages 950 - 953;;TAN ET AL., NATURE COMMUN, vol. 10, 2019, pages 1 - 10;;GAUDELLI ET AL., NATURE, vol. 551, 2017, pages 464 - 471;;LAPINAITE ET AL., SCIENCE, vol. 369, 2020, pages 333 - 337;;JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 821;;GASIUNAS ET AL., PNAS, vol. 109, 2012, pages E2579 - E2586;;CONG ET AL., SCIENCE, vol. 339, 2013, pages 819 - 823;;MALI ET AL., NATURE BIOTECH, vol. 31, 2013, pages 833 - 838;;YAMANO ET AL., CELL, vol. 165, 2016, pages 949 - 62;;PEREZ-PINERA ET AL., NATURE METHODS, vol. 10, 2013, pages 973 - 976;;SHEN ET AL., NATURE METHODS, vol. 11, 2014, pages 399 - 402;;SHMAKOV ET AL., NATURE REV MICROBIOL, vol. 15, 2017, pages 169 - 182;;KARVELIS ET AL., NUCLEIC ACIDS RES, vol. 48, 2020, pages 5016 - 5023;;FEGAN ET AL., CHEMICAL REVIEWS, vol. 110, 2010, pages 3315 - 36;;MIYAMOTO ET AL., NATURE CHEM BIOL, vol. 8, 2012, pages 465 - 70;;KYRIAKAKIS ET AL., ACS SYNTH BIOL, vol. 7, 2018, pages 706 - 717;;PATHAK ET AL., ACS SYNTH BIOL, vol. 3, 2014, pages 832 - 838;;KENNEDY ET AL., NATURE METHODS, vol. 7, 2010, pages 973 - 975;;TASLIMI ET AL., NATURE CHEM BIOL, vol. 12, 2016, pages 425 - 430;;ESVELT ET AL., NAT. METHODS, vol. 10, 2013, pages 1116 - 1121;;SHALEM ET AL., SCIENCE, vol. 343, 2014, pages 84 - 87;;MADDALO ET AL., NATURE, vol. 516, 2014, pages 423 - 427;;GOEDDEL: ""Gene Expression Technology in Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;TIJSSEN: ""Laboratory Techniques in Biochemistry and Molecular Biology - Hybridization with Nucleic Acid Probes"", 1993, ELSEVIER;;BERTHOLDWALTER, BIOLOGICALS, vol. 22, 1994, pages 135 - 150;;CHATTERJEE, CUR OPIN BIOTECH, vol. 17, 2006, pages 353 - 358;;VERWAAL ET AL., YEAST, vol. 35, 2018, pages 201 - 211;;GIETZWOODS: ""Methods in enzymology"", vol. 350, 2002, ELSEVIER, pages: 87 - 96;;REESLIU, NATURE REVIEWS GENET, vol. 19, 2018, pages 770 - 788;;KLUESNER ET AL., CRISPR J, vol. 1, 2018, pages 239 - 250",PENDING
132,US,A1,US 2021/0087222 A1,013-526-431-821-918,2021-03-25,2021,US 201716772119 A,2017-12-11,IB 2017001758 W,2017-12-11,COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS,"The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.",ETHNODYNE;;CENTRE NAT RECH SCIENT,RABHI CHÉRIF;;CARIEL LÉON;;DA COSTA NOBLE CHRISTIAN;;OUAZZANI JAMAL;;ARCILE GUILLAUME;;LE GOFF GÉRALDINE,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (2020-06-19);;ETHNODYNE (2020-06-19),https://lens.org/013-526-431-821-918,Patent Application,yes,0,0,4,013-526-431-821-918;;157-971-537-710-244;;111-485-578-154-229;;080-288-754-926-65X,EP;;WO;;US,4,013-526-431-821-918;;157-971-537-710-244;;111-485-578-154-229;;080-288-754-926-65X,EP;;WO;;US,0,A61P25/28;;C07J41/0055;;C07J71/001;;Y02A50/30;;C07J41/0033;;A61P25/28,C07J41/00;;A61P25/28,,0,0,,,,DISCONTINUED
133,US,A1,US 2024/0110163 A1,045-603-823-211-42X,2024-04-04,2024,US 202218273501 A,2022-01-28,EP 21154421 A;;EP 21166717 A;;NL 2022050042 W,2021-01-29,CRISPR-ASSOCIATED BASED-EDITING OF THE COMPLEMENTARY STRAND,"The invention relates to methods for clustered regularly interspaced short palindromic repeat (CRISPR)-mediated A to G and/or C to T editing of the guide-complementary strand of a double stranded target DNA. The invention further relates to a nucleotide molecule encoding said CRISPR-mediated base editing system, to an expression vector comprising the nucleotide molecule, and to a cell comprising the expression vector. The invention further relates to an isolated Cas nuclease that allows A to G and/or C to T editing of the complementary strand of a double stranded target nucleic acid.",UNIV WAGENINGEN,VAN DER OOST JOHN;;WU WEN YING;;VILLEGAS WARREN RICARDO,WAGENINGEN UNIVERSITEIT (2023-08-29),https://lens.org/045-603-823-211-42X,Patent Application,yes,0,0,3,015-664-466-255-280;;157-302-169-774-157;;045-603-823-211-42X,EP;;WO;;US,3,015-664-466-255-280;;157-302-169-774-157;;045-603-823-211-42X,EP;;WO;;US,229,C12N15/113;;C12N2310/20;;C12N9/22;;C12Y305/04002;;C12Y305/04005;;C07K2319/80;;C12N9/78;;C12N2310/20;;C12N9/22;;C12N9/78;;C12N15/63;;C12Y305/04002;;C12Y305/04005,C12N9/22;;C12N9/78;;C12N15/63,,0,0,,,,PENDING
134,EP,A1,EP 3910046 A1,179-674-910-937-664,2021-11-17,2021,EP 21184452 A,2013-05-29,EP 12305592 A;;EP 13728129 A;;EP 2013061007 W,2012-05-29,PROCESS FOR MANUFACTURING A LUBRICANT COATING,"The invention relates to a process for manufacturing a lubricant coating (5) for a medical injection device, comprising the following steps:- depositing a layer of poly-(dimethylsiloxane) on a surface of the medical injection device, the thickness of said layer being comprised between 90 and 400 nm,- exposing said layer to an oxidizing plasma, so as to form said lubricant coating (5) by oxidizing and cross-linking at least part of the poly-(dimethylsiloxane),wherein the lubricant coating (5) comprises:- a bottom layer (50) in contact with the surface of the medical injection device, comprising a mixture of cross-linked and non-cross-linked poly-(dimethylsiloxane),- an oxidized poly-(dimethylsiloxane) intermediate layer (51) having a thickness comprised between 10 and 30 nm, and- a non-cross-linked poly-(dimethylsiloxane) top layer (52) having a thickness of at most 2 nm.",BECTON DICKINSON FRANCE,FOUCHER CÉDRIC;;SANTUCCI-ARIBERT VIRGINIE,,https://lens.org/179-674-910-937-664,Patent Application,yes,6,0,24,125-625-522-837-901;;179-674-910-937-664;;057-230-927-509-518;;092-398-936-409-234;;029-807-868-784-867;;191-571-085-072-64X;;052-308-409-108-920;;157-738-047-457-126;;102-629-554-673-95X;;156-567-299-937-003;;148-745-720-012-67X;;012-254-545-639-230;;076-519-027-352-048;;015-641-081-883-292;;199-511-552-070-309;;036-601-177-329-902;;013-760-839-057-736;;144-179-909-292-91X;;096-955-535-702-709;;197-969-005-430-338;;082-895-320-796-998;;193-518-349-602-625;;016-694-174-361-077;;105-789-951-364-634,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX;;IN,24,125-625-522-837-901;;179-674-910-937-664;;057-230-927-509-518;;092-398-936-409-234;;029-807-868-784-867;;191-571-085-072-64X;;052-308-409-108-920;;157-738-047-457-126;;102-629-554-673-95X;;156-567-299-937-003;;148-745-720-012-67X;;012-254-545-639-230;;076-519-027-352-048;;015-641-081-883-292;;199-511-552-070-309;;036-601-177-329-902;;013-760-839-057-736;;144-179-909-292-91X;;096-955-535-702-709;;197-969-005-430-338;;082-895-320-796-998;;193-518-349-602-625;;016-694-174-361-077;;105-789-951-364-634,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX;;IN,0,C10M107/50;;A61M2205/0222;;A61M2205/0238;;C10M2229/0415;;A61M2005/3131;;A61M5/3129;;C10N2040/50;;C10N2050/023;;C10N2060/04;;C10N2070/00;;A61M5/31;;C10M107/50;;C10M107/50;;C10M107/50;;A61M2205/0222;;A61M2205/0238;;C10M2229/0415;;A61M2005/3131;;C10N2040/50;;C10N2050/023;;C10N2060/04;;C10N2070/00;;A61M5/3129;;B05D3/147;;B05D3/148;;C10M155/02,C10M107/50;;A61M5/31;;C10N30/06;;C10N40/00;;C10N50/00;;C10N60/04;;C10N70/00,,2,2,113-565-558-689-202;;067-613-607-742-055,pmc3928042;;10.1002/jps.21530;;18704929;;10.1016/s0032-3861(97)00484-9,"JOHN F. CARPENTER ET AL.: ""Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 98, no. 4, April 2009 (2009-04-01);;H. HILLBORG ET AL.: ""Hydrophobicity recovery of polydimethylsiloxane after exposure to corona discharge"", POLYMER, vol. 39, no. 10, 1998, pages 1991 - 1998, XP005924843, DOI: 10.1016/S0032-3861(97)00484-9",ACTIVE
135,WO,A1,WO 2025/049012 A1,064-021-451-142-265,2025-03-06,2025,US 2024/0039616 W,2024-07-25,US 202363578815 P,2023-08-25,DRIPLESS FLUID COUPLING DEVICES AND METHODS OF USE,"The present invention is to a dripless fluid coupling device (a dripless connector) that can be used to driplessly connect and disconnect devices or assemblies to and from each other in a sterile manner. The dripless fluid coupling device of the present invention is easy to manufacture using known materials and methods; easy to use, requiring only a clamping device to connect and disconnect; sterilizable and relatively inexpensive compared to available prior art devices.",EMD MILLIPORE CORP,ORMOND JAMES;;LEE HEEJIN,,https://lens.org/064-021-451-142-265,Patent Application,yes,4,0,1,064-021-451-142-265,WO,1,064-021-451-142-265,WO,0,A61M2039/2473;;A61M2039/268;;A61M39/1011,A61M39/10;;A61M39/24;;A61M39/26,,1,0,,,"""Manual of Patent Examining Procedure"", February 2023, UNITED STATES PATENT AND TRADEMARK OFFICE",PENDING
136,US,A1,US 2021/0338842 A1,175-938-199-558-339,2021-11-04,2021,US 202117219986 A,2021-04-01,CN 202010375037 A,2020-05-03,DUAL-MODALITY NANOPROBE TARGETING GLIOBLASTOMA AND PREPARATION METHOD THEREOF,"A dual-modality nanoprobe targeting glioblastoma and preparation method thereof are described. The dual-modality nanoprobe of the present disclosure comprises DSPE-PEG(2000)-Amine, superparamagnetic iron oxide nanoparticles (SPIONs), Cy7-NHS molecule, targeting polypeptide and/or trans-mirror structure (i.e., enantiomer) thereof. The dual-modality nanoprobe can integrate the advantages of magnetic resonance and fluorescence imaging and thus provide clearer anatomical structure information of brain tumors; in the imaging process, the dual-modality nanoprobe can not only provide clearer image results, but also can specifically identify target sites. Also, the dual-modality nanoprobe of the present disclosure also has good in vivo stability.",WEST CHINA HOSPITAL OF SICHUAN UNIV,WU MIN;;GONG QIYONG;;LV SU;;ZENG FANXIN;;XIE RUOXI,WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY (2021-02-19),https://lens.org/175-938-199-558-339,Patent Application,yes,0,4,3,144-859-222-128-063;;065-852-075-457-733;;175-938-199-558-339,CN;;US,3,144-859-222-128-063;;065-852-075-457-733;;175-938-199-558-339,CN;;US,2,A61K49/0002;;A61K49/0054;;A61K49/0056;;A61K49/186;;A61K49/1866;;B82Y20/00;;B82Y25/00;;B82Y30/00;;B82Y40/00;;A61K49/1866;;A61K49/0002;;A61K49/0032;;A61K49/0056;;B82Y5/00;;B82Y15/00;;B82Y25/00;;H01F1/0054;;A61K49/1866;;A61K49/0002;;A61K49/0054;;A61K49/0056;;B82Y25/00;;B82Y30/00,A61K49/18;;A61K49/00,,0,0,,,,DISCONTINUED
137,US,A1,US 2023/0235325 A1,055-225-430-665-540,2023-07-27,2023,US 202217938857 A,2022-10-07,US 202217938857 A;;US 201815766549 A;;US 2016/0056417 W;;US 201562239714 P;;US 201662352788 P,2015-10-09,Compositions and Methods for Treating Huntington's Disease and Related Disorders,"Compositions and methods are provided for the inhibition, treatment and/or prevention of Huntington's disease and related disorders.",CHILDRENS HOSPITAL PHILADELPHIA,DAVIDSON BEVERLY L;;MONTEYS ALEJANDRO MAS;;EBANKS SHAUNA,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2017-07-06),https://lens.org/055-225-430-665-540,Patent Application,yes,2,0,9,152-437-018-244-454;;055-225-430-665-540;;081-441-961-307-063;;005-194-624-566-521;;087-647-356-854-845;;072-627-473-275-030;;148-412-989-407-732;;196-744-707-221-342;;123-310-566-048-34X,AU;;EP;;WO;;US;;CA,9,152-437-018-244-454;;055-225-430-665-540;;081-441-961-307-063;;005-194-624-566-521;;087-647-356-854-845;;072-627-473-275-030;;148-412-989-407-732;;196-744-707-221-342;;123-310-566-048-34X,AU;;EP;;WO;;US;;CA,0,C12N15/102;;C12N15/66;;C12N15/861;;C12N15/88;;C12N2330/51;;C12N2310/20;;C12N15/113;;A61P25/00;;C12N9/22;;C12N2310/20;;C12N15/861;;C12N15/88;;C12N15/66;;C12N15/102;;C12N2330/51;;A61K48/005;;C12N15/113;;A61P25/00;;C12N9/22;;C12N2800/80,C12N15/113;;A61K48/00;;A61P25/00;;C12N9/22;;C12N15/10;;C12N15/66;;C12N15/861;;C12N15/88,,2,2,095-403-907-008-354;;185-369-744-640-369,27634650;;10.1093/hmg/ddw286;;28172889;;pmc6078600;;10.1016/j.lfs.2024.122562;;38492921,"Shin, Permanent Inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Human Molecular Genetics, Vol. 25, No. 20 (Year: 2016);;Tandon Polyglutamine disorders Pathogenesis and potential drug interventions. Life Sciences, 344: 1-17 (Year: 2024)",PENDING
138,US,A1,US 2021/0393881 A1,102-629-554-673-95X,2021-12-23,2021,US 202117464397 A,2021-09-01,US 202117464397 A;;EP 12305592 A;;US 201815978475 A;;US 201414404153 A;;EP 2013061007 W,2012-05-29,Lubricant Coating and Medical Injection Device Comprising Such a Coating,"The invention relates to a lubricant coating (5) for a medical injection device (1), comprising successively: —a bottom layer (50) in contact with the medical device surface (21) of the container to be lubricated, comprising a mixture of cross-linked and non-cross-linked poly-(dimethylsiloxane), —an intermediate layer (51) consisting essentially of oxidized poly-(dimethylsiloxane) and having a thickness comprised between 10 and 30 nm and, —a top layer (52) consisting essentially of non-cross-linked poly-(dimethylsiloxane) and having a thickness of at most 2 nm. The invention also relates to a medical injection device comprising such a lubricant coating, and a manufacturing process for said coating.",BECTON DICKINSON FRANCE,FOUCHER CÉDRIC;;SANTUCCI-ARIBERT VIRGINIE,BECTON DICKINSON FRANCE (2015-01-17),https://lens.org/102-629-554-673-95X,Patent Application,yes,0,3,24,125-625-522-837-901;;179-674-910-937-664;;057-230-927-509-518;;092-398-936-409-234;;029-807-868-784-867;;191-571-085-072-64X;;052-308-409-108-920;;157-738-047-457-126;;102-629-554-673-95X;;156-567-299-937-003;;148-745-720-012-67X;;012-254-545-639-230;;076-519-027-352-048;;015-641-081-883-292;;199-511-552-070-309;;036-601-177-329-902;;013-760-839-057-736;;144-179-909-292-91X;;096-955-535-702-709;;197-969-005-430-338;;082-895-320-796-998;;193-518-349-602-625;;016-694-174-361-077;;105-789-951-364-634,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX;;IN,24,125-625-522-837-901;;179-674-910-937-664;;057-230-927-509-518;;092-398-936-409-234;;029-807-868-784-867;;191-571-085-072-64X;;052-308-409-108-920;;157-738-047-457-126;;102-629-554-673-95X;;156-567-299-937-003;;148-745-720-012-67X;;012-254-545-639-230;;076-519-027-352-048;;015-641-081-883-292;;199-511-552-070-309;;036-601-177-329-902;;013-760-839-057-736;;144-179-909-292-91X;;096-955-535-702-709;;197-969-005-430-338;;082-895-320-796-998;;193-518-349-602-625;;016-694-174-361-077;;105-789-951-364-634,KR;;JP;;RU;;EP;;CN;;ES;;WO;;US;;MX;;IN,0,C10M107/50;;A61M2205/0222;;A61M2205/0238;;C10M2229/0415;;A61M2005/3131;;A61M5/3129;;C10N2040/50;;C10N2050/023;;C10N2060/04;;C10N2070/00;;A61M5/31;;C10M107/50;;C10M107/50;;C10M107/50;;A61M2205/0222;;A61M2205/0238;;C10M2229/0415;;A61M2005/3131;;C10N2040/50;;C10N2050/023;;C10N2060/04;;C10N2070/00;;A61M5/3129;;B05D3/147;;B05D3/148;;C10M155/02,A61M5/31;;B05D3/14;;C10M107/50;;C10M155/02,,0,0,,,,ACTIVE
139,US,A1,US 2023/0002811 A1,064-198-886-470-19X,2023-01-05,2023,US 201816631157 A,2018-04-12,CN 201710573752 A;;CN 2018082769 W,2017-07-14,"APPLICATION OF CAS PROTEIN, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT","The present invention provides a use of a Cas protein, and a method and a kit for detecting target nucleic acid molecules. The method for detecting target nucleic acid molecules comprises adding a guide RNA, a Cas12a, and a nucleic acid probe into a reaction system containing target nucleic acid molecules to be detected, and detecting it after the reaction is completed.",SHANGHAI TOLO BIOTECHNOLOGY COMPANY LTD,WANG JIN;;CHENG QIUXIANG;;LI SHIYUAN;;LI XIAOYAN;;LI LINXIAN,SHANGHAI TOLO BIOTECHNOLOGY COMPANY LIMITED (2021-04-29),https://lens.org/064-198-886-470-19X,Patent Application,yes,2,8,30,188-338-376-763-732;;000-357-254-046-693;;167-291-034-689-651;;005-230-907-918-473;;169-338-679-313-377;;127-531-152-618-140;;123-834-886-214-826;;029-011-244-777-569;;039-039-476-465-342;;199-346-807-574-896;;169-539-579-851-208;;099-947-998-303-818;;037-429-420-849-030;;195-437-029-187-416;;084-506-917-058-93X;;090-397-521-838-048;;077-368-927-838-861;;148-811-981-581-603;;064-198-886-470-19X;;159-025-965-911-837;;082-196-448-398-064;;174-801-931-046-294;;116-694-218-386-192;;107-859-039-687-850;;009-013-513-195-799;;145-352-663-035-907;;016-908-784-205-515;;083-036-865-775-741;;029-165-084-843-804;;142-444-697-415-763,AU;;JP;;EA;;US;;CA;;BR;;MX;;PH;;KR;;MY;;CN;;EP;;IL;;ZA;;WO;;SG;;NZ;;MA,32,188-338-376-763-732;;000-357-254-046-693;;167-291-034-689-651;;127-531-152-618-140;;050-084-189-713-383;;169-338-679-313-377;;005-230-907-918-473;;123-834-886-214-826;;029-011-244-777-569;;039-039-476-465-342;;199-346-807-574-896;;169-539-579-851-208;;099-947-998-303-818;;037-429-420-849-030;;195-437-029-187-416;;084-506-917-058-93X;;094-129-148-887-443;;090-397-521-838-048;;077-368-927-838-861;;148-811-981-581-603;;064-198-886-470-19X;;159-025-965-911-837;;082-196-448-398-064;;174-801-931-046-294;;116-694-218-386-192;;107-859-039-687-850;;009-013-513-195-799;;145-352-663-035-907;;016-908-784-205-515;;083-036-865-775-741;;029-165-084-843-804;;142-444-697-415-763,AU;;JP;;EA;;US;;CA;;BR;;MX;;PH;;KR;;MY;;CN;;EP;;IL;;ZA;;WO;;SG;;NZ;;MA,187,C12Q1/6816;;C12N9/22;;C12N15/113;;C12N2310/20;;C12Q1/6816;;C12Q1/6823;;C12N2310/20;;C12Q1/683;;Y02A50/30;;C12Q1/6816;;C12Q2563/107;;C12N2310/20;;C12N9/22;;C12N15/113;;C12Q1/6823;;C12Q1/6886,C12Q1/6823;;C12N9/22;;C12N15/113;;C12Q1/6886,,3,3,056-684-628-689-109;;052-369-304-913-682;;098-768-909-251-420,7580930;;10.1101/gr.4.6.357;;10.1126/science.aaf5573;;27256883;;pmc5127784;;10.1101/054742;;10.1038/s41551-017-0091,"Livak, Kenneth J., et al. ""Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization."" Genome Research 4.6 (1995): 357-362 (Year: 1995);;Abudayyeh, Omar O., et al. ""C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector."" Science 353.6299 (5 August 2016): aaf5573 (Year: 2016);;Zuo, Xiaolei, Chunhai Fan, and Hong-Yuan Chen. ""Biosensing: CRISPR-powered diagnostics."" Nature Biomedical Engineering 1.6 (13 June 2017): 0091 (Year: 2017)",ACTIVE
140,US,A1,US 2022/0119507 A1,048-193-685-886-161,2022-04-21,2022,US 201917274960 A,2019-09-13,US 201917274960 A;;CN 2018105733 W;;CN 2018106144 W;;US 201962867244 P;;CN 2019105824 W,2018-09-14,"MEDICINAL COMPOSITION CONTAINING MONOCLONAL ANTIBODY OR ANTIBODY FAB FRAGMENT THEREOF, AND USE THEREOF","The present invention provides a PTX3 monoclonal antibody or antibody Fab fragment thereof and use thereof. The aforementioned monoclonal antibody or antibody Fab fragment thereof specifically inhibit or slow down the binding of PTX3 to the PTX3 receptor, and may be used for a kit and method for detecting PTX3, and a pharmaceutical composition which inhibits or slows down diseases or symptoms associated with PTX3 and PTX3 receptor binding, and a use thereof.",OHEALTH BIOPHARMACEUTICAL SUZHOU CO LTD,WANG JU-MING;;LEE I-CHEN;;HSIAO YU-WEI;;CHI JHIH-YING;;DU JYUN-YI;;LIANG HSIN-YIN;;CHENG CHAO-CHUN;;KO CHIUNG-YUAN;;CHEN FENG-WEI;;LIU JHIH-YUN,OHEALTH BIOPHARMACEUTICAL (SUZHOU) CO. LTD (2021-03-03),https://lens.org/048-193-685-886-161,Patent Application,yes,1,1,20,043-055-382-434-689;;197-333-240-888-468;;058-149-492-525-049;;004-660-581-757-967;;158-261-956-004-360;;118-228-695-939-647;;099-620-477-368-638;;067-038-083-122-200;;039-665-725-819-729;;069-363-693-391-784;;137-796-427-238-734;;035-076-522-505-200;;180-047-857-115-030;;076-487-151-324-251;;125-812-783-636-722;;079-019-381-572-690;;017-786-848-405-086;;048-193-685-886-161;;061-932-003-857-425;;016-364-852-385-149,JP;;AU;;US;;TW;;CA;;MX;;PH;;BR;;KR;;CN;;EP;;ZA;;WO;;SG,20,043-055-382-434-689;;197-333-240-888-468;;048-193-685-886-161;;004-660-581-757-967;;158-261-956-004-360;;099-620-477-368-638;;118-228-695-939-647;;067-038-083-122-200;;039-665-725-819-729;;069-363-693-391-784;;137-796-427-238-734;;035-076-522-505-200;;180-047-857-115-030;;076-487-151-324-251;;125-812-783-636-722;;079-019-381-572-690;;017-786-848-405-086;;016-364-852-385-149;;061-932-003-857-425;;058-149-492-525-049,JP;;AU;;US;;TW;;CA;;MX;;PH;;BR;;KR;;EP;;CN;;ZA;;WO;;SG,41,C07K16/18;;C07K2317/56;;A61P35/00;;C07K16/18;;G01N33/577;;C07K2317/76;;C07K2317/92;;C07K2317/34;;A61K2039/505;;A61P11/00;;C07K2317/70;;A61K39/395;;A61K31/337;;A61P35/04;;A61P1/16;;A61P13/12;;C07K16/18;;A61P35/00;;G01N33/577;;C07K2317/24;;C07K2317/31;;A61K2039/505;;A61P35/00;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/31;;C07K2317/34;;C07K2317/76;;C07K2317/92;;G01N33/577,C07K16/18;;A61P35/00;;G01N33/577,,1,1,061-178-025-801-420,2439094;;10.1146/annurev.bb.16.060187.001035,"Mariuzza (Annu. Rev. Biophys. Biophys. Chem., 16: 139-159, 1987)",ACTIVE
141,EP,A1,EP 4389906 A1,000-240-500-156-814,2024-06-26,2024,EP 23153574 A,2023-01-27,US 202263476433 P,2022-12-21,METHODS FOR THE ENZYMATIC TREATMENT OF WHOLE STILLAGE,The present invention relates to methods of treating whole stillage with a xylanase to increase the solids content by increasing the protein content in thin stillage.,BASF SE,BLOCQUEL DAVID;;HUFFMAN JAMES R;;QURESHI ASFIA;;RISOER MICHAEL WULFF,DANSTAR FERMENT AG (2025-01-01),https://lens.org/000-240-500-156-814,Patent Application,yes,21,0,2,129-823-256-287-435;;000-240-500-156-814,EP;;WO,2,129-823-256-287-435;;000-240-500-156-814,EP;;WO,2,C12P21/00;;C12N9/2402;;C12Y302/01008;;C12P7/06;;A23K10/14;;A23K10/38,C12P21/00;;A23J1/16;;A23K10/38;;C12N9/24;;C12P7/06,,4,2,020-256-773-288-339;;032-728-154-591-070,15652973;;10.1016/j.femsre.2004.06.005;;10.1016/0022-2836(70)90057-4;;5420325,"SHEI ET AL., BIOTECH. AND BIOENG., vol. XXVII, 1985, pages 533 - 538;;FOURNIER ET AL., BIOTECH. BIOENG, vol. XXVII, 1985, pages 539 - 546;;COLLINS ET AL.: ""FEMS Microbiology Reviews"", vol. 29, 2005, pages: 3 - 23;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1979, pages 443 - 453",DISCONTINUED
142,US,A1,US 2021/0230677 A1,050-084-189-713-383,2021-07-29,2021,US 202117224541 A,2021-04-07,US 202117224541 A;;CN 201710573752 A;;US 201816631157 A;;CN 2018082769 W,2017-07-14,"APPLICATION OF CAS PROTEIN, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT","The present invention provides a use of a Cas protein, and a method and a kit for detecting target nucleic acid molecules. The method for detecting target nucleic acid molecules comprises adding a guide RNA, a Cas12a, and a nucleic acid probe into a reaction system containing target nucleic acid molecules to be detected, and detecting it after the reaction is completed.",SHANGHAI TOLO BIOTECHNOLOGY COMPANY LTD,WANG JIN;;CHENG QIUXIANG;;LI SHIYUAN;;LI XIAOYAN;;LI LINXIAN,SHANGHAI TOLO BIOTECHNOLOGY COMPANY LIMITED (2021-04-29),https://lens.org/050-084-189-713-383,Patent Application,yes,0,3,2,094-129-148-887-443;;050-084-189-713-383,US,32,188-338-376-763-732;;000-357-254-046-693;;167-291-034-689-651;;127-531-152-618-140;;050-084-189-713-383;;169-338-679-313-377;;005-230-907-918-473;;123-834-886-214-826;;029-011-244-777-569;;039-039-476-465-342;;199-346-807-574-896;;169-539-579-851-208;;099-947-998-303-818;;037-429-420-849-030;;195-437-029-187-416;;084-506-917-058-93X;;094-129-148-887-443;;090-397-521-838-048;;077-368-927-838-861;;148-811-981-581-603;;064-198-886-470-19X;;159-025-965-911-837;;082-196-448-398-064;;174-801-931-046-294;;116-694-218-386-192;;107-859-039-687-850;;009-013-513-195-799;;145-352-663-035-907;;016-908-784-205-515;;083-036-865-775-741;;029-165-084-843-804;;142-444-697-415-763,AU;;JP;;EA;;US;;CA;;BR;;MX;;PH;;KR;;MY;;CN;;EP;;IL;;ZA;;WO;;SG;;NZ;;MA,187,C12Q1/6844;;C12Q1/6823,C12Q1/6823,,0,0,,,,ACTIVE
143,EP,A1,EP 4289867 A1,127-025-862-248-699,2023-12-13,2023,EP 22748944 A,2022-01-24,CN 202110172889 A;;CN 2022073560 W,2021-02-08,CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY,The present application provides an endogenous chimeric antigen receptor (ECAR). An antigen-binding domain in the endogenous chimeric antigen receptor is an endogenous protein molecule. The engineered immune cells in the present invention can kill a variety of cells specifically and selectively.,UNIV ZHEJIANG,YING SONGMIN;;CHEN SISI,,https://lens.org/127-025-862-248-699,Patent Application,yes,0,0,9,059-627-326-138-967;;017-683-221-377-77X;;198-562-616-749-040;;075-948-712-155-375;;028-698-476-960-44X;;127-025-862-248-699;;171-102-604-089-957;;026-370-450-778-867;;031-129-943-207-675,JP;;CN;;EP;;WO;;US,9,031-129-943-207-675;;017-683-221-377-77X;;198-562-616-749-040;;075-948-712-155-375;;028-698-476-960-44X;;127-025-862-248-699;;171-102-604-089-957;;026-370-450-778-867;;059-627-326-138-967,JP;;EP;;CN;;WO;;US,28,C07K14/7051;;C07K14/5409;;C07K14/523;;C12N9/6462;;C07K14/70521;;C07K14/70517;;C12N15/86;;C12N5/0636;;A61P11/06;;A61P29/00;;C12Y304/21073;;C07K2319/02;;C07K2319/03;;C07K2319/33;;C12N2740/15043;;C12N2800/107;;C12N2510/00;;A61K35/17;;C12N2740/10043;;C07K2319/02;;C07K2319/03;;C07K14/7051;;A61K2239/31;;A61K2239/38;;C12N15/86;;A61P11/06;;A61K40/31;;A61K40/11;;A61K40/4217;;A61K40/4219;;A61K2239/15;;C12N5/0636;;A61K2239/31;;A61K2239/38;;A61K40/4202;;A61K40/11;;A61K40/31;;A61K40/4217;;A61K40/4219;;A61P35/00;;A61K2239/21;;A61K2239/15;;A61K2239/17;;A61K35/17;;C07K14/523;;C07K14/5409;;C07K14/7051;;C07K14/70517;;C07K14/70521;;C07K2319/02;;C07K2319/03;;C07K2319/33;;C12N15/86;;C12N2510/00;;C12N2740/10043;;C12N2740/15043,C07K19/00;;A61K35/17;;A61P35/00;;C12N5/10;;C12N15/62,,0,0,,,,PENDING
144,US,A1,US 2024/0424020 A1,028-698-476-960-44X,2024-12-26,2024,US 202218264604 A,2022-01-24,CN 202110172889 A;;CN 2022073560 W,2021-02-08,CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY,An endogenous chimeric antigen receptor (ECAR) has an antigen-binding domain that is an endogenous protein molecule. The engineered immune cells expressing the ECAR can kill a variety of cells specifically and selectively.,UNIV ZHEJIANG,YING SONGMIN;;CHEN SISI,ZHEJIANG UNIVERSITY (2023-07-31),https://lens.org/028-698-476-960-44X,Patent Application,yes,0,0,9,059-627-326-138-967;;017-683-221-377-77X;;198-562-616-749-040;;075-948-712-155-375;;028-698-476-960-44X;;127-025-862-248-699;;171-102-604-089-957;;026-370-450-778-867;;031-129-943-207-675,JP;;CN;;EP;;WO;;US,9,031-129-943-207-675;;017-683-221-377-77X;;198-562-616-749-040;;075-948-712-155-375;;028-698-476-960-44X;;127-025-862-248-699;;171-102-604-089-957;;026-370-450-778-867;;059-627-326-138-967,JP;;EP;;CN;;WO;;US,28,C07K14/7051;;C07K14/5409;;C07K14/523;;C12N9/6462;;C07K14/70521;;C07K14/70517;;C12N15/86;;C12N5/0636;;A61P11/06;;A61P29/00;;C12Y304/21073;;C07K2319/02;;C07K2319/03;;C07K2319/33;;C12N2740/15043;;C12N2800/107;;C12N2510/00;;A61K35/17;;C12N2740/10043;;C07K2319/02;;C07K2319/03;;C07K14/7051;;A61K2239/31;;A61K2239/38;;C12N15/86;;A61P11/06;;A61K40/31;;A61K40/11;;A61K40/4217;;A61K40/4219;;A61K2239/15;;C12N5/0636;;A61K2239/31;;A61K2239/38;;A61K40/4202;;A61K40/11;;A61K40/31;;A61K40/4217;;A61K40/4219;;A61P35/00;;A61K2239/21;;A61K2239/15;;A61K2239/17;;A61K35/17;;C07K14/523;;C07K14/5409;;C07K14/7051;;C07K14/70517;;C07K14/70521;;C07K2319/02;;C07K2319/03;;C07K2319/33;;C12N15/86;;C12N2510/00;;C12N2740/10043;;C12N2740/15043,A61K35/17;;A61K39/00;;A61P35/00;;C07K14/52;;C07K14/54;;C07K14/705;;C07K14/725;;C12N5/0783;;C12N15/86,,0,0,,,,PENDING
145,US,A1,US 2023/0131421 A1,188-338-376-763-732,2023-04-27,2023,US 202218085121 A,2022-12-20,US 202218085121 A;;CN 201710573752 A;;US 202117224541 A;;US 202016631157 A;;CN 2018082769 W,2017-07-14,"APPLICATION OF CAS PROTEIN, METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULE AND KIT","The present invention provides use of a Case protein, and a method and a kit for detecting target nucleic acid molecules. The method for detecting target nucleic acid molecules comprises adding a guide RNA, a Cas12a, and a nucleic acid probe into a reaction system containing target nucleic acid molecules to be detected, and detecting it after the reaction is completed.",SHANGHAI TOLO BIOTECHNOLOGY COMPANY LTD,WANG JIN;;CHENG QIUXIANG;;LI SHIYUAN;;LI XIAOYAN;;LI LINXIAN,SHANGHAI TOLO BIOTECHNOLOGY COMPANY LIMITED (2021-04-29),https://lens.org/188-338-376-763-732,Patent Application,yes,0,1,30,188-338-376-763-732;;000-357-254-046-693;;167-291-034-689-651;;005-230-907-918-473;;169-338-679-313-377;;127-531-152-618-140;;123-834-886-214-826;;029-011-244-777-569;;039-039-476-465-342;;199-346-807-574-896;;169-539-579-851-208;;099-947-998-303-818;;037-429-420-849-030;;195-437-029-187-416;;084-506-917-058-93X;;090-397-521-838-048;;077-368-927-838-861;;148-811-981-581-603;;064-198-886-470-19X;;159-025-965-911-837;;082-196-448-398-064;;174-801-931-046-294;;116-694-218-386-192;;107-859-039-687-850;;009-013-513-195-799;;145-352-663-035-907;;016-908-784-205-515;;083-036-865-775-741;;029-165-084-843-804;;142-444-697-415-763,AU;;JP;;EA;;US;;CA;;BR;;MX;;PH;;KR;;MY;;CN;;EP;;IL;;ZA;;WO;;SG;;NZ;;MA,32,188-338-376-763-732;;000-357-254-046-693;;167-291-034-689-651;;127-531-152-618-140;;050-084-189-713-383;;169-338-679-313-377;;005-230-907-918-473;;123-834-886-214-826;;029-011-244-777-569;;039-039-476-465-342;;199-346-807-574-896;;169-539-579-851-208;;099-947-998-303-818;;037-429-420-849-030;;195-437-029-187-416;;084-506-917-058-93X;;094-129-148-887-443;;090-397-521-838-048;;077-368-927-838-861;;148-811-981-581-603;;064-198-886-470-19X;;159-025-965-911-837;;082-196-448-398-064;;174-801-931-046-294;;116-694-218-386-192;;107-859-039-687-850;;009-013-513-195-799;;145-352-663-035-907;;016-908-784-205-515;;083-036-865-775-741;;029-165-084-843-804;;142-444-697-415-763,AU;;JP;;EA;;US;;CA;;BR;;MX;;PH;;KR;;MY;;CN;;EP;;IL;;ZA;;WO;;SG;;NZ;;MA,0,C12Q1/6816;;C12N9/22;;C12N15/113;;C12N2310/20;;C12Q1/6816;;C12Q1/6823;;C12N2310/20;;C12Q1/683;;Y02A50/30;;C12Q1/6816;;C12Q2563/107;;C12N2310/20;;C12N9/22;;C12N15/113;;C12Q1/6823;;C12Q1/6886,C12Q1/6823,,0,0,,,,PENDING
146,US,A1,US 2025/0287949 A1,126-877-559-516-367,2025-09-18,2025,US 202519222656 A,2025-05-29,US 202519222656 A;;EP 18213341 A;;EP 19169751 A;;US 202117414827 A;;EP 2019085251 W,2018-12-18,ACTIVE COMPOUND COMBINATIONS HAVING INSECTICIDAL/ACARICIDAL PROPERTIES,"The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound of the formula (II), which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarids and/or unwanted nematodes.",BAYER AG,HERRMANN STEFAN;;FISCHER REINER;;JOHN MARITA,,https://lens.org/126-877-559-516-367,Patent Application,yes,0,0,4,194-965-784-376-571;;101-626-991-667-558;;126-877-559-516-367;;067-375-603-023-52X,WO;;US,5,081-762-252-167-675;;194-965-784-376-571;;101-626-991-667-558;;126-877-559-516-367;;067-375-603-023-52X,AR;;WO;;US,0,A01N27/00;;A01P7/04;;A01P7/02;;A01P5/00;;A01P1/00;;A01N43/90,A01N43/90;;A01P1/00;;A01P5/00;;A01P7/02;;A01P7/04,,0,0,,,,PENDING
147,US,A1,US 2025/0197882 A1,031-982-004-479-013,2025-06-19,2025,US 202218847958 A,2022-03-22,CN 202210263097 A;;CN 2022082179 W,2022-03-17,USE OF JAZ PROTEIN AND ITS DERIVATIVES IN AGRICULTURAL PEST PREVENTION AND CONTROL,"The present invention discloses a use of JAZ protein and derivatives thereof in prevention and control of agricultural pest. The present invention provides a use of a GhJAZ protein comprising a NGR domain, or coding nucleic acid thereof, or a recombinant vector, an expression cassette, or a recombinant bacterium, or a substance having the GhJAZ protein as an active ingredient in at least one of: 1) killing insect; 2) insect resistance; 3) preparation of insecticidal or insect resistant products; 4) improvement of plant insect resistance; 5) cultivation of insect resistant plants. The present invention discovered for the first time that a JAZ protein, especially NGR-JAZ and derived polypeptides thereof, have broad-spectrum insect resistance, for which no relevant reports are found yet all over the world, and it has significant application value in major agricultural pest control.",INSTITUTE OF COTTON RES OF THE CHINESE ACADEMY OF AGRICULTURAL SCIENCES,LI FUGUANG;;REN MAOZHI;;MO HUIJUAN,INSTITUTE OF COTTON RESEARCH OF THE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (2024-11-04),https://lens.org/031-982-004-479-013,Patent Application,yes,0,0,3,031-982-004-479-013;;026-810-675-669-131;;054-543-415-192-711,CN;;WO;;US,3,031-982-004-479-013;;026-810-675-669-131;;054-543-415-192-711,CN;;WO;;US,48,A01H5/00;;A01H6/46;;A01H6/60;;A01H6/82;;C07K14/415;;C12N15/82;;Y02A40/146;;C12N15/8286;;C12N15/8205;;A01N37/46;;A01P7/04;;A01N63/50;;A01P7/04;;C12N15/8205;;C12N15/8286,C12N15/82;;A01N63/50;;A01P7/04,,0,0,,,,PENDING
148,WO,A1,WO 2020/212620 A1,133-358-669-744-474,2020-10-22,2020,EP 2020060966 W,2020-04-20,EP 2019060092 W;;EP 2020050508 W,2019-04-18,EXTREME THERMOPHILIC BACTERIA OF THE GENUS CALDICELLULOSIRUPTOR SUITABLE FOR THE CONVERSION OF CELLULOSIC AND STARCHY BIOMASS,"The technology provided herein relates to novel isolated cellulolytic extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures and microbial compositions. The novel bacteria are in particular suitable for the production of fermentation products such as lactic acid from any carbon source, not limited to cellulosic material but especially useful for converting cellulosic biomass like ligniocellulosic biomass and/or starch containing biomass.",BLUCON BIOTECH GMBH,SVETLICHNY VITALY;;KRÄMER MARCO;;SVETLICHNAYA TATIANA,,https://lens.org/133-358-669-744-474,Patent Application,yes,7,0,12,089-119-531-590-175;;115-550-975-719-514;;106-926-783-096-283;;066-052-449-652-084;;138-616-557-731-08X;;021-008-914-874-694;;172-502-806-357-592;;133-358-669-744-474;;048-949-088-739-646;;003-861-881-697-091;;011-659-486-716-10X;;049-754-984-984-152,JP;;AU;;KR;;CN;;EP;;WO;;ZA;;US;;CA;;BR,14,115-550-975-719-514;;089-119-531-590-175;;106-926-783-096-283;;138-616-557-731-08X;;172-502-806-357-592;;133-358-669-744-474;;003-861-881-697-091;;086-689-386-250-961;;011-659-486-716-10X;;066-052-449-652-084;;049-754-984-984-152;;021-008-914-874-694;;056-386-385-249-081;;048-949-088-739-646,JP;;AU;;KR;;EP;;CN;;WO;;ZA;;US;;CA;;BR,8,C12P7/56;;C12N1/22;;C12N1/20;;C12P2203/00;;C12R2001/01;;C12N1/205;;Y02E50/10;;C12N1/205;;C12N1/22;;C12P7/56;;C12R2001/01;;C12P2203/00;;C12N1/205;;C12R2001/145;;C12N1/22;;C12P7/56;;C12P2203/00,C12N1/20;;C12N1/22;;C12P7/56;;C12R1/01,,12,10,006-719-136-734-034;;014-462-529-725-525;;085-869-145-963-428;;066-387-858-103-89X;;006-719-136-734-034;;042-507-242-580-682;;006-719-136-734-034;;093-619-101-976-938;;074-488-197-260-232;;019-979-499-270-526,10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;pmc168907;;12824352;;10.1093/nar/gkg500;;10.1111/j.1432-1033.1970.tb00830.x;;4984993;;10.1016/s0723-2020(83)80048-4;;23194591;;10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1099/ijs.0.017731-0;;19801388;;10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1128/aem.53.4.832-838.1987;;16347327;;pmc203765;;18587891;;10.1002/bit.260331118;;10.1093/bioinformatics/17.12.1244;;11751241,"RAINEY F A ET AL: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: An obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOLOGY LETTERS, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 120, no. 3, 15 July 1994 (1994-07-15), pages 263 - 266, XP023916519, ISSN: 0378-1097, [retrieved on 19940715], DOI: 10.1111/J.1574-6968.1994.TB07043.X;;CHENNA RSUGAWARA HKOIKE TLOPEZ RGIBSON TJHIGGINS DGTHOMPSON JD: ""Multiple sequence alignment with the Clustal series of programs"", NUCLEIC ACIDS RES., vol. 13, 2003, pages 3497 - 3500, XP002316493, DOI: 10.1093/nar/gkg500;;DE LEY ET AL., EUR. J. BIOCHEM., vol. 12, 1970, pages 133 - 142;;HUG ET AL., SYST APPL. MICROBIOL., vol. 4, 1983, pages 184 - 192;;RAINEY ET AL.: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov.: an obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOL. LETT., vol. 120, 1994, pages 263 - 266, XP023916519, DOI: 10.1111/j.1574-6968.1994.tb07043.x;;SVETLICHNYI ET AL.: ""Anaerocellum thermophilum gen. nov. sp. nov. an extremely thermophilic cellulolytic eubacterium isolated from hot-springs in the valley of geysers"", MIKROBIOLOGIA, vol. 59, 1990, pages 598 - 604;;YANG ET AL.: ""Classification of 'Anaerocellum thermophilum' strain DSM 6725 as Caldicellulosiruptor bescii sp. nov"", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 60, no. 9, 2010, XP055022136, DOI: 10.1099/ijs.0.017731-0;;RAINEY FADONNISON AMJANSSEN PHSAUL DRODRIGO ABERGQUIST PLDANIEL RMSTACKEBRANDT EMORGAN HW: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: an obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOL LETT, vol. 120, 1994, pages 263 - 266, XP023916519, DOI: 10.1111/j.1574-6968.1994.tb07043.x;;SISSONS CHSHARROCK KRDANIEL RMMORGAN HW: ""Isolation of cellulolytic anaerobic extreme thermophiles from New Zealand thermal sites"", APPL ENVIRON MICROBIOL., vol. 53, 1987, pages 832 - 838;;DONNISON AMBROCKELSBY CMMORGAN HWDANIEL RM: ""The degradation of lignocellulosics by extremely thermophilic microorganisms"", BIOTECHNOL BIOENG., vol. 33, 1989, pages 1495 - 1499;;HUNGATE RE: ""Methods in Microbiology"", 1969, ACADEMIC PRESS, article ""A roll tube method for cultivation of strict anaerobes"", pages: 118 - 132;;KUMAR STAMURA KJAKOBSEN IBNEI M: ""MEGA2: molecular evolutionary genetics analysis software"", BIOINFORMATICS, vol. 17, 2001, pages 1244 - 1245",PATENTED
149,EP,A1,EP 3862363 A1,158-261-956-004-360,2021-08-11,2021,EP 19861063 A,2019-09-13,CN 2018105733 W;;CN 2018106144 W;;US 201962867244 P;;CN 2019105824 W,2018-09-14,"MEDICINAL COMPOSITION CONTAINING MONOCLONAL ANTIBODY OR ANTIBODY FAB FRAGMENT THEREOF, AND USE THEREOF","The present invention provides a PTX3 monoclonal antibody or antibody Fab fragment thereof and use thereof. The aforementioned monoclonal antibody or antibody Fab fragment thereof specifically inhibit or slow down the binding of PTX3 to the PTX3 receptor, and may be used for a kit and method for detecting PTX3, and a pharmaceutical composition which inhibits or slows down diseases or symptoms associated with PTX3 and PTX3 receptor binding, and a use thereof.",OHEALTH BIOPHARMACEUTICAL SUZHOU CO LTD,WANG JU-MING;;LEE I-CHEN;;HSIAO YU-WEI;;CHI JHIH-YING;;DU JYUN-YI;;LIANG HSIN-YIN;;CHENG CHAO-CHUN;;KO CHIUNG-YUAN;;CHEN FENG-WEI;;LIU JHIH-YUN,,https://lens.org/158-261-956-004-360,Patent Application,yes,0,0,20,043-055-382-434-689;;197-333-240-888-468;;058-149-492-525-049;;004-660-581-757-967;;158-261-956-004-360;;118-228-695-939-647;;099-620-477-368-638;;067-038-083-122-200;;039-665-725-819-729;;069-363-693-391-784;;137-796-427-238-734;;035-076-522-505-200;;180-047-857-115-030;;076-487-151-324-251;;125-812-783-636-722;;079-019-381-572-690;;017-786-848-405-086;;048-193-685-886-161;;061-932-003-857-425;;016-364-852-385-149,JP;;AU;;US;;TW;;CA;;MX;;PH;;BR;;KR;;CN;;EP;;ZA;;WO;;SG,20,043-055-382-434-689;;197-333-240-888-468;;048-193-685-886-161;;004-660-581-757-967;;158-261-956-004-360;;099-620-477-368-638;;118-228-695-939-647;;067-038-083-122-200;;039-665-725-819-729;;069-363-693-391-784;;137-796-427-238-734;;035-076-522-505-200;;180-047-857-115-030;;076-487-151-324-251;;125-812-783-636-722;;079-019-381-572-690;;017-786-848-405-086;;016-364-852-385-149;;061-932-003-857-425;;058-149-492-525-049,JP;;AU;;US;;TW;;CA;;MX;;PH;;BR;;KR;;EP;;CN;;ZA;;WO;;SG,41,C07K16/18;;C07K2317/56;;A61P35/00;;C07K16/18;;G01N33/577;;C07K2317/76;;C07K2317/92;;C07K2317/34;;A61K2039/505;;A61P11/00;;C07K2317/70;;A61K39/395;;A61K31/337;;A61P35/04;;A61P1/16;;A61P13/12;;C07K16/18;;A61P35/00;;G01N33/577;;C07K2317/24;;C07K2317/31;;A61K2039/505;;A61P35/00;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/31;;C07K2317/34;;C07K2317/76;;C07K2317/92;;G01N33/577,C07K16/18;;A61K39/395;;A61P35/00;;G01N33/577,,0,0,,,,PENDING
150,US,A1,US 2021/0315243 A1,197-041-669-837-079,2021-10-14,2021,US 202017270064 A,2020-04-23,CN 202010129611 A;;CN 2020086401 W,2020-02-28,"LUCUMA NERVOSA ESSENCE AND LUCUMA NERVOSA AROMA ENHANCER, PREPARATION METHOD AND APPLICATIONS THEREOF","A Lucuma nervosa essence, a Lucuma nervosa aroma enhancer, a preparation method and applications thereof are disclosed. The Lucuma nervosa aroma enhancer includes methyl 3,7-dimethyl-6-octenoate and/or 3-(methylthio)propyl butyrate. A mass percentage of the Lucuma nervosa aroma enhancer in a Lucuma nervosa essence is 0.08%-1.1%, the Lucuma nervosa essence includes a substrate and the Lucuma nervosa aroma enhancer. The preparation method of the Lucuma nervosa essence includes mixing the components of the Lucuma nervosa essence. The Lucuma nervosa essence can be applied in preparing a food and/or a flavoring with a Lucuma nervosa flavor. When the Lucuma nervosa aroma enhancer provided by the present invention is used in combination with a Lucuma nervosa extract, or mixed with a composition in conjunction with other essence raw materials, the prepared Lucuma nervosa essence has full fruity aroma and strong sulfide aroma, thus effectively improving the aroma and taste of final products.",SHANGHAI INST TECH,XIAO ZUOBING;;ZHU JIANCAI;;NIU YUNWEI,SHANGHAI INSTITUTE OF TECHNOLOGY (2021-01-30),https://lens.org/197-041-669-837-079,Patent Application,yes,0,1,4,104-949-595-299-904;;125-978-563-857-005;;008-433-237-959-653;;197-041-669-837-079,CN;;WO;;US,4,104-949-595-299-904;;125-978-563-857-005;;008-433-237-959-653;;197-041-669-837-079,CN;;WO;;US,0,A23L27/29;;A21D2/16;;A21D2/36;;A23L2/64;;A23L27/12;;A23L27/2024;;A23L27/2028;;A23L27/88;;A23V2002/00;;A23L27/11;;A23L27/115;;A23L27/12;;A23L27/2028;;A23L27/60;;A23L27/88;;A23L27/12;;A23L27/11;;A23L27/115;;A23L27/88,A23L27/12;;A23L27/00;;A23L27/10,,2,0,,,"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 13346428, 3,7-Dimethyl-6-octenyl 3,7-dimethyl-6-octenoate; [cited 2023 May 5]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/3_7-Dimethyl-6-octeny;;PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 85520, 3-(Methylthio)propyl butyrate; [cited 2023 May 5]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/3-_Methylthio_propyl-butyrate",ACTIVE
151,US,A1,US 2022/0112513 A1,078-898-556-017-62X,2022-04-14,2022,US 202117543763 A,2021-12-07,US 202117543763 A;;CN 201810735328 A;;US 201916612764 A;;CN 2018106586 W,2018-07-06,MALE STERILE CROP MUTATED ON TY-5 GENE,"A method for creating a new germplasm of a male sterile crop by gene editing and an application thereof are provided. In this method, the gene editing is performed on an exon region of a Ty-5 gene, and a deletion of DNA sequence is introduced by using a repair mechanism of plants themselves to double-strand breaks (DSBs), causing a loss of function of Ty-5 gene, thereby obtaining a male-sterile character. The method can be applied without being limited by crop categories. After the gene editing is performed on Ty-5 genes of various crops, new germplasms can be quickly obtained. The new germplasms have the same agronomic characters as the previous materials, and only differ in sexual aspect, which effectively solves the problem of the lack of male sterile materials and unstable fertility in natural resources.",JIANGSU ACAD AGRICULTURAL SCI,WANG YINLEI;;ZHAO TONGMIN;;YU WENGUI;;ZHAO LIPING;;ZHOU RONG;;SONG LIUXIA,JIANGSU ACADEMY OF AGRICULTURAL SCIENCES (2019-05-20),https://lens.org/078-898-556-017-62X,Patent Application,yes,1,0,7,123-231-303-805-067;;141-108-193-391-383;;075-420-967-295-534;;078-898-556-017-62X;;064-498-787-275-297;;135-141-674-891-968;;027-732-408-408-266,CN;;WO;;US,7,123-231-303-805-067;;141-108-193-391-383;;075-420-967-295-534;;078-898-556-017-62X;;135-141-674-891-968;;064-498-787-275-297;;027-732-408-408-266,CN;;WO;;US,7,C12N9/22;;C12N15/8213;;C12N15/8289;;C12N9/22;;C12N15/8213;;C12N15/8289;;C12N2310/20;;C12N9/22;;C12N15/111;;C12N15/8213;;C12N15/8289,C12N15/82;;C12N9/22;;C12N15/11,,1,1,058-213-872-192-171,pmc4246194;;25262227;;10.1093/jxb/eru389,Jeong et al 2014 (Journal of Experimental Botany 22: p.6693-6709). (Year: 2014),ACTIVE
152,US,A1,US 2022/0061323 A1,194-965-784-376-571,2022-03-03,2022,US 201917414827 A,2019-12-16,EP 18213341 A;;EP 19169751 A;;EP 2019085251 W,2018-12-18,ACTIVE COMPOUND COMBINATIONS HAVING INSECTICIDAL/ACARICIDAL PROPERTIES,"The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound of the formula (II), which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarids and/or unwanted nematodes.",BAYER AG,HERRMANN STEFAN;;FISCHER REINER;;JOHN MARITA,BAYER AKTIENGESELLSCHAFT (2022-01-20),https://lens.org/194-965-784-376-571,Patent Application,yes,0,1,4,194-965-784-376-571;;101-626-991-667-558;;126-877-559-516-367;;067-375-603-023-52X,WO;;US,5,081-762-252-167-675;;194-965-784-376-571;;101-626-991-667-558;;126-877-559-516-367;;067-375-603-023-52X,AR;;WO;;US,0,A01N27/00;;A01P7/04;;A01P7/02;;A01P5/00;;A01P1/00;;A01N43/90,A01N43/90;;A01P1/00;;A01P5/00;;A01P7/02;;A01P7/04,,2,0,,,"Park, et al. Scientific Reports 7, Article number: 40902 (2017).;;No new references cited by the Examiner.",ACTIVE
153,US,A1,US 2025/0049792 A1,196-055-099-260-191,2025-02-13,2025,US 202218292086 A,2022-07-27,US 202218292086 A;;US 202163203555 P;;US 2022/0038434 W,2021-07-27,COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH,"The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).",VERASTEM INC;;FRANCIS CRICK INST,COMA SILVIA;;PACHTER JONATHAN A;;STUGLIK BRIAN M;;DOWNWARD JULIAN;;MOLINA ARCAS MIRIAM,VERASTEM INC (2022-11-17);;FRANCIS CRICK INSTITUTE (2024-01-16),https://lens.org/196-055-099-260-191,Patent Application,yes,0,0,11,104-219-995-054-637;;026-711-385-523-886;;062-028-278-777-943;;150-273-021-256-658;;187-056-781-373-701;;180-247-666-890-233;;102-695-977-271-608;;042-364-060-256-712;;028-754-684-421-137;;196-055-099-260-191;;079-503-438-096-213,KR;;JP;;AU;;CN;;IL;;EP;;WO;;US;;CA;;MX,11,196-055-099-260-191;;026-711-385-523-886;;062-028-278-777-943;;150-273-021-256-658;;042-364-060-256-712;;180-247-666-890-233;;102-695-977-271-608;;079-503-438-096-213;;028-754-684-421-137;;187-056-781-373-701;;104-219-995-054-637,JP;;AU;;KR;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61K45/06;;A61K31/506;;A61K31/519;;A61K39/00;;A61P35/00;;A61K45/06;;A61K2300/00;;A61K31/506;;A61K31/519;;A61K39/00;;A61K31/513;;A61K39/39558;;A61K31/519;;A61K45/06;;A61P35/00;;C07K16/2818;;C07K16/2827;;A61K2300/00;;A61K2039/505;;A61K2039/545;;A61K39/00;;A61K31/506;;A61K39/3955;;A61K45/06,A61K31/506;;A61K39/395;;A61K45/06,,0,0,,,,PENDING
154,US,A1,US 2021/0332433 A1,028-767-898-562-800,2021-10-28,2021,US 202117194252 A,2021-03-06,CN 202010152999 A;;CN 202010177021 A;;CN 202010177023 A,2020-03-06,Method for identifying genetic sex of Portunus trituberculatus,"A method for identifying the genetic sex of Portunus trituberculatus is provided. The SNP markers provided by the present invention presents biallelic heterozygosity in male individuals, but presents homozygous allele type in female individuals, and can be detected by PCR amplification and sequencing method, HRM method or KASP method. The detection method is flexible and the results are stable. Among them, the KASP and HRM detection methods have high throughput, fast detection speed, and simple application. It provides an important tool for the breeding of all-female population of P. trituberculatus.",UNIV NINGBO,LI RONGHUA;;LU JUNKAI;;ZHANG ZHOUYI;;ZHANG WEIJIA;;WANG CHUNLIN;;MU CHANGKAO;;SONG WEIWEI,,https://lens.org/028-767-898-562-800,Patent Application,yes,0,3,1,028-767-898-562-800,US,5,114-488-484-811-307;;028-767-898-562-800;;087-767-949-414-219;;020-805-139-150-77X;;051-904-046-523-31X,CN;;US,6,C12Q1/6879;;C12Q2600/156;;C12Q1/6879;;C12Q1/6858;;C12Q2600/156,C12Q1/6879;;C12Q1/6858,,1,0,,,Lv et al. (Frontiers in Genetics 2018 Vol 9 P. 1-9) (Year: 2018),DISCONTINUED
155,WO,A1,WO 2023/009572 A1,180-247-666-890-233,2023-02-02,2023,US 2022/0038434 W,2022-07-27,US 202163203555 P,2021-07-27,COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH,"The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).",VERASTEM INC;;FRANCIS CRICK INST,COMA SILVIA;;PACHTER JONATHAN A;;STUGLIK BRIAN M;;DOWNWARD JULIAN;;MOLINA ARCAS MIRIAM,,https://lens.org/180-247-666-890-233,Patent Application,yes,3,11,11,104-219-995-054-637;;026-711-385-523-886;;062-028-278-777-943;;150-273-021-256-658;;187-056-781-373-701;;180-247-666-890-233;;102-695-977-271-608;;042-364-060-256-712;;028-754-684-421-137;;196-055-099-260-191;;079-503-438-096-213,KR;;JP;;AU;;CN;;IL;;EP;;WO;;US;;CA;;MX,11,196-055-099-260-191;;026-711-385-523-886;;062-028-278-777-943;;150-273-021-256-658;;042-364-060-256-712;;180-247-666-890-233;;102-695-977-271-608;;079-503-438-096-213;;028-754-684-421-137;;187-056-781-373-701;;104-219-995-054-637,JP;;AU;;KR;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61K45/06;;A61K31/506;;A61K31/519;;A61K39/00;;A61P35/00;;A61K45/06;;A61K2300/00;;A61K31/506;;A61K31/519;;A61K39/00;;A61K31/513;;A61K39/39558;;A61K31/519;;A61K45/06;;A61P35/00;;C07K16/2818;;C07K16/2827;;A61K2300/00;;A61K2039/505;;A61K2039/545;;A61K39/00;;A61K31/506;;A61K39/3955;;A61K45/06,A61K31/33;;A61K31/00;;A61K31/18;;A61K31/4375;;A61K31/4433,,1,0,,,See also references of EP 4376828A4,PENDING
156,US,A1,US 2025/0066826 A1,064-386-251-830-612,2025-02-27,2025,US 202418801905 A,2024-08-13,CN 2023113928 W,2023-08-21,ARTIFICIAL SYNTHESIS METHOD FOR MALONYL-COENZYME A (COA) AND USE THEREOF,"An artificial synthesis method for malonyl-CoA and use thereof are provided. By means of heterologous expression of an aminotransferase and a malonyl-CoA reductase, an artificial synthesis pathway for synthesizing malonyl-CoA by using β-alanine (β-ala) as a precursor is constructed as follows: firstly, under catalysis of a transaminase, β-ala transfers amino groups to α-ketonic acid (such as pyruvic acid, oxaloacetic acid, or α-ketoglutaric acid, etc.), to form an intermediate product 3-oxopropanoate and a corresponding amino acid; the 3-oxopropanoate generates malonyl-CoA under the action of the malonyl-CoA reductase. This pathway addresses the defects of the natural malonyl-CoA synthesis pathway, such as low carbon utilization, consumption of energy substance ATP, release of greenhouse gas CO2, and strict regulation of pathway enzymes, a pyruvate dehydrogenase (PDH) and an acetyl-CoA carboxylase (ACC), thereby achieving high yielding of products using malonyl-CoA as a precursor, including flaviolin, octanoic acid, phloroglucinol, pentadecaheptaene, natamycin, and spinosad.",UNIV SHANGHAI JIAOTONG,TAN ZAIGAO;;LIU TIANGANG;;LI JIAN,SHANGHAI JIAO TONG UNIVERSITY (2024-06-18),https://lens.org/064-386-251-830-612,Patent Application,yes,0,1,2,064-386-251-830-612;;137-863-284-567-676,WO;;US,2,064-386-251-830-612;;137-863-284-567-676,WO;;US,0,C12P11/00;;C12N15/70;;C12P17/06;;C12P7/40;;C12Y206/01018;;C12N9/1096;;C12P7/22;;C12N9/0004;;C12P13/005;;C12P19/32;;C12P11/00;;C12N9/1096;;C12Y206/01018;;C12P17/06;;C12N15/70;;C12P7/40;;C12P7/22;;C12N9/0004,C12P11/00;;C12N9/02;;C12N9/10;;C12N15/70;;C12P7/22;;C12P7/40;;C12P17/06,,0,0,,,,PENDING
157,US,A1,US 2025/0027100 A1,024-312-146-425-073,2025-01-23,2025,US 202418651582 A,2024-04-30,CN 202310897060 A,2023-07-21,"USE OF MfERF026 GENE REGULATION IN GROWTH, DEVELOPMENT, AND STRESS TOLERANCE OF MEDICAGO SATIVA","Provided is use of MfERF026 regulation in growth, development, and stress tolerance of Medicago sativa, which belongs to the technical field of plant genetic engineering. Provided is use of a regulatory agent for MfERF026, which is an ethylene responsive factor (ERF) in Medicago falcata, in promoting growth and development and improving drought tolerance and cold tolerance of M. sativa. The inhibited expression of MfERF026, the ERF in M. falcata may enhance the drought tolerance and cold tolerance of the M. sativa. Moreover, the inhibited expression of MfERF026, the ERF in M. falcata, may regulate the growth and development of M. sativa, thereby accelerating the growth rate of M. sativa to increase the number of leaves. The inhibited expression of MfERF026 provides a novel theoretical basis and a candidate gene for cultivating novel leguminous forage varieties with high resistance, yield, and protein content.",UNIV INNER MONGOLIA,NIU YIDING;;FU JIABIN;;HAO JINFENG;;WANG YU,INNER MONGOLIA UNIVERSITY (2024-03-15),https://lens.org/024-312-146-425-073,Patent Application,yes,1,0,3,094-856-047-816-727;;024-312-146-425-073;;036-311-643-815-073,CN;;US,3,094-856-047-816-727;;024-312-146-425-073;;036-311-643-815-073,CN;;US,0,C07K14/415;;C12N15/8218;;C12N15/8273;;C12N15/8261;;C12N15/8205;;C12N2310/14;;C12N15/8218;;C12N15/8205;;C12N15/8262;;C12N15/8261;;C12N15/8273;;C07K14/415;;C12N15/8205;;C12N15/8218;;C12N15/8262;;C12N2310/14,C12N15/82,,3,2,040-909-568-556-77X;;070-318-053-499-618,34245021;;10.1111/nph.17610;;29216408;;10.1111/pce.13114,"Hilty et al., Plant growth: the What, the How, and the Why, 2021, New Phytologist, 232:25–41 (Year: 2021);;Zhuo et al., A cold responsive ethylene responsive factor from Medicago falcata confers cold tolerance by up‐regulation of polyamine turnover, antioxidant protection, and proline accumulation, 2018, Plant Cell Environ, 41:2021–2032 (Year: 2018);;GenBank Accession No. EX525415 (Year: 2007)",PENDING
158,EP,A1,EP 4187312 A1,008-019-730-520-747,2023-05-31,2023,EP 21851272 A,2021-07-29,CN 202010760135 A;;CN 2021109100 W,2020-07-31,"CONTACT LENS CLEANER, AND PROTEIN REMOVAL AND STERILIZATION METHOD BY MEANS OF ELECTROPHORESIS DISSOCIATION","A contact lens cleaner and a method for protein removal and sterilization by electrophoresis dissociation are disclosed. The contact lens cleaner comprises a lens cleaning tank (10), two electrophoresis dissociation probes (20) are arranged in the lens cleaning tank (10) opposite each other, and the electrophoresis dissociation probes (20) are electrically connected to a circuit power supply. The lens cleaning tank (10) is filled with an electrolyte solution; a lens to be cleaned is placed in the lens cleaning tank (10); and a switch is turned on, and the two electrophoresis dissociation probes (20) in the lens cleaning tank (10) form an anode and a cathode. There are lacrimal proteins on the surface of the lens to be cleaned, the lacrimal proteins are charged in the solution, and the charged lacrimal proteins move to the electrode opposite to the electrical property thereof in the cleaning tank (10) according to the phenomenon of electrophoresis. The electrolyte solution reacts chemically in the cleaning tank (10) to produce hypochlorite having a strong oxidizing property, and the hypochlorite can degrade the lacrimal proteins, and also can sterilize and disinfect.",SUZHOU 3N BIOLOGICAL TECH CO LTD,SUN BIXIA,,https://lens.org/008-019-730-520-747,Patent Application,yes,0,0,5,196-427-746-150-664;;194-106-115-038-705;;149-788-379-004-76X;;008-019-730-520-747;;012-846-208-572-257,EP;;CN;;WO;;US,5,196-427-746-150-664;;194-106-115-038-705;;149-788-379-004-76X;;008-019-730-520-747;;012-846-208-572-257,EP;;CN;;WO;;US,0,G02C13/008;;A61L2/18;;G02C13/008;;A61L12/023;;A61L2101/06;;A61L12/107;;B08B3/10;;A61L2101/06;;A61L12/02;;A61L12/107;;B08B3/10;;G02C13/008,G02C13/00;;A61L12/02;;A61L12/10,,0,0,,,,PENDING
159,EP,A1,EP 4294385 A1,128-088-206-623-440,2023-12-27,2023,EP 22706786 A,2022-02-15,EP 21305196 A;;EP 2022053655 W,2021-02-17,COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER,,CENTRE NAT RECH SCIENT;;UNIV MONTPELLIER,LAGUETTE NADINE;;VILA ISABELLE KRYSTEL;;STEER ALIZÉE JULIE,,https://lens.org/128-088-206-623-440,Patent Application,yes,1,0,4,128-088-206-623-440;;184-197-770-734-17X;;129-178-994-605-790;;104-816-654-091-013,EP;;WO;;US,4,128-088-206-623-440;;184-197-770-734-17X;;129-178-994-605-790;;104-816-654-091-013,EP;;WO;;US,0,A61K31/365;;A61K31/407;;A61K31/352;;A61K31/7084;;A61K31/4184;;A61K31/5415;;A61K31/00;;A61P35/00;;A61P31/12;;A61K45/06;;A61P31/14;;A61K31/366;;A61K31/12;;A61K31/519;;A61K31/5377;;A61K31/343;;A61K31/05;;A61K31/6615;;A61K31/133;;A61P35/00;;A61K31/343;;A61K31/352;;A61K31/407;;A61K31/5415;;A61K31/6615,A61K31/365;;A61K31/00;;A61K31/05;;A61K31/12;;A61K31/133;;A61K31/343;;A61K31/352;;A61K31/366;;A61K31/407;;A61K31/4184;;A61K31/519;;A61K31/5377;;A61K31/5415;;A61K31/6615;;A61K31/7084;;A61K45/06;;A61K47/00;;A61P31/12;;A61P31/14;;A61P35/00,,2,0,,,"ANONYMOUS: ""Aduro Biotech Presents Preliminary Results Phase 1 Trials of STING agonist ADU-S100"", HOLLANDBIO, 9 November 2018 (2018-11-09), pages 1 - 7, XP055850563, Retrieved from the Internet <URL:https://www.hollandbio.nl/nieuws/aduro-biotech-presents-preliminary-results-phase-1-trials-of-sting-agonist-adu-s100/> [retrieved on 20211012];;See also references of WO 2022175257A1",PENDING
160,US,A1,US 2023/0285979 A1,185-748-864-805-148,2023-09-14,2023,US 202318133193 A,2023-04-11,US 202318133193 A;;US 202217581434 A;;US 202163140342 P,2021-01-22,SYSTEM AND METHOD FOR IMPROVING THE CORN WET MILL AND DRY MILL PROCESS,"This novel corn milling process includes a continuous steeping step, early separation of easy-to-access starch (e.g., starch in the floury endosperm part of a corn kernel), fine milling to secure germ protein without the use of solvents or heat, and performing a phase separation to collect the product of fermentation. The continuous steeping process uses a continuous steeping tank. The steeping liquid, which includes probiotics, flows in from the bottom of the tank in a countercurrent flow. Other features include efficiently producing high purity starch or sugar using the starch in the floury endosperm of the corn kernel, producing alcohols such as ethanol and butanol that can be used as sustainable aviation fuel or feedstock for sustainable aviation fuel, and producing a high protein animal feed product that includes yeast and germ protein without using toxic solvents.",LEE TECH LLC,LEE CHIE YING,LEE TECH LLC (2023-05-11),https://lens.org/185-748-864-805-148,Patent Application,yes,0,0,1,185-748-864-805-148,US,7,185-748-864-805-148;;127-617-377-925-915;;093-536-613-709-24X;;169-089-920-531-158;;094-724-464-484-933;;107-882-447-037-502;;017-492-200-179-545,CN;;WO;;US;;BR,0,C12P7/16;;C08B30/044;;C12P7/06;;C12P19/02;;C12P19/14;;Y02E50/10;;B02B5/02;;C08B30/044;;C12P7/06;;C12P7/16,B02B5/02;;C08B30/04;;C12P7/06;;C12P7/16,,0,0,,,,PENDING
161,EP,A1,EP 4166224 A1,007-616-614-455-908,2023-04-19,2023,EP 22201808 A,2016-08-17,IN 2581DE2015 A;;IN 2610DE2015 A;;EP 16753648 A;;EP 2016069475 W,2015-08-20,IMPROVED METHOD FOR ENHANCING FILTRATION YIELDS IN TANGENTIAL FLOW FILTRATION SYSTEM,"The disclosure generally relates to methods and apparatus for the efficient quantitative recovery of valuable biological fluids from filtration systems 20, more particularly to efficient quantitative recovery of valuable biological fluids from high precision separation systems suitable for use in the pharmaceutical and biotechnology industries.",CYTIVA SWEDEN AB,NUTALAPATI SASI;;GEBAUER KLAUS;;VERNEKAR AJIT;;SHARMA AMIT;;LUNDSTROM FREDRIK;;LIDERFELT KARL;;KARMARKAR NACHIKET;;RAGHU RAMACHANDRAN SANGEETHA,,https://lens.org/007-616-614-455-908,Patent Application,yes,22,0,18,100-807-773-833-278;;023-389-772-587-511;;136-165-627-743-72X;;109-162-976-660-188;;134-551-265-480-143;;007-616-614-455-908;;089-707-740-956-47X;;193-528-998-424-987;;195-558-042-567-81X;;011-007-733-023-834;;137-674-262-295-179;;187-827-634-079-484;;160-764-780-738-294;;102-202-996-003-31X;;030-536-138-054-225;;189-515-581-780-372;;190-767-467-600-784;;057-327-911-544-635,JP;;CN;;EP;;WO;;US,18,134-551-265-480-143;;023-389-772-587-511;;136-165-627-743-72X;;109-162-976-660-188;;089-707-740-956-47X;;007-616-614-455-908;;100-807-773-833-278;;193-528-998-424-987;;195-558-042-567-81X;;011-007-733-023-834;;137-674-262-295-179;;187-827-634-079-484;;160-764-780-738-294;;030-536-138-054-225;;102-202-996-003-31X;;189-515-581-780-372;;190-767-467-600-784;;057-327-911-544-635,JP;;EP;;CN;;WO;;US,0,B01D61/20;;B01D2315/10;;B01D2315/14;;B01D61/18;;B01D61/22;;B01D2311/2512;;B01D61/20;;B01D2315/10;;B01D2315/14;;B01D2311/2512;;B01D61/18;;B01D61/22;;B01D2311/08;;B01D2311/16;;B01D61/10;;B01D61/12;;B01D65/02;;B01D2313/243;;B01D2321/02;;C07K1/34,B01D61/18;;B01D61/20;;B01D61/22,,4,4,060-401-001-640-274;;005-088-858-377-791;;017-426-468-964-741;;067-704-405-472-097,10.1002/(sici)1097-0290(19971005)56:1<71::aid-bit8>3.0.co;2-s;;18636611;;10.1002/bit.260431009;;18615443;;10.1016/s0376-7388(96)00319-5;;10.1016/0011-9164(88)85054-9,"R. VAN REIS ET AL., BIOTECH, BIOENG., vol. 56, 1997, pages 71 - 82;;S. SAKSENA ET AL., BIOTECH. BIOENG., vol. 43, 1994, pages 960 - 968;;R VAN REIS ET AL., J. MEMBRANE SCI., vol. 129, 1997, pages 19 - 29;;S. NAKAO ET AL., DESALINATION, vol. 70, 1988, pages 191 - 205",ACTIVE
162,WO,A1,WO 2024/215306 A1,091-993-679-125-870,2024-10-17,2024,US 2023/0018136 W,2023-04-11,US 2023/0018136 W,2023-04-11,SYSTEM AND METHOD FOR IMPROVING THE CORN WET MILL AND DRY MILL PROCESS,"This novel corn milling process includes a continuous steeping step, early separation of easy-to-access starch (e.g., starch in the floury endosperm part of a corn kernel), fine milling to secure germ protein without the use of solvents or heat, and performing a phase separation to collect the product of fermentation. The continuous steeping process uses a continuous steeping tank. The steeping liquid, which includes probiotics, flows in from the bottom of the tank in a countercurrent flow. Other features include efficiently producing high purity starch or sugar using the starch in the floury endosperm of the corn kernel, producing alcohols such as ethanol and butanol that can be used as sustainable aviation fuel or feedstock for sustainable aviation fuel, and producing a high protein animal feed product that includes yeast and germ protein without using toxic solvents.",LEE TECH LLC,LEE CHIE YING,,https://lens.org/091-993-679-125-870,Patent Application,yes,6,0,1,091-993-679-125-870,WO,1,091-993-679-125-870,WO,0,C08B30/02;;C12C1/02;;B02B1/06;;C08B30/044,C12C1/02;;B02B1/06;;B65D88/26;;C08B30/02;;C08B30/04,,0,0,,,,PENDING
163,US,A1,US 2023/0314845 A1,012-846-208-572-257,2023-10-05,2023,US 202118018592 A,2021-07-29,CN 202010760135 A;;CN 2021109100 W,2020-07-31,"CONTACT LENS CLEANER, AND PROTEIN REMOVAL AND STERILIZATION METHOD BY MEANS OF ELECTROPHORESIS DISSOCIATION","A contact lens cleaner and a method for protein removal and sterilization by electrophoresis dissociation are disclosed. The contact lens cleaner comprises a lens cleaning tank (10), two electrophoresis dissociation probes (20) are arranged in the lens cleaning tank (10) opposite each other, and the electrophoresis dissociation probes (20) are electrically connected to a circuit power supply. The lens cleaning tank (10) is filled with an electrolyte solution; a lens to be cleaned is placed in the lens cleaning tank (10); and a switch is turned on, and the two electrophoresis dissociation probes (20) in the lens cleaning tank (10) form an anode and a cathode. There are lacrimal proteins on the surface of the lens to be cleaned, the lacrimal proteins are charged in the solution, and the charged lacrimal proteins move to the electrode opposite to the electrical property thereof in the cleaning tank (10) according to the phenomenon of electrophoresis. The electrolyte solution reacts chemically in the cleaning tank (10) to produce hypochlorite having a strong oxidizing property, and the hypochlorite can degrade the lacrimal proteins, and also can sterilize and disinfect.",SUZHOU 3N BIOLOGICAL TECH CO LTD,SUN BIXIA,,https://lens.org/012-846-208-572-257,Patent Application,yes,5,0,5,196-427-746-150-664;;194-106-115-038-705;;149-788-379-004-76X;;008-019-730-520-747;;012-846-208-572-257,EP;;CN;;WO;;US,5,196-427-746-150-664;;194-106-115-038-705;;149-788-379-004-76X;;008-019-730-520-747;;012-846-208-572-257,EP;;CN;;WO;;US,0,G02C13/008;;A61L2/18;;G02C13/008;;A61L12/023;;A61L2101/06;;A61L12/107;;B08B3/10;;A61L2101/06;;A61L12/02;;A61L12/107;;B08B3/10;;G02C13/008,G02C13/00;;A61L12/02;;A61L12/10;;B08B3/10,,2,0,,,WO 91/04060 (Year: 1991);;FR 2502011 (Year: 1982),PENDING
164,US,A1,US 2021/0009649 A1,001-148-001-029-671,2021-01-14,2021,US 202017030319 A,2020-09-23,CN 201810251703 A;;CN 2018114605 W,2018-03-26,INTRON FOR INCREASING EXPRESSION LEVEL OF RHNGF,"A gene combination for expressing recombinant human nerve growth factor (rhNGF) includes an rhNGF precursor gene and an intron. The intron can have a nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2. A eukaryotic expression vector for rHNGF expression including the gene combination, a CHO cell including the eukaryotic expression vector, and methods for preparing rhNGF using the gene combination, the expression vector, and the CHO cell are also disclosed.",XINTRUM PHARMACEUTICALS LTD,CHEN HAI;;SUN HONGLIANG;;ZHANG YI;;WANG YUESHENG,,https://lens.org/001-148-001-029-671,Patent Application,yes,0,0,3,040-912-079-079-850;;001-148-001-029-671;;086-132-356-724-822,CN;;WO;;US,3,040-912-079-079-850;;001-148-001-029-671;;086-132-356-724-822,CN;;WO;;US,10,C07K14/48;;C12N15/85;;C12N2840/002;;C12N15/85;;C07K14/48;;C12N2830/42;;C07K14/48;;C12N15/85;;C12N2830/42,C07K14/48;;C12N15/85,,4,3,009-038-527-136-15X;;000-810-483-130-939;;070-728-022-282-709,8954121;;10.1006/bbrc.1996.1795;;2666869;;10.1016/s0197-4580(89)80015-6;;1402913;;10.1111/j.1471-4159.1992.tb10998.x,"Gurtu et al. IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines. Biochemical and Biophysical Research Communications, Vol. 229, 295-298, 1996. (Year: 1996);;GenBank Accession No. U89672.1, publicly available March 1997, printed as pages 1/2-2/2. (Year: 1997);;Bruce et al. Production and characterization of biologically active recombinant human nerve growth factor. Neurobiology of Aging, Vol. 10, No. 1, pages 89-94, 1989. (Year: 1989);;Schmelzer et al. Biochemical characterization of recombinant human nerve growth factor. Journal of Neurochemistry, Vol. 95, No. 5, pages 1675-1683, November 1992. (Year: 1992)",DISCONTINUED
165,WO,A1,WO 2024/022411 A1,113-236-537-279-098,2024-02-01,2024,CN 2023109437 W,2023-07-26,US 202263392341 P,2022-07-26,COMPOUNDS AND COMPOSITIONS FOR TREATING INFLUENZA,"A method of treating influenza infection, comprising administering to a subject in need thereof an effective amount of a composition comprising one or more compounds of Formula (I) or a pharmaceutically acceptable salt thereof.",SYNEURX INT TAIWAN CORP,TSAI GUOCHUAN EMIL;;WU YU-JUNG;;HSIEH HAN-YI;;HU JHE-WEI;;SHIH TSAI-MIAO;;MAO YI-WEN,,https://lens.org/113-236-537-279-098,Patent Application,yes,5,0,2,113-236-537-279-098;;161-507-056-534-775,WO;;TW,2,113-236-537-279-098;;161-507-056-534-775,WO;;TW,4,A61K31/7024;;A61P31/14;;A61K45/06;;A61K31/415;;A61K31/40;;A61K31/235;;A61K36/22;;A61K36/82,A61K31/7024;;A61K31/351;;A61K31/7032;;A61P31/14,,0,0,,,,PENDING
166,US,A1,US 2021/0290833 A1,003-886-331-963-157,2021-09-23,2021,US 202016823431 A,2020-03-19,US 202016823431 A,2020-03-19,"METHOD, MICROCHANNEL STRUCTURE AND MICROCHANNEL SYSTEM FOR REMOVING CIRCULATING TUMOR CELLS IN BLOOD","The present invention provides a microchannel structure for removing circulating tumor cells in a circulating blood system without damaging cells in the blood, wherein the microchannel is loaded with a plurality of beads. The microchannel structure includes: a blood sample entrance passing a blood sample therethrough; a bead mooring section including: a first end connected to the blood sample entrance; a second end; a first section being relatively close to the first end, and cooperating with the first end to cause the plurality of beads to form a bead array in the bead mooring section for decreasing a flow rate of the blood sample through an interstice among neighboring ones of the plurality of beads; and a second section being relatively close to the second end, and causing the treated blood sample to smoothly flow therethrough; and a blood sample exit connected to the second end. One of the applications of this invention is to remove cancer cells in cancer patient's circulating blood system.",LIFECODE BIOTECH,DOONG JOE-YUAN;;TSAI SUNG-CHI,LIFECODE BIOTECH (2020-03-09),https://lens.org/003-886-331-963-157,Patent Application,yes,6,2,1,003-886-331-963-157,US,1,003-886-331-963-157,US,0,A61M1/3679;;A61M2205/0244;;B01L3/502746;;B01L3/502761;;B01L2200/0668;;B01L2300/0883;;A61M1/3621;;A61M1/361;;A61M1/38,A61M1/36;;A61M1/38,,0,0,,,,DISCONTINUED
167,CN,A,CN 116601292 A,015-559-021-843-309,2023-08-15,2023,CN 202180080699 A,2021-10-29,US 202163252832 P;;US 2021/0057426 W,2021-10-06,Compositions comprising rna directors targeting BCL11A and uses thereof,"The present invention relates to compositions comprising RNA guides targeting BCL11A, methods of characterizing these compositions, cells comprising these compositions, and methods of using these compositions.",ARBOR BIOTECH,Q N WEISSEL;;HASWELL JASON R;;DI TOMMASO THOMAS M;;JAKIMO NAJIB M,,https://lens.org/015-559-021-843-309,Patent Application,no,0,0,1,015-559-021-843-309,CN,9,108-573-749-836-083;;130-678-964-419-176;;109-418-947-255-69X;;029-195-359-541-31X;;101-993-208-640-527;;131-269-451-056-591;;082-574-187-017-07X;;135-660-417-600-538;;015-559-021-843-309,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,0,,C12N15/10,,0,0,,,,PENDING
168,KR,A,KR 20230053010 A,028-417-570-580-343,2023-04-21,2023,KR 20210134898 A,2021-10-12,KR 20210134898 A,2021-10-12,A composition for improving preventing or treating of pain inflammatory or atopic dermatitis comprising a Dendropanox morbifera Leveille extract a Acanthopanax koreanum Nakai extract and a mixture of herbal medicines as active ingredients,"The present invention relates to a composition for alleviating, preventing, or treating pain, inflammation, or atopic dermatitis containing as active ingredients an extract of Dendropanox morbifera Leveille, an extract of Acanthopanax koreanum, and a mixture of herbal medicinal ingredients. More specifically, the cosmetic composition of the present invention contains as active ingredients an extract of Dendropanox morbifera Leveille, an extract of Acanthopanax koreanum, and a mixture of herbal medicinal ingredients and can effectively suppress pain, inflammation, or atopic dermatitis by mixing the ingredients at a specific mixing ratio to be used as a composition for alleviating, preventing, or treating atopic dermatitis. In addition, by using natural materials, the cosmetic composition has no side effects on the human body and has excellent stability. Moreover, the cosmetic composition not only has excellent anti-inflammatory and anti-atopic effects, but can further improve skin's moisture retention and antioxidant effects, in particular, due to a synergistic effect of the ingredients caused by mixed use of the extract of Dendropanox morbifera Leveille and the extract of Acanthopanax koreanum, and has significantly superior physiological activity.",SC BIOTECH,LEE BONG HUI;;LI DONG XUAN,,https://lens.org/028-417-570-580-343,Patent Application,no,1,0,1,028-417-570-580-343,KR,1,028-417-570-580-343,KR,0,A61K8/9789;;A61K8/9761;;A61K8/19;;A61Q19/00;;A61Q19/005;;A61K36/25;;A61K36/254;;A61K36/72;;A61K36/14;;A61K36/258;;A61K9/0014;;A61P29/00;;A61P17/00;;A23L33/105;;A61K2800/5922;;A61K2300/00;;A23V2002/00;;A23V2200/324;;A23V2200/318,A61K8/9789;;A61K8/19;;A61K8/9761;;A61K9/00;;A61K36/14;;A61K36/25;;A61K36/254;;A61K36/258;;A61K36/72;;A61P29/00;;A61Q19/00,,0,0,,,,DISCONTINUED
169,WO,A1,WO 2022/269001 A1,034-588-927-315-598,2022-12-29,2022,EP 2022067269 W,2022-06-23,EP 21305865 A;;EP 21306467 A,2021-06-23,PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1R AGONISTS,"The present invention relates to a pharmaceutical composition comprising a GLP-1R agonist such as liraglutide or semaglutide, a buffer selected from a tromethamine buffer and a phosphate buffer, and an isotonic agent selected from glucose, a polyethylene glycol and glycerol. The present invention also relates to said pharmaceutical composition for use in a method for treating joint diseases.",4MOVING BIOTECH,RATTENBACH REVITAL;;BERENBAUM FRANCIS;;BISMUTH KEREN;;MARTIN CÉLINE;;MEUROT CORALIE,,https://lens.org/034-588-927-315-598,Patent Application,yes,3,1,7,161-065-996-408-159;;162-236-787-532-313;;134-316-180-302-591;;034-588-927-315-598;;090-258-190-792-101;;154-912-544-045-888;;097-356-964-954-260,JP;;AU;;KR;;EP;;WO;;US;;CA,9,161-065-996-408-159;;162-236-787-532-313;;115-629-263-216-013;;134-316-180-302-591;;079-489-756-778-326;;034-588-927-315-598;;090-258-190-792-101;;097-356-964-954-260;;154-912-544-045-888,JP;;KR;;AU;;EP;;CN;;WO;;US;;CA,3,A61K38/26;;A61P19/02;;A61K47/26;;A61K47/38;;A61K47/36;;A61K47/34;;A61K47/42;;A61K47/10;;A61K47/02;;A61K47/18;;A61K9/0019;;A61K9/0019;;A61K47/18;;A61K47/02;;A61K47/26;;A61K47/10;;A61K47/34;;A61K38/26;;A61P19/02;;A61P19/02;;A61K9/0019;;A61K38/26;;A61K47/10;;A61K47/18;;A61K47/26,A61K38/26;;A61K9/00;;A61P19/02,,1,0,,,"NOVO NORDISK: ""HIGHLIGHTS OF PRESCRIBING VICTOZA"", 1 August 2017 (2017-08-01), XP055865895, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf> [retrieved on 20211125]",PENDING
170,FR,A1,FR 3154416 A1,095-747-170-572-557,2025-04-25,2025,FR 2311470 A,2023-10-23,FR 2311470 A,2023-10-23,PROCEDE DE PRODUCTION DE COMPOSES D’INTERET PAR FERMENTATION,"La présente invention concerne un procédé de production d’au moins un composé d’intérêt par fermentation à l’état solide, comprenant les étapes suivantes :- culture de microorganismes sur un substrat solide, ledit substrat étant placé sur une membrane perméable aux liquides mais non perméable aux microorganismes ni au substrat,- élution d’au moins un composé d’intérêt par répartition d’un liquide sur la surface supérieure dudit substrat solide,- collecte du liquide contenant au moins un composé d’intérêt dans un compartiment situé sous la membrane perméable, caractérisé en ce que le procédé est réalisé en continu.",ALT BIOTECH,PELLET JADE;;ELKASSOUANI SAKINA,,https://lens.org/095-747-170-572-557,Patent Application,no,4,0,1,095-747-170-572-557,FR,1,095-747-170-572-557,FR,0,C12P1/02;;C12P1/04;;C12M21/16;;C12P23/00;;C12P21/00;;C12P7/40;;C12M29/04,C12P1/00;;C12P7/48;;C12P21/00;;C12P23/00,,6,6,038-623-363-843-745;;132-512-272-178-562;;037-378-114-353-224;;020-281-038-237-978;;124-465-373-858-541;;002-330-709-625-273,10.1002/bit.20206;;15334419;;10.3390/su9020224;;10.1007/s11814-020-0579-1;;10.1016/s0960-8524(01)00151-1;;11848378;;19494694;;10.4014/jmb.0807.457;;16484722;;10.1385/abab:128:2:131,"VAN DE LAGEMAAT J. ET AL: ""Solid-state fermentation: A continuous process for fungal tannase production"", BIOTECHNOLOGY AND BIOENGINEERING, JOHN WILEY, HOBOKEN, USA, vol. 87, no. 7, 24 August 2004 (2004-08-24), pages 924 - 929, XP071151547, ISSN: 0006-3592, DOI: 10.1002/BIT.20206;;ABU YAZID N. ET AL: ""Solid-State Fermentation as a Novel Paradigm for Organic Waste Valorization: A Review"", SUSTAINABILITY, vol. 9, no. 2, 8 February 2017 (2017-02-08), CH, pages 224, XP093149854, ISSN: 2071-1050, DOI: 10.3390/su9020224;;PRATAVIEIRA DE OLIVEIRA S. ET AL: ""Solid-liquid extraction of cellulases from fungal solid-state cultivation in a packed bed bioreactor"", KOREAN JOURNAL OF CHEMICAL ENGINEERING, SPRINGER US, NEW YORK, vol. 37, no. 9, 10 August 2020 (2020-08-10), pages 1530 - 1540, XP037236375, ISSN: 0256-1115, [retrieved on 20200810], DOI: 10.1007/S11814-020-0579-1;;HUANG YLWU ZZHANG LCHEUNG CMYANG ST.: ""Production of carboxylic acids from hydrolyzed corn meal by immobilized cell fermentation in a fibrous-bed bioreactor"", BIORESOUR TECHNOL, vol. 82, no. l, March 2002 (2002-03-01), pages 51 - 9, XP055120987;;EL-NAGGAR MYEL-ASSAR SAABDUL-GAWAD SM.: ""Solid-state fermentation for the production of meroparamycin by streptomyces sp. strain MAR01"", J MICROBIOL BIOTECHNOL, vol. 19, no. 5, May 2009 (2009-05-01), pages 468 - 73;;SILVEIRA STOLIVEIRA MSCOSTA JAKALIL SJ.: ""Optimization of glucoamylase production by Aspergillus niger in solid-state fermentation"", APPL BIOCHEM BIOTECHNOL, vol. 128, no. 2, February 2006 (2006-02-01), pages 131 - 40",PENDING
171,US,A1,US 2024/0158729 A1,097-721-008-950-916,2024-05-16,2024,US 202218549740 A,2022-04-12,KR 20210047258 A;;KR 20220044922 A;;KR 2022005272 W,2021-04-12,INTRACELLULAR DELIVERY PLATFORM,"The present invention relates to an intracellular delivery platform including: a first channel through which a fluid comprising cells and delivery materials flows, and a second channel and a third channel which are connected to the first channel at an angle and through which the fluid comprising cells and delivery materials flows, wherein the fluid forms at least one of a collision region and a vortex region of the fluid in at least one of the first channel, the second channel, and the third channel. According to the present invention, material can be effectively delivered into cells by forming a vortex in channels.",MXT BIOTECH,CHUNG A-RAM;;HUR JEONG-SOO,MXT BIOTECH (2023-08-10),https://lens.org/097-721-008-950-916,Patent Application,yes,0,0,3,117-205-002-265-638;;138-793-828-015-972;;097-721-008-950-916,KR;;WO;;US,6,174-656-514-206-690;;097-721-008-950-916;;047-285-545-211-092;;117-205-002-265-638;;079-096-726-288-45X;;138-793-828-015-972,KR;;CN;;EP;;WO;;US,0,C12N15/87;;C12M35/04;;C12M35/04;;C12M23/16;;C12M41/38;;C12N15/87;;C12M23/04;;C12M23/34,C12M1/00;;C12M1/12,,0,0,,,,PENDING
172,EP,A1,EP 4481044 A1,145-983-916-217-17X,2024-12-25,2024,EP 23180698 A,2023-06-21,EP 23180698 A,2023-06-21,CELL SPECIFIC TRANSLATION OF RNA MOLECULES,"The invention provides an improved RNA construct that allows for a target cell specific translation of a protein of interest in eukaryotic cells. The invention applies RNA constructs that are introduced directly into eukaryotic cells, and which are only translated into a protein in the presence of a specific trigger RNA sequence. The invention allows for a controlled expression of proteins or any proteinaceous antigen in target cells. The invention is useful for medical applications such as RNA based vaccination approaches to restrict antigen expression to target tissues.",SRTD BIOTECH,HOFFMANN BERND;;RATSFELD FREDERIK,,https://lens.org/145-983-916-217-17X,Patent Application,yes,2,0,2,145-983-916-217-17X;;127-832-700-192-400,EP;;WO,2,145-983-916-217-17X;;127-832-700-192-400,EP;;WO,4,C12N15/67;;C12N15/79;;C12N2310/11;;C12N2310/50;;C12N2840/007;;C12N2840/102;;C12N2840/203;;C12N2830/50;;A61K31/7115,A61K31/7105;;C12N15/79;;C12N15/113;;C12N15/67,,12,9,014-432-816-475-680;;008-285-595-751-666;;117-834-207-541-028;;087-330-410-524-738;;059-577-188-234-21X;;116-292-030-677-252;;059-393-958-757-089;;074-254-924-910-683;;058-032-369-859-095,10.1016/0005-2736(75)90233-3;;52374;;10.1016/s0169-409x(01)00203-4;;11744175;;21074848;;10.1016/j.biomaterials.2010.10.029;;21193867;;10.1038/nrd3320;;10699311;;10.1016/s0169-409x(99)00062-9;;pmc10348343;;10.1038/s41586-022-05280-1;;36198803;;10.1101/2022.05.25.493141;;10.1038/35078107;;11373684;;pmc312613;;10.1101/gad.862301;;11157775;;14758366;;10.1038/nbt936,"HOFFMANN MARCO ET AL: ""Selectively expressed RNA molecules: a new dimension in functionalized cell targeting"", BIORXIV, 11 May 2022 (2022-05-11), XP093106880, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2022.05.10.491309v1.full> [retrieved on 20231129], DOI: 10.1101/2022.05.10.491309;;D. PAPAHADJOPOULOSM. MOSCARELLOE. H. EYLART. ISAC, BIOCHIM. BIOPHYS. ACTA, vol. 401, 1975, pages 317;;QIUPARK, ADVANCED DRUG DELIVERY REVIEWS, vol. 53, 2001, pages 321 - 339;;SHAMAY: ""Light induced drug delivery into cancer cells"", BIOMATERIALS, vol. 32, 2011, pages 1377 - 86, XP027537936;;LAPPANO RMAGGIOLINI M., NAT REV DRUG DISCOV., vol. 10, 2011, pages 47 - 60;;SUDIMACK JLEE R J., ADV DRUG DELIV REV., vol. 41, 2000, pages 147 - 62;;QIAN ET AL., NATURE, vol. 610, 2022, pages 713 - 721;;KASENIIT ET AL., NATURE BIOTECHNOLOGY, vol. 41, 2023, pages 482 - 487;;ZHAO ET AL., NATURE BIOTECHNOLOGY, vol. 40, 2022, pages 539 - 545;;ELBASHIR S MHARBORTH JLENDECKEL WYALCIN AWEBER KTUSCHL T.: ""Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells"", NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 8, XP002529540, DOI: 10.1038/35078107;;ELBASHIR S MLENDECKEL WTUSCHL T: ""RNA interference is mediated by 21- and 22-nucleotide RNAs"", GENES DEV., vol. 15, no. 2, 15 January 2001 (2001-01-15), pages 188 - 200, XP002206453, DOI: 10.1101/gad.862301;;REYNOLDS ALEAKE DBOESE QSCARINGE SMARSHALL WSKHVOROVAA: ""Rational siRNA design for RNA interference"", NAT BIOTECHNOL., vol. 22, no. 3, March 2004 (2004-03-01), pages 326 - 30, XP002311429, DOI: 10.1038/nbt936",PENDING
173,KR,A,KR 20220113285 A,189-472-759-321-468,2022-08-12,2022,KR 20220014543 A,2022-02-04,KR 20210016012 A,2021-02-04,COMPOSITIONS COMPRISING POLYSACCHARIDES OR EXTRACT DERIVED FROM LACTOBACILLUS PLANTARUM,"The present invention relates to a composition which contains a polysaccharide or an extract derived from Lactobacillus plantarum. More specifically, by containing a polysaccharide derived from Lactobacillus plantarum or an extract of Lactobacillus plantarum can inhibit inflammatory response, inhibit lipogenesis, inhibit intracellular glucose uptake, reduce insulin resistance, and reduce hepatic steatosis, and can exhibit an effect of treating or preventing metabolic diseases.",NEOREGEN BIOTECH,SEO JEONG MIN;;LEE JAE HOON,,https://lens.org/189-472-759-321-468,Patent Application,no,3,1,5,005-146-690-760-836;;029-815-409-073-468;;003-062-187-785-760;;189-472-759-321-468;;073-656-819-415-424,KR;;CN;;EP,10,026-134-353-184-739;;005-146-690-760-836;;147-815-073-378-708;;189-848-492-967-472;;073-656-819-415-424;;186-166-729-431-389;;189-472-759-321-468;;174-915-703-153-202;;029-815-409-073-468;;003-062-187-785-760,JP;;KR;;CN;;EP;;WO;;US,60,C12P19/04;;A23L33/135;;A23L33/125;;A23V2200/3262;;A23V2200/328;;A23V2200/332;;A23V2400/169;;A23V2200/324;;A61K35/747;;A61P3/00;;A61K35/747;;A61K31/7004;;A61P3/10;;A61P3/06;;A61P1/16;;A61P3/04;;A61P29/00;;A23L33/135;;A23V2002/00;;A23V2200/328;;A23V2200/3262;;A23V2200/332;;A23V2200/324;;A23V2400/169,A61K35/747;;A23L33/135;;A61K31/7004;;A61P1/16;;A61P3/04;;A61P3/06;;A61P3/10;;A61P29/00,,0,0,,,,ACTIVE
174,EP,A1,EP 4007775 A1,193-220-673-363-476,2022-06-08,2022,EP 20753900 A,2020-07-30,EP 19306004 A;;EP 2020071547 W,2019-08-02,NOVEL IL-17B ANTIBODIES,,OREGA BIOTECH,BASTID JÉRÉMY;;BONNEFOY NATHALIE;;BENSUSSAN ARMAND;;ALBERICI GILLES,,https://lens.org/193-220-673-363-476,Patent Application,yes,0,0,4,193-220-673-363-476;;021-826-985-741-412;;122-458-295-772-727;;076-776-223-761-858,JP;;EP;;WO;;US,4,193-220-673-363-476;;021-826-985-741-412;;122-458-295-772-727;;076-776-223-761-858,JP;;EP;;WO;;US,0,C07K16/24;;C07K16/244;;C07K2317/34;;C07K2317/76;;C07K16/244;;A61K39/3955;;C12N15/64;;C12P21/005;;G01N33/6869;;G01N2333/54,C07K16/24,,1,0,,,See references of WO 2021023624A1,PENDING
175,MX,A,MX 2024013761 A,060-885-276-227-95X,2024-12-06,2024,MX 2024013761 A,2024-11-07,US 202318136419 A;;US 2024/0021859 W,2023-04-19,CRYOPRESERVATION DEVICE WITH INTEGRATED TRACKING DEVICE CHAMBER,The present invention provides a cryopreservation device with an integrated tracking device chamber. The tracking device can be an RFID tag which can be placed in the cryopreservation device as part of the procedure for vitrification of a biological specimen. The cryopreservation device maintains its integrity and keeps the RFID tag securely in the chamber at both ambient conditions when the specimen is collected and under liquid nitrogen where the specimen is stored. The cryopreservation device with an integrated tracking device chamber allows for each individual biological sample to have its own tracking device for monitoring during cryogenic storage.,BIOTECH INC,PARRA-ALMANZA JORGE E,,https://lens.org/060-885-276-227-95X,Patent Application,no,0,0,10,047-592-826-495-933;;162-489-143-820-817;;147-477-893-597-624;;141-146-935-123-247;;060-885-276-227-95X;;046-595-929-205-924;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,AU;;JP;;KR;;CN;;IL;;EP;;MX,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,A01N1/147;;G06K19/0723;;C12N5/547;;G06K19/0723;;A01N1/146;;A01N1/147;;G06K19/0723;;A01N1/144,G06K19/07;;A01N1/10;;A01N1/144,,0,0,,,,PENDING
176,CL,A1,CL 2024002699 A1,170-381-455-868-719,2025-03-28,2025,CL 2024002699 A,2024-09-09,US 202318136419 A,2023-04-19,Dispositivo de crioconservación con cámara de seguimiento integrada.,La presente invención proporciona un dispositivo de crioconservación con una cámara de dispositivo de seguimiento integrado. El dispositivo de seguimiento puede ser una etiqueta RFID que puede colocarse en el dispositivo de crioconservación como parte del procedimiento de vitrificación de una muestra biológica. El dispositivo de crioconservación mantiene su integridad y conserva la etiqueta RFID de forma segura en la cámara tanto en condiciones ambientales cuando se recoge el espécimen como bajo nitrógeno líquido cuando se almacena el espécimen. El dispositivo de crioconservación con una cámara de dispositivo de seguimiento integrado permite que cada muestra biológica individual tenga su propio dispositivo de seguimiento para su supervisión durante el almacenamiento criogénico.,BIOTECH INC,JORGE E PARRA-ALMANZA,,https://lens.org/170-381-455-868-719,Patent Application,no,0,0,6,170-381-455-868-719;;061-368-949-232-149;;131-163-295-300-269;;118-651-602-690-001;;016-237-892-665-506;;117-296-648-200-709,AR;;CL;;WO;;US,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,G06K19/0723;;A01N1/147;;G06K19/0723;;A01N1/146,,,0,0,,,,PENDING
177,WO,A1,WO 2022/185193 A1,074-452-294-194-13X,2022-09-09,2022,IB 2022051777 W,2022-03-01,FR 2102018 A,2021-03-02,DENTAL PROSTHETIC DEVICE,"The invention relates to a dental prosthetic device comprising at least an implant, a cap (22) and an abutment which is interposed between the implant and the cap (22). The abutment comprises an abutment head (12) which is at least partially delimited by an abutment external face (54) and which is equipped with retaining means (34) for retaining the cap (22). The abutment (4) comprises an abutment body (11) provided with means of attachment to the implant. The retaining means (34) comprise interfitting means (35b) of fitting the abutment head (12) inside a cavity (36) which is formed inside the cap (22) and which is at least partially delimited by a cap internal face (46). The retaining means (34) comprise means (35a) for screwing the cap (22) onto the abutment head (12). The cap internal face (46) is provided with a tab (52) which is in contact against the abutment external face (54). A space (56) is left between a point of contact (53) of the cap internal face (46) and a cone lip (55) of the cap internal face (46) between the abutment external face (54) and the cap internal face (46).",BIOTECH DENTAL,BREYSSE PASCAL,,https://lens.org/074-452-294-194-13X,Patent Application,yes,5,0,9,019-363-140-965-748;;187-080-580-128-005;;052-193-428-912-212;;056-269-316-781-258;;021-911-244-760-284;;074-452-294-194-13X;;096-026-210-549-527;;162-987-004-657-206;;187-566-910-286-875,EP;;ES;;WO;;US;;FR,9,019-363-140-965-748;;187-080-580-128-005;;056-269-316-781-258;;052-193-428-912-212;;021-911-244-760-284;;074-452-294-194-13X;;187-566-910-286-875;;162-987-004-657-206;;096-026-210-549-527,EP;;ES;;WO;;US;;FR,0,A61C8/0048;;A61C8/008;;A61C8/0068;;A61C8/0068;;A61C8/0069;;A61C8/008,A61C8/00,,0,0,,,,PATENTED
178,EP,A1,EP 3946377 A1,002-809-273-531-843,2022-02-09,2022,EP 20718247 A,2020-04-02,EP 19305438 A;;EP 2020059434 W,2019-04-03,COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS,,OREGA BIOTECH,BONNEFOY NATHALIE;;BASTID JÉRÉMY,,https://lens.org/002-809-273-531-843,Patent Application,yes,0,0,5,002-809-273-531-843;;111-070-178-496-436;;026-458-336-004-83X;;074-457-640-639-588;;137-340-950-812-694,JP;;EP;;WO;;US,5,002-809-273-531-843;;111-070-178-496-436;;026-458-336-004-83X;;074-457-640-639-588;;137-340-950-812-694,JP;;EP;;WO;;US,0,A61K45/06;;A61K39/3955;;A61K31/713;;A61P35/00;;A61P31/12;;A61P31/06;;A61P31/00;;A61P33/06;;C07K2317/76;;A61K2039/505;;A61K2039/507;;C07K16/2818;;C07K16/244;;Y02A50/30;;A61P35/00;;A61K31/713;;A61K45/06;;C07K16/244;;C07K16/2818,A61K31/713;;A61K39/395;;A61K45/06;;A61P31/00;;A61P31/06;;A61P31/12;;A61P35/00,,0,0,,,,PENDING
179,FR,A1,FR 3136479 A1,029-087-290-109-538,2023-12-15,2023,FR 2205675 A,2022-06-13,FR 2205675 A,2022-06-13,Dispositif d’isolement de cellules de sperme et procédé de sélection de cellules de sperme de haute qualité,"L’invention concerne un dispositif de sélection de cellules de sperme ayant une plaque de support (2) comprenant une entrée (3) pour recevoir un échantillon de cellules de sperme, une sortie (4) pour collecter au moins certaines des cellules de sperme de l’échantillon, et un système microfluidique entre ladite entrée et ladite sortie, ledit système microfluidique comprenant une cuvette agencée pour recevoir un milieu et ayant une zone d'entrée et une zone de sortie respectivement à proximité de l'entrée et de la sortie, l'entrée (3) et la sortie (4) étant agencées pour fournir une différence de pression hydrostatique entre ladite zone d'entrée et ladite zone de sortie lorsqu'un milieu est ajouté à la cuvette par l'intermédiaire de la sortie, et la zone d'entrée et la zone de sortie étant en communication fluidique par l’intermédiaire d’un canal principal agencé dans la cuvette ayant une zone de largeur réduite entre la zone d'entrée et la zone de sortie formant une zone de rhéotaxie. Figure pour l’abrégé : Fig. 1",BEEZ BIOTECH,SHUKLA SHIVA KANT,,https://lens.org/029-087-290-109-538,Patent Application,no,6,0,5,164-514-809-775-341;;189-852-813-611-832;;198-373-535-208-40X;;061-603-376-262-742;;029-087-290-109-538,CN;;EP;;WO;;FR,5,189-852-813-611-832;;029-087-290-109-538;;198-373-535-208-40X;;061-603-376-262-742;;164-514-809-775-341,EP;;CN;;WO;;FR,0,C12M21/06;;C12M47/04;;C12N5/0612;;A61D19/02,C12M3/00;;A61B17/43;;B01L3/00;;C12M1/26;;C12N5/076;;C12Q1/24,,16,14,132-615-913-786-392;;057-248-534-047-258;;098-278-528-710-96X;;044-831-232-843-917;;013-172-766-527-846;;006-436-297-405-91X;;058-581-968-906-342;;166-104-047-110-79X;;015-685-034-510-711;;021-825-812-746-851;;066-352-862-122-241;;038-415-595-243-224;;061-539-002-320-967;;089-616-048-387-828,10.1093/biolre/iox173;;29228115;;pmc4594619;;26386468;;10.1093/humupd/dmv042;;28981654;;pmc6455044;;10.1093/humupd/dmx022;;25458617;;pmc4254491;;10.1016/j.fertnstert.2014.10.021;;10.1088/2057-1976/aab10d;;28326513;;10.5603/gp.a2017.0012;;10.1093/oxfordjournals.humrep.a138198;;7691866;;10.1095/biolreprod.107.065623;;18199884;;30954892;;10.1016/j.fsigen.2019.03.012;;10.15252/embj.2019102363;;pmc7024840;;31957048;;pmc7496921;;10.1002/anie.202005657;;32392393;;10.1373/clinchem.2012.190686;;23322907;;27025866;;10.1039/c6lc00256k;;27281780;;10.1016/j.fertnstert.2016.05.008,"DE GEYTER ET AL., ART IN EUROPE, 2014;;OSEGUERA-LΔPEZ ET AL.: ""S. Novel Techniques of Sperm Sélection for Improving IVF and ICSI Outcomes"", FRONT CELL DEV BIOL, 2019;;PÉREZ-CEREZALES: ""The oviduct : From sperm sélection to the epigenetic landscape of the embryo"", BIOL REPROD, 2018;;SAKKAS ET AL.: ""What can we learn from Mother Nature to improve assisted reproduction outcomes?"", HUM REPROD UPDATE;;LEVINE ET AL.: ""emporal trends in sperm count : A systematic review and meta-regression analysis"", HUM REPROD UPDATE, 2017;;WANGSWERDLOFF: ""Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests"", FERTIL STERIL, 2014;;SHUKLA ET AL.: ""Automated analysis of rat sperm motility in microchannels"", BIOMED PHYS ENG EXPRESS, 2018, pages 4;;TALARCZYK-DESOLE ET AL.: ""Manual vs. computer-assisted sperm analysis : Can CASA replace manual assessment of human semen in clinical practice?"", GINEKOL POL, 2017, pages 88;;ALVAREZ ET AL.: ""Centrifugation of human spermatozoa induces sublethal damage ; séparation of human spermatozoa from seminal plasma by a dextran swim-up procedure without centrifugation extends their motile lifetime"", HUM REPROD, 1993;;FERNÂNDEZ-GONZALEZ ET AL.: ""Long-term effects of mouse intracytoplasmic sperm injection with DNA-fragmented sperm on health and behavior of adult offspring"", BIOL REPROD, 2008;;CLARK ET AL.: ""Acoustic trapping of sperm cells from mock sexual assault samples"", FORENSIC SCI INT GENET, 2019, pages 41;;SCHIFFER ET AL.: ""Rotational motion and rheotaxis of human sperm do not require functional CatSper channels and transmembrane Ca2+ signaling"", EMBO J, 2020;;XU ET AL.: ""agnetic Micromotors for Multiple Motile Sperm Cells Capture, Transport, and Enzymatic Release"", ANGEW CHEMIE - INT ED, 2020, pages 59;;CHEN, CHEN ET AL.: ""Direct characterization of motion-dependent parameters of sperm in a microfluidic device : Proof of principle"", CLIN CHEM, 2013;;DE WAGENAAR ET AL.: ""Towards microfluidic sperm refinement : Impedance-based analysis and sorting of sperm cells"", LAB CHIP, 2016, pages 16;;DE WAGENAAR ET AL.: ""Spermometer : electrical characterization of single boar sperm motility"", FERTIL STERIL, 2016, pages 106",PENDING
180,US,A1,US 2022/0249651 A1,063-495-431-381-013,2022-08-11,2022,US 202217589484 A,2022-01-31,US 202217589484 A;;US 202163144068 P,2021-02-01,UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION,"The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (TH) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavirus, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene under the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.",AEGLE BIOTECH,LUBIT BEVERLY W;;GARIBYAN LILIT;;HAO HELEN;;O'CONNELL SEAN,AEGLE BIOTECH (2021-01-28),https://lens.org/063-495-431-381-013,Patent Application,yes,0,2,3,063-495-431-381-013;;000-030-189-779-422;;027-433-889-927-680,WO;;US,3,063-495-431-381-013;;000-030-189-779-422;;027-433-889-927-680,WO;;US,12,A61P31/16;;C07K14/005;;C12N2740/16122;;C12N2740/16134;;C12N2740/16222;;C12N2740/16234;;C12N2770/20022;;C12N2770/20034;;A61K39/145;;A61K2039/543;;A61K2039/545;;A61K2039/572;;A61P31/16;;C07K14/005;;C12N7/00;;C12N15/86,A61K39/145;;A61P31/16;;C07K14/005;;C12N7/00;;C12N15/86,,0,0,,,,DISCONTINUED
181,EP,A1,EP 4301273 A1,056-269-316-781-258,2024-01-10,2024,EP 22707520 A,2022-03-01,FR 2102018 A;;IB 2022051777 W,2021-03-02,DENTAL PROSTHETIC DEVICE,,BIOTECH DENTAL,BREYSSE PASCAL,,https://lens.org/056-269-316-781-258,Patent Application,yes,0,0,9,019-363-140-965-748;;187-080-580-128-005;;052-193-428-912-212;;056-269-316-781-258;;021-911-244-760-284;;074-452-294-194-13X;;096-026-210-549-527;;162-987-004-657-206;;187-566-910-286-875,EP;;ES;;WO;;US;;FR,9,019-363-140-965-748;;187-080-580-128-005;;056-269-316-781-258;;052-193-428-912-212;;021-911-244-760-284;;074-452-294-194-13X;;187-566-910-286-875;;162-987-004-657-206;;096-026-210-549-527,EP;;ES;;WO;;US;;FR,0,A61C8/0048;;A61C8/008;;A61C8/0068;;A61C8/0068;;A61C8/0069;;A61C8/008,A61C8/00,,0,0,,,,ACTIVE
182,US,A1,US 2023/0088420 A1,106-514-051-912-58X,2023-03-23,2023,US 202217949763 A,2022-09-21,US 202217949763 A;;US 202163247107 P,2021-09-22,METHOD FOR PRODUCTION OF LACTOBACILLUS PLANTARUM,"This application provides a method for culturing Lactobacillus plantarum, which comprises culturing Lactobacillus plantarum in a medium comprising molasses, a yeast extract and sucrose at a temperature from 32° C. to 37° C.",ASAHI BIOCYCLE CO LTD,YASUDA GENTARO;;TANAKA KOTOYO,ASAHI BIOCYCLE CO. LTD (2021-10-20),https://lens.org/106-514-051-912-58X,Patent Application,yes,2,0,3,106-514-051-912-58X;;088-549-508-243-435;;105-042-124-934-036,WO;;US;;TW,3,106-514-051-912-58X;;088-549-508-243-435;;105-042-124-934-036,WO;;US;;TW,0,C12N1/20;;C12N1/205;;C12R2001/25;;Y02P60/87;;C12N1/205;;C12N2500/16;;C12N2500/34;;C12N2500/38;;C12N2500/60;;C12N2500/74;;C12R2001/25,C12N1/20,,8,2,041-989-924-878-599;;090-438-130-292-293,10.1007/s00284-020-01979-4;;32328749;;10.15446/agron.colomb.v39n1.89674,"Choi et al., JMB, 31(5):717-725 (2021) (Year: 2021);;Emanuel et al., Afr. J. Biotech., 4(5):403-408 (2005 (Year: 2005);;Jaimes et al., Chem. Eng. Trans., 37:427-432 (2014) (Year: 2014);;Krzywonos et al., Electron. J. Biotech., 14(2):1-9 (2011) (Year: 2011);;Othman et al., App. Food. Biotech., 5(2):57-96 (2018) (Year: 2018);;Papizadeh et al., Cur. Microbiol., 77:1756-1766 (2020) (Year: 2020);;Saavedra et al., Agro. Colomb., 39(1), 98-107 (2021) (Year: 2021);;Seruga et al., Pol. J. Environ. Stud., 24(2):683-688 (2015) (Year: 2015)",DISCONTINUED
183,US,A1,US 2023/0265492 A1,092-781-881-682-496,2023-08-24,2023,US 202118006592 A,2021-07-27,CN 202010730125 A;;CN 2021108534 W,2020-07-27,"SURFACE LINKER OF SEMICONDUCTOR CHIP, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF","The present invention relates to the field of biochips, and provides a surface linker for a semiconductor chip, a preparation method therefor and an application thereof. The chip surface linker reacts with a chip surface by means of using silanized molecules as a solute and toluene as a solvent so as to form bonding molecules connected to the chip surface, and is prepared by reacting with functionalized molecules to modify a hydroxyl group and an ester group. The chip surface linker obtained by the present invention may be stably bonded to the chip surface, is stable under acidic and alkaline conditions, has good electrical conductivity, electrical stability and resistance to organic solvents required for nucleic acid synthesis, and is extremely advantageous for subsequent nucleic acid.",NANJING GENSCRIPT BIOTECH CO LTD,HU FEICHI;;LIU CHUNYAN;;WU CHENG-HSIEN;;LIN YONGLONG,NANJING GENSCRIPT BIOTECH CO. LTD (2022-03-24),https://lens.org/092-781-881-682-496,Patent Application,yes,0,0,6,092-781-881-682-496;;119-144-273-625-11X;;137-137-246-866-29X;;053-782-837-774-676;;141-079-131-209-494;;043-471-776-168-144,EP;;CN;;WO;;US,6,092-781-881-682-496;;043-471-776-168-144;;137-137-246-866-29X;;053-782-837-774-676;;141-079-131-209-494;;119-144-273-625-11X,CN;;EP;;WO;;US,3,C12Q1/68;;B01J19/0046;;B01J2219/00608;;B01J2219/00626;;B01J2219/00612;;B01J2219/00576;;B01J2219/00632;;B01J2219/00722;;B01J19/0046;;C12Q1/6837,C12Q1/6837;;B01J19/00,,0,0,,,,PENDING
184,EP,A1,EP 4191638 A1,119-144-273-625-11X,2023-06-07,2023,EP 21848553 A,2021-07-27,CN 202010730125 A;;CN 2021108534 W,2020-07-27,"SURFACE LINKER OF SEMICONDUCTOR CHIP, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF","The present invention relates to the field of biochips, and provides a surface linker for a semiconductor chip, a preparation method therefor and an application thereof. The chip surface linker reacts with a chip surface by means of using silanized molecules as a solute and toluene as a solvent so as to form bonding molecules connected to the chip surface, and is prepared by reacting with functionalized molecules to modify a hydroxyl group and an ester group. The chip surface linker obtained by the present invention may be stably bonded to the chip surface, is stable under acidic and alkaline conditions, has good electrical conductivity, electrical stability and resistance to organic solvents required for nucleic acid synthesis, and is extremely advantageous for subsequent nucleic acid synthesis and other applications.",NANJING GENSCRIPT BIOTECH CO LTD,HU FEICHI;;LIU CHUNYAN;;WU CHENG-HSIEN;;LIN YONGLONG,,https://lens.org/119-144-273-625-11X,Patent Application,yes,0,0,6,092-781-881-682-496;;119-144-273-625-11X;;137-137-246-866-29X;;053-782-837-774-676;;141-079-131-209-494;;043-471-776-168-144,EP;;CN;;WO;;US,6,092-781-881-682-496;;043-471-776-168-144;;137-137-246-866-29X;;053-782-837-774-676;;141-079-131-209-494;;119-144-273-625-11X,CN;;EP;;WO;;US,3,C12Q1/68;;B01J19/0046;;B01J2219/00608;;B01J2219/00626;;B01J2219/00612;;B01J2219/00576;;B01J2219/00632;;B01J2219/00722;;B01J19/0046;;C12Q1/6837,H01L21/00,,0,0,,,,PENDING
185,US,A1,US 2022/0348691 A1,074-503-268-493-352,2022-11-03,2022,US 202017636720 A,2020-08-20,CN 201910775971 A;;CN 2020110234 W,2019-08-21,Blumea Balsamifera Monoterpene Synthase BBTPS3 And Related Biological Materials Thereof and Use Thereof,"Provided are a Blumea balsamifera monoterpene synthase BbTPS3 and related biological materials thereof and use thereof. BbTPS3 is: A1) a protein having the amino acid sequence shown in SEQ ID NO: 2; A2) a fusion protein obtained by linking protein-tags at the N-terminus or/and the C-terminus of the protein shown in SEQ ID NO: 2; and A3) a protein having at least 90% identity and the same function as the protein shown in A1), which is obtained by performing substitution and/or deletion and/or addition of one or more amino acid residues on the amino acid sequence shown in SEQ ID NO: 2. BbTPS3 can catalyze GPP to form l-borneol, and can be used to regulate and produce plant monoterpene compounds and cultivate Blumea balsamifera (L.) DC.",SICHUAN HONGHE BIOTECHNOLOGY CO LTD,HUANG LUQI;;SU PING;;MA RUI;;GAO WEI;;CUI GUANGHONG;;JIN BAOLONG;;HU YATING;;BAO JICHEN;;GUO JUAN,SICHUAN HONGHE BIOTECHNOLOGY CO. LTD (2022-01-28),https://lens.org/074-503-268-493-352,Patent Application,yes,0,0,4,074-473-116-362-092;;035-862-584-920-651;;155-736-473-652-926;;074-503-268-493-352,CN;;WO;;US,4,074-473-116-362-092;;035-862-584-920-651;;155-736-473-652-926;;074-503-268-493-352,CN;;WO;;US,2,C12N9/88;;C07K2319/21;;C07K2319/23;;C07K2319/24;;C07K2319/41;;C07K2319/42;;C07K2319/43;;C12N15/81;;C12P7/02;;C12N15/62;;C12N9/16;;C12N9/88;;C12N15/81;;C12P7/02;;C12Y301/07;;C07K19/00;;C12N15/10;;C12N15/62;;C12N15/81,C07K19/00;;C12N15/10;;C12N15/62;;C12N15/81,,0,0,,,,ACTIVE
186,US,A1,US 2022/0267814 A1,011-659-486-716-10X,2022-08-25,2022,US 202017604630 A,2020-04-20,EP 2019060092 W;;EP 2020050508 W;;EP 2020060966 W,2019-04-18,EXTREME THERMOPHILIC BACTERIA OF THE GENUS CALDICELLULOSIRUPTOR SUITABLE FOR THE CONVERSION OF CELLULOSIC AND STARCHY BIOMASS,"Isolated cellulolytic extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures and microbial compositions. The novel bacteria are in particular suitable for the production of fermentation products such as lactic acid from any carbon source, not limited to cellulosic material but especially useful for converting cellulosic biomass like lignocellulosic biomass and/or starch containing biomass.",BLUCON BIOTECH GMBH,SVETLICHNY VITALY;;KRÄMER MARCO;;SVETLICHNAYA TATIANA,BLUCON BIOTECH GMBH (2021-11-22),https://lens.org/011-659-486-716-10X,Patent Application,yes,1,0,12,089-119-531-590-175;;115-550-975-719-514;;106-926-783-096-283;;066-052-449-652-084;;138-616-557-731-08X;;021-008-914-874-694;;172-502-806-357-592;;133-358-669-744-474;;048-949-088-739-646;;003-861-881-697-091;;011-659-486-716-10X;;049-754-984-984-152,JP;;AU;;KR;;CN;;EP;;WO;;ZA;;US;;CA;;BR,14,115-550-975-719-514;;089-119-531-590-175;;106-926-783-096-283;;138-616-557-731-08X;;172-502-806-357-592;;133-358-669-744-474;;003-861-881-697-091;;086-689-386-250-961;;011-659-486-716-10X;;066-052-449-652-084;;049-754-984-984-152;;021-008-914-874-694;;056-386-385-249-081;;048-949-088-739-646,JP;;AU;;KR;;EP;;CN;;WO;;ZA;;US;;CA;;BR,8,C12P7/56;;C12N1/22;;C12N1/20;;C12P2203/00;;C12R2001/01;;C12N1/205;;Y02E50/10;;C12N1/205;;C12N1/22;;C12P7/56;;C12R2001/01;;C12P2203/00;;C12N1/205;;C12R2001/145;;C12N1/22;;C12P7/56;;C12P2203/00,C12P7/56;;C12N1/20;;C12N1/22,,0,0,,,,ACTIVE
187,US,A1,US 2023/0287333 A1,107-285-339-368-982,2023-09-14,2023,US 202218064272 A,2022-12-11,CN 202210285129 A,2022-03-11,PRODUCTION METHOD OF RECOMBINANT ESCHERICHIA COLI AND HIGH-PURITY URSODEOXYCHOLIC ACID,"The present invention belongs to the field of bioengineering technologies, and in particular, to a production method of recombinant Escherichia coli (E. coli) and high-purity ursodeoxycholic acid (UDCA). The present invention constructs novel double-enzyme co-expression gene engineered bacteria, that is, recombinant E. coli. The bacteria simultaneously expresses 7β-hydroxysteroid dehydrogenase (7β-HSDH) and glucose dehydrogenase (GDH). The bacteria is applicable to the production of high-purity UDCA. The yield of a target product is increased through the joint expression and application of 7β-HSDH and GDH. The production method of high-purity UDCA in the present invention is simple, generates a small amount of impurities in a production process, is a green process that satisfies environmental protection requirements, and has significant industrial application value.",ZHANG TIAN;;XUE TONG;;ZHU LIHUI;;XIAN YUEDA BIOTECHNOLOGY CO LTD,ZHANG TIAN;;XUE TONG;;ZHU LIHUI,XI'AN YUEDA BIOTECHNOLOGY CO. LTD (2022-12-09),https://lens.org/107-285-339-368-982,Patent Application,yes,0,1,5,107-285-339-368-982;;114-500-357-174-13X;;080-711-968-426-226;;136-785-606-158-676;;085-755-958-754-003,JP;;CN;;US,5,107-285-339-368-982;;114-500-357-174-13X;;080-711-968-426-226;;136-785-606-158-676;;085-755-958-754-003,JP;;CN;;US,0,C12N9/0006;;C12N15/70;;C12N1/20;;C12P33/06;;C12Y101/01201;;C12Y101/01047;;C12N2800/22;;C12N9/0006;;C12Y101/01047;;C12N15/70;;C12Y101/01201;;C12R2001/19;;C12P33/02;;C12N1/205;;C12R2001/19;;C12N9/0006;;C12N15/70;;C12Y101/01047;;C12Y101/01201,C12N1/20;;C12N9/04;;C12N15/70,,0,0,,,,PENDING
188,US,A1,US 2021/0095270 A1,159-197-178-172-271,2021-04-01,2021,US 201816648529 A,2018-08-23,CN 201710840332 A;;CN 2018101878 W,2017-09-18,METHOD FOR ANALYZING IMPURITIES OF OLIGONUCLEOTIDE SEQUENCE BASED ON HIGH-THROUGHPUT SEQUENCING AND APPLICATION,"The present invention provides a method for analyzing impurities of an oligonucleotide sequence based on high-throughput sequencing. The method of the present invention comprises the following steps: constructing a high-throughput sequencing library for analysis of impurities of an oligonucleotide sequence; subjecting the high-throughput sequencing library to high-throughput sequencing, and analyzing the nucleotide sequence components according to the sequencing results; the sequence of the extension primer used in the construction of the high-throughput sequencing library consisting of the DNA molecule set forth in positions 1-22 of SEQ ID NO: 2 and N bases (A, T, C or G) in sequence; and N being an integer greater than or equal to 6. It is proved by experiments that the method for analyzing impurities of an oligonucleotide sequence based on high-throughput sequencing of the present invention can quickly, accurately, and comprehensively analyze the purity and content of each component in the oligonucleotide sequence.",SUZHOU GENESCI CO LTD;;SUZHOU GENEPHARMA CO LTD,GUO LIANGRANG;;ZHANG PEIZHUO;;YU LEI,SUZHOU GENEPHARMA CO. LTD (2020-03-13);;SUZHOU GENESCI CO. LTD (2020-03-13),https://lens.org/159-197-178-172-271,Patent Application,yes,1,0,9,159-197-178-172-271;;072-241-993-045-755;;165-213-498-205-479;;188-223-812-443-04X;;109-969-388-423-837;;070-881-681-976-318;;085-904-173-360-14X;;146-618-230-325-476;;173-599-039-617-356,JP;;EP;;CN;;WO;;US,9,159-197-178-172-271;;072-241-993-045-755;;165-213-498-205-479;;188-223-812-443-04X;;109-969-388-423-837;;070-881-681-976-318;;085-904-173-360-14X;;146-618-230-325-476;;173-599-039-617-356,JP;;EP;;CN;;WO;;US,27,C12Q1/6869;;C40B50/06;;C12Q1/6806;;C12Q1/6848;;C12Q1/6869;;C40B50/06;;C12N15/1093;;C12Q1/6806;;C12Q1/6869,C12N15/10;;C12Q1/6806;;C12Q1/6869,,1,1,122-108-754-517-726,10.1038/nprot.2013.038;;23493070,"Gansauge et al., ""Single-stranded DNA library preparation for the sequencing of ancient or damaged DNA,"" Nat. Protoc. 2013, 8:737-748. (Year: 2013)",ACTIVE
189,US,A1,US 2024/0389561 A1,042-195-657-197-52X,2024-11-28,2024,US 202418409695 A,2024-01-10,CN 202310584888 A,2023-05-23,KIT FOR BREEDING A TGEV INFECTION RESISTANT PIG AND USE THEREOF,"A kit for breeding a pig breed with resistance to the porcine transmissible gastroenteritis virus infection and application thereof. The systems includes a genetically edited protein, pAPN-sgRNA-1, pAPN-sgRNA-2, and a donor DNA. Effectively enzymatic cleavage can be made in two target sites of a pAPN gene by the gene editing protein. By replacing the fragment to be site-directed modified located between two target sites with donor DNA, a codon encoding tryptophan at position 737 in pAPN protein can be mutated to a codon encoding alanine, thereby achieving precise mutation of tryptophan to alanine at position 737 in a pAPN protein. The systems can avoid disruption or alteration of the normal expression of other amino acids in pAPN protein, therefore, the present invention maximally retains the physiological activity function of pAPN protein on the basis of resisting TGEV infection.",AGSINO GENSOURCES CO LTD,LI KUI;;MU YULIAN;;HUANG LEI,AGSINO GENSOURCES CO. LTD (2023-12-08),https://lens.org/042-195-657-197-52X,Patent Application,yes,0,0,4,042-195-657-197-52X;;031-826-820-791-019;;138-678-628-250-827;;075-808-776-340-612,CN;;US,4,042-195-657-197-52X;;031-826-820-791-019;;138-678-628-250-827;;075-808-776-340-612,CN;;US,0,C12N9/22;;C12N15/113;;C12N15/8509;;C12N15/89;;C12N15/907;;C12N15/8778;;A61D19/04;;A01K67/0275;;C12N2310/20;;A01K2217/07;;A01K2227/108;;A01K2267/02;;Y02A50/30;;C12N9/22;;A01K2227/108;;A01K2267/0337;;C12N15/11;;C12N2015/8581;;C12N2310/20;;A01K67/0275;;A01K2207/12;;C12N15/8509;;A01K2267/02;;C12N15/907;;C12N15/113;;C12N2310/20;;A01K67/0275;;A01K2207/12;;A01K2227/108;;A01K2267/0337;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8581,A01K67/0275;;C12N9/22;;C12N15/11;;C12N15/85,,0,0,,,,ACTIVE
190,KR,A,KR 20240121994 A,009-938-989-286-607,2024-08-12,2024,KR 20230014616 A,2023-02-03,KR 20230014616 A,2023-02-03,Method for producing exosome from culture medium of stem cells and cosmetic composition comprising exosome produced using the same,"본원은 줄기세포의 배양액 유래 엑소좀의 제조방법 및 상기 제조방법을 이용하여 제조된 엑소좀을 포함하는 화장료 조성물에 관한 것이다. 더욱 상세하게, 본원은 줄기세포를 배양하는 과정에 얻어지는 줄기세포 배양액에 함유되어 있는 엑소좀을 간단한 방법으로 고수율로 분리하여 경제적으로 제조할 수 있는 줄기세포의 배양액 유래의 엑소좀의 제조방법 및 상기 제조방법을 이용하여 제조된 엑소좀을 포함하는 화장료 조성물에 관한 것이다.",PANACELL BIOTECH,CHOI SEUNG HO;;KIM HYEONG SOO,,https://lens.org/009-938-989-286-607,Patent Application,no,3,0,2,009-938-989-286-607;;071-508-971-700-599,KR,2,009-938-989-286-607;;071-508-971-700-599,KR,0,C12N5/0667;;A61K8/98;;A61Q19/00,C12N5/0775;;A61K8/98;;A61Q19/00,,0,0,,,,ACTIVE
191,EP,A1,EP 4281772 A1,040-657-732-636-029,2023-11-29,2023,EP 22700146 A,2022-01-20,FR 2100559 A;;EP 2022051259 W,2021-01-21,"SYSTEM FOR RAPID ANALYSIS OF A CAPILLARY BLOOD SAMPLE FROM A SUBJECT, FOR DETECTING THE PRESENCE OF AT LEAST ONE ANALYTE IN SAID CAPILLARY BLOOD SAMPLE",,NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/040-657-732-636-029,Patent Application,yes,0,0,6,155-229-762-993-894;;029-059-928-128-933;;137-748-071-813-315;;128-681-643-629-960;;040-657-732-636-029;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,6,155-229-762-993-894;;029-059-928-128-933;;128-681-643-629-960;;040-657-732-636-029;;137-748-071-813-315;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,0,G01N33/54388;;G01N33/558;;G01N33/54388;;A61B5/150022;;A61B5/150267;;A61B5/150358;;A61B2560/0406;;A61B2560/0443;;G01N33/558,G01N33/543;;G01N33/558,,0,0,,,,PENDING
192,WO,A1,WO 2022/085819 A1,025-242-249-070-338,2022-04-28,2022,KR 2020014490 W,2020-10-22,KR 20200137400 A,2020-10-22,COMPOSITION FOR OSTEOGENESIS PROMOTION,"The present invention relates to a composition for osteogenesis promotion comprising Enterococcus faecium L15 KCTC13498BP. The composition of the present invention can promote the induction of osteogenic differentiation of osteoblasts and stem cells, and can prevent or treat bone diseases that are curable by osteogenesis or osteoanagenesis.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/025-242-249-070-338,Patent Application,yes,1,0,3,051-695-701-640-670;;025-242-249-070-338;;116-412-637-856-402,KR;;WO,3,051-695-701-640-670;;025-242-249-070-338;;116-412-637-856-402,KR;;WO,12,A61K35/744;;A61L27/54;;A61P19/00;;C12N1/20;;C12N5/06;;C12R2001/46;;C12N5/0654;;A61K35/744;;A61L27/54;;A61L2430/02;;A61P19/00;;C12N2500/72;;C12N2501/90;;C12N2506/1361;;C12R2001/46,A61K35/744;;A61P19/00;;C12N1/20;;C12R1/46,,4,4,021-131-565-669-978;;035-163-015-003-949;;052-610-892-326-596;;049-446-889-007-594,30709061;;10.3390/ijms20030624;;pmc6386954;;10.1007/s12602-020-09635-w;;32162154;;27262294;;10.1007/s10529-016-2142-z;;10.1016/j.ijbiomac.2014.07.026;;25062992,"KIM HYEWON, PARK SANGKYU, KIM KICHUL, KU SEOCKMO, SEO JEONGMIN, ROH SANGHO: ""Enterococcus faecium L-15 Cell-Free Extract Improves the Chondrogenic Differentiation of Human Dental Pulp Stem Cells"", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 3, 31 January 2019 (2019-01-31), pages 624, XP055924018, DOI: 10.3390/ijms20030624;;KIM KICHUL; PARK SANGKYU; KIM HYEWON; MIN SOL; KU SEOCKMO; SEO JEONGMIN; ROH SANGHO: ""L-15 Extract Enhances the Self-Renewal and Proliferation of Mouse Skin-Derived Precursor Cells"", PROBIOTICS AND ANTIMICROBIAL PROTEINS, NEW YORK, NY ; HEIDELBERG : SPRINGER, NEW YORK, NY ; HEIDELBERG : SPRINGER, vol. 12, no. 4, 11 March 2020 (2020-03-11), New York, NY ; Heidelberg : Springer , pages 1492 - 1501, XP037294949, ISSN: 1867-1306, DOI: 10.1007/s12602-020-09635-w;;DENG ZUHUI; WANG SHUAI; HENG BOON CHIN; YUAN CHANGYONG; ZHANG CHENGFEI: ""Enterococcus faecalispromotes osteoclast differentiation within an osteoblast/osteoclast co-culture system"", BIOTECHNOLOGY LETTERS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, vol. 38, no. 9, 4 June 2016 (2016-06-04), Dordrecht , pages 1443 - 1448, XP036028378, ISSN: 0141-5492, DOI: 10.1007/s10529-016-2142-z;;ABDHUL KAJA, GANESH MOHAN, SHANMUGHAPRIYA SANTHANAM, KANAGAVEL MURUGESAN, ANBARASU KUMARASAMY, NATARAJASEENIVASAN KALIMUTHUSAMY: ""Antioxidant activity of exopolysaccharide from probiotic strain Enterococcus faecium (BDU7) from Ngari"", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 70, 1 September 2014 (2014-09-01), NL , pages 450 - 454, XP055924020, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2014.07.026",PENDING
193,KR,A,KR 20230067489 A,061-500-031-815-450,2023-05-16,2023,KR 20220085139 A,2022-07-11,KR 20220085139 A;;KR 20210152376 A,2021-11-08,NOVEL OXADIAZOLE DERIVATIVES AND USE THEREOF,"The present invention relates to an oxadiazole derivative and a composition containing the same for preventing or treating diseases related to NADPH oxidase (NOX), which can be used for the treatment of diseases related to NADPH oxidase (NOX) through excellent action on inhibiting NOX.",CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,,https://lens.org/061-500-031-815-450,Patent Application,no,0,0,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,0,A61K31/4245;;A61K31/495;;A61K45/06;;A61P25/28;;A61P35/00;;C07D271/113;;C07D413/10;;C07D413/04;;C07D413/14;;C07D271/06;;C07D271/113;;A61K31/4245;;A61P25/00;;C07D413/10;;A61P35/00;;A61K31/4245;;A61K45/06;;C07D271/113;;C07D413/10,C07D271/113;;A61K31/4245;;A61P25/00;;C07D413/10,,0,0,,,,DISCONTINUED
194,CN,A,CN 114051414 A,095-811-519-008-224,2022-02-15,2022,CN 202080048417 A,2020-06-09,FR 1906208 A;;FR 2020050975 W,2019-06-11,Combination of markers for predicting response to Vx-001,"The invention relates to the use of an anti-tumor vaccine composed of two peptides of nine amino acids - native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumor cells, and the optimized variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumor expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.",VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS (KOSTAS);;MENEZ-JAMET JEANNE,,https://lens.org/095-811-519-008-224,Patent Application,no,2,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,0,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/00;;A61P35/00;;G01N33/50,,3,0,,,"CESARE GRIDELLI 等: """"Clinical activity of a htert (vx-001) cancer vaccine as postchemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial"""", 《BRITISH JOURNAL OF CANCER》, pages 1461 - 1466;;VASSILIS GEORGOULIAS 等: ""“A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics”"", 《CLINICAL LUNG CANCER》, vol. 14, no. 4, pages 461 - 465, XP002774759, DOI: 10.1016/j.cllc.2013.02.001;;盛宏旭 等: ""“非小细胞肺癌的免疫治疗进展”"", 《现代生物医学进展》, vol. 17, no. 10, pages 1968 - 1985",PENDING
195,FR,A1,FR 3157208 A1,156-424-704-733-269,2025-06-27,2025,FR 2314790 A,2023-12-21,FR 2314790 A,2023-12-21,"Procédé pour induire une amélioration de la résistance mécanique d’un dispositif implantable comprenant un ou des fil(s) en PLA au terme d’une hydrolyse déterminée, et dispositif implantable susceptible d’être obtenu par ledit procédé","La présente invention a pour objet un procédé pour induire une amélioration de la résistance mécanique (N/cm) d’un dispositif implantable après une période déterminée d’hydrolyse, ledit procédé comprenant :i)- une étape de fourniture d’un dispositif implantable comprenant un ou des fil(s) comprenant au moins un (co)polymère d’acide lactique;ii)- une étape de traitement dudit dispositif implantable avec du dioxyde de carbone (CO2) supercritique ;iii)- une étape d’obtention d’un dispositif implantable ayant une résistance mécanique supérieure ou égale à 10 N/cm, de préférence supérieure ou égale à 25 N/cm, après 20 semaines d’hydrolyse, en particulier dans un milieu aqueux. La présente invention a également pour objet un dispositif implantable susceptible d’être obtenu par ledit procédé, et l’utilisation du (CO2) supercritique pour induire une amélioration de la résistance mécanique d’un dispositif implantable comprenant un ou des fil(s) comprenant un (co)polymère d’acide lactique. Figure pour l’abrégé : Fig.5.",COUSIN BIOTECH,SOLECKI GILLES;;OUERGHEMMI SAFA,,https://lens.org/156-424-704-733-269,Patent Application,no,6,0,3,156-424-704-733-269;;068-034-657-178-990;;186-405-819-895-457,EP;;US;;FR,3,156-424-704-733-269;;068-034-657-178-990;;186-405-819-895-457,EP;;US;;FR,0,A61L27/58;;A61L27/18;;A61L2400/18;;A61F2/0063;;C08G63/08;;D01F6/625;;A61F2/0063;;A61F2002/0068;;A61F2210/0004;;A61F2240/001,A61L27/18;;A61F2/02,,1,0,,,"TEXTILES - MONOFILAMENTS- DÉTERMINATION DES PROPRIÉTÉS EN TRACTION, June 2003 (2003-06-01)",PENDING
196,PT,T,PT 3471788 T,178-305-483-091-464,2020-12-04,2020,PT 17734262 T,2017-06-16,FR 1655645 A,2016-06-17,BIOLOGICAL PROSTHESIS INTENDED FOR THE TREATMENT OF PARASTOMAL HERNIAS,,MECCELLIS BIOTECH,,,https://lens.org/178-305-483-091-464,Patent Application,no,0,0,10,102-575-500-735-405;;014-813-058-532-306;;101-919-244-259-154;;009-933-431-519-747;;178-305-483-091-464;;133-546-275-488-568;;129-323-804-414-917;;040-775-029-966-39X;;114-623-439-776-425;;063-123-047-449-012,ES;;EP;;WO;;US;;CA;;FR;;PT,10,102-575-500-735-405;;014-813-058-532-306;;101-919-244-259-154;;009-933-431-519-747;;178-305-483-091-464;;133-546-275-488-568;;129-323-804-414-917;;040-775-029-966-39X;;114-623-439-776-425;;063-123-047-449-012,ES;;EP;;WO;;US;;CA;;FR;;PT,0,A61L27/362;;A61F2250/0036;;A61F2/0063;;A61F2250/0036;;A61L27/362,A61L27/36,,0,0,,,,PENDING
197,BR,A2,BR 112021024995 A2,183-974-752-783-709,2022-02-15,2022,BR 112021024995 A,2020-06-09,FR 2020050975 W;;FR 1906208 A,2019-06-11,Combinação de marcadores para prognosticar a resposta a vx-001,"combinação de marcadores para prognosticar a resposta a vx-001. a invenção refere-se à utilização de uma vacina antitumoral composta por dois peptídeos de nove aminoácidos - o tert572 (rlffyrksv, seq id nº 1) nativo críptico, expresso por células tumorais, e sua variante otimizada tert572y (ylffyrksv, seq id nº 2), para o tratamento de um tumor que expressa a telomerase transcriptase reversa (tert), em um paciente hla-a*0201 que apresenta uma taxa normal de gama glutamina transferase (ggt) e/ou uma taxa normal de lactato desidrogenase (ldh).",VAXON BIOTECH,MENEZ-JAMET JEANNE;;KOSTANTINOS (KOSTAS) KOSMATOPOULOS,KRIPTIC PHARMACEUTICALS LIMITED (IE) (2024-07-16);;VAXON BIOTECH (FR) (2024-06-25),https://lens.org/183-974-752-783-709,Patent Application,no,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,0,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/395;;A61K39/00;;A61P35/00;;G01N33/50,,0,0,,,,PENDING
198,KR,A,KR 20230128803 A,184-402-581-972-013,2023-09-05,2023,KR 20220026136 A,2022-02-28,KR 20220026136 A,2022-02-28,NOVEL HYDANTOIN DERIVATIVES AND USE THEREOF,"The present invention relates to novel hydantoin derivatives and a composition containing the same for preventing or treating diseases related to NADPH oxidase (NOX). Through an excellent NOX inhibition effect, the hydantoin derivatives can be used to treat diseases related to NADPH oxidase (NOX).",CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,,https://lens.org/184-402-581-972-013,Patent Application,no,0,0,2,145-831-308-530-207;;184-402-581-972-013,KR;;WO,2,145-831-308-530-207;;184-402-581-972-013,KR;;WO,0,A61K31/4166;;A61K31/454;;A61P17/06;;A61P25/28;;A61P35/00;;C07D233/86;;C07D401/04;;C07D233/86;;A61K31/4166;;A61K31/454;;A61P17/06;;A61P25/28;;A61P35/00;;C07D401/04,C07D233/86;;A61K31/4166;;A61K31/454;;A61P17/06;;A61P25/28;;A61P35/00;;C07D401/04,,0,0,,,,PENDING
199,WO,A1,WO 2023/156683 A1,115-218-990-954-833,2023-08-24,2023,EP 2023054333 W,2023-02-21,EP 22305190 A;;EP 22305677 A,2022-02-21,TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES,"The present invention relates to an inhibitor of GPVI signaling pathway, in particular an isolated humanized protein binding to human Glycoprotein VI (hGPVI), for treating a GPVI-related condition in a subject in need thereof, in particular an acute ischemic stroke, comprising the administration of said inhibitor GPVI signaling pathway, in particular said anti-human glycoprotein VI antibody or fragment thereof, to a human patient in need thereof.",ACTICOR BIOTECH,AVENARD GILLES;;PLETAN YANNICK;;GROUIN JEAN-MARIE;;BINAY SOPHIE;;TOLEDANO ELIE;;COMENDUCCI ANDREA,,https://lens.org/115-218-990-954-833,Patent Application,yes,11,3,3,115-218-990-954-833;;199-959-012-899-787;;039-894-679-475-898,EP;;WO;;US,3,115-218-990-954-833;;199-959-012-899-787;;039-894-679-475-898,EP;;WO;;US,28,C07K16/2803;;A61P7/02;;A61K2039/545;;A61K2039/505;;C07K2317/55;;C07K2317/24;;C07K2317/76;;A61K39/39533;;A61P7/02;;A61K2039/505;;C07K16/2803;;C07K2317/24;;C07K2317/565,C07K16/28;;A61K39/395;;A61P7/02,,42,32,027-951-876-602-852;;048-464-468-757-779;;190-065-637-167-076;;017-693-519-334-261;;005-560-967-514-755;;049-134-753-209-354;;054-250-934-559-758;;066-749-017-721-197;;013-795-151-218-458;;002-664-741-683-318;;055-513-241-719-139;;112-279-469-781-943;;002-538-319-677-230;;038-994-369-651-86X;;118-515-940-171-179;;023-929-032-945-955;;021-641-900-032-887;;060-971-733-861-077;;137-607-161-868-61X;;034-331-211-704-877;;066-141-497-990-023;;106-753-778-592-300;;020-855-322-534-259;;000-499-911-678-177;;083-019-407-395-691;;008-587-496-850-953;;051-940-176-386-905;;021-430-782-622-770;;013-892-028-709-221;;003-502-861-629-038;;062-353-036-290-103;;057-343-886-357-239,pmc5390959;;10.1177/1747493016654532;;27312676;;10.1007/s00228-017-2264-9;;28523478;;36128904;;10.1161/strokeaha.122.039790;;25977585;;10.1182/blood-2015-02-629717;;1908882;;10.4049/jimmunol.147.5.1709;;10.1016/0022-2836(87)90412-8;;3681981;;3889592;;10.1016/0161-5890(85)90151-8;;10.1073/pnas.90.14.6444;;pmc46948;;8341653;;9780179;;10.4049/jimmunol.161.8.4083;;1404389;;10.1016/0022-2836(92)90224-8;;10.1006/jmbi.1996.0636;;8951372;;10541349;;10.1016/s0161-5890(99)00029-2;;10444002;;10.1093/nar/gkv694;;10592230;;10.1093/nar/27.1.209;;pmc148137;;9847182;;10.1093/nar/gkv895;;10.1093/nar/gkv675;;10.1093/nar/gki065;;10.1093/nar/gkv1028;;pmc102442;;pmc540019;;10.1093/nar/28.1.219;;15608269;;2622909;;10.1002/prot.340060405;;10.1006/meth.1999.0921;;10694450;;10.1002/j.1460-2075.1995.tb00142.x;;pmc394555;;7556106;;10.1111/j.1749-6632.1949.tb27297.x;;10.1137/0148063;;1907718;;10.1038/352624a0;;pmc321012;;6546423;;10.1093/nar/12.1part1.387;;10.1038/256495a0;;1172191;;10.1016/0022-2836(91)90498-u;;1748994;;1402660;;10.1084/jem.176.4.1191;;pmc2119390;;1573276;;10.4049/jimmunol.148.9.2918;;886304;;10.1099/0022-1317-36-1-59;;10.1073/pnas.77.7.4216;;6933469;;pmc349802;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1016/j.ab.2009.02.035;;19268418;;26683650;;10.1080/19420862.2015.1116657;;pmc4966575;;10.1006/cyto.2001.0936;;11741351;;pmc2074309;;10.1038/bjc.1996.32;;8546903,"ISURU INDURUWA ET AL: ""Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke"", INTERNATIONAL JOURNAL OF STROKE, vol. 11, no. 6, 9 July 2016 (2016-07-09), pages 618 - 625, XP055510399, ISSN: 1747-4930, DOI: 10.1177/1747493016654532;;ACTICOR BIOTECH: ""Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke - NCT05070260"", CLINICAL TRIALS.GOV, 7 October 2021 (2021-10-07), XP093037078, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT05070260?term=NCT05070260&draw=2&rank=1> [retrieved on 20230403];;ACTICOR BIOTECH: ""Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome"", PRESS RELEASE, 2 February 2022 (2022-02-02), XP093037087, Retrieved from the Internet <URL:https://uploads-ssl.webflow.com/60ed4d696fc45c656e3cfb6a/61fabf8f539bfa2c5f8b4b29_220202_Acticor_PR_Garden_EN_vf.pdf> [retrieved on 20230403];;MAZIGHI M ET AL: ""LPB0051 - ACTIMIS Trial: Safety Interim Analysis Data of Glenzocimab, a Novel Antiplatelet Agent on Top of Acute Ischemic Stroke Standard of Care"", EUROPEAN STROKE JOURNAL, vol. 5, no. 2_suppl, 1 October 2021 (2021-10-01), GB, pages 24, XP093037355, ISSN: 2475-0379, Retrieved from the Internet <URL:https://dul.usage.elsevier.com/doi/> DOI: 10.1002/rth2.12589;;FLORIAN PETER ET AL: ""Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber"", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 73, no. 8, 18 May 2017 (2017-05-18), pages 949 - 956, XP036275053, ISSN: 0031-6970, [retrieved on 20170518], DOI: 10.1007/S00228-017-2264-9;;WICHAIYO SURASAK ET AL: ""Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke"", STROKE, vol. 53, no. 11, 21 September 2022 (2022-09-21), US, pages 3506 - 3513, XP093037091, ISSN: 0039-2499, Retrieved from the Internet <URL:http://dx.doi.org/10.1161/STROKEAHA.122.039790> DOI: 10.1161/STROKEAHA.122.039790;;MAZIGHI M ET AL: ""GLENZOCIMAB, A NOVEL ANTITHROMBOTIC, IS ASSOCIATED WITH REDUCED INTRACRANIAL HEMORRHAGE AND MORTALITY RATES WHEN COMBINED WITH STANDARD-OF-CARE REPERFUSION THERAPIES: THE ACTIMIS STUDY"", EUROPEAN STROKE JOURNAL, vol. 7, no. 1_suppl, 3 May 2022 (2022-05-03), pages 547, XP055981771, DOI: https://doi.org/10.1177/23969873221094907;;MAMMADOVA-BACH ET AL., BLOOD, vol. 126, no. 5, 2015, pages 683 - 91;;KABAT ET AL., J. IMMUNOL., vol. 147, no. 5, 1991, pages 1709 - 19;;CHOTHIA C.A.M. LESK, J. MOL. BIOL., vol. 196, no. 4, 1987, pages 901 - 917;;BURTON, MOLEC. IMMUNOL., vol. 22, 1985, pages 161 - 206;;HOLLIGER ET AL., PROC. NATL. ACAD. SCI., vol. 90, no. 14, 1993, pages 6444 - 6448;;ROUX ET AL., J. IMMUNOL., vol. 161, no. 8, 1998, pages 4083 - 90;;KABAT, ELVIN A.: ""Sequences of proteins of immunological interest"", 1983, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA ET AL., J. MOL. BIOL., vol. 227, no. 3, 1992, pages 799 - 817;;TRAMONTANO ET AL., J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 410;;WILLIAMS ET AL., J. MOL. BIOL., vol. 264, no. 5, 1996, pages 220 - 232;;QU ET AL., CLIN. CANCER RES., vol. 5, 1999, pages 3095 - 3100;;ONO ET AL., MOL. IMMUNOL., vol. 36, 1999, pages 387 - 395;;LEFRANC ET AL., NUCLEIC ACID RES, vol. 27, 1999, pages 209 - 212;;TRAMONTANO ET AL., PROTEINS, vol. 6, 1989, pages 382 - 94;;MOREA ET AL., METHODS, vol. 20, 2000, pages 267 - 279;;TOMLINSON ET AL., EMBO J., vol. 14, 1995, pages 4628 - 4638;;SCATCHARD G: ""molecules and ions"", ANN NY ACAD SCI, vol. 51, 1949, pages 660 - 672, XP008000889, DOI: 10.1111/j.1749-6632.1949.tb27297.x;;CARILLO ET AL., SIAM J. APPL. MATH., vol. 48, no. 5, 1988, pages 1073 - 1082;;DOUGLAS W. SMITH: ""Biocomputing: Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;HUGH G. GRIFFINANNETTE M. GRIFFIN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;GUNNAR VON HEINJE: ""Sequence Analysis in Molecular Biology: Treasure Trove or Trivial Pursuit"", 1987, ACADEMIC PRESS;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 12, no. 1, 1984, pages 387 - 395;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;CARON ET AL., J. EXP. MED., vol. 176, 1992, pages 1191 - 1195;;SHOPES, B., J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;TM4, MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;MUZARD ET AL., ANALYTICAL BIOCHEMISTRY, vol. 388, 2009, pages 331 - 338;;LAKHRIF ET AL., MABS, vol. 8, no. 2, 2016, pages 379 - 88;;LEONG ET AL., CYTOKINES, vol. 16, no. 3, 2001, pages 106 - 119;;DELGADO ET AL., BR. J. CANCER, vol. 73, no. 2, 1996, pages 175 - 182",PENDING
200,NZ,A,NZ 804299 A,014-153-327-755-348,2025-07-25,2025,NZ 80429922 A,2022-04-15,US 2022/0024946 W;;US 202163175603 P,2021-04-16,Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease,"In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or grafi-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmimized egg product obtained from an egg- producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecaUs, Enterococcus faecalis eytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis. isolated Enterococcus faecal is eytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.",PRODIGY BIOTECH,IYER SUBRAMANIAN;;PATEL SUNNY,,https://lens.org/014-153-327-755-348,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,PENDING
201,FR,A1,FR 3147092 A1,002-940-935-945-732,2024-10-04,2024,FR 2302903 A,2023-03-27,FR 2302903 A,2023-03-27,"Dispositif implantable, notamment de réfection pariétale","La présente invention a pour objet un dispositif implantable, notamment pour la chirurgie pariétale, comprenant un tricot à mailles jetées, ledit tricot comprenant :- une première nappe tricotée comprenant un fil monofilamentaire A tricoté avec des mailles tricots,- une seconde nappe tricotée comprenant un fil monofilamentaire B tricoté avec des mailles tricots,- une troisième nappe tricotée avec un fil monofilamentaire C tricoté avec des mailles tricots, et- ledit tricot à mailles jetées comprend un fond tricoté et comprend des boucles tricotées agrippantes se projetant dudit fond tricoté et inclinées vers ledit fond tricoté. La présente invention a pour objet également un procédé de fabrication d’un tel dispositif. Figure pour l’abrégé : Fig.1.",COUSIN BIOTECH,SOLECKI GILLES;;OUERGHEMMI SAFA;;CAILLIBOTTE MICHEL,,https://lens.org/002-940-935-945-732,Patent Application,no,7,0,3,002-940-935-945-732;;053-980-496-867-926;;022-418-116-132-598,WO;;FR,3,022-418-116-132-598;;053-980-496-867-926;;002-940-935-945-732,WO;;FR,0,D04B21/12;;D04B21/04;;D10B2509/08;;A61F2002/0068,A61F2/00;;A61L27/50;;D04B21/00,,0,0,,,,PENDING
202,US,A1,US 2023/0045494 A1,022-553-777-332-361,2023-02-09,2023,US 202117792631 A,2021-02-25,EP 20305206 A;;EP 2021054744 W,2020-02-28,COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS,"The present invention concerns the combination of CTLA4 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-CTLA4 therapies.",OREGA BIOTECH,BONNEFOY NATHALIE;;BASTID JÉRÉMY;;BENSUSSAN ARMAND,OREGA BIOTECH (2022-07-05),https://lens.org/022-553-777-332-361,Patent Application,yes,3,0,4,165-047-073-231-97X;;022-553-777-332-361;;009-483-702-664-175;;116-429-825-164-359,JP;;EP;;WO;;US,4,165-047-073-231-97X;;022-553-777-332-361;;009-483-702-664-175;;116-429-825-164-359,JP;;EP;;WO;;US,0,C07K16/2818;;C07K16/244;;C07K2317/76;;C07K2317/24;;A61P35/00;;A61K2039/507;;A61K2039/545;;Y02A50/30;;A61P35/00;;C07K16/244;;C07K16/2818;;C07K2317/24;;C07K2317/76,C07K16/28;;A61P35/00;;C07K16/24,,4,2,006-411-089-705-773;;052-992-654-166-01X,10.1093/cid/cis275;;22474176;;pmc3404719;;pmc8992532;;35582566;;10.20517/cdr.2019.28,"Hersh et al, Clinical Infectious Diseases 2012;54(11 ):1677-8 (Year: 2012);;Costello et al. (Pancreat Disord Ther; Suppl 4; doi:10.4172/2165-7092.S4-002) (Year: 2013);;Fenton et al. (Cancer Drug Resist. 2019 Sep 19;2(3):744-761) (Year: 2019);;Liu et al. (Front Pharmacol. 2019 Feb 1:10:65) (Year: 2019)",PENDING
203,CN,A,CN 117043350 A,005-146-690-760-836,2023-11-10,2023,CN 202280013651 A,2022-02-04,KR 20210016012 A;;KR 2022001731 W,2021-02-04,Compositions comprising polysaccharides or extracts derived from lactobacillus plantarum,"The present invention relates to a composition comprising a polysaccharide or an extract derived from Lactobacillus plantarum, and more particularly, to a composition comprising a polysaccharide or an extract derived from Lactobacillus plantarum, as a result, it is possible to exhibit the effects of inhibiting inflammatory response, inhibiting adipogenesis, inhibiting intracellular glucose absorption, reducing insulin resistance, and alleviating hepatic fatty disease, and it is also possible to exhibit the effect of treating or preventing metabolic diseases.",NEORENAISSANCE BIOTECH,SEO JEONG-MIN;;LEE JAE-HOON,,https://lens.org/005-146-690-760-836,Patent Application,no,0,1,5,005-146-690-760-836;;029-815-409-073-468;;003-062-187-785-760;;189-472-759-321-468;;073-656-819-415-424,KR;;CN;;EP,10,026-134-353-184-739;;005-146-690-760-836;;147-815-073-378-708;;189-848-492-967-472;;073-656-819-415-424;;186-166-729-431-389;;189-472-759-321-468;;174-915-703-153-202;;029-815-409-073-468;;003-062-187-785-760,JP;;KR;;CN;;EP;;WO;;US,0,C12P19/04;;A23L33/135;;A23L33/125;;A23V2200/3262;;A23V2200/328;;A23V2200/332;;A23V2400/169;;A23V2200/324;;A61K35/747;;A61P3/00;;A61K35/747;;A61K31/7004;;A61P3/10;;A61P3/06;;A61P1/16;;A61P3/04;;A61P29/00;;A23L33/135;;A23V2002/00;;A23V2200/328;;A23V2200/3262;;A23V2200/332;;A23V2200/324;;A23V2400/169,C12P19/04,,0,0,,,,PENDING
204,PE,A1,PE 20241469 A1,051-382-287-611-008,2024-07-15,2024,PE 2021000451 A,2021-04-06,US 201862691319 P;;US 2019/0039878 W,2018-06-28,COMPOSICIONES FARMACEUTICAS Y METODOS PARA EL TRATAMIENTO DE LA TROMBOSIS Y ENTREGA MEDIANTE DISPOSITIVOS MEDICOS,"Se provee una composicion farmaceutica para el tratamiento de la trombosis. La composicion farmaceutica comprende una enzima proteolitica o una mezcla de enzimas proteoliticas, acetilsalicilato racemico de Lisini, y un excipiente farmaceuticamente aceptable. Ademas, el metodo incluye la administracion de la composicion farmaceutica a un trombo hasta que este se disuelva, asi como el uso de uno o mas cateteres de globo.",MARIZYME BIOTECH,HANDLEY MICHAEL K,,https://lens.org/051-382-287-611-008,Patent Application,no,0,0,11,051-382-287-611-008;;167-215-822-759-142;;183-488-193-693-681;;113-909-928-705-465;;128-633-861-675-942;;127-500-590-414-920;;170-810-794-749-231;;079-567-751-821-998;;004-868-784-372-613;;191-235-790-311-105;;066-411-304-959-220,CR;;JP;;AU;;CN;;EA;;EP;;WO;;CA;;BR;;PE,13,051-382-287-611-008;;128-633-861-675-942;;113-909-928-705-465;;183-488-193-693-681;;170-810-794-749-231;;074-210-751-277-44X;;004-868-784-372-613;;028-302-916-315-724;;066-411-304-959-220;;167-215-822-759-142;;127-500-590-414-920;;079-567-751-821-998;;191-235-790-311-105,CR;;JP;;AU;;EP;;CN;;EA;;WO;;US;;CA;;BR;;PE,0,A61B17/12136;;A61B17/12036;;A61B17/1204;;A61M2025/105;;A61M2025/1052;;A61K38/4806;;A61K38/4826;;C12Y304/21004;;C12Y304/21001;;A61K38/26;;A61K31/616,A61B17/12;;A61K38/43;;A61M25/10,,0,0,,,,PENDING
205,KR,A,KR 20220033000 A,067-885-163-952-391,2022-03-15,2022,KR 20210038909 A,2021-03-25,KR 20200114698 A,2020-09-08,PEPTIDE DERIVATIVE WITH COLLAGENASE INHIBITORY ACTIVITY AND USE THEREOF,"The present invention relates to a peptide derivative having a collagenase inhibitory activity or a use thereof, and has advantages of increasing percutaneous absorption, inhibiting collagenase activity, and alleviating wrinkles. Since the peptide derivative of the present invention is effective for wrinkle alleviation, there is the advantage that the peptide derivative can be widely used as a material in various fields such as the pharmaceutical industry, the food industry, and the cosmetic industry.",SUNMARINE BIOTECH,PARK SI HYANG;;HWANG SU YEON;;JUNG JAE EUN;;KIM YE RA,,https://lens.org/067-885-163-952-391,Patent Application,no,6,0,4,095-290-416-583-110;;003-407-118-310-930;;067-885-163-952-391;;127-632-859-398-287,KR;;WO;;US,4,095-290-416-583-110;;003-407-118-310-930;;067-885-163-952-391;;127-632-859-398-287,KR;;WO;;US,0,C07K5/0806;;A23L33/18;;A61K8/64;;A61K38/06;;A61Q19/08;;C07K5/0823;;C07K5/0806;;A23L33/18;;A23V2002/00;;A23V2200/318;;A61K8/64;;A61K38/06;;A61Q19/00;;C07K5/0806;;A23L33/18;;A61K8/64;;A61Q19/08,C07K5/083;;A23L33/18;;A61K8/64;;A61K38/06;;A61Q19/00,,0,0,,,,ACTIVE
206,EP,A1,EP 3912681 A1,086-603-296-213-93X,2021-11-24,2021,EP 21165971 A,2017-03-14,US 201662307606 P;;US 201662404780 P;;EP 17710894 A;;EP 2017056011 W,2016-03-14,ANTI-CD39 ANTIBODIES,"The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.",OREGA BIOTECH,GAUTHIER LAURENT;;PATUREL CARINE;;PERROT IVAN,,https://lens.org/086-603-296-213-93X,Patent Application,yes,11,0,5,189-017-350-252-853;;197-899-711-730-601;;160-156-667-026-122;;051-266-721-982-760;;086-603-296-213-93X,EP;;WO;;US,5,189-017-350-252-853;;197-899-711-730-601;;160-156-667-026-122;;051-266-721-982-760;;086-603-296-213-93X,EP;;WO;;US,35,C07K16/2896;;A61P35/00;;C07K16/30;;C07K16/40;;C07K2317/24;;C07K2317/33;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/94;;C07K16/2896;;A61P35/00;;C07K16/30;;C07K16/40;;C07K2317/24;;C07K2317/33;;C07K2317/41;;C07K2317/52;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/574,A61P35/00;;C07K16/28;;C07K16/30;;C07K16/40,,38,28,084-832-052-674-218;;012-615-164-896-584;;010-583-084-540-282;;022-866-678-832-587;;077-779-211-707-723;;032-820-729-763-323;;020-753-772-581-741;;030-630-100-818-462;;049-134-753-209-354;;117-139-548-093-070;;071-483-483-784-246;;066-141-497-990-023;;056-201-471-905-934;;023-671-461-261-193;;007-845-004-248-599;;007-875-147-167-216;;058-785-562-688-810;;106-913-361-572-38X;;064-154-489-632-47X;;158-507-543-443-389;;053-539-488-560-898;;023-387-459-517-550;;016-822-781-096-504;;101-311-338-877-580;;108-678-479-650-537;;052-291-047-965-424;;088-086-720-613-343;;019-268-737-620-851,pmc4485743;;10.1080/2162402x.2014.1003015;;26155397;;10.1158/2326-6066.cir-14-0018;;25403716;;24489992;;pmc3902223;;1286869;;10.1111/j.1600-065x.1992.tb01525.x;;10.1016/0076-6879(83)92046-3;;6190069;;10.1038/368856a0;;8159246;;10.1093/intimm/6.4.579;;8018598;;10.1038/348552a0;;2247164;;10.1016/0022-2836(87)90412-8;;3681981;;10.1016/j.molimm.2008.05.022;;18614234;;10.1016/0952-7915(93)90014-j;;8507403;;pmc321012;;6546423;;10.1093/nar/12.1part1.387;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;7602137;;10.1016/0022-1759(95)00021-2;;10.1006/abio.1998.3000;;10036128;;10.1021/ac012452f;;11354508;;10.1006/jmbi.1998.1930;;9680475;;8812707;;10.1006/meth.1996.0059;;10.1002/(sici)1096-9888(200004)35:4<493::aid-jms987>3.0.co;2-i;;10797646;;10.1021/ac9811120;;10330909;;7529940;;10.1126/science.7529940;;10.1038/355275a0;;1731227;;pmc4152847;;1710913;;10.1002/jmr.300030507;;7691860;;10.1016/s0021-9673(99)87017-4;;10.1002/(sici)1521-3773(19981217)37:23<3308::aid-anie3308>3.0.co;2-;;10.1002/(sici)1521-3773(19981217)37:23<3308::aid-anie3308>3.0.co;2-#;;29711422;;12392942;;10.1016/s0956-5663(02)00085-4;;19896358;;10.1016/j.copbio.2009.10.011;;18941257;;10.4049/jimmunol.181.9.6664,"NATHALIE BONNEFOY ET AL: ""CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression"", ONCOIMMUNOLOGY, vol. 4, no. 5, 3 February 2015 (2015-02-03), pages e1003015, XP055371480, DOI: 10.1080/2162402X.2014.1003015;;J. BASTID ET AL: ""Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity"", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 3, 17 November 2014 (2014-11-17), US, pages 254 - 265, XP055340441, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0018;;SEBASTIAN FM HÄUSLER ET AL: ""Original Article Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion"", AM J TRANSL RES, 1 January 2014 (2014-01-01), XP055252605, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902223/pdf/ajtr0006-0129.pdf>;;HAYES ET AL., AM. J. TRANSL. RES., vol. 7, no. 6, 2015, pages 1181 - 1188;;""Genbank"", Database accession no. P49961;;CARILLO ET AL., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073;;PLUCKTHUN, IMMUNOL., vol. 130, 1992, pages 151;;MULLER, METH. ENZYMOL., vol. 92, 1983, pages 589 - 601;;GREEN ET AL., NATURE GENET, vol. 7, 1994, pages 13;;LONBERG ET AL., NATURE, vol. 368, 1994, pages 856;;TAYLOR ET AL., INT IMMUN, vol. 6, 1994, pages 579;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 553;;KABAT ET AL.: ""Sequences of Protein of Immunological Interest"", 1991, UNITED STATES PUBLIC HEALTH SERVICE, NATIONAL INSTITUTE OF HEALTH;;CHOTHIALESK, J. MOL. BIOL, vol. 196, 1987, pages 901 - 917;;ABHINANDANMARTIN, MOLECULAR IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839;;SKERRA ET AL., CURR. OPINION IN IMMUNOL., vol. 5, 1993, pages 256;;""Computer Analysis of Sequence Data"", 1994, HUMANA PRESS;;VON HEINJE, G.: ""Sequence Analysis in Molecular Biology"", 1987, ACADEMIC PRESS;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 12, 1984, pages 387;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;SAUNAL, J. IMMUNOL. METHODS, vol. 183, 1995, pages 33 - 41;;EHRING H, ANALYTICAL BIOCHEMISTRY, vol. 267, no. 2, 1999, pages 252 - 259;;ENGEN, J. R.SMITH, D. L., ANAL. CHEM., vol. 73, 2001, pages 256A - 265A;;ERNST SCHERING RES FOUND WORKSHOP, vol. 44, 2004, pages 149 - 67;;HUANG ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 281, no. 1, 1998, pages 61 - 67;;SAITOPATTERSON, METHODS, vol. 9, no. 3, June 1996 (1996-06-01), pages 516 - 24;;DOWNARD, J MASS SPECTROM., vol. 35, no. 4, April 2000 (2000-04-01), pages 493 - 503;;KISELARDOWNARD, ANAL CHEM., vol. 71, no. 9, 1 May 1999 (1999-05-01), pages 1792 - 1801;;CLACKSONWELLS, SCIENCE, vol. 267, 1995, pages 383 - 386;;WELLS, PROC NATL ACAD SCI USA, vol. 93, 1996, pages 1 - 6;;WANG ET AL., NATURE, vol. 355, 1992, pages 275 - 278;;FAGERSTAM ET AL., JOURNAL OF MOLECULAR RECOGNITION, vol. 3, 1990, pages 208 - 14;;NICE ET AL., J. CHROMA-TOGR., vol. 646, 1993, pages 159 - 168;;LEIPERT ET AL., ANGEW. CHEM. INT. ED., vol. 37, 1998, pages 3308 - 3311;;KROGER ET AL., BIOSENSORS AND BIOELECTRONICS, vol. 17, 2002, pages 937 - 944;;STROHL, W., CURR. OPIN. BIOTECHNOL., vol. 20, no. 6, 2009, pages 685 - 691;;BAUDINO ET AL., J. IMMUNOL., vol. 181, 2008, pages 6664 - 69;;REMINGTON: ""The Science and Practice of Pharmacy"", 1995",DISCONTINUED
207,KR,A,KR 20240106889 A,134-444-839-594-075,2024-07-08,2024,KR 20230021385 A,2023-02-17,KR 20220189771 A,2022-12-29,Composition for preventing or treating obesity fatty liver and metabolic disease syndrome containing complex plant extracts as active ingredients,"본 발명은 산딸기 미숙과(unriped Rubus crataegifolius), 커피생두(Coffea arabica) 복합 추출물을 유효성분으로 함유하는 비만억제, 지방간억제 및 대사질환 증후군 억제의 예방 및 치료용 약학적 조성물 및 식품조성물에 관한 것이다. 상세하게, 복합 추출물은 체중, 지방 및 당내성도(FBG, PBG)를 감소시켜, 비만 억제 및 지방간을 예방, 억제 한다. 이러한 복합 추출물은 ALT, AST를 감소시키며, 중성지질(TG), 콜레스테롤(TC), LDL-콜레스테롤(LDL-C)을 감소키며, HDL-콜레스테롤(HDL-C)을 증가시킨다. 또한, 본 발명의 복합 추출물은 식욕조절 인자인 Leptin을 감소시키며, Adiponectin을 증가시키며, 지방산 합성 인자를 조절(FAS↓, HMG-GA↓ 및 CPT↑)하며, 혈액순환(Anticoagulant, Antiplatelet aggregation)을 촉진하여, 혈전 질환의 예방, 치료용으로 사용가능하여, 심장질환 억제에도 사용 가능하다. 상기와 같이 본 발명의 복합 추출물은 항비만, 항 지방간 및 대사증후군 예방·치료에 유용하게 사용할 수 있다.",LEES BIOTECH,LEE YOUNG IK;;LEE HUI JIN;;PYO SU JIN;;PARK YONG HYUN;;CHO JIN SOOK,,https://lens.org/134-444-839-594-075,Patent Application,no,0,0,1,134-444-839-594-075,KR,1,134-444-839-594-075,KR,0,A61K36/73;;A61P3/00;;A61P1/16;;A23L33/105;;A61K2300/00;;A23V2002/00;;A23V2200/332;;A61K36/742;;A23V2250/21;;A61K2236/33;;A23V2300/14,A61K36/73;;A23L33/105;;A61K36/74;;A61P1/16;;A61P3/00;;A61P3/04,,0,0,,,,DISCONTINUED
208,FR,A1,FR 3110074 A1,123-011-641-195-420,2021-11-19,2021,FR 2004780 A,2020-05-14,FR 2004780 A,2020-05-14,"Dispositif implantable, notamment de type espaceur intervertébral","La présente invention a pour objet un dispositif implantable (100) pour maintenir un écartement intervertébral entre des vertèbres, comprenant une cale intervertébrale (10) comprenant une zone supérieure d’appui et une zone inférieure d’appui, et au moins un premier ressort latéral (20) ayant une position A par rapport à la cale intervertébrale (10) dans une position d’introduction du dispositif implantable (100), et une position B par rapport à la cale intervertébrale (10) dans une position d’implantation du dispositif implantable, les positions A et B étant différentes, et le premier ressort latéral (20) est configuré :- pour passer de la position A à la position B librement, et - former un organe de retenue agencé par rapport à la cale intervertébrale (10) pour bloquer la migration de la cale intervertébrale (10) vers le canal rachidien au moins dans la position B. Figure pour l’abrégé: Fig.1.",COUSIN BIOTECH,HOFFMANN ELÉONORE;;BECQUART LUCIE;;CAILLIBOTTE MICHEL,,https://lens.org/123-011-641-195-420,Patent Application,no,6,0,8,049-681-138-955-067;;123-011-641-195-420;;119-331-982-537-853;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;052-804-849-360-014,EP;;ES;;WO;;US;;FR,8,049-681-138-955-067;;123-011-641-195-420;;052-804-849-360-014;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;119-331-982-537-853,EP;;ES;;WO;;US;;FR,0,A61B17/7053;;A61B17/7062;;A61B17/7064;;A61B17/7065;;A61B17/7067;;A61B17/7061;;A61B17/7065;;A61B17/7067,A61B17/70,,0,0,,,,PENDING
209,WO,A1,WO 2025/143714 A1,142-881-357-691-855,2025-07-03,2025,KR 2024020949 W,2024-12-23,KR 20230192582 A,2023-12-27,DIAGNOSTIC KIT FOR BOVINE DIARRHEA-CAUSING VIRUS,"The present invention relates to a diagnostic kit for bovine viral diarrhea virus (BVDV), which enables rapid on-site identification and diagnosis of BVDV1 and BVDV2, which are genotypes of the BVD virus that are pathogens causing bovine diarrhea, within a short time of approximately 15 minutes.",BOREDA BIOTECH,CHOI DONG OK;;PARK JIN-HO;;CHOI KYOUNG-SEONG,,https://lens.org/142-881-357-691-855,Patent Application,yes,0,0,2,001-327-221-425-960;;142-881-357-691-855,KR;;WO,2,001-327-221-425-960;;142-881-357-691-855,KR;;WO,6,A61K39/12;;G01N33/569;;C12N15/70;;C07K14/005;;A61P31/14,C07K14/005;;A61K39/12;;A61P31/14;;C12N15/70;;G01N33/569,,0,0,,,,PENDING
210,WO,A1,WO 2023/080765 A1,132-341-914-065-460,2023-05-11,2023,KR 2022095004 W,2022-01-04,KR 20210152376 A,2021-11-08,NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF,The present invention pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present invention can be used to treat NADPH oxidase (NOX)-related diseases through an excellent NOX inhibitory effect.,CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,,https://lens.org/132-341-914-065-460,Patent Application,yes,0,1,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,0,A61K31/4245;;A61K31/495;;A61K45/06;;A61P25/28;;A61P35/00;;C07D271/113;;C07D413/10;;C07D413/04;;C07D413/14;;C07D271/06;;C07D271/113;;A61K31/4245;;A61P25/00;;C07D413/10;;A61P35/00;;A61K31/4245;;A61K45/06;;C07D271/113;;C07D413/10,C07D271/113;;A61K31/4245;;A61K31/495;;A61K45/06;;A61P25/28;;A61P35/00;;C07D413/10,,6,4,120-845-305-090-752;;041-110-357-764-164;;042-259-155-400-540;;032-661-789-346-710,24563256;;pmc3965630;;10.4049/jimmunol.1303049;;10.1016/j.bmcl.2016.04.058;;27156770;;pmc4888807;;pmc6310635;;30472604;;10.1016/j.ejmech.2018.11.036;;21075637;;10.1016/j.bmc.2010.10.036,"BOSHTA NADER M.; ELGAMAL ENAS A.; EL-SAYED IBRAHIM E.: ""Bioactive amide andα-aminophosphonate inhibitors for methicillin-resistantStaphylococcus aureus(MRSA)"", MONATSHEFTE FÜR CHEMIE - CHEMICAL MONTHLY, SPRINGER VIENNA, VIENNA, vol. 149, no. 12, 16 October 2018 (2018-10-16), Vienna, pages 2349 - 2358, XP036634492, ISSN: 0026-9247, DOI: 10.1007/s00706-018-2303-y;;SUN KEER, METZGER DENNIS W.: ""Influenza Infection Suppresses NADPH Oxidase–Dependent Phagocytic Bacterial Clearance and Enhances Susceptibility to Secondary Methicillin-Resistant Staphylococcus aureus Infection"", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 192, no. 7, 1 April 2014 (2014-04-01), US , pages 3301 - 3307, XP093063560, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1303049;;MOCHONA BEREKET; QI XIN; EUYNNI SURESH; SIKAZWI DONALD; MATEEVA NELLY; SOLIMAN KARAM F.: ""Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 26, no. 12, 21 April 2016 (2016-04-21), Amsterdam NL , pages 2847 - 2851, XP029557110, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2016.04.058;;KAUR JATINDER; SOTO-VELASQUEZ MONICA; DING ZHONG; GHANBARPOUR AHMADREZA; LILL MARKUS A.; VAN RIJN RICHARD M.; WATTS VAL J.; FLAHER: ""Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 162, 2019, AMSTERDAM, NL , pages 568 - 585, XP085568970, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.11.036;;CHENG, T.J.R. ; WU, Y.T. ; YANG, S.T. ; LO, K.H. ; CHEN, S.K. ; CHEN, Y.H. ; HUANG, W.I. ; YUAN, C.H. ; GUO, C.W. ; HUANG, L.Y. ; : ""High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase"", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 24, 15 December 2010 (2010-12-15), AMSTERDAM, NL, pages 8512 - 8529, XP027524846, ISSN: 0968-0896;;""Remington's Pharmaceutical Science"", MACK PUBLISHING COMPANY",PENDING
211,US,A1,US 2024/0390479 A1,181-480-637-787-293,2024-11-28,2024,US 202418794478 A,2024-08-05,US 202418794478 A;;US 202318140326 A;;US 202263336464 P,2022-04-29,TAIL-CONJUGATED RNAS,"Tail-tail RNA conjugates translatable by eukaryotic ribosomes, and pharmaceutically acceptable compositions including the same are provided. Methods for preparing such molecules, using them for treating and preventing diseases are described. In addition, processes for producing desired polypeptides using the molecules are also described.",TIBA BIOTECH,CHAHAL JASDAVE S;;MCPARTLAN JUSTINE S,,https://lens.org/181-480-637-787-293,Patent Application,yes,0,0,1,181-480-637-787-293,US,4,181-480-637-787-293;;150-767-732-294-917;;162-792-275-011-351;;069-398-973-008-292,WO;;US,0,A61K38/195;;C07K14/523;;C12P19/34;;C07K14/005;;C12N2760/16134;;A61K39/12;;A61K2039/53;;A61K39/145;;C12P19/34;;C07K14/005;;C07K14/523;;A61K38/195,A61K39/145;;A61K38/19;;C07K14/005;;C07K14/52;;C12P19/34,,0,0,,,,PENDING
212,US,A1,US 2025/0205033 A1,186-405-819-895-457,2025-06-26,2025,US 202418987116 A,2024-12-19,FR 2314790 A,2023-12-21,"Method for inducing an improvement in the mechanical strength of an implantable device comprising one or more yarns of PLA at the end of a determined hydrolysis, and implantable device which can be obtained by said method","The present disclosure relates to a method for inducing an improvement in the mechanical strength (N/cm) of an implantable device after a determined period of hydrolysis. The method includes a step of providing an implantable device that has one or more yarns comprising at least one lactic acid (co)polymer; a step of treating the implantable device with supercritical carbon dioxide (CO2); and a step of obtaining an implantable device having a mechanical strength greater than or equal to 10 N/cm, preferably greater than or equal to 25 N/cm, after 20 weeks of hydrolysis, in particular in an aqueous medium. The present disclosure also relates to an implantable device that can be obtained by the method, and the use of supercritical (CO2) for inducing an improvement in the mechanical strength of an implantable device comprising one or more yarns comprising a lactic acid (co)polymer.",COUSIN BIOTECH,SOLECKI GILLES;;OUERGHEMMI SAFA,COUSIN BIOTECH (2025-01-06),https://lens.org/186-405-819-895-457,Patent Application,yes,0,0,3,156-424-704-733-269;;068-034-657-178-990;;186-405-819-895-457,EP;;US;;FR,3,156-424-704-733-269;;068-034-657-178-990;;186-405-819-895-457,EP;;US;;FR,0,A61L27/58;;A61L27/18;;A61L2400/18;;A61F2/0063;;C08G63/08;;D01F6/625;;A61F2/0063;;A61F2002/0068;;A61F2210/0004;;A61F2240/001,A61F2/00,,0,0,,,,PENDING
213,EP,A1,EP 4149376 A1,047-899-447-872-248,2023-03-22,2023,EP 21724311 A,2021-05-11,FR 2004780 A;;FR 2100980 A;;EP 2021062514 W,2020-05-14,"IMPLANTABLE DEVICE, IN PARTICULAR OF THE INTERVERTEBRAL SPACER TYPE",,COUSIN BIOTECH,HOFFMANN ELÉONORE;;BECQUART LUCIE;;CAILLIBOTTE MICHEL,COUSIN BIOTECH (2024-11-13),https://lens.org/047-899-447-872-248,Patent Application,yes,0,2,8,049-681-138-955-067;;123-011-641-195-420;;119-331-982-537-853;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;052-804-849-360-014,EP;;ES;;WO;;US;;FR,8,049-681-138-955-067;;123-011-641-195-420;;052-804-849-360-014;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;119-331-982-537-853,EP;;ES;;WO;;US;;FR,0,A61B17/7053;;A61B17/7062;;A61B17/7064;;A61B17/7065;;A61B17/7067;;A61B17/7061;;A61B17/7065;;A61B17/7067,A61B17/70,,0,0,,,,ACTIVE
214,EP,A1,EP 3818980 A1,077-967-932-310-425,2021-05-12,2021,EP 19830345 A,2019-07-04,KR 20180078585 A;;KR 20190080244 A;;KR 2019008235 W,2018-07-06,PHARMACEUTICAL COMPOSITION COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT,"The present disclosure relates to a composition for preventing or treating wound. The composition according to the present disclosure contains, as an active ingredient, an indirubin derivative alone or one or more selected from a group consisting of an indirubin derivative, an Euodia sutchuenensis Dode extract, methyl vanillate, hesperidin and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring not only in a normal state but also in a diabetic state. Furthermore, since the composition exhibits excellent effects in healing diabetic wound as well as general wound, it can be usefully used as a pharmaceutical composition, cosmetic composition or food composition for alleviating, preventing or treating general wound or diabetic wound, or as a veterinary composition for treating diabetic wound.",CK BIOTECH,CHOI KANG-YELL;;KIM EUNHWAN;;SEO SEOL HWA;;YOON MINGUEN,CK REGEON INC. (2025-02-26),https://lens.org/077-967-932-310-425,Patent Application,yes,0,0,10,100-574-593-464-511;;010-723-737-446-421;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;070-530-775-976-218;;097-170-205-131-938;;112-312-169-379-233;;152-346-690-972-536;;146-551-039-853-613,CN;;EP;;WO;;US,14,100-574-593-464-511;;010-723-737-446-421;;143-789-168-119-782;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;097-170-205-131-938;;152-346-690-972-536;;156-171-049-575-889;;061-609-337-961-572;;070-530-775-976-218;;112-312-169-379-233;;016-089-837-812-567;;146-551-039-853-613,KR;;CN;;EP;;WO;;US,0,A61P17/02;;A61Q19/00;;A61K31/404;;A61K31/7048;;A23L33/10;;A61K8/492;;A61K36/754;;A23K20/137;;A23K20/111;;A23K10/30;;A23K20/163;;A23K20/121;;A61K9/107;;A61K45/06;;A61K31/216;;A23L33/105;;A23L33/40;;A61K8/9789;;A61P17/02;;A23V2002/00;;A61K8/06;;A61K8/345;;A61K8/37;;A61K8/492;;A61K8/602;;A61K8/604;;A61K8/738;;A61K8/922;;A61K9/0014;;A61K9/0056;;A61K9/06;;A61K9/107;;A61K31/235;;A61K31/404;;A61K31/7048;;A61K36/754;;A61K47/10;;A61K47/26;;A61K47/40;;A61K47/44;;A61Q19/00;;C07D403/04,A61K31/404;;A23L33/10;;A61K8/49;;A61K8/60;;A61K8/9789;;A61K31/7048;;A61K36/75;;A61P17/02;;A61Q19/00,,0,0,,,,ACTIVE
215,EP,A1,EP 3784304 A1,139-461-547-392-590,2021-03-03,2021,EP 19720975 A,2019-04-05,FR 1853737 A;;FR 2019050803 W,2018-04-27,IMPLANTABLE DEVICE COMPRISING A TEXTILE COMPONENT COMPRISING MULTIFILAMENT THREADS AND/OR SPUN THREADS MADE OF FIBERS COMPLETELY OR PARTIALLY COATED IN CYCLODEXTRIN POLYMER,,COUSIN BIOTECH,VERMET GUILLAUME;;MARTEL BERNARD;;BLANCHEMAIN NICOLAS;;DEGOUTIN STÉPHANIE,,https://lens.org/139-461-547-392-590,Patent Application,yes,0,0,7,053-308-548-907-374;;112-913-282-239-076;;139-461-547-392-590;;187-182-390-874-290;;064-793-778-008-949;;119-792-058-090-103;;197-537-156-836-512,ES;;EP;;WO;;US;;FR,7,053-308-548-907-374;;112-913-282-239-076;;139-461-547-392-590;;187-182-390-874-290;;064-793-778-008-949;;119-792-058-090-103;;197-537-156-836-512,ES;;EP;;WO;;US;;FR,0,A61L27/54;;C08L5/16;;C09D105/16;;A61L27/34;;A61L27/16;;A61L27/54;;A61L2300/402;;A61L2300/406;;A61L2420/02;;A61L2420/06;;C08L5/16;;D01F8/14;;D01F8/16;;D02G3/045;;D02G3/448,A61L27/54;;C08L5/16,,1,0,,,See references of WO 2019207227A1,ACTIVE
216,US,A1,US 2022/0017880 A1,031-378-032-288-299,2022-01-20,2022,US 202117229653 A,2021-04-13,CN 202010687851 A,2020-07-16,HIGH-FIDELITY POLYMERASE WITH PREFERENCE FOR GAPPED DNA AND USE THEREOF,"The disclosure provides a high-fidelity polymerase with preference for gapped DNA and use thereof. The Klenow fragment (KlenDr) derived from Deinococcus radiodurans DNA polymerase I, which has the high-fidelity polymerization characteristics, is independent of 3′-5′ proofreading exonuclease activity, has the preference for binding gapped DNA, and is different from the existing commercial high-fidelity polymerase. Due to the specific affinity of KlenDr to gapped DNA substrate, the 3′ end of the forward primer will not be cut off, and the downstream nucleotide chain is rarely replaced.",UNIV ZHEJIANG,HUA YUEJIN;;ZHOU XINGRU;;WANG LIANGYAN;;CHEN XUANYI,ZHEJIANG UNIVERSITY (2021-03-19),https://lens.org/031-378-032-288-299,Patent Application,yes,2,0,4,005-767-157-063-321;;141-846-571-459-037;;031-378-032-288-299;;193-126-760-886-813,CN;;US,4,005-767-157-063-321;;141-846-571-459-037;;031-378-032-288-299;;193-126-760-886-813,CN;;US,8,C12N9/1252;;C12P19/34;;C12Q1/6806;;C12Y207/07007;;C40B50/06;;C12N9/1252;;C12Q1/6844;;C12Y207/07007;;C12N9/1252;;C07K14/195;;C12Q1/6844,C12N9/12;;C07K14/195;;C12Q1/6844,,4,1,072-370-062-059-009,15994074;;10.1016/j.copbio.2005.06.004,"Chica et al. Curr Opin Biotechnol. 2005 Aug;16(4):378-84. (Year: 2005);;Singh et al. Curr Protein Pept Sci. 2017, 18, 1-11 (Year: 2017);;Accession P52027. 01-OCT-1996 (Year: 1996);;Accession BDD80092. 06-OCT-2016 (Year: 2018)",ACTIVE
217,WO,A1,WO 2022/157500 A1,072-841-812-650-34X,2022-07-28,2022,GB 2022050158 W,2022-01-20,GB 202100754 A;;GB 202116519 A,2021-01-20,METHODS FOR HIGH THROUGHPUT SCREENING OF CHIMERIC ANTIGEN RECEPTORS,"A method for high-throughput screening of a chimeric antigen receptor (CAR) cell library is provided comprising the steps of (a) providing a recognition sequence library, a hinge region sequence library, a transmembrane sequence library and an intracellular domain sequence library; (b) preparing a CAR library; (c) preparing a CAR-cell library by introduction to, and expression of, the plurality of CAR sequences of the CAR library in one or more cells or a cell line; (d) screening the CAR-cell library in an assay; (e) evaluating the at least one function of each member of the CAR-cell library; (f) obtaining one or more sequences of one or more CARs expressed in the CAR-cell library and linking the obtained sequence(s) to the at least one function of the members of the CAR-cell library; g) identifying and selecting the or each sequence based on function. Methods of preparing the CAR library and a CAR-cell library and uses thereof are also provided.",CODING BIO LTD,BORNSCHEIN SIMON;;LAMPI YOULIA,,https://lens.org/072-841-812-650-34X,Patent Application,yes,8,4,4,140-278-679-095-571;;072-841-812-650-34X;;087-647-117-405-022;;031-120-515-454-417,EP;;WO;;US;;CA,6,140-278-679-095-571;;072-841-812-650-34X;;053-129-622-717-832;;072-773-859-805-124;;087-647-117-405-022;;031-120-515-454-417,EP;;WO;;US;;CA;;GB,0,C07K14/7051;;C12N5/0636;;C12N2510/00;;G01N33/505;;G01N33/56972;;G01N33/6845;;C07K2319/00;;C07K2319/03;;C07K2319/33;;C12N2740/16043;;A61K2239/28;;A61K40/11;;A61K40/31;;A61K40/4215;;C12N15/1037;;C12N15/1055;;G01N33/6845;;A61K2239/28;;C12N5/0636;;A61K40/11;;A61K40/31;;A61K40/4215,C12N15/85,,16,12,085-886-833-194-081;;027-552-012-139-76X;;044-580-881-421-913;;098-491-388-193-819;;087-158-345-650-030;;014-161-213-709-781;;061-725-825-847-427;;142-730-526-162-199;;023-411-430-607-883;;074-817-300-512-106;;013-323-148-570-367;;132-196-672-668-454,31272471;;10.1186/s13045-019-0763-0;;pmc6610960;;23550147;;10.1158/2159-8290.cd-12-0548;;pmc3667586;;31477906;;10.1038/s41591-019-0549-5;;pmc3804130;;10.1158/1078-0432.ccr-13-0330;;23620405;;32739874;;10.1016/j.ebiom.2020.102931;;pmc7393540;;10.1158/0008-5472.can-15-0159;;pmc4560113;;26330166;;10.1038/s41419-019-1711-1;;31209210;;pmc6572851;;18453625;;10.4049/jimmunol.180.10.7028;;pmc2585549;;pmc7704745;;32827460;;10.1016/j.ymthe.2020.08.003;;2677748;;10.1038/341544a0;;10.1016/j.tibtech.2003.08.007;;14573361;;10.1517/14712598.5.1.111;;15709914,"LIU DELONG ET AL: ""Engineering switchable and programmable universal CARs for CAR T therapy"", vol. 12, no. 1, 4 July 2019 (2019-07-04), pages 1 - 9, XP055772193, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s13045-019-0763-0/fulltext.html> DOI: 10.1186/s13045-019-0763-0;;KÖKSAL HAKAN ET AL: ""Abstract"", vol. 2, no. 2, 5 April 2019 (2019-04-05), pages 56 - 63, XP055847791, Retrieved from the Internet <URL:https://academic.oup.com/abt/article-pdf/2/2/56/35906335/tbz007.pdf> DOI: 10.1093/abt/tbz007;;M. SADELAIN ET AL: ""The Basic Principles of Chimeric Antigen Receptor Design"", CANCER DISCOVERY, vol. 3, no. 4, 1 April 2013 (2013-04-01), US, pages 388 - 398, XP055287277, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0548;;GHORASHIAN, S.KRAMER, A. M.ONUOHA, S.WRIGHT, G.BARTRAM, J.RICHARDSON, R. ET AL.: ""Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR"", NATURE MEDICINE, 2019, Retrieved from the Internet <URL:https://doi.org/10.1038/s41591-019-0549-5>;;HUDECEK, M., LUPO-STANGHELLINI, M. T., KOSASIH, P. L., SOMMERMEYER, D., JENSEN, M. C., RADER, C., RIDDELL, S. R.: "" Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells"", CLINICAL CANCER RESEARCH, 2013, Retrieved from the Internet <URL:https://doi.org/10.1158/1078-0432.CCR-13-0330>;;""CAR-T design: Elements and their synergistic function"", EBIOMEDICINE, vol. 58, August 2020 (2020-08-01), pages 102931;;LIU, X.JIANG, S.FANG, C.YANG, S.OLALERE, D.PEQUIGNOT, E. C. ET AL.: ""Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice"", CANCER RESEARCH, 2015, Retrieved from the Internet <URL:https://doi.org/10.1158/0008-5472.CAN-15-0159>;;ZHANG, Z.JIANG, D.YANG, H.HE, Z.LIU, X.QIN, W. ET AL.: ""Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor"", CELL DEATH AND DISEASE, 2019, Retrieved from the Internet <URL:https://doi.org/10.1038/s41419-019-1711-1>;;JAMES, S. E., GREENBERG, P. D., JENSEN, M. C., LIN, Y., WANG, J., TILL, B. G., PRESS, O. W.: ""Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane"", THE JOURNAL OF IMMUNOLOGY, 2008, Retrieved from the Internet <URL:https://doi.org/10.4049/jimmunol.180.10.7028>;;DI ROBERTO, R. B. ET AL.: ""A functional Screening strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation"", MOLECULAR THERAPY, vol. 28, no. 12, pages 2564 - 2576;;LIU DELONG ET AL., J. HEMATOLOGY & ONCOLOGY, vol. 12, 2019, pages 1;;GREENSAMBROOK: ""Molecular Cloning: A Laboratory Manual"", 2012, COLD SPRING HARBOR LABORATORY PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 2016, JOHN WILEY & SONS;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;HOLT ET AL., TRENDS BIOTECHNOL, vol. 21, no. 11, November 2003 (2003-11-01), pages 484 - 90;;REVETS ET AL., EXPERT OPIN BIOL THER, vol. 5, no. 1, January 2005 (2005-01-01), pages 111 - 24",PENDING
218,KR,A,KR 20210072212 A,019-180-994-615-467,2021-06-17,2021,KR 20190161841 A,2019-12-06,KR 20190161841 A,2019-12-06,Enrichment and extraction method of nucleic acid for detecting foodborne pathogenic bacteria in food,"The present invention relates to a nucleic acid extraction method for detecting food poisoning bacteria, which comprises the following steps: (a) adding an enrichment medium to a sample and performing cultivation to acquire an enrichment solution; (b) adding a lysis buffer to a pellet acquired by first centrifuging the enrichment solution and performing incubation to acquire a lysate; (c) removing flow-through by putting the lysate in a column and performing a second centrifugation; (d) adding a washing buffer to the lysate from which the flow-through has been removed after the second centrifugation and performing a third centrifugation to remove the flow-through; and (e) adding an elution buffer to the lysate from which the flow-through is removed after the third centrifugation and performing a fourth centrifugation to extract nucleic acids. According to the present invention, the nucleic acid extraction method for detecting food poisoning bacteria, particularly Listeria monocytogenes, commonly found in meat or processed meat products simplifies an extraction step, shortens an extraction time in comparison with the existing commercialized nucleic acid extraction method and does not use enzymes so that it is not required to adjust the optimum temperature for the enzymes, thereby performing nucleic acid extraction with high purity and yield at room temperature.",BOREDA BIOTECH,YOHAN YOON;;JEEYEON LEE;;YEONGEUN SEO;;YUNA CHOI,,https://lens.org/019-180-994-615-467,Patent Application,no,2,0,2,019-180-994-615-467;;129-974-548-270-473,KR,2,019-180-994-615-467;;129-974-548-270-473,KR,0,C12Q1/6806;;C12N15/1003,C12Q1/6806;;C12N15/10,,0,0,,,,ACTIVE
219,CA,A1,CA 3141365 A1,035-920-971-458-658,2020-12-17,2020,CA 3141365 A,2020-06-09,FR 1906208 A;;FR 2020050975 W,2019-06-11,COMBINATION OF MARKERS FOR PREDICTING THE RESPONSE TO VX-001,"The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids - native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.",VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS (KOSTAS);;MENEZ-JAMET JEANNE,,https://lens.org/035-920-971-458-658,Patent Application,no,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,0,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/00;;A61K39/395;;A61P35/00;;G01N33/50,,0,0,,,,PENDING
220,KR,A,KR 20230062182 A,060-565-405-781-402,2023-05-09,2023,KR 20210147186 A,2021-10-29,KR 20210147186 A,2021-10-29,Functional Clothing With Improved Moisture Absorption And Drying Function,"The present invention relates to functional clothing with improved cool sensation, capable of quickly absorbing sweat and heat generated from the skin surface and discharging the absorbed sweat and heat to the outside, thereby allowing a user to feel cool sensation. Accordingly, the functional clothing comprises: an elastic fabric part which absorbs and discharges sweat; and a plurality of cooling parts, in which a water repellent containing fluoroalkyl acrylate copolymer, tripropylene glycol, and polyoxyethylene glycol alkyl ether is mixed with a heat absorbing material which absorbs heat by including polyoxymethylene melamine, styrene maleic anhydride monomethyl maleate polymer, and a phase change material, and which are arranged at regular intervals on one surface of the fabric part.",K BIOTECH,PARK JUN HO,,https://lens.org/060-565-405-781-402,Patent Application,no,5,0,2,060-565-405-781-402;;122-843-834-187-537,KR,2,060-565-405-781-402;;122-843-834-187-537,KR,0,A41D31/18;;A41D31/12;;D06M15/277;;D06M15/53;;D06M15/423;;D06M2200/12;;D10B2401/021,A41D31/18;;A41D31/12;;D06M15/277;;D06M15/423;;D06M15/53,,0,0,,,,ACTIVE
221,WO,A1,WO 2022/207890 A1,064-690-104-175-773,2022-10-06,2022,EP 2022058725 W,2022-03-31,FR 2103428 A;;FR 2105705 A;;FR 2108249 A,2021-04-02,"DEVICE FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLE, FOR EXAMPLE A SALIVARY BIOLOGICAL SAMPLE","The present invention relates to a device for rapid analysis of a biological sample, for example a salivary biological sample, intended for detecting the presence of at least one analyte in the biological sample. The rapid analysis device (1) comprises: a sampling member (2) for collecting the biological sample; and a housing (3) which comprises a location (31) for receiving a chromatographic strip (7) and an interface (32), adapted to receive the sampling member (2) in an assembled final configuration. The sampling member (2) and the interface (32) comprise sealed-assembly means (5) comprising guide means (6) which are structured to guide a relative movement of the sampling member (2) in relation to the interface (32) from an initial positioning configuration to the assembled final configuration, the relative movement comprising two movements: a relative translation movement, intended to apply compression to the absorbent block (21); and a relative rotational movement, intended to apply torsion to the absorbent block (21).",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/064-690-104-175-773,Patent Application,yes,5,0,1,064-690-104-175-773,WO,4,064-690-104-175-773;;017-608-966-926-024;;054-640-202-927-803;;057-060-284-581-620,WO;;FR,0,G01N33/54388;;A61B10/0051;;B01L3/5023;;B01L3/5029;;B01L9/52;;B01L2200/027;;B01L2300/0825,G01N33/543;;A61B10/00;;B01L3/00,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",PENDING
222,MX,A,MX 2021015239 A,101-129-685-353-481,2022-04-06,2022,MX 2021015239 A,2020-06-09,FR 1906208 A;;FR 2020050975 W,2019-06-11,COMBINATION OF MARKERS FOR PREDICTING THE RESPONSE TO VX-001.,"The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids - native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.",VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS ( KOSTAS );;MENEZ-JAMET JEANNE,,https://lens.org/101-129-685-353-481,Patent Application,no,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,0,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/395;;A61P35/00;;G01N33/50,,0,0,,,,PENDING
223,US,A1,US 2023/0312643 A1,095-290-416-583-110,2023-10-05,2023,US 202018025167 A,2020-12-30,KR 20200114698 A;;KR 2020019459 W,2020-09-08,"PEPTIDE DERIVATIVE WITH COLLAGENASE INHIBITORY ACTIVITY, AND USE THEREOF","The present invention relates to a peptide derivative, having collagenase inhibitory activity, or a use thereof and has the effects of increasing a percutaneous absorption rate, inhibiting collagenase activity, and reducing wrinkles.",SUNMARINE BIOTECH,PARK SI HYANG;;HWANG SU YEON;;JUNG JAE EUN;;KIM YE RA,SUNMARINE BIOTECH (2023-03-07),https://lens.org/095-290-416-583-110,Patent Application,yes,0,0,4,095-290-416-583-110;;003-407-118-310-930;;067-885-163-952-391;;127-632-859-398-287,KR;;WO;;US,4,095-290-416-583-110;;003-407-118-310-930;;067-885-163-952-391;;127-632-859-398-287,KR;;WO;;US,0,C07K5/0806;;A23L33/18;;A61K8/64;;A61K38/06;;A61Q19/08;;C07K5/0823;;C07K5/0806;;A23L33/18;;A23V2002/00;;A23V2200/318;;A61K8/64;;A61K38/06;;A61Q19/00;;C07K5/0806;;A23L33/18;;A61K8/64;;A61Q19/08,C07K5/083;;A61Q19/08,,0,0,,,,PENDING
224,KR,A,KR 20220037178 A,114-198-310-741-69X,2022-03-24,2022,KR 20200119811 A,2020-09-17,KR 20200119811 A,2020-09-17,Cosmetic composition for improving inflammation containing oyster-derived peptides,"The present invention relates to a cosmetic composition containing oyster-derived peptides for mitigating inflammation and, more specifically, to a cosmetic composition containing oyster-derived peptides for mitigating inflammation, which contains an oyster-derived PGN peptide represented by the formula 1 or a derivative thereof as an active ingredient. According to the present invention, since the cosmetic composition includes an oyster-derived PGN peptide or a derivative thereof as an active ingredient to exhibit NO inhibitory activity and PEG2 production inhibitory activity, skin inflammatory response induced by various stimulating factors including fine dust and air pollution can be mitigated, thereby providing an effect of being usefully applied as an anti-inflammatory or anti-pollution cosmetic.",SUNMARINE BIOTECH,PARK SI HYANG;;HWANG SU YEON;;JUNG JAE EUN;;KIM YE RA,,https://lens.org/114-198-310-741-69X,Patent Application,no,5,0,3,175-876-550-450-181;;149-460-081-025-331;;114-198-310-741-69X,KR;;WO,3,175-876-550-450-181;;149-460-081-025-331;;114-198-310-741-69X,KR;;WO,0,A61K8/64;;A61K8/98;;A61Q19/00;;A61K8/987;;A61K8/64;;A61K2800/522;;A61Q19/00,A61K8/98;;A61K8/64;;A61Q19/00,,1,1,130-866-956-943-435,12403191,"1. Pothikamjorn SL, Ruxrungtham K, Thampanitchawong P, Fuangthong R, Srasuebkul P, Sangahsapaviriyah A, et al. Impact of particulate air pollutants on allergic diseases, allergic skin reactivity and lung function. Asian Pac J Allergy Immunol 2002;20:77-83.",ACTIVE
225,KR,A,KR 20220126387 A,122-985-227-872-245,2022-09-16,2022,KR 20210030564 A,2021-03-09,KR 20210030564 A,2021-03-09,Rubus Genus Crataegus Genus Cinnamomum Genus Pharmaceutical composition comprising Rubus Crataegus and Cinnamomum Genus extracts for prevention or treatment of metabolic syndrome,"A composite extract of a Rubus genus extract, a Crataegus genus extract and/or a Cinnamomum genus extract of the present invention, compared to a single extract, in an obese animal model, significantly reduces food intake, dietary hormones and leptin, and significantly increases adiponectin, thereby reducing body weight and body fat weight, reducing liver weight and AST and ALT levels, which are liver enzymes, reducing hepatic lipid and a size and number of fat globules in fatty liver tissue, and significantly reducing activity of enzymes related to liver lipid metabolism. In addition, the composite extract shows effects of significantly increasing beta-oxidation-related CPT activity, lowering blood sugar, overcoming glucose tolerance, inhibiting blood coagulation and platelet aggregation, and significantly inhibiting arteriosclerosis, to be usefully used for preventing, treating, or alleviating metabolic syndrome diseases.",LEES BIOTECH,LEE YOUNG IK;;NAM MI KYUNG;;AHTESHAM HUSSAIN;;CHO JIN SOOK;;LEE HYE BIN,,https://lens.org/122-985-227-872-245,Patent Application,no,1,1,1,122-985-227-872-245,KR,1,122-985-227-872-245,KR,0,A61K36/73;;A23L33/105;;A23V2002/00;;A23V2200/326;;A23V2200/328;;A61K36/54;;A61K36/734;;A61K2300/00;;A61P3/00;;A61P3/10;;A61P7/02,A61K36/73;;A23L33/105;;A61K36/54;;A61K36/734;;A61P3/00;;A61P3/10;;A61P7/02,,0,0,,,,DISCONTINUED
226,WO,A1,WO 2022/054029 A1,154-571-988-495-799,2022-03-17,2022,IB 2021058373 W,2021-09-14,US 202063078274 P,2020-09-14,"SH3YL1 ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF","The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.",CELROS BIOTECH,BAE YUN SOO;;AN EUNJUNG;;YOO JUNG-YEON;;SHIM HYUNBO;;LEE HYE EUN,,https://lens.org/154-571-988-495-799,Patent Application,yes,4,1,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,100,C07K16/3053;;C07K16/18;;C07K2317/622;;C07K2317/92;;G01N33/532;;G01N33/533;;C07K2317/21;;A61P13/12;;A61P1/16;;C07K16/18;;A61P1/16;;A61P13/12;;G01N33/563;;C07K2317/622;;C07K2317/565;;C07K2317/92;;A61K2039/505;;C07K16/18;;G01N33/6854;;A61P1/16;;A61P13/12;;A61K2039/505;;C07K2317/52;;C07K2317/624;;C07K2317/622;;C07K2317/55;;C07K2317/565,C07K16/18;;A61K39/00;;A61P1/16;;A61P13/12;;A61P29/00;;A61P37/00,,1,1,032-108-321-872-359,10.1016/s0923-1811(02)00140-8;;12615363,"SHIMOMURA YUTAKA, AOKI NORIAKI, ITO KAORU, ITO MASAAKI: ""Gene expression of Sh3d19, a novel adaptor protein with five Src homology 3 domains, in anagen mouse hair follicles"", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 31, no. 1, 1 February 2003 (2003-02-01), AMSTERDAM, NL , pages 43 - 51, XP055911343, ISSN: 0923-1811, DOI: 10.1016/S0923-1811(02)00140-8",PENDING
227,US,A1,US 2024/0349717 A1,061-368-949-232-149,2024-10-24,2024,US 202418584399 A,2024-02-22,US 202418584399 A;;US 202318136419 A,2023-04-19,CRYOPRESERVATION DEVICE WITH INTEGRATED TRACKING DEVICE CHAMBER,The present invention provides a cryopreservation device with an integrated tracking device chamber. The tracking device can be an RFID tag which can be placed in the cryopreservation device as part of the procedure for vitrification of a biological specimen. The cryopreservation device maintains its integrity and keeps the RFID tag securely in the chamber at both ambient conditions when the specimen is collected and under liquid nitrogen where the specimen is stored. The cryopreservation device with an integrated tracking device chamber allows for each individual biological sample to have its own tracking device for monitoring during cryogenic storage.,BIOTECH INC,PARRA-ALMANZA JORGE E,BIOTECH INC (2023-04-18),https://lens.org/061-368-949-232-149,Patent Application,yes,4,0,6,170-381-455-868-719;;061-368-949-232-149;;131-163-295-300-269;;118-651-602-690-001;;016-237-892-665-506;;117-296-648-200-709,AR;;CL;;WO;;US,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,G06K19/0723;;A01N1/147;;G06K19/0723;;A01N1/146,A01N1/02;;G06K19/07,,0,0,,,,ACTIVE
228,US,A1,US 2022/0354554 A1,162-607-064-867-160,2022-11-10,2022,US 202017763247 A,2020-09-22,FR 1910501 A;;EP 2020076426 W,2019-09-24,A STRAPPING DEVICE FOR STABILISING A PERIPROSTHETIC FRACTURE,"The present disclosure relates to an implantable strapping device comprising an elongate hollow textile element comprising an attachment portion and an adjustable loop, the perimeter of the adjustable loop is adjustable by sliding a portion of the adjustable loop in an interior volume of a sleeve arranged in the textile element, and a strapping closing member comprising a front part with which the adjustable loop or the attachment portion is connected, and a rear part comprising a first U-shaped housing configured to receive part of the attachment portion or of the adjustable loop. The strapping device thus comprises a clamping position of the strapping by sliding the adjustable loop in the sleeve, and a locking position in which the sliding of the adjustable loop is prevented by the sleeve.",COUSIN BIOTECH,NOEL STÉPHANE;;OUERGHEMMI SAFA,COUSIN BIOTECH (2022-04-07),https://lens.org/162-607-064-867-160,Patent Application,yes,28,0,6,031-436-170-927-143;;172-725-303-782-499;;188-116-875-532-695;;143-738-056-402-866;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,6,031-436-170-927-143;;172-725-303-782-499;;143-738-056-402-866;;188-116-875-532-695;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,0,A61B17/82;;A61B17/82,A61B17/82,,0,0,,,,ACTIVE
229,US,A1,US 2023/0042455 A1,158-597-309-178-152,2023-02-09,2023,US 202017757848 A,2020-12-28,FR 1915796 A;;EP 2020087936 W,2019-12-31,COMPOSITION FOR WEIGHT MANAGEMENT OF A SUBJECT,"A composition for managing the weight of a subject, wherein the composition includes at least one high-viscosity, resorbable, biocompatible material, intended to be injected into the submucosal space of the digestive tract of a subject and thus creating a long-lasting raising of the corresponding mucosa is disclosed. Also disclosed is a kit including a composition according to the invention and structure for injecting the composition. Finally, the disclosure also relates to the use of a composition according to the invention for managing the weight of a subject.",MRS BIOTECH,MARÇAIS OLIVIER,MRS-BIOTECH (2022-06-20),https://lens.org/158-597-309-178-152,Patent Application,yes,0,0,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,0,A61K31/728;;A61K31/722;;A61K31/715;;A61K9/0019;;A61K47/26;;A61K47/38;;A61K47/02;;A61K45/06;;A61K9/0019;;A61K31/728;;A61K45/06,A61K31/728;;A61K9/00;;A61K45/06,,1,1,034-834-915-107-75X,19281055;;10.2147/cia.s3118;;pmc2682392,"Bogdan Allemann et al., Published 05 December 2008, Clinical Interventions in Aging, Vol. 3, Issue 4, pp. 629-634 (Year: 2008)",PENDING
230,EP,A1,EP 4556492 A1,090-022-413-976-848,2025-05-21,2025,EP 23306974 A,2023-11-14,EP 23306974 A,2023-11-14,TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES IN SUBPOPULATIONS OF SUBJECTS,"The present invention relates to the treatment of cardiovascular diseases or events. In particular, the present invention relates to a method for treating a cardiovascular disease or event, in particular a stroke, comprising the administration of an inhibitor of the GPVI signaling pathway, in particular an anti-human glycoprotein VI antibody or fragment thereof.",ACTICOR BIOTECH,The designation of the inventor has not yet been filed,,https://lens.org/090-022-413-976-848,Patent Application,yes,4,0,2,091-120-489-058-82X;;090-022-413-976-848,EP;;WO,2,091-120-489-058-82X;;090-022-413-976-848,EP;;WO,21,A61P9/10;;C07K16/2803;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K2317/55,C07K16/28;;A61P9/10,,23,17,138-317-472-779-009;;051-070-536-351-428;;190-065-637-167-076;;110-815-857-364-563;;017-693-519-334-261;;005-560-967-514-755;;049-134-753-209-354;;060-971-733-861-077;;137-607-161-868-61X;;034-331-211-704-877;;066-141-497-990-023;;106-753-778-592-300;;020-855-322-534-259;;013-892-028-709-221;;003-502-861-629-038;;007-002-813-911-754;;102-818-694-846-317,10.1056/nejmoa2214403;;36762865;;34653924;;10.1016/j.clineuro.2021.106978;;36128904;;10.1161/strokeaha.122.039790;;10.1016/s1474-4422(23)00427-1;;38267188;;25977585;;10.1182/blood-2015-02-629717;;1908882;;10.4049/jimmunol.147.5.1709;;10.1016/0022-2836(87)90412-8;;3681981;;10.1111/j.1749-6632.1949.tb27297.x;;10.1137/0148063;;1907718;;10.1038/352624a0;;pmc321012;;6546423;;10.1093/nar/12.1part1.387;;10.1038/256495a0;;1172191;;10.1016/0022-2836(91)90498-u;;1748994;;10.1016/j.ab.2009.02.035;;19268418;;26683650;;10.1080/19420862.2015.1116657;;pmc4966575;;19147716;;10.3174/ajnr.a1408;;pmc7051470;;pmc8367626;;34140276;;10.3174/ajnr.a7181,"SARRAJ AMROU ET AL: ""Trial of Endovascular Thrombectomy for Large Ischemic Strokes"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 388, no. 14, 6 April 2023 (2023-04-06), US, pages 1259 - 1271, XP093149505, ISSN: 0028-4793, DOI: 10.1056/NEJMoa2214403;;BAYDEMIR RECEP ET AL: ""Role of modified TAN score in predicting prognosis in patients with acute ischemic stroke undergoing endovascular therapy"", CLINICAL NEUROLOGY AND NEUROSURGERY., vol. 210, 1 November 2021 (2021-11-01), NL, XP093149593, ISSN: 0303-8467, DOI: 10.1016/j.clineuro.2021.106978;;ANONYMOUS: ""Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)"", PLOS ONE, 22 February 2023 (2023-02-22), XP093149697, Retrieved from the Internet <URL:https://uploads-ssl.webflow.com/60ed4d6a6fc45c3a0e3cfb8f/621488b1a5b1f0b3c02c537a_Acticor_PR_ACTIMIS_Resultats_EN_vf-2.pdf> [retrieved on 20240409];;WICHAIYO SURASAK ET AL: ""Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke"", STROKE, vol. 53, no. 11, 21 September 2022 (2022-09-21), US, pages 3506 - 3513, XP093037091, ISSN: 0039-2499, Retrieved from the Internet <URL:http://dx.doi.org/10.1161/STROKEAHA.122.039790> DOI: 10.1161/STROKEAHA.122.039790;;ACTICOR BIOTECH: ""Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke - NCT05070260"", CLINICAL TRIALS.GOV, 7 October 2021 (2021-10-07), XP093037078, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT05070260?term=NCT05070260&draw=2&rank=1> [retrieved on 20230403];;MAZIGHI MIKAËL ET AL: ""Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial"", THE LANCET NEUROLOGY, vol. 23, no. 2, 1 February 2024 (2024-02-01), AMSTERDAM, NL, pages 157 - 167, XP093149371, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(23)00427-1;;MAMMADOVA-BACH ET AL., BLOOD., vol. 126, no. 5, 2015, pages 683 - 91;;KABAT ET AL.: ""Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites"", J IMMUNOL., vol. 147, no. 5, 1 September 1991 (1991-09-01), pages 1709 - 19, XP055204516;;CHOTHIA C.A.M. LESK: ""Canonical structures for the hypervariable regions of immunoglobulins"", J MOL BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17, XP024010426, DOI: 10.1016/0022-2836(87)90412-8;;SCATCHARD G ET AL.: ""The attractions of proteins for small molecules and ions"", ANN NY ACAD SCI, vol. 51, 1949, pages 660 - 672, XP008000889, DOI: 10.1111/j.1749-6632.1949.tb27297.x;;CARILLO ET AL., SIAM J. APPL. MATH., vol. 48, no. 5, 1988, pages 1073 - 1082;;DOUGLAS W. SMITH: ""Biocomputing: Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;HUGH G. GRIFFINANNETTE M. GRIFFIN: ""Computer Analysis of Sequence Data, Part 1"", 1994, HUMANA PRESS;;GUNNAR VON HEINJ E: ""Sequence Analysis in Molecular Biology: Treasure Trove or Trivial Pursuit"", 1987, ACADEMIC PRESS;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 12, no. 1, 1984, pages 387 - 395;;ALTSCHUL1990 ET AL., J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 410;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;MUZARD ET AL., ANALYTICAL BIOCHEMISTRY, vol. 388, 2009, pages 331 - 338;;LAKHRIF ET AL., MABS., vol. 8, no. 2, 2016, pages 379 - 88;;TAN ET AL.: ""CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct"", AJNR AM J NEURORADIOL., vol. 30, no. 3, March 2009 (2009-03-01), pages 525 - 31;;LYNDON ET AL.: ""Hypoperfusion Intensity Ratio Correlates with CTA Collateral Status in Large-Vessel Occlusion Acute Ischemic Stroke"", AJNR AM J NEURORADIOL., vol. 42, no. 8, August 2021 (2021-08-01), pages 1380 - 1386",DISCONTINUED
231,WO,A1,WO 2021/250026 A1,018-467-375-895-086,2021-12-16,2021,EP 2021065337 W,2021-06-08,EP 20305610 A,2020-06-08,USE OF ANTI-GPVI ANTIBODIES FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME,"The present invention relates to an isolated protein binding to human Glycoprotein VI (hGPVI) for treating or preventing an acute respiratory distress syndrome (ARDS), in particular a SARS-CoV-2-related ARDS.",ACTICOR BIOTECH,AVENARD GILLES;;JANDROT-PERRUS MARTINE;;LEBEL-BINAY SOPHIE;;PLETAN YANNICK,,https://lens.org/018-467-375-895-086,Patent Application,yes,5,0,1,018-467-375-895-086,WO,1,018-467-375-895-086,WO,24,C07K16/2803;;A61K2039/545;;A61P7/02;;A61P11/00;;C07K2317/24;;C07K2317/76,C07K16/28;;A61P7/02;;A61P11/00,,44,33,024-197-963-695-398;;085-220-866-472-657;;088-975-731-112-456;;053-888-456-267-625;;072-812-982-311-452;;118-759-753-295-046;;021-696-389-288-831;;009-558-800-142-104;;005-560-967-514-755;;049-134-753-209-354;;054-250-934-559-758;;055-513-241-719-139;;112-279-469-781-943;;002-538-319-677-230;;118-515-940-171-179;;002-664-741-683-318;;023-929-032-945-955;;013-795-151-218-458;;002-664-741-683-318;;137-607-161-868-61X;;034-331-211-704-877;;066-141-497-990-023;;106-753-778-592-300;;020-855-322-534-259;;000-499-911-678-177;;083-019-407-395-691;;008-587-496-850-953;;051-940-176-386-905;;021-430-782-622-770;;013-892-028-709-221;;003-502-861-629-038;;062-353-036-290-103;;057-343-886-357-239,10.1097/ccm.0b013e31819fff2c;;19384216;;10.1161/atvbaha.118.312314;;31017822;;10.1038/s41573-020-0061-0;;32132678;;10.1021/acs.jmedchem.0c00262;;32463237;;10.3390/biomedicines8070230;;pmc7399831;;32708068;;pmc7244436;;32450344;;10.1016/j.phrs.2020.104950;;23043249;;10.1146/annurev-physiol-030212-183752;;pmc3670819;;10.1182/blood.2020007252;;32678428;;pmc7483437;;1908882;;10.4049/jimmunol.147.5.1709;;10.1016/0022-2836(87)90412-8;;3681981;;3889592;;10.1016/0161-5890(85)90151-8;;10.1006/jmbi.1996.0636;;8951372;;10541349;;10.1016/s0161-5890(99)00029-2;;10444002;;2622909;;10.1002/prot.340060405;;1404389;;10.1016/0022-2836(92)90224-8;;10.1006/meth.1999.0921;;10694450;;9780179;;10.4049/jimmunol.161.8.4083;;1404389;;10.1016/0022-2836(92)90224-8;;10.1137/0148063;;1907718;;10.1038/352624a0;;pmc321012;;6546423;;10.1093/nar/12.1part1.387;;10.1038/256495a0;;1172191;;10.1016/0022-2836(91)90498-u;;1748994;;1402660;;10.1084/jem.176.4.1191;;pmc2119390;;1573276;;10.4049/jimmunol.148.9.2918;;886304;;10.1099/0022-1317-36-1-59;;10.1073/pnas.77.7.4216;;6933469;;pmc349802;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1016/j.ab.2009.02.035;;19268418;;26683650;;10.1080/19420862.2015.1116657;;pmc4966575;;10.1006/cyto.2001.0936;;11741351;;pmc2074309;;10.1038/bjc.1996.32;;8546903,"JEAN-LOUIS VINCENT ET AL: ""A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome* :"", CRITICAL CARE MEDICINE., vol. 37, no. 6, 1 June 2009 (2009-06-01), US, pages 1874 - 1880, XP055750759, ISSN: 0090-3493, DOI: 10.1097/CCM.0b013e31819fff2c;;CHRISTINE VOORS-PETTE ET AL: ""Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab : First-in-Human Healthy Volunteer Trial"", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 39, no. 5, 1 May 2019 (2019-05-01), pages 956 - 964, XP055749562, ISSN: 1079-5642, DOI: 10.1161/ATVBAHA.118.312314;;MACKMAN NIGEL ET AL: ""Therapeutic strategies for thrombosis: new targets and approaches"", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 19, no. 5, 4 March 2020 (2020-03-04), pages 333 - 352, XP037111796, ISSN: 1474-1776, [retrieved on 20200304], DOI: 10.1038/S41573-020-0061-0;;ACTICOR BIOTECH: ""Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 - NCT04659109"", CLINICALTRIALS.GOV, 9 December 2020 (2020-12-09), XP055835585, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04659109?cond=NCT04659109&draw=2&rank=1> [retrieved on 20210827];;HOLLY FOSTER ET AL: ""Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 21, 28 May 2020 (2020-05-28), pages 12213 - 12242, XP055750356, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c00262;;CHUAN-MU CHEN ET AL: ""Antiplatelet Therapy for Acute Respiratory Distress Syndrome"", BIOMEDICINES, vol. 8, no. 7, 21 July 2020 (2020-07-21), pages 1 - 18, XP055750196, DOI: 10.3390/biomedicines8070230;;GENENTECH ET AL: ""Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome -NCT01438853"", CLINICALTIRALS.GOV, 22 September 2011 (2011-09-22), XP055750744, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT01438853?term=phase+I+AND+antibody&cond=Acute+Respiratory+Distress+Syndrome&draw=2&rank=1> [retrieved on 20201116];;VIECCA MAURIZIO ET AL: ""Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study"", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 158, 23 May 2020 (2020-05-23), XP086195719, ISSN: 1043-6618, [retrieved on 20200523], DOI: 10.1016/J.PHRS.2020.104950;;ANDREW S. WEYRICH ET AL: ""Platelets in Lung Biology"", ANNUAL REVIEW OF PHYSIOLOGY., vol. 75, no. 1, 10 February 2013 (2013-02-10), US, pages 569 - 591, XP055750221, ISSN: 0066-4278, DOI: 10.1146/annurev-physiol-030212-183752;;EUGENIO D HOTTZ ET AL: ""Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19"", BLOOD, vol. 136, no. 11, 10 September 2020 (2020-09-10), US, pages 1330 - 1341, XP055750169, ISSN: 0006-4971, DOI: 10.1182/blood.2020007252;;KABAT ET AL., J. IMMUNOL., vol. 147, no. 5, 1991, pages 1709 - 19;;CHOTHIA C.A.M. LESK, J. MOL. BIOL., vol. 196, no. 4, 1987, pages 901 - 917;;BURTON, MOLEC. IMMUNOL, vol. 22, 1985, pages 161 - 206;;WILLIAMS ET AL., J. MOL. BIOL., vol. 264, no. 5, 1996, pages 220 - 232;;QU ET AL., CLIN. CANCER RES., vol. 5, 1999, pages 3095 - 3100;;ONO ET AL., MOL. IMMUNOL., vol. 36, 1999, pages 387 - 395;;LEFRANC ET AL., NUCLEIC ACID RES, vol. 27, 1999, pages 209 - 212, Retrieved from the Internet <URL:http://im.gt.cines.fr>;;TRAMONTANO ET AL., PROTEINS, vol. 6, 1989, pages 382 - 94;;CHOTHIA ET AL., J. MOL. BIOL, vol. 227, 1992, pages 799 - 817;;MOREA ET AL., METHODS, vol. 20, 2000, pages 267 - 279;;TOMLINSON ET AL., EMBO J, vol. 14, 1995, pages 4628 - 4638, Retrieved from the Internet <URL:http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVK.html>;;ROUX ET AL., J. IMMUNOL., vol. 161, no. 8, 1998, pages 4083 - 90;;KABAT, ELVIN A: ""Sequences of proteins of immunological interest"", 1983, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA ET AL., J. MOL. BIOL., vol. 227, no. 3, 1992, pages 799 - 817;;TRAMONTANO ET AL., J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 410;;CARILLO ET AL., SIAM J. APPL. MATH, vol. 48, no. 5, 1988, pages 1073 - 1082;;DOUGLAS W. SMITH: ""Biocomputing:Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;HUGH G. GRIFFINANNETTE M. GRIFFIN: ""Pluckthun in The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;GUNNAR VON HEINJE: ""Sequence Analysis in Molecular Biology: Treasure Trove or Trivial Pursuit"", 1987, ACADEMIC PRESS;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;DEVEREUX ET AL.: ""Nucl. Acid. Res."", vol. 12, 1984, GENETICS COMPUTER GROUP, UNIVERSITY OF WISCONSIN BIOTECHNOLOGY CENTER, pages: 387 - 395;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;ANN NY ACAD SCI, vol. 51, 1949, pages 660 - 672;;CARON ET AL., J. EXP. MED., vol. 176, 1992, pages 1191 - 1195;;SHOPES, B., J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, no. 59, 1977;;CHO, URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;TM4, MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;MUZARD ET AL., ANALYTICAL BIOCHEMISTRY, vol. 388, 2009, pages 331 - 338;;LAKHRIF ET AL., MABS, vol. 8, no. 2, 2016, pages 379 - 88;;LEONG ET AL., CYTOKINES, vol. 16, no. 3, 2001, pages 106 - 119;;DELGADO ET AL., BR. J. CANCER, vol. 73, no. 2, 1996, pages 175 - 182",PENDING
232,US,A1,US 2024/0218034 A1,013-782-908-083-215,2024-07-04,2024,US 202318499332 A,2023-11-01,US 202318499332 A;;EP 2017025141 W;;EP 2017025298 W;;US 201916613879 A;;IB 2018000622 W,2017-05-22,MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION,"Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.",RESQ BIOTECH,SKRETAS GEORGIOS,,https://lens.org/013-782-908-083-215,Patent Application,yes,0,0,8,131-072-574-548-538;;189-155-360-030-870;;038-099-177-552-92X;;055-071-589-161-88X;;073-053-458-008-213;;150-374-653-668-709;;013-782-908-083-215;;053-009-248-694-127,EP;;WO;;US,8,189-155-360-030-870;;131-072-574-548-538;;038-099-177-552-92X;;055-071-589-161-88X;;013-782-908-083-215;;053-009-248-694-127;;150-374-653-668-709;;073-053-458-008-213,EP;;WO;;US,0,C07K5/101;;C07K5/126;;C07K7/64;;C07K7/06;;C12N9/0089;;G01N33/6842;;G01N33/6896;;G01N2500/10;;G01N2800/28;;G01N2800/2821;;A61K38/00;;C07K14/4711;;C12Y115/01001;;C12N15/1075;;C40B30/06,C07K14/47;;A61K38/00;;C12N15/10;;G01N33/68,,0,0,,,,PENDING
233,WO,A1,WO 2021/250006 A1,046-331-989-819-750,2021-12-16,2021,EP 2021065306 W,2021-06-08,FR 2006148 A;;FR 2012068 A,2020-06-12,"SYSTEM FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLE, INTENDED FOR DETECTING THE PRESENCE OF AT LEAST ONE ANALYTE IN THE BIOLOGICAL SAMPLE","The present invention relates to a system for rapid analysis of a biological sample (E), intended for detecting the presence of at least one analyte (A) in the biological sample (E). The rapid analysis system comprises: - at least one collection device (2), suitable for collecting the biological sample (E), - at least one chromatographic test strip (3) designed to detect the presence of the at least one analyte (A), - a buffer solution (4) for implementing the chromatographic technique, and - at least one interface device (5) suitable for receiving the at least one chromatographic test strip (3) in order to implement the chromatographic technique, which interface device (5) comprises at least two recesses (51, 52) in fluid communication, with at least one first recess (51) intended to receive at least the buffer solution (4) and at least one second recess (52) designed for inserting at least the deposition area (311) of the at least one chromatographic test strip (3), the second recess (52) being intended to receive the buffer solution (4), possibly mixed with the biological sample (E), flowing from the at least one first recess (51).",NG BIOTECH,STANKOV MILOVAN,,https://lens.org/046-331-989-819-750,Patent Application,yes,3,0,5,197-877-393-616-549;;046-331-989-819-750;;027-789-513-586-109;;139-860-241-882-093;;147-781-090-954-815,EP;;WO;;FR,5,197-877-393-616-549;;046-331-989-819-750;;139-860-241-882-093;;027-789-513-586-109;;147-781-090-954-815,EP;;WO;;FR,0,G01N33/54388;;B01L3/5029;;B01L9/52;;B01L2300/0663;;B01L2300/0825;;B01L2300/0832;;B01L2300/0864,G01N33/558,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",PENDING
234,US,A1,US 2025/0041043 A1,043-522-560-544-427,2025-02-06,2025,US 202218718913 A,2022-12-14,FR 2113580 A;;EP 2022085949 W,2021-12-15,IMPLANTABLE DEVICE WITH GRADUAL RELEASE OF ONE OR MORE FUNCTIONAL AGENTS AND METHOD FOR MANUFACTURING SUCH A DEVICE,"The present invention relates to an implantable device, in particular for the reconstruction of an anterior cruciate ligament or a tendon, comprising an elongate core (20) and a hollow elongate covering member comprising an inside volume at least partially receiving said elongate core, wherein said elongate core comprises a polymer matrix that is bioerodible in an aqueous medium and one or more functional agents, and the covering member comprises through-holes in fluid communication with said inside volume. The invention also relates to a method for manufacturing such an implantable device.",COUSIN BIOTECH,NOEL STÉPHANE,COUSIN BIOTECH (2024-06-12),https://lens.org/043-522-560-544-427,Patent Application,yes,0,0,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,0,A61F2/08;;A61F2250/0031;;A61F2250/0067;;A61F2210/0004;;A61L2430/10;;A61L27/54;;A61L27/58;;A61L27/18;;A61L27/34;;A61L2420/04;;A61L27/28;;A61L27/306;;A61L27/32;;A61L27/56;;A61F2/08;;A61F2210/0004,A61F2/08,,0,0,,,,PENDING
235,US,A1,US 2023/0105449 A1,070-530-775-976-218,2023-04-06,2023,US 202218046536 A,2022-10-14,US 202218046536 A;;KR 20180078585 A;;KR 20190080244 A;;US 202016973646 A;;KR 2019008235 W,2018-07-06,"PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT","The present disclosure relates to a composition for preventing or treating wound. The composition according to the present disclosure contains, as an active ingredient, an indirubin derivative alone or one or more selected from a group consisting of an indirubin derivative, an Euodia sutchuenensis Dode extract, methyl vanillate, hesperidin and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring not only in a normal state but also in a diabetic state. Furthermore, since the composition exhibits excellent effects in healing diabetic wound as well as general wound, it can be usefully used as a pharmaceutical composition, cosmetic composition or food composition for alleviating, preventing or treating general wound or diabetic wound, or as a veterinary composition for treating diabetic wound.",CK BIOTECH,CHOI KANG-YELL;;KIM EUNHWAN;;SEO SEOL HWA;;YOON MINGUEN,CK REGEON INC (2020-11-27),https://lens.org/070-530-775-976-218,Patent Application,yes,0,0,10,100-574-593-464-511;;010-723-737-446-421;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;070-530-775-976-218;;097-170-205-131-938;;112-312-169-379-233;;152-346-690-972-536;;146-551-039-853-613,CN;;EP;;WO;;US,14,100-574-593-464-511;;010-723-737-446-421;;143-789-168-119-782;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;097-170-205-131-938;;152-346-690-972-536;;156-171-049-575-889;;061-609-337-961-572;;070-530-775-976-218;;112-312-169-379-233;;016-089-837-812-567;;146-551-039-853-613,KR;;CN;;EP;;WO;;US,0,A61P17/02;;A61Q19/00;;A61K31/404;;A61K31/7048;;A23L33/10;;A61K8/492;;A61K36/754;;A23K20/137;;A23K20/111;;A23K10/30;;A23K20/163;;A23K20/121;;A61K9/107;;A61K45/06;;A61K31/216;;A23L33/105;;A23L33/40;;A61K8/9789;;A61P17/02;;A23V2002/00;;A61K8/06;;A61K8/345;;A61K8/37;;A61K8/492;;A61K8/602;;A61K8/604;;A61K8/738;;A61K8/922;;A61K9/0014;;A61K9/0056;;A61K9/06;;A61K9/107;;A61K31/235;;A61K31/404;;A61K31/7048;;A61K36/754;;A61K47/10;;A61K47/26;;A61K47/40;;A61K47/44;;A61Q19/00;;C07D403/04,C07D403/04;;A23L33/00;;A23L33/105;;A61K8/06;;A61K8/34;;A61K8/37;;A61K8/49;;A61K8/60;;A61K8/73;;A61K8/92;;A61K8/9789;;A61K9/00;;A61K9/06;;A61K9/107;;A61K31/235;;A61K31/404;;A61K31/7048;;A61K36/754;;A61K47/10;;A61K47/26;;A61K47/40;;A61K47/44;;A61P17/02;;A61Q19/00,,0,0,,,,ACTIVE
236,US,A1,US 2023/0346980 A1,069-398-973-008-292,2023-11-02,2023,US 202318140326 A,2023-04-27,US 202318140326 A;;US 202263336464 P,2022-04-29,TAIL-CONJUGATED RNAS,"Tail-tail RNA conjugates translatable by eukaryotic ribosomes, and pharmaceutically acceptable compositions including the same are provided. Methods for preparing such molecules, using them for treating and preventing diseases are described. In addition, processes for producing desired polypeptides using the molecules are also described.",TIBA BIOTECH,CHAHAL JASDAVE S;;MCPARTLAN JUSTINE S,TIBA BIOTECH LLC (2023-04-26),https://lens.org/069-398-973-008-292,Patent Application,yes,4,0,3,150-767-732-294-917;;069-398-973-008-292;;162-792-275-011-351,WO;;US,4,181-480-637-787-293;;150-767-732-294-917;;162-792-275-011-351;;069-398-973-008-292,WO;;US,0,A61K48/0066;;A61P37/02;;A61P37/02;;A61K48/0066,A61K48/00;;A61P37/02,,7,2,081-600-939-787-449;;070-488-519-521-779,26537402;;10.1017/s0033583515000141;;7480149;;10.1111/j.1751-1097.1995.tb08712.x,"El-Sagheer et al. (2015) “A triazole linkage that mimics the DNA phosphodiester group in living systems” Quarterly Reviews of Biophysics, 48(4), 429-436. (Year: 2015);;GenBank LC311024.1, “Mammalian expression vector EGFP-MCS-pcDNA3.1 DNA, complete sequence”, entered: 20-Jul-2017, available from: National Library of Medicine (US), National Center for Biotechnology Information, [item V continued...] (Year: 2017);;[... item V continued] https://www.ncbi.nlm.nih.gov/nucleotide/LC311024.1?report=genbank&log$=nuclalign&blast_rank=1&RID=USS69ZRD01N. (Year: 2017);;Chalfie, M. (1995) “Green fluorescent protein” Photochemistry and photobiology, 62(4), 651-656. (Year: 1995);;GenBank KM403567.1, “SEAP expression vector pSA928, complete sequence”, entered: 02-Oct-2014, available from: National Library of Medicine (US), National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/nuccore/KM403567.1#feature_KM403567.1. (Year: 2014);;GenBank AY015993.1, “Gaussia princeps (T. Scott, 1894) luciferase mRNA, complete cds”, entered: 18-Oct-2005, available from: National Library of Medicine (US), National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/nuccore/AY015993.1. (Year: 2005);;GenBank MF169983.1, “Synthetic construct clone pPK2-BAR-mCherry mCherry (mCherry) and BAR (bar) genes, complete cds”, entered: 15-Aug-2017, available from: National Library of Medicine (US), National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/nuccore/MF169983.1. (Year: 2017)",ACTIVE
237,WO,A1,WO 2024/261300 A1,127-832-700-192-400,2024-12-26,2024,EP 2024067532 W,2024-06-21,EP 23180698 A,2023-06-21,CELL SPECIFIC TRANSLATION OF RNA MOLECULES,"[1] The invention provides an improved RNA construct that allows for a target cell specific translation of a protein of interest in eukaryotic cells. The invention applies RNA constructs that are introduced directly into eukaryotic cells, and which are only translated into a protein in the presence of a specific trigger RNA sequence. The invention allows for a controlled expression of proteins or any proteinaceous antigen in target cells. The invention is useful for medical applications such as RNA based vaccination approaches to restrict antigen expression to target tissues.",SRTD BIOTECH,HOFFMANN BERND,,https://lens.org/127-832-700-192-400,Patent Application,yes,2,0,2,145-983-916-217-17X;;127-832-700-192-400,EP;;WO,2,145-983-916-217-17X;;127-832-700-192-400,EP;;WO,4,C12N15/67;;C12N15/79;;C12N2310/11;;C12N2310/50;;C12N2840/007;;C12N2840/102;;C12N2840/203;;C12N2830/50;;A61K31/7115,C12N15/79;;A61K31/7105;;C12N15/113;;C12N15/67,,14,11,032-307-042-738-589;;014-432-816-475-680;;008-285-595-751-666;;117-834-207-541-028;;087-330-410-524-738;;059-577-188-234-21X;;116-292-030-677-252;;059-393-958-757-089;;074-254-924-910-683;;058-032-369-859-095;;140-188-395-960-034,10.1038/s41587-021-01068-2;;34711989;;10.1016/0005-2736(75)90233-3;;52374;;10.1016/s0169-409x(01)00203-4;;11744175;;21074848;;10.1016/j.biomaterials.2010.10.029;;21193867;;10.1038/nrd3320;;10699311;;10.1016/s0169-409x(99)00062-9;;pmc10348343;;10.1038/s41586-022-05280-1;;36198803;;10.1101/2022.05.25.493141;;10.1038/35078107;;11373684;;pmc312613;;10.1101/gad.862301;;11157775;;14758366;;10.1038/nbt936;;pmc10516663;;37427788;;10.1093/nar/gkad569,"HOFFMANN MARCO ET AL: ""Selectively expressed RNA molecules: a new dimension in functionalized cell targeting"", BIORXIV, 11 May 2022 (2022-05-11), XP093106880, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2022.05.10.491309v1.full> [retrieved on 20231129], DOI: 10.1101/2022.05.10.491309;;ZHAO EVAN M ET AL: ""RNA-responsive elements for eukaryotic translational control"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 40, no. 4, 28 October 2021 (2021-10-28), pages 539 - 545, XP037799148, ISSN: 1087-0156, [retrieved on 20211028], DOI: 10.1038/S41587-021-01068-2;;D. PAPAHADJOPOULOSM. MOSCARELLOE. H. EYLART. ISAC, BIOCHIM. BIOPHYS. ACTA, vol. 401, 1975, pages 317;;QIUPARK, ADVANCED DRUG DELIVERY REVIEWS, vol. 53, 2001, pages 321 - 339;;SHAMAYCOLLEAGUES: ""Light induced drug delivery into cancer cells"", BIOMATERIALS, vol. 32, 2011, pages 1377 - 86, XP027537936;;LAPPANO RMAGGIOLINI M, NAT REV DRUG DISCOV, vol. 10, 2011, pages 47 - 60;;SUDIMACK JLEE R J, ADV DRUG DELIV REV, vol. 41, 2000, pages 147 - 62;;QIAN ET AL., NATURE, vol. 610, 2022, pages 713 - 721;;KASENIIT ET AL., NATURE BIOTECHNOLOGY, vol. 41, 2023, pages 482 - 487;;ZHAO ET AL., NATURE BIOTECHNOLOGY, vol. 40, 2022, pages 539 - 545;;ELBASHIR S MHARBORTH JLENDECKEL WYALCIN AWEBER KTUSCHL T: ""Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells"", NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 8, XP002529540, DOI: 10.1038/35078107;;ELBASHIR S MLENDECKEL WTUSCHL T: ""RNA interference is mediated by 21- and 22-nucleotide RNAs"", GENES DEV, vol. 15, no. 2, 15 January 2001 (2001-01-15), pages 188 - 200, XP002206453, DOI: 10.1101/gad.862301;;REYNOLDS ALEAKE DBOESE QSCARINGE SMARSHALL W SKHVOROVA A: ""Rational siRNA design for RNA interference"", NAT BIOTECHNOL., vol. 22, no. 3, March 2004 (2004-03-01), pages 326 - 30, XP002311429, DOI: 10.1038/nbt936;;""The structure and mechanism of action of a distinct class of dicistrovirus intergenic region IRES"", NUCLEIC ACIDS RESEARCH, vol. 51, 2023, pages 9294 - 9313",PENDING
238,WO,A1,WO 2023/212213 A1,150-767-732-294-917,2023-11-02,2023,US 2023/0020227 W,2023-04-27,US 202263336464 P,2022-04-29,TAIL-CONJUGATED RNAS,"Tail-tail RNA conjugates translatable by eukaryotic ribosomes are provided. Protein expression systems comprising the conjugates, vaccines and pharmaceutically acceptable compositions including the same are described. Methods for preparing tail-tail RNA conjugates, using them for treating and preventing diseases are provided. In addition, processes for producing desired polypeptides using the molecules are also described.",TIBA BIOTECH,CHAHAL JASDAVE S;;MCPARTLAN JUSTINE S,,https://lens.org/150-767-732-294-917,Patent Application,yes,2,1,3,150-767-732-294-917;;069-398-973-008-292;;162-792-275-011-351,WO;;US,4,181-480-637-787-293;;150-767-732-294-917;;162-792-275-011-351;;069-398-973-008-292,WO;;US,22,A61K48/0066;;A61P37/02;;A61P37/02;;A61K48/0066,C12N15/52;;A61K31/7088;;A61K48/00;;A61P31/00;;A61P35/00;;C12N15/11,,0,0,,,,PENDING
239,KR,A,KR 20230064568 A,161-894-778-262-516,2023-05-10,2023,KR 20220143827 A,2022-11-01,KR 20210147674 A,2021-11-01,Uses of polysaccharide derived from strains belonging to the Enterococcus genus,"The present invention relates to polysaccharides derived from Enterococcus genus strains and uses thereof. Polysaccharides derived from Enterococcus genus strains can promote osteogenic differentiation of stem cells and can be used to promote bone formation, and thus can be used for preventing or treating bone diseases that can be treated through bone regeneration.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/161-894-778-262-516,Patent Application,no,1,0,1,161-894-778-262-516,KR,2,031-984-878-968-458;;161-894-778-262-516,KR;;WO,24,A61K35/744;;A61P19/08;;A61P19/10,A61K35/744;;A61P19/08;;A61P19/10,,0,0,,,,DISCONTINUED
240,KR,A,KR 20210030192 A,170-330-171-755-464,2021-03-17,2021,KR 20200086398 A,2020-07-13,KR 20190111795 A,2019-09-09,Pharmaceutical composition containing complex Rubus crataegifolius Crataegus pinnatifida Bunge Cinnamomum cassia extracts for prevention or treatment of metabolic syndrome,"A complex extract of a Rubus crataegifolius extract, a Crataegus pinnatifida extract and/or a Cinnamomum cassia extract of the present invention can significantly reduce the amount of food and dietary hormone and leptin and significantly increase adiponectin to reduce body weight and body fat weight, can reduce liver weight and the level of liver enzymes AST and ALT, can reduce hepatic lipid and the size and number of fat globules in fatty liver tissue, can significantly reduce the activity of hepatic lipid metabolism-related enzymes, and can also have effects of significantly increasing beta-oxidation-related CPT activity, lowering blood sugar, overcoming glucose tolerance, inhibiting blood clotting and platelet aggregation, and significantly inhibiting arteriosclerosis, in an obese animal model compared to a single extract. Thus the complex extract can be advantageously used for the prevention, treatment or amelioration of metabolic syndrome diseases.",LEES BIOTECH,LEE YOUNG IK;;NAM MI KYUNG;;AHTESHAM HUSSAIN;;CHO JIN SOOK;;LEE HYE BIN,,https://lens.org/170-330-171-755-464,Patent Application,no,1,2,1,170-330-171-755-464,KR,1,170-330-171-755-464,KR,0,A61K36/73;;A23L33/105;;A23V2002/00;;A23V2200/3262;;A23V2200/328;;A61K36/54;;A61K36/734;;A61K2300/00;;A61P3/00,A61K36/73;;A23L33/105;;A61K36/54;;A61K36/734;;A61P3/00,,0,0,,,,DISCONTINUED
241,BR,A2,BR 112021004809 A2,191-235-790-311-105,2021-06-22,2021,BR 112021004809 A,2019-06-28,US 2019/0039878 W;;US 201862691319 P,2018-06-28,composições farmacêuticas e métodos para o tratamento de trombose e aplicação por dispositivos médicos,"a presente invenção se refere a uma composição farmacêutica e um método de uso da composição farmacêutica para o tratamento de trombose. a composição farmacêutica pode incluir uma mistura de enzimas proteolíticas e, opcionalmente, compostos adicionais. a composição farmacêutica pode incluir um composto antiagregante ou antitrombótico, tal como lisini racemici acetilsalicilase. o método pode incluir administrar a composição farmacêutica a um paciente em necessidade da mesma, incluindo a administração da composição farmacêutica a um trombo até que o trombo seja dissolvido. o método também pode incluir administrar um ou mais cateteres de balão ao paciente.",MARIZYME BIOTECH,MICHAEL K HANDLEY,,https://lens.org/191-235-790-311-105,Patent Application,no,0,0,11,051-382-287-611-008;;167-215-822-759-142;;183-488-193-693-681;;113-909-928-705-465;;128-633-861-675-942;;127-500-590-414-920;;170-810-794-749-231;;079-567-751-821-998;;004-868-784-372-613;;191-235-790-311-105;;066-411-304-959-220,CR;;JP;;AU;;CN;;EA;;EP;;WO;;CA;;BR;;PE,13,051-382-287-611-008;;128-633-861-675-942;;113-909-928-705-465;;183-488-193-693-681;;170-810-794-749-231;;074-210-751-277-44X;;004-868-784-372-613;;028-302-916-315-724;;066-411-304-959-220;;167-215-822-759-142;;127-500-590-414-920;;079-567-751-821-998;;191-235-790-311-105,CR;;JP;;AU;;EP;;CN;;EA;;WO;;US;;CA;;BR;;PE,0,A61B17/12136;;A61B17/12036;;A61B17/1204;;A61M2025/105;;A61M2025/1052;;A61K38/4806;;A61K38/4826;;C12Y304/21004;;C12Y304/21001;;A61K38/26;;A61K31/616,A61K38/43;;A61B17/12;;A61M25/10,,0,0,,,,DISCONTINUED
242,IL,A,IL 314588 A,175-404-859-503-282,2024-09-01,2024,IL 31458824 A,2024-07-28,US 202318136419 A;;US 2024/0021859 W,2023-04-19,Cryopreservation device with integrated tracking device chamber,,BIOTECH INC,,,https://lens.org/175-404-859-503-282,Patent Application,no,0,0,10,047-592-826-495-933;;162-489-143-820-817;;147-477-893-597-624;;141-146-935-123-247;;060-885-276-227-95X;;046-595-929-205-924;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,AU;;JP;;KR;;CN;;IL;;EP;;MX,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,A01N1/147;;G06K19/0723;;C12N5/547;;G06K19/0723;;A01N1/146;;A01N1/147;;G06K19/0723;;A01N1/144,G06K19/07,,0,0,,,,PENDING
243,AU,A1,AU 2020/234406 A1,192-739-981-521-282,2021-10-21,2021,AU 2020/234406 A,2020-03-11,KR 20190028069 A;;KR 20190134094 A;;KR 20190134095 A;;KR 2020003411 W,2019-03-12,Microfluidic system for intracellular delivery of substances and method therefor,"Provided is a microfluidic system for delivering external substances into cells by cell perforation performed using inertia, the system comprising a fluid channel structure through which a solution containing cells and external substances continuously flows, wherein the fluid channel structure includes a junction between one or more channels, a local vortex occurs near the interface of the junction, the cells are deformed by the vortex, the vortex causes a temporary discontinuity in the cell membrane, and the external substances are introduced into the cells by solution exchange between the cells and the fluid around the cells.",MXT BIOTECH,CHUNG ARAM;;KANG GUM-YOUNG;;HUR JEONG SOO,MXT BIOTECH (2022-04-14),https://lens.org/192-739-981-521-282,Patent Application,no,0,0,6,192-739-981-521-282;;087-398-948-678-30X;;038-969-224-010-709;;189-668-374-060-388;;024-118-496-642-378;;139-814-893-133-277,AU;;KR;;CA,15,087-398-948-678-30X;;082-793-049-954-233;;096-790-774-056-908;;037-551-344-657-81X;;043-014-864-297-188;;157-614-637-845-300;;157-574-542-535-066;;024-118-496-642-378;;139-814-893-133-277;;180-723-113-124-234;;090-125-859-924-606;;038-969-224-010-709;;189-668-374-060-388;;192-739-981-521-282;;058-435-618-856-570,KR;;JP;;AU;;CN;;EP;;WO;;US;;CA,0,B01L3/5027;;B01L2200/0647;;B01L2300/08,B01L3/00,,0,0,,,,DISCONTINUED
244,US,A1,US 2025/0154252 A1,199-959-012-899-787,2025-05-15,2025,US 202318840227 A,2023-02-21,EP 22305190 A;;EP 22305677 A;;EP 2023054333 W,2022-02-21,TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES,"An inhibitor of GPVI signaling pathway, in particular an isolated humanized protein binding to human Glycoprotein VI (hGPVI), for treating a GPVI-related condition in a subject in need thereof, in particular an acute ischemic stroke, including the administration of the inhibitor GPVI signaling pathway, in particular the anti-human glycoprotein VI antibody or fragment thereof, to a human patient in need thereof.",ACTICOR BIOTECH,AVENARD GILLES;;PLETAN YANNICK;;GROUIN JEAN-MARIE;;BINAY SOPHIE;;TOLEDANO ELIE;;COMENDUCCI ANDREA,,https://lens.org/199-959-012-899-787,Patent Application,yes,0,0,3,115-218-990-954-833;;199-959-012-899-787;;039-894-679-475-898,EP;;WO;;US,3,115-218-990-954-833;;199-959-012-899-787;;039-894-679-475-898,EP;;WO;;US,0,C07K16/2803;;A61P7/02;;A61K2039/545;;A61K2039/505;;C07K2317/55;;C07K2317/24;;C07K2317/76;;A61K39/39533;;A61P7/02;;A61K2039/505;;C07K16/2803;;C07K2317/24;;C07K2317/565,C07K16/28;;A61K39/00;;A61P7/02,,0,0,,,,PENDING
245,US,A1,US 2022/0298210 A1,144-112-959-044-117,2022-09-22,2022,US 202217698300 A,2022-03-18,US 202217698300 A;;US 202163163475 P,2021-03-19,ARTIFICIAL ALPHAVIRUS-DERIVED RNA REPLICON EXPRESSION SYSTEMS,"Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.",TIBA BIOTECH,CHAHAL JASDAVE S;;MCPARTLAN JUSTINE S,TIBA BIOTECH LLC (2022-04-04),https://lens.org/144-112-959-044-117,Patent Application,yes,1,3,16,156-730-897-184-635;;123-822-468-012-115;;146-988-830-328-636;;079-117-464-181-766;;159-200-196-700-263;;033-093-540-580-062;;000-572-155-574-53X;;011-246-353-857-210;;145-932-627-198-240;;030-541-408-727-343;;153-822-783-784-770;;007-251-062-496-699;;157-860-903-399-862;;061-486-848-693-613;;008-542-809-190-126;;144-112-959-044-117,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA,16,156-730-897-184-635;;123-822-468-012-115;;146-988-830-328-636;;079-117-464-181-766;;159-200-196-700-263;;033-093-540-580-062;;000-572-155-574-53X;;011-246-353-857-210;;145-932-627-198-240;;030-541-408-727-343;;153-822-783-784-770;;007-251-062-496-699;;157-860-903-399-862;;061-486-848-693-613;;008-542-809-190-126;;144-112-959-044-117,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA,46,C12Y304/22028;;A61P35/00;;A61K38/4873;;A61K38/162;;A61K38/1793;;C12N9/506;;C12N15/86;;C12N2770/36122;;C12N2770/36121;;C07K14/005;;C12N7/00;;C12N2770/32134;;A61K2039/53;;A61K2039/55516;;A61K39/39;;A61K2039/876;;C07K14/005;;A61K2039/55516;;C12N2770/36121;;A61K2039/53;;C12N2770/36122;;C12N2770/36143;;A61K2039/6075;;C12N7/00;;C07K2319/00;;A61K2039/5256;;A61K2039/552;;C12N2770/36133;;A61K2039/585;;C12N9/506;;C12N2770/32134;;A61K39/12;;A61K38/162;;C12N2770/36134;;C12N15/86;;A61K38/1793;;C12N15/86;;C12N7/00;;C07K14/005;;A61K48/00;;A61K39/12;;A61K38/1793;;A61K38/4873;;A61K38/162;;A61P35/00;;C12N2770/36121;;C12N2770/36122;;C12N2770/36134;;C12N2770/36144;;C12N2770/32022;;C07K14/005;;A61K2039/585;;C12N9/506;;C12Y304/22028;;C07K14/7156;;C12N15/86;;A61P35/00;;A61K39/12;;A61K38/162;;A61K38/1793;;A61K38/4873;;A61K45/06;;C12N2770/36143;;C12N2770/36133;;C12N2770/36122;;C12N2770/36121;;A61K2039/552;;C12N2770/36134;;A61K2039/5256;;A61K2039/53;;C07K2319/00;;A61K2039/6075;;C12N7/00,C07K14/005;;A61K38/16;;A61K38/17;;A61K38/48;;A61K39/12;;A61K45/06;;A61P35/00;;C07K14/715;;C12N7/00;;C12N9/50;;C12N15/86,,12,4,019-987-576-673-098;;008-398-078-266-591;;027-678-975-979-423;;003-183-636-144-207,3088830;;10.1016/0042-6822(86)90142-x;;10.1099/0022-1317-73-12-3301;;1469368;;10.1016/0042-6822(89)90347-4;;2524126;;10.1074/jbc.271.9.4864;;8617757,Kinney et al. (Virology. 1986; 152: 400-413);;Kinney et al. (Journal of General Virology. 1992; 73: 3301-3305);;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 17;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 20;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 21;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 22;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 23;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 24;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 25;;sequence alignment of GenEmbl database accession no: EEVNSPEPA Kinney-1986 with: nt 500-7600 of instant SEQ ID NO: 26;;Kinney et al. (Virology. 1989; 170: 19-30);;Snijder et al. (Journal of Biological Chemistry. 1996; 271 (9): 4864-4871),ACTIVE
246,US,A1,US 2024/0067955 A1,087-647-117-405-022,2024-02-29,2024,US 202218261425 A,2022-01-20,GB 202100754 A;;GB 202116519 A;;GB 2022050158 W,2021-01-20,METHODS FOR HIGH THROUGHPUT SCREENING OF CHIMERIC ANTIGEN RECEPTORS,"A method for high-throughput screening of a chimeric antigen receptor (CAR) cell library is provided comprising the steps of (a) providing a recognition sequence library, a hinge region sequence library, a transmembrane sequence library and an intracellular domain sequence library; (b) preparing a CAR library; (c) preparing a CAR-cell library by introduction to, and expression of, the plurality of CAR sequences of the CAR library in one or more cells or a cell line; (d) screening the CAR-cell library in an assay; (e) evaluating the at least one function of each member of the CAR-cell library; (f) obtaining one or more sequences of one or more CARs expressed in the CAR-cell library and linking the obtained sequence(s) to the at least one function of the members of the CAR-cell library; g) identifying and selecting the or each sequence based on function. Methods of preparing the CAR library and a CAR-cell library and uses thereof are also provided.",CODING BIO LTD,BORNSCHEIN SIMON;;LAMPI YOULIA,CODING BIO LIMITED (2023-10-03),https://lens.org/087-647-117-405-022,Patent Application,yes,0,0,4,140-278-679-095-571;;072-841-812-650-34X;;087-647-117-405-022;;031-120-515-454-417,EP;;WO;;US;;CA,6,140-278-679-095-571;;072-841-812-650-34X;;053-129-622-717-832;;072-773-859-805-124;;087-647-117-405-022;;031-120-515-454-417,EP;;WO;;US;;CA;;GB,0,C07K14/7051;;C12N5/0636;;C12N2510/00;;G01N33/505;;G01N33/56972;;G01N33/6845;;C07K2319/00;;C07K2319/03;;C07K2319/33;;C12N2740/16043;;A61K2239/28;;A61K40/11;;A61K40/31;;A61K40/4215;;C12N15/1037;;C12N15/1055;;G01N33/6845;;A61K2239/28;;C12N5/0636;;A61K40/11;;A61K40/31;;A61K40/4215,C12N15/10;;G01N33/68,,0,0,,,,PENDING
247,US,A1,US 2024/0077478 A1,026-968-490-956-88X,2024-03-07,2024,US 202218262296 A,2022-01-20,FR 2100559 A;;EP 2022051259 W,2021-01-21,"SYSTEM FOR RAPID ANALYSIS OF A CAPILLARY BLOOD SAMPLE FROM A SUBJECT, INTENDED FOR DETECTING THE PRESENCE OF AT LEAST ONE ANALYTE IN SAID CAPILLARY BLOOD SAMPLE","Disclosed is a system for rapid analysis of a capillary blood sample from a subject, intended for detecting the presence of at least one analyte in the capillary blood sample. The rapid analysis system includes an analysis module in which is incorporated at least one immunochromatographic strip. The analysis module includes: a pricking member, suitable for generating a drop of capillary blood; and a collecting member, including a fixed duct, suitable for capillary blood to flow therethrough. The duct has an inlet suitable for collecting the drop of capillary blood, and an outlet, arranged opposite the deposition area and suitable for depositing the drop of capillary blood onto the deposition area, and a container, separate from/independent of the analysis module, in which is packed a buffer solution suitable for implementing the immunochromatographic technique.",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,NG BIOTECH (2023-09-01),https://lens.org/026-968-490-956-88X,Patent Application,yes,0,0,6,155-229-762-993-894;;029-059-928-128-933;;137-748-071-813-315;;128-681-643-629-960;;040-657-732-636-029;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,6,155-229-762-993-894;;029-059-928-128-933;;128-681-643-629-960;;040-657-732-636-029;;137-748-071-813-315;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,0,G01N33/54388;;G01N33/558;;G01N33/54388;;A61B5/150022;;A61B5/150267;;A61B5/150358;;A61B2560/0406;;A61B2560/0443;;G01N33/558,G01N33/543;;A61B5/15;;G01N33/558,,0,0,,,,PENDING
248,WO,A1,WO 2021/040086 A1,078-971-396-073-988,2021-03-04,2021,KR 2019011010 W,2019-08-28,KR 2019011010 W,2019-08-28,"NOVEL LACTIC ACID BACTERIA, AND COMPOSITION AND HEALTH FUNCTIONAL FOOD, EACH COMPRISING SAME","The present invention relates to Lactobacillus plantarum L-14 KCTC13497BP strain, and a composition and a health functional food, each comprising same, wherein the strain exhibits various activities such as antibacterial activity, anticancer activity, inhibition of differentiation to adipocytes, antiobesity activity, etc. Accordingly, the strain can be preferably utilized in a medicinal composition, a health functional food, and so on.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/078-971-396-073-988,Patent Application,yes,5,1,1,078-971-396-073-988,WO,1,078-971-396-073-988,WO,4,A01N63/10;;A23L33/135;;A61K8/99;;A61K35/747;;A61P29/00;;A61P31/04;;A61P35/00;;A61Q19/00;;C12N1/20;;C12N1/205;;C12R2001/25,C12N1/20;;A01N63/10;;A23L33/135;;A61K8/99;;A61K35/747;;A61P29/00;;A61P31/04;;A61P35/00;;A61Q19/00;;C12R1/25,,0,0,,,,PENDING
249,KR,A,KR 20230158258 A,089-433-950-591-135,2023-11-20,2023,KR 20220057747 A,2022-05-11,KR 20220057747 A,2022-05-11,Composition for Skin-lightening and Improving Wrinkles Using Wheat Bran Extracts and Fermented Wheat Bran,"Disclosed in the present invention are a composition for skin whitening and skin wrinkle alleviation using a wheat bran extract and a wheat bran fermented product that inhibits melanin biosynthesis and inhibits elastase and collagenase activity in mouse melanoma cells. The composition for skin whitening and skin wrinkle alleviation of the present invention can be commercialized as pharmaceuticals, functional foods, and the like.",MILEX BIOTECH,LEE HAI SOO,,https://lens.org/089-433-950-591-135,Patent Application,no,0,0,1,089-433-950-591-135,KR,1,089-433-950-591-135,KR,0,A23L33/105;;A23L7/115;;A23L7/104;;A61K8/9794;;A61Q19/02;;A61Q19/08;;A23V2200/318;;A23V2002/00;;A61K2800/85,A23L33/105;;A23L7/10;;A23L7/104;;A61K8/9794;;A61Q19/02;;A61Q19/08,,0,0,,,,DISCONTINUED
250,CO,A2,CO 2021013376 A2,094-245-079-296-583,2021-10-20,2021,CO 2021013376 A,2021-10-06,EP 2020059308 W;;EP 2019058635 W,2019-04-05,Preparación y almacenamiento de formulaciones de arn liposómico adecuadas para terapia,"La presente divulgación se refiere a métodos para preparar partículas de ARN lipoplejo para el suministro de ARN a tejidos diana después de la administración parenteral, en particular después de la administración intravenosa, y composiciones que comprenden tales partículas de ARN lipoplejo. La presente divulgación también se refiere a métodos que 5 permiten preparar partículas lipoplejo de ARN de una manera que cumple con las GMP industriales. Además, la presente divulgación se refiere a métodos y composiciones para almacenar partículas de ARN lipoplejo sin pérdida sustancial de la calidad del producto y, en particular, sin pérdida sustancial de actividad de ARN.",BIOTECH SE,HAAS HEINRICH;;HÖRNER SEBASTIAN;;HILLER THOMAS MICHAEL,,https://lens.org/094-245-079-296-583,Patent Application,no,0,0,22,144-169-015-054-817;;056-611-846-620-612;;104-436-998-407-064;;149-713-649-334-819;;136-257-571-216-071;;075-978-215-780-804;;071-050-837-529-944;;179-355-543-162-351;;099-030-719-710-951;;075-595-853-821-289;;094-245-079-296-583;;117-486-292-432-003;;126-233-214-021-234;;108-624-448-283-101;;028-353-109-557-882;;100-993-196-674-714;;127-545-460-518-683;;168-839-894-850-430;;095-285-896-873-451;;015-334-213-986-059;;165-972-243-510-92X;;096-920-128-931-555,AU;;JP;;CL;;US;;CO;;CA;;MX;;BR;;CU;;KR;;CN;;EP;;IL;;ES;;WO;;ZA;;SG;;DK,22,144-169-015-054-817;;056-611-846-620-612;;104-436-998-407-064;;149-713-649-334-819;;136-257-571-216-071;;075-978-215-780-804;;071-050-837-529-944;;179-355-543-162-351;;099-030-719-710-951;;075-595-853-821-289;;094-245-079-296-583;;117-486-292-432-003;;126-233-214-021-234;;108-624-448-283-101;;028-353-109-557-882;;100-993-196-674-714;;127-545-460-518-683;;168-839-894-850-430;;095-285-896-873-451;;015-334-213-986-059;;165-972-243-510-92X;;096-920-128-931-555,AU;;JP;;CL;;US;;CO;;CA;;MX;;BR;;CU;;KR;;CN;;EP;;IL;;ES;;WO;;ZA;;SG;;DK,0,A61K9/0019;;A61K9/08;;A61K9/19;;A61K9/1272;;A61K9/0019;;A61K9/08;;A61K9/1272;;A61K9/19;;A61K9/1272;;A61K47/02;;A61K47/26;;A61K47/22;;A61K47/183;;A61K9/19;;A61K9/08;;A61K9/0019;;A61K31/7105;;A61K31/7105;;A61K47/02;;A61K47/183;;A61K47/22;;A61K47/26,A61K9/00;;A61K9/08;;A61K9/127;;A61K9/19,,0,0,,,,PENDING
251,US,A1,US 2022/0098292 A1,146-259-696-598-191,2022-03-31,2022,US 202117474359 A,2021-09-14,US 202117474359 A;;US 202063078274 P,2020-09-14,"SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof","The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.",CELROS BIOTECH,BAE YUN SOO;;AN EUNJUNG;;YOO JUNG-YEON;;SHIM HYUNBO;;LEE HYE EUN,EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (2021-11-29);;CELROS BIOTECH (2021-11-24),https://lens.org/146-259-696-598-191,Patent Application,yes,2,0,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,100,C07K16/3053;;C07K16/18;;C07K2317/622;;C07K2317/92;;G01N33/532;;G01N33/533;;C07K2317/21;;A61P13/12;;A61P1/16;;C07K16/18;;A61P1/16;;A61P13/12;;G01N33/563;;C07K2317/622;;C07K2317/565;;C07K2317/92;;A61K2039/505;;C07K16/18;;G01N33/6854;;A61P1/16;;A61P13/12;;A61K2039/505;;C07K2317/52;;C07K2317/624;;C07K2317/622;;C07K2317/55;;C07K2317/565,C07K16/18;;A61P1/16;;A61P13/12;;G01N33/68,,2,1,027-477-313-726-928,6804947;;pmc346105;;10.1073/pnas.79.6.1979,"Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. 1982 Mar;79(6):1979-83. (Year: 1982);;Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295. (Year: 1993)",ACTIVE
252,EP,A1,EP 4165411 A1,147-781-090-954-815,2023-04-19,2023,EP 21730235 A,2021-06-08,FR 2006148 A;;FR 2012068 A;;EP 2021065306 W,2020-06-12,"SYSTEM FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLE, INTENDED FOR DETECTING THE PRESENCE OF AT LEAST ONE ANALYTE IN THE BIOLOGICAL SAMPLE",,NG BIOTECH,STANKOV MILOVAN,,https://lens.org/147-781-090-954-815,Patent Application,yes,0,0,5,197-877-393-616-549;;046-331-989-819-750;;027-789-513-586-109;;139-860-241-882-093;;147-781-090-954-815,EP;;WO;;FR,5,197-877-393-616-549;;046-331-989-819-750;;139-860-241-882-093;;027-789-513-586-109;;147-781-090-954-815,EP;;WO;;FR,0,G01N33/54388;;B01L3/5029;;B01L9/52;;B01L2300/0663;;B01L2300/0825;;B01L2300/0832;;B01L2300/0864,G01N33/558,,1,0,,,See references of WO 2021250006A1,DISCONTINUED
253,EP,A2,EP 4447861 A2,178-362-014-477-760,2024-10-23,2024,EP 22839210 A,2022-12-14,FR 2113580 A;;EP 2022085949 W,2021-12-15,IMPLANTABLE DEVICE WITH GRADUAL RELEASE OF ONE OR MORE FUNCTIONAL AGENTS AND METHOD FOR MANUFACTURING SUCH A DEVICE,,COUSIN BIOTECH,NOEL STÉPHANE,,https://lens.org/178-362-014-477-760,Patent Application,yes,0,0,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,0,A61F2/08;;A61F2250/0031;;A61F2250/0067;;A61F2210/0004;;A61L2430/10;;A61L27/54;;A61L27/58;;A61L27/18;;A61L27/34;;A61L2420/04;;A61L27/28;;A61L27/306;;A61L27/32;;A61L27/56;;A61F2/08;;A61F2210/0004,A61F2/08,,0,0,,,,PENDING
254,KR,A,KR 20230159996 A,177-033-175-458-727,2023-11-23,2023,KR 20220059494 A,2022-05-16,KR 20220059494 A,2022-05-16,Novel oxadiazole derivative compounds and pharmaceutical composition for preventing and treating neuroinflammatory disease comprising the same,"The present invention relates to a composition for preventing or treating neuroinflammatory diseases comprising a novel oxadiazole derivative compound or a pharmaceutically acceptable salt thereof. The present invention has an excellent effect with respect to NADPH oxidase (NOX) inhibition, has an excellent neuroinflammation inhibitory effect, and has excellent blood-brain barrier permeability and metabolic stability, thereby being used to treat neuroinflammatory diseases associated with NOX.",CELROS BIOTECH,YUN SOO BAE;;DA UN JEONG;;JIHYEON LEE,,https://lens.org/177-033-175-458-727,Patent Application,no,0,1,2,177-033-175-458-727;;080-979-757-936-303,KR;;WO,2,177-033-175-458-727;;080-979-757-936-303,KR;;WO,0,A61K31/4245;;A61P25/00;;C07D271/113;;C07D271/113;;A61K31/4245;;A61P25/00,C07D271/113;;A61K31/4245;;A61P25/00,,0,0,,,,PENDING
255,US,A1,US 2022/0281967 A1,076-776-223-761-858,2022-09-08,2022,US 202017632370 A,2020-07-30,EP 19306004 A;;EP 2020071547 W,2019-08-02,NOVEL IL-17B ANTIBODIES,The invention relates to novel IL-17B antagonist antibodies and their use in the diagnosis or treatment of IL-17B mediated diseases.,OREGA BIOTECH,BASTID JÉRÉMY;;BONNEFOY NATHALIE;;BENSUSSAN ARMAND;;ALBERICI GILLES,OREGA BIOTECH (2022-02-16),https://lens.org/076-776-223-761-858,Patent Application,yes,3,0,4,193-220-673-363-476;;021-826-985-741-412;;122-458-295-772-727;;076-776-223-761-858,JP;;EP;;WO;;US,4,193-220-673-363-476;;021-826-985-741-412;;122-458-295-772-727;;076-776-223-761-858,JP;;EP;;WO;;US,71,C07K16/24;;C07K16/244;;C07K2317/76;;C07K2317/34;;A61K39/3955;;C07K16/244;;C12N15/64;;C12P21/005;;G01N33/6869;;G01N2333/54,C07K16/24;;A61K39/395;;C12N15/64;;C12P21/00;;G01N33/68,,1,0,,,"""Q9UHF5.IL17B_Human"", Uniprot, accessed May 9, 2025. (Year: 2025)",PENDING
256,WO,A1,WO 2024/200464 A1,022-418-116-132-598,2024-10-03,2024,EP 2024058149 W,2024-03-26,FR 2302903 A,2023-03-27,"IMPLANTABLE DEVICE, IN PARTICULAR FOR PARIETAL REPAIR","The present invention relates to an implantable device, in particular for parietal surgery, comprising a warp knitted fabric, the knitted fabric comprising: - a first knitted layer comprising a monofilament yarn A knitted with knitted stitches; - a second knitted layer comprising a monofilament yarn B knitted with knitted stitches; - a third knitted layer with a monofilament yarn C knitted with knitted stitches; and - the warp knitted fabric comprises a knitted bottom and comprises gripping knitted loops which project from the knitted bottom and are inclined toward the knitted bottom. The present invention also relates to a method for producing such a device.",COUSIN BIOTECH,SOLECKI GILLES;;OUERGHEMMI SAFA;;CAILLIBOTTE MICHEL,,https://lens.org/022-418-116-132-598,Patent Application,yes,5,0,3,002-940-935-945-732;;053-980-496-867-926;;022-418-116-132-598,WO;;FR,3,022-418-116-132-598;;053-980-496-867-926;;002-940-935-945-732,WO;;FR,0,D04B21/12;;D04B21/04;;D10B2509/08;;A61F2002/0068,D04B21/04;;A61F2/00;;D04B21/12,,0,0,,,,PENDING
257,WO,A2,WO 2022/165340 A2,000-030-189-779-422,2022-08-04,2022,US 2022/0014572 W,2022-01-31,US 202163144068 P,2021-02-01,UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION,"The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (TH) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavims, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene uder the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.",AEGLE BIOTECH,LUBIT BEVERLY;;GARIBYAN LILIT;;HAO HELEN;;O'CONNELL SEAN,,https://lens.org/000-030-189-779-422,Patent Application,yes,0,4,3,063-495-431-381-013;;000-030-189-779-422;;027-433-889-927-680,WO;;US,3,063-495-431-381-013;;000-030-189-779-422;;027-433-889-927-680,WO;;US,12,A61P31/16;;C07K14/005;;C12N2740/16122;;C12N2740/16134;;C12N2740/16222;;C12N2740/16234;;C12N2770/20022;;C12N2770/20034;;A61K39/145;;A61K2039/543;;A61K2039/545;;A61K2039/572;;A61P31/16;;C07K14/005;;C12N7/00;;C12N15/86,A61K39/145,,0,0,,,,PENDING
258,WO,A1,WO 2021/023624 A1,021-826-985-741-412,2021-02-11,2021,EP 2020071547 W,2020-07-30,EP 19306004 A,2019-08-02,NOVEL IL-17B ANTIBODIES,The invention relates to novel IL-17B antagonist antibodies and their use in the diagnosis or treatment of IL-17B mediated diseases.,OREGA BIOTECH,BASTID JÉRÉMY;;BONNEFOY NATHALIE;;BENSUSSAN ARMAND;;ALBERICI GILLES,,https://lens.org/021-826-985-741-412,Patent Application,yes,41,0,4,193-220-673-363-476;;021-826-985-741-412;;122-458-295-772-727;;076-776-223-761-858,JP;;EP;;WO;;US,4,193-220-673-363-476;;021-826-985-741-412;;122-458-295-772-727;;076-776-223-761-858,JP;;EP;;WO;;US,71,C07K16/24;;C07K16/244;;C07K2317/34;;C07K2317/76;;C07K16/244;;A61K39/3955;;C12N15/64;;C12P21/005;;G01N33/6869;;G01N2333/54,C07K16/24,,49,32,074-817-300-512-106;;004-967-483-820-738;;049-134-753-209-354;;017-150-654-990-340;;002-264-966-090-625;;047-628-694-575-326;;019-054-728-196-071;;127-328-160-524-466;;008-112-873-506-738;;004-659-036-981-797;;053-251-957-094-365;;051-940-176-386-905;;030-607-398-087-475;;006-759-717-925-361;;042-204-626-457-327;;016-599-925-793-124;;022-023-983-891-895;;010-157-107-750-37X;;039-004-732-914-566;;115-435-737-255-802;;010-670-795-970-321;;000-499-911-678-177;;083-019-407-395-691;;106-366-349-457-629;;110-064-055-648-252;;004-835-722-303-291;;054-802-024-202-015;;026-348-959-945-874;;060-228-863-888-525;;049-686-753-852-759;;071-905-879-572-474;;110-781-390-248-557,2677748;;10.1038/341544a0;;6409417;;10.1016/0092-8674(83)90014-4;;10.1016/0022-2836(87)90412-8;;3681981;;10.1126/science.3140379;;3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2820955;;10.1093/oxfordjournals.jbchem.a121995;;10.1016/0006-291x(87)90502-x;;3122749;;10.1016/s0092-8674(85)80021-0;;3921262;;1366592;;10.1007/bf00143675;;6327467;;10.1016/0378-1119(84)90143-4;;10.1073/pnas.78.3.1527;;pmc319164;;6262811;;10.1073/pnas.77.7.4216;;6933469;;pmc349802;;10.1073/pnas.81.21.6851;;6436822;;pmc392030;;10.1016/0022-1759(94)90096-5;;8308283;;10.1038/332323a0;;3127726;;6095112;;10.1038/312604a0;;10.1016/0161-5890(91)90163-e;;1905784;;7937712;;10.1093/protein/7.6.805;;8302875;;10.1073/pnas.91.3.969;;pmc521435;;6175244;;10.1016/0003-2697(81)90168-8;;10.1016/0076-6879(87)38030-9;;2439875;;1402660;;10.1084/jem.176.4.1191;;pmc2119390;;1573276;;10.4049/jimmunol.148.9.2918;;11058597;;10.1074/jbc.m008289200;;10.1007/978-3-662-04605-0;;10.1165/rcmb.2005-0034oc;;15860795;;10.1038/nri2586;;pmc2821718;;19575028;;21349428;;10.1016/j.immuni.2011.02.012;;21993848;;10.1038/ni.2156;;10.1002/art.23455;;18512780;;10.4049/jimmunol.169.2.642;;12097364;;17982105;;10.4049/jimmunol.179.10.7128,"WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;GILLIES SD ET AL., CELL, vol. 33, no. 3, 1983, pages 717 - 28;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;""FUNDAMENTAL IMMUNOLOGY"", 1993;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MIZUKAMI T ET AL., J BIOCHEM, vol. 101, no. 5, 1987, pages 1307 - 10;;KUWANA Y ET AL., BIOCHEM BIOPHYS RES COMM., vol. 149, no. 3, 1987, pages 960 - 8;;MASON JO ET AL., CELL, vol. 41, no. 2, 1985, pages 479 - 87;;MIYAJI H ET AL., CYTOTECHNOLOGY, vol. 3, no. 2, 1990, pages 133 - 140;;BRADY G ET AL., GENE, vol. 27, no. 2, 1984, pages 223 - 32;;O'HARE K ET AL., PROC. NATL. ACAD. SCI USA, vol. 78, no. 3, 1981, pages 1527 - 31;;URLAUB G, PROC NATL ACAD SCI USA, vol. 77, no. 7, 1980, pages 4216 - 20;;MORRISON SL ET AL., PROC NATL ACAD SCI USA, vol. 81, no. 21, 1984, pages 6851 - 5;;SHITARA K ET AL., J IMMUNOL METHODS, vol. 167, no. 1-2, 1994, pages 271 - 8;;RIECHMANN L ET AL., NATURE, vol. 332, no. 6162, 1988, pages 323 - 7;;NEUBERGER MS ET AL., NATURE, vol. 312, no. 5995, 1985, pages 604 - 8;;PADLAN EA, MOL IMMUNOL., vol. 28, no. 4-5, 1991, pages 489 - 98;;STUDNICKA GM ET AL., PROTEIN ENG., vol. 7, no. 6, 1994, pages 805 - 14;;ROGUSKA MA ET AL., PROC NATL ACAD SCI USA, vol. 91, no. 3, 1994, pages 969 - 73;;EDGE, AS ET AL., ANAL BIOCHEM, vol. 118, no. 1, 1981, pages 131 - 7;;THOTAKURA, NR ET AL., METHODS ENZYMOL., vol. 138, 1987, pages 350 - 9;;CARON PC ET AL., J. EXP. MED., vol. 176, no. 4, 1992, pages 1191 - 5;;SHOPES B.,, J. IMMUNOL., vol. 148, no. 9, 1992, pages 2918 - 22;;JALKANEN ET AL., J. CELL. BIOL., vol. 101, 1985, pages 1287 - 1288;;JALKANEN ET AL., J. CELL BIOL., vol. 105, 1987, pages 3087 - 1038,1570-1580;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", vol. 1, 1989, JOHN WILEY & SONS, INC.;;SAMBROOK ET AL.: ""Molecular Cloning A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;LEE, J. ET AL.: ""IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rhl"", J BIOL CHEM, vol. 276, no. 2, 2001, pages 1660 - 1664, XP002196319, DOI: 10.1074/jbc.M008289200;;""DNA Cloning"", vol. I, II, 1985;;PERBAL: ""Transcription And Translation"", 1984, ACADEMIC PRESS, INC., article ""A Practical Guide To Molecular Cloning; the treatise"";;FRESHNEY: ""Immunochemical Methods In Cell And Molecular Biology"", 1987, COLD SPRING HARBOR LABORATORY;;""Handbook Of Experimental Immunology"", vol. I-IV, 1986, COLD SPRING HARBOR LABORATORY PRESS;;""Protein Engineering, A Practical Approach"", vol. 154 ; 155, 1995, IRL PRESS AT OXFORD UNIV. PRESS, article ""General principles of protein engineering are set forth"";;CAMPBELL ET AL.: ""Laboratory Techniques in Biochemistry and Molecular Biology"", 1984, SINAUER ASSOCIATES, article ""Monoclonal Antibody Technology"";;""Current Protocols in Immunology"", 1994, JOHN WILEY & SONS;;""Monoclonal Antibodies, Hybridoma: A New Dimension in Biological Analyses"", 1980, W.H. FREEMAN AND CO.;;KLEIN: ""J., Immunology: The Science of Self-Nonself Discrimination"", 1982, JOHN WILEY & SONS;;""Kuby Immunnology"", 2000, H. FREEMAND & CO.;;KONTERMANNDUBEL: ""Antibody Engineering"", 2001, SPRINGER VERLAN;;WONG, C. K. ET AL.: ""Interleukin-25-induced chemokines and interleukin-6 release from eosinophils is mediated by p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and nuclear factor-kappaB"", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 33, no. 2, 2005, pages 186 - 194;;DIEFFENBACHDVEKSLER: ""PCR Primer"", vol. VIII, 2003, COLD SPRING HARBOR PRESS;;HARLOWLANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;GAFFEN, S. L.: ""Structure and signalling in the IL-17 receptor family"", NATURE REVIEWS. IMMUNOLOGY, vol. 9, no. 8, 2009, pages 556 - 567, XP055052444, DOI: 10.1038/nri2586;;IWAKURA, Y. ET AL.: ""Functional specialization of interleukin-17 family members"", IMMUNITY, vol. 34, no. 2, 2011, pages 149 - 162, XP055537648, DOI: 10.1016/j.immuni.2011.02.012;;RAMIREZ-CARROZZI, V. ET AL.: ""IL-17C regulates the innate immune function of epithelial cells in an autocrine manner"", NAT IMMUNOL, vol. 12, no. 12, 2011, pages 1159 - 1166, XP002666790, DOI: 10.1038/NI.2156;;STAMP, L. K. ET AL.: ""Different T cell subsets in the nodule and synovial membrane: absence of interleukin-17A in rheumatoid nodules"", ARTHRITIS RHEUM, vol. 58, no. 6, 2008, pages 1601 - 1608;;STARNES, T. ET AL.: ""Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis"", J IMMUNOL, vol. 169, no. 2, 2002, pages 642 - 646, XP002471332;;YAMAGUCHI: ""IL-17B and IL-17C are associated with TNF-a production and contribute to the exacerbation of inflammatory arthritis"", J. IMMUNOL, vol. 179, 2007, pages 7128 - 7136, XP002629391",PENDING
259,WO,A1,WO 2020/249895 A1,075-787-912-294-121,2020-12-17,2020,FR 2020050975 W,2020-06-09,FR 1906208 A,2019-06-11,COMBINATION OF MARKERS FOR PREDICTING THE RESPONSE TO VX-001,"The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids - native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.",VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS (KOSTAS);;MENEZ-JAMET JEANNE,,https://lens.org/075-787-912-294-121,Patent Application,yes,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,2,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/00;;A61K39/395;;A61P35/00;;G01N33/50,,14,8,006-397-181-302-362;;023-807-389-777-602;;004-308-421-751-408;;022-737-803-341-920;;023-807-389-777-602;;016-640-527-380-991;;037-092-608-111-221;;046-503-066-966-531,10.1038/s41416-020-0785-y;;pmc7217860;;32210365;;10.1016/j.cllc.2013.02.001;;23647738;;21873272;;10.1093/annonc/mdr396;;26802161;;10.1093/annonc/mdw016;;10.1016/j.cllc.2013.02.001;;23647738;;10.21037/atm.2016.05.15;;pmc4971378;;27563653;;29327044;;pmc5885829;;10.1001/jamaoncol.2017.4771;;11093159;;10.1002/1521-4141(2000012)30:12<3411::aid-immu3411>3.0.co;2-r,"CESARE GRIDELLI ET AL: ""Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial"", BRITISH JOURNAL OF CANCER, 25 March 2020 (2020-03-25), GB, XP055680259, ISSN: 0007-0920, DOI: 10.1038/s41416-020-0785-y;;GEORGOULIAS VASSILIS ET AL: ""A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics"", CLINICAL LUNG CANCER JUL 2013,, vol. 14, no. 4, 1 July 2013 (2013-07-01), pages 461 - 465, XP002774759, ISSN: 1938-0690, DOI: 10.1016/J.CLLC.2013.02.001;;ANONYMOUS: ""vaxon-biotech > VX-001"", 8 April 2017 (2017-04-08), XP055680260, Retrieved from the Internet <URL:https://web.archive.org/web/20170408155422/http://vaxon-biotech.com/?page_id=122> [retrieved on 20200327];;ANONYMOUS: ""Novel Vaccine Shows Association With Survival Based on Smoking History in Patients With Advanced NSCLC"", 18 September 2017 (2017-09-18), XP055680262, Retrieved from the Internet <URL:https://www.targetedonc.com/conference/esmo-2017/novel-vaccine-shows-association-with-survival-based-on-smoking-history-in-patients-with-advanced-nsclc> [retrieved on 20200327];;KOTSAKIS A ET AL: ""Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: Results of an expanded phase II study"", ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, vol. 23, no. 2, 1 February 2012 (2012-02-01), pages 442 - 449, XP002724182, ISSN: 0923-7534, [retrieved on 20110825], DOI: 10.1093/ANNONC/MDR396;;ANONYMOUS: ""Lung cancer: Vaxon announces results of its Vx-001 therapeutic vaccine Phase IIb trial - Andrew Lloyd & Associates"", 1 June 2017 (2017-06-01), XP055680267, Retrieved from the Internet <URL:https://ala.com/vaxon-announces-results-of-its-phase-iib-lung-cancer-trial-of-vx-001-a-therapeutic-vaccine-based-on-optimized-cryptic-peptides/> [retrieved on 20200327];;FERRUCCI ET AL., ANNALS ONCOL., 2016;;GEORGOULIAS ET AL., CLIN LUNG CANCER., 2013;;FERRUCCI ET AL., ANNALS ONCOL, 2016;;FERRUCCI PFASCIERTO PA ET AL.: ""Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab."", ANN ONCOL., vol. 27, no. 4, pages 732 - 8;;GEORGOULIAS V ET AL.: ""A multicenter randomized phase llb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics"", CLIN LUNG CANCER., vol. 14, no. 4, July 2013 (2013-07-01), pages 461 - 5, XP002774759, DOI: 10.1016/j.cllc.2013.02.001;;MENEZ-JAMET J ET AL.: ""Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines"", ANN TRANSI MED., vol. 4, no. 14, July 2016 (2016-07-01), pages 266, XP055415775, DOI: 10.21037/atm.2016.05.15;;MEZQUITA, L. ET AL.: ""Association of the Lung Immune Prognostic Index With Immune checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer"", JAMA ONCOL., vol. 4, no. 3, 1 March 2018 (2018-03-01), pages 351 - 357;;TOURDOT S ET AL.: ""A général strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes"", EUR J IMMUNOL., vol. 30, no. 12, December 2000 (2000-12-01), pages 3411 - 21, XP002781815, DOI: 10.1002/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0.CO;2-R",PENDING
260,KR,A,KR 20230051010 A,091-945-640-135-784,2023-04-17,2023,KR 20210134489 A,2021-10-08,KR 20210134489 A,2021-10-08,carbon dioxide mitigation system in multiuse facility using photosynthetic microalgae,"The present invention relates to a carbon reduction system using microalgae in multi-use facilities. According to the present invention, devices such as an advertising panel part, a lighting panel part, and a microalgae culture part stably supply carbon and light to microalgae and allow a microalgae culture medium to absorb fine dust through a special fan. According to the present invention, the air in multi-use facilities can be purified.",WATER BIOTECH,SEO HAE DONG;;LEE HEON WOO,,https://lens.org/091-945-640-135-784,Patent Application,no,0,0,1,091-945-640-135-784,KR,1,091-945-640-135-784,KR,0,Y02A50/20;;B01D53/84;;B01D53/62;;F21V33/0064;;C12N1/12;;C12M41/08;;C12M41/34;;B01D2251/95;;F21Y2115/10,B01D53/84;;B01D53/62;;C12M1/34;;F21V33/00,,0,0,,,,DISCONTINUED
261,FR,A1,FR 3119023 A1,137-748-071-813-315,2022-07-22,2022,FR 2100559 A,2021-01-21,FR 2100559 A,2021-01-21,"Système pour l’analyse rapide d’un échantillon de sang capillaire provenant d’un sujet, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon de sang capillaire","La présente invention concerne un système pour l’analyse rapide d’un échantillon de sang capillaire provenant d’un sujet, destiné à la détection de la présence d’au moins un analyte (A) dans ledit échantillon de sang capillaire (E). Le système d’analyse rapide (1) comprend : (i) un module d’analyse (2) dans lequel est incorporée au moins une bandelette immunochromatographique (4), lequel module d’analyse (2) comporte : - un organe piqueur (7), adapté à générer une goutte de sang capillaire, et - un organe collecteur (8) comprenant un conduit (81), fixe, adapté à un écoulement du sang capillaire, lequel conduit (81) comporte une entrée (811) adaptée à la collecte de ladite goutte de sang capillaire, et une sortie (812), ménagée en regard d’une zone de dépôt (41) et adaptée à la dépose de ladite goutte de sang capillaire sur ladite zone de dépôt (41), et (ii) un réservoir (5), distinct / indépendant dudit module d’analyse (2), dans lequel est conditionné une solution tampon (51) adaptée à la mise en œuvre de ladite technique immunochromatographique. Figure pour l’abrégé : 1",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/137-748-071-813-315,Patent Application,no,5,0,6,155-229-762-993-894;;029-059-928-128-933;;137-748-071-813-315;;128-681-643-629-960;;040-657-732-636-029;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,6,155-229-762-993-894;;029-059-928-128-933;;128-681-643-629-960;;040-657-732-636-029;;137-748-071-813-315;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,0,G01N33/54388;;G01N33/558;;G01N33/54388;;A61B5/150022;;A61B5/150267;;A61B5/150358;;A61B2560/0406;;A61B2560/0443;;G01N33/558,G01N33/558;;A61B5/1468;;A61M5/32,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",ACTIVE
262,KR,A,KR 20220053216 A,116-412-637-856-402,2022-04-29,2022,KR 20200137400 A,2020-10-22,KR 20200137400 A,2020-10-22,COMPOSITION FOR PROMOTING BORN FORMATION,"The present invention relates to a composition for promoting osteoblast comprising Enterococcus faecium L15 KCTC13498BP. The composition of the present invention can promote osteoblast and stem cell osteogenic differentiation induction, and can prevent or treat bone diseases treatable by bone formation or bone regeneration.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/116-412-637-856-402,Patent Application,no,2,1,3,051-695-701-640-670;;025-242-249-070-338;;116-412-637-856-402,KR;;WO,3,051-695-701-640-670;;025-242-249-070-338;;116-412-637-856-402,KR;;WO,24,A61K35/744;;A61L27/54;;A61P19/00;;C12N1/20;;C12N5/06;;C12R2001/46;;C12N5/0654;;A61K35/744;;A61L27/54;;A61L2430/02;;A61P19/00;;C12N2500/72;;C12N2501/90;;C12N2506/1361;;C12R2001/46,C12N5/077;;A61K35/744;;A61L27/54;;A61P19/00;;C12R1/46,,4,0,,,"KIM, H. 등, Internatinal Journal of Molecular Sciences, 2019, 20권, 문헌번호 624, 페이지 1-10;;KIM, K. 등, Probiotics and Antimicrobial Proteins, 2020.03.11, 12권, 페이지 1492-1501;;DENG, Z. 등, Biotechnology letters, 2016, 38권, 페이지 1443-1448;;ABDHUL, K. 등, International Journal of Biological Macromolecules, 2014, 70권, 페이지 450-454",ACTIVE
263,KR,A,KR 20230116180 A,119-464-359-856-587,2023-08-04,2023,KR 20220012792 A,2022-01-28,KR 20220012792 A,2022-01-28,Method for Preparing Cakes Using an Extract of Wheat Bran,"The present invention relates to a method for producing bread using a wheat bran extract. The bread obtained according to the method of the present invention has improved storage properties and has anti-obesity functionality. The method for producing bread includes the steps of: (a) adding a wheat bran extract to bread ingredients, mixing the same and kneading the dough; and (b) molding the dough into an appropriate size and baking the same.",MILEX BIOTECH,LEE HAI SOO,,https://lens.org/119-464-359-856-587,Patent Application,no,0,0,1,119-464-359-856-587,KR,1,119-464-359-856-587,KR,0,A21D2/36;;A21D8/06;;A21D13/047;;A23V2002/00;;A23V2200/332;;A23V2250/21,A21D2/36;;A21D8/06;;A21D13/047,,0,0,,,,DISCONTINUED
264,KR,A,KR 20220112239 A,126-708-672-769-000,2022-08-10,2022,KR 20227001011 A,2020-06-09,FR 1906208 A;;FR 2020050975 W,2019-06-11,Vx-001에 대한 반응을 예측하기 위한 마커의 조합,"본 발명은 정상 수준의 감마 글루타민 전이효소(gGT) 및/또는 정상 수준의 젖산 탈수소효소(LDH)를 갖는 HLA-A*0201 환자의, 텔로머라제 역전사효소(TERT)를 발현하는 종양(tumor)의 치료를 위한, 종양 세포에 의해 발현되는 천연 크립틱 TERT572 (RLFFYRKSV, SEQ ID No. 1), 및 이의 최적화된 발현체 TERT572Y (YLFFYRKSV, SEQ ID No. 2)의, 9개 아미노산의 2개의 펩타이드로 구성된, 항-종양 백신의 용도에 관한 것이다.",VAXON BIOTECH,MENEZ JAMET JEANNE;;KOSMATOPOULOS KOSTANTINOS (KOSTAS),,https://lens.org/126-708-672-769-000,Patent Application,no,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,4,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/00;;A61P35/00,,0,0,,,,PENDING
265,BR,A2,BR 112020026157 A2,120-385-487-064-832,2021-03-16,2021,BR 112020026157 A,2019-06-21,EP 2019066522 W;;FR 1855590 A,2018-06-22,"matriz dérmica acelular, em particular para próteses mamárias","matriz dérmica acelular, em particular para próteses mamárias. o objeto da invenção é uma matriz dérmica acelular (1) que compreende uma folha sólida e flexível (10) que tem uma multiplicidade de aberturas (4), e é caracterizada pelo fato de que as aberturas (4) exibem uma forma alongada, em particular formando fendas (40). as aberturas podem particularmente se abrir em forma de losango.",MECCELLIS BIOTECH,ANTHONY PERES;;AURÉLIE LAMMELIN;;GUILLAME HOFMANSKI,,https://lens.org/120-385-487-064-832,Patent Application,no,0,0,6,139-547-900-762-909;;070-098-005-354-797;;120-385-487-064-832;;090-394-499-961-280;;156-613-870-734-649;;027-370-764-314-367,EP;;WO;;US;;BR;;FR,6,139-547-900-762-909;;090-394-499-961-280;;120-385-487-064-832;;070-098-005-354-797;;156-613-870-734-649;;027-370-764-314-367,EP;;WO;;US;;BR;;FR,0,A61F2/0063;;A61F2/0077;;A61F2/12;;A61L27/362;;A61L27/50;;A61L2430/04;;A61L27/3683;;A61L27/362;;A61L27/3683;;A61L27/50;;A61L2430/04,A61F2/10;;A61F2/12,,0,0,,,,DISCONTINUED
266,FR,A1,FR 3142094 A1,140-591-710-197-578,2024-05-24,2024,FR 2212116 A,2022-11-21,FR 2212116 A,2022-11-21,DISPOSITIF DE REGENERATION OSSEUSE,"La présente invention concerne un dispositif (1) destiné à la régénération osseuse qui comprend une plaque de recouvrement réalisée sur mesure qui recouvre un défaut osseux dont la forme permet de recréer la surface de l’os préalablement à l’apparition du défaut osseux, laquelle plaque de recouvrement s’appuie sur l’os sain encadrant ledit défaut osseux et est réalisée en titane de grade 1 ou de grade 2.",BIOTECH DENTAL,KELLER PIERRE,,https://lens.org/140-591-710-197-578,Patent Application,no,5,0,4,034-331-614-393-962;;003-490-762-913-644;;140-591-710-197-578;;183-335-424-671-299,EP;;US;;FR,4,140-591-710-197-578;;003-490-762-913-644;;034-331-614-393-962;;183-335-424-671-299,EP;;US;;FR,0,B33Y80/00;;A61L2430/02;;A61L31/022;;A61L31/146;;A61L2430/12;;A61F2/2803;;A61F2002/285;;A61F2002/3092;;A61F2002/3093;;A61F2002/30957;;A61F2002/30985;;A61F2310/00023,A61L27/06;;A61F2/28,,1,1,104-634-992-853-626,28251470;;10.1007/s10856-017-5862-2,"ZHU WEI ET AL: ""3D-printed porous titanium changed femoral head repair growth patterns: osteogenesis and vascularisation in porous titanium"", JOURNAL OF MATERIALS SCIENCE: MATERIALS IN MEDICINE, SPRINGER US, NEW YORK, vol. 28, no. 4, 1 March 2017 (2017-03-01), pages 1 - 11, XP036202525, ISSN: 0957-4530, [retrieved on 20170301], DOI: 10.1007/S10856-017-5862-2",PENDING
267,KR,A,KR 20230030940 A,144-347-514-658-796,2023-03-07,2023,KR 20210113219 A,2021-08-26,KR 20210113219 A,2021-08-26,A cosmetic composition containing a sea urchin roe hydrolyzate or a sea urchin roe hydrolyzed fermented product which has a function of improving wrinkles and regenerating skin and a method for producing the same,"The present invention relates to a cosmetic composition having wrinkle-alleviating and skin regenerating functions, and more specifically, provides a cosmetic composition having wrinkle-alleviating and skin regenerating functions by containing a sea urchin hydrolyzate or a fermented sea urchin hydrolyzed product as an active ingredient. According to the present invention, the sea urchin hydrolyzate or the fermented sea urchin hydrolyzed product has effects of exhibiting an antioxidant function of ABTS radical scavenging activity and DPPH radical scavenging activity, a wrinkle alleviating function by elastase inhibitory activity and a skin regeneration function by skin cell proliferation activity.",SUNMARINE BIOTECH,PARK SI HYANG;;JUNG JAE EUN;;KIM YE RA;;PARK YONG OH,,https://lens.org/144-347-514-658-796,Patent Application,no,7,0,2,026-695-048-990-865;;144-347-514-658-796,KR,2,026-695-048-990-865;;144-347-514-658-796,KR,0,A61K8/987;;A61Q19/00;;A61Q19/08;;A61K2800/85;;A61K2800/522;;A61K2800/782,A61K8/98;;A61Q19/00;;A61Q19/08,,0,0,,,,ACTIVE
268,KR,A,KR 20220117043 A,152-436-699-744-942,2022-08-23,2022,KR 20210020659 A,2021-02-16,KR 20210020659 A,2021-02-16,Carbon dioxide reduction lighting system using microalgae,"The present invention relates to a lighting system for reducing carbon dioxide using microalgae. The lighting system for reducing carbon dioxide fixedly installs microalga filters on four surfaces inside the appearance of the lighting system for reducing carbon dioxide and devices for light intensity and culture adjustment on an inner surface of a lower portion, installs a microalga filter fixing frame, and uses a transparent material in the microalga filters to culture microalgae, thereby reducing carbon dioxide.",WATER BIOTECH,SEO HAE DONG,,https://lens.org/152-436-699-744-942,Patent Application,no,0,0,1,152-436-699-744-942,KR,1,152-436-699-744-942,KR,0,Y02A50/20;;F21V33/0064;;B01D53/84;;C12M23/22;;C12M25/02;;C12M41/08;;C12M41/34;;C12N1/12;;F21Y2115/10,F21V33/00;;B01D53/84;;C12M1/00;;C12M1/12;;C12M1/34;;C12N1/12,,0,0,,,,DISCONTINUED
269,WO,A1,WO 2024/220212 A1,118-651-602-690-001,2024-10-24,2024,US 2024/0021859 W,2024-03-28,US 202318136419 A,2023-04-19,CRYOPRESERVATION DEVICE WITH INTEGRATED TRACKING DEVICE CHAMBER,The present invention provides a cryopreservation device with an integrated tracking device chamber. The tracking device can be an RFID tag which can be placed in the cryopreservation device as part of the procedure for vitrification of a biological specimen. The cryopreservation device maintains its integrity and keeps the RFID tag securely in the chamber at both ambient conditions when the specimen is collected and under liquid nitrogen where the specimen is stored. The cryopreservation device with an integrated tracking device chamber allows for each individual biological sample to have its own tracking device for monitoring during cryogenic storage.,BIOTECH INC,PARRA-ALMANZA JORGE,,https://lens.org/118-651-602-690-001,Patent Application,yes,1,0,6,170-381-455-868-719;;061-368-949-232-149;;131-163-295-300-269;;118-651-602-690-001;;016-237-892-665-506;;117-296-648-200-709,AR;;CL;;WO;;US,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,G06K19/0723;;A01N1/147;;G06K19/0723;;A01N1/146,A01N1/02,,0,0,,,,PATENTED
270,CA,A1,CA 3215464 A1,141-325-916-412-450,2022-10-20,2022,CA 3215464 A,2022-04-15,US 202163175603 P;;US 2022/0024946 W,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE,"In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or grafi-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmimized egg product obtained from an egg- producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecaUs, Enterococcus faecalis eytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis. isolated Enterococcus faecal is eytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.",PRODIGY BIOTECH,IYER SUBRAMANIAN V;;PATEL SUNNY,,https://lens.org/141-325-916-412-450,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,PENDING
271,KR,A,KR 20250115295 A,033-392-726-099-656,2025-07-30,2025,KR 20240113732 A,2024-08-23,KR 20240008776 A,2024-01-19,- Anti-erythrocyte antibodies and use thereof for hemostasis,"본 발명은 적혈구의 응집을 촉진하는 항체를 지혈제로 제공한다. 본 발명의 지혈제는 합성고분자를 이용한 지혈제와 달리 재조합 인간화 단클론 항체를 이용하는 바 생체 적합성 및 생분해성이 우수하고 대량생산이 가능하며, 항원-항체 면역반응을 이용하여 신속한 지혈이 가능한 바, 외상성 상처뿐만 아니라 주술기 혈액응고 관리, 수술과정 중 출혈 조절이 가능하다. 본 발명의 지혈제는 연고, 반찬고형, 액상, 에어로졸, 스프레이 형태 및 파우더형 등 다양한 형태의 지혈제로 이용될 수 있다.",BOREDA BIOTECH,CHOI DONG OK,,https://lens.org/033-392-726-099-656,Patent Application,no,0,0,1,033-392-726-099-656,KR,1,033-392-726-099-656,KR,0,C07K16/36;;A61P7/04;;A61L24/0005;;A61F2013/00463;;A61L2400/04;;A61K2039/505,C07K16/36;;A61F13/00;;A61K39/00;;A61L24/00;;A61P7/04,,1,1,028-570-753-771-055,10.7317/pk.2019.43.4.629,"Polymer(Korea), Vol. 43, No. 4, pp. 629-639 (2019)",PENDING
272,CL,A1,CL 2023003066 A1,122-898-617-556-701,2024-05-03,2024,CL 2023003066 A,2023-10-13,US 202163175603 P,2021-04-16,Producto de huevo hiperinmunizado para hepatopatía alcohólica y la enfermedad de injerto contra el hospedero,"En un aspecto, la presente divulgación se dirige a un método para prevenir o tratar la enfermedad hepática alcohólica o la enfermedad de injerto contra el hospedero en un sujeto que lo necesite, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un producto de huevo hiperinmunizado obtenido de un animal productor de huevos, previniendo o tratando así la enfermedad hepática alcohólica o la enfermedad de injerto contra el hospedero en el sujeto, en donde el producto de huevo hiperinmunizado comprende una cantidad terapéuticamente efectiva de uno o más anticuerpos contra un antígeno seleccionado del grupo que consiste en Enterococcus faecalis, la toxina citolisina de Enterococcus faecalis, y Enterococcus faecium. La presente divulgación también se dirige a huevos hiperinmunizados y productos de huevo producidos por un animal que se hiperinmunizó con un antígeno seleccionado del grupo que consiste en Enterococcus faecalis, la toxina citolisina aislada de Enterococcus faecalis, y Enterococcus faecium. Los métodos para preparar los huevos hiperinmunizados y los productos de huevo también se divulgan.",PRODIGY BIOTECH,SUBRAMANIAN V IYER;;SUNNY PATEL,,https://lens.org/122-898-617-556-701,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16,,0,0,,,,PENDING
273,US,A1,US 2023/0295241 A1,011-246-353-857-210,2023-09-21,2023,US 202318167257 A,2023-02-10,US 202318167257 A;;US 202217698300 A;;US 202163163475 P,2021-03-19,ARTIFICIAL ALPHAVIRUS-DERIVED RNA REPLICON EXPRESSION SYSTEMS,"Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.",TIBA BIOTECH,CHAHAL JASDAVE S;;MCPARTLAN JUSTINE S,TIBA BIOTECH LLC (2022-04-04),https://lens.org/011-246-353-857-210,Patent Application,yes,0,0,16,156-730-897-184-635;;123-822-468-012-115;;146-988-830-328-636;;079-117-464-181-766;;159-200-196-700-263;;033-093-540-580-062;;000-572-155-574-53X;;011-246-353-857-210;;145-932-627-198-240;;030-541-408-727-343;;153-822-783-784-770;;007-251-062-496-699;;157-860-903-399-862;;061-486-848-693-613;;008-542-809-190-126;;144-112-959-044-117,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA,16,156-730-897-184-635;;123-822-468-012-115;;146-988-830-328-636;;079-117-464-181-766;;159-200-196-700-263;;033-093-540-580-062;;000-572-155-574-53X;;011-246-353-857-210;;145-932-627-198-240;;030-541-408-727-343;;153-822-783-784-770;;007-251-062-496-699;;157-860-903-399-862;;061-486-848-693-613;;008-542-809-190-126;;144-112-959-044-117,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA,0,C12Y304/22028;;A61P35/00;;A61K38/4873;;A61K38/162;;A61K38/1793;;C12N9/506;;C12N15/86;;C12N2770/36122;;C12N2770/36121;;C07K14/005;;C12N7/00;;C12N2770/32134;;A61K2039/53;;A61K2039/55516;;A61K39/39;;A61K2039/876;;C07K14/005;;A61K2039/55516;;C12N2770/36121;;A61K2039/53;;C12N2770/36122;;C12N2770/36143;;A61K2039/6075;;C12N7/00;;C07K2319/00;;A61K2039/5256;;A61K2039/552;;C12N2770/36133;;A61K2039/585;;C12N9/506;;C12N2770/32134;;A61K39/12;;A61K38/162;;C12N2770/36134;;C12N15/86;;A61K38/1793;;C12N15/86;;C12N7/00;;C07K14/005;;A61K48/00;;A61K39/12;;A61K38/1793;;A61K38/4873;;A61K38/162;;A61P35/00;;C12N2770/36121;;C12N2770/36122;;C12N2770/36134;;C12N2770/36144;;C12N2770/32022;;C07K14/005;;A61K2039/585;;C12N9/506;;C12Y304/22028;;C07K14/7156;;C12N15/86;;A61P35/00;;A61K39/12;;A61K38/162;;A61K38/1793;;A61K38/4873;;A61K45/06;;C12N2770/36143;;C12N2770/36133;;C12N2770/36122;;C12N2770/36121;;A61K2039/552;;C12N2770/36134;;A61K2039/5256;;A61K2039/53;;C07K2319/00;;A61K2039/6075;;C12N7/00,C07K14/005;;A61K38/16;;A61K38/17;;A61K38/48;;A61K39/12;;A61K45/06;;A61P35/00;;C07K14/715;;C12N7/00;;C12N9/50;;C12N15/86,,0,0,,,,PENDING
274,FR,A1,FR 3121515 A1,017-608-966-926-024,2022-10-07,2022,FR 2108249 A,2021-07-29,FR 2103428 A;;FR 2105705 A,2021-04-02,"Dispositif pour l’analyse rapide d’un échantillon biologique, par exemple un échantillon biologique salivaire","La présente invention concerne un dispositif pour l’analyse rapide d’un échantillon biologique, par exemple un échantillon biologique salivaire, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique. Le dispositif d’analyse rapide (1) comprend : - un organe de prélèvement (2), destiné au prélèvement dudit échantillon biologique, et - un boîtier (3) qui comporte un emplacement (31) destiné à recevoir une bandelette chromatographique (7) et une interface (32), adaptée à recevoir ledit organe de prélèvement (2) dans une configuration finale assemblée. L’organe de prélèvement (2) et l’interface (32) comportent des moyens d’assemblage étanche (5) comprenant des moyens de guidage (6) qui sont structurés pour guider un mouvement relatif entre ledit organe de prélèvement (2) et ladite interface (32) depuis une configuration initiale de positionnement jusqu’à la configuration finale assemblée, ledit mouvement relatif comprenant deux mouvements : - un mouvement de translation relatif, prévu pour appliquer une compression audit bloc absorbant (21), et - un mouvement de rotation relatif, prévu pour appliquer une torsion audit bloc absorbant (21). Figure pour l’abrégé : 1",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/017-608-966-926-024,Patent Application,no,5,0,1,017-608-966-926-024,FR,4,064-690-104-175-773;;017-608-966-926-024;;054-640-202-927-803;;057-060-284-581-620,WO;;FR,0,A61B10/0051;;A61B2010/0006;;B01L3/50273;;B01L3/5029;;B01L2200/027;;B01L2300/069;;B01L2300/0825;;B01L2400/0406;;G01N33/54388,G01N33/543;;A61B10/02;;B01L3/00;;G01N1/10,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",PENDING
275,CN,A,CN 112334131 A,010-723-737-446-421,2021-02-05,2021,CN 201980040165 A,2019-07-04,KR 20180078585 A;;KR 20190080244 A;;KR 2019008235 W,2018-07-06,PHARMACEUTICAL COMPOSITION COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT,"The present invention relates to a composition for preventing or treating wounds, wherein the composition according to the present invention comprises, as an active ingredient, an indirubin derivativealone, or one or more selected from the group consisting of an indirubin derivative, an extract of Aruncus dioicus var. kamtschaticus, methyl vanillate, hesperidin, and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring, not only in a normal state, but also in a diabetic state. Furthermore, the composition exhibits excellent effects in healing diabetic wounds as well as general wounds, and thus can be used in a beneficial way as a pharmaceutical composition, a cosmetic composition, and a food composition for alleviating, preventing, or treating general wounds or diabetic wounds, or as a veterinary composition for treating diabetic wounds.",CK BIOTECH,CHOI KANG-YELL;;KIM EUN-HWAN;;SEO SEOL-HWA;;YOON MIN-GUEN,,https://lens.org/010-723-737-446-421,Patent Application,no,4,0,10,100-574-593-464-511;;010-723-737-446-421;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;070-530-775-976-218;;097-170-205-131-938;;112-312-169-379-233;;152-346-690-972-536;;146-551-039-853-613,CN;;EP;;WO;;US,14,100-574-593-464-511;;010-723-737-446-421;;143-789-168-119-782;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;097-170-205-131-938;;152-346-690-972-536;;156-171-049-575-889;;061-609-337-961-572;;070-530-775-976-218;;112-312-169-379-233;;016-089-837-812-567;;146-551-039-853-613,KR;;CN;;EP;;WO;;US,0,A61P17/02;;A61Q19/00;;A61K31/404;;A61K31/7048;;A23L33/10;;A61K8/492;;A61K36/754;;A23K20/137;;A23K20/111;;A23K10/30;;A23K20/163;;A23K20/121;;A61K9/107;;A61K45/06;;A61K31/216;;A23L33/105;;A23L33/40;;A61K8/9789;;A61P17/02;;A23V2002/00;;A61K8/06;;A61K8/345;;A61K8/37;;A61K8/492;;A61K8/602;;A61K8/604;;A61K8/738;;A61K8/922;;A61K9/0014;;A61K9/0056;;A61K9/06;;A61K9/107;;A61K31/235;;A61K31/404;;A61K31/7048;;A61K36/754;;A61K47/10;;A61K47/26;;A61K47/40;;A61K47/44;;A61Q19/00;;C07D403/04,A61K31/404;;A23L33/10;;A61K8/49;;A61K8/60;;A61K8/9789;;A61K31/7048;;A61K36/75;;A61P17/02;;A61Q19/00,,0,0,,,,ACTIVE
276,EP,A1,EP 4371583 A1,034-331-614-393-962,2024-05-22,2024,EP 23206089 A,2023-10-26,FR 2212116 A,2022-11-21,NEW BONE REGENERATION DEVICE,"La présente invention concerne un dispositif (1) destiné à la régénération osseuse qui comprend une plaque de recouvrement en titane de grade 1 ou de grade 2 réalisée sur mesure qui recouvre un défaut osseux dont la forme permet de recréer la surface de l'os préalablement à l'apparition du défaut osseux et, éventuellement, au moins un moyen de fixation.",BIOTECH DENTAL,KELLER PIERRE,,https://lens.org/034-331-614-393-962,Patent Application,yes,8,0,4,034-331-614-393-962;;003-490-762-913-644;;140-591-710-197-578;;183-335-424-671-299,EP;;US;;FR,4,140-591-710-197-578;;003-490-762-913-644;;034-331-614-393-962;;183-335-424-671-299,EP;;US;;FR,0,B33Y80/00;;A61L2430/02;;A61L31/022;;A61L31/146;;A61L2430/12;;A61F2/2803;;A61F2002/285;;A61F2002/3092;;A61F2002/3093;;A61F2002/30957;;A61F2002/30985;;A61F2310/00023,A61L27/06;;A61L27/36;;A61L27/50;;A61L31/02;;A61L31/14;;B33Y80/00,,3,3,104-634-992-853-626;;086-365-517-401-82X;;059-617-256-464-935,28251470;;10.1007/s10856-017-5862-2;;29026646;;10.1093/rb/rbx027;;pmc5633690;;10.3390/prosthesis2020011,"ZHU WEI ET AL: ""3D-printed porous titanium changed femoral head repair growth patterns: osteogenesis and vascularisation in porous titanium"", JOURNAL OF MATERIALS SCIENCE: MATERIALS IN MEDICINE, SPRINGER US, NEW YORK, vol. 28, no. 4, 1 March 2017 (2017-03-01), pages 1 - 11, XP036202525, ISSN: 0957-4530, [retrieved on 20170301], DOI: 10.1007/S10856-017-5862-2;;LIU ET AL., REGENERATIVE BIOMATERIALS, vol. 4, 2017, pages 315 - 323;;NICHOLSON, PROSTHESIS, vol. 2, 2020, pages 100 - 116",PENDING
277,EP,A1,EP 4324926 A1,047-285-545-211-092,2024-02-21,2024,EP 22788395 A,2022-04-12,KR 20210047258 A;;KR 2022005272 W,2021-04-12,INTRACELLULAR DELIVERY PLATFORM,"The present invention relates to an intracellular delivery platform including: a first channel through which a fluid comprising cells and delivery materials flows, and a second channel and a third channel which are connected to the first channel at an angle and through which the fluid comprising cells and delivery materials flows, wherein the fluid forms at least one of a collision region and a vortex region of the fluid in at least one of the first channel, the second channel, and the third channel. According to the present invention, material can be effectively delivered into cells by forming a vortex in channels.",MXT BIOTECH,CHUNG A-RAM;;HUR JEONG-SOO,,https://lens.org/047-285-545-211-092,Patent Application,yes,0,0,3,047-285-545-211-092;;079-096-726-288-45X;;174-656-514-206-690,KR;;EP;;CN,6,174-656-514-206-690;;097-721-008-950-916;;047-285-545-211-092;;117-205-002-265-638;;079-096-726-288-45X;;138-793-828-015-972,KR;;CN;;EP;;WO;;US,0,C12N15/87;;C12M35/04;;C12M35/04;;C12M41/38;;C12M23/16;;C12N15/87,C12N15/87;;C12M1/42;;C12M3/06,,0,0,,,,PENDING
278,FR,A1,FR 3100968 A1,043-850-336-999-665,2021-03-26,2021,FR 1910501 A,2019-09-24,FR 1910501 A,2019-09-24,"Dispositif de cerclage, notamment pour la consolidation d’une fracture péri-prothétique","La présente invention a pour objet un dispositif de cerclage implantable (600) comprenant un élément textile longiligne creux (500) comprenant une portion d’attache (540) et une boucle réglable (510) dont le périmètre est réglable par coulissement d’une portion de la boucle réglable (510) dans un volume intérieur d’un manchon (530) agencé dans ledit élément textile (500), et un organe de fermeture du cerclage (100) comprenant une partie avant avec laquelle la boucle réglable (510) ou la portion d’attache (540) est en liaison, et une partie arrière comprenant un premier logement en forme de U (170,180) configuré pour recevoir, une partie de la portion d’attache (540) ou de la boucle réglable (510). Le dispositif de cerclage (600) comprend ainsi une position de serrage du cerclage par coulissement de la boucle réglable (510) dans ledit manchon (530), et une position de verrouillage dans laquelle le coulissement de la boucle réglable (510) est empêché par ledit manchon (530). La présente invention concerne également un dispositif d’ostéosynthèse comprenant ledit dispositif de cerclage (600). Figure pour l’abrégé : Fig. 7.",COUSIN BIOTECH,NOEL STÉPHANE;;OUERGHEMMI SAFA,,https://lens.org/043-850-336-999-665,Patent Application,no,10,0,6,031-436-170-927-143;;172-725-303-782-499;;188-116-875-532-695;;143-738-056-402-866;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,6,031-436-170-927-143;;172-725-303-782-499;;143-738-056-402-866;;188-116-875-532-695;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,0,A61B17/82;;A61B17/82,A61B17/82,,1,1,106-834-460-375-562,31326103;;10.1016/j.injury.2019.06.034,"I. PEETERSA. DEPOVERA. VAN TONGELL. DE WILDE: ""A review ofmetallic and non-metallic cerclage in orthopaedic surgery: Is there still a place for metallic cerclage ?"", INJURY, vol. 0, no. 0, July 2019 (2019-07-01)",ACTIVE
279,EP,A1,EP 4108252 A1,079-489-756-778-326,2022-12-28,2022,EP 21305865 A,2021-06-23,EP 21305865 A,2021-06-23,PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1R AGONISTS,"The present invention relates to a pharmaceutical composition comprising a GLP-1R agonist such as liraglutide, a buffer selected from a tromethamine buffer and a phosphate buffer, and an isotonic agent selected from glucose, a polyethylene glycol and glycerol. The present invention also relates to said pharmaceutical composition for use in a method for treating joint diseases.",4MOVING BIOTECH,RATTENBACH REVITAL;;BERENBAUM FRANCIS;;BISMUTH KEREN;;MARTIN CÉLINE;;MEUROT CORALIE,,https://lens.org/079-489-756-778-326,Patent Application,yes,3,0,1,079-489-756-778-326,EP,9,161-065-996-408-159;;162-236-787-532-313;;115-629-263-216-013;;134-316-180-302-591;;079-489-756-778-326;;034-588-927-315-598;;090-258-190-792-101;;097-356-964-954-260;;154-912-544-045-888,JP;;KR;;AU;;EP;;CN;;WO;;US;;CA,3,A61K38/26;;A61P19/02;;A61K9/0019;;A61K9/08;;A61K47/02,A61K38/26;;A61K9/00;;A61P19/02,,1,0,,,"NOVO NORDISK: ""HIGHLIGHTS OF PRESCRIBING VICTOZA"", 1 August 2017 (2017-08-01), XP055865895, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf> [retrieved on 20211125]",DISCONTINUED
280,WO,A1,WO 2021/228876 A1,072-161-856-670-423,2021-11-18,2021,EP 2021062514 W,2021-05-11,FR 2004780 A;;FR 2100980 A,2020-05-14,"IMPLANTABLE DEVICE, IN PARTICULAR OF THE INTERVERTEBRAL SPACER TYPE","The subject matter of the present invention is an implantable device (100) for maintaining an intervertebral gap between vertebrae, comprising an intervertebral wedge (10) comprising an upper bearing zone and a lower bearing zone, and at least one first lateral spring (20) having a position A relative to the intervertebral wedge (10) in a position for inserting the implantable device (100), and a position B relative to the intervertebral wedge (10) in a position for implanting the implantable device, the positions A and B being different, and the first lateral spring (20) is configured: - to freely transition from position A to position B; and - to form a retention component arranged relative to the intervertebral wedge (10) in order to block the migration of the intervertebral wedge (10) towards the spinal canal in position B.",COUSIN BIOTECH,HOFFMANN ELÉONORE;;BECQUART LUCIE;;CAILLIBOTTE MICHEL,,https://lens.org/072-161-856-670-423,Patent Application,yes,6,0,8,049-681-138-955-067;;123-011-641-195-420;;119-331-982-537-853;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;052-804-849-360-014,EP;;ES;;WO;;US;;FR,8,049-681-138-955-067;;123-011-641-195-420;;052-804-849-360-014;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;119-331-982-537-853,EP;;ES;;WO;;US;;FR,0,A61B17/7053;;A61B17/7062;;A61B17/7064;;A61B17/7065;;A61B17/7067;;A61B17/7061;;A61B17/7065;;A61B17/7067,A61B17/70,,0,0,,,,PENDING
281,US,A1,US 2021/0291174 A1,088-966-736-969-200,2021-09-23,2021,US 202016823595 A,2020-03-19,US 202016823595 A,2020-03-19,"MICROCHANNEL CHIP, MICROCHANNEL STRUCTURE AND DETECTING METHOD USING THE SAME","The present invention provides a microchannel structure loaded with a bead having a particle size for detecting whether a biological substance exists in a sample. The microchannel structure includes a structure body for passing a sample through the microchannel structure to have a test or a treatment. The structure body includes a sample entrance having a first aperture to allow the sample passing therethrough, a resistance-increasing section connected with the sample entrance, and having a second aperture being smaller than the first aperture, a detecting section connecting with the resistance-increasing section, and a bead mooring structure coupled to the second end for mooring the bead in the detecting section. The present invention can be used to capture rare cells in a biological system, such as human blood.",LIFECODE BIOTECH,DOONG JOE-YUAN;;TSAI SUNG-CHI,LIFECODE BIOTECH (2020-03-09),https://lens.org/088-966-736-969-200,Patent Application,yes,1,0,2,088-966-736-969-200;;175-323-994-301-355,US,2,088-966-736-969-200;;175-323-994-301-355,US,0,B01L3/502746;;B01L3/502761;;B01L2200/0668;;B01L2300/0883;;G01N33/54366;;G01N33/57492;;B01L3/502715;;B01L3/50273;;B01L3/502761;;B01L2200/0647;;B01L2300/06;;B01L2300/0819;;B01L2300/0832;;B01L2300/0848;;B01L2300/0858;;B01L2300/0883;;B01L2300/12;;B01L2400/08;;G01N33/5091,B01L3/00;;G01N33/50,,0,0,,,,ACTIVE
282,KR,A,KR 20240136207 A,098-618-771-491-435,2024-09-13,2024,KR 20230131700 A,2023-10-04,KR 20230029284 A,2023-03-06,SPECIMEN CONTAINER WITH REDUCED UNINTENTIONAL LIQUID TRANSFER,"의도치 않게 용기 본체 내부의 액체 및/또는 검체가 용기 캡으로 흘러들어가는 현상이 억제되거나 완화된 검체 용기가 제공된다. 상기 검체 용기는 용기 본체; 캡 측벽부를 포함하여, 상기 용기 본체 상단에서 결합되도록 구성된 용기 캡; 및 상기 용기 캡과 직간접적으로 결합되도록 구성된 유로 조절 부재를 포함하되, 상기 유로 조절 부재의 하단은, 상기 용기 캡의 하단 보다 작은 폭을 갖는다.",GOLDEN BIOTECH,JIN YOUNG SEOK,,https://lens.org/098-618-771-491-435,Patent Application,no,0,0,4,129-829-727-120-963;;159-893-387-795-255;;008-022-965-521-450;;098-618-771-491-435,KR,4,129-829-727-120-963;;159-893-387-795-255;;008-022-965-521-450;;098-618-771-491-435,KR,0,B01L3/508;;B01L2300/042;;B01L2200/0689;;B01L2200/082;;B01L2200/085;;B01L2300/044;;B01L2200/141;;B01L2300/0877,B01L3/00,,1,0,,,KR 10-1934819 B1 (특허문헌 2) KR 20-0490307 Y1 (특허문헌 3) KR 10-2056068 B1 (특허문헌 4) KR 10-2436698 B1 (특허문헌 5) KR 20-0490214 Y1 (특허문헌 6) KR 10-2020-0134132 A (특허문헌 7) KR 10-2020-0134133 A (특허문헌 8) KR 10-2020-0134134 A,PENDING
283,EP,A1,EP 3914186 A1,110-691-661-281-107,2021-12-01,2021,EP 20705237 A,2020-01-22,FR 1900592 A;;FR 2020050087 W,2019-01-23,"RETENTION DEVICE COMPRISING A RETENTION APPARATUS AND POSITIONING KEYS, AND METHOD FOR PRODUCING SUCH A RETENTION DEVICE",,BIOTECH DENTAL,SIREIX DOMINIQUE;;SIREIX CHRISTOPHE,,https://lens.org/110-691-661-281-107,Patent Application,yes,0,0,5,110-691-661-281-107;;126-044-206-429-536;;025-428-841-604-963;;178-868-448-030-374;;056-836-595-540-649,EP;;WO;;US;;FR,5,025-428-841-604-963;;126-044-206-429-536;;110-691-661-281-107;;178-868-448-030-374;;056-836-595-540-649,EP;;WO;;US;;FR,0,A61C5/007;;A61C13/0004;;A61C13/0022;;B33Y70/00;;B33Y80/00;;A61C7/08;;A61C7/002;;B33Y50/00;;B33Y80/00,A61C5/00;;A61C13/00;;B33Y70/00;;B33Y80/00,,1,0,,,See references of WO 2020152421A1,DISCONTINUED
284,FR,A1,FR 3130129 A1,105-490-792-344-022,2023-06-16,2023,FR 2113580 A,2021-12-15,FR 2113580 A,2021-12-15,Dispositif implantable à libération progressive d’un ou plusieurs agent(s) fonctionnel(s) et procédé de fabrication d’un tel dispositif,"La présente invention a pour objet un dispositif implantable, en particulier pour la reconstruction d’un ligament croisé antérieur ou d’un tendon, comprenant une âme longiligne (20) et un membre de couverture longiligne creux comprenant un volume intérieur recevant au moins en partie ladite âme longiligne, ladite âme longiligne comprend une matrice polymère bio-érodable en milieu aqueux et un ou plusieurs agent(s) fonctionnel(s), et le membre de couverture comprend des orifices traversants en communication fluidique avec ledit volume intérieur. La présente invention a également pour objet un procédé de fabrication d’un tel dispositif implantable. Figure pour l’abrégé : Fig. 4.",COUSIN BIOTECH,NOEL STÉPHANE,,https://lens.org/105-490-792-344-022,Patent Application,no,7,0,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,0,A61F2/08;;A61F2250/0031;;A61F2250/0067;;A61F2210/0004;;A61L2430/10;;A61L27/54;;A61L27/58;;A61L27/18;;A61L27/34;;A61L2420/04;;A61L27/28;;A61L27/306;;A61L27/32;;A61L27/56;;A61F2/08;;A61F2210/0004,A61F2/08;;A61L27/14;;A61L27/44,,1,1,002-000-496-900-531,10.1016/j.biomaterials.2006.01.017;;16448693,"TADASHI KOKUBOTAKADAMA, BIOMATERIALS, vol. 27, no. 15, 1 May 2006 (2006-05-01), pages 2907 - 15",ACTIVE
285,FR,A1,FR 3111432 A1,113-001-325-919-376,2021-12-17,2021,FR 2006244 A,2020-06-16,FR 2006244 A,2020-06-16,"Système d’analyse rapide d’un échantillon biologique, pour discriminer les anticorps sérologiques spécifiques d’un agent infectieux présents dans ledit échantillon biologique","La présente invention concerne un système d’analyse rapide d’un échantillon biologique, pour discriminer les anticorps sérologiques spécifiques d’un agent infectieux présents dans ledit échantillon biologique. Le système d’analyse rapide (1) comprend au moins une bandelette chromatographique (2) qui comporte différentes zones successives, dont : - une zone de libération (4) qui comprend au moins un réactif de détection (41, 42) et - au moins une zone de capture (5) qui comprend au moins un réactif de capture (51, 52), immobilisé sur la bandelette chromatographique (2). La combinaison réactif(s) de détection (41, 42) / réactif(s) de capture (51, 52) est choisie parmi les combinaisons réactif(s) de détection (41, 42) / réactif(s) de capture (51, 52) adaptées à discriminer au moins deux groupes d’anticorps sérologiques : - un premier groupe d’anticorps sérologiques (A1), dits « anticorps neutralisants », comprenant les anticorps sérologiques spécifiques dudit agent infectieux, aptes à annuler, ou au moins à réduire, le pouvoir infectieux dudit agent infectieux, et - un second groupe d’anticorps sérologiques (A2), dit « anticorps non-neutralisants », comprenant les anticorps sérologiques spécifiques dudit agent infectieux, autres que lesdits anticorps appartenant audit premier groupe d’anticorps sérologiques (A1). Figure pour l’abrégé : 1",NG BIOTECH,STANKOV MILOVAN,,https://lens.org/113-001-325-919-376,Patent Application,no,3,0,2,106-838-925-865-923;;113-001-325-919-376,WO;;FR,2,106-838-925-865-923;;113-001-325-919-376,WO;;FR,0,G01N33/52;;G01N33/543;;G01N33/54388;;G01N33/56983;;G01N2333/165,G01N33/558;;A61B5/15;;B01D15/38,,10,6,034-914-541-248-215;;040-851-635-207-678;;075-495-112-026-570;;024-604-669-146-49X;;030-869-269-245-190;;043-021-132-202-150,33563967;;pmc7249039;;10.1038/s41420-020-0275-2;;32501411;;32704169;;10.21203/rs.3.rs-24574/v1;;10.1038/s41587-020-0631-z;;pmc7273274;;10.1101/2020.05.27.20114652;;32511506;;32391022;;10.3389/fimmu.2020.00879;;pmc7194125;;32479758;;pmc7256507;;10.1016/j.jaci.2020.05.020;;15054081;;pmc7108132;;10.1373/clinchem.2004.031096,"MARZIA NUCCETELLI ET AL: ""SARS-CoV-2 infection serology: a useful tool to overcome lockdown?"", CELL DEATH DISCOVERY, vol. 6, no. 1, 26 May 2020 (2020-05-26), XP055767362, ISSN: 2058-7716, DOI: 10.1038/s41420-020-0275-2;;TAN CHEE WAH ET AL: ""A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction"", RESEARCH SQUARE, 23 April 2020 (2020-04-23), pages 1 - 15, XP055781210, Retrieved from the Internet <URL:https://www.researchsquare.com/article/rs-24574/v1> [retrieved on 20210302], DOI: 10.21203/rs.3.rs-24574/v1;;JAMES R BYRNES ET AL: ""A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding"", MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES, 29 May 2020 (2020-05-29), XP055769216, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.05.27.20114652v1.full.pdf> [retrieved on 20210127], DOI: 10.1101/2020.05.27.20114652;;CHERYL YI-PIN LEE ET AL: ""Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control"", FRONTIERS IN IMMUNOLOGY, vol. 11, 24 April 2020 (2020-04-24), pages 879, XP055737286, DOI: 10.3389/fimmu.2020.00879;;ÖZÇÜRÜMEZ MUSTAFA K ET AL: ""SARS-CoV-2 antibody testing-questions to be asked"", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 146, no. 1, 29 May 2020 (2020-05-29), pages 35 - 43, XP086207350, ISSN: 0091-6749, [retrieved on 20200529], DOI: 10.1016/J.JACI.2020.05.020;;""GenBank"", Database accession no. MN908947;;CHEN Z ET AL., CLIN CHEM, vol. 50, 2004, pages 988 - 95;;ZHOU P ET AL., NATURE, 2020;;LU R, LANCET, vol. 395, 2020, pages 565 - 74;;HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",DISCONTINUED
286,WO,A1,WO 2022/157256 A1,155-229-762-993-894,2022-07-28,2022,EP 2022051259 W,2022-01-20,FR 2100559 A,2021-01-21,"SYSTEM FOR RAPID ANALYSIS OF A CAPILLARY BLOOD SAMPLE FROM A SUBJECT, FOR DETECTING THE PRESENCE OF AT LEAST ONE ANALYTE IN SAID CAPILLARY BLOOD SAMPLE","The present invention relates to a system for rapid analysis of a capillary blood sample from a subject, for detecting the presence of at least one analyte (A) in the capillary blood sample (E). The rapid analysis system (1) comprises: (i) an analysis module (2) in which at least one immunochromatographic strip (4) is incorporated, which analysis module (2) includes: a pricking member (7), suitable for generating a drop of capillary blood, and a collecting member (8) comprising a fixed duct (81), suitable for a flow of capillary blood, which duct (81) comprises an inlet (811) suitable for collecting the drop of capillary blood, and an outlet (812), provided opposite the depositing area (41) and suitable for the depositing of the drop of capillary blood on the depositing area (41), and (ii) a reservoir (5), that is separate and independent from the analysis module (2), in which a buffer solution (51) suitable for implementing said immunochromatographic technique is packaged.",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/155-229-762-993-894,Patent Application,yes,5,0,6,155-229-762-993-894;;029-059-928-128-933;;137-748-071-813-315;;128-681-643-629-960;;040-657-732-636-029;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,6,155-229-762-993-894;;029-059-928-128-933;;128-681-643-629-960;;040-657-732-636-029;;137-748-071-813-315;;026-968-490-956-88X,CN;;EP;;WO;;US;;FR,0,G01N33/54388;;G01N33/558;;G01N33/54388;;A61B5/150022;;A61B5/150267;;A61B5/150358;;A61B2560/0406;;A61B2560/0443;;G01N33/558,G01N33/543;;G01N33/558,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",PENDING
287,WO,A2,WO 2022/169283 A2,147-815-073-378-708,2022-08-11,2022,KR 2022001731 W,2022-02-04,KR 20210016012 A;;KR 20220014543 A,2021-02-04,COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM-DERIVED POLYSACCHARIDE OR EXTRACT,"The present invention relates to a composition comprising Lactobacillus plantarum-derived polysaccharide or extract and, more specifically, by comprising Lactobacillus plantarum-derived polysaccharide or a Lactobacillus plantarum extract, may exhibit inflammatory inhibition, adipogenesis inhibition, intracellular glucose absorption inhibition, insulin resistance reduction and hepatic steatosis reduction effects, and may exhibit effects of treating or preventing a metabolic disease.",NEOREGEN BIOTECH,SEO JEONG MIN;;LEE JAE HOON,,https://lens.org/147-815-073-378-708,Patent Application,yes,0,1,5,174-915-703-153-202;;147-815-073-378-708;;189-848-492-967-472;;026-134-353-184-739;;186-166-729-431-389,JP;;WO;;US,10,026-134-353-184-739;;005-146-690-760-836;;147-815-073-378-708;;189-848-492-967-472;;073-656-819-415-424;;186-166-729-431-389;;189-472-759-321-468;;174-915-703-153-202;;029-815-409-073-468;;003-062-187-785-760,JP;;KR;;CN;;EP;;WO;;US,30,C12P19/04;;A61K31/716;;A61K35/747;;A61P3/10;;A61P29/00;;A61P3/04;;A61P1/16;;A61P1/16;;A61P3/04;;A61P3/10;;A61P29/00;;A61K31/716;;A61K35/747,C12P19/04,,0,0,,,,PENDING
288,EP,A1,EP 3737473 A1,199-723-110-486-467,2020-11-18,2020,EP 19703397 A,2019-01-10,FR 1850204 A;;FR 1853192 A;;FR 2019050047 W,2018-01-10,STABLE EMULSIONS BASED ON PLANT OILS AND ON ESSENTIAL OILS FORMULATED WITHOUT SURFACTANT,,GENIALIS BIOTECH,DESJARDINS-LAVISSE ISABELLE,,https://lens.org/199-723-110-486-467,Patent Application,yes,0,0,5,199-723-110-486-467;;128-341-618-814-960;;080-923-487-575-612;;177-242-669-845-269;;061-671-566-994-80X,EP;;WO;;FR,5,199-723-110-486-467;;128-341-618-814-960;;080-923-487-575-612;;177-242-669-845-269;;061-671-566-994-80X,EP;;WO;;FR,0,A61Q5/02;;A61K8/062;;A61K8/922;;A61K8/9789;;A61K2800/33;;A61K2800/82;;A61Q13/00;;A61Q19/00;;A61Q19/06;;A61Q19/10,A61Q5/02;;A61K8/06;;A61K8/92;;A61Q13/00;;A61Q19/00;;A61Q19/10,,1,0,,,See references of WO 2019138190A1,DISCONTINUED
289,EP,A1,EP 3740153 A1,015-420-136-206-311,2020-11-25,2020,EP 19705554 A,2019-01-16,FR 1850434 A;;FR 2019050091 W,2018-01-19,"METHOD FOR CONSTRUCTING A CONTAINMENT DEVICE COMPRISING A CONTAINMENT DEVICE AND A POSITIONING DUCT, AND DEVICE FOR CONTAINMENT OBTAINED",,BIOTECH DENTAL,FOREST ALEXANDRE;;SIREIX CHRISTOPHE,,https://lens.org/015-420-136-206-311,Patent Application,yes,0,0,6,013-787-513-592-974;;032-761-265-495-975;;070-327-427-931-888;;015-420-136-206-311;;043-256-962-755-498;;092-711-581-928-833,EP;;WO;;FR,6,013-787-513-592-974;;032-761-265-495-975;;070-327-427-931-888;;015-420-136-206-311;;043-256-962-755-498;;092-711-581-928-833,EP;;WO;;FR,0,A61C5/007;;A61C7/08;;A61C13/0013;;A61C13/0022;;A61K6/90,A61C5/00;;A61C7/00;;A61C7/08;;A61K6/00,,1,0,,,See references of WO 2019141943A1,ACTIVE
290,BR,A2,BR 112023021345 A2,084-793-644-582-609,2023-12-19,2023,BR 112023021345 A,2022-04-15,US 2022/0024946 W;;US 202163175603 P,2021-04-16,Produto de ovo hiperimunizado para tratamento ou prevenção de doença hepática alcoólica e doença enxerto contra hospedeiro,"produto de ovo hiperimunizado para tratamento ou prevenção de doença hepática alcoólica e doença enxerto contra hospedeiro. em um aspecto, a presente invenção é direcionada a um método para prevenir ou tratar doença hepática alcoólica ou doença enxerto contra hospedeiro em um indivíduo com necessidade do mesmo, compreendendo administrar ao indivíduo uma quantidade terapeuticamente eficaz de um produto de ovo hiperimunizado obtido a partir de um animal produtor de ovos, prevenindo ou tratando assim a doença hepática alcoólica ou a doença enxerto contra hospedeiro no indivíduo, em que o produto de ovo hiperimunizado compreende uma quantidade terapeuticamente eficaz de um ou mais anticorpos para um antígeno selecionado a partir do grupo que consiste em enterococcus faecalis, toxina de citolisina de enterococcus faecalis, e enterococcus faecium. a presente invenção também é direcionada a ovos hiperimunizados e produtos de ovos produzidos por um animal que foi hiperimunizado com um antígeno selecionado a partir do grupo que consiste em enterococcus faecalis, toxina de citolisina isolada de enterococcus faecalis, e enterococcus faecium. métodos de preparação de ovos hiperimunizados e produtos de ovos também são descritos.",PRODIGY BIOTECH,IYER SUBRAMANIAN;;PATEL SUNNY,,https://lens.org/084-793-644-582-609,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61P1/16;;A61K35/57;;A61P37/06,,0,0,,,,PENDING
291,WO,A1,WO 2025/104204 A1,091-120-489-058-82X,2025-05-22,2025,EP 2024082416 W,2024-11-14,EP 23306974 A,2023-11-14,TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES IN SUBPOPULATIONS OF SUBJECTS,"The present invention relates to the treatment of cardiovascular diseases or events. In particular, the present invention relates to a method for treating a cardiovascular disease or event, in particular a stroke, comprising the administration of an inhibitor of the GPVI signaling pathway, in particular an anti-human glycoprotein VI antibody or fragment thereof.",ACTICOR BIOTECH,BINAY SOPHIE;;TOLEDANO ELIE,,https://lens.org/091-120-489-058-82X,Patent Application,yes,8,0,2,091-120-489-058-82X;;090-022-413-976-848,EP;;WO,2,091-120-489-058-82X;;090-022-413-976-848,EP;;WO,25,A61P9/10;;C07K16/2803;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K2317/55,C07K16/28;;A61P9/10,,23,18,138-317-472-779-009;;051-070-536-351-428;;190-065-637-167-076;;110-815-857-364-563;;017-693-519-334-261;;005-560-967-514-755;;049-134-753-209-354;;060-971-733-861-077;;137-607-161-868-61X;;034-331-211-704-877;;066-141-497-990-023;;056-201-471-905-934;;106-753-778-592-300;;020-855-322-534-259;;013-892-028-709-221;;003-502-861-629-038;;007-002-813-911-754;;102-818-694-846-317,10.1056/nejmoa2214403;;36762865;;34653924;;10.1016/j.clineuro.2021.106978;;36128904;;10.1161/strokeaha.122.039790;;10.1016/s1474-4422(23)00427-1;;38267188;;25977585;;10.1182/blood-2015-02-629717;;1908882;;10.4049/jimmunol.147.5.1709;;10.1016/0022-2836(87)90412-8;;3681981;;10.1111/j.1749-6632.1949.tb27297.x;;10.1137/0148063;;1907718;;10.1038/352624a0;;pmc321012;;6546423;;10.1093/nar/12.1part1.387;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1038/256495a0;;1172191;;10.1016/0022-2836(91)90498-u;;1748994;;10.1016/j.ab.2009.02.035;;19268418;;26683650;;10.1080/19420862.2015.1116657;;pmc4966575;;19147716;;10.3174/ajnr.a1408;;pmc7051470;;pmc8367626;;34140276;;10.3174/ajnr.a7181,"SARRAJ AMROU ET AL: ""Trial of Endovascular Thrombectomy for Large Ischemic Strokes"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 388, no. 14, 6 April 2023 (2023-04-06), US, pages 1259 - 1271, XP093149505, ISSN: 0028-4793, DOI: 10.1056/NEJMoa2214403;;BAYDEMIR RECEP ET AL: ""Role of modified TAN score in predicting prognosis in patients with acute ischemic stroke undergoing endovascular therapy"", CLINICAL NEUROLOGY AND NEUROSURGERY., vol. 210, 1 November 2021 (2021-11-01), NL, XP093149593, ISSN: 0303-8467, DOI: 10.1016/j.clineuro.2021.106978;;ANONYMOUS: ""Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)"", PLOS ONE, 22 February 2023 (2023-02-22), XP093149697, Retrieved from the Internet <URL:https://uploads-ssl.webflow.com/60ed4d6a6fc45c3a0e3cfb8f/621488b1a5b1f0b3c02c537a_Acticor_PR_ACTIMIS_Resultats_EN_vf-2.pdf> [retrieved on 20240409];;WICHAIYO SURASAK ET AL: ""Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke"", vol. 53, no. 11, 21 September 2022 (2022-09-21), US, pages 3506 - 3513, XP093037091, ISSN: 0039-2499, Retrieved from the Internet <URL:http://dx.doi.org/10.1161/STROKEAHA.122.039790> DOI: 10.1161/STROKEAHA.122.039790;;MAZIGHI MIKAËL ET AL: ""Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial"", THE LANCET NEUROLOGY, vol. 23, no. 2, 1 February 2024 (2024-02-01), AMSTERDAM, NL, pages 157 - 167, XP093149371, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(23)00427-1;;ACTICOR BIOTECH: ""Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke - NCT05070260"", CLINICAL TRIALS.GOV, 7 October 2021 (2021-10-07), XP093037078, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT05070260?term=NCT05070260&draw=2&rank=1> [retrieved on 20230403];;MAMMADOVA-BACH ET AL., BLOOD, vol. 126, no. 5, 2015, pages 683 - 91;;KABAT ET AL.: ""Identical V region amino acid sequences and segments of sequences in antibodies of different specificities"", J IMMUNOL., vol. 147, no. 5, 1 September 1991 (1991-09-01), pages 1709 - 19, XP055204516;;CHOTHIA C.A.M. LESK: ""Canonical structures for the hypervariable regions of immunoglobulins"", J MOL BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17, XP024010426, DOI: 10.1016/0022-2836(87)90412-8;;SCATCHARD G ET AL.: ""The attractions of proteins for small molecules and ions"", ANN NY ACAD SCI, vol. 1949, no. 51, pages 660 - 672, XP008000889, DOI: 10.1111/j.1749-6632.1949.tb27297.x;;CARILLO ET AL., SIAM J. APPL. MATH., vol. 48, no. 5, 1988, pages 1073 - 1082;;DOUGLAS W. SMITH: ""Biocomputing: Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;HUGH G. GRIFFINANNETTE M. GRIFFIN: ""Computer Analysis of Sequence Data, Part 1"", 1994, HUMANA PRESS;;GUNNAR VON HEINJE: ""Sequence Analysis in Molecular Biology: Treasure Trove or Trivial Pursuit"", 1987, ACADEMIC PRESS;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 12, no. 1, 1984, pages 387 - 395;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 410;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;MUZARD ET AL., ANALYTICAL BIOCHEMISTRY, vol. 388, 2009, pages 331 - 338;;LAKHRIF ET AL., MABS, vol. 8, no. 2, 2016, pages 379 - 88;;TAN ET AL.: ""CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct"", AJNR AM J NEURORADIOL., vol. 30, no. 133652-38-7, March 2009 (2009-03-01), pages 525 - 31;;LYNDON ET AL.: ""Hypoperfusion Intensity Ratio Correlates with CTA Collateral Status in Large-Vessel Occlusion Acute Ischemic Stroke"", AJNR AM J NEURORADIOL., vol. 42, no. 8, August 2021 (2021-08-01), pages 1380 - 1386",PENDING
292,US,A1,US 2022/0144752 A1,014-007-147-810-981,2022-05-12,2022,US 202017432430 A,2020-01-22,KR 20190018998 A;;KR 2020001090 W,2019-02-19,"WATER-SOLUBLE NAPHTHOQUINONE DERIVATIVE COMPOSITION AND METHOD FOR PRODUCING SAME, WATER-SOLUBLE COMPOSITION FOR CONTROLLING HARMFUL ALGAE, METHOD FOR CONTROLLING LARGE-SCALE HARMFUL ALGAE, AND AUTOMATION SYSTEM FOR AI-MONITORING, REMOVING, AND PREVENTING LARGE-SCALE HARMFUL ALGAE","Provided are a water-soluble naphthoquinone derivative composition and a method for preparing the same, a water-soluble composition for controlling harmful algae, a method of controlling large-scale harmful algae, and an automated system for artificial intelligence monitoring, removal, and prevention of large-scale harmful algae. According to one embodiment, a method of preparing a water-soluble naphthoquinone derivative composition includes reacting a 1,4-naphthoquinone compound with N,N-diethylethylenediamine to obtain an intermediate product of [Chemical Formula 2]; and reacting an intermediate product of [Chemical Formula 2] with hydrochloric acid to obtain a compound of [Chemical Formula 1]. In addition, the water-soluble naphthoquinone derivative composition represented by the following [Chemical Formula 1] is proposed. In addition, a water-soluble composition is proposed for controlling harmful algae, a method for controlling large-scale harmful algae using the water-soluble composition for controlling harmful algae, and an automated system for artificial intelligence monitoring, removal, and prevention of large-scale harmful algae.",WATER BIOTECH,SEO HAE-DONG;;HAN MYUNG-SOO,WATER-BIOTECH (2021-08-09),https://lens.org/014-007-147-810-981,Patent Application,yes,1,2,6,006-294-958-950-819;;159-133-716-548-713;;014-007-147-810-981;;197-433-543-836-137;;078-162-398-010-702;;012-311-234-664-736,AU;;KR;;CN;;WO;;US,6,006-294-958-950-819;;159-133-716-548-713;;014-007-147-810-981;;197-433-543-836-137;;078-162-398-010-702;;012-311-234-664-736,AU;;KR;;CN;;WO;;US,0,B63B35/00;;C02F1/40;;C07C221/00;;G08B21/18;;C07C225/30;;A01N33/12;;A01P13/00;;B64U2101/45;;C07C221/00;;A01N25/26;;C07C225/30;;C02F1/40;;A01N33/10;;A01N25/12;;G08B21/182;;B63B2035/008;;B64U2201/20;;B64U2101/45;;B64C39/024;;A01P13/02;;A01N25/12;;A01N33/10;;C07C225/30;;B64U2201/20;;B64U2101/45,C07C225/30;;A01N25/12;;A01N33/10;;A01P13/02;;B64C39/02,,0,0,,,,PENDING
293,KR,A,KR 20240110714 A,094-411-172-309-845,2024-07-16,2024,KR 20230002441 A,2023-01-06,KR 20230002441 A,2023-01-06,Cosmetic composition for skin whitening and anti-wrinkle effect comprising hydrolysate of Enteromorpha linza,"본 발명은 잎파래(Enteromorpha linza) 가수분해물을 유효성분으로 포함하는 피부 미백 또는 주름 개선용 화장료 조성물 및 피부 외용제 조성물에 관한 것이다. 본 발명에 따르면, 잎파래(Enteromorpha linza) 가수분해물이 멜라닌 세포 내 멜라닌 생성을 저해하고, 엘라스타제(Elastase) 저해 및 프로콜라겐(Procollagen) 생성량을 증대시킴으로써, 탁월한 피부 미백, 색소 침착 개선 및 주름 개선 효능을 나타낸다. 또한, 상기 조성물은 세포 증식을 보다 촉진함으로써 창상치유 활성을 나타낼 수 있다. 또한 독성이 없고 피부 자극이 없어 화장료 조성물 및 피부 외용제 조성물로 안전하고 다양하게 활용할 수 있다.",SUNMARINE BIOTECH,PARK SI HYANG;;KIM YE RA;;PARK SU JIN;;JEONG JI HYEON,,https://lens.org/094-411-172-309-845,Patent Application,no,2,0,2,094-411-172-309-845;;033-222-090-203-195,KR,2,094-411-172-309-845;;033-222-090-203-195,KR,0,A61K8/9722;;A61Q19/00;;A61Q19/02;;A61Q19/08;;A61K2800/782;;A61K2800/805,A61K8/9722;;A61Q19/00;;A61Q19/02;;A61Q19/08,,0,0,,,,ACTIVE
294,US,A1,US 2025/0084449 A1,098-831-400-161-093,2025-03-13,2025,US 202218292393 A,2022-07-21,CN 202110853028 A;;CN 2022106920 W,2021-07-27,SUCROSE SYNTHETASE AND USE THEREOF,"Provided are a sucrose synthetase and the use thereof. Compared with SEQ ID NO: 11, an amino acid sequence of the sucrose synthetase contains differences in amino acid residues selected from one or more of the following residue positions: an amino acid at position 36 being V, an amino acid at position 43 being E, an amino acid at position 179 being A, an amino acid at position 395 being R, an amino acid at position 447 being P, an amino acid at position 455 being L, and an amino acid at position 654 being R; and the sucrose synthetase has an activity not lower than that of a sucrose synthetase having an amino acid sequence as shown in SEQ ID NO: 11. By means of catalyzing the synthesis of rebaudioside A, rebaudioside D or rebaudioside M by using a glucosyltransferase and the sucrose synthetase in a combined manner, a cascade reaction is achieved, thereby providing a variety of possibilities for the selection of raw materials.",ABIOCHEM BIOTECHNOLOGY GROUP CO LTD,WU YAN;;TIAN ZHENHUA;;WANG SHU;;ZHENG XIAOFU;;XING LITONG,ABIOCHEM BIOTECHNOLOGY (GROUP) CO. LTD (2023-12-26),https://lens.org/098-831-400-161-093,Patent Application,yes,0,0,7,000-139-956-443-348;;079-237-594-854-072;;006-709-876-635-825;;067-382-443-012-594;;098-831-400-161-093;;109-433-842-642-496;;049-223-533-718-434,JP;;CN;;EP;;WO;;US,7,000-139-956-443-348;;079-237-594-854-072;;006-709-876-635-825;;067-382-443-012-594;;098-831-400-161-093;;109-433-842-642-496;;049-223-533-718-434,JP;;CN;;EP;;WO;;US,0,C12P19/56;;C12R2001/19;;C12N15/70;;C12N9/1062;;C12P19/305;;C12P19/32;;C12N9/1062;;C12P19/18;;C12P19/56;;C12Y204/01013,C12P19/56;;C12N9/10;;C12P19/18,,0,0,,,,PENDING
295,US,A1,US 2024/0164869 A1,029-804-011-916-038,2024-05-23,2024,US 202318516144 A,2023-11-21,FR 2212115 A,2022-11-21,SURGICAL GUIDE FOR PLACING DENTAL IMPLANTS,"A surgical guide system for the placement of dental implants includes a guide base attachable to the maxillary or mandibular bone, an aligner attachable to the base and to be positioned in the space relative to the reference tooth, teeth, or other anatomical landmarks remaining in the mouth, and a drilling guide attachable to the guide base and including at least one drill guide hole for guiding a drill. wherein the guide base: is substantially rigid; is resting mostly on the mucosa; is essentially matching the shape of a maxilla or a mandible and present a central part placed on the interior surface of the jaw, intended to provide lingual or palatal support, and is widely perforated along the maxillary or mandibular ridge, in order to allow past any teeth still present at the start of the operation or implants to be installed during the operation.",BIOTECH DENTAL,KELLER PIERRE,BIOTECH DENTAL (2023-12-05),https://lens.org/029-804-011-916-038,Patent Application,yes,0,0,4,133-402-258-255-671;;029-804-011-916-038;;169-200-571-166-553;;185-137-173-008-972,EP;;US;;FR,4,133-402-258-255-671;;029-804-011-916-038;;169-200-571-166-553;;185-137-173-008-972,EP;;US;;FR,0,A61C1/084;;A61C1/085;;A61C8/0089;;A61C13/087;;A61C13/26;;B33Y80/00;;A61C13/225;;A61C8/005;;A61C1/084;;A61C8/0068;;A61C8/0089;;A61C2201/00,A61C1/08;;A61C8/00,,0,0,,,,PENDING
296,KR,A,KR 20210154341 A,073-662-860-488-896,2021-12-21,2021,KR 20200071259 A,2020-06-12,KR 20200071259 A,2020-06-12,Disinfectant composition comprising Lactobacillus plantarum culture medium,"The present invention relates to a disinfectant composition comprising a culture medium of Lactobacillus plantarum. The culture medium of the Lactobacillus plantarum strain, which exhibits antimicrobial properties, has disinfection efficacy. Therefore, the culture medium can be used as a hypoallergenic disinfectant composition, and can also be preferably used as a cleaning agent, cosmetics, and the like. The disinfectant composition of the present invention comprises: 62-70 wt% of ethanol; 0.001-10 wt% of a culture medium of Lactobacillus plantarum L14 (KCTC13497BP); 0.1-10 wt% of glycerin; 0.001-0.2 wt% of a fragrance additive; and remaining purified water.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/073-662-860-488-896,Patent Application,no,1,2,1,073-662-860-488-896,KR,1,073-662-860-488-896,KR,8,A01N63/20;;A01N25/06;;A01N31/02;;A61K8/99;;A61Q11/00;;A61Q17/005,A01N63/20;;A01N25/06;;A01N31/02;;A61K8/99;;A61Q11/00;;A61Q17/00,,0,0,,,,DISCONTINUED
297,FR,A1,FR 3110073 A1,119-331-982-537-853,2021-11-19,2021,FR 2100980 A,2021-02-02,FR 2004780 A,2020-05-14,"Dispositif implantable, notamment de type espaceur intervertébral","La présente invention a pour objet un dispositif implantable (100) pour maintenir un écartement intervertébral entre des vertèbres, comprenant une cale intervertébrale (10) comprenant une zone supérieure d’appui et une zone inférieure d’appui, et au moins un premier ressort latéral (20) ayant une position A par rapport à la cale intervertébrale (10) dans une position d’introduction du dispositif implantable (100), et une position B par rapport à la cale intervertébrale (10) dans une position d’implantation du dispositif implantable, les positions A et B étant différentes, et le premier ressort latéral (20) est configuré :- pour passer de la position A à la position B librement, et - former un organe de retenue agencé par rapport à la cale intervertébrale (10) pour bloquer la migration de la cale intervertébrale (10) vers le canal rachidien au moins dans la position B. Figure pour l’abrégé: Fig.1.",COUSIN BIOTECH,HOFFMANN ELÉONORE;;BECQUART LUCIE;;CAILLIBOTTE MICHEL,,https://lens.org/119-331-982-537-853,Patent Application,no,6,0,8,049-681-138-955-067;;123-011-641-195-420;;119-331-982-537-853;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;052-804-849-360-014,EP;;ES;;WO;;US;;FR,8,049-681-138-955-067;;123-011-641-195-420;;052-804-849-360-014;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;119-331-982-537-853,EP;;ES;;WO;;US;;FR,0,A61B17/7053;;A61B17/7062;;A61B17/7064;;A61B17/7065;;A61B17/7067;;A61B17/7061;;A61B17/7065;;A61B17/7067,A61B17/70;;A61B17/58;;A61B17/88;;A61F2/44;;A61F2/46,,0,0,,,,ACTIVE
298,WO,A1,WO 2023/222728 A1,118-120-700-155-237,2023-11-23,2023,EP 2023063184 W,2023-05-16,FR 2204858 A,2022-05-20,SYSTEM FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLE INTENDED FOR DETECTING THE PRESENCE OF AT LEAST ONE ANALYTE IN THE BIOLOGICAL SAMPLE,The present invention relates to a system for rapid analysis of a biological sample intended for detecting the presence of at least one analyte in the biological sample. The rapid analysis device (1) comprises a housing (2) and a cap (8) defining an internal volume (8') that is capable pf covering an absorbent block (7). The cap (8) comprises at least one through-opening (81) that leads into the internal volume (8') and which is suitable for introducing a liquid reagent (R) into the internal volume (8') of the cap (8).,NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/118-120-700-155-237,Patent Application,yes,5,0,2,118-120-700-155-237;;180-832-820-464-732,WO;;FR,2,118-120-700-155-237;;180-832-820-464-732,WO;;FR,0,A61B10/0051;;A61B2010/0006;;B01L3/5029;;B01L9/52;;B01L2300/046;;B01L2300/0825;;G01N33/54388,A61B10/00;;B01L3/00;;B01L9/00,,0,0,,,,PENDING
299,WO,A2,WO 2023/111075 A2,172-219-721-448-790,2023-06-22,2023,EP 2022085949 W,2022-12-14,FR 2113580 A,2021-12-15,IMPLANTABLE DEVICE WITH GRADUAL RELEASE OF ONE OR MORE FUNCTIONAL AGENTS AND METHOD FOR MANUFACTURING SUCH A DEVICE,"The present invention relates to an implantable device, in particular for the reconstruction of an anterior cruciate ligament or a tendon, comprising an elongate core (20) and a hollow elongate covering member comprising an inside volume at least partially receiving said elongate core, wherein said elongate core comprises a polymer matrix that is bioerodible in an aqueous medium and one or more functional agent(s), and the covering member comprises through-holes in fluid communication with said inside volume. The invention also relates to a method for manufacturing such an implantable device.",COUSIN BIOTECH,NOEL STÉPHANE,,https://lens.org/172-219-721-448-790,Patent Application,yes,0,0,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,6,115-424-008-344-318;;178-362-014-477-760;;105-490-792-344-022;;172-219-721-448-790;;043-522-560-544-427;;189-091-757-949-236,EP;;WO;;US;;FR,0,A61F2/08;;A61F2250/0031;;A61F2250/0067;;A61F2210/0004;;A61L2430/10;;A61L27/54;;A61L27/58;;A61L27/18;;A61L27/34;;A61L2420/04;;A61L27/28;;A61L27/306;;A61L27/32;;A61L27/56;;A61F2/08;;A61F2210/0004,A61F2/08,,1,1,002-000-496-900-531,10.1016/j.biomaterials.2006.01.017;;16448693,"TADASHI KOKUBOTAKADAMA, BIOMATERIALS, vol. 27, no. 15, 1 May 2006 (2006-05-01), pages 2907 - 15",PENDING
300,KR,A,KR 20220076353 A,158-159-983-916-92X,2022-06-08,2022,KR 20210165461 A,2021-11-26,KR 20200163847 A,2020-11-30,PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF HAIR LOSS AND COSMETIC COMPOSITION FOR PREVENTION AND IMPROVEMENT OF HAIR LOSS,"본 발명을 탈모 예방 또는 치료용 약학 조성물 및 탈모 예방 또는 개선용 화장료 조성물에 관한 것으로, 모낭 세포의 증식을 촉진하여 탈모의 예방, 개선 또는 치료에 효과가 있다.",NEOREGEN BIOTECH,SEO JEONG MIN;;PARK SANG KYU,,https://lens.org/158-159-983-916-92X,Patent Application,no,3,0,2,158-159-983-916-92X;;019-077-822-102-598,KR,2,158-159-983-916-92X;;019-077-822-102-598,KR,16,A61K38/16;;A61P17/14;;A61K8/64;;A61Q7/00,A61K38/16;;A61K8/64;;A61P17/14;;A61Q7/00,,0,0,,,,ACTIVE
301,EP,A1,EP 4034014 A1,172-725-303-782-499,2022-08-03,2022,EP 20772321 A,2020-09-22,FR 1910501 A;;EP 2020076426 W,2019-09-24,"BANDING DEVICE, IN PARTICULAR FOR STABILISING A PERIPROSTHETIC FRACTURE",,COUSIN BIOTECH,NOEL STEPHANE;;OUERGHEMMI SAFA,,https://lens.org/172-725-303-782-499,Patent Application,yes,0,0,6,031-436-170-927-143;;172-725-303-782-499;;188-116-875-532-695;;143-738-056-402-866;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,6,031-436-170-927-143;;172-725-303-782-499;;143-738-056-402-866;;188-116-875-532-695;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,0,A61B17/82;;A61B17/82,A61B17/82,,0,0,,,,PENDING
302,FR,A1,FR 3135785 A1,180-832-820-464-732,2023-11-24,2023,FR 2204858 A,2022-05-20,FR 2204858 A,2022-05-20,"Dispositif pour l’analyse rapide d’un échantillon biologique, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique","La présente invention concerne dispositif pour l’analyse rapide d’un échantillon biologique, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique. Le dispositif d’analyse rapide (1) comprend un boîtier (2) et un capuchon (8) délimitant un volume interne (8’) apte à envelopper un bloc absorbant (7). Le capuchon (8) comporte au moins un orifice traversant (81) qui débouche au sein dudit volume interne (8’) et qui est adapté à l’introduction d’un réactif liquide (R) dans le volume interne (8’) du capuchon (8). Figure pour l’abrégé : 4",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/180-832-820-464-732,Patent Application,no,5,0,2,118-120-700-155-237;;180-832-820-464-732,WO;;FR,2,118-120-700-155-237;;180-832-820-464-732,WO;;FR,0,A61B10/0051;;A61B2010/0006;;B01L3/5029;;B01L9/52;;B01L2300/046;;B01L2300/0825;;G01N33/54388,G01N33/543;;B01L3/00;;G01N33/558,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",PENDING
303,US,A1,US 2025/0002896 A1,183-518-072-959-361,2025-01-02,2025,US 202218694956 A,2022-09-23,US 202218694956 A;;US 202163247800 P;;US 2022/0044601 W,2021-09-23,METHODS AND DEVICES FOR SAMPLING BODILY FLUIDS,"In an embodiment, the present disclosure pertains to a method of detecting specific sequences of cell-free DNA (cfDNA) from a biological sample. In an additional embodiment, the present disclosure pertains to a dipstick for capturing cfDNA from a biological sample. In a further embodiment, the present disclosure pertains to a method for at-home isolation of cfDNA from raw biological fluids. In another embodiment, the present disclosure pertains to a method for identifying optimal diagnostic toehold-mediated DNA strand displacement (TMSD) probing sites for sequence detection. In other embodiments, the present disclosure pertains to a system for visual detection of microbial cfDNA from raw biological fluids.",AMA BIOTECH,MIHAILOVIC MIA;;AMADOR PAUL;;MIHELIC SAMUEL,AMA BIOTECH (2024-11-15),https://lens.org/183-518-072-959-361,Patent Application,yes,0,0,2,183-518-072-959-361;;010-599-436-268-849,WO;;US,2,183-518-072-959-361;;010-599-436-268-849,WO;;US,0,C12N15/1006;;B01L3/5029;;C12Q1/6806;;B01L3/5029;;C12N15/1006;;C12Q1/6806,C12N15/10;;B01L3/00;;C12Q1/6806,,0,0,,,,PENDING
304,US,A1,US 2022/0175815 A1,137-340-950-812-694,2022-06-09,2022,US 202017600235 A,2020-04-02,EP 19305438 A;;EP 2020059434 W,2019-04-03,COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS,"The present invention concerns the combination of PD1 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-PD1 therapies.",OREGA BIOTECH,BONNEFOY NATHALIE;;BASTID JÉRÉMY,OREGA BIOTECH (2021-09-14),https://lens.org/137-340-950-812-694,Patent Application,yes,0,0,5,002-809-273-531-843;;111-070-178-496-436;;026-458-336-004-83X;;074-457-640-639-588;;137-340-950-812-694,JP;;EP;;WO;;US,5,002-809-273-531-843;;111-070-178-496-436;;026-458-336-004-83X;;074-457-640-639-588;;137-340-950-812-694,JP;;EP;;WO;;US,0,A61K45/06;;A61K39/3955;;A61K31/713;;A61P35/00;;A61P31/12;;A61P31/06;;A61P31/00;;A61P33/06;;C07K2317/76;;A61K2039/505;;A61K2039/507;;C07K16/2818;;C07K16/244;;Y02A50/30;;A61P35/00;;A61K31/713;;A61K45/06;;C07K16/244;;C07K16/2818,A61K31/713;;A61K45/06;;A61P35/00;;C07K16/24;;C07K16/28,,0,0,,,,PENDING
305,US,A1,US 2022/0087779 A1,025-428-841-604-963,2022-03-24,2022,US 202017424637 A,2020-01-22,FR 1900592 A;;FR 2020050087 W,2019-01-23,"RETENTION DEVICE COMPRISING A RETENTION APPARATUS AND POSITIONING CLIPS, AND METHOD FOR PRODUCING SUCH A RETENTION DEVICE","Disclosed is a retention device including at least one retention apparatus, designed to be bonded on a portion of a dental arch, and at least two clips, positioned apart from one another; each clip being a rigid hook and rigidly attached to the retention apparatus, and configured to fasten to the dental arch. Also disclosed is a method for producing such a retention device.",BIOTECH DENTAL,SIREIX DOMINIQUE;;SIREIX CHRISTOPHE,BIOTECH DENTAL (2021-08-02),https://lens.org/025-428-841-604-963,Patent Application,yes,6,0,5,110-691-661-281-107;;126-044-206-429-536;;025-428-841-604-963;;178-868-448-030-374;;056-836-595-540-649,EP;;WO;;US;;FR,5,025-428-841-604-963;;126-044-206-429-536;;110-691-661-281-107;;178-868-448-030-374;;056-836-595-540-649,EP;;WO;;US;;FR,0,A61C5/007;;B33Y80/00;;A61C13/0004;;B33Y70/00;;A61C13/0022;;B33Y50/00;;B33Y80/00;;A61C7/002;;A61C7/08,A61C7/08;;A61C7/00;;B33Y50/00;;B33Y80/00,,0,0,,,,DISCONTINUED
306,KR,A,KR 20230093398 A,034-034-012-831-629,2023-06-27,2023,KR 20230075571 A,2023-06-13,KR 20200109702 A;;KR 20200109703 A;;KR 20210113920 A,2020-08-28,NOVEL THIOHYDANTOIN DERIVATIVES AND USE THEREOF,"The present invention relates to a thiohydantoin derivative and a composition containing the same for preventing or treating diseases related to NADPH oxidase (NOX), which can be used for the treatment of diseases related to NADPH oxidase (NOX) through its excellent action on NOX inhibition.",CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,,https://lens.org/034-034-012-831-629,Patent Application,no,3,0,12,093-579-398-771-71X;;156-791-964-355-553;;070-070-682-690-304;;124-789-339-853-086;;060-972-361-938-778;;033-625-275-136-618;;168-747-464-256-935;;017-157-468-377-560;;063-005-551-370-904;;103-101-669-491-524;;034-034-012-831-629;;083-590-826-781-522,JP;;KR;;CN;;EP;;WO;;US,12,033-625-275-136-618;;156-791-964-355-553;;070-070-682-690-304;;168-747-464-256-935;;083-590-826-781-522;;017-157-468-377-560;;063-005-551-370-904;;060-972-361-938-778;;124-789-339-853-086;;103-101-669-491-524;;093-579-398-771-71X;;034-034-012-831-629,JP;;KR;;EP;;CN;;WO;;US,0,A23L33/10;;A61P25/16;;C07D233/96;;A61K31/4166;;A61P27/02;;A61P25/28;;A61P25/16;;C07D233/96;;A61P25/16;;A61K31/4166,C07D233/96;;A61K31/4166;;A61P25/16;;A61P25/28;;A61P27/02,,1,1,080-696-462-366-171,27407031;;10.1016/j.bmc.2016.06.056,"Bioorganic & Medicinal Chemistry, (2016) Vol. 24, pp. 4144-4151*",ACTIVE
307,EP,A1,EP 4211161 A1,077-119-603-416-18X,2023-07-19,2023,EP 21866203 A,2021-09-14,US 202063078274 P;;IB 2021058373 W,2020-09-14,"SH3YL1 ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF",,CELROS BIOTECH,BAE YUN SOO;;AN EUNJUNG;;YOO JUNG-YEON;;SHIM HYUNBO;;LEE HYE EUN,,https://lens.org/077-119-603-416-18X,Patent Application,yes,0,0,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,100,C07K16/3053;;C07K16/18;;C07K2317/622;;C07K2317/92;;G01N33/532;;G01N33/533;;C07K2317/21;;A61P13/12;;A61P1/16;;C07K16/18;;A61P1/16;;A61P13/12;;G01N33/563;;C07K2317/622;;C07K2317/565;;C07K2317/92;;A61K2039/505;;C07K16/18;;G01N33/6854;;A61P1/16;;A61P13/12;;A61K2039/505;;C07K2317/52;;C07K2317/624;;C07K2317/622;;C07K2317/55;;C07K2317/565,C07K16/18;;A61K39/00;;A61P1/16;;A61P13/12;;A61P29/00;;A61P37/00,,0,0,,,,PENDING
308,KR,A,KR 20220141256 A,079-096-726-288-45X,2022-10-19,2022,KR 20220044922 A,2022-04-12,KR 20210047258 A,2021-04-12,Intracellular delivery platform,"The present invention relates to an intracellular substance delivery platform comprising: a first channel through which a fluid containing cells and a transmitter flows with a flow; and a second channel and a third channel which are connected to the first channel at an angle so that the fluid including the cells and the transmitter flows with a flow, wherein the fluid forms at least one of a collision region and a vortex region in at least one of the first channel, the second channel, and the third channel. According to the present invention, an intracellular substance can be effectively delivered by forming a vortex in the channels.",MXT BIOTECH,CHUNG ARAM;;HUR JEONG SOO,,https://lens.org/079-096-726-288-45X,Patent Application,no,0,0,3,047-285-545-211-092;;079-096-726-288-45X;;174-656-514-206-690,KR;;EP;;CN,6,174-656-514-206-690;;097-721-008-950-916;;047-285-545-211-092;;117-205-002-265-638;;079-096-726-288-45X;;138-793-828-015-972,KR;;CN;;EP;;WO;;US,0,C12N15/87;;C12M35/04;;C12M35/04;;C12M41/38;;C12M23/16;;C12N15/87,C12M1/42;;C12M1/34;;C12M3/06;;C12N15/87,,0,0,,,,DISCONTINUED
309,FR,A1,FR 3121513 A1,054-640-202-927-803,2022-10-07,2022,FR 2105705 A,2021-05-31,FR 2103428 A,2021-04-02,"Dispositif pour l’analyse rapide d’un échantillon biologique, par exemple un échantillon biologique salivaire","La présente invention concerne un dispositif pour l’analyse rapide d’un échantillon biologique, par exemple un échantillon biologique salivaire, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique. Le dispositif d’analyse rapide (1) comprend : - un organe de prélèvement (2), destiné au prélèvement dudit échantillon biologique, et - un boîtier (3) qui comporte un emplacement (31) destiné à recevoir une bandelette chromatographique (7) et une interface (32), adaptée à recevoir ledit organe de prélèvement (2) dans une configuration finale assemblée. L’organe de prélèvement (2) et l’interface (32) comportent des moyens d’assemblage étanche (5) comprenant des moyens de guidage (6) qui sont structurés pour guider un mouvement relatif entre ledit organe de prélèvement (2) et ladite interface (32) depuis une configuration initiale de positionnement jusqu’à la configuration finale assemblée, ledit mouvement relatif comprenant deux mouvements : - un mouvement de translation relatif, prévu pour appliquer une compression audit bloc absorbant (21), et - un mouvement de rotation relatif, prévu pour appliquer une torsion audit bloc absorbant (21). Figure pour l’abrégé : 1",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/054-640-202-927-803,Patent Application,no,5,0,2,057-060-284-581-620;;054-640-202-927-803,FR,4,064-690-104-175-773;;017-608-966-926-024;;054-640-202-927-803;;057-060-284-581-620,WO;;FR,0,G01N33/54388;;A61B10/0051;;A61B2010/0006;;B01L3/50273;;B01L3/5029;;B01L2200/027;;B01L2300/069;;B01L2300/0825;;B01L2400/0406,G01N33/543;;A61B10/02;;B01L3/00;;G01N1/10,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",DISCONTINUED
310,FR,A1,FR 3107517 A1,067-151-215-553-032,2021-08-27,2021,FR 2001811 A,2020-02-24,FR 2001811 A,2020-02-24,RECHARGE A POCHE COMPRENANT DES MOYENS DE DEGAZAGE DE LA POCHE ET BOITIER DISTRIBUTEUR COMPRENANT UNE TELLE RECHARGE A POCHE.,"L’invention porte sur une recharge (100) à poche et un boitier distributeur associé, comprenant une poche (101) destinée à contenir un liquide actif à distribuer sous pression, un mécanisme de valve comprenant une valve reliée à un tube de distribution (103) inséré à l’intérieur de la poche (101), un dôme (104) supportant le mécanisme de valve et comprenant une embase (106) de fixation de la poche (101), caractérisée en ce que la recharge (100) comporte des moyens de dégazage (4) de la poche (101), lesquels moyens de dégazage comportent un trou d’accès à l’intérieur de la poche (101) et une membrane (40) hydrophobe recouvrant le trou d’accès, ladite membrane (40) laissant passer le gaz produit par le liquide lorsqu’il est sous pression. Figure à publier avec l’abrégé : Fig. 3",VENTUM BIOTECH,KACHOU LOUFTI,,https://lens.org/067-151-215-553-032,Patent Application,no,6,0,3,067-151-215-553-032;;176-687-061-163-310;;061-974-551-372-045,WO;;FR,3,067-151-215-553-032;;176-687-061-163-310;;061-974-551-372-045,WO;;FR,0,B65D83/62;;A61L2/18;;A61L2202/15;;A61L2202/181;;B65D83/38;;B65D83/70,B65D83/14;;B05B1/02;;B65D83/62,,0,0,,,,ACTIVE
311,EP,A1,EP 3812051 A1,090-537-718-423-673,2021-04-28,2021,EP 20202129 A,2020-10-15,FR 1911766 A,2019-10-21,METHOD AND DEVICE FOR SEPARATING HEMP TRICHOMES,"Procédé de séparation des trichomes de plantes de chanvre comprenant les étapes :a) fourniture d'un dispositif de séparation (1) comprenant :- un bâti (2),- au moins un tambour (3) monté rotatif par rapport au bâti (2), dont la paroi périphérique (31) est constituée d'un tamis (32),- un circuit de recirculation et de tri (4),b) mise en rotation du tambour (3) par rapport au bâti (2),c) insertion de pellets de glace carbonique dans le tambour (3),d) insertion de plantes de chanvre dans le tambour (3),e) réception de la matière en sortie du tambour (3),f) tri de la matière réceptionnée en sortie du tambour (3) puis amenée des pellets de glace carbonique en entrée du tambour (3),g) évacuation des trichomes,dans lequel les étapes b) à g) sont effectuées simultanément et en continu au cours du procédé.",ELICAN BIOTECH,MEXMAIN GÉRALD,,https://lens.org/090-537-718-423-673,Patent Application,yes,3,2,4,155-480-105-741-195;;076-552-631-125-356;;028-744-306-086-58X;;090-537-718-423-673,EP;;FR;;MA,4,155-480-105-741-195;;076-552-631-125-356;;028-744-306-086-58X;;090-537-718-423-673,EP;;FR;;MA,0,B07B1/26;;A61K2236/00;;A61K36/185,B07B1/26;;A61K36/185,,0,0,,,,DISCONTINUED
312,FR,A1,FR 3097123 A1,081-212-639-641-312,2020-12-18,2020,FR 1906208 A,2019-06-11,FR 1906208 A,2019-06-11,Combinaison de marqueurs pour prédire la réponse à Vx-001,"L'invention concerne l'utilisation d'un vaccin antitumoral composé de deux peptides de neuf acides aminés - le TERT572 (RLFFYRKSV, SEQ ID N °1) natif cryptique, exprimé par des cellules tumorales, et sa variante optimisée TERT572Y (YLFFYRKSV, SEQ ID N °2), pour le traitement d’une tumeur exprimant la télomérase transcriptase inverse (TERT), chez un patient HLA-A*0201 présentant un taux normal de gamma Glutamine Transférase (gGT) et/ou un taux normal lactate déshydrogénase (LDH).",VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS (KOSTAS);;MENEZ-JAMET JEANNE,,https://lens.org/081-212-639-641-312,Patent Application,no,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,0,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K38/02;;A61P35/00,,14,8,006-397-181-302-362;;023-807-389-777-602;;004-308-421-751-408;;022-737-803-341-920;;023-807-389-777-602;;016-640-527-380-991;;037-092-608-111-221;;046-503-066-966-531,10.1038/s41416-020-0785-y;;pmc7217860;;32210365;;10.1016/j.cllc.2013.02.001;;23647738;;21873272;;10.1093/annonc/mdr396;;26802161;;10.1093/annonc/mdw016;;10.1016/j.cllc.2013.02.001;;23647738;;10.21037/atm.2016.05.15;;pmc4971378;;27563653;;29327044;;pmc5885829;;10.1001/jamaoncol.2017.4771;;11093159;;10.1002/1521-4141(2000012)30:12<3411::aid-immu3411>3.0.co;2-r,"CESARE GRIDELLI ET AL: ""Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial"", BRITISH JOURNAL OF CANCER, 25 March 2020 (2020-03-25), GB, XP055680259, ISSN: 0007-0920, DOI: 10.1038/s41416-020-0785-y;;GEORGOULIAS VASSILIS ET AL: ""A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics"", CLINICAL LUNG CANCER JUL 2013,, vol. 14, no. 4, 1 July 2013 (2013-07-01), pages 461 - 465, XP002774759, ISSN: 1938-0690, DOI: 10.1016/J.CLLC.2013.02.001;;ANONYMOUS: ""vaxon-biotech > VX-001"", 8 April 2017 (2017-04-08), XP055680260, Retrieved from the Internet <URL:https://web.archive.org/web/20170408155422/http://vaxon-biotech.com/?page_id=122> [retrieved on 20200327];;ANONYMOUS: ""Novel Vaccine Shows Association With Survival Based on Smoking History in Patients With Advanced NSCLC"", 18 September 2017 (2017-09-18), XP055680262, Retrieved from the Internet <URL:https://www.targetedonc.com/conference/esmo-2017/novel-vaccine-shows-association-with-survival-based-on-smoking-history-in-patients-with-advanced-nsclc> [retrieved on 20200327];;KOTSAKIS A ET AL: ""Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: Results of an expanded phase II study"", ANNALS OF ONCOLOGY, KLUWER, DORDRECHT, NL, vol. 23, no. 2, 1 February 2012 (2012-02-01), pages 442 - 449, XP002724182, ISSN: 0923-7534, [retrieved on 20110825], DOI: 10.1093/ANNONC/MDR396;;ANONYMOUS: ""Lung cancer: Vaxon announces results of its Vx-001 therapeutic vaccine Phase IIb trial - Andrew Lloyd & Associates"", 1 June 2017 (2017-06-01), XP055680267, Retrieved from the Internet <URL:https://ala.com/vaxon-announces-results-of-its-phase-iib-lung-cancer-trial-of-vx-001-a-therapeutic-vaccine-based-on-optimized-cryptic-peptides/> [retrieved on 20200327];;FERRUCCI ET AL., ANNALS ONCOL., 2016;;GEORGOULIAS ET AL., CLIN LUNG CANCER, 2013;;FERRUCCI ET AL., ANNALS ONCOL, 2016;;FERRUCCI PFASCIERTO PA ET AL.: ""Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab"", ANN ONCOL., vol. 27, no. 4, April 2016 (2016-04-01), pages 732 - 8;;GEORGOULIAS V ET AL.: ""A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics"", CLIN LUNG CANCER, vol. 14, no. 4, July 2013 (2013-07-01), pages 461 - 5, XP002774759, DOI: 10.1016/j.cllc.2013.02.001;;MENEZ-JAMET J ET AL.: ""Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines"", ANN TRANSI MED., vol. 4, no. 14, July 2016 (2016-07-01), pages 266, XP055415775, DOI: 10.21037/atm.2016.05.15;;MEZQUITA, L. ET AL.: ""Association of the Lung Immune Prognostic Index With Immune checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer"", JAMA ONCOL., vol. 4, no. 3, 1 March 2018 (2018-03-01), pages 351 - 357;;TOURDOT S ET AL.: ""A général strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes"", EUR J IMMUNOL., vol. 30, no. 12, December 2000 (2000-12-01), pages 3411 - 21, XP002781815, DOI: 10.1002/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0.CO;2-R",DISCONTINUED
313,WO,A1,WO 2024/215878 A1,086-821-078-881-556,2024-10-17,2024,US 2024/0024057 W,2024-04-11,US 202363495392 P,2023-04-11,DETECTION OF MYCOBACTERIUM TUBERCULOSIS,"The invention is directed to processes and methods for rapidly isolating, detecting, and/or quantitating Mycobacterium tuberculosis (MTB) from biological samples. The processes and methods involve contacting the biological samples with one or more aptamers anti-PE_PGRS or one or more aptamers anti-PE_PGRS fused with a label and detecting the presence or absence of PE_PGRS, wherein a positive detection of PE_PGRS indicates that MTP is present. The invention also concerns a kit including a combination of two or more binding elements selected from a first aptamer anti-PE_PGRS, a second aptamer anti-PE_PGRS, and an antibody against Trem2 and/or Mincle, wherein the first and second aptamers do not bind to the same proteins.",IMPRESA BIOTECH,ALLEN PENNER GREGORY;;ANGEL BOJORQUEZ VAZQUEZ LUIS;;DAUM LUKE THOMAS,,https://lens.org/086-821-078-881-556,Patent Application,yes,3,0,1,086-821-078-881-556,WO,1,086-821-078-881-556,WO,121,C12N15/115;;C12N2310/16;;C12N2310/3517;;C12Q1/04;;G01N33/5695,C12N15/115,,7,6,059-315-427-959-884;;047-823-114-919-895;;028-055-602-160-533;;036-947-831-962-71X;;012-987-818-717-643;;112-406-714-842-033,7687254;;pmc501296;;10.1136/jcp.46.6.559;;pmc3232962;;10.1128/jcm.05434-11;;21956978;;10.26226/morressier.56d5ba2ad462b80296c9658a;;24586675;;10.1371/journal.pone.0089301;;pmc3935858;;34441287;;pmc8391981;;10.3390/diagnostics11081352;;10.1016/s0732-8893(03)00138-x;;14596969;;23637290;;10.1128/jcm.00508-13;;pmc3697694,"""Latent tuberculosis infection: updated and consolidated guidelines for programmatic management"", vol. 2018, 15 February 2023, WORLD HEALTH ORGANIZATION, article ""TB/HIV and multi drug/rifampicin-resistant TB (MDR/RR-TB"";;ELLIS RCZABROWARNY LA: ""Safer staining method for acid fast bacilli"", JOURNAL OF CLINICAL PATHOLOGY, vol. 3, no. 46, 1993, pages 559 - 560;;ZEKA ANTASBAKAN SCAVUSOGLU C.: ""Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens"", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 49, no. 12, 2011, pages 4138 - 41;;RAIZADA NSACHDEVA KSSREENIVAS AVADERA BGUPTA RSPARMAR MKULSANGE SBABRE ATHAKUR RGRAY C: ""Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India"", PLOS ONE, vol. 9, no. 2, 2014, pages 89301;;MARTIN DRSIBUYI NRDUBE PFADAKA AOCLOETE RONANI MMADIEHE AMMEYER M.: ""Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care"", DIAGNOSTICS, vol. 11, no. 8, 2021, pages 1352;;BURDZ TVNWOLFE JKABANI A.: ""Evaluation of sputum decontamination methods for Mycobacterium tuberculosis using viable colony counts and flow cytometry"", DIAG MICROBIOL INFECT DIS., vol. 47, 2003, pages 503 - 9, XP055097275, DOI: 10.1016/S0732-8893(03)00138-X;;BRADNER LROBBE-AUSTERMAN SBEITZ DCSTABEL JR.: ""Chemical decontamination with N-acetyl-L-cysteine-sodium hydroxide improves recovery of viable Mycobacterium avium subsp. paratuberculosis organisms from cultured milk"", J CLIN MICROBIOL., vol. 51, no. 7, 2003, pages 2139 - 46",PENDING
314,US,A1,US 2020/0347448 A1,102-403-894-616-028,2020-11-05,2020,US 201816758684 A,2018-10-23,US 201816758684 A;;US 201762575841 P;;IB 2018001312 W,2017-10-23,FUNCTIONAL METAGENOMICS,"The present disclosure describes methods for identifying a microbe that modulates an activity of a target cell, a target virus, or an enzymatic reaction of a target substrate.",WILD BIOTECH,BACHELET IDO;;KOPEL MORAN AVRAHAM;;BASSALI LIRON ANNA;;RAAB NETA,,https://lens.org/102-403-894-616-028,Patent Application,yes,0,0,2,005-376-622-373-918;;102-403-894-616-028,WO;;US,2,005-376-622-373-918;;102-403-894-616-028,WO;;US,0,C12Q1/02;;C12Q1/68;;C12Q1/6869;;C12Q1/6869;;C12Q1/686;;C12Q2563/185,C12Q1/6869;;C12Q1/686,,0,0,,,,DISCONTINUED
315,US,A1,US 2023/0330067 A1,103-101-669-491-524,2023-10-19,2023,US 202118043408 A,2021-08-27,KR 20200109702 A;;KR 20200109703 A;;KR 2021011535 W,2020-08-28,NOVEL THIOHYDANTOIN DERIVATIVES AND USES THEREOF,"The present invention relates to a thiohydantoin derivative and a composition for preventing or treating NADPH oxidase (NOX)-associated diseases comprising same, and can be used to treat NADPH oxidase (NOX)-associated diseases through excellent actions on NOX inhibition.",CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (2023-02-27);;CELROS BIOTECH (2023-02-27),https://lens.org/103-101-669-491-524,Patent Application,yes,0,0,12,093-579-398-771-71X;;156-791-964-355-553;;070-070-682-690-304;;124-789-339-853-086;;060-972-361-938-778;;033-625-275-136-618;;168-747-464-256-935;;017-157-468-377-560;;063-005-551-370-904;;103-101-669-491-524;;034-034-012-831-629;;083-590-826-781-522,JP;;KR;;CN;;EP;;WO;;US,12,033-625-275-136-618;;156-791-964-355-553;;070-070-682-690-304;;168-747-464-256-935;;083-590-826-781-522;;017-157-468-377-560;;063-005-551-370-904;;060-972-361-938-778;;124-789-339-853-086;;103-101-669-491-524;;093-579-398-771-71X;;034-034-012-831-629,JP;;KR;;EP;;CN;;WO;;US,0,A23L33/10;;A61P25/16;;C07D233/96;;A61K31/4166;;A61P27/02;;A61P25/28;;A61P25/16;;C07D233/96;;A61P25/16;;A61K31/4166,A61K31/4166;;A61P25/16,,0,0,,,,PENDING
316,KR,A,KR 20250047256 A,117-205-002-265-638,2025-04-03,2025,KR 20250039540 A,2025-03-27,KR 20210047258 A;;KR 20220044922 A,2021-04-12,Intracellular delivery platform,"본 발명은 세포 및 전달물질을 포함하는 유체가 흐름을 가지고 유동하는 제1채널; 상기 제1채널과 각도를 가지고 연결되어 세포 및 전달물질을 포함하는 상기 유체가 흐름을 가지고 유동하는 제2채널 및 제3채널; 및 상기 제1채널, 제2채널 및 제3채널 중 적어도 어느 하나에서 상기 유체가 충돌 및 와류 영역 중 적어도 어느 하나를 형성하는, 세포 내 물질 전달 플랫폼에 관한 것이다. 본 발명에 따르면, 채널 내에 와류를 형성하여 세포 내에 물질을 효과적으로 전달할 수 있다.",MXT BIOTECH,CHUNG A RAM;;HUR JEONG SOO,,https://lens.org/117-205-002-265-638,Patent Application,no,0,0,3,117-205-002-265-638;;138-793-828-015-972;;097-721-008-950-916,KR;;WO;;US,6,174-656-514-206-690;;097-721-008-950-916;;047-285-545-211-092;;117-205-002-265-638;;079-096-726-288-45X;;138-793-828-015-972,KR;;CN;;EP;;WO;;US,0,C12N15/87;;C12M35/04;;C12M35/04;;C12M23/16;;C12M41/38;;C12N15/87;;C12M23/04;;C12M23/34,C12M1/42;;C12M1/34;;C12M3/06;;C12N15/87,,0,0,,,,PENDING
317,EP,A1,EP 4371523 A1,133-402-258-255-671,2024-05-22,2024,EP 23211092 A,2023-11-21,FR 2212115 A,2022-11-21,SURGICAL GUIDE FOR THE PLACEMENT OF DENTAL IMPLANTS,"L'invention concerne un guide (1) chirurgical pour la pose d'implants dentaires, comprenant une base (2) apte à être fixée à l'os maxillaire ou mandibulaire, une gouttière (3) apte à être fixée à la base (2) et à être positionnée dans l'espace par rapport au référentiel dent ou anatomie restant en bouche, et un guide de perçage (4) apte à être fixé à la base (2) et comprenant au moins un alésage (5) de guidage d'un foret et où la base :- est sensiblement rigide ;- s'appuie généreusement sur les muqueuses ;- épouse sensiblement la forme d'un maxillaire ou d'une mandibule et présente une partie centrale disposée sur la face interne de la mâchoire qui constitue un appui lingual ou palatal ; et- est largement ajourée le long de la crête maxillaire ou mandibulaire, afin de laisser passer des dents encore présentes en début d'opération ou des implants à installer en cours d'opération.",BIOTECH DENTAL,KELLER PIERRE,,https://lens.org/133-402-258-255-671,Patent Application,yes,7,0,4,133-402-258-255-671;;029-804-011-916-038;;169-200-571-166-553;;185-137-173-008-972,EP;;US;;FR,4,133-402-258-255-671;;029-804-011-916-038;;169-200-571-166-553;;185-137-173-008-972,EP;;US;;FR,0,A61C1/084;;A61C1/085;;A61C8/0089;;A61C13/087;;A61C13/26;;B33Y80/00;;A61C13/225;;A61C8/005;;A61C1/084;;A61C8/0068;;A61C8/0089;;A61C2201/00,A61C1/08;;A61C8/00;;A61C13/225;;A61C13/271;;B33Y80/00,,0,0,,,,PENDING
318,FR,A1,FR 3105729 A1,138-108-042-954-128,2021-07-02,2021,FR 1915796 A,2019-12-31,FR 1915796 A,2019-12-31,Composition pour la gestion du poids d’un sujet,"La présente demande a pour objet une composition pour la gestion du poids d’un sujet, ladite composition comprenant au moins un matériau biocompatible résorbable et haute viscosité, destinée à être injectée dans l’espace sous-muqueux du tractus digestif d’un sujet et créer ainsi une surélévation durable de la muqueuse correspondante. La présente demande a également pour objet un kit comprenant une composition selon l’invention et des moyens d’injection de la composition. La présente demande a enfin pour objet l’utilisation d’une composition selon l’invention pour la gestion du poids d’un sujet. Figure à publier avec l’abrégé : Fig. 1",MRS BIOTECH,MARÇAIS OLIVIER,,https://lens.org/138-108-042-954-128,Patent Application,no,5,0,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,0,A61K31/728;;A61K9/0019;;A61K31/715;;A61K31/722;;A61K45/06;;A61K47/02;;A61K47/26;;A61K47/38;;A61K31/728;;A61K9/0019;;A61K45/06,A61K31/728;;A61K47/36;;A61P41/00,,3,3,133-841-739-679-736;;133-841-739-679-736;;023-121-871-453-52X,10.1007/s11695-015-1648-0;;25812529;;10.1007/s11695-015-1648-0;;25812529;;22573940;;pmc3345931;;10.2147/ceg.s29704,"DARGENT JEROME ET AL: ""Multicenter Randomized Study of Obesity Treatment with Minimally Invasive Injection of Hyaluronic Acid Versus and Combined with Intragastric Balloon"", OBESITY SURGERY, RAPID COMMUNICATIONS OF OXFORD, OXFORD, GB, vol. 25, no. 10, 27 March 2015 (2015-03-27), pages 1842 - 1847, XP035540956, ISSN: 0960-8923, [retrieved on 20150327], DOI: 10.1007/S11695-015-1648-0;;J. DARGENT ET AL.: ""Multicenter randomized study of obesity treatment with minimally invasive injection of hyaluronic acid versus and combined with intragastric balloon"", OBESITY SURGERY, vol. 25, 2015, pages 1842 - 7, XP035540956, DOI: 10.1007/s11695-015-1648-0;;H. AL-TAIE ET AL.: ""Efficacy of submucosal injection of différent solutions inclusive blood components on mucosa élévation for endoscopic resection"", CLINICAL AND EXPÉRIMENTAL GASTROEN-TEROLOGY, vol. 5, 2012, pages 43 - 48",ACTIVE
319,KR,A,KR 20240155853 A,147-477-893-597-624,2024-10-29,2024,KR 20247022623 A,2024-03-28,US 202318136419 A;;US 2024/0021859 W,2023-04-19,통합 추적 장치 챔버를 구비한 냉동 보존 장치,본 발명은 일체로 된 추적 장치 챔버를 구비한 냉동 보존 장치를 제공한다. 추적 장치는 생물학적 시료의 유리화를 위한 절차의 일부로서 냉동 보존 장치 내에 배치될 수 있는 RFID 태그일 수 있다. 냉동 보존 장치는 그 무결성을 유지하고 시료가 수집될 때와 시료가 저장되는 액체 질소 하에서 주변 조건 모두에서 RFID 태그를 챔버 내에 안전하게 유지한다. 통합 추적 장치 챔버를 구비한 냉동 보존 장치는 극저온 저장 동안 모니터링을 위한 각각의 개별 생물학적 시료가 자체의 추적 장치를 갖도록 한다.,BIOTECH INC,JORGE E PARRA ALMANZA,,https://lens.org/147-477-893-597-624,Patent Application,no,0,0,10,047-592-826-495-933;;162-489-143-820-817;;147-477-893-597-624;;141-146-935-123-247;;060-885-276-227-95X;;046-595-929-205-924;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,AU;;JP;;KR;;CN;;IL;;EP;;MX,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,A01N1/147;;G06K19/0723;;C12N5/547;;G06K19/0723;;A01N1/146;;A01N1/147;;G06K19/0723;;A01N1/144,A01N1/02;;G06K19/07,,0,0,,,,PENDING
320,KR,A,KR 20230159748 A,098-054-803-724-643,2023-11-22,2023,KR 20220058564 A,2022-05-12,KR 20220058564 A,2022-05-12,Bovine diarrhea-causing virus and protozoa multi-diagnosis kit,"The present invention relates to a bovine diarrhea-causing virus and a protozoan multi-diagnosis kit. In the present invention, a recombinant antigen of BCV, BVDV, BRV, and Giardia, pathogens that cause bovine diarrhea, and a monoclonal antibody that specifically binds to the recombinant antigen are produced. In addition, an antibody pair with excellent antigen-antibody reactions with the recombinant antigen is selected and a kit is prepared using the selected antibody pair. It is confirmed that the kit has high sensitivity and specificity. The effectiveness of the kit that can simultaneously detect BCV, BVDV, BRV, and Giardia, pathogens that cause bovine diarrhea is also confirmed. Accordingly, the kit has excellent sensitivity and specificity and thus can be usefully used in related industries.",BOREDA BIOTECH,DONG OK CHOI;;DONG HO SHIN;;EUN JI PARK,,https://lens.org/098-054-803-724-643,Patent Application,no,1,0,2,062-776-661-554-770;;098-054-803-724-643,KR,2,062-776-661-554-770;;098-054-803-724-643,KR,16,C07K14/005;;G01N33/56983;;C12N2770/20022;;C12N2770/24022;;C12N2720/12022;;G01N2333/165;;G01N2333/185;;G01N2333/14,C07K14/005;;G01N33/569,,0,0,,,,DISCONTINUED
321,CO,A2,CO 2023014297 A2,084-546-024-256-441,2023-10-30,2023,CO 2023014297 A,2023-10-25,US 2022/0024946 W;;US 202163175603 P,2021-04-16,Producto de huevo hiperinmunizado para el tratamiento o la prevención de la hepatopatía alcohólica y la enfermedad de injerto contra el hospedero,"En un aspecto, la presente divulgación se dirige a un método para prevenir o tratar la enfermedad hepática alcohólica o la enfermedad de injerto contra el hospedero en un sujeto que lo necesite, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un producto de huevo hiperinmunizado obtenido de un animal productor de huevos, previniendo o tratando así la enfermedad hepática alcohólica o la enfermedad de injerto contra el hospedero en el sujeto, en donde el producto de huevo hiperinmunizado comprende una cantidad terapéuticamente efectiva de uno o más anticuerpos contra un antígeno seleccionado del grupo que consiste en Enterococcus faecalis, la toxina citolisina de Enterococcus faecalis, y Enterococcus faecium. La presente divulgación también se dirige a huevos hiperinmunizados y productos de huevo producidos por un animal que se hiperinmunizó con un antígeno seleccionado del grupo que consiste en Enterococcus faecalis, la toxina citolisina aislada de Enterococcus faecalis, y Enterococcus faecium. Los métodos para preparar los huevos hiperinmunizados y los productos de huevo también se divulgan.",PRODIGY BIOTECH,IYER SUBRAMANIAN V;;PATEL SUNNY,,https://lens.org/084-546-024-256-441,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,PENDING
322,WO,A1,WO 2022/221616 A1,042-752-952-137-131,2022-10-20,2022,US 2022/0024946 W,2022-04-15,US 202163175603 P,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE,"In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or grafi-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmimized egg product obtained from an egg- producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecaUs, Enterococcus faecalis eytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis. isolated Enterococcus faecal is eytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.",PRODIGY BIOTECH,IYER SUBRAMANIAN;;PATEL SUNNY,,https://lens.org/042-752-952-137-131,Patent Application,yes,3,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,2,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,PATENTED
323,FR,A1,FR 3120303 A1,019-363-140-965-748,2022-09-09,2022,FR 2102018 A,2021-03-02,FR 2102018 A,2021-03-02,Dispositif prothétique dentaire,"Dispositif prothétique dentaire L’invention concerne un dispositif prothétique dentaire (1) comprenant au moins un implant (2), une coiffe (22) et un pilier (4). Le pilier (4) est interposé entre l’implant (2) et la coiffe (22). Le pilier (4) comprend une tête de pilier (12) équipée de moyens de rétention (34) de la coiffe (22) et un corps de pilier (11) pourvu de moyens de fixation (24) sur l’implant (2). Les moyens de rétention (34) comprennent des moyens d’emboîtement (35b) de la tête de pilier (12) à l’intérieur d’une cavité (36) ménagée à l’intérieur de la coiffe (22). Les moyens de rétention (34) comprennent des moyens de vissage (35a) de la coiffe (22) sur la tête de pilier (12). Figure de l’abrégé : Figure 1",BIOTECH DENTAL,BREYSSE PASCAL,,https://lens.org/019-363-140-965-748,Patent Application,no,5,1,9,019-363-140-965-748;;187-080-580-128-005;;052-193-428-912-212;;056-269-316-781-258;;021-911-244-760-284;;074-452-294-194-13X;;096-026-210-549-527;;162-987-004-657-206;;187-566-910-286-875,EP;;ES;;WO;;US;;FR,9,019-363-140-965-748;;187-080-580-128-005;;056-269-316-781-258;;052-193-428-912-212;;021-911-244-760-284;;074-452-294-194-13X;;187-566-910-286-875;;162-987-004-657-206;;096-026-210-549-527,EP;;ES;;WO;;US;;FR,0,A61C8/0048;;A61C8/008;;A61C8/0068;;A61C8/0068;;A61C8/0069;;A61C8/008,A61C8/00;;A61C13/225,,0,0,,,,ACTIVE
324,KR,A,KR 20250103818 A,001-327-221-425-960,2025-07-08,2025,KR 20230192582 A,2023-12-27,KR 20230192582 A,2023-12-27,Bovine diarrhea-causing virus -diagnosis kit,"본 발명은 소 설사병 BVDV 진단키트에 관한 것으로, 15분 정도의 짧은 시간내에 소 설사병 유발 병원체인 BVD virus 유전형인 BVDV1과 BVDV2를 현장에서 빠르게 구분하여 진단할 수 있다.",BOREDA BIOTECH,CHOI DONG OK;;PARK JIN HO;;CHOI KYOUNG SEONG,,https://lens.org/001-327-221-425-960,Patent Application,no,1,0,2,001-327-221-425-960;;142-881-357-691-855,KR;;WO,2,001-327-221-425-960;;142-881-357-691-855,KR;;WO,0,A61K39/12;;G01N33/569;;C12N15/70;;C07K14/005;;A61P31/14,C07K14/005;;A61K39/12;;A61P31/14;;C12N15/70;;G01N33/569,,0,0,,,,PENDING
325,EP,A1,EP 4482863 A1,039-894-679-475-898,2025-01-01,2025,EP 23707047 A,2023-02-21,EP 22305190 A;;EP 22305677 A;;EP 2023054333 W,2022-02-21,TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES,,ACTICOR BIOTECH,AVENARD GILLES;;PLETAN YANNICK;;GROUIN JEAN-MARIE;;BINAY SOPHIE;;TOLEDANO ELIE;;COMENDUCCI ANDREA,,https://lens.org/039-894-679-475-898,Patent Application,yes,0,0,3,115-218-990-954-833;;199-959-012-899-787;;039-894-679-475-898,EP;;WO;;US,3,115-218-990-954-833;;199-959-012-899-787;;039-894-679-475-898,EP;;WO;;US,0,C07K16/2803;;A61P7/02;;A61K2039/545;;A61K2039/505;;C07K2317/55;;C07K2317/24;;C07K2317/76;;A61K39/39533;;A61P7/02;;A61K2039/505;;C07K16/2803;;C07K2317/24;;C07K2317/565,C07K16/28;;A61K39/395;;A61P7/02,,0,0,,,,PENDING
326,US,A1,US 2024/0115632 A1,026-134-353-184-739,2024-04-11,2024,US 202218275902 A,2022-02-04,KR 20210016012 A;;KR 20220014543 A;;KR 2022001731 W,2021-02-04,COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM-DERIVED POLYSACCHARIDE OR EXTRACT,"A method for preventing or treating a metabolic disease includes administering to an individual a composition comprising at least one of a Lactobacillus plantarum-derived polysaccharide or and a Lactobacillus plantarum extract. The metabolic disease may be metabolic disease is at least one selected from the group consisting of insulin resistance, type 2 diabetes, hyperlipidemia, fatty liver, obesity and/or inflammation.",NEOREGEN BIOTECH,SEO JEONG MIN;;LEE JAE HOON,NEOREGEN BIOTECH (2023-08-01),https://lens.org/026-134-353-184-739,Patent Application,yes,0,0,5,174-915-703-153-202;;147-815-073-378-708;;189-848-492-967-472;;026-134-353-184-739;;186-166-729-431-389,JP;;WO;;US,10,026-134-353-184-739;;005-146-690-760-836;;147-815-073-378-708;;189-848-492-967-472;;073-656-819-415-424;;186-166-729-431-389;;189-472-759-321-468;;174-915-703-153-202;;029-815-409-073-468;;003-062-187-785-760,JP;;KR;;CN;;EP;;WO;;US,30,C12P19/04;;A61K31/716;;A61K35/747;;A61P3/10;;A61P29/00;;A61P3/04;;A61P1/16;;A61P1/16;;A61P3/04;;A61P3/10;;A61P29/00;;A61K31/716;;A61K35/747,A61K35/747;;A61K31/716;;A61P1/16;;A61P3/04;;A61P3/10;;A61P29/00,,0,0,,,,PENDING
327,AU,A1,AU 2020/225797 A1,078-162-398-010-702,2021-10-14,2021,AU 2020/225797 A,2020-01-22,KR 20190018998 A;;KR 2020001090 W,2019-02-19,"Water-soluble naphthoquinone derivative composition and method for producing same, water-soluble composition for controlling harmful algae, method for controlling large-scale harmful algae, and automation system for AI-monitoring, removing, and preventing large-scale harmful algae","The present invention pertains to: a water-soluble naphthoquinone derivative composition and a method for producing same; a water-soluble composition for controlling harmful algae; a method for controlling large-scale harmful algae; and an automation system for AI-monitoring, removing, and preventing large-scale harmful algae. According to an embodiment of the present invention, proposed is a method for producing a water-soluble naphthoquinone derivative composition, the method being characterized in that a 1,4-naphthoquinone compound is reacted with N,N-diethylenediamine to obtain an intermediate product of chemical formula 2, and the intermediate product of chemical formula 2 is reacted with hydrochloric acid to obtain a compound of chemical formula 1. In addition, a water-soluble naphthoquinone derivative composition represented by chemical formula 1 is proposed. Furthermore, a water-soluble composition for controlling harmful algae; a method for controlling large-scale harmful algae using the water-soluble composition for controlling harmful algae; and an automation system for AI-monitoring, removing, and preventing large-scale harmful algae are proposed.",WATER BIOTECH,SEO HAEDONG;;HAN MYUNGSOO,,https://lens.org/078-162-398-010-702,Patent Application,no,0,0,6,006-294-958-950-819;;159-133-716-548-713;;014-007-147-810-981;;197-433-543-836-137;;078-162-398-010-702;;012-311-234-664-736,AU;;KR;;CN;;WO;;US,6,006-294-958-950-819;;159-133-716-548-713;;014-007-147-810-981;;197-433-543-836-137;;078-162-398-010-702;;012-311-234-664-736,AU;;KR;;CN;;WO;;US,0,B63B35/00;;C02F1/40;;C07C221/00;;G08B21/18;;C07C225/30;;A01N33/12;;A01P13/00;;B64U2101/45;;C07C221/00;;A01N25/26;;C07C225/30;;C02F1/40;;A01N33/10;;A01N25/12;;G08B21/182;;B63B2035/008;;B64U2201/20;;B64U2101/45;;B64C39/024;;A01P13/02;;A01N25/12;;A01N33/10;;C07C225/30;;B64U2201/20;;B64U2101/45,C07C221/00,,0,0,,,,PENDING
328,EP,A1,EP 4110810 A1,116-429-825-164-359,2023-01-04,2023,EP 21708621 A,2021-02-25,EP 20305206 A;;EP 2021054744 W,2020-02-28,COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS,,OREGA BIOTECH,BONNEFOY NATHALIE;;BASTID JÉRÉMY;;BENSUSSAN ARMAND,,https://lens.org/116-429-825-164-359,Patent Application,yes,0,0,4,165-047-073-231-97X;;022-553-777-332-361;;009-483-702-664-175;;116-429-825-164-359,JP;;EP;;WO;;US,4,165-047-073-231-97X;;022-553-777-332-361;;009-483-702-664-175;;116-429-825-164-359,JP;;EP;;WO;;US,0,C07K16/2818;;A61K2039/507;;A61K2039/545;;A61P35/00;;C07K16/244;;C07K2317/24;;C07K2317/76;;Y02A50/30;;C07K16/2818;;A61P35/00;;C07K16/244;;C07K2317/24;;C07K2317/76,C07K16/24;;A61K39/00;;A61P35/00;;C07K16/28,,1,0,,,See references of WO 2021170750A1,PENDING
329,US,A1,US 2023/0174919 A1,129-201-338-010-978,2023-06-08,2023,US 202318162198 A,2023-01-31,US 202318162198 A;;FR 1902859 A;;US 202016824074 A,2019-03-20,"METHOD FOR GAS ENRICHMENT AND SIMULTANEOUSLY FOR DISPLACEMENT OF A FLUID, AND SYSTEM FOR CONTROLLING THE CELL ENVIRONMENT ON A CORRESPONDING MULTI-WELL CELL CULTURE PLATE","A method for displacing a fluid and simultaneously gas enriching a liquid cell culture medium with a gas. The method includes injecting a controlled volume of a gas or gas mixture into a one chamber by using a gas flow controller, the injection taking place through a gas inlet into a volume of liquid. This injection produces bubbling and agitation of the volume of liquid; a build-up of gas or gas mixture due to buoyancy in a hermetic space formed by the volume of liquid and the chamber, and a pressure increase in the chamber until a sufficient controlled pressure is reached of less than or equal to 10 bar. This increase displaces the volume of liquid by a fluid outlet connecting the volume of liquid to the exterior of the chamber. Also provided are a device implementing the method and a cell culture system in a multi-well culture plate.",CHERRY BIOTECH,HOMS CORBERA ANTONI;;BONINSEGNA MATTEO;;VITAL THEO,,https://lens.org/129-201-338-010-978,Patent Application,yes,0,1,10,074-777-174-104-238;;041-886-071-832-676;;015-271-609-170-253;;120-302-541-227-131;;113-282-743-402-63X;;129-201-338-010-978;;096-553-350-150-15X;;083-217-074-268-164;;199-783-134-699-293;;015-554-930-815-169,EP;;ES;;US;;FR,10,074-777-174-104-238;;041-886-071-832-676;;015-271-609-170-253;;120-302-541-227-131;;113-282-743-402-63X;;129-201-338-010-978;;096-553-350-150-15X;;083-217-074-268-164;;015-554-930-815-169;;199-783-134-699-293,EP;;ES;;US;;FR,0,C12M23/16;;C12M23/12;;C12M29/26;;C12M29/10;;C12M29/06;;C12M41/40;;C12M29/14;;B01L3/502715;;B01L2300/047;;B01L2300/0829;;C12M23/12;;C12M23/16;;C12M27/00;;C12M29/06;;C12M41/40,C12M1/34;;B01L3/00;;C12M1/00;;C12M1/02;;C12M1/32;;C12M3/06,,0,0,,,,ACTIVE
330,KR,A,KR 20210005355 A,156-171-049-575-889,2021-01-14,2021,KR 20190080244 A,2019-07-03,KR 20190080244 A,2019-07-03,composition for preventing or treating for preventing or treating diabetic wound comprising Indirubin derivative compound,"A composition containing at least one indirubin derivatives selected from chemical formula 1 to 4 of the present invention as active components is excellent in alleviating, preventing or treating diabetic wounds by promoting a wound healing rate in diabetic conditions, thereby being able to be usefully used as a pharmaceutical composition, a cosmetic composition, and a food composition for alleviating, preventing, or treating diabetic wounds, or an animal pharmaceutical composition for treating diabetic wounds.",CK BIOTECH,KANG YELL CHOI;;KIM EUNHWAN;;SEOL HWA SEO,,https://lens.org/156-171-049-575-889,Patent Application,no,5,0,2,061-609-337-961-572;;156-171-049-575-889,KR,14,100-574-593-464-511;;010-723-737-446-421;;143-789-168-119-782;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;097-170-205-131-938;;152-346-690-972-536;;156-171-049-575-889;;061-609-337-961-572;;070-530-775-976-218;;112-312-169-379-233;;016-089-837-812-567;;146-551-039-853-613,KR;;CN;;EP;;WO;;US,0,A61K31/4045;;A23L33/10;;A23V2002/00;;A23V2200/318;;A23V2200/328;;A23V2250/30;;A61K8/492;;A61K8/86;;A61K9/0014;;A61K9/107;;A61K47/10;;A61K47/44;;A61K2800/596;;A61P3/10;;A61P17/02;;A61Q19/00,A61K31/4045;;A23L33/10;;A61K8/49;;A61K8/86;;A61K9/00;;A61K9/107;;A61K47/10;;A61K47/44;;A61P3/10;;A61P17/02;;A61Q19/00,,0,0,,,,ACTIVE
331,KR,A,KR 20210030193 A,151-601-631-547-969,2021-03-17,2021,KR 20200086401 A,2020-07-13,KR 20190111794 A,2019-09-09,Pharmaceutical composition containing single or mixture of extract of Rubus crataegifolius extract of Lespedeza cuneata and extract of Crataegus pinnatifida for prevention or treatment benign prostatic hyperplasia,"An extract of Rubus crataegifolius and an extract of Lespedeza cuneata of the present invention have the effect of reducing the overgrowth of epithelial cells of the prostate. The extracts of Rubus crataegifolius and Lespedeza cuneata have the effect of reducing the concentration of DHT and PSA, and interfering with the binding of DHT and AR, thereby inhibiting 5-alpha reductase. In addition, the extract of Rubus crataegifolius, an extract of Crataegus pinnatifida and the extract of Lespedeza cuneata significantly inhibit the expression of α-1D adrenergic receptors, and thus have the effect of alleviating urination disorders through the relaxation of smooth muscle of the prostate bladder neck. Accordingly, the extract of Rubus crataegifolius, a mixture of the Rubus crataegifolius and Lespedeza cuneata extracts, a mixture of the Rubus crataegifolius and Crataegus pinnatifida extracts, a mixture of the Lespedeza cuneata and Crataegus pinnatifida extracts, or a mixture of the Rubus crataegifolius, Lespedeza cuneata and Crataegus pinnatifida extracts can be advantageously used for prevention or treatment of benign prostatic hyperplasia.",LEES BIOTECH,LEE YOUNG IK;;LEE JO WOON YI;;AZIZ ABDUR RAHMAN;;CHO JIN SOOK;;NAM MI KYUNG,,https://lens.org/151-601-631-547-969,Patent Application,no,6,0,2,044-791-981-504-505;;151-601-631-547-969,KR,2,044-791-981-504-505;;151-601-631-547-969,KR,18,A61K36/73;;A23L33/105;;A23V2002/00;;A23V2200/30;;A61K36/48;;A61K36/734;;A61K2300/00;;A61P13/08,A61K36/73;;A23L33/105;;A61K36/48;;A61K36/734;;A61P13/08,,0,0,,,,ACTIVE
332,US,A1,US 2022/0056145 A1,189-017-350-252-853,2022-02-24,2022,US 202117197097 A,2021-03-10,US 202117197097 A;;US 201816084249 A;;EP 2017056011 W;;US 201662307606 P;;US 201662404780 P,2016-03-14,ANTI-CD39 ANTIBODIES,"The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.",OREGA BIOTECH,GAUTHIER LAURENT;;PATUREL CARINE;;PERROT IVAN,,https://lens.org/189-017-350-252-853,Patent Application,yes,4,1,5,189-017-350-252-853;;197-899-711-730-601;;160-156-667-026-122;;051-266-721-982-760;;086-603-296-213-93X,EP;;WO;;US,5,189-017-350-252-853;;197-899-711-730-601;;160-156-667-026-122;;051-266-721-982-760;;086-603-296-213-93X,EP;;WO;;US,35,C07K16/2896;;A61P35/00;;C07K16/30;;C07K16/40;;C07K2317/24;;C07K2317/33;;C07K2317/41;;C07K2317/524;;C07K2317/526;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/94;;C07K16/2896;;A61P35/00;;C07K16/30;;C07K16/40;;C07K2317/24;;C07K2317/33;;C07K2317/41;;C07K2317/52;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/574,C07K16/28;;A61P35/00;;C07K16/30;;C07K16/40;;G01N33/574,,0,0,,,,DISCONTINUED
333,KR,A,KR 20230069150 A,199-514-190-314-778,2023-05-18,2023,KR 20237012240 A,2021-09-14,US 202063078274 P;;IB 2021058373 W,2020-09-14,"SH3YL1 항체, 이를 포함하는 조성물, 및 벡터 및 이의 용도","본 개시내용은 SH3YL1 단클론 항체 및 SH3YL1 단클론 항체를 포함하는 조성물에 관한 것이다. 본 개시내용은 또한 SH3YL1 항체를 암호화하는 단리된 핵산 분자, 상기 핵산 분자를 포함하는 벡터, 및 상기 벡터를 포함하는 숙주 세포에 관한 것이다. 또한, SH3YL1 항체를 투여함을 포함하여, 면역 반응을 조절하는 방법, 당뇨병성 신증을 치료하는 방법, 및 비알콜성 지방증 간염을 치료하는 방법이 개시되어 있다. 또한, SH3YL1 항체를 투여함을 포함하여, 급성 신장 손상을 치료하는 방법 및 염증성 장 질환을 치료하는 방법이 개시되어 있다.",CELROS BIOTECH,BAE YUN SOO;;AN EUNJUNG;;YOO JUNG YEON;;SHIM HYUNBO;;LEE HYE EUN,,https://lens.org/199-514-190-314-778,Patent Application,no,0,0,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,200,C07K16/3053;;C07K16/18;;C07K2317/622;;C07K2317/92;;G01N33/532;;G01N33/533;;C07K2317/21;;A61P13/12;;A61P1/16;;C07K16/18;;A61P1/16;;A61P13/12;;G01N33/563;;C07K2317/622;;C07K2317/565;;C07K2317/92;;A61K2039/505;;C07K16/18;;G01N33/6854;;A61P1/16;;A61P13/12;;A61K2039/505;;C07K2317/52;;C07K2317/624;;C07K2317/622;;C07K2317/55;;C07K2317/565,C07K16/18;;A61K39/00;;A61P1/16;;A61P13/12;;G01N33/563,,0,0,,,,PENDING
334,CN,A,CN 112638289 A,167-215-822-759-142,2021-04-09,2021,CN 201980057015 A,2019-06-28,US 201862691319 P;;US 2019/0039878 W,2018-06-28,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF THROMBOSIS AND DELIVERY BY MEDICAL DEVICES,"A pharmaceutical composition and a method of using the pharmaceutical composition for the treatment of thrombosis are provided. The pharmaceutical composition can include a mixture of proteolytic enzymes, and optionally, additional compounds. The pharmaceutical composition can include an antiaggregatory or anti -thrombotic compound, such as Lisini racemici acetylsalicylase. The method can include administering the pharmaceutical composition to a patient in need thereof, including administration of the pharmaceutical composition to a thrombus until the thrombus is dissolved. The method can also include administering one or more balloon catheters to the patient.",MARIZYME BIOTECH,HANDLEY MICHAEL K,,https://lens.org/167-215-822-759-142,Patent Application,no,10,0,11,051-382-287-611-008;;167-215-822-759-142;;183-488-193-693-681;;113-909-928-705-465;;128-633-861-675-942;;127-500-590-414-920;;170-810-794-749-231;;079-567-751-821-998;;004-868-784-372-613;;191-235-790-311-105;;066-411-304-959-220,CR;;JP;;AU;;CN;;EA;;EP;;WO;;CA;;BR;;PE,13,051-382-287-611-008;;128-633-861-675-942;;113-909-928-705-465;;183-488-193-693-681;;170-810-794-749-231;;074-210-751-277-44X;;004-868-784-372-613;;028-302-916-315-724;;066-411-304-959-220;;167-215-822-759-142;;127-500-590-414-920;;079-567-751-821-998;;191-235-790-311-105,CR;;JP;;AU;;EP;;CN;;EA;;WO;;US;;CA;;BR;;PE,0,A61B17/12136;;A61B17/12036;;A61B17/1204;;A61M2025/105;;A61M2025/1052;;A61K38/4806;;A61K38/4826;;C12Y304/21004;;C12Y304/21001;;A61K38/26;;A61K31/616,A61B17/12;;A61K38/43;;A61M25/10,,0,0,,,,DISCONTINUED
335,AR,A1,AR 132438 A1,117-296-648-200-709,2025-06-25,2025,AR P240100954 A,2024-04-16,US 202318136419 A,2023-04-19,DISPOSITIVO DE CRÍO-PRESERVACIÓN CON CÁMARA DE SEGUIMIENTO INTEGRADA,La presente invención proporciona un dispositivo de crio preservación con una cámara de dispositivo de seguimiento integrada. El dispositivo de seguimiento puede ser una etiqueta RFID que puede colocarse en el dispositivo de crio preservación como parte del procedimiento de vitrificación de una muestra biológica. El dispositivo de crio preservación mantiene su integridad y mantiene la etiqueta RFID de forma segura en la cámara tanto en condiciones ambientales cuando se recolecta la muestra como bajo nitrógeno líquido donde se almacena la muestra. El dispositivo de crio preservación con una cámara de dispositivo de seguimiento integrada permite que cada muestra biológica individual tenga su propio dispositivo de seguimiento para el seguimiento durante el almacenamiento criogénico.,BIOTECH INC,PARRA-ALMANZA JORGE E,,https://lens.org/117-296-648-200-709,Patent Application,no,0,0,6,170-381-455-868-719;;061-368-949-232-149;;131-163-295-300-269;;118-651-602-690-001;;016-237-892-665-506;;117-296-648-200-709,AR;;CL;;WO;;US,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,G06K19/0723;;A01N1/147;;G06K19/0723;;A01N1/146,G06K19/07,,0,0,,,,PENDING
336,EP,A1,EP 4498810 A1,052-663-530-006-017,2025-02-05,2025,EP 24734786 A,2024-03-28,US 202318136419 A;;US 2024/0021859 W,2023-04-19,CRYOPRESERVATION DEVICE WITH INTEGRATED TRACKING DEVICE CHAMBER,,BIOTECH INC,PARRA-ALMANZA JORGE E,,https://lens.org/052-663-530-006-017,Patent Application,yes,0,0,10,047-592-826-495-933;;162-489-143-820-817;;147-477-893-597-624;;141-146-935-123-247;;060-885-276-227-95X;;046-595-929-205-924;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,AU;;JP;;KR;;CN;;IL;;EP;;MX,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,A01N1/147;;G06K19/0723;;C12N5/547;;G06K19/0723;;A01N1/146;;A01N1/147;;G06K19/0723;;A01N1/144,A01N1/02,,0,0,,,,PENDING
337,WO,A1,WO 2020/201442 A1,111-070-178-496-436,2020-10-08,2020,EP 2020059434 W,2020-04-02,EP 19305438 A,2019-04-03,COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS,"The present invention concerns the combination of PD1 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-PD1 therapies.",OREGA BIOTECH,BONNEFOY NATHALIE;;BASTID JÉRÉMY,,https://lens.org/111-070-178-496-436,Patent Application,yes,44,0,5,002-809-273-531-843;;111-070-178-496-436;;026-458-336-004-83X;;074-457-640-639-588;;137-340-950-812-694,JP;;EP;;WO;;US,5,002-809-273-531-843;;111-070-178-496-436;;026-458-336-004-83X;;074-457-640-639-588;;137-340-950-812-694,JP;;EP;;WO;;US,0,A61K45/06;;A61K39/3955;;A61K31/713;;A61P35/00;;A61P31/12;;A61P31/06;;A61P31/00;;A61P33/06;;C07K2317/76;;A61K2039/505;;A61K2039/507;;C07K16/2818;;C07K16/244;;Y02A50/30;;A61P35/00;;A61K31/713;;A61K45/06;;C07K16/244;;C07K16/2818,A61K31/713;;A61K39/395;;A61K45/06;;A61P31/00;;A61P31/06;;A61P31/12;;A61P35/00,,13,10,072-891-374-771-875;;029-785-086-606-666;;029-448-692-424-048;;001-514-511-662-247;;072-891-374-771-875;;001-514-511-662-247;;047-694-762-082-562;;054-802-024-202-015;;074-817-300-512-106;;013-323-148-570-367,10.1016/j.ctrv.2016.11.007;;27951441;;29357948;;pmc5778665;;10.1186/s40425-018-0316-z;;29371916;;10.18632/oncotarget.23008;;pmc5768333;;28163164;;10.1016/j.ijid.2017.01.028;;10.1016/j.ctrv.2016.11.007;;27951441;;28163164;;10.1016/j.ijid.2017.01.028;;pmc4190567;;10.3390/cancers6031769;;25198391;;10.1038/nri2586;;pmc2821718;;19575028;;2677748;;10.1038/341544a0;;10.1016/j.tibtech.2003.08.007;;14573361,"O'DONNELL JAKE S ET AL: ""Resistance to PD1/PDL1 checkpoint inhibition"", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 52, 27 November 2016 (2016-11-27), pages 71 - 81, XP029865198, ISSN: 0305-7372, DOI: 10.1016/J.CTRV.2016.11.007;;JUN GONG ET AL: ""Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 6, no. 1, 23 January 2018 (2018-01-23), pages 1 - 18, XP021252783, DOI: 10.1186/S40425-018-0316-Z;;LAPREVOTTE EMILIE ET AL: ""The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway"", ONCOTARGET, vol. 8, no. 69, 26 December 2017 (2017-12-26), pages 113360 - 113372, XP002794513;;RAO MARTIN ET AL: ""Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm"", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES, HAMILTON, CA, vol. 56, 2 February 2017 (2017-02-02), pages 221 - 228, XP029940218, ISSN: 1201-9712, DOI: 10.1016/J.IJID.2017.01.028;;O'DONNELL ET AL., CANCER TREATMENT REVIEWS, vol. 52, 2017, pages 71 - 81;;RAO ET AL., INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol. 56, 2017, pages 221 - 228;;HOUSMAN ET AL., CANCER, vol. 6, 2014, pages 1769 - 1792;;GAFFEN, S. L., NATURE REVIEWS. IMMUNOLOGY, vol. 9, no. 8, 2009, pages 556 - 567;;WARD ET AL., NATURE, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 6;;HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, 2003, pages 484 - 490;;KABAT ET AL.: ""Sequences of Protein of Immunological Interest"", 1991, UNITED STATES PUBLIC HEALTH SERVICE;;GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1985, pages 1277 - 1280;;""Goodmand and Gilman's The Pharmacological Basis of Therapeutics"", 1985, pages: 1287 - 1288",PENDING
338,US,A1,US 2024/0130839 A1,021-911-244-760-284,2024-04-25,2024,US 202218548157 A,2022-03-01,FR 2102018 A;;IB 2022051777 W,2021-03-02,DENTAL PROSTHETIC DEVICE,"Disclosed is a dental prosthetic device having an implant, a cap and an abutment interposed between the implant and the cap. The abutment includes an abutment head which is at least partially delimited by an abutment external face and which is configured to retain the cap. The abutment has an abutment body with an attachment to the implant. Retention is accomplished by a nesting arraignment for fitting the abutment head inside a cavity which is formed inside the cap and which is at least partially delimited by a cap internal face. The cap is screwed onto the abutment head. The cap internal face is provided with a tab which is in contact against the abutment external face. A space is left between a point of contact of the cap internal face and a cone lip of the cap internal face between the abutment external face and the cap internal face.",BIOTECH DENTAL,BREYSSE PASCAL,BIOTECH DENTAL (2023-09-06),https://lens.org/021-911-244-760-284,Patent Application,yes,0,0,9,019-363-140-965-748;;187-080-580-128-005;;052-193-428-912-212;;056-269-316-781-258;;021-911-244-760-284;;074-452-294-194-13X;;096-026-210-549-527;;162-987-004-657-206;;187-566-910-286-875,EP;;ES;;WO;;US;;FR,9,019-363-140-965-748;;187-080-580-128-005;;056-269-316-781-258;;052-193-428-912-212;;021-911-244-760-284;;074-452-294-194-13X;;187-566-910-286-875;;162-987-004-657-206;;096-026-210-549-527,EP;;ES;;WO;;US;;FR,0,A61C8/0048;;A61C8/008;;A61C8/0068;;A61C8/0068;;A61C8/0069;;A61C8/008,A61C8/00,,0,0,,,,PENDING
339,WO,A1,WO 2022/055045 A1,003-407-118-310-930,2022-03-17,2022,KR 2020019459 W,2020-12-30,KR 20200114698 A,2020-09-08,"PEPTIDE DERIVATIVE WITH COLLAGENASE INHIBITORY ACTIVITY, AND USE THEREOF","The present invention relates to a peptide derivative, having collagenase inhibitory activity, or a use thereof and has the effects of increasing a percutaneous absorption rate, inhibiting collagenase activity, and reducing wrinkles.",SUNMARINE BIOTECH,PARK SI HYANG;;HWANG SU YEON;;JUNG JAE EUN;;KIM YE RA,,https://lens.org/003-407-118-310-930,Patent Application,yes,5,0,4,095-290-416-583-110;;003-407-118-310-930;;067-885-163-952-391;;127-632-859-398-287,KR;;WO;;US,4,095-290-416-583-110;;003-407-118-310-930;;067-885-163-952-391;;127-632-859-398-287,KR;;WO;;US,0,C07K5/0806;;A23L33/18;;A61K8/64;;A61K38/06;;A61Q19/08;;C07K5/0823;;C07K5/0806;;A23L33/18;;A23V2002/00;;A23V2200/318;;A61K8/64;;A61K38/06;;A61Q19/00;;C07K5/0806;;A23L33/18;;A61K8/64;;A61Q19/08,C07K5/083;;A23L33/18;;A61K8/64;;A61K38/06;;A61Q19/00,,0,0,,,,PENDING
340,US,A1,US 2023/0172643 A1,052-804-849-360-014,2023-06-08,2023,US 202117924131 A,2021-05-11,FR 2004780 A;;FR 2100980 A;;EP 2021062514 W,2020-05-14,"IMPLANTABLE DEVICE, IN PARTICULAR OF THE INTERVERTEBRAL SPACER TYPE","An implantable device including an intervertebral wedge including an upper bearing zone and a lower bearing zone and at least one first lateral spring having a position A relative to the intervertebral wedge in a position for inserting the implantable device and a position B relative to the intervertebral wedge in a position for implanting the implantable device, the positions A and B being different and the first lateral spring being configured: to freely translate from position A to position B and to form a retention component arranged relative to the intervertebral wedge to block the migration of the intervertebral wedge toward the spinal canal in position B.",COUSIN BIOTECH,HOFFMANN ELÉONORE;;BECQUART LUCIE;;CAILLIBOTTE MICHEL,COUSIN BIOTECH (2023-02-01),https://lens.org/052-804-849-360-014,Patent Application,yes,7,0,8,049-681-138-955-067;;123-011-641-195-420;;119-331-982-537-853;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;052-804-849-360-014,EP;;ES;;WO;;US;;FR,8,049-681-138-955-067;;123-011-641-195-420;;052-804-849-360-014;;047-899-447-872-248;;072-161-856-670-423;;082-917-237-237-137;;143-091-312-289-31X;;119-331-982-537-853,EP;;ES;;WO;;US;;FR,0,A61B17/7053;;A61B17/7062;;A61B17/7064;;A61B17/7065;;A61B17/7067;;A61B17/7061;;A61B17/7065;;A61B17/7067,A61B17/70,,0,0,,,,PENDING
341,KR,A,KR 20230086975 A,057-607-242-578-809,2023-06-16,2023,KR 20210175508 A,2021-12-09,KR 20210175508 A,2021-12-09,CLINICAL SPECIMEN VESSEL,The present invention relates to a specimen container containing a preservative solution therein. The present invention comprises: a container body having an accommodating space open on one side therein; a locking protrusion convexly extending along the outer circumference of one side of the container body; a cap portion coupled to the opening of the container body; a skirt portion extending from an end of the circumference of the cap portion toward the locking protrusion; a plurality of cut portions spaced apart from each other at a predetermined distance along the circumference of the skirt portion and cut toward a side facing the locking protrusion; and an inclined portion formed to be inclined at an inner end of the skirt portion.,GOLDEN BIOTECH,JIN YOUNG SEOK,,https://lens.org/057-607-242-578-809,Patent Application,no,4,0,2,057-607-242-578-809;;018-851-556-183-551,KR,2,057-607-242-578-809;;018-851-556-183-551,KR,0,B01L3/50825;;A61B10/0096;;B01L2300/044;;B01L2300/0672;;B01L2300/06,B01L3/00;;A61B10/00,,0,0,,,,ACTIVE
342,CR,A,CR 20210059 A,079-567-751-821-998,2021-12-23,2021,CR 20210059 A,2019-06-28,US 201862691319 P;;US 2019/0039878 W,2018-06-28,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF THROMBOSIS AND DELIVERY BY MEDICAL DEVICES,"A pharmaceutical composition and a method of using the pharmaceutical composition for the treatment of thrombosis are provided. The pharmaceutical composition can include a mixture of proteolytic enzymes, and optionally, additional compounds. The pharmaceutical composition can include an antiaggregatory or anti -thrombotic compound, such as <em>Lisini racemici acetylsalicylase</em>. The method can include administering the pharmaceutical composition to a patient in need thereof, including administration of the pharmaceutical composition to a thrombus until the thrombus is dissolved. The method can also include administering one or more balloon catheters to the patient.",MARIZYME BIOTECH,HANDLEY MICHAEL K,,https://lens.org/079-567-751-821-998,Patent Application,no,0,0,11,051-382-287-611-008;;167-215-822-759-142;;183-488-193-693-681;;113-909-928-705-465;;128-633-861-675-942;;127-500-590-414-920;;170-810-794-749-231;;079-567-751-821-998;;004-868-784-372-613;;191-235-790-311-105;;066-411-304-959-220,CR;;JP;;AU;;CN;;EA;;EP;;WO;;CA;;BR;;PE,13,051-382-287-611-008;;128-633-861-675-942;;113-909-928-705-465;;183-488-193-693-681;;170-810-794-749-231;;074-210-751-277-44X;;004-868-784-372-613;;028-302-916-315-724;;066-411-304-959-220;;167-215-822-759-142;;127-500-590-414-920;;079-567-751-821-998;;191-235-790-311-105,CR;;JP;;AU;;EP;;CN;;EA;;WO;;US;;CA;;BR;;PE,0,A61B17/12136;;A61B17/12036;;A61B17/1204;;A61M2025/105;;A61M2025/1052;;A61K38/4806;;A61K38/4826;;C12Y304/21004;;C12Y304/21001;;A61K38/26;;A61K31/616,A61K38/43;;A61B17/12;;A61M25/10,,0,0,,,,PENDING
343,KR,A,KR 20250064013 A,084-821-123-719-644,2025-05-09,2025,KR 20230147621 A,2023-10-31,KR 20230147621 A,2023-10-31,COMPOSITION FOR PREVENTING HAIR LOSS AND IMPROVING CONDITION OF SCALP,"본 출원은 성게껍질의 가수분해발효물; 물레고동, 군소 및 멍게껍질의 점액 추출물; 및 해조류 복합 추출물; 을 유효성분으로 포함하는 탈모 방지 및 두피 개선용 조성물에 관한 것이다.",SUNMARINE BIOTECH,PARK SI HYANG;;KIM YE RA;;LEE SONG MIN;;JEONG JI HYEON,,https://lens.org/084-821-123-719-644,Patent Application,no,1,0,1,084-821-123-719-644,KR,1,084-821-123-719-644,KR,0,A61K35/616;;A61K35/655;;A61K36/02;;A61K36/03;;A61K36/05;;A61P17/14;;A61K8/987;;A61K8/9711;;A61K8/9722;;A61Q7/00;;A61Q5/00;;A61Q5/006;;A23L33/10;;A23L33/105;;A61K2300/00;;A61K2800/805;;A61K2800/85;;A61K2800/84;;A23V2002/00;;A23V2250/2042;;A23V2250/202;;A23V2200/318,A61K35/616;;A61K8/9711;;A61K8/9722;;A61K8/98;;A61K35/655;;A61K36/02;;A61K36/03;;A61K36/05;;A61P17/14;;A61Q5/00;;A61Q7/00,,0,0,,,,PENDING
344,KR,A,KR 20240139100 A,087-563-393-263-35X,2024-09-23,2024,KR 20230030464 A,2023-03-08,KR 20230030464 A,2023-03-08,Method for producing exosome from whey and cosmetic composition comprising exosome produced using the same,"본원은 유청 유래 엑소좀의 제조방법 및 상기 제조방법을 이용하여 제조된 엑소좀을 포함하는 화장료 조성물에 관한 것이다. 더욱 상세하게, 본원은 유청에 함유되어 있는 엑소좀을 간단한 방법으로 고수율로 분리하여 경제적으로 제조할 수 있는 유청 유래 엑소좀의 제조방법 및 상기 제조방법을 이용하여 제조된 엑소좀을 포함하는 화장료 조성물에 관한 것이다.",PANACELL BIOTECH,CHOI SEUNG HO;;KIM HYEONG SOO;;HWA JIN BAEK;;WOOJUN HUR;;MAIERDANJIANG WUFUER,,https://lens.org/087-563-393-263-35X,Patent Application,no,3,0,2,030-039-555-135-459;;087-563-393-263-35X,KR,2,030-039-555-135-459;;087-563-393-263-35X,KR,0,A61K8/986;;A61K8/14;;A61Q19/00;;A61Q19/08;;A61Q19/02;;A61Q19/005;;C12N5/0602;;C12N2509/00,A61K8/98;;A61K8/14;;A61Q19/00;;A61Q19/02;;A61Q19/08;;C12N5/071,,0,0,,,,ACTIVE
345,FR,A1,FR 3111430 A1,139-860-241-882-093,2021-12-17,2021,FR 2006148 A,2020-06-12,FR 2006148 A,2020-06-12,"Système pour l’analyse rapide d’un échantillon biologique, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique","La présente invention concerne un système pour l’analyse rapide d’un échantillon biologique (E), destiné à la détection de la présence d’au moins un analyte (A) dans ledit échantillon biologique (E). Le système d’analyse rapide comprend : - au moins un dispositif de prélèvement (2), adapté au prélèvement dudit échantillon biologique (E), - au moins une bandelette chromatographique (3), conçue pour détecter la présence dudit au moins un analyte (A), - une solution tampon (4), pour la mise en œuvre de la technique chromatographique, et - au moins un dispositif d’interface (5), adapté à recevoir ladite au moins une bandelette chromatographique (3) pour la mise en œuvre de ladite technique chromatographique, lequel dispositif d’interface (5) comporte au moins deux logements (51, 52) en communication fluidique avec au moins un premier logement (51) destiné à recevoir au moins ladite solution tampon (4) et au moins un second logement (52) conçu pour introduire au moins la zone de dépôt (311) de ladite au moins une bandelette chromatographique (3), ledit second logement (52) étant destiné à recevoir ladite solution tampon (4), éventuellement mélangée avec ledit échantillon biologique (E), s’écoulant depuis ledit au moins un premier logement (51). Figure pour l’abrégé : 9",NG BIOTECH,STANKOV MILOVAN,,https://lens.org/139-860-241-882-093,Patent Application,no,3,0,5,197-877-393-616-549;;046-331-989-819-750;;027-789-513-586-109;;139-860-241-882-093;;147-781-090-954-815,EP;;WO;;FR,5,197-877-393-616-549;;046-331-989-819-750;;139-860-241-882-093;;027-789-513-586-109;;147-781-090-954-815,EP;;WO;;FR,0,G01N33/54388;;B01L3/5029;;B01L9/52;;B01L2300/0663;;B01L2300/0825;;B01L2300/0832;;B01L2300/0864,G01N33/50;;A61B5/00;;A61B10/00;;G01N1/02;;G01N33/487;;G01N33/544,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",ACTIVE
346,WO,A1,WO 2022/220539 A1,138-793-828-015-972,2022-10-20,2022,KR 2022005272 W,2022-04-12,KR 20210047258 A;;KR 20220044922 A,2021-04-12,INTRACELLULAR DELIVERY PLATFORM,"The present invention relates to an intracellular delivery platform comprising: a first channel through which a fluid comprising cells and transmitters flows; and a second channel and a third channel which are connected to the first channel at an angle and through which the fluid comprising cells and transmitters flows, wherein the fluid forms a collision and/or vortex area in at least one from among the first channel, the second channel and the third channel. According to the present invention, material can be effectively delivered into cells by forming a vortex in channels.",MXT BIOTECH,CHUNG A-RAM;;HUR JEONG-SOO,,https://lens.org/138-793-828-015-972,Patent Application,yes,3,0,3,117-205-002-265-638;;138-793-828-015-972;;097-721-008-950-916,KR;;WO;;US,6,174-656-514-206-690;;097-721-008-950-916;;047-285-545-211-092;;117-205-002-265-638;;079-096-726-288-45X;;138-793-828-015-972,KR;;CN;;EP;;WO;;US,0,C12N15/87;;C12M35/04;;C12M35/04;;C12M23/16;;C12M41/38;;C12N15/87;;C12M23/04;;C12M23/34,C12N15/87;;C12M1/42;;C12M3/06,,3,3,049-687-491-281-689;;011-970-325-211-487;;010-787-214-486-718,32069037;;10.1021/acsnano.9b07930;;10.1016/j.ijpharm.2012.07.057;;22884778;;pmc6397276;;30824814;;10.1038/s41598-019-40147-y,"KANG GEOUMYOUNG, CARLSON DANIEL W., KANG TAE HO, LEE SEUNGKI, HAWARD SIMON J., CHOI INHEE, SHEN AMY Q., CHUNG ARAM J.: ""Intracellular Nanomaterial Delivery via Spiral Hydroporation"", ACS NANO, AMERICAN CHEMICAL SOCIETY, US, vol. 14, no. 3, 24 March 2020 (2020-03-24), US , pages 3048 - 3058, XP055977461, ISSN: 1936-0851, DOI: 10.1021/acsnano.9b07930;;L. CAPRETTO, S. MAZZITELLI, G. COLOMBO, R. PIVA, L. PENOLAZZI, R. VECCHIATINI, X. ZHANG, C. NASTRUZZI: ""Production of polymeric micelles by microfluidic technology for combined drug delivery: Application to osteogenic differentiation of human periodontal ligament mesenchymal stem cells (hPDLSCs)"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, vol. 440, no. 2, 1 January 2013 (2013-01-01), pages 195 - 206, XP055084157, ISSN: 03785173, DOI: 10.1016/j.ijpharm.2012.07.057;;JUSTIN A. JARRELL, AMYA.TWITE, KATHERINE H.W. J. LAU, MOEIN N. KASHANI, ADRIANA. LIEVANO, JULYANAACEVEDO, CRAIG PRIEST, JORGE NIE: ""Intracellular Delivery of mRNA to Human Primary T Cells With Microfluidic Vortex Shedding"", SCIENTIFIC REPORTS, vol. 9, 1 March 2019 (2019-03-01), pages 1 - 11, XP055740840, DOI: 10.1038/s41598-019-40147-y",PENDING
347,US,A1,US 2021/0260245 A1,156-613-870-734-649,2021-08-26,2021,US 201917254573 A,2019-06-21,FR 1855590 A;;EP 2019066522 W,2018-06-22,"ACELLULAR DERMAL MATRIX, IN PARTICULAR FOR A MAMMARY PROSTHESIS","The object of the invention is an acellular dermal matrix (1) comprising a solid and flexible sheet (10) which is provided with a plurality of through-openings (4) and is characterized in that the openings (4) have an elongated shape and, in particular, are forming slits (40). The openings are particularly suitable for opening in the form of a diamond.",MECCELLIS BIOTECH,PERES ANTHONY;;HOFMANSKI GUILLAUME;;LAMMELIN AURÉLIE,MECCELLIS BIOTECH (2021-03-26),https://lens.org/156-613-870-734-649,Patent Application,yes,4,3,6,139-547-900-762-909;;070-098-005-354-797;;120-385-487-064-832;;090-394-499-961-280;;156-613-870-734-649;;027-370-764-314-367,EP;;WO;;US;;BR;;FR,6,139-547-900-762-909;;090-394-499-961-280;;120-385-487-064-832;;070-098-005-354-797;;156-613-870-734-649;;027-370-764-314-367,EP;;WO;;US;;BR;;FR,0,A61F2/0063;;A61F2/0077;;A61F2/12;;A61L27/362;;A61L27/50;;A61L2430/04;;A61L27/3683;;A61L27/362;;A61L27/3683;;A61L27/50;;A61L2430/04,A61L27/36;;A61L27/50,,0,0,,,,DISCONTINUED
348,WO,A1,WO 2024/245616 A1,170-814-454-069-06X,2024-12-05,2024,EP 2024058052 W,2024-03-26,FR 2305473 A,2023-06-01,SYSTEM FOR VERTEBRAL IMPLANTATION OF A VERTEBRAL SPACER ELEMENT,"The invention relates to a system (10) for vertebral implantation of a vertebral spacer element (100) that is at least partially elastically deformable between a deployed state and a compressed state, the implantation system comprising a compression device (40) configured to move the vertebral spacer element from the deployed state to the compressed state; a guide device (20) having an open distal end (20b) and comprising an implantation tube (36), it being possible to connect the guide device to the compression device; and a pushing device (60) which is configured to cooperate with the compression device when the guide device is connected thereto, in order to push the vertebral spacer element in the compressed state from the housing of the compression device to the inside of the implantation tube of the guide device; and to cooperate with the guide device in order to push the vertebral spacer element in the compressed state along the implantation tube to the distal end of the guide device, so as to extract the vertebral spacer element from the guide device.",COUSIN BIOTECH,HOFFMANN ELÉONORE;;CAILLIBOTTE MICHEL,,https://lens.org/170-814-454-069-06X,Patent Application,yes,9,0,4,170-814-454-069-06X;;038-450-039-195-78X;;165-237-353-296-740;;126-411-008-097-421,WO;;TW;;FR,4,170-814-454-069-06X;;038-450-039-195-78X;;165-237-353-296-740;;126-411-008-097-421,WO;;TW;;FR,0,A61B17/7065;;A61B17/7064;;A61F2002/4627;;A61F2/4611,A61B17/70,,0,0,,,,PENDING
349,US,A1,US 2024/0158485 A1,089-049-236-127-398,2024-05-16,2024,US 202318515723 A,2023-11-21,US 202318515723 A;;US 202117474359 A;;US 202063078274 P,2020-09-14,"SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof","The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.",CELROS BIOTECH,BAE YUN SOO;;AN EUNJUNG;;YOO JUNG-YEON;;SHIM HYUNBO;;LEE HYE EUN,EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (2021-11-29);;CELROS BIOTECH (2021-11-24),https://lens.org/089-049-236-127-398,Patent Application,yes,0,0,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,9,146-259-696-598-191;;140-849-895-068-144;;199-514-190-314-778;;082-575-986-957-089;;077-119-603-416-18X;;089-049-236-127-398;;154-571-988-495-799;;005-209-205-383-551;;015-502-910-947-856,JP;;KR;;CN;;EP;;WO;;US,0,C07K16/3053;;C07K16/18;;C07K2317/622;;C07K2317/92;;G01N33/532;;G01N33/533;;C07K2317/21;;A61P13/12;;A61P1/16;;C07K16/18;;A61P1/16;;A61P13/12;;G01N33/563;;C07K2317/622;;C07K2317/565;;C07K2317/92;;A61K2039/505;;C07K16/18;;G01N33/6854;;A61P1/16;;A61P13/12;;A61K2039/505;;C07K2317/52;;C07K2317/624;;C07K2317/622;;C07K2317/55;;C07K2317/565,C07K16/18;;A61P1/16;;A61P13/12;;G01N33/68,,0,0,,,,PENDING
350,EP,A1,EP 4205740 A1,017-157-468-377-560,2023-07-05,2023,EP 21862132 A,2021-08-27,KR 20200109702 A;;KR 20200109703 A;;KR 2021011535 W,2020-08-28,NOVEL THIOHYDANTOIN DERIVATIVES AND USES THEREOF,"The present invention relates to a thiohydantoin derivative and a composition for preventing or treating NADPH oxidase (NOX)-associated diseases comprising same, and can be used to treat NADPH oxidase (NOX)-associated diseases through excellent actions on NOX inhibition.",CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,CELROS BIOTECH (2025-03-05),https://lens.org/017-157-468-377-560,Patent Application,yes,0,0,12,093-579-398-771-71X;;156-791-964-355-553;;070-070-682-690-304;;124-789-339-853-086;;060-972-361-938-778;;033-625-275-136-618;;168-747-464-256-935;;017-157-468-377-560;;063-005-551-370-904;;103-101-669-491-524;;034-034-012-831-629;;083-590-826-781-522,JP;;KR;;CN;;EP;;WO;;US,12,033-625-275-136-618;;156-791-964-355-553;;070-070-682-690-304;;168-747-464-256-935;;083-590-826-781-522;;017-157-468-377-560;;063-005-551-370-904;;060-972-361-938-778;;124-789-339-853-086;;103-101-669-491-524;;093-579-398-771-71X;;034-034-012-831-629,JP;;KR;;EP;;CN;;WO;;US,0,A23L33/10;;A61P25/16;;C07D233/96;;A61K31/4166;;A61P27/02;;A61P25/28;;A61P25/16;;C07D233/96;;A61P25/16;;A61K31/4166,A61K31/4166;;A23L33/10;;A61P25/16;;A61P25/28;;A61P27/02;;C07D233/86,,0,0,,,,ACTIVE
351,AU,A1,AU 2024/227778 A1,047-592-826-495-933,2024-11-21,2024,AU 2024/227778 A,2024-03-28,US 202318136419 A;;US 2024/0021859 W,2023-04-19,CRYOPRESERVATION DEVICE WITH INTEGRATED TRACKING DEVICE CHAMBER,,BIOTECH INC,PARRA-ALMANZA JORGE,,https://lens.org/047-592-826-495-933,Patent Application,no,3,0,10,047-592-826-495-933;;162-489-143-820-817;;147-477-893-597-624;;141-146-935-123-247;;060-885-276-227-95X;;046-595-929-205-924;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,AU;;JP;;KR;;CN;;IL;;EP;;MX,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,A01N1/147;;G06K19/0723;;C12N5/547;;G06K19/0723;;A01N1/146;;A01N1/147;;G06K19/0723;;A01N1/144,G06K19/07;;A01N1/02,,0,0,,,,ACTIVE
352,FR,A1,FR 3141610 A1,096-263-089-243-508,2024-05-10,2024,FR 2211649 A,2022-11-09,FR 2211649 A,2022-11-09,"Ligament artificiel implantable, et procédé de fabrication d’un tel ligament artificiel",La présente invention a pour objet un ligament artificiel (10) comprenant une gaine creuse textile (20) recevant un insert déformable et élastique décalant la phase de déformation rigide dudit ligament artificiel (10) lorsque l’on lui applique une force de traction longitudinale. Figure pour l’abrégé : Fig. 1.,COUSIN BIOTECH,BECQUART LUCIE;;AUBERT FRANÇOIS;;NOEL STÉPHANE;;CAILLIBOTTE MICHEL,,https://lens.org/096-263-089-243-508,Patent Application,no,6,0,3,096-263-089-243-508;;129-033-786-332-743;;161-361-545-244-534,EP;;WO;;FR,3,096-263-089-243-508;;129-033-786-332-743;;161-361-545-244-534,EP;;WO;;FR,0,A61F2/08;;A61F2240/001;;A61F2210/0071;;A61L27/50;;A61L2430/10;;A61L27/18,A61F2/08,,0,0,,,,PENDING
353,US,A1,US 2022/0233607 A1,060-251-494-869-075,2022-07-28,2022,US 202017614771 A,2020-05-29,EP 19305686 A;;EP 2020065086 W,2019-05-29,TOXOPLASMA PLATFORM FOR TREATING CANCER,"A strain of an Apicomplexa of the family Sarcocystidae, wherein the strain is replicative and expresses one or more heterologous protein(s) selected from the group including therapeutic proteins, antigens, recombinant surface receptor or combinations thereof, and wherein the strain is selected from the group including Toxoplasma gondii and Neospora caninium. Also, the use of the strain for preventing or treating cancers or infectious diseases in a subject in need thereof.",UNIV TOURS;;KYMERIS THERAPEUTICS INC;;INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT;;INSTITUT NATIONAL DE RECH POUR LAGRICULTURE L ALIMENTATION ET LENVIRONNEMENT,DIMIER-POISSON ISABELLE;;MEVELEC MARIE-NOËLLE;;DI TOMMASO ANNE;;AUBREY NICOLAS;;LANTIER LOUIS;;LEE GORDON,KYMERIS THERAPEUTICS INC (2022-01-05);;UNIVERSITÉ DE TOURS (2022-01-05);;INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE L'ALIMENTATION ET L'ENVIRONNEMENT (2022-01-05),https://lens.org/060-251-494-869-075,Patent Application,yes,0,1,3,060-251-494-869-075;;081-456-389-959-387;;045-342-721-981-025,EP;;WO;;US,3,081-456-389-959-387;;060-251-494-869-075;;045-342-721-981-025,EP;;WO;;US,57,A61K35/68;;A61K2039/505;;A61P35/00;;C07K14/5443;;C07K14/7155;;C07K14/77;;C07K16/2851;;C07K2319/42;;C07K2319/912;;C12N2800/22;;C12N2810/859;;A61K35/68;;A61K2039/505;;C07K14/5443;;C07K14/7155;;C07K14/77;;C07K16/2851;;C07K2319/42;;C07K2319/912;;C12N2800/22;;C12N2810/859,A61K35/68;;C07K14/54;;C07K14/715;;C07K14/77;;C07K16/28,,0,0,,,,DISCONTINUED
354,EP,A1,EP 3983005 A1,115-911-824-759-253,2022-04-20,2022,EP 20742803 A,2020-06-09,FR 1906208 A;;FR 2020050975 W,2019-06-11,COMBINATION OF MARKERS FOR PREDICTING THE RESPONSE TO VX-001,,VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS (KOSTAS);;MENEZ-JAMET JEANNE,KRIPTIC PHARMACEUTICALS LIMITED (2023-07-26),https://lens.org/115-911-824-759-253,Patent Application,yes,0,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,0,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/00;;A61K39/395;;A61P35/00;;G01N33/50,,0,0,,,,ACTIVE
355,FR,A1,FR 3149183 A1,165-237-353-296-740,2024-12-06,2024,FR 2305473 A,2023-06-01,FR 2305473 A,2023-06-01,Système d’implantation vertébrale d’un élément d’écartement vertébral,"Système d’implantation vertébrale d’un élément d’écartement vertébral Système d’implantation vertébrale (10) d’un élément d’écartement vertébral (100) au moins partiellement déformable élastiquement entre un état déployé et un état comprimé, le système d’implantation comprenant un dispositif de compression (40) configuré pour faire passer ledit élément d’écartement vertébral de l’état déployé à l’état comprimé ; un dispositif de guidage (20) présentant une extrémité distale (20b) ouverte et comprenant un tube d’implantation (36), le dispositif de guidage pouvant être connecté audit dispositif de compression ; et un dispositif de poussée (60) configuré pour coopérer avec le dispositif de compression, lorsque le dispositif de guidage est connecté à ce dernier, pour pousser l’élément d’écartement vertébral dans l’état comprimé depuis le logement du dispositif de compression jusqu’à l’intérieur du tube d’implantation du dispositif de guidage ; et avec le dispositif de guidage pour pousser l’élément d’écartement vertébral dans l’état comprimé le long du tube d’implantation jusqu’à l’extrémité distale du dispositif de guidage, de manière à extraire ledit élément d’écartement vertébral hors du dispositif de guidage. Figure pour l’abrégé : Fig. 10.",COUSIN BIOTECH,HOFFMANN ELÉONORE;;CAILLIBOTTE MICHEL,,https://lens.org/165-237-353-296-740,Patent Application,no,9,0,4,170-814-454-069-06X;;038-450-039-195-78X;;165-237-353-296-740;;126-411-008-097-421,WO;;TW;;FR,4,170-814-454-069-06X;;038-450-039-195-78X;;165-237-353-296-740;;126-411-008-097-421,WO;;TW;;FR,0,A61B17/7065;;A61B17/7064;;A61F2002/4627;;A61F2/4611,A61B17/70;;A61F2/44,,0,0,,,,PENDING
356,FR,A1,FR 3111431 A1,197-877-393-616-549,2021-12-17,2021,FR 2012068 A,2020-11-24,FR 2006148 A,2020-06-12,"Système pour l’analyse rapide d’un échantillon biologique, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique","La présente invention concerne un système pour l’analyse rapide d’un échantillon biologique (E), destiné à la détection de la présence d’au moins un analyte (A) dans ledit échantillon biologique (E). Le système d’analyse rapide comprend : - au moins un dispositif de prélèvement (2), adapté au prélèvement dudit échantillon biologique (E), - au moins une bandelette chromatographique (3), conçue pour détecter la présence dudit au moins un analyte (A), - une solution tampon (4), pour la mise en œuvre de la technique chromatographique, et - au moins un dispositif d’interface (5), adapté à recevoir ladite au moins une bandelette chromatographique (3) pour la mise en œuvre de ladite technique chromatographique, lequel dispositif d’interface (5) comporte au moins deux logements (51, 52) en communication fluidique avec au moins un premier logement (51) destiné à recevoir au moins ladite solution tampon (4) et au moins un second logement (52) conçu pour introduire au moins la zone de dépôt (311) de ladite au moins une bandelette chromatographique (3), ledit second logement (52) étant destiné à recevoir ladite solution tampon (4), éventuellement mélangée avec ledit échantillon biologique (E), s’écoulant depuis ledit au moins un premier logement (51). Figure pour l’abrégé : 9",NG BIOTECH,STANKOV MILOVAN,,https://lens.org/197-877-393-616-549,Patent Application,no,3,0,5,197-877-393-616-549;;046-331-989-819-750;;027-789-513-586-109;;139-860-241-882-093;;147-781-090-954-815,EP;;WO;;FR,5,197-877-393-616-549;;046-331-989-819-750;;139-860-241-882-093;;027-789-513-586-109;;147-781-090-954-815,EP;;WO;;FR,0,G01N33/54388;;B01L3/5029;;B01L9/52;;B01L2300/0663;;B01L2300/0825;;B01L2300/0832;;B01L2300/0864,G01N33/544;;A61B5/00;;A61B5/15;;A61B10/00;;C12R1/93;;G01N1/02;;G01N33/50,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",DISCONTINUED
357,KR,A,KR 20240104874 A,198-771-054-859-758,2024-07-05,2024,KR 20220187530 A,2022-12-28,KR 20220187530 A,2022-12-28,Pharmaceutical composition for improving blood circulation and preventing or treating blood clots containing plant extracts as active ingredients,"본 발명은 산딸기(Rubus crataegifolius), 산사(Crataegus pinnatifida), 하고초(Prunella vulgaris), 커피생두(Coffea green bean/Coffea arabica)의 2종 또는 3종 추출물의 유효성분을 함유하는 혈행 개선 및 혈전질환 예방 또는 치료용 조성물에 관한 것으로, 2종 또는 3종 혼합물은 피브린 형성에 관여하는 트롬빈(thrombin)활성을 억제하며, 프로트롬빈(prothrombin) 시간을 연장하는 혈액 응고 억제 효과를 나타내고, 우수한 혈소판 활성 억제능을 나타냄을 증명하였다. 또한 mouse tail bleeding 실험에서 in vivo, 혈행 개선(bleeding time, bleeding volume, bleeding index) 효능을 입증하였으며, 폐색전증(pulmonary thromboembolism/PTE) 모델을 이용하여 ADP+epinephrine injection에 의한 platelet activation(Cox-1, Cox-2, TXA2) 및 endothelial dysfunction(eNOS/NO) 억제 효능 및 조직학적(폐, 대동맥) 정상화 효능을 증명하였다. 따라서 상기 4종의 천연물 중 2종 또는 3종의 천연물의 유효성분을 혈행 개선용 조성물 또는 혈전질환의 예방 및 치료용 약학적 조성물로 유용하게 사용될 수 있다.",LEES BIOTECH,LEE YOUNG IK;;LEE HUI JIN;;PYO SU JIN;;CHO JIN SOOK,,https://lens.org/198-771-054-859-758,Patent Application,no,0,0,1,198-771-054-859-758,KR,1,198-771-054-859-758,KR,0,A61K36/73;;A61K36/536;;A61P9/00;;A61P7/02;;A23L33/105;;A61K2300/00;;A23V2002/00;;A23V2200/326;;A61K36/742;;A23V2250/21;;A61K2236/33;;A61K2236/35;;A23V2300/14,A61K36/73;;A23L33/105;;A61K36/536;;A61K36/734;;A61K36/74;;A61P7/02;;A61P9/00,,0,0,,,,DISCONTINUED
358,EP,A1,EP 4322973 A1,134-869-970-778-682,2024-02-21,2024,EP 22726551 A,2022-04-15,US 202163175603 P;;US 2022/0024946 W,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE,,PRODIGY BIOTECH,IYER SUBRAMANIAN V;;PATEL SUNNY,,https://lens.org/134-869-970-778-682,Patent Application,yes,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,ACTIVE
359,AU,A1,AU 2022/258701 A1,106-998-188-340-301,2023-10-26,2023,AU 2022/258701 A,2022-04-15,US 202163175603 P;;US 2022/0024946 W,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE,"In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or grafi-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmimized egg product obtained from an egg- producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecaUs, Enterococcus faecalis eytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis. isolated Enterococcus faecal is eytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.",PRODIGY BIOTECH,IYER SUBRAMANIAN;;PATEL SUNNY,,https://lens.org/106-998-188-340-301,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,PENDING
360,WO,A1,WO 2020/240024 A1,045-342-721-981-025,2020-12-03,2020,EP 2020065086 W,2020-05-29,EP 19305686 A,2019-05-29,TOXOPLASMA PLATFORM FOR TREATING CANCER,"The present invention relates to a strain of an Apicomplexa of the family Sarcocystidae, wherein the strain is replicative and expresses one or more heterologous protein(s) selected from the group comprising therapeutic proteins, antigens, recombinant surface receptor or combinations thereof, and wherein the strain is selected from the group comprising Toxoplasma gondii and Neospora caninium. The present invention further relates to the use of said strain for preventing or treating cancers or infectious diseases in a subject in need thereof.",UNIV TOURS;;KYMERIS THERAPEUTICS INC;;INSTITUT NATIONAL DE RECH POUR LAGRICULTURE L ALIMENTATION ET LENVIRONNEMENT,DIMIER-POISSON ISABELLE;;MEVELEC MARIE-NOËLLE;;DI TOMMASO ANNE;;AUBREY NICOLAS;;LANTIER LOUIS;;LEE GORDON,,https://lens.org/045-342-721-981-025,Patent Application,yes,6,3,3,060-251-494-869-075;;081-456-389-959-387;;045-342-721-981-025,EP;;WO;;US,3,081-456-389-959-387;;060-251-494-869-075;;045-342-721-981-025,EP;;WO;;US,57,A61K35/68;;A61K2039/505;;A61P35/00;;C07K14/5443;;C07K14/7155;;C07K14/77;;C07K16/2851;;C07K2319/42;;C07K2319/912;;C12N2800/22;;C12N2810/859;;A61K35/68;;A61K2039/505;;C07K14/5443;;C07K14/7155;;C07K14/77;;C07K16/2851;;C07K2319/42;;C07K2319/912;;C12N2800/22;;C12N2810/859,A61K35/68;;A61K38/17;;A61K38/20;;A61P35/00;;C07K14/54;;C07K14/715;;C07K16/28;;C12N15/79,,32,20,085-221-736-823-441;;104-305-602-412-052;;019-604-864-885-414;;093-712-038-756-428;;066-392-596-425-94X;;064-302-240-873-122;;021-792-724-841-05X;;022-004-096-099-259;;024-730-060-375-935;;122-860-745-541-439;;141-822-401-062-25X;;056-201-471-905-934;;017-150-654-990-340;;032-720-983-972-675;;062-353-036-290-103;;057-343-886-357-239;;031-462-208-300-936;;083-679-671-760-153;;015-286-250-814-754;;072-336-411-333-311,20149795;;10.1016/j.jim.2010.01.013;;pmc2855898;;pmc3177786;;10.1186/1756-3305-4-168;;21871123;;10.1016/s0166-6851(98)00154-6;;10029312;;9405194;;10.1006/meth.1997.0503;;10.3346/jkms.2007.22.s.s38;;17923753;;pmc2694397;;30064894;;pmc6171074;;10.1016/j.ymthe.2018.07.013;;10.1186/1750-9378-8-8;;pmc3583726;;23391314;;10.1016/j.molbiopara.2010.08.007;;20817048;;pmc3566937;;23374751;;10.1186/1742-2094-10-19;;10.4103/0973-1482.144638;;26148590;;10.1016/j.micpath.2019.01.040;;30708042;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1126/science.3140379;;3140379;;10.1006/jmbi.1997.1354;;9367782;;10.1006/cyto.2001.0936;;11741351;;pmc2074309;;10.1038/bjc.1996.32;;8546903;;24663679;;10.4049/jimmunol.1302350;;pmc336954;;10.1093/nar/20.11.2902;;1614888;;27217584;;10.4049/jimmunol.1600019;;pmc258615;;2323815;;10.1128/iai.58.5.1240-1246.1990,"BENJAMIN J DANIEL ET AL: ""A simple method to detect Toxoplasma gondii-specific cytotoxic T cells in vivo"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 355, 8 February 2010 (2010-02-08), pages 86 - 90, XP055642033;;JUN ZOU ET AL: ""Evaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts"", PARASITES & VECTORS, BIOMED CENTRAL LTD, LONDON UK, vol. 4, no. 1, 28 August 2011 (2011-08-28), pages 168, XP021109662, ISSN: 1756-3305, DOI: 10.1186/1756-3305-4-168;;BARBARA A FOX ET AL: ""Stable transformation of Toxoplasma gondii based on a pyrimethamine resistant trifunctional dihydrofolate reductase-cytosine deaminase-thymidylate synthase gene that confers sensitivity to 5-fluorocytosine"", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 98, no. 1, 6 January 1999 (1999-01-06), pages 93 - 103, XP055642270;;KARSTEN V ET AL: ""Targeting the Secretory Pathway of Toxoplasma gondii"", METHODS, ACADEMIC PRESS, NL, vol. 13, no. 2, 1 October 1997 (1997-10-01), pages 103 - 111, XP004466552, ISSN: 1046-2023, DOI: 10.1006/METH.1997.0503;;JU-OCK KIM ET AL: ""Inhibition of Lewis Lung Carcinoma Growth by Toxoplasma gondii through Induction of Th1 Immune Responses and Inhibition of Angiogenesis"", J. KOREAN MED SCI, vol. 22, no. Suppl., 1 September 2007 (2007-09-01), pages S38 - S46, XP055642266;;KOWALSKY STACY J ET AL: ""Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade"", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 26, no. 10, 3 October 2018 (2018-10-03), pages 2476 - 2486, XP002794091, ISSN: 1525-0024;;SIVASAKTHIVEL THIRUGNANAM ET AL: ""Possible role of Toxoplasma gondii in brain cancer through modulation of host microRNAs"", INFECTIOUS AGENTS AND CANCER, BIOMED CENTRAL LTD, LO, vol. 8, no. 1, 8 February 2013 (2013-02-08), pages 8, XP021140123, ISSN: 1750-9378, DOI: 10.1186/1750-9378-8-8;;ELLIS J ET AL: ""Microarray analyses of mouse responses to infection by Neospora caninum identifies disease associated cellular pathways in the host response"", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 174, no. 2, 1 December 2010 (2010-12-01), pages 117 - 127, XP027494890, ISSN: 0166-6851, [retrieved on 20101115], DOI: 10.1016/J.MOLBIOPARA.2010.08.007;;MARBEL TORRES ET AL: ""MyD88 is crucial for the development of a protective CNS immune response to Toxoplasma gondii infection"", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 10, no. 1, 1 February 2013 (2013-02-01), pages 19, XP021139795, ISSN: 1742-2094, DOI: 10.1186/1742-2094-10-19;;MARYAM S SEYEDEH ET AL: ""Low titer of antibody against Toxoplasma gondii may be related to resistant to cancer"", J CANCER RES THER., 1 April 2015 (2015-04-01), pages 305 - 307, XP055643839, Retrieved from the Internet <URL:http://www.cancerjournal.net/printarticle.asp?issn=0973-1482;year=2015;volume=11;issue=2;spage=305;epage=307;aulast=Seyedeh> [retrieved on 20191119], DOI: 10.4103/0973-1482.144638;;ANVARI DAVOOD ET AL: ""Seroprevalence ofToxoplasma gondii infection in cancer patients: A systematic review and meta-analysis"", MICROBIAL PATHOGENESIS, vol. 129, 29 January 2019 (2019-01-29), pages 30 - 42, XP085640947, ISSN: 0882-4010, DOI: 10.1016/J.MICPATH.2019.01.040;;CARILLO ET AL., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073;;""Biocomputing: Informatics and Genome Projects"", 1993, ACADEMIC PRESS;;""Computer Analysis of Sequence Data"", 1994, HUMANA PRESS;;VON HEINJE, G.: ""Sequence Analysis in Molecular Biology"", 1987, ACADEMIC PRESS;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH;;DEVEREUX ET AL., NUCL. ACID. RES., vol. 2, no. 387, 1984;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL.: ""Using Antibodies: A Laboratory Manual"", 1999, COLD SPRING HARBOR LABORATORY PRESS;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual"", 1989, COLD SPRING HARBOR;;HOUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948;;LEONG ET AL., CYTOKINES, vol. 16, no. 3, 2001, pages 106 - 119;;DELGADO ET AL., BR. J. CANCER, vol. 73, no. 2, 1996, pages 175 - 182;;MADAAN ET AL., JOURNAL OF BIOLOGICAL METHODS, vol. 1, 2014;;FERREIRA ET AL., JOURNAL OF IMMUNOLOGY, vol. 192, no. 9, 2014, pages 4210 - 20;;SRIMPTON ET AL., MOL. IMMUNOL., 2009;;SAMBROOK J.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;VAN DEN HOFF ET AL., NUCLEIC ACIDS RES., vol. 20, no. 11, 11 June 1992 (1992-06-11), pages 2902;;DESBOIS ET AL., J IMMUNOL., vol. 197, no. 1, 1 July 2016 (2016-07-01), pages 168 - 178;;CHARDES ET AL., INFECTION AND IMMUNITY, 1990",PENDING
361,KR,A,KR 20230151600 A,009-155-946-274-613,2023-11-02,2023,KR 20220051076 A,2022-04-25,KR 20220051076 A,2022-04-25,AIR PURIFIER CONTAINING MICROALGAE,"An air purifier that purifies the air comprises: an upper end part that includes an air inlet, a fine dust filter disposed below the air inlet, an air absorption fan disposed below the fine dust filter, an air sensor for detecting air components, and an air supply passage; a middle end part that is disposed below the upper end part and includes a light-transparent culture tank and an air outlet; and a lower end part that is disposed below the middle end part and includes a stirrer and a second light emitting diode (LED). The air absorption fan introduces air from outside the air purifier into the air purifier through the air inlet, the fine dust filter filters the air introduced inside, the air supply passage leads filtered air to the culture tank, the culture tank includes a handle and a stirring blade, the stirring blade rotates through interaction with the stirrer to stir the induced air, and the air outlet may lead the stirred air to the outside of the air purifier. Thus, the present invention can manufacture the air purifier that contains microalgae, which are photosynthetic microorganisms, and is combined with a fine dust filter.",WATER BIOTECH,SEO HAE DONG;;LEE HEON WOO,,https://lens.org/009-155-946-274-613,Patent Application,no,0,1,1,009-155-946-274-613,KR,1,009-155-946-274-613,KR,0,F24F8/175;;F24F8/60;;F24F8/108;;F24F8/80;;F24F13/20;;F24F13/28;;F24F11/52;;C12M31/02;;C12M27/02;;C12M29/18;;C12N1/12;;F24F2110/50,F24F8/175;;C12M1/00;;C12M1/06;;C12N1/12;;F24F8/108;;F24F8/60;;F24F8/80;;F24F11/52;;F24F13/20;;F24F13/28;;F24F110/50,,0,0,,,,PENDING
362,KR,A,KR 20200139635 A,042-773-274-946-425,2020-12-14,2020,KR 20200065807 A,2020-06-01,KR 20190065991 A,2019-06-04,NEW PEPTIDE AND COMPOSITION FOR FIBROBLAST AND SKIN REGENERATION,"The present invention relates to a novel peptide capable of inducing strong proliferation by stimulating fibroblasts and having excellent cell permeation efficiency, and a composition for promoting skin fibroblast proliferation and a composition for skin regeneration including the same. The peptide consists of a sequence represented by following general formula 1: M-(H)_n-R_1-(linker)-R_2.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/042-773-274-946-425,Patent Application,no,1,0,2,042-773-274-946-425;;103-401-188-608-327,KR,2,042-773-274-946-425;;103-401-188-608-327,KR,12,C07K14/00;;C07K14/503;;C07K2319/10,C07K14/00;;C07K14/50,,0,0,,,,ACTIVE
363,FR,A1,FR 3121514 A1,057-060-284-581-620,2022-10-07,2022,FR 2103428 A,2021-04-02,FR 2103428 A,2021-04-02,"Dispositif pour l’analyse rapide d’un échantillon biologique, par exemple un échantillon biologique salivaire","La présente invention concerne un dispositif pour l’analyse rapide d’un échantillon biologique, par exemple un échantillon biologique salivaire, destiné à la détection de la présence d’au moins un analyte dans ledit échantillon biologique. Le dispositif d’analyse rapide (1) comprend : - un organe de prélèvement (2), destiné au prélèvement dudit échantillon biologique, et - un boîtier (3) qui comporte un emplacement (31) destiné à recevoir une bandelette chromatographique (7) et une interface (32), adaptée à recevoir ledit organe de prélèvement (2) dans une configuration finale assemblée. L’organe de prélèvement (2) et l’interface (32) comportent des moyens d’assemblage étanche (5) comprenant des moyens de guidage (6) qui sont structurés pour guider un mouvement relatif entre ledit organe de prélèvement (2) et ladite interface (32) depuis une configuration initiale de positionnement jusqu’à la configuration finale assemblée, ledit mouvement relatif comprenant deux mouvements : - un mouvement de translation relatif, prévu pour appliquer une compression audit bloc absorbant (21), et - un mouvement de rotation relatif, prévu pour appliquer une torsion audit bloc absorbant (21). Figure pour l’abrégé : 1",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/057-060-284-581-620,Patent Application,no,3,0,2,057-060-284-581-620;;054-640-202-927-803,FR,4,064-690-104-175-773;;017-608-966-926-024;;054-640-202-927-803;;057-060-284-581-620,WO;;FR,0,G01N33/54388;;A61B10/0051;;A61B2010/0006;;B01L3/50273;;B01L3/5029;;B01L2200/027;;B01L2300/069;;B01L2300/0825;;B01L2400/0406,G01N33/543;;A61B10/02;;B01L3/00;;G01N1/10,,1,0,,,"HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",DISCONTINUED
364,US,A1,US 2021/0261529 A1,152-346-690-972-536,2021-08-26,2021,US 201916973646 A,2019-07-04,KR 20180078585 A;;KR 20190080244 A;;KR 2019008235 W,2018-07-06,"PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT","The present disclosure relates to a composition for preventing or treating wound. The composition according to the present disclosure contains, as an active ingredient, an indirubin derivative alone or one or more selected from a group consisting of an indirubin derivative, an Euodia sutchuenensis Dode extract, methyl vanillate, hesperidin and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring not only in a normal state but also in a diabetic state. Furthermore, since the composition exhibits excellent effects in healing diabetic wound as well as general wound, it can be usefully used as a pharmaceutical composition, cosmetic composition or food composition for alleviating, preventing or treating general wound or diabetic wound, or as a veterinary composition for treating diabetic wound.",CK BIOTECH,CHOI KANG-YELL;;KIM EUNHWAN;;SEO SEOL HWA;;YOON MINGUEN,CK BIOTECH (2020-11-27),https://lens.org/152-346-690-972-536,Patent Application,yes,3,0,10,100-574-593-464-511;;010-723-737-446-421;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;070-530-775-976-218;;097-170-205-131-938;;112-312-169-379-233;;152-346-690-972-536;;146-551-039-853-613,CN;;EP;;WO;;US,14,100-574-593-464-511;;010-723-737-446-421;;143-789-168-119-782;;032-643-700-987-417;;033-013-944-550-545;;077-967-932-310-425;;097-170-205-131-938;;152-346-690-972-536;;156-171-049-575-889;;061-609-337-961-572;;070-530-775-976-218;;112-312-169-379-233;;016-089-837-812-567;;146-551-039-853-613,KR;;CN;;EP;;WO;;US,0,A61P17/02;;A61Q19/00;;A61K31/404;;A61K31/7048;;A23L33/10;;A61K8/492;;A61K36/754;;A23K20/137;;A23K20/111;;A23K10/30;;A23K20/163;;A23K20/121;;A61K9/107;;A61K45/06;;A61K31/216;;A23L33/105;;A23L33/40;;A61K8/9789;;A61P17/02;;A23V2002/00;;A61K8/06;;A61K8/345;;A61K8/37;;A61K8/492;;A61K8/602;;A61K8/604;;A61K8/738;;A61K8/922;;A61K9/0014;;A61K9/0056;;A61K9/06;;A61K9/107;;A61K31/235;;A61K31/404;;A61K31/7048;;A61K36/754;;A61K47/10;;A61K47/26;;A61K47/40;;A61K47/44;;A61Q19/00;;C07D403/04,C07D403/04;;A23L33/00;;A23L33/105;;A61K8/06;;A61K8/34;;A61K8/37;;A61K8/49;;A61K8/60;;A61K8/73;;A61K8/92;;A61K8/9789;;A61K9/00;;A61K9/06;;A61K9/107;;A61K31/235;;A61K31/404;;A61K31/7048;;A61K36/754;;A61K47/10;;A61K47/26;;A61K47/40;;A61K47/44;;A61P17/02;;A61Q19/00,,1,1,008-515-541-390-907,pmc1087919;;15837920;;10.1073/pnas.0409467102,"Nam et al, Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America (2005), 102(17), 5998-6003 (Year: 2005)",DISCONTINUED
365,WO,A1,WO 2021/170750 A1,165-047-073-231-97X,2021-09-02,2021,EP 2021054744 W,2021-02-25,EP 20305206 A,2020-02-28,COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS,"The present invention concerns the combination of CTLA4 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-CTLA4 therapies.",OREGA BIOTECH,BONNEFOY NATHALIE;;BASTID JÉRÉMY;;BENSUSSAN ARMAND,,https://lens.org/165-047-073-231-97X,Patent Application,yes,47,0,4,165-047-073-231-97X;;022-553-777-332-361;;009-483-702-664-175;;116-429-825-164-359,JP;;EP;;WO;;US,4,165-047-073-231-97X;;022-553-777-332-361;;009-483-702-664-175;;116-429-825-164-359,JP;;EP;;WO;;US,0,C07K16/2818;;C07K16/244;;C07K2317/76;;C07K2317/24;;A61P35/00;;A61K2039/507;;A61K2039/545;;Y02A50/30;;A61P35/00;;C07K16/244;;C07K16/2818;;C07K2317/24;;C07K2317/76,C07K16/24;;A61K39/00;;A61P35/00;;C07K16/28,,18,15,091-714-385-993-854;;030-984-256-000-024;;057-307-040-432-890;;092-999-513-706-513;;096-152-178-726-139;;062-418-979-939-961;;038-148-647-017-832;;001-794-565-499-683;;010-102-248-891-848;;022-496-430-844-474;;123-601-793-698-406;;077-279-012-124-305;;054-802-024-202-015;;074-817-300-512-106;;013-323-148-570-367,12196291;;10.1016/s1074-7613(02)00362-x;;10.1038/ni0702-611;;12087419;;10.1016/1074-7613(95)90125-6;;7584144;;10.1126/science.270.5238.985;;7481803;;10.1084/jem.192.2.303;;pmc2193248;;10899917;;8596936;;10.1126/science.271.5256.1734;;10.1056/nejmoa1003466;;pmc3549297;;20525992;;10.1056/nejmoa1104621;;21639810;;25667295;;10.1200/jco.2014.56.2736;;pmc5089162;;10.1097/cmr.0b013e328353e65c;;22516968;;10.1038/nrclinonc.2016.58;;27141885;;10.1038/nri.2017.112;;pmc5991909;;28990586;;10.1038/nri2586;;pmc2821718;;19575028;;2677748;;10.1038/341544a0;;10.1016/j.tibtech.2003.08.007;;14573361,"COLLINS ET AL., IMMUNITY, vol. 17, no. 2, 2002, pages 201 - 10;;EGEN ET AL., NAT IMMUNOL., vol. 3, no. 7, 2002, pages 611 - 8;;TIVOL ET AL., IMMUNITY, vol. 3, no. 5, 1995, pages 541 - 7;;WATERHOUSE ET AL., SCIENCE, vol. 270, no. 5238, 1995, pages 985 - 8;;ISE ET AL., NAT IMMUNOL, vol. 11, no. 2, 2010, pages 129 - 35;;TAKAHASHI T ET AL., J EXP MED, vol. 192, no. 2, 2000, pages 3 03 - 10;;LEACH ET AL., SCIENCE, vol. 271, no. 5256, 1996, pages 1734 - 6;;HODI ET AL., N ENGL J MED, vol. 363, no. 8, 2010, pages 711 - 23;;ROBERT ET AL., N ENGL J MED, vol. 364, no. 26, 2011, pages 2517 - 26;;SCHADENDORF ET AL., J CLIN ONCOL, vol. 33, no. 17, 2015, pages 1889 - 94;;FAROLFI ET AL., MELANOMA RES, vol. 22, no. 3, 2012, pages 263 - 70;;BOUTROS ET AL., NAT REV CLIN ONCOL., vol. 13, no. 8, 2016, pages 473 - 86;;WYKES ET AL., NAT REV IMMUNOL, vol. 18, no. 2, 2018, pages 91 - 104;;HOUSMAN ET AL., CANCER, vol. 6, no. 17, 2014, pages 69 - 1792;;GAFFEN, S. L.: ""Nature reviews"", IMMUNOLOGY, vol. 9, no. 8, 2009, pages 556 - 567;;""GenBank"", Database accession no. NP_001304916.1, NP_055258.1;;WARD ET AL., NATURE, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 6;;HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, 2003, pages 484 - 490",PENDING
366,WO,A1,WO 2021/148229 A1,173-148-050-182-143,2021-07-29,2021,EP 2020087936 W,2020-12-28,FR 1915796 A,2019-12-31,COMPOSITION FOR WEIGHT MANAGEMENT OF A SUBJECT,"The present application relates to a composition for managing the weight of a subject, wherein said composition comprises at least one high-viscosity, resorbable, biocompatible material, intended to be injected into the submucosal space of the digestive tract of a subject and thus to create a long-lasting raising of the corresponding mucosa. The present application also relates to a kit comprising a composition according to the invention and means for injecting the composition. Finally, the present application relates to the use of a composition according to the invention for managing the weight of a subject.",MRS BIOTECH,MARÇAIS OLIVIER,,https://lens.org/173-148-050-182-143,Patent Application,yes,5,0,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,0,A61K31/728;;A61K31/722;;A61K31/715;;A61K9/0019;;A61K47/26;;A61K47/38;;A61K47/02;;A61K45/06;;A61K9/0019;;A61K31/728;;A61K45/06,A61K31/728;;A61K9/00;;A61K31/715;;A61K31/722;;A61P3/04,,4,3,133-841-739-679-736;;133-841-739-679-736;;023-121-871-453-52X,10.1007/s11695-015-1648-0;;25812529;;10.1007/s11695-015-1648-0;;25812529;;22573940;;pmc3345931;;10.2147/ceg.s29704,"DARGENT JEROME ET AL: ""Multicenter Randomized Study of Obesity Treatment with Minimally Invasive Injection of Hyaluronic Acid Versus and Combined with Intragastric Balloon"", OBESITY SURGERY, RAPID COMMUNICATIONS OF OXFORD, OXFORD, GB, vol. 25, no. 10, 27 March 2015 (2015-03-27), pages 1842 - 1847, XP035540956, ISSN: 0960-8923, [retrieved on 20150327], DOI: 10.1007/S11695-015-1648-0;;DE J. DARGENT ET AL.: ""Multicenter randomized study of obesity treatment with minimally invasive injection of hyaluronic acid versus and combined with intragastric balloon"", OBESITY SURGERY, vol. 25, 2015, pages 1842 - 7, XP035540956, DOI: 10.1007/s11695-015-1648-0;;L'INJECTION D'ACIDE HYALURONIQUE EST INEFFICACE COMPARATIVEMENT AVEC LA POSE D'UN BALLON INTRA-GASTRIQUE POUR INDUIRE LA PERTE DE POIDS, pages 1846;;H. AL-TAIE ET AL.: ""Efficacy of submucosal injection of différent solutions inclusive blood components on mucosa élévation for endoscopic resection"", CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, vol. 5, 2012, pages 43 - 48",PENDING
367,AU,A1,AU 2025/213589 A1,141-146-935-123-247,2025-08-21,2025,AU 2025/213589 A,2025-08-06,AU 2025/213589 A;;AU 2024/227778 A;;US 202318136419 A;;US 2024/0021859 W,2023-04-19,Cryopreservation Device With Integrated Tracking Device Chamber,"The present invention provides a cryopreservation device. The cryopreservation device comprises: an elongated stick comprising an RFID section, an elongated body, and a specimen collection tip, and a cap comprising a hollow chamber, wherein the hollow chamber has a length sufficient to accommodate the specimen collection tip. The cap can enclose the specimen collection tip within the hollow chamber when the cap is removably attached to the elongated stick. The RFID section is distal to the specimen collection tip and the RFID section comprises an RFID chamber capable of holding an RFID tag, an RFID opening through which the RFID tag can be placed into the RFID chamber, and a locking mechanism abutting a circumference of the RFID opening. A length of the RFID opening is along a longitudinal axis of the elongated stick. The locking mechanism comprises a circumferential flap bending inward towards the RFID chamber. The present invention provides a cryopreservation device. The cryopreservation device comprises: an elongated stick comprising an RFID section, an elongated body, and a specimen collection tip, and a cap comprising a hollow chamber, wherein the hollow chamber has a length sufficient to accommodate the specimen collection tip. The cap can enclose the specimen collection tip within the hollow chamber when the cap is removably attached to the elongated stick. The RFID section is distal to the specimen collection tip and the RFID section comprises an RFID chamber capable of holding an RFID tag, an RFID opening through which the RFID tag can be placed into the RFID chamber, and a locking mechanism abutting a circumference of the RFID opening. A length of the RFID opening is along a longitudinal axis of the elongated stick. The locking mechanism comprises a circumferential flap bending inward towards the RFID chamber. ug u g h e p r e s e n t i n v e n t i o n p r o v i d e s a c r y o p r e s e r v a t i o n d e v i c e h e c r y o p r e s e r v a t i o n d e v i c e c o m p r i s e s : a n e l o n g a t e d s t i c k c o m p r i s i n g a n s e c t i o n , a n e l o n g a t e d b o d y , a n d a s p e c i m e n c o l l e c t i o n t i p , a n d a c a p c o m p r i s i n g a h o l l o w c h a m b e r , w h e r e i n t h e h o l l o w c h a m b e r h a s a l e n g t h s u f f i c i e n t t o a c c o m m o d a t e t h e s p e c i m e n c o l l e c t i o n t i p h e c a p c a n e n c l o s e t h e s p e c i m e n c o l l e c t i o n t i p w i t h i n t h e h o l l o w c h a m b e r w h e n t h e c a p i s r e m o v a b l y a t t a c h e d t o t h e e l o n g a t e d s t i c k h e s e c t i o n i s d i s t a l t o t h e s p e c i m e n c o l l e c t i o n t i p a n d t h e s e c t i o n c o m p r i s e s a n c h a m b e r c a p a b l e o f h o l d i n g a n t a g , a n o p e n i n g t h r o u g h w h i c h t h e t a g c a n b e p l a c e d i n t o t h e c h a m b e r , a n d a l o c k i n g m e c h a n i s m a b u t t i n g a c i r c u m f e r e n c e o f t h e o p e n i n g l e n g t h o f t h e o p e n i n g i s a l o n g a l o n g i t u d i n a l a x i s o f t h e e l o n g a t e d s t i c k h e l o c k i n g m e c h a n i s m c o m p r i s e s a c i r c u m f e r e n t i a l f l a p b e n d i n g i n w a r d t o w a r d s t h e c h a m b e r",BIOTECH INC,PARRA-ALMANZA JORGE,,https://lens.org/141-146-935-123-247,Patent Application,no,0,0,10,047-592-826-495-933;;162-489-143-820-817;;147-477-893-597-624;;141-146-935-123-247;;060-885-276-227-95X;;046-595-929-205-924;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,AU;;JP;;KR;;CN;;IL;;EP;;MX,16,170-381-455-868-719;;162-489-143-820-817;;016-237-892-665-506;;147-477-893-597-624;;131-163-295-300-269;;141-146-935-123-247;;061-368-949-232-149;;046-595-929-205-924;;117-296-648-200-709;;047-592-826-495-933;;118-651-602-690-001;;060-885-276-227-95X;;175-404-859-503-282;;052-663-530-006-017;;111-842-307-008-783;;172-094-673-993-893,JP;;KR;;AU;;AR;;CL;;CN;;IL;;EP;;WO;;US;;MX,0,A01N1/147;;G06K19/0723;;C12N5/547;;G06K19/0723;;A01N1/146;;A01N1/147;;G06K19/0723;;A01N1/144,G06K19/07;;A01N1/10,,0,0,,,,PENDING
368,US,A1,US 2024/0199723 A1,159-616-868-022-776,2024-06-20,2024,US 202218555338 A,2022-04-15,US 202218555338 A;;US 202163175603 P;;US 2022/0024946 W,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE,"In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or graft-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecalis, Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis, isolated Enterococcus faecalis cytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.",PRODIGY BIOTECH,IYER SUBRAMANIAN V;;PATEL SUNNY,PRODIGY BIOTECH (2021-07-22),https://lens.org/159-616-868-022-776,Patent Application,yes,1,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,2,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,C07K16/02;;A61K9/00;;A61K39/00;;A61P1/16;;C07K16/12,,1,1,001-948-910-943-802,19042153;;10.1016/j.ijmm.2008.10.001,"Ha¨llgren et al., Molecular detection of aggregation substance, enterococcal surface protein, and cytolysin genes and in vitro adhesion to urinary catheters of Enterococcus faecalis and E. faecium of clinical origin. International Journal of Medical Microbiology 299:323–332, 2009.",PENDING
369,PL,T3,PL 4322973 T3,132-243-120-561-850,2025-08-18,2025,PL 22726551 T,2022-04-15,US 202163175603 P;;US 2022/0024946 W,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE,,PRODIGY BIOTECH,IYER SUBRAMANIAN V;;PATEL SUNNY,,https://lens.org/132-243-120-561-850,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61K39/00;;A61P1/16;;A61P37/06,,0,0,,,,PENDING
370,WO,A1,WO 2023/242209 A1,198-373-535-208-40X,2023-12-21,2023,EP 2023065838 W,2023-06-13,FR 2205675 A,2022-06-13,DEVICE FOR SPERM CELL ISOLATION AND METHOD FOR SELECTION OF HIGH QUALITY SPERM CELLS,"The invention is directed to a device for sperm cell selection having a support plate comprising an inlet to receive a sample of sperm cells, an outlet to collect at least some of the sperm cells comprised in said sample, and a microfluidic system between said inlet and outlet, wherein said microfluidic system comprises a basin arranged to receive a medium and having an inlet zone and an outlet zone respectively at the proximity of the inlet and the outlet, and wherein the inlet and the outlet are arranged to provide a hydrostatic pressure difference between said inlet zone and said outlet zone when medium is added to the basin via the outlet, so as to provoke a stream of said medium from the outlet zone towards the inlet zone to initiate sperm cell migration of sperm cells from the sample of sperm cells from the inlet zone towards the outlet zone, and wherein the inlet zone and the outlet zone are in fluidic communication with each other via a main channel arranged in the basin, the channel having a zone of reduced width arranged between the inlet zone and the outlet zone in order to form a rheotaxis zone, whereby said sample of sperm cells undergoes a selection by passing through said rheotaxis zone during said sperm cell migration thus enabling to collect a sample of quality sperm cells from the outlet zone at the outlet.",BEEZ BIOTECH,SHUKLA SHIVA KANT,,https://lens.org/198-373-535-208-40X,Patent Application,yes,6,0,5,164-514-809-775-341;;189-852-813-611-832;;198-373-535-208-40X;;061-603-376-262-742;;029-087-290-109-538,CN;;EP;;WO;;FR,5,189-852-813-611-832;;029-087-290-109-538;;198-373-535-208-40X;;061-603-376-262-742;;164-514-809-775-341,EP;;CN;;WO;;FR,0,C12M21/06;;C12M47/04;;C12N5/0612;;A61D19/02,C12M3/00;;B01L3/00;;C12M1/00;;C12N5/071,,17,17,073-076-662-858-591;;007-577-445-380-749;;132-615-913-786-392;;057-248-534-047-258;;084-707-558-526-682;;098-278-528-710-96X;;044-831-232-843-917;;013-172-766-527-846;;006-436-297-405-91X;;058-581-968-906-342;;166-104-047-110-79X;;015-685-034-510-711;;021-825-812-746-851;;066-352-862-122-241;;038-415-595-243-224;;061-539-002-320-967;;089-616-048-387-828,10.1093/hropen/hoac022;;35795850;;pmc9252765;;10.3389/fcell.2019.00298;;pmc6896825;;31850340;;10.1093/biolre/iox173;;29228115;;pmc4594619;;26386468;;10.1093/humupd/dmv042;;31749341;;pmc7994658;;10.5534/wjmh.190088;;28981654;;pmc6455044;;10.1093/humupd/dmx022;;25458617;;pmc4254491;;10.1016/j.fertnstert.2014.10.021;;10.1088/2057-1976/aab10d;;28326513;;10.5603/gp.a2017.0012;;10.1093/oxfordjournals.humrep.a138198;;7691866;;10.1095/biolreprod.107.065623;;18199884;;30954892;;10.1016/j.fsigen.2019.03.012;;10.15252/embj.2019102363;;pmc7024840;;31957048;;pmc7496921;;10.1002/anie.202005657;;32392393;;10.1373/clinchem.2012.190686;;23322907;;27025866;;10.1039/c6lc00256k;;27281780;;10.1016/j.fertnstert.2016.05.008,"DE GEYTER ET AL.: ""2014: Results generated from European registries by ESHRE"", HUM REPROD, 2018;;OSEGUERA-LOPEZ ET AL.: ""S. Novel Techniques of Sperm Selection for Improving IVF and ICSI Outcomes"", FRONT CELL DEV BIOL, 2019;;PEREZ-CEREZALES ET AL.: ""The oviduct: From sperm selection to the epigenetic landscape of the embryo"", BIOL REPROD, 2018;;SAKKAS ET AL.: ""What can we learn from Mother Nature to improve assisted reproduction outcomes?"", HUM REPROD, 2015;;DOUGLAS ET AL.: ""A novel approach to improving the reliability of manual semen analysis: A paradigm shift in the workup of infertile men"", WORLD J MENS HEALTH, 2019;;LEVINE ET AL.: ""temporal trends in sperm count: A systematic review and meta-regression analysis"", HUM REPROD, 2017;;WANGSWERDLOFF: ""Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests"", FERTIL STERIL, 2014;;SHUKLA ET AL.: ""Automated analysis of rat sperm motility in microchannels"", BIOMED PHYS ENG EXPRESS, 2018, pages 4;;TALARCZYK-DESOLE ET AL.: ""Manual vs. computer-assisted sperm analysis: Can CASA replace manual assessment of human semen in clinical practice?"", GINEKOL POL, 2017, pages 88;;ALVAREZ ET AL.: ""Centrifugation of human spermatozoa induces sublethal damage; separation of human spermatozoa from seminal plasma by a dextran swim-up procedure without centrifugation extends their motile lifetime"", HUM REPROD, 1993;;FERNANDEZ-GONZALEZ ET AL.: ""Long-term effects of mouse intracytoplasmic sperm injection with DNA-fragmented sperm on health and behavior of adult offspring"", BIOL REPROD, 2008;;CLARK ET AL.: ""Acoustic trapping of sperm cells from mock sexual assault samples"", FORENSIC SCI INT GENET, 2019, pages 41;;SCHIFFER ET AL.: ""Rotational motion and rheotaxis of human sperm do not require functional CatSper channels and transmembrane Ca2+ signaling"", EMBO J, 2020;;XU ET AL.: ""agnetic Micromotors for Multiple Motile Sperm Cells Capture, Transport, and Enzymatic Release"", ANGEW CHEMIE - INT ED, 2020, pages 59;;CHEN, CHEN ET AL.: ""Direct characterization of motion-dependent parameters of sperm in a microfluidic device: Proof of principle"", CLIN CHEM, 2013;;DE WAGENAAR ET AL.: ""Towards microfluidic sperm refinement: Impedance-based analysis and sorting of sperm cells"", LAB CHIP, 2016, pages 16;;DE WAGENAAR ET AL.: ""Spermometer: electrical characterization of single boar sperm motility"", FERTIL STERIL, 2016, pages 106",PENDING
371,AU,A1,AU 2023/229574 A1,096-790-774-056-908,2023-10-05,2023,AU 2023/229574 A,2023-09-15,AU 2023/229574 A;;AU 2020/234406 A;;KR 20190028069 A;;KR 20190134094 A;;KR 20190134095 A;;KR 2020003411 W,2019-03-12,MICROFLUIDIC SYSTEM FOR INTRACELLULAR DELIVERY OF MATERIALS AND METHOD THEREFOR,"WO 2020/184992 PCT/KR2020/003411 There is provided a microfluidic system delivering external materials into a cell by cell mechanoporation using inertia, the microfluidic system including a fluidic channel structure through which a solution containing a cell and external materials flows continuously, in which the fluidic channel structure includes a junction between one or more channels, a localized vortex is generated near an interface of the junction, the cell is deformed by the vortex, and transient discontinuities are generated in a cell membrane by the vortex and the external materials are introduced into the cell by solution exchange between the cell and fluid around the cell.",MXT BIOTECH,CHUNG ARAM;;KANG GUM-YOUNG;;HUR JEONG SOO,,https://lens.org/096-790-774-056-908,Patent Application,no,0,0,9,096-790-774-056-908;;157-614-637-845-300;;082-793-049-954-233;;157-574-542-535-066;;037-551-344-657-81X;;180-723-113-124-234;;090-125-859-924-606;;058-435-618-856-570;;043-014-864-297-188,AU;;JP;;EP;;CN;;WO;;US,15,087-398-948-678-30X;;082-793-049-954-233;;096-790-774-056-908;;037-551-344-657-81X;;043-014-864-297-188;;157-614-637-845-300;;157-574-542-535-066;;024-118-496-642-378;;139-814-893-133-277;;180-723-113-124-234;;090-125-859-924-606;;038-969-224-010-709;;189-668-374-060-388;;192-739-981-521-282;;058-435-618-856-570,KR;;JP;;AU;;CN;;EP;;WO;;US;;CA,0,B01L3/502761;;B01L2200/0652;;B01L2400/0487;;C12M23/16;;C12M33/10;;C12M35/04;;C12M41/40;;C12M29/14;;C12M23/16;;C12M27/02;;C12M29/14;;C12M33/10;;C12M41/40,B01L3/00,,0,0,,,,DISCONTINUED
372,US,A1,US 2022/0177819 A1,037-551-344-657-81X,2022-06-09,2022,US 202017437984 A,2020-03-11,KR 20190028069 A;;KR 20190134094 A;;KR 20190134095 A;;KR 2020003411 W,2019-03-12,MICROFLUIDIC SYSTEM FOR INTRACELLULAR DELIVERY OF MATERIALS AND METHOD THEREFOR,"There is provided a microfluidic system delivering external materials into a cell by cell mechanoporation using inertia, the microfluidic system including a fluidic channel structure through which a solution containing a cell and external materials flows continuously, in which the fluidic channel structure includes a junction between one or more channels, a localized vortex is generated near an interface of the junction, the cell is deformed by the vortex, and transient discontinuities are generated in a cell membrane by the vortex and the external materials are introduced into the cell by solution exchange between the cell and fluid around the cell.",MXT BIOTECH,CHUNG ARAM;;KANG GEOUM-YOUNG;;HUR JEONG-SOO,KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (2021-09-08);;MXT BIOTECH (2022-03-15),https://lens.org/037-551-344-657-81X,Patent Application,yes,4,2,9,096-790-774-056-908;;157-614-637-845-300;;082-793-049-954-233;;157-574-542-535-066;;037-551-344-657-81X;;180-723-113-124-234;;090-125-859-924-606;;058-435-618-856-570;;043-014-864-297-188,AU;;JP;;EP;;CN;;WO;;US,15,087-398-948-678-30X;;082-793-049-954-233;;096-790-774-056-908;;037-551-344-657-81X;;043-014-864-297-188;;157-614-637-845-300;;157-574-542-535-066;;024-118-496-642-378;;139-814-893-133-277;;180-723-113-124-234;;090-125-859-924-606;;038-969-224-010-709;;189-668-374-060-388;;192-739-981-521-282;;058-435-618-856-570,KR;;JP;;AU;;CN;;EP;;WO;;US;;CA,0,B01L3/502761;;B01L2200/0652;;B01L2400/0487;;C12M23/16;;C12M33/10;;C12M35/04;;C12M41/40;;C12M29/14;;C12M23/16;;C12M27/02;;C12M29/14;;C12M33/10;;C12M41/40,C12M3/06;;C12M1/00;;C12M1/06;;C12M1/26;;C12M1/34,,0,0,,,,PENDING
373,US,A1,US 2022/0249642 A1,008-471-920-863-709,2022-08-11,2022,US 202017617690 A,2020-06-09,FR 1906208 A;;FR 2020050975 W,2019-06-11,Combination of Markers for Predicting the Response to Vx-001,"The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.",VAXON BIOTECH,KOSMATOPOULOS KOSTANTINOS (KOSTAS);;MENEZ-JAMET JEANNE,KRIPTIC PHARMACEUTICALS LIMITED (2023-02-11);;VAXON BIOTECH (2020-06-25),https://lens.org/008-471-920-863-709,Patent Application,yes,1,0,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;088-557-857-182-167;;075-787-912-294-121;;114-476-409-259-243;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,17,101-129-685-353-481;;094-386-523-629-436;;126-708-672-769-000;;097-432-227-560-706;;008-471-920-863-709;;035-920-971-458-658;;075-787-912-294-121;;114-476-409-259-243;;088-557-857-182-167;;095-811-519-008-224;;155-836-565-806-433;;183-974-752-783-709;;081-212-639-641-312;;158-863-792-289-803;;060-884-668-647-81X;;115-911-824-759-253;;054-361-143-721-300,JP;;AU;;HU;;US;;CA;;MX;;BR;;PL;;KR;;EP;;CN;;ES;;WO;;FR,2,A61K39/001157;;A61P35/00;;G01N33/50;;G01N2800/52;;G01N2333/9108;;G01N2333/904;;A61K2039/70;;A61P35/00;;A61K2039/57;;A61K2039/572;;A61K2039/812;;A61K2039/852;;A61K39/001157;;A61K2039/70;;A61K2039/54;;G01N2800/52;;G01N2333/91085;;G01N2333/904;;A61K39/001157;;A61P35/00;;A61K2039/86;;A61K2039/54;;A61K2039/57;;A61K2039/572;;A61K2039/70;;A61K2039/812;;A61K2039/852;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52;;A61K38/08;;A61P35/00;;A61K39/001157;;A61K2039/54;;A61K2039/572;;A61K2039/70;;G01N33/50;;G01N2333/904;;G01N2333/9108;;G01N2333/91085;;G01N2800/52,A61K39/00;;A61P35/00;;G01N33/50,,6,6,133-044-709-885-190;;021-001-695-775-343;;002-153-177-723-969;;023-807-389-777-602;;043-651-911-590-89X;;039-447-741-600-211,10.1016/j.vaccine.2017.09.011;;28893481;;10.5306/wjco.v11.i2.53;;pmc7046919;;32133275;;10.1080/14737159.2019.1579644;;30722710;;10.1016/j.cllc.2013.02.001;;23647738;;10.1016/j.lungcan.2014.07.018;;25130084;;29137398;;pmc5663570;;10.18632/oncotarget.20233,"Kailashiya C. et al. Telomerase based anticancer immunotherapy and vaccines approaches. Vaccine. 2017 (Year: 2017);;Aykan NF. et al. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol. 2020 (Year: 2020);;Bozkaya, Y. et al. Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer. Expert Review of Molecular Diagnostics. 2019 (Year: 2019);;Georgoulias, V. et al. A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics. Clin Lung Cancer (2013) (Year: 2013);;Kotsakis A. et al. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 2014 (Year: 2014);;Lin, G. et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017 (Year: 2017)",PENDING
374,WO,A1,WO 2023/049396 A1,010-599-436-268-849,2023-03-30,2023,US 2022/0044601 W,2022-09-23,US 202163247800 P,2021-09-23,METHODS AND DEVICES FOR SAMPLING BODILY FLUIDS,"In an embodiment, the present disclosure pertains to a method of detecting specific sequences of cell-free DNA (cfDNA) from a biological sample. In an additional embodiment, the present disclosure pertains to a dipstick for capturing cfDNA from a biological sample. In a further embodiment, the present disclosure pertains to a method for at-home isolation of cfDNA from raw biological fluids. In another embodiment, the present disclosure pertains to a method for identifying optimal diagnostic toehold-mediated DNA strand displacement (TMSD) probing sites for sequence detection. In other embodiments, the present disclosure pertains to a system for visual detection of microbial cfDNA from raw biological fluids.",AMA BIOTECH,MIHAILOVIC MIA;;AMADOR PAUL;;MIHELIC SAMUEL,,https://lens.org/010-599-436-268-849,Patent Application,yes,2,0,2,183-518-072-959-361;;010-599-436-268-849,WO;;US,2,183-518-072-959-361;;010-599-436-268-849,WO;;US,12,C12N15/1006;;B01L3/5029;;C12Q1/6806;;B01L3/5029;;C12N15/1006;;C12Q1/6806,G01N1/40;;B01L3/00;;C12N15/10;;C12Q1/6844;;G01N33/50,,0,0,,,,PENDING
375,EP,A2,EP 4289962 A2,029-815-409-073-468,2023-12-13,2023,EP 22750032 A,2022-02-04,KR 20210016012 A;;KR 2022001731 W,2021-02-04,COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM-DERIVED POLYSACCHARIDE OR EXTRACT,"The present invention relates to a composition including Lactobacillus plantarum-derived polysaccharide or extract, and more specifically, by including the Lactobacillus plantarum-derived polysaccharide or the Lactobacillus plantarum extract, may exhibit inflammatory inhibition, adipogenesis inhibition, intracellular glucose absorption inhibition, insulin resistance reduction and hepatic steatosis reduction effects, and may exhibit effects of treating or preventing a metabolic disease.",NEOREGEN BIOTECH,SEO JEONG MIN;;LEE JAE HOON,,https://lens.org/029-815-409-073-468,Patent Application,yes,0,1,5,005-146-690-760-836;;029-815-409-073-468;;003-062-187-785-760;;189-472-759-321-468;;073-656-819-415-424,KR;;CN;;EP,10,026-134-353-184-739;;005-146-690-760-836;;147-815-073-378-708;;189-848-492-967-472;;073-656-819-415-424;;186-166-729-431-389;;189-472-759-321-468;;174-915-703-153-202;;029-815-409-073-468;;003-062-187-785-760,JP;;KR;;CN;;EP;;WO;;US,30,C12P19/04;;A23L33/135;;A23L33/125;;A23V2200/3262;;A23V2200/328;;A23V2200/332;;A23V2400/169;;A23V2200/324;;A61K35/747;;A61P3/00;;A61K35/747;;A61K31/7004;;A61P3/10;;A61P3/06;;A61P1/16;;A61P3/04;;A61P29/00;;A23L33/135;;A23V2002/00;;A23V2200/328;;A23V2200/3262;;A23V2200/332;;A23V2200/324;;A23V2400/169,C12P19/04;;A23L33/125;;A61K31/7004;;A61K31/715;;A61K35/747;;A61P1/16;;A61P3/00;;A61P29/00;;C12N1/20;;C12R1/25,,0,0,,,,PENDING
376,EP,A1,EP 4084800 A1,054-112-170-551-602,2022-11-09,2022,EP 20829530 A,2020-12-28,FR 1915796 A;;EP 2020087936 W,2019-12-31,COMPOSITION FOR WEIGHT MANAGEMENT OF A SUBJECT,,MRS BIOTECH,MARÇAIS OLIVIER,,https://lens.org/054-112-170-551-602,Patent Application,yes,0,0,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,0,A61K31/728;;A61K9/0019;;A61K31/715;;A61K31/722;;A61K45/06;;A61K47/02;;A61K47/26;;A61K47/38;;A61K31/728;;A61K9/0019;;A61K45/06,A61K31/728;;A61K9/00;;A61K31/715;;A61K31/722;;A61P3/04,,1,0,,,See references of WO 2021148229A1,PENDING
377,IT,A1,IT 202000009478 A1,061-107-647-950-289,2021-10-30,2021,IT 202000009478 A,2020-04-30,IT 202000009478 A,2020-04-30,Dispositivo di protezione individuale perfezionato e unità filtrante.,,BIOTECH SRL,MANFRE' BERNARDO,,https://lens.org/061-107-647-950-289,Patent Application,no,5,0,1,061-107-647-950-289,IT,1,061-107-647-950-289,IT,0,A62B18/025;;A61L9/20;;A62B23/00,A62B/,,0,0,,,,PENDING
378,EP,A1,EP 4431498 A1,080-044-373-818-996,2024-09-18,2024,EP 22890496 A,2022-01-04,KR 20210152376 A;;KR 2022095004 W,2021-11-08,NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF,The present disclosure pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present disclosure can be used to treat NADPH oxidase (NOX)-related diseases through an excellent NOX inhibitory effect.,CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,,https://lens.org/080-044-373-818-996,Patent Application,yes,0,0,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,0,A61K31/4245;;A61K31/495;;A61K45/06;;A61P25/28;;A61P35/00;;C07D271/113;;C07D413/10;;C07D413/04;;C07D413/14;;C07D271/06;;C07D271/113;;A61K31/4245;;A61P25/00;;C07D413/10;;A61P35/00;;A61K31/4245;;A61K45/06;;C07D271/113;;C07D413/10,C07D271/113;;A61K31/4245;;A61K31/495;;A61K45/06;;A61P25/28;;A61P35/00;;C07D413/10,,0,0,,,,PENDING
379,WO,A1,WO 2021/255021 A1,106-838-925-865-923,2021-12-23,2021,EP 2021066103 W,2021-06-15,FR 2006244 A,2020-06-16,SYSTEM FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLE FOR DISTINGUISHING SPECIFIC SEROLOGICAL ANTIBODIES OF AN INFECTIOUS AGENT PRESENT IN THE BIOLOGICAL SAMPLE,"The present invention relates to a system for rapid analysis of a biological sample for distinguishing specific serological antibodies of an infectious agent present in the biological sample. The rapid analysis system (1) comprises at least one chromatographic strip (2) comprising different consecutive zones, namely: - a release zone (4) comprising at least one detection reagent (41, 42) and - at least one capture zone (5) comprising at least one capture reagent (51, 52) immobilised on the chromatographic strip (2). The combination of detection reagents (41, 42)/capture reagents (51, 52) is selected from combinations of detection reagents (41, 42)/capture reagents (51, 52) suitable for distinguishing at least two groups of serological antibodies: - a first group of serological antibodies (A1), referred to as 'neutralising antibodies', which comprise the specific serological antibodies of the infectious agent and are capable of neutralising, or at least reducing, the infectivity of the infectious agent, and - a second group of serological antibodies (A2), referred to as 'non-neutralising antibodies', which comprise the specific serological antibodies of the infectious agent and are different from the antibodies belonging to the first group of serological antibodies (A1).",NG BIOTECH,STANKOV MILOVAN,,https://lens.org/106-838-925-865-923,Patent Application,yes,3,0,2,106-838-925-865-923;;113-001-325-919-376,WO;;FR,2,106-838-925-865-923;;113-001-325-919-376,WO;;FR,0,G01N33/52;;G01N33/543;;G01N33/54388;;G01N33/56983;;G01N2333/165,G01N33/52;;G01N33/543;;G01N33/558;;G01N33/569,,10,6,034-914-541-248-215;;040-851-635-207-678;;075-495-112-026-570;;024-604-669-146-49X;;030-869-269-245-190;;043-021-132-202-150,33563967;;pmc7249039;;10.1038/s41420-020-0275-2;;32501411;;32704169;;10.21203/rs.3.rs-24574/v1;;10.1038/s41587-020-0631-z;;pmc7273274;;10.1101/2020.05.27.20114652;;32511506;;32391022;;10.3389/fimmu.2020.00879;;pmc7194125;;32479758;;pmc7256507;;10.1016/j.jaci.2020.05.020;;15054081;;pmc7108132;;10.1373/clinchem.2004.031096,"MARZIA NUCCETELLI ET AL: ""SARS-CoV-2 infection serology: a useful tool to overcome lockdown?"", CELL DEATH DISCOVERY, vol. 6, no. 1, 26 May 2020 (2020-05-26), XP055767362, ISSN: 2058-7716, DOI: 10.1038/s41420-020-0275-2;;TAN CHEE WAH ET AL: ""A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction"", RESEARCH SQUARE, 23 April 2020 (2020-04-23), pages 1 - 15, XP055781210, Retrieved from the Internet <URL:https://www.researchsquare.com/article/rs-24574/v1> [retrieved on 20210302], DOI: 10.21203/rs.3.rs-24574/v1;;JAMES R BYRNES ET AL: ""A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding"", MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES, 29 May 2020 (2020-05-29), XP055769216, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.05.27.20114652v1.full.pdf> [retrieved on 20210127], DOI: 10.1101/2020.05.27.20114652;;CHERYL YI-PIN LEE ET AL: ""Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control"", FRONTIERS IN IMMUNOLOGY, vol. 11, 24 April 2020 (2020-04-24), pages 879, XP055737286, DOI: 10.3389/fimmu.2020.00879;;ÖZÇÜRÜMEZ MUSTAFA K ET AL: ""SARS-CoV-2 antibody testing-questions to be asked"", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 146, no. 1, 29 May 2020 (2020-05-29), pages 35 - 43, XP086207350, ISSN: 0091-6749, [retrieved on 20200529], DOI: 10.1016/J.JACI.2020.05.020;;""GenBank"", Database accession no. MN908947;;CHEN Z ET AL., CLIN CHEM, vol. 50, 2004, pages 988 - 95;;ZHOU P ET AL., NATURE, 2020;;LU R, LANCET, vol. 395, 2020, pages 565 - 74;;HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",PENDING
380,KR,A,KR 20220125896 A,099-947-121-557-408,2022-09-15,2022,KR 20210029620 A,2021-03-05,KR 20210029620 A,2021-03-05,Composition for detecting Listeria Monocytogenes and kit comprising same,"The present invention relates to a composition for detecting Listeria monocytogenes, which comprises a primer set consisting of nucleotide sequences of SEQ ID NOs: 1 to 6, a kit for detecting Listeria monocytogenes comprising the same, and a method for detecting Listeria monocytogenes using the same. The composition for detecting the Listeria monocytogenes of the present invention has an effect of specifically detecting and diagnosing only the Listeria monocytogenes from Listeria bacteria.",BOREDA BIOTECH,CHOI DONG OK;;YOON MI JIN,,https://lens.org/099-947-121-557-408,Patent Application,no,2,0,1,099-947-121-557-408,KR,1,099-947-121-557-408,KR,14,C12Q1/689;;C12Q1/6804;;C12Q2527/101;;C12Q2565/625;;G01N33/56911;;G01N2458/10,C12Q1/689;;C12Q1/6804;;G01N33/569,,0,0,,,,DISCONTINUED
381,WO,A1,WO 2021/058477 A1,143-738-056-402-866,2021-04-01,2021,EP 2020076426 W,2020-09-22,FR 1910501 A,2019-09-24,"BANDING DEVICE, IN PARTICULAR FOR STABILISING A PERIPROSTHETIC FRACTURE","The present invention relates to an implantable banding device (600) comprising an elongated hollow textile element (500) which comprises an attachment portion (540) and an adjustable loop (510) the perimeter of which is adjustable by sliding a portion of the adjustable loop (510) into an interior space of a sleeve (530) arranged in the textile element (500), and a member for closing the banding (100) which comprises a front portion to which the adjustable loop (510) or the attachment portion (540) is connected, and a rear portion comprising a first U-shaped recess (170, 180) configured to receive part of the attachment portion (540) or part of the adjustable loop (510). The banding device (600) thus comprises a position in which the banding is tightened by sliding the adjustable loop (510) into the sleeve (530) and a locking position in which sliding of the adjustable loop (510) is prevented by the sleeve (530). The present invention also relates to an osteosynthesis device comprising the banding device (600).",COUSIN BIOTECH,NOEL STEPHANE;;OUERGHEMMI SAFA,,https://lens.org/143-738-056-402-866,Patent Application,yes,10,0,6,031-436-170-927-143;;172-725-303-782-499;;188-116-875-532-695;;143-738-056-402-866;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,6,031-436-170-927-143;;172-725-303-782-499;;143-738-056-402-866;;188-116-875-532-695;;043-850-336-999-665;;162-607-064-867-160,EP;;WO;;US;;FR,0,A61B17/82;;A61B17/82,A61B17/82,,1,1,106-834-460-375-562,31326103;;10.1016/j.injury.2019.06.034,"I. PEETERSA. DEPOVERA. VAN TONGELL. DE WILDE: ""A review of metallic and non-metallic cerclage in orthopaedic surgery: Is there still a place for metallic cerclage ?"", INJURY, vol. 0, no. 0, July 2019 (2019-07-01)",PATENTED
382,US,A1,US 2025/0051293 A1,156-352-092-558-710,2025-02-13,2025,US 202218708461 A,2022-01-04,KR 20210152376 A;;KR 2022095004 W,2021-11-08,NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF,The present disclosure pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present disclosure can be used to treat NADPH oxidase (NOX)-related diseases through an excellent NOX inhibitory effect.,CELROS BIOTECH,BAE YUN SOO;;JEONG DA UN,CELROS BIOTECH (2024-05-07),https://lens.org/156-352-092-558-710,Patent Application,yes,0,0,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,8,105-229-926-251-480;;080-044-373-818-996;;084-165-062-236-362;;076-579-387-085-400;;156-352-092-558-710;;022-513-934-606-463;;061-500-031-815-450;;132-341-914-065-460,JP;;KR;;EP;;CN;;WO;;US,0,A61K31/4245;;A61K31/495;;A61K45/06;;A61P25/28;;A61P35/00;;C07D271/113;;C07D413/10;;C07D413/04;;C07D413/14;;C07D271/06;;C07D271/113;;A61K31/4245;;A61P25/00;;C07D413/10;;A61P35/00;;A61K31/4245;;A61K45/06;;C07D271/113;;C07D413/10,C07D271/113;;A61K31/4245;;A61K45/06;;A61P35/00;;C07D413/10,,0,0,,,,PENDING
383,KR,A,KR 20230149643 A,173-066-688-838-907,2023-10-27,2023,KR 20220049112 A,2022-04-20,KR 20220049112 A,2022-04-20,Composition for promoting hair growth containing a compound isolated from hydrolyzed and fermented sea urchin shells as an active ingredient,"The present invention relates to a composition for promoting hair growth comprising as an active ingredient a compound isolated from a hydrolyzed and fermented of sea urchin shells. According to the invention, the composition has an effect of promoting hair growth by increasing the production of hair growth inducing factors as well as proliferating hair follicle cells. The composition of the invention can therefore be used in various fields such as pharmacy, cosmetics, food, quasi-drugs and cosmetology.",SUNMARINE BIOTECH,PARK SI HYANG;;CHOI YEUNG JUN;;KIM YE RA;;PARK SU JIN;;JEONG JI HYEON,,https://lens.org/173-066-688-838-907,Patent Application,no,5,0,2,056-405-706-931-067;;173-066-688-838-907,KR,2,056-405-706-931-067;;173-066-688-838-907,KR,0,A61K31/426;;A61K35/616;;A61P17/14;;A23L33/10;;A61K8/49;;A61Q7/00;;A23V2002/00;;A23V2250/2042;;A23V2250/30,A61K31/426;;A23L33/10;;A61K8/49;;A61K35/616;;A61P17/14;;A61Q7/00,,0,0,,,,ACTIVE
384,IT,A1,IT 202100026054 A1,184-304-119-063-355,2023-04-12,2023,IT 202100026054 A,2021-10-12,IT 202100026054 A,2021-10-12,"Unità filtrante perfezionata, in particolare per dispositivi di protezione individuale, e dispositivo di protezione individuale provvisto di tale unità filtrante.",,BIOTECH SRL,MANFRE' BERNARDO,,https://lens.org/184-304-119-063-355,Patent Application,no,2,0,1,184-304-119-063-355,IT,1,184-304-119-063-355,IT,0,A62B19/00;;A62B23/02,A62B/,,0,0,,,,PENDING
385,FR,A1,FR 3142079 A1,185-137-173-008-972,2024-05-24,2024,FR 2212115 A,2022-11-21,FR 2212115 A,2022-11-21,Guide chirurgical pour la pose d’implants dentaires,"L’invention concerne un guide (1) chirurgical pour la pose d’implants dentaires, comprenant une base (2) apte à être fixée à l’os maxillaire ou mandibulaire, une gouttière (3) apte à être fixée à la base (2) et à être positionnée dans l’espace par rapport au référentiel dent ou anatomie restant en bouche, et un guide de perçage (4) apte à être fixé à la base (2) et comprenant au moins un alésage (5) de guidage d’un foret. Figure d’abrégé : Figure 1",BIOTECH DENTAL,KELLER PIERRE,,https://lens.org/185-137-173-008-972,Patent Application,no,6,0,4,133-402-258-255-671;;029-804-011-916-038;;169-200-571-166-553;;185-137-173-008-972,EP;;US;;FR,4,133-402-258-255-671;;029-804-011-916-038;;169-200-571-166-553;;185-137-173-008-972,EP;;US;;FR,0,A61C1/084;;A61C1/085;;A61C8/0089;;A61C13/087;;A61C13/26;;B33Y80/00;;A61C13/225;;A61C8/005;;A61C1/084;;A61C8/0068;;A61C8/0089;;A61C2201/00,A61C1/08;;A61C8/00,,0,0,,,,PENDING
386,US,A1,US 2021/0052772 A1,053-308-548-907-374,2021-02-25,2021,US 201917050063 A,2019-04-05,FR 1853737 A;;FR 2019050803 W,2018-04-27,IMPLANTABLE DEVICE COMPRISING A TEXTILE COMPONENT COMPRISING MULTIFILAMENT YARNS AND/OR SPUN YARNS MADE OF FIBERS COMPLETELY OR PARTIALLY COATED IN CYCLODEXTRIN POLYMER,"The present invention relates to an implantable device comprising a textile component at least partially coated with a host polymer coating, said host polymer coating comprises a polymer of cyclodextrin(s) and/or derivatives of cyclodextrin(s) and/or inclusion complex(es) of cyclodextrin and/or inclusion complex(es) of cyclodextrin derivatives. Advantageously, said textile component comprises multifilament yarns and/or spun yarns made of fibers, at least a part of the filaments and/or fibers each having a diameter less than or equal to 25 micrometers.",COUSIN BIOTECH,VERMET GUILLAUME;;MARTEL BERNARD;;BLANCHEMAIN NICOLAS;;DEGOUTIN STÉPHANIE,COUSIN BIOTECH (2020-12-21),https://lens.org/053-308-548-907-374,Patent Application,yes,5,1,7,053-308-548-907-374;;112-913-282-239-076;;139-461-547-392-590;;187-182-390-874-290;;064-793-778-008-949;;119-792-058-090-103;;197-537-156-836-512,ES;;EP;;WO;;US;;FR,7,053-308-548-907-374;;112-913-282-239-076;;139-461-547-392-590;;187-182-390-874-290;;064-793-778-008-949;;119-792-058-090-103;;197-537-156-836-512,ES;;EP;;WO;;US;;FR,0,A61L27/54;;C08L5/16;;C09D105/16;;A61L27/34;;A61L27/16;;A61L27/54;;A61L2300/402;;A61L2300/406;;A61L2420/02;;A61L2420/06;;C08L5/16;;D01F8/14;;D01F8/16;;D02G3/045;;D02G3/448,A61L27/34;;A61L27/16;;A61L27/54;;C08L5/16;;D01F8/14;;D01F8/16;;D02G3/04;;D02G3/44,,1,0,,,"Cytodiagnostics, Stabilized Gold Nanoparticles, accessed 3/23/2023, pgs. 1-4 (Year: 2023)",DISCONTINUED
387,MX,A,MX 2023012232 A,117-367-185-959-916,2023-11-22,2023,MX 2023012232 A,2022-04-15,US 202163175603 P;;US 2022/0024946 W,2021-04-16,HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE.,"In one aspect, the present disclosure is directed to a method for preventing or treating alcoholic liver disease or grafi-versus-host disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmimized egg product obtained from an egg- producing animal, thereby preventing or treating the alcoholic liver disease or the graft-versus-host disease in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to an antigen selected from the group consisting of Enterococcus faecaUs, Enterococcus faecalis eytolysin toxin, and Enterococcus faecium. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from the group consisting of Enterococcus faecalis. isolated Enterococcus faecal is eytolysin toxin, and Enterococcus faecium. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.",PRODIGY BIOTECH,IYER SUBRAMANIAN V;;PATEL SUNNY,,https://lens.org/117-367-185-959-916,Patent Application,no,0,0,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,19,117-684-166-669-904;;014-153-327-755-348;;133-243-914-617-808;;159-571-927-560-341;;004-354-052-341-514;;042-752-952-137-131;;084-546-024-256-441;;134-869-970-778-682;;117-367-185-959-916;;069-229-429-924-855;;141-325-916-412-450;;139-259-298-221-07X;;159-616-868-022-776;;106-998-188-340-301;;097-627-962-816-173;;122-898-617-556-701;;132-243-120-561-850;;181-648-379-329-826;;084-793-644-582-609,JP;;AU;;CL;;US;;CO;;CA;;MX;;BR;;PL;;KR;;EP;;IL;;CN;;ZA;;WO;;NZ,0,A61K35/57;;A61K2039/505;;A61K2039/507;;A61P1/16;;A61P37/06;;A61K35/57;;A61K2039/507;;A61K2039/505;;A61P1/16;;A61P37/06;;A61K35/57;;A61K39/40;;A61P1/16;;A61P37/06;;A61K2039/505;;A61P1/16;;A61K9/0053;;A61K2039/505;;A61K2039/545;;C07K16/02;;C07K16/1228;;C07K2317/11,A61K35/57;;A61P1/16;;A61P37/06,,0,0,,,,PENDING
388,EP,A1,EP 3810034 A1,070-098-005-354-797,2021-04-28,2021,EP 19737004 A,2019-06-21,FR 1855590 A;;EP 2019066522 W,2018-06-22,"ACELLULAR DERMAL MATRIX, IN PARTICULAR FOR A MAMMARY PROSTHESIS",,MECCELLIS BIOTECH,PERES ANTHONY;;HOFMANSKI GUILLAME;;LAMMELIN AURÉLIE,,https://lens.org/070-098-005-354-797,Patent Application,yes,0,0,6,139-547-900-762-909;;070-098-005-354-797;;120-385-487-064-832;;090-394-499-961-280;;156-613-870-734-649;;027-370-764-314-367,EP;;WO;;US;;BR;;FR,6,139-547-900-762-909;;090-394-499-961-280;;120-385-487-064-832;;070-098-005-354-797;;156-613-870-734-649;;027-370-764-314-367,EP;;WO;;US;;BR;;FR,0,A61F2/0063;;A61F2/0077;;A61F2/12;;A61L27/362;;A61L27/50;;A61L2430/04;;A61L27/3683;;A61L27/362;;A61L27/3683;;A61L27/50;;A61L2430/04,A61F2/10;;A61F2/12,,0,0,,,,ACTIVE
389,EP,A1,EP 4615363 A1,161-361-545-244-534,2025-09-17,2025,EP 23802276 A,2023-11-09,FR 2211649 A;;EP 2023081265 W,2022-11-09,"IMPLANTABLE ARTIFICIAL LIGAMENT, AND PROCESS FOR MANUFACTURING SUCH AN ARTIFICIAL LIGAMENT",,COUSIN BIOTECH,BECQUART LUCIE;;AUBERT FRANÇOIS;;NOEL STÉPHANE;;CAILLIBOTTE MICHEL,,https://lens.org/161-361-545-244-534,Patent Application,yes,0,0,3,096-263-089-243-508;;129-033-786-332-743;;161-361-545-244-534,EP;;WO;;FR,3,096-263-089-243-508;;129-033-786-332-743;;161-361-545-244-534,EP;;WO;;FR,0,A61F2/08;;A61F2240/001;;A61F2210/0071;;A61L27/50;;A61L2430/10;;A61L27/18,A61F2/08;;A61L27/18;;A61L27/50,,0,0,,,,PENDING
390,WO,A1,WO 2024/100177 A1,129-033-786-332-743,2024-05-16,2024,EP 2023081265 W,2023-11-09,FR 2211649 A,2022-11-09,"IMPLANTABLE ARTIFICIAL LIGAMENT, AND PROCESS FOR MANUFACTURING SUCH AN ARTIFICIAL LIGAMENT","The present invention relates to an artificial ligament (10) comprising an elongate braided hollow sheath (20) having an inner volume and a deformable insert (30) accommodated in the inner volume over at least part of the length of the sheath. The insert is elastic, thus delaying the rigid deformation phase of the artificial ligament (10) when a longitudinal tensile force is applied thereto.",COUSIN BIOTECH,BECQUART LUCIE;;AUBERT FRANÇOIS;;NOEL STÉPHANE;;CAILLIBOTTE MICHEL,,https://lens.org/129-033-786-332-743,Patent Application,yes,6,0,3,096-263-089-243-508;;129-033-786-332-743;;161-361-545-244-534,EP;;WO;;FR,3,096-263-089-243-508;;129-033-786-332-743;;161-361-545-244-534,EP;;WO;;FR,0,A61F2/08;;A61F2240/001;;A61F2210/0071;;A61L27/50;;A61L2430/10;;A61L27/18,A61F2/08;;A61L27/18;;A61L27/50,,0,0,,,,PENDING
391,EP,A1,EP 4574178 A1,068-034-657-178-990,2025-06-25,2025,EP 24221924 A,2024-12-19,FR 2314790 A,2023-12-21,METHOD FOR INDUCING AN IMPROVED MECHANICAL STRENGTH OF AN IMPLANTABLE DEVICE INCLUDING PLA WIRE(S) FOR A DETERMINED HYDROLYSIS AND IMPLANTABLE DEVICE OBTAINABLE THEREBY,"La présente invention a pour objet un procédé pour induire une amélioration de la résistance mécanique (N/cm) d'un dispositif implantable après une période déterminée d'hydrolyse, ledit procédé comprenant :i)- une étape de fourniture d'un dispositif implantable comprenant un ou des fil(s) comprenant au moins un (co)polymère d'acide lactique;ii)- une étape de traitement dudit dispositif implantable avec du dioxyde de carbone (CO<sub>2</sub>) supercritique ;iii)- une étape d'obtention d'un dispositif implantable ayant une résistance mécanique supérieure ou égale à 10 N/cm, de préférence supérieure ou égale à 25 N/cm, après 20 semaines d'hydrolyse, en particulier dans un milieu aqueux.La présente invention a également pour objet un dispositif implantable susceptible d'être obtenu par ledit procédé, et l'utilisation du (CO<sub>2</sub>) supercritique pour induire une amélioration de la résistance mécanique d'un dispositif implantable comprenant un ou des fil(s) comprenant un (co)polymère d'acide lactique.",COUSIN BIOTECH,SOLECKI GILLES;;OUERGHEMMI SAFA,,https://lens.org/068-034-657-178-990,Patent Application,yes,7,0,3,156-424-704-733-269;;068-034-657-178-990;;186-405-819-895-457,EP;;US;;FR,3,156-424-704-733-269;;068-034-657-178-990;;186-405-819-895-457,EP;;US;;FR,0,A61L27/58;;A61L27/18;;A61L2400/18;;A61F2/0063;;C08G63/08;;D01F6/625;;A61F2/0063;;A61F2002/0068;;A61F2210/0004;;A61F2240/001,A61L27/18;;A61F2/00;;A61L27/58;;C08L67/04,,1,0,,,TEXTILES - MONOFILAMENTS- DÉTERMINATION DES PROPRIÉTÉS EN TRACTION,PENDING
392,WO,A1,WO 2021/170916 A1,061-974-551-372-045,2021-09-02,2021,FR 2020051443 W,2020-08-06,FR 2001811 A,2020-02-24,POCKET REFILL COMPRISING MEANS FOR DEGASSING THE POCKET AND DISPENSER CASING COMPRISING SUCH A POCKET REFILL,"The invention relates to a pocket refill (100) and an associated dispenser casing, comprising a pocket (101) for containing an active liquid to be dispensed under pressure, a valve mechanism comprising a valve connected to a dispensing tube (103) inserted inside the pocket (101), a dome (104) supporting the valve mechanism and comprising a base (106) for attaching the pocket (101), characterised in that the refill (100) comprises means (4) for degassing the pocket (101), which degassing means comprise a hole for access inside the pocket (101) and a hydrophobic membrane (40) covering the access hole, the membrane (40) allowing the gas produced by the liquid to pass through when said liquid is under pressure.",VENTUM BIOTECH,KACHOU LOUFTI,,https://lens.org/061-974-551-372-045,Patent Application,yes,6,0,3,067-151-215-553-032;;176-687-061-163-310;;061-974-551-372-045,WO;;FR,3,067-151-215-553-032;;176-687-061-163-310;;061-974-551-372-045,WO;;FR,0,B65D83/62;;A61L2/18;;A61L2202/15;;A61L2202/181;;B65D83/38;;B65D83/70,B65D83/62;;A61L9/14;;B65D83/38;;B65D83/70,,0,0,,,,PENDING
393,CA,A1,CA 3163170 A1,099-451-519-736-669,2021-07-29,2021,CA 3163170 A,2020-12-28,FR 1915796 A;;EP 2020087936 W,2019-12-31,COMPOSITION FOR WEIGHT MANAGEMENT OF A SUBJECT,"The present application relates to a composition for managing the weight of a subject, wherein said composition comprises at least one high-viscosity, resorbable, biocompatible material, intended to be injected into the submucosal space of the digestive tract of a subject and thus to create a long-lasting raising of the corresponding mucosa. The present application also relates to a kit comprising a composition according to the invention and means for injecting the composition. Finally, the present application relates to the use of a composition according to the invention for managing the weight of a subject.",MRS BIOTECH,MARCAIS OLIVIER,,https://lens.org/099-451-519-736-669,Patent Application,no,0,0,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,7,138-108-042-954-128;;173-990-604-588-159;;018-201-178-272-017;;158-597-309-178-152;;054-112-170-551-602;;173-148-050-182-143;;099-451-519-736-669,CN;;EP;;WO;;US;;CA;;FR,0,A61K31/728;;A61K31/722;;A61K31/715;;A61K9/0019;;A61K47/26;;A61K47/38;;A61K47/02;;A61K45/06;;A61K9/0019;;A61K31/728;;A61K45/06,A61K31/728;;A61K31/722;;A61P3/04,,0,0,,,,PENDING
394,KR,A,KR 20250009896 A,131-448-037-572-463,2025-01-20,2025,KR 20240036020 A,2024-03-14,KR 20230089984 A,2023-07-11,COSMETIC COMPOSITION FOR REDUCING SKIN PORE COMPRISING EXTRACT OF EUSCAPHIS JAPONICA OR ALNUS FIRMA AS ACTIVE INGREDIENT,"본 발명은 말오줌때나무 추출물 및 사방오리나무 추출물 중 어느 하나 이상을 유효성분으로 포함하는 화장료 조성물에 관한 것으로, 피부 모공 수축 효과가 우수하다는 장점이 있다.",SUNMARINE BIOTECH,PARK SI HYANG,,https://lens.org/131-448-037-572-463,Patent Application,no,1,0,1,131-448-037-572-463,KR,1,131-448-037-572-463,KR,0,A61K8/9789;;A61Q19/00;;A61Q19/08;;A61K2800/522;;A61K2800/782;;A61K2800/5922,A61K8/9789;;A61Q19/00;;A61Q19/08,,0,0,,,,PENDING
395,GB,D0,GB 202305826 D0,138-259-362-941-287,2023-06-07,2023,GB 202305826 A,2023-04-20,GB 202305826 A,2023-04-20,Oocyte screening,,BEECH BIOTECH,,,https://lens.org/138-259-362-941-287,Patent Application,no,0,0,1,138-259-362-941-287,GB,1,138-259-362-941-287,GB,0,,,,0,0,,,,DISCONTINUED
396,KR,A,KR 20220076352 A,172-828-301-219-24X,2022-06-08,2022,KR 20210165460 A,2021-11-26,KR 20200163845 A,2020-11-30,PEPTIDE AND METHOD FOR MANFATURING THE SAME,"본 발명은 펩타이드 및 이의 제조방법에 관한 것으로, 기존에 알려진 세포 투과 펩타이드 보다 세포 투과 효율 및 생산 수율이 높은 것으로, 세포막의 투과가 용이하지 않은 물질들을 세포 내로 효율적으로 도입하여 질환의 치료 등에 적용할 수 있다.",NEOREGEN BIOTECH,SEO JEONG MIN,,https://lens.org/172-828-301-219-24X,Patent Application,no,2,0,2,078-474-771-533-273;;172-828-301-219-24X,KR,2,078-474-771-533-273;;172-828-301-219-24X,KR,20,C07K14/001;;C12N15/70;;C12N2511/00,C07K14/00;;C12N15/70,,0,0,,,,ACTIVE
397,FR,A1,FR 3109636 A1,152-515-271-631-539,2021-10-29,2021,FR 2004105 A,2020-04-24,FR 2004105 A,2020-04-24,Système et procédé pour l’analyse rapide grande capacité d’échantillons biologiques,"La présente invention concerne un système pour l’analyse rapide grande capacité d’échantillons biologiques (E), destiné à la détection de la présence d’au moins un analyte d’intérêt (A) dans lesdits échantillons biologiques (E). Le système d’analyse rapide comprend au moins les composants suivants : - une microplaque (2) comportant N puits (21), avantageusement 96 puits (21), qui sont adaptés à recevoir lesdits échantillons biologiques (E), - une solution tampon (3) conditionnée dans un premier contenant (4), laquelle solution tampon (3) est destinée à être rapportée dans plusieurs puits (21) et à être mélangée avec un échantillon biologique (E) pour la mise en œuvre d’une technique chromatographique, - des bandelettes chromatographiques (5) conditionnées dans un second contenant (6), avantageusement des bandelettes immunochromatographiques, lesquelles bandelettes chromatographiques (5) présentent une largeur (L1) qui est inférieure à la largeur (P1) d’un puits (21), de sorte à autoriser leur insertion individuelle et érigée dans un puits (21), lesquelles bandelettes chromatographiques (5) sont réalisées dans un matériau apte à rester érigé dans ledit puits (21) suite à la migration de la solution tampon (3). Figure pour l’abrégé : 1",NG BIOTECH,STANKOV MILOVAN;;STANKOV-PUGES MILOVAN,,https://lens.org/152-515-271-631-539,Patent Application,no,2,0,2,152-515-271-631-539;;181-399-139-674-95X,FR,2,152-515-271-631-539;;181-399-139-674-95X,FR,0,G01N33/54388,G01N33/558;;G01N33/569,,3,2,030-539-404-436-730;;063-661-692-191-171,10.1016/j.foodcont.2010.12.003;;10.1016/j.jhazmat.2020.122348;;32143157,"JING-JHIH WANG ET AL: ""Sensitive competitive direct enzyme-linked immunosorbent assay and gold nanoparticle immunochromatographic strip for detecting aflatoxin M1 in milk"", FOOD CONTROL, BUTTERWORTH, LONDON, GB, vol. 22, no. 6, 4 December 2010 (2010-12-04), pages 964 - 969, XP028128497, ISSN: 0956-7135, [retrieved on 20101215], DOI: 10.1016/J.FOODCONT.2010.12.003;;ZHANG WANJUN ET AL: ""Multiplex SERS-based lateral flow immunosensor for the detection of major mycotoxins in maize utilizing dual Raman labels and triple test lines"", JOURNAL OF HAZARDOUS MATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 393, 19 February 2020 (2020-02-19), XP086148430, ISSN: 0304-3894, [retrieved on 20200219], DOI: 10.1016/J.JHAZMAT.2020.122348;;HANSEN T.M., IVD TECHNOLOGY, vol. 4, 2003, pages 35 - 40",ACTIVE
398,FR,A1,FR 3102072 A1,155-480-105-741-195,2021-04-23,2021,FR 1911766 A,2019-10-21,FR 1911766 A,2019-10-21,Procédé et dispositif de séparation des trichomes du chanvre,"Procédé de séparation des trichomes de plantes de chanvre comprenant les étapes : a) fourniture d’un dispositif de séparation (1) comprenant : - un bâti (2), - au moins un tambour (3) monté rotatif par rapport au bâti (2), dont la paroi périphérique (31) est constituée d’un tamis (32), - un circuit de recirculation et de tri (4), b) mise en rotation du tambour (3) par rapport au bâti (2), c) insertion de pellets de glace carbonique dans le tambour (3), d) insertion de plantes de chanvre dans le tambour (3), e) réception de la matière en sortie du tambour (3), f) tri de la matière réceptionnée en sortie du tambour (3) puis amenée des pellets de glace carbonique en entrée du tambour (3), g) évacuation des trichomes, dans lequel les étapes b) à g) sont effectuées simultanément et en continu au cours du procédé. Figure pour l’abrégé : Figure 1",ELICAN BIOTECH,MEXMAIN GÉRALD,,https://lens.org/155-480-105-741-195,Patent Application,no,3,0,4,155-480-105-741-195;;076-552-631-125-356;;028-744-306-086-58X;;090-537-718-423-673,EP;;FR;;MA,4,155-480-105-741-195;;076-552-631-125-356;;028-744-306-086-58X;;090-537-718-423-673,EP;;FR;;MA,0,B07B1/26;;A61K36/185;;A61K2236/00,B07B1/22;;A61K36/185;;B07B1/46,,0,0,,,,INACTIVE
399,US,A1,US 2024/0164906 A1,183-335-424-671-299,2024-05-23,2024,US 202318516353 A,2023-11-21,FR 2212116 A,2022-11-21,NEW GUIDED BONE REGENERATION DEVICE,"A device for guided bone regeneration includes a custom-made covering plate that covers a bone defect, whose shape allows for the surface of the bone to be restored as it was prior to the appearance of the bone defect. The covering plate rests on the healthy bone surrounding the bone defect and is made of grade 1 or grade 2 titanium.",BIOTECH DENTAL,KELLER PIERRE,BIOTECH DENTAL (2023-12-05),https://lens.org/183-335-424-671-299,Patent Application,yes,0,0,4,034-331-614-393-962;;003-490-762-913-644;;140-591-710-197-578;;183-335-424-671-299,EP;;US;;FR,4,140-591-710-197-578;;003-490-762-913-644;;034-331-614-393-962;;183-335-424-671-299,EP;;US;;FR,0,B33Y80/00;;A61L2430/02;;A61L31/022;;A61L31/146;;A61L2430/12;;A61F2/2803;;A61F2002/285;;A61F2002/3092;;A61F2002/3093;;A61F2002/30957;;A61F2002/30985;;A61F2310/00023,A61F2/28,,0,0,,,,PENDING
400,EP,A1,EP 3813687 A1,004-868-784-372-613,2021-05-05,2021,EP 19824845 A,2019-06-28,US 201862691319 P;;US 2019/0039878 W,2018-06-28,PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF THROMBOSIS AND DELIVERY BY MEDICAL DEVICES,,MARIZYME BIOTECH,HANDLEY MICHAEL K,"MARIZYME, INC. (2023-04-26)",https://lens.org/004-868-784-372-613,Patent Application,yes,0,0,11,051-382-287-611-008;;167-215-822-759-142;;183-488-193-693-681;;113-909-928-705-465;;128-633-861-675-942;;127-500-590-414-920;;170-810-794-749-231;;079-567-751-821-998;;004-868-784-372-613;;191-235-790-311-105;;066-411-304-959-220,CR;;JP;;AU;;CN;;EA;;EP;;WO;;CA;;BR;;PE,13,051-382-287-611-008;;128-633-861-675-942;;113-909-928-705-465;;183-488-193-693-681;;170-810-794-749-231;;074-210-751-277-44X;;004-868-784-372-613;;028-302-916-315-724;;066-411-304-959-220;;167-215-822-759-142;;127-500-590-414-920;;079-567-751-821-998;;191-235-790-311-105,CR;;JP;;AU;;EP;;CN;;EA;;WO;;US;;CA;;BR;;PE,0,A61B17/12136;;A61B17/12036;;A61B17/1204;;A61M2025/105;;A61M2025/1052;;A61K38/4806;;A61K38/4826;;C12Y304/21004;;C12Y304/21001;;A61K38/26;;A61K31/616,A61B17/12;;A61K38/43;;A61M25/10,,0,0,,,,DISCONTINUED
401,EP,A1,EP 4536800 A1,189-852-813-611-832,2025-04-16,2025,EP 23732542 A,2023-06-13,FR 2205675 A;;EP 2023065838 W,2022-06-13,DEVICE FOR SPERM CELL ISOLATION AND METHOD FOR SELECTION OF HIGH QUALITY SPERM CELLS,,BEEZ BIOTECH,SHUKLA SHIVA KANT,,https://lens.org/189-852-813-611-832,Patent Application,yes,0,0,5,164-514-809-775-341;;189-852-813-611-832;;198-373-535-208-40X;;061-603-376-262-742;;029-087-290-109-538,CN;;EP;;WO;;FR,5,189-852-813-611-832;;029-087-290-109-538;;198-373-535-208-40X;;061-603-376-262-742;;164-514-809-775-341,EP;;CN;;WO;;FR,0,C12M21/06;;C12M47/04;;C12N5/0612;;A61D19/02,C12M3/00;;B01L3/00;;C12M1/00;;C12N5/071,,0,0,,,,PENDING
402,WO,A1,WO 2024/234728 A1,079-362-815-744-479,2024-11-21,2024,CN 2024074208 W,2024-01-26,CN 202310565102 A,2023-05-18,"6'-CYANO-MODIFIED LOCKED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID POLYMER","The present invention relates to the field of biotechnology, and provided thereby are a 6'-cyano-modified locked nucleoside, nucleotide, and nucleic acid polymer. The 6'-cyano-modified locked nucleoside provided by the present invention is of an R configuration or an S configuration, and is further modified to obtain the nucleotide and the nucleic acid polymer. It has been found by the inventors via study that the 6'-cyano-modified nucleic acid polymer has better nuclease tolerance than unmodified nucleic acid polymers or other modified nucleic acid polymers, thus reducing or regulating interaction between the nucleic acid polymer and intracellular proteins. Therefore, the 6'-cyano-modified locked nucleoside, nucleotide, and nucleic acid polymer provided by the present invention have significant application value in the aspect of nucleic acid drugs. Preparation methods for the locked nucleoside, nucleotide, and nucleic acid polymer provided by the present invention are efficient, stable, and practical, and are compatible with various substituted or unsubstituted bases.",ACAD OF MILITARY MEDICAL SCIENCES,HE XIAOYANG;;WANG SHENGQI;;DENG XINXIU;;SHI ANZHE,,https://lens.org/079-362-815-744-479,Patent Application,yes,5,0,7,112-675-338-780-072;;079-362-815-744-479;;055-053-062-967-394;;015-456-195-610-108;;078-563-713-664-691;;062-319-088-568-69X;;143-293-634-517-640,JP;;EP;;CN;;WO;;ZA,7,112-675-338-780-072;;079-362-815-744-479;;055-053-062-967-394;;015-456-195-610-108;;078-563-713-664-691;;062-319-088-568-69X;;143-293-634-517-640,JP;;EP;;CN;;WO;;ZA,2,C07H19/167;;C07H19/067;;C07H19/10;;C07H21/02;;C07H21/04;;C07H23/00;;C07B2200/07;;Y02P20/55;;C07H1/00;;C07H19/067;;C07H19/167;;C07H21/04,C07H19/167;;A61K31/7088;;C07H19/067;;C07H19/10;;C07H21/02;;C07H21/04;;C07H23/00,,9,1,171-377-007-130-985,10.1093/nar/gkv1429,"LIU TIANTIAN, WANG AIPING, HONGTAO JIN: ""Development of Chiral Drugs and their Regulatory Guidelines"", YAOWU PINGJIA YANJIU [=DRUG EVALUATION RESEARCH], YAOWU PINGJIA YANJIU ZAZHI BIANJIBU, CN, vol. 41, no. 12, 8 December 2018 (2018-12-08), CN , pages 2362 - 2368, XP093234507, ISSN: 1674-6376, DOI: 10.7501/j.issn.1674-6376.2018.12.045;;NUCLEIC ACIDS RES., vol. 44, 2016, pages 3892;;NATURE BIOTECH., vol. 35, 2017, pages 230;;NUCLEIC ACIDS RES., vol. 46, 2018, pages 2204;;NATURE BIOTECH., vol. 37, 2019, pages 640;;NUCLEIC ACIDS RES., vol. 47, 2019, pages 10865;;J. AM. CHEM. SOC., vol. 142, 2020, pages 14754;;NATURE BIOTECH.,, vol. 37, 2019, pages 640;;See also references of EP 4484439A4",PENDING
403,WO,A1,WO 2023/177371 A1,009-129-591-140-165,2023-09-21,2023,TR 2022051306 W,2022-11-16,TR 2022004180 A,2022-03-18,OBTAINING BACTERIAL CELLULOSE WITH KOMAGATAEIBACTER SP. GUS3,"The invention relates to obtaining bacterial cellulose from the vinegar isolate Komagataeibacter sp GUS3, which produces 1.644 ±0,4016 g/L cellulose.",ISTANBUL SABAHATTIN ZAIM UENIVERSITESI,BÜYÜKDUMAN EDA;;METİN BANU,,https://lens.org/009-129-591-140-165,Patent Application,yes,0,0,3,198-484-860-003-717;;009-129-591-140-165;;062-418-435-796-94X,TR;;WO;;US,3,198-484-860-003-717;;009-129-591-140-165;;062-418-435-796-94X,TR;;WO;;US,0,C12P19/04;;C12R2001/01;;C12N1/205;;C12N1/205;;C12R2001/02;;C12P19/04,C12N1/20;;C12P19/04,,1,0,,,"BÜYÜKDUMAN, EDA: ""Isolation, molecular identification and determination of technological properties of acetic acid bacteria from home-made vinegar and fresh apricot"", MASTER THESIS, ISTANBUL SABAHATTIN ZAIM UNIVERSITY, TURKEY, 31 July 2021 (2021-07-31), Turkey, pages 1 - 102, XP009549951",PENDING
404,EP,A1,EP 3721877 A1,189-828-989-060-704,2020-10-14,2020,EP 20175482 A,2015-07-02,EP 14306075 A;;EP 15734651 A;;EP 2015065161 W,2014-07-02,NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES,"The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof,in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.",INFLECTIS BIOSCIENCE,GUEDAT PHILIPPE,,https://lens.org/189-828-989-060-704,Patent Application,yes,14,0,29,075-609-077-733-693;;095-672-832-610-839;;185-384-156-564-422;;071-293-347-817-712;;128-274-449-943-122;;044-229-322-325-935;;122-543-047-017-868;;188-043-781-282-248;;110-257-649-602-076;;036-746-778-866-719;;057-303-990-927-899;;135-401-381-525-807;;163-351-720-360-414;;129-013-530-411-554;;049-652-645-619-84X;;088-687-740-503-938;;009-281-941-774-683;;149-258-394-271-913;;010-623-546-867-807;;186-034-156-462-684;;038-235-431-831-961;;010-447-111-178-965;;154-901-424-104-659;;116-463-898-755-28X;;189-828-989-060-704;;005-517-783-400-776;;054-249-965-865-960;;153-162-811-420-878;;141-934-193-247-060,JP;;AU;;RU;;US;;CA;;MX;;PT;;PL;;KR;;CN;;ES;;EP;;IL;;WO;;DK,29,075-609-077-733-693;;095-672-832-610-839;;185-384-156-564-422;;071-293-347-817-712;;128-274-449-943-122;;044-229-322-325-935;;122-543-047-017-868;;188-043-781-282-248;;110-257-649-602-076;;036-746-778-866-719;;057-303-990-927-899;;135-401-381-525-807;;163-351-720-360-414;;129-013-530-411-554;;049-652-645-619-84X;;088-687-740-503-938;;009-281-941-774-683;;149-258-394-271-913;;010-623-546-867-807;;186-034-156-462-684;;038-235-431-831-961;;010-447-111-178-965;;154-901-424-104-659;;116-463-898-755-28X;;189-828-989-060-704;;005-517-783-400-776;;054-249-965-865-960;;153-162-811-420-878;;141-934-193-247-060,JP;;AU;;RU;;US;;CA;;MX;;PT;;PL;;KR;;CN;;ES;;EP;;IL;;WO;;DK,0,C07C281/18;;C07D213/53;;C07D253/075;;A61K31/155;;A61K31/44;;A61K31/53;;A61P1/00;;A61P1/18;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P9/12;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P27/06;;A61P43/00;;Y02A50/30;;A61K31/155;;A61K31/44;;A61K31/53;;A61P25/00;;A61K31/155;;A61K31/44;;A61K31/53;;A61K31/155;;A61K31/165;;A61K31/216;;A61K31/44;;A61K31/53;;A61P25/00;;C07C281/18;;C07D213/61;;C07D253/075;;A61K31/155;;A61K31/44;;A61K31/53,A61K31/155;;A61K31/44;;A61K31/53;;A61P29/00;;A61P31/00,,45,36,086-302-270-112-373;;074-359-068-341-131;;069-268-364-030-050;;048-488-274-211-184;;047-514-486-113-885;;030-221-847-248-851;;114-253-746-007-241;;012-363-177-208-076;;065-509-341-657-79X;;077-433-787-763-674;;026-105-631-952-02X;;023-401-285-629-138;;115-593-045-774-146;;056-749-692-061-02X;;020-596-434-085-36X;;037-848-385-935-772;;023-069-604-788-354;;075-006-084-072-683;;009-334-675-431-579;;018-146-818-971-424;;020-509-349-838-365;;009-789-821-753-48X;;004-045-052-300-65X;;063-417-939-115-126;;006-988-234-555-895;;080-105-158-569-401;;039-622-002-950-539;;007-364-858-655-289;;040-485-078-920-552;;074-519-085-676-195;;004-851-667-216-346;;054-463-930-276-08X;;043-828-828-104-513;;021-991-082-666-692;;005-301-726-511-549;;059-575-396-895-697,20138519;;10.1016/j.bmcl.2010.01.031;;pmc2291559;;18431471;;10.1371/journal.pone.0001981;;10.1126/science.1201396;;21385720;;10.1038/ncomms7532;;25766071;;pmc4360920;;24005281;;10.1523/jneurosci.2961-13.2013;;pmc6618381;;pmc3461828;;10.1523/jneurosci.5367-11.2012;;22399753;;10.1126/science.1101902;;15705855;;pmc186318;;10.1101/gad.992302;;12050113;;15210964;;pmc470729;;10.1073/pnas.0403015101;;pmc2600758;;19015277;;10.1101/gad.1673408;;pmc3044817;;21204267;;10.1002/emmm.201000109;;10.1002/jnr.22066;;pmc3076940;;19330777;;10.1016/j.neuron.2007.12.021;;pmc2267889;;18255032;;pmc3381724;;10.1093/brain/aws140;;22689911;;11114256;;10.1006/nbdi.2000.0323;;12111842;;10.1002/jnr.10255;;12460545;;10.1006/nbdi.2002.0545;;10.1016/s0896-6273(02)01045-0;;pmc4603660;;12441049;;10.1038/nn.2297;;19330001;;18640110;;10.1016/j.ejphar.2008.06.103;;pmc3246718;;22216020;;10.1155/2012/589589;;pmc2676739;;10.4161/pri.3.1.8072;;19363299;;10.1186/1471-2474-14-197;;23816340;;pmc3711788;;23178987;;10.1016/j.cellsig.2012.11.015;;pmc3593652;;pmc3748169;;23659896;;10.1016/j.nbd.2013.04.021;;10.1523/jneurosci.5685-07.2008;;pmc2925257;;18579727;;10.1126/science.8209258;;8209258;;833720;;10.1002/jps.2600660104;;10.1016/j.jneumeth.2005.05.003;;15975663;;3259619;;10.1111/j.1471-4159.1988.tb02495.x;;10.1096/fj.07-095398;;18364399;;pmc6786088;;10087060;;10.1523/jneurosci.19-07-02455.1999;;10.1002/jnr.23193;;23404368;;pmc3481343;;10.1074/jbc.m112.386821;;22869374;;pmc1682779;;1384324;;10.1038/ng0896-422;;8696336,"BAIRWA R ET AL: ""Novel molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 5, 1 March 2010 (2010-03-01), pages 1623 - 1625, XP026911319, ISSN: 0960-894X, [retrieved on 20100217], DOI: 10.1016/J.BMCL.2010.01.031;;D. TRIBOUILLARD-TANVIER ET AL., PLOS ONE, vol. 3, 2008, pages e1981;;TSAYTLER ET AL., SCIENCE, vol. 332, no. 1, 2011, pages 91 - 94;;WAY ET AL., NATURE COMMUNICATIONS, vol. 6, 2015, pages 6532;;BROWN ET AL., FRONTIERS IN PHYSIOLOGY, vol. 3, 2012;;HARDING ET AL., PROC NATL ACAD SCI USA, vol. 106, 2009, pages 1832 - 1837;;STOVEKEN, THE JOURNAL OF NEUROSCIENCE, vol. 33, no. 36, 2013, pages 14285 - 14287;;COLLA ET AL., J. OF NEUROSCIENCE, vol. 32, no. 10, 2012, pages 3306 - 3320;;BOYCE ET AL., SCIENCE, vol. 307, 2005, pages 935 - 939;;NISHITOH ET AL., GENES DEV, vol. 16, 2002, pages 1345 - 55;;ROUSSEAU ET AL., PROC NATL ACAD SCI U S A, vol. 101, 2004, pages 9648 - 53;;DUENNWALDLINDQUIST, GENES DEV, vol. 22, 2008, pages 3308 - 19;;BARBEZIER ET AL., EMBO, vol. 3, 2011, pages 35 - 49;;D'ANTONIO ET AL., J NEUROSCI RES, vol. 87, 2009, pages 3241 - 9;;PENNUTO ET AL., NEURON, vol. 57, 2008, pages 393 - 405;;D'ANTONIO ET AL., J.EXP. MED, 2013, pages 1 - 18;;SAPORTA ET AL., BRAIN, vol. 135, 2012, pages 2032 - 2047;;COLBY ET AL., NEUROBIOL.DISEASE, vol. 7, 2000, pages 561 - 573;;KLEOPA ET AL., J. NEUROSCI. RES., vol. 68, 2002, pages 522 - 534;;YUM ET AL., NEUROBIOL. DIS., vol. 11, 2002, pages 43 - 52;;GOW ET AL., NEURON, vol. 36, 2002, pages 585 - 596;;MATUS ET AL., INT. J. CELL BIOL., 2013, Retrieved from the Internet <URL:http://dx.doi.org/10.1155/2013/674751>;;SAXENA ET AL., NATURE NEUROSCIENCE, vol. 12, 2009, pages 627 - 636;;JIANG ET AL., NEUROSCIENCE, 2014;;DAS ET AL., SCIENCE, vol. 388, 2015, pages 239 - 242;;ITOSUZUKI, BRAIN, vol. 132, 2009, pages 87 - 15;;NOREZ ET AL., EUR. J. PHARMACOL., vol. 592, 2008, pages 33 - 40;;GORBATYUKGORBATYUK, MOLECULAR VISION, vol. 19, 2013, pages 1985 - 1998;;JING ET AL., EXP DIABETES RES, vol. 2012, 2012, pages 589589;;COLBERT ET AL., PRION, vol. 3, no. 1, 2009, pages 15 - 16;;YOKOTA ET AL., BMC MUSCULOSKELETAL DISORDERS, vol. 14, 2013, pages 197;;HE ET AL., CELLULAR SIGNALING, vol. 25, 2013, pages 552 - 560;;OHRI ET AL., NEUROBIOLOGY OF DISEASE, vol. 58, 2013, pages 29 - 37;;NAIDOO ET AL., J NEUROSCI, vol. 28, 2008, pages 6539 - 48;;GURNEY ET AL., SCIENCE, vol. 264, 1994, pages 1772 - 1775;;""Remington's Pharmaceutical Sciences"", 1985, JOHN WILEY AND SONS;;BERGE ET AL., J PHARM SCI, vol. 66, 1977, pages 1 - 19;;YANG ET AL., J NEUROSCI METHODS, vol. 149, no. 1, 2005, pages 50 - 6;;SCHINELLI, J. NEUROCHEM, vol. 50, 1988, pages 1900 - 07;;VISANJI ET AL., FASEB J, vol. 22, no. 7, 2008, pages 2488 - 97;;SINGER ET AL., J. NEUROSCIENCE, vol. 19, 1999, pages 2455 - 63;;CALLIZOT ET AL., J.NEUROSCI. RES., vol. 91, 2013, pages 706 - 16;;MOCKEL ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 37483 - 494;;STRAUTNIEKS ET AL., AM. J. HUM. GENET., vol. 51, no. 4, 1992, pages 871 - 878;;GOWLAZZARINI, NAT GENET., vol. 13, no. 4, 1996, pages 422 - 8",DISCONTINUED
405,WO,A1,WO 2023/011660 A1,000-760-283-684-299,2023-02-09,2023,CN 2022110828 W,2022-08-08,CN 202210098137 A;;CN 202110901455 A;;CN 202111294356 A;;CN 202210143116 A,2021-08-06,"COMPOSITIONS FOR LIQUEFYING A VISCOUS BIOLOGICAL SAMPLE, COMBINATION PRODUCTS, LIQUEFYING AGENTS, AND KITS THEREOF, AND METHODS AND APPLICATION THEREOF","This disclosure relates to a viscous biological sample liquefying composition comprising guaifenesin and a first strong base, further relates to a combination product, a liquefying agent and a kit containing the viscous biological sample liquefying composition, and further relates to a liquefaction method, a processing method and application of the viscous biological sample using the viscous biological sample liquefying composition or the combination product or kit thereof.",SANSURE BIOTECH INC,DAI LIZHONG;;DENG ZHONGPING;;CHEN SHIYAO;;DENG YONG;;LIU JIA,,https://lens.org/000-760-283-684-299,Patent Application,yes,43,1,3,029-988-201-374-240;;000-760-283-684-299;;096-598-390-329-102,EP;;WO;;US,9,002-080-375-644-431;;000-760-283-684-299;;144-362-510-994-19X;;041-173-534-281-082;;035-176-540-239-119;;029-988-201-374-240;;155-998-968-218-101;;096-598-390-329-102;;017-979-807-796-325,CN;;EP;;WO;;US,0,C12Q1/6806;;C12N15/1006;;C12Q1/6806;;C12Q1/6851,C12N15/10;;C12Q1/6806,,3,1,032-405-750-279-079,10890904;;pmc26937;;10.1073/pnas.140225597,"LYAMICHEV ET AL., NAT.BIOTECH., vol. 17, 1999, pages 292;;HALL ET AL., PNAS,USA, vol. 97, 2000, pages 8272;;BARANAY, PROC.NATL.ACAD.SCI USA, vol. 88, 1991, pages 189 - 93",PENDING
406,WO,A1,WO 2022/149619 A1,197-584-652-242-782,2022-07-14,2022,KE 2021000057 W,2021-12-21,KE P202003768 A,2020-12-11,"COVID 19 VIRUS/FLU AEROSOL SPRAY COMPOSITION AND METHODS FOR COMBATING, CONTRACTING AND SPREADING OF VIRUSES AND COLDS","The covid 19 virus/Flu aerosol spray is a formulation and method of combating the contracting and spread of viruses and colds. It is composed of antibacterial and antiviral natural herbs that allows you to instantly respond to incidents of potential viral exposure by safely cleansing your hands, other surfaces and additionally instantly killing any possible virus exposure through your nose and mouth.",BIGHAM HERMAN LEE JR,BIGHAM HERMAN,,https://lens.org/197-584-652-242-782,Patent Application,yes,5,0,1,197-584-652-242-782,WO,1,197-584-652-242-782,WO,0,A61P31/14;;A23L33/105;;A61K9/0073;;A61K36/58;;A61K36/61;;A61K36/752,A61P31/14;;A61K9/00;;A61K36/58;;A61K36/61;;A61K36/752,,4,2,044-960-843-702-364;;001-543-641-242-622,27034694;;pmc4791507;;10.1155/2016/7382506;;10.1007/s10787-020-00744-0;;pmc7427755;;32803479,"MOHAMMAD A. ALZOHAIRY: ""Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment"", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2016, 1 January 2016 (2016-01-01), US, pages 1 - 11, XP055696834, ISSN: 1741-427X, DOI: 10.1155/2016/7382506;;ASIF MUHAMMAD ET AL: ""COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties"", INFLAMMOPHARMACOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 28, no. 5, 14 August 2020 (2020-08-14), pages 1153 - 1161, XP037257443, ISSN: 0925-4692, [retrieved on 20200814], DOI: 10.1007/S10787-020-00744-0;;PARIDA PRATAP KUMAR ET AL: ""‐2 targets"", PHYSIOTHERAPY RESEARCH, vol. 34, no. 12, 1 December 2020 (2020-12-01), GB, pages 3420 - 3433, XP055811133, ISSN: 0951-418X, DOI: 10.1002/ptr.6868;;JOURNAL OF COMMUNICABLE DISEASES",PENDING
407,EP,A1,EP 4379050 A1,067-382-443-012-594,2024-06-05,2024,EP 22848384 A,2022-07-21,CN 202110853028 A;;CN 2022106920 W,2021-07-27,SUCROSE SYNTHETASE AND USE THEREOF,"Provided are a sucrose synthetase and the use thereof. Compared with SEQ ID NO: 11, an amino acid sequence of the sucrose synthetase contains differences in amino acid residues selected from one or more of the following residue positions: an amino acid at position 36 being V, an amino acid at position 43 being E, an amino acid at position 179 being A, an amino acid at position 395 being R, an amino acid at position 447 being P, an amino acid at position 455 being L, and an amino acid at position 654 being R; and the sucrose synthetase has an activity not lower than that of a sucrose synthetase having an amino acid sequence as shown in SEQ ID NO: 11. By means of catalyzing the synthesis of rebaudioside A, rebaudioside D or rebaudioside M by using a glucosyltransferase and the sucrose synthetase in a combined manner, a cascade reaction is achieved, thereby providing a variety of possibilities for the selection of raw materials.",ABIOCHEM BIOTECHNOLOGY GROUP CO LTD,WU YAN;;TIAN ZHENHUA;;WANG SHU;;ZHENG XIAOFU;;XING LITONG,,https://lens.org/067-382-443-012-594,Patent Application,yes,0,0,7,000-139-956-443-348;;079-237-594-854-072;;006-709-876-635-825;;067-382-443-012-594;;098-831-400-161-093;;109-433-842-642-496;;049-223-533-718-434,JP;;CN;;EP;;WO;;US,7,000-139-956-443-348;;079-237-594-854-072;;006-709-876-635-825;;067-382-443-012-594;;098-831-400-161-093;;109-433-842-642-496;;049-223-533-718-434,JP;;CN;;EP;;WO;;US,29,C12P19/56;;C12R2001/19;;C12N15/70;;C12N9/1062;;C12P19/305;;C12P19/32;;C12N9/1062;;C12P19/18;;C12P19/56;;C12Y204/01013,C12N9/10;;C12N15/54;;C12N15/63;;C12P19/00,,0,0,,,,PENDING
408,WO,A1,WO 2023/001658 A1,197-327-608-430-666,2023-01-26,2023,EP 2022069586 W,2022-07-13,EP 21187190 A,2021-07-22,PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM,"This invention relates to bacterial strains, compositions comprising bacterial strains as well as methods and uses of said strains and compositions for use in boosting the immune system. More specifically, the invention relates to bacterial strains having immunomodulatory properties providing specific health benefits in a subject in need thereof.",DUPONT NUTRITION BIOSCI APS,LEHTINEN MARKUS;;LATVALA SINIKKA ANNELI;;LEHTORANTA LIISA,,https://lens.org/197-327-608-430-666,Patent Application,yes,6,1,4,073-924-657-099-817;;197-327-608-430-666;;171-178-027-813-394;;004-453-823-950-339,EP;;CN;;WO;;US,4,073-924-657-099-817;;197-327-608-430-666;;171-178-027-813-394;;004-453-823-950-339,EP;;CN;;WO;;US,0,A61K35/747;;A61P31/04;;A61P31/12;;A61P35/00;;A61P29/00;;A61P37/04;;A61K35/741,A61K35/747;;A61P29/00;;A61P31/04;;A61P31/12;;A61P35/00,,6,4,011-471-459-116-817;;056-146-348-122-716;;029-197-829-160-95X;;013-300-232-711-554,34224309;;10.1080/19490976.2021.1939598;;pmc8259724;;pmc7916596;;10.3390/microorganisms9020349;;33578806;;17226902;;10.3748/wjg.v13.i2.236;;pmc4065951;;10.1111/j.1574-695x.2008.00413.x;;18422632,"PELLON AIZE ET AL: ""The commensal bacterium Lactiplantibacillus plantarum imprints innate memory-like responses in mononuclear phagocytes"", vol. 13, no. 1, 1 January 2021 (2021-01-01), United States, pages 1 - 18, XP055872325, ISSN: 1949-0976, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/19490976.2021.1939598?needAccess=true> DOI: 10.1080/19490976.2021.1939598;;GARCIA-GONZALEZ NATALIA ET AL: ""Health-Promoting Role of Lactiplantibacillus plantarum Isolated from Fermented Foods"", vol. 9, no. 2, 10 February 2021 (2021-02-10), pages 349, XP055872658, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916596/pdf/microorganisms-09-00349.pdf> DOI: 10.3390/microorganisms9020349;;ANONYMOUS: ""Vivatlac Synbiotikum (10 magensaftresistente Kapseln)"", 1 June 2021 (2021-06-01), pages 1 - 3, XP055872674, Retrieved from the Internet <URL:https://vivatrex.de/wp-content/uploads/PZN-17195433-Vivatlac-Synbiotikum-10-MRK-Vivatrex-2021-06-01-LMIV.pdf> [retrieved on 20211214];;LATVALA S, PHILIPP S, LEHTINEN MK, LEHTORANTA L, OUWEHAND AC: ""Health Benefits of a Combination Probiotics; FlorMidabil[TM]"", INTERNATIONAL JOURNAL OF PROBIOTICS, vol. 14, 2019, XP009532182;;FOLIGNE BENOIT ET AL: ""Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria"", WORLD JOURNAL OF GASTROENTEROLOGY, WJG PRESS, CN, vol. 13, no. 2, 14 January 2007 (2007-01-14), pages 236 - 243, XP002563273, ISSN: 1007-9327;;DAMIEN PAINEAU ET AL: ""Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial"", FEMS IMMUNOLOGY & MEDICAL MICROBIOLOGY, vol. 53, no. 1, 1 June 2008 (2008-06-01), pages 107 - 113, XP055274946, ISSN: 0928-8244, DOI: 10.1111/j.1574-695X.2008.00413.x",PENDING
409,WO,A1,WO 2023/137245 A1,172-738-312-377-404,2023-07-20,2023,US 2023/0060202 W,2023-01-06,US 202263298257 P,2022-01-11,COMPOSITIONS AND METHODS FOR CONTROLLING PLANT PARASITIC NEMATODES,"A nematicide composition is provided that includes: (i) swertiamarin; (ii) berberine; (iii) chitosan, (iv) glutathione; and (v) cellulose-based polymer. The composition can kill root knot nematodes within a minute of contact. This result is surprising, given that each of swertiamarin, berberine, chitosan, and glutathione when applied individually, repels, but does not kill nematodes. In addition, coleoptile length resulting from corn seed treated with the composition was significantly increased. Further, the composition applied in furrow in cotton and soybean field trials reduced reniform and root knot nematodes, respectively, and increased yield. The nematicide composition can also exhibit antifungal and insecticidal activities.",KANNAR EARTH SCIENCE LTD,CLOETE SAMUEL;;HABIB AHSAN,,https://lens.org/172-738-312-377-404,Patent Application,yes,6,0,2,172-738-312-377-404;;108-069-781-334-355,AR;;WO,2,172-738-312-377-404;;108-069-781-334-355,AR;;WO,0,A01P1/00;;A01P3/00;;A01P5/00;;A01P7/04;;A01P21/00;;A01N43/90,A01N31/06;;A01N25/30;;A01N27/00;;A01N31/08,,0,0,,,,PENDING
410,US,A1,US 2023/0138600 A1,187-010-553-950-390,2023-05-04,2023,US 202218069975 A,2022-12-21,CN 2021128404 W,2021-11-03,"POSITIVE ELECTRODE SLURRY, POSITIVE ELECTRODE PLATE, LITHIUM-ION BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRICAL DEVICE","A positive electrode slurry includes a manganese-containing positive active material and a positive electrode additive. The positive electrode additive includes a compound represented by Formula (I), where A and B are same and are any one selected from atoms N, O, and S, and R1, R2, R3, R4, R5, R6, R7, and R8 are, each independently, selected from hydrogen or an alkyl with a carbon number of 1-7.",CONTEMPORARY AMPEREX TECHNOLOGY CO LTD,ZHANG QIANQIAN;;ZHAO YANJIE;;LI XING;;JIN HAIZU,CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (2024-08-06);;CONTEMPORARY AMPEREX TECHNOLOGY CO. LIMITED (2022-03-03),https://lens.org/187-010-553-950-390,Patent Application,yes,0,0,9,058-270-227-936-669;;187-010-553-950-390;;073-775-336-219-121;;122-803-807-608-715;;144-472-366-149-879;;172-707-564-263-612;;148-976-335-922-069;;198-198-675-928-040;;140-632-960-211-270,KR;;JP;;EP;;CN;;WO;;US,9,058-270-227-936-669;;187-010-553-950-390;;073-775-336-219-121;;122-803-807-608-715;;172-707-564-263-612;;144-472-366-149-879;;148-976-335-922-069;;198-198-675-928-040;;140-632-960-211-270,KR;;JP;;EP;;CN;;WO;;US,0,Y02E60/10;;H01M4/131;;H01M4/505;;H01M4/625;;H01M4/622;;H01M10/0525;;H01M4/62;;H01M2004/028;;H01M4/525;;H01M4/0404;;H01M4/131;;H01M4/505;;H01M10/4235;;H01M4/62;;H01M4/525;;H01M4/622;;H01M4/625;;H01M10/0525;;H01M2004/028;;H01M4/62;;H01M4/485;;H01M4/505;;H01M4/525;;H01M2004/028;;H01M4/625;;H01M4/0404;;H01M10/0525;;H01M4/622,H01M4/62;;H01M4/04;;H01M4/485;;H01M4/505;;H01M4/525;;H01M10/0525,,0,0,,,,PENDING
411,US,A1,US 2025/0049038 A1,185-752-631-148-660,2025-02-13,2025,US 202218720433 A,2022-12-15,US 202218720433 A;;US 202163290032 P;;US 2022/0053049 W,2021-12-15,ANHYDROUS SILVER COMPOSITIONS AND USES THEREOF,"Compositions that contain a substrate and silver particles are provided. where the composition are anhydrous, optionally having antimicrobial properties in either the anhydrous or a rehydrated form.",AMERICAN SILVER LLC,HOLLADAY ROBERT J;;MOELLER NATHAN R;;REVELLI JERRY S,,https://lens.org/185-752-631-148-660,Patent Application,yes,0,0,2,185-752-631-148-660;;185-920-419-381-975,WO;;US,2,185-752-631-148-660;;185-920-419-381-975,WO;;US,0,A01N59/16;;A61K33/38;;A01P1/00;;A61L15/24;;A61L26/0014;;A61L26/0066;;A61L15/44;;A61L2300/104;;A01P1/00;;A01N25/12;;A01N25/34;;A01N59/16,A01N59/16;;A01N25/12;;A01N25/34;;A01P1/00,,0,0,,,,PENDING
412,WO,A1,WO 2023/114425 A1,185-920-419-381-975,2023-06-22,2023,US 2022/0053049 W,2022-12-15,US 202163290032 P,2021-12-15,ANHYDROUS SILVER COMPOSITIONS AND USES THEREOF,"Compositions that contain a substrate and silver particles are provided, where the composition are anhydrous, optionally having antimicrobial properties in either the anhydrous or a rehydrated form.",AMERICAN SILVER LLC,HOLLADAY ROBERT;;MOELLER NATHAN;;REVELLI JERRY,,https://lens.org/185-920-419-381-975,Patent Application,yes,7,0,2,185-752-631-148-660;;185-920-419-381-975,WO;;US,2,185-752-631-148-660;;185-920-419-381-975,WO;;US,0,A01N59/16;;A61K33/38;;A01P1/00;;A61L15/24;;A61L26/0014;;A61L26/0066;;A61L15/44;;A61L2300/104;;A01P1/00;;A01N25/12;;A01N25/34;;A01N59/16,A61K33/38;;A01N59/16;;A61L15/42;;A61L31/08,,0,0,,,,PENDING
413,KR,A,KR 20230139656 A,126-954-297-628-030,2023-10-05,2023,KR 20220038251 A,2022-03-28,KR 20220038251 A,2022-03-28,pPLA pPLA gene inducing haploid plant and uses thereof,"The present invention relates to pPLAⅡγ gene inducing haploid plants and uses thereof, and in the present invention, it has been shown that the haploid plants can be induced by inhibiting the expression of the pPLAⅡγ gene, the genes of the present invention can be usefully utilized as a strategy for constructing breeding material for purebreds with fixed traits in a short period of time.",UNIV NAT CHONNAM IND FOUND,OK RAN LEE;;JIN HOON JANG,,https://lens.org/126-954-297-628-030,Patent Application,no,0,0,2,126-954-297-628-030;;014-537-878-850-598,KR,2,126-954-297-628-030;;014-537-878-850-598,KR,26,C12N15/8218;;C12N15/8213;;A01H1/08;;C12N15/113;;C12N9/22;;C12N2310/20,C12N15/82;;A01H1/08;;C12N9/22;;C12N15/113,,2,0,,,비특허문헌1(PLANT BREED. BIOTECH.)*;;비특허문헌3(서열)*,ACTIVE
414,US,A1,US 2024/0299556 A1,099-986-523-467-79X,2024-09-12,2024,US 202017803393 A,2020-12-24,CN 201911370139 A;;CN 2020139058 W,2019-12-26,"Magnolol and Sulforaphane Conjgate, and Preparation Method and Use Thereof","Disclosed in the present invention are a magnolol and sulforaphane conjugate, and a preparation method and use thereof. The magnolol and sulforaphane conjugate comprises C25H29NO2S2 (CT-1), C25H29NO4S2(CT-2), and C25H29NO3S2(CT-3). By using the drug combination principle, the present invention achieved the first synthesis of the magnolol and sulforaphane conjugate (CT-1, CT-2, CT-3). According to biological evaluation, the conjugate has an antitumor effect remarkably superior to that of magnolol and sulforaphane, has a broad spectrum of antitumor activity and strong druggability. It is an antitumor compound with development potential, and also provides new ideas and approaches for development of a novel antitumor drug.",SHENZHEN ZHENXING BIOMEDICINE RES CENTER CO LTD,WU ZHENGZI;;TAO CHENG;;CHEN JIAN;;ZENG YONGCHANG;;LIU JIEREN;;LI LIMIN,,https://lens.org/099-986-523-467-79X,Patent Application,yes,0,0,7,070-886-893-998-941;;119-270-864-752-580;;024-622-374-944-725;;186-093-990-984-652;;185-822-936-920-923;;099-986-523-467-79X;;090-398-453-431-020,JP;;EP;;CN;;WO;;US,7,070-886-893-998-941;;119-270-864-752-580;;024-622-374-944-725;;186-093-990-984-652;;185-822-936-920-923;;099-986-523-467-79X;;090-398-453-431-020,JP;;EP;;CN;;WO;;US,0,C07C331/20;;A61P35/00;;C07C331/20;;A61K47/55;;A61P35/00;;C07C331/20,A61K47/55;;A61P35/00,,0,0,,,,PENDING
415,US,A1,US 2021/0095269 A1,097-145-547-667-164,2021-04-01,2021,US 201816960037 A,2018-12-30,CN 201810001073 A;;CN 2018125973 W,2018-01-03,Method For Isolating DNA By Using Cas Protein System,"The present invention relates to a method for isolating DNA from a solution, and relates in particular to a method and kit for isolating DNA from a solution by using a Cas protein. The present invention may effectively increase efficiency in extracting cell-free DNA.",CURE GENETICS CO LTD,WU YAO;;WANG XINGXING;;LI QIUSHI,GENEVIDE BIOTECH CO. LTD (2022-12-14);;CURE GENETICS CO. LTD (2020-06-28),https://lens.org/097-145-547-667-164,Patent Application,yes,1,2,8,195-430-228-307-060;;038-114-590-924-910;;037-366-897-851-968;;039-602-254-634-331;;097-145-547-667-164;;174-973-198-080-393;;189-806-784-709-98X;;199-018-770-170-27X,EP;;CN;;WO;;US,8,195-430-228-307-060;;038-114-590-924-910;;037-366-897-851-968;;097-145-547-667-164;;039-602-254-634-331;;174-973-198-080-393;;189-806-784-709-98X;;199-018-770-170-27X,EP;;CN;;WO;;US,34,C12N15/1003;;C12N9/22;;C07K2319/00;;C12N9/22;;C12N15/1006;;C12N15/1013;;C07K2319/30;;C07K2319/43;;C07K2319/21;;C07K2319/70;;C07K2319/20;;C12N11/14;;C12N9/22;;C12N15/1006;;C12N15/11;;C12Q1/6806,C12N15/10;;C12N9/22;;C12N15/11;;C12Q1/6806,,4,0,,,"Ahern, H. The Scientist 9(15) : 20 (Year: 1995);;The Stratagene Catalog pg.39 (Year: 1988);;ThermoFisher Product description Dynabeads Protein G for Immunoprecipitation (2006-2023) . (Year: 2006);;Fujita et al . Supplemental Materials 11 pages (Year: 2016)",DISCONTINUED
416,EP,A1,EP 3722422 A1,195-430-228-307-060,2020-10-14,2020,EP 18898516 A,2018-12-30,CN 201810001073 A;;CN 2018125973 W,2018-01-03,METHOD FOR ISOLATING DNA BY USING CAS PROTEIN SYSTEM,"The present invention relates to a method for isolating DNA from a solution, and relates in particular to a method and kit for isolating DNA from a solution by using a Cas protein. The present invention may effectively increase efficiency in extracting cell-free DNA.",CURE GENETICS CO LTD,WU YAO;;WANG XINGXING;;LI QIUSHI,,https://lens.org/195-430-228-307-060,Patent Application,yes,0,0,8,195-430-228-307-060;;038-114-590-924-910;;037-366-897-851-968;;039-602-254-634-331;;097-145-547-667-164;;174-973-198-080-393;;189-806-784-709-98X;;199-018-770-170-27X,EP;;CN;;WO;;US,8,195-430-228-307-060;;038-114-590-924-910;;037-366-897-851-968;;097-145-547-667-164;;039-602-254-634-331;;174-973-198-080-393;;189-806-784-709-98X;;199-018-770-170-27X,EP;;CN;;WO;;US,36,C12N15/1003;;C12N9/22;;C07K2319/00;;C12N9/22;;C12N15/1006;;C12N15/1013;;C07K2319/30;;C07K2319/43;;C07K2319/21;;C07K2319/70;;C07K2319/20;;C12N11/14;;C12N9/22;;C12N15/1006;;C12N15/11;;C12Q1/6806,C12N15/10;;C12N9/22,,0,0,,,,ACTIVE
417,EP,A1,EP 4083019 A1,070-886-893-998-941,2022-11-02,2022,EP 20908276 A,2020-12-24,CN 201911370139 A;;CN 2020139058 W,2019-12-26,"MAGNOLOL AND SULFORAPHANE CONJUGATE, AND PREPARATION METHOD THEREFOR","Disclosed in the present invention are a magnolol and sulforaphane conjugate, and a preparation method and use thereof. The magnolol and sulforaphane conjugate comprises C<sub>25</sub>H<sub>29</sub>NO<sub>2</sub>S<sub>2</sub>(CT-1), C<sub>25</sub>H<sub>29</sub>NO<sub>4</sub>S<sub>2</sub>(CT-2), and C<sub>25</sub>H<sub>29</sub>NO<sub>3</sub>S<sub>2</sub> (CT-3). By using the drug combination principle, the present invention achieved the first synthesis of the magnolol and sulforaphane conjugate (CT-1, CT-2, CT-3). According to biological evaluation, the conjugate has an antitumor effect remarkably superior to that of magnolol and sulforaphane, has a broad spectrum of antitumor activity and strong druggability. It is an antitumor compound with development potential, and also provides new ideas and approaches for development of a novel antitumor drug.",SHENZHEN ZHENXING BIOMEDICINE RES CENTER CO LTD,WU ZHENGZHI;;TAO CHENG;;CHEN JIAN;;ZENG YONGCHANG;;LIU JIEREN;;LI LIMIN,"ZENG, YONGCHANG (2023-10-04)",https://lens.org/070-886-893-998-941,Patent Application,yes,0,0,7,070-886-893-998-941;;119-270-864-752-580;;024-622-374-944-725;;186-093-990-984-652;;185-822-936-920-923;;099-986-523-467-79X;;090-398-453-431-020,JP;;EP;;CN;;WO;;US,7,070-886-893-998-941;;119-270-864-752-580;;024-622-374-944-725;;186-093-990-984-652;;185-822-936-920-923;;099-986-523-467-79X;;090-398-453-431-020,JP;;EP;;CN;;WO;;US,0,C07C331/20;;A61P35/00;;C07C331/20;;A61K47/55;;A61P35/00;;C07C331/20,C07C331/20;;A61P35/00,,0,0,,,,DISCONTINUED
418,WO,A2,WO 2025/147558 A2,146-832-939-426-634,2025-07-10,2025,US 2025/0010156 W,2025-01-03,CN 2024070786 W;;CN 2024088774 W,2024-01-05,METHODS AND COMPOSITIONS FOR MODIFYING FLOWERING TIME GENES IN PLANTS,"Methods and compositions are provided for modifying the flowering time and/or maturity time of soybean plants to enable them to be cultivated in a variety of geographical locations having different day lengths. Modified soybean plants are disclosed comprising non-natural mutant alleles at the E1, E2, E3, E4, E1La and/or E1Lb locus. The modified plants have a shorter flowering and/or maturity time than control plants.",SYNGENTA CROP PROTECTION AG;;INST OF CROP SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES;;SYNGENTA CROP PROTECTION LLC,HAN TIANFU;;SUN SHI;;SU QIANG;;YUAN SHAN;;CAI YUPENG;;HOU WENSHENG;;GAO YANG;;CHEN LI,,https://lens.org/146-832-939-426-634,Patent Application,yes,0,0,4,111-226-550-226-722;;146-832-939-426-634;;165-578-635-472-488;;103-608-005-101-805,WO,4,111-226-550-226-722;;146-832-939-426-634;;165-578-635-472-488;;103-608-005-101-805,WO,79,C07K14/415;;C12N15/827,C12N15/82;;C07K14/415,,0,0,,,,PENDING
419,US,A1,US 2021/0330740 A1,071-813-879-953-148,2021-10-28,2021,US 202117239289 A,2021-04-23,KR 20200049341 A;;KR 20200184526 A,2020-04-23,RUNX3 MODIFIED PROTEIN FOR PREVENTION OR TREATMENT OF CANCER,"In the present invention, it was confirmed that the modified protein in which the 356th serine of Runx3 is substituted with alanine has an increased activity of maintaining the complex with Brd2 by more than 10 times compared to the wild-type Runx3, and the apoptosis effect is improved in various cancer cell lines compared to the wild-type Runx3. Therefore, the modified protein in which the 356th serine of Runx3 is substituted with an amino acid that cannot be phosphorylated by a kinase of the present invention, the polynucleotide coding thereof, the vector carrying the polynucleotide, or the virus or cell transformed with the vector can be used as a therapeutic agent for various cancers.",RUN X CORP,BAE SUK CHUL;;LEE JUNG WON;;LEE YOU SOUB,RUN-X CORPORATION (2021-04-16);;GENECRAFT INC (2022-07-26),https://lens.org/071-813-879-953-148,Patent Application,yes,3,0,10,043-148-341-933-126;;075-526-906-943-177;;112-479-061-713-257;;042-086-442-802-443;;024-947-839-025-565;;040-142-377-569-083;;120-372-864-415-640;;140-374-168-625-374;;155-039-815-731-859;;071-813-879-953-148,KR;;US,10,112-479-061-713-257;;075-526-906-943-177;;043-148-341-933-126;;042-086-442-802-443;;024-947-839-025-565;;155-039-815-731-859;;120-372-864-415-640;;140-374-168-625-374;;071-813-879-953-148;;040-142-377-569-083,KR;;US,64,A61P35/00;;A61K31/519;;A61K38/1709;;A61K38/17;;A61K31/436;;C12N2710/10343;;Y02A50/30;;C07K14/4702;;G01N33/6845;;G01N33/6893;;G01N33/57423;;A61K38/16;;A61P35/00;;G01N2500/02;;A61P35/00;;A61K38/17;;A61K47/46;;C12N7/00;;C12N2750/14143;;A61K31/436;;A61K31/519;;A61K38/1709;;C07K14/4702,A61K38/17;;A61K47/46;;A61P35/00;;C12N7/00,,5,3,047-667-417-684-235;;042-073-528-537-908;;060-437-712-320-626,pmc139241;;10.1073/pnas.242603899;;12477932;;14684267;;10.1016/j.jconrel.2003.09.013;;pmc2671927;;19351720;;10.1242/jcs.040709,"Strausberg et al. (Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)) (Year: 2002);;Sequence Alignment of SEQ ID NO:3 (17239289) with SEQ ID NO: 3744 (WO2013/151672) (Year: 2022);;Anas El-Aneed (Journal of Controlled Release. 2004; 9:1-14) (Year: 2004);;Zhang et al. PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradation. J Cell Sci. 2009 May 1;122(Pt 9):1382-9. doi: 10.1242/jcs.040709. Epub 2009 Apr 7. (Year: 2009);;Sequence alignment of SEQ ID NO: 2 (17239289) with SEQ ID NO: 8280 (15425813); Sequence alignment of SEQ ID NO: 4 (17239289) with SEQ ID NO: 1 (12051649) (Year: 2022)",ACTIVE
420,US,A1,US 2021/0215714 A1,039-855-614-818-843,2021-07-15,2021,US 201917058547 A,2019-05-28,US 201917058547 A;;US 201862676858 P;;US 201862750048 P;;US 2019/0034210 W,2018-05-25,COMPLEMENT ALTERNATIVE PATHWAY-ASSOCIATED NEPHROPATHY BIOMARKERS,Provided herein are methods for using determinative urinary biomarkers for identifying a human subject suffering from an alternative pathway (AP)-associated nephropathy. Also provided herein is a method for using determinative urinary biomarkers to determine whether a human subject suffering from a complement mediated nephropathy is likely to respond to an inhibitor of the alternative complement pathway (“AP”) in treating the complement mediated nephropathy. Further provided herein is a method for using urinary biomarkers to assess the therapeutic response of a human subject suffering from an AP-associated nephropathy receiving inhibitors of the complement alternative pathway (AP inhibitors).,ACHILLION PHARMACEUTICALS INC,HUANG MINGJUN;;PODOS STEVEN D;;YANG WENGANG;;ZHAO YONGSEN,ACHILLION PHARMACEUTICALS INC (2019-07-16),https://lens.org/039-855-614-818-843,Patent Application,yes,1,0,5,192-553-167-383-49X;;039-855-614-818-843;;030-675-050-951-298;;110-131-222-008-752;;005-737-290-697-481,JP;;EP;;WO;;US,5,030-675-050-951-298;;039-855-614-818-843;;192-553-167-383-49X;;110-131-222-008-752;;005-737-290-697-481,JP;;EP;;WO;;US,0,A61K31/506;;A61K31/517;;G01N2333/4716;;G01N33/6893;;G01N2800/347;;G01N2333/96441;;G01N2800/52;;G01N2800/245;;G01N33/564;;A61K31/506;;A61K31/517;;G01N33/6893;;G01N2333/4716;;G01N2800/347;;G01N2800/52;;G01N33/564,G01N33/68;;A61K31/506;;A61K31/517,,2,2,068-807-593-206-893;;007-407-895-683-26X,10.2174/0929867326666191001130342;;31573880;;10.5772/23314,"Wiles et al., “Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471),” Curr. Med. Chem., 2020, vol. 27, No 25, pp. 4165-4180;;Ohlsson, “Urinary Biomarkers in Glomerulonephritis,” In: An Update on Glomerulopathies - Etiology and Pathogenesis, Ed. Sharma Prabhakar, Chapter 14, pp. 269-276, published: 06 September 2011",DISCONTINUED
421,US,A1,US 2023/0079787 A1,194-376-659-917-96X,2023-03-16,2023,US 202117474028 A,2021-09-13,US 202117474028 A,2021-09-13,PIGM GENE RELATED TO NILAPARVATA LUGENS (STÅL) REPRODUCTION AND APPLICATION THEREOF,"A nucleotide sequence is shown in SEQ ID NO.1. The gene encodes mannosyltransferase I. The gene plays an important role in the normal reproductive development of the Nilaparvata lugens (Stål). Inhibition of the function of the gene may reduce the survival rate of the Nilaparvata lugens (Stål) and hinder embryonic development. With respect to reduction of the survival rate of the Nilaparvata lugens (Stål) and hindering of embryonic development, the present invention can reduce the harm of the Nilaparvata lugens (Stål) to rice by killing the Nilaparvata lugens (Stål). By using the characteristic that the nucleotide sequence of a highly conserved target gene has no homology with the nucleotide sequence of natural enemies of the Nilaparvata lugens (Stål), RNA interference is performed at a nucleic acid level, to avoid the harm to non-target organisms such as natural enemies, thereby realizing green control of the Nilaparvata lugens (Stål) while controlling pests.",UNIV JILIANG CHINA,LI YABIN;;ZHENG RONGER;;XU YIPENG;;YU XIAOPING,,https://lens.org/194-376-659-917-96X,Patent Application,yes,0,1,2,194-376-659-917-96X;;009-823-531-055-727,US,2,194-376-659-917-96X;;009-823-531-055-727,US,1,A01P7/04;;A01N63/14;;C07K14/43563;;C12N9/1051;;C12Y204/01142;;C12N15/1137;;C12N2310/14;;C07K14/325;;A01N63/10;;C12N15/11,A01N63/10;;C07K14/325,,0,0,,,,ACTIVE
422,US,A1,US 2022/0125935 A1,007-761-517-711-958,2022-04-28,2022,US 201917292404 A,2019-10-23,KR 20180135892 A;;KR 2019013970 W,2018-11-07,COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS COMPRISING SKIN-PENETRATING NUCLEIC ACID COMPLEX AS EFFECTIVE COMPONENT,"The present invention relates to a composition for preventing or treating skin diseases, comprising a skin-penetrating nucleic acid complex as an effective component, and more specifically, to a pharmaceutical composition or a cosmetic composition for preventing, alleviating, or treating atopic dermatitis, comprising a skin-penetrating nucleic acid complex in which a carrier peptide nucleic acid and a bioactive nucleic acid targeting TLR2 or IL-4Rα are connected by complementary binding. The skin-penetrating nucleic acid complex according to the present invention, in which the carrier peptide nucleic acid and the bioactive nucleic acid targeting TLR2 or IL-4Rα are connected by complementary binding, has high skin permeation and skin retention, and thus is useful in the prevention, alleviation or treatment of skin diseases such as atopic dermatitis.",SEASUN THERAPEUTICS,YU JI-YEON;;KIM HYE JOO;;KANG YUSUN;;LEE DONG IN;;PARK HEE KYUNG,,https://lens.org/007-761-517-711-958,Patent Application,yes,0,2,15,009-890-281-774-891;;089-555-474-113-372;;042-040-118-717-710;;073-941-791-821-115;;136-098-238-844-407;;071-938-501-998-810;;063-572-187-959-499;;149-365-382-754-831;;007-761-517-711-958;;094-812-089-614-424;;011-873-995-374-192;;137-305-663-223-025;;005-418-049-578-250;;006-922-136-614-220;;003-448-510-594-991,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,15,009-890-281-774-891;;089-555-474-113-372;;042-040-118-717-710;;073-941-791-821-115;;136-098-238-844-407;;071-938-501-998-810;;063-572-187-959-499;;149-365-382-754-831;;007-761-517-711-958;;094-812-089-614-424;;011-873-995-374-192;;137-305-663-223-025;;005-418-049-578-250;;006-922-136-614-220;;003-448-510-594-991,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,19,A61P17/00;;A61Q19/00;;A61K31/713;;A61K9/0014;;A61K9/06;;A61K8/606;;A61K47/549;;A61K47/541;;A61K47/64;;A61K47/6455;;A01K2207/20;;A01K2227/105;;A01K2267/0368;;C12N15/87;;C12N15/1138;;C12N2310/11;;C12N2310/3181;;C12N2310/3513;;C12N2320/32;;A61K48/0033;;A61K47/549;;A61K31/7088;;A61K9/0014;;A61P17/00;;A61K8/606;;A61Q19/00;;A61K2800/57;;A61K47/64;;A61K47/549;;A61P17/00,A61K47/54;;A61K47/64;;A61P17/00,,5,2,008-928-144-627-267;;144-823-634-965-883,pmc4393649;;24840552;;10.1038/nrg3742;;10.17226/18577,"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 2024 (Skin Diseases, Conditions & Disorders, p. 1-4) .;;Kotterman et al., 2014 (Nature Reviews, Vol. 15, p. 445-451).;;Shim et al., 2017 (Current Gene Therapy, Vol. 17, No. 5, p. 1-18).;;Lenzi et al., 2014 (NCBI Bookshelf, A Service of the National Library of Medicine, National Institute of Health, Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Advisory Committee. Washington (DC): National Academies Press (US), pages 1-16).;;Drag et al., 2023 (IOVS, Vol. 64, No. 7, article 39, p. 1-17).",PENDING
423,US,A1,US 2024/0084313 A1,025-259-287-055-623,2024-03-14,2024,US 202118272355 A,2021-12-31,CN 2021143731 W,2021-12-31,HIV Pseudovirus Particles and Method for Preparing the Same,"HIV pseudovirus particles and method for preparing the same. The pseudovirus particles contain conserved sequences of gag, pol and LTR regions on genes from HIV-1 and a protein from phage MS2. The method comprises the following steps: designing and selecting target fragments and a sequence of gene from phage MS2; direct synthesizing both of them respectively; inserting the sequence of gene from phage MS2 into pETDuet-1 vector to obtain pETDuet-MS2 vector; inserting the target fragments into pETDuet-MS2 vector to obtain pETDuet-MS2-HIV recombinant expression vector. The sequence of gene from phage MS2 and target fragments respectively are located between any restriction sites behind the 3′ends of two T7 promoters of pseudovirus particles. The pseudovirus particles are encapsulated with a plurality of RNA conserved fragments from HIV-1 simultaneously, and have high yield and good stability. The method is fast, convenient, efficient and cost-effective.",CHENGDU BOE OPTOELECT TECH CO;;BOE TECHNOLOGY GROUP CO LTD,JING HAIRONG,CHENGDU BOE OPTOELECTRONICS TECHNOLOGY CO. LTD (2023-05-24);;BOE TECHNOLOGY GROUP CO. LTD (2023-05-24),https://lens.org/025-259-287-055-623,Patent Application,yes,0,0,3,106-483-789-494-258;;025-259-287-055-623;;195-134-683-257-740,CN;;WO;;US,3,106-483-789-494-258;;025-259-287-055-623;;195-134-683-257-740,CN;;WO;;US,11,C12N7/04;;C12N15/70;;C12N9/22;;C07K14/005;;C12N7/00;;C12N15/86;;C07K14/005;;C12N7/00;;C12N9/22;;C12N15/70;;C12N2740/16022,C12N15/70;;C07K14/005;;C12N7/00;;C12N9/22,,0,0,,,,PENDING
424,US,A1,US 2020/0392566 A1,008-245-257-080-314,2020-12-17,2020,US 201916673021 A,2019-11-04,CN 201910510071 A,2019-06-13,"Primer, And Kit For Rapid Detection Of Bacteria And Application Thereof","The present disclosure relates to a primer and a kit for rapid detection of bacteria and an application thereof, belonging to the technical field of bacterial detection. The present disclosure provides a primer for rapid detection of bacteria, a nucleotide sequence of a forward primer for the detection is shown in SEQ ID NO.1, and a nucleotide sequence of a reverse primer is shown in SEQ ID NO.2; a degenerate base W=A/T in the forward primer, and a degenerate base R=A/G in the reverse primer. The primer of the present disclosure may achieve rapid, wide, high-sensitivity and quantitative detection of bacteria, can be applied in the field of bacterial detection, and is more suitable for the clinical research and application of cells and stem cell-based products.",SHANGHAI EAST HOSPITAL EAST HOSPITAL AFFILIATED TO TONGJI UNIV,LIU ZHONGMIN;;JIA WENWEN;;BAI ZHIHUI;;TANG HONGMING,SHANGHAI EAST HOSPITAL (EAST HOSPITAL AFFILIATED TO TONGJI UNIVERSITY) (2019-10-08),https://lens.org/008-245-257-080-314,Patent Application,yes,0,1,2,008-245-257-080-314;;035-743-129-819-170,CN;;US,2,008-245-257-080-314;;035-743-129-819-170,CN;;US,3,C12Q1/689;;C12Q1/689;;C12Q1/689,C12Q1/689,,0,0,,,,DISCONTINUED
425,WO,A1,WO 2023/222617 A1,070-930-183-682-331,2023-11-23,2023,EP 2023063001 W,2023-05-15,EP 22173516 A,2022-05-16,ENDOGENOUS SIGNALING MOLECULE ACTIVATING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF GENERATION THEREOF,"The present invention provides an endogenous signaling molecule activating chimeric antigen receptor (ESMA-CAR) comprising a) an antigen binding domain specific for an antigen, b) a first transmembrane domain, and c) an intracellular signaling domain comprising a co- stimulatory domain but no stimulatory domain, wherein said first transmembrane domain, when expressed on the cell surface of an immune cell, is able to recruit a stimulatory domain of an endogenous signaling molecule of said immune cell, wherein said endogenous signaling molecule is a protein comprising a second transmembrane domain and an intracellular signaling domain comprising a stimulatory domain, and wherein the interaction of the first transmembrane domain and the second transmembrane domain activates said immune cell upon binding of said antigen to said antigen binding domain of said ESMA-CAR. The present invention also discloses an immune cell expressing said ESMA-CAR and an in-vitro method for the generation of said ESMA-CAR.",MILTENYI BIOTEC BV & CO KG,EBBINGHAUS MIRA;;PFEIFER RITA,,https://lens.org/070-930-183-682-331,Patent Application,yes,7,0,2,070-930-183-682-331;;158-796-587-857-827,EP;;WO,2,070-930-183-682-331;;158-796-587-857-827,EP;;WO,42,C07K14/7051;;C07K14/70517;;C07K14/70521;;C07K14/70535;;C07K14/70578;;C07K14/70596;;C07K2319/00;;C07K2319/03;;C07K2319/33;;A61K2239/22;;A61K2239/21;;A61K40/4204;;A61K40/11;;A61K40/31,C07K14/705,,2,2,099-939-408-274-595;;002-370-817-269-196,20222863;;10.2174/156652310791111001;;10.4049/jimmunol.161.12.6604;;9862688,"BRIDGEMAN JOHN S ET AL: ""Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy"", CURRENT GENE THERAPY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 10, no. 2, 1 April 2010 (2010-04-01), pages 77 - 90, XP009187229, ISSN: 1566-5232, DOI: 10.2174/156652310791111001;;ANNENKOV A E ET AL: ""LOSS OF ORIGINAL ANTIGENIC SPECIFICITY IN T CELL HYBRIDOMAS TRANSDUCED WITH A CHNIMERIC RECEPTOR CONTAINING SINGLE-CHAIN FV OF AN ANTI-COLLAGEN ANTIBODY AND FCERI-SIGNALING GAMMA SUBUNIT"", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 161, no. 12, 15 December 1998 (1998-12-15), pages 6604 - 6613, XP000925641, ISSN: 0022-1767",PENDING
426,EP,A1,EP 4299746 A1,018-593-016-985-968,2024-01-03,2024,EP 21935490 A,2021-04-06,CN 2021085609 W,2021-04-06,MODIFIED PRP43 HELICASE AND USE THEREOF,"The present application relates to a modified Prp43 helicase and use thereof. The Prp43 helicase has enhanced ATP hydrolytic or unwinding activity due to introduction of mutations and/or introduction of an auxiliary protein, and can remain binding to the target polynucleotide for a long period of time, thereby allowing the enzyme to control the rate of movement of the polynucleotide continuously and stably at a suitable rate required for sequencing. Thus, the modified or engineered Prp43 helicase mutant of the present application allows for the control of movement of a target polynucleotide in a more advantageous manner, which can be used for nanopore sequencing.",QITAN TECH LTD CHENGDU,ZHANG ZHOUGANG;;LI WEN;;WANG YANSHUANG;;WANG MUYANG,,https://lens.org/018-593-016-985-968,Patent Application,yes,0,0,5,192-496-689-978-61X;;015-659-181-090-754;;018-593-016-985-968;;170-025-577-890-382;;001-722-957-299-75X,CN;;EP;;WO;;US,5,192-496-689-978-61X;;015-659-181-090-754;;018-593-016-985-968;;001-722-957-299-75X;;170-025-577-890-382,CN;;EP;;WO;;US,44,C12Q1/6869;;C12N9/14;;C12N9/90;;C12N9/14;;C12N15/70;;C12Q1/6869;;C12Y306/04013;;G01N33/48721,C12N15/55;;C12M1/34;;C12N9/14;;C12Q1/6869;;G01N33/48,,0,0,,,,PENDING
427,EP,A1,EP 3939701 A1,157-614-637-845-300,2022-01-19,2022,EP 20770856 A,2020-03-11,KR 20190028069 A;;KR 20190134094 A;;KR 20190134095 A;;KR 2020003411 W,2019-03-12,MICROFLUIDIC SYSTEM FOR INTRACELLULAR DELIVERY OF SUBSTANCES AND METHOD THEREFOR,"There is provided a microfluidic system delivering external materials into a cell by cell mechanoporation using inertia, the microfluidic system including a fluidic channel structure through which a solution containing a cell and external materials flows continuously, in which the fluidic channel structure includes a junction between one or more channels, a localized vortex is generated near an interface of the junction, the cell is deformed by the vortex, and transient discontinuities are generated in a cell membrane by the vortex and the external materials are introduced into the cell by solution exchange between the cell and fluid around the cell.",UNIV KOREA RES & BUS FOUND,CHUNG A-RAM;;KANG GUM-YOUNG;;HUR JEONG-SOO,MXT BIOTECH (2022-10-12),https://lens.org/157-614-637-845-300,Patent Application,yes,0,0,9,096-790-774-056-908;;157-614-637-845-300;;082-793-049-954-233;;157-574-542-535-066;;037-551-344-657-81X;;180-723-113-124-234;;090-125-859-924-606;;058-435-618-856-570;;043-014-864-297-188,AU;;JP;;EP;;CN;;WO;;US,15,087-398-948-678-30X;;082-793-049-954-233;;096-790-774-056-908;;037-551-344-657-81X;;043-014-864-297-188;;157-614-637-845-300;;157-574-542-535-066;;024-118-496-642-378;;139-814-893-133-277;;180-723-113-124-234;;090-125-859-924-606;;038-969-224-010-709;;189-668-374-060-388;;192-739-981-521-282;;058-435-618-856-570,KR;;JP;;AU;;CN;;EP;;WO;;US;;CA,0,B01L3/502761;;B01L2200/0652;;B01L2400/0487;;C12M23/16;;C12M29/14;;C12M33/10;;C12M35/04;;C12M41/40;;C12M23/16;;C12M27/02;;C12M29/14;;C12M33/10;;C12M41/40,B01L3/00,,0,0,,,,PENDING
428,US,A1,US 2025/0082694 A1,004-453-823-950-339,2025-03-13,2025,US 202218580713 A,2022-07-13,EP 21187190 A;;EP 2022069586 W,2021-07-22,PROBIOTICS FOR USE IN BOOSTING THE IMMUNE SYSTEM,"This invention relates to bacterial strains, compositions comprising bacterial strains as well as methods and uses of said strains and compositions for use in boosting the immune system. More specifically, the invention relates to bacterial strains having immunomodulatory properties providing specific health benefits in a subject in need thereof.",INT N&H DENMARK APS,LEHTINEN MARKUS;;LATVALA SINIKKA ANNELI;;LEHTORANTA LIISA,,https://lens.org/004-453-823-950-339,Patent Application,yes,0,0,4,073-924-657-099-817;;197-327-608-430-666;;171-178-027-813-394;;004-453-823-950-339,EP;;CN;;WO;;US,4,073-924-657-099-817;;197-327-608-430-666;;171-178-027-813-394;;004-453-823-950-339,EP;;CN;;WO;;US,0,A61K35/747;;A61P31/04;;A61P31/12;;A61P35/00;;A61P29/00;;A61P37/04;;A61K35/741,A61K35/741;;A61P37/04,,0,0,,,,PENDING
429,EP,A1,EP 3995567 A1,050-566-235-609-571,2022-05-11,2022,EP 20835360 A,2020-07-06,CN 201910596633 A;;CN 201910597371 A;;CN 201910996538 A;;CN 201910997521 A;;CN 2020100482 W,2019-07-04,"TRICHODERMA REESEI STRAIN, CULTURE METHOD THEREFOR, AND APPLICATION THEREOF",The invention relates to a strain of Trichoderma reesei BLCY-007 and its application in the production of xylooligosaccharides.,SHANDONG BAILONG CHUANGYUAN BIO TECH CO LTD,GAN ZHAOBO;;DOU BAODE;;DOU GUANGPENG;;SHAO XIANBAO;;LI FANGHUA;;DU QIAN,,https://lens.org/050-566-235-609-571,Patent Application,yes,0,0,6,107-700-779-362-758;;093-348-529-629-935;;023-961-973-536-205;;078-612-902-834-678;;074-591-748-182-126;;050-566-235-609-571,EP;;CN;;WO;;US;;CA,9,107-700-779-362-758;;093-348-529-629-935;;023-961-973-536-205;;069-416-658-580-105;;090-867-640-075-112;;074-591-748-182-126;;078-612-902-834-678;;050-566-235-609-571;;192-549-148-852-674,EP;;CN;;WO;;US;;CA,0,C12N9/248;;C12N1/14;;C12N1/145;;C12P19/00;;C12P19/04;;C12P19/12;;C12P19/14;;C12P21/02;;C12R2001/885;;C12Y302/01008;;C12P19/14;;C12N1/145;;C12N9/248;;C12P21/00;;C12P2203/00;;C12R2001/885,C12N1/14;;C12N9/24;;C12P19/00;;C12P19/04;;C12P19/12;;C12P19/14,,0,0,,,,PENDING
430,US,A1,US 2025/0049872 A1,141-097-348-458-693,2025-02-13,2025,US 202318564997 A,2023-06-26,CN 202211276970 A;;CN 2023102281 W,2022-10-18,hypoallergenic milk with immune enhancing function and preparation method thereof,"The present disclosure relates to a hypoallergenic milk with immune enhancing function and a preparation method thereof. To solve the problem of milk allergy and lactose intolerance populations being unable to intake milk nutrition through traditional dairy products, the present disclosure provides a hypoallergenic milk with immune enhancing function, including raw milk, collagen peptide, and yeast β-glucan, acerola cherry powder, maltitol, lactase, stabilizer, essence and water; and the raw milk is A2β-casein organic raw milk. The hypoallergenic milk provided by the present disclosure reduces allergenic substances and risk in terms of formula composition and production process, especially suitable for lactose intolerance and A1β-casein allergy populations. The present disclosure further adopts a triple immune science formula, retaining the active ingredients and high-quality nutrients in milk. Long term consumption can effectively improve human immunity, and is suitable for people who need to supplement milk nutrition and enhance immunity.",BEIDAHUANG WANDA MOUNTAINS DAIRY CO LTD,ZHENG YANG;;LIANG CHAO;;XIA JIE;;WANG ZHANDONG;;WANG QINGYUN,,https://lens.org/141-097-348-458-693,Patent Application,yes,0,0,3,141-097-348-458-693;;128-000-329-583-240;;186-899-660-322-480,CN;;WO;;US,3,141-097-348-458-693;;128-000-329-583-240;;186-899-660-322-480,CN;;WO;;US,0,A23C9/156;;A23C9/152;;A23C9/1526;;A23C9/1206;;A61K31/716;;A61P37/08;;A23C9/1322;;A61K38/39;;A23C9/1307;;C12Y302/01108;;A61K38/47;;A23C9/1206;;A61K31/375;;A23C9/133;;A61K36/736;;A61K35/20;;A61K31/7004;;A61P37/08;;A23C9/1206;;A23C9/1307;;A23C9/1322;;A23C9/133;;A61K31/375;;A61K31/716;;A61K36/185;;A61K38/39;;A61K38/47;;C12Y302/01108,A61K36/185;;A23C9/12;;A23C9/13;;A23C9/133;;A61K31/375;;A61K31/716;;A61K38/39;;A61K38/47;;A61P37/08,,0,0,,,,PENDING
431,EP,A1,EP 4119573 A1,198-877-147-345-399,2023-01-18,2023,EP 22744363 A,2022-01-14,CN 202110520499 A;;CN 2022071968 W,2021-05-13,"RECOMBINANT HUMAN TYPE XVII COLLAGEN, PREPARATION METHOD AND APPLICATION THEREOF","The present disclosure provides a recombinant human type XVII collagen. The recombinant human type XVII collagen consists of an amino acid sequence shown in (A)<sub>n</sub> or includes the amino acid sequence shown in (A)<sub>n</sub>, where A is a sequence set forth in SEQ ID NO: 2, a sequence undergoing an amino acid modification to a predetermined extent based on SEQ ID NO: 2, or a sequence that has more than 80% homology with SEQ ID NO: 2; n is an integer greater than or equal to 1; and A represents a basic unit, and when there are two or more basic units, the two or more basic units are identical or different and are directly connected in tandem through a peptide bond. In the present disclosure, it is confirmed that the recombinant human type XVII collagen can undergo efficient secretory and soluble expression in eukaryotic host cells such as Pichia pastoris (P. pastoris), and also exhibits more excellent cell adhesion activity, cell migration-promoting activity, tissue regeneration-promoting activity, and hair follicle repair and regeneration-promoting activity than commercial native human collagen, and can be industrially produced.",JIANGSU TRAUTEC MEDICAL TECH CO LTD,LI JIAJIA;;WANG LIPING;;QIAN SONG,,https://lens.org/198-877-147-345-399,Patent Application,yes,0,0,16,170-184-022-250-996;;106-317-028-483-366;;100-381-864-362-103;;049-516-407-964-238;;024-253-392-498-414;;003-713-328-386-795;;059-765-198-772-271;;137-246-534-751-131;;165-988-581-795-119;;131-192-256-191-015;;106-710-689-138-720;;126-464-251-875-085;;185-280-610-699-620;;016-136-726-398-841;;064-587-092-012-84X;;198-877-147-345-399,JP;;KR;;MY;;EP;;ES;;CN;;WO;;US;;PL,16,170-184-022-250-996;;106-317-028-483-366;;100-381-864-362-103;;049-516-407-964-238;;024-253-392-498-414;;003-713-328-386-795;;059-765-198-772-271;;137-246-534-751-131;;165-988-581-795-119;;131-192-256-191-015;;106-710-689-138-720;;126-464-251-875-085;;185-280-610-699-620;;016-136-726-398-841;;064-587-092-012-84X;;198-877-147-345-399,JP;;KR;;MY;;EP;;ES;;CN;;WO;;US;;PL,10,C07K14/78;;C12N15/815;;A61P17/02;;A61P17/14;;A61K8/65;;A61Q7/00;;A61L27/24;;A61L27/54;;A61L31/16;;A61L31/044;;A23L33/17;;C12N2800/102;;C12N2800/22;;A61K38/00;;A61L2300/412;;A23V2002/00;;C12R2001/84;;C12N15/815;;Y02A50/30;;A23L33/17;;A23L29/284;;A61K8/65;;A61K8/9728;;A61Q19/00;;A61K2800/10;;C07K14/78;;A61K38/00;;C07K14/78;;C12N15/815;;A61K38/00;;A61K36/06;;A61K8/65;;A61K8/9728;;A61Q19/00;;A23L29/284;;A23L33/17;;C07K2319/20;;C12R2001/84;;A23V2200/318;;A23V2002/00;;A61P17/02;;C07K14/78;;C12N15/81,C07K14/78;;C12N15/12,,0,0,,,,ACTIVE
432,EP,A1,EP 4592398 A1,171-012-390-525-100,2025-07-30,2025,EP 24837520 A,2024-09-20,CN 202311674732 A;;CN 202311677300 A;;CN 2024120027 W,2023-12-07,NUCLEIC ACID DETECTION METHOD,"The application belongs to the field of molecular biological detection, particularly relates to a nucleic acid detection method, and more particularly relates to a method for rapidly extracting and detecting nucleic acids. The application provides a nucleic acid detection method which includes the following steps: S1, mixing a to-be-tested sample with a direct amplification preservation solution, and performing ultrasonic treatment to obtain a sample nucleic acid solution; S2, adding the sample nucleic acid solution obtained in step S1 into an amplification reaction solution to obtain a mixed solution; S3, carrying out amplification reaction by the mixed solution, and detecting nucleic acids; where the direct amplification preservation solution includes a protective agent, a nuclease inhibitor, a surfactant, a buffer system and a bacteriostatic agent. By the method provided by the application, the whole detection process is simple and less affected, and the detection time is short.",SANSURE BIOTECH INC,DAI LIZHONG;;SUN QINGZHI;;TAN DEYONG;;XU SIYAO;;WANG JIAN;;GUO JUN;;JI BOZHI;;WU KANG;;LIU JIA,,https://lens.org/171-012-390-525-100,Patent Application,yes,0,0,2,171-012-390-525-100;;098-540-428-728-848,EP;;US,5,145-830-638-132-979;;029-525-162-208-782;;171-012-390-525-100;;049-945-664-948-066;;098-540-428-728-848,CN;;EP;;WO;;US,0,C12Q1/6848;;C12Q1/6806;;C12Q1/686;;C12Q1/70;;C12R2001/91;;C12Q1/686;;C12Q1/6848;;C12Q1/6806,C12Q1/6806;;C12Q1/686;;C12Q1/70;;C12R1/93,,0,0,,,,PENDING
433,US,A1,US 2021/0024927 A1,158-760-023-728-435,2021-01-28,2021,US 201816958625 A,2018-12-28,CN 201711476630 A;;CN 2018124687 W,2017-12-29,CHIMERIC PROMOTER WITH HIGH TRANSCRIPTIONAL ACTIVITY IN T-CELLS,"Provided is a chimeric promoter with a high transcriptional activity in T-cells. The chimeric promoter consists of an enhancer sDTS and a promoter operably linked to the enhancer. The sequence of the enhancer is as shown in SEQ ID NO: 1. The enhancer is located at the 5′ or 3′ terminus of the promoter. Also provided are nucleic acid constructs, vectors and T-cells comprising the chimeric promoter. The chimeric promoter can drive the efficient expression of exogenous genes in T-cells.",SHANGHAI CELL THERAPY RES INST;;SHANGHAI CELL THERAPY GROUP CO LTD,QIAN QIJUN;;JIN HUAJUN;;WANG CHAO;;HE ZHOU;;LI LINFANG;;SUN JUANJUAN;;HUANG CHEN,SHANGHAI CELL THERAPY RESEARCH INSTITUTE (2020-12-01);;SHANGHAI CELL THERAPY GROUP CO. LTD (2020-12-01),https://lens.org/158-760-023-728-435,Patent Application,yes,6,0,7,188-186-593-954-471;;107-087-404-432-884;;197-793-383-772-961;;158-760-023-728-435;;127-205-858-818-618;;115-529-918-905-55X;;147-031-414-918-560,JP;;CN;;EP;;WO;;US,7,188-186-593-954-471;;107-087-404-432-884;;197-793-383-772-961;;158-760-023-728-435;;127-205-858-818-618;;115-529-918-905-55X;;147-031-414-918-560,JP;;CN;;EP;;WO;;US,12,C12N15/113;;C12N15/85;;C12N5/0636;;C07K16/2818;;C12N2830/15;;C12N2510/02;;C12N15/63;;C12N5/0636;;C12N2510/00;;C12N2501/52;;C12N2501/51;;C12N5/0636;;C12N5/10;;C12N15/113;;C12N15/63;;C12N2830/15,C12N15/113;;C12N5/0783;;C12N5/10;;C12N15/63,,7,5,012-513-862-089-432;;035-976-233-926-571;;012-360-930-072-655;;029-452-788-165-724;;013-412-290-595-260,10.1016/0093-691x(95)00355-c;;10.1002/(sici)1097-4547(19960701)45:1<57::aid-jnr5>3.0.co;2-g;;8811512;;10.1016/0168-1656(94)90062-0;;7764960;;18243312;;10.1016/j.cimid.2007.11.005;;pmc7112688;;27100458;;pmc5410105;;10.1099/jgv.0.000487;;25582824;;10.1038/mt.2015.4;;pmc4395796,"Wall et Al. (Theriogenology, Vol. 45, Pg. 57-68, 1996) (Year: 1996);;Houdebine et Al. (Journal of Biotechnology, Vol. 34, Pg. 269- 287, 1994) (Year: 1994);;Kappell et Al. (Current Opinions in Biotechnology, Vol. 3, Pg. 548-553, 1992) (Year: 1992);;Houdebine (Comparative Immunology, Microbiology, and Infectious Diseases, Vol. 32, Pg. 107-121, 2009) (Year: 2009);;Schmidt (Journal of General Virology, Vol. 97, Pg. 1597-1603, 2016) (Year: 2016);;Liu (Cancer Research, Vol. 69, No. 19, Pg. 1-15, 2009) (Year: 2009);;Curran (Molecular Therapy, Vol. 23, NO. 4, Pg. 769-778, 2015) (Year: 2015)",DISCONTINUED
434,EP,A1,EP 3878474 A1,094-812-089-614-424,2021-09-15,2021,EP 19882198 A,2019-10-23,KR 20180135892 A;;KR 2019013970 W,2018-11-07,COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS COMPRISING SKIN-PENETRATING NUCLEIC ACID COMPLEX AS EFFECTIVE COMPONENT,"The present invention relates to a composition for preventing or treating skin diseases, comprising a skin-penetrating nucleic acid complex as an effective component, and more specifically, to a pharmaceutical composition or a cosmetic composition for preventing, alleviating, or treating atopic dermatitis, comprising a skin-penetrating nucleic acid complex in which a carrier peptide nucleic acid and a bioactive nucleic acid targeting TLR2 or IL-4Rα are connected by complementary binding. The skin-penetrating nucleic acid complex according to the present invention, in which the carrier peptide nucleic acid and the bioactive nucleic acid targeting TLR2 or IL-4Rα are connected by complementary binding, has high skin permeation and skin retention, and thus is useful in the prevention, alleviation or treatment of skin diseases such as atopic dermatitis.",SEASUN THERAPEUTICS,YU JI-YEON;;KIM HYE JOO;;KANG YUSUN;;LEE DONG IN;;PARK HEE KYUNG,"SEASUN THERAPEUTICS, INC. (2023-12-06)",https://lens.org/094-812-089-614-424,Patent Application,yes,0,0,15,009-890-281-774-891;;089-555-474-113-372;;042-040-118-717-710;;073-941-791-821-115;;136-098-238-844-407;;071-938-501-998-810;;063-572-187-959-499;;149-365-382-754-831;;007-761-517-711-958;;094-812-089-614-424;;011-873-995-374-192;;137-305-663-223-025;;005-418-049-578-250;;006-922-136-614-220;;003-448-510-594-991,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,15,009-890-281-774-891;;089-555-474-113-372;;042-040-118-717-710;;073-941-791-821-115;;136-098-238-844-407;;071-938-501-998-810;;063-572-187-959-499;;149-365-382-754-831;;007-761-517-711-958;;094-812-089-614-424;;011-873-995-374-192;;137-305-663-223-025;;005-418-049-578-250;;006-922-136-614-220;;003-448-510-594-991,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,19,A61P17/00;;A61Q19/00;;A61K31/713;;A61K9/0014;;A61K9/06;;A61K8/606;;A61K47/549;;A61K47/541;;A61K47/64;;A61K47/6455;;A01K2207/20;;A01K2227/105;;A01K2267/0368;;C12N15/87;;C12N15/1138;;C12N2310/11;;C12N2310/3181;;C12N2310/3513;;C12N2320/32;;A61K48/0033;;A61K47/549;;A61K31/7088;;A61K9/0014;;A61P17/00;;A61K8/606;;A61Q19/00;;A61K2800/57;;A61K47/64;;A61K47/549;;A61P17/00,A61K48/00;;A61K8/60;;A61K9/00;;A61K31/7088;;A61K47/54;;A61P17/00;;A61Q19/00,,0,0,,,,DISCONTINUED
435,WO,A1,WO 2024/068795 A1,053-372-339-966-673,2024-04-04,2024,EP 2023076807 W,2023-09-27,GB 202214112 A;;GB 202303918 A;;GB 202309780 A,2022-09-27,METHOD FOR RELEASING VIRAL VECTORS,The present invention provides a method of releasing viral vectors from cells producing those viral vectors by contacting the cells with a photosensitising agent which is then irradiated to disrupt the plasma membrane of the cells to release the viral vectors which may be collected and/or purified. The product of such methods as well as kits and apparatuses for performing the methods are also provided.,PCI BIOTECH AS,LUHR MORTEN;;HØGSET ANDERS;;NORD KARIN,,https://lens.org/053-372-339-966-673,Patent Application,yes,6,0,8,053-372-339-966-673;;073-548-856-272-516;;039-905-932-940-556;;161-476-346-615-865;;149-370-005-256-235;;170-349-508-469-720;;199-893-370-646-692;;186-430-792-041-017,AU;;KR;;IL;;CN;;EP;;CL;;WO;;MX,10,053-372-339-966-673;;073-548-856-272-516;;039-905-932-940-556;;009-730-603-400-460;;161-476-346-615-865;;149-370-005-256-235;;170-349-508-469-720;;199-893-370-646-692;;033-983-591-210-517;;186-430-792-041-017,AU;;KR;;IL;;CN;;EP;;CL;;WO;;GB;;MX,4,C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2750/14151;;C07D487/22;;C12N15/86;;C12N2750/14152;;C07D487/22;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12M23/14;;C12M47/12;;C12N2750/14143;;C12N2750/14151;;C12N2750/14152,C12N15/86;;C07D487/00,,5,4,049-882-217-657-982;;086-319-270-884-171;;025-666-878-097-68X;;022-427-389-139-60X,10.1111/j.1365-2818.2005.01471.x;;15857375;;32075165;;10.3390/jcm9020528;;pmc7073817;;10.3791/52894;;pmc4781703;;26863087;;10.1111/j.1751-1097.1997.tb08578.x;;9077120,"BERG K ET AL: ""Porphyrin-related photosensitizers for cancer imaging and therapeutic applications"", JOURNAL OF MICROSCOPY, BLACKWELL SCIENCE, GB, vol. 218, 1 May 2005 (2005-05-01), pages 133 - 147, XP002610347, ISSN: 0022-2720;;JERJES WASEEM ET AL: ""Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research"", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 2, 14 February 2020 (2020-02-14), pages 528, XP055852369, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073817/pdf/jcm-09-00528.pdf> DOI: 10.3390/jcm9020528;;EHRKE-SCHULZ ET AL., J. VIS. EXP., vol. 107, 2016, pages e52894;;GRIEGER ET AL., MOLEC. THER., vol. 24, no. 2, 2016, pages 287 - 297;;BERG ET AL., J. PHOTOCHEMISTRY AND PHOTOBIOLOGY,, vol. 65, 1997, pages 403 - 409",PENDING
436,US,A1,US 2025/0003006 A1,114-032-132-673-988,2025-01-02,2025,US 202418603164 A,2024-03-12,CN 202310770107 A,2023-06-27,USE OF TMED8 GENE IN PREPARATION OF DRUG AND DIAGNOSTIC KIT FOR PANCREATIC CANCER,"The present disclosure provides use of a transmembrane emp24 domain 8 (TMED8) gene in preparation of a drug and a diagnostic kit for pancreatic cancer, and belongs to the technical field of precision tumor medicine. In the present disclosure, it is found that up-regulating an expression level of the TMED8 gene has significantly inhibited migration and proliferation of pancreatic cancer cells, and then promoted apoptosis of the pancreatic cancer cells; the TMED8 gene is further found to be related to a mitogen-activated protein kinase (MAPK) signaling pathway. Therefore, the TMED8 gene may be used as an effective target for gene diagnosis and treatment of the pancreatic cancer.",AFFILIATED HOSPITAL OF NANTONG UNIV,XIAO MINGBING;;WU TONG;;FAN XINGJUAN;;SHI JIAHAI;;ZHENG WENJIE;;NI WENKAI;;GUAN CHENGQI;;CHEN ZIWEI,AFFILIATED HOSPITAL OF NANTONG UNIVERSITY (2024-02-28),https://lens.org/114-032-132-673-988,Patent Application,yes,0,0,8,178-623-211-502-278;;177-778-703-443-083;;114-032-132-673-988;;098-382-537-473-177;;107-731-931-725-624;;137-986-825-323-624;;013-203-476-911-291;;010-742-052-833-027,DE;;JP;;CN;;WO;;US;;GB,8,178-623-211-502-278;;177-778-703-443-083;;114-032-132-673-988;;098-382-537-473-177;;107-731-931-725-624;;137-986-825-323-624;;013-203-476-911-291;;010-742-052-833-027,DE;;JP;;CN;;WO;;US;;GB,0,C12Q1/6886;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q2600/158;;C12Q1/6886,C12Q1/6886,,0,0,,,,PENDING
437,US,A1,US 2024/0376160 A1,176-521-233-236-206,2024-11-14,2024,US 202218255368 A,2022-08-30,CN 202210870801 A;;CN 2022115683 W,2022-07-22,MOLECULAR PEPTIDE MUTANT WITH A HIGH ESTER BOND FORMATION EFFICIENCY,"The invention relates to a molecular peptide mutant with a high ester bond formation efficiency, the amino acid sequence of which is as shown in SEQ ID NO: 1. The invention introduces mutations at three sites on the basis of not affecting the spatial structure of Catcher, and through three mutations, obtains the Catcher mutant EBCatcher, which significantly improves the stability of the Catcher in water solution and can improve the binding efficiency to EBTag.",NANJING UNIVERSITY OF TECHNOLOGY,JIANG LING;;CHEN YAO;;CHEN YUJIN;;ZHU LIYING;;LIU WEI,NANJING TECH UNIVERSITY (2023-04-12),https://lens.org/176-521-233-236-206,Patent Application,yes,0,0,3,176-521-233-236-206;;050-614-753-257-725;;098-089-627-073-393,CN;;WO;;US,3,176-521-233-236-206;;098-089-627-073-393;;050-614-753-257-725,CN;;WO;;US,0,C07K14/315;;C12N15/70;;C12R2001/19;;Y02A50/30;;C12R2001/19;;C07K14/315;;C12N15/70;;C07K14/245;;C12R2001/19;;C07K14/315;;C12N15/70,C07K14/315;;C12N15/70;;C12R1/19,,0,0,,,,PENDING
438,WO,A1,WO 2024/121327 A1,102-146-081-909-750,2024-06-13,2024,EP 2023084745 W,2023-12-07,EP 2022085064 W;;EP 23200769 A,2022-12-08,CO-GRANULATE FOR ANIMAL FEED,"An animal feed comprising an animal feed additive, said additive comprising co-granules, each co- granule comprising at least two classes of enzymes, said co-granules comprising a core unit and a protective coating such that the dose of each of the enzymes in the feed is set in each granule rather than by the level of homogeneity of single-enzyme granules or by the efficiency of the mixing.",NOVOZYMES AS;;DSM IP ASSETS BV,BORUP FLEMMING;;GAYTAN PEREZ IVAN DE JESUS,,https://lens.org/102-146-081-909-750,Patent Application,yes,17,1,4,102-146-081-909-750;;117-877-089-459-241;;019-853-797-838-93X;;096-922-596-681-090,AU;;CN;;WO;;MX,4,102-146-081-909-750;;117-877-089-459-241;;019-853-797-838-93X;;096-922-596-681-090,AU;;CN;;WO;;MX,62,A23K20/189;;A23K40/10;;A23K40/30;;A23K50/30;;A23K50/75;;A23K50/80;;C12N9/16;;C12N9/2411;;C12N9/248;;C12N9/50;;C12N9/98;;C12N9/244;;C12N9/2437,A23K20/189;;A23K40/10;;A23K40/30;;A23K50/30;;A23K50/75;;A23K50/80;;C12N9/16;;C12N9/24;;C12N9/26;;C12N9/50;;C12N9/98,,3,0,,,"A.O.A.C.: ""Official Methods of Analysis"", 1984, ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS;;""Nutrient requirements in swine"", 1988, NATIONAL ACADEMY PRESS, pages: 2 - 6;;""European Table of Energy Values for Poultry Feed-stuffs, Spelderholt centre for poultry research and extension"", pages: 7361",PENDING
439,WO,A1,WO 2025/145510 A1,111-226-550-226-722,2025-07-10,2025,CN 2024088774 W,2024-04-19,CN 2024070786 W,2024-01-05,METHODS AND COMPOSITIONS FOR MODIFYING FLOWERING TIME GENES IN PLANTS,"Methods and compositions are provided for modifying the flowering time and/or maturity time of soybean plants to enable them to be cultivated in a variety of geographical locations having different day lengths. Modified soybean plants are disclosed comprising non-natural mutant alleles at the E1, E2, E3, E4, E1La and/or E1Lb locus. The modified plants have a shorter flowering and/or maturity time than control plants.",SYNGENTA CROP PROTECTION AG;;SYNGENTA GROUP CO LTD;;INST OF CROP SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES,CHEN LI;;GAO YANG;;HOU WENSHENG;;CAI YUPENG;;YUAN SHAN;;SU QIANG;;SUN SHI;;HAN TIANFU,,https://lens.org/111-226-550-226-722,Patent Application,yes,0,0,4,111-226-550-226-722;;146-832-939-426-634;;165-578-635-472-488;;103-608-005-101-805,WO,4,111-226-550-226-722;;146-832-939-426-634;;165-578-635-472-488;;103-608-005-101-805,WO,79,C07K14/415;;C12N15/827,C12N15/82;;A01H1/02;;A01H1/04;;A01H5/00;;A01H6/54,,0,0,,,,PENDING
440,US,A1,US 2022/0396802 A1,068-144-435-917-791,2022-12-15,2022,US 202017774705 A,2020-11-05,CN 201911082325 A;;CN 2020126683 W,2019-11-07,"Cinnamomum Burmannii Monoterpene Synthase CBTPS1, Related Biomaterial Thereof And Application Thereof","Provided are a Cinnamomum burmannii monoterpene synthase CbTPS1, an amino acid sequence thereof, a nucleic acid molecule encoding the protein, an use thereof in preparing the monoterpene synthase, and a method for preparing dextrorotatory borneol by using the Cinnamomum burmannii monoterpene synthase CbTPS1.",SICHUAN HONGHE BIOTECHNOLOGY CO LTD,HUANG LUQI;;SU PING;;MA RUI;;CUI GUANGHONG;;GUO JUAN;;JIN BAOLONG;;HU YATING;;BAO JICHEN,SICHUAN HONGHE BIOTECHNOLOGY CO. LTD (2022-05-04),https://lens.org/068-144-435-917-791,Patent Application,yes,1,1,6,068-144-435-917-791;;027-699-992-121-157;;146-655-374-712-507;;074-865-895-515-926;;076-038-495-167-399;;060-205-605-300-192,EP;;CN;;WO;;US,6,068-144-435-917-791;;027-699-992-121-157;;146-655-374-712-507;;076-038-495-167-399;;074-865-895-515-926;;060-205-605-300-192,EP;;CN;;WO;;US,9,C12N9/88;;C12N15/70;;C12N15/81;;C12P7/26;;C12N15/70;;C12N15/81;;C12N9/88;;C12P5/007;;C12N9/88;;C12N15/70;;C12N15/81;;C12N15/82;;C12P5/007;;C12P7/02,C12N15/81;;C12N9/88;;C12N15/70;;C12N15/82;;C12P5/00;;C12P7/02,,3,3,094-264-969-943-117;;004-824-951-264-333;;150-721-931-060-466,30626928;;10.1038/s41477-018-0337-0;;pmc6784883;;19793600;;10.1016/j.phytochem.2009.07.030;;10.5455/njppp.2019.9.1236702022019,"Chaw et al., UniProt Database, Acc. No. A0A3S3NMD7. ""Stout camphor tree genome fills gaps in understanding of flowering plant genome evolution."" Nature Plants, 2019; 5:63-73. (Year: 2019);;Degenhardt, J., Köllner, T. G., & Gershenzon, J. (2009). Monoterpene and sesquiterpene synthases and the origin of terpene skeletal diversity in plants. Phytochemistry, 70(15-16), 1621-1637. (Year: 2009);;Plumeriastuti, H., & Effendi, M. H. (2019). Identification of bioactive compound of the essential oils of Cinnamomum burmannii from several areas in Indonesia by gas chromatography–mass spectrometry method for antidiabetic potential. Natl Jour of Physiology, Pharmacy and Pharmacology, 9(4), 279-283. (Year: 2019)",PENDING
441,US,A1,US 2023/0119018 A1,016-136-726-398-841,2023-04-20,2023,US 202217908258 A,2022-01-14,CN 202110520499 A;;CN 2022071968 W,2021-05-13,"RECOMBINANT HUMAN TYPE XVII COLLAGEN, AND PREPARATION METHOD AND USE THEREOF","A recombinant human type XVII collagen consists of an amino acid sequence shown in (A)n or includes the amino acid sequence shown in (A)n, where A is a sequence set forth in SEQ ID NO: 2, a sequence undergoing an amino acid modification to a predetermined extent based on SEQ ID NO: 2, or a sequence that has more than 80% homology with SEQ ID NO: 2; n is an integer greater than or equal to 1; and A represents a basic unit, and when there are two or more basic units, the two or more basic units are identical or different and are directly connected in tandem through a peptide bond. In the present disclosure, it is confirmed that the recombinant human type XVII collagen can undergo efficient secretory and soluble expression in eukaryotic host cells such as Pichia pastoris (P. pastoris).",JIANGSU TRAUTEC MEDICAL TECH CO LTD,LI JIAJIA;;WANG LIPING;;QIAN SONG,JIANGSU TRAUTEC MEDICAL TECHNOLOGY CO. LTD (2022-06-17),https://lens.org/016-136-726-398-841,Patent Application,yes,1,10,16,170-184-022-250-996;;106-317-028-483-366;;100-381-864-362-103;;049-516-407-964-238;;024-253-392-498-414;;003-713-328-386-795;;059-765-198-772-271;;137-246-534-751-131;;165-988-581-795-119;;131-192-256-191-015;;106-710-689-138-720;;126-464-251-875-085;;185-280-610-699-620;;016-136-726-398-841;;064-587-092-012-84X;;198-877-147-345-399,JP;;KR;;MY;;EP;;ES;;CN;;WO;;US;;PL,16,170-184-022-250-996;;106-317-028-483-366;;100-381-864-362-103;;049-516-407-964-238;;024-253-392-498-414;;003-713-328-386-795;;059-765-198-772-271;;137-246-534-751-131;;165-988-581-795-119;;131-192-256-191-015;;106-710-689-138-720;;126-464-251-875-085;;185-280-610-699-620;;016-136-726-398-841;;064-587-092-012-84X;;198-877-147-345-399,JP;;KR;;MY;;EP;;ES;;CN;;WO;;US;;PL,10,C07K14/78;;C12N15/815;;A61P17/02;;A61P17/14;;A61K8/65;;A61Q7/00;;A61L27/24;;A61L27/54;;A61L31/16;;A61L31/044;;A23L33/17;;C12N2800/102;;C12N2800/22;;A61K38/00;;A61L2300/412;;A23V2002/00;;C12R2001/84;;C12N15/815;;Y02A50/30;;A23L33/17;;A23L29/284;;A61K8/65;;A61K8/9728;;A61Q19/00;;A61K2800/10;;C07K14/78;;A61K38/00;;C07K14/78;;C12N15/815;;A61K38/00;;A61K36/06;;A61K8/65;;A61K8/9728;;A61Q19/00;;A23L29/284;;A23L33/17;;C07K2319/20;;C12R2001/84;;A23V2200/318;;A23V2002/00;;A61P17/02;;C07K14/78;;C12N15/81,C07K14/78;;A61P17/02;;C12N15/81,,0,0,,,,ACTIVE
442,US,A1,US 2024/0230677 A1,024-650-089-628-684,2024-07-11,2024,US 202218562985 A,2022-05-31,EP 21176833 A;;NL 2022050298 W,2021-05-31,Protein Biomarkers For Non-Alcoholic Fatty Liver Disease (NAFLD),"The invention relates to methods for typing and analysing blood, serum or plasma samples of subjects for the presence of protein biomarkers for non-alcoholic fatty liver disease (NAFLD), and to methods for classifying and diagnosing subjects on the basis of such protein biomarkers and/or for monitoring treatment of NAFLD.",TNO,HANEMAAIJER JAN ROELAND OCCO;;VAN KOPPEN ARIANNE;;VERSCHUREN LARS,NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO (2023-01-08),https://lens.org/024-650-089-628-684,Patent Application,yes,0,1,4,022-724-166-978-503;;026-537-179-973-463;;100-218-620-871-796;;024-650-089-628-684,EP;;WO;;US;;CA,4,022-724-166-978-503;;026-537-179-973-463;;100-218-620-871-796;;024-650-089-628-684,EP;;WO;;US;;CA,0,G01N2800/085;;G01N2800/56;;G01N33/6893;;G01N2800/60;;G01N33/6893;;G01N2800/085;;G01N2800/52;;G01N2800/60,G01N33/68,,0,0,,,,PENDING
443,US,A1,US 2025/0188532 A1,098-540-428-728-848,2025-06-12,2025,US 202519049663 A,2025-02-10,CN 202311674732 A;;CN 202311677300 A;;CN 2024120027 W,2023-12-07,NUCLEIC ACID DETECTION METHOD,"Disclosed is a nucleic acid detection method, and more particularly a method for rapidly extracting and detecting nucleic acids. The application provides a nucleic acid detection method which includes the following steps: S1, mixing a to-be-tested sample with a direct amplification preservation solution, and performing ultrasonic treatment to obtain a sample nucleic acid solution; S2, adding the sample nucleic acid solution obtained in step S1 into an amplification reaction solution to obtain a mixed solution; S3, carrying out amplification reaction by the mixed solution, and detecting nucleic acids; where the direct amplification preservation solution includes a protective agent, a nuclease inhibitor, a surfactant, a buffer system and a bacteriostatic agent. By the method provided by the application, the whole detection process is simple and less affected, and the detection time is short.",SANSURE BIOTECH INC,DAI LIZHONG;;SUN QINGZHI;;TAN DEYONG;;XU SIYAO;;WANG JIAN;;GUO JUN;;JI BOZHI;;WU KANG;;LIU JIA,SANSURE BIOTECH INC (2025-01-09),https://lens.org/098-540-428-728-848,Patent Application,yes,0,0,2,171-012-390-525-100;;098-540-428-728-848,EP;;US,5,145-830-638-132-979;;029-525-162-208-782;;171-012-390-525-100;;049-945-664-948-066;;098-540-428-728-848,CN;;EP;;WO;;US,0,C12Q1/6848;;C12Q1/6806;;C12Q1/686;;C12Q1/70;;C12R2001/91;;C12Q1/686;;C12Q1/6848;;C12Q1/6806,C12Q1/686;;C12Q1/6806;;C12Q1/6848,,0,0,,,,PENDING
444,EP,A1,EP 3733850 A1,127-205-858-818-618,2020-11-04,2020,EP 18894129 A,2018-12-28,CN 201711476630 A;;CN 2018124687 W,2017-12-29,CHIMERIC PROMOTER WITH HIGH TRANSCRIPTIONAL ACTIVITY IN T-CELLS,"Provided is a chimeric promoter with a high transcriptional activity in T-cells. The chimeric promoter consists of an enhancer sDTS and a promoter operably linked to the enhancer. The sequence of the enhancer is as shown in SEQ ID NO: 1. The enhancer is located at the 5' or 3' terminus of the promoter. Also provided are nucleic acid constructs, vectors and T-cells comprising the chimeric promoter. The chimeric promoter can drive the efficient expression of exogenous genes in T-cells.",SHANGHAI CELL THERAPY GROUP CO LTD,QIAN QIJUN;;JIN HUAJUN;;WANG CHAO;;HE ZHOU;;LI LINFANG;;SUN JUANJUAN;;HUANG CHEN,,https://lens.org/127-205-858-818-618,Patent Application,yes,0,0,7,188-186-593-954-471;;107-087-404-432-884;;197-793-383-772-961;;158-760-023-728-435;;127-205-858-818-618;;115-529-918-905-55X;;147-031-414-918-560,JP;;CN;;EP;;WO;;US,7,188-186-593-954-471;;107-087-404-432-884;;197-793-383-772-961;;158-760-023-728-435;;127-205-858-818-618;;115-529-918-905-55X;;147-031-414-918-560,JP;;CN;;EP;;WO;;US,12,C12N15/113;;C12N15/85;;C12N5/0636;;C07K16/2818;;C12N2830/15;;C12N2510/02;;C12N15/63;;C12N5/0636;;C12N2510/00;;C12N2501/52;;C12N2501/51;;C12N5/0636;;C12N5/10;;C12N15/113;;C12N15/63;;C12N2830/15,C12N15/113;;C12N5/0783;;C12N15/63,,0,0,,,,PENDING
445,EP,A1,EP 4207389 A1,144-472-366-149-879,2023-07-05,2023,EP 21943315 A,2021-11-03,CN 2021128404 W,2021-11-03,"POSITIVE ELECTRODE SLURRY, POSITIVE ELECTRODE PLATE, LITHIUM ION BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRICAL DEVICE","Embodiments of this application provide a positive electrode slurry, and provide a positive electrode plate containing the slurry according to this application, a lithium-ion battery, a battery module, a battery pack, and an electrical device. The positive electrode slurry includes: a manganese-containing positive active material, and a positive electrode additive. The positive electrode additive is a compound represented by Formula (I), where, A is equal to B and is any one selected from atoms N, O, and S, and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>8</sub> are, each independently, selected from hydrogen or a C<sub>1</sub> to C<sub>7</sub> alkyl. The positive electrode slurry according to this application can significantly reduce deposition of manganese ions on the surface of a negative electrode material by effectively capturing the manganese ions, thereby slowing down capacity fading of a lithium-manganese-oxide-based lithium-ion battery during cycling and storage, and improving a service life, high-temperature cycle performance, and high-temperature storage performance of the battery.",CONTEMPORARY AMPEREX TECHNOLOGY CO LTD,LI XING;;ZHANG QIANGIAN;;ZHAO YANJIE,CONTEMPORARY AMPEREX TECHNOLOGY(HONG KONG) LIMITED (2024-10-02),https://lens.org/144-472-366-149-879,Patent Application,yes,0,0,9,058-270-227-936-669;;187-010-553-950-390;;073-775-336-219-121;;122-803-807-608-715;;144-472-366-149-879;;172-707-564-263-612;;148-976-335-922-069;;198-198-675-928-040;;140-632-960-211-270,KR;;JP;;EP;;CN;;WO;;US,9,058-270-227-936-669;;187-010-553-950-390;;073-775-336-219-121;;122-803-807-608-715;;172-707-564-263-612;;144-472-366-149-879;;148-976-335-922-069;;198-198-675-928-040;;140-632-960-211-270,KR;;JP;;EP;;CN;;WO;;US,0,Y02E60/10;;H01M4/131;;H01M4/505;;H01M4/625;;H01M4/622;;H01M10/0525;;H01M4/62;;H01M2004/028;;H01M4/525;;H01M4/0404;;H01M4/131;;H01M4/505;;H01M10/4235;;H01M4/62;;H01M4/525;;H01M4/622;;H01M4/625;;H01M10/0525;;H01M2004/028;;H01M4/62;;H01M4/485;;H01M4/505;;H01M4/525;;H01M2004/028;;H01M4/625;;H01M4/0404;;H01M10/0525;;H01M4/622,H01M4/62;;H01M4/13,,0,0,,,,PENDING
446,US,A1,US 2021/0299047 A1,179-428-314-837-778,2021-09-30,2021,US 202117344039 A,2021-06-10,US 202117344039 A;;US 202016919741 A;;US 201715816916 A;;US 201662424274 P,2016-11-18,ZINC MELOXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND PROCESSES FOR MAKING THE SAME,Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.,PACIRA PHARMACEUTICALS INC,GARCIA LOUIE DANIEL;;KURZ STEPHANIE;;ARDEKANI SOROUSH;;LOS KATHLEEN DUNNE ALBRIGHT;;STONE KATHERINE;;SCHUTT ERNEST G;;KHARITONOV VLADIMIR,,https://lens.org/179-428-314-837-778,Patent Application,yes,7,0,10,157-618-863-465-750;;041-930-546-945-961;;192-257-597-921-482;;179-428-314-837-778;;124-156-985-668-344;;196-891-066-370-232;;101-168-780-370-628;;109-278-947-409-378;;085-069-681-302-425;;191-574-747-499-380,EP;;CN;;WO;;US,11,157-618-863-465-750;;041-930-546-945-961;;192-257-597-921-482;;179-428-314-837-778;;124-156-985-668-344;;196-891-066-370-232;;101-168-780-370-628;;109-278-947-409-378;;085-069-681-302-425;;007-709-693-620-096;;191-574-747-499-380,EP;;CN;;WO;;US,0,A61K9/127;;A61K31/5415;;A61K9/1277;;A61P29/00;;A61K9/0019;;A61K9/1277;;A61K31/555;;A61P29/00;;A61K9/0019;;A61K47/24;;A61K9/127;;A61K31/5415,A61K9/127;;A61K9/00;;A61K31/5415;;A61K31/555;;A61K47/24;;A61P29/00,,2,1,042-974-993-617-557,10.1080/13102818.2015.1074873,"Dyakova, L. et al. 3d metal complexes with meloxicam as therapeutic agents in the fight against human glioblastoma multiforme and cervical carcinoma. Biotech & Biotech Equip 29:6, 1190-1200. DOI: 10.1080/13102818.2015.107483 (Year: 2015);;Culita, D.C., et al. Evaluation of cytotoxic and antiproliferative activity of Co(II), Ni(II), Cu(II) and Zn(II) complexes with meloxicam on virus transformed tumore cells. Rev. Chim. 63(4), 384-389. (Year: 2012)",PENDING
447,US,A1,US 2023/0257819 A1,103-807-820-086-690,2023-08-17,2023,US 202218148062 A,2022-12-29,CN 202210141027 A,2022-02-16,APPLICATION OF BIOMARKERS IN PREPARING DIAGNOSTIC TOOLS FOR COMBINED ALLERGIC RHINITIS AND ASTHMA SYNDROME,"Disclosed is an application of biomarkers in preparing diagnostic tools for combined allergic rhinitis and asthma syndrome (CARAS), including circ_0070934, MGAT3 and miR-199a-5p. The biomarker of the present application can be effectively used for the diagnosis of CARAS, and when circ_0070934, miR-199a-5p and MGAT3 are combined, the diagnostic effectiveness of CARAS is the highest.",THE AFFILIATED CHANGZHOU SECOND PEOPLES HOSPITAL OF NANJING MEDICAL UNIV,ZHANG QIAN,THE AFFILIATED CHANGZHOU SECOND PEOPLE'S HOSPITAL OF NANJING MEDICAL UNIVERSITY (2022-12-23),https://lens.org/103-807-820-086-690,Patent Application,yes,0,0,3,103-807-820-086-690;;076-226-786-973-428;;073-732-234-941-500,CN;;US,3,103-807-820-086-690;;076-226-786-973-428;;073-732-234-941-500,CN;;US,0,C12Q1/6883;;C12Q2600/158;;C12Q2600/178;;G01N33/573;;G01N33/6893;;G01N2333/91102;;G01N2800/122;;G01N2800/14;;G16B20/20;;C12Q1/6883;;C12Q1/6883;;C12Q2600/118;;C12Q2600/158;;C12Q2600/178,C12Q1/6883,,0,0,,,,PENDING
448,EP,A1,EP 3943932 A1,067-092-923-764-589,2022-01-26,2022,EP 20779207 A,2020-03-19,JP 2019054249 A;;JP 2020012386 W,2019-03-22,METHOD FOR PROVIDING IMMUNE CELLS,"An object is to quickly provide immune cells to a recipient. A system for providing immune cells obtained from a donor (non-recipient) to a recipient, which comprises the following steps: the step of preparing a formulation of immune cells collected from a donor in a unit suitable for administration; the step of performing an evaluation test on the formulation; the step of refrigerating or freezing the formulation and stocking it with immune type information of the donor; and the step of selecting a formulation suitable for the recipient from stocked formulations subjected to the evaluation test or identifying a recipient suitable for one selected stocked formulation subjected to the evaluation test.",GAIA BIOMEDICINE INC;;YONEMITSU YOSHIKAZU,HARADA YUI;;KURAMORI KAZUYUKI;;YONEMITSU YOSHIKAZU,,https://lens.org/067-092-923-764-589,Patent Application,yes,0,0,9,118-570-931-377-759;;146-177-245-430-120;;079-466-988-508-542;;061-120-601-586-502;;024-774-777-888-679;;133-150-237-522-330;;149-094-893-783-771;;033-648-905-880-604;;067-092-923-764-589,JP;;KR;;AU;;EP;;CN;;WO;;US,9,118-570-931-377-759;;024-774-777-888-679;;079-466-988-508-542;;061-120-601-586-502;;146-177-245-430-120;;133-150-237-522-330;;149-094-893-783-771;;033-648-905-880-604;;067-092-923-764-589,JP;;KR;;AU;;CN;;EP;;WO;;US,0,A61P35/00;;A61P37/04;;C12N5/0646;;A61K40/15;;A61K40/42;;G01N33/15;;C12N5/0646;;A61P35/00;;A61P37/04;;A61K2239/46;;A61K40/15;;A61P35/00;;C12N5/0646;;A61K40/15;;A61K40/42,G01N33/15;;A61K35/17;;A61P35/00;;A61P37/04;;G01N33/48,,0,0,,,,PENDING
449,US,A1,US 2022/0184122 A1,033-648-905-880-604,2022-06-16,2022,US 202017441439 A,2020-03-19,JP 2019054249 A;;JP 2020012386 W,2019-03-22,A METHOD FOR PROVIDING IMMUNE CELLS,"An object is to quickly provide immune cells to a recipient. A system for providing immune cells obtained from a donor (non-recipient) to a recipient, which comprises the following steps: the step of preparing a formulation of immune cells collected from a donor in a unit suitable for administration; the step of performing an evaluation test on the formulation; the step of refrigerating or freezing the formulation and stocking it with immune type information of the donor; and the step of selecting a formulation suitable for the recipient from stocked formulations subjected to the evaluation test or identifying a recipient suitable for one selected stocked formulation subjected to the evaluation test.",YONEMITSU YOSHIKAZU;;GAIA BIOMEDICINE INC,HARADA YUI;;YONEMITSU YOSHIKAZU;;KURAMORI KAZUYUKI,,https://lens.org/033-648-905-880-604,Patent Application,yes,3,0,9,118-570-931-377-759;;146-177-245-430-120;;079-466-988-508-542;;061-120-601-586-502;;024-774-777-888-679;;133-150-237-522-330;;149-094-893-783-771;;033-648-905-880-604;;067-092-923-764-589,JP;;KR;;AU;;EP;;CN;;WO;;US,9,118-570-931-377-759;;024-774-777-888-679;;079-466-988-508-542;;061-120-601-586-502;;146-177-245-430-120;;133-150-237-522-330;;149-094-893-783-771;;033-648-905-880-604;;067-092-923-764-589,JP;;KR;;AU;;CN;;EP;;WO;;US,0,A61P35/00;;A61P37/04;;C12N5/0646;;A61K40/15;;A61K40/42;;G01N33/15;;C12N5/0646;;A61P35/00;;A61P37/04;;A61K2239/46;;A61K40/15;;A61P35/00;;C12N5/0646;;A61K40/15;;A61K40/42,A61K35/17;;A61P35/00;;C12N5/0783,,4,2,090-033-490-931-102;;011-158-224-156-899,10.1007/978-1-4939-8935-5_9;;30539437;;pmc6777725;;pmc7315024;;32321785;;10.1128/jcm.01492-19,"Perry et al, Procurement, Storage, and Use of Blood in Biobanks. In: Yong, W. (eds) Biobanking. Methods in Molecular Biology, vol 1897. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8935-5_9. First Online: 12 December 2018. (Year: 2018);;Gebo JET, Lau AF. Sterility Testing for Cellular Therapies: What Is the Role of the Clinical Microbiology Laboratory? J Clin Microbiol. 2020 Jun 24;58(7):e01492-19. doi: 10.1128/JCM.01492-19. PMID: 32321785; PMCID: PMC7315024. (Year: 2020);;Tonog P, Lakhkar AD. Normal Saline. [Updated 2022 Oct 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545210/ (Year: 2022);;Thesaurus.com. (2025). https://www.thesaurus.com/browse/in-conjunction-with (Year: 2025)",PENDING
450,WO,A2,WO 2024/147780 A2,183-789-038-664-230,2024-07-11,2024,TR 2024050007 W,2024-01-05,TR 2023000206 A;;TR 2023002881 A,2023-01-06,A NOVEL CHEMOGENETIC TOOL PERMITTING MODULATION OF INTRACELLULAR PH,The invention relates to a new chemogenetic tool manipulating intracellular pH levels and hydrogen sulfide levels in living cells and tissues with high spatio-temporal resolution.,UNIV ISTANBUL MEDIPOL;;UNIV SABANCI,ZAKI ASAL GHAFFARI;;MIRI SEYED MOHAMMAD;;OZTURK GURKAN;;EROGLU EMRAH,,https://lens.org/183-789-038-664-230,Patent Application,yes,0,1,2,088-500-795-944-391;;183-789-038-664-230,WO,2,088-500-795-944-391;;183-789-038-664-230,WO,22,C12N9/88;;C12Y404/01015,C12M1/00;;C07K14/705,,0,0,,,,PENDING
451,US,A1,US 2022/0306996 A1,014-177-634-771-555,2022-09-29,2022,US 202117507800 A,2021-10-21,US 202117507800 A;;US 202117215476 A,2021-03-29,"Mutant Glucose Dehydrogenase Having Improved Thermal Stability, and Use Thereof","The present invention provides a mutant FAD-dependent glucose dehydrogenase comprising: a catalytic subunit; an electron transfer subunit; and a hitchhiker subunit; wherein each of the amino acid sequence of the catalytic subunit and the amino acid sequence of the electron transfer subunit comprises a cysteine residue introduced therein, the catalytic subunit and the electron transfer subunit being bound to each other through a disulfide bond between the cysteine residues to achieve improved thermal stability of the FAD-dependent glucose dehydrogenase.",UNIV NORTH CAROLINA CHAPEL HILL;;ARKRAY INC,SODE KOJI;;SHIMAZAKI JUNKO;;KOJIMA KATSUHIRO;;TSUKADA MASASHI,THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2021-11-10);;ARKRAY INC (2021-12-04),https://lens.org/014-177-634-771-555,Patent Application,yes,1,1,1,014-177-634-771-555,US,4,014-177-634-771-555;;198-378-410-548-294;;085-831-701-413-520;;153-435-090-591-845,JP;;EP;;CN;;US,31,C12N9/0006;;C12Y101/05;;C12R2001/01;;C12Y101/9901;;C12Y101/9901;;C12N9/0006,C12N9/04,,5,5,004-045-350-565-461;;082-769-764-075-019;;059-692-559-205-578;;082-769-764-075-019;;059-692-559-205-578,10.1016/j.coelec.2018.07.013;;31478907;;10.1107/s2059798319010878;;pmc6719666;;10.1002/bit.24861;;23404255;;31478907;;10.1107/s2059798319010878;;pmc6719666;;10.1002/bit.24861;;23404255,"Yamashita et al. Current Opinion in Electrochemistry, 2018, 12, 92-100 (Year: 2018);;Yoshida et al. Acta Cryst., 2019, D75, 841-851 (Year: 2019);;Hirakawa et al. Biotech. and Bioengin., 2013, 110, 1858-1864 (Year: 2013);;Yoshida et al. Acta Cryst., 2019, D75, 841-851 (Year: 2019);;Hirakawa et al. Biotech. and Bioengin., 2013, 110, 1858-1864 (Year: 2013)",PENDING
452,EP,A1,EP 4056699 A1,027-699-992-121-157,2022-09-14,2022,EP 20884412 A,2020-11-05,CN 201911082325 A;;CN 2020126683 W,2019-11-07,"CINNAMOMUM BURMANNII MONOTERPENE SYNTHASE CBTPS1, RELATED BIOMATERIAL THEREOF AND APPLICATION THEREOF","Provided are a Cinnamomum burmannii monoterpene synthase CbTPS1, an amino acid sequence thereof, a nucleic acid molecule encoding the protein, an use thereof in preparing the monoterpene synthase, and a method for preparing dextrorotatory borneol by using the Cinnamomum burmannii monoterpene synthase CbTPS1.",SICHUAN HONGHE BIOTECHNOLOGY CO LTD,HUANG LUQI;;SU PING;;MA RUI;;CUI GUANGHONG;;GUO JUAN;;JIN BAOLONG;;HU YATING;;BAO JICHEN,,https://lens.org/027-699-992-121-157,Patent Application,yes,0,0,6,068-144-435-917-791;;027-699-992-121-157;;146-655-374-712-507;;074-865-895-515-926;;076-038-495-167-399;;060-205-605-300-192,EP;;CN;;WO;;US,6,068-144-435-917-791;;027-699-992-121-157;;146-655-374-712-507;;076-038-495-167-399;;074-865-895-515-926;;060-205-605-300-192,EP;;CN;;WO;;US,15,C12N9/88;;C12N15/70;;C12N15/81;;C12P7/26;;C12N15/70;;C12N9/88;;C12N15/81;;C12P5/007;;C12N15/81;;C12N9/88;;C12N15/70;;C12N15/82;;C12P5/007;;C12P7/02,C12N9/88;;C12N15/60;;C12N15/70;;C12P9/00;;C12R1/865,,0,0,,,,PENDING
453,US,A1,US 2020/0397858 A1,180-010-000-230-268,2020-12-24,2020,US 201916444909 A,2019-06-18,US 201916444909 A;;US 201615117629 A;;US 2015/0015761 W;;US 201461939499 P,2014-02-13,COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE,"Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).",UNIV NORTHWESTERN,STEHLIK CHRISTIAN,NORTHWESTERN UNIVERSITY (2014-03-26),https://lens.org/180-010-000-230-268,Patent Application,yes,0,0,5,027-664-805-504-161;;196-203-757-269-510;;003-105-575-398-903;;101-702-138-125-585;;180-010-000-230-268,WO;;US,5,027-664-805-504-161;;196-203-757-269-510;;003-105-575-398-903;;101-702-138-125-585;;180-010-000-230-268,WO;;US,63,A61K38/1709;;A61K38/1709,A61K38/17,,0,0,,,,ACTIVE
454,WO,A1,WO 2025/145424 A1,165-578-635-472-488,2025-07-10,2025,CN 2024070786 W,2024-01-05,CN 2024070786 W,2024-01-05,METHODS AND COMPOSITIONS FOR MODIFYING FLOWERING TIME GENES IN PLANTS,"Methods and compositions are provided for modifying the flowering time and/or maturity time of soybean plants to enable them to be cultivated in a variety of geographical locations having different day lengths. Modified soybean plants are disclosed comprising non-natural mutant alleles at the E1, E2, E3, E4, E1La and/or E1Lb locus. The modified plants have a shorter flowering and/or maturity time than control plants.",SYNGENTA CROP PROTECTION AG;;SYNGENTA GROUP CO LTD;;INST OF CROP SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES,CHEN LI;;GAO YANG;;HOU WENSHENG;;CAI YUPENG;;YUAN SHAN;;SU QIANG;;SUN SHI;;HAN TIANFU,,https://lens.org/165-578-635-472-488,Patent Application,yes,0,0,4,111-226-550-226-722;;146-832-939-426-634;;165-578-635-472-488;;103-608-005-101-805,WO,4,111-226-550-226-722;;146-832-939-426-634;;165-578-635-472-488;;103-608-005-101-805,WO,71,C07K14/415;;C12N15/827,C12N15/82;;A01H1/02;;A01H1/04;;A01H5/00;;A01H6/54,,0,0,,,,PENDING
455,US,A1,US 2022/0125876 A1,155-326-432-922-377,2022-04-28,2022,US 202017430552 A,2020-02-14,US 202017430552 A;;US 201962805397 P;;CA 2020050192 W,2019-02-14,A METHOD OF IMMUNE MODULATION BY MODULATING ABCF1,"The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of inflammation and immune responses by modulation of ABCF1. Modulation of ABCF1 may be useful in the treatment of sepsis, autoimmune diseases, cancer or infections.",PACIFIC MYCO BIOSCIENCES LTD,JEFFERIES WILFRED;;ARORA HITESH;;WILCOX SARA;;MUNRO LONNA;;PFEIFER CHERYL,,https://lens.org/155-326-432-922-377,Patent Application,yes,0,1,10,053-690-747-087-735;;184-092-998-758-492;;027-352-421-394-394;;165-116-927-209-888;;169-832-700-186-581;;115-221-092-606-818;;112-994-423-955-293;;187-542-461-794-893;;155-326-432-922-377;;016-670-386-350-090,KR;;AU;;JP;;EP;;IL;;CN;;WO;;US;;CA,10,053-690-747-087-735;;169-832-700-186-581;;027-352-421-394-394;;165-116-927-209-888;;112-994-423-955-293;;184-092-998-758-492;;115-221-092-606-818;;187-542-461-794-893;;155-326-432-922-377;;016-670-386-350-090,KR;;JP;;AU;;IL;;CN;;EP;;WO;;US;;CA,0,A61P29/00;;A61P37/02;;G01N2333/9015;;G01N2800/24;;G01N2800/065;;G01N2800/042;;C12Q1/25;;G01N2500/00;;A01K2217/075;;A01K2227/105;;A01K2267/0337;;A61K38/177;;C07K14/705;;C07K2319/60;;A01K2217/075;;A01K2227/105;;A01K2267/0337;;A61K38/177;;A61P29/00;;A61P37/02;;C07K14/705;;C07K2319/60;;C12Q1/25;;G01N2333/9015;;G01N2500/00;;G01N2800/042;;G01N2800/065;;G01N2800/24;;A61K38/177;;A61P37/02;;A61P29/00;;A61P19/02;;A61P1/18;;C07K14/705;;C12Q1/25;;C12Q1/68;;C07K2319/60;;C12Q2600/158;;A61P37/02;;A61P19/02;;A61K38/177,A61K38/17;;A61P19/02;;A61P37/02,,3,2,012-551-705-911-434;;013-778-556-918-482,28542262;;10.1371/journal.pone.0175918;;pmc5438103;;10.1038/npp.2016.169;;pmc5143493;;27555379,"Wilcox, Sara M.et al, ""The role of the innate immune response regulatory gene abcf1 in mammalian embryogenesis and development."" PLoS ONE (2017) 12(5) e0175918;;Barnes, Jacob et al; ""Genetic contributions of inflammation to depression."" Neuropsychopharmacol. Rev. (2017) 42 p81-98;;Uniprot database entry for human ABCF1, downloaded 2024",PENDING
456,US,A1,US 2025/0171837 A1,096-598-390-329-102,2025-05-29,2025,US 202418681762 A,2024-02-06,CN 202110901455 A;;CN 202111294356 A;;CN 202210098137 A;;CN 202210143116 A;;CN 2022110828 W,2021-08-06,"COMPOSITON FOR LIQUEFYING VISCOUS BIOLOGICAL SAMPLE, COMBINTATION PRODUCT, LIQUEFYING AGENT, AND KIT THEREOF, AND METHOD AND APPLICATION THEREOF","Disclosed is a viscous biological sample liquefying composition comprising guaifenesin and a first strong base, further relates to a combination product, a liquefying agent and a kit containing the viscous biological sample liquefying composition, and further relates to a liquefaction method, a processing method and application of the viscous biological sample using the viscous biological sample liquefying composition or the combination product or kit thereof.",SANSURE BIOTECH INC,DAI LIZHONG;;DENG ZHINGPING;;CHEN SHIYAO;;DENG YONG;;LIU JIA,SANSURE BIOTECH INC (2023-11-24),https://lens.org/096-598-390-329-102,Patent Application,yes,0,0,3,029-988-201-374-240;;000-760-283-684-299;;096-598-390-329-102,EP;;WO;;US,9,002-080-375-644-431;;000-760-283-684-299;;144-362-510-994-19X;;041-173-534-281-082;;035-176-540-239-119;;029-988-201-374-240;;155-998-968-218-101;;096-598-390-329-102;;017-979-807-796-325,CN;;EP;;WO;;US,0,C12Q1/6806;;C12N15/1006;;C12Q1/6806;;C12Q1/6851,C12Q1/6851;;C12Q1/6806,,0,0,,,,PENDING
457,KR,A,KR 20220149144 A,157-692-755-320-824,2022-11-08,2022,KR 20210056401 A,2021-04-30,KR 20210056401 A,2021-04-30,Novel Acetobacter pasteurianus and method for producing vinegar using the same,"The present invention relates to a strain and a method for producing vinegar using the same. The Acetobacter pasteurianus DS strain according to the present invention has excellent acetic acid production ability and has resistance to acetic acid and ethanol, and thus vinegar with excellent taste and quality can be produced through stable acetic acid fermentation, and the strain can be usefully used in various food fields.",DAESANG CORP,RYU BYUNG HEE;;CHUNG JUNG HWAN;;SHIN MIN KYEONG;;BYUN MYUNG HEE,,https://lens.org/157-692-755-320-824,Patent Application,no,9,1,2,157-692-755-320-824;;078-403-316-002-19X,KR,2,157-692-755-320-824;;078-403-316-002-19X,KR,6,C12N1/205;;C12J1/04;;C12G3/024;;C12G3/022;;C12R2001/02,C12N1/20;;C12G3/022;;C12G3/024;;C12J1/04;;C12R1/02,,1,0,,,"3 Biotech.,10(115):1-11(2020.2.14.)*",ACTIVE
458,WO,A1,WO 2024/215987 A1,126-329-453-418-745,2024-10-17,2024,US 2024/0024213 W,2024-04-12,US 202363496222 P;;EP 23173531 A,2023-04-14,IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES,"An immune cell population for use in treatment of cancer in a subject in combination with a conjugate, which comprises: (i) a polypeptide comprising the amino acid sequence of the interleukin 15 (IL-15) or a derivative thereof; and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of an interleukin 15-receptor alpha (IL-15Rα) or a derivative thereof.",SOTIO BIOTECH INC;;SOTIO BIOTECH AG,JENSEN AMY;;KUIPER EMILY;;WHITEMAN KATHLEEN;;ADKINS IRENA,,https://lens.org/126-329-453-418-745,Patent Application,yes,68,0,1,126-329-453-418-745,WO,1,126-329-453-418-745,WO,94,A61K2300/00;;A61K2039/55527;;A61P35/00;;A61K40/4251;;A61K40/11;;A61K40/31,A61K39/00;;A61K35/17;;A61K38/20;;A61P35/00,,79,48,077-957-151-449-353;;043-622-776-825-867;;033-442-418-364-094;;141-667-135-840-911;;001-431-119-334-376;;078-075-594-063-240;;062-915-083-335-003;;050-318-511-556-953;;027-590-135-109-808;;059-142-582-871-089;;069-528-364-703-532;;045-728-526-507-231;;042-334-592-036-115;;016-166-700-584-053;;020-323-378-319-681;;067-577-074-748-984;;097-783-333-259-858;;028-712-744-929-499;;008-354-652-359-916;;027-695-205-373-112;;077-034-558-952-043;;135-020-829-679-590;;118-842-213-569-760;;075-809-016-742-584;;004-806-965-782-319;;025-103-366-396-011;;001-811-611-132-180;;042-513-916-881-571;;094-857-606-776-915;;061-074-625-914-019;;032-728-154-591-070;;016-098-355-348-014;;105-044-393-253-406;;085-764-009-624-439;;020-273-453-652-888;;013-196-935-848-429;;061-775-876-651-980;;048-946-542-600-182;;084-566-494-607-400;;017-216-732-209-839;;053-099-598-663-55X;;044-862-347-072-130;;003-562-221-195-045;;004-501-509-965-050;;007-538-000-443-231;;036-489-877-612-736;;062-970-265-050-860;;002-558-024-277-844,32159390;;10.1080/14712598.2020.1738379;;pmc390337;;15034147;;10.1093/nar/gkh340;;3115332;;10.1182/blood.v70.4.1069.bloodjournal7041069;;10.1182/blood.v70.4.1069.1069;;10229830;;10.4049/jimmunol.162.10.5931;;pmc253118;;2831375;;10.1128/jvi.62.4.1120-1124.1988;;pmc5568475;;28733484;;10.4049/jimmunol.1700069;;12579196;;10.1038/nm827;;pmc3208293;;21849486;;10.1182/blood-2011-04-348540;;pmc5022178;;27518241;;10.1038/bcj.2016.61;;29706540;;pmc5984158;;10.1016/j.cell.2018.03.038;;10.1182/blood.v126.23.3085.3085;;10.1182/blood-2002-07-1989;;12393484;;pmc8394762;;34439285;;10.3390/cancers13164129;;pmc45737;;10.1073/pnas.90.2.720;;8421711;;11878513;;10.3109/08830180109054417;;15976182;;10.1182/blood-2005-01-0064;;10.1186/s13045-021-01083-5;;33933160;;pmc8088725;;10.1093/nar/gkq313;;10.1172/jci80008;;26258412;;pmc4588307;;15246157;;10.1016/j.exphem.2004.03.011;;10.1038/sj.leu.2403302;;14961035;;10.1371/journal.pone.0018556;;pmc3084703;;21602908;;10.1021/jacs.5b00106;;25692571;;10.1002/ijc.2910180405;;789258;;10.1182/blood.v82.3.845.845;;8393352;;10.1182/blood.v82.3.845.bloodjournal823845;;10.1016/j.stem.2018.06.002;;pmc6084450;;30082067;;29296519;;pmc5739565;;10.1080/2162402x.2017.1368604;;163658;;10.1182/blood.v45.3.321.321;;10.1182/blood.v45.3.321.bloodjournal453321;;10.1016/0092-8674(83)90344-6;;6678608;;pmc8316981;;32934330;;10.1038/s41571-020-0426-7;;10.1016/0022-2836(70)90057-4;;5420325;;pmc9216673;;10.1016/j.iotech.2019.06.002;;35755322;;pmc8080836;;10.1038/s12276-021-00576-0;;33707742;;3162770;;10.1073/pnas.85.8.2444;;pmc280013;;21830940;;10.1056/nejmoa1103849;;pmc3387277;;18978797;;pmc2749734;;10.1038/nm.1882;;10.1089/hum.2006.17.ft-249;;10.1089/hum.2006.17.1027;;17007566;;pmc3501574;;23104097;;10.1038/ni.2449;;10.3389/fimmu.2022.835762;;35309357;;pmc8928448;;10.1016/0196-8858(81)90046-4;;19646987;;pmc2786060;;10.1016/j.jim.2009.07.010;;33824268;;10.1038/s41408-021-00459-7;;pmc8024391;;10.1158/1078-0432.ccr-12-1449;;23032741;;15601438;;10.1111/j.1365-2885.2004.00600.x;;10.1158/0008-5472.can-11-3890;;pmc3319867;;22315351;;31790761;;10.1016/j.canlet.2019.11.033;;pmc5355494;;28367149;;10.3389/fimmu.2017.00292;;34072732;;pmc8197981;;10.3390/ijms22115899,"KNUDSON K M ET AL: ""Rationale for IL-15 superagonists in cancer immunotherapy"", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 20, no. 7, 11 March 2020 (2020-03-11), pages 705 - 709, XP093030394, ISSN: 1471-2598, DOI: 10.1080/14712598.2020.1738379;;""NCBI"", Database accession no. NP_000576.1;;""UniProt"", Database accession no. Q13261;;""GenBank"", Database accession no. HQ401283.1;;EDGAR, R. C., NUCLEIC ACIDS RES, vol. 32, no. 5, 2004, pages 1792 - 1797;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR PRESS;;B. PERBAL ET AL.: ""A practical Guide To Molecular Cloning"", 1984;;""Handbook of Experimental Immunology"", 1987, HUMANA PRESS, article ""Gene Transfer Vectors for Mammalian Cells"";;J. P. MATHERP. E. ROBERTS: ""Introduction to Cell and Tissue Culture"", 1998, PLENUM PRESS;;""Cell and Tissue Culture: Laboratory Procedures"", August 1993, J. WILEY AND SONS;;HORI, T. ET AL., BLOOD, vol. 70, no. 4, 1987, pages 1069 - 1072;;""PCR: The Polymerase Chain Reaction"", 1994;;""Current Protocols in Immunology"", 1991;;GEIGER, T. L. ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 162, no. 10, 1999, pages 5931 - 5939;;C. A. JANEWAYP. TRAVERS: ""Immunobiology"", 1997;;MARKOWITZ, D. ET AL., J VIROL, vol. 62, no. 4, 1988, pages 1120 - 1124;;""Monoclonal antibodies: a practical approach"", 2000, OXFORD UNIVERSITY PRESS;;""The Antibodies"", 1995, HARWOOD ACADEMIC PUBLISHERS;;""DNA Cloning: A practical Approach"", vol. 1,2, 1985;;""Immobilized Cells and Enzymes"", 1986, LRL PRESS;;BETTINI, M. L. ET AL., J IMMUNOL, vol. 199, no. 5, 2017, pages 1555 - 1560;;BRENTJENS, R. J. ET AL., SCI TRANSL MED, vol. 5, no. 177, 2013, pages 177 - 138;;BRENTJENS, R. J. ET AL., NAT MED, vol. 9, no. 3, 2003, pages 279 - 286;;BRENTJENS, R. J. ET AL., BLOOD, vol. 118, no. 18, 2011, pages 4817 - 4828;;CAO, Y. ET AL., ANGEW CHEM INT ED ENGL, vol. 55, no. 26, 2016, pages 7520 - 7524;;CARTELLIERI, M. ET AL., BLOOD CANCER J, vol. 6, no. 8, 2016, pages e458;;CHO, J. H. ET AL., CELL, vol. 173, no. 6, 2018, pages 1426 - 1438;;CHU, Y. ET AL., BLOOD, vol. 126, no. 23, 2015, pages 3085 - 3085;;COOPER, L. J. ET AL., BLOOD, vol. 101, no. 4, 2003, pages 1637 - 1644;;DU, N. ET AL., CANCERS, vol. 13, no. 16, 2021, pages 4129;;ESHHAR, Z. ET AL., PROC NATL ACAD SCI U S A, vol. 90, no. 2, 1993, pages 720 - 724;;FEHNIGER, T. A.M. A. CALIGIURI, INT REV IMMUNOL, vol. 20, no. 3-4, 2001, pages 503 - 534;;GIRON-MICHEL, J. ET AL., BLOOD, vol. 106, no. 7, 2005, pages 2302 - 2310;;GONG, Y. ET AL., J HEMATOL ONCOL, vol. 14, no. 1, 2021, pages 73;;GOUJON, M. ET AL., NUCLEIC ACIDS RES, vol. 38, 2010, pages W695 - 699;;GUBIN, M. M. ET AL., J CLIN INVEST, vol. 125, no. 9, 2015, pages 3413 - 3421;;HARADA, H. ET AL., JPN J CANCER RES, vol. 93, no. 3, 2002, pages 313 - 319;;HARADA, H. ET AL., EXP HEMATOL, vol. 32, no. 7, 2004, pages 614 - 621;;HU, Q. ET AL., SCI REP, vol. 8, no. 1, 2018, pages 7675;;IMAI, C. ET AL., LEUKEMIA, vol. 18, no. 4, 2004, pages 676 - 684;;JAYARAMAN, J. ET AL., EBIOMEDICINE, vol. 59, 2020, pages 102975;;KIM, J. H. ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages e18556;;KIM, M. S. ET AL., J AM CHEM SOC, vol. 137, no. 8, 2015, pages 2832 - 2835;;KLEIN, E. ET AL., INT J CANCER, vol. 18, no. 4, 1976, pages 421 - 431;;KOCHENDERFER, J. N. ET AL., BLOOD, vol. 119, no. 17, 2012, pages 3940 - 3950;;KUDO, K. ET AL., CANCER RES, vol. 74, no. 1, 2014, pages 93 - 103;;KUO, M. L. ET AL., BLOOD, vol. 82, no. 3, 1993, pages 845 - 852;;LI, Y. ET AL., CELL STEM CELL, vol. 23, no. 2, 2018, pages 181 - 192;;LINNEMANN, C. ET AL., NAT MED, vol. 21, no. 1, 2015, pages 81 - 85;;LIU, E. ET AL., LEUKEMIA, vol. 32, no. 2, 2018, pages 520 - 531;;LOHMUELLER, J. J. ET AL., ONCOIMMUNOLOGY, vol. 7, no. 1, 2017, pages el368604;;LOZZIO, C. B.B. B. LOZZIO, BLOOD, vol. 45, no. 3, 1975, pages 321 - 334;;MA, J. S. ET AL., PROC NATL ACAD SCI U S A, vol. 113, no. 4, 2016, pages E450 - 458;;MANN, R. ET AL., CELL, vol. 33, no. 1, 1983, pages 153 - 159;;MENDES, B. B. ET AL., NATURE REVIEWS METHODS PRIMERS, vol. 2, no. 1, 2022, pages 24;;MORGAN, M. A. ET AL., FRONT IMMUNOL, vol. 11, 2020, pages 611163;;MYERS, J. A.J. S. MILLER, NATURE REVIEWS CLINICAL ONCOLOGY, vol. 18, no. 2, 2021, pages 85 - 100;;NEEDLEMAN, S. B.C. D. WUNSCH, J MOL BIOL, vol. 48, no. 3, 1970, pages 443 - 453;;NUSSBAUMER, O.M. KOSLOWSKI, IMMUNOONCOL TECHNOL, vol. 1, 2019, pages 3 - 10;;PARK, J. H.H. K. LEE, EXP MOL MED, vol. 53, no. 3, 2021, pages 318 - 327;;PEARSON, W. R.D. J. LIPMAN, PROC NATL ACAD SCI U S A, vol. 85, no. 8, 1988, pages 2444 - 2448;;PORTER, D. L. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, no. 8, 2011, pages 725 - 733;;PULE, M. A. ET AL., NAT MED, vol. 14, no. 11, 2008, pages 1264 - 1270;;RABINOVICH, P. M. ET AL., HUMAN GENE THERAPY, vol. 17, no. 10, 2006, pages 1027 - 1035;;RING, A. M. ET AL., NAT IMMUNOL, vol. 13, no. 12, 2012, pages 1187 - 1195;;SHAFER, P. ET AL., FRONT IMMUNOL, vol. 13, 2022, pages 835762;;SIEVERS, N. M. ET AL., INT J MOL SCI, vol. 21, no. 10, 2020;;SMITH, T. F.M. S. WATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, no. 4, 1981, pages 482 - 489;;SOMAN, G. ET AL., J IMMUNOL METHODS, vol. 348, no. 1-2, 2009, pages 83 - 94;;STERNER, R. C.R. M. STERNER, BLOOD CANCER JOURNAL, vol. 11, no. 4, 2021, pages 69;;TAMADA, K. ET AL., CLIN CANCER RES, vol. 18, no. 23, 2012, pages 6436 - 6445;;TOUTAIN, P. L.A. BOUSQUET-MELOU, J VET PHARMACOL THER, vol. 27, no. 6, 2004, pages 427 - 439;;URBANSKA, K. ET AL., CANCER RES, vol. 72, no. 7, 2012, pages 1844 - 1852;;WANG, S. ET AL., BMC MEDICINE, vol. 19, no. 1, 2021, pages 140;;WANG, W. ET AL., CANCER LETT, vol. 472, 2020, pages 175 - 180;;WEI, X. ET AL., J IMMUNOL, vol. 167, no. 1, 2001, pages 277 - 282;;WIECZOREK, M. ET AL., FRONT IMMUNOL, vol. 8, 2017, pages 292;;WRONA, E. ET AL., INT J MOL SCI, vol. 22, no. 11, 2021;;YING, Z. ET AL., NAT MED, vol. 25, no. 6, 2019, pages 947 - 953",PENDING
459,WO,A1,WO 2021/224328 A1,089-245-332-235-573,2021-11-11,2021,EP 2021061859 W,2021-05-05,EP 20173705 A,2020-05-08,MICROFLUIDIC DEVICE,"The present invention relates to a microfluidic device (1), preferably for producing a three-dimensional cell culture, having at least one chamber (2), and a fluid channel (3) which flows through at least part of the chamber (2) in order to provide a fluid stream which flows through the chamber (2) preferably continuously, wherein the chamber (2) is connected to a loading opening (4) and via the loading opening (4) can be loaded with hydrogel up to a desired fill level, characterised in that the chamber (2) comprises a main chamber (5) and a secondary chamber (6) connected to the main chamber (5), wherein, when the chamber (2) is being loaded with hydrogel up to the desired fill level, the secondary chamber is at least partially filled with hydrogel backed up from the main chamber (5).",UNIV WIEN TECH,ROTHBAUER MARIO;;ERTL PETER;;SCHOBESBERGER SILVIA,,https://lens.org/089-245-332-235-573,Patent Application,yes,6,1,4,102-187-828-447-031;;000-004-191-279-719;;073-997-077-324-536;;089-245-332-235-573,EP;;WO;;US,4,102-187-828-447-031;;073-997-077-324-536;;000-004-191-279-719;;089-245-332-235-573,EP;;WO;;US,0,B01L3/502715;;B01L2300/0816;;B01L2300/0829;;C12M23/16;;C12M23/34;;G01N33/4833;;G01N33/5082;;C12M23/16;;C12M21/08;;C12M23/20;;C12M23/34;;G01N33/5082,B01L3/00;;C12M1/00;;C12M1/12;;C12M1/32;;C12M3/06;;G01N33/483;;G01N33/50,,5,5,076-196-806-192-22X;;037-459-360-512-993;;059-785-210-636-554;;112-354-367-654-991;;058-890-730-043-558,pmc8335790;;20576885;;10.1126/science.1188302;;29143053;;10.1039/c7lc00815e;;26133396;;10.1016/j.biotechadv.2015.06.006;;30189349;;10.1016/j.copbio.2018.08.009;;10.3390/bios9030110;;31546916;;pmc6784383,"HUH, D. ET AL., SCIENCE, vol. 328, no. 5986, 2010, pages 1662 - 8;;ROTHBAUER M ET AL., LAB CHIP, vol. 18, 2018, pages 249 - 270;;ROTHBAUER M ET AL., BIOTECH ADV, vol. 33, 2015, pages 948 - 961;;ROTHBAUER M ET AL., CURR OPIN BIOTECH, vol. 55, 2019, pages 81 - 86;;KRATZ SRA ET AL., BIOSENSORS, vol. 9, no. 3, 2019, pages 110",PENDING
460,US,A1,US 2023/0092846 A1,153-047-389-743-028,2023-03-23,2023,US 202117792468 A,2021-01-14,US 202117792468 A;;US 202062961131 P;;CN 2021071685 W,2020-01-14,COMBINATION FOR THE TREATMENT OF CANCER AND APPLICATION THEREOF,"A combination, comprising a first component and a second component; the first component is selected from a group composed of the following: the compound of formula (I), a pharmaceutically acceptable salt thereof, and a combination thereof, wherein A is a C1-C8 aliphatic hydrocarbon group optionally containing a carbonyl group as needed; X is H or OH; Y is O; and R1 is H or is not present, the condition being that when R1 is not present, Y and A bond to form a five-membered ring; and the second component is selected from a group composed of the following: a topoisomerase inhibitor, a microtubule assembly inhibitor, a platinum-based agent, an antimetabolite, and a combination thereof.",EVERFRONT BIOTECH INC,CHIOU TZYY-WEN;;HARN HORNG-JYH;;LIN SHINN-ZONG;;LEE JUI-HAO;;LIU JEN-WEI;;LIN SZU-YIN,EVERFRONT BIOTECH INC (2022-07-06),https://lens.org/153-047-389-743-028,Patent Application,yes,2,0,8,046-880-906-227-074;;113-827-592-847-558;;129-549-319-682-565;;153-047-389-743-028;;106-622-160-733-853;;038-545-779-662-218;;039-037-290-131-88X;;147-415-281-578-090,JP;;CN;;WO;;US;;TW,8,113-827-592-847-558;;046-880-906-227-074;;129-549-319-682-565;;153-047-389-743-028;;106-622-160-733-853;;038-545-779-662-218;;147-415-281-578-090;;039-037-290-131-88X,JP;;CN;;WO;;US;;TW,0,A61K31/365;;A61P35/00;;A61P35/04;;A61P35/00;;A61K31/365,A61P35/00;;A61K31/365,,1,1,078-202-371-357-283,10.1152/physrev.00016.2008;;19342610,"Tisdale, Mechanisms of Cancer Cachexia, Physiological Reviews Vol. 89, April 2009, Pages 381-410. (Year: 2009)",PENDING
461,WO,A1,WO 2024/215989 A1,122-400-822-606-834,2024-10-17,2024,US 2024/0024215 W,2024-04-12,US 202363459432 P;;EP 23173530 A,2023-04-14,ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS,"A combined therapy for treating cancer in a subject, comprising an immune cell population and an Interleukin-2/Interleukin-15 receptor beta gamma (IL-2/IL-15Rβγ) agonist. The immune cell population comprises genetically engineered immune cells expressing or overexpressing a metabolism-regulating polypeptide, which may (a) improves glucose uptake activity; (b) modulates the Krebs cycle; (c) enhances lactate concentration; and/or (d) diverts or redirects glucose metabolites out of a glycolysis pathway.",SOTIO BIOTECH INC;;SOTIO BIOTECH AG,JENSEN AMY;;KUIPER EMILY;;WHITEMAN KATHLEEN;;ADKINS IRENA,,https://lens.org/122-400-822-606-834,Patent Application,yes,89,0,1,122-400-822-606-834,WO,1,122-400-822-606-834,WO,99,A61K2300/00;;A61P35/00;;C12N5/0636;;C12N2501/72;;C12N2510/00;;A61K40/4251;;A61K40/11;;A61K40/31,A61K39/00;;A61K35/17;;A61K38/20;;A61P35/00;;C12N5/10,,105,68,077-957-151-449-353;;042-011-927-610-363;;039-125-610-813-629;;043-622-776-825-867;;033-442-418-364-094;;016-166-700-584-053;;141-667-135-840-911;;104-929-489-398-476;;010-421-605-901-118;;125-797-224-548-408;;065-155-315-342-529;;078-075-594-063-240;;062-915-083-335-003;;050-318-511-556-953;;027-590-135-109-808;;024-473-945-114-05X;;020-076-805-106-133;;046-168-719-116-29X;;059-142-582-871-089;;106-725-639-159-058;;020-984-227-302-397;;042-334-592-036-115;;020-323-378-319-681;;056-571-404-523-117;;067-577-074-748-984;;097-783-333-259-858;;008-354-652-359-916;;023-863-935-499-694;;027-695-205-373-112;;016-251-294-671-51X;;077-034-558-952-043;;135-020-829-679-590;;118-842-213-569-760;;001-811-611-132-180;;075-809-016-742-584;;077-957-151-449-353;;004-806-965-782-319;;002-951-590-894-039;;025-103-366-396-011;;042-513-916-881-571;;094-857-606-776-915;;007-943-524-351-855;;001-431-119-334-376;;030-363-795-939-151;;061-074-625-914-019;;032-728-154-591-070;;016-098-355-348-014;;105-044-393-253-406;;085-764-009-624-439;;006-287-393-526-299;;020-273-453-652-888;;013-196-935-848-429;;061-775-876-651-980;;048-946-542-600-182;;021-290-479-100-791;;084-566-494-607-400;;060-457-303-562-024;;017-216-732-209-839;;053-099-598-663-55X;;130-046-685-714-847;;044-862-347-072-130;;003-562-221-195-045;;019-672-418-800-737;;004-501-509-965-050;;007-538-000-443-231;;007-537-738-700-121;;036-489-877-612-736;;062-970-265-050-860,32159390;;10.1080/14712598.2020.1738379;;35507536;;pmc9067639;;10.1371/journal.pone.0266980;;10.1136/jitc-2022-sitc2022.0238;;pmc390337;;15034147;;10.1093/nar/gkh340;;3115332;;10.1182/blood.v70.4.1069.bloodjournal7041069;;10.1182/blood.v70.4.1069.1069;;pmc45737;;10.1073/pnas.90.2.720;;8421711;;10229830;;10.4049/jimmunol.162.10.5931;;10.1016/0022-1759(88)90145-7;;3263444;;11062441;;10.1038/81199;;10.1158/1538-7445.am2017-1594;;26861458;;10.1158/1078-0432.ccr-15-1696;;pmc5568475;;28733484;;10.4049/jimmunol.1700069;;12579196;;10.1038/nm827;;pmc3208293;;21849486;;10.1182/blood-2011-04-348540;;pmc5022178;;27518241;;10.1038/bcj.2016.61;;pmc3304468;;10.4049/jimmunol.1003961;;21984699;;28678791;;pmc5497954;;10.1371/journal.pone.0179431;;22447977;;10.4049/jimmunol.1101883;;29706540;;pmc5984158;;10.1016/j.cell.2018.03.038;;pmc6350412;;10.1089/jir.2018.0019;;29889594;;10.1182/blood-2002-10-3089;;12609842;;pmc8394762;;34439285;;10.3390/cancers13164129;;11878513;;10.3109/08830180109054417;;10.1038/ncomms12878;;27650575;;pmc5036003;;15976182;;10.1182/blood-2005-01-0064;;10.1186/s13045-021-01083-5;;33933160;;pmc8088725;;10.1172/jci80008;;26258412;;pmc4588307;;pmc3221918;;10.1016/j.cyto.2011.09.028;;22019703;;15246157;;10.1016/j.exphem.2004.03.011;;8495422;;10.1038/sj.leu.2403302;;14961035;;10.1371/journal.pone.0018556;;pmc3084703;;21602908;;10.1021/jacs.5b00106;;25692571;;29296519;;pmc5739565;;10.1080/2162402x.2017.1368604;;10.1002/ijc.2910180405;;789258;;32159390;;10.1080/14712598.2020.1738379;;10.1182/blood.v82.3.845.845;;8393352;;10.1182/blood.v82.3.845.bloodjournal823845;;10.4049/jimmunol.169.4.1760;;12165497;;10.1016/j.stem.2018.06.002;;pmc6084450;;30082067;;163658;;10.1182/blood.v45.3.321.321;;10.1182/blood.v45.3.321.bloodjournal453321;;10.1016/0092-8674(83)90344-6;;6678608;;30045932;;pmc6239933;;10.1158/1078-0432.ccr-18-0945;;pmc253118;;2831375;;10.1128/jvi.62.4.1120-1124.1988;;10.1182/blood-2018-99-115638;;pmc8316981;;32934330;;10.1038/s41571-020-0426-7;;10.1016/0022-2836(70)90057-4;;5420325;;pmc9216673;;10.1016/j.iotech.2019.06.002;;35755322;;pmc8080836;;10.1038/s12276-021-00576-0;;33707742;;3162770;;10.1073/pnas.85.8.2444;;pmc280013;;10.1016/j.cyto.2010.07.129;;21830940;;10.1056/nejmoa1103849;;pmc3387277;;18978797;;pmc2749734;;10.1038/nm.1882;;10.1089/hum.2006.17.ft-249;;10.1089/hum.2006.17.1027;;17007566;;pmc3501574;;23104097;;10.1038/ni.2449;;10.1016/j.imlet.2017.08.010;;28823521;;pmc5774016;;10.3389/fimmu.2022.835762;;35309357;;pmc8928448;;30626941;;10.1038/s41586-018-0830-7;;pmc6521699;;10.1016/0196-8858(81)90046-4;;19646987;;pmc2786060;;10.1016/j.jim.2009.07.010;;22032984;;pmc3327885;;10.1016/j.tips.2011.09.004;;33824268;;10.1038/s41408-021-00459-7;;pmc8024391;;10.1158/1078-0432.ccr-12-1449;;23032741;;10.1007/s10719-015-9627-1;;26563299;;pmc7537637;;15601438;;10.1111/j.1365-2885.2004.00600.x;;10.1158/0008-5472.can-11-3890;;pmc3319867;;22315351;;23948423;;10.1016/j.jim.2013.07.012;;31790761;;10.1016/j.canlet.2019.11.033;;pmc5355494;;28367149;;10.3389/fimmu.2017.00292,"KNUDSON K M ET AL: ""Rationale for IL-15 superagonists in cancer immunotherapy"", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 20, no. 7, 11 March 2020 (2020-03-11), pages 705 - 709, XP093030394, ISSN: 1471-2598, DOI: 10.1080/14712598.2020.1738379;;HICKMAN T L ET AL: ""BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity."", PLOS ONE, vol. 17, no. 5, E0266980, 4 May 2022 (2022-05-04), XP093019390, ISSN: 1932-6203;;HINDS J ET AL: ""Exogenous GOT2 in CAR-T cells improves metabolic function and preserves early memory T cell subsets"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 10, no. Suppl. 2, 238, 7 November 2022 (2022-11-07), 37th Annual Meeting of the Society for Immunotherapy of Cancer; Boston, MA, USA; 8-10 November 2022, pages A252, XP093092001, ISSN: 2051-1426, DOI: 10.1136/jitc-2022-SITC2022.0238;;EDGAR, R. C., NUCLEIC ACIDS RES, vol. 32, no. 5, 2004, pages 1792 - 1797;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR PRESS;;B. PERBAL ET AL.: ""A practical Guide To Molecular Cloning"", 1984;;HORI, T. ET AL., BLOOD, vol. 70, no. 4, 1987, pages 1069 - 1072;;J. P. MATHERP. E. ROBERTS: ""Introduction to Cell and Tissue Culture"", 1998, PLENUM PRESS;;ESHHAR, Z. ET AL., PROC NATL ACAD SCI U S A, vol. 90, no. 2, 1993, pages 720 - 724;;""Handbook of Experimental Immunology"", 1994, ACADEMIC PRESS, INC.;;""Current Protocols in Immunology"", 1991;;GEIGER, T. L. ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 162, no. 10, 1999, pages 5931 - 5939;;C. A. JANEWAYP. TRAVERS: ""Immunobiology"", 1997;;GEARING, A. J.R. THORPE, J IMMUNOL METHODS, vol. 114, no. 1-2, 1988, pages 3 - 9;;SHANAFELT, A. B. ET AL., NAT BIOTECHNOL, vol. 18, no. 11, 2000, pages 1197 - 1202;;""The Antibodies"", 1995, HARWOOD ACADEMIC PUBLISHERS;;""DNA Cloning: A practical Approach"", 1985;;""Immobilized Cells and Enzymes"", 1986, LRL PRESS;;ARENAS-RAMIREZ, N. ET AL., SCI TRANSL MED, vol. 8, no. 367, 2016, pages 367 - 166;;BACAC, M. ET AL., CANCER RESEARCH, vol. 77, no. 13, 2017, pages 1594;;BACAC, M. ET AL., CLIN CANCER RES, vol. 22, no. 13, 2016, pages 3286 - 3297;;BERNETT, M. J. ET AL., PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 58, 2017, pages 408;;BETTINI, M. L. ET AL., J IMMUNOL, vol. 199, no. 5, 2017, pages 1555 - 1560;;BRENTJENS, R. J. ET AL., SCI TRANSL MED, vol. 5, no. 177, 2013, pages 177 - 138;;BRENTJENS, R. J. ET AL., NAT MED, vol. 9, no. 3, 2003, pages 279 - 286;;BRENTJENS, R. J. ET AL., BLOOD, vol. 118, no. 18, 2011, pages 4817 - 4828;;CAO, Y. ET AL., ANGEW CHEM INT ED ENGL, vol. 55, no. 26, 2016, pages 7520 - 7524;;CARTELLIERI, M. ET AL., BLOOD CANCER J, vol. 6, no. 8, 2016, pages e458;;CASTRO, 1. ET AL., J IMMUNOL, vol. 187, no. 10, 2011, pages 5170 - 5182;;CHARYCH, D. ET AL., PLOS ONE, vol. 12, no. 7, 2017, pages e0179431;;CHARYCH, D. H. ET AL., CLINICAL CANCER RESEARCH, vol. 22, no. 3, 2016, pages 680;;CHENOWETH, M. J. ET AL., J IMMUNOL, vol. 188, no. 9, 2012, pages 4149 - 4157;;CHO, J. H. ET AL., CELL, vol. 173, no. 6, 2018, pages 1426 - 1438;;CONLON, K. C. ET AL., J INTERFERON CYTOKINE RES, vol. 39, no. 1, 2019, pages 6 - 21;;COOPER, L. J. ET AL., BLOOD, vol. 101, no. 12, 2003, pages 4853 - 4861;;DU, N. ET AL., CANCERS, vol. 13, no. 16, 2021, pages 4129;;FEHNIGER, T. A.M. A. CALIGIURI, INT REV IMMUNOL, vol. 20, no. 3-4, 2001, pages 503 - 534;;GHASEMI, R. ET AL., NAT COMMUN, vol. 7, 2016, pages 12878;;GIRON-MICHEL, J. ET AL., BLOOD, vol. 106, no. 7, 2005, pages 2302 - 2310;;GONG, Y. ET AL., J HEMATOL ONCOL, vol. 14, no. 1, 2021, pages 73;;GOUJON, M. ET AL., NUCLEIC ACIDS RES, vol. 38, 2010, pages 695 - 699;;GUBIN, M. M. ET AL., J CLIN INVEST, vol. 125, no. 9, 2015, pages 3413 - 3421;;HAN, K. P. ET AL., CYTOKINE, vol. 56, no. 3, 2011, pages 804 - 810;;HARADA, H. ET AL., JPN J CANCER RES, vol. 93, no. 3, 2002, pages 313 - 319;;HARADA, H. ET AL., EXP HEMATOL, vol. 32, no. 7, 2004, pages 614 - 621;;HEATON, K. M. ET AL., CANCER RES, vol. 53, no. 11, 1993, pages 2597 - 2602;;HU, Q. ET AL., SCI REP, vol. 8, no. 1, 2018, pages 7675;;IMAI, C. ET AL., LEUKEMIA, vol. 18, no. 4, 2004, pages 676 - 684;;JAYARAMAN, J ET AL., EBIOMEDICINE, vol. 59, 2020, pages 102975;;JOSEPH, I. B. ET AL., PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 60, 2019, pages 838;;KIM, J. H. ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages e18556;;KIM, M. S. ET AL., J AM CHEM SOC, vol. 137, no. 8, 2015, pages 2832 - 2835;;KLEIN, C., JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 2, 2014, pages 18 - 18;;KLEIN, C ET AL., CANCER RESEARCH, vol. 73, 2013, pages 8;;LOHMUELLER, J. J. ET AL., ONCOIMMUNOLOGY, vol. 7, no. 1, 2017, pages e1368604;;KLEIN, E. ET AL., INT J CANCER, vol. 18, no. 4, 1976, pages 421 - 431;;KNUDSON, K. M. ET AL., EXPERT OPIN BIOL THER, vol. 20, no. 7, 2020, pages 705 - 709;;KOCHENDERFER, J. N. ET AL., BLOOD, vol. 119, no. 17, 2012, pages 3940 - 3950;;KUDO, K. ET AL., CANCER RES, vol. 74, no. 1, 2014, pages 93 - 103;;KUO, M. L. ET AL., BLOOD, vol. 82, no. 3, 1993, pages 845 - 852;;KUROWSKA, M. ET AL., J IMMUNOL, vol. 169, no. 4, 2002, pages 1760 - 1767;;LI, Y. ET AL., CELL STEM CELL, vol. 23, no. 2, 2018, pages 181 - 192;;LINNEMANN, C. ET AL., NAT MED, vol. 21, no. 1, 2015, pages 81 - 85;;LIU, B ET AL., CYTOKINE, vol. 107, 2018, pages 105 - 112;;LIU, E ET AL., LEUKEMIA, vol. 32, no. 2, 2018, pages 520 - 531;;LOPES, J. E. ET AL., J IMMUNOTHER CANCER, vol. 1, 2020, pages 8;;LOZZIO, C. B.B. B. LOZZIO, BLOOD, vol. 45, no. 3, 1975, pages 321 - 334;;MA, J. S. ET AL., PROC NATL ACAD SCI U S A, vol. 113, no. 4, 2016, pages 450 - 458;;MANN, R. ET AL., CELL, vol. 33, no. 1, 1983, pages 153 - 159;;MARGOLIN, K. ET AL., CLIN CANCER RES, vol. 24, no. 22, 2018, pages 5552 - 5561;;MARKOWITZ, D. ET AL., J VIROL, vol. 62, no. 4, 1988, pages 1120 - 1124;;MENDES, B. B. ET AL., NATURE REVIEWS METHODS PRIMERS, vol. 2, no. 1, 2022, pages 24;;MIYAZAKI, T. ET AL., BLOOD, vol. 132, 2018, pages 2952 - 2952;;MORGAN, M. A. ET AL., FRONT IMMUNOL, vol. 11, 2020, pages 611163;;MYERS, J. A.J. S. MILLER, NATURE REVIEWS CLINICAL ONCOLOGY, vol. 18, no. 2, 2021, pages 85 - 100;;NEEDLEMAN, S. B.C. D. WUNSCH, J MOL BIOL, vol. 48, no. 3, 1970, pages 443 - 453;;NUSSBAUMER, OM. KOSLOWSKI, IMMUNOONCOL TECHNOL, vol. 1, 2019, pages 3 - 10;;PARK, J. H.H. K. LEE, EXP MOL MED, vol. 53, no. 3, 2021, pages 318 - 327;;PEARSON, W. RD. J. LIPMAN, PROC NATL ACAD SCI U S A, vol. 85, no. 8, 1988, pages 2444 - 2448;;PERDREAU, H. ET AL., EUR CYTOKINE NETW, vol. 21, no. 4, 2010, pages 297 - 307;;PORTER, D. L. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, no. 8, 2011, pages 725 - 733;;PULE, M. A. ET AL., NAT MED, vol. 14, no. 11, 2008, pages 1264 - 1270;;RABINOVICH, P. M. ET AL., HUMAN GENE THERAPY, vol. 17, no. 10, 2006, pages 1027 - 1035;;RHODE, P. R. ET AL., CANCER IMMUNOL RES, vol. 4, no. 1, 2016, pages 49 - 60;;RING, A. M. ET AL., NAT IMMUNOL, vol. 13, no. 12, 2012, pages 1187 - 1195;;ROBINSON, T. O.K. S. SCHLUNS, IMMUNOL LETT, vol. 190, 2017, pages 159 - 168;;ROSEN, D. B. ET AL., J IMMUNOTHER CANCER, vol. 7, 2022, pages 10;;SHAFER, P. ET AL., FRONT IMMUNOL, vol. 13, 2022, pages 835762;;SIEVERS, N. M. ET AL., INT J MOL SCI, vol. 10, 2020, pages 21;;SILVA, D.-A. ET AL., NATURE, vol. 565, no. 7738, 2019, pages 186 - 191;;SMITH, T. F.M. S. WATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, no. 4, 1981, pages 482 - 489;;SOMAN, G. ET AL., J IMMUNOL METHODS, vol. 348, no. 1-2, 2009, pages 83 - 94;;STEEL, J. C. ET AL., TRENDS PHARMACOL SCI, vol. 33, no. 1, 2012, pages 35 - 41;;STERNER, R. C.R. M. STERNER: ""11"", BLOOD CANCER JOURNAL, no. 4, 2021, pages 69;;TAMADA, K. ET AL., CLIN CANCER RES, vol. 18, no. 23, 2012, pages 6436 - 6445;;THAYSEN-ANDERSEN, M. ET AL., GLYCOCONJ J, vol. 33, no. 3, 2016, pages 417 - 433;;TOUTAIN, P. L.A. BOUSQUET-MELOU, J VET PHARMACOL THER, vol. 27, no. 6, 2004, pages 427 - 439;;URBANSKA, K. ET AL., CANCER RES, vol. 72, no. 7, 2012, pages 1844 - 1852;;WADHWA, M. ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 397, no. 1, 2013, pages 1 - 7;;WANG, S. ET AL., BMC MEDICINE, vol. 19, no. 1, 2021, pages 140;;WANG, W. ET AL., CANCER LETT, vol. 472, 2020, pages 175 - 180;;WEI, X. ET AL., J IMMUNOL, vol. 167, no. 1, 2001, pages 277 - 282;;WIECZOREK, M. ET AL., FRONT IMMUNOL, vol. 8, 2017, pages 292;;WRONA, E. ET AL., INT J MOL SCI, vol. 11, 2021, pages 22;;YING, Z. ET AL., NAT MED, vol. 25, no. 6, 2019, pages 947 - 953",PENDING
462,EP,A1,EP 3907007 A1,000-004-191-279-719,2021-11-10,2021,EP 20173705 A,2020-05-08,EP 20173705 A,2020-05-08,MICROFLUIDIC DEVICE,"Die vorliegende Erfindung betrifft eine mikrofluidische Vorrichtung 1, vorzugsweise zum Herstellen einer dreidimensionalen Zellkultur, mit mindestens einer Kammer 2, und einem die Kammer 2 zumindest teilweise durchlaufenden Fluidkanal 3 zum Bereitstellen eines die Kammer 2 vorzugsweise kontinuierlich durchlaufenden Fluidstroms, wobei die Kammer 2 mit einer Ladungsöffnung 4 verbunden und über die Ladungsöffnung 4 bis zu einem Sollfüllstand mit Hydrogel beladbar ist, dadurch gekennzeichnet, dass die Kammer 2 eine Hauptkammer 5 und eine mit der Hauptkammer 5 verbundene Nebenkammer 6 umfasst, wobei die Nebenkammer 6 beim Beladen der Kammer 2 mit Hydrogel bis zum Sollfüllstand zumindest teilweise mit Hydrogel befüllbar ist.",UNIV WIEN TECH,SCHOBESBERGER SILVIA;;ROTHBAUER MARIO;;ERTL PETER;;BACHMANN BARBARA EVA MARIA,,https://lens.org/000-004-191-279-719,Patent Application,yes,3,2,4,102-187-828-447-031;;000-004-191-279-719;;073-997-077-324-536;;089-245-332-235-573,EP;;WO;;US,4,102-187-828-447-031;;073-997-077-324-536;;000-004-191-279-719;;089-245-332-235-573,EP;;WO;;US,0,B01L3/502715;;B01L2300/0816;;B01L2300/0829;;C12M23/16;;C12M23/34;;G01N33/4833;;G01N33/5082;;C12M23/16;;C12M21/08;;C12M23/20;;C12M23/34;;G01N33/5082,B01L3/00;;C12M1/12;;C12M1/32;;C12M3/06;;G01N33/483;;G01N33/50,,5,5,076-196-806-192-22X;;037-459-360-512-993;;059-785-210-636-554;;112-354-367-654-991;;058-890-730-043-558,pmc8335790;;20576885;;10.1126/science.1188302;;29143053;;10.1039/c7lc00815e;;26133396;;10.1016/j.biotechadv.2015.06.006;;30189349;;10.1016/j.copbio.2018.08.009;;10.3390/bios9030110;;31546916;;pmc6784383,"HUH, D. ET AL., SCIENCE, vol. 328, no. 5986, 2010, pages 1662 - 8;;ROTHBAUER M ET AL., LAB CHIP, vol. 18, 2018, pages 249 - 270;;ROTHBAUER M ET AL., BIOTECH ADV, vol. 33, 2015, pages 948 - 961;;ROTHBAUER M ET AL., CURR OPIN BIOTECH, vol. 55, 2019, pages 81 - 86;;KRATZ SRA ET AL., BIOSENSORS, vol. 9, no. 3, 2019, pages 110",DISCONTINUED
463,US,A1,US 2022/0411882 A1,001-391-169-484-918,2022-12-29,2022,US 202217845893 A,2022-06-21,CN 202110687624 A;;CN 202110688122 A;;CN 202110796789 A,2021-06-21,SNP MOLECULAR MARKER FOR WEIGHT GAIN TRAIT SELECTION AND GENETIC SEX IDENTIFICATION OF ICTALURUS PUNCTATUS AS WELL AS SCREENING METHOD AND APPLICATION OF SNP MOLECULAR MARKER,"An SNP molecular marker for weight gain trait selection and genetic sex identification of Ictalurus punctatus as well as a screening method and application of the SNP molecular marker are provided. At least one of 17 SNP molecular markers for weight gain trait selection of Ictalurus punctatus and a molecular control means for genetic sex and weight gain trait selection and control of Ictalurus punctatus are further provided. Efficient and scientific identification of Ictalurus punctatus is achieved by means of simple PCR reactions and nucleic acid test strips, and the accuracy rate reaches 100%. A traditional agarose gel electrophoresis method is not used in the whole identification process, the cumbersome steps of gel preparation and running electrophoresis are omitted, nucleic acid dyes are not used, and the experimental process is safe and environmentally friendly.",FRESHWATER FISHERIES RES INSTITUTE OF JIANGSU PROVINCE,ZHANG SHIYONG;;CHEN XIAOHUI;;WANG MINGHUA;;ZHONG LIQIANG;;XU SIQI;;DUAN YONGQIANG;;LIU HONGYAN;;SHAO JUNJIE;;BIAN WENJI,FRESHWATER FISHERIES RESEARCH INSTITUTE OF JIANGSU PROVINCE (2022-06-16),https://lens.org/001-391-169-484-918,Patent Application,yes,0,7,1,001-391-169-484-918,US,7,111-627-507-656-038;;108-437-986-940-734;;001-391-169-484-918;;144-662-576-736-016;;077-109-069-842-680;;111-678-510-355-893;;173-098-476-609-017,CN;;US,69,C12Q1/6883;;C12Q2600/156;;C12Q2600/124;;C12Q1/6879;;C12Q1/6869;;C12Q1/6888;;C12Q1/6879;;C12Q1/6858;;C12Q2600/156;;C12Q2600/124,C12Q1/6888;;C12Q1/6879,,2,0,,,"Liu et al. (Nature Communications, Article Number 11757, June 20, 2016). (Year: 2016);;NEB catalog (1998/1999), pp. 121, 284. (Year: 1998)",PENDING
464,EP,A1,EP 4202040 A1,161-625-815-249-535,2023-06-28,2023,EP 22210324 A,2011-07-01,US 36074110 P;;EP 11801512 A;;US 2011/0042855 W,2010-07-01,METHODS FOR CULTURING UNDIFFERENTIATED CELLS USING SUSTAINED RELEASE COMPOSITIONS,"Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.",REGENERATIVE RES FOUNDATION,STERN JEFFREY;;STERN SALLY TEMPLE,,https://lens.org/161-625-815-249-535,Patent Application,yes,21,0,18,114-254-787-530-471;;029-154-680-206-146;;006-327-434-063-15X;;188-282-633-648-883;;175-640-022-322-353;;070-376-860-962-870;;161-625-815-249-535;;025-644-653-726-45X;;108-716-684-356-729;;090-847-110-609-57X;;121-534-674-411-222;;087-871-362-230-242;;051-601-162-816-357;;199-307-221-503-028;;123-550-719-620-443;;033-021-022-983-889;;037-491-601-298-503;;094-800-036-383-388,JP;;EP;;WO;;US;;CA,18,114-254-787-530-471;;029-154-680-206-146;;006-327-434-063-15X;;188-282-633-648-883;;175-640-022-322-353;;070-376-860-962-870;;161-625-815-249-535;;025-644-653-726-45X;;108-716-684-356-729;;090-847-110-609-57X;;121-534-674-411-222;;087-871-362-230-242;;051-601-162-816-357;;199-307-221-503-028;;123-550-719-620-443;;033-021-022-983-889;;037-491-601-298-503;;094-800-036-383-388,JP;;EP;;WO;;US;;CA,4,C12N5/0696;;C12N5/0606;;C12N5/0621;;C12N5/0623;;C12N2501/115;;C12N2501/602;;C12N2501/603;;C12N2501/604;;C12N2501/606;;C12N2506/1307;;C12N2531/00;;C12N2533/40;;C12N5/0696;;C12N5/0606;;C12N5/0607;;C12N5/0621;;C12N5/0623;;C12N2500/16;;C12N2500/34;;C12N2501/115;;C12N2501/602;;C12N2501/603;;C12N2501/604;;C12N2501/606;;C12N2506/1307;;C12N2531/00;;C12N2533/40,C12N5/0735;;C07K14/475;;C07K14/50;;C12N5/02;;C12N5/074,,100,69,000-542-994-625-644;;041-488-701-061-252;;057-187-726-067-150;;110-391-734-963-826;;151-536-167-760-759;;131-685-838-219-546;;074-024-076-400-563;;070-046-441-246-43X;;009-795-571-593-743;;041-236-307-200-313;;086-668-398-207-191;;139-751-042-044-481;;033-592-018-671-224;;056-843-553-509-630;;110-391-734-963-826;;147-159-170-904-308;;017-670-683-429-869;;015-159-858-231-168;;017-272-154-884-328;;008-206-139-027-692;;004-270-192-716-703;;139-376-199-575-430;;048-827-849-291-757;;037-480-189-672-490;;094-613-178-206-340;;069-938-984-657-372;;016-743-212-084-022;;079-458-745-329-822;;024-374-337-212-576;;110-391-734-963-826;;031-933-089-611-974;;095-050-980-581-957;;081-762-779-850-964;;059-038-435-839-492;;039-312-419-452-38X;;007-161-773-585-269;;039-384-864-129-401;;026-148-170-669-52X;;111-501-633-494-339;;021-612-452-406-271;;016-347-316-515-662;;000-173-179-070-389;;037-584-067-235-416;;041-754-496-294-59X;;125-224-683-592-610;;032-330-914-541-050;;035-238-575-653-10X;;051-076-139-709-120;;063-477-776-074-132;;035-238-575-653-10X;;106-743-303-476-905;;023-790-885-065-390;;014-591-921-668-271;;070-724-994-526-036;;040-091-367-301-676;;055-300-069-911-743;;048-827-849-291-757;;139-376-199-575-430;;015-588-994-910-638;;009-667-187-974-975;;026-032-495-703-525;;013-100-127-617-076;;001-448-961-546-793;;035-408-859-604-034;;006-678-033-097-046;;005-197-931-855-458;;084-315-199-000-490;;012-292-936-419-400;;049-497-396-381-887,20738064;;10.1166/jbn.2010.1102;;pmc4035024;;10.1089/ten.2006.12.537;;16579687;;1742404;;10.1016/0142-9612(91)90107-l;;10.1038/71916;;10625391;;pmc2812420;;19953308;;10.1007/s11095-009-0014-0;;pmc1949933;;10859025;;10.1007/bf03401776;;10.1007/s10529-006-0005-8;;16614931;;16862139;;10.1038/nmeth902;;pmc6578195;;7751935;;10.1523/jneurosci.15-05-03653.1995;;7646883;;10.1016/0896-6273(95)90030-6;;10.1523/jneurosci.18-19-07869.1998;;pmc6792996;;9742155;;10417880;;10.1016/s0070-2153(08)60329-4;;10.1016/0896-6273(90)90215-2;;2171589;;21112568;;10.1016/j.stem.2010.11.017;;10.1038/71916;;10625391;;10.4061/2010/218142;;20690713;;10.1021/bm100413w;;pmc3218097;;17554338;;10.1038/nature05934;;12893756;;10.1182/blood-2003-05-1664;;17325691;;10.1038/cr.2007.4;;10.1182/blood.v78.1.55.bloodjournal78155;;2070060;;10.1182/blood.v78.1.55.55;;10.1002/cyto.a.20674;;19023891;;pmc2640229;;10.1016/s0076-6879(06)19007-2;;pmc2387081;;17141055;;9212098;;10.1038/nm0797-730;;21150899;;pmc3059767;;10.1038/nature09587;;1541279;;10.1111/j.1432-1033.1992.tb16678.x;;10.1016/j.biomaterials.2007.08.038;;17881048;;10.1016/s0142-9612(03)00340-5;;12922147;;10.1016/j.bone.2004.02.027;;15268909;;10.1038/71916;;10625391;;10.1073/pnas.82.2.488;;pmc397064;;3881765;;10.1006/bbrc.1999.1372;;10491297;;10683722;;10.2144/00282bm01;;11252783;;10.2144/01303bm04;;10.2144/00295bm09;;11084857;;1518797;;10.1093/protein/5.5.467;;9512562;;10.1093/nar/26.7.1848;;pmc147442;;8655519;;pmc178091;;10.1128/jb.178.11.3346-3349.1996;;8590473;;10.1007/bf00315788;;8850009;;10.1385/0-89603-332-5:229;;12110702;;10.1634/stemcells.20-4-329;;15890332;;10.1016/j.ydbio.2005.03.040;;20161753;;pmc2817745;;10.1371/journal.pone.0009121;;10.1073/pnas.0711983105;;18287077;;pmc2268554;;18371324;;18371336;;10.1016/j.stem.2007.05.009;;10.1016/j.cell.2006.07.024;;16904174;;18035408;;10.1016/j.cell.2007.11.019;;10.1126/science.1151526;;18029452;;10.1101/gad.1963910;;pmc2956203;;20952534;;18035408;;10.1016/j.cell.2007.11.019;;16870554;;10.1042/cbi20090414;;20187873;;15319535;;10.1159/000080341;;pmc2634175;;10.4161/org.6048;;19279711;;16697959;;10.3410/f.30634.374603;;10.3410/f.30634.375123;;10.1016/j.ccr.2006.03.030;;10.1002/jcp.1041500215;;1310324;;10.1016/s0076-6879(06)19007-2;;pmc2387081;;17141055;;10.1002/cyto.a.20674;;19023891;;pmc2640229;;10.1126/science.1095505;;15060285;;19041776;;10.1016/j.stem.2008.11.008;;10.1634/stemcells.2004-0331;;16109759;;19351838;;10.1158/0008-5472.can-08-3886;;pmc2785462;;18029281;;10.1016/j.expneurol.2007.09.031;;10.1634/stemcells.2005-0439;;16527900;;10.1016/s0168-3659(02)00320-6;;12490371;;9971898;;10.1016/s0168-3659(98)00116-3;;10.1016/j.expneurol.2006.04.020;;16764857;;10.1021/jm000089j;;10891119;;10.1167/iovs.05-1622;;16877436;;pmc1904392,"KALAJI NADER ET AL: ""Controlled release carriers of growth factors FGF-2 and TGFbeta1: synthesis, characterization and kinetic modelling"", JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, AMERICAN SCIENTIFIC PUBLISHERS, US, vol. 6, no. 2, 1 April 2010 (2010-04-01), pages 106 - 116, XP009173957, ISSN: 1550-7033, DOI: 10.1166/JBN.2010.1102;;MOIOLI EDUARDO K., HONG LIU, GUARDARO JESSE ET AL.: ""SUSTAINED RELEASE OF TGFBETA3 FROM PLGA MICROSPHERES AND ITS EFFECT ON EARLY OSTEOGENIC DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS"", TISSUE ENGINEERING, vol. 12, no. 3, 1 February 2005 (2005-02-01), pages 537 - 546, XP055070840;;EDELMAN E R ET AL: ""Controlled and modulated release of basic fibroblast growth factor"", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 12, no. 7, 1 September 1991 (1991-09-01), pages 619 - 626, XP024141692, ISSN: 0142-9612, [retrieved on 19910901], DOI: 10.1016/0142-9612(91)90107-L;;ZHU GAOZHONG ET AL: ""Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)"", NATURE BIOTECHNOLOGY, vol. 18, no. 1, 1 January 2000 (2000-01-01), New York, pages 52 - 57, XP055878083, ISSN: 1087-0156, Retrieved from the Internet <URL:https://www.nature.com/articles/nbt0100_52.pdf> DOI: 10.1038/71916;;QINGHUA SUN ET AL: ""Sustained Release of Multiple Growth Factors from Injectable Polymeric System as a Novel Therapeutic Approach Towards Angiogenesis"", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 27, no. 2, 1 December 2009 (2009-12-01), pages 264 - 271, XP019773691, ISSN: 1573-904X;;AMIT, M. ET AL., DEV BIOL, vol. 2, 2000, pages 271 - 78;;ITSKOVITZ-ELDOR, J. ET AL., MOL MED, vol. 2, 2000, pages 88 - 95;;XU, C. ET AL., NAT BIOTECHNOL., vol. 10, 2001, pages 971 - 74;;DING, V. ET AL., BIOTECHNOL LETT, vol. 7, 2006, pages 491 - 95;;LEVENSTEIN, M.E. ET AL., STEM CELLS, vol. 24, 2006, pages 1564 - 1572;;LUDWIG, T.E. ET AL., NAT METHODS, vol. 8, 2006, pages 637 - 46;;BENDALL, S.C. ET AL., NATURE, vol. 340, 1989, pages 1015 - 473;;VESCOVI, A.L. ET AL., NEURON, vol. 5, 1993, pages 951 - 56;;KILPATRICK, T.J.BARTLETT, P.F., J NEUROSCI, vol. 5, 1995, pages 3653 - 61;;TEMPLE, S.QIAN, X, NEURON, vol. 2, 1995, pages 249 - 52;;QIAN, X. ET AL., NEURON, vol. 1, 1997, pages 81 - 83;;CICCOLINI, F.SVENDSEN, C.N., J NEUROSCI., vol. 19, 1998, pages 7869 - 80;;VACCARINO FM ET AL., CURR TOP DEV BIOL, vol. 46, 1999, pages 179 - 00;;RABALLO R ET AL., J NEUROSCI., vol. 13, pages 5012 - 23;;MCKINNON ET AL., NEURON, vol. 5, no. 5, November 1990 (1990-11-01), pages 603 - 14;;BECKERVORDERSANDFORTH, CELL STEM CELL, vol. 7, 2010, pages 744 - 758;;ZHU ET AL., NATURE BIOTECHNOLOGY, vol. 18, 2000, pages 52 - 57;;YUN ET AL., J. TISSUE ENG., 7 November 2010 (2010-11-07), pages 218142;;MACDONALD ET AL., BIOMACROMOLECULES, vol. 11, no. 8, 9 August 2010 (2010-08-09), pages 2053 - 2059;;OKITA ET AL., NATURE, vol. 448, 2007, pages 313 - 317;;PITTINGER ET AL., SCIENCE, vol. 284, 1999, pages 143 - 7;;HERZOG, BLOOD, vol. 102, 2003, pages 3483 - 93;;XU ET AL., CELL RESEARCH, vol. 17, 2007, pages 240 - 248;;SIMMONSTOROK-STORB, BLOOD, vol. 78, 1991, pages 55 - 62;;CHALLEN ET AL., CYTOMETRY A;, vol. 75, 2009, pages 14 - 24;;HAWLEY ET AL., METHODS IN ENZYMOL, vol. 419, 2006, pages 149 - 179;;BONNETDICK, NATURE MEDICINE, vol. 3, 1997, pages 730 - 737;;KAI ET AL., BREAST CANCER, vol. 17, 2010, pages 80 - 85;;GIBSON ET AL., NATURE, vol. 468, 2010, pages 1095 - 9;;CACCIA ET AL., EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 204, 1992, pages 649 - 655;;ASHTON ET AL., BIOMATERIALS, vol. 28, no. 36, 2007, pages 5518;;DRURY, J. L. ET AL., BIOMATERIALS, vol. 24, 2003, pages 4337 - 4351;;SIMMONS, C. A. ET AL., BONE, vol. 35, 2004, pages 562 - 569;;ZHU, G. ET AL., NAT BIOTECH, vol. 18, 2000, pages 52 - 57;;SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;B. PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984;;""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS, INC.;;KUNKEL, PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492;;FUKUOKA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 263, 1999, pages 357 - 360;;KIMMAAS, BIOTECH, vol. 28, 2000, pages 196 - 198;;PARIKHGUENGERICH, BIOTECH, vol. 24, no. 4, 1998, pages 28 - 431;;RAYNICKOLOFF, BIOTECH, vol. 13, 1992, pages 342 - 346;;WANG ET AL., BIOTECH, vol. 19, 1995, pages 556 - 559;;WANGMALCOLM, BIOTECH, vol. 26, 1999, pages 639 - 641;;HOGREFE, STRATEGIES, vol. 14, no. 3;;ANGAGSCHUTZ, BIOTECH, vol. 30, 2001, pages 486 - 488;;WANGWILKINSON, BIOTECH, vol. 29, 2000, pages 976 - 978;;KANG ET AL., BIOTECH, vol. 20, 1996, pages 44 - 46;;OGELMCPHERSON, PROTEIN ENGINEER, vol. 5, 1992, pages 467 - 468;;KIRSCHJOLY, NUC. ACIDS. RES., vol. 26, 1998, pages 1848 - 1850;;RHEMHANCOCK, J. BACTERIOL., vol. 178, 1996, pages 3346 - 3349;;BOLESMIOGSA, CURR. GENET., vol. 28, 1995, pages 197 - 198;;BARRENTTINO ET AL., NUC. ACIDS. RES., vol. 22, 1993, pages 541 - 542;;TESSIERTHOMAS, METHS. MOLEC. BIOL., vol. 57, pages 229 - 237;;PONS ET AL., METH. MOLEC. BIOL., vol. 67, pages 209 - 218;;HENDERSON, JK ET AL., STEM CELLS, vol. 20, no. 4, 2002, pages 329 - 37;;ABRAMOVA ET AL., DEVELOPMENTAL BIOLOGY, vol. 283, 2005, pages 269 - 81;;SHOEMAKER ET AL., PLOS ONE, vol. 5, 2010, pages e9121;;LOWRY, W.E. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 2883 - 2888;;MAHERALI, N. ET AL., CELL STEM CELL, vol. 1, 2007, pages 55 - 70;;PARK ET AL., NATURE, vol. 451, 2008, pages 141 - 146;;TAKAHASHI, K.YAMANAKA, S, CELL, vol. 126, 2006, pages 663 - 676;;TAKAHASHI, K. ET AL., CELL, vol. 131, 2007, pages 861 - 872;;YU, J. ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920;;STADTFELDHOCHEDLINGER, GENES DEV, vol. 24, 2010, pages 2239 - 2263;;TAKAHASHI ET AL., CELL, vol. 131, 30 November 2007 (2007-11-30), pages 861 - 872;;LU ET AL., HAEMATOLOGICA, vol. 91, 2006, pages 1017 - 26;;ZEDDOU ET AL., CELL BIOL INT, vol. 34, 2010, pages 693 - 701;;LEE ET AL., CELL PHYSIOL BIOCHEM, vol. 14, 2004, pages 311 - 324;;ROSENBAUM ET AL., ORGANOGENESIS, vol. 4, 2008, pages 23027;;LEE ET AL., CANCER CELL, vol. 9, 2006, pages 391 - 403;;RICCI-VITIANI ET AL., NATURE, vol. 445, pages 11 - 115;;NEW YEOMAN, J CELL OPHYSIOL, vol. 150, 1992, pages 320 - 326;;HAWLEY ET AL., METHODS ENZYMOL, vol. 419, 2006, pages 149 - 179;;CHALLEN ET AL., CYTOMETRY A, vol. 75, 2009, pages 14 - 24;;SHEN Q ET AL., SCIENCE, vol. 304, 2004, pages 1338 - 40;;MAHERALIHOCHEDLINGER, CELL STEM CELL, vol. 3, 2008, pages 595 - 605;;SOTIROPOULOU PA ET AL., STEM CELLS, vol. 24, no. 2, February 2006 (2006-02-01), pages 462 - 71;;CAO, L. ET AL., BMC GASTROENTEROL, vol. 11, no. 1, pages 71;;WAKIMOTO ET AL., CANCER RES., vol. 69, no. 8, 15 April 2009 (2009-04-15), pages 3472 - 81;;LOWRY, N. ET AL., EXP NEUROL, vol. 209, no. 2, February 2008 (2008-02-01), pages 510 - 22;;YAN J ET AL., PLOS MED, vol. 4, no. 2, February 2007 (2007-02-01), pages e39;;YEOH ET AL., STEM CELLS, vol. 24, 2006, pages 1564 - 1572;;EDLUND ET AL., ADVANCES IN POLYMER SCIENCE, vol. 157, 2002, pages 67;;ZHAO ET AL., BIOMAGNETIC RESEARCH AND TECHNOLOGY, vol. 5, 2007, pages 2;;YA-PING LI ET AL., J. OF CONTROLLED RELEASE, vol. 71, 2001, pages 203 - 211;;MU, L.FENG, S., J. OF CONTROLLED RELEASE, vol. 86, 2003, pages 33 - 48;;GOVENDER ET AL., J. OF CONTROLLED RELEASE, vol. 57, 1999, pages 171 - 185;;PIANTINO ET AL., EXP NEUROL., vol. 201, no. 2, 2006, pages 359 - 67;;CALDWELL, M. ET AL., EXP NEUROL, vol. 188, 2004, pages 405 - 420;;J. MED. CHEM., vol. 43, no. 13, 2000, pages 2591 - 2600;;BURKE, C. M. ET AL., EXP EYE RES, vol. 62, 1996, pages 63;;MAMINISHKIS, A. ET AL., INVEST OPHTHALMOL VIS SCI, vol. 47, 2006, pages 3612;;DE, S. ET AL., ARCH OPHTHALMOL, vol. 125, no. 5, pages 641 - 5",PENDING
465,US,A1,US 2022/0090004 A1,160-366-474-987-715,2022-03-24,2022,US 202017289180 A,2020-12-10,CN 201911257762 A;;CN 2020135275 W,2019-12-10,LIVE-ATTENUATED LISTERIA MONOCYTOGENES AND METHODS FOR USING THE SAME,"The present invention provides a construction method and application of a live-attenuated Listeria monocytogenes, in which a wild-type strain of Listeria monocytogenes EGD-e is used as construction parental strains, and the residues N478 and V479 of LLO are respectively mutated into plasmid free alanine. The live-attenuated strain of Listeria monocytogenes in the present invention can be used as a live vaccine vector and an immunologic adjuvant.",UNIV ZHEJIANG A&F,SONG HOUHUI;;CHENG CHANGYONG,ZHEJIANG A&F UNIVERSITY (2020-12-09),https://lens.org/160-366-474-987-715,Patent Application,yes,0,0,3,144-182-343-795-864;;020-109-891-014-531;;160-366-474-987-715,CN;;WO;;US,3,144-182-343-795-864;;020-109-891-014-531;;160-366-474-987-715,CN;;WO;;US,18,C07K14/195;;A61K39/0208;;A61K2039/522;;A61P31/04;;C07K16/00;;C12N15/74;;C12N1/205;;A61K39/0208;;A61K2039/522;;A61P31/04;;C07K14/195;;C12N15/74;;C12R2001/01;;C12N1/205;;A61K39/0208;;A61K2039/522;;C07K16/1296;;C12N15/74;;C12R2001/01,C12N1/20;;A61K39/02;;C07K16/12;;C12N15/74,,0,0,,,,DISCONTINUED
466,WO,A1,WO 2024/036404 A1,014-830-723-580-557,2024-02-22,2024,CA 2023051087 W,2023-08-17,US 202263371976 P,2022-08-19,CHITOSAN FILM AND METHOD OF PRODUCTION THEREOF,"A chitosan film, wherein the chitosan film comprises a reduced salt content compared to a conventional chitosan film, among other possible characteristics, is provided. A method for producing a chitosan film is also provided. The method comprises the steps of: A) providing a dried uncured chitosan film; B) curing the dried uncured chitosan film with an alcohol solvent to produce a cured chitosan film, and C) drying the cured chitosan film to produce the chitosan film, wherein the dried uncured chitosan film has been produced using an aqueous acidic chitosan solution. A composite fiber stock material comprising paper or a fibrous substrate at least partially coated with the chitosan film of the present invention or the chitosan film produced according to the method of the present invention is also provided.",9418 3712 QUEBEC INC,DI NARDO THOMAS,,https://lens.org/014-830-723-580-557,Patent Application,yes,1,0,1,014-830-723-580-557,WO,1,014-830-723-580-557,WO,0,D21H19/10;;C08L5/08;;C08J5/18;;D21H17/24;;D21H21/16;;D21H27/10;;C08B37/003;;C08J2305/08,C08L5/08;;C08J5/18;;D21H19/10,,0,0,,,,PENDING
467,US,A1,US 2021/0205394 A1,102-442-428-761-078,2021-07-08,2021,US 202117177016 A,2021-02-16,US 202117177016 A;;FR 1553092 A;;FR 1562033 A;;US 201715564985 A;;GB 2016051014 W,2015-04-10,"EUTECTIC EXTRACTION SOLVENTS, EXTRACTION METHODS BY EUTECTIGENESIS USING SAID SOLVENTS, AND EXTRACTS DERIVED FROM SAID EXTRACTION METHODS","A eutectic extraction solvent for extracting plant (e.g. vegetable) and/or animal and/or prokaryotic biological material, wherein the solvent is a clear, stable and fluid mixture comprising:(a) betaine or a hydrated form of betaine;(b) at least one hydrogen bond donor compound selected from the group consisting of polyols and organic acids; and(c) waterwith the proviso that the eutectic extraction solvent does not contain any exogenous sugar and/or amine salt and/or anion.",NATUREX;;UNIV D'AVIGNON ET DES PAYS DE VAUCLUSE,LAVAUD ALEXIS;;LAGUERRE MICHAEL;;BIRTIC SIMONA;;FABIANO TIXIER ANNE SYLVIE;;ROLLER MARC;;CHEMAT FARID;;BILY ANTOINE CHARLES,GIVAUDAN FRANCE NATURALS SAS (2017-11-09);;AVIGNON UNIVERSITÉ (2017-11-09),https://lens.org/102-442-428-761-078,Patent Application,yes,0,1,23,026-032-539-193-61X;;032-746-506-575-998;;006-099-726-043-183;;151-353-230-282-998;;032-085-172-387-819;;102-442-428-761-078;;046-342-966-142-39X;;190-469-543-162-902;;172-468-767-034-806;;048-605-233-291-296;;006-787-504-429-047;;095-480-526-993-775;;173-094-596-337-716;;112-130-813-237-942;;111-720-154-097-379;;122-483-715-789-07X;;016-884-193-299-384;;183-912-828-875-957;;117-883-516-946-310;;126-055-455-506-719;;020-729-226-437-443;;031-825-267-021-857;;102-249-517-184-095,KR;;EP;;ES;;CN;;WO;;HK;;US;;FR;;PL,23,026-032-539-193-61X;;032-746-506-575-998;;006-099-726-043-183;;151-353-230-282-998;;032-085-172-387-819;;102-442-428-761-078;;046-342-966-142-39X;;190-469-543-162-902;;172-468-767-034-806;;048-605-233-291-296;;006-787-504-429-047;;095-480-526-993-775;;173-094-596-337-716;;112-130-813-237-942;;111-720-154-097-379;;122-483-715-789-07X;;016-884-193-299-384;;183-912-828-875-957;;117-883-516-946-310;;126-055-455-506-719;;020-729-226-437-443;;031-825-267-021-857;;102-249-517-184-095,KR;;EP;;ES;;CN;;WO;;HK;;US;;FR;;PL,0,A23L33/105;;A61K36/53;;A61K36/63;;B01D11/02;;B01D11/0288;;B01D11/0288;;A61K36/53;;A61K36/63;;A23L33/105;;B01D11/02;;A61P17/16;;A61P17/18;;A61P29/00;;A61P39/06;;A61P43/00;;A23L33/105;;A61K36/53;;A61K36/63;;B01D11/0288;;B01D11/0288;;A61K36/53;;A61K36/63;;A23L33/105;;B01D11/02;;A61K36/11;;A61K36/23;;A61K36/31;;A61K36/736;;A61K36/88;;A61K2236/331,A61K36/736;;A23L33/105;;A61K36/11;;A61K36/23;;A61K36/31;;A61K36/53;;A61K36/63;;A61K36/88;;B01D11/02,,0,0,,,,ACTIVE
468,WO,A1,WO 2024/093910 A1,121-677-484-557-325,2024-05-10,2024,CN 2023127755 W,2023-10-30,CN 202211351369 A,2022-10-31,ANTIVIRAL-BASED HAND SANITIZER AND USE THEREOF,"Provided are an antiviral-based hand sanitizer and use thereof. The hand sanitizer possesses antibacterial and antiviral effects and a good killing effect against common bacteria and fungi such as Escherichia coli, Staphylococcus aureus, and Candida albicans. The addition of antivirals imparts to the hand sanitizer protective functionality against SARS-CoV-2 and other coronaviruses and the effect of protecting the hand skin due to the non-irritative nature of proteins.",KANGMA HEATHCODE SHANGHAI BIOTECH CO LTD;;KANGMA SHANGHAI MARINE TECH CO LTD,GUO MIN;;WU ZHI;;LIU ZHANG;;XU LIQIONG;;YU XUE,,https://lens.org/121-677-484-557-325,Patent Application,yes,9,0,2,121-677-484-557-325;;054-452-285-738-021,CN;;WO,2,121-677-484-557-325;;054-452-285-738-021,CN;;WO,15,A61K8/64;;A61K8/416;;A61K8/345;;A61Q19/10;;A61Q17/005;;A61P31/14;;A61Q17/00;;A61K8/41;;A61K8/64;;A61Q19/10;;A01N37/46;;A61P1/00;;A61K8/34;;A61P31/14,A61K8/64;;A01N37/46;;A61P1/00;;A61Q17/00,,1,0,,,"YAN TAO: ""Comparison of Different Pretreatments for Goggles Fogging in the Prevention and Control of Coronavirus Disease 2019"", MILITARY NURSING, vol. 37, no. 8, 15 August 2020 (2020-08-15), pages 90 - 92, XP093166307, ISSN: 1008-9993, DOI: 10.3969/j.issn.1008-9993.2020.08.023",PENDING
469,EP,A1,EP 3943944 A1,033-883-437-736-715,2022-01-26,2022,EP 20382667 A,2020-07-24,EP 20382667 A,2020-07-24,FLOW CYTOMETRY MULTIPLEXED METHOD FOR THE DETECTION OF SARS-COV-2 ANTIBODIES,"The present invention relates to a first method for in vitro detection of anti-S protein antibodies against SARS-CoV2 in a subject and a second method for diagnostic of the exposure to SARS-CoV2 virus of a subject, based both in flow cytometry, which comprising stable expressing either by transfection or viral transduction of a vector comprising the S protein of SARS-CoV2 in a cell line in suspension. Further, the present invention relates to a kit for in vitro detection of anti-S protein antibodies against SARS-CoV2 and a kit for diagnostic of the exposure to SARS-CoV2, as well as its uses.",CONSEJO SUPERIOR INVESTIGACION,ALARCÓN SÁNCHEZ BALBINO;;HORNDLER GIL LYDIA;;DELGADO CAÑAVERAS PILAR;;BALABANOV IVAYLO;;MARTIEN VAN SANTEN HISSE,,https://lens.org/033-883-437-736-715,Patent Application,yes,3,0,2,160-750-747-471-148;;033-883-437-736-715,EP;;WO,2,160-750-747-471-148;;033-883-437-736-715,EP;;WO,4,G01N33/56983;;G01N2333/165;;G01N2469/20,G01N33/569,,8,7,137-890-458-564-920;;012-875-844-037-055;;004-942-971-800-954;;057-509-593-896-869;;020-904-772-781-458;;012-647-812-080-126;;022-794-230-919-668,32611558;;pmc7327913;;10.1136/bmj.m2516;;10.1016/j.jim.2017.07.015;;28855105;;9628219;;10.1016/s0166-0934(97)00188-2;;32320687;;pmc7166309;;10.1016/j.jmb.2020.04.009;;10.1101/2020.02.19.956581;;pmc7102599;;10.1016/j.cell.2020.02.058;;32155444;;32404473;;10.1136/jclinpath-2020-206685;;10.1016/s1525-0016(16)36610-2,"DENNIS LAPUENTE ET AL: ""Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2"", MEDRXIV, 13 May 2020 (2020-05-13), XP055759485, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.05.09.20091447v1.full.pdf> [retrieved on 20201215], DOI: 10.1101/2020.05.09.20091447;;MAYARA LISBOA BASTOS ET AL: ""Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis"", BMJ, 1 July 2020 (2020-07-01), pages m2516, XP055759583, DOI: 10.1136/bmj.m2516;;MERAT SABRINA J ET AL: ""Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 454, 30 August 2017 (2017-08-30), pages 15 - 26, XP085350994, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2017.07.015;;DE SWART R L ET AL: ""Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay"", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 71, no. 1, 1 March 1998 (1998-03-01), pages 35 - 44, XP027296725, ISSN: 0166-0934, [retrieved on 19980301];;JAVIER A. JAIMES ET AL: ""Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop"", JOURNAL OF MOLECULAR BIOLOGY, vol. 432, no. 10, 1 May 2020 (2020-05-01), United Kingdom, pages 3309 - 3325, XP055759670, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2020.04.009;;WALLS, A. C. ET AL., CELL, vol. 181, 2020, pages 281 - 292;;VENTER, M.RICHTER, K., J. CLIN. PATHOL., vol. 73, 2020, pages 370 - 377;;WANG, X. ET AL.: ""A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells"", BLOOD, vol. 118, 2011, pages 1255 - 1263, XP055062819, DOI: 10.1182/blood-2011-02-337360",DISCONTINUED
470,US,A1,US 2021/0015739 A1,118-649-593-655-622,2021-01-21,2021,US 202016915025 A,2020-06-29,US 202016915025 A;;US 201816019258 A;;US 201313966637 A;;US 56568709 A;;US 9950008 P,2008-09-23,"Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same","Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.",LABORATORY SKIN CARE INC,OGAWA TETSURO;;YAMAMOTO AKIRA,LABORATORY SKIN CARE INC (2010-10-12),https://lens.org/118-649-593-655-622,Patent Application,yes,5,0,42,141-256-968-199-501;;042-140-058-968-910;;045-509-685-129-944;;145-805-597-578-784;;010-213-175-819-723;;041-611-087-631-614;;129-730-601-020-481;;013-221-870-117-167;;178-523-163-824-847;;053-140-260-371-21X;;118-649-593-655-622;;098-501-798-954-20X;;047-152-917-761-02X;;046-594-885-115-200;;029-204-084-297-160;;161-422-974-721-77X;;002-887-303-801-538;;043-154-953-685-945;;082-286-657-218-903;;093-287-805-073-27X;;063-247-912-756-995;;154-561-894-108-832;;121-191-583-912-046;;060-011-023-362-005;;092-327-161-861-998;;146-095-882-296-658;;023-116-639-568-342;;141-831-499-054-841;;123-461-185-906-433;;160-582-808-450-464;;084-654-951-629-42X;;135-492-810-503-750;;038-668-274-480-304;;164-279-398-017-636;;118-929-433-718-301;;108-632-939-724-303;;092-916-720-813-024;;178-067-032-159-166;;174-850-986-017-07X;;032-490-530-664-425;;164-629-646-251-358;;053-313-735-936-61X,AU;;JP;;CL;;EA;;US;;CA;;BR;;MX;;KR;;MY;;IL;;EP;;CN;;WO;;ZA;;SG;;NZ,42,141-256-968-199-501;;042-140-058-968-910;;045-509-685-129-944;;145-805-597-578-784;;010-213-175-819-723;;041-611-087-631-614;;129-730-601-020-481;;013-221-870-117-167;;178-523-163-824-847;;053-140-260-371-21X;;118-649-593-655-622;;098-501-798-954-20X;;047-152-917-761-02X;;046-594-885-115-200;;029-204-084-297-160;;161-422-974-721-77X;;002-887-303-801-538;;043-154-953-685-945;;082-286-657-218-903;;093-287-805-073-27X;;063-247-912-756-995;;154-561-894-108-832;;121-191-583-912-046;;060-011-023-362-005;;092-327-161-861-998;;146-095-882-296-658;;023-116-639-568-342;;141-831-499-054-841;;123-461-185-906-433;;160-582-808-450-464;;084-654-951-629-42X;;135-492-810-503-750;;038-668-274-480-304;;164-279-398-017-636;;118-929-433-718-301;;108-632-939-724-303;;092-916-720-813-024;;178-067-032-159-166;;174-850-986-017-07X;;032-490-530-664-425;;164-629-646-251-358;;053-313-735-936-61X,AU;;JP;;CL;;EA;;US;;CA;;BR;;MX;;KR;;MY;;IL;;EP;;CN;;WO;;ZA;;SG;;NZ,0,A61K31/05;;A61K31/23;;A61K31/66;;A61K47/02;;A61K8/368;;A61K9/1611;;A61K8/24;;A61Q19/008;;A61K8/0279;;A61K2800/56;;A61K9/0014;;A61K31/216;;A61K31/60;;Y10S977/773;;Y10S977/906;;A61P17/00;;A61K8/0279;;A61K8/24;;A61K8/368;;A61K9/0014;;A61K9/143;;A61K9/1611;;A61K31/60;;A61K31/66;;A61Q19/008;;A61K2800/56;;A61K31/05;;A61K31/23;;A61K31/66;;A61K47/02;;A61K8/368;;A61K9/1611;;A61K8/24;;A61Q19/008;;A61K8/0279;;A61K2800/56;;A61K9/0014;;A61K9/143;;A61K31/216;;A61K31/60;;Y10S977/773;;Y10S977/906,A61K9/00;;A61K8/02;;A61K8/24;;A61K8/368;;A61K9/14;;A61K9/16;;A61K31/05;;A61K31/216;;A61K31/23;;A61K31/60;;A61K31/66;;A61K47/02;;A61Q19/00,,1,0,,,"""Retinoids, Topical"". AOCD. Accessed online on 10/6/2022 at <https://www.aocd.org/page/Retinoidstopical#>. (Year: 2022)",DISCONTINUED
471,US,A1,US 2022/0073610 A1,048-834-004-798-981,2022-03-10,2022,US 201917418856 A,2019-12-26,CN 201811622069 A;;CN 2019128582 W,2018-12-28,"BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION","Provided are a bivalent bispecific antibody and a preparation method thereof, a coding gene, a host cell and a composition. The bivalent bispecific antibody comprises: a) a single-chain variable fragment scFv, a flexible peptide, a heavy chain IgG1 constant region CH1 and a hinge region partial sequence of the antibody that specifically binds to a first antigen, and b) a single-chain variable fragment scFv, and a light chain constant region CL, that is, scFv1-CL or CL-scFv1, of the antibody that specifically binds to a second antigen; or comprises: c) a light chain and a heavy chain of the antibody that specifically binds to the first antigen, and d) a light chain and a heavy chain of the antibody that specifically binds to the second antigen.",CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD,FENG XIAO;;JIN LEI;;WANG TAO;;GUO HONGRUI;;LIU SHUANG;;CHEN YUHENG;;HAN NING;;LIANG YANGQIU,CHANGCHUN GENESCIENCE PHARMACEUTICAL CO. LTD (2021-03-25),https://lens.org/048-834-004-798-981,Patent Application,yes,3,0,11,097-661-274-088-511;;121-284-070-690-84X;;002-028-754-723-166;;194-592-262-585-094;;003-666-865-754-152;;151-577-873-500-904;;008-735-780-927-868;;075-569-656-914-874;;021-294-817-512-528;;048-834-004-798-981;;022-467-561-335-394,JP;;CN;;EP;;WO;;US,11,121-284-070-690-84X;;097-661-274-088-511;;002-028-754-723-166;;194-592-262-585-094;;003-666-865-754-152;;151-577-873-500-904;;008-735-780-927-868;;075-569-656-914-874;;021-294-817-512-528;;048-834-004-798-981;;022-467-561-335-394,JP;;CN;;EP;;WO;;US,24,C07K16/468;;C07K16/2803;;C07K16/2827;;C12N5/0603;;C12N5/0686;;C07K2317/31;;C07K2317/24;;C07K2317/92;;C12N2510/02;;A61P35/00;;C07K2317/31;;C07K2317/622;;C07K2317/60;;C07K2317/64;;C07K2317/35;;C07K2317/92;;C07K16/2803;;C07K16/2827;;C07K2317/24;;C07K16/468;;C07K16/2803;;C07K16/2827;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/622;;C07K2317/92,C07K16/28,,0,0,,,,ACTIVE
472,EP,A1,EP 4239074 A1,194-652-244-434-390,2023-09-06,2023,EP 21885299 A,2021-10-29,CN 202011191136 A;;CN 2021127313 W,2020-10-30,RECOMBINANT VECTOR AND EXPRESSION PURIFICATION METHOD FOR HEAT-LABILE UNG FUSION PROTEIN,"Provided are a recombinant vector and an expression purification method for a heat-labile UNG fusion protein. The method comprises: cloning a gene sequence of Cod UNG to a pCold-sumo plasmid to construct a recombinant plasmid pCold-sumo-Cod UNG, transforming the recombinant plasmid into an Escherichia coli BL21 (DE3) competent cell, simultaneously transforming a plasmid pG-Tf2 which expresses chaperone into the competent cell, and carrying out low-temperature-induced expression to obtain a soluble sumo-Cod UNG fusion protein. According to the method, the problem of insoluble Cod UNG expression products is overcome.",UNIV XIAMEN;;XIAMEN ZEESAN BIOTECH CO LTD,ZHANG YONGYOU;;WANG DAN;;SONG NAJIE,,https://lens.org/194-652-244-434-390,Patent Application,yes,0,0,5,194-652-244-434-390;;147-792-055-885-387;;045-470-863-243-358;;053-044-412-085-985;;003-787-510-661-169,EP;;CN;;WO;;US,5,194-652-244-434-390;;147-792-055-885-387;;045-470-863-243-358;;053-044-412-085-985;;003-787-510-661-169,EP;;CN;;WO;;US,5,C12N15/70;;C12N9/2497;;C07K2319/21;;C07K2319/95;;C12Y302/02027;;C12N9/2497;;C12N15/70;;C12N9/2402;;C07K2319/21;;C07K2319/95;;C12N9/2497;;C12N15/70;;C12N2800/101;;C12Y302/02027,C12N15/70;;C12N9/24;;C12N15/56,,0,0,,,,DISCONTINUED
473,EP,A1,EP 4467647 A1,086-971-017-227-300,2024-11-27,2024,EP 23908690 A,2023-12-26,CN 202310368832 A;;CN 2023141727 W,2023-04-10,"RECOMBINANT TYPE III HUMANIZED COLLAGEN ¿1, EXPRESSION VECTOR THEREOF AND USE THEREOF","A recombinant humanized collagen type III alpha-1 (rhCol III a1), and an expression vector and use thereof are provided, relating to the technical field of bioengineering. A sequence on positions 154 to 1,221 of a human type III collagen α chain is ligated to an optimized vector pcDNA3.1, a resulting optimized expression vector is transfected into a human embryonic kidney cell Expi293F, and then rhCol III a1 is secreted to form a fusion protein with a soluble green fluorescent protein (GFP). The expressed rhCol III a1 that forms the fusion protein with the GFP shows an activity of promoting the migration of BALB/c 3T3 cells, thus exhibiting a great application potential in the field of skin care.",SHANDONG D NUTRIMEC BIOMEDICAL CO LTD,GUO ZHIDONG;;SHAO JIAJIA;;MA HONGWEI,,https://lens.org/086-971-017-227-300,Patent Application,yes,0,0,6,064-484-165-384-82X;;005-105-206-022-436;;168-009-332-166-351;;174-935-047-427-479;;086-971-017-227-300;;103-787-093-656-013,CN;;EP;;WO;;US,6,064-484-165-384-82X;;005-105-206-022-436;;168-009-332-166-351;;174-935-047-427-479;;086-971-017-227-300;;103-787-093-656-013,CN;;EP;;WO;;US,0,C07K14/78;;C12N15/85;;C12N2800/107;;C12N2800/22;;C07K2319/02;;C07K2319/60;;C07K2319/50;;Y02A50/30;;C07K2319/02;;C07K14/78;;C07K2319/50;;C07K2319/60;;C07K2319/00;;C12N15/85;;A61Q19/00;;A61Q19/08;;A61K8/65;;C12N5/0068;;C12N2533/54;;A61K38/00;;C07K14/78;;C07K2319/02;;C07K2319/50;;C07K2319/60;;C12M21/02;;C12N5/0037;;C12N5/0686;;C12N15/85;;C12N2500/02;;C12N2523/00;;C12N2527/00;;C12N2800/22,C12N15/12;;C07K19/00;;C12N15/62;;C12N15/64;;C12N15/85,,0,0,,,,PENDING
474,US,A1,US 2021/0238634 A1,111-674-271-956-086,2021-08-05,2021,US 201816644955 A,2018-12-03,CN 201811274640 A;;CN 2018118888 W,2018-10-30,USE OF GENOMIC NW_006882077.1 IN CHO CELL FOR STABLY EXPRESSING A PROTEIN,"Use of genomic NW_006882077.1 in CHO cell for stably expressing a protein is disclosed. The certain site in CHO cell genome for stably expressing a protein is positioned at a base of No. 691045 in a CHO cell gene NW_006882077.1; a sequence of 5′ NNNNNNNNNNNNNNNNNNNNNGG3′ that can be identified by CRISPR/Cas9 technology and positioned in a base range of No. 690980-691090 around the certain site is a target sequence. Various of protein genes are introduced into a fixed site in CHO cell genome, and expressed stably in the present disclosure.",UNIV JIANGNAN,LI HUAZHONG;;JIN JIAN;;ZHOU SONGTAO;;CHEN YUN;;DUAN ZUOYING;;GONG XIAOHAI,JIANGNAN UNIVERSITY (2020-01-14),https://lens.org/111-674-271-956-086,Patent Application,yes,0,0,5,119-613-762-841-007;;179-734-068-785-874;;178-418-524-247-228;;111-674-271-956-086;;169-673-841-524-884,CN;;WO;;US,5,119-613-762-841-007;;179-734-068-785-874;;178-418-524-247-228;;111-674-271-956-086;;169-673-841-524-884,CN;;WO;;US,9,C12N15/907;;C12N5/0682;;C12N15/85;;C12N2510/02;;C12N2800/107;;C12N2810/10;;C12N15/907;;C12N2310/20;;C12N15/907;;C12N5/0682;;C12N15/85;;C12N2510/02;;C12N2810/10,C12N15/90;;C12N5/071;;C12N15/85,,1,0,,,"Zhou, S et al. CN107557390A machine translation. p. 1-16. 2018. (Year: 2018)",ACTIVE
475,US,A1,US 2021/0251157 A1,104-578-670-985-956,2021-08-19,2021,US 202117204857 A,2021-03-17,US 202117204857 A;;US 201916396134 A;;US 201816029627 A;;US 201715841923 A;;US 201715784112 A;;US 201715609472 A,2017-05-31,CANNABIS PRODUCTION SYSTEMS AND METHODS,"A vertically-integrated Cannabis-related product production method is described, the method comprises, producing a distilled cannabinoid and/or a crystallized cannabinoid from Cannabis plants, comprising: in a farming system, growing the Cannabis plants, the Cannabis plants comprise a cannabinoid; in an extraction system, extracting the cannabinoid from the Cannabis plants; in a purification system, purifying the cannabinoid to produce a purified cannabinoid; and in a distillation and/or a crystallization system, distilling and/or crystallizing the purified cannabinoid to produce the distilled cannabinoid and/or the crystallized cannabinoid. Various ways to purify, distill, and process the cannabinoids are described. An insect pest management system may be integrated with the farming system to grow the Cannabis plants in the presence of predatory mites which feed on insects and/or spider mites.",INSECTERGY LLC,LEO DANIEL MICHAEL,INSECTERGY US LLC (2025-07-25);;INSECTERGY LLC (2022-03-07),https://lens.org/104-578-670-985-956,Patent Application,yes,1,23,3,104-578-670-985-956;;037-952-121-946-929;;060-855-319-568-416,US,26,058-054-431-084-217;;085-574-638-548-005;;157-423-228-342-751;;028-164-556-832-37X;;185-192-914-211-233;;001-344-221-031-704;;060-855-319-568-416;;148-436-283-806-869;;042-679-102-032-271;;111-826-766-672-958;;064-425-037-095-29X;;170-355-923-356-564;;158-624-137-053-548;;067-987-987-119-199;;026-307-316-684-024;;104-578-670-985-956;;092-810-517-376-708;;009-014-541-102-937;;094-358-954-127-691;;032-630-425-075-508;;113-545-755-268-871;;032-843-672-094-035;;080-470-163-610-961;;109-942-608-793-152;;156-504-604-542-115;;037-952-121-946-929,US,0,A01G22/00;;A01H4/005;;A01H6/28;;A61K36/185;;A61L2/12;;B01D9/0004;;B01D9/0018;;B01D9/004;;B01D11/0203;;B01D11/0207;;B01D11/0226;;B01D11/0257;;B01D11/028;;B01D11/0288;;B01D11/0296;;A61K2236/00;;A23L33/105;;B01D1/222;;B01D1/227;;A01K67/30;;A01G22/00;;B01D1/065;;B01D9/0018;;B01D2009/0086;;B01D3/12;;A23L33/105;;B01D9/004;;A61K31/437,A01G22/00;;A23L33/105;;B01D1/06;;B01D3/12;;B01D9/00,,1,1,044-759-646-768-298,28324579;;pmc4362737;;10.1007/s13205-014-0214-0,"Jaiswal, et al., 3 Biotech, 5:123. (Year: 2015)",ACTIVE
476,US,A1,US 2025/0257119 A1,103-787-093-656-013,2025-08-14,2025,US 202318834531 A,2023-12-26,CN 202310368832 A;;CN 2023141727 W,2023-04-10,"Recombinant Humanized Collagen Type III Alpha-1, and Expression Vector and Use Thereof","A recombinant humanized collagen type III alpha-1 (rhCol III a1), and an expression vector and use thereof are provided, relating to the technical field of bioengineering. A sequence on positions 154 to 1,221 of a human type III collagen α chain is ligated to an optimized vector pcDNA3.1, a resulting optimized expression vector is transfected into a human embryonic kidney cell Expi293F, and then rhCol III a1 is secreted to form a fusion protein with a soluble green fluorescent protein (GFP). The expressed rhCol III a1 that forms the fusion protein with the GFP shows an activity of promoting the migration of BALB/c 3T3 cells, thus exhibiting a great application potential in the field of skin care.",SHANDONG D NUTRIMEC BIOMEDICAL CO LTD,GUO ZHIDONG;;SHAO JIAJIA;;MA HONGWEI,SHANDONG D-NUTRIMEC BIOMEDICAL CO. LTD (2024-07-18),https://lens.org/103-787-093-656-013,Patent Application,yes,0,0,6,064-484-165-384-82X;;005-105-206-022-436;;168-009-332-166-351;;174-935-047-427-479;;086-971-017-227-300;;103-787-093-656-013,CN;;EP;;WO;;US,6,064-484-165-384-82X;;005-105-206-022-436;;168-009-332-166-351;;174-935-047-427-479;;086-971-017-227-300;;103-787-093-656-013,CN;;EP;;WO;;US,0,C07K14/78;;C12N15/85;;C12N2800/107;;C12N2800/22;;C07K2319/02;;C07K2319/60;;C07K2319/50;;Y02A50/30;;C07K2319/02;;C07K14/78;;C07K2319/50;;C07K2319/60;;C07K2319/00;;C12N15/85;;A61Q19/00;;A61Q19/08;;A61K8/65;;C12N5/0068;;C12N2533/54;;A61K38/00;;C07K14/78;;C07K2319/02;;C07K2319/50;;C07K2319/60;;C12M21/02;;C12N5/0037;;C12N5/0686;;C12N15/85;;C12N2500/02;;C12N2523/00;;C12N2527/00;;C12N2800/22,C07K14/78;;A61K38/00;;C12M1/00;;C12N5/00;;C12N5/071;;C12N15/85,,2,2,125-351-767-570-584;;048-988-711-781-806,31075413;;pmc6579750;;10.1016/j.gene.2019.05.003;;10.18926/amo/30743;;16838047,"Kulvaniemi et al., 2019, Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases, Gene, 707: 151-171.;;Sumiyoshi et al., 2006, Multifactor complex containing B element binding factor, BBF, and repressors regulate the human alpha 1 (III) collagen gene (COL3A1), Acta Medica Okayama, 60(3): 181-189.",PENDING
477,US,A1,US 2021/0386851 A1,126-422-619-239-971,2021-12-16,2021,US 202117444242 A,2021-08-02,US 202117444242 A;;US 201414511864 A;;US 201213476835 A;;US 40773009 A;;US 8077202 A;;US 27074501 P,2001-02-22,"MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION","The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.",UNIV FLORIDA,YAMAMOTO JANET K,,https://lens.org/126-422-619-239-971,Patent Application,yes,0,0,11,124-319-429-387-502;;009-539-798-949-502;;000-030-718-895-200;;067-789-804-546-589;;198-238-344-833-649;;126-422-619-239-971;;123-227-602-202-352;;055-795-833-004-426;;179-334-053-046-830;;136-274-930-284-784;;066-474-382-315-875,AU;;WO;;US,11,124-319-429-387-502;;009-539-798-949-502;;000-030-718-895-200;;067-789-804-546-589;;198-238-344-833-649;;126-422-619-239-971;;123-227-602-202-352;;055-795-833-004-426;;066-474-382-315-875;;136-274-930-284-784;;179-334-053-046-830,AU;;WO;;US,68,A61K39/21;;A61K39/12;;A61P31/14;;A61P31/18;;A61P37/04;;C12N2740/15034;;C12Q1/702;;G01N33/56983;;G01N33/56988;;G01N33/6854;;G01N2333/155;;G01N2469/20;;A61K39/21;;A61K39/12;;A61K39/295;;A61K2039/575;;A61K2039/58;;A61K2039/70;;C07K14/155;;C07K14/161;;C07K14/162;;C12N2740/15011;;C12N2740/15022;;C12N2740/15034;;C12N2740/16111;;C12N2740/16122;;C12N2740/16134;;C12N2740/16211;;C12N2740/16222;;C12N2740/16234;;C12Q1/702;;G01N33/56983;;G01N33/56988;;G01N33/6854;;G01N2333/155;;G01N2469/20,A61K39/21;;A61K39/12;;A61K39/295;;A61P31/14;;A61P31/18;;C07K14/16;;C12Q1/70;;G01N33/569;;G01N33/68,,0,0,,,,DISCONTINUED
478,US,A1,US 2021/0145911 A1,127-745-438-488-402,2021-05-20,2021,US 201916976376 A,2019-03-08,KR 20180027741 A;;KR 2019002737 W,2018-03-09,"FUNCTIONAL FOOD COMPOSITION FOR ENHANCING MUSCULAR FUNCTION AND MOBILITY COMPRISING LOTUS LEAF EXTRACT, AND METHOD FOR PREPARING SAME","The present invention relates to a functional food composition for enhancing muscular function and exercise performance and a method for preparing same. According to the present invention, provided is a composition which enables increased generation of factors associated with myogenesis and energy metabolism and thus enhances exercise performance and muscular function. More particularly, mitochondria and muscle cell synthesis is increased and muscular atrophy is inhibited, and thus muscle exercise effects can be increased and fatigue is reduced. The composition can be applied as a health function composition to various fields such as foods.",COSMAX NS INC;;COSMAX NBT INC,KIM JIN HAK;;JANG JI HWAN;;GEUM JEONG HO;;KWEON MIN SON;;CHOI SU YOUNG;;KIM SANG WOO;;HWANG JAE KWAN,COSMAX NBT INC (2020-08-18);;COSMAX NS INC (2020-08-18),https://lens.org/127-745-438-488-402,Patent Application,yes,0,0,6,075-200-236-674-800;;093-544-584-858-333;;147-970-663-195-178;;127-745-438-488-402;;009-581-303-431-330;;101-852-071-881-91X,KR;;CN;;WO;;US,6,075-200-236-674-800;;009-581-303-431-330;;147-970-663-195-178;;127-745-438-488-402;;093-544-584-858-333;;101-852-071-881-91X,KR;;CN;;WO;;US,0,A61P21/06;;A23L33/105;;A61K36/62;;A61K2236/331;;A61K2236/333;;A61K2236/37;;A23L33/105;;A23V2002/00;;A23V2200/316;;A23V2300/14;;A61K36/185;;A23L33/105;;A23L33/40;;A23V2002/00;;A61K2236/331;;A61K2236/333;;A61K2236/37;;A61P21/06,A61K36/185;;A23L33/00;;A23L33/105;;A61P21/06,,0,0,,,,DISCONTINUED
479,US,A1,US 2020/0385775 A1,045-807-702-679-32X,2020-12-10,2020,US 202017000285 A,2020-08-22,US 202017000285 A;;US 201715792572 A;;US 201514429878 A;;US 2013/0064003 W;;US 201261715496 P,2012-10-18,AUTOMATED YEAST BUDDING MEASUREMENT,"The invention generally relates to analyzing yeast viability and reproduction rate of yeasts. More particularly, the invention relates to efficient and effective methods and compositions for accessing and measuring budding percentages, viability and concentration of yeast cells.",NEXCELOM BIOSCIENCE LLC,CHAN LEO L;;QIU JEAN;;LI PETER;;FLANAGAN KEVIN,NEXCELOM BIOSCIENCE HOLDINGS LLC (2023-10-30);;REVVITY HEALTH SCIENCES INC (2023-10-30),https://lens.org/045-807-702-679-32X,Patent Application,yes,1,0,8,193-693-063-408-34X;;011-142-374-750-336;;169-385-982-389-552;;132-185-235-764-233;;120-290-549-005-941;;038-502-718-996-986;;045-807-702-679-32X;;040-237-413-578-553,CN;;EP;;WO;;US,8,193-693-063-408-34X;;011-142-374-750-336;;169-385-982-389-552;;132-185-235-764-233;;120-290-549-005-941;;038-502-718-996-986;;040-237-413-578-553;;045-807-702-679-32X,CN;;EP;;WO;;US,0,C12Q1/02;;C12N1/16;;G01N15/01;;G01N15/1433;;G01N21/6428;;G01N21/6458;;G01N2015/0092;;G01N2015/1497;;G01N2021/6441;;G01N2333/395;;C12Q1/02;;C12N1/16;;G01N15/01;;G01N15/1433;;G01N21/6428;;G01N21/6458;;G01N2015/0092;;G01N2015/1497;;G01N2021/6441;;G01N2333/395,C12Q1/02;;C12N1/16;;G01N15/14;;G01N21/64,,3,2,066-121-865-284-504;;053-470-786-688-563,21785623;;10.1093/ecam/neq010;;pmc3135625;;10864990;;10.1046/j.1537-2995.2000.40060693.x,"Mohan et al. IN VITRO ULTRAMORPHOLOGICAL ASSESSMENT OF APOPTOSIS ON CEMSS INDUCED BY LINOLEIC ACID-RICH FRACTION FROM TYPHONIUM FLAGELLIFORME TUBER; Evidence-Based Complementary and Alternative Medicine, Vol. 2011, pp. 1-12. (Year: 2011);;Mascotti et al. HPC VIABILITY MEASUREMENT: TRYPAN BLUE VERSUS ACRIDINE ORANGE AND PROPIDIUM IODIDE; Transfusion, Vol. 40, pp. 693-696. (Year: 2000);;Anonymous. PHOSPHATE BUFFERED SALINE (PBS), PH 7.4 AND 7.2; Smart Buffers, pp. 1-2. downloaded from http://www. medicago.se/sites/default/files/pdf/productsheets/PBS_Buffer_v._01.pdf on 10/14/2022. (Year: 2022)",DISCONTINUED
480,US,A1,US 2024/0318153 A1,064-381-925-181-16X,2024-09-26,2024,US 202418614748 A,2024-03-25,CN 202310299778 A,2023-03-25,Construction Method and Applications of Glycosyltransferase BS-YjiC Mutant,"A glycosyltransferase BS-YjiC mutant, a construction method and an application thereof provided, relating to the field of genetic engineering technologies. The glycosyltransferase BS-YjiC mutant is obtained by performing site-directed mutation on amino acids at the 125th, 178th, 313th, 125th and 178th, or 125th and 313th positions of a wild-type glycosyltransferase BS-YjiC with the amino acid sequence as shown in SEQ ID NO: 1. Compared with the wild-type glycosyltransferase BS-YjiC, the glycosyltransferase BS-YjiC mutant is more suitable for catalyzing protopanaxadiol (PPD) to generate rare ginsenosides F12 and Rh2, which is more conducive to the flexibility of the production process.",UNIV NORTHWEST,LI WEINA;;FAN DAIDI;;ZHU CHENHUI,NORTHWEST UNIVERSITY (2024-03-24),https://lens.org/064-381-925-181-16X,Patent Application,yes,0,1,4,121-448-008-876-086;;064-381-925-181-16X;;007-244-453-595-779;;117-858-682-349-55X,CN;;US,4,121-448-008-876-086;;064-381-925-181-16X;;007-244-453-595-779;;117-858-682-349-55X,CN;;US,0,C12N9/1051;;C12N15/70;;C12P33/20;;C12Y204/01;;C12R2001/19;;C12N9/1051;;C12Y204/01;;C12P17/06;;C12N15/70;;C12N9/1048;;C12N9/1051;;C12N15/70;;C12P17/06;;C12Y204/01,C12N9/10;;C12N15/70;;C12P17/06,,3,3,021-149-656-528-99X;;075-081-330-670-962;;005-785-085-836-32X,33152360;;10.1016/j.ijbiomac.2020.10.238;;10.1016/j.mcat.2021.111937;;10.1016/j.procbio.2023.07.005,"Liu et al. Structural and biochemical studies of the glycosyltransferase Bs-YjiC from Bacillus subtilis. International Journal of Biological Macromolecules (2021), 166: 806-817. (Year: 2021);;Zhao et al. Single site mutations of glycosyltransferase with improved activity and regioselectivity for directed biosynthesis of unnatural protopanaxatriol-type ginsenoside product. Molecular Catalysis (2021), 515: 111937. (Year: 2021);;Guo et al. Enhancement of thermal stability of Bacillus subtilis 168 glycosyltransferase YjiC based on PoPMuSiC algorithm and its catalytic conversion of rare ginsenoside PPD. Process Biochemistry (2023), 132:1-12. (Year: 2023)",ACTIVE
481,WO,A1,WO 2020/211941 A1,086-689-386-250-961,2020-10-22,2020,EP 2019060092 W,2019-04-18,EP 2019060092 W,2019-04-18,EXTREME THERMOPHILIC BACTERIA OF THE GENUS CALDICELLULOSIRUPTOR,"The technology provided herein relates to novel isolated cellulolytic extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures and microbial compositions. The novel bacteria are in particular suitable for the production of fermentation products such as lactic acid from any carbon source, not limited to cellulosic but especially useful for converting cellulosic and ligniocellulosic biomass.",BLUCON BIOTECH GMBH,KRÄMER MARCO;;SVETLICHNY VITALY,,https://lens.org/086-689-386-250-961,Patent Application,yes,2,0,1,086-689-386-250-961,WO,14,115-550-975-719-514;;089-119-531-590-175;;106-926-783-096-283;;138-616-557-731-08X;;172-502-806-357-592;;133-358-669-744-474;;003-861-881-697-091;;086-689-386-250-961;;011-659-486-716-10X;;066-052-449-652-084;;049-754-984-984-152;;021-008-914-874-694;;056-386-385-249-081;;048-949-088-739-646,JP;;AU;;KR;;EP;;CN;;WO;;ZA;;US;;CA;;BR,4,C12N1/20;;C12N1/205;;C12N1/22;;C12P7/56;;C12P2203/00;;C12R2001/01,C12N1/20;;C12N1/22;;C12P7/56;;C12R1/01,,9,7,006-719-136-734-034;;085-869-145-963-428;;006-719-136-734-034;;093-619-101-976-938;;074-488-197-260-232;;014-462-529-725-525;;019-979-499-270-526,10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1111/j.1432-1033.1970.tb00830.x;;4984993;;10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1128/aem.53.4.832-838.1987;;16347327;;pmc203765;;18587891;;10.1002/bit.260331118;;pmc168907;;12824352;;10.1093/nar/gkg500;;10.1093/bioinformatics/17.12.1244;;11751241,"RAINEY F A ET AL: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: An obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOLOGY LETTERS, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 120, no. 3, 15 July 1994 (1994-07-15), pages 263 - 266, XP023916519, ISSN: 0378-1097, [retrieved on 19940715], DOI: 10.1111/J.1574-6968.1994.TB07043.X;;DE LEY ET AL., EUR. J. BIOCHEM., vol. 12, 1970, pages 133 - 142;;HUΒ ET AL., SYST. APPL. MICROBIOL., vol. 4, 1983, pages 184 - 192;;RAINEY FA; DONNISON AM; JANSSEN PH; SAUL D; RODRIGO A; BERGQUIST PL; DANIEL RM; STACKEBRANDT E; MORGAN HW: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: an obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOL LETT., vol. 120, 1994, pages 263 - 266, XP023916519, DOI: doi:10.1111/j.1574-6968.1994.tb07043.x;;SISSONS CH; SHARROCK KR; DANIEL RM; MORGAN HW: ""Isolation of cellulolytic anaerobic extreme thermophiles from New Zealand thermal sites"", APPL ENVIRON MICROBIOL., vol. 53, 1987, pages 832 - 838;;DONNISON AM; BROCKELSBY CM; MORGAN HW; DANIEL RM: ""The degradation of lignocellulosics by extremely thermophilic microorganisms"", BIOTECHNOL BIOENG, vol. 33, 1989, pages 1495 - 1499;;HUNGATE RE: ""Methods in Microbiology"", 1969, ACADEMIC PRESS, article ""A roll tube method for cultivation of strict anaerobes"", pages: 118 - 132;;CHENNA R; SUGAWARA H; KOIKE T; LOPEZ R; GIBSON TJ; HIGGINS DG; THOMPSON JD: ""Multiple sequence alignment with the Clustal series of programs"", NUCLEIC ACIDS RES., vol. 13, 2003, pages 3497 - 3500, XP002316493, DOI: doi:10.1093/nar/gkg500;;KUMAR S; TAMURA K; JAKOBSEN IB; NEI M: ""MEGA2: molecular evolutionary genetics analysis software"", BIOINFORMATICS, vol. 17, 2001, pages 1244 - 1245",PENDING
482,EP,A1,EP 4502164 A1,109-752-232-636-37X,2025-02-05,2025,EP 23777819 A,2023-03-14,CN 202210326236 A;;CN 2023081232 W,2022-03-30,GLUCOSE-REGULATED GENE EXPRESSION LOOP CONTROL SYSTEM AND USE THEREOF IN REGULATING AND CONTROLLING BLOOD GLUCOSE,"Provided are a glucose-regulated gene expression loop control system and use thereof in regulating and controlling blood glucose. The control system comprises a transcription repressor HexR, a glucose-induced strong promoter, and a sequence to be transcribed. Also provided are an expression vector, an engineered cell, a sensor, or a recombinant probiotic comprising the control system and use thereof in preparing a drug for treating diabetes. Further provided are a plasmid, a glucose-induced strong promoter, and a primer pair which are involved in the control system.",UNIV EAST CHINA NORMAL,YE HAIFENG;;GUAN NINGZI;;GAO XIANYUN,,https://lens.org/109-752-232-636-37X,Patent Application,yes,0,0,3,073-227-212-119-017;;109-752-232-636-37X;;111-964-291-200-433,EP;;CN;;WO,3,073-227-212-119-017;;109-752-232-636-37X;;111-964-291-200-433,EP;;CN;;WO,0,C12N15/70;;C07K14/4703;;C12N15/64;;C12N15/635;;A61K38/1709;;A61K48/005;;A61K48/0008;;A61K48/0075;;A61P3/10;;C12N2800/60;;C12N2830/001;;C12N2830/005;;C12N15/11;;A61P3/10;;A61K48/00;;C12N15/90;;C12N15/85;;C07K14/4703;;A61K48/0075;;A61K48/005;;A61K48/0008;;A61K48/0058;;C12N15/635;;C12N15/70;;A61K38/00,C12N15/85;;A61K48/00;;A61P3/10;;C12N15/11;;C12N15/90,,0,0,,,,PENDING
483,US,A1,US 2023/0256019 A1,143-332-030-941-351,2023-08-17,2023,US 202118012273 A,2021-06-30,JP 2020113083 A;;JP 2021024808 W,2020-06-30,"METHOD FOR STABILIZING BINDING OF NK CELL AND ANTIBODY, AND USE THEREOF","The object of the invention is to stably bind an antibody to NK cells. A method for stabilizing binding of an antibody and an NK cell is provided, which method uses a substance having a region I that can bind to a surface protein of the NK cell, and a region II that can bind to the antibody. The substance may further contain a linker portion for linkage in addition to the region I and the region II.",GAIA BIOMEDICINE INC,HARADA YUI;;YONEMITSU YOSHIKAZU,GAIA BIOMEDICINE INC (2022-11-21),https://lens.org/143-332-030-941-351,Patent Application,yes,0,0,9,171-228-810-185-927;;010-473-062-143-713;;061-174-373-267-254;;053-019-923-477-089;;143-332-030-941-351;;167-263-695-246-438;;067-584-469-979-854;;133-405-413-928-471;;198-069-885-801-485,JP;;AU;;KR;;EP;;CN;;WO;;US;;TW,9,198-069-885-801-485;;010-473-062-143-713;;061-174-373-267-254;;053-019-923-477-089;;143-332-030-941-351;;167-263-695-246-438;;067-584-469-979-854;;133-405-413-928-471;;171-228-810-185-927,KR;;JP;;AU;;EP;;CN;;WO;;US;;TW,42,A61P31/00;;C12N5/0646;;C12N2501/515;;C12N2501/2302;;C07K2317/24;;C07K2317/76;;C07K16/2866;;C07K2319/00;;C07K2317/622;;C07K16/2803;;C07K16/2887;;C07K16/2863;;C07K16/32;;C07K16/3084;;A61K40/15;;A61K40/42;;C07K16/2803;;C12N5/0646;;A61K39/395;;A61P35/00;;A61P31/00;;A61K2039/505;;C07K2317/622;;C07K2319/00;;C07K16/2866;;C07K16/2896;;C07K2317/622;;C12N5/0006;;C12N5/0646;;A61K40/15;;A61K40/42,A61K35/17;;C07K16/28;;C12N5/00;;C12N5/0783,,0,0,,,,PENDING
484,US,A1,US 2024/0352531 A1,154-806-648-673-636,2024-10-24,2024,US 202418432678 A,2024-02-05,CN 202310413024 A,2023-04-18,METHOD FOR DETECTING CD19 EXPRESSION,"The present invention belongs to the technical field of molecular biology, and specifically relates to the technical field of efficacy monitoring of a chimeric antigen receptor (CAR)-T cell therapy. The present invention provides use of a primer combination in the preparation of a product for detecting a prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, where the primer combination includes primers shown in Table 1. The present invention provides use of a primer combination in the preparation of a product for detecting an expression state of CD19 on a surface of a tumor cell in a tumor patient, where the primer combination includes primers shown in Table 1. The present invention provides a product for detecting a prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, where the product includes primers shown in Table 1 as effective components.",UNION HOSPITAL TONGJI MEDICAL COLLEGE HUST,MEI HENG;;LI CHENGGONG;;ZHOU FEN;;KANG YUN,UNION HOSPITAL TONGJI MEDICAL COLLEGE HUST (2024-01-17),https://lens.org/154-806-648-673-636,Patent Application,yes,0,0,4,163-994-913-477-757;;174-035-873-294-969;;154-806-648-673-636;;137-042-346-020-150,CN;;WO;;US,4,163-994-913-477-757;;174-035-873-294-969;;154-806-648-673-636;;137-042-346-020-150,CN;;WO;;US,0,C12Q1/6886;;C12Q1/6851;;C12Q1/6869;;C12Q2600/118;;C12Q2600/158;;C12Q2600/166;;Y02A50/30;;C12Q2600/158;;C12Q2600/166;;C12Q2600/156;;C12Q1/6886;;C12Q2600/106;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q2600/166,C12Q1/6886,,0,0,,,,PENDING
485,US,A1,US 2021/0269521 A1,024-461-955-257-603,2021-09-02,2021,US 201917254862 A,2019-06-28,CN 201810720048 A;;CN 2019093548 W,2018-07-03,BISPECIFIC ANTIBODY AND USE THEREOF,"The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC(NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.",L&L BIOPHARMA CO LTD,LIU JIAJIAN,,https://lens.org/024-461-955-257-603,Patent Application,yes,2,0,10,061-013-097-759-721;;012-439-943-786-86X;;046-499-372-815-935;;024-461-955-257-603;;127-944-131-716-919;;065-567-545-545-154;;061-521-350-876-042;;104-347-072-526-647;;095-278-822-286-400;;094-882-944-011-653,JP;;EP;;CN;;WO;;US,10,061-013-097-759-721;;046-499-372-815-935;;012-439-943-786-86X;;024-461-955-257-603;;127-944-131-716-919;;065-567-545-545-154;;061-521-350-876-042;;104-347-072-526-647;;095-278-822-286-400;;094-882-944-011-653,JP;;EP;;CN;;WO;;US,34,C07K16/2803;;C07K16/2818;;A61P35/00;;A61P35/02;;C07K2317/31;;C07K2317/24;;C07K2317/92;;C07K2317/565;;C07K2317/76;;A61P35/00;;A61P35/02;;C07K2317/31;;C07K16/2803;;C07K2317/92;;C07K16/2818;;C07K2317/73;;C07K2317/76;;C07K2317/24;;C07K2317/94;;A61P35/00;;A61K39/39541;;A61K47/00;;A61K47/22;;A61K47/26;;A61K2039/505;;C07K16/2803;;C07K16/2818;;C07K2317/31;;C07K2317/622;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/68;;G01N2333/70503;;G01N2333/70521,C07K16/28;;A61K39/395;;A61K47/00;;A61K47/22;;A61K47/26;;A61P35/00;;G01N33/68,,9,6,027-477-313-726-928;;028-957-881-551-731;;029-611-134-469-353;;012-513-862-089-432;;035-976-233-926-571;;012-360-930-072-655,6804947;;pmc346105;;10.1073/pnas.79.6.1979;;10.1038/nbt1193-1293;;7764191;;10.1016/s0923-2494(94)80039-1;;7516563;;10.1016/0093-691x(95)00355-c;;10.1002/(sici)1097-4547(19960701)45:1<57::aid-jnr5>3.0.co;2-g;;8811512;;10.1016/0168-1656(94)90062-0;;7764960;;18243312;;10.1016/j.cimid.2007.11.005;;pmc7112688,"Bendig M. M. (Methods: A Companion to Methods in Enzymology, 1995; 8:83-93) (Year: 1995);;Rudikoff et al. (Proceedings of the National Academy of Sciences USA, Vol., 79, Pg. 1979-1983, 1982) (Year: 1982);;Harris (Biotechnology, Vol. 11, Pg. 1293-1297, 1993) (Year: 1993);;Colman P. M. (Research in Immunology, 145:33-36, 1994) (Year: 1994);;Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295 (Year: 1993);;Wall et Al., Theriogenology, Vol. 45, Pg. 57-68, 1996 (Year: 1996);;Houdebine et Al., Journal of Biotechnology, Vol. 34, Pg. 269- 287, 1994 (Year: 1994);;Kappell et Al., Current Opinions in Biotechnology, Vol. 3, Pg. 548-553, 1992 (Year: 1992);;Houdebine (Comparative Immunology, Microbiology, and Infectious Diseases, Vol. 32, Pg. 107-121, 2009) (Year: 2009)",PENDING
486,US,A1,US 2021/0032337 A1,134-315-698-669-211,2021-02-04,2021,US 201916531101 A,2019-08-04,US 201916531101 A,2019-08-04,METHOD FOR EFFICIENTLY ACTIVATING AND EXPANDING T CELLS,"The present invention discloses that T cells can be efficiently activated and expanded by a simple monomeric single chain bispecific antibody without using complicated beads, accessory cells, antibody-coating plates, or tetrameric antibody complex. The present invention also discloses that T cells activated and expanded by the monomeric single chain bispecific antibody can be efficiently transduced by virus.",ZHOU WENYUN,ZHOU WENYUN,,https://lens.org/134-315-698-669-211,Patent Application,yes,0,0,1,134-315-698-669-211,US,1,134-315-698-669-211,US,1,A61K35/17;;C07K16/2809;;C07K16/2818;;C07K2317/31;;C12N5/0636;;C07K2317/622;;C07K2317/75;;C12N2510/00;;C07K16/2809;;A61K35/17;;C12N5/0636;;C07K16/2818;;C07K2317/24;;C07K16/2875;;C07K16/2827;;C07K2317/31;;C07K16/2878,C07K16/28;;A61K35/17;;C12N5/0783,,0,0,,,,DISCONTINUED
487,US,A1,US 2025/0297284 A1,024-051-547-944-832,2025-09-25,2025,US 19231418,2025-06-06,CN 202211576110.3,2022-12-08,MUTANT OF ADENO-ASSOCIATED VIRUS AND USE THEREOF,"Provided are a mutant of an adeno-associated virus (AAV) targeting a resting or activated T cell, a use of the mutant of the AAV, and a heterologous peptide targeting a T cell. An amino acid sequence of the heterologous peptide is set forth in any one of SEQ ID NOS: 1-5. The mutant of the AAV exhibits high efficiency in targeting resting or activated T cells, and has advantages such as low dose, strong infectivity, and high safety. A recombinant adeno-associated virus (rAAV) can be constructed from a mutant of an AAV capsid protein of the present application. Nucleic acid sequences carried by rAAV can not be integrated into the genome of the host cell. T he rAAV can be used for the quick infection and reinfusion of activated T cells, which reduces the unnecessary quality control and in vitro dwell time.","PACKGENE BIOTECH CO., LTD.",Ying Fan;;Huapeng Li;;Ye Bu;;Yujian Zhong;;Zhiyong Dai;;Keqin Tan;;Youwei Zhang,,https://lens.org/024-051-547-944-832,Patent Application,yes,0,0,1,024-051-547-944-832,US,1,024-051-547-944-832,US,0,C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14143,C12N15/86;;C07K14/005,,0,0,,,,UNKNOWN
488,US,A1,US 2022/0009928 A1,046-155-274-784-750,2022-01-13,2022,US 202117353462 A,2021-06-21,US 202117353462 A;;US 201916678788 A;;US 201816229460 A;;US 201715591711 A;;US 201514853855 A;;US 201462051063 P,2014-09-16,SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR,"The present invention provides crystalline forms, solvates and hydrates of 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one, and methods of making.",GILEAD SCIENCES INC,DIAZ KRISTA MARIE;;ANDRES PATRICIA;;SMOLENSKAYA VALERIYA N,GILEAD SCIENCES INC (2015-09-08);;ALBANY MOLECULAR RESEARCH INC (2015-09-08),https://lens.org/046-155-274-784-750,Patent Application,yes,0,0,39,148-240-491-344-166;;158-419-039-501-340;;065-888-956-016-377;;098-886-672-067-12X;;192-574-447-649-304;;119-275-279-448-863;;100-851-125-902-130;;034-825-741-754-425;;108-334-518-940-547;;046-155-274-784-750;;044-684-142-221-690;;126-987-715-933-195;;157-915-892-856-655;;097-606-390-389-678;;105-754-448-573-025;;078-271-444-779-372;;053-477-010-430-452;;002-183-368-838-643;;183-636-166-623-508;;180-508-725-311-258;;109-889-113-782-056;;003-067-848-162-898;;198-663-569-613-409;;170-934-699-944-420;;086-322-088-163-957;;057-169-514-746-638;;056-434-113-176-177;;197-096-941-062-937;;074-922-074-632-47X;;117-032-940-870-460;;192-950-298-214-724;;191-076-765-344-698;;016-581-400-827-293;;026-114-336-527-092;;015-945-277-064-048;;130-920-001-394-634;;167-380-852-670-201;;071-614-474-220-200;;141-676-939-965-861,AU;;JP;;EA;;US;;TW;;SI;;CA;;MX;;BR;;PT;;KR;;AR;;CN;;EP;;IL;;ES;;WO;;SG;;UY,39,148-240-491-344-166;;158-419-039-501-340;;065-888-956-016-377;;098-886-672-067-12X;;192-574-447-649-304;;119-275-279-448-863;;100-851-125-902-130;;034-825-741-754-425;;108-334-518-940-547;;046-155-274-784-750;;044-684-142-221-690;;126-987-715-933-195;;157-915-892-856-655;;097-606-390-389-678;;105-754-448-573-025;;078-271-444-779-372;;053-477-010-430-452;;002-183-368-838-643;;183-636-166-623-508;;180-508-725-311-258;;109-889-113-782-056;;003-067-848-162-898;;198-663-569-613-409;;170-934-699-944-420;;086-322-088-163-957;;057-169-514-746-638;;056-434-113-176-177;;197-096-941-062-937;;074-922-074-632-47X;;117-032-940-870-460;;192-950-298-214-724;;191-076-765-344-698;;016-581-400-827-293;;026-114-336-527-092;;015-945-277-064-048;;130-920-001-394-634;;167-380-852-670-201;;071-614-474-220-200;;141-676-939-965-861,AU;;JP;;EA;;US;;TW;;SI;;CA;;MX;;BR;;PT;;KR;;AR;;CN;;EP;;IL;;ES;;WO;;SG;;UY,0,A61K31/519;;C07D487/04;;A61K45/06;;C07D475/06;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P35/00;;A61P37/04;;A61P43/00;;C07D475/06;;A61K31/519;;A61K45/06;;C07D487/04;;A61K2300/00;;C07B2200/13;;A61K31/519;;C07D487/04;;A61K45/06;;C07D475/06,C07D475/06;;A61K31/519;;A61K45/06;;C07D487/04,,0,0,,,,ACTIVE
489,EP,A1,EP 3819313 A1,061-013-097-759-721,2021-05-12,2021,EP 19831370 A,2019-06-28,CN 201810720048 A;;CN 2019093548 W,2018-07-03,BISPECIFIC ANTIBODY AND USE THEREOF,"The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC(NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.",L&L BIOPHARMA CO LTD,LIU JIAJIAN,,https://lens.org/061-013-097-759-721,Patent Application,yes,0,0,10,061-013-097-759-721;;012-439-943-786-86X;;046-499-372-815-935;;024-461-955-257-603;;127-944-131-716-919;;065-567-545-545-154;;061-521-350-876-042;;104-347-072-526-647;;095-278-822-286-400;;094-882-944-011-653,JP;;EP;;CN;;WO;;US,10,061-013-097-759-721;;046-499-372-815-935;;012-439-943-786-86X;;024-461-955-257-603;;127-944-131-716-919;;065-567-545-545-154;;061-521-350-876-042;;104-347-072-526-647;;095-278-822-286-400;;094-882-944-011-653,JP;;EP;;CN;;WO;;US,34,C07K16/2803;;C07K16/2818;;A61P35/00;;A61P35/02;;C07K2317/31;;C07K2317/24;;C07K2317/92;;C07K2317/565;;C07K2317/76;;A61P35/00;;A61P35/02;;C07K2317/31;;C07K16/2803;;C07K2317/92;;C07K16/2818;;C07K2317/73;;C07K2317/76;;C07K2317/24;;C07K2317/94;;A61P35/00;;A61K39/39541;;A61K47/00;;A61K47/22;;A61K47/26;;A61K2039/505;;C07K16/2803;;C07K16/2818;;C07K2317/31;;C07K2317/622;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K2317/94;;G01N33/68;;G01N2333/70503;;G01N2333/70521,C07K16/46;;A61K39/395;;A61P35/00;;C12N5/10;;C12N15/13;;C12N15/63,,0,0,,,,PENDING
490,EP,A1,EP 4173640 A1,061-174-373-267-254,2023-05-03,2023,EP 21833985 A,2021-06-30,JP 2020113083 A;;JP 2021024808 W,2020-06-30,METHOD FOR STABILIZING BINDING OF ANTIBODY TO NK CELL AND USE THEREOF,"The object of the invention is to stably bind an antibody to NK cells. A method for stabilizing binding of an antibody and an NK cell is provided, which method uses a substance having a region I that can bind to a surface protein of the NK cell, and a region II that can bind to the antibody. The substance may further contain a linker portion for linkage in addition to the region 1 and the region II.",GAIA BIOMEDICINE INC,HARADA YUI;;YONEMITSU YOSHIKAZU,,https://lens.org/061-174-373-267-254,Patent Application,yes,0,0,9,171-228-810-185-927;;010-473-062-143-713;;061-174-373-267-254;;053-019-923-477-089;;143-332-030-941-351;;167-263-695-246-438;;067-584-469-979-854;;133-405-413-928-471;;198-069-885-801-485,JP;;AU;;KR;;EP;;CN;;WO;;US;;TW,9,198-069-885-801-485;;010-473-062-143-713;;061-174-373-267-254;;053-019-923-477-089;;143-332-030-941-351;;167-263-695-246-438;;067-584-469-979-854;;133-405-413-928-471;;171-228-810-185-927,KR;;JP;;AU;;EP;;CN;;WO;;US;;TW,66,A61P31/00;;C12N5/0646;;C12N2501/515;;C12N2501/2302;;C07K2317/24;;C07K2317/76;;C07K16/2866;;C07K2319/00;;C07K2317/622;;C07K16/2803;;C07K16/2887;;C07K16/2863;;C07K16/32;;C07K16/3084;;A61K40/15;;A61K40/42;;C07K16/2803;;C12N5/0646;;A61K39/395;;A61P35/00;;A61P31/00;;A61K2039/505;;C07K2317/622;;C07K2319/00;;C07K16/2866;;C07K16/2896;;C07K2317/622;;C12N5/0006;;C12N5/0646;;A61K40/15;;A61K40/42,A61K47/42;;A61K35/17;;A61K39/395;;A61P31/00;;A61P35/00;;C07K16/18;;C07K19/00;;C12N5/0783,,0,0,,,,PENDING
491,EP,A1,EP 4121060 A1,141-609-151-320-339,2023-01-25,2023,EP 21717687 A,2021-03-16,US 202062990337 P;;US 2021/0022622 W,2020-03-16,METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF,,UNIV TEXAS;;MOLECULIN BIOTECH INC,PRIEBE WALDEMAR;;FOKT IZABELA;;ZIELINSKI RAFAL;;SKORA STANISLAW;;PICKER DONALD;;KLEMP WALTER,,https://lens.org/141-609-151-320-339,Patent Application,yes,0,0,11,126-747-447-923-587;;027-847-804-445-544;;164-411-824-994-727;;187-223-265-214-523;;068-372-616-285-732;;036-433-635-021-682;;123-771-676-281-267;;188-982-353-405-964;;181-912-032-212-741;;141-609-151-320-339;;173-495-002-905-470,JP;;AU;;KR;;IL;;CN;;EP;;WO;;US;;CA;;BR;;MX,11,126-747-447-923-587;;068-372-616-285-732;;164-411-824-994-727;;187-223-265-214-523;;036-433-635-021-682;;027-847-804-445-544;;123-771-676-281-267;;188-982-353-405-964;;181-912-032-212-741;;141-609-151-320-339;;173-495-002-905-470,JP;;AU;;KR;;IL;;CN;;EP;;WO;;US;;CA;;BR;;MX,0,A61K31/7024;;A61K31/70;;Y02A50/30;;A61K31/70;;Y02A50/30;;A61K31/7024;;A61K31/70;;A61K31/7004;;A61K31/7024;;A61P31/12;;A61K31/70;;A61K31/7004;;A61K31/7008;;A61K31/7012,A61K31/70;;A61K31/7024,,2,0,,,"ANONYMOUS: ""COVID-19 - Moleculin Biotech"", 11 May 2020 (2020-05-11), pages 1 - 10, XP55815011, Retrieved from the Internet <URL:https://web.archive.org/web/20200511015214/https://www.moleculin.com/covid-19/> [retrieved on 20210617];;TAYLOR NICK PAUL: ""Moleculin advances plan to strip and starve COVID-19 | FierceBiotech"", 20 March 2020 (2020-03-20), XP55815025, Retrieved from the Internet <URL:https://www.fiercebiotech.com/biotech/moleculin-advances-plan-to-strip-and-starve-covid-19> [retrieved on 20210617]",PENDING
492,US,A1,US 2024/0018611 A1,003-864-565-742-026,2024-01-18,2024,US 202318475264 A,2023-09-27,CN 202111212401 A;;CN 202110613870 A;;CN 202210027310 A;;CN 2022080846 W,2021-06-02,IMMUNE MOLECULE VIRUS PARTICLE DETECTION KIT,"An immune molecule virus particle detection kit is provided. A monoclonal antibody of a virus envelope antigen is modified with biotin, magnetic beads are coupled with streptavidin, and the biotin-modified monoclonal antibody is incubated with a virus-containing solution to form a complex with virus particles or antigens, and then the streptavidin-coupled magnetic beads are added for incubation. The streptavidin on the magnetic beads binds with the biotin-modified monoclonal antibody with high specificity and affinity, and then specifically captures the virus particles with envelopes. After separating a supernatant through a magnetic separator, complete viral particles, empty-shell viruses, and free envelope antigens can be separated from other virus components, and the magnetic bead conjugates can be qualitatively or quantitatively detected through polymerase chain reaction (PCR) amplification. The immune molecule virus particle detection method using the kit has the characteristics of simplicity, rapidity, accuracy, and low cost, and has good application prospects.",UNIV CHONGQING MEDICAL,WANG DEQIANG;;MA YUANYAN;;WU XIAOLI;;LIU JUNYE;;CAI XUEFEI;;ZHANG SHAOCHENG;;WANG WEN;;MAO SHENGLAN;;SHEN SHIMEI;;LI YALAN;;HUANG JINYU;;WEN ZIXIN;;WANG YUNYOU,CHONGQING MEDICAL UNIVERSITY (2023-09-21),https://lens.org/003-864-565-742-026,Patent Application,yes,0,1,2,003-864-565-742-026;;020-627-891-383-169,WO;;US,7,197-495-521-472-460;;003-864-565-742-026;;020-627-891-383-169;;034-487-352-648-304;;013-374-206-610-516;;178-581-356-714-834;;060-577-759-424-259,CN;;WO;;US,0,C12Q1/6851;;C12N1/20;;C12N7/02;;C12N2710/00;;C12Q1/68;;C12Q1/6804;;C12Q1/70;;C12Q1/701;;C12Q1/701;;C12Q1/6804;;C12Q1/6851,C12Q1/70;;C12Q1/6851,,0,0,,,,PENDING
493,KR,A,KR 20220159769 A,150-575-780-110-960,2022-12-05,2022,KR 20210067791 A,2021-05-26,KR 20210067791 A,2021-05-26,Novel Serratia sp. strain and uses thereof,"The present invention relates to a novel Serratia sp. DM1 strain and a use thereof. The novel Serratia sp. DM1 strain isolated according to the present invention has excellent oil degradation capability and biosurfactant production capability, so the strain can be advantageously utilized in a method for purifying contamination caused by petroleum hydrocarbons (PHs) without any problem of occurrence of secondary contaminants. The Serratia sp. DM1 strain and a biosurfactant produced therefrom according to the present invention can be advantageously utilized in various industrial fields that need a surfactant, such as fields of detergents, soaps, or cosmetics.",UNIV EWHA IND COLLABORATION,CHO KYUNG SUK;;YANG HYO JU,,https://lens.org/150-575-780-110-960,Patent Application,no,2,0,2,150-575-780-110-960;;182-493-762-330-240,KR,2,150-575-780-110-960;;182-493-762-330-240,KR,0,C12N1/205;;B09C1/10;;C02F3/34;;B01D53/84;;C12N9/16;;C11D3/381;;A61K8/99;;A61Q19/00;;C12R2001/425,C12N1/20;;A61K8/99;;A61Q19/00;;B01D53/84;;B09C1/10;;C02F3/34;;C11D3/38;;C12N9/16;;C12R1/425,,1,0,,,"Debajit Borah 등, 3 Biotech., 9, 페이지1-12, 2019.*",ACTIVE
494,US,A1,US 2022/0186272 A1,093-348-529-629-935,2022-06-16,2022,US 202017253082 A,2020-07-06,CN 201910596633 A;;CN 201910597371 A;;CN 201910996538 A;;CN 201910997521 A;;CN 2020100482 W,2019-07-04,STRAIN OF TRICHODERMA REESEI AND CULTURE METHOD AND USE THEREOF,The invention relates to a strain of Trichoderma reesei BLCY-007 and its application in the production of xylooligosaccharides.,SHANDONG BAILONG CHUANGYUAN BIO TECH CO LTD,DOU BAODE;;DOU GUANGPENG;;GAN ZHAOBO;;SHAO XIANBAO;;LI FANGHUA;;DU QIAN,SHANDONG BAILONG CHUANGYUAN BIO-TECH CO. LTD (2021-01-08),https://lens.org/093-348-529-629-935,Patent Application,yes,11,0,6,107-700-779-362-758;;093-348-529-629-935;;023-961-973-536-205;;078-612-902-834-678;;074-591-748-182-126;;050-566-235-609-571,EP;;CN;;WO;;US;;CA,9,107-700-779-362-758;;093-348-529-629-935;;023-961-973-536-205;;069-416-658-580-105;;090-867-640-075-112;;074-591-748-182-126;;078-612-902-834-678;;050-566-235-609-571;;192-549-148-852-674,EP;;CN;;WO;;US;;CA,0,C12P19/12;;C12N1/14;;C12P19/14;;C12P19/04;;C12P19/00;;C12N9/248;;C12P21/02;;C12Y302/01008;;C12R2001/885;;C12N1/145;;C12R2001/885;;C12N1/145;;C12N9/248;;C12P19/14;;C12P21/00;;C12P2203/00,C12P19/14;;C12N1/14;;C12N9/24;;C12P21/00,,10,9,042-421-257-720-759;;021-569-025-825-657;;144-896-223-237-942;;109-308-744-461-437;;007-596-273-239-522;;090-410-621-592-675;;003-496-376-551-638;;046-068-640-348-428;;020-910-503-583-673,10.1007/s10570-017-1408-5;;10.1016/j.foodhyd.2019.03.043;;10.1590/s1517-83822006000400011;;10.1016/j.biortech.2017.09.128;;28982088;;10.1007/s12155-019-09991-8;;10.1016/j.indcrop.2017.03.017;;10.1016/j.biombioe.2016.06.017;;10.1016/j.biortech.2011.10.083;;22100233;;10.1007/s12649-017-9963-4,"Germec et al., Cellulose, 24:4337-4353 (2017) (Year: 2017);;Zhang et al., Food Hydrocolloids, 94:439-450 (2019) (Year: 2019);;DSMZ, 129. Potato Dextrose Agar (2007) (Year: 2007);;Kar et al., Brazil. J. Microbiol., 37:462-464 (2006) (Year: 2006);;Michelin et al., Bioresource Technol., 247:582-590 (2018) (Year: 2018);;Michelin et al., BioEnergy Res., 12:583-592 (2019) (Year: 2019);;Singh et al., Indust. Crops Products, 102:65-74 (2017) (Year: 2017);;Zhu et al., Biomass Bioenergy, 93:269-278 (2016) (Year: 2016);;Chapla et al (Bioresource Technology 115 (2012) 215–221) (Year: 2012);;Jnawali et al (Enzymatic Production of Xylooligosaccharides from Brown Coconut Husk Treated with Sodium Hydroxide. Waste Biomass Valor 9, 1757–1766 (2018); published online 17 May 2017) (Year: 2017)",PENDING
495,US,A1,US 2021/0228632 A1,199-997-903-703-087,2021-07-29,2021,US 202117217195 A,2021-03-30,US 202117217195 A;;NL 2015728 A;;NL 2017439 A;;US 201815773610 A;;EP 2016076758 W,2015-11-05,COMPOSTION FOR USE IN IMMUNOTHERAPY,"In the fields of immunology and medicine, and more specifically in the fields of cancer treatment and immunotherapy, a composition for use in immunotherapy, in particular in a subject having a tumor is provided. The use of immunosuppressive pharmaceutical compositions is provided, in particular for use prior to immunotherapy. Methods for providing compositions for use in immunotherapy are also provided.",GLYCOSTEM THERAPEUTICS B V,JONGEN WIM;;SPANHOLTZ JAN,GLYCOSTEM THERAPEUTICS B.V (2018-09-03),https://lens.org/199-997-903-703-087,Patent Application,yes,0,1,8,071-149-245-679-383;;198-768-657-679-652;;171-223-770-635-491;;098-021-121-846-263;;199-997-903-703-087;;021-008-500-859-611;;007-794-995-565-431;;169-835-937-546-024,JP;;KR;;EP;;CN;;WO;;US;;CA,9,071-149-245-679-383;;198-768-657-679-652;;171-223-770-635-491;;021-008-500-859-611;;199-997-903-703-087;;098-021-121-846-263;;007-794-995-565-431;;189-435-194-169-071;;169-835-937-546-024,NL;;JP;;KR;;EP;;CN;;WO;;US;;CA,0,A61K35/51;;A61P1/04;;A61P15/00;;A61P17/00;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/04;;A61P37/06;;A61P43/00;;A61P7/00;;A61K2239/38;;A61K2239/48;;A61K40/10;;A61K40/4204;;A61K40/4253;;A61P35/00;;A61K35/51;;A61K2239/48;;A61K35/17;;A61K35/28;;A61K9/0019;;A61K9/0014;;A61P35/02;;A61P35/04;;C12N5/0647;;A61K2239/46;;C12N2501/22;;C12N2501/21;;C12N2501/23;;C12N2501/235;;C12N2501/125;;C12N2501/26;;C12N2501/145;;A61K40/10;;A61K40/42;;A61P35/02;;A61K35/51;;C12N5/0647;;A61K2239/48;;A61K2239/38;;A61K40/10;;A61K40/4204;;A61K40/4253,A61K35/17;;A61K35/51;;A61P35/02;;C12N5/0789,,0,0,,,,DISCONTINUED
496,EP,A1,EP 4434579 A1,150-270-371-703-434,2024-09-25,2024,EP 23382269 A,2023-03-23,EP 23382269 A,2023-03-23,OBESTATIN FOR USE AS ANTINEOPLASTIC AGENT IN THE TREATMENT OF PANCREATIC CANCER,Obestatin for use as antineoplastic agent in the treatment of pancreatic cancer. The present invention refers to the use obestatin as antineoplastic agent in the treatment of pancreatic cancer.,SERVIZO GALEGO DE SAUDE;;FUNDACION INSTITUTO DE INVESTIG SANITARIA DE SANTIAGO DE COMPOSTELA FIDIS;;UNIV SANTIAGO COMPOSTELA,PAZOS RANDULFE YOLANDA;;PÉREZ CAMIÑA JESÚS;;DOMÍNGUEZ MUÑOZ JUAN ENRIQUE;;CID DÍAZ TANIA;;SANTOS ZÁS ICÍA;;LEAL LÓPEZ SAÚL;;CALVIÑO LODEIRO ANDREA,,https://lens.org/150-270-371-703-434,Patent Application,yes,2,0,2,150-270-371-703-434;;076-004-170-944-609,EP;;WO,2,150-270-371-703-434;;076-004-170-944-609,EP;;WO,18,A61K38/25;;C07K14/60;;A61P5/48;;C07K14/4702;;C12N9/12;;C12Y207/11024,A61P5/48;;A61K38/25;;C07K14/60,,8,7,011-788-760-812-251;;077-148-818-897-323;;051-106-753-531-064;;058-223-094-324-754;;040-319-341-323-883;;048-028-500-416-78X;;084-078-130-297-090,10.1016/j.pan.2020.07.252;;23056203;;pmc3464274;;10.1371/journal.pone.0045434;;10.1186/s12885-018-4439-x;;29728096;;pmc5935964;;31117041;;10.6004/jnccn.2019.5007;;10.3748/wjg.v28.i21.2383;;pmc9185216;;35800184;;22154931;;pmc3878823;;10.1016/j.jconrel.2011.11.031;;10.3390/cancers14174257;;pmc9454856;;36077794,"LEAL-L OPEZ S ET AL: ""e-P237 - Effect of obestatin on the migration and invasion of pancreatic tumor cells."", PANCREATOLOGY, vol. 20, 4 December 2020 (2020-12-04), pages S135, XP093064816, DOI: 10.1016/j.pan.2020.07.252;;ESTÉVEZ PÉREZ LARA SOFÍA: ""Endogenous systems involved in the development of pancreatic cancer: role of the obestatin/GPR39 system"", 2019, XP093065129, Retrieved from the Internet <URL:https://minerva.usc.es/xmlui/bitstream/handle/10347/18839/rep_1792.pdf?sequence=1&isAllowed=y> [retrieved on 20230719];;BEGONA O. ALEN ET AL.: ""The NMR structure of human obestatin in membrane-like environments: insights into the structure-bioactivity relationship of obestatin"", PLOS ONE, vol. 7, no. 10, 2012, pages e45434, XP055565407, DOI: 10.1371/journal.pone.0045434;;DOMINGUEZ-MUNOZ JE ET AL.: ""Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis"", BMC CANCER, no. 1, 2018, pages 534;;TEMPERO MA: ""NCCN Guidelines Updates: Pancreatic Cancer"", J NATL COMPR CANC NETW, vol. 17, no. 5.5, 1 May 2019 (2019-05-01), pages 603 - 605;;KAUR J ET AL.: ""Endoscopic ultrsound-guided injectable therapy for pancreatic cancer: a systematic review"", WORLD J GASTROENTEROL, vol. 28, no. 21, 2022, pages 2383 - 2395;;WOLINSKY JB, ET AL.: ""Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers"", J CONTROL RELEASE, vol. 159, no. 1, 2012, pages 14 - 26, XP055364798, DOI: 10.1016/j.jconrel.2011.11.031;;BAZEED AY ET AL.: ""Pancreatic cancer: Challenges and opportunities in locoregional therapies"", CANCERS, vol. 14, 2022, pages 4257",DISCONTINUED
497,US,A1,US 2023/0110749 A1,075-200-236-674-800,2023-04-13,2023,US 202217885854 A,2022-08-11,US 202217885854 A;;KR 20180027741 A;;US 202016976376 A;;KR 2019002737 W,2018-03-09,"FUNCTIONAL FOOD COMPOSITION FOR ENHANCING MUSCULAR FUNCTION AND MOBILITY COMPRISING LOTUS LEAF EXTRACT, AND METHOD FOR PREPARING SAME","The present invention relates to a functional food composition for enhancing muscular function and exercise performance and a method for preparing same. According to the present invention, provided is a composition which enables increased generation of factors associated with myogenesis and energy metabolism and thus enhances exercise performance and muscular function. More particularly, mitochondria and muscle cell synthesis is increased and muscular atrophy is inhibited, and thus muscle exercise effects can be increased and fatigue is reduced. The composition can be applied as a health function composition to various fields such as foods.",COSMAX NS INC;;COSMAX NBT INC,KIM JIN HAK;;JANG JI HWAN;;GEUM JEONG HO;;KWEON MIN SON;;CHOI SU YOUNG;;KIM SANG WOO;;HWANG JAE KWAN,COSMAX NBT INC (2020-08-18);;COSMAX NS INC (2020-08-18),https://lens.org/075-200-236-674-800,Patent Application,yes,2,0,6,075-200-236-674-800;;093-544-584-858-333;;147-970-663-195-178;;127-745-438-488-402;;009-581-303-431-330;;101-852-071-881-91X,KR;;CN;;WO;;US,6,075-200-236-674-800;;009-581-303-431-330;;147-970-663-195-178;;127-745-438-488-402;;093-544-584-858-333;;101-852-071-881-91X,KR;;CN;;WO;;US,0,A61P21/06;;A23L33/105;;A61K36/62;;A61K2236/331;;A61K2236/333;;A61K2236/37;;A23L33/105;;A23V2002/00;;A23V2200/316;;A23V2300/14;;A61K36/185;;A23L33/105;;A23L33/40;;A23V2002/00;;A61K2236/331;;A61K2236/333;;A61K2236/37;;A61P21/06,A61K36/185;;A23L33/00;;A23L33/105;;A61P21/06,,2,2,018-834-772-320-915;;106-562-579-910-044,10.2174/1381612043383070;;15544525;;10.1021/jf9804692,"Raskin et al. (2004) Current Pharmaceutical Design 10, 3419-3429. (Year: 2004);;Revilla et al. (1998) J. Agric. Food Chem. 46: 4592-4597. (Year: 1998)",DISCONTINUED
498,US,A1,US 2024/0377292 A1,137-321-410-854-312,2024-11-14,2024,US 202218688650 A,2022-03-09,CN 202111019944 A;;CN 2022079854 W,2021-09-01,CLEARING AND EXPANSION METHOD AND IMAGING METHOD FOR BIOLOGICAL TISSUE,"Provided are a clearing and expansion method and an imaging method for biological tissue. The clearing and expansion method for biological tissue comprises: (1) degreasing a fixed biological tissue sample; (2) soaking the degreased biological tissue sample in a solution of gel monomer molecules, such that the monomer molecules permeate into the degreased biological tissue sample; (3) inducing a polymerization reaction of the monomer molecules permeating into the biological tissue sample so as to form a polymer gel; and (4) placing the biological tissue sample which has been subjected to a gelation treatment into water for expansion. The clearing and expansion method for biological tissue avoids the sample treatment steps of heating and enzymatic digestion that cause fluorescent quenching and the destruction of biological tissue, and thus has the advantages of high retention of endogenous fluorescent proteins, high mechanical strength of expanded biological tissue, a short sample treatment time, etc. Moreover, the advantage of an adjustable expansion ratio is further achieved by means of changing the components of a monomer reagent.",UNIV WESTLAKE,GAO LIANG;;CHEN YANLU;;LU JING;;FENG RUILI,WESTLAKE UNIVERSITY (2024-02-21),https://lens.org/137-321-410-854-312,Patent Application,yes,0,0,3,153-663-767-124-291;;177-078-254-434-87X;;137-321-410-854-312,CN;;WO;;US,3,153-663-767-124-291;;177-078-254-434-87X;;137-321-410-854-312,CN;;WO;;US,0,G01N1/28;;G01N1/44;;G01N1/36;;G01N1/30;;G01N1/30;;G01N1/36;;G01N21/6428;;G01N21/6456;;G01N2021/6439,G01N1/30;;G01N1/36;;G01N21/64,,0,0,,,,PENDING
499,US,A1,US 2023/0091960 A1,158-502-346-040-342,2023-03-23,2023,US 202017798640 A,2020-02-26,CN 202010086392 A;;CN 2020076736 W,2020-02-11,"CULTURE MEDIUM FOR PRIMARY CELLS OF ESOPHAGEAL SQUAMOUS CARCINOMA, AND CULTIVATION METHOD THEREFOR","Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.",PRECEDO PHARMACEUTICALS CO LTD,LIU QINGSONG;;HU JIE;;CHEN CHENG;;WANG WENCHAO;;WANG LI,PRECEDO PHARMACEUTICALS CO. LTD (2022-08-10),https://lens.org/158-502-346-040-342,Patent Application,yes,2,0,8,195-226-840-441-540;;128-263-336-880-029;;004-807-614-629-843;;149-182-758-137-267;;158-502-346-040-342;;071-250-163-394-946;;075-125-197-320-307;;065-472-439-007-65X,JP;;EP;;CN;;WO;;US,8,195-226-840-441-540;;128-263-336-880-029;;004-807-614-629-843;;149-182-758-137-267;;158-502-346-040-342;;071-250-163-394-946;;075-125-197-320-307;;065-472-439-007-65X,JP;;EP;;CN;;WO;;US,0,C12N5/0693;;G01N33/5011;;C12N2509/00;;C12N2501/734;;C12N2501/33;;C12N2501/105;;C12N2500/32;;C12N2501/39;;C12N2500/84;;C12N2502/02;;C12N2503/02;;G01N2500/10;;G01N33/5011;;C12N5/0679;;C12N5/0693;;C12N2500/32;;C12N2501/734;;C12N2500/84;;C12N2501/105;;C12N2503/02;;C12N5/0693;;C12N2500/32;;C12N2500/84;;C12N2501/105;;C12N2501/33;;C12N2501/39;;C12N2501/734;;C12N2503/02;;G01N33/5011;;G01N2500/10,C12N5/09;;G01N33/50,,2,2,015-936-623-200-643;;115-181-548-920-538,10.3791/55243;;28362412;;pmc5408910;;30510992;;pmc6260338;;10.1016/j.jcmgh.2018.09.003,"Jensen, Todd J., et al. ""Conditional reprogramming of pediatric human esophageal epithelial cells for use in tissue engineering and disease investigation."" Journal of Visualized Experiments: Jove 121: 55243. (Year: 2017);;Kijima, Takashi, et al. ""Three-dimensional organoids reveal therapy resistance of esophageal and oropharyngeal squamous cell carcinoma cells."" Cellular and molecular gastroenterology and hepatology 7.1: 73-91. (Year: 2019)",PENDING
500,WO,A1,WO 2024/246945 A1,190-757-323-067-176,2024-12-05,2024,IN 2024050630 W,2024-05-29,IN 202341037655 A,2023-05-31,A VERSATILE MICROFLUIDIC APPARATUS AND AN ATTACHMENT THEREOF,"The present invention relates to a versatile microfluidic apparatus (100, 400) and a cell culture chamber attachment thereof. The present invention discloses a high-throughput and versatile multi-compartment organ-on-chip microfluidic apparatus to culture various 3D cell models and mimics the organ model with specific parenchyma and stroma. The cell culture chamber attachments (11) are replaceable and based on the variant of the 3D cell or tissue models. The apparatus (100, 400) is suitable for a variety of 3D cell models such as spheroid, biopsy tissue, organoid, hydrogel embedded tissue, 3D patterned, and 3D bio-printed culture models.",INDIAN INSTITUTE OF TECH HYDERABAD,MEHTA VIRAJ;;NARAYAN RATH SUBHA,,https://lens.org/190-757-323-067-176,Patent Application,yes,1,0,2,066-407-541-328-906;;190-757-323-067-176,WO,2,066-407-541-328-906;;190-757-323-067-176,WO,0,C12M23/16;;C12M23/12;;C12M25/14;;C12M21/08,C12M3/00;;B01L3/00,,0,0,,,,PENDING
501,EP,A1,EP 4105320 A1,195-226-840-441-540,2022-12-21,2022,EP 20918987 A,2020-02-26,CN 202010086392 A;;CN 2020076736 W,2020-02-11,"CULTURE MEDIUM FOR PRIMARY CELLS OF ESOPHAGEAL SQUAMOUS CARCINOMA, AND CULTIVATION METHOD THEREFOR","Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.",PRECEDO PHARMACEUTICALS CO LTD,LIU QINGSONG;;HU JIE;;CHEN CHENG;;WANG WENCHAO;;WANG LI,,https://lens.org/195-226-840-441-540,Patent Application,yes,0,0,8,195-226-840-441-540;;128-263-336-880-029;;004-807-614-629-843;;149-182-758-137-267;;158-502-346-040-342;;071-250-163-394-946;;075-125-197-320-307;;065-472-439-007-65X,JP;;EP;;CN;;WO;;US,8,195-226-840-441-540;;128-263-336-880-029;;004-807-614-629-843;;149-182-758-137-267;;158-502-346-040-342;;071-250-163-394-946;;075-125-197-320-307;;065-472-439-007-65X,JP;;EP;;CN;;WO;;US,0,C12N5/0693;;G01N33/5011;;C12N2509/00;;C12N2501/734;;C12N2501/33;;C12N2501/105;;C12N2500/32;;C12N2501/39;;C12N2500/84;;C12N2502/02;;C12N2503/02;;G01N2500/10;;G01N33/5011;;C12N5/0679;;C12N5/0693;;C12N2500/32;;C12N2501/734;;C12N2500/84;;C12N2501/105;;C12N2503/02;;C12N5/0693;;C12N2500/32;;C12N2500/84;;C12N2501/105;;C12N2501/33;;C12N2501/39;;C12N2501/734;;C12N2503/02;;G01N33/5011;;G01N2500/10,C12N5/09,,0,0,,,,PENDING
502,WO,A1,WO 2024/061639 A1,182-082-496-368-396,2024-03-28,2024,EP 2023074566 W,2023-09-07,US 202263408637 P,2022-09-21,REMOVAL OF POLYMERS FROM A SOLUTION BY USING MACROCYCLES AND/OR HYDROPHOBIC PARTICLES,"The present invention relates to a method for removing free polymers present in a solution containing a hydrophobic protein, wherein the method comprises: (a) contacting the solution containing the free polymers not bound to the hydrophobic protein, with a macrocycle and/or a hydrophobic particle so that the free polymers bind to the macrocycle and/or hydrophobic particle to obtain a complex of said polymers and the macrocycle and/or hydrophobic particle, and (b) removing the complex of polymer and the macrocycle and/or hydrophobic protein from the solution. Furthermore, there is described the use of a macrocycle and/or hydrophobic particle in this method, a composition of a macrocycle for this method as well as a kit containing a macrocycle and/or hydrophobic particle to be employed in this method.",CUBE BIOTECH GMBH,MAERTENS BARBARA;;KUBICEK JAN;;FABIS ROLAND;;HANISCH PHILIPP TIMO;;BALANDA SERGEJ;;ERKELENZ MICHAEL;;HECKMANN NINA VALESKA,,https://lens.org/182-082-496-368-396,Patent Application,yes,10,0,2,128-285-324-640-113;;182-082-496-368-396,EP;;WO,2,128-285-324-640-113;;182-082-496-368-396,EP;;WO,0,C07K1/145,C07K1/14,,18,16,036-960-288-917-672;;036-265-847-135-059;;011-925-687-024-192;;018-521-902-094-948;;028-583-386-701-030;;027-230-618-209-61X;;030-822-955-708-505;;027-230-618-209-61X;;028-786-040-133-697;;013-062-716-811-032;;002-729-321-663-323;;010-569-015-005-170;;080-146-486-941-891;;020-900-834-612-548;;131-543-929-261-164;;030-400-937-800-033,10.1016/j.tibs.2022.02.008;;35331611;;pmc9847468;;33568813;;10.1038/s41586-021-03196-w;;pmc8433533;;10.1073/pnas.2104820118;;34475213;;pmc6914677;;10.3389/fcell.2019.00291;;31921835;;18177658;;10.1016/j.chroma.2007.11.118;;14753773;;10.1016/j.chroma.2003.09.045;;10.1021/bc060130i;;16848391;;14753773;;10.1016/j.chroma.2003.09.045;;10.1039/c3py00194f;;10.1021/ja711260m;;18357989;;10.1016/0301-4622(80)87012-8;;16997258;;27254461;;10.1038/nprot.2016.070;;10.1039/d1nr03811g;;35040850;;10.1039/b9py00301k;;10.1021/acs.biomac.0c00929;;32602705;;pmc5826593;;29171274;;10.1021/jacs.7b10591,"NOTTI RYAN Q ET AL: ""Native-like environments afford novel mechanistic insights into membrane proteins"", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 47, no. 7, 21 March 2022 (2022-03-21), pages 561 - 569, XP087092430, ISSN: 0968-0004, [retrieved on 20220321], DOI: 10.1016/J.TIBS.2022.02.008;;ZHANG YIXIAO ET AL: ""Visualization of the mechanosensitive ion channel MscS under membrane tension"", NATURE, vol. 590, no. 7846, 10 February 2021 (2021-02-10), pages 509 - 514, XP037370500, DOI: 10.1038/S41586-021-03196-W;;COX CHARLES D. ET AL: ""Cyclodextrins increase membrane tension and are universal activators of mechanosensitive channels"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 118, no. 36, 2 September 2021 (2021-09-02), XP093110837, ISSN: 0027-8424, DOI: 10.1073/pnas.2104820118;;MIKHAIL A ZHUKOVSKYANGELA FILOGRANAALBERTO LUINIDANIELA CORDACARMEN VALENTE: ""Protein Amphipathic Helix Insertion: A Mechanism to Induce Membrane Fission"", FRONT CELL DEV BIOL., vol. 10, no. 7, December 2019 (2019-12-01), pages 291;;UNGER KKSKUDAS RSCHULTE MM.: ""Particle packed columns and monolithic columns in high-performance liquid chromatography - comparison and critical appraisal."", J CHROMATOGR A, vol. 1184, 2008, pages 393 - 415, XP022503351, DOI: 10.1016/j.chroma.2007.11.118;;XIANGLING HETIANWEI TANBINGZE XUJAN-CHRISTER JANSON: ""Separation and purification of puerarin using cyclodextrin-coupled agarose gel media"", JOURNAL OF CHROMATOGRAPHY A, vol. 1022, 2004, pages 77 - 82, XP004473608, DOI: 10.1016/j.chroma.2003.09.045;;TRUNG NGUYENNEEL S. JOSHIMATTHEW B. FRANCIS: ""An Affinity-Based Method for the Purification of Fluorescently-Labeled Biomolecules"", BIOCONJUGATE CHEM., vol. 17, 2008, pages 869 - 872;;XIANGLING HETIANWEI TANBINGZE XUJAN-CHRISTER JANSON: ""Separation and purification of puerarin using -cyclodextrin-coupled agarose gel media"", JOURNAL OF CHROMATOGRAPHY A, vol. 1022, 2004, pages 77 - 82, XP004473608, DOI: 10.1016/j.chroma.2003.09.045;;WIKTOROWICZ, H. TENHUV. ASEYEV, POLYM. CHEM., vol. 4, 2013, pages 2898;;C. S. Y. TANJ. LIUA. S. GROOMBRIDGES. J. BARROWC. A. DREISSO. A. SCHERMAN, ADV. FUNCT MATER., vol. 28, 2018, pages 1702994;;T. OGOSHIS. KANAIS. FUJINAMIT. A. YAMAGISHIY. NAKAMOTO, J. AM. CHEM. SOC., vol. 130, 2008, pages 5022 - 5023;;FENG QING-ZHENGMENG QING-QIANGWANG JIA-XINGMA GUANG-HUIMA RUN-YUSU ZHI-GUO: ""Preparation of Butyl-agarose Chromatography Media with Controlled Ligand Density through Direct Coupling Reaction"", THE CHINESE JOURNAL OF PROCESS ENGINEERING, vol. 6, no. 6, 2006, pages 959 - 963;;SHINTARO SUGAINOBUMICHI OHNO: ""Conformational transitions of the hydrophobic polyacids"", BIOPHYSICAL CHEMISTRY, vol. 11, 4 June 1980 (1980-06-04), pages 387 - 395, XP026591960, DOI: 10.1016/0301-4622(80)87012-8;;LEE, NATURE PROTOCOLS, vol. 11, no. 7, 2016, pages 1149 - 1162;;BARTHOLOMAUS DANIELCZAKMARIE RASCHEJULIA LENZEUGENIO PEREZ PATALLOSOPHIE WEYRAUCHFLORIAN MAHLERMICHAEL TOPE AGBADAOLAANNETTE MEIST: ""A bioinspired glycopolymer for capturing membrane proteins in native-like lipid-bilayer nanodiscs, DOI: 10.1039/D1NR03811G (Paper"", NANOSCALE, vol. 14, 2022, pages 1855 - 1867;;SIMON HARRISSONFRANCESCA ERCOLEBENJAMIN W. MUIR: ""Living spontaneous gradient copolymers of acrylic acid and styrene: one-pot synthesis of pH-responsive amphiphiles"", POLYM. CHEM., vol. 1, 2010, pages 326 - 332;;MARCONNET, A.MICHON, B.LE BON, C.GIUSTI, F.TRIBET, C.ZOONENS, M.: ""Solubilization and stabilization of membrane proteins by cycloalkane-modified amphiphilic polymers."", BIOMACROMOLECULES., 2020;;YASUHARA KARAKIDA JRAVULA TRAMADUGU SKSAHOO BKIKUCHI JIRAMAMOORTHY A.: ""Spontaneous Lipid Nanodisc Fomation by Amphiphilic Polymethacrylate Copolymers"", J AM CHEM SOC., vol. 139, no. 51, 2017, pages 18657 - 18663",PENDING
503,WO,A1,WO 2023/098308 A1,006-049-165-365-16X,2023-06-08,2023,CN 2022124823 W,2022-10-12,CN 202111450746 A,2021-11-30,A GENETICALLY ENGINEERED BACTERIUM AND ITS APPLICATION IN THE PREPARATION OF SIALYLLACTOSE,"The invention discloses a genetically engineered bacterium and its application in the preparation of sialyllactose. The genetically engineered bacterium has an N-acetylneuraminic acid biosynthesis pathway, comprises multiple copies of a gene neuB for encoding sialic acid synthase, and the gene neuB is initiated for expression by a strong promoter. Using the genetically engineered bacteria of the invention to produce sialyllactose has the advantages of high yield and low overall cost.",SYNAURA BIOTECHNOLOGY SHANGHAI CO LTD,WU YAN;;LIU YUROU;;TANG JING;;XU HONG;;WANG SHU,,https://lens.org/006-049-165-365-16X,Patent Application,yes,5,0,5,133-429-540-772-146;;006-049-165-365-16X;;188-492-264-366-578;;160-833-593-403-241;;010-243-752-767-925,EP;;CN;;WO;;US,5,133-429-540-772-146;;006-049-165-365-16X;;188-492-264-366-578;;160-833-593-403-241;;010-243-752-767-925,EP;;CN;;WO;;US,84,C12N15/52;;C12N9/88;;C12N9/1205;;C12N9/2471;;C12N9/90;;C12N9/1029;;C12N9/1096;;C12N9/1241;;C12N9/1081;;C12N15/70;;C12P19/26;;C12Y302/01023;;C12Y401/03;;C12Y207/0106;;C12Y501/03008;;C12Y203/01004;;C12Y206/01016;;C12Y207/07043;;C12Y204/99001;;C12Y204/99004;;C12N2830/003;;C12N1/20;;C12N9/1085;;C12N15/52;;C12P19/26;;A23L33/125;;A23L29/30;;C12Y205/01056;;C12Y501/03008;;C12Y203/01004;;C12Y206/01016;;C12Y207/09002;;Y02A50/30;;C12N1/205;;C12R2001/19;;C12N9/1029;;C12N9/1081;;C12N9/1085;;C12N9/1096;;C12N9/1241;;C12N9/1294;;C12N9/16;;C12N9/90;;C12N15/70;;C12P19/18;;C12P19/26;;C12Y203/01004;;C12Y204/99001;;C12Y204/99004;;C12Y205/01056;;C12Y206/01016;;C12Y207/07043;;C12Y207/09002;;C12Y301/03;;C12Y501/03014,A23L33/125;;C12N1/20;;C12N9/10;;C12N15/52;;C12P19/26,,3,0,,,"""GenBank"", Database accession no. NP_l 16637;;""NCBI"", Database accession no. WP_003512903.1;;METAB ENG, vol. 7, no. 3, May 2005 (2005-05-01), pages 201 - 14",PENDING
504,US,A1,US 2023/0105761 A1,135-355-247-036-725,2023-04-06,2023,US 202217937930 A,2022-10-04,US 202217937930 A;;US 202163252009 P;;US 202263347331 P,2021-10-04,MULTI-SENSORY ENRICHMENT WITH SELF-ADMINISTERING HEALTH PRODUCT DELIVERY SYSTEM,The present disclosure describes a self-sprayer device for self-administering an animal product to an animal and providing environmental enrichment to the animal.,UNIV TEXAS TECH SYSTEM,MCGLONE JOHN J,TEXAS TECH UNIVERSITY SYSTEM (2021-11-11),https://lens.org/135-355-247-036-725,Patent Application,yes,13,0,2,135-355-247-036-725;;073-427-095-527-359,WO;;US,4,073-427-095-527-359;;137-736-794-718-321;;135-355-247-036-725;;196-846-865-702-018,WO;;US,0,A61D7/00;;A61D1/025;;A01K13/003;;A01K13/003;;A61D7/00;;A61K39/0275;;A61D1/025,A61D7/00;;A01K11/00;;A01K13/00;;A01K29/00;;A61K9/12;;A61K31/47;;A61K31/568;;A61K39/112,,1,0,,,Animal Biotech Boar Better Pheromones (https://www.boar-better.com/benefits/) (Year: 2019),DISCONTINUED
505,US,A1,US 2023/0193234 A1,003-787-510-661-169,2023-06-22,2023,US 202218051933 A,2022-11-02,CN 202011191136 A;;CN 2021127313 W,2020-10-30,RECOMBINANT VECTOR OF THERMOLABILE UNG FUSED PROTEIN AND AN EXPRESSING AND PURIFYING METHOD,"A recombinant vector of a thermolabile UNG fused protein and an expressing and purifying method are provided. The method comprises cloning a Cod UNG genetic sequence to a pCold-SUMO vector to construct a recombinant vector pCold-SUMO-Cod UNG, transforming to E. coli BL21 (DE3) competent cells, transforming and expressing molecular chaperone plasmids pG-Tf2, and inducing the expression at a low temperature to obtain a soluble SUMO-Cod UNG fused protein.",UNIV XIAMEN;;XIAMEN ZEESAN BIOTECH CO LTD,ZHANG YONGYOU;;WANG DAN;;SONG NAJIE,XIAMEN UNIVERSITY (2022-09-20);;XIAMEN ZEESAN BIOTECH CO. LTD (2022-09-20),https://lens.org/003-787-510-661-169,Patent Application,yes,0,1,5,194-652-244-434-390;;147-792-055-885-387;;045-470-863-243-358;;053-044-412-085-985;;003-787-510-661-169,EP;;CN;;WO;;US,5,194-652-244-434-390;;147-792-055-885-387;;045-470-863-243-358;;053-044-412-085-985;;003-787-510-661-169,EP;;CN;;WO;;US,0,C12N15/70;;C12N9/2497;;C07K2319/21;;C07K2319/95;;C12Y302/02027;;C12N9/2497;;C12N15/70;;C12N9/2402;;C07K2319/21;;C07K2319/95;;C12N9/2497;;C12N15/70;;C12N2800/101;;C12Y302/02027,C12N9/24;;C12N15/70,,0,0,,,,PENDING
506,EP,A1,EP 3904392 A1,008-735-780-927-868,2021-11-03,2021,EP 19904064 A,2019-12-26,CN 201811622069 A;;CN 2019128582 W,2018-12-28,"BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION","Provided are a bivalent bispecific antibody and a preparation method thereof, a coding gene, a host cell and a composition. The bivalent bispecific antibody comprises: a) a single-chain variable fragment scFv, a flexible peptide, a heavy chain IgG1 constant region CH1 and a hinge region partial sequence of the antibody that specifically binds to a first antigen, and b) a single-chain variable fragment scFv, and a light chain constant region CL, that is, scFv1-CL or CL-scFv1, of the antibody that specifically binds to a second antigen; or comprises: c) a light chain and a heavy chain of the antibody that specifically binds to the first antigen, and d) a light chain and a heavy chain of the antibody that specifically binds to the second antigen.",CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD,FENG XIAO;;JIN LEI;;WANG TAO;;GUO HONGRUI;;LIU SHUANG;;CHEN YUHENG;;HAN NING;;LIANG YANGQIU,,https://lens.org/008-735-780-927-868,Patent Application,yes,0,0,11,097-661-274-088-511;;121-284-070-690-84X;;002-028-754-723-166;;194-592-262-585-094;;003-666-865-754-152;;151-577-873-500-904;;008-735-780-927-868;;075-569-656-914-874;;021-294-817-512-528;;048-834-004-798-981;;022-467-561-335-394,JP;;CN;;EP;;WO;;US,11,121-284-070-690-84X;;097-661-274-088-511;;002-028-754-723-166;;194-592-262-585-094;;003-666-865-754-152;;151-577-873-500-904;;008-735-780-927-868;;075-569-656-914-874;;021-294-817-512-528;;048-834-004-798-981;;022-467-561-335-394,JP;;CN;;EP;;WO;;US,24,C07K16/468;;C07K16/2803;;C07K16/2827;;C12N5/0603;;C12N5/0686;;C07K2317/31;;C07K2317/24;;C07K2317/92;;C12N2510/02;;A61P35/00;;C07K2317/31;;C07K2317/622;;C07K2317/60;;C07K2317/64;;C07K2317/35;;C07K2317/92;;C07K16/2803;;C07K16/2827;;C07K2317/24;;C07K16/468;;C07K16/2803;;C07K16/2827;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/622;;C07K2317/92,C07K16/46;;A61K39/395;;A61P35/00;;C07K16/00,,0,0,,,,PENDING
507,US,A1,US 2020/0316208 A1,012-191-995-955-323,2020-10-08,2020,US 201816753447 A,2018-10-09,DE 102017009799 A;;IB 2018057788 W,2017-10-12,MECHANICAL PROCESSING OF BIOPOLYMERS,Embodiments described herein generally relate to methods of processing of biopolymers and applications utilizing these biopolymers.,SOLYPLUS BERLIN GMBH,ANDERSEN RICHARD DOLPH;;ASSOGBA-ZANDT ANNETTE;;LAI TINA;;LIETZAU ISA;;MALTSEVA ELENA;;VOIGT ANDREAS,SOLYPLUS GMBH (2020-03-30),https://lens.org/012-191-995-955-323,Patent Application,yes,4,0,8,178-720-376-119-036;;156-945-146-795-169;;071-794-254-372-166;;108-914-116-639-867;;073-050-443-288-642;;009-545-352-368-325;;012-191-995-955-323;;100-127-301-368-647,JP;;EP;;WO;;US;;CA;;MX;;BR,8,178-720-376-119-036;;108-914-116-639-867;;071-794-254-372-166;;156-945-146-795-169;;073-050-443-288-642;;009-545-352-368-325;;012-191-995-955-323;;100-127-301-368-647,JP;;EP;;WO;;US;;CA;;MX;;BR,0,A61K9/0021;;A61K9/06;;A61K9/10;;A61K9/7007;;A61K31/417;;A61K47/36;;A61K47/44;;A61K47/36;;A61K9/0092;;A61K9/7007;;A61K45/06;;C08B37/0072;;C08J3/075;;C08J2305/08,A61K47/36;;A61K9/00;;A61K9/70;;A61K45/06;;C08B37/08;;C08J3/075,,9,3,119-845-715-013-367;;040-065-922-517-62X;;081-595-413-053-527,27987766;;10.1016/j.msec.2016.10.063;;22097906;;10.1517/17425247.2011.610304;;10.1016/j.actbio.2013.03.005;;23507088;;pmc3669638,"Yu W, Jiang G, Liu D, Li L, Chen H, Liu Y, Huang Q, Tong Z, Yao J, Kong X. Fabrication of biodegradable composite microneedles based on calcium sulfate and gelatin for transdermal delivery of insulin. Materials Science and Engineering: C. 2017 Feb 1;71:725-34. (Year: 2017);;Roasted Potato Bread from Bon Appetit, August 19, 2014 (Year: 2014);;""The Hyaluronic Acid Diet"" from https://intothegloss.com/2018/10/foods-that-contain-hyaluronic-acid/, accessed September 20, 2022 (Year: 2022);;Loh ZH, Er DZ, Chan LW, Liew CV, Heng PW. Spray granulation for drug formulation. Expert opinion on Drug delivery. 2011 Dec 1;8(12):1645-61. (Year: 2011);;Machine translation of KR 101538122B1, original document published April 2015 (Year: 2015);;Espacenet English language abstract of KR 101538122B1, original document published April 2015 (Year: 2015);;Machine translation of KR 101513812B1, original document published April 2015 (Year: 2015);;Espacenet English language abstract of KR 101513812B1, original document published April 2015 (Year: 2015);;Fakhari A, Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta biomaterialia. 2013 Jul 1;9(7):7081-92. (Year: 2013)",DISCONTINUED
508,US,A1,US 2022/0133867 A1,170-968-254-050-251,2022-05-05,2022,US 202117554486 A,2021-12-17,US 202117554486 A;;DE 102014216985 A;;US 201916404441 A;;US 201715506481 A;;EP 2015069341 W,2014-08-26,USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN,"The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and/or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and/or prevention of disorders or diseases which are associated with a rise in the level of troponin I and/or T.",PROTEO BIOTECH AG,BARGMANN BIRGE;;WIEDOW OLIVER;;HENRIKSEN PETER,TIAKIS BIOTECH AG (2022-09-07);;PROTEO BIOTECH AG (2017-02-22),https://lens.org/170-968-254-050-251,Patent Application,yes,0,0,9,193-543-490-489-769;;065-691-106-119-290;;170-968-254-050-251;;070-183-948-289-026;;079-090-778-031-317;;099-289-263-610-735;;018-524-358-767-937;;152-224-091-859-501;;009-005-707-612-837,JP;;EP;;WO;;US,9,193-543-490-489-769;;009-005-707-612-837;;152-224-091-859-501;;070-183-948-289-026;;079-090-778-031-317;;099-289-263-610-735;;018-524-358-767-937;;170-968-254-050-251;;065-691-106-119-290,JP;;EP;;WO;;US,4,A61K38/57;;A61K38/55;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P11/00;;A61P13/12;;A61P21/00;;A61P21/04;;A61P29/00;;A61P37/06;;A61P43/00;;A61K38/57;;A61K38/55,A61K38/57;;A61K38/55,,0,0,,,,DISCONTINUED
509,US,A1,US 2025/0179457 A1,027-337-058-013-722,2025-06-05,2025,US 202519061780 A,2025-02-24,US 202519061780 A;;US 202117430013 A;;US 2020/0019168 W;;US 201962808984 P,2019-02-22,LACHNOSPIRACEAE BACTERIUM ND2006 CAS12A MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME,"This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.",INTEGRATED DNA TECH INC,BEAUDOIN SARAH FRANZ;;COLLINGWOOD MICHAEL ALLEN;;VAKULSKAS CHRISTOPHER ANTHONY,,https://lens.org/027-337-058-013-722,Patent Application,yes,0,0,15,029-329-622-658-39X;;058-449-205-314-113;;032-574-241-614-710;;117-434-220-464-335;;027-337-058-013-722;;078-891-336-290-358;;085-658-454-612-517;;071-016-722-647-343;;182-960-389-817-340;;174-990-019-882-281;;143-602-874-701-11X;;033-590-227-876-681;;087-793-987-467-695;;042-568-367-050-836;;053-995-502-718-903,JP;;AU;;CN;;EP;;WO;;US;;CA,15,029-329-622-658-39X;;058-449-205-314-113;;032-574-241-614-710;;117-434-220-464-335;;027-337-058-013-722;;078-891-336-290-358;;085-658-454-612-517;;071-016-722-647-343;;182-960-389-817-340;;174-990-019-882-281;;143-602-874-701-11X;;033-590-227-876-681;;087-793-987-467-695;;042-568-367-050-836;;053-995-502-718-903,JP;;AU;;CN;;EP;;WO;;US;;CA,0,C12N9/22;;C12N15/52;;C12N2310/20;;C12N9/22;;C12N15/11,C12N9/22;;C12N15/11,,0,0,,,,PENDING
510,US,A1,US 2024/0254434 A1,030-663-867-924-376,2024-08-01,2024,US 202017787381 A,2020-12-18,US 202017787381 A;;EP 19217672 A;;US 201962949480 P;;EP 2020087338 W,2019-12-18,GENETICALLY MODIFIED CLOSTRIDIUM STRAINS AND USES THEREOF,"The present invention relates to genetically modified Clostridium strains that provide an improved combination of replication and physiological characteristics useful for a variety of clinical and industrial applications. In particular, clinical grade spores generated from the Clostridium strains described herein can be efficiently stored, formulated, and advantageously used in the prevention and/or treatment of medical conditions, such as cancer.",EXOMNIS BIOTECH B V;;EXOMNIS BIOTECH BV,KUBIAK ALEKSANDRA MARIA,EXOMNIS BIOTECH BV (2020-12-14);;LIVINGMED BIOTECH S.R.L (2023-01-01),https://lens.org/030-663-867-924-376,Patent Application,yes,2,0,4,126-390-477-769-817;;061-972-711-156-263;;155-216-333-141-092;;030-663-867-924-376,CN;;EP;;WO;;US,4,126-390-477-769-817;;061-972-711-156-263;;155-216-333-141-092;;030-663-867-924-376,CN;;EP;;WO;;US,64,A61K35/74;;C07K14/33;;C12N1/36;;C12N3/00;;C12N1/205;;C12R2001/145;;A61K35/74;;C12N1/36,C12N1/20;;A61K35/74;;C12N1/36;;C12R1/145,,1,1,010-074-022-220-042,10.1074/jbc.m110.118554;;20581111;;pmc2934687,"GONZALEZ D.J. ET AL., ""Clostridiolysin S, a Post-translationally Modified Biotoxin from Clostridium botulinum"", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Sept. 2010, VOL. 285, NO. 36, pp. 28220–28228. (Year: 2010)",PENDING
511,EP,A2,EP 4570917 A2,014-488-307-987-007,2025-06-18,2025,EP 24207684 A,2015-04-01,EP 14163165 A;;EP 15155361 A;;EP 15712970 A;;EP 2015057164 W,2014-04-02,METHOD FOR DETECTING MULTISPECIFIC ANTIBODY LIGHT CHAIN MISPAIRING,Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.,HOFFMANN LA ROCHE,MOLHOJ MICHAEL;;KOENIG MAXIMILIANE;;LARRAILLET VINCENT;;MONTAN KATJA;;GRUENWALDER BIANCA,,https://lens.org/014-488-307-987-007,Patent Application,yes,67,0,16,094-250-395-094-39X;;143-970-204-871-194;;087-223-647-826-327;;019-265-026-723-535;;001-072-038-315-294;;150-309-117-377-018;;143-461-991-471-855;;039-913-131-136-373;;053-387-891-354-779;;181-432-142-670-329;;014-488-307-987-007;;050-954-164-799-842;;091-969-160-385-713;;171-938-643-523-808;;119-433-091-527-018;;110-410-395-077-352,KR;;JP;;EP;;CN;;WO;;SG;;US,62,161-769-601-492-348;;183-799-390-116-830;;163-564-800-682-877;;019-265-026-723-535;;025-452-963-854-960;;039-913-131-136-373;;158-697-191-125-685;;087-100-081-672-540;;015-722-023-150-829;;072-776-495-566-823;;162-133-605-850-221;;181-432-142-670-329;;003-853-285-180-133;;000-006-426-260-414;;023-295-346-057-908;;042-350-582-448-298;;087-533-976-859-043;;186-062-326-707-380;;119-433-091-527-018;;110-410-395-077-352;;094-250-395-094-39X;;012-421-979-675-330;;087-223-647-826-327;;105-700-832-568-067;;096-921-159-574-84X;;006-048-228-874-769;;015-841-004-987-14X;;110-663-749-008-73X;;169-954-808-555-954;;193-701-260-273-533;;075-500-548-119-122;;090-621-075-351-144;;014-488-307-987-007;;171-938-643-523-808;;091-969-160-385-713;;053-724-821-508-730;;083-528-304-947-428;;189-499-549-918-645;;174-572-160-355-358;;062-653-195-425-700;;002-030-418-191-562;;028-205-671-798-208;;115-844-489-645-242;;143-970-204-871-194;;055-404-914-395-43X;;040-841-626-358-205;;019-659-040-625-749;;062-364-771-310-346;;001-072-038-315-294;;191-315-205-190-139;;150-309-117-377-018;;118-656-253-685-10X;;132-222-762-596-278;;107-519-980-928-147;;156-832-093-053-266;;005-865-645-468-36X;;143-461-991-471-855;;053-387-891-354-779;;190-616-457-515-254;;140-466-821-025-709;;050-954-164-799-842;;070-485-927-911-801,JP;;HU;;EA;;SI;;CA;;LT;;MX;;HR;;PL;;MY;;EP;;CN;;ZA;;WO;;NZ;;AU;;CL;;US;;TW;;PH;;BR;;PT;;PE;;CR;;KR;;AR;;IL;;ES;;UA;;SG;;RS;;DK,0,C12Q1/37;;G01N33/6848;;G01N33/6854;;G01N33/6857;;C12Q1/37;;G01N33/6854;;G01N33/6857;;G01N33/6848;;C12Q1/37;;G01N33/6848;;G01N33/6854;;G01N33/6857;;C12Q1/37;;G01N33/6857;;G01N33/6854;;G01N33/6848,C12Q1/37,,68,55,000-744-158-906-358;;015-080-564-314-169;;034-331-211-704-877;;002-490-451-363-036;;030-607-398-087-475;;051-208-529-712-079;;042-204-626-457-327;;030-323-674-660-051;;022-023-983-891-895;;009-746-604-420-355;;009-483-512-107-343;;015-395-754-996-662;;106-032-800-597-23X;;001-256-484-369-395;;003-570-249-164-056;;010-953-281-569-514;;048-564-471-521-204;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;034-345-578-106-977;;030-630-100-818-462;;032-071-991-081-664;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;022-133-574-143-973;;072-378-691-723-546;;117-775-899-628-564;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;066-749-017-721-197;;035-232-534-898-963;;031-719-370-148-435;;077-532-829-551-519;;047-111-956-440-199;;000-079-995-565-389;;092-325-088-257-225;;052-515-652-666-158;;045-003-131-652-516;;054-716-942-503-895;;053-688-216-326-220;;106-475-314-919-873;;098-504-635-610-65X;;052-515-652-666-158;;043-044-953-372-634;;035-796-690-562-525;;124-805-115-929-413;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;144-287-049-672-055;;103-405-698-907-771,12271440;;10.1002/jms.356;;18293943;;10.1021/ac701629v;;1907718;;10.1038/352624a0;;17161664;;10.1016/j.jchromb.2006.11.018;;10.1073/pnas.81.21.6851;;6436822;;pmc392030;;10.2741/2786;;17981654;;10.1038/332323a0;;3127726;;2513570;;pmc298637;;10.1073/pnas.86.24.10029;;10.1016/0161-5890(91)90163-e;;1905784;;pmc2363493;;10901379;;10.1054/bjoc.2000.1226;;1350088;;10.1073/pnas.89.10.4285;;pmc49066;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;11470598;;10.1016/s1367-5931(00)00216-7;;10.1016/j.coi.2008.06.004;;18606226;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.133.6.3001;;6092464;;10.1073/pnas.0511285103;;16505368;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;10.1385/1-59259-240-6:001;;11968478;;10.1038/348552a0;;2247164;;1404359;;10.1016/0022-2836(92)90894-p;;10.1016/j.jmb.2004.05.051;;15236968;;15306681;;pmc515084;;10.1073/pnas.0401786101;;14736422;;10.1016/j.jim.2003.11.001;;10.1146/annurev.immunol.12.1.433;;10.1146/annurev.iy.12.040194.002245;;8011287;;7679990;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;10.1038/305537a0;;6137772;;10.1002/j.1460-2075.1991.tb04932.x;;1834458;;pmc453097;;10.1126/science.3925553;;3925553;;1531669;;10.4049/jimmunol.148.5.1547;;10.1073/pnas.90.14.6444;;pmc46948;;8341653;;10.4049/jimmunol.152.11.5368;;8189055;;10.1038/nbt0297-159;;9035142;;16151406;;10.1038/nbt1142;;17190998;;10.1159/000101046;;17496428;;10.1159/000096832;;17126853;;10.1016/j.jim.2006.09.020;;8844834;;10.1093/protein/9.7.617;;10.1038/nbt0798-677;;9661204;;10.1006/jmbi.1997.1116;;9231898;;10.4049/jimmunol.160.6.2802;;9510182;;pmc3131342;;21690412;;10.1073/pnas.1019002108;;10.1016/s0969-8051(97)00228-x;;9639301;;10.1038/sj.onc.1202489;;10208432;;10.1038/nbt0798-677;;9661204;;14970502;;10.1385/1-59259-666-5:255;;10.1038/nbt1028;;15529166;;16429149;;10.1038/nbt1178;;886304;;10.1099/0022-1317-36-1-59;;6774781;;10.1095/biolreprod23.1.243;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;6933469;;pmc349802;;11536142;;10.1002/bit.1179;;10.1002/pro.5560041120;;pmc2143013;;8563639,"J. IMMUNOL. METH., vol. 181, 1995, pages 259 - 267;;MATSUDA ET AL., FEBS LETT., vol. 473, 2000, pages 349 - 357;;VILLANUEVA ET AL., J. MASS SPECTROM., vol. 37, 2002, pages 974 - 984;;KLEEMANN ET AL., ANAL. CHEM., vol. 80, 2008, pages 2001 - 2009;;CLACKSON, T. ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;FLATMAN, S. ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;MORRISON, S.L., NATURE BIOTECH., vol. 25, 2007, pages 1290 - 1297;;PORTOLANO, S. ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 - 2632;;MORRISON, S.L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;ALMAGRO, J.C.FRANSSON, J., FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;RIECHMANN, I. ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;DALL'ACQUA, W.F. ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;PADLAN, E.A., MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498;;KLIMKA, A. ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;CARTER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 - 4289;;BACA, M. ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK, M.J. ET AL., J. BIOL. CHEM., vol. 271, pages 22611 - 22618;;VAN DIJK, M.A.VAN DE WINKEL, J.G., CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 374;;LONBERG, N., CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459;;LONBERG, N., NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125;;KOZBOR, D., J. IMMUNOL., vol. 133, 1984, pages 3001 - 3005;;BRODEUR, B.R. ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;BOERNER, P. ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69;;LI, J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NI, J., XIANDAI MIANYIXUE, vol. 26, 2006, pages 265 - 268;;VOLLMERS, H.P.BRANDLEIN, S., HISTOLOGY AND HISTOPATHOLOGY, vol. 20, 2005, pages 927 - 937;;VOLLMERS, H.P.BRANDLEIN, S., METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, 2005, pages 185 - 191;;HOOGENBOOM, H.R. ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 178, 2001, pages 1 - 37;;MCCAFFERTY, J. ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;HOOGENBOOM, H.R.WINTER, G., J. MOL. BIOL., vol. 227, 1992, pages 381 - 388;;MARKS, J.D.BRADBURY, A., METHODS IN MOLECULAR BIOLOGY, vol. 248, 2003, pages 161 - 175;;SIDHU, S.S. ET AL., J. MOL. BIOL., vol. 340, 2004, pages 1073 - 1093;;FELLOUSE, F.A., PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 12467 - 12472;;LEE, C.V. ET AL., J. IMMUNOL. METHODS, vol. 284, 2004, pages 119 - 132;;WINTER, G. ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;MILSTEIN, C.CUELLO, A.C., NATURE, vol. 305, 1983, pages 537 - 540;;TRAUNECKER, A. ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659;;BRENNAN, M. ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83;;KOSTELNY, S.A. ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;GRUBER, M ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 - 5374;;COLOMA, M.J., NATURE BIOTECH., vol. 15, 1997, pages 159 - 163;;HOLLIGER, P., NATURE BIOTECH., vol. 23, 2005, pages 1126 - 1136;;FISCHER, N.LÉGER, O., PATHOBIOLOGY, vol. 74, 2007, pages 3 - 14;;SHEN, J., J. IMMUNOL. METHODS, vol. 318, 2007, pages 65 - 74;;RIDGWAY, J.B. ET AL., PROTEIN ENG., vol. 9, 1996, pages 617 - 621;;MERCHANT, A.M. ET AL., NATURE BIOTECH., vol. 16, 1998, pages 677 - 681;;ATWELL, S. ET AL., J. MOL. BIOL., vol. 270, 1997, pages 26 - 35;;MORRISON, S.L. ET AL., J. IMMUNOL., vol. 160, 1998, pages 2802 - 2808;;SCHAEFER, W. ET AL., PNAS, vol. 108, 2011, pages 11187 - 1191;;RAJAGOPAL, V. ET AL., PROT. ENG., 1997, pages 1453 - 59;;KOBAYASHI, H. ET AL., NUCLEAR MEDICINE & BIOLOGY, vol. 25, 1998, pages 387 - 393;;SCHMIDT, M. ET AL., ONCOGENE, vol. 18, 1999, pages 1711 - 1721;;MERCHANT, A.M. ET AL., NAT. BIOTECHNOL., vol. 16, 1998, pages 677 - 681;;YAZAKI, P.WU, A.M.: ""Methods in Molecular Biology"", vol. 248, 2004, HUMANA PRESS, pages: 255 - 268;;GERNGROSS, T.U., NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI, H. ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215;;GRAHAM, F.L. ET AL., J. GEN VIROL., vol. 36, 1977, pages 59 - 74;;MATHER, J.P, BIOL. REPROD., vol. 23, 1980, pages 243 - 252;;MATHER, J.P ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, PUBLIC HEALTH SERVICE;;SAMBROOK, J. ET AL.: ""Molecular Cloning: A laboratory manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""Current Protocols in Cell Biology"", 2000, JOHN WILEY & SONS, INC;;MEISSNER, P. ET AL., BIOTECHNOL. BIOENG., vol. 75, 2001, pages 197 - 203;;PACE ET AL., PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 1423",PENDING
512,US,A1,US 2021/0238296 A1,037-331-389-779-090,2021-08-05,2021,US 201917051205 A,2019-05-03,DK PA201800195 A;;DK PA201800644 A;;EP 2019061455 W,2018-05-03,ANTIBODY VARIANT COMBINATIONS AND USES THEREOF,"Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.",GENMAB BV,DE JONG ROB;;BEURSKENS FRANK;;OOSTINDIE SIMONE;;LABRIJN ARAN FRANK;;STRUMANE KRISTIN;;SCHUURMAN JANINE;;DE KREUK BART-JAN,GENMAB B.V (2021-03-02),https://lens.org/037-331-389-779-090,Patent Application,yes,0,2,16,100-563-812-224-97X;;185-659-050-958-271;;003-130-429-027-607;;192-154-721-769-333;;059-449-607-067-318;;131-824-901-056-952;;037-331-389-779-090;;094-491-037-627-595;;058-460-972-586-061;;094-231-791-428-589;;112-745-678-091-936;;060-229-079-919-636;;150-936-405-756-752;;119-777-209-644-084;;107-045-904-716-917;;043-393-676-819-72X,JP;;AU;;US;;CA;;BR;;PH;;MX;;KR;;EP;;CN;;WO;;SG;;MA,17,006-556-732-290-210;;100-563-812-224-97X;;003-130-429-027-607;;185-659-050-958-271;;192-154-721-769-333;;059-449-607-067-318;;131-824-901-056-952;;037-331-389-779-090;;058-460-972-586-061;;094-491-037-627-595;;094-231-791-428-589;;112-745-678-091-936;;060-229-079-919-636;;150-936-405-756-752;;107-045-904-716-917;;119-777-209-644-084;;043-393-676-819-72X,JP;;AU;;EA;;US;;CA;;BR;;PH;;MX;;KR;;CN;;EP;;WO;;SG;;MA,201,C07K16/2878;;C07K16/2887;;C07K16/2893;;C07K16/2896;;C07K16/468;;C07K2317/31;;C07K2317/52;;C07K2317/71;;C07K2317/72;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/94;;A61K2039/505;;A61K2039/507;;C07K16/2887;;C07K16/2893;;C07K16/2896;;C07K16/2833;;C07K16/2809;;A61P35/00;;C07K2317/565;;C07K2317/31;;C07K2317/52;;C07K2317/71;;C07K2317/72;;C07K2317/73;;C07K2317/94;;A61K2039/505;;A61K2039/507;;A61K45/06;;C07K16/2809;;C07K16/2818;;C07K16/2833;;C07K16/2878;;C07K16/2887;;C07K16/2893;;C07K16/2896;;C07K2317/565;;C07K2317/732;;C07K2317/734,C07K16/28;;A61K45/06,,1,1,161-793-386-298-744,pmc9546771;;35879362;;10.1038/s41587-022-01384-1,Oostindie et al. Nature Biotech 40:1509-1519 (Year: 2022),ACTIVE
513,US,A1,US 2021/0040443 A1,049-023-091-475-626,2021-02-11,2021,US 202016938079 A,2020-07-24,US 202016938079 A;;US 201816126594 A;;US 201514763397 A;;US 2014/0029734 W;;US 201361783594 P,2013-03-14,In Vitro Production of Medial Ganglionic Eminence Precursor Cells,Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.,UNIV CALIFORNIA,NICHOLAS CORY R;;RUBENSTEIN JOHN L;;KRIEGSTEIN ARNOLD R;;ALVAREZ-BUYLLA ARTURO,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2016-03-21),https://lens.org/049-023-091-475-626,Patent Application,yes,3,3,35,056-071-957-727-709;;043-928-723-254-521;;149-046-705-008-000;;165-020-178-338-722;;124-927-891-391-981;;043-132-601-544-869;;159-277-045-830-744;;163-896-609-712-303;;087-883-410-316-269;;119-436-348-338-575;;051-117-515-317-939;;135-624-918-572-987;;104-950-358-749-439;;051-359-749-267-403;;197-187-289-436-216;;088-035-539-509-162;;049-023-091-475-626;;105-952-765-397-237;;107-571-654-952-959;;104-244-747-165-99X;;055-595-364-631-016;;057-556-379-126-291;;141-217-689-320-629;;161-490-089-274-617;;160-666-697-542-865;;126-726-658-592-068;;063-770-259-362-585;;006-296-152-610-363;;173-736-270-776-85X;;124-447-970-730-061;;023-348-703-756-851;;084-696-185-866-949;;150-818-988-994-543;;163-257-873-135-700;;082-881-549-875-70X,JP;;AU;;EP;;CN;;WO;;HK;;US;;CA,35,056-071-957-727-709;;043-928-723-254-521;;149-046-705-008-000;;165-020-178-338-722;;124-927-891-391-981;;043-132-601-544-869;;159-277-045-830-744;;163-896-609-712-303;;087-883-410-316-269;;119-436-348-338-575;;051-117-515-317-939;;135-624-918-572-987;;104-950-358-749-439;;051-359-749-267-403;;197-187-289-436-216;;088-035-539-509-162;;049-023-091-475-626;;105-952-765-397-237;;107-571-654-952-959;;104-244-747-165-99X;;055-595-364-631-016;;057-556-379-126-291;;141-217-689-320-629;;161-490-089-274-617;;160-666-697-542-865;;063-770-259-362-585;;126-726-658-592-068;;006-296-152-610-363;;173-736-270-776-85X;;124-447-970-730-061;;023-348-703-756-851;;084-696-185-866-949;;150-818-988-994-543;;163-257-873-135-700;;082-881-549-875-70X,JP;;AU;;EP;;CN;;WO;;HK;;US;;CA,28,C12N5/0619;;C12N2501/13;;C12N2501/41;;C12N2501/727;;C12N2501/999;;C12N2506/02;;A61P25/00;;C12N2501/42;;C12N5/0619;;C12N2501/13;;C12N2501/41;;C12N2501/727;;C12N2501/999;;C12N2506/02;;C12N15/63;;C12N5/0618;;C12N2500/90;;C12N2506/45,C12N5/079;;C12N5/0793;;C12N15/63,,1,1,094-392-245-890-191,10.1038/nbt1310;;17529971,"Watanabe et al. (2007) Nat. Biotech., Vol. 25(6), 681-686",ACTIVE
514,US,A1,US 2021/0109112 A1,190-840-340-850-151,2021-04-15,2021,US 202017015006 A,2020-09-08,US 202017015006 A;;US 201815910586 A;;US 201614917786 A;;CA 2014050852 W;;US 201361879314 P;;US 201361875162 P,2013-09-09,METHOD OF TREATING AND PROGNOSING SCOLIOTIC PATIENT SUBGROUPS,"The present invention provides a method of treating a subject in need thereof comprising classifying the subject into functional group FG1, FG2 or FG3, wherein i) when the subject is classified into the FG1 functional group, (A) the level of OPN or the activity of OPN in said subject is increased; (B) the subject is not treated with a brace; or (C) a combination of (A) and (B); and ii) when the subject is classified into the FG2 or FG3 functional group, (A) the level of OPN or the activity of OPN in said subject is decreased; (B) the subject is treated with a brace; or (C) a combination of (A) and (B).",CHU SAINTE JUSTINE,MOREAU ALAIN;;AKOUME NDONG MARIE-YVONNE,CHU SAINTE-JUSTINE (2013-10-15),https://lens.org/190-840-340-850-151,Patent Application,yes,4,0,20,140-731-149-454-437;;120-364-837-475-090;;164-781-843-199-09X;;018-897-886-195-145;;190-840-340-850-151;;074-848-865-681-750;;129-324-600-358-612;;068-873-109-167-550;;086-266-900-980-381;;020-775-561-926-700;;043-644-281-754-38X;;098-182-997-581-439;;150-643-050-106-822;;186-090-400-533-226;;134-537-147-102-060;;102-218-190-074-836;;155-735-090-250-570;;051-684-898-408-467;;157-779-199-731-973;;024-572-920-848-632,EP;;WO;;HK;;US;;CA,20,140-731-149-454-437;;120-364-837-475-090;;190-840-340-850-151;;018-897-886-195-145;;164-781-843-199-09X;;129-324-600-358-612;;074-848-865-681-750;;020-775-561-926-700;;043-644-281-754-38X;;068-873-109-167-550;;086-266-900-980-381;;098-182-997-581-439;;150-643-050-106-822;;186-090-400-533-226;;134-537-147-102-060;;102-218-190-074-836;;155-735-090-250-570;;051-684-898-408-467;;157-779-199-731-973;;024-572-920-848-632,EP;;WO;;HK;;US;;CA,20,G01N33/6893;;A61F5/02;;A61F5/026;;A61K31/4045;;A61K31/713;;A61K33/04;;A61K38/19;;A61K45/06;;G01N33/48728;;G01N2800/10;;G01N2800/52;;G01N33/6893;;A61F5/02;;A61F5/026;;A61K31/4045;;A61K31/713;;A61K33/04;;A61K38/08;;A61K38/19;;A61K45/06;;C12N15/1138;;C12N2310/14;;C12N2320/30;;G01N33/48728;;G01N33/53;;G01N2333/04;;G01N2333/47;;G01N2333/726;;G01N2800/10;;G01N2800/50;;G01N2800/52,G01N33/68;;A61F5/02;;A61K31/4045;;A61K31/713;;A61K33/04;;A61K38/19;;A61K45/06;;C12N15/113;;G01N33/487,,8,7,140-036-581-905-327;;046-294-286-996-996;;007-100-649-072-686;;049-128-472-304-856;;127-764-320-344-677;;149-566-597-263-256;;098-788-057-625-987,11901207;;10.1124/mol.61.4.707;;10.1111/j.1535-7511.2007.00223.x;;pmc2238643;;18265885;;10.1093/ndt/gfr575;;21940482;;10.1373/clinchem.2013.205716;;pmc3972213;;23873716;;15897808;;23986522;;10.1152/ajprenal.00387.2013;;10.1161/01.res.0000202805.73038.48;;16397141,"Feldman, 2002, Molecular Pharmacology. 61(4): 707-709;;Janigro (2008, Epilepsy Currents 8(1): 23-24);;Breit et al. (2012, Nephrol. Dial. Transplant. 27:70-75);;Ho et al. (2013, Clin. Chem. 59:1613-1620);;Abulizi et al. (2017, Sci. Rep. 7(1):1037; pp. 1-10);;Zimmers et al. (2005, Shock 23(6):543-548);;Mazagova et al. (2013, Am. J. Physiol. Renal Physiol. 305:F1249-F1264);;Kempf et al. (2006, Cir. Res. 98:351-350)",ACTIVE
515,US,A1,US 2022/0111021 A1,152-224-091-859-501,2022-04-14,2022,US 202117557874 A,2021-12-21,US 202117557874 A;;DE 102014216985 A;;US 201916404441 A;;US 201715506481 A;;EP 2015069341 W,2014-08-26,USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN,"The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and/or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and/or prevention of disorders or diseases which are associated with a rise in the level of troponin I and/or T.",PROTEO BIOTECH AG,BARGMANN BIRGE;;WIEDOW OLIVER;;HENRIKSEN PETER,TIAKIS BIOTECH AG (2022-09-07);;PROTEO BIOTECH AG (2017-02-22),https://lens.org/152-224-091-859-501,Patent Application,yes,0,0,9,193-543-490-489-769;;065-691-106-119-290;;170-968-254-050-251;;070-183-948-289-026;;079-090-778-031-317;;099-289-263-610-735;;018-524-358-767-937;;152-224-091-859-501;;009-005-707-612-837,JP;;EP;;WO;;US,9,193-543-490-489-769;;009-005-707-612-837;;152-224-091-859-501;;070-183-948-289-026;;079-090-778-031-317;;099-289-263-610-735;;018-524-358-767-937;;170-968-254-050-251;;065-691-106-119-290,JP;;EP;;WO;;US,4,A61K38/57;;A61K38/55;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P11/00;;A61P13/12;;A61P21/00;;A61P21/04;;A61P29/00;;A61P37/06;;A61P43/00;;A61K38/57;;A61K38/55,A61K38/57;;A61K38/55,,0,0,,,,DISCONTINUED
516,US,A1,US 2024/0167053 A1,181-195-743-619-346,2024-05-23,2024,US 202217720369 A,2022-04-14,US 202217720369 A;;DE 102014207153 A;;US 201615303823 A;;EP 2015057987 W,2014-04-14,AAV VECTORS FOR VASCULAR GENE THERAPY IN CORONARY HEART DISEASE AND PERIPHERAL ISCHEMIA,The invention relates to the provision of a gene therapy for coronary heart disease and peripheral ischemia in mammals. One embodiment is an adeno-associated viral vector (AAV vector) comprising a first gene encoding a myocardin-related transcription factor A (MRTF-A). The invention further also relates to a pharmaceutical composition comprising an AAV vector of the invention and a pharmaceutically acceptable carrier. Methods for preparing the vector of the invention are also disclosed.,KUPATT CHRISTIAN,KUPATT CHRISTIAN;;HINKEL RABEA,,https://lens.org/181-195-743-619-346,Patent Application,yes,0,0,8,188-426-567-253-428;;001-913-199-300-409;;181-195-743-619-346;;107-945-189-029-408;;111-877-467-032-424;;084-790-309-449-719;;061-161-125-448-563;;027-404-155-790-635,DE;;EP;;ES;;WO;;US,8,188-426-567-253-428;;001-913-199-300-409;;181-195-743-619-346;;107-945-189-029-408;;111-877-467-032-424;;084-790-309-449-719;;061-161-125-448-563;;027-404-155-790-635,DE;;EP;;ES;;WO;;US,17,C12N2750/14143;;C12N15/86;;A61K38/18;;C12N2750/14143;;C12N15/86;;A61K38/18;;A61K48/005;;C12N7/00,C12N15/86;;A61K38/18;;A61K48/00;;C12N7/00,,4,2,103-844-440-085-437;;032-462-599-753-874,10.1002/jgm.1576;;21674736;;pmc3984922;;10.1038/mt.2011.95;;21629257;;pmc3129793,"Luchsinger (Thesis, 2011, pg 1-269);;Kupatt (J Am Clin Cardiol, 2010, Vol. 56, pg 414-422);;Prasad (J. Gene Med., 2011, Vol. 13, pg 333-341);;Forsayeth (Mol. Therapy, 2011, Vol. 19, No. 6, pg 1006-1007)",PENDING
517,US,A1,US 2021/0095257 A1,052-274-459-160-169,2021-04-01,2021,US 202016912400 A,2020-06-25,US 202016912400 A;;US 201916239452 A;;US 201715489600 A;;US 201615069730 A;;US 201313896259 A;;US 201213637334 A;;US 2011/0030598 W;;US 31949410 P;;US 39372410 P;;US 40689210 P,2010-03-31,REPROGRAMMING CELLS,"The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3′-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.",SCRIPPS RESEARCH INST,ZHU SAIYONG;;DING SHENG,THE SCRIPPS RESEARCH INSTITUTE (2012-11-29),https://lens.org/052-274-459-160-169,Patent Application,yes,1,0,36,195-585-831-970-488;;002-842-767-189-608;;058-264-688-796-792;;029-763-009-469-031;;003-001-402-893-010;;137-888-676-990-255;;143-337-269-477-40X;;064-254-452-756-821;;128-303-794-843-675;;165-495-887-558-532;;171-316-334-992-495;;060-886-924-399-958;;075-616-860-943-911;;087-535-214-921-030;;103-361-969-171-750;;052-274-459-160-169;;130-973-685-589-633;;143-029-445-700-873;;125-458-546-935-658;;178-219-657-962-258;;004-465-467-525-659;;013-011-767-203-379;;016-307-303-456-249;;062-994-998-109-555;;103-371-334-160-256;;146-714-511-428-949;;060-551-885-752-32X;;063-292-669-283-712;;193-698-160-093-645;;120-516-146-348-308;;120-387-688-224-408;;001-860-265-768-362;;125-325-654-059-764;;065-224-828-360-542;;197-441-713-500-792;;005-263-264-464-631,JP;;AU;;CN;;EP;;ES;;WO;;HK;;US;;CA,36,058-264-688-796-792;;002-842-767-189-608;;143-337-269-477-40X;;137-888-676-990-255;;003-001-402-893-010;;029-763-009-469-031;;005-263-264-464-631;;195-585-831-970-488;;128-303-794-843-675;;171-316-334-992-495;;064-254-452-756-821;;060-886-924-399-958;;075-616-860-943-911;;087-535-214-921-030;;103-361-969-171-750;;052-274-459-160-169;;130-973-685-589-633;;143-029-445-700-873;;125-458-546-935-658;;178-219-657-962-258;;004-465-467-525-659;;013-011-767-203-379;;016-307-303-456-249;;062-994-998-109-555;;103-371-334-160-256;;146-714-511-428-949;;060-551-885-752-32X;;063-292-669-283-712;;193-698-160-093-645;;125-325-654-059-764;;120-387-688-224-408;;001-860-265-768-362;;120-516-146-348-308;;065-224-828-360-542;;197-441-713-500-792;;165-495-887-558-532,JP;;AU;;EP;;ES;;CN;;WO;;HK;;US;;CA,57,C12N2501/065;;C12N2501/15;;C12N2501/41;;C12N2501/602;;C12N2501/603;;C12N2501/604;;C12N2501/606;;C12N2501/727;;C12N2506/094;;C12N2506/28;;C12N5/0696;;C12N2501/065;;C12N2501/15;;C12N2501/41;;C12N2501/602;;C12N2501/603;;C12N2501/604;;C12N2501/606;;C12N2501/727;;C12N2506/094;;C12N2506/28;;C12N5/0696;;C12N2501/73;;C12N2506/03,C12N5/074,,1,1,111-171-671-905-195,10.1038/nbt1418;;18568017;;pmc6334647,"Huangfu (Nature Biotech., 2008, Vol. 26, pg 795-797)",DISCONTINUED
518,WO,A1,WO 2025/012364 A1,075-731-410-702-022,2025-01-16,2025,EP 2024069620 W,2024-07-11,EP 23185079 A;;EP 23190789 A,2023-07-12,COMPOSITIONS OF PNEUMOCOCCAL ANTIGENS,"The present invention relates to a composition comprising a first pneumococcal antigen comprising a first pneumococcal peptide epitope or a nucleic acid encoding said first pneumococcal antigen, a second pneumococcal antigen comprising a second pneumococcal peptide epitope or a nucleic acid encoding said second pneumococcal antigen, and a third pneumococcal antigen comprising a third pneumococcal peptide epitope or a nucleic acid encoding said third pneumococcal antigen, wherein said first pneumococcal peptide epitope is derived from the non-proline block (NPB) of the Pneumococcal surface protein A (PspA), said second pneumococcal peptide epitope is derived from the proline-rich region (PR) of the Pneumococcal surface protein A (PspA), and said third pneumococcal peptide epitope is derived from the surface-exposed pneumococcal protein PhtE of the histidine triad (Pht) protein family.",VIROMETIX AG,STERGIOU LILLI;;RODRIGUEZ BALBOA JAVIER;;LAMPROKOSTOPOULOU AGARISTI;;RASSEK OLIVER;;SPOULOU VANA;;MANSOUR MARC;;DAIKOPOULOU VASILIKI,,https://lens.org/075-731-410-702-022,Patent Application,yes,22,0,1,075-731-410-702-022,WO,1,075-731-410-702-022,WO,236,A61P31/04;;A61K39/092;;A61K2039/70;;C07K14/3156;;A61K2039/55555;;A61K2039/6018;;A61K2039/55572;;A61K2039/627;;A61K2039/575;;A61K2039/572,A61K39/00;;A61K39/09;;A61P31/04;;C07K14/315,,31,24,014-394-060-473-17X;;126-512-678-364-78X;;053-197-930-260-437;;014-394-060-473-17X;;021-791-810-972-916;;124-040-165-051-133;;048-980-441-195-076;;053-197-930-260-437;;125-874-407-349-512;;045-741-950-699-742;;027-625-149-487-102;;023-402-827-208-309;;029-185-459-671-50X;;126-512-678-364-78X;;058-400-586-848-743;;059-757-516-639-346;;060-618-145-348-632;;034-666-701-599-39X;;065-384-943-147-619;;001-244-331-352-711;;006-994-456-595-973;;117-560-589-519-380;;045-626-027-908-519;;029-999-650-182-336,pmc6466302;;10.3390/vaccines7010009;;30669439;;pmc4693222;;26501327;;10.3390/vaccines3040850;;10.1128/iai.01199-09;;pmc2863538;;20194601;;pmc6466302;;10.3390/vaccines7010009;;30669439;;10.1111/j.1574-6968.2006.00360.x;;16907734;;26396191;;10.1074/jbc.m115.666818;;pmc4646002;;29263108;;pmc5820952;;10.1128/iai.00673-17;;10.1128/iai.01199-09;;pmc2863538;;20194601;;11069242;;10.1086/317602;;10992499;;10.1128/iai.68.10.5889-5900.2000;;pmc101551;;10699322;;10.1016/s0264-410x(99)00530-7;;24807052;;10.1128/cvi.00239-14;;pmc4097434;;10.1128/cvi.00430-09;;20089795;;pmc2837969;;pmc4693222;;26501327;;10.3390/vaccines3040850;;22076829;;10.1002/cbic.201100586;;28075558;;10.1021/acsnano.6b07343;;10.1016/j.vaccine.2017.04.078;;28487056;;15837514;;10.1016/s0065-3233(05)70004-8;;10.1016/j.addr.2009.07.001;;pmc7103283;;19619593;;12065487;;pmc128085;;10.1128/iai.70.7.3479-3492.2002;;7691722;;pmc1421980;;11016652;;10.1016/j.vaccine.2014.02.024;;24583006;;24824905;;10.1002/ijc.28968,"THEANO LAGOUSI ET AL: ""Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens"", VACCINES, vol. 7, no. 1, 19 January 2019 (2019-01-19), pages 9, XP055612409, DOI: 10.3390/vaccines7010009;;MARCO TAMBORRINI ET AL: ""A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A"", VACCINES, vol. 3, no. 4, 16 October 2015 (2015-10-16), pages 850 - 874, XP055570895, DOI: 10.3390/vaccines3040850;;C. C. DANIELS ET AL: ""The Proline-Rich Region of Pneumococcal Surface Proteins A and C Contains Surface-Accessible Epitopes Common to All Pneumococci and Elicits Antibody-Mediated Protection against Sepsis"", INFECTION AND IMMUNITY, vol. 78, no. 5, 1 May 2010 (2010-05-01), pages 2163 - 2172, XP055115771, ISSN: 0019-9567, DOI: 10.1128/IAI.01199-09;;T. LAGOUSI ET AL., VACCINES, vol. 7, 2019, pages 9;;C. GIEFING ET AL., J. EXP. MED., vol. 205, 2008, pages 117 - 131;;E. BEGHETTO ET AL., FEMS MICROBIOL. LETT, vol. 262, 2006, pages 14 - 21;;T. LAGOUSI ET AL., J. BIOL. CHEM., vol. 290, 2015, pages 27500 - 27510;;T. PAPASTAMATIOU ET AL., INFECTION AND IMMUNITY, vol. 86, no. 3, 2018, pages 00673 - 17;;C.C. DANIELS ET AL., INFECT. IMMUN, vol. 78, 2010, pages 2163 - 2172;;D.E. BRILES ET AL., J. INFECT. DIS, vol. 182, 2000, pages 1694 - 1701;;S.K. HOLLINGSHEAD ET AL., INFECT. IMMUN, vol. 68, 2000, pages 5889 - 5900;;NABORS ET AL., VACCINE, vol. 18, 2000, pages 1743 - 1754;;C.F.M. VADESILHO ET AL., CLIN. VACCINE IMMUNOL, vol. 21, 2014, pages 940 - 948;;A.T. MORENO ET AL., CLIN. VACCINE IMMUNOL, vol. 17, 2010, pages 439 - 446;;Q. O. KING ET AL., J. INFECT. DIS, vol. 200, 2009, pages 537 - 545;;M. TAMBORRINI ET AL., VACCINES, vol. 3, 2015, pages 850 - 874;;A. GHASPARIAN ET AL., CHEMBIOCHEM, vol. 12, 2011, pages 2829 - 109;;KT GAUSE ET AL., ACS NANO, vol. 11, no. 1, 2017, pages 54 - 68;;M BROKER ET AL., VACCINE, vol. 35, 2017, pages 3286 - 3294;;R. SHARMA ET AL., PLOS ONE, vol. 7, 2012, pages 43248;;WOOLFSON, D.N., ADV. PROT. CHEM, vol. 70, 2005, pages 79 - 112;;WEBER ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 61, no. 11, 2009, pages 965 - 976;;CARO-AGUILAR ET AL., INFECT. IMMUN, vol. 70, no. 7, 2002, pages 3479 - 3492;;MISHRA ET AL., IMMUNOLOGY, vol. 79, no. 3, 1993, pages 362 - 367;;KOBAYASHI ET AL., CANCER RESEARCH, vol. 60, no. 18, 2000, pages 5228 - 523;;FRASER ET AL., VACCINE, vol. 32, no. 24, 2014, pages 2896 - 2903;;GRABOWSKA ET AL., INT. J. CANCER, vol. 136, no. 1, 2015, pages 212 - 224;;GREG T. HERMANSON: ""Bioconjugate Techniques"", 2008, ACADEMIC PRESS;;""Pierce Catalog and Handbook"", 1997, PIERCE CHEMICAL COMPANY;;""Pierce Biotechnology"", 2013, THERMO FISHER SCIENTIFIC;;LI, B., DONG, Y: ""Methods in Molecular Biology"", vol. 1632, HUMANA PRESS, article ""RNA Nanostructures""",PENDING
519,FR,A1,FR 3155535 A1,191-410-994-230-169,2025-05-23,2025,FR 2312853 A,2023-11-22,FR 2312853 A,2023-11-22,Procédé de traitement d’huiles lubrifiantes usagées comprenant des esters,"La présente demande relève du domaine des traitements des compositions lubrifiantes et/ou de refroidissement usagées. En particulier, la présente divulgation concerne une méthode de traitement des compositions lubrifiantes et/ou de refroidissement usagées comprenant des esters, afin d’améliorer leur recyclabilité.",TOTALENERGIES ONETECH,AL FARRA AHMAD;;LIMOGE ALICE;;DALIX LAURENT,,https://lens.org/191-410-994-230-169,Patent Application,no,3,0,2,079-900-185-969-969;;191-410-994-230-169,WO;;FR,2,079-900-185-969-969;;191-410-994-230-169,WO;;FR,0,C10M175/00,C10G1/00;;C10G67/10;;C10M175/00;;C10M175/02,,1,1,061-316-367-376-498,10.1002/jctb.4137,"J. CHEM. TECHNOL. BIOTECH, vol. 88, 2013, pages 1780 - 1793",PENDING
520,WO,A1,WO 2022/018276 A1,160-750-747-471-148,2022-01-27,2022,EP 2021070718 W,2021-07-23,EP 20382667 A,2020-07-24,FLOW CYTOMETRY MULTIPLEXED METHOD FOR THE DETECTION OF SARS-CoV-2 ANTIBODIES,"The present invention relates to a first method for in vitro detection of anti-S protein antibodies against SARS-CoV2 in a subject and a second method for diagnostic of the exposure to SARS-CoV2 virus of a subject, based both in flow cytometry, which comprising stable expressing either by transfection or viral transduction of a vector comprising the S protein of SARS-CoV2 in a cell line in suspension. Further, the present invention relates to a kit for in vitro detection of anti-S protein antibodies against SARS-CoV2 and a kit for diagnostic of the exposure to SARS-CoV2, as well as its uses.",CONSEJO SUPERIOR INVESTIGACION,ALARCÓN SÁNCHEZ BALBINO;;HORNDLER GIL LYDIA;;DELGADO CAÑAVERA PILAR;;BALABANOV IVAYLO;;MARTIEN VAN SANTEN HISSE,,https://lens.org/160-750-747-471-148,Patent Application,yes,3,1,2,160-750-747-471-148;;033-883-437-736-715,EP;;WO,2,160-750-747-471-148;;033-883-437-736-715,EP;;WO,4,G01N33/56983;;G01N2333/165;;G01N2469/20,G01N33/569,,8,7,137-890-458-564-920;;012-875-844-037-055;;004-942-971-800-954;;057-509-593-896-869;;020-904-772-781-458;;012-647-812-080-126;;022-794-230-919-668,32611558;;pmc7327913;;10.1136/bmj.m2516;;10.1016/j.jim.2017.07.015;;28855105;;9628219;;10.1016/s0166-0934(97)00188-2;;32320687;;pmc7166309;;10.1016/j.jmb.2020.04.009;;10.1101/2020.02.19.956581;;pmc7102599;;10.1016/j.cell.2020.02.058;;32155444;;32404473;;10.1136/jclinpath-2020-206685;;10.1016/s1525-0016(16)36610-2,"DENNIS LAPUENTE ET AL: ""Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2"", MEDRXIV, 13 May 2020 (2020-05-13), XP055759485, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.05.09.20091447v1.full.pdf> [retrieved on 20201215], DOI: 10.1101/2020.05.09.20091447;;MAYARA LISBOA BASTOS ET AL: ""Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis"", BMJ, 1 July 2020 (2020-07-01), pages m2516, XP055759583, DOI: 10.1136/bmj.m2516;;MERAT SABRINA J ET AL: ""Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 454, 30 August 2017 (2017-08-30), pages 15 - 26, XP085350994, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2017.07.015;;DE SWART R L ET AL: ""Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay"", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 71, no. 1, 1 March 1998 (1998-03-01), pages 35 - 44, XP027296725, ISSN: 0166-0934, [retrieved on 19980301];;JAVIER A. JAIMES ET AL: ""Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop"", JOURNAL OF MOLECULAR BIOLOGY, vol. 432, no. 10, 1 May 2020 (2020-05-01), United Kingdom, pages 3309 - 3325, XP055759670, ISSN: 0022-2836, DOI: 10.1016/j.jmb.2020.04.009;;WALLS, A. C. ET AL., CELL, vol. 181, 2020, pages 281 - 292.e6;;VENTER, M.RICHTER, K., J. CLIN. PATHOL., vol. 73, 2020, pages 370 - 377;;WANG, X. ET AL.: ""A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells"", BLOOD, vol. 118, 2011, pages 1255 - 1263, XP055062819, DOI: 10.1182/blood-2011-02-337360",PENDING
521,EP,A1,EP 3750561 A1,015-857-766-691-886,2020-12-16,2020,EP 19751328 A,2019-01-08,KR 20180015751 A;;KR 2019000246 W,2018-02-08,SKIN-PERMEATING CARRIER CONTAINING NUCLEIC ACID COMPLEX AND USE THEREOF,"The present invention relates to a skin-penetrating carrier containing a nucleic acid complex having a novel structure, which is capable of introducing a bioactive nucleic acid into cells, and a composition for diagnosing, preventing or treating disease comprising the same, and more particularly to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability, and a composition for diagnosing, preventing or treating disease comprising the same.According to the invention, the skin-penetrating carrier containing the nucleic acid complex having the structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. In particular, the carrier according to the invention enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, and thus enables external treatment by application to the skin surface.",SEASUN THERAPEUTICS,KIM HYE JOO;;YU JI-YEON;;LEE DONG IN;;KANG YUSUN;;PARK HEE KYUNG,"SEASUN THERAPEUTICS, INC. (2024-03-13)",https://lens.org/015-857-766-691-886,Patent Application,yes,0,0,15,091-423-651-288-286;;083-991-064-957-962;;054-828-359-819-848;;132-347-244-657-498;;049-449-261-798-056;;131-975-993-694-799;;041-564-817-428-361;;196-605-749-119-127;;038-031-718-661-301;;145-518-772-093-919;;197-707-408-740-162;;112-391-286-472-662;;109-841-192-095-162;;015-857-766-691-886;;160-710-636-157-037,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,15,091-423-651-288-286;;083-991-064-957-962;;054-828-359-819-848;;132-347-244-657-498;;049-449-261-798-056;;131-975-993-694-799;;041-564-817-428-361;;196-605-749-119-127;;038-031-718-661-301;;145-518-772-093-919;;197-707-408-740-162;;112-391-286-472-662;;109-841-192-095-162;;015-857-766-691-886;;160-710-636-157-037,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,49,A61K47/64;;A61K47/549;;A61K45/06;;A61K31/7052;;A61K31/7088;;A61K31/713;;A61K9/0014;;A61P17/00;;A61P35/00;;A61P27/02;;A61P9/10;;A61P9/00;;A61P3/10;;A61P3/00;;A61P17/06;;A61P17/02;;C12Q1/6886;;C12Q1/6883;;A61K45/06;;A61K47/6455;;A61K47/549;;C12N15/87;;C12N15/111;;C12N2310/3519;;C12N2310/3181;;C12N2320/32;;A61K47/549;;A61K9/0014;;A61K48/0041;;A61K45/06;;A61K47/6455;;A61K47/549;;A61P17/06;;A61P17/00;;A61P17/02;;A61P35/04;;A61K9/0014;;A61K48/00;;C12N15/113;;C12N15/1138;;C12N2310/11;;C12N2310/14;;C12N2310/3513;;C12N2310/3519,A61K47/54;;A61K9/00;;A61K45/06;;A61K48/00,,0,0,,,,PENDING
522,WO,A1,WO 2025/147560 A1,185-369-304-188-321,2025-07-10,2025,US 2025/0010159 W,2025-01-03,CN 2024070788 W,2024-01-05,METHODS AND COMPOSITIONS FOR MODIFYING FLOWERING TIME GENES IN PLANTS,"Methods and compositions are provided for modifying the flowering time and/or maturity time of soybean plants to enable them to be cultivated in a variety of geographical locations having different day lengths. Modified soybean plants are disclosed comprising non-natural mutant alleles at the FT2a, FT2b, FT5a, and/or ELF3 locus. The modified plants have a shorter flowering and/or maturity time than control plants.",SYNGENTA CROP PROTECTION AG;;INST OF CROP SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES;;SYNGENTA CROP PROTECTION LLC,CHEN LI;;GAO YANG;;HOU WENSHENG;;CAI YUPENG;;YUAN SHAN;;SU QIANG;;SUN SHI;;HAN TIANFU,,https://lens.org/185-369-304-188-321,Patent Application,yes,3,0,2,185-369-304-188-321;;157-796-206-485-358,WO,2,185-369-304-188-321;;157-796-206-485-358,WO,47,C07K14/415;;C12N9/22;;C12N2310/20;;C12N15/102;;C12N15/827,C12N15/82;;A01H5/00;;A01H6/54;;C07K14/415;;C12N9/22;;C12N15/63,,0,0,,,,PENDING
523,US,A1,US 2022/0056496 A1,112-634-671-122-291,2022-02-24,2022,US 202117520811 A,2021-11-08,CN 202010342426 A;;CN 2020102671 W,2020-04-27,Preparation of Thermophilic beta-Glucosidase and Application Thereof,"The disclosure discloses the preparation of thermophilic β-glucosidase and the application thereof, which belongs to the technical field of genetic engineering and fermentation engineering. The present disclosure heterologously expresses the β-glucosidase TpBgl3A derived from thermophilic fungus Talaromyces piceae by constructing a recombinant bacteria. The enzyme production of recombinant bacteria can reach 2324 U/mL in a 3.6 L fermenter. The resulting β-glucosidase TpBgl3A can produce gentioligosaccharides with a high conversion rate using glucose as a substrate at a lower enzyme amount added, which significantly reduces production costs. In the reaction system using glucose and cellobiose as substrates, the conversion rate of gentioligosaccharide reaches 26.2%, which has the potential for industrial production of gentioligosaccharide.",UNIV JIANGNAN,WU JING;;XIA WEI;;XU XINGHAO;;HUANG YAN,JIANGNAN UNIVERSITY (2021-10-26),https://lens.org/112-634-671-122-291,Patent Application,yes,0,0,5,068-969-639-490-490;;189-655-571-571-205;;115-195-170-114-944;;144-352-798-955-106;;112-634-671-122-291,CN;;WO;;US,5,068-969-639-490-490;;189-655-571-571-205;;115-195-170-114-944;;144-352-798-955-106;;112-634-671-122-291,CN;;WO;;US,3,C12N9/2445;;C12Y302/01021;;C12N15/815;;C12P19/14;;C12P19/12;;C12P19/00;;C12N9/2445;;C12P19/14;;C12Y302/01021;;C12R2001/84;;C12P19/12;;C12P19/00;;C12N9/2445;;C12P19/14;;C12Y302/01021,C12P19/14;;C12N9/42,,1,0,,,"He et al. 3 Biotech., 2017, 7, 368, 1-4 (Year: 2017)",ACTIVE
524,EP,A1,EP 3797767 A1,143-353-334-259-653,2021-03-31,2021,EP 20206600 A,2010-10-29,EP 09306048 A;;EP 19216647 A;;EP 10773302 A;;EP 2010066510 W,2009-11-03,LEVOSIMENDAN FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS,"The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder.",PHARNEXT,COHEN DANIEL;;CHUMAKOV ILYA;;NABIROCHKIN SERGUEI,,https://lens.org/143-353-334-259-653,Patent Application,yes,0,0,25,124-160-442-657-616;;131-672-242-423-228;;046-116-048-938-086;;041-408-023-684-510;;153-211-909-073-358;;048-352-657-230-582;;077-034-459-757-154;;086-639-015-486-048;;058-609-648-372-638;;036-572-593-281-442;;159-529-644-875-360;;154-576-584-234-093;;162-686-204-408-643;;037-872-751-610-821;;130-542-700-008-733;;135-379-971-065-62X;;143-353-334-259-653;;072-913-649-276-609;;104-455-269-743-74X;;126-508-439-982-108;;031-518-669-657-030;;150-737-030-552-785;;049-571-206-508-553;;150-769-016-940-999;;075-371-408-083-094,JP;;AR;;ES;;EP;;CN;;EA;;IL;;WO;;US;;CA;;MX;;BR,27,124-160-442-657-616;;131-672-242-423-228;;046-116-048-938-086;;197-016-243-711-95X;;041-408-023-684-510;;153-211-909-073-358;;048-352-657-230-582;;077-034-459-757-154;;086-639-015-486-048;;058-609-648-372-638;;036-572-593-281-442;;023-380-318-812-140;;159-529-644-875-360;;154-576-584-234-093;;162-686-204-408-643;;037-872-751-610-821;;130-542-700-008-733;;135-379-971-065-62X;;143-353-334-259-653;;072-913-649-276-609;;104-455-269-743-74X;;126-508-439-982-108;;031-518-669-657-030;;150-737-030-552-785;;049-571-206-508-553;;150-769-016-940-999;;075-371-408-083-094,JP;;AR;;ES;;EP;;CN;;EA;;IL;;WO;;US;;CA;;MX;;BR,0,A61K45/06;;A61K31/137;;A61K31/155;;A61K31/167;;A61K31/185;;A61K31/195;;A61K31/197;;A61K31/343;;A61K31/423;;A61K31/4985;;A61K31/50;;A61K31/635;;A61K31/155;;A61K31/167;;A61K31/185;;A61K31/195;;A61K31/197;;A61K31/343;;A61K31/423;;A61K31/4985;;A61K45/06;;A61P9/00;;A61P25/28;;A61P43/00;;A61K31/137;;A61K31/155;;A61K31/167;;A61K31/185;;A61K31/195;;A61K31/343;;A61K31/423;;A61K31/4985;;A61K45/06;;A61K2300/00,A61K31/197;;A61P25/28,,51,49,086-327-778-602-26X;;047-068-260-438-399;;047-802-035-479-753;;001-060-867-130-424;;053-602-673-604-943;;073-145-062-332-859;;003-852-258-590-095;;113-645-826-017-120;;013-405-535-958-475;;033-031-652-911-416;;116-118-289-397-563;;064-433-923-907-707;;006-427-751-434-434;;019-147-450-716-329;;020-798-450-711-581;;091-408-670-399-082;;079-004-710-947-368;;025-529-582-760-090;;059-819-690-573-857;;014-170-828-316-487;;008-709-934-709-179;;008-894-368-308-932;;083-267-715-794-38X;;072-441-042-618-120;;061-192-008-228-926;;000-273-703-989-550;;014-577-000-388-610;;007-873-826-790-166;;036-963-683-469-594;;011-883-176-340-457;;086-199-377-232-794;;086-662-552-681-848;;066-476-142-553-910;;004-362-147-901-73X;;042-929-255-556-534;;007-045-872-033-664;;074-013-814-481-745;;054-463-930-276-08X;;110-578-068-399-652;;024-196-984-783-43X;;036-126-478-657-299;;035-424-626-160-452;;013-369-899-259-645;;091-905-902-572-049;;036-412-890-677-379;;007-745-815-035-302;;039-602-406-890-634;;035-784-299-694-682;;017-177-562-222-811,10.1186/1471-2377-10-97;;20964834;;pmc2978146;;10.1136/jnnp-2018-320288;;pmc6817985;;31315908;;11079548;;10.1002/1531-8249(200011)48:5<806::aid-ana18>3.0.co;2-f;;10.1002/1531-8249(200011)48:5<806::aid-ana18>3.3.co;2-6;;10.1038/nm0498-452;;9546792;;10.1097/00001756-199704140-00043;;9172170;;10.1093/jnen/60.5.483;;11379823;;15322526;;10.1038/nrn1495;;12223532;;10.1124/pr.54.3.469;;10.1001/archneur.1994.00540240042014;;7986174;;9117552;;10.1006/neur.1996.0052;;6242724;;17684513;;10.1038/nrn2194;;16887118;;10.1016/j.ejphar.2006.06.045;;10.1126/science.1566067;;1566067;;1759558;;10.1007/bf00308809;;10.1111/j.1750-3639.2005.tb00104.x;;15779241;;pmc8095797;;12130773;;10.1126/science.1072994;;10.1016/s0733-8619(05)70232-2;;11072267;;10839362;;10.1016/s0896-6273(00)81176-9;;10.1016/s0896-6273(00)80637-6;;9856475;;pmc2141700;;9348295;;10.1083/jcb.139.3.797;;10.1073/pnas.0704179104;;pmc1891225;;17548836;;17712357;;10.1038/nrm2249;;pmc1828119;;10.1016/j.bbrc.2007.01.110;;17276402;;14557259;;pmc4374490;;10.1074/jbc.m310389200;;15210937;;10.1073/pnas.0403382101;;pmc478568;;10.1089/152581699319795;;10645770;;10.1089/ars.2006.8.1391;;16986999;;10.4067/s0716-97602004000400027;;15709699;;10.1016/s0960-9822(03)00446-9;;12842030;;15126504;;10.1074/jbc.m401399200;;10.1074/jbc.275.13.9792;;10734133;;12514174;;10.1074/jbc.m208373200;;10.1038/ncb714;;11780126;;14507915;;10.1074/jbc.m308302200;;17334389;;10.1038/sj.onc.1210347;;12840034;;10.1074/jbc.c300239200;;pmc6786088;;10087060;;10.1523/jneurosci.19-07-02455.1999;;10.1016/j.neuron.2005.06.030;;pmc1373682;;16039562;;17904642;;10.1016/j.jneumeth.2007.08.008;;11773429;;10.1101/lm.43701;;9302276;;10.1093/hmg/6.11.1951;;8810256;;10.1126/science.274.5284.99;;10.1161/01.str.28.7.1418;;9227694;;16877359;;pmc1698785;;10.2353/ajpath.2006.060002;;10.1111/j.1600-079x.2004.00121.x;;15066046;;15673661;;10.1523/jneurosci.4335-04.2005;;pmc6725614;;17003227;;10.1124/jpet.106.112102;;10.1016/j.molbrainres.2005.02.011;;15893605,"ROEHL ANNA B ET AL: ""Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury"", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 10, no. 1, 21 October 2010 (2010-10-21), pages 97, XP021074880, ISSN: 1471-2377, DOI: 10.1186/1471-2377-10-97;;AMMAR AL-CHALABI ET AL: ""Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled tria"", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., vol. 90, no. 10, 17 July 2019 (2019-07-17), GB, pages 1165 - 1170, XP055770885, ISSN: 0022-3050, DOI: 10.1136/jnnp-2018-320288;;HOULDEN H.BAKER M. ET AL.: ""Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations"", ANN NEUROL, vol. 48, no. 5, 2000, pages 806 - 8;;""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER;;ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY;;CROOK R.VERKKONIEMI A. ET AL.: ""A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1"", NAT MED, vol. 4, no. 4, 1998, pages 452 - 5;;KWOK J.B.TADDEI K. ET AL.: ""Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype"", NEUROREPORT, vol. 8, no. 6, 1997, pages 1537 - 42, XP009034735, DOI: 10.1097/00001756-199704140-00043;;VERKKONIEMI A.KALIMO H. ET AL.: ""Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype"", JNEUROPATHOL EXP NEUROL, vol. 60, no. 5, 2001, pages 483 - 92;;CITRON M.: ""Strategies for disease modification in Alzheimer's disease"", NAT REV NEUROSCI, vol. 5, no. 9, 2004, pages 677 - 85, XP009065997, DOI: 10.1038/nrn1495;;SUH Y.H.CHECLER F.: ""Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease"", PHARMACOL REV, vol. 54, no. 3, 2002, pages 469 - 525, XP002476151, DOI: 10.1124/pr.54.3.469;;BLACKER D.ALBERT M.S. ET AL.: ""Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative"", ARCH NEUROL, vol. 51, no. 12, 1994, pages 1198 - 204;;ROSSOR M.N.FOX N.C. ET AL.: ""Clinical features of sporadic and familial Alzheimer's disease."", NEURODEGENERATION, vol. 5, no. 4, 1996, pages 393 - 7;;GLENNER G.G.WONG C.W. ET AL.: ""The amyloid deposits in Alzheimer's disease: their nature and pathogenesis"", APPL PATHOL, vol. 2, no. 6, 1984, pages 357 - 69;;BALLATORE C.LEE V.M. ET AL.: ""Tau-mediated neurodegeneration in Alzheimer's disease and related disorders"", NAT REV NEUROSCI, vol. 8, no. 9, 2007, pages 663 - 72, XP009179485, DOI: 10.1038/nrn2194;;BELL K.F.CLAUDIO CUELLO A: ""Altered synaptic function in Alzheimer's disease"", EUR JPHARMACOL, vol. 545, no. 1, 2006, pages 11 - 21, XP028029225, DOI: 10.1016/j.ejphar.2006.06.045;;HARDY J.A.HIGGINS G.A.: ""Alzheimer's disease: the amyloid cascade hypothesis"", SCIENCE, vol. 256, no. 5054, 1992, pages 184 - 5;;BRAAK H.BRAAK E.: ""Neuropathological stageing of Alzheimer-related changes"", ACTA NEUROPATHOL, vol. 82, no. 4, 1991, pages 239 - 59;;GOLDE T.E.: ""The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease"", BRAIN PATHOL, vol. 15, no. 1, 2005, pages 84 - 7;;HARDY J.SELKOE D.J.: ""The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics"", SCIENCE, vol. 297, no. 5580, 2002, pages 353 - 6, XP055310378, DOI: 10.1126/science.1072994;;SELKOE D.J.: ""The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins"", NEUROL CLIN, vol. 18, no. 4, 2000, pages 903 - 22;;HUANG Y.Z.WON S. ET AL.: ""Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses"", NEURON, vol. 26, no. 2, 2000, pages 443 - 55;;NARUSE S.THINAKARAN G. ET AL.: ""Effects of PS1 deficiency on membrane protein trafficking in neurons"", NEURON, vol. 21, no. 5, 1998, pages 1213 - 21, XP085044074, DOI: 10.1016/S0896-6273(00)80637-6;;LEEUWEN F.N.KAIN H.E. ET AL.: ""The guanine nucleotide exchange factor Tiaml affects neuronal morphology; opposing roles for the small GTPases Rac and Rho"", J CELL BIOL, vol. 139, no. 3, 1997, pages 797 - 807, XP002141547, DOI: 10.1083/jcb.139.3.797;;GE G.FERNANDEZ C.A. ET AL.: ""Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor"", PROC NATL ACAD SCI USA., vol. 104, no. 24, 2007, pages 10010 - 5;;HARDIE D.G.: ""AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy"", NAT REV MOL CELL BIOL, vol. 8, no. 10, 2007, pages 774 - 85, XP055208647, DOI: 10.1038/nrm2249;;REIHILL J.A.EWART M.A. ET AL.: ""AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production"", BIOCHEM BIOPHYS RES COMMUN, vol. 354, no. 4, 2007, pages 1084 - 8;;OUCHI N.KOBAYASHI H. ET AL.: ""Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells"", JBIOL CHEM, vol. 279, no. 2, 2004, pages 1304 - 9, XP002993957, DOI: 10.1074/jbc.M310389200;;HUG C.WANG J. ET AL.: ""T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin"", PROC NATL ACAD SCI U S A, vol. 101, no. 28, 2004, pages 10308 - 13;;ENGLISH D.KOVALA A.T. ET AL.: ""Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis"", JHEMATOTHER STEM CELL RES, vol. 8, no. 6, 1999, pages 627 - 34, XP008018336, DOI: 10.1089/152581699319795;;GORLACH A.KLAPPA P. ET AL.: ""The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control"", ANTIOXIDREDOX SIGNAL, vol. 8, no. 9-10, 2006, pages 1391 - 418;;VERKHRATSKY A: ""Endoplasmic reticulum calcium signaling in nerve cells"", BIOL RES, vol. 37, no. 4, 2004, pages 693 - 9;;COOKSON M.R.: ""Neurodegeneration: how does parkin prevent Parkinson's disease"", CURR BIOL, vol. 13, no. 13, 2003, pages R522 - 4;;SZE C.I.SU M. ET AL.: ""Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease"", JBIOL CHEM, vol. 279, no. 29, 2004, pages 30498 - 506;;WALCHLI S.CURCHOD M.L. ET AL.: ""Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on ''substrate-trapping'' mutants"", JBIOL CHEM, vol. 275, no. 13, 2000, pages 9792 - 6;;CHANG N.S.DOHERTY J. ET AL.: ""JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis"", J BIOL CHEM., vol. 278, no. 11, 2003, pages 9195 - 202;;D'ORAZI G.CECCHINELLI B. ET AL.: ""Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis"", NAT CELL BIOL, vol. 4, no. 1, 2002, pages 11 - 9, XP001099171, DOI: 10.1038/ncb714;;ZHU H.WU L. ET AL.: ""MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53"", JBIOL CHEM, vol. 278, no. 49, 2003, pages 49286 - 92;;RODRIGUES S.DE WEVER O. ET AL.: ""Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis"", ONCOGENE, vol. 26, no. 38, 2007, pages 5615 - 25, XP002537858, DOI: 10.1038/SJ.ONC.1210347;;TANIGUCHI Y.KIM S.H. ET AL.: ""Presenilin-dependent ''gamma-secretase'' processing of deleted in colorectal cancer (DCC"", JBIOL CHEM, vol. 278, no. 33, 2003, pages 30425 - 8, XP002324234, DOI: 10.1074/jbc.C300239200;;SINGER C.FIGUEROA-MASOT X.BATCHELOR R.DORSA D: ""Mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons"", J. NEUROSCIENCE, vol. 19, no. 7, 1999, pages 2455 - 2463;;MCGOWAN E.: ""A042 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice"", NEURON, vol. 47, 2005, pages 191 - 199, XP055010338, DOI: 10.1016/j.neuron.2005.06.030;;LEIGHTY R.E. ET AL.: ""Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice"", JOURNAL OF NEUROSCIENCE METHODS, vol. 167, 2008, pages 358 - 366, XP022386797;;ASHE KH: ""Learning and memory in transgenic mice modelling Alzheimer's disease"", LEARNING AND MEMORY, vol. 8, 2001, pages 301 - 308;;CARLSON GA ET AL.: ""Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice"", HUMAN MOLECULAR GENETICS, vol. 6, 1997, pages 1951 - 1959;;HSIAO K ET AL.: ""Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice"", SCIENCE, vol. 274, 1996, pages 99 - 102;;GREENBERG S.M.VONSATTEL J.P.: ""Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy"", STROKE, vol. 28, no. 7, 1997, pages 1418 - 22;;SCHINDOWSKI K. ET AL.: ""Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits"", AM J PATHOL, vol. 169, 2006, pages 599 - 616;;LAHIRI DK ET AL.: ""Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex"", JOURNAL OF PINEAL RESEARCH, vol. 36, 2004, pages 224 - 231;;BASHA MR ET AL.: ""The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain"", JOURNAL OF NEUROSCIENCE, vol. 25, 2005, pages 823 - 829;;LAHIRI D.K. ET AL.: ""Experimental Alzheimer's Disease Drug Posiphen[(Phenserine] Lowers Amyloid-betaPeptide Levels in Cell Culture and Mice"", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 320, 2007, pages 386 - 396;;PARIS D ET AL.: ""Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells"", BRAIN RES MOL BRAIN RES, vol. 136, 2005, pages 212 - 30",DISCONTINUED
525,US,A1,US 2023/0127135 A1,091-843-952-601-599,2023-04-27,2023,US 202217818389 A,2022-08-09,CN 202010888117 A;;CN 2021114793 W,2020-08-28,CONSTRUCTION OF RECOMBINANT SACCHAROMYCES CEREVISIAE FOR SYNTHESIZING CARMINIC ACID AND APPLICATION THEREOF,"The disclosure discloses construction of recombinant Saccharomyces cerevisiae for synthesizing carminic acid and application thereof and belongs to the technical field of genetic engineering and bioengineering. The disclosure obtains recombinant S. cerevisiae CA-B2 capable of synthesizing carminic acid by heterologously expressing cyclase Zhul, aromatase ZhuJ, OKS of Octaketide synthase 1, C-glucosyltransferase UGT2, monooxygenase aptC and 4′-phosphopantetheinyl transferase npgA in S. cerevisiae. The recombinant S. cerevisiae can be used for synthesizing carminic acid by taking self-synthesized acetyl-CoA and malonyl-CoA as a precursor. On this basis, OKS, cyclase, aromatase, C-glucosyltransferase and monooxygenase relevant to carminic acid are integrated to a high copy site, which can remarkably improve the yield of carminic acid. The yield of carminic acid can be increased to 2664.6 µg/L by optimizing fermentation conditions, and the fermentation time is shortened significantly. Therefore, the recombinant S. cerevisiae plays an important role in the fields of cosmetics, textiles and food.",UNIV JIANGNAN,ZHOU JINGWEN;;ZHANG QIAN;;GAO SONG;;CHEN JIAN;;ZENG WEIZHU;;DU GUOCHENG,JIANGNAN UNIVERSITY (2022-08-01),https://lens.org/091-843-952-601-599,Patent Application,yes,0,1,5,060-355-081-912-828;;079-824-480-329-567;;125-660-678-313-403;;114-651-161-577-525;;091-843-952-601-599,CN;;WO;;US,5,060-355-081-912-828;;125-660-678-313-403;;079-824-480-329-567;;114-651-161-577-525;;091-843-952-601-599,CN;;WO;;US,0,C12N15/81;;C12N9/0004;;C12N9/1029;;C12N9/1051;;C12N9/12;;C12N15/905;;C12P17/06;;C12N9/12;;C07K14/395;;C12N1/18;;C12N9/0071;;C12N9/1029;;C12N9/1085;;C12N9/93;;C12N15/81;;C12P7/66;;C12P19/18;;C12R2001/66;;C12R2001/865;;C12Y114/14;;C12Y114/14001;;C12Y203/01;;C12Y204/01;;C12Y207/08007;;C12N1/185;;C12N9/12;;C12N15/815;;C12Y207/00,C12N1/18;;C12N9/12;;C12N15/81,,0,0,,,,ACTIVE
526,EP,A1,EP 3835403 A1,044-420-206-355-518,2021-06-16,2021,EP 19215115 A,2019-12-11,EP 19215115 A,2019-12-11,AUTOMATED MEDIUM EXCHANGE STRATEGY FOR SUSPENSION CELLS,"The present invention relates to a method of changing culture medium of a suspension culture, the suspension culture comprising cells suspended in the culture medium, the method comprising: (i) transferring a fraction of the suspension culture into a container, wherein the container comprises at least one opening at the bottom; (ii) allowing the cells comprised in the fraction of the suspension to settle at the at least one opening at the bottom of the container by gravitation, thereby forming a supernatant; (iii) dispensing the cells settled at the bottom of the container (back) into the suspension culture; (iv) discarding the supernatant.",SARTORIUS STEDIM BIOTECH GMBH;;REPAIRON GMBH,HAUPT LUIS;;HUPFELD JULIA,SARTORIUS STEDIM BIOTECH GMBH (2025-01-22);;REPAIRON GMBH (2025-01-22),https://lens.org/044-420-206-355-518,Patent Application,yes,5,0,9,076-975-535-551-27X;;017-325-812-491-945;;175-407-302-254-34X;;044-420-206-355-518;;199-765-781-503-198;;187-414-599-108-650;;024-332-599-424-477;;104-758-043-062-405;;078-652-960-432-980,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,9,017-325-812-491-945;;076-975-535-551-27X;;175-407-302-254-34X;;044-420-206-355-518;;199-765-781-503-198;;024-332-599-424-477;;187-414-599-108-650;;104-758-043-062-405;;078-652-960-432-980,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,0,C12M29/18;;C12M33/22;;C12M47/02;;C12M29/18;;C12M33/22;;C12M47/02;;C12N5/0696;;C12M33/22;;C12M27/02;;C12M29/18;;C12M47/02,C12M1/00;;C12M1/26,,10,10,095-386-043-355-68X;;032-330-914-541-050;;002-343-538-662-178;;062-078-761-000-697;;098-009-520-600-314;;036-984-300-939-839;;012-911-618-463-633;;019-767-724-381-245;;002-034-380-841-504;;056-854-995-903-751,10.1126/science.282.5391.1145;;9804556;;10.1016/j.cell.2006.07.024;;16904174;;10.1038/nmeth.1591;;21460823;;24411336;;10.1016/j.biomaterials.2013.12.050;;pmc3193421;;21243013;;10.1038/cr.2011.12;;10.1016/j.stemcr.2015.08.015;;pmc4624993;;26411904;;10.1007/s12015-010-9149-y;;20431964;;28382727;;10.1002/term.2435;;29679475;;pmc6055717;;10.1002/bit.26719;;pmc3460618;;22519745;;10.1089/ten.tec.2011.0717,"THOMSON ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147;;TAKAHASHIYAMANAKA, CELL, vol. 126, 2006, pages 663 - 676;;OKITA ET AL.: ""A more efficient method to generate integration-free human iPS cells"", NATURE METHODS, vol. 8, no. 5, May 2011 (2011-05-01), pages 409 - 411, XP055176852, DOI: 10.1038/nmeth.1591;;LU ET AL.: ""A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells"", BIOMATERIALS, vol. 35, 2014, pages 2816e2826;;CHOU ET AL., CELL RESEARCH, vol. 21, 2011, pages 518 - 529;;BAGHBADERANI ET AL., STEM CELL REPORTS, vol. 5, no. 4, 2015, pages 647 - 659;;AMIT, MICHALCHEBATH, JUDITHMARGULETS, VICTORIALAEVSKY, ILANAMIROPOLSKY, YAELSHARIKI, KOHAVA ET AL.: ""Suspension culture of undifferentiated human embryonic and induced pluripotent stem cells"", STEM CELL REVIEWS, vol. 6, no. 2, 2010, pages 248 - 259, XP055015267, DOI: 10.1007/s12015-010-9149-y;;KWOK, CHEE KEONGUEDA, YUICHIROKADARI, ASIFIQBALGUNTHER, KATHARINAERGUN, SULEYMANHERON, ANTOINE ET AL.: ""Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single-use bioreactors"", JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, vol. 12, no. 2, 2018, pages e1076 - e1087;;LIPSITZ, YONATAN Y.TONGE, PETER D.ZANDSTRA, PETER W.: ""Chemically controlled aggregation of pluripotent stem cells"", BIOTECHNOLOGY AND BIOENGINEERING, vol. 115, no. 8, 2018, pages 2061 - 2066;;OLMER, RUTHLANGE, ANDREASSELZER, SEBASTIANKASPER, CORNELIAHAVERICH, AXELMARTIN, ULRICHZWEIGERDT, ROBERT: ""Suspension Culture of Human Pluripotent Stem Cells in Controlled, Stirred Bioreactors"", TISSUE ENGINEERING. PART C, METHODS, vol. 18, no. 10, 2012, pages 772 - 784, XP055637355, DOI: 10.1089/ten.tec.2011.0717",PENDING
527,US,A1,US 2023/0383270 A1,056-681-994-889-561,2023-11-30,2023,US 202118031313 A,2021-10-12,US 202118031313 A;;US 202163183545 P;;US 202063091880 P;;US 202063090685 P;;US 2021/0054636 W,2020-10-12,CRISPR/CAS-BASED BASE EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION,Disclosed herein are CRISPR/Cas-based base editing compositions and methods for treating Duchenne Muscular Dystrophy by restoring dystrophin function.,UNIV DUKE,GERSBACH CHARLES A;;GOUGH VERONICA,DUKE UNIVERSITY (2023-05-08),https://lens.org/056-681-994-889-561,Patent Application,yes,0,5,5,091-496-605-974-493;;056-681-994-889-561;;153-044-543-580-72X;;169-469-854-576-490;;161-526-499-551-025,JP;;EP;;WO;;US,5,091-496-605-974-493;;056-681-994-889-561;;153-044-543-580-72X;;169-469-854-576-490;;161-526-499-551-025,JP;;EP;;WO;;US,74,C12N9/22;;C12N9/96;;C12N9/78;;C12N2310/20;;C12N15/113;;A61K48/005;;C12N2320/33;;A61P21/00;;C07K14/4708;;C07K2319/85;;C12N2310/20;;A61P21/00;;C12N9/22;;C12N9/78;;C12N2320/33;;C12Y305/04001,C12N9/22;;A61P21/00;;C12N9/78,,0,0,,,,PENDING
528,WO,A1,WO 2025/109048 A1,079-900-185-969-969,2025-05-30,2025,EP 2024083074 W,2024-11-21,FR 2312853 A,2023-11-22,METHOD FOR TREATING WASTE LUBRICATING OILS COMPRISING ESTERS,"The present application relates to the field of treatments for waste lubricating and/or cooling compositions. In particular, the present disclosure relates to a method for treating waste lubricating and/or cooling compositions comprising esters, in order to improve their recyclability.",TOTALENERGIES ONETECH,AL FARRA AHMAD;;LIMOGES ALICE;;DALIX LAURENT,,https://lens.org/079-900-185-969-969,Patent Application,yes,3,0,2,079-900-185-969-969;;191-410-994-230-169,WO;;FR,2,079-900-185-969-969;;191-410-994-230-169,WO;;FR,0,C10M175/00,C10M175/00;;C07C67/03,,1,1,061-316-367-376-498,10.1002/jctb.4137,"J. CHEM. TECHNOL. BIOTECH, vol. 88, 2013, pages 1780 - 1793",PENDING
529,US,A1,US 2025/0282842 A1,136-966-965-314-864,2025-09-11,2025,US 202519072126 A,2025-03-06,US 202519072126 A;;US 202463562482 P,2024-03-07,DECOY-RESISTANT INTERLEUKIN 18 ARMORED CELLS AND RELATED METHODS,"Provided are nucleic acids that encode decoy-resistant interleukin 18 (DR-18) polypeptides, as well as vectors and cells comprising such nucleic acids and cells that comprise such vectors. Cells encoding DR-18 polypeptides may be referred to as DR-18 armored cells. The nucleic acids may further encode a chimeric antigen receptor (CAR) or multiple CARs, including CARs that bind to antigens described herein. Methods are also provided, including methods of making the nucleic acids, vectors, and/or cells, as well as methods of use, such as employing the nucleic acids, vectors, and/or cells, in the treatment of a subject having cancer.",SIMCHA IL 18 INC,UPPAL HIRDESH;;LINDQUIST JEFFREY N,SIMCHA THERAPEUTICS INC (2025-05-14);;SIMCHA IL-18 INC (2025-06-13),https://lens.org/136-966-965-314-864,Patent Application,yes,0,0,1,136-966-965-314-864,US,1,136-966-965-314-864,US,0,C07K14/54;;C07K16/2863;;A61K40/11;;A61K40/31;;A61K40/35;;C12N2510/00;;A61K40/4234;;A61P35/00;;C12N5/0636;;C07K2319/02;;A61K40/4204,C07K14/54;;A61K40/11;;A61K40/31;;A61K40/35;;A61K40/42;;A61P35/00;;C07K16/28;;C12N5/0783,,0,0,,,,PENDING
530,WO,A1,WO 2025/145425 A1,157-796-206-485-358,2025-07-10,2025,CN 2024070788 W,2024-01-05,CN 2024070788 W,2024-01-05,METHODS AND COMPOSITIONS FOR MODIFYING FLOWERING TIME GENES IN PLANTS,"Methods and compositions are provided for modifying the flowering time and/or maturity time of soybean plants to enable them to be cultivated in a variety of geographical locations having different day lengths. Modified soybean plants are disclosed comprising non-natural mutant alleles at the FT2a, FT2b, FT5a, and/or ELF3 locus. The modified plants have a shorter flowering and/or maturity time than control plants.",SYNGENTA CROP PROTECTION AG;;SYNGENTA GROUP CO LTD;;INST OF CROP SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES,CHEN LI;;GAO YANG;;HOU WENSHENG;;CAI YUPENG;;YUAN SHAN;;SU QIANG;;SUN SHI;;HAN TIANFU,,https://lens.org/157-796-206-485-358,Patent Application,yes,0,0,2,185-369-304-188-321;;157-796-206-485-358,WO,2,185-369-304-188-321;;157-796-206-485-358,WO,47,C07K14/415;;C12N9/22;;C12N2310/20;;C12N15/102;;C12N15/827,C12N15/82;;A01H1/02;;A01H1/04;;A01H5/00;;A01H6/54,,0,0,,,,PENDING
531,US,A1,US 2021/0228645 A1,016-493-328-520-018,2021-07-29,2021,US 202117227497 A,2021-04-12,US 202117227497 A;;JP 2011258209 A;;JP 2011258210 A;;JP 2011258211 A;;JP 2011258212 A;;JP 2012043080 A;;JP 2012043081 A;;JP 2012043082 A;;JP 2012043083 A;;US 201414360534 A;;JP 2012080366 W,2011-11-25,METHODS FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELL,"The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serumcontaining medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.",SUMITOMO CHEMICAL CO;;RIKEN,NAKANO TOKUSHIGE;;ANDO SATOSHI;;SASAI YOSHIKI;;EIRAKU MOTOTSUGU,,https://lens.org/016-493-328-520-018,Patent Application,yes,3,0,18,173-436-538-032-719;;125-758-500-343-133;;086-548-126-166-465;;047-507-099-991-308;;060-033-471-349-522;;084-550-706-588-779;;034-701-828-837-034;;033-689-591-889-999;;114-277-273-466-662;;148-088-580-836-038;;035-280-399-078-597;;195-135-684-400-996;;114-353-692-275-061;;184-686-936-857-880;;119-286-166-913-697;;016-493-328-520-018;;146-543-849-123-68X;;057-696-228-106-087,AU;;KR;;EP;;ES;;CN;;WO;;US;;CA;;IN,26,034-701-828-837-034;;057-696-228-106-087;;148-088-580-836-038;;195-135-684-400-996;;063-699-163-559-026;;114-353-692-275-061;;119-286-166-913-697;;016-493-328-520-018;;188-552-757-237-987;;032-535-165-324-882;;173-436-538-032-719;;125-758-500-343-133;;086-548-126-166-465;;060-033-471-349-522;;047-507-099-991-308;;084-550-706-588-779;;033-689-591-889-999;;114-277-273-466-662;;194-739-322-439-624;;035-280-399-078-597;;049-542-239-775-188;;184-686-936-857-880;;163-922-561-372-616;;017-084-799-992-459;;190-930-977-746-246;;146-543-849-123-68X,KR;;JP;;AU;;ES;;CN;;EP;;WO;;US;;CA;;IN,0,A61L27/3633;;A61L27/3834;;A61L27/3895;;C12N5/0621;;A61L2430/16;;C12N2501/16;;C12N2501/415;;C12N2506/02;;C12N2501/42;;C12N2533/90;;C12N2500/90;;A61K35/30;;C12N5/0621;;C12N2501/415;;C12N2506/02;;C12N2501/42;;A61L27/3834;;C12N2533/90;;A61L27/3895;;A61L2430/16;;A61L27/3633;;C12N2501/16;;C12N2500/90;;A61K35/30;;C12N5/062;;C12N2500/84;;G01N33/5058,A61K35/30;;A61L27/36;;A61L27/38;;C12N5/079;;C12N5/0793;;G01N33/50,,6,4,058-213-116-464-522;;103-292-570-135-874;;003-730-777-448-386;;026-546-990-460-733,11069920;;10.1074/jbc.m008882200;;pmc3412675;;21678528;;10.1002/stem.674;;pmc4480425;;10.1095/biolreprod.110.090704;;21734264;;10.1167/iovs.10-6504;;21345990;;pmc3175935,"Mikkola et al. ""Superactivation of Pax6-mediated transactivation from paired domain-binding sites by dna-independent recruitment of different homeodomain proteins.""J Biol Chem.2001 Feb 9;276(6):4109-18. (Year: 2001);;Meyer et al. ""Optic vesicle-like structures derived from human pluripotent stem cells facilitate a customized approach to retinal disease treatment.""Stem Cells. 2011 Aug;29(8):1206-18. (Year: 2011);;De Gendt et al. ""Expression of Tubb3, a Beta-Tubulin Isotype, Is Regulated by Androgens in Mouse and Rat Sertoli Cells.""Biology of Reproduction, Volume 85, Issue 5, 1 November 2011, Pages 934–945, (Year: 2011);;Roberts et al. ""Retinoid X Receptor γ Is Necessary to Establish the S-opsin Gradient in Cone Photoreceptors of the Developing Mouse Retina."" Investigative Ophthalmology & Visual Science August 2005, Vol.46, 2897-2904. (Year: 2005);;Lamba et al. ""Microarray Characterization of Human Embryonic Stem Cell–Derived Retinal Cultures."" Investigative Ophthalmology & Visual Science June 2011, Vol.52, 4897-4906. (Year: 2011);;""Merriam-Webster. ""Orderly Definition and Meaning."" https://www.merriam-webster.com/dictionary/orderly. Webstite acessed 1/14/2025. (Year: 2025)",PENDING
532,EP,A1,EP 3750995 A1,136-857-622-711-099,2020-12-16,2020,EP 19751530 A,2019-01-08,KR 2019000245 W;;KR 20180015750 A,2018-02-08,"PEPTIDE NUCLEIC ACID COMPLEX HAVING ENDOSOMAL ESCAPE CAPACITY, AND USE THEREOF","The present invention relates to a nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease comprising the same, and a method of regulating target gene expression using the same, and more particularly to a nucleic acid complex in which a bioactive nucleic acid, which comprises a material for facilitating endosomal escape, and a carrier peptide nucleic acid, are complementarily bound to each other, a composition for treating or diagnosing disease comprising the same, a composition for regulating target gene expression using the same, and a method of regulating target gene expression using the same.A nucleic acid complex of Structural Formula (1) according to the present invention, which comprises a bioactive nucleic acid and a carrier peptide nucleic acid, may increase the stability of the bioactive nucleic acid, reduce loss of the bioactive nucleic acid, such as precipitation caused by self-aggregation, increase the intracellular delivery efficiency of the bioactive nucleic acid, and easily regulate target gene expression.",SEASUN THERAPEUTICS,KIM HYE JOO;;YU JI-YEON;;LEE DONG IN;;KANG YUSUN;;PARK HEE KYUNG,"SEASUN THERAPEUTICS, INC. (2024-03-13)",https://lens.org/136-857-622-711-099,Patent Application,yes,0,0,15,083-552-660-116-508;;187-145-423-721-782;;114-072-474-924-739;;025-416-710-852-424;;032-315-616-338-884;;019-502-597-859-408;;186-541-230-347-235;;094-190-987-096-805;;108-442-656-941-132;;004-073-704-247-531;;099-969-534-752-305;;136-857-622-711-099;;030-407-195-972-486;;013-828-810-469-567;;161-610-599-155-195,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,15,083-552-660-116-508;;187-145-423-721-782;;114-072-474-924-739;;025-416-710-852-424;;032-315-616-338-884;;019-502-597-859-408;;186-541-230-347-235;;094-190-987-096-805;;108-442-656-941-132;;004-073-704-247-531;;099-969-534-752-305;;136-857-622-711-099;;030-407-195-972-486;;013-828-810-469-567;;161-610-599-155-195,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,86,C12N15/113;;C12N15/1136;;A61P35/00;;A61P29/00;;A61P27/02;;A61P9/10;;A61P3/10;;A61P11/00;;A61P9/00;;A61P17/00;;A61P3/00;;A61P17/02;;A61P17/06;;C12Q1/6886;;C12Q1/6883;;C12N2310/3181;;C12Q2600/158;;C12Q2600/178;;C12N2320/32;;C12N2310/53;;C12N2310/3513;;C12N2310/3181;;C12N15/111;;C12N2310/331;;C12N15/113;;C12N15/1138;;C12N15/1137;;C12Y301/04017;;C12N15/1136;;A61P35/00;;C07K14/003;;A61K47/6455;;C12N15/111;;C07K14/003;;C12Q1/6883;;A61K47/549;;C12N2310/31;;C12N2310/3181;;C12Q2525/107;;C12Q2525/113;;C12Q2600/158;;A61K47/64;;A61P35/00;;C12N15/1136;;C12N2310/3513;;C12N15/113;;C12N2310/3181;;C07K14/003;;A61P17/06;;C12Q2525/107,C12N15/11;;A61K47/54;;C07K14/00;;C12Q1/6883,,0,0,,,,ACTIVE
533,EP,A1,EP 4471141 A1,137-200-816-956-422,2024-12-04,2024,EP 21969695 A,2021-12-31,CN 2021143658 W,2021-12-31,"NUCLEIC ACID MOLECULE CAPABLE OF BLOCKING MOTOR PROTEIN, AND CONSTRUCTION METHOD AND APPLICATION THEREOF","The present invention relates to a nucleic acid molecule capable of blocking motor protein, a library containing the nucleic acid molecule, a method for constructing the nucleic acid molecule or library containing the same, and an application of the nucleic acid molecule or library containing same. The nucleic acid molecule contains at the end a modified nucleotide capable of blocking a motor protein, and the modified nucleotide is as shown in Formula I or Formula I':",BGI SHENZHEN,WANG OU;;SHI XIAO;;XU XUN;;ZHANG WENWEI;;GUO FEI;;BAO SIYU;;DONG YULIANG;;ZENG TAO,"BGI SHENZHEN (2025-04-16);;BGI SHENZHEN CO., LTD (2025-04-16)",https://lens.org/137-200-816-956-422,Patent Application,yes,0,0,4,188-764-080-870-311;;175-842-095-955-659;;137-200-816-956-422;;130-839-940-377-500,CN;;EP;;WO;;US,4,188-764-080-870-311;;175-842-095-955-659;;137-200-816-956-422;;130-839-940-377-500,CN;;EP;;WO;;US,0,C12Q1/6806;;C12N15/113;;C12Q1/6869;;C12N15/11;;C12N15/1093;;C12Q1/6869,C12N15/113;;C12Q1/6806;;C12Q1/6869;;C40B40/06,,0,0,,,,PENDING
534,KR,A,KR 20200124827 A,022-196-683-138-16X,2020-11-04,2020,KR 20190048135 A,2019-04-25,KR 20190048135 A,2019-04-25,ALZHEIMER'S DISEASE CLASSIFICATION BASED ON MULTI-FEATURE FUSION,"Disclosed is a method for classifying Alzheimer′s disease based on multi-feature fusion, which combines morphological and texture features as diagnostic biomarkers of magnetic resonance imaging and using machine learning techniques so as to classify Alzheimer′s disease, mild cognitive impairment, and normal people. This classification method comprises: an MR image acquisition step of acquiring a scanned magnetic resonance (MR) image; an image processing step of performing noise removal, non-homogeneous correction, contrast normalization, and patch-based hippocampal region segmentation for the MR image; a feature extraction step of extracting volume factor-based morphological features and extracting texture features using a gray-level co-occurrence matrix (GLCM) and a gabor filter for the hippocampus image segmented in the image processing step; a feature selection step of selecting and classifying a certain number of feature sets from feature vectors of morphological and texture features extracted from the feature extraction step; and a result analysis step of calculating a difference among Alzheimer′s disease, mild cognitive impairment, and normal group by using machine learning and measuring accuracy of classification.",UNIV INJE IND ACAD COOP FOUND,CHOI HEUNG KOOK;;MADUSANKA NUWAN;;SO JAE HONG,,https://lens.org/022-196-683-138-16X,Patent Application,no,4,8,2,022-196-683-138-16X;;093-874-176-070-549,KR,2,022-196-683-138-16X;;093-874-176-070-549,KR,0,G16H20/70;;A61B5/0037;;A61B5/0042;;A61B5/4088,G16H20/70;;A61B5/00,,1,0,,,"Hong Xia et al., Int. Conf. Biomedical Eng. Biotech.(2012) 1부.*",ACTIVE
535,US,A1,US 2021/0177984 A1,041-564-817-428-361,2021-06-17,2021,US 201916968378 A,2019-01-08,KR 20180015751 A;;KR 2019000246 W,2018-02-08,Skin-Permeating Carrier Containing Nucleic Acid Complex and Use Thereof,"A skin-penetrating carrier containing a nucleic acid complex having a novel structure which introduces a bioactive nucleic acid into cells. Composition for diagnosing, preventing or treating disease and to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability. Skin-penetrating carrier containing nucleic acid complex having structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. Carrier enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, thus enables external treatment by application to the skin surface.",SEASUN THERAPEUTICS INC,KIM HYE JOO;;YU JI-YEON;;LEE DONG IN;;KANG YUSUN;;PARK HEE KYUNG,SEASUN THERAPEUTICS INC (2020-08-18),https://lens.org/041-564-817-428-361,Patent Application,yes,5,0,15,091-423-651-288-286;;083-991-064-957-962;;054-828-359-819-848;;132-347-244-657-498;;049-449-261-798-056;;131-975-993-694-799;;041-564-817-428-361;;196-605-749-119-127;;038-031-718-661-301;;145-518-772-093-919;;197-707-408-740-162;;112-391-286-472-662;;109-841-192-095-162;;015-857-766-691-886;;160-710-636-157-037,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,15,091-423-651-288-286;;083-991-064-957-962;;054-828-359-819-848;;132-347-244-657-498;;049-449-261-798-056;;131-975-993-694-799;;041-564-817-428-361;;196-605-749-119-127;;038-031-718-661-301;;145-518-772-093-919;;197-707-408-740-162;;112-391-286-472-662;;109-841-192-095-162;;015-857-766-691-886;;160-710-636-157-037,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,49,A61K47/64;;A61K47/549;;A61K45/06;;A61K31/7052;;A61K31/7088;;A61K31/713;;A61K9/0014;;A61P17/00;;A61P35/00;;A61P27/02;;A61P9/10;;A61P9/00;;A61P3/10;;A61P3/00;;A61P17/06;;A61P17/02;;C12Q1/6886;;C12Q1/6883;;A61K45/06;;A61K47/6455;;A61K47/549;;C12N15/87;;C12N15/111;;C12N2310/3519;;C12N2310/3181;;C12N2320/32;;A61K47/549;;A61K9/0014;;A61K48/0041;;A61K45/06;;A61K47/6455;;A61K47/549;;A61P17/06;;A61P17/00;;A61P17/02;;A61P35/04;;A61K9/0014;;A61K48/00;;C12N15/113;;C12N15/1138;;C12N2310/11;;C12N2310/14;;C12N2310/3513;;C12N2310/3519,A61K47/64;;A61K9/00;;A61K47/54;;A61P17/00;;A61P17/02;;A61P17/06;;A61P35/04;;C12N15/113,,3,1,018-472-101-649-941,17408236;;10.1208/aapsj0901003;;pmc2751301,Martin et al. (AAPS Journal 2007; 9 (1) Article 3). Peptide-guided Gene Delivery (Year: 2007);;English language translation of the JP2008220366A publication obtained by Esapcenet (Year: 2008);;English language translation of the CN105463002A publication obtained by Google patent (Year: 2016),ACTIVE
536,US,A1,US 2021/0253690 A1,026-220-205-555-80X,2021-08-19,2021,US 202117175129 A,2021-02-12,US 202117175129 A;;US 202062976582 P,2020-02-14,Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody,"Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.",JANSSEN BIOTECH INC,JOHANNS JEWEL;;LI KATHERINE;;MARANO COLLEEN;;STRAUSS RICHARD;;ZHANG HONGYAN;;O'BRIEN CHRISTOPHER;;ADEDOKUN OMONIYI;;SHIELDS-TUTTLE KIMBERLY,,https://lens.org/026-220-205-555-80X,Patent Application,yes,1,2,15,026-220-205-555-80X;;171-248-884-654-157;;145-884-094-313-918;;177-574-177-812-314;;068-354-489-970-518;;128-964-639-228-54X;;115-420-606-944-26X;;163-529-567-638-429;;005-580-283-767-979;;021-746-032-216-432;;113-354-302-344-921;;132-876-715-846-708;;126-140-307-301-371;;003-279-405-687-198;;191-393-313-887-412,JP;;AU;;KR;;EP;;CN;;IL;;WO;;US;;CA;;BR;;MX,15,026-220-205-555-80X;;171-248-884-654-157;;145-884-094-313-918;;177-574-177-812-314;;068-354-489-970-518;;128-964-639-228-54X;;115-420-606-944-26X;;163-529-567-638-429;;005-580-283-767-979;;021-746-032-216-432;;113-354-302-344-921;;132-876-715-846-708;;126-140-307-301-371;;003-279-405-687-198;;191-393-313-887-412,JP;;AU;;KR;;EP;;CN;;IL;;WO;;US;;CA;;BR;;MX,11,A61P1/04;;C07K16/244;;A61K2039/505;;A61K2039/545;;A61K2039/55;;C07K2317/56;;A61K9/0019;;A61P1/04;;C07K2317/56;;C07K2317/565;;A61K2039/505;;A61K2039/545;;C07K16/244;;A61K2039/55;;C07K16/244;;A61P1/04;;C07K2317/56;;A61K47/22;;A61K47/26;;A61K47/20;;A61K47/183;;A61K9/0019;;A61K2039/505;;A61K2039/545;;C07K16/244;;A61P1/04;;A61K2039/545;;C07K2317/565;;A61K2039/505,C07K16/24;;A61P1/04,,1,0,,,"Janssen Biotech, Inc., “HIGHLIGHTS OF PRESCRIBING INFORMATION” of STELARA® (ustekinumab) injection (10/2019)",DISCONTINUED
537,US,A1,US 2023/0193275 A1,186-541-230-347-235,2023-06-22,2023,US 202218048851 A,2022-10-23,US 202218048851 A;;KR 20180015750 A;;US 202016968334 A;;KR 2019000245 W,2018-02-08,"PEPTIDE NUCLEIC ACID COMPLEX HAVING ENDOSOMAL ESCAPE CAPACITY, AND USE THEREOF","A nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease including the same, and a method of regulating target gene expression using the same, are described. The nucleic acid complex may include a bioactive nucleic acid, which includes a material for facilitating endosomal escape, and a carrier peptide nucleic acid, complementarily bound to each other, as useful in a composition for treating or diagnosing disease, or a composition for regulating target gene expression. Such nucleic acid complex may increase the stability of the bioactive nucleic acid, reduce loss of the bioactive nucleic acid, such as precipitation caused by self-aggregation, increase the intracellular delivery efficiency of the bioactive nucleic acid, and easily regulate target gene expression.",SEASUN THERAPEUTICS INC,KIM HYE JOO;;YU JI-YEON;;LEE DONG IN;;KANG YUSUN;;PARK HEE KYUNG,,https://lens.org/186-541-230-347-235,Patent Application,yes,0,0,15,083-552-660-116-508;;187-145-423-721-782;;114-072-474-924-739;;025-416-710-852-424;;032-315-616-338-884;;019-502-597-859-408;;186-541-230-347-235;;094-190-987-096-805;;108-442-656-941-132;;004-073-704-247-531;;099-969-534-752-305;;136-857-622-711-099;;030-407-195-972-486;;013-828-810-469-567;;161-610-599-155-195,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,15,083-552-660-116-508;;187-145-423-721-782;;114-072-474-924-739;;025-416-710-852-424;;032-315-616-338-884;;019-502-597-859-408;;186-541-230-347-235;;094-190-987-096-805;;108-442-656-941-132;;004-073-704-247-531;;099-969-534-752-305;;136-857-622-711-099;;030-407-195-972-486;;013-828-810-469-567;;161-610-599-155-195,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,0,C12N15/113;;C12N15/1136;;A61P35/00;;A61P29/00;;A61P27/02;;A61P9/10;;A61P3/10;;A61P11/00;;A61P9/00;;A61P17/00;;A61P3/00;;A61P17/02;;A61P17/06;;C12Q1/6886;;C12Q1/6883;;C12N2310/3181;;C12Q2600/158;;C12Q2600/178;;C12N2320/32;;C12N2310/53;;C12N2310/3513;;C12N2310/3181;;C12N15/111;;C12N2310/331;;C12N15/113;;C12N15/1138;;C12N15/1137;;C12Y301/04017;;C12N15/1136;;A61P35/00;;C07K14/003;;A61K47/6455;;C12N15/111;;C07K14/003;;C12Q1/6883;;A61K47/549;;C12N2310/31;;C12N2310/3181;;C12Q2525/107;;C12Q2525/113;;C12Q2600/158;;A61K47/64;;A61P35/00;;C12N15/1136;;C12N2310/3513;;C12N15/113;;C12N2310/3181;;C07K14/003;;A61P17/06;;C12Q2525/107,C12N15/113;;A61K47/64;;A61P17/06;;A61P35/00;;C07K14/00,,0,0,,,,DISCONTINUED
538,US,A1,US 2024/0252606 A1,004-393-125-687-287,2024-08-01,2024,US 201917059665 A,2019-03-26,CN 201810551372 A;;CN 2019079708 W,2018-05-31,"Phosphorylated Polypeptide Antigen Vaccine, Preparation Method Therefor and Application Thereof","The present invention discloses a phosphorylated polypeptide antigen vaccine, comprising at least two polypeptide fragments or conservatively modified variants thereof from human full-length Tau protein, wherein the polypeptide fragments or conservatively modified variants thereof contain phosphorylation sites. The present invention also discloses a complex vaccine formed by coupling a phosphorylated polypeptide antigen vaccine with a carrier. The polypeptide antigen vaccine and the complex vaccine can be used for preventing and/or treating tauopathy comprising Alzheimer's disease (AD).",CHANGCHUN BCHT BIOTECHNOLOGY CO;;UNIV JILIN,KONG WEI;;WU HUI;;SUN YAO;;GUO YONGQING,JILIN UNIVERSITY (2020-11-20);;CHANGCHUN BCHT BIOTECHNOLOGY CO (2020-11-20),https://lens.org/004-393-125-687-287,Patent Application,yes,0,0,7,052-333-404-700-516;;074-175-379-901-216;;076-958-022-943-898;;004-393-125-687-287;;085-994-502-021-053;;008-523-294-571-46X;;174-240-616-434-345,EP;;CN;;WO;;US,7,052-333-404-700-516;;074-175-379-901-216;;076-958-022-943-898;;004-393-125-687-287;;085-994-502-021-053;;008-523-294-571-46X;;174-240-616-434-345,EP;;CN;;WO;;US,1366,A61K39/0005;;A61K39/385;;A61P25/28;;A61K2039/6068;;A61K2039/627;;A61P25/28;;C07K14/4711;;A61K39/0007;;A61K2039/6075;;A61K2039/6006;;A61K2039/62;;C07K16/18;;C07K16/44;;C07K2317/34;;Y02A50/30;;A61P25/28;;A61P37/04;;A61K39/0007;;A61K2039/55561;;A61K2039/55566;;A61K2039/6031;;A61K2039/6037;;A61K2039/6068;;A61K2039/6075;;A61K2039/6081;;A61K2039/627,A61K39/00;;A61P25/28;;A61P37/04,,1,0,,,NONE CITED.,ACTIVE
539,US,A1,US 2021/0147887 A1,052-642-453-999-55X,2021-05-20,2021,US 202017117788 A,2020-12-10,CN 202010176582 A,2020-03-13,METHOD FOR PRODUCING LYSINE BY UTILIZING ADSORPTION AND IMMOBILIZED FERMENTATION OF RECOMBINANT CORYNEBACTERIUM GLUTAMICUM,"The invention discloses a method for producing lysine by utilizing adsorption and immobilized fermentation of a recombinant Corynebacterium glutamicum, wherein the recombinant Corynebacterium glutamicum is constructed by simultaneously overexpressing an adenosine triphosphate ATPase while knocking out an extracellular nuclease ExeR in a Corynebacterium glutamicum. The recombinant Corynebacterium glutamicum can effectively improve eDNA secretion of the Corynebacterium glutamicum and reduce eDNA degradation of the Corynebacterium glutamicum, so that the Corynebacterium glutamicum can be more easily adsorbed on a surface of a solid carrier for immobilized fermentation, such that a yield of continuous immobilized fermentation of the Corynebacterium glutamicum is increased by 49.67% than that of free fermentation of an original bacterium, and a fermentation cycle is shortened by 29.17%.",NANJING UNIVERSITY OF TECHNOLOGY,YING HANJIE;;LIU DONG;;CHEN YONG;;OUYANG PINGKAI;;LIU QINGGUO;;NIU HUANQING;;YU BIN;;PENG XIWEI;;LEI MING;;CAO XINGYUAN,NANJING TECH UNIVERSITY (2020-12-02),https://lens.org/052-642-453-999-55X,Patent Application,yes,0,1,9,159-848-672-611-600;;111-263-511-089-262;;052-642-453-999-55X;;128-562-005-867-401;;137-830-451-616-674;;076-138-314-094-572;;021-871-086-839-857;;188-602-086-449-534;;192-198-607-222-507,JP;;CN;;US;;GB,9,159-848-672-611-600;;111-263-511-089-262;;076-138-314-094-572;;137-830-451-616-674;;052-642-453-999-55X;;128-562-005-867-401;;021-871-086-839-857;;188-602-086-449-534;;192-198-607-222-507,JP;;CN;;US;;GB,27,C12N9/22;;C12N9/14;;C12N11/08;;C12N11/12;;C12N11/14;;C12P13/08;;C12Y306/01003;;C12N15/77;;C12N2310/20;;C12N9/22;;C12Y306/01003;;C12N9/14;;C12N11/14;;C12P13/08;;C12N1/20;;C12N11/08;;C12N11/084;;C12N11/096;;C12N11/12;;C12N11/14;;C12N15/01;;C12N15/09;;C12P13/08;;C12N11/084;;C12N11/096;;C12N9/14;;C12N9/22;;C12N11/12;;C12N11/14;;C12P13/08;;C12Y306/01003,C12P13/08;;C12N9/14;;C12N9/22;;C12N11/12,,0,0,,,,ACTIVE
540,US,A1,US 2022/0136024 A1,075-688-806-601-809,2022-05-05,2022,US 202117522523 A,2021-11-09,US 202117522523 A;;US 202016842401 A;;US 201715555026 A;;US 2016/0020729 W;;US 201562127778 P,2015-03-03,"PROTECTING GROUP CHEMISTRY FOR CLEAN, REDUCTANT-FREE DYEING","The present disclosure relates to the biosynthesis of indigoid dye precursors and their conversion to indigoid dyes. Specifically, the present disclosure relates to methods of using polypeptides to produce indigoid dye precursors from indole feed compounds, and the use of the indigoid dye precursors to produce indigoid dyes.",UNIV CALIFORNIA,DUEBER JOHN EUGENE;;RUSS ZACHARY NICHOLAS;;HSU TAMMY MELODY;;JOHNSON JR TERRY DON;;CERVANTES BERNARDO;;PRATHURI RAMYA LAKSHMI;;BHAKTA SHYAM PRAVIN;;FONG III ARTHUR MUIR;;LATIMER LUKE NATHANIEL,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2017-09-09),https://lens.org/075-688-806-601-809,Patent Application,yes,0,0,8,070-826-140-564-036;;104-466-308-832-336;;112-810-858-320-271;;009-747-539-634-860;;075-688-806-601-809;;174-398-268-106-491;;166-011-368-173-756;;185-557-926-608-296,EP;;WO;;US,8,070-826-140-564-036;;009-747-539-634-860;;112-810-858-320-271;;104-466-308-832-336;;075-688-806-601-809;;174-398-268-106-491;;166-011-368-173-756;;185-557-926-608-296,EP;;WO;;US,30,C12N9/0071;;C12N9/0073;;C12N9/1051;;C12N9/13;;C12Y114/13008;;C12Y114/14001;;C12P17/165;;C12Y208/02001;;C12P19/60;;C12N9/14;;C12Y204/01115;;C12N9/0073;;C12N9/1051;;C12N9/13;;C12Y114/13008;;C12P17/165;;C12Y208/02001;;C12Y114/14001;;C12N9/0071;;C12P19/60;;C09B7/02;;C09B7/04;;C12N9/14;;C12Y204/01115,C12P19/60;;C09B7/02;;C09B7/04;;C12N9/02;;C12N9/10;;C12N9/14;;C12P17/16,,1,1,023-582-040-828-644,10.1007/s12010-009-8638-4;;19440664,"Pathak et al.( Appl biochem., biotech. 2010, 160, pp 1616-1626.",ACTIVE
541,US,A1,US 2023/0212670 A1,035-048-349-854-790,2023-07-06,2023,US 202217851843 A,2022-06-28,CN 202210007779 A,2022-01-06,RAPID VIRAL NUCLEIC ACID DETECTION KIT PREPARED BY USING NOVEL RECA ENZYME AND DETECTION METHOD THEREOF,"The present invention provides a rapid viral nucleic acid detection kit prepared by using a novel RecA enzyme and the detection method thereof. By editing the recombinase RecA gene, the expressed RecA protein has better solubility and recombinase activity. The RecA protein is used to prepare recombinase dry powder, further the formula of the recombinase dry powder and the ratio are optimized; and specific primers for the ASFV p72 gene are designed for the rapid nucleic acid detection of ASFV, significantly improving the detection sensitivity. In addition, the detection time is short, which effectively avoids missed detection and false detection, and helps prevention of epidemic.",ZHEJIANG SHANCE HEQISHI BIO SCI & TECH CO LTD,CHENG QI;;WANG JINHUI;;HU DONGJIE;;CHEN JUN;;DENG ZIXIN,ZHEJIANG SHANCE HEQISHI BIO-SCI & TECH. CO. LTD (2022-02-27),https://lens.org/035-048-349-854-790,Patent Application,yes,0,0,2,164-365-700-316-815;;035-048-349-854-790,CN;;US,2,164-365-700-316-815;;035-048-349-854-790,CN;;US,13,C12N9/22;;C12Q1/6844;;C12Q1/701;;C12Q2600/166;;C12Q1/6876;;C12N9/48;;C12Q1/6844;;C12Q1/70;;C12Q1/701;;Y02A50/30;;C12Q1/6876;;C12N9/48;;C12Q1/6844;;C12Q2600/16,C12Q1/6876;;C12N9/48;;C12Q1/6844,,0,0,,,,PENDING
542,US,A1,US 2021/0213034 A1,098-092-191-548-251,2021-07-15,2021,US 201917058924 A,2019-05-24,EP 18174223 A;;EP 2019063548 W,2018-05-25,"SYNERGESTIC COMBINATION COMPOSITION COMPRISING A STEROIDAL SAPONIN, A FIRST POLYPHENOLIC COMPOUND AND A SECOND POLYPHENOLIC COMPOUND","A combination composition including as active components, in synergistically effective amounts of (i) a steroidal saponin of natural or synthetic origin, a pharmaceutical acceptable salt thereof or a plant extract containing steroidal saponin, and (ii) at least a first polyphenolic compound selected from the group of hydroxycinnamic acids, flavonoids, hydroxybenzoic acids, and (iii) optionally, a second polyphenolic compound, wherein the second polyphenolic compound is hydroxycinnamic acids and its use in preventing, inhibiting, retarding or treating a subject suffering from a neurodegenerative disease or condition.",NEURALIA,CALLIZOT NOËLLE,NEURALIA (2020-11-24),https://lens.org/098-092-191-548-251,Patent Application,yes,3,2,12,128-274-774-552-870;;153-253-760-723-468;;173-312-387-167-856;;139-640-829-591-153;;116-191-602-399-786;;021-925-835-787-144;;153-377-135-952-69X;;065-426-263-902-345;;056-739-714-378-847;;175-503-510-308-277;;089-016-816-066-359;;098-092-191-548-251,JP;;ES;;EP;;WO;;US;;CA;;PT,12,128-274-774-552-870;;153-253-760-723-468;;173-312-387-167-856;;139-640-829-591-153;;153-377-135-952-69X;;021-925-835-787-144;;116-191-602-399-786;;065-426-263-902-345;;056-739-714-378-847;;089-016-816-066-359;;175-503-510-308-277;;098-092-191-548-251,JP;;EP;;ES;;WO;;US;;CA;;PT,0,A61K31/192;;A61K31/194;;A61K31/216;;A61K31/58;;A61P25/16;;A61P25/28;;A23L33/105;;A61P25/28;;A61K31/192;;A61K31/58;;A61K36/48;;A61K36/894;;A61K36/8965;;A61K36/90;;A61K2236/33,A61K31/58;;A23L33/105;;A61K31/192;;A61K36/48;;A61K36/894;;A61K36/8965;;A61K36/90;;A61P25/28,,1,1,024-202-527-656-839,pmc4931034;;10.5625/lar.2016.32.2.105;;27382379,"Koh, Lab Anim Res 2016: 32(2), 105-115. (Year: 2016)",ACTIVE
543,US,A1,US 2021/0285948 A1,138-043-113-060-056,2021-09-16,2021,US 202017129091 A,2020-12-21,US 202017129091 A;;US 201715510223 A;;US 2015/0049528 W;;US 201462048537 P,2014-09-10,PEPTIDE MICROARRAYS AND NOVEL BIOMARKERS FOR CELIAC DISEASE,"The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.",VIBRANT HOLDINGS LLC,RAJASEKARAN JOHN J;;JAYARAMAN VASANTH;;BEI KANG;;WANG TIANHAO;;KRISHNA KARTHIK;;KRISHNAMURTHY HARI KRISHNAN,VIBRANT HOLDINGS LLC (2017-04-27),https://lens.org/138-043-113-060-056,Patent Application,yes,0,0,19,180-314-485-185-030;;018-276-715-607-692;;035-246-810-322-969;;140-525-154-065-703;;043-977-385-437-376;;007-325-762-380-450;;138-043-113-060-056;;164-415-458-416-465;;015-591-223-827-411;;167-519-411-585-718;;196-989-518-065-307;;101-661-995-920-809;;016-762-205-185-056;;112-292-139-420-236;;160-970-693-502-272;;079-624-488-057-053;;156-911-443-766-633;;096-335-133-466-304;;125-509-351-589-393,AU;;JP;;EP;;WO;;US;;NZ;;CA,19,180-314-485-185-030;;018-276-715-607-692;;035-246-810-322-969;;140-525-154-065-703;;043-977-385-437-376;;007-325-762-380-450;;138-043-113-060-056;;164-415-458-416-465;;015-591-223-827-411;;167-519-411-585-718;;196-989-518-065-307;;101-661-995-920-809;;016-762-205-185-056;;112-292-139-420-236;;160-970-693-502-272;;079-624-488-057-053;;156-911-443-766-633;;096-335-133-466-304;;125-509-351-589-393,AU;;JP;;EP;;WO;;US;;NZ;;CA,129,A61K39/00;;C40B40/10;;G01N33/6854;;G01N33/6878;;G01N2800/02;;C07K7/08;;G01N33/564;;A61K38/10;;G01N33/6878;;C07K7/08;;C40B40/10;;A61K39/00;;G01N33/6854;;G01N2800/02;;G01N33/564;;A61K38/10;;G01N2800/24,G01N33/564;;A61K38/10;;A61K39/00;;C07K7/08;;C40B40/10;;G01N33/68,,1,1,026-745-539-509-442,10.1038/7018;;10096295,"Reineke et al. (Nat. Biotech., 1999, 17:271-275) (Year: 1999)",PENDING
544,US,A1,US 2024/0309416 A1,010-243-752-767-925,2024-09-19,2024,US 202218576640 A,2022-10-12,CN 202111450746 A;;CN 2022124823 W,2021-11-30,A GENETICALLY ENGINEERED BACTERIUM AND ITS APPLICATION IN THE PREPARATION OF SIALYLLACTOSE,"The invention discloses a genetically engineered bacterium and its application in the preparation of sialyllactose. The genetically engineered bacterium has an N-acetylneuraminic acid biosynthesis pathway, includes multiple copies of a gene neuB for encoding sialic acid synthase, and the gene neuB is initiated for expression by a strong promoter. Using the genetically engineered bacteria of the invention to produce sialyllactose has the advantages of high yield and low overall cost.",SYNAURA BIOTECHNOLOGY SHANGHAI CO LTD,WU YAN;;TANG JING;;WANG SHU;;TIAN ZHENHUA;;YAO FEI;;LI MIAO;;XU HONG;;HUANG CHENXI;;LIU YUROU,SYNAURA BIOTECHNOLOGY (SHANGHAI) CO. LTD (2024-06-24),https://lens.org/010-243-752-767-925,Patent Application,yes,0,0,5,133-429-540-772-146;;006-049-165-365-16X;;188-492-264-366-578;;160-833-593-403-241;;010-243-752-767-925,EP;;CN;;WO;;US,5,133-429-540-772-146;;006-049-165-365-16X;;188-492-264-366-578;;160-833-593-403-241;;010-243-752-767-925,EP;;CN;;WO;;US,0,C12N15/52;;C12N9/88;;C12N9/1205;;C12N9/2471;;C12N9/90;;C12N9/1029;;C12N9/1096;;C12N9/1241;;C12N9/1081;;C12N15/70;;C12P19/26;;C12Y302/01023;;C12Y401/03;;C12Y207/0106;;C12Y501/03008;;C12Y203/01004;;C12Y206/01016;;C12Y207/07043;;C12Y204/99001;;C12Y204/99004;;C12N2830/003;;C12N1/20;;C12N9/1085;;C12N15/52;;C12P19/26;;A23L33/125;;A23L29/30;;C12Y205/01056;;C12Y501/03008;;C12Y203/01004;;C12Y206/01016;;C12Y207/09002;;Y02A50/30;;C12N1/205;;C12R2001/19;;C12N9/1029;;C12N9/1081;;C12N9/1085;;C12N9/1096;;C12N9/1241;;C12N9/1294;;C12N9/16;;C12N9/90;;C12N15/70;;C12P19/18;;C12P19/26;;C12Y203/01004;;C12Y204/99001;;C12Y204/99004;;C12Y205/01056;;C12Y206/01016;;C12Y207/07043;;C12Y207/09002;;C12Y301/03;;C12Y501/03014,C12P19/26;;C12N1/20;;C12N9/10;;C12N9/12;;C12N9/16;;C12N9/90;;C12N15/70;;C12P19/18;;C12R1/19,,0,0,,,,PENDING
545,EP,A1,EP 3804748 A1,076-958-022-943-898,2021-04-14,2021,EP 19812111 A,2019-03-26,CN 201810551372 A;;CN 2019079708 W,2018-05-31,"PHOSPHORYLATED POLYPEPTIDE ANTIGEN VACCINE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF","The present invention discloses a phosphorylated polypeptide antigen vaccine, comprising at least two polypeptide fragments or conservatively modified variants thereof from human full-length Tau protein, wherein the polypeptide fragments or conservatively modified variants thereof contain phosphorylation sites. The present invention also discloses a complex vaccine formed by coupling a phosphorylated polypeptide antigen vaccine with a carrier. The polypeptide antigen vaccine and the complex vaccine can be used for preventing and/or treating tauopathy comprising Alzheimer's disease (AD).",CHANGCHUN BCHT BIOTECHNOLOGY CO;;UNIV JILIN,KONG WEI;;WU HUI;;SUN YAO;;GUO YONGQING,,https://lens.org/076-958-022-943-898,Patent Application,yes,0,0,7,052-333-404-700-516;;074-175-379-901-216;;076-958-022-943-898;;004-393-125-687-287;;085-994-502-021-053;;008-523-294-571-46X;;174-240-616-434-345,EP;;CN;;WO;;US,7,052-333-404-700-516;;074-175-379-901-216;;076-958-022-943-898;;004-393-125-687-287;;085-994-502-021-053;;008-523-294-571-46X;;174-240-616-434-345,EP;;CN;;WO;;US,1377,A61K39/0005;;A61K39/385;;A61P25/28;;A61K2039/6068;;A61K2039/627;;A61P25/28;;C07K14/4711;;A61K39/0007;;A61K2039/6075;;A61K2039/6006;;A61K2039/62;;C07K16/18;;C07K16/44;;C07K2317/34;;Y02A50/30;;A61P25/28;;A61P37/04;;A61K39/0007;;A61K2039/55561;;A61K2039/55566;;A61K2039/6031;;A61K2039/6037;;A61K2039/6068;;A61K2039/6075;;A61K2039/6081;;A61K2039/627,A61K39/00;;A61K39/395;;A61P25/28;;C07K14/47,,0,0,,,,PENDING
546,US,A1,US 2023/0167411 A1,197-521-272-942-21X,2023-06-01,2023,US 202117922731 A,2021-04-30,US 202117922731 A;;US 202063018824 P;;IB 2021053646 W,2020-05-01,USE OF CD34 AS A MARKER FOR SINOATRIAL NODE-LIKE PACEMAKER CELLS,The invention relates to the use of CD34 as a cell surface marker to detect sinoatrial node-like pacemaker cells (SANLPCs) in a population of cells and to generate cell preparations highly enriched for SANLPCs. Also provides herein are methods of using SANLPC-enriched cell preparations for cardiac cell therapy.,UNIV HEALTH NETWORK,PROTZE STEPHANIE I;;KELLER GORDON M;;LOHBIHLER MICHELLE;;LIM AMOS CHUN-HIN ADRIAN,UNIVERSITY HEALTH NETWORK (2021-05-03),https://lens.org/197-521-272-942-21X,Patent Application,yes,0,0,3,091-420-994-877-353;;154-342-076-809-768;;197-521-272-942-21X,JP;;WO;;US,3,091-420-994-877-353;;154-342-076-809-768;;197-521-272-942-21X,JP;;WO;;US,0,A61K35/34;;A61P9/00;;G01N33/53;;C12Q1/6881;;C12Q2600/158;;G01N2333/70596;;C12N2506/02;;C12N5/0657;;A61K35/34;;C12N5/0657;;C12N2501/115;;C12N2501/155;;C12N2501/16;;C12N2501/165;;C12N2501/415;;C12N2506/45;;C12Q1/6869;;C12Q1/6881;;G01N33/56966;;G01N2333/70596,C12N5/077;;A61K35/34;;C12Q1/6881;;G01N33/569,,1,0,,,"Protze et al (Nature Biotech, 35, 56–68, 2017 (Year: 2017)",PENDING
547,US,A1,US 2025/0136974 A1,130-839-940-377-500,2025-05-01,2025,US 202118725483 A,2021-12-31,CN 2021143658 W,2021-12-31,"NUCLEIC ACID MOLECULE CAPABLE OF BLOCKING MOTOR PROTEIN, AND CONSTRUCTION METHOD AND APPLICATION THEREOF","The present invention relates to a nucleic acid molecule capable of blocking motor protein, a library containing the nucleic acid molecule, a method for constructing the nucleic acid molecule or library containing the same, and an application of the nucleic acid molecule or library containing same. The nucleic acid molecule contains at the end a modified nucleotide capable of blocking a motor protein, and the modified nucleotide is as shown in Formula I or Formula I′:",BGI SHENZHEN,WANG OU;;SHI XIAO;;XU XUN;;ZHANG WENWEI;;GUO FEI;;BAO SIYU;;DONG YULIANG;;ZENG TAO,BGI SHENZHEN (2025-02-18);;BGI SHENZHEN CO. LTD (2025-02-18),https://lens.org/130-839-940-377-500,Patent Application,yes,0,0,4,188-764-080-870-311;;175-842-095-955-659;;137-200-816-956-422;;130-839-940-377-500,CN;;EP;;WO;;US,4,188-764-080-870-311;;175-842-095-955-659;;137-200-816-956-422;;130-839-940-377-500,CN;;EP;;WO;;US,13,C12Q1/6806;;C12N15/113;;C12Q1/6869;;C12N15/11;;C12N15/1093;;C12Q1/6869,C12N15/11;;C12N15/10;;C12Q1/6869,,0,0,,,,PENDING
548,EP,A1,EP 4039279 A1,194-741-694-169-031,2022-08-10,2022,EP 20871804 A,2020-10-02,JP 2019183082 A;;JP 2020037640 W,2019-10-03,TRANSMUCOSAL DELIVERY SYSTEM FOR MEDICINAL ACTIVE INGREDIENT TO SUBMUCOSA OF BLADDER,"As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.",SEIKAGAKU KOGYO CO LTD,NARITA MUNETO;;ISHII KENSUKE;;SHIMURA AKIHITO,,https://lens.org/194-741-694-169-031,Patent Application,yes,0,0,7,152-179-666-763-536;;132-365-096-681-62X;;192-654-480-827-379;;190-613-012-486-274;;194-741-694-169-031;;088-263-459-438-864;;038-068-741-288-84X,JP;;EP;;WO;;US,7,152-179-666-763-536;;132-365-096-681-62X;;192-654-480-827-379;;190-613-012-486-274;;194-741-694-169-031;;088-263-459-438-864;;038-068-741-288-84X,JP;;EP;;WO;;US,0,A61K47/61;;A61P13/10;;A61P43/00;;G01N33/5088;;G01N2800/34;;A61K47/61;;A61K31/573;;A61K49/0004,A61K47/61;;A61K31/192;;A61K31/196;;A61K31/495;;A61K31/575;;A61K31/58;;A61K45/00;;A61P13/10;;A61P43/00;;G01N33/15;;G01N33/50,,0,0,,,,PENDING
549,US,A1,US 2022/0370630 A1,190-613-012-486-274,2022-11-24,2022,US 202017762279 A,2020-10-02,JP 2019183082 A;;JP 2020037640 W,2019-10-03,TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER,"As a system that enables effective delivery of a pharmaceutical active ingredient to a submucosal tissue of the bladder, a transmucosal delivery system including a conjugate of a hydrophobic compound containing the pharmaceutical active ingredient and chondroitin sulfate is provided.",SEIKAGAKU KOGYO CO LTD,NARITA MUNETO;;ISHII KENSUKE;;SHIMURA AKIHITO,SEIKAGAKU CORPORATION (2022-03-14),https://lens.org/190-613-012-486-274,Patent Application,yes,3,0,7,152-179-666-763-536;;132-365-096-681-62X;;192-654-480-827-379;;190-613-012-486-274;;194-741-694-169-031;;088-263-459-438-864;;038-068-741-288-84X,JP;;EP;;WO;;US,7,152-179-666-763-536;;132-365-096-681-62X;;192-654-480-827-379;;190-613-012-486-274;;194-741-694-169-031;;088-263-459-438-864;;038-068-741-288-84X,JP;;EP;;WO;;US,0,A61K47/61;;A61P13/10;;A61P43/00;;G01N33/5088;;G01N2800/34;;A61K47/61;;A61K31/573;;A61K49/0004,A61K47/61;;A61K31/573;;A61K49/00,,0,0,,,,PENDING
550,US,A1,US 2024/0082147 A1,145-805-597-578-784,2024-03-14,2024,US 202318238940 A,2023-08-28,US 202318238940 A;;US 202016915025 A;;US 201816019258 A;;US 201313966637 A;;US 56568709 A;;US 9950008 P,2008-09-23,"Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same","Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.",LABORATORY SKIN CARE INC,OGAWA TETSURO;;YAMAMOTO AKIRA,LABORATORY SKIN CARE INC (2010-10-12),https://lens.org/145-805-597-578-784,Patent Application,yes,0,0,42,141-256-968-199-501;;042-140-058-968-910;;045-509-685-129-944;;145-805-597-578-784;;010-213-175-819-723;;041-611-087-631-614;;129-730-601-020-481;;013-221-870-117-167;;178-523-163-824-847;;053-140-260-371-21X;;118-649-593-655-622;;098-501-798-954-20X;;047-152-917-761-02X;;046-594-885-115-200;;029-204-084-297-160;;161-422-974-721-77X;;002-887-303-801-538;;043-154-953-685-945;;082-286-657-218-903;;093-287-805-073-27X;;063-247-912-756-995;;154-561-894-108-832;;121-191-583-912-046;;060-011-023-362-005;;092-327-161-861-998;;146-095-882-296-658;;023-116-639-568-342;;141-831-499-054-841;;123-461-185-906-433;;160-582-808-450-464;;084-654-951-629-42X;;135-492-810-503-750;;038-668-274-480-304;;164-279-398-017-636;;118-929-433-718-301;;108-632-939-724-303;;092-916-720-813-024;;178-067-032-159-166;;174-850-986-017-07X;;032-490-530-664-425;;164-629-646-251-358;;053-313-735-936-61X,AU;;JP;;CL;;EA;;US;;CA;;BR;;MX;;KR;;MY;;IL;;EP;;CN;;WO;;ZA;;SG;;NZ,42,141-256-968-199-501;;042-140-058-968-910;;045-509-685-129-944;;145-805-597-578-784;;010-213-175-819-723;;041-611-087-631-614;;129-730-601-020-481;;013-221-870-117-167;;178-523-163-824-847;;053-140-260-371-21X;;118-649-593-655-622;;098-501-798-954-20X;;047-152-917-761-02X;;046-594-885-115-200;;029-204-084-297-160;;161-422-974-721-77X;;002-887-303-801-538;;043-154-953-685-945;;082-286-657-218-903;;093-287-805-073-27X;;063-247-912-756-995;;154-561-894-108-832;;121-191-583-912-046;;060-011-023-362-005;;092-327-161-861-998;;146-095-882-296-658;;023-116-639-568-342;;141-831-499-054-841;;123-461-185-906-433;;160-582-808-450-464;;084-654-951-629-42X;;135-492-810-503-750;;038-668-274-480-304;;164-279-398-017-636;;118-929-433-718-301;;108-632-939-724-303;;092-916-720-813-024;;178-067-032-159-166;;174-850-986-017-07X;;032-490-530-664-425;;164-629-646-251-358;;053-313-735-936-61X,AU;;JP;;CL;;EA;;US;;CA;;BR;;MX;;KR;;MY;;IL;;EP;;CN;;WO;;ZA;;SG;;NZ,0,A61K31/05;;A61K31/23;;A61K31/66;;A61K47/02;;A61K8/368;;A61K9/1611;;A61K8/24;;A61Q19/008;;A61K8/0279;;A61K2800/56;;A61K9/0014;;A61K31/216;;A61K31/60;;Y10S977/773;;Y10S977/906;;A61P17/00;;A61K8/0279;;A61K8/24;;A61K8/368;;A61K9/0014;;A61K9/143;;A61K9/1611;;A61K31/60;;A61K31/66;;A61Q19/008;;A61K2800/56;;A61K31/05;;A61K31/23;;A61K31/66;;A61K47/02;;A61K8/368;;A61K9/1611;;A61K8/24;;A61Q19/008;;A61K8/0279;;A61K2800/56;;A61K9/0014;;A61K9/143;;A61K31/216;;A61K31/60;;Y10S977/773;;Y10S977/906,A61K9/00;;A61K8/02;;A61K8/24;;A61K8/368;;A61K9/14;;A61K9/16;;A61K31/05;;A61K31/216;;A61K31/23;;A61K31/60;;A61K31/66;;A61K47/02;;A61Q19/00,,0,0,,,,PENDING
551,US,A1,US 2021/0171953 A1,108-442-656-941-132,2021-06-10,2021,US 201916968334 A,2019-01-08,KR 20180015750 A;;KR 2019000245 W,2018-02-08,"Peptide Nucleic Acid Complex Having Endosomal Escape Capacity, And Use Thereof","The present invention relates to a nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease comprising the same, and a method of regulating target gene expression using the same, and more particularly to a nucleic acid complex in which a bioactive nucleic acid, which comprises a material for facilitating endosomal escape, and a carrier peptide nucleic acid, are complementarily bound to each other, a composition for treating or diagnosing disease comprising the same, a composition for regulating target gene expression using the same, and a method of regulating target gene expression using the same.A nucleic acid complex of Structural Formula (1) according to the present invention, which comprises a bioactive nucleic acid and a carrier peptide nucleic acid, may increase the stability of the bioactive nucleic acid, reduce loss of the bioactive nucleic acid, such as precipitation caused by self-aggregation, increase the intracellular delivery efficiency of the bioactive nucleic acid, and easily regulate target gene expression.",SEASUN THERAPEUTICS INC,KIM HYE JOO;;YU JI-YEON;;LEE DONG IN;;KANG YUSUN;;PARK HEE KYUNG,SEASUN THERAPEUTICS INC (2020-08-18),https://lens.org/108-442-656-941-132,Patent Application,yes,5,1,15,083-552-660-116-508;;187-145-423-721-782;;114-072-474-924-739;;025-416-710-852-424;;032-315-616-338-884;;019-502-597-859-408;;186-541-230-347-235;;094-190-987-096-805;;108-442-656-941-132;;004-073-704-247-531;;099-969-534-752-305;;136-857-622-711-099;;030-407-195-972-486;;013-828-810-469-567;;161-610-599-155-195,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,15,083-552-660-116-508;;187-145-423-721-782;;114-072-474-924-739;;025-416-710-852-424;;032-315-616-338-884;;019-502-597-859-408;;186-541-230-347-235;;094-190-987-096-805;;108-442-656-941-132;;004-073-704-247-531;;099-969-534-752-305;;136-857-622-711-099;;030-407-195-972-486;;013-828-810-469-567;;161-610-599-155-195,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA,86,C12N15/113;;C12N15/1136;;A61P35/00;;A61P29/00;;A61P27/02;;A61P9/10;;A61P3/10;;A61P11/00;;A61P9/00;;A61P17/00;;A61P3/00;;A61P17/02;;A61P17/06;;C12Q1/6886;;C12Q1/6883;;C12N2310/3181;;C12Q2600/158;;C12Q2600/178;;C12N2320/32;;C12N2310/53;;C12N2310/3513;;C12N2310/3181;;C12N15/111;;C12N2310/331;;C12N15/113;;C12N15/1138;;C12N15/1137;;C12Y301/04017;;C12N15/1136;;A61P35/00;;C07K14/003;;A61K47/6455;;C12N15/111;;C07K14/003;;C12Q1/6883;;A61K47/549;;C12N2310/31;;C12N2310/3181;;C12Q2525/107;;C12Q2525/113;;C12Q2600/158;;A61K47/64;;A61P35/00;;C12N15/1136;;C12N2310/3513;;C12N15/113;;C12N2310/3181;;C07K14/003;;A61P17/06;;C12Q2525/107,C12N15/113;;A61K47/64;;A61P35/00,,1,1,018-472-101-649-941,17408236;;10.1208/aapsj0901003;;pmc2751301,"Martin et al (The AAPS J., Vol. 9, No. 1, pages E18-E29 (2007)) (Year: 2007)",DISCONTINUED
552,US,A1,US 2025/0043030 A1,038-394-609-015-215,2025-02-06,2025,US 202418806346 A,2024-08-15,US 202418806346 A;;US 202318211178 A;;US 202263353480 P,2022-06-17,SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSES,System for and method of producing a pure starch slurry and alcohol by using combined corn wet and dry milling processes. A simple and lower cost process to obtain starch inside floury endosperm is provided. The starch can be highly purified to meet green technology process needs. The remaining starch inside the corn kernels can be used as feedstock for alcohol production and to produce valuable co-products such as oil and various animal feeds.,LEE TECH LLC,LEE CHIE YING,LEE TECH LLC (2024-05-12),https://lens.org/038-394-609-015-215,Patent Application,yes,2,0,6,125-939-550-205-073;;025-837-787-059-489;;026-753-504-621-864;;038-394-609-015-215;;050-613-247-775-349;;095-070-115-589-231,CN;;WO;;US,6,125-939-550-205-073;;025-837-787-059-489;;026-753-504-621-864;;038-394-609-015-215;;050-613-247-775-349;;095-070-115-589-231,CN;;WO;;US,0,C08B30/044;;C08B30/02;;C08B30/06;;C08B30/08;;A23K40/10;;A23K20/147;;A23K10/38;;A23K10/12;;A23K10/37;;A23K50/75;;A23K50/30;;A23K10/30;;A23K20/163;;A23K40/25;;Y02P60/87;;C08B30/02;;C08B30/044;;C08B30/08;;A23K40/10;;C08B30/06,C08B30/02;;A23K40/10;;C08B30/04;;C08B30/06;;C08B30/08,,0,0,,,,ACTIVE
553,EP,A1,EP 4317411 A1,049-683-853-329-961,2024-02-07,2024,EP 22774314 A,2022-03-24,CN 202110316031 A;;CN 2022082787 W,2021-03-24,"LACTOBACILLUS RHAMNOSUS, FERMENT LYSATE FOR REGULATING SKIN MICROECOLOGY, PREPARATION METHOD, AND APPLICATION","Disclosed are a Lactobacillus rhamnosus strain having accession number CCTCC NO: M 2021185, a ferment lysate prepared thereby for regulating skin microecology, and a preparation method for the ferment lysate. The ferment lysate comprises the following components in mass percentages of same in the ferment lysate: 0.2-1% of proteins, 0.3-0.8% of polysaccharides, and 0.2-1% of amino acids. The ferment lysate obtained by using the above bacterial strain for fermentation can strongly inhibit the reproduction and growth of pathogenic bacteria, has a promotion effect on some of probiotics, has a strong inhibition effect on pathogenic hyphae of Candida albicans, can not only generate antimicrobial peptides during fermentation, but also increase the expression level of antimicrobial peptides in skin cells at the genetic level and the protein level, thereby improving skin immunity.",BLOOMAGE BIOTECHNOLOGY CORP LTD,LU ZHEN;;WEI YUJIE;;SUN YUANJUN;;DU RANRAN;;ZHAO YAN;;GUO XUEPING,,https://lens.org/049-683-853-329-961,Patent Application,yes,0,0,6,049-683-853-329-961;;178-503-640-420-346;;186-820-581-963-437;;045-796-928-587-777;;103-009-141-890-429;;151-695-327-322-327,EP;;CN;;WO;;US,6,178-503-640-420-346;;049-683-853-329-961;;186-820-581-963-437;;045-796-928-587-777;;103-009-141-890-429;;151-695-327-322-327,CN;;EP;;WO;;US,3,C12P21/00;;C12P19/04;;C12P13/04;;A61K8/99;;A61Q17/005;;A61Q19/00;;A61P37/04;;A61P17/00;;A61P31/10;;A61K2800/85;;C12N1/205;;C12R2001/225;;A61K8/99;;A61K2800/85;;A61Q17/005;;A61Q19/00;;C12N1/205;;C12R2001/225;;A61K8/99;;A61K2800/85;;A61Q17/005;;C12P13/04;;C12P19/04;;C12P21/00,C12N1/20;;A61K8/99;;A61P17/00;;A61P31/10;;A61P37/04;;A61Q17/00;;A61Q19/00;;C12P13/04;;C12P19/04;;C12P21/00;;C12R1/225,,0,0,,,,PENDING
554,US,A1,US 2022/0073620 A1,182-754-181-841-125,2022-03-10,2022,US 201917418838 A,2019-12-26,CN 201811620872 A;;CN 2019128585 W,2018-12-28,"ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF","Provided are an antibody fusion protein, a preparation method thereof and an application thereof. The antibody fusion protein is high in expression quantity, and the transient expression quantity in mammalian cells 293E is 100-150 mg/L; the antibody fusion protein is high in assembly rate, and the correct assembly rate exceeds 95%; the antibody fusion protein has a high affinity, and a single-sided antibody/fusion protein and antigen binding KD value is equivalent to a positive control monoclonal antibody/fusion protein and antigen binding KD value; the antibody fusion protein is convenient to purify, and the purity can reach more than 95% in one-step purification by using Protein A or Protein L, and the tumor inhibition rate in a pharmacodynamic experiment animal can reach up to 92%.",CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD,FENG XIAO;;WANG TAO;;JIN LEI;;GUO HONGRUI;;LIU SHUANG;;HAN NING;;LIANG YANGQIU;;CHEN YUHENG,CHANGCHUN GENESCIENCE PHARMACEUTICAL CO. LTD (2021-03-25),https://lens.org/182-754-181-841-125,Patent Application,yes,3,1,10,165-394-395-748-513;;123-782-005-735-524;;058-266-496-035-760;;050-844-515-229-132;;079-384-028-065-861;;003-269-813-756-720;;163-082-508-071-081;;182-754-181-841-125;;141-070-043-045-10X;;156-254-552-443-537,KR;;AU;;CN;;EP;;WO;;US;;CA,10,165-394-395-748-513;;123-782-005-735-524;;050-844-515-229-132;;003-269-813-756-720;;079-384-028-065-861;;058-266-496-035-760;;163-082-508-071-081;;182-754-181-841-125;;141-070-043-045-10X;;156-254-552-443-537,KR;;AU;;CN;;EP;;WO;;US;;CA,13,C07K16/2827;;A61K45/00;;A61K47/6803;;A61K47/6817;;A61P3/10;;A61P9/10;;A61P35/00;;A61P35/02;;C07K16/22;;C07K16/46;;C07K2317/31;;C07K2317/52;;C07K2317/56;;C12N15/70;;A61P3/10;;A61K38/00;;A61K2039/505;;A61P9/10;;A61P35/00;;A61P35/02;;C07K16/2827;;C07K2317/24;;C07K2317/31;;C07K2317/55;;C07K2317/60;;C07K2317/622;;C07K2317/70;;C07K2317/76;;C07K2317/92;;C07K2319/00;;C07K16/2827;;A61K2039/505;;A61P35/00;;C07K16/22;;C07K16/46;;C07K16/2827;;A61K47/6817;;A61P35/02;;C07K16/22;;C12N15/62,C07K16/28;;A61K47/68;;A61P35/02;;C07K16/22;;C12N15/62,,0,0,,,,DISCONTINUED
555,US,A1,US 2022/0073603 A1,184-496-056-016-058,2022-03-10,2022,US 202117389533 A,2021-07-30,US 202117389533 A;;US 202063058966 P,2020-07-30,Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody,"Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.",JANSSEN BIOTECH INC,HSU MING-CHUN;;LI SHU;;RANDAZZO BRUCE;;SONG KUN;;ZHU YAOWEI,,https://lens.org/184-496-056-016-058,Patent Application,yes,1,1,7,025-090-788-566-973;;030-256-872-816-857;;148-630-739-296-596;;131-694-077-071-78X;;084-095-011-962-232;;184-496-056-016-058;;119-824-897-118-756,AU;;EP;;WO;;US;;CA,7,030-256-872-816-857;;025-090-788-566-973;;148-630-739-296-596;;131-694-077-071-78X;;084-095-011-962-232;;184-496-056-016-058;;119-824-897-118-756,AU;;EP;;WO;;US;;CA,11,A61K39/395;;A61P17/06;;C07K16/244;;A61K2039/505;;A61P17/06;;A61K2039/505;;C07K16/244;;C07K2317/565,C07K16/24;;A61P17/06,,1,0,,,"Janssen Biotech, HIGHLIGHTS OF PRESCRIBING INFORMATION - STELARA® (ustekinumab) injection, for subcutaneous or intravenous use (2016).",DISCONTINUED
556,US,A1,US 2020/0325484 A1,042-331-012-528-102,2020-10-15,2020,US 201916382210 A,2019-04-12,US 201916382210 A,2019-04-12,Enhancing gene expression by linking self-amplifying transcription factor with viral 2A-like peptide,"The invention describes a nucleic acid system, named as “2A-transcription amplifier”, for enhancing gene expression by linking a gene of interest (GOI) to a self-amplifying transcription factor with a viral 2A-like peptide. The system comprises an upstream activation sequence (UAS) at upstream promoter region and another sequence encoding a specific transcription factor (TF), a viral 2A-like peptide, and a gene of interest (GOI). The said compositions are operably linked in a way that the initially expressed TF protein binds the UAS region and promotes more TF and GOI co-expression. The viral 2A-like peptide separates the co-expressed TF and GOI protein during protein translation by the mechanism of ribosomal skidding. The system creates a transcription amplification loop that can be employed for enhancing expression of exogenous or endogenous gene of interest (GOI) in eukaryotic cells, tissues or whole organisms.",LIANG DELIN,LIANG DELIN,,https://lens.org/042-331-012-528-102,Patent Application,yes,0,3,1,042-331-012-528-102,US,1,042-331-012-528-102,US,30,C12N15/81;;C12N15/902;;C12N2840/20;;C12N15/63;;A01K67/61;;C12N15/635;;C12N15/86;;C12N15/81,C12N15/63;;C12N15/81;;C12N15/86,,0,0,,,,DISCONTINUED
557,US,A1,US 2021/0037868 A1,173-770-268-534-615,2021-02-11,2021,US 201916964199 A,2019-01-22,EP 18155930 A;;EP 2019051443 W,2018-02-09,OIL-IN WATER- EMULSIFIED FOOD COMPOSITION WITH MULBERRY EXTRACT,"The present invention relates to an oil-in-water-emulsified food product comprising: Vegetable oil,Water,0.01 to 1.5 wt % of extract of Morus alba,acid,wherein the extract of Morus alba comprises more than 0.6 wt %, based on the dry weight of the extract, of total polyphenols.",CONOPCO INC DBA UNILEVER,ERMACORA ALESSIA;;SILVA PAES SABRINA;;VERHOEF PETRA,CONOPCO INC. D/B/A UNILEVER (2019-04-24),https://lens.org/173-770-268-534-615,Patent Application,yes,4,0,12,063-668-911-488-162;;106-308-878-025-80X;;046-124-008-655-655;;110-565-664-877-064;;017-637-643-819-358;;015-950-709-543-55X;;036-418-518-763-761;;043-648-410-275-00X;;041-747-088-863-903;;060-238-976-932-288;;173-770-268-534-615;;163-903-463-789-043,AR;;ES;;CL;;EP;;WO;;US;;CA;;PH;;MX;;BR,12,063-668-911-488-162;;106-308-878-025-80X;;046-124-008-655-655;;110-565-664-877-064;;017-637-643-819-358;;015-950-709-543-55X;;036-418-518-763-761;;173-770-268-534-615;;041-747-088-863-903;;060-238-976-932-288;;043-648-410-275-00X;;163-903-463-789-043,AR;;ES;;CL;;EP;;WO;;US;;CA;;PH;;MX;;BR,0,A23D7/0053;;A23V2002/00;;A23L27/60;;A23L33/105;;A23L27/60;;A23L29/10;;A23L33/105;;A23D7/0056;;A23V2002/00,A23L33/105;;A23D7/005;;A23L27/60;;A23L29/10,,5,2,134-712-149-677-445;;073-484-307-217-602,10.1016/j.foodres.2014.12.020;;10.1016/s0076-6879(99)99017-1,"Donno et al., ""Foodomics for mulberry fruit (Morus spp.): Analytical fingerprint as antioxidants' and health properties' determination tool, Food Research International 69 (2015), 179-188 (Year: 2015);;V.L. Singleton et al., “Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent”, Methods in Enzymology 299, 152-178, 1999. (Year: 1999);;Dharmananda, S. “Fruit as Medicine, Morus Fruit”, Institute for Traditional Medicine, (2003) 1-7, downloaded on January 30, 2023 from www.itmonline.org/arts/morus.htm (Year: 2003);;RU-2213490-C2 (machine translation from Clarivate) (Year: 2003);;KR20140083507A (KR ‘507) (Espace.net machine translation version) (Year: 2014)",DISCONTINUED
558,WO,A1,WO 2023/244840 A1,025-837-787-059-489,2023-12-21,2023,US 2023/0025624 W,2023-06-16,US 202263353480 P,2022-06-17,SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSES,System for and method of producing a pure starch slurry and alcohol by using combined corn wet and dry milling processes. A simple and lower cost process to obtain starch inside floury endosperm is provided. The starch can be highly purified to meet green technology process needs. The remaining starch inside the corn kernels can be used as feedstock for alcohol production and to produce valuable co-products such as oil and various animal feeds.,LEE TECH LLC,LEE CHIE YING,,https://lens.org/025-837-787-059-489,Patent Application,yes,3,1,6,125-939-550-205-073;;025-837-787-059-489;;026-753-504-621-864;;038-394-609-015-215;;050-613-247-775-349;;095-070-115-589-231,CN;;WO;;US,6,125-939-550-205-073;;025-837-787-059-489;;026-753-504-621-864;;038-394-609-015-215;;050-613-247-775-349;;095-070-115-589-231,CN;;WO;;US,0,C08B30/044;;C08B30/02;;C08B30/06;;C08B30/08;;A23K40/10;;A23K20/147;;A23K10/38;;A23K10/12;;A23K10/37;;A23K50/75;;A23K50/30;;A23K10/30;;A23K20/163;;A23K40/25;;Y02P60/87;;C08B30/02;;C08B30/044;;C08B30/08;;A23K40/10;;C08B30/06,A23K10/30;;C08B30/04;;C11B1/10,,0,0,,,,PENDING
559,US,A1,US 2022/0119791 A1,080-568-297-636-281,2022-04-21,2022,US 202117559782 A,2021-12-22,US 202117559782 A;;US 201815939231 A;;US 201762477846 P,2017-03-28,METHOD OF PRODUCING COLLAGENASE,"The present invention relates to the fields of collagenase production and collagenase products, and particularly to improving the reproducibility, purity, and stability of collagenase I and collagenase II compositions, where the compositions are pure to at least 95% by area as measured by reverse phase high pressure liquid chromatography (RP-HPLC) and essentially free of neutral protease.",ENDO VENTURES LTD,SHEAFFER CHRISTINE A;;BERBAUM MICHAEL;;HANNA JOHN;;DZIADOSZ JASON;;SHANAFELT DANIEL,ENDO VENTURES UNLIMITED COMPANY (2023-05-30);;ENDO VENTURES LTD (2018-05-08);;ENDO OPERATIONS LIMITED (2023-05-31),https://lens.org/080-568-297-636-281,Patent Application,yes,2,3,29,080-273-852-412-888;;080-404-001-920-005;;026-368-712-532-582;;026-295-199-097-06X;;018-156-259-562-104;;185-349-750-505-43X;;098-726-908-191-889;;114-955-805-702-639;;080-568-297-636-281;;016-343-155-060-223;;054-168-194-715-301;;137-884-644-371-216;;025-557-434-775-432;;067-423-178-348-019;;056-241-769-875-770;;134-785-010-858-476;;108-628-760-864-558;;027-500-000-927-385;;002-402-837-303-48X;;097-509-833-936-34X;;129-606-682-042-552;;143-367-932-351-238;;082-865-655-541-260;;049-435-614-669-720;;018-847-625-854-16X;;194-887-805-960-398;;044-612-716-496-325;;080-207-361-061-141;;082-523-331-740-95X,AU;;JP;;US;;CA;;MX;;BR;;KR;;AR;;IL;;CN;;EP;;WO;;NZ,29,080-273-852-412-888;;080-404-001-920-005;;026-368-712-532-582;;026-295-199-097-06X;;018-156-259-562-104;;185-349-750-505-43X;;098-726-908-191-889;;114-955-805-702-639;;080-568-297-636-281;;016-343-155-060-223;;054-168-194-715-301;;137-884-644-371-216;;025-557-434-775-432;;067-423-178-348-019;;056-241-769-875-770;;134-785-010-858-476;;108-628-760-864-558;;027-500-000-927-385;;002-402-837-303-48X;;097-509-833-936-34X;;129-606-682-042-552;;143-367-932-351-238;;082-865-655-541-260;;049-435-614-669-720;;018-847-625-854-16X;;194-887-805-960-398;;044-612-716-496-325;;080-207-361-061-141;;082-523-331-740-95X,AU;;JP;;US;;CA;;MX;;BR;;KR;;AR;;IL;;CN;;EP;;WO;;NZ,6,C12N9/52;;C12Y304/24003;;A61K38/00;;C12N9/52;;A61K31/00;;C12Y304/24003;;C12N9/52;;A61K38/4886;;C12Y304/24003;;A61K38/00;;C12N9/52;;A61K31/00;;C12Y304/24003;;G01N33/56911,C12N9/52,,6,5,059-392-696-613-143;;151-997-929-491-981;;039-527-317-342-815;;113-996-363-713-772;;050-820-502-289-148,10.1007/s00253-009-1953-4;;pmc3085789;;19333597;;10.1080/15422110601166007;;10.1007/s12010-009-8673-1;;19475515;;25874705;;2822678;;10.1093/oxfordjournals.jbchem.a122028,"Ducka et al. (Applied Microbiol. Biotech., 2009, vol. 83, pages 1055-1065).;;Gutierrez et al. (Separation & Purification Reviews, vol. 36, 2007, Issue 1, pages 71-111);;Cawston et al. (Biochem. Biophys. Acta, 455, 1976, pages 711-722);;Wu et al. (Applied Biochem. Biotech., 2010, 160:129-139).;;Jovanovic et al. (Wounds 2012, 24(9) pages 242-253);;Endo et al. (J. Biochem., vol 102, pages 163-170, 1987)",PENDING
560,US,A1,US 2023/0193408 A1,125-836-211-886-335,2023-06-22,2023,US 202117925675 A,2021-07-16,CN 202010426283 A;;CN 2021106843 W;;CN 202010251367 A,2020-04-01,"NUCLEIC ACID TEST KIT, TEST METHOD, AND USE","Disclosed is a nucleic acid test kit, comprising a Cpf1 test system, said Cpf1 test system comprising: a guide RNA, a Cpf1 protein, a nucleic acid probe, and a manganese ion-containing solution. Also provided is a mutated Cpf1 protein and a nucleic acid test kit containing the mutated Cpf1 protein. Also provided is a crRNA for testing coronavirus nucleic acid, and a nucleic acid test kit containing said crRNA. Further provided is a use of the nucleic acid test kit, and a test method for the nucleic acid. When the nucleic acid test kit, mutated Cpf1 protein, or crRNA of the present invention are used for nucleic acid testing (for example, testing the nucleic acid of a SARS-related coronavirus or MERS coronavirus), the signal strength during the test is substantially enhanced, and the test time is thus reduced and the test efficiency improved. In addition, the sensitivity, specificity, and accuracy are high, the test is visual, the cost is low, the operation is simple and convenient, and no large-scale complex t equipment is required.",UNIV SHANGHAI TECHNOLOGY,MA PEIXIANG;;WANG XINJIE,SHANGHAITECH UNIVERSITY (2022-08-24),https://lens.org/125-836-211-886-335,Patent Application,yes,0,0,7,170-310-999-227-129;;181-440-222-906-207;;018-633-281-207-714;;008-487-471-480-222;;125-836-211-886-335;;185-458-282-329-756;;169-655-741-640-475,CN;;WO;;US,7,170-310-999-227-129;;181-440-222-906-207;;018-633-281-207-714;;008-487-471-480-222;;125-836-211-886-335;;185-458-282-329-756;;169-655-741-640-475,CN;;WO;;US,81,C12Q1/701;;C12Q1/6844;;Y02A50/30;;C12Q1/701;;C12Q1/701,C12Q1/70,,0,0,,,,PENDING
561,US,A1,US 2022/0370982 A1,024-009-824-114-513,2022-11-24,2022,US 202217749276 A,2022-05-20,US 202217749276 A;;US 202163191491 P,2021-05-21,IONIC-FUNCTIONALIZED WOOD PULP AND RELATED METHODS FOR WATER TREATMENT,"The disclosure relates to modified wood pulp and methods using the same for removal for per- and polyfluoroalkyl substances (collectively “PFAS”) from contaminated water. Cationic-modified wood pulp can be used to adsorb anionic PFAS contaminants from water, and anionic-modified wood pulp can be used to adsorb cationic PFAS contaminants from water. The modified wood pulp has high adsorption efficiencies, rapid adsorption kinetics, and high adsorption efficiencies for a range of different PFAS contaminants.",UNIV MICHIGAN REGENTS,MCNEIL ANNE J;;HARRIS JUSTIN T,THE REGENTS OF THE UNIVERSITY OF MICHIGAN (2022-05-25),https://lens.org/024-009-824-114-513,Patent Application,yes,1,4,2,024-009-824-114-513;;198-630-665-016-988,WO;;US,2,024-009-824-114-513;;198-630-665-016-988,WO;;US,0,B01J20/24;;B01J20/3425;;B01J20/28016;;B01J20/28023;;B01J20/3085;;C02F1/286;;C02F2101/36;;B01J20/24;;B01J20/28023;;B01J20/28016;;C02F2303/16;;B01J20/3425;;C02F1/286;;C02F2101/36;;B01J20/3085,B01J20/24;;B01J20/28;;B01J20/30;;B01J20/34;;C02F1/28,,1,0,,,"Mehmood et al., “Advances in lignocellulosic biotechnology”, Adv. Bioscience and Biotech., (2014) (Year: 2014)",PENDING
562,US,A1,US 2023/0002818 A1,038-484-260-662-063,2023-01-05,2023,US 202117563794 A,2021-12-28,CN 202110719256 A,2021-06-28,PREPARATION METHOD OF HIGH-STABILITY SUPEROXIDE DISMUTASE WITH TRANSMEMBRANE CAPABILITY,"The present disclosure belongs to the technical field of genetic modification of an enzyme preparation and particularly relates to a preparation method of a high-stability superoxide dismutase with a transmembrane capability. The method includes the following steps: extracting mRNA from Geobacillus stearothermophilus, synthesizing cDNA by a reverse transcription method, amplifying a large number of coding regions of the cDNA by designing a specific primer, ligating the coding regions to an E. coli expression vector, and transforming the coding regions into engineering bacteria BL21 (DE3). A point mutation technology is used to enhance stability of the superoxide dismutase and a flexible polypeptide linker GGGSGGGS (SEQ ID NO: 11) is designed, such that a soluble fusion expression of a transmembrane peptide YGRKKRRQRRR (SEQ ID NO: 10) and the superoxide dismutase is successfully realized.",XIA YONG,XIA YONG,,https://lens.org/038-484-260-662-063,Patent Application,yes,2,0,4,050-822-144-790-715;;127-229-083-417-152;;038-484-260-662-063;;086-027-047-709-712,CN;;US,4,050-822-144-790-715;;127-229-083-417-152;;038-484-260-662-063;;086-027-047-709-712,CN;;US,15,C12N9/0089;;C12N15/70;;C12Y115/01001;;C12N9/0089;;C12Q1/689;;C12Y115/01001;;Y02A50/30;;C12Q1/6865;;C12N9/0089;;C12Y115/01001,C12Q1/6865;;C12N9/02,,0,0,,,,ACTIVE
563,EP,A1,EP 3904381 A1,163-082-508-071-081,2021-11-03,2021,EP 19901455 A,2019-12-26,CN 201811620872 A;;CN 2019128585 W,2018-12-28,"ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF","Provided are an antibody fusion protein, a preparation method thereof and an application thereof. The antibody fusion protein is high in expression quantity, and the transient expression quantity in mammalian cells 293E is 100-150 mg/L; the antibody fusion protein is high in assembly rate, and the correct assembly rate exceeds 95%; the antibody fusion protein has a high affinity, and a single-sided antibody/fusion protein and antigen binding KD value is equivalent to a positive control monoclonal antibody/fusion protein and antigen binding KD value; the antibody fusion protein is convenient to purify, and the purity can reach more than 95% in one-step purification by using Protein A or Protein L, and the tumor inhibition rate in a pharmacodynamic experiment animal can reach up to 92%.",CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD,FENG XIAO;;WANG TAO;;JIN LEI;;GUO HONGRUI;;LIU SHUANG;;HAN NING;;LIANG YANGQIU;;CHEN YUHENG,,https://lens.org/163-082-508-071-081,Patent Application,yes,0,0,10,165-394-395-748-513;;123-782-005-735-524;;058-266-496-035-760;;050-844-515-229-132;;079-384-028-065-861;;003-269-813-756-720;;163-082-508-071-081;;182-754-181-841-125;;141-070-043-045-10X;;156-254-552-443-537,KR;;AU;;CN;;EP;;WO;;US;;CA,10,165-394-395-748-513;;123-782-005-735-524;;050-844-515-229-132;;003-269-813-756-720;;079-384-028-065-861;;058-266-496-035-760;;163-082-508-071-081;;182-754-181-841-125;;141-070-043-045-10X;;156-254-552-443-537,KR;;AU;;CN;;EP;;WO;;US;;CA,13,C07K16/2827;;A61K45/00;;A61K47/6803;;A61K47/6817;;A61P3/10;;A61P9/10;;A61P35/00;;A61P35/02;;C07K16/22;;C07K16/46;;C07K2317/31;;C07K2317/52;;C07K2317/56;;C12N15/70;;A61P3/10;;A61K38/00;;A61K2039/505;;A61P9/10;;A61P35/00;;A61P35/02;;C07K16/2827;;C07K2317/24;;C07K2317/31;;C07K2317/55;;C07K2317/60;;C07K2317/622;;C07K2317/70;;C07K2317/76;;C07K2317/92;;C07K2319/00;;C07K16/2827;;A61K2039/505;;A61P35/00;;C07K16/22;;C07K16/46;;C07K16/2827;;A61K47/6817;;A61P35/02;;C07K16/22;;C12N15/62,C07K16/18;;A61K39/00;;C07K16/46;;C07K19/00,,1,0,,,See references of WO 2020135556A1,DISCONTINUED
564,EP,A1,EP 4177272 A1,141-596-362-129-884,2023-05-10,2023,EP 21885284 A,2021-10-29,CN 202011191447 A;;CN 202110566040 A;;CN 2021127234 W,2020-10-30,USE OF REGULATOR OF ITPRIPL1 IN PREPARATION OF DRUG THAT REGULATES IMMUNE RESPONSES OR FIGHTS TUMORS,"Provided is a use of a regulator of ITPRIPL1 in the preparation of a drug that regulates immune responses or resists tumors, the regulator being used to increase or decrease the expression or function of the ITPRIPL1 gene or protein in an organism. Also provided is a pharmaceutical composition, which comprises the regulator used in the use. Also provided are an isolated ITPRIPL1 recombinant protein and an antibody that recognizes and binds to the ITPRIPL1. On the basis of the principle that an ITPRIPL1 protein binds to CD3ε and NRP2 receptors to regulate the functions of different immune cells, and then participates in the regulation of immune responses and a process of immune evasion of a tumor, it is confirmed that a regulator of ITPRIPL1 may be used to prepare a drug or a pharmaceutical composition, and may be applied to suppress tumors, autoimmune disease, transplant rejection, allergies and infections and other diseases.",UNIV FUDAN,XU JIE;;DENG SHOUYAN;;SONG TENG;;WANG YITING;;WANG YUNGANG;;WANG HUANBIN;;CHI HAO,FUDAN UNIVERSITY (2023-08-16);;BIOTROY THERAPEUTICS (2023-08-16),https://lens.org/141-596-362-129-884,Patent Application,yes,0,0,10,141-596-362-129-884;;117-737-465-635-380;;012-830-691-339-749;;179-940-049-730-189;;135-379-822-371-797;;041-548-457-590-030;;062-258-159-691-155;;069-312-271-266-182;;016-306-660-334-86X;;113-203-764-994-760,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,16,170-885-356-470-384;;155-511-236-801-038;;057-702-964-073-154;;082-179-368-407-966;;141-596-362-129-884;;100-638-283-986-592;;117-737-465-635-380;;179-940-049-730-189;;135-379-822-371-797;;041-548-457-590-030;;062-258-159-691-155;;003-380-232-194-921;;012-830-691-339-749;;113-203-764-994-760;;016-306-660-334-86X;;069-312-271-266-182,KR;;JP;;AU;;CN;;EP;;WO;;US;;CA,99,A61P35/00;;C07K2317/76;;C07K2317/92;;C07K2317/73;;A61K2039/505;;C07K2317/24;;C07K16/28;;C07K16/18;;C12N9/22;;C07K14/705;;A61K39/39;;A61K2039/585;;C07K2319/21;;A61K39/00;;C12N15/113;;C12N2310/14;;C12N2310/20;;C07K2317/34;;C07K2319/30;;C07K16/18;;C07K16/28;;C07K14/4702;;C07K14/705;;C12N9/22;;C12N15/113;;A61P35/00;;G01N33/574;;C07K2317/24;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12N2310/20;;A61K39/00;;A61P35/00;;A61K31/7088;;A61K38/1709;;A61K38/465;;A61K48/005;;C07K14/47;;C07K16/18;;C07K2317/24;;C07K2317/31;;C07K2317/76;;C07K2317/92;;C12N15/113;;G01N33/57488;;A61K39/00,C07K16/30;;A61K39/00;;A61P35/00;;C07K19/00;;C12N15/13;;C12N15/62,,0,0,,,,PENDING
565,US,A1,US 2025/0049947 A1,094-330-373-340-844,2025-02-13,2025,US 202418409684 A,2024-01-10,CN 202311010685 A,2023-08-11,"PAPN MUTANT, METHOD FOR SITE-DIRECTED MODIFICATION OF PAPN GENE AND USE THEREOF","This description relates to a substance causing a mutation at position 727 in an amino acid residue of the pAPN protein in any of the following: 1) constructing a cell line with site-directed modification of the pAPN gene for non-disease diagnostic and therapeutic purposes; 2) preparing a cell with resistance to the porcine transmissible gastroenteritis virus; and so on. A system for site-directed modification of the pAPN gene may effectively cleave two target sites of the pAPN gene, thereby achieving the precise mutation at position 727 in an amino acid of pAPN. Based on the precise modification of the pAPN gene while capable of avoiding disruption or alteration of the normal expression of other amino acids in the pAPN, the physiological activity function of pAPN protein on the basis of resisting TGEV infection is retained.",AGSINO GENSOURCES CO LTD,LI KUI;;MU YULIAN;;HUANG LEI,AGSINO GENSOURCES CO. LTD (2023-12-08),https://lens.org/094-330-373-340-844,Patent Application,yes,0,0,3,193-611-191-257-636;;094-330-373-340-844;;020-256-089-526-716,CN;;US,3,193-611-191-257-636;;094-330-373-340-844;;020-256-089-526-716,CN;;US,0,C12N5/0656;;C12N15/1137;;C12N9/22;;C12N15/8778;;C12N15/89;;C12N15/907;;A01K67/0275;;C12Y304/11002;;C12N2310/20;;A01K2217/07;;A01K2227/108;;A01K2267/0337;;C12N2800/80;;C12N15/11;;C12Y304/11002;;A61K38/48;;C12N9/22;;C12N2310/20;;C12N15/907;;C12N9/485;;A61K48/0033;;A01K2227/108;;A01K67/027;;C12N15/85;;C12N2310/20;;A61K38/48;;A61K48/0033;;C12N9/22;;C12N9/485;;C12N15/11;;C12N15/907;;C12N2800/80;;C12Y304/11002,A61K48/00;;A61K38/48;;C12N9/22;;C12N9/48;;C12N15/11;;C12N15/90,,0,0,,,,PENDING
566,US,A1,US 2024/0034776 A1,041-548-457-590-030,2024-02-01,2024,US 202118034568 A,2021-10-29,CN 202011191447 A;;CN 202110566040 A;;CN 2021127234 W,2020-10-30,USE OF REGULATOR OF ITPRIPL1 IN PREPARATION OF DRUG THAT REGULATES IMMUNE RESPONSES OR FIGHTS TUMORS,"Provided is a use of a regulator of ITPRIPL1 in the preparation of a drug that regulates immune responses or resists tumors, the regulator being used to increase or decrease the expression or function of the ITPRIPL1 gene or protein in an organism. Also provided is a pharmaceutical composition, which comprises the regulator used in the use. Also provided are an isolated ITPRIPL1 recombinant protein and an antibody that recognizes and binds to the ITPRIPL1. On the basis of the principle that an ITPRIPL1 protein binds to CD3ε and NRP2 receptors to regulate the functions of different immune cells, and then participates in the regulation of immune responses and a process of immune evasion of a tumor, it is confirmed that a regulator of ITPRIPL1 may be used to prepare a drug or a pharmaceutical composition, and may be applied to suppress tumors, autoimmune disease, transplant rejection, allergies and infections and other diseases.",UNIV FUDAN;;BIOTROY THERAPEUTICS,XU JIE;;DENG SHOUYAN;;SONG TENG;;WANG YITING;;WANG YUNGANG;;WANG HUANBIN;;CHI HAO,FUDAN UNIVERSITY (2023-04-06);;BIOTROY THERAPEUTICS (2023-04-06),https://lens.org/041-548-457-590-030,Patent Application,yes,0,0,10,141-596-362-129-884;;117-737-465-635-380;;012-830-691-339-749;;179-940-049-730-189;;135-379-822-371-797;;041-548-457-590-030;;062-258-159-691-155;;069-312-271-266-182;;016-306-660-334-86X;;113-203-764-994-760,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,16,170-885-356-470-384;;155-511-236-801-038;;057-702-964-073-154;;082-179-368-407-966;;141-596-362-129-884;;100-638-283-986-592;;117-737-465-635-380;;179-940-049-730-189;;135-379-822-371-797;;041-548-457-590-030;;062-258-159-691-155;;003-380-232-194-921;;012-830-691-339-749;;113-203-764-994-760;;016-306-660-334-86X;;069-312-271-266-182,KR;;JP;;AU;;CN;;EP;;WO;;US;;CA,82,A61P35/00;;C07K2317/76;;C07K2317/92;;C07K2317/73;;A61K2039/505;;C07K2317/24;;C07K16/28;;C07K16/18;;C12N9/22;;C07K14/705;;A61K39/39;;A61K2039/585;;C07K2319/21;;A61K39/00;;C12N15/113;;C12N2310/14;;C12N2310/20;;C07K2317/34;;C07K2319/30;;C07K16/18;;C07K16/28;;C07K14/4702;;C07K14/705;;C12N9/22;;C12N15/113;;A61P35/00;;G01N33/574;;C07K2317/24;;C07K2317/73;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12N2310/20;;A61K39/00;;A61P35/00;;A61K31/7088;;A61K38/1709;;A61K38/465;;A61K48/005;;C07K14/47;;C07K16/18;;C07K2317/24;;C07K2317/31;;C07K2317/76;;C07K2317/92;;C12N15/113;;G01N33/57488;;A61K39/00,C07K16/18;;A61K31/7088;;A61K38/17;;A61K38/46;;A61K48/00;;A61P35/00;;C07K14/47;;C12N15/113;;G01N33/574,,0,0,,,,PENDING
567,US,A1,US 2021/0317412 A1,053-830-260-916-046,2021-10-14,2021,US 201917260049 A,2019-07-16,SG 10201806072Q A;;SG 2019050346 W,2018-07-16,Method For Isolating A Cardiomyocyte Population,"The present application relates to, inter alia, the identification, isolation and/or purification of cardiomyocytes in a sample. The method for isolating a cardiomyocyte population from a heterogeneous population of differentiated cells comprises: (a) contacting the sample with at least one agent that specifically binds to at least one cardiomyocyte surface marker selected from JAK2, DDR2, ACVRL1, CD200, SRPX, PRKACB, MST1R, P2RX1, TNFRSF10A, CHRND, KIAA0319, CD274, CCRL2, MBL2, ADORA3 and CD181; and (b) isolating the cells bound to the said agent. A preferred embodiment comprises contacting the sample with a first agent that specifically binds to a cell surface marker selected from JAK2, DDR2, ACVRL1, CD200, SRPX, PRKACB and MST1R to provide ventricular cardiomyocytes and a second agent that specifically binds to a cell surface marker selected from P2RX1, TNFRSF10A, CHRND, KIAA0319, CD274, CCRL2, MBL2, ADORA3 and CD181 to provide atrial cardiomyocytes. Another embodiment relates to the use of the isolated cardiomyocyte population for treating cardiovascular disease or disorder.",AGENCY SCIENCE TECH & RES,SOH BOON SENG,AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (2020-12-14),https://lens.org/053-830-260-916-046,Patent Application,yes,1,1,5,078-398-643-123-294;;079-181-955-802-754;;182-931-355-744-507;;069-754-566-178-487;;053-830-260-916-046,CN;;WO;;SG;;US,5,078-398-643-123-294;;079-181-955-802-754;;069-754-566-178-487;;182-931-355-744-507;;053-830-260-916-046,CN;;WO;;SG;;US,0,A61P9/00;;A61K35/34;;G01N33/56966;;G01N2800/32;;A61K35/34;;C12N5/0657;;G01N33/56966,C12N5/077;;A61K35/34;;G01N33/569,,5,4,047-957-827-563-036;;005-088-209-613-432;;087-757-615-847-20X;;044-977-393-460-556,10.1007/s12015-011-9273-3;;21614516;;pmc3226695;;10.1038/nbt.2005;;22020386;;pmc4949030;;26692321;;10.1186/s13045-015-0227-0;;pmc4687327;;28071970;;10.1080/19420862.2016.1268307;;pmc5297537,"Wiencierz, Anne Maria, et al. ""Differential expression levels of integrin α6 enable the selective identification and isolation of atrial and ventricular cardiomyocytes."" PLoS One 10.11 (2015): e0143538. (Year: 2015);;Lee, Yee-Ki, et al. ""Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes."" Stem Cell Reviews and Reports 7 (2011): 976-986. (Year: 2011);;Dubois, Nicole C., et al. ""SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells."" Nature biotechnology 29.11 (2011): 1011-1018. (Year: 2011);;Fan, Gaowei, et al. ""Bispecific antibodies and their applications."" Journal of hematology & oncology 8 (2015): 1-14. (Year: 2015);;Brinkmann, Ulrich, and Roland E. Kontermann. ""The making of bispecific antibodies."" MAbs. Vol. 9. No. 2. Taylor & Francis, 2017. (Year: 2017)",PENDING
568,US,A1,US 2023/0406963 A1,026-753-504-621-864,2023-12-21,2023,US 202318211178 A,2023-06-16,US 202318211178 A;;US 202263353480 P,2022-06-17,SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSES,System for and method of producing a pure starch slurry and alcohol by using combined corn wet and dry milling processes. A simple and lower cost process to obtain starch inside floury endosperm is provided. The starch can be highly purified to meet green technology process needs. The remaining starch inside the corn kernels can be used as feedstock for alcohol production and to produce valuable co-products such as oil and various animal feeds.,LEE TECH LLC,LEE CHIE YING,LEE TECH LLC (2024-05-12),https://lens.org/026-753-504-621-864,Patent Application,yes,1,0,6,125-939-550-205-073;;025-837-787-059-489;;026-753-504-621-864;;038-394-609-015-215;;050-613-247-775-349;;095-070-115-589-231,CN;;WO;;US,6,125-939-550-205-073;;025-837-787-059-489;;026-753-504-621-864;;038-394-609-015-215;;050-613-247-775-349;;095-070-115-589-231,CN;;WO;;US,0,C08B30/044;;C08B30/02;;C08B30/06;;C08B30/08;;A23K40/10;;A23K20/147;;A23K10/38;;A23K10/12;;A23K10/37;;A23K50/75;;A23K50/30;;A23K10/30;;A23K20/163;;A23K40/25;;Y02P60/87;;C08B30/02;;C08B30/044;;C08B30/08;;A23K40/10;;C08B30/06,C08B30/02;;A23K40/10;;C08B30/04;;C08B30/06;;C08B30/08,,0,0,,,,ACTIVE
569,CN,A,CN 117247932 A,174-021-276-598-035,2023-12-19,2023,CN 202210654223 A,2022-06-10,CN 202210654223 A,2022-06-10,Method for improving hat analogue utilization rate in in-vitro transcription,"According to the method for improving the utilization rate of the cap analogues in the co-transcription capping reaction process, the additional citrate or analogues thereof are added into an in-vitro transcription system, so that the utilization rate of the cap analogues is improved, the dosage of the cap analogues is reduced, and the material cost in the capping mRNA production process is greatly saved.",VAZYME BIOTECH NANJING CO LTD,XU XIAOYU;;JIN QIUHENG;;ZHANG KUNKUN;;DAI YA,,https://lens.org/174-021-276-598-035,Patent Application,no,2,0,1,174-021-276-598-035,CN,1,174-021-276-598-035,CN,0,C12N15/10,C12N15/10,,1,0,,,"VAZYME BIOTECH CO., LTD.: ""T7 High Yield RNA Transcription Kit"", Retrieved from the Internet <URL:www.vazyme.com>",PENDING
570,US,A1,US 2021/0310004 A1,019-955-894-430-765,2021-10-07,2021,US 201917264727 A,2019-07-29,EP 18186997 A;;EP 2019070363 W,2018-08-02,METHOD OF IDENTIFYING OR PRODUCING AN APTAMER FOR A DENATURED PEPTIDE OR PROTEIN,"The invention relates to a method of identifying or producing an aptamer, the method comprising the steps of: a) Providing a candidate mixture of nucleic acids; b) Contacting the candidate mixture with a target sample; c) Partitioning nucleic acids that bind to the target sample from those that do not bind; d) Amplifying the binding nucleic acids to produce a population of nucleic acids that bind the target sample; e) Single strand displacement of the amplified nucleic acids, f) optionally repeating the steps a) to e), thereby identifying or producing an aptamer, wherein the target sample provides one or more peptides and/or proteins in a denatured form.",UNIV BONN RHEINISCHE FRIEDRICH WILHELMS,MAYER GÜNTER;;KARNOWSKI NORA;;HAMANN MAREN;;LEGEN TJASA,RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (2021-01-25),https://lens.org/019-955-894-430-765,Patent Application,yes,2,0,4,019-346-327-090-545;;049-814-093-697-83X;;019-955-894-430-765;;153-837-073-284-087,EP;;WO;;US,4,019-346-327-090-545;;049-814-093-697-83X;;019-955-894-430-765;;153-837-073-284-087,EP;;WO;;US,7,C12Q1/6811;;C12N15/111;;C12N2310/16;;C12N2320/13;;G01N33/5308;;C12N15/115;;C12N2310/16;;C12N2320/13;;G01N33/5308,C12N15/115;;G01N33/53,,1,1,010-082-525-152-299,10.1007/s00253-015-6858-9;;26293334,"Mondal et al. (Appl. Micro. Biotech. (2015) 99, pages 9791-9803. (Year: 2015)",DISCONTINUED
571,US,A1,US 2024/0102112 A1,146-458-896-105-605,2024-03-28,2024,US 202318480799 A,2023-10-04,CN 202211126454 A;;CN 2022131935 W,2022-09-16,SOYASAPONIN-RELATED KOMPETITIVE ALLELE-SPECIFIC POLYMERASE CHAIN REACTION MARKERS AND APPLICATION THEREOF,"Soyasaponin-related Kompetitive Allele Specific polymerase chain reaction (KASP) markers and an application thereof are provided in the present application, belonging to the technical field of molecular breeding. The KASP markers include one or two of S07_43139773G/T, and S07_43139033A/G; the S07_43139773G/T comprises a base of G/T at a position of 43139773 bp on chromosome 7 of a soybean genome, the S07_43139033A/G comprises a base of A/G at a position of 43139033 bp on the chromosome 7 of the soybean genome. The KASP markers are applied to improve soyasaponin germplasm breeding.",JIANGSU ACAD AGRICULTURAL SCI,CHEN HUATAO;;ZHANG HONGMEI;;LIU XIAOQING;;ZHANG WEI;;WANG QIONG,JIANGSU ACADEMY OF AGRICULTURAL SCIENCES (2023-09-28),https://lens.org/146-458-896-105-605,Patent Application,yes,0,0,5,081-779-013-346-458;;014-913-321-155-359;;055-256-163-524-613;;158-970-153-936-828;;146-458-896-105-605,CN;;WO;;US,5,081-779-013-346-458;;014-913-321-155-359;;055-256-163-524-613;;158-970-153-936-828;;146-458-896-105-605,CN;;WO;;US,0,C12Q1/6895;;C12Q1/6858;;C12Q1/6895;;C12Q2600/13;;C12Q1/6858,C12Q1/6895;;C12Q1/6858,,0,0,,,,ACTIVE
572,KR,A,KR 20240023705 A,076-261-760-858-871,2024-02-22,2024,KR 20247004922 A,2014-06-27,US 201361840872 P;;KR 20227045978 A;;US 2014/0044731 W,2013-06-28,XTEN THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF,"본 발명은 VWF 링커를 통해 이종 잔기에 융합된 VWF 단백질을 포함하는 키메라 분자를 제공한다. 본 발명은 트롬빈의 존재하에서 절단될 수 있는 효율적인 VWF 링커를 제공한다. 키메라 분자는 FVIII 단백질 및 제2의 이종 잔기를 포함하는 폴리펩타이드를 추가로 포함할 수 있으며, 여기서 VWF 단백질을 포함하는 쇄 및 FVIII 단백질을 포함하는 쇄는 서로 연합되어 있다. 본 발명은 또한 뉴클레오타이드, 벡터, 숙주 세포, 키메라 단백질을 사용하는 방법을 포함한다.",BIOVERATIV THERAPEUTICS INC,CHHABRA EKTA SETH;;KULMAN JOHN;;LIU TONGYAO,,https://lens.org/076-261-760-858-871,Patent Application,no,6,0,54,056-718-336-435-548;;108-625-289-146-437;;109-771-699-937-997;;002-165-063-396-670;;147-512-909-538-698;;017-012-347-694-001;;076-271-810-654-631;;119-697-552-952-420;;099-126-103-150-219;;029-333-572-689-244;;008-198-383-701-266;;076-261-760-858-871;;064-341-713-517-18X;;155-291-821-543-779;;172-354-536-644-302;;084-550-627-519-978;;164-925-363-099-655;;168-913-968-616-472;;167-500-165-440-918;;133-093-648-281-625;;083-035-056-505-835;;049-111-109-878-205;;110-641-169-115-275;;158-557-344-575-069;;030-218-245-315-538;;017-037-321-916-367;;171-428-884-150-184;;143-424-667-648-644;;021-643-554-676-127;;096-232-075-824-633;;151-219-706-489-947;;053-056-909-811-813;;129-980-048-265-003;;098-555-575-403-893;;170-274-741-862-875;;103-102-945-487-105;;071-101-427-339-168;;159-367-652-525-249;;134-629-877-058-864;;151-297-505-939-124;;134-953-901-803-786;;160-998-209-843-724;;113-319-920-311-736;;072-394-016-707-323;;010-659-590-791-402;;000-290-433-355-21X;;029-101-185-233-420;;075-040-116-634-652;;025-332-123-992-598;;188-609-854-261-430;;091-806-928-029-93X;;037-735-308-492-356;;130-701-282-402-687;;100-247-148-502-200,JP;;AU;;EA;;CL;;US;;TW;;CA;;MX;;BR;;PH;;KR;;EP;;CN;;IL;;WO;;HK;;SG;;NZ,54,056-718-336-435-548;;108-625-289-146-437;;109-771-699-937-997;;002-165-063-396-670;;147-512-909-538-698;;017-012-347-694-001;;076-271-810-654-631;;119-697-552-952-420;;099-126-103-150-219;;029-333-572-689-244;;008-198-383-701-266;;076-261-760-858-871;;064-341-713-517-18X;;155-291-821-543-779;;172-354-536-644-302;;084-550-627-519-978;;164-925-363-099-655;;168-913-968-616-472;;167-500-165-440-918;;133-093-648-281-625;;083-035-056-505-835;;049-111-109-878-205;;110-641-169-115-275;;158-557-344-575-069;;030-218-245-315-538;;017-037-321-916-367;;171-428-884-150-184;;143-424-667-648-644;;021-643-554-676-127;;096-232-075-824-633;;151-219-706-489-947;;053-056-909-811-813;;129-980-048-265-003;;098-555-575-403-893;;170-274-741-862-875;;103-102-945-487-105;;071-101-427-339-168;;159-367-652-525-249;;134-629-877-058-864;;151-297-505-939-124;;134-953-901-803-786;;160-998-209-843-724;;113-319-920-311-736;;072-394-016-707-323;;010-659-590-791-402;;000-290-433-355-21X;;029-101-185-233-420;;075-040-116-634-652;;025-332-123-992-598;;188-609-854-261-430;;091-806-928-029-93X;;037-735-308-492-356;;130-701-282-402-687;;100-247-148-502-200,JP;;AU;;EA;;CL;;US;;TW;;CA;;MX;;BR;;PH;;KR;;EP;;CN;;IL;;WO;;HK;;SG;;NZ,184,A61K38/00;;C07K2319/00;;C07K2319/50;;C07K14/755;;A61P1/00;;A61P1/02;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/00;;A61P25/00;;A61P7/04;;C07K14/755;;C07K2319/00;;C07K2319/90;;C07K2319/30;;C07K2319/70;;A61K38/00;;A61K38/37;;A61K48/00;;C07K2319/50;;C07K2319/35;;A61P17/02;;A61P1/00;;A61P19/02;;A61P7/04;;A61P19/00;;A61P1/02;;A61P21/00;;A61P19/08;;A61P25/00;;C07K14/755;;C07K2319/50;;C07K2319/30;;A61K38/00;;C07K2319/00;;C07K2319/50;;C07K14/755;;A61K38/37;;A61K48/00;;C07K2319/30;;C07K2319/35;;C07K2319/70;;C07K2319/90,C07K14/755,,1,0,,,"Nature Biotech., Vol. 27, No. 12, pp.1186-1190 (2009. 11. 15.)",DISCONTINUED
573,US,A1,US 2024/0117329 A1,008-585-136-143-009,2024-04-11,2024,US 202318489816 A,2023-10-18,CN 202110755649 A;;CN 2022089839 W,2021-07-05,COCAINE ESTERASE MUTANT AND USE THEREOF,"Disclosed are a cocaine esterase mutant and use thereof. The cocaine esterase mutant is obtained by mutating a wildtype cocaine esterase, an amino acid sequence of the wildtype cocaine esterase is shown as SEQ ID No.1, the cocaine esterase mutant is T172R/G173Q/L196C/I301C, or additionally added with V116K point mutation, or additionally added with A51 site mutation, and the A51 site mutation is L, Y, V, F or W. Catalytic efficiency of the cocaine esterase mutant screened on a cocaine toxic metabolite benzoylecgonine is greatly improved compared with that of a wildtype enzyme.",UNIV HANGZHOU NORMAL,CHEN XIABIN;;YAO JIANZHUANG;;HOU SHURONG;;DENG XINGYU;;ZHANG YUN;;TONG JUNSEN,HANGZHOU NORMAL UNIVERSITY (2023-10-09),https://lens.org/008-585-136-143-009,Patent Application,yes,0,0,5,008-585-136-143-009;;000-957-561-095-486;;133-591-929-050-93X;;061-051-469-993-103;;041-012-650-570-255,CN;;WO;;US,5,008-585-136-143-009;;000-957-561-095-486;;133-591-929-050-93X;;061-051-469-993-103;;041-012-650-570-255,CN;;WO;;US,0,C12N9/18;;C12Y301/01084;;A61K38/465;;A61P39/02;;C02F3/342;;B09C1/10;;C02F2101/34;;C02F2101/38;;C12N9/18;;C12Y301/01084;;B09C1/10;;C02F2101/34;;C02F3/342;;B09C1/10;;C02F3/342;;C02F2101/38;;C12N9/18;;C12Y301/01084,C12N9/18;;B09C1/10;;C02F3/34,,0,0,,,,ACTIVE
574,WO,A1,WO 2024/099909 A1,059-386-930-738-606,2024-05-16,2024,EP 2023080714 W,2023-11-03,US 202263423177 P,2022-11-07,METHOD FOR LYSING CELLS AND TISSUE BY EMPLOYING A POLYMER AND THE USE OF THE POLYMER FOR THIS METHOD,Described is a method for lysing cells and tissue by employing certain polymers as well as the use of these polymers for totally or partially lysing cells and tissue.,CUBE BIOTECH GMBH,FABIS ROLAND;;MAERTENS BARBARA;;KUBICEK JAN;;HANISCH PHILIPP TIMO;;GALLEGO-BELLON ANA BELEN;;BUSCH RAMONA VIVIAN,,https://lens.org/059-386-930-738-606,Patent Application,yes,11,0,3,137-608-893-467-306;;036-142-034-852-093;;059-386-930-738-606,AU;;EP;;WO,3,137-608-893-467-306;;036-142-034-852-093;;059-386-930-738-606,AU;;EP;;WO,0,C12N1/06;;C12P21/00,C12N1/06,,13,11,145-892-407-043-825;;006-946-398-837-455;;038-544-196-380-759;;061-764-117-822-458;;014-104-522-551-163;;002-729-321-663-323;;080-146-486-941-891;;020-900-834-612-548;;131-543-929-261-164;;030-400-937-800-033;;021-050-318-438-473,10.1016/j.chempr.2020.08.004;;24903487;;10.1007/s00232-014-9679-3;;10.1021/acs.analchem.2c01746;;36200347;;21545287;;10.1146/annurev-biophys-042910-155219;;21166383;;10.1021/bm1011739;;10.1016/0301-4622(80)87012-8;;16997258;;10.1039/d1nr03811g;;35040850;;10.1039/b9py00301k;;10.1021/acs.biomac.0c00929;;32602705;;pmc5826593;;29171274;;10.1021/jacs.7b10591;;pmc7433539;;30667600;;10.1002/smll.201804813,"SMITH ANTON A.A. ET AL: ""Lipid Nanodiscs via Ordered Copolymers"", CHEM, vol. 6, no. 10, 1 October 2020 (2020-10-01), US, pages 2782 - 2795, XP093052980, ISSN: 2451-9294, DOI: 10.1016/j.chempr.2020.08.004;;MARIE E ET AL: ""Amphiphilic Macromolecules on Cell Membranes: From Protective Layers to Controlled Permeabilization"", JOURNAL OF MEMBRANE BIOLOGY, SPRINGER NEW YORK LLC, US, vol. 247, no. 9, 1 October 2014 (2014-10-01), pages 861 - 881, XP036830438, ISSN: 0022-2631, [retrieved on 20141001], DOI: 10.1007/S00232-014-9679-3;;MARCONNET ANAÏS ET AL: ""Influence of Hydrophobic Groups Attached to Amphipathic Polymers on the Solubilization of Membrane Proteins along with Their Lipids"", ANALYTICAL CHEMISTRY, vol. 94, no. 41, 6 October 2022 (2022-10-06), US, pages 14151 - 14158, XP093123391, ISSN: 0003-2700, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.analchem.2c01746> DOI: 10.1021/acs.analchem.2c01746;;J.-L. POPOT ET AL: ""Amphipols From A to Z*"", ANNUAL REVIEW OF BIOPHYSICS, vol. 40, no. 1, 9 June 2011 (2011-06-09), pages 379 - 408, XP055276256, ISSN: 1936-122X, DOI: 10.1146/annurev-biophys-042910-155219;;SOVADINOVA IVA ET AL: ""Mechanism of Polymer-Induced Hemolysis: Nanosized Pore Formation and Osmotic Lysis"", BIOMACROMOLECULES, vol. 12, no. 1, 17 December 2010 (2010-12-17), US, pages 260 - 268, XP093125038, ISSN: 1525-7797, DOI: 10.1021/bm1011739;;ANONYMOUS: ""RIPA Lysis and Extraction Buffer Catalog Numbers 89900 and 89901"", THERMOSCIENTIFIC PRODUCT INFORMATION SHEET, 28 January 2020 (2020-01-28), XP093125167;;SHINTARO SUGAINOBUMICHI OHNO: ""Conformational transitions of the hydrophobic polyacids"", BIOPHYSICAL CHEMISTRY, vol. 11, June 1980 (1980-06-01), pages 387 - 395, XP026591960, DOI: 10.1016/0301-4622(80)87012-8;;LEE: ""Hydrolysis of anhydride copolymer to diisobutylene-co- maleic acid"", NATURE PROTOCOLS, vol. 11, no. 7, 2016, pages 1149 - 1162;;B. DANIELCZAKM. RASCHEJ. LENZE. PEREZ PATALLOS. WEYRAUCHF. MAHLERM. TOPE AGBADAOLAA. MEISTERJ. OYEBAMIJI BABALOLAC. VARGAS: ""A bioinspired glycopolymer for capturing membrane proteins in native-like lipid-bilayer nanodiscsf"", NANOSCALE, vol. 14, 2022, pages 1855 - 1867, XP093100830, DOI: 10.1039/D1NR03811G;;S. HARRISSONF. ERCOLEB. W. MUIR: ""Living spontaneous gradient copolymers of acrylic acid and styrene: one-pot synthesis of pH-responsive amphiphiles"", POLYM. CHEM., vol. 1, 2010, pages 326 - 332;;MARCONNET, A.MICHON, B.LE BON, C.GIUSTI, F.TRIBET, C.ZOONENS, M.: ""Solubilization and stabilization of membrane proteins by cycloalkane-modified amphiphilic polymers"", BIOMACROMOLECULES, 2020;;YASUHARA KARAKIDA JRAVULA TRAMADUGU SKSAHOO BKIKUCHI JIRAMAMOORTHY A: ""Spontaneous Lipid Nanodisc Formation by Amphiphilic Polymethacrylate Copolymers"", J AM CHEM SOC., vol. 139, no. 51, 2017, pages 18657 - 18663;;N. Z. HARDINT. RAVULAG. DI MAUROA. RAMAMOORTHY: ""Hydrophobic Functionalization of Polyacrylic Acid as a Versatile Platform for the Development of Polymer Lipid Nanodisks"", SMALL, vol. 15, no. 9, March 2019 (2019-03-01), pages 1804813, XP093100842, DOI: 10.1002/smll.201804813",PENDING
575,US,A1,US 2025/0042973 A1,147-575-808-455-170,2025-02-06,2025,US 202418788909 A,2024-07-30,CN 202310959039 A,2023-08-01,RECOMBINANT PROTEIN OF GPER,Recombinant protein of GPER is provided. The recombinant protein has the biological activity of G protein-coupled estrogen receptor.,UNIV WUHAN,XIANG JIN;;ZHAO YING;;QI MIAOMIAO;;REN JING;;YAN YUJIE,WUHAN UNIVERSITY (2024-07-22),https://lens.org/147-575-808-455-170,Patent Application,yes,0,0,2,147-575-808-455-170;;189-745-394-298-701,CN;;US,2,147-575-808-455-170;;189-745-394-298-701,CN;;US,0,C07K14/721;;C12N15/70;;C12N2800/101;;C12R2001/19;;C12N15/63;;C07K2319/43;;C07K14/723;;G01N33/535;;C07K14/721;;C07K14/723;;C07K2319/43;;C12N15/63;;G01N33/535,C07K14/72;;C12N15/63;;G01N33/535,,0,0,,,,PENDING
576,EP,A1,EP 4516924 A1,071-560-857-490-020,2025-03-05,2025,EP 23909692 A,2023-11-08,CN 202211720270 A;;CN 2023130567 W,2022-12-30,"RECOMBINASE-MEDIATED FULL-FREEZE-DRYING CONSTANT-TEMPERATURE AMPLIFICATION SYSTEM, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a recombinase-mediated full-freeze-dried constant-temperature amplification system, a preparation method therefor, and use thereof. The full-freeze-dried constant-temperature amplification system includes two parts: a first part being an enzyme system, a second part being a primer, a probe and an activation system; the freeze-dried form of the enzyme system is freeze-dried powder, and that of the primer and the probe and the activation system are freeze-dried pellets. By preparing the enzyme system into freeze-dried powder, and mixing and preparing the activation system and the primer and the probe into freeze-dried pellets, the smoothness and homogeneity of liquid are improved, thereby avoiding the problem of unstable results due to high thickness of the whole system and thus difficult to disperse and homogenize during freeze-dried processes. Full-freeze-dried for RPA is achieved by easy operation of one-step sample loading. A kit including the full-freeze-dried constant-temperature amplification system has high sensitivity and specificity.",SANSURE BIOTECH INC,DING PINGHUI;;CAO CHANGZHENG;;JI BOZHI;;LIU JIA;;DAI LIZHONG,,https://lens.org/071-560-857-490-020,Patent Application,yes,0,0,3,185-377-428-708-691;;012-928-747-742-373;;071-560-857-490-020,CN;;EP;;WO,3,185-377-428-708-691;;012-928-747-742-373;;071-560-857-490-020,CN;;EP;;WO,8,Y02A50/30;;C12Q1/6844,C12Q1/6844;;C12N15/11;;C12Q1/70;;C12R1/93,,0,0,,,,PENDING
577,KR,A,KR 20240057912 A,010-369-916-614-356,2024-05-03,2024,KR 20220138727 A,2022-10-25,KR 20220138727 A,2022-10-25,Composition for skin improving comprising Citrus nippokoreana exosomes,"The present invention provides a cosmetic composition containing Citrus nippokoreana exosomes, which exhibit excellent moisturizing activity, skin wrinkle and elasticity improvement activity. The cosmetic composition is characterized by containing Citrus nippokoreana exosomes as an effective ingredient. According to the present invention, the Citrus nippokoreana exosomes are safe as a natural raw material, and exhibit excellent moisturizing activity and skin wrinkle and elasticity improvement activity.",DERMALAB,PARK HYUN CHUL;;KANG JUN CHUL;;YOON YOO GYEONG,,https://lens.org/010-369-916-614-356,Patent Application,no,4,0,2,089-194-217-479-743;;010-369-916-614-356,KR,2,089-194-217-479-743;;010-369-916-614-356,KR,0,A61K8/9789;;A61Q19/00;;A61Q19/007;;A61Q19/08;;A61K2800/591,A61K8/9789;;A61Q19/00;;A61Q19/08,,1,0,,,"블루뉴스. [BioTech] 요즘 대세 ‘엑소좀’, 줄기세포 아닌 ‘식물 엑소좀’ 뜬다. [online], (2022.05.25. 공개)*",ACTIVE
578,US,A1,US 2024/0197847 A1,043-027-043-978-229,2024-06-20,2024,US 202318398273 A,2023-12-28,CN 202110759727 A;;CN 2022082141 W,2021-07-05,RECOMBINANT PROTEIN CAPABLE OF RESISTING MULTIPLE SCLEROSIS AND PREPARATION METHOD AND APPLICATION THEREOF,"The present invention discloses a recombinant protein capable of resisting multiple sclerosis and a preparation method and application thereof, and belongs to the technical field of biopharmacy. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and 6-segment tandem repeat myelin oligodendroglia glycoprotein antigen epitope polypeptides with multiple sclerosis autoimmune antigen characteristics at the 33rd-55th sites. The recombinant protein capable of resisting multiple sclerosis is used for preparing multiple sclerosis vaccines and/or preparing multiple sclerosis drugs. The present invention can play a role in preventing multiple sclerosis and can avoid side effects caused by most of disease modifying therapy (DMT) drugs.",INST OF ZOOLOGY GUANGDONG ACADEMY OF SCIENCES,SUN YUNXIAO;;RAO JUNHUA;;CAO DAINAN;;PENG ZHEN;;ZHANG LIBIAO;;LI BIHAI;;HE XIANGYANG;;JI FANG,INSTITUTE OF ZOOLOGY GUANGDONG ACADEMY OF SCIENCES (2023-12-21),https://lens.org/043-027-043-978-229,Patent Application,yes,0,0,9,188-648-881-260-021;;088-248-240-181-456;;143-697-626-013-064;;083-888-554-176-194;;079-935-420-276-661;;047-288-206-835-769;;043-353-125-682-249;;007-892-654-789-014;;043-027-043-978-229,NL;;AU;;JP;;CN;;WO;;US,9,188-648-881-260-021;;088-248-240-181-456;;143-697-626-013-064;;083-888-554-176-194;;079-935-420-276-661;;007-892-654-789-014;;043-353-125-682-249;;047-288-206-835-769;;043-027-043-978-229,NL;;AU;;JP;;CN;;WO;;US,0,C07K14/35;;C07K14/4713;;C12N15/70;;A61K39/0008;;A61P25/00;;A61P37/02;;C07K2319/35;;C07K2319/21;;C12N2800/22;;A61K38/00;;A61K39/0008;;A61K2039/55544;;A61K2039/6043;;A61K2039/627;;A61K2039/64;;A61P37/06;;C07K14/35;;C07K14/4713;;C07K2319/00;;C07K2319/21;;A61P25/28;;A61P37/06;;A61K39/0008;;A61K2039/543;;C07K14/47;;C12N15/70;;C12P21/02,A61K39/00;;A61P25/28;;A61P37/06;;C07K14/47;;C12N15/70;;C12P21/02,,0,0,,,,PENDING
579,US,A1,US 2024/0317825 A1,143-932-244-233-632,2024-09-26,2024,US 202418607763 A,2024-03-18,CN 202310275338 A,2023-03-21,FISH-DERIVED PEPTIDOGLYCAN RECOGNITION PROTEIN MUTANTAND APPLICATION THEREOF,"A fish-derived peptidoglycan recognition protein mutant and an application thereof are provided. An amino acid sequence of the mutant is shown in SEQ ID NO.1, a nucleotide sequence of the mutant is shown in SEQ ID NO.2. The present disclosure provides the preparation method for the mutant with a broad-spectrum antibacterial activity and robust inhibitory effects on both Gram-positive and Gram-negative bacteria. Compared with the wild-type LcPGRP5 protein, the mutant protein demonstrates a stronger ability to inhibit the activity against Staphylococcus aureus and enhance the phagocytic ability of fish macrophages.",OCEAN UNIV CHINA,LI QINGFEI;;AI QINGHUI,,https://lens.org/143-932-244-233-632,Patent Application,yes,1,0,4,199-592-135-775-217;;073-291-611-674-276;;038-696-859-779-270;;143-932-244-233-632,CN;;US,4,199-592-135-775-217;;073-291-611-674-276;;143-932-244-233-632;;038-696-859-779-270,CN;;US,0,C07K14/461;;C12N15/70;;A61P31/04;;A61P37/04;;A23K20/147;;C12N2800/101;;A61K38/00;;A61P31/04;;A61K38/00;;C07K14/461;;A61P37/04;;A61P37/04;;A61P31/04;;A61K38/00;;C07K14/461,C07K14/46;;A61K38/00;;A61P31/04;;A61P37/04,,2,1,088-665-930-669-595,10.1016/j.dci.2021.104130;;34081942,"English translation of KR-20200014975-A obtained from PE2E ON 31 May 2024 (Year: 2024);;Li et al., “Molecular identification of peptidoglycan recognition protein 5 and its functional characterization in innate immunity of large yellow croaker, Larimichthys crocea”, Developmental and Comparative Immunology, 124, 10 pages, available online 31 May 2021 (Year: 2021)",ACTIVE
580,WO,A1,WO 2022/006745 A1,094-313-148-785-199,2022-01-13,2022,CN 2020100684 W,2020-07-07,CN 2020100684 W,2020-07-07,GUIDE RNA FOR HSV-1 GENE EDITING AND METHOD THEREOF,"Provided is a guide RNA (gRNA) comprising a guide sequence capable of targeting a Cas9 protein to a target sequence in an ICP6 gene of type 1-herpes simplex virus (HSV-1) to provide a specific cleavage event, wherein the target sequence comprises a GATC insertion as compared to a wild-type HSV-1. Also provided is a HSV-1 gene-editing system and a gene-editing method for generating a desired recombinant HSV-1 by using said gRNA.",ORIENGENE BIOTECHNOLOGY LTD,LI XIAOMING;;SHU XIAO;;JIA RU;;WANG NING,,https://lens.org/094-313-148-785-199,Patent Application,yes,9,1,5,026-391-008-715-575;;106-714-745-042-220;;190-721-428-784-716;;057-883-392-418-027;;094-313-148-785-199,JP;;EP;;CN;;WO;;US,5,026-391-008-715-575;;106-714-745-042-220;;094-313-148-785-199;;057-883-392-418-027;;190-721-428-784-716,JP;;EP;;CN;;WO;;US,36,C12N9/22;;C12N15/1133;;C12N2310/20;;C12N15/113;;C12N9/22;;C12N2310/20,C12N15/113;;A61P31/22;;C12N5/10;;C12N15/90,,1,1,123-456-711-771-596,32122544;;10.1016/bs.mie.2019.08.011,"BOMMAREDDY PRAVEEN, PETERS COLE, KAUFMAN HOWARD: ""Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption"", METHODS IN ENZYMOLOGY, vol. 635, 31 December 2019 (2019-12-31), pages 167 - 184, XP009533949, ISSN: 0076-6879, DOI: 10.1016/bs.mie.2019.08.011",PENDING
581,JP,A,JP 2022548150 A,102-296-912-186-260,2022-11-16,2022,JP 2022517150 A,2020-09-16,EP 19197876 A;;EP 19214837 A;;EP 2020075840 W,2019-09-17,高濃縮タンパク質製剤中の粘度低減剤としてのカンファースルホン酸およびそのカチオン性賦形剤との組み合わせ,本発明は、低減された粘度を示す高度に濃縮されたタンパク質の組成物に関し、これは、少なくともカンファースルホン酸の添加によって誘導される。調製される製剤に含有されるタンパク質は、凝集および変性に対して安定化されており、およびしたがって、患者への投与まで十分に保管安定性である。,メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング,ローゼンクランツ，トビアス;;ギュベリ，ラファエル ヨハネス;;ヘンツラー，タンヤ;;クローグ，アレクサンドラ;;ヒルデブラント，クリスティアン,,https://lens.org/102-296-912-186-260,Patent Application,no,3,0,11,063-371-590-300-407;;048-324-904-902-182;;031-708-403-034-642;;029-309-235-543-893;;040-990-546-327-395;;126-075-017-749-364;;102-296-912-186-260;;045-522-800-320-864;;010-720-890-326-764;;193-707-121-897-108;;198-317-477-383-915,AU;;JP;;KR;;CN;;EP;;WO;;US;;CA;;PH;;BR,11,063-371-590-300-407;;048-324-904-902-182;;126-075-017-749-364;;029-309-235-543-893;;102-296-912-186-260;;040-990-546-327-395;;031-708-403-034-642;;045-522-800-320-864;;010-720-890-326-764;;193-707-121-897-108;;198-317-477-383-915,JP;;AU;;KR;;EP;;CN;;WO;;US;;CA;;PH;;BR,0,A61K39/395;;A61K47/183;;A61K47/18;;A61K47/20;;A61K9/19;;A61K9/08;;A61K9/08;;A61K9/0019;;A61K47/42;;A61K47/183;;A61K47/20;;C07K16/241;;C07K16/40;;C07K16/244;;A61K39/39591;;A61K9/08;;A61K47/20;;A61K47/183;;A61K39/39591;;A61K9/0019;;C07K16/241;;C07K16/244;;C07K16/40;;A61K47/183;;A61K47/20;;C07K16/241,A61K38/00;;A61K9/08;;A61K39/395;;A61K47/18;;A61K47/20;;A61P37/02,,1,0,,,"BIOTECH BIOENG, vol. 108, no. 3, JPN6024034178, 2010, pages 632 - 636, ISSN: 0005663921",PENDING
582,US,A1,US 2024/0301461 A1,014-059-171-347-565,2024-09-12,2024,US 202418414523 A,2024-01-17,CN 202310067492 A;;CN 202310081810 A,2023-01-17,Recombinant Escherichia Coli for Expressing Synthesis Pathway of Asiaticoside and Application Thereof,"The present disclosure discloses recombinant Escherichia coli for expressing a synthesis pathway of asiaticoside and application thereof, and belongs to the field of bioengineering. Rhamnosyltransferase with an amino acid sequence shown in any one of SEQ ID NO: 25 to SEQ ID NO: 29, glucosyltransferase with an amino acid sequence shown in any one of SEQ ID NO: 10 to SEQ ID NO: 17 and UGT73AH1 reported in a document are transferred into E. coli BL21 (DE3)Δpgi to realize co-expression. Fermentation results show that all 5 rhamnosyltransferases screened in the present disclosure can achieve effects, and a unique new peak appears at 0.596 min, which is consistent with a characteristic ion flow of an asiaticoside standard product. According to the present disclosure, barriers of the prior art are broken through, a new biosynthesis method for asiaticoside is provided, and industrialization of biosynthesis of asiaticoside becomes possible.",UNIV JIANGNAN,ZHOU JINGWEN;;ZENG WEIZHU;;ZHAO XINGYING;;XU SHA;;CHEN JIAN,JIANGNAN UNIVERSITY (2024-01-16),https://lens.org/014-059-171-347-565,Patent Application,yes,0,1,1,014-059-171-347-565,US,5,112-545-010-987-12X;;097-487-318-866-426;;014-059-171-347-565;;131-255-136-213-22X;;160-798-659-911-994,CN;;US,0,C12P19/485;;C12N9/1051;;C12N1/205;;C12P19/485;;C12N9/1051;;C12N2527/00;;C12R2001/19;;C12N1/205,C12P19/48;;C12N1/20;;C12N9/10;;C12R1/19,,0,0,,,,PENDING
583,US,A1,US 2023/0374524 A1,194-445-339-917-414,2023-11-23,2023,US 202318313946 A,2023-05-08,US 202318313946 A;;US 202017004338 A;;US 201514685568 A;;KR 2013009488 W;;US 201361837481 P;;US 201361803599 P;;US 201261717324 P,2012-10-23,"COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF","The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.",TOOLGEN INC,KIM JIN-SOO;;CHO SEUNG WOO;;KIM SOJUNG,,https://lens.org/194-445-339-917-414,Patent Application,yes,5,6,109,130-193-940-233-072;;129-607-003-526-518;;035-618-733-330-299;;057-446-886-215-734;;127-549-298-150-195;;097-555-909-158-175;;051-821-222-074-637;;011-821-151-065-889;;061-220-095-007-712;;185-902-249-050-217;;105-111-999-326-195;;057-369-364-461-923;;117-727-924-933-530;;096-099-831-053-724;;052-629-887-742-27X;;007-260-819-731-609;;064-673-784-003-646;;183-064-880-999-923;;028-486-214-586-545;;101-092-591-283-121;;131-214-511-514-833;;014-840-008-005-245;;182-718-813-217-534;;065-097-459-392-557;;023-431-041-854-205;;131-869-669-498-092;;159-545-351-423-782;;161-080-785-927-704;;021-901-917-844-951;;180-668-678-010-964;;138-424-581-682-410;;112-008-928-354-656;;068-053-373-511-820;;133-846-170-804-135;;167-568-777-804-816;;088-125-944-222-287;;088-582-528-857-949;;030-608-013-793-227;;070-700-572-458-583;;055-609-004-368-415;;098-581-702-902-679;;120-652-329-956-572;;123-699-563-080-270;;065-910-833-830-457;;051-814-430-727-326;;192-987-291-639-323;;033-567-348-838-598;;177-695-598-479-506;;158-459-392-803-450;;048-722-510-967-286;;184-668-493-787-705;;192-853-032-254-61X;;095-366-157-591-447;;192-557-543-862-24X;;051-264-365-896-057;;173-713-854-270-527;;127-613-188-840-068;;054-278-592-273-358;;138-994-530-399-687;;080-254-367-991-659;;108-064-841-017-448;;166-152-538-383-73X;;186-387-595-633-32X;;072-446-814-719-97X;;194-445-339-917-414;;085-873-432-525-166;;039-997-534-626-693;;054-560-061-068-24X;;158-412-271-368-829;;147-749-038-378-830;;138-340-719-079-262;;064-777-781-226-912;;100-591-804-244-397;;055-326-696-570-779;;005-140-747-443-018;;010-096-259-422-563;;124-234-505-651-086;;069-905-377-705-650;;087-943-610-339-950;;129-761-556-820-106;;015-922-341-817-517;;005-718-012-045-447;;094-734-204-003-83X;;170-443-187-193-348;;146-981-713-284-839;;123-702-309-042-265;;034-473-129-108-084;;005-109-914-186-616;;163-661-732-094-065;;035-978-097-386-37X;;137-672-321-829-339;;002-916-472-744-255;;004-627-840-896-618;;135-992-463-739-38X;;036-607-372-891-762;;030-699-264-319-358;;177-814-713-874-691;;094-185-834-205-381;;097-656-827-354-351;;012-834-894-257-792;;168-332-172-411-37X;;100-055-655-457-567;;003-423-663-192-466;;080-090-719-627-706;;036-828-625-723-126;;054-377-993-393-127;;093-355-771-725-808;;033-580-807-394-92X;;089-333-977-926-398,AU;;JP;;US;;CA;;BR;;PT;;PL;;DE;;KR;;EP;;CN;;ES;;WO;;HK;;SG;;DK,120,130-193-940-233-072;;129-607-003-526-518;;035-618-733-330-299;;057-446-886-215-734;;127-549-298-150-195;;097-555-909-158-175;;051-821-222-074-637;;011-821-151-065-889;;061-220-095-007-712;;185-902-249-050-217;;105-111-999-326-195;;057-369-364-461-923;;117-727-924-933-530;;096-099-831-053-724;;052-629-887-742-27X;;007-260-819-731-609;;064-673-784-003-646;;183-064-880-999-923;;028-486-214-586-545;;101-092-591-283-121;;014-840-008-005-245;;131-214-511-514-833;;182-718-813-217-534;;065-097-459-392-557;;023-431-041-854-205;;131-869-669-498-092;;159-545-351-423-782;;161-080-785-927-704;;021-901-917-844-951;;112-008-928-354-656;;138-424-581-682-410;;180-668-678-010-964;;068-053-373-511-820;;133-846-170-804-135;;167-568-777-804-816;;088-125-944-222-287;;088-582-528-857-949;;030-608-013-793-227;;070-700-572-458-583;;120-652-329-956-572;;098-581-702-902-679;;055-609-004-368-415;;065-910-833-830-457;;123-699-563-080-270;;051-814-430-727-326;;133-981-962-143-795;;192-987-291-639-323;;033-567-348-838-598;;177-695-598-479-506;;158-459-392-803-450;;048-722-510-967-286;;184-668-493-787-705;;192-853-032-254-61X;;095-366-157-591-447;;192-557-543-862-24X;;173-713-854-270-527;;051-264-365-896-057;;127-613-188-840-068;;054-278-592-273-358;;138-994-530-399-687;;080-254-367-991-659;;108-064-841-017-448;;166-152-538-383-73X;;085-873-432-525-166;;072-446-814-719-97X;;194-445-339-917-414;;186-387-595-633-32X;;039-997-534-626-693;;054-560-061-068-24X;;158-412-271-368-829;;147-749-038-378-830;;138-340-719-079-262;;064-777-781-226-912;;100-591-804-244-397;;055-326-696-570-779;;005-140-747-443-018;;085-442-901-489-619;;010-096-259-422-563;;124-234-505-651-086;;069-905-377-705-650;;087-943-610-339-950;;015-922-341-817-517;;129-761-556-820-106;;176-988-092-014-907;;005-718-012-045-447;;094-734-204-003-83X;;170-443-187-193-348;;123-702-309-042-265;;146-981-713-284-839;;056-900-418-432-675;;193-803-852-476-614;;116-724-065-439-656;;034-473-129-108-084;;133-401-815-546-638;;005-109-914-186-616;;163-661-732-094-065;;035-978-097-386-37X;;110-479-838-667-091;;137-672-321-829-339;;002-916-472-744-255;;004-627-840-896-618;;135-992-463-739-38X;;036-607-372-891-762;;030-699-264-319-358;;058-963-107-844-489;;177-814-713-874-691;;094-185-834-205-381;;097-656-827-354-351;;012-834-894-257-792;;168-332-172-411-37X;;100-055-655-457-567;;003-423-663-192-466;;080-090-719-627-706;;147-940-000-392-747;;036-828-625-723-126;;054-377-993-393-127;;093-355-771-725-808;;036-489-637-038-675;;033-580-807-394-92X;;089-333-977-926-398,AU;;JP;;US;;CA;;BR;;PT;;PL;;DE;;KR;;EP;;CN;;ES;;WO;;HK;;SG;;DK,0,C12N2310/531;;C12N15/8216;;C12Y301/21;;C12N9/22;;C12N15/102;;C12N15/63;;C12N9/16;;C12N15/52;;C12N15/111;;C12N2310/20;;C12N15/907;;A61K48/005;;C12N9/16;;C12N15/113;;C12N15/8216;;C12N15/8509;;C12Q1/683;;C12N15/85;;C12N15/907;;C12N9/22;;C12Y301/21;;C12N15/8216;;C12N2310/531;;C12N15/102;;C12N15/63;;C12N15/111;;C12N2310/10;;C12N2310/20;;C12N9/16;;C12N15/52,C12N15/52;;C12N9/16;;C12N9/22;;C12N15/10;;C12N15/11;;C12N15/63;;C12N15/82;;C12N15/85;;C12N15/90,,8,1,015-250-384-665-091,10.1038/nbt.2357;;22965054,"Barrangou in “RNA-mediated programmable DNA cleavage” (Nature Biotechnology Vol 30, No. 9, September, 2012). (Year: 2012);;Chang et al (Cell Research published online March 26, 2013). (Year: 2013);;Lei et al (Cell Vol. 152, pages 1173-1183; February 28, 2013). (Year: 2013);;Cho et al Nature Biotech Supplemental 2013 (Year: 2013);;Cho et al Nature Biotech 2013 (Year: 2013);;Lei et al Cell vol 152 Feb 2013 (Year: 2013);;Cho_et_al_Genetics_Nov_2013 (Year: 2013);;Woo_et_al_2015 (Year: 2015)",PENDING
584,WO,A2,WO 2025/136809 A2,094-964-625-543-248,2025-06-26,2025,US 2024/0060005 W,2024-12-13,US 202363611956 P,2023-12-19,FOXP3 PEPTIDES AND USES THEREOF,"The present disclosure relates to methods and compositions that involve isolated FOXP3 peptides, and the use of such methods and compositions for FOXP3-mediated targeting of regulatory T (Treg) cells.",REGENERON PHARMA,SALZLER ROBERT;;VAN METER MICHAEL;;GLATMAN ZARETSKY ARIELLE,,https://lens.org/094-964-625-543-248,Patent Application,yes,30,0,2,170-899-575-466-761;;094-964-625-543-248,WO,2,170-899-575-466-761;;094-964-625-543-248,WO,74,A61K39/001152;;A61K2039/804;;C07K7/06,A61K39/00;;C07K7/06,,40,25,012-864-412-905-003;;095-050-980-581-957;;081-762-779-850-964;;059-038-435-839-492;;039-312-419-452-38X;;007-161-773-585-269;;039-384-864-129-401;;026-148-170-669-52X;;111-501-633-494-339;;021-612-452-406-271;;095-816-628-799-005;;141-208-529-655-994;;184-768-281-734-589;;055-967-816-032-116;;023-548-466-854-445;;044-155-666-905-31X;;138-162-461-737-942;;006-831-258-306-759;;161-964-195-854-30X;;110-090-195-698-322;;010-901-227-513-259;;124-322-713-188-743;;044-250-687-171-939;;127-620-478-044-380;;146-477-151-265-851,pmc50400;;10.1073/pnas.89.22.10658;;1438262;;10.1006/bbrc.1999.1372;;10491297;;10683722;;10.2144/00282bm01;;11252783;;10.2144/01303bm04;;10.2144/00295bm09;;11084857;;1518797;;10.1093/protein/5.5.467;;9512562;;10.1093/nar/26.7.1848;;pmc147442;;8655519;;pmc178091;;10.1128/jb.178.11.3346-3349.1996;;8590473;;10.1007/bf00315788;;8850009;;10.1385/0-89603-332-5:229;;17328535;;10.1021/jm0613368;;pmc4226423;;25311806;;10.4049/jimmunol.1400800;;pmc2191874;;7836906;;10.1084/jem.181.2.493;;1525820;;10.1016/0092-8674(92)90252-8;;10.2210/pdb1hsa/pdb;;10.1126/science.1323878;;10.2210/pdb1vaa/pdb;;1323878;;8552612;;pmc40213;;10.1073/pnas.93.1.236;;10072510;;10.4049/jimmunol.162.5.2671;;9469415;;10.4049/jimmunol.160.4.1598;;10.4049/jimmunol.168.7.3145;;11907065;;10.4049/jimmunol.178.10.6280;;17475856;;10.1182/blood-2009-03-211714;;pmc2929689;;19451549;;22395641;;10.1093/jnci/djs033;;pmc3328421;;8840994;;pmc2195739;;10.1084/jem.190.11.1669;;10587357;;10.1182/blood.v98.1.49;;11418462,"SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;SAMBROOK ET AL.: ""DNA Cloning: A Practical Approach"", 1985, D.N. GLOVER;;B. PERBAL: ""A Practical Guide To Molecular Cloning"", 1984;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS, INC.;;MAGE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10658 - 10662;;FUKUOKA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, vol. 263, 1999, pages 357 - 360;;KIMMAAS, BIOTECH, vol. 28, 2000, pages 196 - 198;;PARIKHGUENGERICH, BIOTECH, vol. 24, no. 4, 1998, pages 28 - 431;;RAYNICKOLOFF, BIOTECH, vol. 19, 1995, pages 556 - 559;;WANGMALCOLM, BIOTECH, vol. 26, 1999, pages 639 - 641;;HOGREFE, STRATEGIES, vol. 14, no. 3, 2001, pages 74 - 75;;ANGAGSCHUTZ, BIOTECH, vol. 30, 2001, pages 486 - 488;;WANGWILKINSON, BIOTECH, vol. 29, 2000, pages 976 - 978;;KANG ET AL., BIOTECH, vol. 20, 1996, pages 44 - 46;;OGELMCPHERSON, PROTEIN ENGINEER, vol. 5, 1992, pages 467 - 468;;KIRSCHJOLY, NUCL. ACIDS. RES, vol. 26, 1998, pages 1848 - 1850;;RHEMHANCOCK, J. BACTERIOL, vol. 178, 1996, pages 3346 - 3349;;BOLESMIOGSA, CURR. GENET, vol. 28, 1995, pages 197 - 198;;BARRENTTINO ET AL., NUC. ACIDS. RES, vol. 22, 1993, pages 541 - 542;;TESSIERTHOMAS, METHS. MOLEC. BIOL, vol. 57, pages 229 - 237;;PONS ET AL., METH. MOLEC. BIOL, vol. 67, pages 209 - 218;;MEZIERE C. ET AL., J IMMUNOL, 1997;;DOUAT-CASASSUS ET AL., J. MED. CHEM, vol. 50, no. 7, 2007, pages 1598 - 609;;HOPPES ET AL., J. IMMUNOL, vol. 193, no. 10, 2014, pages 4803 - 13;;MOTTEZ ET AL., J. EXP. MED., vol. 181, 1995, pages 493 - 502;;MADDEN ET AL., CELL, vol. 70, 1992, pages 1035 - 1048;;MATSUMURA ET AL., SCIENCE, vol. 257, 1992, pages 927 - 934;;TOSHITANI ET AL., PROC. NAT'L ACAD. SCI., vol. 93, 1996, pages 236 - 240;;WHITE ET AL., J. IMMUNOL., vol. 162, 1999, pages 2671 - 2676;;UGERBARBER, J. IMMUNOL., vol. 160, 1998, pages 1598 - 1605;;YU ET AL., J. IMMUNOL., vol. 168, 2002, pages 3145 - 3149;;TRUSCOTT ET AL., J. IMMUNOL., vol. 178, 2007, pages 6280 - 6289;;""GenBank"", Database accession no. X00497;;JOHNSON ET AL., BLOOD, vol. 114, no. 3, 2009, pages 535 - 46;;SCHLOM, J NATL CANCER INST, vol. 104, no. 8, 2012, pages 599 - 613;;SALGALLER, CANCER RES., vol. 56, no. 20, 1996, pages 4749 - 57;;MARCHAND, INT J CANCER, vol. 80, no. 2, 1999, pages 219 - 30;;THURNER, J EXP MED., vol. 190, no. 11, 1999, pages 1669 - 78;;VAN TENDELOO, BLOOD, vol. 98, no. 1, 2001, pages 49 - 56",PENDING
585,US,A1,US 2022/0395476 A1,130-935-663-752-13X,2022-12-15,2022,US 202017765354 A,2020-09-29,CN 201910943781 A;;CN 2020118945 W,2019-09-30,"DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF","Provided are a drug for treating artery-related diseases and the use thereof. Specifically, provided are the use of a class of compounds of formula I in the treatment of artery-related diseases. Experiments show that the compounds of formula I have a significant effect on aneurysm, intramural hematoma and/or atrerial dissection.",SHANGHAI INST MATERIA MEDICA CAS,JIANG BAOHONG;;ZHANG XIANJING;;DING YUCHAO;;ZHAI ZIYI,SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (2022-03-15),https://lens.org/130-935-663-752-13X,Patent Application,yes,0,1,8,041-286-803-614-828;;162-193-101-772-375;;116-767-179-960-28X;;185-706-802-201-044;;130-935-663-752-13X;;043-900-448-140-76X;;036-528-482-359-878;;031-648-229-398-480,JP;;CN;;EP;;WO;;US,8,041-286-803-614-828;;162-193-101-772-375;;116-767-179-960-28X;;185-706-802-201-044;;130-935-663-752-13X;;043-900-448-140-76X;;031-648-229-398-480;;036-528-482-359-878,JP;;CN;;EP;;WO;;US,0,A61K31/216;;A61K31/192;;A61K31/37;;A61K31/085;;A61K35/644;;A61K36/534;;A61K36/23;;A61K36/232;;A61K36/11;;A61K36/236;;A61K36/71;;A61K36/725;;A61K36/287;;A61K36/61;;A61K36/53;;A61K36/70;;A61K36/185;;A61K36/234;;A61K36/85;;A61K36/537;;A61K36/63;;A61K36/282;;A61K36/83;;A61K36/748;;A61K36/258;;A61K36/39;;A61K36/43;;A61K36/52;;A61K36/75;;A61K36/9062;;A61K36/575;;A61K36/88;;A61K36/328;;A61K36/738;;A61K36/74;;A61K36/54;;A61K36/899;;A61K36/535;;A61K36/8962;;A23L33/00;;A61P9/14;;A23V2002/00;;A61P9/14;;A61K31/216;;A61K36/534;;A61K31/192;;A61K31/37;;A61K31/085;;A61P9/00;;A61K31/05;;A61K31/343;;A61K31/12;;A61K31/05;;A61K31/12;;A61K31/192;;A61K31/216;;A61K31/37;;A61K36/185,A61K31/12;;A61K31/05;;A61K31/192;;A61K31/216;;A61K31/37;;A61K36/185,,4,3,039-426-414-825-437;;139-484-684-404-30X;;042-981-073-961-721,pmc3696626;;10.5625/lar.2013.29.2.63;;23825478;;pmc6789891;;31390798;;10.3390/ph12030118;;pmc6391314;;10.3389/fphar.2019.00097;;30842735,"Andrea Harriot, ""Idiopathic Non-atherosclerotic Carotid Artery Disease, Cerebrovascular Disease and Stroke (S Silverman, Section Editor) Published: 14 November 2019 (Year: 2019);;Gim et al., “”Ferulic acid regulates the AKT/GSK-3B/CRMP-2 Signaling pathway in a middle cerebral artery occlusion animal model”, Lab Anim Res., June 24, 2013 (Year: 2013);;Maguire et al., “Matrix Metalloproteinase in Abdominal Aortic Aneurysm and Aortic Dissection”, Pharmaceuticals, August 6, 2019 (Year: 2019);;Ma et al., “Salvianolic Acids: Potential Source of Natural Drugs for the Treatment of Fibrosis Disease and Cancer”, Front Pharmacol. February 19, 2019 (Year: 2019)",PENDING
586,US,A1,US 2022/0017897 A1,190-721-428-784-716,2022-01-20,2022,US 202017040796 A,2020-07-20,CN 2020100684 W,2020-07-07,GUIDE RNA FOR HSV-1 GENE EDITING AND METHOD THEREOF,"The invention relates to a guide RNA (gRNA) comprising a guide sequence capable of targeting a Cas9 protein to a target sequence in an ICP6 gene of type 1-herpes simplex virus (HSV-1) to provide a specific cleavage event, wherein the target sequence comprises a GATC insertion as compared to a wild-type HSV-1. The invention also relates to a HSV-1 gene-editing system and a gene-editing method for generating a desired recombinant HSV-1 by using said gRNA.",ORIENGENE BIOTECHNOLOGY LTD,LI XIAOMING;;SHU XIAO;;JIA RU;;WANG NING,ORIENGENE BIOTECHNOLOGY LTD (2020-07-24),https://lens.org/190-721-428-784-716,Patent Application,yes,0,0,5,026-391-008-715-575;;106-714-745-042-220;;190-721-428-784-716;;057-883-392-418-027;;094-313-148-785-199,JP;;EP;;CN;;WO;;US,5,026-391-008-715-575;;106-714-745-042-220;;094-313-148-785-199;;057-883-392-418-027;;190-721-428-784-716,JP;;EP;;CN;;WO;;US,36,C12N9/22;;C12N15/1133;;C12N2310/20;;C12N15/113;;C12N2310/20;;C12N9/22,C12N15/113;;C12N9/22,,7,4,002-106-384-191-115;;011-259-975-523-162;;012-850-232-858-863;;018-538-384-825-51X,18345032;;pmc7100519;;10.1038/onc.2008.53;;10.3390/v8030072;;26959050;;pmc4810262;;6313347;;10.1002/j.1460-2075.1983.tb01468.x;;pmc555066;;pmc250519;;2824847;;10.1128/jvi.62.1.196-205.1988,"Aghi et al. 2008. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 27:4249-4524 (Year: 2008);;Yuan et al. 2016. CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses. Viruses 8:72 (Year: 2016);;Kalnins (et al. 1983. Sequence of the lacZ gene of Escherichia coli. EMBO J. 2[4]:593-597; “Kalnins”) (Year: 1983);;Goldstein (and Weller. 1988. Herpes Simplex Virus Type 1-Induced Ribonucleotide Reductase Activity Is Dispensable for Virus Growth and DNA Synthesis: Isolation and Characterization of an ICP6 lacZ Insertion Mutant. J. Virol. 62[1]:196-205) (Year: 1988);;New England Biolabs. 2024. “MboI”. Available online at neb.com. Accessed on 23 July 23, 2024 (Year: 2024);;IDT (2024. What is the PAM sequence for CRISPR and where is it? Available online at idtdna.com. Accessed on 23 July 2024) (Year: 2024);;Wikipedia (2024. Wild type. Available online at Wikipedia.org. Accessed on 23 July 2024) (Year: 2024)",DISCONTINUED
587,CN,A,CN 113151063 A,154-544-973-140-852,2021-07-23,2021,CN 202110317983 A,2021-03-25,CN 202110317983 A,2021-03-25,Citrobacter freundii AS11 and application thereof in sewage treatment,"The invention belongs to the technical field of microorganisms, and particularly relates to the technical field of microorganism wastewater treatment. The invention discloses a strain of Citrobacter freundii AS11 with a preservation number of CGMCC No.21283. The strain is preserved in the China General Microbiological Culture Collection Center on December 2, 2020, the China General Microbiological Culture Collection Center is called CGMCC for short, the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.21283. The strain can realize synchronous removal of ammonia nitrogen, total nitrogen and COD under an aerobic condition.",INST MICROBIOLOGY CAS,LI SHAOJIE;;CAO XIANHE;;SUN XIANYUN;;ZHANG ZHENYING;;HU CHENGCHENG,,https://lens.org/154-544-973-140-852,Patent Application,no,3,2,2,154-544-973-140-852;;036-163-170-554-755,CN,2,154-544-973-140-852;;036-163-170-554-755,CN,0,C02F3/34;;C02F2101/16;;C02F2103/20;;C12N1/20,C12N1/20;;C02F3/34;;C02F101/16;;C02F103/20;;C12R1/01,,1,0,,,"A S VIJAYARAJ等: ""Effective bioremediation and toxicity assessment of tannery wastewaters treated with indigenous bacteria"", 《3 BIOTECH.》",ACTIVE
588,EP,A1,EP 4043012 A1,116-767-179-960-28X,2022-08-17,2022,EP 20872584 A,2020-09-29,CN 201910943781 A;;CN 2020118945 W,2019-09-30,"DRUG FOR TREATING ARTERY-RELATED DISEASES, AND USE THEREOF","Provided are a drug for treating artery-related diseases and the use thereof. Specifically, provided are the use of a class of compounds of formula I in the treatment of artery-related diseases. Experiments show that the compounds of formula I have a significant effect on aneurysm, intramural hematoma and/or atrerial dissection.",SHANGHAI INST MATERIA MEDICA CAS,JIANG BAOHONG;;ZHANG XIANJING;;DING YUCHAO;;ZHAI ZIYI,,https://lens.org/116-767-179-960-28X,Patent Application,yes,0,0,8,041-286-803-614-828;;162-193-101-772-375;;116-767-179-960-28X;;185-706-802-201-044;;130-935-663-752-13X;;043-900-448-140-76X;;036-528-482-359-878;;031-648-229-398-480,JP;;CN;;EP;;WO;;US,8,041-286-803-614-828;;162-193-101-772-375;;116-767-179-960-28X;;185-706-802-201-044;;130-935-663-752-13X;;043-900-448-140-76X;;031-648-229-398-480;;036-528-482-359-878,JP;;CN;;EP;;WO;;US,0,A61K31/216;;A61K31/192;;A61K31/37;;A61K31/085;;A61K35/644;;A61K36/534;;A61K36/23;;A61K36/232;;A61K36/11;;A61K36/236;;A61K36/71;;A61K36/725;;A61K36/287;;A61K36/61;;A61K36/53;;A61K36/70;;A61K36/185;;A61K36/234;;A61K36/85;;A61K36/537;;A61K36/63;;A61K36/282;;A61K36/83;;A61K36/748;;A61K36/258;;A61K36/39;;A61K36/43;;A61K36/52;;A61K36/75;;A61K36/9062;;A61K36/575;;A61K36/88;;A61K36/328;;A61K36/738;;A61K36/74;;A61K36/54;;A61K36/899;;A61K36/535;;A61K36/8962;;A23L33/00;;A61P9/14;;A23V2002/00;;A61P9/14;;A61K31/216;;A61K36/534;;A61K31/192;;A61K31/37;;A61K31/085;;A61P9/00;;A61K31/05;;A61K31/343;;A61K31/12;;A61K31/05;;A61K31/12;;A61K31/192;;A61K31/216;;A61K31/37;;A61K36/185,A61K31/216;;A61K31/05;;A61K31/085;;A61K31/12;;A61K31/192;;A61K31/352;;A61K31/37;;A61K31/621;;A61P9/00,,0,0,,,,PENDING
589,US,A1,US 2025/0171816 A1,104-197-898-535-717,2025-05-29,2025,US 202519041885 A,2025-01-30,CN 202310885687 A;;CN 2024108982 W,2023-07-19,COMPOSITE ENGINEERED BACTERIA AND METHOD FOR PRODUCING D-PSICOSE,"The present invention relates to an enzyme combination, genetically engineered bacteria, and application thereof in producing D-psicose. Glucose isomerase and D-psicose 3-epimerase from specific sources are separately co-expressed in Bacillus subtilis, a combination enzyme containing glucose isomerase and D-psicose 3-epimerase is obtained through fermentation, and the combination enzyme is used to catalyze a glucose substrate to perform isomerization to eventually prepare D-psicose. The method provided in the present invention can clearly increase a conversion rate of D-psicose, which greatly reduces the time of converting glucose into D-psicose. In addition, inexpensive glucose is used as a raw material, so that the production costs of D-psicose are greatly reduced. In the present invention, fructose syrup may be synchronously produced, so that the input for a whole set of production lines of fructose syrup is omitted, thereby greatly improving the economic benefits.",HENAN ZHONGDA HENGYUAN BIOTECHNOLOGY STOCK CO LTD,WANG SANYING;;JIN ZIHENG;;WEN YANJUN;;LI LINZHENG;;WEN CHENHUI;;XIE RONGRONG;;PAN TIANYI,HENAN ZHONGDA HENGYUAN BIOTECHNOLOGY STOCK CO. LTD (2025-01-28),https://lens.org/104-197-898-535-717,Patent Application,yes,0,0,3,041-465-884-413-377;;104-197-898-535-717;;143-981-095-099-927,CN;;WO;;US,3,041-465-884-413-377;;104-197-898-535-717;;143-981-095-099-927,CN;;WO;;US,0,C12P19/02;;C12P19/24;;C12N9/92;;C12N9/90;;C12Y503/01018;;C12Y501/03;;C12N15/75;;A23L33/125;;C13K1/00;;C13K11/00;;C13K13/00;;C12R2001/125;;C12N2800/22;;A23V2002/00;;C12N9/92;;C12N15/75;;C12R2001/125;;C12P19/02;;C12Y501/03;;C12P19/24;;C12N9/90;;C12N1/205;;C12R2001/125;;C12N9/92;;C12N15/75;;C12P19/02;;C12P19/24;;C12Y501/03,C12P19/02;;C12N9/92;;C12N15/75;;C12P19/24;;C12R1/125,,0,0,,,,PENDING
590,US,A1,US 2024/0009254 A1,095-016-837-773-770,2024-01-11,2024,US 202118024495 A,2021-09-06,KR 20200114168 A;;KR 2021012046 W,2020-09-07,"COMPOSITION FOR PREVENTING OR TREATING PERIODONTAL DISEASES, COMPRISING BACILLUS VELEZENSIS STRAIN, CULTURE MEDIUM THEREOF, OR CULTURE SUPERNATANT THEREOF AS ACTIVE INGREDIENT","The present invention relates to a composition for preventing or treating periodontal diseases comprising a Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient, and more particularly, to a pharmaceutical composition for preventing or treating periodontal diseases or halitosis comprising a Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient, and a quasi-drug composition, a health functional food composition and a food composition for preventing or improving periodontal diseases and halitosis comprising a Bacillus velezensis strain, or a culture medium or culture supernatant thereof as an active ingredient.",IL DONG PHARMA,LEE BYEONGHUN;;KIM MIN GOO;;EUN SUHYEON;;KIM HYEOUNGEUN;;IM A RANG;;HAN CHIYOUNG;;LEE DONG HOON,IL DONG PHARMACEUTICAL CO. LTD (2023-03-05),https://lens.org/095-016-837-773-770,Patent Application,yes,0,2,7,095-016-837-773-770;;194-938-807-435-797;;172-156-749-238-650;;000-070-812-938-728;;122-054-209-039-764;;015-480-833-886-580;;104-830-555-055-528,KR;;AR;;EP;;WO;;US;;TW,7,095-016-837-773-770;;194-938-807-435-797;;172-156-749-238-650;;000-070-812-938-728;;122-054-209-039-764;;015-480-833-886-580;;104-830-555-055-528,KR;;AR;;EP;;WO;;US;;TW,4,A61K8/99;;A61Q11/00;;A61P1/02;;A61K35/742;;A23L33/135;;A61K35/742;;A61P1/02;;A61P31/04;;A61K8/99;;A61Q11/00;;A23L33/135;;A23V2002/00;;A23V2200/312;;A23L33/135;;A61P1/02;;C12R2001/07;;A61K8/99;;A61K35/742;;A61Q11/00,A61K35/742;;A23L33/135;;A61K8/99;;A61P1/02;;A61Q11/00,,1,0,,,"Yoo et al (J. Biotech. Volume 298, available online April 12, 2019, Pages 57-63).",PENDING
591,US,A1,US 2021/0095321 A1,138-569-549-599-841,2021-04-01,2021,US 202017085380 A,2020-10-30,US 202017085380 A;;EP 14193151 A;;US 201715505809 A;;EP 2015076449 W,2014-11-14,MUTANT MICROORGANISMS RESISTANT TO LACTOSE KILLING,"The present invention relates to a method to produce mutated microorganisms which resist the phenomenon of lactose killing and to the microorganisms obtainable via said method. Such engineered microorganisms can be applied for the production of specialty products, such as but not limited to specialty carbohydrates, glycolipids and galactosylated compounds.",INBIOSE NV,BEAUPREZ JOERI;;DE MAESENEIRE SOFIE;;TIMMERMANS ERIC,,https://lens.org/138-569-549-599-841,Patent Application,yes,3,0,29,066-754-180-906-892;;017-847-041-945-889;;167-082-186-518-420;;050-886-540-733-58X;;088-411-077-848-915;;056-300-468-638-787;;022-193-792-413-446;;035-465-663-303-708;;006-490-510-948-209;;109-945-743-546-617;;195-146-381-925-035;;111-332-230-041-883;;138-569-549-599-841;;175-038-570-022-624;;022-458-808-555-125;;110-336-536-322-161;;162-037-874-473-217;;098-943-582-534-087;;188-677-332-880-407;;122-869-758-729-642;;000-134-091-379-160;;126-537-871-137-90X;;101-220-633-362-965;;171-967-372-112-400;;196-319-367-815-111;;085-114-444-949-794;;156-592-375-858-791;;018-740-527-150-759;;142-435-761-901-690,AU;;JP;;RU;;US;;CA;;BR;;KR;;ES;;CN;;EP;;WO;;SG;;DK,29,066-754-180-906-892;;017-847-041-945-889;;167-082-186-518-420;;050-886-540-733-58X;;088-411-077-848-915;;056-300-468-638-787;;022-193-792-413-446;;035-465-663-303-708;;006-490-510-948-209;;109-945-743-546-617;;195-146-381-925-035;;111-332-230-041-883;;138-569-549-599-841;;175-038-570-022-624;;022-458-808-555-125;;110-336-536-322-161;;162-037-874-473-217;;098-943-582-534-087;;188-677-332-880-407;;122-869-758-729-642;;000-134-091-379-160;;126-537-871-137-90X;;101-220-633-362-965;;171-967-372-112-400;;196-319-367-815-111;;085-114-444-949-794;;156-592-375-858-791;;018-740-527-150-759;;142-435-761-901-690,AU;;JP;;RU;;US;;CA;;BR;;KR;;ES;;CN;;EP;;WO;;SG;;DK,58,C12N15/09;;C12N15/81;;C12P19/12;;C12N15/10;;C12N15/63;;C12N9/1051;;C12Y204/01022;;C12N15/09;;C12N15/63;;C12P19/12;;C12N15/10;;C07K14/245;;C12N15/81;;C12P19/12,C12P19/12;;C07K14/245;;C12N15/10;;C12N15/81,,6,5,000-938-322-005-89X;;061-859-656-899-093;;132-695-844-930-786;;002-237-474-008-345;;032-993-201-887-34X,10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.3.co;2-j;;10944397;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.0.co;2-s;;15029827;;10.1017/s0033583503003901;;10512619;;10.1021/bi990993h;;10.1016/s0969-2126(01)00703-1;;11796105;;10.1093/glycob/cwg014;;12626410,"Davos et al., (Proteins: Structure, Function and Genetics, 2000, Vol. 41: 98-107;;Wristlock et al., (Quarterly Reviews of Biophysics 2003, Vol. 36 (3): 307-340;;Kwiatkowski et al., (Biochemistry 38:11643-11650, 1999;;Kisselev L., (Structure, 2002, Vol. 10: 8-9;;Tilman Grerngross ( nature BIOtechnol. 2004, 22(11) pp 1-6.;;Abe et al. (Glycobiology 2003, 13(2) pp 87-95",PENDING
592,US,A1,US 2024/0110171 A1,025-557-434-775-432,2024-04-04,2024,US 202318169480 A,2023-02-15,US 202318169480 A;;US 202117559782 A;;US 201815939231 A;;US 201762477846 P,2017-03-28,METHOD OF PRODUCING COLLAGENASE,"The present invention relates to the fields of collagenase production and collagenase products, and particularly to improving the reproducibility, purity, and stability of collagenase I and collagenase II compositions, where the compositions are pure to at least 95% by area as measured by reverse phase high pressure liquid chromatography (RP-HPLC) and essentially free of neutral protease.",ENDO VENTURES LTD,SHEAFFER CHRISTINE A;;BERBAUM MICHAEL;;HANNA JOHN;;DZIADOSZ JASON;;SHANAFELT DANIEL,ENDO OPERATIONS LIMITED (F/K/A OPERAND PHARMACEUTICALS III LIMITED) (2024-06-20);;ENDO VENTURES UNLIMITED COMPANY (2023-05-30),https://lens.org/025-557-434-775-432,Patent Application,yes,2,0,29,080-273-852-412-888;;080-404-001-920-005;;026-368-712-532-582;;026-295-199-097-06X;;018-156-259-562-104;;185-349-750-505-43X;;098-726-908-191-889;;114-955-805-702-639;;080-568-297-636-281;;016-343-155-060-223;;054-168-194-715-301;;137-884-644-371-216;;025-557-434-775-432;;067-423-178-348-019;;056-241-769-875-770;;134-785-010-858-476;;108-628-760-864-558;;027-500-000-927-385;;002-402-837-303-48X;;097-509-833-936-34X;;129-606-682-042-552;;143-367-932-351-238;;082-865-655-541-260;;049-435-614-669-720;;018-847-625-854-16X;;194-887-805-960-398;;044-612-716-496-325;;080-207-361-061-141;;082-523-331-740-95X,AU;;JP;;US;;CA;;MX;;BR;;KR;;AR;;IL;;CN;;EP;;WO;;NZ,29,080-273-852-412-888;;080-404-001-920-005;;026-368-712-532-582;;026-295-199-097-06X;;018-156-259-562-104;;185-349-750-505-43X;;098-726-908-191-889;;114-955-805-702-639;;080-568-297-636-281;;016-343-155-060-223;;054-168-194-715-301;;137-884-644-371-216;;025-557-434-775-432;;067-423-178-348-019;;056-241-769-875-770;;134-785-010-858-476;;108-628-760-864-558;;027-500-000-927-385;;002-402-837-303-48X;;097-509-833-936-34X;;129-606-682-042-552;;143-367-932-351-238;;082-865-655-541-260;;049-435-614-669-720;;018-847-625-854-16X;;194-887-805-960-398;;044-612-716-496-325;;080-207-361-061-141;;082-523-331-740-95X,AU;;JP;;US;;CA;;MX;;BR;;KR;;AR;;IL;;CN;;EP;;WO;;NZ,0,C12N9/52;;C12Y304/24003;;A61K38/00;;C12N9/52;;A61K31/00;;C12Y304/24003;;C12N9/52;;A61K38/4886;;C12Y304/24003;;A61K38/00;;C12N9/52;;A61K31/00;;C12Y304/24003;;G01N33/56911,C12N9/52,,1,1,110-785-243-986-961,21845384;;10.1007/s00253-011-3532-8,"Ji-Wei et al. (Appl. Microbiol. Biotech., 2011, vol. 92, pages 253-262)",PENDING
593,US,A1,US 2020/0385477 A1,082-408-685-914-028,2020-12-10,2020,US 201816954354 A,2018-11-08,CN 201810252273 A;;CN 2018114594 W,2018-03-26,GENE COMBINATION CAPABLE OF HIGH-EFFICIENCY EXPRESSION OF RECOMBINANT HUMAN NERVE GROWTH FACTOR,"A gene combination capable of high-efficiency expression of rhNGF is provided to optimize gene expression regulation components of a recombinant human nerve growth factor. The gene combination enhances expression of rhNGF. As shown by experiments, the gene combination is capable of high-efficiency expression of a recombinant human nerve growth factor (rhNGF) with natural activity in a eukaryotic expression system.",XINTRUM PHARMACEUTICALS LTD,CHEN HAI;;SUN HONGLIANG;;ZHANG YI;;WANG YUESHENG,JIANGSU KANION PHARMACEUTICAL CO. LTD (2025-03-11),https://lens.org/082-408-685-914-028,Patent Application,yes,0,0,5,149-811-699-416-934;;082-408-685-914-028;;099-258-470-954-416;;103-170-387-962-016;;028-619-368-891-733,CN;;WO;;US,5,149-811-699-416-934;;082-408-685-914-028;;099-258-470-954-416;;103-170-387-962-016;;028-619-368-891-733,CN;;WO;;US,10,C07K14/48;;C07K14/48;;A61K38/185;;C07K2319/02;;C07K2319/35;;Y02P20/582;;C07K16/2875;;A61K38/185,C07K16/28;;A61K38/18,,0,0,,,,ACTIVE
594,US,A1,US 2022/0009852 A1,011-568-215-205-419,2022-01-13,2022,US 202117349960 A,2021-06-17,CN 202010657940 A,2020-07-09,BACILLUS SUBTILIS BS40-4 STRAIN AND METHOD FOR COMPOSTING ORGANIC WASTES BY USING THE SAME,A Bacillus subtilis BS40-4 strain is deposited in China General Microbiological Culture Collection Center (CGMCC) with an accession number CGMCC No. 19757.,UNIV HEBEI SCIENCE & TECH,LI ZAIXING;;MA JUN;;WU XIAOSHA;;HUANG YALI;;HAN XUEBIN;;QIN XUE;;LIU SHUANG,HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY (2021-06-01),https://lens.org/011-568-215-205-419,Patent Application,yes,2,4,4,171-175-205-813-335;;127-979-157-020-055;;011-568-215-205-419;;005-899-847-643-037,AU;;CN;;US,4,011-568-215-205-419;;127-979-157-020-055;;171-175-205-813-335;;005-899-847-643-037,AU;;CN;;US,3,C12N1/20;;C12N11/10;;C12N11/14;;C05F17/20;;C12R2001/125;;C12N1/205;;Y02W30/40;;C05F17/20;;C12N1/205;;C12R2001/125;;C12N1/20;;Y02P20/145;;C05F17/20;;C12N1/205;;C12R2001/125;;C12N11/10;;C12N11/14,C05F17/20;;C12N1/20;;C12N11/10;;C12N11/14,,1,0,,,"over Pan et al. 3 Biotech vol. 2, pp. 127-134, 2012 (Year: 2012)",DISCONTINUED
595,WO,A1,WO 2024/194484 A1,145-136-242-348-618,2024-09-26,2024,EP 2024057843 W,2024-03-22,EP 23305394 A,2023-03-23,MODULATING THE EXPRESSION AND/OR ACTIVITY OF GAS7 FOR MODULATING VIRAL REPLICATION,"Macrophages (MØ) are critical for the detection and clearance of pathogens and yet also serve as replication niches for multiple infectious agents. This delicate balance between viral replication and antiviral response remains poorly understood at the molecular level. Addressing this question is of physiological importance given the ever-present threat posed by emerging viral pathogens. Now, the inventors show that the expression of GAS7 in macrophages limits the replication of viral pathogens belonging to all the major viral groups. They show that the antiviral activity of GAS7 is present even in conditions where the classical antiviral response mediated by type I Interferon is neutralized. In particular, the inventor shows that in human monocyte-derived macrophages, silencing GAS7 boosts the replication of multiple viral pathogens representative of the most relevant viral groups. These include the retroviruses HIV- 1 and HIV-2, the RNA viruses ZIKA (RNAss +), SINDBIS (RNAss +), Sendai (RNAss-), VSV (RNAss-) and Measles (RNAss-), and the DNA virus HSV-1 (DNA ds). Importantly, the antiviral activity of GAS7 is present even in conditions where type I Interferon is neutralized, by the addition of the B18R protein (which blocks efficiently type I receptor). Moreover, the inventors show that enforcing the over-expression of GAS7 by macrophages further protects them against HIV-1 infection, compared with cells expressing normal levels of this factor. Accordingly, the present invention relates to the modulation of the expression and/or activity of GAS7 for modulating viral replication in a population of macrophages.",INST NAT SANTE RECH MED;;INST CURIE;;UNIV PARIS CITE;;CENTRE NAT RECH SCIENT,BENAROCH PHILIPPE;;RODRIGUES VASCO;;HANOUNA ANAËL;;COULON PIERRE-GRÉGOIRE,,https://lens.org/145-136-242-348-618,Patent Application,yes,26,0,1,145-136-242-348-618,WO,1,145-136-242-348-618,WO,2,A61P31/12;;C12N15/67,A61P31/12;;C12N15/67,,23,19,092-478-884-536-046;;012-285-805-517-718;;102-970-600-893-056;;048-373-243-368-875;;032-728-154-591-070;;100-369-989-382-851;;008-852-327-818-500;;091-971-107-194-021;;138-110-930-123-894;;011-044-513-524-031;;004-869-107-852-139;;067-865-631-992-303;;081-261-184-471-003;;018-351-311-634-843;;006-666-864-672-904;;033-871-147-051-365;;077-117-988-028-532;;040-149-530-797-042;;007-990-953-327-337,15372081;;10.1038/nrmicro975;;pmc7097272;;10.1007/s00253-004-1783-3;;pmc7082807;;15592828;;10.1038/s41598-021-84237-2;;pmc7910288;;33637799;;10.1371/journal.pone.0198943;;pmc5995401;;29889899;;10.1016/0022-2836(70)90057-4;;5420325;;pmc2931596;;20715849;;10.1021/bc100041r;;20059641;;10.1111/j.1365-2796.2009.02189.x;;pmc5308083;;10.1038/nbt1402;;pmc3014085;;18438401;;21784981;;pmc3156157;;10.1073/pnas.1106379108;;10.3410/f.1120117.576261;;18695239;;pmc2575310;;10.1073/pnas.0805434105;;19259063;;pmc2835134;;10.1038/mt.2009.36;;10.1038/nbt.1989;;21983520;;pmc3212614;;pmc8724758;;34983972;;10.1038/s41576-021-00439-4;;10467368;;10.1038/sj.gt.3300965;;10.1007/s11095-004-1873-z;;15835741;;10.1016/b978-0-323-03432-6.50031-3;;10.1038/nature04688;;16565705;;16054724;;10.1016/j.jconrel.2005.06.014;;pmc2648695;;10.1172/jci37515;;19229107;;10.1089/hum.2008.928;;18257677,"""2nd ASIAN REGIONAL DENGUE RESEARCH NETWORK MEETING"", INTERNET CITATION, 28 September 2005 (2005-09-28), pages 1 - 217, XP002513276, Retrieved from the Internet <URL:http://www.pdvi.org/PDFs/Singapore%20Abstract%20Book.pdf> [retrieved on 20090203];;CLERCQ ERIK DE: ""Antivirals and antiviral strategies"", NATURE REVIEWS MICROBIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 2, no. 9, 1 September 2004 (2004-09-01), pages 704 - 720, XP037065615, ISSN: 1740-1526, DOI: 10.1038/NRMICRO975;;JULIA MAGDEN ET AL: ""Inhibitors of virus replication: recent developments and prospects"", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 66, no. 6, 1 March 2005 (2005-03-01), pages 612 - 621, XP019331763, ISSN: 1432-0614, DOI: 10.1007/S00253-004-1783-3;;MASUJIN, KKITAMURA, TKAMEYAMA, K. ET AL.: ""An immortalized porcine macrophage cell line competent for the isolation of African swine fever virus"", SCI REP, vol. 11, 2021, pages 4759;;TACIAK BBIALASEK MBRANIEWSKA ASAS ZSAWICKA PKIRAGA LRYGIEL TKROL M: ""Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages"", PLOSONE, vol. 13, no. 6, 11 June 2018 (2018-06-11), pages e0198943, XP055931472, DOI: 10.1371/journal.pone.0198943;;NEEDLEMANSAUL B. & WUNSCHCHRISTIAN D: ""A general method applicable to the search for similarities in the amino acid sequence of two proteins"", JOURNAL OF MOLECULAR BIOLOGY, vol. 48, no. 3, 1970, pages 443 - 53;;MAHON ET AL., BIOCONJUG CHEM., vol. 21, 2010, pages 1448 - 1454;;SCHROEDER ET AL., J INTERN MED., vol. 267, 2010, pages 9 - 21;;AKINC ET AL., NAT BIOTECHNOL., vol. 26, 2008, pages 561 - 569;;LOVE ET AL., PROC NATL ACAD SCI USA., vol. 107, 2010, pages 1864 - 1869;;SIEGWART ET AL., PROC NATL ACAD SCI US A., vol. 108, 2011, pages 12996 - 3001;;FRANK-KAMENETSKY ET AL., PROC NATL ACAD SCI USA., vol. 105, 2008, pages 11915 - 11920;;AKINC ET AL., MOL THER, vol. 17, 2009, pages 872 - 879;;LEUSCHNER ET AL., NAT BIOTECHNOL., vol. 29, 2011, pages 1005 - 1010;;PAUNOVSKA, KALINADAVID LOUGHREYJAMES E. DAHLMAN: ""Drug delivery systems for RNA therapeutics"", NATURE REVIEWS GENETICS, 2022, pages 1 - 16;;WHEELER ET AL., GENE THERAPY, vol. 6, 1999, pages 1438 - 1447;;JEFFS ET AL., PHARM RES, vol. 22, 2005, pages 362 - 372;;MORRISSEY ET AL., NAT BIOTECHNOL., vol. 2, 2005, pages 1002 - 1007;;ZIMMERMANN ET AL., NATURE, vol. 441, 2006, pages 111 - 114;;HEYES ET AL., J CONTR REL, vol. 107, 2005, pages 276 - 287;;SEMPLE ET AL., NATURE BIOTECH., vol. 28, 2010, pages 172 - 176;;JUDGE ET AL., J CLIN INVEST, vol. 119, 2009, pages 661 - 673;;DEFOUGEROLLES, HUM GENE THER, vol. 19, 2008, pages 125 - 132",PENDING
596,WO,A1,WO 2021/233630 A1,184-282-169-236-942,2021-11-25,2021,EP 2021060310 W,2021-04-21,EP 20184183 A;;CN 2020091561 W,2020-05-21,ORAL CARE COMPOSITION,"The present invention relates to oral care compositions such as toothpastes, gums, mouth-washes and the like. In particular, the present invention relates to an oral care composition containing calcium silicate and hyaluronic acid and/or its derivatives that results in remineralization and/or reduces hypersensitivity. Accordingly, the present invention provides an oral care composition comprising; a) calcium silicate; and b) hyaluronic acid and/or its derivatives; wherein the molecular weight of the hyaluronic acid and/or its derivatives ranges from 500,000 Dalton to 3,000,000 Dalton.",UNILEVER IP HOLDINGS B V;;UNILEVER GLOBAL IP LTD;;CONOPCO INC DBA UNILEVER,LIU WEINING;;WANG WEICHONG;;ZHOU HUANJUN,,https://lens.org/184-282-169-236-942,Patent Application,yes,9,0,6,167-018-982-055-264;;172-235-784-119-775;;061-593-194-785-714;;085-548-249-526-946;;184-282-169-236-942;;023-508-163-979-850,EP;;CL;;CN;;WO;;BR;;PH,6,167-018-982-055-264;;172-235-784-119-775;;061-593-194-785-714;;085-548-249-526-946;;023-508-163-979-850;;184-282-169-236-942,EP;;CL;;CN;;WO;;BR;;PH,0,A61K8/735;;A61Q11/00;;A61K8/25,A61Q11/00;;A61K8/25;;A61K8/73,,1,0,,,"CAS , no. 9004-32-4",PENDING
597,EP,A1,EP 4455305 A1,045-711-098-685-697,2024-10-30,2024,EP 22909929 A,2022-12-19,CN 202111581332 A;;CN 2022139965 W,2021-12-22,METHOD FOR TESTING EXPRESSION LEVEL OF PLURIPOTENCY GENE,"The present invention relates to the use of a reference cell for testing pluripotency gene expression level, wherein the reference cell is selected from cells with low and stable expression level of a pluripotency gene. Preferably, the reference cell is selected from HFF cells, optionally, the pluripotency gene is selected from OCT4, NANOG. The present invention also relates to primers and probes for OCT4 and NANOG. The present invention also relates to a method for testing pluripotency gene expression level. The present invention further relates to a use of the detection method in detecting a hPSC residue level and characterizing a hPSC differentiation process. The method of the present invention has the advantages of simplicity, stability, high sensitivity, wide application range, and high accessibility. Therefore, it is easy to standardize and can provide a unified standard for testing cell pluripotency gene expression level.",BEIJING ZEPHYRM BIOTECHNOLOGY CO LTD,ZHANG YU;;GAN YIDI;;ZHANG SHUAI;;LUO YANCHAO;;XU RANRAN;;WANG SHUYAN,,https://lens.org/045-711-098-685-697,Patent Application,yes,0,0,4,076-244-678-067-46X;;155-116-277-382-159;;188-849-339-936-985;;045-711-098-685-697,CN;;EP;;WO,4,076-244-678-067-46X;;155-116-277-382-159;;188-849-339-936-985;;045-711-098-685-697,CN;;EP;;WO,26,C12Q1/6851;;C12Q1/6881;;C12Q2600/158,C12Q1/6851;;C12N15/11,,0,0,,,,PENDING
598,US,A1,US 2025/0257331 A1,109-289-789-033-128,2025-08-14,2025,US 202519048825 A,2025-02-07,CN 202410179060 A,2024-02-09,FLAVONOID GLYCOSIDE GLYCOSYLTRANSFERASE LbUGT71BX1 IN LAPORTEA BULBIFERA AS WELL AS THE CODING GENE AND THE USE THEREOF,"The invention discloses a flavonoid glycoside glycosyltransferase LbUGT71BX1 in laportea bulbifera as well as the coding gene and the use thereof. The amino acid sequence of the flavonoid glycoside glycosyltransferase LbUGT71BX1 is shown as SEQ ID NO: 2. The nucleotide sequence of the coding gene of the flavonoid glycoside glycosyltransferase LbUGT71BX1 is shown as SEQ ID NO: 1. According to the invention, on the basis of relevant results of the second-generation transcriptome and the third-generation full-length transcriptome sequencing of the laportea bulbifera, the last-step key enzyme LbUGT71BX1 for the synthesis of the flavonoid glycoside in the laportea bulbifera is screened and identified by using a reverse genetics method, filling the terminal blank of the biosynthesis pathway of the flavonoid glycoside in the laportea bulbifera.",INST CHINESE MATERIA MEDICA CHINA ACADEMY OF CMS,WU LAN;;XIANG LI;;GAO RANRAN;;CHEN SHILIN;;SHI YUHUA;;YIN QINGGANG;;WANG MENGYUE;;CHU YANG;;WANG WENTING,,https://lens.org/109-289-789-033-128,Patent Application,yes,0,0,2,109-289-789-033-128;;102-569-109-912-594,CN;;US,2,109-289-789-033-128;;102-569-109-912-594,CN;;US,0,C12N9/1051;;C12P19/60;;C12P19/18;;C12Y204/01;;C12N9/1051;;C12P19/44;;C12P19/18;;C12N9/10;;C12N9/1048;;C12N9/1051;;C12P19/18;;C12P19/44,C12N9/10;;C12P19/18;;C12P19/44,,0,0,,,,PENDING
599,WO,A2,WO 2024/249898 A2,063-984-825-194-250,2024-12-05,2024,US 2024/0032054 W,2024-05-31,US 202363506000 P,2023-06-02,FUSED IL10 POLYPEPTIDES,"The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-10 (IL10). In particular, the disclosure provides fused IL10 polypeptides comprising two IL10 monomers. Also provided are compositions and methods useful for producing such fused IL10 polypeptides, as well as methods for modulating IL10-mediated signaling, and/or for the treatment of conditions associated with the perturbation of signal transduction mediated by IL10.",SYNTHEKINE INC,MORIN ANDREW;;RAMADASS MAHALAKSHMI;;PETOJEVIC TATJANA;;JAYARAMAN BHARGAVI;;VIVONA SANDRO;;LUPARDUS PATRICK,,https://lens.org/063-984-825-194-250,Patent Application,yes,0,0,3,107-156-272-003-741;;192-044-093-503-894;;063-984-825-194-250,WO;;TW,3,107-156-272-003-741;;192-044-093-503-894;;063-984-825-194-250,WO;;TW,0,C07K14/5428;;C07K2319/30;;C07K2319/00;;A61K38/00,C07K14/54;;A61K38/20,,0,0,,,,PENDING
600,CN,A,CN 113025523 A,043-792-051-229-63X,2021-06-25,2021,CN 202110287246 A,2021-03-17,CN 202110287246 A,2021-03-17,"Pseudoxanthomonas mexicana, and application thereof in promoting breeding of hybrid broussonetia papyrifera","The invention relates to the technical field of microorganisms, concretely to a Pseudoxanthomonas mexicana, and application thereof in promotion of hybrid structure breeding. The Pseudoxanthomonas mexicana HTZ4 is preserved in the China General Microbiological Culture Collection Center on January 13, 2021 with the preservation number of CGMCC No.21617, and the Pseudoxanthomonas mexicana HTZ4 has a nitrogen fixation effect, can be applied to growth of the hybrid paper mulberry, and can promote growth and development of axillary bud twig cutting seedling roots of the hybrid paper mulberry effectively; and the Pseudoxanthomonas mexicana also has an inhibiting effect on alternaria solani and fusarium solani, can be used as a microbial bacteriostatic agent, can effectively improve the rooting rate and rooting rate of broussonetia papyrifera axillary bud twig cuttage, increase the survival rate of broussonetia papyrifera cuttage propagation and reduce the cost of tissue culture seedling propagation, and has great significance in planting and popularization of broussonetia papyrifera.",GANSU ACADEMY SCIENCES INST BIOLOGY,GUO QI;;ZHANG JUN;;PENG YINAN;;WANG PEIYA;;YANG HUI;;WANG ZHIYE,,https://lens.org/043-792-051-229-63X,Patent Application,no,2,1,2,167-219-597-807-07X;;043-792-051-229-63X,CN,2,167-219-597-807-07X;;043-792-051-229-63X,CN,0,A01G2/10;;A01G13/00;;A01G17/005;;A01G24/20;;A01N63/27;;C05G3/00,C12N1/20;;A01G2/10;;A01G13/00;;A01G17/00;;A01G24/20;;A01N63/27;;A01P3/00;;A01P21/00;;C05G3/00;;C12R1/38,,1,0,,,"FAKHRA LIAQAT等: ""Identification and characterization of endophytic bacteria isolated from in vitro cultures of peach and pear rootstocks"", 《3 BIOTECH》",ACTIVE
601,WO,A1,WO 2025/059012 A1,037-107-918-706-502,2025-03-20,2025,US 2024/0045941 W,2024-09-10,US 202363582124 P,2023-09-12,BIOSENSOR FOR RAPID DETECTION OF PER- AND POLYFLUOROALKYL SUBSTANCES (PFAS),"Disclosed herein is a biosensor fusion protein comprising an N-terminal half of a human liver fatty acid binding protein (hLFABP) and a C-terminal half of the hLFABP separated by a circularly permuted fluorescent protein (cpFP), wherein the binding of the N-terminal half of the hLFABP and the C-terminal half of the of the hLFABP to a per- or polyfluoroalkyl substance (PFAS) elicits a change in fluorescence of the cpFP. Also disclosed method for detecting per- and polyfluoroalkyl substances (PFAS) in a sample, comprising contacting the sample with the biosensor disclosed herein, assaying the sample for fluorescence, wherein an increase in fluorescence is an indication of the presence of PFAS. In some embodiments, the PFAS is perfluorooctanoic acid (PFOA). In some embodiments, the sample is a water sample.",UNIV VIRGINIA PATENT FOUNDATION,BERGER BRYAN;;MANN MADISON,,https://lens.org/037-107-918-706-502,Patent Application,yes,2,0,1,037-107-918-706-502,WO,1,037-107-918-706-502,WO,14,C07K14/47;;C07K2319/20;;C07K2319/60;;G01N33/542;;G01N33/92;;G01N2430/00;;G01N33/1826,C07K14/47;;G01N21/64;;G01N27/327;;G01N33/68,,1,1,012-895-271-879-340,10.1002/bit.27981;;34723386,"MANN ET AL.: ""Engineering human liver fatty acid binding protein for detection of poly- and perfluoroalkyl substances"", BIOTECHNOLOGY AND BIOENGINEERING, vol. 119, no. 2, 9 November 2021 (2021-11-09), pages 513 - 522, XP093219142, DOI: 10.1002/bit.27981",PENDING
602,US,A1,US 2021/0042645 A1,090-156-081-783-647,2021-02-11,2021,US 202016987279 A,2020-08-06,US 202016987279 A;;US 201962883639 P,2019-08-06,Tensor Exchange for Federated Cloud Learning,"A federated training system comprises a plurality of models, a plurality of training datasets, and a runtime intermediary. Models in the plurality of models have model coefficients responsive to training. Training datasets in the plurality of training datasets are annotated with ground truth labels to train the models. The training datasets are accompanied with training provisioning parameters and privacy parameters. The runtime intermediary is interposed between the models and the training datasets, and configured to receive requests for training the models on the training datasets, the requests accompanied with training acquisition parameters, to respond to the requests by matching the models with the training datasets based on evaluating the training acquisition parameters against the training provisioning parameters, to train the models on the matched training datasets in accordance with the privacy parameters to generate gradients with respect to the model coefficients.",DOC AI INC,SHARMA SRIVATSA AKSHAY;;KAUTZ IV FREDERICK FRANKLIN;;TITOVA MARINA;;DE BROUWER WALTER ADOLF;;ZACCAK GABRIEL GABRA;;RODRÍGUEZ ESMERAL ANDRÉS,SHARECARE AI INC (2021-08-11);;DOC.AI INC (2020-08-15),https://lens.org/090-156-081-783-647,Patent Application,yes,1,30,1,090-156-081-783-647,US,1,090-156-081-783-647,US,0,G06N20/20;;G06N5/04;;G06F16/212;;G06F16/2379;;G06N20/20,G06N5/04;;G06F16/21;;G06F16/23;;G06N20/20,,2,2,151-518-678-753-826;;111-817-583-478-859,10.1109/tsc.2012.14;;10.1109/icact.2014.6779008,"Ardagna D, Panicucci B, Passacantando M. Generalized nash equilibria for the service provisioning problem in cloud systems. IEEE Transactions on Services Computing. 2012 Apr 17; 6(4):429-42. (Year: 2012);;Zhao F, Li C, Liu CF. A cloud computing security solution based on fully homomorphic encryption. In 16th international conference on advanced communication technology 2014 Feb 16 (pp. 485-488). IEEE. (Year: 2014)",DISCONTINUED
603,US,A1,US 2023/0221304 A1,139-493-283-918-902,2023-07-13,2023,US 202117618958 A,2021-02-24,CN 202010199077 A;;CN 2021077652 W,2020-03-20,"NOVEL CORONAVIRUS NUCLEIC ACID RAPID HYBRID CAPTURE IMMUNOFLUORESCENCE DETECTION KIT, AND PREPARATION METHOD AND DETECTION METHOD THEREOF","The invention relates to the technical field of nucleic acid detection and discloses a novel coronavirus nucleic acid rapid hybrid capture immunofluorescence detection kit, and a preparation method and a detection method thereof. The kit includes a COVID-19 reaction solution, wherein the COVID-19 reaction solution is prepared from a COVID-19 fluorescence marker and a COVID-19 probe solution; and the COVID-19 probe solution includes: an ORFlab section probe, an N section probe and an E section probe. Compared with general fluorescence PCR and sequencing detection, the kit has the advantages of stronger signal intensity, better specificity, shorter detection time, no need of professional technicians for operation, no need of refrigeration in transportation and storage, no need of a matched laboratory and a matched PCR instrument, and convenience and rapidness in use.",ANBIO XIAMEN BIOTECHNOLOGY CO LTD,LEI YANG;;ZHANG JIELI;;ZHANG LIWEI;;HUANG RENXUN;;BAI JIAWEI;;LE YICUI;;HU XIAO;;WANG DAMING,ANBIO (XIAMEN) BIOTECHNOLOGY CO. LTD (2021-09-23),https://lens.org/139-493-283-918-902,Patent Application,yes,2,0,6,113-586-983-297-130;;051-806-326-643-288;;051-299-859-199-235;;139-493-283-918-902;;180-066-292-808-318;;043-022-048-323-763,CN;;EP;;WO;;US,6,139-493-283-918-902;;051-299-859-199-235;;051-806-326-643-288;;113-586-983-297-130;;180-066-292-808-318;;043-022-048-323-763,EP;;CN;;WO;;US,3,C12Q1/701;;C12Q1/6804;;Y02A50/30;;C12Q1/701;;C12Q1/6813;;C12Q1/6804;;C12Q1/70;;G01N33/5308;;G01N33/56983,G01N33/53;;C12Q1/70;;G01N33/569,,0,0,,,,DISCONTINUED
604,US,A1,US 2022/0072030 A1,130-067-747-472-883,2022-03-10,2022,US 201917299109 A,2019-11-26,US 201917299109 A;;US 201862774527 P;;US 2019/0063143 W,2018-12-03,PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS SUITABLE TO TREAT MUCOSITIS,"This invention relates to the treatment of mucositis, including oral mucositis, pharmaceutical formulations and compositions suitable for such treatment, the use of such compositions to treat mucositis and methods of such treatment.",SAMUEL ASCULAI;;IVOR HUGHES,SAMUEL ASCULAI;;IVOR HUGHES,,https://lens.org/130-067-747-472-883,Patent Application,yes,3,0,4,005-915-932-542-262;;128-810-580-177-933;;103-710-883-845-534;;130-067-747-472-883,WO;;US;;CA,4,005-915-932-542-262;;128-810-580-177-933;;103-710-883-845-534;;130-067-747-472-883,WO;;US;;CA,0,A61K45/06;;A61K31/728;;A61K31/196;;A61K31/195;;A61K31/728,A61K31/728;;A61K31/195,,2,2,009-910-929-244-558;;088-066-830-530-620,15324476;;10.1211/0022357044085;;22982164;;10.1016/j.ijpharm.2012.08.047,"Sandri, G. et al ""Mucoadhesive and penetration enhancement properties ..."" J. Pharm. Pharmacol., vol 56, pp 1083-1090. (Year: 2004);;Guhmann, M. et al ""Development of oral taste masked diclofenac ..."" Int. J. Pharm., vol 438, pp 81-90. (Year: 2012)",DISCONTINUED
605,EP,A1,EP 4555996 A1,132-330-248-288-350,2025-05-21,2025,EP 24213936 A,2024-11-19,CN 202311556506 A,2023-11-20,GLYCYRRHIZIC ACID BACTERIAL CELLULOSE COMPOSITE FOR PROMOTING THE GROWTH AND DEVELOPMENT OF SKIN HAIR FOLLICLES,"The present disclosure relates to a glycyrrhizic acid bacterial cellulose composite for promoting growth and development of hair follicles in skins, in particular, the glycyrrhizic acid bacterial cellulose composite for promoting growth and development of hair follicles in skin includes glycyrrhizic acid and bacterial cellulose.",CHEN CHAO CHENG;;HONG QING FLOWERY BIO TECH GUANGZHOU CO LTD,CHEN CHAO-CHENG;;WANG QIONG;;ZHENG SI HAN,,https://lens.org/132-330-248-288-350,Patent Application,yes,4,0,4,030-045-146-608-498;;194-678-606-392-825;;069-914-420-673-565;;132-330-248-288-350,JP;;CN;;EP;;US,4,030-045-146-608-498;;194-678-606-392-825;;132-330-248-288-350;;069-914-420-673-565,JP;;CN;;EP;;US,0,A61K47/61;;A61K31/704;;A61K9/0014;;A61P17/14;;A61K8/602;;A61K8/731;;A61Q7/00;;A61K2800/57;;A61K31/704;;A61K31/715;;A61K35/74,A61K8/60;;A61K8/73;;A61Q7/00,,1,1,037-747-940-667-007,37711906;;10.1016/j.crfs.2023.100584;;pmc10497795,"MEI YUQI ET AL: ""Development of antibacterial nanocomposites by combination of bacterial cellulose/chitin nanofibrils and all-natural bioactive nanoparticles"", CURRENT RESEARCH IN FOOD SCIENCE, vol. 7, 1 September 2023 (2023-09-01), pages 100584, XP093264170, ISSN: 2665-9271, DOI: 10.1016/j.crfs.2023.100584",PENDING
606,US,A1,US 2022/0389367 A1,087-582-725-619-513,2022-12-08,2022,US 202017776044 A,2020-10-26,US 202017776044 A;;US 201962935215 P;;US 201962938687 P;;US 2020/0057308 W,2019-11-14,CELL CULTURE VESSELS AND MONITORING SYSTEMS FOR NON-INVASIVE CELL CULTURE MONITORING,"A cell culture vessel, cell culture monitoring system, and Raman spectroscopy system for non-invasive measuring of a cell culture are provided. The vessel includes a cell culture chamber that operates as a closed system, a wall defining a boundary of the cell culture chamber and separating the interior space of the cell culture chamber from an exterior of the cell culture chamber, and a window disposed in the wall and separating the interior space of the cell culture chamber from an exterior of the cell culture chamber. The cell culture chamber includes an interior space for housing at least one of the cell culture and a cell culture media. The window includes a polymer and allows monitoring of the cell culture via a monitoring module disposed on the exterior without the monitoring module coming into physical contact with the cell culture or the cell culture media.",CORNING INC,MARTIN GREGORY ROGER;;SANSON MARK CHRISTIAN;;VASUDEO NIKHIL BABURAM;;WALL JOSEPH CHRISTOPHER,CORNING INCORPORATED (2022-04-11),https://lens.org/087-582-725-619-513,Patent Application,yes,10,2,6,141-649-520-917-939;;162-492-637-973-386;;087-582-725-619-513;;057-816-713-023-326;;176-737-531-390-642;;130-995-594-704-39X,JP;;EP;;CN;;WO;;US,6,141-649-520-917-939;;162-492-637-973-386;;087-582-725-619-513;;057-816-713-023-326;;176-737-531-390-642;;130-995-594-704-39X,JP;;EP;;CN;;WO;;US,0,C12M23/04;;C12M23/08;;C12M41/32;;C12M41/36;;C12M23/20;;C12M23/04;;C12M23/08;;C12M41/32;;C12M41/36,C12M1/34;;C12M1/12;;C12M1/24,,1,0,,,"English translation of DE 202018104472, Grimm et al, Sartorius Stedim Biotech GmbH, generated 2025",PENDING
607,US,A1,US 2025/0161341 A1,194-678-606-392-825,2025-05-22,2025,US 202418950696 A,2024-11-18,CN 202311556506 A,2023-11-20,GLYCYRRHIZIC ACID BACTERIAL CELLULOSE COMPOSITE FOR PROMOTING THE GROWTH AND DEVELOPMENT OF SKIN HAIR FOLLICLES,"The present disclosure relates to a glycyrrhizic acid bacterial cellulose composite for promoting growth and development of hair follicles in skins, in particular, the glycyrrhizic acid bacterial cellulose composite for promoting growth and development of hair follicles in skin includes glycyrrhizic acid and bacterial cellulose.",CHEN CHAO CHENG;;HONG QING FLOWERY BIO TECH GUANGZHOU CO LTD,WANG QIONG;;CHEN CHAO-CHENG;;ZHENG SI HAN,HONG QING FLOWERY BIO-TECH (GUANGZHOU) CO. LTD (2024-11-07);;CHEN CHAO-CHENG (2024-11-14),https://lens.org/194-678-606-392-825,Patent Application,yes,0,0,4,030-045-146-608-498;;194-678-606-392-825;;069-914-420-673-565;;132-330-248-288-350,JP;;CN;;EP;;US,4,030-045-146-608-498;;194-678-606-392-825;;132-330-248-288-350;;069-914-420-673-565,JP;;CN;;EP;;US,0,A61K47/61;;A61K31/704;;A61K9/0014;;A61P17/14;;A61K8/602;;A61K8/731;;A61Q7/00;;A61K2800/57;;A61K31/704;;A61K31/715;;A61K35/74,A61K31/704;;A61K31/715;;A61K35/74,,0,0,,,,PENDING
608,US,A1,US 2021/0198269 A1,190-047-971-501-384,2021-07-01,2021,US 201917273549 A,2019-09-05,EP 18192653 A;;EP 2019073761 W,2018-09-05,INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs),"The present invention relates to 2,6-methanobenzo[g][l]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][l]oxacin-4-one compounds and their analog compounds.",LEAD DISCOVERY CENTER GMBH;;MAX PLANCK GESELLSCHAFT,WALDMANN HERBERT;;ZISCHINSKY GUNTHER;;NUSSBAUMER PETER;;ZIEGLER SLAVA;;SCHWALFENBERG MELANIE;;CERRAJERIA JAVIER DE CEBALLOS;;RECKZEH ELENA SABRINA;;KARAGEORGIS GEORGE,MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V (2021-01-26);;LEAD DISCOVERY CENTER GMBH (2021-01-26),https://lens.org/190-047-971-501-384,Patent Application,yes,0,2,10,179-829-502-981-440;;093-100-555-419-246;;053-843-020-111-401;;087-261-218-961-907;;141-724-001-962-006;;164-638-903-290-88X;;152-940-504-388-427;;020-636-233-710-695;;190-047-971-501-384;;119-577-396-659-890,JP;;AU;;EP;;WO;;US;;CA,10,179-829-502-981-440;;093-100-555-419-246;;053-843-020-111-401;;087-261-218-961-907;;141-724-001-962-006;;164-638-903-290-88X;;152-940-504-388-427;;020-636-233-710-695;;190-047-971-501-384;;119-577-396-659-890,JP;;AU;;EP;;WO;;US;;CA,0,C07D491/08;;A61P35/00;;A61P3/00;;A61P29/00;;A61P37/00;;C07D491/08,C07D491/08,,1,1,015-232-264-467-876,10.1038/s41557-018-0132-6;;30202104,"Karageorgis et al., ""Chromopynones are pseudo natural product glucose uptake inhibitors targeting glucose transporters GLUT-1 and -3"", 2018, Nature Chemistry, vol. 10, pages 1103-1111. (Year: 2018)",ACTIVE
609,US,A1,US 2023/0330088 A1,068-735-622-713-158,2023-10-19,2023,US 202118005012 A,2021-07-13,US 202118005012 A;;US 202063051320 P;;US 2021/0041439 W,2020-07-13,COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH,"The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).",VERASTEM INC,COMA SILVIA;;PACHTER JONATHAN A,VERASTEM INC (2021-01-07),https://lens.org/068-735-622-713-158,Patent Application,yes,0,0,13,028-474-838-825-462;;062-565-553-149-882;;175-076-781-965-611;;083-933-290-716-993;;152-255-820-542-865;;103-243-410-824-709;;159-267-776-265-196;;177-643-290-053-109;;153-460-587-363-391;;067-817-485-269-099;;192-837-855-933-111;;068-735-622-713-158;;138-643-730-497-893,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;BR;;MX,13,028-474-838-825-462;;062-565-553-149-882;;175-076-781-965-611;;083-933-290-716-993;;152-255-820-542-865;;103-243-410-824-709;;159-267-776-265-196;;177-643-290-053-109;;153-460-587-363-391;;067-817-485-269-099;;192-837-855-933-111;;068-735-622-713-158;;138-643-730-497-893,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;BR;;MX,0,A61K45/06;;A61K31/506;;A61K39/395;;C07K16/2818;;A61P35/00;;A61K45/06;;A61K39/395;;A61K2300/00;;A61P35/00;;A61K31/506;;C07K16/2818;;A61P35/00;;A61K31/506;;A61K39/3955,A61K31/506;;A61K31/5377;;A61K39/395;;A61P35/00,,1,1,029-785-086-606-666,29357948;;pmc5778665;;10.1186/s40425-018-0316-z,"Gong et al.; Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations; Journal for ImmunoTherapy of Cancer, 2018, 6:8. (Year: 2018)",PENDING
610,WO,A1,WO 2024/235844 A1,153-932-625-666-231,2024-11-21,2024,EP 2024062916 W,2024-05-10,EP 23305760 A,2023-05-12,METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES,"The CRISPR-Cas9 system has revolutionized our ability to precisely modify the genome and has impelled gene editing into clinical applications. Comprehensive analysis of gene editing products at the targeted cut-site revealed a complex spectrum of outcomes. ON-target genotoxicity is underestimated with standard PCR-based methods and necessitates appropriate and sensitive detection methods. Here, the inventors developed two complementary Fluorescence-Assisted Megabase-scale Rearrangements Detection (FAMReD) systems that enable detection, quantification, and cell sorting of edited cells with megabase-scale loss of heterozygosity (LOH). They revealed rare complex chromosomal rearrangements caused by Cas9-nuclease and showed that LOH frequency depends on cell division rate during editing and p53 status. Cell cycle arrest during editing suppressed the appearance of LOH without compromising editing. These data were confirmed in human stem/progenitor cells, suggesting that clinical trials should consider p53 status and cell proliferation rate during editing to limit this risk and design safer protocols.",INST NAT SANTE RECH MED;;CHU DE BORDEAUX;;UNIV BORDEAUX,MOREAU-GAUDRY FRANÇOIS;;BEDEL AURÉLIE;;FAYET SABRINA,,https://lens.org/153-932-625-666-231,Patent Application,yes,7,0,1,153-932-625-666-231,WO,1,153-932-625-666-231,WO,0,C12N15/102;;C12N2310/20;;C12N15/907;;G01N33/48;;G01N33/5005,C12N15/10;;C12N15/90,,74,70,009-222-271-982-650;;115-910-286-543-185;;029-179-338-514-136;;051-787-904-723-706;;029-179-338-514-136;;066-720-592-894-079;;009-706-440-465-939;;027-105-520-524-520;;084-033-279-775-370;;084-243-600-334-05X;;050-576-388-403-055;;010-425-788-978-502;;042-924-537-342-013;;001-293-592-612-48X;;036-893-292-975-894;;014-787-992-554-081;;014-066-574-367-486;;006-125-585-791-845;;033-574-452-713-467;;008-414-291-688-694;;010-848-040-322-057;;084-561-785-125-898;;040-264-822-193-666;;125-980-003-853-48X;;009-222-271-982-650;;081-363-925-121-586;;071-733-875-337-970;;011-604-266-214-329;;069-367-877-555-120;;060-318-771-737-462;;038-009-762-008-499;;003-874-577-334-07X;;049-135-583-893-222;;032-308-249-713-244;;025-675-300-582-974;;037-705-756-825-487;;018-669-052-040-505;;176-793-186-576-10X;;085-166-967-386-323;;003-813-361-498-084;;014-099-764-126-078;;008-496-947-437-858;;042-466-470-984-63X;;079-409-042-556-892;;029-832-593-201-005;;007-106-338-584-243;;013-773-692-248-660;;094-682-083-491-280;;071-234-932-452-515;;035-695-685-094-162;;001-498-953-390-181;;138-770-496-210-920;;101-655-375-170-823;;005-061-692-181-077;;055-040-250-566-94X;;039-001-012-851-022;;025-037-986-638-285;;053-519-886-935-140;;121-027-552-305-361;;049-143-440-277-211;;159-090-901-519-634;;055-367-973-690-746;;023-008-904-514-014;;162-751-023-491-909;;100-539-200-961-602;;030-261-294-266-932;;090-492-242-003-369;;064-169-626-086-236;;113-497-810-896-51X;;013-520-997-134-490,10.1089/crispr.2021.0120;;35099280;;35304271;;10.1016/j.exphem.2022.03.002;;pmc10333231;;37429857;;10.1038/s41467-023-39632-w;;pmc6187057;;10.1016/j.omtn.2018.09.006;;30317165;;pmc10333231;;37429857;;10.1038/s41467-023-39632-w;;10.1038/nbt.1927;;21738127;;pmc3152587;;pmc3177186;;10.1093/nar/gkr815;;pmc3177181;;10.1093/nar/gkr407;;21727090;;10.1093/nar/gkr739;;21576234;;10.1126/science.1207773;;21700836;;pmc3489282;;21131970;;10.1038/nmeth.1539;;17603476;;10.1038/nbt1317;;20051983;;10.1038/nsmb.1710;;pmc2850169;;10.1534/genetics.111.131433;;pmc3176093;;21828278;;10.1073/pnas.93.3.1156;;8577732;;pmc40048;;12033941;;10.1021/bi020095c;;10.1093/bioinformatics/btn331;;pmc2732218;;18586699;;10.1002/humu.20495;;17311302;;15801831;;10.1021/jm049354h;;16621547;;10.1016/j.bmcl.2006.03.084;;16682184;;10.1016/j.bmcl.2006.04.048;;10632371;;8016116;;pmc44138;;10.1073/pnas.91.13.6064;;pmc5529214;;10.1016/j.dnarep.2016.05.001;;27261202;;25430774;;10.1126/science.1258096;;pmc3795411;;10.1126/science.1231143;;23287718;;10.1089/crispr.2021.0120;;35099280;;10.1038/nbt0918-899c;;30188522;;28561021;;10.1038/ncomms15464;;pmc5460021;;30837594;;10.1038/s41598-019-40181-w;;pmc6401152;;32460021;;10.1016/j.celrep.2020.107689;;34050011;;10.1101/2020.06.05.135913;;10.1073/pnas.2004832117;;pmc8179174;;pmc6408493;;30850590;;10.1038/s41467-019-09006-2;;pmc6919265;;10.1089/crispr.2019.0006;;31742432;;33125898;;10.1016/j.cell.2020.10.025;;10.1073/pnas.2008073117;;pmc7502765;;32873648;;10.1038/s41592-018-0212-y;;30504872;;10.1038/s41467-021-25190-6;;34389729;;pmc8363739;;33846636;;10.1038/s41588-021-00838-7;;pmc8192433;;pmc8494802;;34615869;;10.1038/s41467-021-26097-y;;29178945;;pmc5701507;;10.1186/s13059-017-1354-4;;30089922;;10.1038/s41586-018-0380-z;;pmc7613940;;35773341;;10.1038/s41587-022-01377-0;;10.1016/s0140-6736(09)61925-5;;20226990;;31107154;;pmc6686686;;10.1089/nat.2019.0790;;17380161;;10.1038/nrm2147;;32404993;;10.1038/s41568-020-0262-1;;29892062;;10.1038/s41591-018-0050-6;;29892067;;10.1038/s41591-018-0049-z;;10.1158/0008-5472.can-21-1692;;34750099;;pmc9397613;;10.1038/s41588-020-0623-4;;32424350;;pmc7343612;;30905619;;pmc6458988;;10.1016/j.stem.2019.02.019;;10.1006/scbi.1998.0095;;10101798;;pmc6004076;;10.1101/gad.314351.118;;29802124;;10.1159/000447001;;27493617;;pmc4960354;;10.1073/pnas.0600447103;;pmc1502288;;16818887;;10.1126/science.1140735;;18323444;;10.7554/elife.31723;;pmc5832412;;29334356;;10.7554/elife.31723.021;;pmc4357702;;25672394;;10.1093/nar/gkv084;;pmc6036189;;29414795;;10.1074/jbc.tm118.000371;;pmc7744368;;32967938;;10.1158/1078-0432.ccr-20-2269;;35701408;;10.1038/s41467-022-30480-8;;pmc9197861;;19232554;;pmc2667984;;10.1016/j.ajhg.2009.01.024;;10.1038/s41587-020-0561-9;;32572269;;pmc6535181;;10.1038/s41576-018-0059-1;;30341440;;30323312;;35658035;;10.1126/sciadv.abm9106;;pmc9166625;;10.1016/j.tig.2018.04.002;;29735283;;pmc6469874;;10.1016/j.mrfmmm.2011.04.008;;21575645;;pmc3178001;;pmc3907307;;10.1371/journal.pgen.1004139;;24497845;;26687355;;pmc4687025;;10.1016/j.cell.2015.11.054;;11715018;;10.1038/ncb1101-973;;11231573;;10.1038/35060032,"BOUTIN JULIAN ET AL: ""ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected"", vol. 5, no. 1, 1 February 2022 (2022-02-01), pages 19 - 30, XP093082198, ISSN: 2573-1599, Retrieved from the Internet <URL:http://dx.doi.org/10.1089/crispr.2021.0120> DOI: 10.1089/crispr.2021.0120;;WEN WEI ET AL: ""CRISPR-Cas9 gene editing induced complex on-target outcomes in human cells"", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 110, 15 March 2022 (2022-03-15), pages 13 - 19, XP087060191, ISSN: 0301-472X, [retrieved on 20220315], DOI: 10.1016/J.EXPHEM.2022.03.002;;MIYAHARA: ""Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9"", HUMAN GENE THERAPY, vol. 28, no. 12, 1 December 2017 (2017-12-01), GB, pages A36, XP055742223, ISSN: 1043-0342, DOI: 10.1089/hum.2017.29055.abstracts;;KNOPP YVONNE ET AL: ""Transient retrovirus-based CRISPR/Cas9 All-in-One Particles for efficient, targeted gene knock-out"", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 13, 1 January 2018 (2018-01-01), pages 256 - 274, XP002806692, ISSN: 2162-2531, DOI: 10.1016/J.OMTN.2018.09.006 PUBLISHER:;;CULLOT G. ET AL: ""Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9"", vol. 14, no. 1, 10 July 2023 (2023-07-10), XP093082195, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-023-39632-w> DOI: 10.1038/s41467-023-39632-w;;JENNIFER HOLLYWOOD: ""Cystic fibrosis gene repair: correction of ΔF508 using ZFN and CRISPR/Cas9 guide RNA gene editing tools"", 1 January 2013 (2013-01-01), pages 1 - 193, XP055209264, Retrieved from the Internet <URL:https://cora.ucc.ie/bitstream/handle/10468/1407/JH thesis.pdf?sequence=3> [retrieved on 20150824];;HOCKEMEYER ET AL., NATURE BIOTECH., vol. 29, 2011, pages 731 - 734;;MOSCOU ET AL., SCIENCE, vol. 326, 2009, pages 3501 - 12;;CERMAK ET AL., NUCL. ACIDS RES., vol. 39, 2011, pages e82;;WOOD ET AL., SCIENCE, vol. 333, 2011, pages 307;;DOYON ET AL., NATURE METHODS, vol. 8, 2010, pages 74 - 79;;SZCZEPEK ET AL., NATURE BIOTECH., vol. 25, 2007, pages 786 - 793;;GUO ET AL., J. MOL. BIOL., vol. 200, 2010, pages 96;;HUERTAS, P., NAT. STRUCT. MOL. BIOL., vol. 17, 2010, pages 11 - 16;;CARROLL ET AL., GENETICS SOCIETY OF AMERICA, vol. 188, 2011, pages 773 - 782;;KIM, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 1156 - 1160;;SERA, BIOCHEMISTRY, vol. 41, 2002, pages 7074 - 7081;;LIU, BIOINFORMATICS, vol. 24, 2008, pages 1850 - 1857;;BITINAITE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 10570 - 5;;PETITJEAN AMATHE EKATO SISHIOKA CTAVTIGIAN SVHAINAUT POLIVIER M.: ""Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database"", HUM MUTAT., vol. 28, no. 6, June 2007 (2007-06-01), pages 622 - 9, XP071974067, Retrieved from the Internet <URL:http://p53.iarc.fr> DOI: 10.1002/humu.20495;;TOOGOOD ET AL., J. MED. CHEM., vol. 48, 2005, pages 2388 - 2406;;TU ET AL., BIOORG. MED. CHEM. LETT., vol. 16, 2006, pages 3578 - 3581;;SHIMAMURA ET AL., BIOORG. MED. CHEM. LETT, vol. 16, 2006, pages 3751 - 3754;;KUBO ET AL., CLIN. CANCER RES., vol. 5, 1999, pages 4279 - 4286;;ROUET, P.SMIH, F.JASIN, M.: ""Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells."", PROC. NATL ACAD. SCI. USA, vol. 91, 1994, pages 6064 - 6068, XP002005205, DOI: 10.1073/pnas.91.13.6064;;JASIN, M.HABER, J.E.: ""The democratization of gene editing: Insights from site-specific cleavage and double-strand break repair"", DNA REPAIR (AMST)., vol. 44, 2016, pages 6 - 16, XP029645039, DOI: 10.1016/j.dnarep.2016.05.001;;DOUDNA, J. A.CHARPENTIER, E.: ""Genome editing. The new frontier of genome engineering with CRISPR-Cas9"", SCIENCE, vol. 346, 2014, pages 1258096, XP055162699, DOI: 10.1126/science.1258096;;CONG, L. ET AL.: ""Multiplex genome engineering using CRISPR/Cas systems."", SCIENCE, vol. 339, 2013, pages 819 - 823, XP055871219, DOI: 10.1126/science.1231143;;BOUTIN, J. ET AL.: ""ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected"", CRISPR J., vol. 5, 2022, pages 19 - 30, XP093082198, DOI: 10.1089/crispr.2021.0120;;KOSICKI, M.TOMBERG, K.BRADLEY, A.: ""Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements."", NAT. BIOTECHNOL., vol. 36, 2018, pages 765 - 771, XP036929645, DOI: 10.1038/nbt.4192;;SHIN, H. Y. ET AL.: ""CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome."", NAT. COMMUN., vol. 8, 2017, pages 15464, XP055821911, DOI: 10.1038/ncomms15464;;REZZA, A. ET AL.: ""Unexpected genomic rearrangements at targeted loci associated with CRISPR/Cas9-mediated knock-in"", SCI REP., vol. 9, 2019, pages 3486;;WEISHEIT, I. ET AL.: ""Detection of deleterious on-target effects after HDR mediated CRISPR editing"", CELL REP., vol. 26, 2020, pages 107689;;ALANIS-LOBATO, G. ET AL.: ""Frequent loss of heterozygosity in CRISPR-Cas9- edited early human embryos."", PROC. NATL ACAD. SCI. USA, vol. 118, 2021, pages e2004832117;;CULLOT, G. ET AL.: ""CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations."", NAT. COMMUN., vol. 10, 2019, pages 1136;;RAYNER, E. ET AL.: ""CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods"", CRISPR J., vol. 2, 2019, pages 406 - 416;;ZUCCARO, M. V. ET AL.: ""Allele-specific chromosome removal after Cas9 cleavage in human embryos."", CELL, vol. 29, 2020, pages 31389 - 31391;;DAVIS, L. ET AL.: ""POLQ suppresses interhomolog recombination and loss of heterozygosity at targeted DNA breaks."", PROC. NATL ACAD. SCI. USA, vol. 15, 2020, pages 22900 - 22909;;IKEDA, K. ET AL.: ""Efficient scarless genome editing in human pluripotent stem cells."", NAT METHODS., vol. 15, 2018, pages 1045 - 1047, XP036648015, DOI: 10.1038/s41592-018-0212-y;;BOUTIN, J. ET AL.: ""CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells."", NAT COMMUN., vol. 12, 2021, pages 4922;;LEIBOWITZ, M. L. ET AL.: ""Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing."", NAT. GENET., vol. 53, 2021, pages 895 - 905, XP037475892, DOI: 10.1038/s41588-021-00838-7;;PAPATHANASIOU, S. ET AL.: ""Whole chromosome loss and genomic instability in mouse embryos after CRISPR-Cas9 genome editing."", NAT. COMMUN., vol. 12, 2021, pages 5855;;ZUO, E. ET AL.: ""CRISPR/Cas9-mediated targeted chromosome elimination"", GENOME BIOL., vol. 18, 2017, pages 224, XP055943547, DOI: 10.1186/s13059-017-1354-4;;ADIKUSUMA, F. ET AL.: ""Large deletions induced by Cas9 cleavage."", NATURE, vol. 560, 2018, pages E8 - E9, XP036563461, DOI: 10.1038/s41586-018-0380-z;;NAHMAD, A.D. ET AL.: ""Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage."", NAT BIOTECHNOL., vol. 12, 2022, pages 1807 - 1813;;PUY, H.GOUYA, L.DEYBACH, J.C.: ""Porphyrias."", LANCET., vol. 375, 2010, pages 924 - 937, XP026978225, DOI: 10.1016/S0140-6736(09)61925-5;;VAKULSKAS, C.A.: ""Behlke, M.A. Evaluation and Reduction of CRISPR Off-Target Cleavage Events."", NUCLEIC ACID THER., vol. 29, 2019, pages 167 - 174, XP055728865, DOI: 10.1089/nat.2019.0790;;VOUSDEN, K.H.LANE, D.P.: ""p53 in health and disease."", NAT REV MOL CELL BIOL., vol. 8, 2007, pages 275 - 283;;LEVINE, A.J.: ""p53: 800 million years of evolution and 40 years of discovery."", NAT REV CANCER, vol. 20, 2020, pages 471 - 480, XP037201231, DOI: 10.1038/s41568-020-0262-1;;IHRY, R. ET AL.: ""p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells."", NAT. MED., vol. 24, 2018, pages 939 - 946, XP036542073, DOI: 10.1038/s41591-018-0050-6;;HAAPANIEMI, E. ET AL.: ""CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response."", NAT. MED., vol. 24, 2018, pages 927 - 930, XP036542072, DOI: 10.1038/s41591-018-0049-z;;JIANG, L.: ""CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies."", CANCER RES., vol. 82, 2022, pages 36 - 45;;ENACHE, O.M. ET AL.: ""Cas9 activates the p53 pathway and selects for p53-inactivating mutations."", NAT GENET., vol. 52, 2020, pages 662 - 668, XP037525537, DOI: 10.1038/s41588-020-0623-4;;SCHIROLI, G. ET AL.: ""Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response."", CELL STEM CELL., vol. 24, 2019, pages 551 - 565;;SCHWARTZ DROTTER V.: ""p53-dependent cell cycle control: response to genotoxic stress"", SEMIN CANCER BIOL., vol. 8, 1998, pages 325 - 336;;LEVINE, M.S.HOLLAND, A.J.: ""The impact of mitotic errors on cell proliferation and tumorigenesis"", GENES DEV., vol. 32, 2018, pages 620 - 638;;SCHMIDT M.: ""Palbociclib - from Bench to Bedside and Beyond"", BREAST CARE., vol. 11, 2016, pages 177 - 181;;VASSILEV LT ET AL.: ""Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1."", PROC NATL ACAD SCI USA., vol. 103, 2006, pages 10660 - 10665, XP055590963, DOI: 10.1073/pnas.0600447103;;HALAZONETIS TDGORGOULIS VGBARTEK J.: ""An oncogene-induced DNA damage model for cancer development."", SCIENCE, vol. 319, 2008, pages 1352 - 1355;;ROY, S. ET AL.: ""p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLO pathways"", ELIFE, vol. 7, 2018, pages e31723;;KONDRATOVA, A.: ""Replication fork integrity and intra-S phase checkpoint suppress gene amplification."", NUCLEIC ACIDS RES., vol. 43, 2015, pages 2678 - 2690;;HER, J.BUNTING, S.F.: ""How cells ensure correct repair of DNA double-strand breaks."", J BIOL CHEM., vol. 293, 2018, pages 10502 - 10511, XP055830556, DOI: 10.1074/jbc.TM118.000371;;PESCH, A.M. ET AL.: ""Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers"", CLIN CANCER RES., vol. 26, 2020, pages 6568 - 6580;;KOSICKI, M. ET AL.: ""Cas9-induced large deletions and small InDels are controlled in a convergent fashion."", NAT COMMUN., vol. 13, 2022, pages 3422;;ARLT, M.F.: ""Replication stress induces genome-wide copy number changes in human cells that resemble polymorphic and pathogenic variants"", AM J HUM GENET., vol. 84, 2009, pages 339 - 350;;ANZALONE, A. V.KOBLAN, L. W.LIU, D. R.: ""Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors."", NAT. BIOTECHNOL., vol. 38, 2020, pages 824 - 844, XP037622140, DOI: 10.1038/s41587-020-0561-9;;REES, H. A.LIU, D. R.: ""Base editing: precision chemistry on the genome and transcriptome of living cells."", NAT. REV. GENET., vol. 19, 2018, pages 770 - 788;;TRAN, N.T.: ""Precise CRISPR-Cas-mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells"", SCI ADV., vol. 8, 2022, pages eabm9106;;KRAMARA, J.OSIA, B.MALKOVA, A.: ""Break-induced replication: the where, the why, and the how."", TRENDS GENET., vol. 34, 2018, pages 518 - 531;;MURNANE, J.P: ""Telomere dysfunction and chromosome instability"", MUTAT RES., vol. 730, 2012, pages 28 - 36, XP028436148, DOI: 10.1016/j.mrfmmm.2011.04.008;;HERMETZ, K.E. ET AL.: ""Large inverted duplications in the human genome form via a fold-back mechanism"", PLOS GENET., vol. 10, 2014, pages e1004139;;MACIEJOWSKI, J. ET AL.: ""Chromothripsis and Kataegis Induced by Telomere Crisis."", CELL, vol. 163, 2015, pages 1641 - 1654, XP029360515, DOI: 10.1016/j.cell.2015.11.054;;ZHOU B.P. ET AL.: ""HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation."", NAT. CELL. BIOL., vol. 11, 2001, pages 973 - 982;;ZHOU B.P. ET AL.: ""Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells."", NAT CELL BIOL., vol. 3, 2001, pages 245 - 252",PENDING
611,US,A1,US 2023/0242930 A1,109-127-557-446-562,2023-08-03,2023,US 202218055765 A,2022-11-15,CN 202210110992 A,2022-01-29,METHOD FOR INCREASING METHIONINE CONTENT IN GRAINS BY GENE KNOCKOUT,"The present disclosure provides a method for increasing a methionine content in grains by gene knockout. A maize ZmMETS2 gene is knocked out by a CRISPR/Cas9 technology, and it is found that the methionine content in maize grains is increased to a certain extent after the gene is knocked out. In the present disclosure, the CRISPR/Cas9 target site of the maize ZmMETS2 gene is designed and a function of the gene is found to significantly affect the methionine content. This provides a reference for CRISPR researches of the gene in maize and other crops, and provides a theoretical basis for methionine metabolism of the maize and other crops. Accordingly, the deficiency of human amino acid nutrition is alleviated by increasing the methionine content of transgenic plants.",BIOTECHNOLOGY RES INST CAAS,JIANG LING;;ZHANG CHUNYI;;REN YING;;LIAN TONG;;LIU JI'AN,BIOTECHNOLOGY RESEARCH INSTITUTE CAAS (2022-10-25),https://lens.org/109-127-557-446-562,Patent Application,yes,0,1,3,109-127-557-446-562;;025-233-715-096-857;;044-954-123-418-006,CN;;US,3,109-127-557-446-562;;025-233-715-096-857;;044-954-123-418-006,CN;;US,0,C12N15/8253;;C12N15/8218;;C12N9/22;;C12N9/1085;;C12Q1/6895;;C12Y205/01006;;C12Q2600/156;;C12Q2600/13;;C12N15/8253;;C12N9/22;;C12N15/8251;;A01H5/10;;C12N15/8213;;C07K14/415;;C12N15/11;;C12N2310/20;;C12N9/22;;C12N15/11;;C12N15/8253,C12N15/82;;C12N9/22;;C12N15/11,,0,0,,,,DISCONTINUED
612,WO,A1,WO 2022/015736 A1,067-817-485-269-099,2022-01-20,2022,US 2021/0041439 W,2021-07-13,US 202063051320 P,2020-07-13,COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH,"The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).",VERASTEM INC,COMA SILVIA;;PACHTER JONATHAN A,,https://lens.org/067-817-485-269-099,Patent Application,yes,2,8,13,028-474-838-825-462;;062-565-553-149-882;;175-076-781-965-611;;083-933-290-716-993;;152-255-820-542-865;;103-243-410-824-709;;159-267-776-265-196;;177-643-290-053-109;;153-460-587-363-391;;067-817-485-269-099;;192-837-855-933-111;;068-735-622-713-158;;138-643-730-497-893,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;BR;;MX,13,028-474-838-825-462;;062-565-553-149-882;;175-076-781-965-611;;083-933-290-716-993;;152-255-820-542-865;;103-243-410-824-709;;159-267-776-265-196;;177-643-290-053-109;;153-460-587-363-391;;067-817-485-269-099;;192-837-855-933-111;;068-735-622-713-158;;138-643-730-497-893,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;CA;;BR;;MX,0,A61K45/06;;A61K31/506;;A61K39/395;;C07K16/2818;;A61P35/00;;A61K45/06;;A61K39/395;;A61K2300/00;;A61P35/00;;A61K31/506;;C07K16/2818;;A61P35/00;;A61K31/506;;A61K39/3955,A61K31/4166;;A61K31/4184;;A61K31/4355,,3,1,085-922-227-166-684,10.1158/1078-0432.ccr-18-3488;;31358540,"HAMID OMID, MOLINERO LUCIANA, BOLEN CHRISTOPHER R., SOSMAN JEFFREY A., MUÑOZ-COUSELO EVA, KLUGER HARRIET M., MCDERMOTT DAVID F., P: ""Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab"", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 25, no. 20, 15 October 2019 (2019-10-15), US, pages 6061 - 6072, XP055899004, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-18-3488;;ANONYMOUS: ""FRAME: A Phase I Trial of the Combination of VS-6063 (FAK Inhibitor) and R05126766 ( CH 5126776) (a Dual RAF/MEK Inhibitor"", 24 June 2020 (2020-06-24), pages 1 - 9, XP093021865, Retrieved from the Internet <URL:https://dinica)tria!s.gov/ct2/history/NCT03875820?V_6=View#StudyPageTop> [retrieved on 20210930];;See also references of EP 4178573A4",PENDING
613,EP,A1,EP 3967752 A1,054-577-297-239-261,2022-03-16,2022,EP 20196306 A,2020-09-15,EP 20196306 A,2020-09-15,VIRUS SPECIFIC CYTOKINE-INDUCED KILLER CELLS,"The present invention is directed to Virus specific Cytokine-Induced Killer cells (CIK), their use as a medicament and to a method for obtaining these Virus specific Cytokine-Induced Killer cells.",SCHMIDT WOLF INGO,SCHMIDT-WOLF INGO,,https://lens.org/054-577-297-239-261,Patent Application,yes,2,0,2,054-577-297-239-261;;050-464-703-722-640,EP;;US,2,054-577-297-239-261;;050-464-703-722-640,EP;;US,0,C12N5/0638;;A61P31/14;;C12N2501/22;;C12N2501/25;;C12N2501/2302;;C12N2501/2304;;C12N2502/1121;;A61K2039/572;;A61K2039/5154;;A61K39/12;;A61K2039/5158;;C12N5/0634;;A61K39/215;;A61K2039/5158;;C12N5/0634;;C12N2501/22;;C12N2501/2301;;C12N2501/2302;;C12N2501/2304;;C12N2501/24;;C12N2501/515;;C12N2502/1121;;A61K2039/5154;;C12N5/0638,C12N5/0783;;A61K35/17;;A61K39/215;;A61P31/14,,7,7,083-409-897-681-589;;006-058-074-844-020;;055-886-086-465-272;;055-009-269-092-048;;087-814-399-940-52X;;021-816-728-778-506;;021-816-728-778-506,29754771;;10.1016/j.jcyt.2018.04.005;;26072027;;10.1016/j.jcyt.2015.04.011;;10.1182/blood-2011-02-336321;;21821703;;10.1001/jama.2020.17023;;32876694;;pmc7489434;;10.1084/jem.174.1.139;;1711560;;pmc2118875;;31229666;;10.1016/j.clim.2019.06.007;;31229666;;10.1016/j.clim.2019.06.007,"PFEFFERMANN LISA-MARIE ET AL: ""Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma"", CYTOTHERAPY, vol. 20, no. 6, 1 June 2018 (2018-06-01), GB, pages 839 - 850, XP055775789, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2018.04.005;;PFIRRMANN VERENA ET AL: ""Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus"", CYTOTHERAPY, vol. 17, no. 8, 1 August 2015 (2015-08-01), GB, pages 1139 - 1151, XP055775267, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2015.04.011;;A. PIEVANI ET AL: ""Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity"", BLOOD, vol. 118, no. 12, 22 September 2011 (2011-09-22), US, pages 3301 - 3310, XP055377531, ISSN: 0006-4971, DOI: 10.1182/blood-2011-02-336321;;STERNE JONATHAN A. C. ET AL: ""Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 : A Meta-analysis"", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 324, no. 13, 2 September 2020 (2020-09-02), US, pages 1330, XP055775775, ISSN: 0098-7484, DOI: 10.1001/jama.2020.17023;;SCHMIDT-WOLF I. G. H.NEGRIN R. S.KIEM H.BLUME K. G.WEISSMAN I. L.: ""Use of SCID mouse/human lymphoma modelt o evaluate cytokine-induced killer cells with potent antitumor cell activity"", J. EXP. MED., vol. 174, no. 1, 1991, pages 139 - 149, XP001182112, DOI: 10.1084/jem.174.1.139;;LUAH ET AL.: ""for CMV-specific CIK cells"", CLIN IMMUNOL, vol. 205, August 2019 (2019-08-01), pages 83 - 92;;LUAH YEN HOON ET AL: ""A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance"", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 205, 21 June 2019 (2019-06-21), pages 83 - 92, XP085741128, ISSN: 1521-6616, [retrieved on 20190621], DOI: 10.1016/J.CLIM.2019.06.007",PENDING
614,US,A1,US 2022/0088181 A1,050-464-703-722-640,2022-03-24,2022,US 202117474552 A,2021-09-14,EP 20196306 A,2020-09-15,VIRUS SPECIFIC CYTOKINE-INDUCED KILLER CELLS,"The present invention is directed to Virus specific Cytokine-Induced Killer cells (CIK), their use as a medicament and to a method for obtaining these Virus specific Cytokine-Induced Killer cells.",ABTEILUNG FUER INTEGRIERTE ONKOLOGIE CIO BONN,SCHMIDT-WOLF INGO,ABTEILUNG FUR INTEGRIERTE ONKOLOGIE - CIO BONN (2021-09-20),https://lens.org/050-464-703-722-640,Patent Application,yes,2,0,2,054-577-297-239-261;;050-464-703-722-640,EP;;US,2,054-577-297-239-261;;050-464-703-722-640,EP;;US,0,C12N5/0638;;A61P31/14;;C12N2501/22;;C12N2501/25;;C12N2501/2302;;C12N2501/2304;;C12N2502/1121;;A61K2039/572;;A61K2039/5154;;A61K39/12;;A61K2039/5158;;C12N5/0634;;A61K39/215;;A61K2039/5158;;C12N5/0634;;C12N2501/22;;C12N2501/2301;;C12N2501/2302;;C12N2501/2304;;C12N2501/24;;C12N2501/515;;C12N2502/1121;;A61K2039/5154;;C12N5/0638,A61K39/215;;C12N5/078,,3,2,091-799-421-483-807;;081-307-136-592-856,10.1111/sji.12097;;23841728;;10.1016/j.exphem.2009.01.010;;19375652,"Fu, 2012, Japanese Soc. for Immunol. Vol. 24: 197-206;;Ma, 2013, Scand. J. Immunol. Vol. 78: pages 387-393;;Franceschetti, 2009, Exp. Hem. Vol. 37: 616-628",PENDING
615,US,A1,US 2021/0071102 A1,106-879-826-307-038,2021-03-11,2021,US 201816771447 A,2018-12-10,CN 201711317381 A;;CN 2018120026 W,2017-12-12,Phospholipase C and Encoding Gene Thereof,"According to the present disclosure, on the basis of all existing mutations, the tenth glycine of a BC-PC-PLC is mutated into aspartic acid, a specific enzyme activity thereof is 83% higher than that of a sequence before the mutation, and protein expression and degumming activity of unit enzyme activity do not change, so as to further reduce manufacturing costs.",WILMAR SHANGHAI BIOTECHNOLOGY RES & DEV CT CO LTD,WU WEI;;DAI XIAOJUN;;CAO HAISHENG;;NIU QIWEN,WILMAR (SHANGHAI) BIOTECHNOLOGY RESEARCH & DEVELOPMENT CENTER CO. LTD (2020-06-09),https://lens.org/106-879-826-307-038,Patent Application,yes,0,0,8,106-879-826-307-038;;103-045-640-863-327;;074-814-739-320-254;;011-578-207-401-670;;157-756-530-555-446;;099-277-226-258-738;;109-316-144-883-96X;;016-873-582-286-284,MY;;CN;;EP;;WO;;US,8,106-879-826-307-038;;103-045-640-863-327;;074-814-739-320-254;;011-578-207-401-670;;157-756-530-555-446;;099-277-226-258-738;;109-316-144-883-96X;;016-873-582-286-284,MY;;CN;;EP;;WO;;US,6,C11B3/003;;C12N9/16;;C12N15/815;;C12Y301/04003;;C11B3/003;;C12N9/16;;C12N15/815;;C12Y301/04003;;C11B3/00;;C11B3/003;;C12N9/16;;C12N15/815;;C12Y301/04003,C11B3/00;;C12N9/16;;C12N15/81,,0,0,,,,ACTIVE
616,US,A1,US 2024/0368590 A1,133-351-059-909-495,2024-11-07,2024,US 202418777597 A,2024-07-19,CN 2022106402 W;;CN 202210503831 A,2022-05-10,SPLIT COMPLEMENTARY BASE EDITING SYSTEMS BASED ON BIMOLECULAR DEAMINASES AND USES THEREOF,"Disclosed are split complementary base editing systems based on bimolecular deaminases and uses thereof. A split complementary base editing system mainly includes base editing fusion proteins A and B that are from splitting at a deaminase domain embedded inside a Cas9 nickase (nCas9), and a guide RNA (gRNA). The present disclosures of split complementary cytosine base editing systems can greatly reduce Cas9-dependent and Cas9-independent off-target effects in the genome while maintaining robust on-target cytosine base editing. The present disclosures also provide the split complementary adenine base editing systems. The split complementary cytosine (adenine) base editing systems are widely applicable to various eukaryotic organisms, and can be used in crop genetic breeding, animal breed improvement, and even clinical treatment of human genetic diseases.",UNIV SUN YAT SEN,LI JIANFENG;;XIONG XIANGYU;;LIU KEHUI;;HE XIONGLEI,SUN YAT-SEN UNIVERSITY (2024-07-11),https://lens.org/133-351-059-909-495,Patent Application,yes,0,0,5,018-373-616-438-891;;111-297-762-588-029;;092-793-870-881-009;;133-351-059-909-495;;106-863-303-235-905,CN;;WO;;US,5,106-863-303-235-905;;018-373-616-438-891;;092-793-870-881-009;;133-351-059-909-495;;111-297-762-588-029,CN;;WO;;US,0,C12N9/22;;C12N9/78;;C12N15/113;;C12Y305/04005;;C12Y305/04004;;C07K2319/00;;C07K2319/09;;C12N2310/20;;C12N15/111;;C12N15/85;;C12N15/81;;C12N2310/20;;C12N15/82;;C12N9/22;;C12N9/78;;C12N15/102;;C12N15/90;;C12N2310/20;;C12N9/22;;C12N9/78;;C12N15/111;;C12N15/81;;C12N15/82;;C12N15/85,C12N15/11;;C12N9/22;;C12N9/78;;C12N15/81;;C12N15/82;;C12N15/85,,0,0,,,,ACTIVE
617,EP,A1,EP 3725878 A1,099-277-226-258-738,2020-10-21,2020,EP 18889610 A,2018-12-10,CN 201711317381 A;;CN 2018120026 W,2017-12-12,PHOSPHOLIPASE C AND ENCODING GENE THEREOF,"According to the present disclosure, on the basis of all existing mutations, the tenth glycine of a BC-PC-PLC is mutated into aspartic acid, a specific enzyme activity thereof is 83% higher than that of a sequence before the mutation, and protein expression and degumming activity of unit enzyme activity do not change, so as to further reduce manufacturing costs.",WILMAR SHANGHAI BIOTECHNOLOGY RES & DEV CT CO LTD,WU WEI;;DAI XIAOJUN;;CAO HAISHENG;;NIU QIWEN,,https://lens.org/099-277-226-258-738,Patent Application,yes,0,0,8,106-879-826-307-038;;103-045-640-863-327;;074-814-739-320-254;;011-578-207-401-670;;157-756-530-555-446;;099-277-226-258-738;;109-316-144-883-96X;;016-873-582-286-284,MY;;CN;;EP;;WO;;US,8,106-879-826-307-038;;103-045-640-863-327;;074-814-739-320-254;;011-578-207-401-670;;157-756-530-555-446;;099-277-226-258-738;;109-316-144-883-96X;;016-873-582-286-284,MY;;CN;;EP;;WO;;US,6,C11B3/003;;C12N9/16;;C12N15/815;;C12Y301/04003;;C11B3/003;;C12N9/16;;C12N15/815;;C12Y301/04003;;C11B3/00;;C11B3/003;;C12N9/16;;C12N15/815;;C12Y301/04003,C12N9/20;;C11B3/00;;C12N9/16;;C12N15/55;;C12N15/81,,0,0,,,,PENDING
618,KR,A,KR 20230054218 A,136-083-126-164-878,2023-04-24,2023,KR 20210179185 A,2021-12-14,KR 20210137835 A,2021-10-15,METHOD FOR CULTURING A CELL EXPRESSING A PROTEIN,"The present invention relates to a method for culturing a cell line expressing a target protein, which is a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 1 or a polypeptide having at least 75% sequence homology thereto. More specifically, the present invention provides a culture method comprises a step of culturing the cell line expressing the protein, wherein the step of culturing the cell line includes adjustment of the pH of a culture medium. In addition, the culture method of the target protein according to the present invention can be used to mass-produce the target protein while reducing the production cost of the target protein.",SK BIOSCIENCE CO LTD,JEONG OH SEOK;;OH HOO KEUN;;KIM SEOK CHEON;;KIM PAN KYEOM;;AHN HYE BIN;;CHOI WOO YOUNG,,https://lens.org/136-083-126-164-878,Patent Application,no,2,0,12,191-533-680-790-737;;059-583-375-621-742;;089-716-543-246-49X;;061-048-263-761-174;;126-518-013-326-161;;056-399-916-304-936;;136-083-126-164-878;;175-149-811-373-081;;003-098-255-241-883;;031-381-100-159-139;;024-742-618-342-488;;110-241-011-086-651,KR;;WO,19,126-518-013-326-161;;097-527-062-238-998;;061-048-263-761-174;;059-583-375-621-742;;056-399-916-304-936;;115-709-793-387-717;;031-381-100-159-139;;199-003-573-604-786;;110-241-011-086-651;;165-656-277-854-427;;089-716-543-246-49X;;191-533-680-790-737;;175-149-811-373-081;;136-083-126-164-878;;134-339-829-853-964;;003-098-255-241-883;;024-742-618-342-488;;137-074-070-203-613;;041-766-951-381-512,KR;;WO,6,A61K39/00;;A61K39/215;;A61K39/385;;A61P31/14;;B01D61/14;;B04B5/10;;C07K1/34;;C07K1/16;;C07K14/005;;A61K39/215;;A61P31/14;;C12N5/0682;;C07K14/005;;C12N15/85;;C12N2770/20052;;C12N2770/20034;;C12N2511/00;;C12N2500/34;;C12N2500/32;;C12N2500/38,A61K39/215;;A61K39/00;;A61K39/385;;A61P31/14,,2,1,033-587-201-248-559,34484641;;10.18502/ajmb.v13i3.6365;;pmc8377406,"Avicenna J Med Biotech, 13(3): 123-130(2021.07-09)*;;PLOS ONE 제16권 제2호 e0242890 (2021.02.)*",ACTIVE
619,KR,A,KR 20210010730 A,192-935-730-990-218,2021-01-28,2021,KR 20190087113 A,2019-07-18,KR 20190087113 A,2019-07-18,KASP KASP Marker Set for Genetic Mapping of Korean Japonica Rice Varieties,"The present invention relates to a primer set for kompetitive allele specific PCR (KASP) for the genetic mapping of japonica rice varieties and a use thereof. The primer set for KASP of the present invention can be used to promote the excavation of excellent genes that Korean japonica rice varieties have, thereby being usefully used for rice molecular breeding studies.",REPUBLIC KOREA MAN RURAL DEV ADMIN,JI HYEONSO;;KIM KYUNG HWAN;;CHOI INCHAN;;BAEK JEONG HO;;WON YONG JAE;;IN SUN YOON;;HAN JUNG HEON;;CHEON KYEONG SEONG;;KIM SONG LIM;;OH JUN;;KANG DO YU;;OH HYO JA,,https://lens.org/192-935-730-990-218,Patent Application,no,5,0,2,192-935-730-990-218;;067-975-139-230-873,KR,2,192-935-730-990-218;;067-975-139-230-873,KR,0,C12Q1/6895;;C12Q2600/156,C12Q1/6895,,1,1,056-150-301-229-454,10.9787/pbb.2018.6.4.391,"Kyeong-Seong Cheon et al., Plant. Breed. Biotech., 6(4), pp.391-403, 2018.",ACTIVE
620,US,A1,US 2025/0277782 A1,178-995-278-577-829,2025-09-04,2025,US 202218262441 A,2022-01-21,EP 21152718 A;;EP 2022051300 W,2021-01-21,APPLICATION OF PERMITTIVITY MEASUREMENT PROBES IN AN SUSPENSION CULTURE AGGREGATE COMPRISING CELL AGGREGATES,"The present disclosure relates to a method of measuring cell density in a cell suspension comprising cell aggregates, the method comprising (i) Measuring the permittivity of the cell suspension; (ii) Comparing the measured permittivity with a predetermined value that is indicative of the cell density, thereby determining the cell density. Further described is a of a permittivity probe for determining the cell density of a suspension cell culture comprising cell aggregates.",SARTORIUS STEDIM BIOTECH GMBH;;REPAIRON GMBH,HAUPT LUIS;;HUPFELD JULIA,,https://lens.org/178-995-278-577-829,Patent Application,yes,0,0,9,121-015-559-480-260;;178-995-278-577-829;;151-453-072-680-218;;143-033-822-450-147;;055-319-748-782-760;;109-778-446-233-23X;;046-085-675-950-624;;061-251-268-200-919;;157-215-763-790-365,KR;;AU;;JP;;EP;;CN;;WO;;US;;CA,9,121-015-559-480-260;;178-995-278-577-829;;151-453-072-680-218;;143-033-822-450-147;;055-319-748-782-760;;109-778-446-233-23X;;046-085-675-950-624;;061-251-268-200-919;;157-215-763-790-365,KR;;AU;;JP;;EP;;CN;;WO;;US;;CA,0,G01N33/48735;;G01N27/221;;G01N27/026;;G01N27/221;;G01N33/48735,G01N33/487;;G01N27/02;;G01N27/22,,0,0,,,,PENDING
621,US,A1,US 2022/0090009 A1,061-202-697-929-395,2022-03-24,2022,US 202117540023 A,2021-12-01,US 202117540023 A;;US 201514986382 A;;US 201462098838 P,2014-12-31,HUMAN PLURIPOTENT STEM CELL-BASED SYSTEM FOR GENERATING ENDOTHELIAL CELLS,"The present invention relates to chemically defined and xenogeneic material-free methods for deriving endothelial cells from human pluripotent stem cells. In particular, the present invention provides highly efficient and reproducible methods of obtaining human endothelial cells from human pluripotent stem cells, where endothelial cells derived from the methods provided herein are suitable for clinically relevant therapeutic applications.",WISCONSIN ALUMNI RES FOUND,THOMSON JAMES A;;ZHANG JUE,WISCONSIN ALUMNI RESEARCH FOUNDATION (2015-01-15),https://lens.org/061-202-697-929-395,Patent Application,yes,3,1,3,189-519-007-852-149;;061-202-697-929-395;;063-955-660-133-35X,US,3,189-519-007-852-149;;061-202-697-929-395;;063-955-660-133-35X,US,0,C12N5/069;;C12N2501/115;;C12N2501/15;;C12N2501/155;;C12N2501/16;;C12N2501/415;;C12N2501/727;;C12N2506/45;;C12N5/069;;C12N2501/115;;C12N2501/15;;C12N2501/155;;C12N2501/16;;C12N2501/415;;C12N2501/727;;C12N2506/45,C12N5/071,,8,7,016-945-405-594-702;;081-079-236-248-225;;018-465-828-803-086;;061-167-440-056-516;;070-046-441-246-43X;;022-484-169-741-085;;020-492-731-292-406,20081865;;10.1038/nbt.1605;;pmc2931334;;20674971;;10.1016/j.biomaterials.2010.07.037;;20512120;;10.1038/nbt.1629;;10.1016/j.immuni.2004.06.006;;15345218;;16862139;;10.1038/nmeth902;;11917100;;10.1073/pnas.032074999;;pmc123658;;10.1089/scd.2012.0313;;22931470;;pmc3564485,"James (Nature Biotech, Feb 2010, Vol. 28, No. 2, pg 161-166);;Prowse (Biomaterials, Nov 2010, Vol. 31, No. 32, pg 8281-8288);;Melkoumian (Nature Biotech., June 2010, Vol. 28, No. 6, pg 606-610);;Wang (Immunity, 2004, Vol. 21, Pg 31-41);;Ludwig (Nature Methods, Aug. 2006, Vol. 3, No. 8, pg 637-646);;definition of embryoid bodies (Wikipedia 2021);;Levenberg (PNAS, 2002, Vol. 99, No. 7, pg 4391-4396);;Shi (Stem cells and Development, 2012, Vol. 22, No. 4, pg 631-642)",PENDING
622,US,A1,US 2022/0064264 A1,173-609-715-716-365,2022-03-03,2022,US 202117530542 A,2021-11-19,US 202117530542 A;;JP 2009068631 A;;JP 2009213901 A;;US 201916298032 A;;US 201514680250 A;;US 201113257145 A;;JP 2010054767 W,2009-03-19,ANTIBODY CONSTANT REGION VARIANT,"By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.",CHUGAI PHARMACEUTICAL CO LTD,IGAWA TOMOYUKI;;KURAMOCHI TAICHI;;MAEDA ATSUHIKO;;SHIRAIWA HIROTAKE,CHUGAI SEIYAKU KABUSHIKI KAISHA (2011-11-04),https://lens.org/173-609-715-716-365,Patent Application,yes,2,8,21,041-840-605-106-449;;077-538-849-760-569;;022-236-164-373-671;;157-918-086-314-230;;144-946-073-287-372;;182-711-196-550-187;;104-290-407-144-09X;;197-278-639-571-420;;170-128-282-306-849;;048-544-737-612-106;;040-398-105-174-079;;036-548-581-759-090;;197-928-192-843-996;;047-059-577-131-980;;027-345-838-975-690;;020-213-151-399-683;;193-095-196-559-109;;147-402-973-845-783;;116-559-495-118-581;;148-928-354-369-362;;173-609-715-716-365,JP;;EP;;WO;;US;;TW,21,041-840-605-106-449;;077-538-849-760-569;;157-918-086-314-230;;022-236-164-373-671;;144-946-073-287-372;;182-711-196-550-187;;104-290-407-144-09X;;197-278-639-571-420;;170-128-282-306-849;;048-544-737-612-106;;148-928-354-369-362;;197-928-192-843-996;;036-548-581-759-090;;047-059-577-131-980;;027-345-838-975-690;;193-095-196-559-109;;020-213-151-399-683;;147-402-973-845-783;;040-398-105-174-079;;116-559-495-118-581;;173-609-715-716-365,JP;;EP;;WO;;US;;TW,43,C07K16/2866;;C07K16/2875;;C07K2317/522;;C07K2317/526;;C07K2317/53;;C07K2317/92;;C07K2317/94;;C07K2317/515;;C07K2317/52;;C07K2317/524;;C07K2317/528;;C07K2317/71;;C07K2317/72;;C07K16/2866;;C07K16/2875;;C07K2317/522;;C07K2317/526;;C07K2317/53;;C07K2317/92;;C07K2317/94;;C07K2317/515;;C07K2317/52;;C07K2317/524;;C07K2317/528;;C07K2317/71;;C07K2317/72;;C07K16/00;;C07K2317/76,C07K16/00;;C07K16/28,,2,2,075-221-862-753-349;;002-610-056-319-135,10.1038/nbt1207-1369;;18066027;;10.4049/jimmunol.177.2.1129;;16818770,Salfeld (Nature Biotech. 25(12): 1369-1372 (2007));;Dall'Acqua (J. Immunol. 177:1129-1138 (2006)),PENDING
623,US,A1,US 2024/0108869 A1,173-394-424-590-525,2024-04-04,2024,US 202318525612 A,2023-11-30,US 202318525612 A;;US 202016909695 A;;US 201715513110 A;;US 2015/0052901 W;;US 201462057887 P,2014-09-30,Active Agent Delivery Devices and Methods of Using the same,Provided are active agent delivery devices configured to deliver an active agent formulation into or through a mucosal layer in a subject. The active agent delivery devices include a power reservoir configured to eject the active agent formulation at a pressure sufficient to deliver the active agent formulation into or through a mucosal layer in a subject. Methods of using the subject active agent delivery devices are also provided.,UNIV CALIFORNIA,ARAN KIANA;;PAREDES JACOBO;;MURTHY NIREN;;LIEPMANN DORIAN;;LEE KUNWOO,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2015-10-07),https://lens.org/173-394-424-590-525,Patent Application,yes,0,0,6,084-149-525-665-623;;189-769-588-689-352;;038-106-211-423-180;;001-186-277-414-009;;040-700-066-920-933;;173-394-424-590-525,WO;;US,6,084-149-525-665-623;;189-769-588-689-352;;038-106-211-423-180;;001-186-277-414-009;;040-700-066-920-933;;173-394-424-590-525,WO;;US,0,A61K9/006;;A61M31/00;;A61K9/006;;A61M31/00;;A61K39/0005;;A61K2039/542;;A61M31/002;;A61M2202/064;;A61M2205/3324;;A61M2205/3334;;A61M2205/36,A61M31/00;;A61K9/00;;A61K39/00,,0,0,,,,PENDING
624,US,A1,US 2024/0417711 A1,031-127-296-691-165,2024-12-19,2024,US 202318490030 A,2023-10-19,CN 202310706300 A,2023-06-14,PAPN MUTANT AND COMPOSITION FOR SITE-DIRECTED MODIFICATION OF PAPN GENE AND APPLICATION THEREOF,"The present invention provides a pAPN mutant and a composition for site-directed modification of pAPN gene and application thereof, involving the field of gene editing technology. The mutated pAPN mutant with an alanine at position 734 can maintain its normal expression, while reducing the ability of a host expressing the pAPN mutant to specifically bind to TGEV, which has important scientific and practical significance in pig disease resistance breeding.",AGSINO GENSOURCES CO LTD,LI KUI;;MU YULIAN;;HUANG LEI,AGSINO GENSOURCES CO. LTD (2023-10-12),https://lens.org/031-127-296-691-165,Patent Application,yes,0,0,4,031-127-296-691-165;;092-399-326-844-022;;008-554-432-445-587;;123-544-114-335-331,CN;;US,4,031-127-296-691-165;;092-399-326-844-022;;008-554-432-445-587;;123-544-114-335-331,CN;;US,0,C07K14/70596;;C12N9/485;;C12N15/1138;;C12N15/102;;C12N9/22;;C12N5/0625;;C12N5/0656;;C12N5/0679;;C12N15/8509;;C12N15/8778;;A01K67/0275;;C12Y304/11002;;A61P31/14;;C12N2310/20;;C12N2510/00;;A01K2227/108;;A01K2267/02;;C12N2800/107;;A61K38/00;;A01K67/0275;;C12N9/485;;C12N15/907;;C12N9/22;;C12N15/11;;A01K2227/108;;C12Y304/11002;;C12N2310/20;;A01K2217/05;;C12N15/113;;A01K2217/075;;A01K67/0276;;C12N15/90;;C12N2310/20;;A01K67/0275;;A01K2217/05;;A01K2227/108;;C12N9/485;;C12N15/907;;C12Y304/11002;;C07H21/04,C12N9/48;;A01K67/027;;C12N9/22;;C12N15/11;;C12N15/90,,0,0,,,,ACTIVE
625,US,A1,US 2020/0316352 A1,189-769-588-689-352,2020-10-08,2020,US 202016909695 A,2020-06-23,US 202016909695 A;;US 201715513110 A;;US 2015/0052901 W;;US 201462057887 P,2014-09-30,Active Agent Delivery Devices and Methods of Using the Same,Provided are active agent delivery devices configured to deliver an active agent formulation into or through a mucosal layer in a subject. The active agent delivery devices include a power reservoir configured to eject the active agent formulation at a pressure sufficient to deliver the active agent formulation into or through a mucosal layer in a subject. Methods of using the subject active agent delivery devices are also provided.,UNIV CALIFORNIA,ARAN KIANA;;PAREDES JACOBO;;MURTHY NIREN;;LIEPMANN DORIAN;;LEE KUNWOO,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2015-10-07),https://lens.org/189-769-588-689-352,Patent Application,yes,6,3,6,084-149-525-665-623;;189-769-588-689-352;;038-106-211-423-180;;001-186-277-414-009;;040-700-066-920-933;;173-394-424-590-525,WO;;US,6,084-149-525-665-623;;189-769-588-689-352;;038-106-211-423-180;;001-186-277-414-009;;040-700-066-920-933;;173-394-424-590-525,WO;;US,0,A61K9/006;;A61M31/00;;A61K9/006;;A61M31/00;;A61K39/0005;;A61K2039/542;;A61M31/002;;A61M2202/064;;A61M2205/3324;;A61M2205/3334;;A61M2205/36,A61M31/00;;A61K9/00;;A61K39/00,,0,0,,,,ACTIVE
626,WO,A1,WO 2021/013746 A1,134-584-043-502-766,2021-01-28,2021,EP 2020070348 W,2020-07-17,US 201962876261 P;;US 201962931578 P;;US 202062962632 P,2019-07-19,AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER,The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.,GENMAB AS,JANMAAT MAARTEN;;PENCHEVA NORA;;BREIJ ESTHER;;BOSHUIZEN JULIA;;PEEPER DANIEL;;FORSSMANN ULF;;AHMADI TAHAMTAN;;CASTRO PATRICIA,,https://lens.org/134-584-043-502-766,Patent Application,yes,21,2,3,191-829-414-625-491;;081-628-868-663-418;;134-584-043-502-766,EP;;WO;;US,274,005-944-002-831-650;;088-825-071-177-292;;191-829-414-625-491;;077-641-345-365-448;;055-693-640-711-792;;118-964-440-011-180;;113-907-992-013-106;;031-630-939-437-266;;176-524-535-590-247;;011-017-873-286-037;;108-708-181-749-248;;074-958-452-762-349;;049-134-930-455-506;;031-645-007-908-584;;183-122-337-393-914;;078-765-562-036-369;;054-762-117-103-047;;069-517-806-608-628;;049-190-114-691-179;;134-955-364-678-295;;092-839-742-428-85X;;143-461-547-532-594;;137-439-712-749-837;;122-644-288-456-59X;;020-633-922-837-794;;016-023-766-978-081;;015-802-990-532-179;;057-221-171-857-082;;026-744-838-469-175;;185-603-013-858-72X;;077-396-771-330-604;;174-631-020-211-157;;031-243-329-021-124;;116-189-271-417-448;;029-652-108-080-345;;024-352-610-560-217;;131-160-739-188-981;;114-171-545-309-260;;071-089-623-482-798;;119-736-198-079-33X;;091-729-346-635-79X;;174-253-976-461-972;;082-214-328-550-670;;171-940-164-109-389;;018-444-513-356-848;;069-041-348-565-905;;079-205-410-881-185;;145-057-489-903-948;;135-553-886-184-094;;145-492-380-916-426;;002-265-061-280-074;;016-069-129-450-691;;002-058-354-655-878;;162-223-027-902-809;;057-623-371-766-320;;161-405-306-346-201;;116-181-093-775-552;;085-357-718-490-13X;;050-632-540-760-780;;129-128-140-615-375;;154-327-037-132-47X;;034-014-081-502-935;;141-281-694-692-191;;128-575-396-857-392;;139-390-336-323-004;;037-232-668-630-412;;066-821-397-577-839;;089-194-259-206-022;;139-015-774-484-858;;081-628-868-663-418;;046-308-333-606-749;;117-663-566-551-013;;162-068-009-354-944;;166-881-777-377-994;;099-738-596-266-718;;085-455-540-050-450;;119-649-093-615-428;;117-751-314-954-65X;;196-237-606-393-325;;043-495-995-004-162;;121-531-669-007-571;;191-321-626-059-658;;091-378-463-072-752;;045-424-142-858-013;;178-156-883-737-336;;088-477-946-790-404;;041-751-601-684-095;;147-543-501-742-929;;123-072-555-896-174;;104-692-430-778-666;;158-932-708-577-324;;105-625-071-146-806;;042-800-380-924-597;;102-215-024-577-426;;039-986-776-041-109;;106-439-669-091-368;;022-598-559-472-55X;;186-132-977-744-266;;061-459-927-012-86X;;010-765-563-915-472;;014-267-676-037-307;;113-456-637-918-955;;101-436-445-895-994;;035-368-920-976-264;;031-031-013-921-586;;047-872-394-934-686;;010-531-190-973-247;;007-229-018-985-881;;016-773-784-325-976;;138-128-228-536-555;;127-075-162-855-952;;084-253-794-976-649;;134-825-111-554-504;;123-802-385-903-002;;184-360-550-410-234;;042-109-070-702-159;;100-393-590-498-473;;160-491-192-701-937;;107-305-688-804-733;;187-409-115-433-822;;074-190-176-455-354;;058-978-782-568-440;;148-512-109-743-403;;123-586-863-440-142;;102-244-717-491-505;;060-497-322-558-182;;001-317-549-363-901;;009-994-693-216-34X;;122-245-547-758-077;;051-147-426-323-162;;009-662-633-431-450;;179-443-711-437-255;;156-974-242-520-408;;031-852-865-053-561;;026-957-605-422-789;;147-077-304-300-069;;079-640-262-995-792;;155-237-583-986-162;;189-368-091-285-304;;040-120-116-419-717;;147-357-989-151-698;;001-941-945-141-752;;059-066-933-144-165;;083-010-674-546-019;;178-982-083-592-647;;050-250-573-229-044;;172-525-100-113-520;;170-242-677-437-332;;176-025-626-476-62X;;148-433-807-889-252;;079-746-536-347-30X;;032-517-419-154-678;;055-174-789-658-403;;026-247-665-776-013;;134-584-043-502-766;;122-216-965-584-257;;136-008-862-167-022;;033-009-784-613-321;;100-977-155-934-663;;034-377-288-985-578;;085-975-435-799-91X;;184-794-912-139-620;;024-714-933-679-971;;081-275-929-853-039;;121-277-968-926-091;;102-431-285-090-233;;036-304-159-516-703;;160-491-449-116-347;;068-692-267-436-311;;104-506-697-137-479;;165-040-602-436-320;;126-692-075-442-778;;113-204-360-280-846;;036-542-304-400-744;;052-233-672-909-262;;102-530-319-807-591;;073-844-022-478-645;;005-156-128-794-771;;113-344-559-275-352;;191-061-909-778-152;;136-542-853-306-887;;124-927-687-110-804;;149-651-655-872-815;;070-446-095-718-352;;078-736-130-215-504;;014-691-769-582-112;;114-701-496-932-624;;048-162-614-026-525;;117-775-369-020-324;;196-374-405-092-279;;044-029-844-512-352;;067-297-780-471-162;;198-250-903-991-662;;044-725-402-975-164;;053-686-630-909-879;;086-765-321-901-497;;121-289-321-445-615;;123-315-348-069-153;;023-550-333-423-185;;008-266-865-574-775;;120-005-985-431-028;;015-346-926-279-248;;036-098-086-472-521;;177-369-752-468-28X;;134-184-500-217-176;;190-243-574-790-723;;055-525-627-890-199;;124-677-258-837-571;;040-721-379-430-268;;170-973-628-819-675;;136-239-846-672-625;;099-204-602-438-699;;041-386-378-927-070;;010-900-365-092-419;;147-001-020-402-492;;199-088-309-459-060;;046-339-240-609-723;;032-407-504-213-815;;082-497-921-989-791;;088-761-878-168-856;;077-885-269-634-36X;;178-654-659-490-457;;049-808-112-957-609;;053-021-763-251-517;;004-587-467-387-984;;020-510-556-952-88X;;048-737-889-792-16X;;084-209-283-150-61X;;053-855-000-169-858;;100-765-752-018-298;;183-920-423-689-582;;133-305-531-135-60X;;067-619-212-346-143;;107-632-450-472-423;;177-701-931-877-494;;159-409-113-268-207;;066-197-585-717-02X;;084-634-178-581-167;;034-875-214-961-516;;083-916-165-384-630;;161-683-324-095-362;;162-954-352-948-471;;100-050-327-044-031;;131-822-751-248-57X;;147-111-148-769-725;;079-052-131-798-51X;;061-170-197-439-708;;048-454-338-919-937;;107-754-502-900-967;;147-748-498-993-725;;117-292-945-365-050;;097-559-801-410-330;;026-878-156-913-324;;040-682-114-559-147;;143-695-741-475-898;;064-258-255-046-917;;154-400-287-437-311;;132-888-127-266-238;;086-381-869-843-015;;054-476-496-648-196;;156-277-805-513-903;;152-118-716-008-469;;125-641-993-106-347;;065-881-828-873-84X;;125-345-272-919-800;;057-557-583-020-309;;131-244-138-012-137;;108-743-400-396-977;;112-137-505-113-501;;177-973-051-288-375;;004-233-995-505-325;;018-742-104-741-740;;108-311-297-755-548;;154-812-687-011-361,DE;;JP;;KR;;CN;;EP;;ES;;WO;;FI;;US;;SG;;TW;;DK,154,C07K16/2863;;C07K2317/76;;A61K2039/505;;C07K16/2818;;C07K16/2827;;C07K2317/565;;A61K47/68031;;A61K47/6843;;A61P35/00;;A61K47/02;;A61K2121/00;;A61K47/68031;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/68,,40,24,012-898-541-517-029;;086-170-287-861-854;;036-950-065-020-834;;019-267-991-274-566;;034-069-611-582-935;;111-127-199-115-043;;090-637-698-058-127;;001-077-377-691-158;;074-817-300-512-106;;013-323-148-570-367;;017-150-654-990-340;;038-994-369-651-86X;;148-754-122-006-960;;032-728-154-591-070;;022-439-235-146-469;;022-439-235-146-469;;101-469-357-932-063;;075-789-057-546-584;;031-839-171-222-141;;100-094-677-395-960;;004-272-966-072-139;;024-461-630-893-070;;041-178-419-334-452;;036-560-802-994-476,pmc6445096;;30940805;;10.1038/s41467-019-09415-3;;pmc4758865;;10.1016/j.immuni.2015.11.024;;26872698;;10.18632/oncotarget.21125;;29163786;;pmc5685707;;pmc5474155;;28289089;;10.1158/1078-0432.ccr-17-0189;;23649974;;10.1002/ijc.28246;;pmc3342018;;10.1517/14728222.2010.515980;;20809868;;19633687;;10.1038/onc.2009.212;;10.1016/j.coph.2015.05.011;;26047524;;pmc4516625;;2677748;;10.1038/341544a0;;10.1016/j.tibtech.2003.08.007;;14573361;;10.1126/science.3140379;;3140379;;10.1093/nar/gkv694;;10592230;;10.1093/nar/27.1.209;;pmc148137;;9847182;;10.1093/nar/gkv895;;10.1093/nar/gkv675;;10.1093/nar/gki065;;10.1093/nar/gkv1028;;pmc102442;;pmc540019;;10.1093/nar/28.1.219;;15608269;;pmc2447746;;10.1093/nar/gkn316;;18503082;;10.1016/0022-2836(70)90057-4;;5420325;;10827456;;10.1016/s0168-9525(00)02024-2;;10827456;;10.1016/s0168-9525(00)02024-2;;23913155;;10.1007/978-1-62703-541-5_18;;10.1016/s0163-7258(99)00018-2;;10511457;;10.1006/jmbi.1993.1203;;8478936;;23872061;;10.1016/j.ymeth.2013.07.018;;12778055;;10.1038/nbt832;;17660381;;10.1182/blood-2007-02-075010;;pmc5685550;;10.1016/j.cell.2017.09.028;;29033130;;30753825;;10.1016/j.ccell.2019.01.003,"LIU P. ET AL: ""Crizotinib-induced immunogenic cell death in non-small cell lung cancer"", NATURE COMMUNICATIONS, vol. 10, no. 1, 1486, 2 April 2019 (2019-04-02), XP055735534;;PFIRSCHKE C. ET AL: ""Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy"", IMMUNITY, CELL PRESS, AMSTERDAM, NL, vol. 44, no. 2, 9 February 2016 (2016-02-09), pages 343 - 354, XP029428475;;ZHIQIANG GUO ET AL: ""Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models"", ONCOTARGET, vol. 8, no. 52, 27 October 2017 (2017-10-27), pages 89761 - 89774, XP055640893, DOI: 10.18632/oncotarget.21125;;TODD A. AGUILERA ET AL: ""Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase"", CLINICAL CANCER RESEARCH, vol. 23, no. 12, 13 March 2017 (2017-03-13), US, pages 2928 - 2933, XP055735547, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-0189;;PACCEZ ET AL., INT. J. CANCER, vol. 134, 2013, pages 1024 - 1033;;LECONET ET AL., ONCOGENE, 2013, pages 1 - 10;;LINGER ET AL., EXPERT OPIN. THER. TARGETS, vol. 14, no. 10, 2010, pages 1073 - 1090;;LI ET AL., ONCOGENE, vol. 28, 2009, pages 3442 - 3455;;YE ET AL., ONCOGENE, 2010, pages 1 - 11;;LIDA ET AL., ANTICANCER RESEARCH, vol. 34, 2014, pages 1821 - 1828;;SUNSHINE, J.TAUBE, J., CURR. OPIN. PHARMACOL., vol. 23, 2015, pages 32 - 38;;O'DONNELL ET AL., GENOME MEDICINE, vol. 8, 2016, pages 111;;""UniprotKB"", Database accession no. Q14393-5;;CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. P30530-2;;""Genbank"", Database accession no. NP_054862.1;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, November 2003 (2003-11-01), pages 484 - 90;;REVETS ET AL., EXPERT OPIN BIOL THER., vol. 5, no. 1, January 2005 (2005-01-01), pages lll-24;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;""Fundamental Immunology"", 1989, RAVEN PRESS;;LEFRANC MP. ET AL., NUCLEIC ACIDS RESEARCH, vol. 27, 1999, pages 209 - 212;;BROCHET X., NUCL. ACIDS RES., vol. 36, 2008, pages W503 - 508;;KABAT, E.A. ET AL.: ""Sequences of proteins of immunological interest."", 1991, US DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 662,680,689;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453;;RICE ET AL., EMBOSS: THE EUROPEAN MOLECULAR BIOLOGY OPEN SOFTWARE SUITE, 2000;;TRENDS GENET., vol. 16, pages 276 - 277;;""NCBI"", Database accession no. BLOSUM62;;L. BASSA: ""Antibody-Drug-Conjugates, Methods in Molecular Biology"", vol. 1045, 2013, SPRINGER SCIENCE+BUSINESS MEDIA, LLC, article ""Drug-to-Antibody Ratio (DAR) and Dug Load Distribution by LC-ESI-MS"", pages: 285 - 293;;DUBOWCHIKWALKER: ""Pharm. Therapeutics"", vol. 83, 1999, pages: 67 - 123;;WHO DRUG INFORMATION, vol. 31, no. 4, 2017, pages 665 - 668;;J R AHNERT, JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15, 2018;;""Remington: The Science and Practice of Pharmacy"", 1995, MACK PUBLISHING CO.;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;BARBAS, CF., J MOL BIOL., vol. 230, no. 3, 5 April 1993 (1993-04-05), pages 812 - 23;;VINK ET AL., METHODS, vol. 65, no. 1, 2014, pages 5 - 10;;DORONINA, S.O. ET AL., NAT. BIOTECHNOL., vol. 21, 2003, pages 778 - 784;;JORRITSMA ET AL., BLOOD, vol. 110, 2007, pages 3564 - 3572;;BOSHUIZEN ET AL., NATURE MED, 2018;;RIAZ, N. ET AL., CELL, vol. 171, 2017, pages 934 - 949;;GIDE, T. N. ET AL., CANCER CELL, vol. 35, 2019, pages 238 - 255",PENDING
627,EP,A1,EP 4328308 A1,167-144-096-701-185,2024-02-28,2024,EP 23155034 A,2023-02-06,DE 102022121159 A,2022-08-22,MODIFIED TRNA-SYNTHETASE FOR THE INCORPORATION OF NON-CANONICAL AMINO ACIDS,"The present invention refers to modified enzymes, namely mutated tRNA synthetases and provides a system employing such modified enzymes together with tRNA-pairs as well as a platform for the generation of site-specifically modified, recombinant polypeptides or proteins - iter alia - for scientific or medical purposes.",UNIV BERLIN TECH,KOCH NIKOLAJ;;BUDISA PROF DR NEDILJKO,,https://lens.org/167-144-096-701-185,Patent Application,yes,6,0,1,167-144-096-701-185,EP,1,167-144-096-701-185,EP,14,C12N9/93;;C12N15/67;;C12N15/70;;C12P21/02;;C12Y601/01026;;C40B40/08,C12N15/10;;C12N9/00;;C12P21/02,,6,3,045-122-806-056-635;;019-484-040-990-066;;045-295-064-464-810,33837709;;pmc8086897;;10.1016/bs.enz.2020.06.004;;pmc4016821;;10.1016/j.bbapap.2014.03.002;;24631543;;pmc6620406;;31010904;;10.1128/jb.00091-19,"""Biology of Aminoacyl-tRNA Synthetases"", vol. 48, 8 September 2020, ELSEVIER, ISBN: 978-0-12-820260-9, ISSN: 1874-6047, article KRAHN NATALIE ET AL: ""Engineering aminoacyl-tRNA synthetases for use in synthetic biology"", pages: 351 - 395, XP093048412, DOI: 10.1016/bs.enz.2020.06.004;;WAN WEI ET AL: ""Pyrrolysyl-tRNA synthetase: An ordinary enzyme but an outstanding genetic code expansion tool"", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1844, no. 6, 12 March 2014 (2014-03-12), pages 1059 - 1070, XP028638306, ISSN: 1570-9639, DOI: 10.1016/J.BBAPAP.2014.03.002;;""Genbank"", Database accession no. Q12UB6.1;;STRYER ET AL., BIOCHEMISTRY, 2015;;BERG, J. M.TYMOCZKO, J. LGATTO, G. J. JRSTRYER, L: ""Biochemistry"", 2015, W.H. FREEMAN AND COMPANY;;SAIER, M. H: ""Understanding the Genetic Code"", J. BACTERIOL, vol. 201, no. 15, 2019, pages 1 - 12, Retrieved from the Internet <URL:https://doi.rg/10.1128/JB.00091-19>",PENDING
628,DE,A1,DE 102020103267 A1,134-494-344-532-61X,2021-08-12,2021,DE 102020103267 A,2020-02-10,DE 102020103267 A,2020-02-10,Verfahren und Vorrichtung zum Nachweis von Schlachtnebenprodukten und/oder Separatorenfleisch,"Die Erfindung betrifft ein in vitro Verfahren zum Nachweis von Schlachtnebenprodukten und/oder Separatorenfleisch in einer Probe, wobei das Verfahren Schritte umfasst, bei denen man eine Probe bereitstellt, und das Markerprotein oder mindestens ein für das Markerprotein spezifisches Peptidfragment mittels eines geeigneten Verfahrens nachweist.",GFL GES FUER LEBENSMITTEL FORSCHUNG MBH;;HOCHSCHULE BREMERHAVEN,WITTKE STEFAN JOHANNES;;HOFSOMMER MIKKO,"GFL GESELLSCHAFT FUER LEBENSMITTEL-FORSCHUNG M, DE (2024-07-05)",https://lens.org/134-494-344-532-61X,Patent Application,no,0,0,4,160-126-932-514-235;;134-494-344-532-61X;;116-403-349-125-950;;047-774-436-059-359,DE;;EP,4,160-126-932-514-235;;134-494-344-532-61X;;116-403-349-125-950;;047-774-436-059-359,DE;;EP,0,G01N33/6887;;G01N33/6848,G01N33/12;;G01N33/68,,1,1,057-114-426-178-775,1369054;;10.1271/bbb.56.1541,"Converting Enzyme from Thermolysin Digest of Dried Bonito; Biosci. Biotech. Biochem., 56 (10), 1541-1545, Japan;1992",PENDING
629,EP,A1,EP 3797791 A1,138-597-426-269-074,2021-03-31,2021,EP 19382827 A,2019-09-26,EP 19382827 A,2019-09-26,THERAPEUTIC EFFICACY BY PULMONARY DELIVERY OF LIVE ATTENUATED MYCOBACTERIA,"The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTBVAC strain having a i) PhoP- phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM- phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.",UNIV ZARAGOZA,AGUILÓ JUAN IGNACIO;;MARTÍN MONTAÑES CARLOS;;TARANCÓN ÍÑIGUEZ RAQUEL;;MATA LOZANO ELENA;;URANGA MAÍZ SANTIAGO;;VANEVA MARINOVA DESSISLAVA,,https://lens.org/138-597-426-269-074,Patent Application,yes,1,0,12,121-502-967-901-114;;092-107-940-695-779;;030-222-543-737-167;;138-597-426-269-074;;092-526-361-253-825;;042-484-781-613-894;;034-538-340-189-857;;144-833-816-145-244;;033-012-730-810-343;;015-121-441-353-182;;029-562-245-679-953;;070-725-490-247-388,JP;;AU;;KR;;CN;;EP;;WO;;US;;CA;;MX,12,121-502-967-901-114;;092-107-940-695-779;;030-222-543-737-167;;138-597-426-269-074;;092-526-361-253-825;;042-484-781-613-894;;034-538-340-189-857;;144-833-816-145-244;;033-012-730-810-343;;015-121-441-353-182;;029-562-245-679-953;;070-725-490-247-388,JP;;AU;;KR;;CN;;EP;;WO;;US;;CA;;MX,46,A61K39/04;;C07K14/35;;A61K2039/522;;A61K2039/54;;A61K2039/544;;A61K2039/58;;A61K2039/577;;A61K39/04;;A61P11/06;;A61P31/04;;A61P31/06;;C07K14/35;;A61K2039/522;;A61K2039/54;;A61K2039/544;;A61K2039/58;;A61K2039/577;;A61P11/06;;A61P37/08;;A61P31/06;;A61K35/74;;A61K2039/522;;A61K2039/544;;A61K2039/577;;A61K2039/58,A61K39/04;;A61K8/04;;A61K39/00;;A61K39/02;;C07K14/35;;C12N1/36,,36,33,074-298-411-894-141;;102-026-688-837-62X;;083-063-132-412-736;;030-527-621-343-17X;;015-804-704-505-241;;027-134-466-383-394;;025-084-188-194-79X;;067-535-709-258-642;;074-389-592-060-376;;021-397-781-043-820;;003-914-015-333-642;;085-485-960-193-797;;019-702-979-738-587;;089-068-713-766-162;;102-026-688-837-62X;;046-703-570-343-671;;040-283-102-215-234;;009-014-977-925-168;;010-103-581-088-869;;033-100-816-282-684;;048-960-283-129-314;;041-515-641-736-430;;141-044-901-986-354;;145-102-249-714-849;;028-791-866-663-631;;014-795-123-346-520;;019-702-979-738-587;;026-254-270-582-754;;073-895-707-566-090;;019-906-398-676-714;;020-867-961-424-978;;072-874-260-264-512;;030-632-368-481-134,30794653;;pmc6386280;;10.1371/journal.pone.0212751;;10.1016/j.vaccine.2013.07.051;;23965219;;10.1007/s11095-019-2704-6;;31650321;;pmc7607971;;31099236;;10.1021/acsinfecdis.9b00008;;25869894;;10.1016/j.vaccine.2015.03.060;;pmc1838109;;10.1136/bmj.299.6710.1259;;2513902;;27518660;;10.1056/nejmoa1508749;;pmc5137793;;22561831;;10.1038/nm.2731;;10.1165/rcmb.2015-0295oc;;pmc5070104;;27248771;;10.4049/jimmunol.164.12.6166;;10843666;;20673988;;10.1016/j.jaci.2010.06.010;;10.1084/jem.187.4.561;;9463406;;pmc2212158;;10.1016/j.jaci.2007.09.033;;18037160;;10.1371/journal.pone.0106807;;pmc4156387;;25192550;;10.1016/j.vaccine.2013.07.051;;23965219;;29326700;;10.3389/fimmu.2017.01803;;pmc5736532;;26598141;;10.1016/s2213-2600(15)00435-x;;10.1080/14760584.2017.1324303;;28447476;;11901655;;10.1016/s1473-3099(02)00182-2;;9634230;;10.1038/31159;;10564470;;10.1046/j.1365-2958.1999.01593.x;;pmc3422549;;10.1038/nri3073;;21997792;;11544450;;10.1067/mai.2001.117457;;10.1067/mai.2000.111241;;11112907;;10.1016/s1081-1206(10)61890-x;;12086366;;10.1016/j.jaci.2010.07.039;;20933258;;10.1016/j.jaci.2007.09.033;;18037160;;pmc1745787;;10.1136/thorax.55.6.449;;10817790;;10.1111/j.1365-2222.2005.02408.x;;16393268;;31116888;;10.1111/all.13923;;pmc3909500;;10.1016/j.jaci.2010.03.037;;20513526;;pmc4713452;;26768622;;10.1007/s11882-015-0587-0;;10.1016/s0140-6736(12)60988-x;;22901886,"MARIANA GUERRA-MAUPOME ET AL: ""Aerosol vaccination with Bacille Calmette-Guerin induces a trained innate immune phenotype in calves"", PLOS ONE, vol. 14, no. 2, 22 February 2019 (2019-02-22), pages e0212751, XP055672698, DOI: 10.1371/journal.pone.0212751;;ARBUES AINHOA ET AL: ""Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuatedM. tuberculosis-based vaccine to enter clinical trials"", VACCINE, vol. 31, no. 42, 17 August 2013 (2013-08-17), pages 4867 - 4873, XP028717050, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2013.07.051;;BRAUNSTEIN MIRIAM ET AL: ""Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs"", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 36, no. 12, 24 October 2019 (2019-10-24), XP036966006, ISSN: 0724-8741, [retrieved on 20191024], DOI: 10.1007/S11095-019-2704-6;;CARIDAD DÍAZ ET AL: ""Comparative Metabolomics between Mycobacterium tuberculosis and the MTBVAC Vaccine Candidate"", ACS INFECTIOUS DISEASES, vol. 5, no. 8, 9 August 2019 (2019-08-09), US, pages 1317 - 1326, XP055672637, ISSN: 2373-8227, DOI: 10.1021/acsinfecdis.9b00008;;LEWIS SCHRAGER ET AL: ""Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings"", VACCINE, vol. 33, no. 26, 1 June 2015 (2015-06-01), AMSTERDAM, NL, pages 3038 - 3046, XP055672653, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2015.03.060;;STRACHAN DP: ""Hay fever, hygiene, and household size"", BMJ, vol. 299, 1989, pages 1259 - 60;;STEIN MMHRUSCH CLGOZDZ JIGARTUA CPIVNIOUK VMURRAY SE ET AL.: ""Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children"", N ENGL J MED, vol. 375, 2016, pages 411 - 21;;HOLGATE STWENZEL SPOSTMA DSWEISS STRENZ HSLY PD, ASTHMA. NAT REV DIS PRIMERS, vol. 1, 2015, pages 15025;;HOLGATE ST: ""Innate and adaptive immune responses in asthma"", NAT MED, vol. 18, 2012, pages 673 - 83;;GIRODET PONGUYEN DMANCINI JDHUNDAL MZHOU XISRAEL E ET AL.: ""Alternative Macrophage Activation Is Increased in Asthma"", AM J RESPIR CELL MOL BIOL, vol. 55, 2016, pages 467 - 75;;MILLS CDKINCAID KALT JMHEILMAN MJHILL AM: ""M-l/M-2 macrophages and the Thl/Th2 paradigm"", J IMMUNOL, vol. 164, 2000, pages 6166 - 73;;MOREIRA APCAVASSANI KAHULLINGER RROSADA RSFONG DJMURRAY L ET AL.: ""Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease"", J ALLERGY CLIN IMMUNOL, vol. 126, 2010, pages 712 - 21 e7;;ERB KJHOLLOWAY JWSOBECK AMOLL HLE GROS G: ""Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia"", J EXP MED, vol. 187, 1998, pages 561 - 9, XP001055975, doi:10.1084/jem.187.4.561;;LAGRANDERIE MABOLHASSANI MVANOIRBEEK JLEFORT JNAHORI MALAPA ESJR ET AL.: ""M. bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models"", J ALLERGY CLIN IMMUNOL, vol. 121, 2008, pages 471 - 8, XP022471335, doi:10.1016/j.jaci.2007.09.033;;TSUJIMURA YINADA HYONEDA MFUJITA TMATSUO KYASUTOMI Y: ""Effects of mycobacteria major secretion protein, Ag85B, on allergic inflammation in the lung"", PLOS ONE, vol. 9, 2014, pages el06807;;ARBUES AAGUILO JIGONZALO-ASENSIO JMARINOVA DURANGA SPUENTES E ET AL.: ""Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials"", VACCINE, vol. 31, 2013, pages 4867 - 73, XP028717050, doi:10.1016/j.vaccine.2013.07.051;;GONZALO-ASENSIO JMARINOVA DMARTIN CAGUILO N: ""MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic"", FRONT IMMUNOL., vol. 8, 15 December 2017 (2017-12-15), pages 1803;;SPERTINI FAUDRAN RCHAKOUR RKAROUI OSTEINER-MONARD VTHIERRY AC ET AL.: ""Safety of human immunisation with a live-attenuated M. tuberculosis vaccine: a randomised, double-blind, controlled phase I trial"", LANCET RESPIR MED, vol. 3, 2015, pages 953 - 62, XP009191712, doi:10.1016/S2213-2600(15)00435-X;;TAMERIS ET AL.: ""Randomised controlled double blind dose-escalation infant trial of the live-attenuated M. tuberculosis vaccine MTBVAC"", LANCET RESPIR MED, 2019;;DESSISLAVA MARINOVAJESUS GONZALO-ASENSIONACHO AGUILOCARLOS MARTIN: ""MTBVAC from discovery to clinical trials in tuberculosis-endemic countries"", EXPERT REVIEW OF VACCINES, vol. 16, no. 6, 2017, pages 565 - 576, XP055482765, doi:10.1080/14760584.2017.1324303;;BEHR, M. A: ""CG-different strains, different vaccines"", LANCET INFECT DIS, vol. 2, no. 2, 2002, pages 86 - 92, XP004810964, doi:10.1016/S1473-3099(02)00182-2;;REF COLE ET AL.: ""Deciphering the biology of M. tuberculosis from the complete genome sequence"", NATURE, vol. 393, 1998, pages 537 - 544;;CAMACHO ET AL.: ""Identification of a virulence gene cluster of M. tuberculosis by signature-tagged transposon mutagenesis"", MOL MICROBIOL, vol. 34, 1999, pages 257 - 267, XP008129741, doi:10.1046/j.1365-2958.1999.01593.x;;MURRAY PJWYNN TA: ""Protective and pathogenic functions of macrophage subsets"", NAT REV IMMUNOL, vol. 11, 2011, pages 723 - 37, XP055112087, doi:10.1038/nri3073;;SARADNA ADO DCKUMAR SFU QLGAO P: ""Macrophage polarization and allergic asthma"", TRANSL RES, vol. 191, 2018, pages 1 - 14, XP085307289, doi:10.1016/j.trsl.2017.09.002;;VON BUBNOFF DGEIGER EBIEBER T: ""Antigen-presenting cells in allergy"", J ALLERGY CLIN IMMUNOL, vol. 108, 2001, pages 329 - 39;;SARINHO ESCHOR DVELOSO MLIMA M: ""BCG scar diameter and asthma: a case-control study"", J ALLERGY CLIN IMMUNOL, vol. 106, 2000, pages 1199 - 200, XP027376186;;CHOI ISKOH YI: ""Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial"", ANN ALLERGY ASTHMA IMMUNOL, vol. 88, 2002, pages 584 - 91, XP026993841;;ARNOLDUSSEN DLLINEHAN MSHEIKH A: ""BCG vaccination and allergy: a systematic review and meta-analysis"", J ALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 246 - 53,53 el-21;;LAGRANDERIE MABOLHASSANI MVANOIRBEEK JLEFORT JNAHORI MALAPA ESJR ET AL.: ""Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models"", J ALLERGY CLIN IMMUNOL, vol. 121, 2008, pages 471 - 8, XP022471335, doi:10.1016/j.jaci.2007.09.033;;VON MUTIUS EPEARCE NBEASLEY RCHENG SVON EHRENSTEIN OBJORKSTEN B ET AL.: ""International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema"", THORAX, vol. 55, 2000, pages 449 - 53, XP009087377, doi:10.1136/thorax.55.6.449;;OBIHARA CCKIMPEN JLGIE RPLILL SWHOEKSTRA MOMARAIS BJ ET AL.: ""M. tuberculosis infection may protect against allergy in a tuberculosis endemic area"", CLIN EXP ALLERGY, vol. 36, 2006, pages 70 - 6, XP002680183, doi:10.1111/j.1365-2222.2005.02408.x;;TARANCON RURANGA SMARTIN CAGUILO N, MYCOBACTERIUM TUBERCULOSIS INFECTION PREVENTS ASTHMA AND ABROGATES EOSINOPHILOPOIESIS IN AN EXPERIMENTAL MODEL ALLERGY, 22 May 2019 (2019-05-22);;KWOK WWROTI MDELONG JHTAN VWAMBRE EJAMES EA ET AL.: ""Direct ex vivo analysis of allergen-specific CD4+ T cells"", J ALLERGY CLIN IMMUNOL, vol. 125, 2010, pages 1407 - 9 el;;O'HEHIR REPRICKETT SRROLLAND JM: ""T Cell Epitope Peptide Therapy for Allergic Diseases"", CURR ALLERGY ASTHMA REP, vol. 16, 2016, pages 14;;PAVORD IDKORN SHOWARTH PBLEECKER ERBUHL RKEENE ON ET AL.: ""Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial"", LANCET, vol. 380, 2012, pages 651 - 9, XP002714506, doi:10.1016/S0140-6736(12)60988-X",DISCONTINUED
630,US,A1,US 2025/0059562 A1,125-136-698-370-340,2025-02-20,2025,US 202218725285 A,2022-10-28,CN 202111663496 A;;CN 2022128227 W,2021-12-31,RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) GENOME AND SINGLE-POLARITY RAAV VECTOR PACKAGED THEREBY,"Provided are a recombinant adeno-associated virus (rAAV) genome and a single-polarity rAAV (spAAV) vector formed by packaging same. Specifically, provided is an spAAV genome before packaging, two ends of which are both linear open terminuses, wherein one end does not have an inverted terminal repeat (ITR) or a part thereof, and the other end has a truncated ITR (ITRT), and the ITRT does not form a T-shaped hairpin palindromic structure. The spAAV genome is a single-polarity single-stranded DNA. Also provided are an spAAV vector, a method for delivering an exogenous nucleic acid to a cell by using the vector, and a use of the vector in the preparation of a product for gene expression, gene therapy, gene editing or gene regulation.",SUZHOU GENEHEALTH BIOTECHNOLOGY CO LTD,SHAO JIAHONG;;TAN PENGCHENG;;WU XIANG;;ZHAO XIAOMING;;LU YANG;;XUN TINGJUN;;LEI ZHENZHEN,SUZHOU GENEHEALTH BIOTECHNOLOGY CO. LTD (2025-01-06),https://lens.org/125-136-698-370-340,Patent Application,yes,0,0,5,125-136-698-370-340;;168-831-325-200-511;;048-497-578-167-236;;134-621-238-854-390;;065-695-672-388-485,JP;;CN;;EP;;WO;;US,5,125-136-698-370-340;;168-831-325-200-511;;048-497-578-167-236;;134-621-238-854-390;;065-695-672-388-485,JP;;CN;;EP;;WO;;US,0,C07K14/005;;C12N7/00;;C12N15/86;;C12N5/0601;;C12N2750/14121;;C12N2750/14122;;C12N2750/14152;;C12N2750/14143;;C12N2710/14043;;C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2710/14144;;C12N2710/14043;;C07K14/005;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2710/14043;;C12N2710/14044;;C12N2750/14121;;C12N2750/14122;;C12N2750/14143;;C12N2750/14152,C12N15/86;;C07K14/005;;C12N5/07;;C12N7/00,,0,0,,,,PENDING
631,US,A1,US 2022/0180319 A1,173-122-121-797-722,2022-06-09,2022,US 202117541441 A,2021-12-03,US 202117541441 A;;US 202063121093 P,2020-12-03,COLLABORATION PLATFORM FOR ENABLING COLLABORATION ON DATA ANALYSIS ACROSS MULTIPLE DISPARATE DATABASES,"A platform and method for enabling collaboration on data analysis of life sciences data across disparate databases are disclosed. The collaboration platform may allow for performing exploratory analysis for drug discovery and development. The collaboration platform may include a search and graph module for generating a user project and determining and displaying one or more matching data assets and one or more potential collaborators; a collaboration module for coordinating a collaboration between the user and one or more selected collaborators; a data management module for receiving a schema for one or more producer projects, receiving data from the one or more selected data assets, and ingesting the received data using common standards and an ontology; and an insight application for generating disease specific inferences relating to a scientific question using the ingested received data, and receiving a feedback from the user and/or the selected collaborators to improve the search and graph module.",NOVARTIS AG,SAXENA SIDHYANSH;;PLUECKEBAUM ACHIM;;SRINIVASAN BADHRI;;DIEHL CHRISTIAN,NOVARTIS AG (2021-12-02);;NOVARTIS PHARMA AG (2021-12-02),https://lens.org/173-122-121-797-722,Patent Application,yes,0,6,11,125-021-471-386-727;;103-342-771-458-621;;060-239-510-211-571;;067-410-755-006-797;;152-461-740-360-196;;187-746-453-554-077;;173-122-121-797-722;;099-893-580-314-471;;191-473-879-776-981;;108-080-233-060-813;;135-618-556-583-644,JP;;CN;;EP;;WO;;US;;TW,11,125-021-471-386-727;;060-239-510-211-571;;103-342-771-458-621;;135-618-556-583-644;;152-461-740-360-196;;187-746-453-554-077;;173-122-121-797-722;;099-893-580-314-471;;191-473-879-776-981;;108-080-233-060-813;;067-410-755-006-797,JP;;CN;;EP;;WO;;US;;TW,0,G06Q10/101;;G16H80/00;;G16H50/70;;G16H70/40;;G16H10/20;;G06Q10/0631;;G06Q30/02;;Y02A90/10;;G06Q10/101;;G16B50/30;;G16B50/10;;G16B50/20;;G16H80/00,G06Q10/10;;G16B50/10;;G16B50/20;;G16B50/30,,0,0,,,,ACTIVE
632,EP,A1,EP 3960153 A1,061-359-361-535-240,2022-03-02,2022,EP 19901402 A,2019-11-27,CN 201910622830 A;;CN 2019121342 W,2019-07-11,"SKINCARE COMPOSITION FOR TIGHTENING SKIN, AND PREPARATION METHOD THEREFOR","A skin-care composition for tightening skin and a method for preparing same. The skin-care composition is prepared from an emulsifier and an acmella oleracea extract; the emulsifier comprises stearate and stearyl alcohol emulsifier. The skin-care composition for tightening skin of the invention has good effects in tightening skin, preventing wrinkles and resisting aging, has high heat stability, cold stability and mechanical stability, can be applied to various skin-care products without causing skin irritations, and is suitable for oily and sensitive skin.",ZHEJIANG KANGMANJIA DAILY NECESSITIES CO LTD,ZHANG XUNTING;;ZHONG WEIFANG,,https://lens.org/061-359-361-535-240,Patent Application,yes,0,0,5,072-507-853-766-089;;122-545-347-283-112;;061-359-361-535-240;;141-174-622-159-642;;098-485-793-778-107,EP;;CN;;WO,5,072-507-853-766-089;;061-359-361-535-240;;122-545-347-283-112;;141-174-622-159-642;;098-485-793-778-107,EP;;CN;;WO,0,A61K8/342;;A61K8/375;;A61K8/86;;A61K8/9789;;A61Q19/08;;A61K8/9789;;A61K8/342;;A61K8/375;;A61K8/442;;A61K8/645;;A61K8/86;;A61Q19/00;;A61Q19/08,A61K8/9789;;A61K8/34;;A61K8/37;;A61K8/86;;A61Q19/08,,0,0,,,,DISCONTINUED
633,WO,A1,WO 2022/049288 A1,182-446-274-946-597,2022-03-10,2022,EP 2021074502 W,2021-09-06,EP 20194880 A,2020-09-07,ANTIVIRAL AGENTS,The present invention relates to a composition comprising eucalyptus oil and sweet orange oil for use in a method for the treatment of a viral infection.,G POHL BOSKAMP GMBH & CO KG,UECK HENNING;;RÖSCHMANN-DOOSE KRISTINA;;THOMSEN JÖRN;;WITTIG THOMAS HEINZ,,https://lens.org/182-446-274-946-597,Patent Application,yes,3,0,5,088-109-834-247-440;;182-446-274-946-597;;075-058-828-091-807;;001-988-496-315-902;;139-275-751-680-929,DE;;RU;;CN;;EP;;WO,5,088-109-834-247-440;;182-446-274-946-597;;075-058-828-091-807;;001-988-496-315-902;;139-275-751-680-929,DE;;RU;;CN;;EP;;WO,0,A61P11/00;;A61K36/61;;A61K36/752;;A61K2300/00;;A61P31/14;;A61P31/16,A61K36/61;;A61K36/752;;A61P11/00;;A61P31/14;;A61P31/16,,73,58,006-877-012-716-604;;001-543-641-242-622;;062-042-786-799-023;;053-237-435-560-380;;148-789-612-871-535;;041-232-789-677-449;;029-757-469-682-828;;056-918-482-957-981;;071-821-683-274-733;;111-777-362-334-09X;;037-648-185-112-847;;088-611-825-656-799;;054-977-725-113-407;;111-824-798-250-611;;048-389-748-991-124;;123-758-281-329-813;;063-102-848-755-500;;111-777-362-334-09X;;140-737-537-325-685;;010-460-864-497-182;;009-284-907-956-268;;050-141-773-627-060;;075-083-223-831-811;;057-074-092-089-866;;038-535-758-911-781;;035-312-421-238-010;;025-783-856-545-499;;046-425-708-178-780;;007-453-228-852-354;;016-858-268-155-256;;054-977-725-113-407;;052-293-383-081-117;;081-118-560-654-582;;129-563-792-344-407;;042-827-553-676-107;;068-225-884-656-763;;022-345-380-284-860;;001-091-416-802-684;;056-600-183-550-321;;002-390-305-397-328;;038-012-653-096-087;;068-207-624-465-611;;029-549-156-582-125;;013-517-445-835-216;;164-129-300-594-731;;045-037-586-500-91X;;007-856-917-321-774;;038-465-095-616-00X;;042-834-147-531-653;;030-080-270-016-311;;038-116-875-675-064;;012-947-955-914-292;;034-865-768-582-957;;099-675-327-872-917;;021-665-106-859-672;;097-313-003-455-200;;008-317-407-831-110;;130-557-115-034-027,32837899;;pmc7398051;;10.1016/j.aimed.2020.07.005;;10.1007/s10787-020-00744-0;;pmc7427755;;32803479;;10.1055/a-0942-1993;;31167299;;32313366;;pmc7163989;;10.1002/ffj.3252;;10.4193/rhin20.601;;32226949;;10.1007/978-3-642-59770-1_2;;10.1128/jcm.35.11.2864-2868.1997;;pmc230076;;9350748;;pmc7167768;;19653195;;10.1002/ptr.2955;;10.3851/imp2629;;23714753;;22477544;;10.1007/s12325-012-0014-z;;pmc236993;;10.1128/jvi.68.9.5882-5889.1994;;7914550;;17972131;;10.1007/s00284-007-9045-0;;10719616;;10.1055/s-0031-1300178;;10.1155/2015/967473;;pmc7082763;;10.1001/jama.2020.4326;;32191259;;20722639;;10.1111/j.1742-7843.2010.00622.x;;32649077;;32649076;;32649078;;10.1056/nejmc2022236;;32649074;;32649075;;22477544;;10.1007/s12325-012-0014-z;;9825115;;pmc7143164;;10.1056/nejmoa2004500;;32227758;;10.1055/s-0031-1300588;;22282955;;pmc7725513;;32214079;;10.15585/mmwr.mm6912e2;;32105633;;10.1016/s2213-2600(20)30084-9;;pmc7128208;;pmc7265861;;32632415;;10.1016/j.eclinm.2020.100403;;10.3238/arztebl.2020.0271;;pmc7171478;;32519944;;10.1186/1745-9974-9-25;;pmc3842692;;24261680;;pmc7154064;;10.1007/s00134-020-06033-2;;32291463;;32302078;;pmc7182018;;10.1056/nejmc2010419;;32167538;;10.1001/jama.2019.13404;;10.1001/jama.2020.4031;;10.1001/jama.2020.5394;;32250385;;pmc7136855;;10719616;;10.1055/s-0031-1300178;;pmc7169476;;32275812;;10.1056/nejmoa2007016;;10.1016/s0140-6736(20)30183-5;;pmc7159299;;31986264;;30705129;;10.1183/13993003.02339-2018;;10.1136/bmj.m627;;32075791;;10.1016/j.pupt.2004.06.002;;15477123;;12645832;;10.1053/rmed.2003.1432;;27569254;;10.1080/13880209.2016.1216132;;30049972;;pmc6115776;;10.3390/v10080392;;10.1007/s00063-020-00689-w;;32166350;;pmc7080004;;pmc7155395;;32291505;;10.2500/ajra.2014.28.4036;;24980236;;10.1001/jama.2020.4344;;32181795;;pmc7496150;;32364264;;10.1111/his.14134;;10.3410/f.737874004.793575073;;pmc7378547;;32323287;;10.1055/a-1157-9976;;pmc2873403;;20502660;;10.1371/journal.pone.0010717;;10.1001/jama.2012.5669;;22797452;;pmc3521325;;20156758;;10.1186/2047-783x-14-s4-205;;10.1007/s11812-017-0085-5;;32362390;;10.1016/j.healun.2020.03.012;;pmc7118652;;1794831;;32031570;;pmc7042881;;10.1001/jama.2020.1585;;pmc7190303;;10.1016/s0140-6736(20)31022-9;;32423584;;19624838;;pmc2720945;;10.1186/1465-9921-10-69;;10.1001/jamainternmed.2020.0994;;32167524;;pmc7070509;;pmc7102538;;32105632;;10.1016/s2213-2600(20)30079-5;;32290293;;10.3390/ijms21072657;;pmc7177898;;10.1159/000438655;;26849230;;10.1016/s0140-6736(20)30566-3,"ANONYMOUS: ""Gut gewappnet für den Endspurt - So bleiben Sie bis zum Ende der Erkältungssaison fit"", 11 February 2020 (2020-02-11), XP002802172, Retrieved from the Internet <URL:https://www.presseportal.de/pm/67141/4517071> [retrieved on 20210222];;PRALL SEBASTIAN ET AL: ""Effects of essential oils on symptoms and course (duration and severity) of viral respiratory infections in humans: A rapid review"", vol. 7, no. 4, 3 August 2020 (2020-08-03), pages 218 - 221, XP055778009, ISSN: 2212-9588, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.aimed.2020.07.005> DOI: 10.1016/j.aimed.2020.07.005;;DOMINICA PETRIC: ""The_spectrum_of_antimicrobial_activity_of_Gelomyrtol_R_capsules"", April 2020 (2020-04-01), XP002802171, Retrieved from the Internet <URL:https://www.researchgate.net/publication/340385259_The_spectrum_of_antimicrobial_activity_of_Gelomyrtol_R_capsules> [retrieved on 20210219];;ASIF MUHAMMAD ET AL: ""COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties"", INFLAMMOPHARMACOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 28, no. 5, 14 August 2020 (2020-08-14), pages 1153 - 1161, XP037257443, ISSN: 0925-4692, [retrieved on 20200814], DOI: 10.1007/S10787-020-00744-0;;FÜRST ROBERT ET AL: ""ELOM-080 as Add-On Treatment for Respiratory Tract Diseases A Review of Clinical Studies Conducted in China"", vol. 85, no. 09/10, 5 June 2019 (2019-06-05), DE, pages 745 - 754, XP055773408, ISSN: 0032-0943, Retrieved from the Internet <URL:https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0942-1993.pdf> DOI: 10.1055/a-0942-1993;;GYÖRGYI HORVATH ET AL: ""Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review : Essential oils in the treatment of respiratory tract diseases"", FLAVOUR AND FRAGRANCE JOURNAL., vol. 30, no. 5, 26 May 2015 (2015-05-26), GB, pages 331 - 341, XP055391769, ISSN: 0882-5734, DOI: 10.1002/ffj.3252;;FOKKENS ET AL.: ""Executive summary of EPOS 2020 including integrated care pathways"", RHINOLOGY, vol. 58, no. 2, 1 April 2020 (2020-04-01), pages 82 - 111;;APP, E. M: ""Entzundliche Erkrankungen des Bronchialsystems"", 2000, SPRINGER, article ""Stellenwert der Mukusclearance fur das Bronchialsystem- Pathophysiologie und therapeutische Ansatze"";;ARRUDA, E., PITKARANTA, A., WITEK, T., DOYLE, C. A. & HAYDEN, F. G.: ""Frequency and natural history of rhinovirus infections in adults during autumn"", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 35, pages 2864 - 2868;;ASTANI, A.REICHLING, J.SCHNITZLER, P: ""Comparative study on the antiviral activity of selected monoterpenes derived from essential oils. Phytotherapy Research:"", INTERNATIONAL JOURNAL DEVOTED TO PHARMACOLOGICAL TOXICOLOGICAL EVALUATION OF NATURAL PRODUCT DERIVATIVES, vol. 24, 2010, pages 673 - 679;;BAGGA, B., WOODS, C. W., VELDMAN, T. H., GILBERT, A., MANN, A.BALARATNAM, G., LAMBKIN-WILLIAMS, R., OXFORD, J. S., MCCLAIN, M.T.&W: ""Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals "", J ANTIVIR THER, vol. 18, 2013, pages 785 - 791;;BEGROW, F., BOCKENHOLT, C., EHMEN, M., WITTIG, T. & VERSPOHL, E. J.: ""Effect of myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parameters"", ADVANCES IN THERAPY, vol. 29, 2012, pages 350 - 358;;BEUSCHER, N., BIEN, E., ELSTNER, E., KIETZMANN, M. & AMON, U.: ""Myrtol standardized in treatment of sinusitis and bronchitis-Pharmacodynamics and pharmacokinetics"", Z PHYTOTHERAPIE ABSTRACTBAND, vol. 8, 1997, pages 9 - 10;;CASASNOVAS, J. M.SPRINGER, T. A.: ""Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released"", JOURNAL OF VIROLOGY, vol. 68, 1994, pages 5882 - 5889;;CERMELLI, C.FABIO, A.FABIO, G.QUAGLIO, P: ""Effect of eucalyptus essential oil on respiratory bacteria and viruses"", CURRENT MICROBIOLOGY, vol. 56, 2008, pages 89 - 92, XP019587436;;GRAGMANN, J., HIPPELI, S., DORNISCH, K., ROHNERT, U., BEUSCHER , N. & ELSTNER, E.: ""Antioxidant Properties of Essential Oils. Possible explanantions for their anti-inflammatory effects"", ARZNEIMITTELFORSCHUNG, vol. 50, 2000, pages 135 - 139;;MOGHIMI, H. R., SHIRAZI, F. H., ARDESTANI, M. S., OGHABIAN, M. A. SAFFARI, M. & SOJOUDI, J: ""In vitro and in vivo enhancement of antitumoral activity of liposomal antisense oligonucleotides by cineole as a chemical penetration enhancer"", JOURNAL OF NANOMATERIALS,, vol. 16, 2015, pages 345;;VIMALANATHAN, S.HUDSON, J.: ""Anti-influenza virus activity of essential oils and vapors"", AMERICAN JOURNAL OF ESSENTIAL OILS NATURAL PRODUCTS, vol. 2, 2014, pages 47 - 53, XP055676675;;ARENTZ MYIM EKLAFF L ET AL.: ""Characteristics and Outcomes of 21 Critically III Patients With COVID-19 in Washington State"", JAMA, 2020;;BASTOS, V. P. ET AL.: ""Inhaled 1, 8-Cineole Reduces Inflammatory Parameters in Airways of Ovalbumin-Challenged Guinea Pigs"", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 108, 2011, pages 34 - 39;;BEIGEL JH: ""Remdesivir for the Treatment of Covid-19 - Preliminary Report"", NEJM.ORG, 22 May 2020 (2020-05-22);;BEGROW FBOCKENHOLDT CEHMEN MWITTIG TH, VERSPOHL EJ: ""Effects of Myrtol Standardized and Other Substances on the Respiratory Tract: Ciliary Beat Frequency and Mucociliary Clearance as Parameters"", ADV THER, vol. 29, no. 4, 2012, pages 350 - 358;;BEUSCHER NKIETZMANN M, BIEN E ET AL.: ""Interference of Myrtol standardized with inflammatory and allergic mediators"", ARZNEIM.-FORSCH./DRUG RES, vol. 48, 1998, pages 985 - 989;;BHATRAJU PKGHASSEMIEH BJNICHOLS M ET AL.: ""Covid-19 in Critically III Patients in the Seattle Region - Case Series"", N ENGL J MED, 2020;;BROGAN GCAMPBELL NDURIE MNICKSON C: ""Coronavirus disease 2019 (COVID-19"", LITFL CRITICAL CARE COMPENDIUM, 19 April 2020 (2020-04-19), Retrieved from the Internet <URL:https://litfl.com/coronavirus-disease-2019-covid-19/>;;BROGAN GCAMPBELL NDURIE MNICKSON C: ""Coronavirus disease 2019 (COVID-19"", LITFL CRITICAL CARE COMPENDIUM, 30 May 2020 (2020-05-30), Retrieved from the Internet <URL:https://litfl.com/coronavirus-disease-2019-covid-19/#19-management-oxygenation-and-ventilation>;;CAO, L. ET AL.: ""Effect of Myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary disease"", ARZNEIMITTEL-FORSCHUNG, vol. 61, 2010, pages 685 - 692;;""CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19"", MMWR, vol. 69, no. 12, 12 February 2020 (2020-02-12), pages 343 - 346, Retrieved from the Internet <URL:https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6912e2-H.pdf>;;CHEUNG JCHO LTCHENG JV ET AL.: ""Staff safety during emergency airway management for COVID-19 in Hong Kong"", LANCET RESPIR MED, vol. 8, 2020, pages e19;;DESAI AGYAWALI B: ""Endpoints used in phase III randomized controlled trials of treatment options for COVID-19"", ECLINICAL MEDICINE, 2020, Retrieved from the Internet <URL:https://doi.org/10.1016/j.ec!inm.2020.100403.>;;DREHER MKERSTEN ABICKENBACH JBALFANZ PHARTMANN BCORNELISSEN CDAHER ASTOHR RKLEINES MLEMMEN SW: ""The characteristics of 50 hospitalized COVID-19 patients with and without ARDS"", DTSCH ARZTEBL INT, vol. 117, 2020, pages 271 - 8;;FISCHER, JDETHLEFSEN, U: ""Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial"", COUGH, vol. 9, 2013, pages 25, XP021168633, DOI: 10.1186/1745-9974-9-25;;GATTINONI L ET AL.: ""COVID-19 pneumonia: different respiratory treatment for different phenotypes?"", INTENSIVE CARE MEDICINE, 2020;;GOYAL PCHOI JJPINHEIRO LC ET AL.: ""Clinical Characteristics of Covid-19 in New York City"", N ENGL J MED, 2020;;GRASSELLI GPESENTI A, CECCONI M: ""Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response"", JAMA, 2020;;GRASSELLI GZANGRILLO AZANELLA A ET AL.: ""Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy"", JAMA, 2020;;GRAL3>MANN JHIPPELI SDORNISCH K ET AL.: ""Antioxidant Properties of Essential Oils"", ARZNEIMITTELFORSCHUNG, vol. 50, 2000, pages 135 - 139;;GREIN J ET AL.: ""Compassionate Use of Remdesivir for Patients with Severe Covid-19"", N ENGL J MED, vol. 382, 2020, pages 2327 - 36, XP055832045, DOI: 10.1056/NEJMoa2007016;;GUAN WJNI ZYHU Y ET AL.: ""Clinical Characteristics of Coronavirus Disease 2019 in China"", N ENGL J MED, 2020;;HUANG CWANG YLI X ET AL.: ""Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"", LANCET, vol. 395, 2020, pages 497, XP086050317, DOI: 10.1016/S0140-6736(20)30183-5;;HUI DSCHOW BKTHOMAS LOOWEN TVTSANG FWKO, SSNG TGIN MCHAN TV: ""Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks"", EUROPEAN RESPIRATORY JOURNAL, vol. 53, no. 4, 2019, Retrieved from the Internet <URL:https://doi.orq/10.1183/13993003.02339-2018>;;IMRAAN FJHETAM: ""Rapid response to Vetter P. Covid-19: a puzzle with many missing pieces"", BMJ, vol. 368, 2020, pages m627;;JUERGENS, U. R. ET AL.: ""Inhibitory activity of 1, 8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes"", PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 17, 2004, pages 281 - 287, XP004599066, DOI: 10.1016/j.pupt.2004.06.002;;JUERGENS, U. ET AL.: ""Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial"", RESPIRATORY MEDICINE, vol. 97, 2003, pages 250 - 256;;PENG-JIU YULI-MEI WANSHAN-HE WANWEN-YING CHENHUI XIEDONG-MEI MENGJIA-JIE ZHANGXIANG-LIN XIAO: ""Standardized myrtol attenuates lipopolysaccharide induced acute lung injury in mice"", PHARMACEUTICAL BIOLOGY, vol. 54, no. 12, 2016, pages 3211 - 3216;;KASCHKE OBEHRBOHM HSYDOW K: ""The influence of a secretolytic drug on mucociliary clearance of the maxillary sinus"", J RHINOL., vol. 4, no. 1, 1997, pages 29 - 33;;KHOMICH OKOCHETKOV SBARTOSCH B ET AL.: ""Redox Biology of Respiratory Viral Infections"", VIRUSES, vol. 10, 2018, pages 392, XP055841040, DOI: 10.3390/v10080392;;KLUGE SJANSSENS UWELTE TWEBER-CARSTENS SMARX GKARAGIANNIDIS C: ""Recommendations for critically ill patients with COVID-19"", MED KLIN INTENSIVMED NOTFMED, 2020;;LAI YDILIDAER DCHEN BXU GSHI JLEE RJCOHEN NA: ""In vitro studies of Myrtol on upper airway physiology pertaining to mucociliary clearance"", AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, vol. 28, no. 3, 2014, pages 244 - 248;;LENZEN-SCHULTE M: ""Richtig beatmen bei COVID-19"", DTSCH ARZTEBL, vol. 117, no. 18, 2020, pages A938;;LIVINGSTON EBUCHER K: ""Coronavirus Disease 2019 (COVID-19) in Italy"", JAMA, 2020;;MENTER THASLBAUER JDNIENHOLD R ET AL.: ""Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction"", HISTOPATHOLOGY, 4 May 2020 (2020-05-04), Retrieved from the Internet <URL:https://pubmed.ncbi.nlm.nih.gov/32364264/>;;PFEIFER MEWIG SVOSHAAR TRANDERATH WBAUER TGEISELER JDELLWEG DWESTHOFF MWINDISCH WSCHONHOFER B, POSITIONSPAPIER ZUR PRAKTISCHEN UMSETZUNG DER APPARATIVEN DIFFERENZIALTHERAPIE DER AKUTEN RESPIRATORISCHEN INSUFFIZIENZ BEI COVID-19., 17 April 2020 (2020-04-17), Retrieved from the Internet <URL:https://pneumologie.de/fileadmin/userupload/COVID-19/20200417DGPapp.DifferenzialtherapieARICOVID-19.pdf>;;RABOUD JSHIGAYEVA AMCGEER ABONTOVICS ECHAPMAN MGRAVEL D ET AL.: ""Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada"", PLOS ONE, vol. 5, no. 5, 2010, pages e10717;;RANIERI VMRUBENFELD GDTHOMPSON BT ET AL.: ""Acute respiratory distress syndrome: the Berlin Definition"", JAMA, vol. 307, 2012, pages 2526 - 33;;RANTZSCH GVACCA RDUCK RGILLISSEN A: ""Anti-inflammatory effects of Myrtol standardized and other essential oils in alveolar macrophages from patients with chronic obstructive pulmonary disease"", EUR J MED RES, vol. 14, 2009, pages 205 - 209, XP021130248, DOI: 10.1186/2047-783X-14-S4-205;;ROBERT KOCH INSTITUTE: ""Hospital discharge management [German: COVID-19: Kriterien zur Entlassung aus dem Krankenhaus bzw. aus der hauslichen Isolierung"", COVID-19, 24 April 2020 (2020-04-24), Retrieved from the Internet <URL:https://www.rki.de/DE/Content/lnfAZ/N/NeuartigesCoronavirus/Entlassmanagement.html#doc13671260bodyText1>;;ROBERT KOCH INSTITUTE: ""Standiger Arbeitskreis der Kompetenz- und Behandlungszentren fur Krankheiten durch hochpathogene Erreger (STAKOB"", HINWEISE ZU ERKENNUNG, DIAGNOSTIK UND THERAPIE VON PATIENTEN MIT COVID-19, 17 April 2020 (2020-04-17);;SCHINKO, H.FUNK, G.MESCHKAT, M. ET AL.: ""Arterielle Blutgasanalyse"", WIEN. KLIN. WOCHENSCHR. EDUC, vol. 12, 2017, pages 115 - 130, XP036387466, DOI: 10.1007/s11812-017-0085-5;;SIDDIQU HKMEHRA MR: ""COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal"", JOURNAL OF HEART AND LUNG TRANSPLANTATION;;ULMER WTNOLTE DLECHELER JSCHAFER THDIE LUNGENFUNKTION: ""Methodik und klinische Anwendung"", 2003, THIEME VERLAGSGRUPPE;;ULMER W. T.SCHOTT D.: ""Chronic obstructive Bronchitis. Effect of GeloMyrtol forte in a placebo-controlled double-blind study"", FORTSCHRITTE DER MEDIZIN, vol. 109, no. 27, 1991, pages 547 - 550;;WANG DHU BHU C ET AL.: ""Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"", JAMA, 2020;;WANG Y ET AL.: ""Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial"", LANCET, 2020, Retrieved from the Internet <URL:https:/Iwww.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931022-9>;;""Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected Interim guidance"", WHO, 13 March 2020 (2020-03-13), Retrieved from the Internet <URL:https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>;;WICHMANN DSPERHAKE JPLUTGEHETMANN M ET AL., ANN INTERN MED, 6 May 2020 (2020-05-06), Retrieved from the Internet <URL:https://www.acpiournals.org/doi/10.7326/M20-2003>;;WORTH, H.SCHACHER, CDETHLEFSEN, U: ""Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial"", RESPIR RES, vol. 10, 2009, pages 69, XP021055549, DOI: 10.1186/1465-9921-10-69;;WU CCHEN XCAI Y ET AL.: ""Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China"", JAMA INTERN MED, 2020;;WU ZMCGOOGAN JM, JAMA, 2020;;YANG XYU YXU J: ""Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"", LANCET, 2020;;YUNG-FANG TU ET AL.: ""A Review of SARS-CoV-2 and the Ongoing Clinical Trial"", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020;;ZHAO DYHONG-JIN QUJIA-MING GUOHAI-NAN ZHAOYAN-YONG YANGPEI ZHANGKUN CAOXIAO LEIJIAN-GUO CUICONG LIU: ""Protective Effects of Myrtol Standardized Against Radiation-Induced Lung Injury. Cell. Physiol"", BIOCHEM., vol. 38, 2016, pages 619 - 634;;ZHOU FYU TDU R ET AL.: ""Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"", LANCET, vol. 395, 2020, pages 1054, XP086105445, DOI: 10.1016/S0140-6736(20)30566-3",PENDING
634,WO,A1,WO 2021/116361 A1,017-325-812-491-945,2021-06-17,2021,EP 2020085663 W,2020-12-11,EP 19215115 A,2019-12-11,AUTOMATED MEDIUM EXCHANGE STRATEGY FOR SUSPENSION CELLS,"The present invention relates to a method of changing culture medium of a suspension culture, the suspension culture comprising cells suspended in the culture medium, the method comprising: (i) transferring a fraction of the suspension culture into a container, wherein the container comprises at least one opening at the bottom; (ii) allowing the cells comprised in the fraction of the suspension to settle at the at least one opening at the bottom of the container by gravitation, thereby forming a supernatant; (iii) dispensing the cells settled at the bottom of the container (back) into the suspension culture; (iv) discarding the supernatant.",SARTORIUS STEDIM BIOTECH GMBH;;REPAIRON GMBH,HAUPT LUIS;;HUPFELD JULIA,,https://lens.org/017-325-812-491-945,Patent Application,yes,8,1,9,076-975-535-551-27X;;017-325-812-491-945;;175-407-302-254-34X;;044-420-206-355-518;;199-765-781-503-198;;187-414-599-108-650;;024-332-599-424-477;;104-758-043-062-405;;078-652-960-432-980,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,9,017-325-812-491-945;;076-975-535-551-27X;;175-407-302-254-34X;;044-420-206-355-518;;199-765-781-503-198;;024-332-599-424-477;;187-414-599-108-650;;104-758-043-062-405;;078-652-960-432-980,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,0,C12M29/18;;C12M33/22;;C12M47/02;;C12M29/18;;C12M33/22;;C12M47/02;;C12N5/0696;;C12M33/22;;C12M27/02;;C12M29/18;;C12M47/02,C12M1/00;;C12M1/26,,10,10,095-386-043-355-68X;;032-330-914-541-050;;002-343-538-662-178;;062-078-761-000-697;;098-009-520-600-314;;036-984-300-939-839;;012-911-618-463-633;;019-767-724-381-245;;002-034-380-841-504;;056-854-995-903-751,10.1126/science.282.5391.1145;;9804556;;10.1016/j.cell.2006.07.024;;16904174;;10.1038/nmeth.1591;;21460823;;24411336;;10.1016/j.biomaterials.2013.12.050;;pmc3193421;;21243013;;10.1038/cr.2011.12;;10.1016/j.stemcr.2015.08.015;;pmc4624993;;26411904;;10.1007/s12015-010-9149-y;;20431964;;28382727;;10.1002/term.2435;;29679475;;pmc6055717;;10.1002/bit.26719;;pmc3460618;;22519745;;10.1089/ten.tec.2011.0717,"THOMSON ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147;;TAKAHASHIYAMANAKA, CELL, vol. 126, 2006, pages 663 - 676;;OKITA ET AL.: ""A more efficient method to generate integration-free human iPS cells"", NATURE METHODS, vol. 8, no. 5, May 2011 (2011-05-01), pages 409 - 411, XP055176852, DOI: 10.1038/nmeth.1591;;LU ET AL.: ""A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells"", BIOMATERIALS, vol. 35, 2014, pages 2816e2826;;CHOU ET AL., CELL RESEARCH, vol. 21, 2011, pages 518 - 529;;BAGHBADERANI ET AL., STEM CELL REPORTS, vol. 5, no. 4, 2015, pages 647 - 659;;AMIT, MICHALCHEBATH, JUDITHMARGULETS, VICTORIALAEVSKY, ILANAMIROPOLSKY, YAELSHARIKI, KOHAVA ET AL.: ""Suspension culture of undifferentiated human embryonic and induced pluripotent stem cells"", STEM CELL REVIEWS, vol. 6, no. 2, 2010, pages 248 - 259, XP055015267, DOI: 10.1007/s12015-010-9149-y;;KWOK, CHEE KEONGUEDA, YUICHIROKADARI, ASIFIQBALGUNTHER, KATHARINAERGUN, SULEYMANHERON, ANTOINE ET AL.: ""Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single-use bioreactors"", JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, vol. 12, no. 2, 2018, pages e1076 - e1087;;LIPSITZ, YONATAN Y.TONGE, PETER D.ZANDSTRA, PETER W.: ""Chemically controlled aggregation of pluripotent stem cells"", BIOTECHNOLOGY AND BIOENGINEERING, vol. 115, no. 8, 2018, pages 2061 - 2066;;OLMER, RUTHLANGE, ANDREASSELZER, SEBASTIANKASPER, CORNELIAHAVERICH, AXELMARTIN, ULRICHZWEIGERDT, ROBERT: ""Suspension Culture of Human Pluripotent Stem Cells in Controlled, Stirred Bioreactors"", TISSUE ENGINEERING. PART C, METHODS, vol. 18, no. 10, 2012, pages 772 - 784, XP055637355, DOI: 10.1089/ten.tec.2011.0717",PENDING
635,WO,A1,WO 2023/206203 A1,117-651-478-607-488,2023-11-02,2023,CN 2022089781 W,2022-04-28,CN 2022089781 W,2022-04-28,MULTI-FORM ANTIGEN DETECTION REAGENT,"The present invention provides a multi-form antigen detection reagent. The detection reagent is mainly used for detecting whether a specimen contains an antigen of a novel coronavirus COVID-19, and at least one or more specimen absorption pads on which the detection reagent is arranged can perform saliva or dropping liquid dual detection or alternative detection, so that the detection reagent is suitable for being used in different test environments. A cover body can be rapidly bonded on a carrier without a glue or an adhesive, at least one piece of test paper and at least one or more specimen absorption pads are completely clamped and fixed between the carrier and the cover body, and the material of the carrier of the detection reagent is a plant fiber that can be completely recycled, and thus, the carrier can be directly discarded or recycled after detection, and the eco-friendly ecology is not affected.",CHANGZHOU CITY CHENG XIN ENVIRONMENTAL PROTECTION TECH CO LTD,TUNG LIANG-YI;;CHEN MAOYI;;WEI SHIH-PING;;RAN GUANGQUAN,,https://lens.org/117-651-478-607-488,Patent Application,yes,2,0,1,117-651-478-607-488,WO,1,117-651-478-607-488,WO,0,G01N33/53;;G01N33/543;;G01N33/558;;G01N33/569,G01N33/569;;G01N33/53;;G01N33/543;;G01N33/558,,1,0,,,"SAFECARE BIOTECH (HANGZHOU): ""Novel Coronavirus Rapid Test Series"", XP009550497, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s/_J6v5-58abSSj556pELHvw>",PENDING
636,WO,A1,WO 2021/139894 A1,056-386-385-249-081,2021-07-15,2021,EP 2020050508 W,2020-01-10,EP 2020050508 W,2020-01-10,EXTREME THERMOPHILIC BACTERIA OF THE GENUS CALDICELLULOSIRUPTOR SUITABLE FOR THE CONVERSION OF CELLULOSIC AND STARCHY BIOMASS,"The technology provided herein relates to novel isolated cellulolytic extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures and microbial compositions. The novel bacteria are in particular suitable for the production of fermentation products such as lactic acid from any carbon source, not limited to cellulosic material but especially useful for converting cellulosic biomass like ligniocellulosic biomass and/or starch containing biomass.",BLUCON BIOTECH GMBH,SVETLICHNAYA TATIANA;;SVETLICHNY VITALY;;KRÄMER MARCO,,https://lens.org/056-386-385-249-081,Patent Application,yes,7,0,1,056-386-385-249-081,WO,14,115-550-975-719-514;;089-119-531-590-175;;106-926-783-096-283;;138-616-557-731-08X;;172-502-806-357-592;;133-358-669-744-474;;003-861-881-697-091;;086-689-386-250-961;;011-659-486-716-10X;;066-052-449-652-084;;049-754-984-984-152;;021-008-914-874-694;;056-386-385-249-081;;048-949-088-739-646,JP;;AU;;KR;;EP;;CN;;WO;;ZA;;US;;CA;;BR,1,C12N1/205;;C12N1/20;;C12N1/22;;C12P3/00;;C12P7/02;;C12P7/40;;C12P7/56;;C12R2001/01,C12N1/20;;C12P7/56,,9,7,014-462-529-725-525;;085-869-145-963-428;;066-387-858-103-89X;;006-719-136-734-034;;093-619-101-976-938;;074-488-197-260-232;;019-979-499-270-526,pmc168907;;12824352;;10.1093/nar/gkg500;;10.1111/j.1432-1033.1970.tb00830.x;;4984993;;10.1016/s0723-2020(83)80048-4;;23194591;;10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1128/aem.53.4.832-838.1987;;16347327;;pmc203765;;18587891;;10.1002/bit.260331118;;10.1093/bioinformatics/17.12.1244;;11751241,"ANONYMOUS: ""EM_STD:KJ479750"", 10 June 2014 (2014-06-10), XP055676393, Retrieved from the Internet <URL:http://ibis.internal.epo.org/exam/dbfetch.jsp?id=EM_STD:KJ479750> [retrieved on 20200313];;CHENNA RSUGAWARA HKOIKE TLOPEZ RGIBSON TJHIGGINS DGTHOMPSON JD: ""Multiple sequence alignment with the Clustal series of programs"", NUCLEIC ACIDS RES., vol. 13, 2003, pages 3497 - 3500, XP002316493, DOI: 10.1093/nar/gkg500;;DE LEY ET AL., EUR. J. BIOCHEM., vol. 12, 1970, pages 133 - 142;;HUG ET AL., SYST APPL. MICROBIOL., vol. 4, 1983, pages 184 - 192;;RAINEY FADONNISON AMJANSSEN PHSAUL DRODRIGO ABERGQUIST PLDANIEL RMSTACKEBRANDT EMORGAN HW: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: an obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOL LETT, vol. 120, 1994, pages 263 - 266, XP023916519, DOI: 10.1111/j.1574-6968.1994.tb07043.x;;SISSONS CHSHARROCK KRDANIEL RMMORGAN HW: ""Isolation of cellulolytic anaerobic extreme thermophiles from New Zealand thermal sites"", APPL ENVIRON MICROBIOL., vol. 53, 1987, pages 832 - 838;;DONNISON AMBROCKELSBY CMMORGAN HWDANIEL RM: ""The degradation of lignocellulosics by extremely thermophilic microorganisms"", BIOTECHNOL BIOENG, vol. 33, 1989, pages 1495 - 1499;;HUNGATE RE: ""Methods in Microbiology"", 1969, ACADEMIC PRESS, article ""A roll tube method for cultivation of strict anaerobes"", pages: 118 - 132;;KUMAR STAMURA KJAKOBSEN IBNEI M: ""MEGA2: molecular evolutionary genetics analysis software"", BIOINFORMATICS, vol. 17, 2001, pages 1244 - 1245",PENDING
637,WO,A1,WO 2022/157282 A1,046-085-675-950-624,2022-07-28,2022,EP 2022051300 W,2022-01-21,EP 21152718 A,2021-01-21,APPLICATION OF PERMITTIVITY MEASUREMENT PROBES IN AN SUSPENSION CULTURE AGGREGATE COMPRISING CELL AGGREGATES,"The present disclosure relates to a method of measuring cell density in a cell suspension comprising cell aggregates, the method comprising (i) Measuring the permittivity of the cell suspension; (ii) Comparing the measured permittivity with a predetermined value that is indicative of the cell density, thereby determining the cell density. Further described is a of a permittivity probe for determining the cell density of a suspension cell culture comprising cell aggregates.",SARTORIUS STEDIM BIOTECH GMBH;;REPAIRON GMBH,HAUPT LUIS;;HUPFELD JULIA,,https://lens.org/046-085-675-950-624,Patent Application,yes,4,0,9,121-015-559-480-260;;178-995-278-577-829;;151-453-072-680-218;;143-033-822-450-147;;055-319-748-782-760;;109-778-446-233-23X;;046-085-675-950-624;;061-251-268-200-919;;157-215-763-790-365,KR;;AU;;JP;;EP;;CN;;WO;;US;;CA,9,121-015-559-480-260;;178-995-278-577-829;;151-453-072-680-218;;143-033-822-450-147;;055-319-748-782-760;;109-778-446-233-23X;;046-085-675-950-624;;061-251-268-200-919;;157-215-763-790-365,KR;;AU;;JP;;EP;;CN;;WO;;US;;CA,0,G01N33/48735;;G01N27/221;;G01N27/026;;G01N27/221;;G01N33/48735,G01N33/487;;G01N27/22,,19,16,033-864-442-134-408;;095-386-043-355-68X;;032-330-914-541-050;;035-238-575-653-10X;;002-343-538-662-178;;062-078-761-000-697;;098-009-520-600-314;;036-984-300-939-839;;041-431-663-843-36X;;049-912-208-256-508;;083-873-038-857-194;;020-642-954-738-592;;072-348-398-084-856;;142-739-559-167-093;;013-353-841-035-490;;008-150-712-025-535,10.1007/s10616-011-9359-4;;21562973;;pmc3140841;;10.1126/science.282.5391.1145;;9804556;;10.1016/j.cell.2006.07.024;;16904174;;18035408;;10.1016/j.cell.2007.11.019;;10.1038/nmeth.1591;;21460823;;24411336;;10.1016/j.biomaterials.2013.12.050;;pmc3193421;;21243013;;10.1038/cr.2011.12;;10.1016/j.stemcr.2015.08.015;;pmc4624993;;26411904;;27283945;;pmc4919381;;10.1007/s12015-016-9662-8;;22459095;;10.1016/j.scr.2012.02.001;;10.1007/978-1-4939-9477-9_5;;31124104;;25355733;;pmc4250209;;10.5966/sctm.2014-0072;;21419837;;10.1016/j.biotechadv.2011.03.002;;10.1038/nprot.2015.089;;26270394;;27369897;;pmc5031176;;10.5966/sctm.2015-0253;;10.1016/j.procbio.2016.09.032,"JUSTICE C ET AL: ""Online- and offline- monitoring of stem cell expansion on microcarrier"", CYTOTECHNOLOGY, vol. 63, no. 4, 12 May 2011 (2011-05-12), pages 325 - 335, XP019928801, ISSN: 1573-0778, DOI: 10.1007/S10616-011-9359-4;;HAMILTON COMPANY INC: ""Cell Density Applications eBook"", 2018, XP055822649, Retrieved from the Internet <URL:https://craft-sensors.s3.amazonaws.com/Hamilton-Cell-Density-Applications-Ebook.pdf> [retrieved on 20210708];;THOMSON ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147;;TAKAHASHIYAMANAKA, CELL, vol. 126, 2006, pages 663 - 676;;TAKAHASHI ET AL., CELL, vol. 131, no. 5, 2007, pages 861 - 72;;OKITA ET AL.: ""A more efficient method to generate integration-free human iPS cells"", NATURE METHODS, vol. 8, no. 5, May 2011 (2011-05-01), pages 409 - 411, XP055176852, DOI: 10.1038/nmeth.1591;;LU ET AL.: ""A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells"", BIOMATERIALS, vol. 35, 2014, pages 2816 - 2826, XP028829032, DOI: 10.1016/j.biomaterials.2013.12.050;;CHOU ET AL., CELL RESEARCH, vol. 21, 2011, pages 518 - 529;;BAGHBADERANI, B.A.TIAN, X.NEO, B.H.BURKALL, ADIMEZZO, T.SIERRA, G.ZENG, X.WARREN, K.KOVARCIK, D.P.FELLNER, T. ET AL.: ""cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications"", STEM CELL REPORTS, vol. 5, no. 4, 2015, pages 647 - 659, XP055857582, DOI: 10.1016/j.stemcr.2015.08.015;;BAGHBADERANI, B.A.SYAMA, A.SIVAPATHAM, R.PEI, Y.MUKHERJEE, O.FELLNER, T.ZENG, X.RAO, M.S.: ""Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications"", STEM CELL REV AND REP, vol. 12, 2016, pages 394 - 420, XP035989538, DOI: 10.1007/s12015-016-9662-8;;CHEN, V.C.COUTURE, S.M.YE, J.LIN, Z.HUA, G.HUANG, H.-I.PWU, J.HSU, D.CARPENTER, M.K.COUTURE, L.A.: ""Scalable GMP compliant suspension culture system for human ES cells"", STEM CELL RESEARCH, vol. 8, 2012, pages 388 - 402, XP055292525, DOI: 10.1016/j.scr.2012.02.001;;HALLOIN, C.COFFEE, M.MANSTEIN, FZWEIGERDT, R.: ""In Cell-Based Assays Using IPSCs for Drug Development and Testing"", 2019, SPRINGER, article ""Production of Cardiomyocytes from Human Pluripotent Stem Cells by Bioreactor Technologies"", pages: 55 - 70;;HEMMI, N.TOHYAMA, S.NAKAJIMA, K.KANAZAWA, H.SUZUKI, T.HATTORI, F.SEKI, T.KISHINO, Y.HIRANO, A.OKADA, M. ET AL.: ""A Massive Suspension Culture System With Metabolic Purification for Human Pluripotent Stem Cell-Derived Cardiomyocytes"", STEM CELLS TRANSLATIONAL MEDICINE, vol. 3, 2014, pages 1473 - 1483, XP055812655, DOI: 10.5966/sctm.2014-0072;;JIANG, Y.LANGENBERG, K.BORGDORFF, V.DURISKA, M.POST, RBARTULOS, O.DOORNBOS, M.BRAAM, S.REIJERKERK, A.RASCHE, U.: ""12"", CONTROLLED, LARGE-SCALE MANUFACTURING OF HIPSC-DERIVED CARDIOMYOCYTES IN STIRRED-TANK BIOREACTORS, 2019;;JUSTICE, C.BRIX, A.FREIMARK, D.KRAUMEC, M.PFROMM, P.EICHENMUELLER, B.CZERMAK, P: ""Process control in cell culture technology using dielectric spectroscopy"", BIOTECHNOLOGY ADVANCES, vol. 29, no. 4, 2011, pages 391 - 401, XP028384898, DOI: 10.1016/j.biotechadv.2011.03.002;;KEMPF, H.KROPP, C.OLMER, R.MARTIN, U.ZWEIGERDT, R.: ""Cardiac differentiation of human pluripotent stem cells in scalable suspension culture"", NATURE PROTOCOLS, vol. 10, 2015, pages 1345 - 1361, XP037549230, DOI: 10.1038/nprot.2015.089;;KROPP, C.KEMPF, H.HALLOIN, C.ROBLES-DIAZ, D.FRANKE, A.SCHEPER, T.KINAST, K.KNORPP, T.JOOS, T.O.HAVERICH, A. ET AL.: ""Impact of Feeding Strategies on the Scalable Expansion of Human Pluripotent Stem Cells in Single-Use Stirred Tank Bioreactors"", STEM CELLS TRANSLATIONAL MEDICINE, vol. 5, 2016, pages 1289 - 1301, XP055812661, DOI: 10.5966/sctm.2015-0253;;KROPP, C.MASSAI, D.ZWEIGERDT, R.: ""Progress and challenges in large-scale expansion of human pluripotent stem cells"", PROCESS BIOCHEMISTRY, vol. 59, 2017, pages 244 - 254, XP085197611, DOI: 10.1016/j.procbio.2016.09.032;;See also references of EP 4281767A1",PENDING
638,WO,A1,WO 2022/120244 A1,187-746-453-554-077,2022-06-09,2022,US 2021/0061908 W,2021-12-03,US 202063121093 P,2020-12-03,COLLABORATION PLATFORM FOR ENABLING COLLABORATION ON DATA ANALYSIS ACROSS MULTIPLE DISPARATE DATABASES,"A platform and method for enabling collaboration on data analysis of life sciences data across disparate databases are disclosed. The collaboration platform may allow for performing exploratory analysis for drug discovery and development. The collaboration platform may include a search and graph module for generating a user project and determining and displaying one or more matching data assets and one or more potential collaborators; a collaboration module for coordinating a collaboration between the user and one or more selected collaborators; a data management module for receiving a schema for one or more producer projects, receiving data from the one or more selected data assets, and ingesting the received data using common standards and an ontology; and an insight application for generating disease specific inferences relating to a scientific question using the ingested received data, and receiving a feedback from the user and/or the selected collaborators to improve the search and graph module.",NOVARTIS AG,SRINIVASAN BADHRI;;SAXENA SIDHYANSH;;PLUECKEBAUM ACHIM;;DIEHL CHRISTIAN,,https://lens.org/187-746-453-554-077,Patent Application,yes,5,1,11,125-021-471-386-727;;103-342-771-458-621;;060-239-510-211-571;;067-410-755-006-797;;152-461-740-360-196;;187-746-453-554-077;;173-122-121-797-722;;099-893-580-314-471;;191-473-879-776-981;;108-080-233-060-813;;135-618-556-583-644,JP;;CN;;EP;;WO;;US;;TW,11,125-021-471-386-727;;060-239-510-211-571;;103-342-771-458-621;;135-618-556-583-644;;152-461-740-360-196;;187-746-453-554-077;;173-122-121-797-722;;099-893-580-314-471;;191-473-879-776-981;;108-080-233-060-813;;067-410-755-006-797,JP;;CN;;EP;;WO;;US;;TW,0,G06Q10/101;;G16H80/00;;G16H50/70;;G16H70/40;;G16H10/20;;G06Q10/0631;;G06Q30/02;;Y02A90/10;;G06Q10/101;;G16B50/30;;G16B50/10;;G16B50/20;;G16H80/00,G16C20/50;;G06F16/36;;G06F40/20;;G16C20/70;;G16C20/90;;G16H10/20;;G16H50/70;;G16H80/00,,1,0,,,See also references of EP 4214716A4,PENDING
639,US,A1,US 2021/0392886 A1,176-477-425-114-179,2021-12-23,2021,US 202016903770 A,2020-06-17,US 202016903770 A,2020-06-17,Agricultural Composition for the Treatment and Prevention of Bacterial Diseases and Disorders,"The disclosed invention provides agricultural compositions for effective disruption of bacterial biofilms, for the treatment and preventing of bacterial diseases and disorders. The present invention also provides methods for the treatment and of prevention in a plant or plant part thereof, comprising applying to the plant or plant part said agricultural composition.",AMAZON AGROSCIENCES LTDA;;INST AGRONOMICO IAC;;CIACAMP DESENVOLVIMENTO E INOVACAO TECNOLOGICA LTDA,DE SOUZA DELLA COLETTA ALESSANDRA ALVES;;DELLA COLETTA FILHO HELVECIO;;TAKITA MARCO AURELIO;;MACHADO MARCOS ANTONIO;;PICCHI SIMONE CRISTINA;;MURANAKA LÍGIA SEGATTO,CIACAMP DESENVOLVIMENTO E INOVAÇÃO TECNOLÓGICA LTDA (2020-06-04);;AMAZON AGROSCIENCES LTDA (2020-06-04);;INSTITUTO AGRONÔMICO (IAC) (2020-06-04),https://lens.org/176-477-425-114-179,Patent Application,yes,5,2,7,029-143-333-209-074;;044-473-130-071-541;;126-275-533-497-585;;176-477-425-114-179;;180-592-669-133-980;;164-316-562-579-391;;094-728-816-473-233,CN;;EP;;WO;;US;;BR;;MX,7,029-143-333-209-074;;044-473-130-071-541;;126-275-533-497-585;;176-477-425-114-179;;180-592-669-133-980;;164-316-562-579-391;;094-728-816-473-233,CN;;EP;;WO;;US;;BR;;MX,0,A01N37/46;;A01P1/00;;C05G3/60;;C05F11/10;;C05F11/00;;A01N37/46;;A01C21/00;;A01N65/03,A01N37/46;;A01C21/00;;A01N65/03,,1,0,,,"Ray biotech, Data sheet for N-acetylcysteine amide, https://www.raybiotech.com/n-acetylcysteine-amide-332-12740 (Year: 2007)",PENDING
640,US,A1,US 2022/0119802 A1,036-831-718-596-178,2022-04-21,2022,US 202117358440 A,2021-06-25,US 202117358440 A;;US 201916710909 A;;US 201816005583 A;;US 201514821580 A;;US 201213722915 A;;US 56389709 A;;US 61275706 A;;US 92024404 A;;US 49569803 P,2003-08-18,POLYPEPTIDE DISPLAY LIBRARIES AND METHODS OF MAKING AND USING THEREOF,Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.,UNIV CALIFORNIA,DAUGHERTY PATRICK S;;BESSETTE PAUL H;;RICE JEFFREY,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2004-11-02),https://lens.org/036-831-718-596-178,Patent Application,yes,0,0,24,185-126-733-579-201;;099-401-588-087-767;;118-032-203-583-038;;002-574-349-353-876;;073-698-908-891-954;;123-154-852-974-035;;025-399-069-723-894;;030-412-076-759-654;;126-333-141-246-982;;059-154-747-304-698;;036-831-718-596-178;;089-601-561-319-699;;128-299-888-467-798;;054-266-582-476-284;;181-224-706-010-89X;;106-691-946-294-978;;008-535-012-454-23X;;028-292-151-505-924;;153-954-725-262-776;;049-601-711-528-154;;092-360-267-469-841;;034-447-960-177-132;;088-215-685-076-850;;043-270-686-297-822,DE;;JP;;AT;;EP;;WO;;US,24,185-126-733-579-201;;099-401-588-087-767;;118-032-203-583-038;;002-574-349-353-876;;073-698-908-891-954;;123-154-852-974-035;;025-399-069-723-894;;030-412-076-759-654;;126-333-141-246-982;;059-154-747-304-698;;036-831-718-596-178;;089-601-561-319-699;;128-299-888-467-798;;054-266-582-476-284;;181-224-706-010-89X;;106-691-946-294-978;;008-535-012-454-23X;;028-292-151-505-924;;153-954-725-262-776;;049-601-711-528-154;;092-360-267-469-841;;034-447-960-177-132;;088-215-685-076-850;;043-270-686-297-822,DE;;JP;;AT;;EP;;WO;;US,317,C12N15/1037;;C12N15/1044;;C40B40/10;;C12N15/1037;;C07K14/245;;C12N15/1044;;C40B30/04;;C40B40/10;;G01N33/554,C12N15/10;;A61K39/02;;C07H21/04;;C07K14/195;;C07K14/245;;C12N/;;C12N1/21;;C12N15/74;;C12Q1/68;;G01N33/554,,0,0,,,,DISCONTINUED
641,US,A1,US 2020/0318099 A1,002-574-349-353-876,2020-10-08,2020,US 201916710909 A,2019-12-11,US 201916710909 A;;US 201816005583 A;;US 201514821580 A;;US 201213722915 A;;US 56389709 A;;US 61275706 A;;US 92024404 A;;US 49569803 P,2003-08-18,POLYPEPTIDE DISPLAY LIBRARIES AND METHODS OF MAKING AND USING THEREOF,Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.,UNIV CALIFORNIA,DAUGHERTY PATRICK S;;BESSETTE PAUL H;;RICE JEFFREY,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2004-11-02),https://lens.org/002-574-349-353-876,Patent Application,yes,0,0,24,185-126-733-579-201;;099-401-588-087-767;;118-032-203-583-038;;002-574-349-353-876;;073-698-908-891-954;;123-154-852-974-035;;025-399-069-723-894;;030-412-076-759-654;;126-333-141-246-982;;059-154-747-304-698;;036-831-718-596-178;;089-601-561-319-699;;128-299-888-467-798;;054-266-582-476-284;;181-224-706-010-89X;;106-691-946-294-978;;008-535-012-454-23X;;028-292-151-505-924;;153-954-725-262-776;;049-601-711-528-154;;092-360-267-469-841;;034-447-960-177-132;;088-215-685-076-850;;043-270-686-297-822,DE;;JP;;AT;;EP;;WO;;US,24,185-126-733-579-201;;099-401-588-087-767;;118-032-203-583-038;;002-574-349-353-876;;073-698-908-891-954;;123-154-852-974-035;;025-399-069-723-894;;030-412-076-759-654;;126-333-141-246-982;;059-154-747-304-698;;036-831-718-596-178;;089-601-561-319-699;;128-299-888-467-798;;054-266-582-476-284;;181-224-706-010-89X;;106-691-946-294-978;;008-535-012-454-23X;;028-292-151-505-924;;153-954-725-262-776;;049-601-711-528-154;;092-360-267-469-841;;034-447-960-177-132;;088-215-685-076-850;;043-270-686-297-822,DE;;JP;;AT;;EP;;WO;;US,317,C12N15/1037;;C12N15/1044;;C40B40/10;;C12N15/1037;;C07K14/245;;C12N15/1044;;C40B30/04;;C40B40/10;;G01N33/554,C12N15/10;;A61K39/02;;C07H21/04;;C07K14/195;;C07K14/245;;C12N/;;C12N1/21;;C12N15/74;;C12Q1/68;;G01N33/554,,0,0,,,,EXPIRED
642,US,A1,US 2022/0405848 A1,151-676-664-844-034,2022-12-22,2022,US 202217835306 A,2022-06-08,US 202217835306 A;;US 202163209516 P,2021-06-11,METHOD FOR CREATING AND MAINTAINING A MULTI-ASSET RISK ADVERSE EXPENDITURE TARGETED INFLATION HEDGING INVESTMENT VEHICLE,"A method of creating and maintain an investment vehicle by identifying an expenditure target of an investor, determining expenditure target factors, creating an inflationary hedging sleeve including a plurality of equities that have correlate with particular expenditure target factors of the expenditure target, selecting a plurality of groups of securities including equities, fixed income assets, and commodities, determining an asset allocation balance function for investment funding allocation by determining a predetermined portion of subsequent future investment funds to be allocated into each group of securities, selecting an investment vehicle to house the inflationary hedging sleeve plurality of equities and the selected groups of securities with the asset allocation balance function, and naming the selected investment vehicle based on a description of the expenditure target.",LIFEGOAL INVEST LLC,SOHNS BRETT R;;SOHNS TAYLOR P,,https://lens.org/151-676-664-844-034,Patent Application,yes,0,0,1,151-676-664-844-034,US,1,151-676-664-844-034,US,0,G06Q40/06;;G06Q40/04;;G06Q40/06;;G06Q40/04,G06Q40/06;;G06Q40/04,,0,0,,,,DISCONTINUED
643,WO,A1,WO 2021/140110 A1,173-452-266-945-046,2021-07-15,2021,EP 2021050107 W,2021-01-06,EP 2020050528 W,2020-01-10,METHODS OF PRODUCING LACTIC ACID FROM UNMODIFIED STARCH,"The technology provided herein relates to novel methods for producing lactic acid (L-lactic acid, D-lactic acid and D/L-Lactic acid) from starch containing material with extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures, and microbial compositions. The novel methods are in particular suitable for the production of lactic acid from any carbon source, not limited to but especially useful for unmodified starch and/or starch-containing material.",BLUCON BIOTECH GMBH,SVETLICHNAYA TATIANA;;SVETLICHNY VITALY;;KRÄMER MARCO,,https://lens.org/173-452-266-945-046,Patent Application,yes,5,0,5,162-534-289-705-272;;173-452-266-945-046;;135-383-837-596-106;;099-194-556-971-380;;018-410-155-999-177,EP;;CN;;WO;;US,5,162-534-289-705-272;;173-452-266-945-046;;018-410-155-999-177;;099-194-556-971-380;;135-383-837-596-106,CN;;EP;;WO;;US,0,C12N1/22;;C12N1/205;;C12P7/56;;C12R2001/01;;Y02E50/10;;C12P7/56;;C12N1/205;;C12R2001/01,C12N1/22;;C12P7/56;;C12R1/01,,23,18,040-567-353-682-157;;020-598-308-998-773;;083-500-840-960-891;;042-289-974-588-628;;018-020-465-357-555;;018-020-465-357-555;;070-955-528-210-032;;100-275-023-475-753;;087-421-467-604-53X;;001-103-396-696-25X;;097-067-577-395-277;;046-476-956-410-577;;158-430-265-645-649;;006-719-136-734-034;;093-619-101-976-938;;074-488-197-260-232;;014-462-529-725-525;;019-979-499-270-526,10.1007/s002030050196;;10.1201/b19872-10;;17576217;;10.1111/j.1472-765x.2007.02137.x;;10.1016/s1389-1723(04)70230-3;;16233654;;10.1016/j.procbio.2004.01.045;;10.1016/j.procbio.2004.01.045;;10.1128/aem.72.1.269-275.2006;;16391053;;pmc1352207;;17884326;;10.1016/j.biotechadv.2007.07.004;;30388577;;10.1016/j.biortech.2018.10.043;;25937690;;pmc4409858;;10.1002/jctb.4627;;10.1002/1521-4095(200012)12:23<1841::aid-adma1841>3.0.co;2-e;;10.1111/j.1574-6976.1995.tb00168.x;;10.1016/j.ijhydene.2010.05.063;;10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1128/aem.53.4.832-838.1987;;16347327;;pmc203765;;18587891;;10.1002/bit.260331118;;pmc168907;;12824352;;10.1093/nar/gkg500;;10.1093/bioinformatics/17.12.1244;;11751241,"ZUZANA MLADENOVSKA ET AL: ""Isolation and characterization of Caldicellulosiruptor lactoaceticus sp. nov., an extremely thermophilic, cellulolytic, anaerobic bacterium"", ARCHIVES OF MICROBIOLOGY, vol. 163, no. 3, 1 March 1995 (1995-03-01), Berlin/Heidelberg, pages 223 - 230, XP055686487, ISSN: 0302-8933, DOI: 10.1007/BF00305357;;KARMAKAR R.BAN D.GHOSH: ""Comparative study of native and modified starches isolated from conventional and nonconventional sources"", INTERNATIONAL FOOD RESEARCH JOURNAL, vol. 21, no. 2, 2014, pages 597 - 602;;BHANWAR, S.GANGULI, A.: ""Amylase and galactosidase production on potato starch waste by Lactococcus lactis subsp. lactic isolated from pickled yam"", JOURNAL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, vol. 73, 2014, pages 324 - 330;;PANDA H.RAY R.: ""Biochemistry & Biotechnology"", 2016, CRC PRESS, article ""Amylolytic Lactic Acid Bacteria Microbiology and Technological Interventions in Food Fermentations. In book: Fermented foods"";;JOHN, R.P.NAMPOOTHIRI, M.K.PANDEY, A.: ""Polyurethane foam as an inert carrier for the production of L(+) lactic acid by Lactobacillus casei under solid state fermentation"", LETTER IN APPLIED MICROBIOLOGY, vol. 44, 2007, pages 582 - 587;;NARITA, J.NAKAHARA, S.FUKUDA, H.KONDO, A.: ""Efficient production of L-(+)-lactic acid from raw starch by Streptococcus bovis 148"", JOURNAL OF BIOSCIENCE BIOENGINEERING, vol. 97, 2004, pages 423 - 425, XP002507572;;NAVEENA, B.J.ALTAF, MD.BHADRAYYA, K.MADHAVENDRA, S.S.REDDY, G.: ""Production of L(+) lactic acid by Lactobacillus amylophilus GV6 in semi-solid state fermentation using wheat bran"", FOOD TECHNOLOGY AND BIOTECHNOLOGY, vol. 42, 2004, pages 147 - 152;;NAVEENA, B.J.ALTAF, MD.BHADRAYYA, K.MADHAVENDRA, S.S.REDDY, G.: ""Direct fermentation of starch to L (+) lactic acid in SSF by Lactobacillus amylophilus GV6 using wheat bran as support and substrate medium optimization using RSM"", PROCESS BIOCHEMISTRY, vol. 40, 2005, pages 681 - 690, XP025306477, DOI: 10.1016/j.procbio.2004.01.045;;NARITA, J.OKANO, K.KITAO, T.ISHIDA, S.: ""Display of alpha-amylase on the surface of Lactobacillus casei cells by use of the PgsA anchor protein, and production of lactic acid from starch"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 72, 2006, pages 269 - 275, XP055312989, DOI: 10.1128/AEM.72.1.269-275.2006;;REDDY, G.MD. ALTAFNAVEENA, B.J.VENKATESHWAR, M.VIJAY, K.E.: ""Amylolytic bacterial lactic acid fermentation: A review"", BIOTECHNOLOGY ADVANCES, vol. 26, 2008, pages 22 - 34, XP022360243, DOI: 10.1016/j.biotechadv.2007.07.004;;WANG Y.CAI W.LUO J.QI B.WAN Y.: ""One step open fermentation for lactic acid production from inedible starchy biomass by thermophilic Bacillus coagulans IPE22"", BIORESOURCE TECHNOLOGY, vol. 272, 2019, pages 398 - 406;;SMERILLI M.NEUREITER, M.WURZ, STHAAS, C.FRUHAUF, S.FUCHS W.: ""Direct fermentation of potato starch and potato residues to lactic acid by Geobacillus stearothermophilus under non-sterile conditions"", CHEM TECHNOL BIOTECHNOL., vol. 90, 2014, pages 648 - 657;;DRUMRIGHT R.E.GRUBER PRHENTON DE: ""Polylactic acid technology"", ADV MATER, vol. 12, 2000, pages 1841 - 1846, XP000977276, DOI: 10.1002/1521-4095(200012)12:23<1841::AID-ADMA1841>3.3.CO;2-5;;NARAYANAN N.ROYCHOUDHURY P.SRIVASTAVA A.: ""L(+) Lactic acid fermentation and its product polymerization"", ELECTRON J BIOTECHNOL, vol. 7, 2004, pages 167 - 179;;DATTA RTSAI S.BONSIGNORE P.MOON S.FRANK J.: ""Technological and economic potential of poly(lactic acid) and lactic acid derivatives"", FEMS MICROBIOL REV, vol. 16, 1995, pages 221 - 231, XP002372479;;VAIDYAA.PANDEY RMUDLIAR S.SURESH KUMAR M.CHAKRABARTI T.DEVOTTA S.: ""Production and recovery of lactic acid for polylactide-an overview"", CRIT REV ENVIRON SCI TECHNOL, vol. 35, 2005, pages 429 - 467;;MARS A.VEUSKEMS T.BUDDE M.VON DOEVEREN P.LIPIS STBAKKER RDE VRIJECLAASEN P.: ""Biohydrogen production from untreated and hydrolyzed potato steam peels by the extreme thermophiles Caldicellulosiruptor saccharolyticus and Thermotoga neapolitana"", INTERNATIONAL JOURNAL OF HYDROGEN ENERGY, vol. 35, 2010, pages 7730 - 7737;;RAINEY FADONNISON AMJANSSEN PHSAUL DRODRIGO ABERGQUIST PLDANIEL RMSTACKEBRANDT EMORGAN HW: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: an obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOL LETT, vol. 120, 1994, pages 263 - 266, XP023916519, DOI: 10.1111/j.1574-6968.1994.tb07043.x;;SISSONS CHSHARROCK KRDANIEL RMMORGAN HW: ""Isolation of cellulolytic anaerobic extreme thermophiles from New Zealand thermal sites"", APPL ENVIRON MICROBIOL, vol. 53, 1987, pages 832 - 838;;DONNISON AMBROCKELSBY CMMORGAN HWDANIEL RM: ""The degradation of lignocellulosics by extremely thermophilic microorganisms"", BIOTECHNOL BIOENG, vol. 33, 1989, pages 1495 - 1499;;HUNGATE RE: ""Methods in Microbiology"", 1969, ACADEMIC PRESS, article ""A roll tube method for cultivation of strict anaerobes"", pages: 118 - 132;;CHENNA RSUGAWARA HKOIKE TLOPEZ RGIBSON TJHIGGINS DGTHOMPSON JD: ""Multiple sequence alignment with the Clustal series of programs"", NUCLEIC ACIDS RES, vol. 13, 2003, pages 3497 - 3500, XP002316493, DOI: 10.1093/nar/gkg500;;KUMAR STAMURA KJAKOBSEN IBNEI M: ""MEGA2: molecular evolutionary genetics analysis software"", BIOINFORMATICS, vol. 17, 2001, pages 1244 - 1245",PENDING
644,US,A1,US 2023/0002718 A1,076-975-535-551-27X,2023-01-05,2023,US 202017757211 A,2020-12-11,EP 19215115 A;;EP 2020085663 W,2019-12-11,AUTOMATED MEDIUM EXCHANGE STRATEGY FOR SUSPENSION CELLS,"The present invention relates to a method of changing culture medium of a suspension culture, the suspension culture comprising cells suspended in the culture medium, the method comprising: (i) transferring a fraction of the suspension culture into a container, wherein the container comprises at least one opening at the bottom; (ii) allowing the cells comprised in the fraction of the suspension to settle at the at least one opening at the bottom of the container by gravitation, thereby forming a supernatant; (iii) dispensing the cells settled at the bottom of the container (back) into the suspension culture; (iv) discarding the supernatant.",SARTORIUS STEDIM BIOTECH GMBH;;REPAIRON GMBH,HAUPT LUIS;;HUPFELD JULIA,SARTORIUS STEDIM BIOTECH GMBH (2022-05-06);;REPAIRON GMBH (2022-05-05),https://lens.org/076-975-535-551-27X,Patent Application,yes,1,0,9,076-975-535-551-27X;;017-325-812-491-945;;175-407-302-254-34X;;044-420-206-355-518;;199-765-781-503-198;;187-414-599-108-650;;024-332-599-424-477;;104-758-043-062-405;;078-652-960-432-980,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,9,017-325-812-491-945;;076-975-535-551-27X;;175-407-302-254-34X;;044-420-206-355-518;;199-765-781-503-198;;024-332-599-424-477;;187-414-599-108-650;;104-758-043-062-405;;078-652-960-432-980,KR;;JP;;AU;;EP;;CN;;WO;;US;;CA,0,C12M29/18;;C12M33/22;;C12M47/02;;C12M29/18;;C12M47/02;;C12M33/22;;C12N5/0696;;C12M27/02;;C12M29/18;;C12M33/22;;C12M47/02,C12M1/26;;C12M1/00;;C12M1/06,,0,0,,,,PENDING
645,EP,A1,EP 4458976 A1,065-695-672-388-485,2024-11-06,2024,EP 22913750 A,2022-10-28,CN 202111663496 A;;CN 2022128227 W,2021-12-31,RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) GENOME AND SINGLE-POLARITY RAAV VECTOR PACKAGED THEREBY,"Provided are a recombinant adeno-associated virus (rAAV) genome and a single-polarity rAAV (spAAV) vector formedby packaging same. Specifically, provided is an spAAV genome before packaging, two ends of which are both linear open terminuses,wherein one end does not have an inverted terminal repeat (ITR) or a part thereof, and the other end has a truncated ITR (ITRT), andthe ITRT does not form a T-shaped hairpin palindromic structure. The spAAV genome is a single-polarity single-stranded DNA. Alsoprovided are an spAAV vector, a method for delivering an exogenous nucleic acid to a cell by using the vector, and a use of the vectorin the preparation of a product for gene expression, gene therapy, gene editing or gene regulation.",SUZHOU GENEHEALTH BIOTECHNOLOGY CO LTD,SHAO JIAHONG;;TAN PENGCHENG;;WU XIANG;;ZHAO XIAOMING;;LU YANG;;XUN TINGJUN;;LEI ZHENZHEN,,https://lens.org/065-695-672-388-485,Patent Application,yes,0,0,5,125-136-698-370-340;;168-831-325-200-511;;048-497-578-167-236;;134-621-238-854-390;;065-695-672-388-485,JP;;CN;;EP;;WO;;US,5,125-136-698-370-340;;168-831-325-200-511;;048-497-578-167-236;;134-621-238-854-390;;065-695-672-388-485,JP;;CN;;EP;;WO;;US,18,C07K14/005;;C12N7/00;;C12N15/86;;C12N5/0601;;C12N2750/14121;;C12N2750/14122;;C12N2750/14152;;C12N2750/14143;;C12N2710/14043;;C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2710/14144;;C12N2710/14043;;C07K14/005;;C12N5/0601;;C12N7/00;;C12N15/86;;C12N2710/14043;;C12N2710/14044;;C12N2750/14121;;C12N2750/14122;;C12N2750/14143;;C12N2750/14152,C12N15/864;;A61K48/00;;C07K14/015,,0,0,,,,PENDING
646,US,A1,US 2022/0380822 A1,084-825-710-408-232,2022-12-01,2022,US 202017635178 A,2020-08-20,CN 201910782183 A;;CN 2020110232 W,2019-08-23,APPLICATION OF BRANCHED-CHAIN A-KETOACID DEHYDROGENASE COMPLEX IN PREPARATION OF MALONYL COENZYME A,"An application of a branched-chain α-ketoacid dehydrogenase complex in preparation of malonyl coenzyme A. A method for preparing malonyl-CoA using a branched-chain α-ketoacid dehydrogenase complex, the method comprising introducing a gene encoding a branched-chain α-ketoacid dehydrogenase complex into a biological cell strain to obtain a recombinant cell strain capable of expressing the gene encoding the branched-chain α-ketoacid dehydrogenase complex; culturing the recombinant cell strain to prepare malonyl-CoA; the branched-chain α-ketoacid dehydrogenase complex is the following M1) or M2): M1) a set of proteins consisting of a bkdF protein, a bkdG protein, a bkdH protein and a lpdA1 protein; M2) a set of proteins consisting of a bkdA protein, a bkdB protein, a bkdC protein and the lpdA1 protein. Experimental results show that by using the branched-chain α-ketoacid dehydrogenase complex, not only malonyl-CoA can be prepared, but also a target product using malonyl-CoA as an intermediate product can further be prepared.",INST MICROBIOLOGY CAS,LIU WEIFENG;;LIU BO;;CUI QIANQIAN;;TAO YONG,INSTITUTE OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES (2022-02-08),https://lens.org/084-825-710-408-232,Patent Application,yes,15,0,4,194-124-816-693-314;;084-825-710-408-232;;093-503-464-343-035;;074-989-618-676-224,CN;;WO;;US,4,194-124-816-693-314;;084-825-710-408-232;;093-503-464-343-035;;074-989-618-676-224,CN;;WO;;US,61,C12P19/32;;C12P7/42;;C12P13/008;;C12P7/22;;C12P7/26;;C12P7/6409;;C12N9/0008;;C12Y102/04004;;C12N9/88;;C12Y403/01019;;C12N9/1096;;C12Y206/01042;;C12Y401/01031;;C12N15/70;;C12Y102/01075;;C12N9/1029;;C12Y203/01156;;C12N9/10;;C12N15/70;;C12P7/42;;C12N9/88;;C12R2001/19;;C12Y102/01075;;C12N9/1029;;C12N1/205;;C12N9/1029;;C12N15/70;;C12P7/22;;C12P19/32;;C12Y102/01075,C12P19/32;;C12N1/20;;C12N9/10;;C12N15/70;;C12P7/22,,7,1,015-538-749-272-673,15245907;;10.1016/j.tibtech.2004.04.006,"Cui Q, et al. Avermectin biosynthesis: stable functional expression of branched chain α-keto acid dehydrogenase complex from Streptomyces avermitilis in Escherichia coli by selectively regulating individual subunit gene expression. Biotechnol Lett. 2017 Oct;39(10):1567-1574. (Year: 2017).;;Cui Q, Zhou F, Liu W, Tao Y. Avermectin biosynthesis: stable functional expression of branched chain α-keto acid dehydrogenase complex from Streptomyces avermitilis in Escherichia coli by selectively regulating individual subunit gene expression. Biotechnol Lett. 2017 Oct;39(10):1567-1574. (Year: 2017);;Gupta S. Project Report: Codon Optimization. Computational Bioscience, Arizona State University. May 5, 2003. (Year: 2003);;Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004 Jul;22(7):346-53. doi: 10.1016/j.tibtech.2004.04.006. PMID: 15245907. (Year: 2004);;Wen T, et al. CN-106148259 English Translation. November 23, 2016. Obtained from Google Patents. (Year: 2016);;CN-104404058-A, Wang G. March 11, 2015. English translation obtained from Google Patents. (Year: 2015);;CN-102618509-A, Wang G. August 1, 2012. English translation obtained from Google Patents. (Year: 2012)",PENDING
647,US,A1,US 2022/0220190 A1,018-686-674-939-069,2022-07-14,2022,US 202017606699 A,2020-02-24,CN 201910388775 A;;CN 2020076337 W,2019-05-10,"A YEAST-FERMENTED RECOMBINANT FIBRONECTIN PEPTIDE IN SMALL MOLECULE, AND ITS PREPARATION METHOD AND APPLICATIONS THEREOF","The invention discloses a yeast-fermented recombinant fibronectin peptide in small molecule, comprising at least one β subunit binding domain of sodium-potassium ATPase, wherein the amino acid sequence of the β subunit binding domain of sodium-potassium ATPase is shown in SEQ ID NO: 2. The invention also discloses a preparation method for the yeast-fermented recombinant fibronectin peptide in small molecule and applications of the yeast-fermented recombinant fibronectin peptide in small molecule. The yeast-fermented recombinant fibronectin peptide in small molecule of the present invention can be effectively absorbed by a skin, and has excellent healing and repairing effects on traumatic skin lesions or subcutaneous lesions with intact keratin.",MELLGEN SHENZHEN BIOTECHNOLOGY CO LTD,RUAN RENQUAN;;WEN LONGPING,MELLGEN (SHENZHEN) BIOTECHNOLOGY CO. LTD (2021-10-19),https://lens.org/018-686-674-939-069,Patent Application,yes,0,3,5,016-578-946-665-778;;123-044-848-771-641;;115-148-097-108-668;;018-686-674-939-069;;052-458-343-719-422,CN;;WO;;US,5,115-148-097-108-668;;123-044-848-771-641;;016-578-946-665-778;;018-686-674-939-069;;052-458-343-719-422,CN;;WO;;US,7,C07K14/78;;C12N15/815;;A61K8/64;;A61Q19/00;;A61P17/00;;A61K2800/85;;A61K38/00;;A61K8/64;;A61K38/00;;A61K2800/85;;A61Q19/00;;C07K14/78;;C12N15/815;;C07K2319/01;;C07K2319/70;;C12N9/14;;C07K2319/00;;C12R2001/84;;C12N9/00;;A61K8/64;;A61K9/0014;;A61K38/00;;A61K2800/85;;A61Q19/00;;C07K14/39;;C07K14/78;;C12N9/00;;C12N15/815;;A61K38/39;;A61K38/46;;C07K2319/00,C07K14/78;;A61K8/64;;A61K9/00;;A61Q19/00;;C07K14/39;;C12N9/00;;C12N15/81,,0,0,,,,ACTIVE
648,US,A1,US 2025/0290077 A1,005-399-137-941-872,2025-09-18,2025,US 202519053350 A,2025-02-13,CN 202410298113 A,2024-03-15,USE OF ANTISENSE OLIGONUCLEOTIDE IN PREPARATION OF DRUG FOR TREATING DISEASE CAUSED BY ABNORMAL THYROID,"The present disclosure relates to the field of gene therapies of thyroid-associated ophthalmopathy (TAO) and, in particular, to a use of an antisense oligonucleotide in preparation of a drug for treating a disease caused by an abnormal thyroid. Experimental results of the present application indicate that an antisense oligonucleotide S-ASODN-1 with a particular sequence targeting an insulin-like growth factor 1 receptor (IGF-1R) can effectively reduce concentrations of the IGF-1R and an anti-thyroid peroxidase antibody (TPO-Ab), thereby improving a level of thyroid-stimulating hormone (TSH) for treating thyroid-associated ophthalmopathy.",HANGZHOU TIANLONG PHARMACEUTICAL CO LTD,SONG GENGSHEN;;ZHOU YUTING,,https://lens.org/005-399-137-941-872,Patent Application,yes,0,0,3,092-833-231-874-447;;081-868-100-955-053;;005-399-137-941-872,CN;;US,3,092-833-231-874-447;;081-868-100-955-053;;005-399-137-941-872,CN;;US,0,A61K31/7088;;A61K45/06;;A61P43/00;;A61P27/02;;C12N15/1138;;C12N2310/11;;C12N2310/315;;A61K45/06;;A61K31/519;;A61K31/5377;;A61K31/52;;A61P5/14;;A61P5/10;;A61P5/08;;A61K9/0019;;A61K45/06;;C12N15/1138;;C12N2310/11;;C12N2310/14;;C12N2310/321;;C12N2310/3231,C12N15/113;;A61K9/00;;A61K45/06;;A61P5/08,,0,0,,,,PENDING
649,US,A1,US 2021/0222202 A1,161-666-424-707-202,2021-07-22,2021,US 201816644953 A,2018-12-03,CN 201811274680 A;;CN 2018118887 W,2018-10-30,USE OF GENOMIC NW_006880285.1 IN CHO CELL FOR STABLY EXPRESSING A PROTEIN,"Use of genomic NW_006880285.1 in CHO cell for stably expressing a protein is disclosed. The certain site in CHO cell genome for stably expressing a protein is positioned at a base of No. 1235357 in a CHO cell gene NW_006880285.1; a sequence of 5′ NNNNNNNNNNNNNNNNNNNNNGG3′ that can be identified by CRISPR/Cas9 technology and positioned in a base range of No. 1235284-1235429 around the certain site is a target sequence. Various of protein genes are introduced into a fixed site in CHO cell genome, and expressed stably in the present disclosure.",UNIV JIANGNAN,JIN JIAN;;LI HUAZHONG;;ZHOU SONGTAO;;CHEN YUN;;DUAN ZUOYING;;GONG XIAOHAI,JIANGNAN UNIVERSITY (2020-01-14),https://lens.org/161-666-424-707-202,Patent Application,yes,1,0,5,174-286-643-437-318;;153-890-325-374-613;;001-197-164-568-515;;116-306-096-073-536;;161-666-424-707-202,CN;;WO;;US,5,174-286-643-437-318;;001-197-164-568-515;;153-890-325-374-613;;116-306-096-073-536;;161-666-424-707-202,CN;;WO;;US,14,C12N15/85;;C12N5/0682;;C12N15/66;;C12N2510/02;;C12N15/907;;C12N2310/20;;C12N15/907;;C12N15/66;;C12N2310/20;;C12N2510/02;;C12N2800/80,C12N15/90;;C12N15/66,,0,0,,,,ACTIVE
650,WO,A1,WO 2022/123030 A1,198-762-926-933-704,2022-06-16,2022,EP 2021085238 W,2021-12-10,GB 202019454 A,2020-12-10,METHOD FOR PURIFYING VIRUS,"The invention relates to a method for purifying an adenovirus comprising (a) providing a liquid sample comprising adenovirus, (b) clarifying said sample by depth filtration, (c) performing anion exchange chromatography comprising the steps of (i) directly applying the clarified sample of (b) to an anion exchange column, (ii) eluting adenovirus from the anion exchange column to provide an eluate. The invention also relates to adenovirus produced from said methods, and to compositions comprising same.",THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD;;UNIV OXFORD INNOVATION LTD,DOUGLAS ALEXANDER;;JOE CARINA CITRA DEWI,,https://lens.org/198-762-926-933-704,Patent Application,yes,5,1,4,000-133-330-576-635;;198-762-926-933-704;;098-662-724-022-28X;;158-632-818-876-056,EP;;WO;;US;;GB,4,000-133-330-576-635;;198-762-926-933-704;;098-662-724-022-28X;;158-632-818-876-056,EP;;WO;;US;;GB,0,C12N7/00;;C12N2710/10351;;C12N7/02;;A61K39/235;;A61K2039/5256;;B01D15/363;;B01D61/58;;C12N9/16;;C12N2710/10331;;C12N2710/10351;;C12Y301/30002,C12N7/00,,19,17,045-630-992-171-880;;028-854-847-545-66X;;042-985-737-076-062;;055-768-751-939-873;;073-997-477-271-330;;045-630-992-171-880;;005-648-329-379-436;;071-660-255-682-71X;;028-854-847-545-66X;;095-771-313-162-070;;090-871-425-457-021;;045-630-992-171-880;;028-854-847-545-66X;;076-080-292-742-321;;009-504-526-767-625;;045-630-992-171-880;;004-980-520-789-845,31047679;;10.1016/j.vaccine.2019.04.056;;pmc6949866;;pmc8436420;;10.1038/s41586-020-2608-y;;pmc7241103;;32731258;;32511340;;10.1101/2020.05.13.093195;;10.1089/hum.2014.007;;24593243;;10.1016/j.jcyt.2017.02.192;;34585736;;10.1002/bit.27945;;pmc8653296;;31047679;;10.1016/j.vaccine.2019.04.056;;pmc6949866;;10.1126/scitranslmed.3002925;;pmc3627206;;22218691;;pmc3396660;;22808149;;10.1371/journal.pone.0040385;;pmc8436420;;10.1038/s41586-020-2608-y;;pmc7241103;;32731258;;32511340;;10.1101/2020.05.13.093195;;29527232;;pmc5842362;;10.2217/fvl-2016-0070;;14978761;;10.1002/jgm.503;;31047679;;10.1016/j.vaccine.2019.04.056;;pmc6949866;;pmc8436420;;10.1038/s41586-020-2608-y;;pmc7241103;;32731258;;32511340;;10.1101/2020.05.13.093195;;10.1016/j.imlet.2019.03.008;;31026485;;pmc7132387;;26576856;;pmc4649739;;10.1038/srep16756;;31047679;;10.1016/j.vaccine.2019.04.056;;pmc6949866;;25165010;;10.1016/j.jpba.2014.07.037,"N.N.: ""Assessment report: Zabdeno"", 28 May 2020 (2020-05-28), pages 1 - 144, XP055835397, Retrieved from the Internet <URL:https://file.wuxuwang.com/ema/zabdeno-epar-public-assessment-report_en.pdf> [retrieved on 20210826];;FEDOSYUK SOFIYA ET AL: ""Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components"", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 37, no. 47, 30 April 2019 (2019-04-30), pages 6951 - 6961, XP085880218, ISSN: 0264-410X, [retrieved on 20190430], DOI: 10.1016/J.VACCINE.2019.04.056;;VAN DOREMALEN NEELTJE ET AL: ""ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques"", NATURE, vol. 586, no. 7830, 30 July 2020 (2020-07-30), pages 578 - 582, XP037340247, ISSN: 0028-0836, DOI: 10.1038/S41586-020-2608-Y;;JORT VELLINGA ET AL: ""Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment"", HUMAN GENE THERAPY, vol. 25, no. 4, 1 April 2014 (2014-04-01), GB, pages 318 - 327, XP055552022, ISSN: 1043-0342, DOI: 10.1089/hum.2014.007;;MALLORY H A ET AL: ""INDUSTRIALIZATION OF ADENOVIRUS PRODUCTION AND PURIFICATION WITH THE ICELLIS 500 SINGLE-USE BIOREACTOR"", POSTER ABSTRACTS, 2017, pages 1 - 1, XP055835630, Retrieved from the Internet <URL:https://www.isct-cytotherapy.org/action/showPdf?pii=S1465-3249(17)30250-5> [retrieved on 20210827];;JOE CARINA C. D. ET AL: ""Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs"", BIOTECHNOLOGY AND BIOENGINEERING, vol. 119, no. 1, 15 November 2021 (2021-11-15), Hoboken, USA, pages 48 - 58, XP055904587, ISSN: 0006-3592, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/bit.27945> DOI: 10.1002/bit.27945;;FEDOSYUK ET AL.: ""Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components"", VACCINE, vol. 37, 2019, pages 6951 - 6961, XP085880218, DOI: 10.1016/j.vaccine.2019.04.056;;COLLOCA SBARNES EFOLGORI AAMMENDOLA VCAPONE SCIRILLO A ET AL.: ""Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species"", SCI TRANSL MED, vol. 4, no. H5, 2012, pages ii5ra2;;DICKS ET AL., PLOS ONE, vol. 7, no. 7, 2012, pages e40385;;DOREMALEN ET AL., CHADOXI NCOV-19 VACCINATION PREVENTS SARS-COV-2 PNEUMONIA IN RHESUS MACAQUES, 2020;;LANCET., vol. 389, no. i0069, 2017, pages 62i - 8;;MORRIS, S. J. S., SARAHSPENCER, ALEXANDRA J.GILBERT, SARAH C.: ""Simian adenoviruses as vaccine vectors"", FUTURE VIROLOGY, vol. 11, no. 9, 2016, pages 649 - 659, XP055571430, DOI: 10.2217/fvl-2016-0070;;KAMEN, A.O. HENRY: ""Development and optimization of an adenovirus production process"", J GENE MED, 2004, pages S184 - 92, XP055027359, DOI: 10.1002/jgm.503;;FEDOSYUK ET AL., VACCINE, vol. 37, 2019, pages 6951 - 6961;;VAN DOREMALEN, N. ET AL.: ""ChAdOxi nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques"", NATURE, 2020;;PURUSHOTHAM, J.LAMBE, T.GILBERT, S. C.: ""Vaccine platforms for the prevention of Lassa fever"", IMMUNOL LETT, vol. 215, 2019, pages 1 - 11, XP085893391, DOI: 10.1016/j.imlet.2019.03.008;;DICKS, M. D. ET AL.: ""Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOxi is independent of fiber and penton RGD loop sequences in mice"", SCIREP, vol. 5, 2015, pages 16756, XP055400987, DOI: 10.1038/srep16756;;FEDOSYUK, S. ET AL.: ""Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components"", VACCINE, DOI:IO.IOI6/J.VACCINE.20I9.04.056, 2019;;ZHANG, W. ET AL.: ""Development and qualification of a high sensitivity, high throughput Q-PCR assay for quantitation of residual host cell DNA in purification process intermediate and drug substance samples"", J PHARM BIOMED ANAL, vol. 100, 2014, pages 145 - 149, XP029067080, DOI: 10.1016/j.jpba.2014.07.037",PENDING
651,US,A1,US 2024/0035002 A1,000-133-330-576-635,2024-02-01,2024,US 202118039818 A,2021-12-10,GB 202019454 A;;EP 2021085238 W,2020-12-10,METHOD FOR PURIFYING VIRUS,"The invention relates to a method for purifying an adenovirus comprising (a) providing a liquid sample comprising adenovirus, (b) clarifying said sample by depth filtration, (c) performing anion exchange chromatography comprising the steps of (i) directly applying the clarified sample of (b) to an anion exchange column, (ii) eluting adenovirus from the anion exchange column to provide an eluate. The invention also relates to adenovirus produced from said methods, and to compositions comprising same.",UNIV OXFORD INNOVATION LTD,DOUGLAS ALEXANDER;;JOE CARINA CITRA DEWI,OXFORD UNIVERSITY INNOVATION LIMITED (2023-10-27),https://lens.org/000-133-330-576-635,Patent Application,yes,0,0,4,000-133-330-576-635;;198-762-926-933-704;;098-662-724-022-28X;;158-632-818-876-056,EP;;WO;;US;;GB,4,000-133-330-576-635;;198-762-926-933-704;;098-662-724-022-28X;;158-632-818-876-056,EP;;WO;;US;;GB,0,C12N7/00;;C12N2710/10351;;C12N7/02;;A61K39/235;;A61K2039/5256;;B01D15/363;;B01D61/58;;C12N9/16;;C12N2710/10331;;C12N2710/10351;;C12Y301/30002,C12N7/02;;A61K39/235;;B01D15/36;;B01D61/58;;C12N9/16,,0,0,,,,PENDING
652,US,A1,US 2023/0346912 A1,042-983-217-680-275,2023-11-02,2023,US 202318305735 A,2023-04-24,CN 202210449829 A,2022-04-27,RESTRICTIVE EPITOPE PEPTIDE OF MAJOR HISTOCOMPATIBILITY COMPLEX B2 OF H9N2 SUBTYPE AVIAN INFLUENZA VIRUS AND APPLICATION THEREOF,"Disclosed are a restrictive epitope peptide of a major histocompatibility complex (MHC) B2 of an H9N2 subtype Avian influenza virus (AIV) and an application thereof, and relate to the technical field of genetic engineering. The restrictive epitope peptide has an amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID No.4.",UNIV SOUTH CHINA AGRICULT,LIAO MING;;DAI MANMAN;;JIA YUSHENG,SOUTH CHINA AGRICULTURAL UNIVERSITY (2023-04-23),https://lens.org/042-983-217-680-275,Patent Application,yes,0,1,3,042-983-217-680-275;;152-290-051-893-698;;015-130-282-369-391,CN;;US,3,042-983-217-680-275;;152-290-051-893-698;;015-130-282-369-391,CN;;US,0,C07K7/06;;A61K39/12;;A61K2039/552;;A61P31/16;;C12N2760/16134;;A61P31/16;;A61K39/12;;A61K2039/552;;A61K2039/572;;C07K14/005;;C12N2760/16134;;Y02A50/30;;A61K39/145;;A61P31/16;;C07K14/005,A61K39/145;;A61P31/16;;C07K14/005,,0,0,,,,DISCONTINUED
653,US,A1,US 2022/0042040 A1,188-343-422-799-514,2022-02-10,2022,US 201917276472 A,2019-09-13,EP 18194719 A;;EP 2019074485 W,2018-09-17,DUAL VECTOR SYSTEM FOR IMPROVED PRODUCTION OF PROTEINS IN ANIMAL CELLS,"The present invention refers to a dual vector system for production of one or more recombinant proteins in cells of insect origin comprising a first viral vector comprising a T7 promoter operably linked to a targeting sequence comprising a non-coding sequence and which expression can suppress one or more proteins essential for virus production, followed by a T7 termination sequence, and a second viral vector comprising a promoter operably linked to a T7 RNA polymerase encoding sequence, and at least one gene sequence located on the first and/or second vector encoding one or more recombinant proteins of interest. The invention further refers to recombinant insect cells comprising the dual vector system and methods for producing recombinant proteins using said dual vector CA system.",UNIV WIEN BODENKULTUR;;ACIB GMBH,GRABHERR REINGARD;;ERNST WOLFGANG;;KOCZKA KRISZTINA;;KLAUSBERGER MIRIAM,ACIB GMBH (2021-02-05);;UNIVERSITÄT FÜR BODENKULTUR WIEN (2021-02-08),https://lens.org/188-343-422-799-514,Patent Application,yes,0,3,3,126-287-986-619-088;;188-343-422-799-514;;073-075-352-055-684,EP;;WO;;US,3,126-287-986-619-088;;188-343-422-799-514;;073-075-352-055-684,EP;;WO;;US,31,C12N15/86;;C12N2710/14121;;C12N2710/14143;;C12N15/86;;C12N2710/14121;;C12N2710/14143,C12N15/86,,2,2,012-607-676-695-487;;084-408-700-070-47X,10.1038/nbt0395-261;;9634768;;18543127;;10.1007/s12033-008-9075-2,"Poelwijk, F. V., Broer, R., Belsham, G. J., Oudshoorn, P., Vlak, J. M., & Goldbach, R. W. (1995). A hybrid baculovirus-bacteriophage T7 transient expression system. Bio/Technology, 13(3), 261-264. (Year: 1995);;Yao, X., Han, Q., Song, J., Liang, C., Wakita, T., Yang, R., & Chen, X. (2008). Baculovirus mediated production of infectious hepatitis C virus in human hepatoma cells stably expressing T7 RNA polymerase. Molecular biotechnology, 40, 186-194. (Year: 2008)",DISCONTINUED
654,US,A1,US 2021/0283089 A1,075-953-910-262-872,2021-09-16,2021,US 202117335202 A,2021-06-01,CN 201811480562 A;;CN 2019092233 W,2018-12-05,Use of fumaric acid esters and pharmaceutically acceptable salts thereof in preparing pharmaceuticals for treating ferroptosis-related diseases,"Related is use of fumaric acid esters or pharmaceutically acceptable salts thereof in preparing a pharmaceutical for treating ferroptosis-related diseases. The fumaric acid esters includes dimethyl fumarate and/or monomethyl fumarate. The present application reveals, for the first time, the effect of fumaric acid ester and its pharmaceutically acceptable salt on a protein level of a ferroptosis key regulatory gene GPX4, provides a theoretical basis for the research of treatment strategies for the ferroptosis-related diseases, and provides a new outlet for preparing pharmaceuticals used for the ferroptosis-related diseases.",XIANGYA HOSPITAL CENTRAL SOUTH UNIV,CHEN YONGHENG;;LIU TING;;ZHANG YE;;ZHAO SHUANG;;CHEN ZHUCHU,XIANGYA HOSPITAL CENTRAL SOUTH UNIVERSITY (2022-06-14),https://lens.org/075-953-910-262-872,Patent Application,yes,3,2,3,000-304-321-510-320;;075-953-910-262-872;;108-709-650-800-734,CN;;WO;;US,3,000-304-321-510-320;;075-953-910-262-872;;108-709-650-800-734,CN;;WO;;US,0,A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P35/00;;A61K31/225;;A61P1/16;;A61K31/225;;A61P1/16;;A61K9/0019;;A61K31/225,A61K31/225;;A61K9/00;;A61P1/16,,7,6,009-870-076-729-794;;011-789-065-924-010;;023-731-297-171-111;;050-511-030-949-670;;014-390-117-765-950;;126-060-012-845-777,pmc5504366;;10.3748/wjg.v23.i25.4508;;28740339;;pmc4711674;;25435072;;10.1038/cmi.2014.114;;10.3389/fimmu.2016.00278;;pmc4956641;;27499754;;10.4254/wjh.v7.i3.607;;25848485;;pmc4381184;;10.1016/j.cbi.2019.01.029;;30703375;;10.1016/j.biopha.2018.06.060;;29957462,"Takasu C, Vaziri ND, Li S, Robles L, Vo K, Takasu M, Pham C, Farzaneh SH, Shimada M, Stamos MJ, Ichii H. Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury. World J Gastroenterol. 2017 Jul 7;23(25):4508-4516 (Year: 2017) (Year: 2017);;Vego, H., Sand, K., Høglund, R. et al. Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immunol 13, 57–64 (2016) (Year: 2016) (Year: 2016);;Al-Jaderi Z, Maghazachi AA. Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases. Front Immunol. 2016 Jul 22; 7:278 (Year: 2016) (Year: 2016);;CN-107088190-A - machine translation (Year: 2024);;Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J Hepatol. 2015 Mar 27;7(3):607-15 (Year: 2015);;Mohamed E. Mostafa, Ahmed A. Shaaban, Hatem A. Salem, Dimethylfumarate ameliorates hepatic injury and fibrosis induced by carbon tetrachloride, Chemico-Biological Interactions, Volume 302, 2019, Pages 53-60, ISSN 0009-2797 (Year: 2019);;Miao Sui, Xiaofei Jiang, Jun Chen, Haiyan Yang, Yan Zhu, Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway, Biomedicine & Pharmacotherapy, Volume 106, 2018, Pages 125-133 (Year: 2018)",DISCONTINUED
655,US,A1,US 2024/0279662 A1,185-720-462-528-075,2024-08-22,2024,US 202418426681 A,2024-01-30,CN 202310137487 A,2023-02-17,"A shRNA, its recombinant expression vector, transformant, anti-heart failure drug, preparation method, and use as drug thereof","The present invention relates to a shRNA, its recombinant expression vector, transformant, anti-heart failure drug, preparation method, and use as drug thereof, belonging to a field of biomedicine. The present invention provides a shRNA whose DNA sequence is selected from a group consisting of SEQ ID NO. 1, SEQ ID NO. 3, and SEQ ID NO. 5. The present invention also provides a recombinant expression vector, transformant, anti-heart failure drug and its use as drug based on the shRNA, and provides a method for preparing the anti-heart failure drug. It's confirmed by animal experiments that the anti-heart failure drug provided by the present invention can significantly improve heart function of heart failure animals and play an effective anti-heart failure role.",TONGIL HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIV OF SCIENCE AND TECHNOLOGY,WANG DAOWEN;;LI HUAPING;;CHEN CHEN;;XIE RONG,TONGJI HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (2024-01-08),https://lens.org/185-720-462-528-075,Patent Application,yes,0,0,3,185-720-462-528-075;;143-498-853-971-666;;140-844-737-119-951,CN;;US,3,185-720-462-528-075;;143-498-853-971-666;;140-844-737-119-951,CN;;US,0,Y02A50/30;;C12N15/1136;;C12N15/86;;C12N15/113;;C12N15/1136;;C12N15/86;;C12N2310/531;;C12N2750/14143;;C12N2830/008,C12N15/113;;C12N15/86,,0,0,,,,PENDING
656,US,A1,US 2023/0279456 A1,198-929-042-671-931,2023-09-07,2023,US 202218061585 A,2022-12-05,CN 202110447082 A;;CN 2022087318 W,2021-04-25,Genetically Engineered Bacteria Producing Lacto-N-neotetraose and Production Method Thereof,"The disclosure discloses genetically engineered bacteria producing lacto-N-neotetraose and a production method thereof, and belongs to the fields of metabolic engineering and food biotechnology. To solve the problem of low yield of lacto-N-neotetraose produced by a microbial method in the prior art, through exogenous expression of lgtA and lgtB, reasonable combination and regulation of overexpression of lacY, pgm, galE, galT and galK in a lacto-N-neotetraose synthesis pathway, knockout of lacZ expression in an Escherichia coli host, and optimization of a carbon source in the culture process, the disclosure achieves the objectives of regulating the carbon flux of a metabolic pathway and improving the yield of lacto-N-neotetraose. In a shake flask experiment, the yield of lacto-N-neotetraose produced by E. coli increased from 304 mg/L to 1031 mg/L, laying a foundation for industrial production of the lacto-N-neotetraose.",UNIV JIANGNAN,ZHANG TAO;;JIANG BO;;HU MIAOMIAO;;LI MENGLI,JIANGNAN UNIVERSITY (2022-11-17),https://lens.org/198-929-042-671-931,Patent Application,yes,0,0,4,076-812-510-120-08X;;000-784-942-608-289;;095-123-833-926-876;;198-929-042-671-931,CN;;WO;;US,4,076-812-510-120-08X;;095-123-833-926-876;;000-784-942-608-289;;198-929-042-671-931,CN;;WO;;US,0,C12N9/2471;;C12N9/1051;;C12N9/1205;;C12N9/1241;;C12N9/90;;C12N15/52;;C12N15/70;;C12P19/26;;C12Y204/01038;;C12Y204/01222;;C12Y207/01006;;C12Y207/0701;;C12Y302/01023;;C12Y501/03002;;C12Y504/02002;;C12N9/2471;;C12N9/1051;;C12N9/1205;;C12N9/1241;;C12N9/2402;;C12N9/90;;C12N15/70;;C12P19/02;;C12P19/04;;C12P19/18;;C12P19/24;;C12P19/26;;C12Y204/01038;;C12Y204/01222;;C12Y207/01006;;C12Y207/07012;;C12Y501/03002;;C12Y504/02002;;C12P19/26;;C12N9/1051;;C12N9/1205;;C12N9/1241;;C12N9/2471;;C12N9/90;;C12N15/70;;C12Y204/01038;;C12Y204/01222;;C12Y207/01006;;C12Y207/07012;;C12Y501/03002;;C12Y504/02002,C12P19/26;;C12N9/10;;C12N9/12;;C12N9/38;;C12N9/90;;C12N15/70,,0,0,,,,PENDING
657,US,A1,US 2025/0059278 A1,173-295-306-216-707,2025-02-20,2025,US 202218723721 A,2022-12-28,CN 202111639610 A;;CN 2022142626 W,2021-12-29,"ANTIBODY TARGETING CD3, MULTISPECIFIC ANTIBODY, AND USES THEREOF","An antibody targeting CD3 or an antigen-binding fragment thereof, which has a moderate ability to activate T cells and can effectively reduce cell factor release. A multispecific antibody targeting CD3 and other antigens, such as tumor-associated antigens and/or immune checkpoint molecules, which can significantly reduce cytokine release while ensuring efficient and specific killing of target cells, and has a significantly improved safety. The present invention also relates to uses of the antibody targeting CD3 or the antigen-binding fragment thereof, and the multispecific antibody or a composition comprising same in disease treatment.",SICHUAN HUIYU PHARMACEUTICAL CO LTD;;SICHUAN HUIYU SEACROSS PHARMACEUTICAL TECH CO LTD,HU YAN;;GUO SANYOU;;TENG YUMIN;;WEI TAO;;DING ZHAO,SICHUAN HUIYU PHARMACEUTICAL CO. LTD (2024-02-22);;SICHUAN HUIYU SEACROSS PHARMACEUTICAL TECHNOLOGY CO. LTD (2024-02-22),https://lens.org/173-295-306-216-707,Patent Application,yes,0,0,5,104-752-729-119-640;;075-116-326-515-799;;155-578-974-619-226;;199-929-648-535-447;;173-295-306-216-707,JP;;EP;;CN;;WO;;US,5,104-752-729-119-640;;173-295-306-216-707;;155-578-974-619-226;;199-929-648-535-447;;075-116-326-515-799,JP;;EP;;CN;;WO;;US,0,A61P35/00;;C07K16/2809;;C07K2317/622;;C07K16/005;;C07K2317/56;;C07K2317/567;;C07K2317/33;;C07K2317/92;;C07K2317/52;;C07K16/18;;C07K2317/569;;C07K2317/22;;C07K2317/31;;C07K2317/24;;C07K16/2803;;C07K16/2887;;C07K16/30;;C07K16/32;;C07K16/28;;C07K2317/76;;C07K16/28;;C07K16/2803;;C07K16/2809;;C07K16/2887;;C07K16/30;;C07K16/32;;C07K2317/22;;C07K2317/24;;C07K2317/31;;C07K2317/569;;C07K2317/73;;C07K2317/92,C07K16/28;;C07K16/30;;C07K16/32,,0,0,,,,PENDING
658,US,A1,US 2022/0064237 A1,026-271-031-377-424,2022-03-03,2022,US 202017423063 A,2020-01-15,US 202017423063 A;;US 201962792701 P;;US 2020/0013661 W,2019-01-15,HTT REPRESSORS AND USES THEREOF,"Disclosed herein are HTT repressors and methods and compositions for use of these HTT repressors. Disclosed herein are methods and compositions for diagnosing, preventing and/or treating Huntington's Disease. In particular, provided herein are methods and compositions for modifying (e.g., modulating expression of) an HD HTT allele so as to prevent or treat Huntington Disease, including mHTT repressors (that repress mHTT transcripts and thus also repress mHTT protein expression).",SANGAMO THERAPEUTICS INC;;SHIRE HUMAN GENETIC THERAPIES,CAREY GALEN;;CHIOCCO MATTHEW;;CHOI VIVIAN;;FELICE BRIAN;;FROELICH STEVEN;;KLATTE DEBRA;;MILLER JEFFREY;;PASCHON DAVID;;REBAR EDWARD;;ZEITLER BRYAN;;ZHANG LEI;;ZHANG H STEVE,SANGAMO THERAPEUTICS INC (2020-04-17);;SHIRE HUMAN GENETIC THERAPIES INC (2021-07-08);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26),https://lens.org/026-271-031-377-424,Patent Application,yes,3,0,8,156-761-970-524-547;;102-517-633-694-568;;146-755-545-282-205;;151-317-201-432-370;;051-464-393-829-798;;026-271-031-377-424;;021-812-466-615-265;;097-600-834-348-141,JP;;EP;;CN;;WO;;US,8,156-761-970-524-547;;102-517-633-694-568;;151-317-201-432-370;;146-755-545-282-205;;051-464-393-829-798;;026-271-031-377-424;;021-812-466-615-265;;097-600-834-348-141,JP;;EP;;CN;;WO;;US,23,A61K38/00;;A61P25/14;;C07K14/4703;;C07K2319/81;;C07K2319/09;;C12N15/86;;C12N2750/14143;;A61K48/005;;A61P25/14;;A61K38/00;;C07K14/4703;;C07K2319/09;;C07K2319/81;;C12N15/86;;C12N2750/14143;;A61K48/005,C07K14/47;;A61P25/14;;C12N15/86,,1,1,015-048-499-743-724,11821858;;10.1038/nbt0202-135,"Beerli et al., Engineering polydactyl zinc-finger transcription factors, 2002, Nat. Biotech., 20, 135-141. (Year: 2002)",PENDING
659,EP,A1,EP 3964221 A1,139-275-751-680-929,2022-03-09,2022,EP 20194880 A,2020-09-07,EP 20194880 A,2020-09-07,ANTIVIRAL AGENTS,The present invention relates to a composition comprising eucalyptus oil and sweet orange oil for use in a method for the treatment of a viral infection.,G POHL BOSKAMP GMBH & CO KG,UECK HENNING;;RÖSCHMANN-DOOSE KRISTINA;;THOMSEN JÖRN;;WITTIG THOMAS HEINZ,,https://lens.org/139-275-751-680-929,Patent Application,yes,3,0,5,088-109-834-247-440;;182-446-274-946-597;;075-058-828-091-807;;001-988-496-315-902;;139-275-751-680-929,DE;;RU;;CN;;EP;;WO,5,088-109-834-247-440;;182-446-274-946-597;;075-058-828-091-807;;001-988-496-315-902;;139-275-751-680-929,DE;;RU;;CN;;EP;;WO,0,A61P11/00;;A61K36/61;;A61K36/752;;A61K2300/00;;A61P31/14;;A61P31/16,A61K36/61;;A61K36/752;;A61P11/00;;A61P31/14;;A61P31/16,,105,89,006-877-012-716-604;;001-543-641-242-622;;062-042-786-799-023;;053-237-435-560-380;;148-789-612-871-535;;041-232-789-677-449;;029-757-469-682-828;;056-918-482-957-981;;089-401-131-927-137;;071-821-683-274-733;;111-777-362-334-09X;;140-737-537-325-685;;014-453-332-920-146;;037-648-185-112-847;;088-611-825-656-799;;091-018-034-268-977;;013-232-070-465-466;;000-426-453-506-433;;007-136-532-730-491;;012-678-823-175-464;;054-977-725-113-407;;030-161-525-184-056;;018-122-760-103-280;;039-341-432-523-130;;114-426-980-780-286;;031-351-858-715-648;;143-461-851-596-859;;048-398-422-917-084;;142-190-318-797-398;;023-151-791-899-748;;159-024-987-319-303;;060-206-674-185-030;;111-824-798-250-611;;034-206-094-777-539;;088-509-278-000-721;;077-065-259-003-886;;007-856-917-321-774;;000-602-926-849-189;;027-934-191-455-197;;043-861-133-305-786;;048-389-748-991-124;;123-758-281-329-813;;063-102-848-755-500;;111-777-362-334-09X;;140-737-537-325-685;;010-460-864-497-182;;009-284-907-956-268;;050-141-773-627-060;;050-494-230-798-801;;075-083-223-831-811;;057-074-092-089-866;;038-535-758-911-781;;035-312-421-238-010;;025-783-856-545-499;;046-425-708-178-780;;007-453-228-852-354;;016-858-268-155-256;;054-977-725-113-407;;052-293-383-081-117;;081-118-560-654-582;;129-563-792-344-407;;042-827-553-676-107;;068-225-884-656-763;;022-345-380-284-860;;001-091-416-802-684;;056-600-183-550-321;;002-390-305-397-328;;038-012-653-096-087;;068-207-624-465-611;;029-549-156-582-125;;063-374-149-407-207;;013-517-445-835-216;;164-129-300-594-731;;045-037-586-500-91X;;007-856-917-321-774;;038-465-095-616-00X;;039-237-986-072-968;;042-834-147-531-653;;030-080-270-016-311;;038-116-875-675-064;;012-947-955-914-292;;086-779-900-829-079;;034-865-768-582-957;;099-675-327-872-917;;041-252-693-988-726;;021-665-106-859-672;;097-313-003-455-200;;008-317-407-831-110;;130-557-115-034-027,32837899;;pmc7398051;;10.1016/j.aimed.2020.07.005;;10.1007/s10787-020-00744-0;;pmc7427755;;32803479;;10.1055/a-0942-1993;;31167299;;32313366;;pmc7163989;;10.1002/ffj.3252;;10.4193/rhin20.601;;32226949;;10.1007/978-3-642-59770-1_2;;10.1128/jcm.35.11.2864-2868.1997;;pmc230076;;9350748;;pmc7167768;;19653195;;10.1002/ptr.2955;;pmc4393490;;25870747;;10.3851/imp2629;;23714753;;22477544;;10.1007/s12325-012-0014-z;;9825115;;10.1007/s10354-016-0461-2;;pmc4871925;;27174165;;pmc236993;;10.1128/jvi.68.9.5882-5889.1994;;7914550;;17972131;;10.1007/s00284-007-9045-0;;10.1016/j.jpeds.2015.12.034;;26787374;;pmc4808614;;26093501;;pmc4475612;;10.1186/s12889-015-1885-0;;10.4193/rhino12.000;;10.4193/rhino50e2;;22469599;;10.1111/jam.12453;;24779581;;10.1111/irv.12421;;pmc5155651;;27542891;;10719616;;10.1055/s-0031-1300178;;10.3389/fpubh.2015.00035;;25759809;;pmc4338603;;18596815;;pmc2517140;;10.1038/nsmb.1456;;10.1021/acsinfecdis.5b00040;;26448476;;pmc4593503;;pmc3553670;;23297263;;10.1128/cmr.00077-12;;10.1007/bf01863914;;32843157;;10.1016/j.rmed.2020.105939;;10.1002/jmv.24755;;27966790;;10.1002/14651858.cd006089.pub5;;27351430;;10.1007/s10753-016-0394-3;;pmc104573;;9466772;;10.1128/jcm.36.2.539-542.1998;;25687600;;10.1016/j.bpc.2015.02.001;;10.1155/2015/967473;;10.1177/135965350501000204;;15865216;;6606682;;10.1016/0022-1759(83)90303-4;;10.1007/978-1-4939-1571-2_1;;25261302;;pmc4441521;;pmc3521325;;20156758;;10.1186/2047-783x-14-s4-205;;24585130;;10796516;;10.1002/14651858.cd000245.pub3;;pmc6481481;;28626858;;10.1002/14651858.cd000245;;15494994;;11034678;;10.1002/14651858.cd000245.pub2;;10.1007/s00106-017-0401-5;;28861645;;10.1007/s12272-013-0210-7;;23856970;;pmc7082763;;10.1001/jama.2020.4326;;32191259;;20722639;;10.1111/j.1742-7843.2010.00622.x;;32649077;;32649076;;32649078;;10.1056/nejmc2022236;;32649074;;32649075;;22477544;;10.1007/s12325-012-0014-z;;9825115;;pmc7143164;;10.1056/nejmoa2004500;;32227758;;10.1055/s-0031-1300588;;22282955;;pmc7725513;;32214079;;10.15585/mmwr.mm6912e2;;10.1016/s0140-6736(20)30211-7;;32007143;;pmc7135076;;32105633;;10.1016/s2213-2600(20)30084-9;;pmc7128208;;pmc7265861;;32632415;;10.1016/j.eclinm.2020.100403;;10.3238/arztebl.2020.0271;;pmc7171478;;32519944;;10.1186/1745-9974-9-25;;pmc3842692;;24261680;;pmc7154064;;10.1007/s00134-020-06033-2;;32291463;;32302078;;pmc7182018;;10.1056/nejmc2010419;;32167538;;10.1001/jama.2019.13404;;10.1001/jama.2020.4031;;10.1001/jama.2020.5394;;32250385;;pmc7136855;;10719616;;10.1055/s-0031-1300178;;pmc7169476;;32275812;;10.1056/nejmoa2007016;;10.1016/s0140-6736(20)30183-5;;pmc7159299;;31986264;;30705129;;10.1183/13993003.02339-2018;;10.1136/bmj.m627;;32075791;;10.1016/j.pupt.2004.06.002;;15477123;;12645832;;10.1053/rmed.2003.1432;;27569254;;10.1080/13880209.2016.1216132;;30049972;;pmc6115776;;10.3390/v10080392;;10.1007/s00063-020-00689-w;;32166350;;pmc7080004;;pmc7155395;;32291505;;10.2500/ajra.2014.28.4036;;24980236;;10.1001/jama.2020.4344;;32181795;;pmc7496150;;32364264;;10.1111/his.14134;;10.3410/f.737874004.793575073;;10.1016/s2213-2600(20)30110-7;;32145829;;pmc7129706;;pmc7378547;;32323287;;10.1055/a-1157-9976;;pmc2873403;;20502660;;10.1371/journal.pone.0010717;;10.1001/jama.2012.5669;;22797452;;pmc3521325;;20156758;;10.1186/2047-783x-14-s4-205;;10.1007/s11812-017-0085-5;;20923611;;10.3310/hta14460-02;;32362390;;10.1016/j.healun.2020.03.012;;pmc7118652;;1794831;;32031570;;pmc7042881;;10.1001/jama.2020.1585;;pmc7190303;;10.1016/s0140-6736(20)31022-9;;32423584;;10.7326/l20-1206;;33316197;;19624838;;pmc2720945;;10.1186/1465-9921-10-69;;10.1001/jamainternmed.2020.0994;;32167524;;pmc7070509;;10.1001/jama.2020.2648;;32091533;;pmc7102538;;32105632;;10.1016/s2213-2600(20)30079-5;;32290293;;10.3390/ijms21072657;;pmc7177898;;10.1159/000438655;;26849230;;10.1016/s0140-6736(20)30566-3,"ANONYMOUS: ""Gut gewappnet für den Endspurt - So bleiben Sie bis zum Ende der Erkältungssaison fit"", 11 February 2020 (2020-02-11), XP002802172, Retrieved from the Internet <URL:https://www.presseportal.de/pm/67141/4517071> [retrieved on 20210222];;PRALL SEBASTIAN ET AL: ""Effects of essential oils on symptoms and course (duration and severity) of viral respiratory infections in humans: A rapid review"", ADVANCES IN INTEGRATIVE MEDICINE, vol. 7, no. 4, 3 August 2020 (2020-08-03), pages 218 - 221, XP055778009, ISSN: 2212-9588, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.aimed.2020.07.005> DOI: 10.1016/j.aimed.2020.07.005;;DOMINICA PETRIC: ""The_spectrum_of_antimicrobial_activity_of_Gelomyrtol_R_capsules"", April 2020 (2020-04-01), XP002802171, Retrieved from the Internet <URL:https://www.researchgate.net/publication/340385259_The_spectrum_of_antimicrobial_activity_of_Gelomyrtol_R_capsules> [retrieved on 20210219];;ASIF MUHAMMAD ET AL: ""COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties"", INFLAMMOPHARMACOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 28, no. 5, 14 August 2020 (2020-08-14), pages 1153 - 1161, XP037257443, ISSN: 0925-4692, [retrieved on 20200814], DOI: 10.1007/S10787-020-00744-0;;FÜRST ROBERT ET AL: ""ELOM-080 as Add-On Treatment for Respiratory Tract Diseases A Review of Clinical Studies Conducted in China"", PLANTA MEDICA, vol. 85, no. 09/10, 5 June 2019 (2019-06-05), DE, pages 745 - 754, XP055773408, ISSN: 0032-0943, Retrieved from the Internet <URL:https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0942-1993.pdf> DOI: 10.1055/a-0942-1993;;GYÖRGYI HORVATH ET AL: ""Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review : Essential oils in the treatment of respiratory tract diseases"", FLAVOUR AND FRAGRANCE JOURNAL., vol. 30, no. 5, 26 May 2015 (2015-05-26), GB, pages 331 - 341, XP055391769, ISSN: 0882-5734, DOI: 10.1002/ffj.3252;;FOKKENS ET AL.: ""Executive summary of EPOS 2020 including integrated care pathways"", RHINOLOGY, vol. 58, no. 2, 1 April 2020 (2020-04-01), pages 82 - 111;;APP, E. M.: ""Stellenwert der Mukusclearance fur das Bronchialsystem-Pathophysiologie und therapeutische Ansatze"", 2000, SPRINGER, article ""Entzundliche Erkrankungen des Bronchialsystems - Ergebnisse der II. Sylter Sekretolyse-Gesprache"";;ARRUDA, E.PITKARANTA, A.WITEK, T.DOYLE, C. A.HAYDEN, F. G.: ""Frequency and natural history of rhinovirus infections in adults during autumn"", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 35, 1997, pages 2864 - 2868;;ASTANI, A.REICHLING, J.SCHNITZLER, P.: ""Comparative study on the antiviral activity of selected monoterpenes derived from essential oils"", PHYTOTHERAPY RESEARCH: AN INTERNATIONAL JOURNAL DEVOTED TO PHARMACOLOGICAL TOXICOLOGICAL EVALUATION OF NATURAL PRODUCT DERIVATIVES, vol. 24, 2010, pages 673 - 679;;ASTANI, A.SCHNITZLER, P.: ""Antiviral activity of monoterpenes beta-pinene and limonene against herpes simplex virus in vitro"", IRANIAN JOURNAL OF MICROBIOLOGY, vol. 6, 2014, pages 149;;BAGGA, B.WOODS, C. W.VELDMAN, T. H.GILBERT, A.MANN, A.BALARATNAM, G.LAMBKIN-WILLIAMS, R.OXFORD, J. S.MCCLAIN, M. T.WILKINSON, T.: ""Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals"", J ANTIVIR THER, vol. 18, 2013, pages 785 - 791;;BEGROW, F.BOCKENHOLT, C.EHMEN, M.WITTIG, T.VERSPOHL, E. J.: ""Effect of myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parameters"", ADVANCES IN THERAPY, vol. 29, 2012, pages 350 - 358;;BEUSCHER, N.BIEN, E.ELSTNER, E.KIETZMANN, M.AMON, U.: ""Myrtol standardized in treatment of sinusitis and bronchitis-Pharmacodynamics and pharmacokinetics"", Z PHYTOTHERAPIE ABSTRACTBAND, vol. 8, 1997, pages 9 - 10;;BEUSCHER, N.KIETZMANN, M.BIEN, E.CHAMPEROUX, P.: ""Interference of Myrtol standardized with inflammatory and allergic mediators"", ARZNEIMITTEL-FORSCHUNG, vol. 48, 1998, pages 985 - 989;;BLAAS, D.: ""Viral entry pathways: the example of common cold viruses"", WIENER MEDIZINISCHE WOCHENSCHRIFT, vol. 166, 2016, pages 211 - 226, XP035896688, DOI: 10.1007/s10354-016-0461-2;;CASASNOVAS, J. M.SPRINGER, T. A.: ""Pathway of rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound and RNA is released"", JOURNAL OF VIROLOGY, vol. 68, 1994, pages 5882 - 5889;;CERMELLI, C.FABIO, A.FABIO, G.QUAGLIO, P.: ""Effect of eucalyptus essential oil on respiratory bacteria and viruses"", CURRENT MICROBIOLOGY, vol. 56, 2008, pages 89 - 92, XP019587436;;DEMURI, G. P.GERN, J. E.MOYER, S. C.LINDSTROM, M. J.LYNCH, S. V.WALD, E. R.: ""Clinical features, virus identification, and sinusitis as a complication of upper respiratory tract illness in children ages 4-7 years"", THE JOURNAL OF PEDIATRICS, vol. 171, 2016, pages 133 - 139;;EHLKEN, B.ANASTASSOPOULOU, A.HAIN, J.SCHRODER, C.WAHLE, K.: ""Germany-results of a database analysis"", vol. 15, May 2010, BMC PUBLIC HEALTH, article ""Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level"", pages: 578;;FOKKENS, W. J.LUND, V. J.MULLOL, J.BACHERT, C.ALOBID, I.BAROODY, F.COHEN, N.CERVIN, A.DOUGLAS, R.GEVAERT, P.: ""EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists"", RHINOLOGY, vol. 50, 2012, pages 1 - 12;;GILLING, D. H.KITAJIMA, M.TORREY, J.BRIGHT, K. R.: ""Antiviral efficacy and mechanisms of action of oregano essential oil and its primary component carvacrol against murine norovirus"", JOURNAL OF APPLIED MICROBIOLOGY, vol. 116, 2014, pages 1149 - 1163;;GLATTHAAR-SAALMULLER, B.MAIR, K. H.SAALMULLER, A.: ""Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study"", INFLUENZA OTHER RESPIRATORY VIRUSES, vol. 11, 2017, pages 85 - 92;;GRAGMANN, J.HIPPELI, S.DORNISCH, K.ROHNERT, U.BEUSCHER , N.ELSTNER, E.: ""Antioxidant Properties of Essential Oils. Possible explanantions for their anti-inflammatory effects"", ARZNEIMITTELFORSCHUNG, vol. 50, 2000, pages 135 - 139;;HANSEN, M. P.HOFFMANN, T. C.MCCULLOUGH, A. R.VAN DRIEL, M. L.DEL MAR, C. B.: ""Antibiotic resistance: what are the opportunities for primary care in alleviating the crisis?"", FRONTIERS IN PUBLIC HEALTH, vol. 3, 2015, pages 35;;HARRISON, S. C.: ""Viral membrane fusion"", NATURE STRUCTURAL MOLECULAR BIOLOGY, vol. 15, 2008, pages 690, XP037066000, DOI: 10.1038/nsmb.1456;;IVAN OVA, P. T.MYERS, D. S.MILNE, S. B.MCCLAREN, J. L.THOMAS, P. G.BROWN, H. A.: ""Lipid Composition of the Viral Envelope of Three Strains of Influenza Virusn Not All Viruses Are Created Equal"", ACS INFECTIOUS DISEASES, vol. 1, 2015, pages 435 - 442;;JACOBS, S. E.LAMSON, D. M.GEORGE, K. S.WALSH, T. J.: ""Human rhinoviruses"", CLINICAL MICROBIOLOGY REVIEWS, vol. 26, 2013, pages 135 - 162;;KARBER, G.: ""Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche"", NAUNYN-SCHMIEDEBERGS ARCHIV FUR EXPERIMENTED PATHOLOGIE UND PHARMAKOLOGIE, vol. 162, 1931, pages 480 - 483;;KARDOS, P.DINH, Q.FUCHS, K.GILLISSEN, A.KLIMEK, L.KOEHLER, M.SITTER, HWORTH, H.: ""Guidelines of the German Respiratory Society for diagnosis and treatment of adults suffering from acute, subacute and chronic cough"", PNEUMOLOGIE, vol. 73, 2019, pages 143 - 180;;KASCHKE, O.BEHRBOHM, H.SYDOW, K.: ""The influence of a secretolytic drug on mucociliary clearance of the maxillary sinus"", JOURNAL OF RHINOLOGY, vol. 4, 1997, pages 29 - 33;;LAI, Y. N.LI, Y.FU, L. C.ZHAO, F.LIU, N.ZHANG, F. X.XU, P. P.: ""Combinations of 1, 8-cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice"", JOURNAL OF MEDICAL VIROLOGY, vol. 89, 2017, pages 1158 - 1167;;LEMIENGRE, M. B.VAN DRIEL, M. L.MERENSTEIN, D.LIIRA, H.MAKELA, M.DE SUTTER, A. I: ""Antibiotics for acute rhinosinusitis in adults"", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018;;LI, Y.LAI, Y.WANG, Y.LIU, NZHANG, F.XU, P.: ""Cineol protect against influenza-virus-induced pneumonia in mice"", INFLAMMATION, vol. 39, 8 January 2016 (2016-01-08), pages 1582 - 1593, XP036009809, DOI: 10.1007/s10753-016-0394-3;;MAKELA, M. J.PUHAKKA, T.RUUSKANEN, O.LEINONEN, M.SAIKKU, P.KIMPIMAKI, M.BLOMQVIST, S.HYYPIA, T.ARSTILA, P.: ""Viruses and bacteria in the etiology of the common cold"", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, 1998, pages 539 - 542, XP055073860;;MENDANHA, S. A.ALONSO, A.: ""Effects of terpenes on fluidity and lipid extraction in phospholipid membranes"", BIOPHYSICAL CHEMISTRY, vol. 198, 2015, pages 45 - 54;;MOGHIMI, H. R.SHIRAZI, F. H.ARDESTANI, M. S.OGHABIAN, M. A.SAFFARI, M.SOJOUDI, J.: ""In vitro and in vivo enhancement of antitumoral activity of liposomal antisense oligonucleotides by cineole as a chemical penetration enhancer"", JOURNAL OF NANOMATERIALS, vol. 16, 2015, pages 345;;MORFIN, F.DUPUIS-GIROD, S.MUNDWEILER, S.FALCON, D.CARRINGTON, D.SEDLACEK, P.BIERINGS, M.CETKOVSKY, P.KROES, A.VAN TOL, M.: ""In vitro susceptibility of adenovirus to antiviral drugs is species-dependent"", ANTIVIR THER, vol. 10, 2005, pages 225 - 229;;MOSMANN, T.: ""Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 65, 1983, pages 55 - 63, XP023973702, DOI: 10.1016/0022-1759(83)90303-4;;PALMENBERG, A. C.GERN, J. E.: ""Rhinoviruses"", 2015, SPRINGER, article ""Classification and evolution of human rhinoviruses"";;RANTZSCH, U.VACCA, G.DUCK, R.GILLISSEN, A.: ""Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease"", EUROPEAN JOURNAL OF MEDICAL RESEARCH, vol. 14, 2009, pages 205 - 209, XP021130248, DOI: 10.1186/2047-783X-14-S4-205;;SMITH, S. M.FAHEY, T.SMUCNY, J.BECKER, L. A.: ""Antibiotics for acute bronchitis"", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017;;STUCK, B. A.POPERT, U.BEULE, A.JOBST, D.KLIMEK, L.LAUDIEN, M.LELL, M.VOGL, T.: ""Rhinosinusitis. Leitlinie der Deutschen Gesellschaft fur Hals-Nasen-Ohren-Heilkunde"", KOPF- UND HALS-CHIRURGIE, 2017;;VIMALANATHAN, S.HUDSON, J.: ""Anti-influenza virus activity of essential oils and vapors"", AMERICAN JOURNAL OF ESSENTIAL OILS NATURAL PRODUCTS, vol. 2, 2014, pages 47 - 53, XP055676675;;YAMAYA, M.NISHIMURA, H.NADINE, L. K.OTA, C.KUBO, H.NAGATOMI, R.: ""Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells"", ARCHIVES OF PHARMACAL RESEARCH, vol. 37, 2014, pages 520 - 529, XP035312356, DOI: 10.1007/s12272-013-0210-7;;ANONYMOUS: ""Treatment regimens of COVID-19 (Russian: Tepanmq COVID-19"", April 2020, RUSSIAN FEDERAL MEDICAL-BIOLOGICAL AGENCY;;ARENTZ MYIM EKLAFF L ET AL.: ""Characteristics and Outcomes of 21 Critically III Patients With COVID-19 in Washington State"", JAMA, 2020;;AUSTRALIAN NATIONAL COVID-19 CLINICAL EVIDENCE TASKFORCE - NATIONAL COVID-19 CLINICAL EVIDENCE TASKFORCE. AUSTRALIAN GUIDELINES FOR THE CLINICAL CARE OF PEOPLE WITH COVID-19. VERSION 2.1, 23 April 2020 (2020-04-23), Retrieved from the Internet <URL:https:l/app.maqicapp.orq/app#/quideline/4179>;;BASTOS, V. P. ET AL.: ""Inhaled 1, 8-Cineole Reduces Inflammatory Parameters in Airways of Ovalbumin-Challenged Guinea Pigs"", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 108, 2011, pages 34 - 39;;BEIGEL JH.: ""Remdesivir for the Treatment of Covid-19 - Preliminary Report"", 22 May 2020, NEJM.ORG.;;BEGROW FBOCKENHOLDT CEHMEN MWITTIG THVERSPOHL EJ.: ""Effects of Myrtol Standardized and Other Substances on the Respiratory Tract: Ciliary Beat Frequency and Mucociliary Clearance as Parameters"", ADV THER, vol. 29, no. 4, 2012, pages 350 - 358;;BEUSCHER NKIETZMANN MBIEN E ET AL.: ""Interference of Myrtol standardized with inflammatory and allergic mediators"", ARZNEIM.-FORSCH./DRUG RES., vol. 48, 1998, pages 985 - 989;;BHATRAJU PKGHASSEMIEH BJNICHOLS M ET AL.: ""Covid-19 in Critically III Patients in the Seattle Region - Case Series"", N ENGL J MED, 2020;;BROGAN GCAMPBELL NDURIE MNICKSON C.: ""Coronavirus disease 2019 (COVID-19"", LITFL CRITICAL CARE COMPENDIUM, 19 April 2020 (2020-04-19), Retrieved from the Internet <URL:https://litfl.com/coronavirus-disease-2019-covid-19/>;;BROGAN GCAMPBELL NDURIE MNICKSON C.: ""Coronavirus disease 2019 (COVID-19"", LITFL CRITICAL CARE COMPENDIUM, 30 May 2020 (2020-05-30), Retrieved from the Internet <URL:https://litfl.com/coronavirus-disease-2019-covid-19/#19-management-oxygenation-and-ventilation>;;CAO, L. ET AL.: ""Effect of Myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary disease"", ARZNEIMITTEL-FORSCHUNG, vol. 61, 2010, pages 685 - 692;;""CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States"", MMWR 2020, vol. 69, no. 12, 12 February 2020 (2020-02-12), pages 343 - 346, Retrieved from the Internet <URL:https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6912e2-H.pdf>;;CHEN NZHOU MDONG X ET AL.: ""Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"", LANCET, vol. 395, 2020, pages 507, XP086050323, DOI: 10.1016/S0140-6736(20)30211-7;;CHEUNG JCHO LTCHENG JV ET AL.: ""Staff safety during emergency airway management for COVID-19 in Hong Kong"", LANCET RESPIR MED, vol. 8, 2020, pages e19;;DESAI AGYAWALI B.: ""Endpoints used in phase III randomized controlled trials of treatment options for COVID-19"", ECLINICAL MEDICINE, 2020, Retrieved from the Internet <URL:https:/Idoi.org/10.1016/j.eclinm.2020.100403>;;DREHER MKERSTEN ABICKENBACH JBALFANZ PHARTMANN BCORNELISSEN CDAHER ASTOHR RKLEINES MLEMMEN SW: ""The characteristics of 50 hospitalized COVID-19 patients with and without ARDS"", DTSCH ARZTEBL INT, vol. 117, 2020, pages 271 - 8;;FISCHER, J.DETHLEFSEN, U.: ""Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial"", COUGH, vol. 9, 2013, pages 25, XP021168633, DOI: 10.1186/1745-9974-9-25;;GATTINONI L. ET AL.: ""COVID-19 pneumonia: different respiratory treatment for different phenotypes?"", INTENSIVE CARE MEDICINE, 2020;;GOYAL PCHOI JJPINHEIRO LC ET AL.: ""Clinical Characteristics of Covid-19 in New York City"", N ENGL J MED, 2020;;GRASSELLI GPESENTI ACECCONI M.: ""Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response"", JAMA, 2020;;GRASSELLI GZANGRILLO AZANELLA A ET AL.: ""Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy"", JAMA, 2020;;GRAL3>MANN JHIPPELI SDORNISCH K ET AL.: ""Antioxidant Properties of Essential Oils"", ARZNEIMITTELFORSCHUNG, vol. 50, 2000, pages 135 - 139;;GREIN J ET AL.: ""Compassionate Use of Remdesivir for Patients with Severe Covid-19"", N ENGL J MED, vol. 382, 2020, pages 2327 - 36;;GUAN WJNI ZYHU Y ET AL.: ""Clinical Characteristics of Coronavirus Disease 2019 in China"", N ENGL J MED, 2020;;HUANG CWANG YLI X ET AL.: ""Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"", LANCET, vol. 395, 2020, pages 497, XP086050317, DOI: 10.1016/S0140-6736(20)30183-5;;HUI DSCHOW BKTHOMAS LOOWEN TVTSANG FW. KOSS, NG TGIN MCHAN TV.: ""Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks"", EUROPEAN RESPIRATORY JOURNAL, vol. 53, no. 4, 2019, Retrieved from the Internet <URL:https://doi.orq/10.1183/13993003.02339-2018>;;IMRAAN F. JHETAM.: ""Rapid response to Vetter P. Covid-19: a puzzle with many missing pieces"", BMJ, vol. 368, 2020, pages m627;;JUERGENS, U. R. ET AL.: ""Inhibitory activity of 1, 8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes"", PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 17, 2004, pages 281 - 287, XP004599066, DOI: 10.1016/j.pupt.2004.06.002;;JUERGENS, U. ET AL.: ""Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial"", RESPIRATORY MEDICINE, vol. 97, 2003, pages 250 - 256;;PENG-JIU YULI-MEI WANSHAN-HE WANWEN-YING CHENHUI XIEDONG-MEI MENGJIA-JIE ZHANGXIANG-LIN XIAO: ""Standardized myrtol attenuates lipopolysaccharide induced acute lung injury in mice"", PHARMACEUTICAL BIOLOGY, vol. 54, 2016, pages 3211 - 3216;;KASCHKE OBEHRBOHM HSYDOW K.: ""The influence of a secretolytic drug on mucociliary clearance of the maxillary sinus"", J RHINOL., vol. 4, no. 1, 1997, pages 29 - 33;;KHOMICH OKOCHETKOV SBARTOSCH B ET AL.: ""Redox Biology of Respiratory Viral Infections"", VIRUSES, vol. 10, 2018, pages 392;;KLUGE SJANSSENS UWELTE TWEBER-CARSTENS SMARX GKARAGIANNIDIS C: ""Recommendations for critically ill patients with COVID-19"", MED KLIN INTENSIVMED NOTFMED, 2020;;LAI YDILIDAER DCHEN BXU GSHI JLEE RJCOHEN NA.: ""In vitro studies of Myrtol on upper airway physiology pertaining to mucociliary clearance"", AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, vol. 28, no. 3, 2014, pages 244 - 248;;LENZEN-SCHULTE M.: ""Richtig beatmen bei COVID-19"", DTSCH ARZTEBL, vol. 117, no. 18, 2020, pages A938;;LIVINGSTON EBUCHER K.: ""Coronavirus Disease 2019 (COVID-19) in Italy"", JAMA, 2020;;MENTER THASLBAUER JDNIENHOLD R ET AL.: ""Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction"", HISTOPATHOLOGY, 4 May 2020 (2020-05-04), Retrieved from the Internet <URL:https://pubmed.ncbi.nlm.nih.gov/32364264/>;;NAMENDYS-SILVA SA.: ""Respiratory support for patients with COVID-19 infection"", LANCET RESPIR MED, vol. 8, 2020, pages e18;;PFEIFER MEWIG SVOSHAAR TRANDERATH WBAUER TGEISELER JDELLWEG DWESTHOFF MWINDISCH WSCHONHOFER B, POSITIONSPAPIER ZUR PRAKTISCHEN UMSETZUNG DER APPARATIVEN DIFFERENZIALTHERAPIE DER AKUTEN RESPIRATORISCHEN INSUFFIZIENZ BEI COVID-19, 17 April 2020 (2020-04-17), Retrieved from the Internet <URL:https://pneumologie.de/fileadmin/userupload/COVID-19/20200417DGPapp.DifferenzialtherapieARICOVID-19.pdf>;;RABOUD JSHIGAYEVA AMCGEER ABONTOVICS ECHAPMAN MGRAVEL D ET AL.: ""Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada"", PLOS ONE, vol. 5, no. 5, 2010, pages e10717;;RANIERI VMRUBENFELD GDTHOMPSON BT ET AL.: ""Acute respiratory distress syndrome: the Berlin Definition"", JAMA, vol. 307, 2012, pages 2526 - 33;;RANTZSCH GVACCA RDUCK RGILLISSEN A.: ""Anti-inflammatory effects of Myrtol standardized and other essential oils in alveolar macrophages from patients with chronic obstructive pulmonary disease"", EUR J MED RES, vol. 14, 2009, pages 205 - 209, XP021130248, DOI: 10.1186/2047-783X-14-S4-205;;""COVID-19. Hospital discharge management [German: COVID-19: Kriterien zur Entlassung aus dem Krankenhaus bzw. aus der hauslichen Isolierung"", 24 April 2020, ROBERT KOCH INSTITUTE;;""Diagnostik und Therapie von Patienten mit COVID-19"", 17 April 2020, ROBERT KOCH INSTITUTE, article ""Standiger Arbeitskreis der Kompetenz- und Behandlungszentren fur Krankheiten durch hochpathogene Erreger (STAKOB). Hinweise zu Erkennung"";;SCHINKO, H.FUNK, G.MESCHKAT, M. ET AL.: ""Arterielle Blutgasanalyse"", WIEN. KLIN. WOCHENSCHR. EDUC, vol. 12, 2017, pages 115 - 130, XP036387466, DOI: 10.1007/s11812-017-0085-5;;SIMONDS AK, HANAK A, CHATWIN M: ""Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections."", HEALTH TECHNOL ASSESS, vol. 14, 2010, pages 131 - 172;;SIDDIQU HKMEHRA MR.: ""COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal"", JOURNAL OF HEART AND LUNG TRANSPLANTATION;;ULMER WTNOLTE DLECHELER J.SCHAFER TH.: ""Die Lungenfunktion"", 2003, THIEME VERLAGSGRUPPE, article ""Methodik und klinische Anwendung"";;ULMER W. T.SCHOTT D.: ""Chronic obstructive Bronchitis. Effect of GeloMyrtol forte in a placebo-controlled double-blind study"", FORTSCHRITTE DER MEDIZIN, vol. 109, no. 27, 1991, pages 547 - 550;;WANG DHU BHU C ET AL.: ""Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"", JAMA, 2020;;WANG Y ET AL.: ""Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial"", LANCET, 2020, Retrieved from the Internet <URL:https:/Iwww.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931022-9>;;""Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected Interim guidance"", 13 March 2020, WHO;;WICHMANN DSPERHAKE JPLUTGEHETMANN M ET AL.: ""Autopsy Findings and Venous Thromboembolism in Patients With COVID-19"", ANN INTERN MED., 6 May 2020 (2020-05-06), Retrieved from the Internet <URL:https://www.acpiournals.org/doi/10.7326/M20-2003>;;WORTH, H.SCHACHER, C.DETHLEFSEN, U.: ""Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial."", RESPIR RES, vol. 10, 2009, pages 69, XP021055549, DOI: 10.1186/1465-9921-10-69;;WU CCHEN XCAI Y ET AL.: ""Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China"", JAMA INTERN MED, 2020;;WU ZMCGOOGAN JM.: ""Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention"", JAMA, 2020;;YANG XYU YXU J: ""Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"", LANCE, 2020;;YUNG-FANG TU ET AL.: ""A Review of SARS-CoV-2 and the Ongoing Clinical Trial"", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020;;ZHAO DYHONG-JINQU JIA-MINGGUO HAI-NANZHAO YAN-YONGYANG PEI ZHANGKUN CAO XIAOLEI JIAN-GUOCUI CONGLIU JIAN-MING: ""Protective Effects of Myrtol Standardized Against Radiation-Induced Lung Injury"", CELL. PHYSIOL. BIOCHEM., vol. 38, 2016, pages 619 - 634;;ZHOU FYU TDU R ET AL.: ""Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"", LANCET, vol. 395, 2020, pages 1054, XP086105445, DOI: 10.1016/S0140-6736(20)30566-3",DISCONTINUED
660,US,A1,US 2025/0161342 A1,184-474-802-243-045,2025-05-22,2025,US 202418951792 A,2024-11-19,CN 202311555277 A,2023-11-20,METHOD FOR TREATING ECZEMA IN SKIN AND METHOD FOR PREPARING GLYCYRRHININIC ACID BACTERIAL CELLULOSE COMPOSITE,"The present disclosure relates to a glycyrrhizic acid bacterial cellulose composite for treatment of eczema in skin, and the glycyrrhizic acid bacterial cellulose composite includes bacterial cellulose loaded with glycyrrhizic acid. The glycyrrhizic acid bacterial cellulose composite can be topically applied by transdermal application to skin, thereby achieving therapeutic effect by topical utilization on eczema in the skin.",CHEN CHAO CHENG;;HONG QING FLOWERY BIO TECH GUANGZHOU CO LTD,WANG QIONG;;CHEN CHAO-CHENG;;ZHENG SI HAN,HONG QING FLOWERY BIO-TECH (GUANGZHOU) CO. LTD (2024-11-07);;CHEN CHAO-CHENG (2024-11-14),https://lens.org/184-474-802-243-045,Patent Application,yes,0,0,4,022-590-067-598-58X;;118-962-709-835-23X;;184-474-802-243-045;;059-865-600-093-356,JP;;EP;;CN;;US,4,022-590-067-598-58X;;118-962-709-835-23X;;184-474-802-243-045;;059-865-600-093-356,JP;;EP;;CN;;US,0,A61K47/61;;A61K31/704;;A61K9/0014;;A61P17/00;;A61P29/00;;A61K47/38;;A61K31/704;;A61K9/0014;;A61P17/04;;A61K9/06;;C08L1/02;;C08K5/092;;A61K31/717;;A61P17/04;;A61K9/0014;;A61K31/704;;A61K47/38,A61K31/704;;A61K9/00;;A61K47/38;;A61P17/04,,0,0,,,,PENDING
661,US,A1,US 2024/0024505 A1,065-258-812-214-925,2024-01-25,2024,US 202318221206 A,2023-07-12,US 202318221206 A;;US 202263388343 P,2022-07-12,SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF,The disclosure relates generally to methods and compositions for generation or enhancement of partial or complete cellular signaling pathways,UNIV BOSTON,GRINSTAFF MARK W;;KIRSCH JACK R;;WILLIAMSON AMANDA K;;TINGLEY BRETT,TRUSTEES OF BOSTON UNIVERSITY (2023-09-26),https://lens.org/065-258-812-214-925,Patent Application,yes,1,0,3,065-258-812-214-925;;185-044-255-977-168;;168-562-324-118-070,WO;;US,3,065-258-812-214-925;;185-044-255-977-168;;168-562-324-118-070,WO;;US,0,A61K38/28;;A61K38/2221;;A61K48/0033;;A61K9/5123;;A61K9/0019;;C12N15/85;;A61K48/005;;A61K48/0041;;A61K48/0033;;A61K38/28;;A61K38/2221;;A61K9/1617,A61K48/00;;A61K9/16;;A61K38/22;;A61K38/28,,2,1,163-441-701-685-992,10.1016/s0378-1119(04)00142-8;;15145049;;10.1016/j.gene.2004.02.051,"Merrick, Gene, 332, 1-11, (2004);;Damase et al., Frontiers in Bioengineering and Biotech. 202: 1-24, (2021)",ACTIVE
662,EP,A1,EP 4555998 A1,118-962-709-835-23X,2025-05-21,2025,EP 24213935 A,2024-11-19,CN 202311555277 A,2023-11-20,GLYCYRRHIZIC ACID BACTERIAL CELLULOSE COMPOSITE FOR TREATING ECZEMA IN SKIN,"The present disclosure relates to a glycyrrhizic acid bacterial cellulose composite for treatment of eczema in skin, and the glycyrrhizic acid bacterial cellulose composite includes bacterial cellulose loaded with glycyrrhizic acid. The glycyrrhizic acid bacterial cellulose composite can be topically applied by transdermal application to skin, thereby achieving therapeutic effect by topical utilization on eczema in the skin.",CHEN CHAO CHENG;;HONG QING FLOWERY BIO TECH GUANGZHOU CO LTD,CHEN CHAO-CHENG;;WANG QIONG;;ZHENG SI HAN,,https://lens.org/118-962-709-835-23X,Patent Application,yes,5,0,4,022-590-067-598-58X;;118-962-709-835-23X;;184-474-802-243-045;;059-865-600-093-356,JP;;EP;;CN;;US,4,022-590-067-598-58X;;118-962-709-835-23X;;184-474-802-243-045;;059-865-600-093-356,JP;;EP;;CN;;US,0,A61K47/61;;A61K31/704;;A61K9/0014;;A61P17/00;;A61P29/00;;A61K47/38;;A61K31/704;;A61K9/0014;;A61P17/04;;A61K9/06;;C08L1/02;;C08K5/092;;A61K31/717;;A61P17/04;;A61K9/0014;;A61K31/704;;A61K47/38,A61K9/00;;A61K9/06;;A61K31/704;;A61K47/38;;A61P17/04;;C08L1/02,,2,2,105-109-594-802-269;;058-307-873-088-63X,10.1016/b978-0-444-63458-0.00009-3;;10.1080/09546630310014369;;14522625,"LUDWICKA ET AL: ""Chapter 9 - Medical and Cosmetic Applications of Bacterial NanoCellulose"", 30 November 2015 (2015-11-30), XP009531044, ISBN: 978-0-444-63458-0, Retrieved from the Internet <URL:https://api.elsevier.com/content/article/PII:B9780444634580000093?httpAccept=text/plain>;;SAEEDI M ET AL: ""THE TREATMENT OF ATOPIC DERMATITIS WITH LICORICE GEL"", THE JOURNAL OF DERMATOLOGICAL TREATMENT, INFORMA HEALTHCARE, UK, vol. 14, no. 3, 1 September 2003 (2003-09-01), pages 153 - 157, XP009045508, ISSN: 0954-6634, DOI: 10.1080/09546630310014369",PENDING
663,JP,A,JP 2021097614 A,073-794-056-355-640,2021-07-01,2021,JP 2019230525 A,2019-12-20,JP 2019230525 A,2019-12-20,"COMPOSITION FOR FREEZING, METHOD FOR PRODUCING FROZEN PRODUCT, FROZEN PRODUCT, AND AGENT FOR FREEZING CYANOBACTERIUM","To provide a composition for freezing capable of freezing/preserving cyanobacteriums selected from a species belonging to genus Arthrospira or genus Spirulina.SOLUTION: A composition for freezing containing permeation-type freezing/preserving agent, non- permeation-type freezing/preserving agent, cyanobacterium selected from a species belonging to genus Arthrospira or genus Spirulina. It is preferable that the permeation-type freezing/preserving agent be at least one kind of compound selected from the group consisting of dimethyl sulfoxide, ethylene glycol, propylene glycol and glycerol, and the non-permeation-type freezing/preserving agent be at least one kind of compound selected from the group consisting of trehalose, sucrose, lactose, mannitol, glucose, sorbitol, polyvinyl pyrrolidone, dextran, dextran sulfate and albumin.SELECTED DRAWING: None",DAINIPPON INK & CHEMICALS,ITO JUNICHI;;EBARA TAKESHI,,https://lens.org/073-794-056-355-640,Patent Application,no,1,0,2,075-217-753-036-488;;073-794-056-355-640,JP,2,075-217-753-036-488;;073-794-056-355-640,JP,0,,C12N1/12;;C12N1/20,,1,0,,,"ASIAN JR. OF MICROBIOL. BIOTECH. ENV. SC., vol. Vol. 20, No. (4), JPN6023030256, 2018, pages 1115 - 1123, ISSN: 0005174399",ACTIVE
664,US,A1,US 2021/0269870 A1,190-168-132-306-407,2021-09-02,2021,US 202117185021 A,2021-02-25,US 201715492214 A;;US 202117185021 A;;US 201916425743 A;;US 201662325749 P,2016-04-21,ALPHA-HEMOLYSIN VARIANTS AND USES THEREOF,"Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The α-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.",ROCHE SEQUENCING SOLUTIONS INC,CRAIG TIMOTHY K;;AMBROSO MARK R;;HARRIS CORISSA J;;DIPIETRO MATTHEW M;;ZOU YAOZHONG;;PORTER MARSHALL W,,https://lens.org/190-168-132-306-407,Patent Application,yes,4,1,12,143-034-953-064-005;;190-597-146-313-099;;190-168-132-306-407;;119-214-141-725-38X;;171-928-017-996-393;;033-934-097-492-845;;129-764-900-574-340;;106-127-442-046-690;;191-931-335-563-262;;077-376-394-068-234;;007-920-953-431-771;;164-578-943-297-371,JP;;EP;;CN;;WO;;US,12,143-034-953-064-005;;190-597-146-313-099;;190-168-132-306-407;;033-934-097-492-845;;171-928-017-996-393;;119-214-141-725-38X;;129-764-900-574-340;;106-127-442-046-690;;191-931-335-563-262;;077-376-394-068-234;;007-920-953-431-771;;164-578-943-297-371,JP;;EP;;CN;;WO;;US,16,C12Q1/689;;G01N33/48721;;C12Q2600/156;;C07K14/31;;C12Q1/6869;;C12Q1/689;;G01N33/48721;;C12Q2600/156;;C07K14/31;;C12Q1/6869;;G01N27/44791;;G01N2333/31,C12Q1/6869;;C07K14/31;;C12Q1/689;;G01N27/447;;G01N33/487,,1,0,,,"Kerafast/Biotech Company, SpyTag/SpyCatcher Protein Coupling Reagents. see 9 pages downloaded on 12/03/2024 (Year: 2024)",ACTIVE
665,US,A1,US 2022/0025413 A1,080-693-554-273-374,2022-01-27,2022,US 202117341813 A,2021-06-08,US 202117341813 A;;US 201916503092 A;;US 201862693681 P;;US 201862693660 P,2018-07-03,METHODS AND COMPOSITIONS FOR PREPARING TAGATOSE FROM FRUCTOSE,"Disclosed herein are compositions and methods for preparing tagatose from fructose, more particularly, compositions comprising thermophilic fructose C4-epimerases derived from thermophilic microorganisms and methods for preparing tagatose from fructose using the compositions.",ARZEDA CORP,ZANGHELLINI ALEXANDRE;;ROBERTS KYLE;;COCKREM MICHAEL CHARLES MILLER;;DUNCKLEY CHRISTOPHER,ARZEDA CORP (2023-09-15),https://lens.org/080-693-554-273-374,Patent Application,yes,2,0,13,006-149-917-872-251;;098-493-498-205-373;;082-620-909-852-814;;144-538-183-674-864;;183-413-248-233-708;;004-370-862-039-368;;069-753-793-889-065;;080-693-554-273-374;;123-123-206-834-255;;061-418-984-236-500;;051-524-454-568-176;;021-281-498-358-101;;161-185-805-584-376,AU;;EP;;WO;;US;;CA;;BR;;MX,13,006-149-917-872-251;;098-493-498-205-373;;082-620-909-852-814;;144-538-183-674-864;;183-413-248-233-708;;004-370-862-039-368;;069-753-793-889-065;;061-418-984-236-500;;123-123-206-834-255;;080-693-554-273-374;;051-524-454-568-176;;021-281-498-358-101;;161-185-805-584-376,AU;;EP;;WO;;US;;CA;;BR;;MX,444,C12N9/90;;C12P19/24;;C12P19/02;;C12N15/113;;C12N15/63;;C12P7/26,C12P7/42;;C12N9/88;;C12N15/90,,1,1,043-722-570-836-841,28324347;;10.1007/s13205-012-0071-7;;pmc3563746,"Datta et al., Enzyme immobilization: an overview on techniques and support materials. 3 Biotech, 2013, Vol. 3: 1-9. (Year: 2013)",ACTIVE
666,IL,A,IL 320528 A,152-655-662-871-972,2025-06-01,2025,IL 32052825 A,2025-04-27,US 202263421740 P;;US 2023/0078327 W,2022-11-02,Bcma-targeted car-t cell therapy of multiple myeloma,,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,,,https://lens.org/152-655-662-871-972,Patent Application,no,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,A61K40/11;;A61K40/31;;A61K40/42;;A61P35/00,,0,0,,,,PENDING
667,US,A1,US 2025/0000977 A1,182-093-526-282-600,2025-01-02,2025,US 202418639682 A,2024-04-18,US 202418639682 A;;US 202363504184 P;;US 202363497185 P,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,MCNEIL PANAMA LLC (2024-06-04);;CILAG GMBH INTERNATIONAL (2024-06-04);;JANSSEN RESEARCH & DEVELOPMENT LLC (2024-06-05);;JANSSEN PHARMACEUTICA NV (2024-06-04);;JANSSEN BIOTECH INC (2024-06-10);;LEGEND BIOTECH USA INC (2024-07-09),https://lens.org/182-093-526-282-600,Patent Application,yes,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K39/00;;A61P35/00;;C07K14/725;;C07K16/28,,0,0,,,,PENDING
668,WO,A1,WO 2025/132560 A1,051-878-131-102-468,2025-06-26,2025,EP 2024087068 W,2024-12-18,EP 23307258 A,2023-12-19,METHODS OF TREATING CANCER COMBINING UROS INVALIDATION AND PHOTOTHERAPY,"Clinical trials using CRISPR-Cas9 nuclease to ex vivo edit and alter immune cells are ongoing. However, to date, this strategy is not still applied in clinical practice to directly target cancer cells. Here, the inventors propose to mimic a genetic metabolic disorder in cancer cells in order to weaken cancer cells, independently of their genomic abnormalities. Mutations affecting the heme biosynthesis pathway are responsible for porphyria, and most of them are characterized by an accumulation of toxic photoreactive porphyrins. This study aimed to mimic porphyria by using CRISPR-Cas9 to invalidate UROS, leading to porphyrin accumulation in a prostate cancer model. By combining light with gene therapy, the inventors obtained high efficiency in vitro and in vivo, with considerable improvement in the survival of mice. Finally, the inventors achieved the preclinical proof-of-principle of performing cancer CRISPR gene therapy.",INST NAT SANTE RECH MED;;UNIV BORDEAUX;;CHU DE BORDEAUX,MOREAU-GAUDRY FRANÇOIS;;BEDEL AURÉLIE;;BOUTIN JULIAN;;DABERNAT SANDRINE;;GENEVOIS CORALIE,,https://lens.org/051-878-131-102-468,Patent Application,yes,2,0,1,051-878-131-102-468,WO,1,051-878-131-102-468,WO,7,C12N2310/20;;A61P35/00;;C12N15/1137;;C12N9/88;;C12N9/22;;A61K31/7105,C12N15/113;;A61K31/7088;;A61P35/00;;C12N9/22;;C12N9/88,,80,73,017-213-828-587-937;;038-009-762-008-499;;085-888-356-170-990;;032-564-290-121-147;;104-054-285-651-311;;078-200-720-888-519;;001-498-358-384-561;;026-144-786-904-542;;066-720-592-894-079;;009-706-440-465-939;;027-105-520-524-520;;084-033-279-775-370;;084-243-600-334-05X;;050-576-388-403-055;;010-425-788-978-502;;042-924-537-342-013;;001-293-592-612-48X;;036-893-292-975-894;;074-152-306-851-906;;015-349-705-609-665;;049-186-587-657-892;;053-762-502-974-512;;064-908-811-700-011;;011-997-584-919-850;;000-964-302-007-168;;002-027-917-014-58X;;039-002-896-408-476;;103-365-734-157-469;;023-784-290-990-164;;038-009-762-008-499;;041-905-907-309-115;;020-400-232-092-513;;033-367-222-111-40X;;139-805-906-209-599;;018-252-857-207-057;;009-954-310-155-134;;107-483-302-885-238;;025-189-964-395-414;;160-169-164-370-848;;031-779-772-127-658;;019-066-097-430-703;;017-213-828-587-937;;051-866-380-878-920;;035-333-896-032-043;;110-558-071-931-55X;;015-421-515-567-533;;113-984-178-647-509;;053-977-488-802-527;;022-094-303-588-402;;054-249-068-975-019;;147-600-585-002-220;;005-536-180-610-313;;024-676-253-954-496;;009-706-552-379-47X;;068-205-290-240-615;;028-073-769-695-977;;010-980-531-131-181;;014-181-548-874-365;;020-890-643-219-333;;031-116-357-032-89X;;065-547-518-224-912;;083-846-755-715-435;;091-635-461-658-949;;045-814-755-388-839;;021-288-605-103-14X;;026-043-888-421-581;;062-751-290-254-910;;026-905-632-536-963;;030-062-829-906-413;;026-460-890-045-922;;010-524-004-210-858;;047-381-171-897-017;;084-771-821-724-499,24284092;;10.1016/j.pdpdt.2013.03.003;;pmc6408493;;30850590;;10.1038/s41467-019-09006-2;;pmc7439618;;32832641;;10.1126/sciadv.abb4005;;20506125;;10.1002/pro.405;;pmc2895239;;10.1016/j.jid.2018.03.1143;;38596305;;pmc10899051;;10.1016/j.omton.2024.200772;;32795423;;10.1016/j.stemcr.2020.07.015;;pmc7486222;;10.1038/s41586-019-1711-4;;31634902;;pmc6907074;;10.1038/nbt.1927;;21738127;;pmc3152587;;pmc3177186;;10.1093/nar/gkr815;;pmc3177181;;10.1093/nar/gkr407;;21727090;;10.1093/nar/gkr739;;21576234;;10.1126/science.1207773;;21700836;;pmc3489282;;21131970;;10.1038/nmeth.1539;;17603476;;10.1038/nbt1317;;20051983;;10.1038/nsmb.1710;;pmc2850169;;10.1534/genetics.111.131433;;pmc3176093;;21828278;;10.1073/pnas.93.3.1156;;8577732;;pmc40048;;12033941;;10.1021/bi020095c;;10.1093/bioinformatics/btn331;;pmc2732218;;18586699;;34608327;;10.1038/s41587-021-01039-7;;pmc8930418;;10.1016/j.ceb.2004.03.003;;15145354;;17352659;;10.1146/annurev.biochem.76.050106.093909;;16481468;;10.1101/gad.1407606;;10.1126/science.1225829;;pmc6286148;;22745249;;23452860;;10.1016/j.cell.2013.02.022;;pmc3664290;;29813047;;10.1038/nbt.4172;;pmc6126947;;33476633;;10.1016/j.lfs.2021.119087;;10.1016/j.gene.2013.03.137;;23618815;;pmc4368443;;10.1126/scitranslmed.3003761;;22553251;;10.1158/1078-0432.22464411;;10.1158/1078-0432.ccr-16-1300;;pmc5413401;;27815355;;pmc6408493;;30850590;;10.1038/s41467-019-09006-2;;10.1002/jgm.1478;;20586119;;16314073;;10.1016/j.ygeno.2005.08.018;;10.1006/mthe.2001.0467;;11592836;;10.3389/fonc.2019.01540;;pmc6974621;;32010627;;18314007;;10.1016/j.abb.2008.02.015;;10.1056/nejmra1608634;;28854095;;33538338;;10.3322/caac.21660;;10.1038/s41585-021-00431-x;;33637962;;10.1111/cpr.12274;;27389299;;pmc6496272;;10.1016/j.pdpdt.2019.07.021;;31404677;;10.1016/j.pdpdt.2019.05.012;;31100447;;24284092;;10.1016/j.pdpdt.2013.03.003;;9719020;;10.1002/(sici)1097-0045(19980901)36:4<211::aid-pros1>3.0.co;2-i;;10.3390/cancers9020012;;28125024;;pmc5332935;;10.1118/1.4862078;;24506647;;pmc3987698;;33431631;;pmc7802670;;10.1136/jitc-2020-001926;;24028764;;10.1111/bju.12265;;10.1001/jamadermatol.2016.4463;;28199463;;29045820;;10.1016/j.jid.2017.09.033;;26068242;;10.1016/j.niox.2015.05.006;;pmc4545398;;10.2174/0929867323666160812145641;;27776475;;10.1200/jco.2008.19.9968;;19636017;;pmc2734418;;31644357;;10.1200/jco.19.01701;;pmc7194451;;11387054;;10.1089/104303401750195854;;30197041;;pmc7524340;;10.1016/j.euf.2018.08.016;;10.1038/s41591-022-01726-1;;35314843;;pmc10308799;;10340555;;10.1089/10430349950018229;;10.1089/104303401753204535;;11686937;;17427200;;10.1002/pros.20576;;15891776;;10.1038/sj.cgt.7700844;;10.1016/s0360-3016(00)80138-8;;10.1158/1078-0432.ccr-03-0388;;15102659;;21933889;;pmc3865786;;10.1158/1078-0432.ccr-11-1899;;pmc9931527;;35965411;;10.1016/j.ymthe.2022.08.005;;28007457;;10.1016/s1470-2045(16)30661-1;;pmc8848828;;10.1186/s12885-022-09266-0;;35168543;;10.1074/jbc.m006293200;;10982808;;26080435;;pmc4500257;;10.1073/pnas.1507882112;;10.1016/j.euf.2021.02.006;;33648895;;30995089;;10.2214/ajr.18.20845;;28051996;;pmc5355234;;10.18632/oncotarget.14229;;15705868;;10.1158/0008-5472.727.65.3;;10.1038/srep23314;;pmc4800420;;26996325,"FUKUHARA HIDEO ET AL: ""The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer"", PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, vol. 10, no. 4, 12 April 2013 (2013-04-12), pages 399 - 409, XP028785697, ISSN: 1572-1000, DOI: 10.1016/J.PDPDT.2013.03.003;;GRÉGOIRE CULLOT: ""CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations"", vol. 10, no. 1, 8 March 2019 (2019-03-08), UK, XP093169372, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-019-09006-2> DOI: 10.1038/s41467-019-09006-2;;DENG SHAOHUI ET AL: ""Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects"", SCIENCE ADVANCES, vol. 6, no. 29, 17 July 2020 (2020-07-17), US, XP093041938, ISSN: 2375-2548, DOI: 10.1126/sciadv.abb4005;;LAYER GUNHILD ET AL: ""Structure and function of enzymes in heme biosynthesis"", vol. 19, no. 6, 27 April 2010 (2010-04-27), US, pages 1137 - 1161, XP093170189, ISSN: 0961-8368, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895239/pdf/pro0019-1137.pdf> DOI: 10.1002/pro.405;;MASUDA HIDEYUKI ET AL: ""Dual wavelength 5-aminolevulinic acid photodynamic therapy using a novel flexible light-emitting diode unit"", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 93, no. 2, 10 January 2019 (2019-01-10), pages 109 - 115, XP085629303, ISSN: 0923-1811, DOI: 10.1016/J.JDERMSCI.2018.12.006;;JULIAN BOUTIN: ""CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer"", vol. 32, no. 1, 8 February 2024 (2024-02-08), pages 200772, XP093167871, ISSN: 2950-3299, Retrieved from the Internet <URL:https://www.cell.com/action/showPdf?pii=S2950-3299(24)00014-6> DOI: 10.1016/j.omton.2024.200772;;PRAT FLORENCE ET AL: ""Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells"", STEM CELL REPORTS, vol. 15, no. 3, 8 September 2020 (2020-09-08), United States, pages 677 - 693, XP093261798, ISSN: 2213-6711, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S2213671120302927?via%3Dihub> DOI: 10.1016/j.stemcr.2020.07.015;;ANZALONE, ANDREW V. ET AL.: ""Search-and-replace genome editing without double-strand breaks or donor DNA"", NATURE, vol. 576, no. 7785, 2019, pages 149 - 157, XP038006531, DOI: 10.1038/s41586-019-1711-4;;HOCKEMEYER ET AL., NATURE BIOTECH., vol. 29, 2011, pages 731 - 734;;MOSCOU ET AL., SCIENCE, vol. 326, 2009, pages 3501 - 12;;CERMAK ET AL., NUCL. ACIDS RES., vol. 39, 2011, pages e82;;WOOD ET AL., SCIENCE, vol. 333, 2011, pages 307;;DOYON ET AL., NATURE METHODS, vol. 8, 2010, pages 74 - 79;;SZCZEPEK ET AL., NATURE BIOTECH., vol. 25, 2007, pages 786 - 793;;GUO ET AL., J. MOL. BIOL., vol. 200, 2010, pages 96;;HUERTAS, P., NAT. STRUCT. MOL. BIOL., vol. 17, 2010, pages 11 - 16;;CARROLL ET AL., GENETICS SOCIETY OF AMERICA, vol. 188, 2011, pages 773 - 782;;KIM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 1156 - 1160;;SERA, BIOCHEMISTRY, vol. 41, 2002, pages 7074 - 7081;;LIU, BIOINFORMATICS, vol. 24, 2008, pages 1850 - 1857;;BITINAITE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 10570 - 5;;""Genbank"", Database accession no. GL669193765;;NELSON, JAMES W. ET AL.: ""Engineered pegRNAs improve prime editing efficiency"", NATURE BIOTECHNOLOGY, vol. 40, no. 3, 2022, pages 402 - 410, XP093043230, DOI: 10.1038/s41587-021-01039-7;;E. W. MARTIN: ""Remington's Pharmaceutical-Sciences"", 1980, MACK PUBLISHING CO.;;BAKER ET AL., CURRENT OPINION IN CELL BIOLOGY, vol. 16, no. 3, 2004, pages 293 - 299;;CHANG ET AL., ANNUAL REVIEW OF BIOCHEMISTRY, vol. 76, 2007, pages 51 - 74;;BEHM-ANSMANT ET AL., GENES & DEVELOPMENT, vol. 20, no. 4, 2006, pages 391 - 398;;JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 821;;QI ET AL.: ""Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression"", CELL, vol. 152, no. 5, 2013, pages 1173 - 83, XP055346792, DOI: 10.1016/j.cell.2013.02.022;;""Improving cytidine and adenine base-editing enzymes by expression optimization and ancestral reconstruction"", NAT BIOTECHNOL., 29 May 2018 (2018-05-29);;YAHYA, E.B.ALQADHI, A.M.: ""Recent trends in cancer therapy: A review on the current state of gene delivery"", LIFE SCI., vol. 269, 15 March 2021 (2021-03-15), pages 119087;;WIRTH, T.PARKER, N.YLA-HERTTUALA, S.: ""History of gene therapy"", GENE, vol. 525, no. 2, 10 August 2013 (2013-08-10), pages 162 - 9, XP028576972, DOI: 10.1016/j.gene.2013.03.137;;SCHOLLER, J.BRADY, T.L.BINDER-SCHOLL, G.HWANG, W.T.PLESA, G.HEGE, K.M.VOGEL, A.N.KALOS, M.RILEY, J.L.DEEKS, S.G. ET AL.: ""Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells"", SCI TRANSL MED., vol. 4, no. 132, 2 May 2012 (2012-05-02), pages 132 - 53, XP055147841, DOI: 10.1126/scitranslmed.3003761;;REN, J.LIU, X.FANG, C.JIANG, S.JUNE, C.H.ZHAO, Y.: ""Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition"", CLIN CANCER RES., vol. 23, no. 9, 1 May 2017 (2017-05-01), pages 2255 - 2266, XP055565027, DOI: 10.1158/1078-0432.CCR-16-1300;;CULLOT, G.BOUTIN, J.TOUTAIN, J.PRAT, F.PENNAMEN, P.ROORYCK, C.TEICHMANN, M.ROUSSEAU, E.LAMRISSI-GARCIA, I.GUYONNET-DUPERAT, V. ET : ""CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations"", NAT COMMUN., vol. 10, no. 1, 8 March 2019 (2019-03-08), pages 1136;;ROBERT-RICHARD, E.LALANNE, M.LAMRISSI-GARCIA, I.GUYONNET-DUPERAT, V.RICHARD, E.PITARD, V.MAZURIER, F.MOREAU-GAUDRY, F.GED, C.DE VE: ""Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation"", J GENE MED., vol. 12, no. 8, August 2010 (2010-08-01), pages 637 - 46;;GED, C.MENDEZ, M.ROBERT, E.LALANNE, M.LAMRISSI-GARCIA, I.COSTET, P.DANIEL, J.Y.DUBUS, P.MAZURIER, F.MOREAU-GAUDRY, F ET AL.: ""A knock-in mouse model of congenital erythropoietic porphyria"", GENOMICS, vol. 87, no. 1, January 2006 (2006-01-01), pages 84 - 92, XP024929399, DOI: 10.1016/j.ygeno.2005.08.018;;RICHARD, E., MENDEZ, M., MAZURIER, F., MOREL, C., COSTET, P., XIA, P., FONTANELLAS, A., GERONIMI, F., CARIO-ANDRÉ, M., TAINE, L.: ""Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection"", MOL THER., vol. 4, no. 4, October 2001 (2001-10-01), pages 331 - 8;;FIORITO, V.CHIABRANDO, D.PETRILLO, S.BERTINO, F.TOLOSANO, E.: ""The Multifaceted Role of Heme in Cancer"", FRONT ONCOL., vol. 9, 15 January 2020 (2020-01-15), pages 1540;;HEINEMANN, I.U.JAHN, M.JAHN, D.: ""The biochemistry of heme biosynthesis"", ARCH BIOCHEM BIOPHYS., vol. 474, no. 2, 15 June 2008 (2008-06-15), pages 238 - 51, XP022701458, DOI: 10.1016/j.abb.2008.02.015;;BISSELL, D.M.ANDERSON, K.E.BONKOVSKY, H.L.PORPHYRIA., N ENGL J MED., vol. 377, no. 9, 31 August 2017 (2017-08-31), pages 862 - 872;;ERWIN, A.BALWANI, M.DESNICK, R.J.: ""GeneReviews®"", 1993, UNIVERSITY OF WASHINGTON, article ""Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Congenital Erythropoietic Porphyria"";;SUNG, H.FERLAY, J.SIEGE,L R.L.LAVERSANNE, M.SOERJOMATARAM, I.JEMAL, A.BRAY, F.: ""Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries"", CA CANCER J CLIN., vol. 71, no. 3, May 2021 (2021-05-01), pages 209 - 249;;GREGG, J.R.THOMPSON, T.C.: ""Considering the potential for gene-based therapy in prostate cancer"", NAT REV UROL., vol. 18, no. 3, March 2021 (2021-03-01), pages 170 - 184, XP037924696, DOI: 10.1038/s41585-021-00431-x;;POSTIGLIONE, I.BARRA, F.ALOJ, S.M.PALUMBO, G.: ""Photodynamic therapy with 5-aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG2"", CELL PROLIF., vol. 49, no. 4, August 2016 (2016-08-01), pages 523 - 38;;NAKAYAMA, T.KOBAYASHI, T.SHIMPEI, O.FUKUHARA, H.NAMIKAWA, T.INOUE, K.HANAZAKI, K.TAKAHASHI, K.NAKAJIMA, M.TANAKA, T. ET AL.: ""Photoirradiation after aminolevulinic acid treatment suppresses cancer cell proliferation through the HO-1/p21 pathway"", PHOTODIAGNOSIS PHOTODYN THER., vol. 28, December 2019 (2019-12-01), pages 10 - 17, XP085931116, DOI: 10.1016/j.pdpdt.2019.07.021;;SUEKI, F.RUHI, M.K.GÜLSOY, M.: ""The effect of curcumin in antitumor photodynamic therapy: In vitro experiments with Caco-2 and PC-3 cancer lines"", PHOTODIAGNOSIS PHOTODYN THER., vol. 27, September 2019 (2019-09-01), pages 95 - 99, XP085773004, DOI: 10.1016/j.pdpdt.2019.05.012;;FUKUHARA, H.INOUE, K.KURABAYASHI, A.FURIHATA, M.FUJITA, H.UTSUMI, K.SASAKI, J.SHUIN, T.: ""The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer"", PHOTODIAGNOSIS PHOTODYN THER., vol. 10, no. 4, December 2013 (2013-12-01), pages 399 - 409, XP028785697, DOI: 10.1016/j.pdpdt.2013.03.003;;CHAKRABARTI, P., ORIHUELA, E., EGGER, N., NEAL, D.E. JR., GANGULA, R., ADESOKUN, A., MOTAMEDI, M.: ""implication for photodynamic therapy of prostate cancer"", PROSTATE, vol. 36, no. 4, 1 September 1998 (1998-09-01), pages 211 - 8;;SHAFIRSTEIN, G.BELLNIER, D.OAKLEY, E.HAMILTON, S.POTASEK, M.BEESON, K.PARILOV, E.: ""Interstitial Photodynamic Therapy-A Focused Review"", CANCERS, vol. 9, no. 2, 24 January 2017 (2017-01-24), pages 12;;BARAN, T.M.FOSTER, T.H.: ""Comparison of flat cleaved and cylindrical diffusing fibers as treatment sources for interstitial photodynamic therapy"", MED PHYS., vol. 41, no. 2, February 2014 (2014-02-01), pages 022701;;ALZEIBAK, R.MISHCHENKO, T.A.SHILYAGINA, N.Y.BALALAEVA, I.V.VEDUNOVA, M.V.KRYSKO, D.V.: ""Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future"", J IMMUNOTHER CANCER, vol. 9, no. 1, January 2021 (2021-01-01), pages e001926;;AZZOUZI, A.R.BARRET, E.MOORE, C.M.VILLERS, A.ALLEN, C.SCHERZ, A.MUIR, G.DE WILDT, M.BARBER, N.J.LEBDAI, S ET AL.: ""TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer"", BJU INT., vol. 112, no. 6, October 2013 (2013-10-01), pages 766 - 74;;CHOI, S. H.KIM, K. H.SONG, K. H.: ""Effect of methyl aminolevulinate photodynamic therapy with and without ablative fractional laser treatment in patients with microinvasive squamous cell carcinoma: a randomized clinical trial"", JAMA DERMATOL., vol. 153, 2017, pages 289 - 295;;JANSEN, M. H. E., MOSTERD, K., ARITS, A. H. M. M., ROOZEBOOM, M. H., SOMMER, A., ESSERS, B. A. B., VAN PELT, H.P.A., QUAEDVLIEG, P: ""Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma"", J. INVEST. DERMATOL., vol. 138, 2018, pages 527 - 533;;FAHEY, J.M.GIROTTI, A.W.: ""Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: Role of nitric oxide"", NITRIC OXIDE, vol. 49, 15 September 2015 (2015-09-15), pages 47 - 55;;GIROTTI, A.W.FAHEY, J.M.KORYTOWSKI, W.: ""Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy"", CURR MED CHEM., vol. 23, no. 24, 2016, pages 2754 - 2769;;MCNEEL, D.G., DUNPHY, E.J., DAVIES, J.G., FRYE, T.P., JOHNSON, L.E., STAAB, M.J., HORVATH, D.L., STRAUS, J., ALBERTI, D., MARNOCHA: ""Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer"", J CLIN ONCOL., vol. 27, no. 25, 1 September 2009 (2009-09-01), pages 4047 - 54, XP055023558, DOI: 10.1200/JCO.2008.19.9968;;MCNEEL, D.G.EICKHOFF, J.C.JOHNSON, L.E.ROTH, A.R.PERK, T.G.FONG, L.ANTONARAKIS, E. S.WARGOWSKI, E.JERAJ, R.LIU, G.: ""Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients with Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer"", J CLIN ONCOL., vol. 37, no. 36, 20 December 2019 (2019-12-20), pages 3507 - 3517;;BELLDEGRUN, A.TSO, C.L.ZISMAN, A.NAITOH, J.SAID, J.PANTUCK, A.J.HINKEL, A.DEKERNION, J.FIGLIN, R.: ""Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology"", HUM GENE THER., vol. 12, no. 8, 20 May 2001 (2001-05-20), pages 883 - 92;;PARSONS, J.K.PINTO, P.A.PAVLOVICH, C.P.UCHIO, E.KIM, H.L.NGUYEN, M.N.GULLEY, J.L.JAMIESON, C.HSU, P.WOJTOWICZ, M. ET AL.: ""A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study"", EUR UROL FOCUS, vol. 4, no. 5, September 2018 (2018-09-01), pages 636 - 638;;NARAYAN, V.BARBER-ROTENBERG, J.S.JUNG, I.Y.LACEY, S.F.RECH, A.J.DAVIS, M.M.HWANG, W.T.LAL, P.CARPENTER, E.L.MAUDE, S.L. ET AL.: ""PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial"", NAT MED., vol. 28, no. 4, April 2022 (2022-04-01), pages 724 - 734, XP037801527, DOI: 10.1038/s41591-022-01726-1;;HERMAN, J.R.ADLER, H.L.AGUILAR-CORDOVA, E.ROJAS-MARTINEZ, A.WOO, S.TIMME, T.L.WHEELER, T.M.THOMPSON, T.C.SCARDINO, P.T.: ""In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial"", HUM GENE THER., vol. 10, no. 7, 1 May 1999 (1999-05-01), pages 1239 - 49, XP000983940, DOI: 10.1089/10430349950018229;;MILES, B.J.SHALEV, M.AGUILAR-CORDOVA, E.TIMME, T.L.LEE, H.M.YANG, G.ADLER, H.L.KERNEN, K.PRAMUDJI, C.K.SATOH, T. ET AL.: ""Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy"", HUM GENE THER., vol. 12, no. 16, 1 November 2001 (2001-11-01), pages 1955 - 67;;PENG, W., ANDERSON, D.G., BAO, Y., PADERA, R.F.JR., LANGER, R., SAWICKI, J.A.: ""Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors"", PROSTATE, vol. 67, no. 8, 1 June 2007 (2007-06-01), pages 855 - 62;;HATTORI, Y., MAITANI, Y.: ""Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase"", CANCER GENE THER., vol. 12, no. 10, October 2005 (2005-10-01), pages 796 - 809, XP037757305, DOI: 10.1038/sj.cgt.7700844;;DEWEESE, T.L.VAN DER POEL, H.LI, S.MIKHAK, B.DREW, R.GOEMANN, M.HAMPER, U.DEJONG, R.DETORIE, N.RODRIGUEZ, R. ET AL.: ""A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy"", CANCER RES., vol. 61, no. 20, 15 October 2001 (2001-10-15), pages 7464 - 72;;PISTERS, L.L.PETTAWAY, C.A.TRONCOSO, P.MCDONNELL, T.J.STEPHENS, L.C.WOOD, C.G.DO, K.A.BRISBAY, S.M.WANG, X.HOSSAN, E.A. ET AL.: ""Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer"", CLIN CANCER RES., vol. 10, no. 8, 15 April 2004 (2004-04-15), pages 2587 - 93;;SONPAVDE, G.THOMPSON, T.C.JAIN, R.K.AYALA, G.E.KUROSAKA, S.EDAMURA, K.TABATA, K.REN, C.GOLTSOV, A.A.MIMS, M.P. ET AL.: ""GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy"", CLIN CANCER RES., vol. 17, no. 22, 15 November 2011 (2011-11-15), pages 7174 - 82;;LE TKCHERIF COMABE KPARIS CLANNES FAUDEBERT SBAUDELET EHAMIMED MBARBOLOSI DFINETTI P: ""DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer"", MOL THER., vol. 31, no. 2, 13 August 2022 (2022-08-13), pages 471 - 486;;AZZOUZI, A.R., VINCENDEAU, S., BARRET, E., CICCO, A., KLEINCLAUSS, F., VAN DERPOEL, H.G., STIEF, C.G., RASSWEILER, J., SALOMON, G.: "" PCM301 Study Group. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial"", LANCET ONCOL., vol. 18, no. 2, February 2017 (2017-02-01), pages 181 - 191;;LIU, W.ZHU, Y.YE, L.ZHU, Y.WANG, Y.: ""Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate"", BMC CANCER, vol. 22, no. 1, 16 February 2022 (2022-02-16), pages 173;;VERHAEGH, G.W., VAN BOKHOVEN, A., SMIT, F., SCHALKEN, J.A., BUSSEMAKERS, M.J.: ""Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene"", J BIOL CHEM., vol. 275, no. 48, 1 December 2000 (2000-12-01), pages 37496 - 503, XP002284052, DOI: 10.1074/jbc.M006293200;;SALAMEH, A.LEE, A.K.CARDO-VILA, M.NUNES, D.N.EFSTATHIOU, E.STAQUICINI, F.I.DOBROFF, A.S.MARCHIO, S.NAVONE, N.M.HOSOYA, H. ET AL.: ""PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3"", PROC NATL ACAD SCI U S A, vol. 112, no. 27, 7 July 2015 (2015-07-07), pages 8403 - 8;;NAUSEEF, J.T.BANDER, N.H.TAGAWA, S.T.: ""Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond"", EUR UROL FOCUS, vol. 2021, no. 7, pages 254 - 257;;YADAV, M.P.BALLAL, S.SAHOO, R.K.DWIVEDI, S.N.BAL, C.: ""Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis"", AJR AM J ROENTGENOL., vol. 213, no. 2, August 2019 (2019-08-01), pages 275 - 285;;FRIGERIO, B.FRANSSEN, G.LUISON, E.SATTA, A.SEREGNI, E.COLOMBATTI, M.FRACASSO, G.VALDAGNI, R.MEZZANZANICA, D.BOERMAN, O. ET AL.: ""Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging"", ONCOTARGET, vol. 8, no. 7, 14 February 2017 (2017-02-14), pages 10919 - 10930;;GHOSH AWANG XKLEIN EHESTON WD: ""Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness"", CANCER RES., vol. 65, 2005, pages 727 - 731, XP008074421, DOI: 10.1158/0008-5472.CAN-05-0581;;MAZZOCCO, C.FRACASSO, G.GERMAIN-GENEVOIS, C.DUGOT-SENANT, N.FIGINI, M.COLOMBATTI, M.GRENIER, N.COUILLAUD, F.: ""In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe"", SCI REP., vol. 6, 21 March 2016 (2016-03-21), pages 23314;;FELDMAN, J.P.GOLDWASSER, R.MARK, S.SCHWARTZ, J.ORION, I.: ""A Mathematical model for tumour volume evaluation using two dimensions"", J.APPL QUANT METHODS, vol. 2009, no. 4, pages 455 - 62",PENDING
669,US,A1,US 2020/0369758 A1,045-812-309-511-025,2020-11-26,2020,US 202016843763 A,2020-04-08,US 202016843763 A;;EP 09007857 A;;US 201715495641 A;;US 78097110 A,2009-06-16,BISPECIFIC ANTIGEN BINDING PROTEINS,"The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.",HOFFMANN LA ROCHE,IMHOF-JUNG SABINE;;KLEIN CHRISTIAN;;REGULA JOERG THOMAS;;SCHAEFER WOLFGANG;;SCHANZER JUERGEN MICHAEL,,https://lens.org/045-812-309-511-025,Patent Application,yes,1,2,42,050-228-035-108-949;;157-023-760-788-052;;068-077-003-439-549;;163-766-380-712-077;;052-188-395-010-645;;128-381-019-474-892;;005-673-934-694-420;;054-081-802-350-050;;151-336-479-177-726;;132-152-925-686-761;;091-342-368-355-573;;127-912-699-972-492;;198-841-797-212-34X;;032-011-262-775-418;;011-929-605-320-712;;145-545-900-946-925;;193-221-186-153-433;;044-144-914-101-633;;035-063-058-717-45X;;158-814-682-748-270;;147-659-442-903-204;;092-902-254-664-65X;;000-664-630-147-325;;045-812-309-511-025;;137-255-781-341-273;;054-652-511-434-066;;078-265-778-864-453;;162-247-143-537-745;;185-928-564-829-584;;151-166-082-287-725;;105-749-447-806-580;;089-897-757-547-453;;136-091-968-880-07X;;001-748-422-400-749;;018-159-360-516-51X;;086-464-696-973-172;;103-519-567-001-561;;079-152-834-776-956;;004-776-899-950-841;;194-112-227-517-760;;084-810-763-570-514;;186-816-092-826-587,JP;;CY;;SI;;CA;;MX;;HR;;PL;;CN;;EP;;WO;;ZA;;HK;;AU;;RU;;CL;;US;;TW;;BR;;PT;;PE;;KR;;AR;;ES;;IL;;SG;;DK,42,050-228-035-108-949;;157-023-760-788-052;;068-077-003-439-549;;163-766-380-712-077;;052-188-395-010-645;;128-381-019-474-892;;005-673-934-694-420;;054-081-802-350-050;;151-336-479-177-726;;132-152-925-686-761;;091-342-368-355-573;;127-912-699-972-492;;198-841-797-212-34X;;032-011-262-775-418;;011-929-605-320-712;;145-545-900-946-925;;193-221-186-153-433;;158-814-682-748-270;;035-063-058-717-45X;;044-144-914-101-633;;147-659-442-903-204;;092-902-254-664-65X;;000-664-630-147-325;;045-812-309-511-025;;137-255-781-341-273;;054-652-511-434-066;;078-265-778-864-453;;162-247-143-537-745;;185-928-564-829-584;;151-166-082-287-725;;105-749-447-806-580;;089-897-757-547-453;;136-091-968-880-07X;;001-748-422-400-749;;018-159-360-516-51X;;086-464-696-973-172;;103-519-567-001-561;;079-152-834-776-956;;004-776-899-950-841;;194-112-227-517-760;;084-810-763-570-514;;186-816-092-826-587,JP;;CY;;SI;;CA;;MX;;HR;;PL;;CN;;EP;;WO;;ZA;;HK;;AU;;RU;;CL;;US;;TW;;BR;;PT;;PE;;KR;;AR;;ES;;IL;;SG;;DK,11,C07K16/468;;C07K2317/31;;C07K2317/56;;C07K2317/64;;C07K2317/73;;C07K2317/76;;C07K2319/00;;C07K2317/35;;C07K2317/55;;C07K2317/66;;C07K16/22;;A61P35/00;;A61P35/02;;C07K16/46;;C07K16/22;;C12N15/11;;A61K39/395;;C07K16/468;;C07K2317/31;;C07K2317/56;;C07K2317/64;;C07K2317/73;;C07K2317/76;;C07K2319/00;;C07K2317/35;;C07K2317/55;;C07K2317/66;;C07K16/22,C07K16/22;;C07K16/46,,0,0,,,,ACTIVE
670,US,A1,US 2022/0033856 A1,137-980-780-685-367,2022-02-03,2022,US 201917274966 A,2019-09-10,EP 18306191 A;;EP 2019074131 W,2018-09-11,METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES,"The clinical severity of β-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal γ-globin chain production at adult age, a condition termed hereditary persistence of fetal hemoglobin (HPFH). Here, the inventors have compared the extent of fetal hemoglobin (HbF) de-repression following CRISPR/Cas9-mediated targeting of different regions of the HBG1 and HBG2 promoters in an adult erythroid cell line (HUDEP-2). They achieved a potent and pancellular HbF re-activation upon disruption of binding sites for γ-globin repressors located in both HBG1 and HBG2 genes. They validated these findings in Red Blood Cells (RBCs) derived from genome edited Sickle Cell Disease (SCD) patient hematopoietic stem/progenitor cells. Overall, this study identified a binding site for an HbF repressor as a novel and potent target for the treatment of β-hemoglobinopathies. Accordingly, the present invention relates to a method for increasing fetal hemoglobin content in a eukaryotic cell comprising the step of disrupting the binding site for Leukemia/lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter.",INST NAT SANTE RECH MED;;UNIV PARIS;;ASSIST PUBLIQUE HOPITAUX PARIS APHP;;FOND IMAGINE,MICCIO ANNARITA;;WEBER LESLIE,INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (2021-03-16);;UNIVERSITÉ PARIS CITÉ (2022-03-04);;UNIVERSITÉ DE PARIS (2021-03-16);;FONDATION IMAGINE (2021-03-16);;ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (2021-03-16),https://lens.org/137-980-780-685-367,Patent Application,yes,3,0,3,137-980-780-685-367;;023-518-318-071-345;;046-398-465-506-848,EP;;WO;;US,3,137-980-780-685-367;;023-518-318-071-345;;046-398-465-506-848,EP;;WO;;US,24,C07K14/805;;C12N15/102;;C12N2310/20;;C12N15/111;;C12N2320/30;;C12N2310/20;;A61K35/28;;C12N9/22;;C12N15/11;;C12N15/907;;C12N2800/80,C12N15/90;;A61K35/28;;C12N9/22;;C12N15/11,,2,2,015-770-000-852-269;;037-501-193-364-909,23928856;;10.1002/bit.25018;;10.1126/scitranslmed.aaf9336;;27733558;;pmc5500303,"Sun et al., ""Seamless Correction of the Sickle Cell Disease Mutation of the HBB Gene in Human Induced Pluripotent Stem Cells using TALENs"", Biotechnology and Bioengineering, Vol. 111, No. 5, Published 26 August 2013, pages 1048-1052). (Year: 2013);;DeWitt et al., ""Selection-free Genome Editing of the Sickle Mutation in Human Adult Hematopoietic Stem/Progenitor Cells"", Sci Transl Med, Published 12 October 2016, pages 1-11. (Year: 2016)",PENDING
671,EP,A1,EP 3957755 A1,043-022-048-323-763,2022-02-23,2022,EP 21772078 A,2021-02-24,CN 202010199077 A;;CN 2021077652 W,2020-03-20,"NOVEL CORONAVIRUS NUCLEIC ACID RAPID HYBRIDIZATION CAPTURE IMMUNOFLUORESCENCE DETECTION KIT, AND PREPARATION METHOD AND DETECTION METHOD","The invention relates to the technical field of nucleic acid detection and discloses a 2019 novel coronavirus nucleic acid rapid hybrid capture immunofluorescence detection kit, and a preparation method and a detection method thereof. The kit includes COVID-19 reaction liquid, wherein the COVID-19 reaction liquid is prepared from a COVID-19 fluorescence marker and a COVID-19 probe solution; and the COVID-19 probe solution includes: an ORF1ab segment probe, an N segment probe and an E segment probe. Compared with general fluorescence PCR and sequencing detection, the kit has the advantages of stronger signal intensity, better specificity, shorter detection time, no need of professional technicians for operation, no need of refrigeration in transportation and storage, no need of a matched laboratory and a matched PCR instrument, and convenience and rapidness in use.",ANBIO XIAMEN BIOTECHNOLOGY CO LTD,LEI YANG;;ZHANG JIELI;;ZHANG LIWEI;;HUANG RENXUN;;BAI JIAWEI;;LE YICUI;;HU XIAO;;WANG DAMING,,https://lens.org/043-022-048-323-763,Patent Application,yes,0,0,6,113-586-983-297-130;;051-806-326-643-288;;051-299-859-199-235;;139-493-283-918-902;;180-066-292-808-318;;043-022-048-323-763,CN;;EP;;WO;;US,6,139-493-283-918-902;;051-299-859-199-235;;051-806-326-643-288;;113-586-983-297-130;;180-066-292-808-318;;043-022-048-323-763,EP;;CN;;WO;;US,3,C12Q1/701;;C12Q1/6804;;C12Q1/701;;C12Q1/6813;;Y02A50/30;;G01N33/5308;;C12Q1/6804;;C12Q1/70;;G01N33/56983,C12Q1/70;;C12N15/11;;C12Q1/6804,,0,0,,,,DISCONTINUED
672,US,A1,US 2023/0052467 A1,135-383-837-596-106,2023-02-16,2023,US 202017791752 A,2020-01-10,EP 2020050528 W,2020-01-10,METHODS OF PRODUCING LACTIC ACID FROM UNMODIFIED STARCH,"The technology provided herein relates to novel methods for producing lactic acid (L-lactic acid, D-lactic acid and D/L-Lactic acid) from starch containing material with extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures, and microbial compositions. The novel methods are in particular suitable for the production of lactic acid from any carbon source, not limited to but especially useful for unmodified starch and/or starch-containing material.",BLUCON BIOTECH GMBH,SVETLICHNAYA TATIANA;;SVETLICHNY VITALY;;KRAMER MARCO,BLUCON BIOTECH GMBH (2022-08-11),https://lens.org/135-383-837-596-106,Patent Application,yes,0,0,5,162-534-289-705-272;;173-452-266-945-046;;135-383-837-596-106;;099-194-556-971-380;;018-410-155-999-177,EP;;CN;;WO;;US,5,162-534-289-705-272;;173-452-266-945-046;;018-410-155-999-177;;099-194-556-971-380;;135-383-837-596-106,CN;;EP;;WO;;US,0,C12N1/22;;C12N1/205;;C12P7/56;;C12R2001/01;;Y02E50/10;;C12P7/56;;C12N1/205;;C12R2001/01,C12P7/56;;C12N1/20,,0,0,,,,DISCONTINUED
673,WO,A1,WO 2021/058831 A1,092-107-940-695-779,2021-04-01,2021,EP 2020077145 W,2020-09-28,EP 19382827 A,2019-09-26,THERAPEUTIC EFFICACY BY PULMONARY DELIVERY OF LIVE ATTENUATED MYCOBACTERIA,"The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTBVAC strain having a i) PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.",UNIV ZARAGOZA,AGUILÓ JUAN IGNACIO;;MARTÍN MONTAÑES CARLOS;;TARANCÓN ÍÑIGUEZ RAQUEL;;MATA LOZANO ELENA;;URANGA MAÍZ SANTIAGO;;VANEVA MARINOVA DESSISLAVA,,https://lens.org/092-107-940-695-779,Patent Application,yes,1,0,12,121-502-967-901-114;;092-107-940-695-779;;030-222-543-737-167;;138-597-426-269-074;;092-526-361-253-825;;042-484-781-613-894;;034-538-340-189-857;;144-833-816-145-244;;033-012-730-810-343;;015-121-441-353-182;;029-562-245-679-953;;070-725-490-247-388,JP;;AU;;KR;;CN;;EP;;WO;;US;;CA;;MX,12,121-502-967-901-114;;092-107-940-695-779;;030-222-543-737-167;;138-597-426-269-074;;092-526-361-253-825;;042-484-781-613-894;;034-538-340-189-857;;144-833-816-145-244;;033-012-730-810-343;;015-121-441-353-182;;029-562-245-679-953;;070-725-490-247-388,JP;;AU;;KR;;CN;;EP;;WO;;US;;CA;;MX,46,A61K39/04;;C07K14/35;;A61K2039/522;;A61K2039/54;;A61K2039/544;;A61K2039/58;;A61K2039/577;;A61K39/04;;A61P11/06;;A61P31/04;;A61P31/06;;C07K14/35;;A61K2039/522;;A61K2039/54;;A61K2039/544;;A61K2039/58;;A61K2039/577;;A61P11/06;;A61P37/08;;A61P31/06;;A61K35/74;;A61K2039/522;;A61K2039/544;;A61K2039/577;;A61K2039/58,A61K39/04;;A61K8/04;;A61K39/00;;A61K39/02;;C07K14/35;;C12N1/36,,37,34,074-298-411-894-141;;102-026-688-837-62X;;083-063-132-412-736;;030-527-621-343-17X;;015-804-704-505-241;;027-134-466-383-394;;025-084-188-194-79X;;067-535-709-258-642;;074-389-592-060-376;;021-397-781-043-820;;003-914-015-333-642;;085-485-960-193-797;;019-702-979-738-587;;089-068-713-766-162;;102-026-688-837-62X;;046-703-570-343-671;;040-283-102-215-234;;009-014-977-925-168;;010-103-581-088-869;;033-100-816-282-684;;048-960-283-129-314;;041-515-641-736-430;;141-044-901-986-354;;145-102-249-714-849;;028-791-866-663-631;;014-795-123-346-520;;019-702-979-738-587;;026-254-270-582-754;;073-895-707-566-090;;019-906-398-676-714;;020-867-961-424-978;;072-874-260-264-512;;030-632-368-481-134;;040-283-102-215-234,30794653;;pmc6386280;;10.1371/journal.pone.0212751;;10.1016/j.vaccine.2013.07.051;;23965219;;10.1007/s11095-019-2704-6;;31650321;;pmc7607971;;31099236;;10.1021/acsinfecdis.9b00008;;25869894;;10.1016/j.vaccine.2015.03.060;;pmc1838109;;10.1136/bmj.299.6710.1259;;2513902;;27518660;;10.1056/nejmoa1508749;;pmc5137793;;22561831;;10.1038/nm.2731;;10.1165/rcmb.2015-0295oc;;pmc5070104;;27248771;;10.4049/jimmunol.164.12.6166;;10843666;;20673988;;10.1016/j.jaci.2010.06.010;;10.1084/jem.187.4.561;;9463406;;pmc2212158;;10.1016/j.jaci.2007.09.033;;18037160;;10.1371/journal.pone.0106807;;pmc4156387;;25192550;;10.1016/j.vaccine.2013.07.051;;23965219;;29326700;;10.3389/fimmu.2017.01803;;pmc5736532;;26598141;;10.1016/s2213-2600(15)00435-x;;10.1080/14760584.2017.1324303;;28447476;;11901655;;10.1016/s1473-3099(02)00182-2;;9634230;;10.1038/31159;;10564470;;10.1046/j.1365-2958.1999.01593.x;;pmc3422549;;10.1038/nri3073;;21997792;;11544450;;10.1067/mai.2001.117457;;10.1067/mai.2000.111241;;11112907;;10.1016/s1081-1206(10)61890-x;;12086366;;10.1016/j.jaci.2010.07.039;;20933258;;10.1016/j.jaci.2007.09.033;;18037160;;pmc1745787;;10.1136/thorax.55.6.449;;10817790;;10.1111/j.1365-2222.2005.02408.x;;16393268;;31116888;;10.1111/all.13923;;pmc3909500;;10.1016/j.jaci.2010.03.037;;20513526;;pmc4713452;;26768622;;10.1007/s11882-015-0587-0;;10.1016/s0140-6736(12)60988-x;;22901886;;26598141;;10.1016/s2213-2600(15)00435-x,"MARIANA GUERRA-MAUPOME ET AL: ""Aerosol vaccination with Bacille Calmette-Guerin induces a trained innate immune phenotype in calves"", PLOS ONE, vol. 14, no. 2, 22 February 2019 (2019-02-22), pages e0212751, XP055672698, DOI: 10.1371/journal.pone.0212751;;ARBUES AINHOA ET AL: ""Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuatedM. tuberculosis-based vaccine to enter clinical trials"", VACCINE, vol. 31, no. 42, 17 August 2013 (2013-08-17), pages 4867 - 4873, XP028717050, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2013.07.051;;BRAUNSTEIN MIRIAM ET AL: ""Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs"", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 36, no. 12, 24 October 2019 (2019-10-24), XP036966006, ISSN: 0724-8741, [retrieved on 20191024], DOI: 10.1007/S11095-019-2704-6;;CARIDAD DÍAZ ET AL: ""Comparative Metabolomics between Mycobacterium tuberculosis and the MTBVAC Vaccine Candidate"", ACS INFECTIOUS DISEASES, vol. 5, no. 8, 9 August 2019 (2019-08-09), US, pages 1317 - 1326, XP055672637, ISSN: 2373-8227, DOI: 10.1021/acsinfecdis.9b00008;;LEWIS SCHRAGER ET AL: ""Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings"", VACCINE, vol. 33, no. 26, 1 June 2015 (2015-06-01), AMSTERDAM, NL, pages 3038 - 3046, XP055672653, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2015.03.060;;STRACHAN DP.: ""Hay fever, hygiene, and household size"", BMJ, vol. 299, 1989, pages 1259 - 60;;STEIN MMHRUSCH CLGOZDZ JIGARTUA CPIVNIOUK VMURRAY SE ET AL.: ""Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children"", N ENGL J MED, vol. 375, 2016, pages 411 - 21, XP055642341, DOI: 10.1056/NEJMoa1508749;;HOLGATE STWENZEL SPOSTMA DSWEISS STRENZ HSLY PD., ASTHMA. NAT REV DIS PRIMERS, vol. 1, 2015, pages 15025;;HOLGATE ST.: ""Innate and adaptive immune responses in asthma"", NAT MED, vol. 18, 2012, pages 673 - 83;;GIRODET PONGUYEN DMANCINI JDHUNDAL MZHOU XISRAEL E ET AL.: ""Alternative Macrophage Activation Is Increased in Asthma"", AM J RESPIR CELL MOL BIOL, vol. 55, 2016, pages 467 - 75;;MILLS CDKINCAID KALT JMHEILMAN MJHILL AM: ""M-l/M-2 macrophages and the Thl/Th2 paradigm"", J IMMUNOL, vol. 164, 2000, pages 6166 - 73;;MOREIRA APCAVASSANI KAHULLINGER RROSADA RSFONG DJMURRAY L ET AL.: ""Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease"", J ALLERGY CLIN IMMUNOL, vol. 126, 2010, pages 712 - 21 e7;;ERB KJHOLLOWAY JWSOBECK AMOLL HLE GROS G.: ""Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia"", J EXP MED, vol. 187, 1998, pages 561 - 9, XP001055975, DOI: 10.1084/jem.187.4.561;;LAGRANDERIE MABOLHASSANI MVANOIRBEEK JLEFORT JNAHORI MALAPA ESJR ET AL.: ""M. bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models"", J ALLERGY CLIN IMMUNOL, vol. 121, 2008, pages 471 - 8, XP022471335, DOI: 10.1016/j.jaci.2007.09.033;;TSUJIMURA YINADA HYONEDA MFUJITA TMATSUO KYASUTOMI Y: ""Effects of mycobacteria major secretion protein, Ag85B, on allergic inflammation in the lung"", PLOS ONE, vol. 9, 2014, pages el06807;;ARBUES AAGUILO JIGONZALO-ASENSIO JMARINOVA DURANGA SPUENTES E ET AL.: ""Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials"", VACCINE, vol. 31, 2013, pages 4867 - 73, XP028717050, DOI: 10.1016/j.vaccine.2013.07.051;;GONZALO-ASENSIO JMARINOVA DMARTIN CAGUILO N.: ""MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic"", FRONT IMMUNOL., vol. 8, 15 December 2017 (2017-12-15), pages 1803;;SPERTINI FAUDRAN RCHAKOUR RKAROUI OSTEINER-MONARD VTHIERRY AC ET AL.: ""Safety of human immunisation with a live-attenuated M. tuberculosis vaccine: a randomised, double-blind, controlled phase I trial"", LANCET RESPIR MED, vol. 3, 2015, pages 953 - 62, XP009191712, DOI: 10.1016/S2213-2600(15)00435-X;;TAMERIS ET AL.: ""Randomised controlled double blind dose-escalation infant trial of the live-attenuated M. tuberculosis vaccine MTBVAC"", LANCET RESPIR MED, 2019;;DESSISLAVA MARINOVAJESUS GONZALO-ASENSIONACHO AGUILOCARLOS MARTIN: ""MTBVAC from discovery to clinical trials in tuberculosis-endemic countries"", EXPERT REVIEW OF VACCINES, vol. 16, no. 6, 2017, pages 565 - 576, XP055482765, DOI: 10.1080/14760584.2017.1324303;;BEHR, M. A., BCG-DIFFERENT STRAINS, DIFFERENT VACCINES LANCET INFECT DIS, vol. 2, no. 2, 2002, pages 86 - 92;;REF COLE ET AL.: ""Deciphering the biology of M tuberculosis from the complete genome sequence"", NATURE, vol. 393, 1998, pages 537 - 544;;CAMACHO ET AL.: ""Identification of a virulence gene cluster of M tuberculosis by signature-tagged transposon mutagenesis"", MOL MICROBIOL, vol. 34, 1999, pages 257 - 267, XP008129741, DOI: 10.1046/j.1365-2958.1999.01593.x;;MURRAY PJWYNN TA.: ""Protective and pathogenic functions of macrophage subsets"", NAT REV IMMUNOL, vol. 11, 2011, pages 723 - 37, XP055112087, DOI: 10.1038/nri3073;;SARADNA ADO DCKUMAR SFU QLGAO P.: ""Macrophage polarization and allergic asthma"", TRANSL RES, vol. 191, 2018, pages 1 - 14, XP085307289, DOI: 10.1016/j.trsl.2017.09.002;;VON BUBNOFF DGEIGER EBIEBER T.: ""Antigen-presenting cells in allergy"", J ALLERGY CLIN IMMUNOL, vol. 108, 2001, pages 329 - 39;;SARINHO ESCHOR DVELOSO MLIMA M.: ""BCG scar diameter and asthma: a case-control study"", J ALLERGY CLIN IMMUNOL, vol. 106, 2000, pages 1199 - 200, XP027376186;;CHOI ISKOH YI.: ""Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial"", ANN ALLERGY ASTHMA IMMUNOL, vol. 88, 2002, pages 584 - 91, XP026993841;;ARNOLDUSSEN DLLINEHAN MSHEIKH A.: ""BCG vaccination and allergy: a systematic review and meta-analysis"", J ALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 246 - 53,53 el-21;;LAGRANDERIE MABOLHASSANI MVANOIRBEEK JLEFORT JNAHORI MALAPA ESJR ET AL.: ""Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models"", J ALLERGY CLIN IMMUNOL, vol. 121, 2008, pages 471 - 8, XP022471335, DOI: 10.1016/j.jaci.2007.09.033;;VON MUTIUS EPEARCE NBEASLEY RCHENG SVON EHRENSTEIN OBJORKSTEN B ET AL.: ""International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema"", THORAX, vol. 55, 2000, pages 449 - 53, XP009087377, DOI: 10.1136/thorax.55.6.449;;OBIHARA CCKIMPEN JLGIE RPLILL SWHOEKSTRA MOMARAIS BJ ET AL.: ""M. tuberculosis infection may protect against allergy in a tuberculosis endemic area"", CLIN EXP ALLERGY, vol. 36, 2006, pages 70 - 6, XP002680183, DOI: 10.1111/j.1365-2222.2005.02408.x;;TARANCON RURANGA SMARTIN CAGUILO N.: ""Mycobacterium tuberculosis infection prevents asthma and abrogates eosinophilopoiesis"", AN EXPERIMENTAL MODEL ALLERGY, 22 May 2019 (2019-05-22);;KWOK WWROTI MDELONG JHTAN VWAMBRE EJAMES EA ET AL.: ""Direct ex vivo analysis of allergen-specific CD4+ T cells"", J ALLERGY CLIN IMMUNOL, vol. 125, 2010, pages 1407 - 9 el;;O'HEHIR REPRICKETT SRROLLAND JM.: ""T Cell Epitope Peptide Therapy for Allergic Diseases"", CURR ALLERGY ASTHMA REP, vol. 16, 2016, pages 14;;PAVORD IDKORN SHOWARTH PBLEECKER ERBUHL RKEENE ON ET AL.: ""Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial"", LANCET, vol. 380, 2012, pages 651 - 9, XP002714506, DOI: 10.1016/S0140-6736(12)60988-X;;SPERTINI FAUDRAN RCHAKOUR RKAROUI OSTEINER-MONARD VTHIERRY AC ET AL.: ""Safety of human immunisation with a live-attenuatedM tuberculosis vaccine: a randomised, double-blind, controlled phase I trial"", LANCET RESPIR MED, vol. 3, 2015, pages 953 - 62",PENDING
674,US,A1,US 2023/0111340 A1,046-188-178-831-626,2023-04-13,2023,US 202217818176 A,2022-08-08,US 202217818176 A;;US 202117466873 A;;US 202016817864 A;;US 201816140309 A;;US 2017/0041268 W;;US 201662359626 P;;US 201662359627 P;;US 201662432530 P;;US 201662433742 P;;US 201762522623 P;;US 201762526306 P,2016-07-07,ANTIBODY ADJUVANT CONJUGATES,"The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.",UNIV LELAND STANFORD JUNIOR;;BOLT BIOTHERAPEUTICS INC,ALONSO MICHAEL NATHANIEL;;ENGLEMAN EDGAR GEORGE;;ACKERMAN SHELLEY ERIN;;KENKEL JUSTIN;;LEE ARTHUR;;JACKSON DAVID Y,BOLT BIOTHERAPEUTICS INC (2022-01-07);;THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2022-01-07),https://lens.org/046-188-178-831-626,Patent Application,yes,0,0,31,187-998-806-254-565;;142-333-028-623-707;;164-886-607-651-938;;012-216-388-055-874;;050-980-043-820-739;;048-259-602-184-797;;032-177-492-461-676;;133-720-600-137-587;;131-015-636-783-496;;050-815-864-335-23X;;063-795-020-137-061;;169-411-392-372-634;;070-270-864-689-589;;155-662-360-404-353;;107-772-207-257-71X;;130-538-143-620-943;;047-625-547-122-147;;170-254-685-590-773;;128-457-794-126-221;;052-746-858-798-656;;046-188-178-831-626;;196-194-711-751-481;;079-057-537-872-938;;044-005-072-128-716;;028-862-879-676-47X;;003-618-938-035-84X;;064-344-527-854-653;;171-329-720-227-321;;153-850-433-035-014;;144-724-441-789-699;;001-891-091-545-768,KR;;JP;;AU;;CN;;IL;;EP;;ES;;WO;;US;;CA;;BR,41,187-998-806-254-565;;142-333-028-623-707;;015-846-884-112-503;;164-886-607-651-938;;012-216-388-055-874;;050-980-043-820-739;;068-256-311-038-222;;032-177-492-461-676;;048-259-602-184-797;;133-720-600-137-587;;032-836-593-293-209;;002-196-078-622-193;;131-015-636-783-496;;050-815-864-335-23X;;011-354-900-284-932;;063-795-020-137-061;;070-270-864-689-589;;169-411-392-372-634;;067-715-725-047-165;;155-662-360-404-353;;107-772-207-257-71X;;130-538-143-620-943;;047-625-547-122-147;;033-560-513-009-098;;169-494-094-806-699;;170-254-685-590-773;;128-457-794-126-221;;052-746-858-798-656;;046-188-178-831-626;;185-285-993-648-494;;196-194-711-751-481;;079-057-537-872-938;;044-005-072-128-716;;001-891-091-545-768;;028-862-879-676-47X;;003-618-938-035-84X;;153-850-433-035-014;;171-329-720-227-321;;113-296-304-642-225;;144-724-441-789-699;;064-344-527-854-653,KR;;JP;;AU;;CN;;EA;;IL;;EP;;ES;;WO;;US;;CA;;BR,0,A61K39/44;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61P35/00;;A61K2039/55511;;C07K16/30;;A61K47/6849;;A61K47/6851;;A61K47/6855;;A61P35/00;;C07K2317/74;;C07K16/2887;;C07K16/3053;;C07K16/2818;;C07K16/2851;;C07K16/44;;C07K2317/52;;A61K2039/55561;;A61K2039/55572;;A61K2039/55516;;A61K2039/5555;;A61K2039/55511;;A61K47/68;;A61K47/6855;;A61K47/6849;;A61K47/6851;;A61K47/6801;;C07K16/28;;C07K16/30;;A61K47/6851;;A61K47/55;;A61P35/00;;A61K47/6857;;A61K47/6803;;A61K39/39;;C07K16/2803;;C07K16/2887;;C07K16/3061;;C07K16/32;;A61K2039/555;;C07K2317/24;;A61K47/6849;;A61K47/6851;;C07K16/30;;C07K16/28;;A61K47/6855;;A61K47/6801;;A61P35/00;;C07K16/2818,A61K47/68;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
675,US,A1,US 2025/0002988 A1,181-822-130-709-437,2025-01-02,2025,US 202418882493 A,2024-09-11,US 202418882493 A;;US 202318482435 A;;US 202016965796 A;;US 2019/0015452 W;;US 201862623471 P,2018-01-29,METHOD FOR NUCLEIC ACID AMPLIFICATION,"Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for research, diagnostics, and treatment.",ST JUDE CHILDRENS RES HOSPITAL INC,GAWAD CHARLES;;EASTON JOHN;;GONZALEZ-PENA VERONICA,ST. JUDE CHILDREN'S RESEARCH HOSPITAL INC (2022-05-28),https://lens.org/181-822-130-709-437,Patent Application,yes,6,0,35,183-418-482-025-838;;106-527-937-183-403;;083-293-764-837-197;;136-881-707-131-173;;099-724-863-338-935;;029-391-082-212-641;;020-582-786-914-515;;008-068-677-878-635;;122-976-885-345-696;;161-769-849-270-167;;173-018-056-709-801;;067-304-959-913-568;;108-450-780-418-226;;096-183-428-787-332;;168-514-379-657-825;;172-211-559-906-864;;047-338-273-588-350;;115-261-599-053-622;;162-012-601-781-571;;117-209-980-339-456;;181-822-130-709-437;;099-583-673-327-171;;175-782-220-744-067;;008-701-923-181-130;;128-533-454-865-003;;112-981-187-434-476;;134-645-758-642-726;;025-876-585-228-645;;031-120-162-293-346;;145-270-893-209-723;;155-975-483-065-15X;;164-872-066-858-313;;028-745-998-819-899;;077-714-197-024-32X;;078-577-392-046-653,JP;;AU;;EA;;US;;CA;;PL;;KR;;EP;;ES;;CN;;IL;;WO;;SG;;DK,35,183-418-482-025-838;;106-527-937-183-403;;083-293-764-837-197;;136-881-707-131-173;;099-724-863-338-935;;029-391-082-212-641;;020-582-786-914-515;;008-068-677-878-635;;122-976-885-345-696;;161-769-849-270-167;;173-018-056-709-801;;067-304-959-913-568;;108-450-780-418-226;;096-183-428-787-332;;168-514-379-657-825;;172-211-559-906-864;;047-338-273-588-350;;115-261-599-053-622;;162-012-601-781-571;;117-209-980-339-456;;181-822-130-709-437;;099-583-673-327-171;;175-782-220-744-067;;008-701-923-181-130;;128-533-454-865-003;;112-981-187-434-476;;134-645-758-642-726;;025-876-585-228-645;;031-120-162-293-346;;145-270-893-209-723;;155-975-483-065-15X;;164-872-066-858-313;;028-745-998-819-899;;077-714-197-024-32X;;078-577-392-046-653,JP;;AU;;EA;;US;;CA;;PL;;KR;;EP;;ES;;CN;;IL;;WO;;SG;;DK,0,C40B40/06;;C12Q1/6806;;C40B40/06;;C12Q1/6869;;C12N15/1093;;C12Q1/6883;;C12Q1/6806;;C12Q2600/156;;C12Q1/686;;C12Q2525/186;;C12Q2531/119;;C12Q2535/122;;C12Q1/686;;C12Q1/6869;;C40B40/06;;C12Q2600/156;;C12N15/1093;;C12Q1/686;;C12Q1/6869;;C12Q1/6883;;C12Q2600/156;;C12N9/1252;;C12Q1/6844;;C12Q1/6855;;C12Q2521/101;;C12Q2521/319;;C12Q2531/119,C12Q1/686;;C12N15/10;;C12Q1/6869;;C12Q1/6883,,1,1,048-959-495-727-350,10.1016/j.copbio.2012.09.004;;23020966,"Mutz et al, Transcriptome analysis using next-generation sequencing, 2013, Curr Opinion in Biotech, 24, 22-30 (Year: 2013)",PENDING
676,US,A1,US 2025/0163107 A1,171-491-956-342-794,2025-05-22,2025,US 202318865515 A,2023-05-15,CN 202210522162 A;;CN 2023094186 W,2022-05-13,FUSION PROTEIN AND USE THEREOF,"Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.",SHANXI JINBO BIO PHARMACEUTICAL CO LTD;;UNIV FUDAN,LU LU;;JIANG SHIBO;;LIU ZEZHONG;;ZHOU JIE;;WANG QIAN;;YANG XIA;;HE ZHENRUI,SHANXI JINBO BIO-PHARMACEUTICAL CO. LTD (2024-03-11);;FUDAN UNIVERSITY (2024-03-11),https://lens.org/171-491-956-342-794,Patent Application,yes,0,0,10,111-822-544-999-762;;171-491-956-342-794;;110-425-586-969-988;;067-666-334-661-143;;192-542-570-344-884;;084-255-572-856-827;;183-823-870-120-481;;020-929-550-285-126;;039-614-878-059-61X;;064-404-085-637-134,JP;;KR;;CN;;EP;;WO;;US,10,111-822-544-999-762;;171-491-956-342-794;;110-425-586-969-988;;067-666-334-661-143;;192-542-570-344-884;;084-255-572-856-827;;183-823-870-120-481;;020-929-550-285-126;;039-614-878-059-61X;;064-404-085-637-134,JP;;KR;;CN;;EP;;WO;;US,0,C07K14/005;;A61K39/12;;A61K39/39;;A61P31/14;;A61P31/18;;A61P31/16;;C12N2770/20022;;C12N2740/16022;;C12N2760/16022;;C07K2319/00;;A61K2039/6031;;C12N2770/20034;;C12N2740/16034;;C12N2760/16034;;A61K39/12;;A61K39/39;;A61P31/14;;A61P31/16;;A61P31/18;;C07K14/005;;C07K14/78;;C07K2319/40;;C07K2319/70;;C12N2770/20034;;C12N2760/16134;;A61K2039/575;;A61K39/385;;A61K2039/55505;;A61K39/215;;A61K39/145;;C07K14/005;;A61K39/12;;A61K39/215;;A61K39/145;;A61K39/39;;A61P31/14;;A61P31/16;;A61P31/18;;C12N2770/20022;;C12N2770/20034;;C12N2740/16022;;C12N2740/16034;;C12N2760/16022;;C12N2760/16034;;C07K2319/00;;A61P31/14;;A61P31/16;;A61K39/145;;A61K39/215;;C07K14/005;;C07K2319/00;;C12N2760/16122;;C12N2760/16134;;C12N2770/20022;;C12N2770/20034,C07K14/005;;A61K39/145;;A61K39/215;;A61P31/14;;A61P31/16,,0,0,,,,ACTIVE
677,WO,A1,WO 2024/151341 A1,150-806-927-625-789,2024-07-18,2024,US 2023/0079612 W,2023-11-14,US 202363438019 P,2023-01-10,SILICONE POLYETHER OFFERING STABILITY FOR POLYOL SYSTEMS WITH HYDROCARBON BLOWING AGENTS,"A polyol composition comprises a polyol, blowing agent, and a silicone polyether with an average chemical formula R3SiO(R2SiO)x(RRaSiO)ySiR3 where R is a C1-4 alkyl, x is 5-55, y is 1-10, x+y is 6-60, Ra has an average chemical formula -(CH2)p-(EO)n(PO)m(EO)eH where EO is -CH2CH2O-, PO is -CH2CH(CH3)O-, e is 1-50, m is 2-10, n is 1-20, e+n is 25-70, p is one to 10, the PO content is > 0 and <15 weight-percent of the weight of EO+PO, the EO content is > 58 and <75 weight-percent of the silicon polyether weight, and the blowing agent is >70 volume-percent hydrocarbon blowing agent based on blowing agent volume and at least one of the following is true: (i) Ra has a number average molecular weight in a range of 1500 to 2500 grams per mole as determined by size exclusion chromatography; and (ii) the x+y is 50 or less.",DOW SILICONES CORP;;DOW GLOBAL TECHNOLOGIES LLC,TOTH SIMON;;ZHANG FRANK;;BOELTER SCOTT;;OGUNNIYI ADEBOLA;;KERSBULCK JOCHEM,,https://lens.org/150-806-927-625-789,Patent Application,yes,2,0,2,188-037-575-468-139;;150-806-927-625-789,CN;;WO,2,188-037-575-468-139;;150-806-927-625-789,CN;;WO,0,C08G77/46;;C08G18/7664;;C08J9/141;;C08G18/4829;;C08G18/4018;;C08J9/0061,C08G18/40;;C08G18/48;;C08G18/76;;C08G77/46;;C08J9/14,,0,0,,,,PENDING
678,US,A1,US 2025/0213618 A1,158-489-281-454-38X,2025-07-03,2025,US 202519063611 A,2025-02-26,CN 202211570333 A;;CN 202211570537 A;;CN 202211570539 A;;CN 2023136683 W,2022-12-08,"USE OF BOVINE SPLEEN PEPTIDE POWDER IN IMPROVING SLEEP, PREVENTING OR TREATING DEPRESSION, OR IMPROVING INTESTINAL FUNCTION","Provided in the present invention is the use of bovine spleen peptide powder in the preparation of food for improving the sleep of subjects, relieving depression of subjects or improving the intestinal functions of subjects. Further provided in the present application is the use of bovine spleen peptide powder in preparation of drugs for preventing or treating the sleep disorders or depression of subjects, or for improving intestinal functions of subjects.",BEIJING NO 1 BIO TECH DEVELOPMENT CO LTD,ZHANG BOWEN;;ZHENG XINYUE;;CAO YUAN,BEIJING NO.1 BIO-TECHNOLOGY DEVELOPMENT CO. LTD (2025-02-24),https://lens.org/158-489-281-454-38X,Patent Application,yes,5,0,5,158-489-281-454-38X;;145-004-987-379-908;;193-673-263-157-989;;198-081-232-581-704;;198-375-192-768-016,KR;;AU;;EP;;WO;;US,11,193-673-263-157-989;;198-375-192-768-016;;198-081-232-581-704;;158-489-281-454-38X;;084-065-953-591-554;;197-565-032-254-279;;145-004-987-379-908;;105-598-905-995-855;;184-486-286-655-18X;;042-000-248-102-363;;032-248-665-705-532,AU;;KR;;EP;;CN;;WO;;US,0,A23L33/18;;A61P25/20;;A61K35/26;;A61P25/24;;A61P1/10;;A61K38/012;;A61K38/00;;A23L33/18;;A23P10/00;;A61K35/26;;A61K38/01;;A61P1/10;;A61P25/20;;A61P25/24;;A23L13/20;;A23V2250/55;;A23V2200/31;;A23V2200/322;;A23V2200/32;;A23V2300/31;;A23V2300/26;;A23V2300/20;;A23V2300/34;;A23V2300/10;;A23V2002/00;;A23L33/18;;A61P25/24;;A61K35/26;;A61K38/012;;A61K38/1709,A61K35/26;;A23L33/18;;A61K38/01;;A61K38/17;;A61P25/24,,0,0,,,,PENDING
679,US,A1,US 2020/0338044 A1,152-947-823-344-036,2020-10-29,2020,US 201716341186 A,2017-10-13,GB 201617526 A;;GB 201704719 A;;EP 2017076257 W,2016-10-14,TREATMENT OF CHOLANGIOCARCINOMA WITH TPCS-2A INDUCED PHOTOCHEMICAL INTERNALISATION OF GEMCITABINE,"The present invention provides a method of treating a cholangiocarcinoma in a human patient comprising a photochemical internalization method using TPCS2a, and gemcitabine and optionally another cytotoxic agent, preferably cisplatin. Related uses and kit for performing the invention are also provided.",PCI BIOTECH AS,HØGSET ANDERS;;WALDAY PER EDVARD;;SELBO PÅL KRISTIAN;;EIVINDVIK KRISTIN;;FINNESAND LENA,PCI BIOTECH AS (2019-07-09),https://lens.org/152-947-823-344-036,Patent Application,yes,0,0,15,152-947-823-344-036;;040-299-068-474-30X;;040-160-808-795-912;;093-285-845-067-561;;007-670-203-017-636;;121-157-192-029-45X;;120-599-295-798-448;;160-921-610-466-210;;061-611-505-817-602;;001-373-041-626-084;;040-404-063-679-914;;004-956-130-870-007;;112-243-607-444-298;;092-501-943-962-540;;100-511-747-423-598,AU;;JP;;RU;;US;;CA;;PL;;KR;;ES;;EP;;CN;;WO;;SG;;DK,17,152-947-823-344-036;;040-299-068-474-30X;;040-160-808-795-912;;093-285-845-067-561;;007-670-203-017-636;;121-157-192-029-45X;;160-921-610-466-210;;120-599-295-798-448;;122-483-814-701-264;;061-611-505-817-602;;001-373-041-626-084;;040-404-063-679-914;;067-755-752-371-194;;004-956-130-870-007;;112-243-607-444-298;;092-501-943-962-540;;100-511-747-423-598,AU;;JP;;RU;;US;;CA;;PL;;KR;;ES;;EP;;CN;;WO;;SG;;GB;;DK,0,A61K31/409;;A61K31/7068;;A61K33/243;;A61K41/0071;;A61P1/16;;A61P35/00;;A61K41/0071;;A61K31/7068;;A61K33/243;;A61K2300/00;;A61P35/00;;A61K31/409;;A61K9/0019;;A61K31/7068;;A61K33/243;;A61K41/0071;;A61P35/04,A61K31/409;;A61K9/00;;A61K31/7068;;A61K33/243;;A61K41/00;;A61P35/04,,0,0,,,,DISCONTINUED
680,US,A1,US 2021/0199591 A1,180-480-333-908-643,2021-07-01,2021,US 201917057726 A,2019-05-21,CN 201810491322 A;;CN 2019087829 W,2018-05-21,"CHEMICAL LUMINESCENCE ANALYSIS AND MEASUREMENT METHOD, SYSTEM USING SAME, AND KIT","A chemical luminescence immune analysis and measurement method, a system using the chemical luminescence immune analysis and measurement method, and a kit are disclosed. The method broadens a detection range and indicates an HD-HOOK sample or a sample that is beyond the detection range by way of selecting two signal values from signal values that are read in multiple times.",BEYOND DIAGNOSTICS SHANGHAI CO LTD;;CHEMCLIN DIAGNOSTICS CO LTD,YANG YANG;;LIU YUHUI;;LI LIN,CHEMCLIN DIAGNOSTICS (SHANGHAI) CO. LTD (2020-11-30);;CHEMCLIN DIAGNOSTICS CO. LTD (2020-11-30),https://lens.org/180-480-333-908-643,Patent Application,yes,2,4,6,130-183-021-962-013;;180-480-333-908-643;;117-225-361-290-833;;120-445-954-803-06X;;191-635-388-883-589;;165-757-929-916-084,JP;;CN;;EP;;WO;;US,6,165-757-929-916-084;;180-480-333-908-643;;117-225-361-290-833;;120-445-954-803-06X;;191-635-388-883-589;;130-183-021-962-013,JP;;EP;;CN;;WO;;US,0,G01N21/76;;G01N33/53;;G01N33/582;;G01N21/76;;G01N33/53;;G01N33/557;;G01N21/76;;G01N33/53,G01N21/76;;G01N33/53,,0,0,,,,DISCONTINUED
681,WO,A1,WO 2023/249905 A1,036-760-534-119-531,2023-12-28,2023,US 2023/0025655 W,2023-06-19,US 202263354150 P;;US 202263382691 P,2022-06-21,COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS,Embodiments of the present application relate to polymers used as polymeric polyvalent hubs for liquid phase oligonucleotide synthesis. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the polymers are also provided.,HONGENE BIOTECH CORP,YANG GAOMAI;;SONG JINGSHE;;WANG SHENGDONG;;YAO YUN-CHIAO;;YANG HONGRONG;;YU DAVID;;LAU ALDRICH,,https://lens.org/036-760-534-119-531,Patent Application,yes,5,0,7,168-971-791-739-439;;036-760-534-119-531;;040-339-795-636-487;;192-544-057-058-747;;126-960-644-822-980;;079-912-985-896-583;;028-433-792-096-362,JP;;CN;;EP;;WO;;US,7,168-971-791-739-439;;036-760-534-119-531;;040-339-795-636-487;;192-544-057-058-747;;126-960-644-822-980;;079-912-985-896-583;;028-433-792-096-362,JP;;CN;;EP;;WO;;US,0,C08G65/3356;;C08G2650/30;;C08G65/33396;;C08G65/3358;;C08G65/337;;C40B50/12;;C07H21/00;;C07H1/00;;C08F220/286;;C08F220/56;;C08F120/68;;C08G65/33306;;C08G65/33396;;C07H1/00;;C08F120/68;;C08F265/10;;C08F220/56;;C08F220/286,C08G65/335;;C07H21/00;;C08G65/333;;C08G65/337;;C40B50/12,,3,3,135-025-055-227-082;;038-999-484-404-701;;017-903-295-413-659,10.1002/1616-5195(200101)1:1<30::aid-mabi30>3.0.co;2-v;;10.1039/c4py01607f;;pmc330918;;2356115;;10.1093/nar/18.11.3155,"FENG YAKAI, KLEE DORIS, KEUL HELMUT, HÖCKER HARTWIG: ""Synthesis and Characterization of New Block Copolymers with Poly(ethylene oxide) and Poly[3(S)-sec-butylmorpholine-2,5-dione] Sequences"", MACROMOLECULAR BIOSCIENCE, WILEY-VCH VERLAG GMBH, DE, vol. 1, no. 1, 1 January 2001 (2001-01-01), DE , pages 30 - 39, XP093126557, ISSN: 1616-5187, DOI: 10.1002/1616-5195(200101)1:1<30::AID-MABI30>3.0.CO;2-V;;YUN ZHANG, MAOHUA CHEN, XIAOMING LUO, HONG ZHANG, CHAOYU LIU, HUIYAN LIA, XIAOHONG LI: ""Tuning multiple arms for camptothecin and folate conjugations on star-shaped copolymers to enhance glutathione-mediated intracellular drug delivery"", POLYMER CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, vol. 6, no. 12, 28 March 2015 (2015-03-28), Cambridge , pages 2192 - 2203, XP002791077, ISSN: 1759-9954, DOI: 10.1039/C4PY01607F;;GIAN MARIA BONORA, CARLO LUIGI SCREMIN, FRANCESCO PAOLO COLONNA AND ANNA GARBESI: ""HELP (High Efficiency Liquid Phase) new oligonucleotide synthesis on soluble polymeric support"", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 18, 1 January 1990 (1990-01-01), GB , pages 3155 - 3159, XP001538571, ISSN: 0305-1048, DOI: 10.1093/nar/18.11.3155",PENDING
682,US,A1,US 2024/0002420 A1,028-433-792-096-362,2024-01-04,2024,US 202318337233 A,2023-06-19,US 202318337233 A;;US 202263354150 P;;US 202263382691 P,2022-06-21,COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS,Embodiments of the present application relate to polymers used as polymeric polyvalent hubs for liquid phase oligonucleotide synthesis. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the polymers are also provided.,HONGENE BIOTECH CORP,YANG GAOMAI;;SONG JINGSHE;;WANG SHENGDONG;;YAO YUN-CHIAO;;YANG HONGRONG;;YU DAVID;;LAU ALDRICH N K,HONGENE BIOTECH CORPORATION (2023-08-08),https://lens.org/028-433-792-096-362,Patent Application,yes,2,3,7,168-971-791-739-439;;036-760-534-119-531;;040-339-795-636-487;;192-544-057-058-747;;126-960-644-822-980;;079-912-985-896-583;;028-433-792-096-362,JP;;CN;;EP;;WO;;US,7,168-971-791-739-439;;036-760-534-119-531;;040-339-795-636-487;;192-544-057-058-747;;126-960-644-822-980;;079-912-985-896-583;;028-433-792-096-362,JP;;CN;;EP;;WO;;US,0,C08G65/3356;;C08G2650/30;;C08G65/33396;;C08G65/3358;;C08G65/337;;C40B50/12;;C07H21/00;;C07H1/00;;C08F220/286;;C08F220/56;;C08F120/68;;C08G65/33306;;C08G65/33396;;C07H1/00;;C08F120/68;;C08F265/10;;C08F220/56;;C08F220/286,C07H1/00;;C08F120/68;;C08F220/28;;C08F220/56;;C08F265/10,,0,0,,,,ACTIVE
683,US,A1,US 2025/0034192 A1,040-339-795-636-487,2025-01-30,2025,US 202418902678 A,2024-09-30,US 202418902678 A;;US 202318337233 A;;US 202263382691 P;;US 202263354150 P,2022-06-21,COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS,Embodiments of the present application relate to polymers used as polymeric polyvalent hubs for liquid phase oligonucleotide synthesis. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the polymers are also provided.,HONGENE BIOTECH CORP,YANG GAOMAI;;SONG JINGSHE;;WANG SHENGDONG;;YAO YUN-CHIAO;;YANG HONGRONG;;YU DAVID;;LAU ALDRICH N K,,https://lens.org/040-339-795-636-487,Patent Application,yes,0,0,7,168-971-791-739-439;;036-760-534-119-531;;040-339-795-636-487;;192-544-057-058-747;;126-960-644-822-980;;079-912-985-896-583;;028-433-792-096-362,JP;;CN;;EP;;WO;;US,7,168-971-791-739-439;;036-760-534-119-531;;040-339-795-636-487;;192-544-057-058-747;;126-960-644-822-980;;079-912-985-896-583;;028-433-792-096-362,JP;;CN;;EP;;WO;;US,0,C08G65/3356;;C08G2650/30;;C08G65/33396;;C08G65/3358;;C08G65/337;;C40B50/12;;C07H21/00;;C07H1/00;;C08F220/286;;C08F220/56;;C08F120/68;;C08G65/33306;;C08G65/33396;;C07H1/00;;C08F120/68;;C08F265/10;;C08F220/56;;C08F220/286,C07H1/00;;C08F120/68;;C08F220/28;;C08F220/56;;C08F265/10,,0,0,,,,PENDING
684,WO,A1,WO 2024/107452 A1,053-349-117-602-721,2024-05-23,2024,US 2023/0037281 W,2023-11-14,US 202263426554 P,2022-11-18,"METHODS FOR DETECTING AND DETERMINING PROTEIN STRUCTURES AND STABILITY IN FLUIDS, INCLUDING BIOLOGICAL FLUIDS","The present inventions provide methods for detecting and determining protein structures and stability, including heteromeric protein complexes, in biological fluids, such as serum and other bodily fluids. Systems for performing the methods also are provided.",REGENERON PHARMA;;ROSCONI MICHAEL;;LIU NINA;;PYLES ERICA,ROSCONI MICHAEL;;LIU NINA;;PYLES ERICA,,https://lens.org/053-349-117-602-721,Patent Application,yes,6,0,6,053-349-117-602-721;;096-158-028-248-255;;110-301-728-672-449;;024-744-825-169-795;;043-481-858-798-974;;195-939-483-287-150,WO;;US;;TW,6,053-349-117-602-721;;024-744-825-169-795;;110-301-728-672-449;;096-158-028-248-255;;043-481-858-798-974;;195-939-483-287-150,WO;;US;;TW,0,G01N2030/003;;G01N30/0005;;G01N21/6428;;G01N33/56983;;G01N33/582;;G01N2021/6439;;G01N2333/015;;G01N30/0005;;G01N33/6854;;G01N2030/003,G01N30/00,,1,1,058-446-963-794-298,10.1016/j.copbio.2014.06.010;;25005678,"BUTLERSPEARMAN: ""Tile choice of mammalian cell host and possibilities for glycosylation engineering"", CURR. OPIN. BIOTECH., vol. 30, 2014, pages 107 - 112",PENDING
685,WO,A2,WO 2023/034336 A2,028-261-464-725-109,2023-03-09,2023,US 2022/0042088 W,2022-08-30,US 202163238739 P;;US 202263399977 P,2021-08-30,IMPROVED TREATMENTS FOR ADVANCED/METASTATIC CANCERS WITH CHECKPOINT INHIBITOR RESISTANCE OR RESISTANCE SUSCEPTIBILITY,"This invention is in the area of improved therapeutic methods for difficult to treat locally advanced and/or metastatic cancers in patients whose cancer has advanced while being treated with an immune checkpoint inhibitor due to the development of resistance to the inhibitory effects of the immune checkpoint inhibitor or whose cancer is susceptible to the development of resistance to the effects of an immune checkpoint inhibitor. The methods of the present invention are particularly suitable for a select group of hard-to-treat patients with advanced/metastatic triple negative breast cancer (TNBC), recurrent or metastatic non-small cell lung cancer (NSCLC), advanced or metastatic and unresectable colorectal cancer and locally advanced or metastatic urothelial carcinoma, and provides extended progression free survival (PFS) and/or increased overall survival (OS) in these patient populations.",G1 THERAPEUTICS INC,BEELEN ANDREW;;MALIK RAJESH;;YI JOHN,,https://lens.org/028-261-464-725-109,Patent Application,yes,0,1,3,028-261-464-725-109;;051-108-206-344-234;;117-141-899-370-896,WO;;TW,4,045-743-530-523-862;;028-261-464-725-109;;117-141-899-370-896;;051-108-206-344-234,CN;;WO;;TW,0,C07D487/14;;A61K31/519;;A61K39/39541;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2803;;C07K16/2818,A61K31/519;;C07D487/14,,0,0,,,,PENDING
686,WO,A1,WO 2025/046598 A1,196-267-668-665-813,2025-03-06,2025,IN 2024050764 W,2024-06-11,IN 202341057697 A,2023-08-28,SOLID TABLET SEMIOCHEMICAL DISPENSERS FOR MATING DISRUPTION AND MASS TRAPPING OF INSECTS,"The present invention discloses a novel sustained release solid tablet semiochemical/s dispenser wherein Semiochemicals can be pheromone or allelochemicals and method of preparation thereof. The solid tablet semiochemical/s dispenser comprises low-cost release controlling agent oils- mesoporous material mixture in addition to Semiochemicals and other functional ingredients, releases semiochemical/s in sustained manner for prolonged duration when placed in open environment or in agricultural field and can be used for mating disruption or mass trapping-control of targeted insects. Solid tablet dispenser containing attractant semiochemical/s are additionally capable of releasing semiochemical even when submerged in water and providing attraction for mass trapping -control. Solid tablet semiochemical/s dispenser disclosed herein are stable, can be packed in blister pack, stored up to two years under normal storage conditions, and exhibits average release rate from 0.02mg per day to 0.2mg per day for straight chain lepidopteran pheromones whereas 5 mg/day for attractant Semiochemicals.",PHEROMONES BIOTECH LLP;;ATGC BIOTECH PRIVATE LTD,MUKUL MUKESH KUMAR;;MAGANTI RADHA SRIKRISHNA;;PATIL VISHAL;;GORANTLA DR MARKANDEYA;;REDDY KAUKUTTLA AKSHITHA,,https://lens.org/196-267-668-665-813,Patent Application,yes,2,0,2,196-267-668-665-813;;012-605-407-723-380,WO,2,196-267-668-665-813;;012-605-407-723-380,WO,0,A01P7/04;;A01P19/00;;A01N43/22,A01N25/00;;A01N27/00,,0,0,,,,PENDING
687,US,A1,US 2024/0156962 A1,067-268-901-672-946,2024-05-16,2024,US 202318499720 A,2023-11-01,US 202318499720 A;;US 202263421740 P,2022-11-02,BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA,"A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN CHANG;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,JANSSEN RESEARCH & DEVELOPMENT LLC (2023-12-13);;JANSSEN BIOTECH INC (2023-12-13);;LEGEND BIOTECH USA INC (2023-11-21),https://lens.org/067-268-901-672-946,Patent Application,yes,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,A61K39/00;;A61P35/00;;C12Q1/6886,,0,0,,,,PENDING
688,US,A1,US 2023/0061503 A1,169-852-505-734-229,2023-03-02,2023,US 202217740665 A,2022-05-10,US 202217740665 A;;US 202163186872 P,2021-05-11,METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY,The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;MONDELO MARIA MARQUEZ DE;;OLYSLAGER YUNSI;;QIU JUN;;UBANI ENRIQUE ZUDAIRE;;XU JEAN,JANSSEN RESEARCH & DEVELOPMENT LLC (2022-05-19);;JANSSEN PHARMACEUTICA NV (2022-05-13);;JANSSEN BIOTECH INC (2022-05-19);;LEGEND BIOTECH USA INC (2022-05-12),https://lens.org/169-852-505-734-229,Patent Application,yes,1,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,A61K35/17;;A61K31/573;;A61K45/06;;A61P35/00;;G01N33/68,,6,6,045-476-680-279-398;;130-321-728-271-913;;042-563-381-682-300;;070-476-692-044-314;;004-406-253-828-38X;;051-812-788-460-970,pmc12180426;;10.1016/j.bbmt.2018.12.758;;30592986;;10.1016/j.jtct.2021.03.004;;33831353;;10.1158/2159-8290.cd-17-1319;;pmc6385599;;29880584;;31723825;;pmc6746032;;10.1097/hs9.0000000000000186;;10.1016/j.jcrc.2020.04.008;;pmc7321897;;32361219;;33424871;;10.3389/fimmu.2020.620312;;pmc7793717,"Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25: 625-638. (Year: 2019);;Bannerjee et al. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplantation and Cellular Therapy 27: 477.e1-477.e7. (Year: 2021);;Santomasso et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discovery 8: 958-971. (Year: 2018);;Yanez et al. CAR T Cell Toxicity: Current Management and Future Directions. HemaSphere 3. 1-10. (Year: 2019);;Gutierrez et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care 58: 58-64 (Year: 2020);;Zhou et al. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology,. Front. Immunol. 11: 1-16. (Year: 2020)",PENDING
689,FR,A1,FR 3147947 A1,019-415-909-270-876,2024-10-25,2024,FR 2404011 A,2024-04-18,US 202363497185 P;;US 202363504184 P;;US 2023/0031673 W,2023-04-19,Thérapie par cellule CAR-T ciblée par BCMA de Myélome Multiple,La présente invention concerne des procédés de traitement d’un sujet atteint d’un myélome multiple et ayant reçu un à trois traitements antérieurs. Des perfusions de récepteur antigénique chimérique (CAR)-lymphocytes T comprenant un CAR capable de se lier spécifiquement à un épitope de BCMA sont administrées au sujet.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,,https://lens.org/019-415-909-270-876,Patent Application,no,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/17;;A61P35/00,,0,0,,,,PENDING
690,KR,A,KR 20250103641 A,062-534-687-026-106,2025-07-07,2025,KR 20257015147 A,2023-11-01,US 202263421740 P;;US 2023/0078327 W,2022-11-02,다발성 골수종의 BCMA-표적화된 CAR-T 세포 요법,T 세포를 대상체에게 투여하는 단계 및 대상체가 미세 잔존 질병(MRD) 음성 상태를 유지하는 시간 길이에 기초하여 치료에 대한 대상체의 반응성을 평가하는 단계를 포함하는 2가 BCMA-표적화 키메라 항원 수용체(CAR)를 발현하는 T 세포를 포함하는 치료에 대한 대상체의 반응성의 평가 방법.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN CHANG;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,,https://lens.org/062-534-687-026-106,Patent Application,no,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,C12Q1/6886;;A61K40/11;;A61K40/31;;A61K40/42;;A61P35/00,,0,0,,,,PENDING
691,WO,A1,WO 2024/220152 A1,152-849-271-863-276,2024-10-24,2024,US 2024/0017813 W,2024-02-29,US 202363497185 P;;US 202363504184 P;;US 2023/0031673 W,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN;;DE ASCENSAO SLAUGHTER ANA;;LONARDI CAROLINA,,https://lens.org/152-849-271-863-276,Patent Application,yes,1,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,23,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,C07K14/705;;A61K35/17;;A61P35/00,,0,0,,,,PENDING
692,GR,A,GR 20230100701 A,090-150-034-626-246,2024-11-11,2024,GR 20230100701 A,2023-08-30,GR 20230100701 A,2023-08-30,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,,https://lens.org/090-150-034-626-246,Patent Application,no,2,0,2,090-150-034-626-246;;032-548-862-613-906,GR,2,090-150-034-626-246;;032-548-862-613-906,GR,0,A61K2239/13;;A61K2239/48;;A61K2239/21;;A61K2239/22;;A61P35/02;;C07K2317/569;;C07K2317/35;;C07K2317/31;;C07K16/2875;;A61K2239/38;;A61K40/11;;A61K40/4215;;A61K40/31;;A61K39/00;;A61P35/02,A61K39/00;;A61P35/02,,4,3,159-377-963-276-269;;021-215-676-003-253;;088-604-414-954-219,10.1200/jco.22.00842;;35658469;;pmc9937098;;10.1002/jha2.312;;pmc9175662;;35846215;;10.1056/nejmoa2024850;;33626253,"MARTIN THOMAS ET AL: ""Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up"", JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 6, 20 February 2023 (2023-02-20), US, pages 1265 - 1274, XP093143716, ISSN: 0732-183X, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937098/pdf/jco-41-1265.pdf> DOI: 10.1200/JCO.22.00842;;MARTIN THOMAS ET AL: ""Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma"", EJHAEM, vol. 3, no. 1, 1 February 2022 (2022-02-01), pages 97 - 108, XP093143775, ISSN: 2688-6146, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175662/pdf/JHA2-3-97.pdf> DOI: 10.1002/jha2.312;;ANONYMOUS: ""FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma | FDA"", 28 February 2022 (2022-02-28), XP093143644, Retrieved from the Internet <URL:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma> [retrieved on 20240320];;MUNSHI NIKHIL C. ET AL: ""Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 384, no. 8, 25 February 2021 (2021-02-25), US, pages 705 - 716, XP055951668, ISSN: 0028-4793, Retrieved from the Internet <URL:https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024850?articleTools=true> DOI: 10.1056/NEJMoa2024850",ACTIVE
693,AR,A1,AR 125827 A1,182-214-796-170-834,2023-08-16,2023,AR P220101236 A,2022-05-10,US 202163186872 P,2021-05-11,MÉTODOS PARA MINIMIZAR LA NEUROTOXICIDAD ASOCIADA A LA TERAPIA CON CÉLULAS T DEL RECEPTOR DE ANTÍGENO QUIMÉRICO (CAR),"Reivindicación 1: Un método para reducir la neurotoxicidad asociada con la terapia de células T con receptor de antígeno quimérico (CAR), dicho método caracterizado porque comprende: administrar la terapia de células T con CAR a un sujeto; determinar una o más de (i) la carga tumoral del sujeto antes de dicha administración, (ii) los niveles de IL-6 del sujeto al momento de dicha administración, (iii) la expansión de las células T con CAR en dicho sujeto después de dicha administración, (iv) la persistencia de las células T con CAR en sangre periférica de dicho sujeto después de dicha administración, (v) el desarrollo del síndrome de liberación de citocinas (CRS) de grado ³ 2 en dicho sujeto después de dicha administración, (vi) el desarrollo del síndrome de neurotoxicidad asociado a células efectoras inmunitarias (ICANS) en dicho sujeto después de dicha administración, (vii) los niveles pico de IL-6 en sangre periférica en dicho sujeto después de dicha administración, (viii) los niveles pico de INF-g en sangre periférica en dicho sujeto después de dicha administración; y (iv) recuento de linfocitos en dicho sujeto después de dicha administración; y administrar una mitigación terapéutica a dicho sujeto, basada en dicha determinación, para reducir la neurotoxicidad asociada a la terapia de células T con CAR.",JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;MARQUEZ MONDELO MARIA;;OLYSLAGER YUNSI;;QIU JUN;;UBANI ENRIQUE ZUDAIRE;;XU JEAN,,https://lens.org/182-214-796-170-834,Patent Application,no,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,A61K39/00;;G01N33/569;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
694,IL,A,IL 322458 A,194-338-064-490-023,2025-09-01,2025,IL 32245825 A,2025-07-30,IN 202341006870 A;;IN 202341030797 A;;IN 202341057254 A;;IN 2024050099 W,2023-02-02,A process for producing pheromones and applications thereof,,ATGC BIOTECH PVT LTD;;PHEROMONES BIOTECH LLP,,,https://lens.org/194-338-064-490-023,Patent Application,no,0,0,2,194-338-064-490-023;;082-800-807-867-95X,IL;;WO,2,194-338-064-490-023;;082-800-807-867-95X,IL;;WO,0,C12P7/24;;C12P7/6409;;C12P7/6427;;C12P7/04;;C12Y110/03002;;C12R2001/645;;C12Y114/19;;C12N9/0061;;C12N9/0071;;C12N15/52,C12N15/52,,0,0,,,,PENDING
695,WO,A1,WO 2024/236592 A1,168-837-109-432-315,2024-11-21,2024,IN 2024050506 W,2024-05-09,IN 202341034948 A,2023-05-18,AN ENZYMATIC PROCESS FOR THE PRODUCTION OF VERBENONE AND IMPLEMENTATIONS THEREOF,"The present disclosure provides a process for the conversion of α-pinene to verbenone comprising: (a) mixing α-pinene and an aqueous solution comprising laccase, at a temperature in the range of 20 °C and 45 °C to obtain a reaction mixture; and (b) adding a mediator to the reaction mixture in the presence of an oxygen source, to obtain verbenone.",ATGC BIOTECH PVT LTD;;PHEROMONES BIOTECH LLP,DUMBALA SRINIVAS REDDY;;FADNAVIS NITIN WASANTRAO;;NIZAMPATNAM NARASIMHA RAO;;PERAM RAVINDRA BABU;;LACHAGARI VIJAY BHASKER REDDY;;LEKKALA SIVARAM PASAD;;KAUKUTTLA AKSHITHA REDDY;;GORANTLA MARKANDEYA,,https://lens.org/168-837-109-432-315,Patent Application,yes,0,0,1,168-837-109-432-315,WO,1,168-837-109-432-315,WO,0,C12P7/26;;C12Y110/03002;;C12Y111/01006;;C12Y101/03004,C12P1/00;;C12P5/00,,2,2,086-389-155-843-546;;095-644-068-143-746,10.31185/jwsm.167;;10.1016/s1381-1177(99)00117-4,"TAHA ALI A: ""Biotransformation of Natural Compounds by Free and Immobilized Fungal Laccase using Mediator Combinations in the LMS Reaction Model"", WASIT JOURNAL FOR SCIENCE AND MEDICINE, vol. 5, no. 1, 1 January 2012 (2012-01-01), pages 22 - 31, XP093241537;;M.-L NIKU-PAAVOLA ET AL.: ""Enzymatic oxidation of alkenes"", JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC, vol. 10, no. 4, 2000, pages 435 - 444, XP002191960, DOI: 10.1016/S1381-1177(99)00117-4",PENDING
696,US,A1,US 2022/0162543 A1,057-222-872-031-544,2022-05-26,2022,US 201917419122 A,2019-12-27,CN 201811619556 A;;CN 2019129359 W,2018-12-28,PICHIA PASTORIS MUTANT STRAIN FOR EXPRESSING EXOGENOUS GENE,"Provided is a Pichia pastoris mutant strain for expressing an exogenous gene. Specifically, provided is a Pichia pastoris mutant strain comprising, with respect to Pichia pastoris mutant strain GS115 or CICC32806, one or more of the following six mutations: BQ9382_C1-2260, EKK deletions at positions 308-310, a hypothetical protein; BQ9382_C1-3800, E129K, 60S ribosomal subunit assembly/exported protein LOC1; BQ9382_C1-5700, I312M, mitochondrial external NADH dehydrogenase, type II NAD(P)H:quinone oxidoreductase; BQ9382_C2-3950, Q145X, an essential protein having a binding partner Psr1p and used for completely activating a general stress response; BQ9382_C3-2220, E188K, a hypothetical protein; and BQ9382_C3-4370, W196X, orotidine 5\′-phosphate decarboxylase. The provided Pichia pastoris mutant strain is an effective commonly employed host for exogenous expression, and can efficiently express different proteins, especially phospholipase and lipase.",WILMAR SHANGHAI BIOTECHNOLOGY RES & DEV CT CO LTD,WU WEI;;DAI XIAOJUN;;CAO HAISHENG;;ZHOU MEIFENG;;NIU QIWEN,WILMAR (SHANGHAI) BIOTECHNOLOGY RESEARCH & DEVELOPMENT CENTER CO. LTD (2021-07-16),https://lens.org/057-222-872-031-544,Patent Application,yes,2,2,10,174-317-804-960-572;;182-024-886-560-783;;145-970-296-750-084;;057-222-872-031-544;;018-618-229-657-499;;135-789-659-937-544;;147-273-776-370-282;;094-534-430-362-076;;033-671-302-470-185;;000-701-218-554-252,JP;;CN;;EP;;WO;;US,10,174-317-804-960-572;;182-024-886-560-783;;145-970-296-750-084;;057-222-872-031-544;;018-618-229-657-499;;135-789-659-937-544;;147-273-776-370-282;;094-534-430-362-076;;033-671-302-470-185;;000-701-218-554-252,JP;;CN;;EP;;WO;;US,17,C12N9/20;;C12Y301/01003;;C12N9/50;;C12N9/2437;;C12Y302/01004;;C12N9/2411;;C12N9/2465;;C12N9/18;;C12N1/16;;C12N15/815;;C11B3/003;;C11C3/10;;C11C3/10;;C12N9/20;;C12R2001/84;;C11B3/003;;A23K20/147;;A23K20/189;;A23L29/06;;A23L33/14;;A23L33/195;;C12Y106/0501;;C12Y401/01023;;C12N9/88;;C12N9/0036;;C12Y106/05;;C12N9/52;;C07K14/39;;C12N1/165;;C12N15/815;;C12N1/165;;C12R2001/84;;C12N9/16;;C12N15/815;;C12P7/649,C12N1/16;;C12N9/16;;C12N15/81;;C12P7/649,,1,1,029-019-062-596-384,3419283;;10.1007/bf02535672,"Boel et al., “Rhizomucor miehei triglyceride lipase is synthesized as a precursor”, Lipids, 1988, vol. 23 (7), pages 701-706. (Year: 1988)",ACTIVE
697,WO,A1,WO 2024/150040 A1,151-375-276-598-653,2024-07-18,2024,IB 2023054729 W,2023-05-06,IN 202341002655 A,2023-01-12,CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS,": The present disclosure relates to a water dispersible, semi-solid emulsion which can be applied as dollops or sprayed on plant foliage, its surfaces, any support systems in agricultural field to treat, and prevent insect population either by mass trapping, mating disruption or attract & kill technique and method of preparing the composition. The semi-solid composition comprises either semiochemical(s) alone or adsorbed on mesoporous materials or encapsulated with polymer matrix and combination thereof which displays sustained release for a longer period of time. The composition is water dispersible, eco-friendly in nature, cost-effective, exhibits stable physiochemical properties with good adhesion properties to plant surface after application and necessary rain fastness.",PHEROMONES BIOTECH LLP;;ATGC BIOTECH PRIVATE LTD,GORANTLA DR MARKANDEYA;;REDDY KAUKUTTLA AKSHITHA;;MAGANTI RADHA SRIKRISHNA;;PATIL VISHAL;;MUKUL MUKESH KUMAR,,https://lens.org/151-375-276-598-653,Patent Application,yes,2,0,3,151-375-276-598-653;;113-034-682-691-374;;156-781-279-786-612,WO;;US;;IN,3,151-375-276-598-653;;113-034-682-691-374;;156-781-279-786-612,WO;;US;;IN,0,A01N25/04;;A01N37/02;;A01P17/00;;A01N35/02;;A01N35/02;;A01N31/02,A61K9/00;;A01N25/04,,0,0,,,,PENDING
698,US,A1,US 2024/0358754 A1,012-834-079-213-873,2024-10-31,2024,US 202418592234 A,2024-02-29,US 202418592234 A;;US 202363504184 P;;US 202363497185 P,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,MCNEIL PANAMA LLC (2024-06-04);;JANSSEN RESEARCH & DEVELOPMENT LLC (2024-06-05);;CILAG GMBH INTERNATIONAL (2024-06-05);;JANSSEN PHARMACEUTICA NV (2024-06-04);;JANSSEN BIOTECH INC (2024-06-10);;LEGEND BIOTECH USA INC (2024-03-08),https://lens.org/012-834-079-213-873,Patent Application,yes,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/17;;A61K39/00;;A61K45/06;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
699,NL,A,NL 2035704 A,036-468-946-847-588,2024-10-24,2024,NL 2035704 A,2023-08-30,US 202363504184 P;;US 202363497185 P,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s) . Infusions of chimeric antigen receptor (CAR)—T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,JORDAN MARK SCHECTER;;ANA RUTE DE ASCENSAO SLAUGHTER;;YUHONG QIU;;NITIN PATEL;;CAROLINA LONARDI;;LIDA PACAUD;;WILLIAM DERAEDT;;NIKOLETTA LENDVAI,,https://lens.org/036-468-946-847-588,Patent Application,no,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/17;;A61K39/00;;A61P35/00;;C07K14/725;;C12N5/0783,,0,0,,,,PENDING
700,EP,A1,EP 4008342 A1,116-222-870-247-489,2022-06-08,2022,EP 21164128 A,2021-03-23,EP 20211707 A,2020-12-03,IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV,"The invention relates to an immunogenic composition for use as a medicament to prevent and/or treat a medical condition associated with a SARS-CoV infection, said composition comprising one or more bacteria of the human microbiota and/or immunogenic parts thereof, wherein said composition is capable of inducing acquired immunity to said infection. The invention further relates to isolated bacteria of the human microbiota that bind to a neutralising antibody that recognises the spike protein of SARS-CoV, preferably the spike protein of SARS-CoV2. In another aspect, the invention relates to an in vitro method for the diagnosis, prognosis, risk stratification and/or therapy management of a human subject with an increased risk of an adverse event associated with a medical condition associated with a SARS-CoV infection (preferably with SARS-CoV-2).",DEUTSCHES RHEUMA FORSCHUNGSZENTRUM BERLIN,KRUGLOV ANDREY,,https://lens.org/116-222-870-247-489,Patent Application,yes,4,0,1,116-222-870-247-489,EP,5,177-602-220-068-048;;116-222-870-247-489;;098-900-490-400-866;;195-139-328-544-158;;135-962-658-947-165,EP;;WO;;US;;CA,0,A61K39/09;;A61K39/092;;A61K2039/58;;A61K2039/542;;A61K39/12;;C12N2770/20011;;A61P31/14;;A61K2039/521;;C07K16/1003;;A61K39/12;;C07K16/1003,A61K39/12;;A61K39/09;;A61K39/39;;A61P31/14;;C07K16/10,,16,9,011-255-032-933-205;;012-842-346-375-894;;027-174-881-360-743;;051-306-236-164-16X;;013-625-581-405-34X;;058-548-515-716-269;;059-613-353-592-383;;113-555-607-912-222;;113-555-607-912-222,10.23736/s0026-4806.20.06570-2;;32255312;;pmc7358304;;10.3389/fmed.2020.00389;;32733907;;10.1038/s41538-020-00078-9;;33083549;;pmc7536434;;34608166;;10.1007/s10096-015-2491-x;;26385346;;10.1053/j.gastro.2020.05.048;;32442562;;pmc7237927;;10.3389/fmicb.2020.01840;;pmc7411080;;32849438;;29771684;;10.1172/jci97065;;pmc6063483;;pmc4294419;;25121750;;10.1016/j.chom.2014.07.003;;pmc4294419;;25121750;;10.1016/j.chom.2014.07.003,"DI PIERRO FRANCESCO: ""A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2"", MINERVA MEDICA, vol. 111, no. 3, 1 June 2020 (2020-06-01), IT, XP055830162, ISSN: 0026-4806, Retrieved from the Internet <URL:https://www.minervamedica.it/en/getfreepdf/cmR3RW4wQlZ1NU9GWjQzNVY3NzhYVDR5MmdNU2dBRTQrZmlKRDBZenRzWmRUY2lhaG02eG5NVG0wRE01RkF4Uw%3D%3D/R10Y2020N03A0281.pdf> DOI: 10.23736/S0026-4806.20.06570-2;;GABRIELLA D'ETTORRE ET AL: ""Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19"", FRONTIERS IN MEDICINE, vol. 7, 7 July 2020 (2020-07-07), XP055758279, DOI: 10.3389/fmed.2020.00389;;OLAIMAT AMIN N. ET AL: ""The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19"", NPJ SCIENCE OF FOOD, vol. 4, no. 1, 1 December 2020 (2020-12-01), XP055830179, Retrieved from the Internet <URL:https://www.nature.com/articles/s41538-020-00078-9.pdf> DOI: 10.1038/s41538-020-00078-9;;MARCHISIO P ET AL: ""Streptococcus salivarius24SMB administered by nasal spray for the prevention of acute otitis media in otitis-prone children"", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, SPRINGER, WIESBADEN, DE, vol. 34, no. 12, 18 September 2015 (2015-09-18), pages 2377 - 2383, XP035893036, ISSN: 0934-9723, [retrieved on 20150918], DOI: 10.1007/S10096-015-2491-X;;ZUO TAO ET AL: ""Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization"", GASTROENTEROLOGY, ELSEVIER INC, US, vol. 159, no. 3, 20 May 2020 (2020-05-20), pages 944, XP086259055, ISSN: 0016-5085, [retrieved on 20200520], DOI: 10.1053/J.GASTRO.2020.05.048;;BAO LIRONG ET AL: ""Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection"", FRONTIERS IN MICROBIOLOGY, vol. 11, 31 July 2020 (2020-07-31), XP055830199, DOI: 10.3389/fmicb.2020.01840;;NINNEMANN JUSTUS ET AL: ""Induction of cross-reactive antibody responses against the RBD domain of the spike protein of SARS-CoV-2 by commensal microbiota"", BIORXIV, 8 August 2021 (2021-08-08), pages 1 - 27, XP055832001, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.08.08.455272v1.full.pdf> [retrieved on 20210813], DOI: 10.1101/2021.08.08.455272;;REN ET AL., J IMMUNOL, 2012;;MIAYUCHI ET AL., NATURE, 2020;;ROBAK ET AL., JCI, 2018;;ICHINOHE ET AL., PNAS, 2011;;SXHAUP ET AL., CELL, 2020;;ROBAK ET AL., JCI;;TRAMA ET AL., CELL HOST AND MICROBE, 2014;;TRAMA ET AL., CELL HOST & MICROBES, 2014;;GOMES M ET AL., NAT COMMS, 2021",PENDING
701,EP,A1,EP 4563012 A1,198-375-192-768-016,2025-06-04,2025,EP 23899997 A,2023-12-06,CN 202211570537 A;;CN 202211570333 A;;CN 202211570539 A;;CN 2023136683 W,2022-12-08,"USE OF BOVINE SPLEEN PEPTIDE POWDER IN IMPROVING SLEEP, PREVENTING OR TREATING DEPRESSION, OR IMPROVING INTESTINAL FUNCTION","Provided in the present invention is the use of bovine spleen peptide powder in the preparation of food for improving the sleep of subjects, relieving depressionof subjects or improving the intestinal functions of subjects. Further provided in the present application is the use of bovine spleen peptide powder in preparation of drugs for preventing or treating the sleep disorders or depression of subjects, or for improving intestinal functions of subjects.",BEIJING NO 1 BIO TECH DEVELOPMENT CO LTD,ZHANG BOWEN;;ZHENG XINYUE;;CAO YUAN,,https://lens.org/198-375-192-768-016,Patent Application,yes,0,0,5,158-489-281-454-38X;;145-004-987-379-908;;193-673-263-157-989;;198-081-232-581-704;;198-375-192-768-016,KR;;AU;;EP;;WO;;US,11,193-673-263-157-989;;198-375-192-768-016;;198-081-232-581-704;;158-489-281-454-38X;;084-065-953-591-554;;197-565-032-254-279;;145-004-987-379-908;;105-598-905-995-855;;184-486-286-655-18X;;042-000-248-102-363;;032-248-665-705-532,AU;;KR;;EP;;CN;;WO;;US,0,A23L33/18;;A61P25/20;;A61K35/26;;A61P25/24;;A61P1/10;;A61K38/012;;A61K38/00;;A23L33/18;;A23P10/00;;A61K35/26;;A61K38/01;;A61P1/10;;A61P25/20;;A61P25/24;;A23L13/20;;A23V2250/55;;A23V2200/31;;A23V2200/322;;A23V2200/32;;A23V2300/31;;A23V2300/26;;A23V2300/20;;A23V2300/34;;A23V2300/10;;A23V2002/00;;A23L33/18;;A61P25/24;;A61K35/26;;A61K38/012;;A61K38/1709,A23L33/18;;A61K35/26;;A61K38/01;;A61P1/10;;A61P25/20;;A61P25/24,,0,0,,,,PENDING
702,MX,A,MX 2025005091 A,050-228-838-896-205,2025-06-02,2025,MX 2025005091 A,2025-04-30,US 202263421740 P;;US 2023/0078327 W,2022-11-02,BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA,"A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN CHANG;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,,https://lens.org/050-228-838-896-205,Patent Application,no,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,A61K40/31;;A61K35/17;;A61K40/11;;A61K40/42;;A61P35/00;;C07K16/28;;C12Q1/6886,,0,0,,,,PENDING
703,WO,A1,WO 2024/220099 A1,179-806-961-014-503,2024-10-24,2024,US 2023/0031673 W,2023-08-31,US 202363497185 P;;US 202363504184 P,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN;;DE ASCENSAO SLAUGHTER ANA;;LONARDI CAROLINA,,https://lens.org/179-806-961-014-503,Patent Application,yes,1,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,23,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/17;;A61K31/454;;A61K35/00;;A61K39/395;;C07K14/075;;C07K16/28,,1,1,027-699-638-317-94X,10.1182/blood-2021-146072,"COHEN ET AL.: ""Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B- Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T- Cell Therapy, in Lenalidomide- Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2"", BLOOD, vol. 138, no. 1, 23 November 2021 (2021-11-23), pages 3866, XP055913140",PENDING
704,WO,A1,WO 2024/161427 A1,082-800-807-867-95X,2024-08-08,2024,IN 2024050099 W,2024-02-02,IN 202341006870 A;;IN 202341030797 A;;IN 202341057254 A,2023-02-02,A PROCESS FOR PRODUCING PHEROMONES AND APPLICATIONS THEREOF,"The present disclosure relates to a process for producing moth pheromones or precursors thereof, comprising a) obtaining a immobilized and/or permeabilized first yeast cell comprising at least one heterologous gene encoding fatty acid desaturase enzyme; and contacting with a first medium comprising a first substrate to obtain a first reaction mixture comprising mono- or poly-unsaturated C6-C24 fatty acid; b) obtaining a immobilized and/or permeabilized second yeast cell comprising at least one heterologous gene encoding fatty acid reductase enzyme; and contacting with a second medium comprising the first reaction mixture or a second substrate to obtain a second reaction mixture comprising mono- or poly¬ unsaturated C6-C24 fatty alcohol; and c) mixing an aqueous solution of laccase enzyme, the second reaction mixture, a mediator, and an emulsifying agent under a continuous supply of a gas, to obtain the pheromones or precursors thereof.",ATGC BIOTECH PVT LTD;;PHEROMONES BIOTECH LLP,DUMBALA SRINIVAS REDDY;;FADNAVIS NITIN WASANTRAO;;NIZAMPATNAM NARASIMHA RAO;;PERAM RAVINDRA BABU;;LACHAGARI VIJAY BHASKER REDDY;;LEKKALA SIVARAM PASAD;;KAUKUTTLA AKSHITHA REDDY;;ANTONY BINU;;GORANTLA MARKANDEYA,,https://lens.org/082-800-807-867-95X,Patent Application,yes,1,1,2,194-338-064-490-023;;082-800-807-867-95X,IL;;WO,2,194-338-064-490-023;;082-800-807-867-95X,IL;;WO,32,C12P7/24;;C12P7/6409;;C12P7/6427;;C12P7/04;;C12Y110/03002;;C12R2001/645;;C12Y114/19;;C12N9/0061;;C12N9/0071;;C12N15/52,C12N15/82;;C12P1/00;;C12P7/24;;C12P7/64,,2,2,007-519-592-442-393;;083-811-461-463-754,10.1016/j.ymben.2020.10.001;;10.1101/2020.07.15.205047;;33045365;;10.1016/j.cbpa.2017.12.001;;29258054,"CARINA HOLKENBRINK ET AL.: ""Production of moth sex pheromones for pest control by yeast fermentation."", METABOLIC ENGINEERING, vol. 62, November 2020 (2020-11-01), pages 312 - 321, XP086318447, DOI: 10.1016/j.ymben.2020.10.001;;JI LIU ET AL.: ""Recent advances in enzymatic oxidation of alcohols."", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 43, April 2018 (2018-04-01), pages 77 - 86, XP085358764, DOI: 10.1016/j.cbpa.2017.12.001",PENDING
705,EP,A1,EP 4612187 A1,153-388-751-374-284,2025-09-10,2025,EP 23886920 A,2023-11-01,US 202263421740 P;;US 2023/0078327 W,2022-11-02,BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA,,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN CHANG;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,,https://lens.org/153-388-751-374-284,Patent Application,yes,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,C07K16/28;;A61K35/17;;C12N5/10,,0,0,,,,PENDING
706,WO,A1,WO 2025/170902 A1,124-945-677-051-862,2025-08-14,2025,US 2025/0014440 W,2025-02-04,US 202463549995 P,2024-02-05,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,AKRAM MUHAMMAD;;LENDVAI NIKOLETTA;;JETHAVA YOGESH;;SCHECTER JORDAN;;DE BRAGANCA KEVIN,,https://lens.org/124-945-677-051-862,Patent Application,yes,26,0,2,093-517-015-489-773;;124-945-677-051-862,WO;;US,2,093-517-015-489-773;;124-945-677-051-862,WO;;US,23,A61K40/4215;;A61K40/11;;A61K40/31;;A61K2239/13;;A61K2239/38;;C07K16/241;;C07K16/245;;C07K16/248;;A61K39/3955;;A61P35/00;;A61K2239/48;;A61K31/675;;A61K31/216,A61K31/454;;A61K39/395;;A61K40/11;;A61K40/31;;A61K40/42;;A61P35/00;;C07K16/24,,49,36,168-500-357-078-892;;149-997-143-302-972;;011-796-487-203-489;;107-964-291-349-794;;027-528-264-957-646;;043-114-291-493-998;;049-134-753-209-354;;039-515-794-348-090;;050-959-366-576-084;;070-280-788-085-909;;149-205-978-448-517;;017-150-654-990-340;;002-264-966-090-625;;102-694-840-088-330;;063-086-322-407-483;;018-694-860-400-630;;035-100-608-588-913;;003-912-708-516-610;;019-206-191-830-81X;;003-931-599-928-408;;095-945-393-711-654;;060-578-906-283-340;;096-304-191-089-998;;064-758-125-126-733;;035-747-206-252-883;;036-537-002-834-639;;064-187-018-698-676;;032-772-146-652-02X;;071-155-283-247-726;;033-797-614-829-293;;117-599-617-388-110;;025-596-639-921-781;;009-034-724-212-694;;019-817-021-691-872;;032-942-121-304-562;;029-121-321-811-458,36119032;;10.3389/fimmu.2022.991092;;pmc9479060;;10.1182/blood-2019-121731;;10.1200/jco.2020.38.15_suppl.8505;;10.31525/ct1-nct04133636;;34627333;;10.1186/s13045-021-01170-7;;pmc8501733;;10.1084/jem.132.2.211;;pmc2138737;;5508247;;10.1016/0022-2836(87)90412-8;;3681981;;12477501;;10.1016/s0145-305x(02)00039-3;;8502296;;10.1038/363446a0;;10.1038/374168a0;;7877689;;10.2217/nnm.13.86;;23730699;;10.1126/science.3140379;;3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nbt0898-778;;9702779;;10.1038/346776a0;;2201923;;pmc39610;;8622939;;10.1073/pnas.93.8.3346;;10.1093/nar/27.22.4324;;pmc148712;;10536138;;10.1385/1-59259-922-2:123;;16082031;;10.1073/pnas.77.6.3567;;pmc349658;;6251468;;10.1016/0022-2836(81)90321-1;;6271971;;6096211;;10.1016/0378-1119(84)90115-x;;10.1126/science.3039660;;3039660;;13980043;;10.1073/pnas.48.12.2026;;pmc221117;;7460013;;10.1016/0092-8674(80)90558-9;;15385951;;10.1038/sj.gt.3302362;;3037341;;pmc365315;;10.1128/mcb.7.5.2031-2034.1987;;10.1128/mcb.7.5.2031;;825377;;10.1002/eji.1830060713;;6094669;;10.1016/0022-1759(84)90304-1;;10.1016/0076-6879(86)21014-9;;3014265;;10.1126/science.2531466;;2531466;;25061170;;10.1182/blood-2014-06-578989;;pmc4110654;;10.4049/jimmunol.180.3.1309;;18209024;;21926977;;pmc3192229;;10.1038/nm.2446;;6994593;;10.1146/annurev.bb.09.060180.002343;;19561539;;pmc2747302;;10.1097/cji.0b013e3181ac6138;;10.1200/jco.21.01045;;34520219,"CHEKOL ABEBE ENDESHAW ET AL: ""Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma"", FRONTIERS IN IMMUNOLOGY, vol. 13, 2 September 2022 (2022-09-02), Lausanne, CH, XP093143638, ISSN: 1664-3224, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479060/pdf/fimmu-13-991092.pdf> DOI: 10.3389/fimmu.2022.991092;;MADDURI DEEPU ET AL: ""Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)"", BLOOD, ELSEVIER, AMSTERDAM, NL, vol. 134, 13 November 2019 (2019-11-13), pages 577, XP086674286, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-121731;;BERDEJA JESUS G. ET AL: ""Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma"", JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15_suppl, 20 May 2020 (2020-05-20), pages 8505 - 8505, XP093270548, ISSN: 0732-183X, Retrieved from the Internet <URL:https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.8505> DOI: 10.1200/JCO.2020.38.15_suppl.8505;;ANONYMOUS: ""NCT03548207: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)"", 23 January 2024 (2024-01-23), XP093270546, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT03548207?tab=history&a=41#version-content-panel>;;MEI HENG ET AL: ""A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma"", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 14, no. 1, 9 October 2021 (2021-10-09), London UK, XP093148037, ISSN: 1756-8722, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s13045-021-01170-7/fulltext.html> DOI: 10.1186/s13045-021-01170-7;;WUKABAT, J. EXP. MED., vol. 132, 1970, pages 211 - 50;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", vol. 7, 1991, NATIONAL INSTITUTES OF HEALTH, article ""Gene Transfer and Expression Protocols"";;CHOTHIALESK, MOL. BIOL., vol. 196, 1987, pages 901 - 17;;LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77;;HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 8;;GREENBERG ET AL., NATURE, vol. 374, 1995, pages 168 - 73;;HASSANZADEH-GHASSABEH ET AL., NANOMEDICINE, vol. 8, 2013, pages 1013 - 26;;HOLLIGER ET AL., NAT. BIOTECH., vol. 23, no. 9, 2005, pages 1 126 - 1129;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;OSBOURN ET AL., NAT. BIOTECHNOL, vol. 16, 1998, pages 778;;JOHNSTON, NATURE, vol. 346, 1990, pages 776 - 777;;NO ET AL., PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 3346 - 3351;;INDRA ET AL., NUC. ACID. RES., vol. 27, 1999, pages 4324 - 4327;;NUC. ACID. RES., vol. 28, 2000, pages e99;;KRAMERFUSSENEGGER, METHODS MOL. BIOL, vol. 308, 2005, pages 123 - 144;;""Fundamental Immunology"", 1993, RAVEN PRESS, pages: 353 - 363;;WIGLER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 3567;;O'HARE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 2072;;COLBERRE-GARAPIN ET AL., J. MOL. BIOL., vol. 150, 1981, pages 1;;SANTERRE ET AL., GENE, vol. 30, 1984, pages 147;;KENT ET AL., SCIENCE, vol. 237, 1987, pages 901 - 903;;WIGLER ET AL., CELL, vol. 223, 1977;;SZYBALSKASZYBALSKI, PROC. NATL. ACAD. SCI. USA, vol. 48, 1962, pages 2026;;LOWY ET AL., CELL, vol. 22, 1980, pages 817;;CONESE ET AL., GENE THERAPY, vol. 11, 2004, pages 1735 - 1742;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR PRESS;;BRASH ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 2031 - 2034;;KOHLERMILSTEIN, EUR. J. IMMUNOL., vol. 5, 1976, pages 511 - 519;;""Antibodies: A Laboratory Manual"", 1988, CSH PRESS;;HASKARDARCHER, J. IMMUNOL. METHODS, vol. 74, no. 2, 1984, pages 361 - 67;;RODER ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 140 - 67;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 81;;CHAN ET AL.: ""Fmoc Solid Phase Peptide Synthesis"", 2000, OXFORD UNIVERSITY PRESS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS;;RESTIFO, BLOOD, vol. 124, no. 4, 2014, pages 476 - 77;;JOSHI ET AL., J. IMMUNOL., vol. 180, no. 3, 2008, pages 1309 - 15;;GATTINONI ET AL., NAT. MED., vol. 17, 2011, pages 1290 - 7;;FLYNN ET AL., CLIN. TRANSLAT. IMMUNOL., vol. 3, 2014, pages e20;;SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467;;KOCHENDERFER ET AL., J. IMMUNOTHERAPY, vol. 32, no. 7, 2009, pages 689 - 702;;HERMAN ET AL., J. IMMUNOLOGICAL METHODS, vol. 285, no. 1, 2004, pages 25 - 40;;BAZARBACHI ET AL., BLOOD CANCER JOURNAL, vol. 12, no. 47, 2022, pages 1 - 8;;SONNEVELD ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 32, 2021, pages 3613 - 22",PENDING
707,IL,A,IL 305605 A,125-757-598-969-649,2024-11-01,2024,IL 30560523 A,2023-08-31,US 202363497185 P;;US 202363504184 P,2023-04-19,Bcma-targeted car-t cell therapy for multiple myeloma,,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,,,https://lens.org/125-757-598-969-649,Patent Application,no,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61P35/00,,0,0,,,,PENDING
708,US,A1,US 2021/0010023 A1,182-730-469-700-552,2021-01-14,2021,US 202016899540 A,2020-06-11,CN 201910501085 A,2019-06-11,USE OF HAPLOTYPE OF SNP SITE ASSOCIATED WITH HYPOXIA TOLERANCE IN BREEDING OF MEGALOBRAMA AMBLYCEPHALA,"A method of breeding a hypoxia-tolerant Megalobrama amblycephala strain, including: (1) screening genes associated with hypoxia tolerance in Megalobrama amblycephala based on transcriptome data; (2) screening SNP sites from the genes associated with hypoxia tolerance; and (3) applying a haplotype of the SNP sites in the molecular marker-assisted breeding of Megalobrama amblycephala to obtain the hypoxia-tolerant Megalobrama amblycephala strain. The genes associated with hypoxia tolerance include Epo, Hif1α, Hif2α, VhI, Hif1an, Vegfaa Egln1a, Egln1b, Egln2 and Egln3, and the haplotype of the SNP sites is T397T715 of gene Egln2.",UNIV SHANGHAI OCEAN,ZOU SHUMING;;WANG DONGDONG;;ZHENG GUODONG;;CHEN JIE,,https://lens.org/182-730-469-700-552,Patent Application,yes,0,5,3,038-475-677-418-504;;149-334-554-198-148;;182-730-469-700-552,CN;;US,3,038-475-677-418-504;;149-334-554-198-148;;182-730-469-700-552,CN;;US,12,C12Q1/6888;;C12Q2600/124;;C12Q2600/156;;C12Q2600/172;;A01K67/02;;A01K2227/40;;A01K2267/02;;C12Q1/6888;;C12Q2600/156;;C12N15/8509;;A01K67/02;;A01K2227/40,C12N15/85;;A01K67/02,,3,2,118-685-687-715-751;;012-041-912-941-003,10.1016/j.aquaculture.2019.734840;;31726084;;10.1016/j.gene.2019.144175,"Wang (2020, Aquaculture, 519:734840, 7 pages);;Serrote (2020, Gene, 726:144175, 4 pages);;Machine translation of CN110536688974A",DISCONTINUED
709,EP,A1,EP 4509136 A1,183-823-870-120-481,2025-02-19,2025,EP 23803054 A,2023-05-15,CN 202210522162 A;;CN 2023094186 W,2022-05-13,FUSION PROTEIN AND USE THEREOF,"Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.",SHANXI JINBO BIO PHARMACEUTICAL CO LTD;;UNIV FUDAN,LU LU;;JIANG SHIBO;;LIU ZEZHONG;;ZHOU JIE;;WANG QIAN;;YANG XIA;;HE ZHENRUI,,https://lens.org/183-823-870-120-481,Patent Application,yes,0,0,10,111-822-544-999-762;;171-491-956-342-794;;110-425-586-969-988;;067-666-334-661-143;;192-542-570-344-884;;084-255-572-856-827;;183-823-870-120-481;;020-929-550-285-126;;039-614-878-059-61X;;064-404-085-637-134,JP;;KR;;CN;;EP;;WO;;US,10,111-822-544-999-762;;171-491-956-342-794;;110-425-586-969-988;;067-666-334-661-143;;192-542-570-344-884;;084-255-572-856-827;;183-823-870-120-481;;020-929-550-285-126;;039-614-878-059-61X;;064-404-085-637-134,JP;;KR;;CN;;EP;;WO;;US,10,C07K14/005;;A61K39/12;;A61K39/39;;A61P31/14;;A61P31/18;;A61P31/16;;C12N2770/20022;;C12N2740/16022;;C12N2760/16022;;C07K2319/00;;A61K2039/6031;;C12N2770/20034;;C12N2740/16034;;C12N2760/16034;;A61K39/12;;A61K39/39;;A61P31/14;;A61P31/16;;A61P31/18;;C07K14/005;;C07K14/78;;C07K2319/40;;C07K2319/70;;C12N2770/20034;;C12N2760/16134;;A61K2039/575;;A61K39/385;;A61K2039/55505;;A61K39/215;;A61K39/145;;C07K14/005;;A61K39/12;;A61K39/215;;A61K39/145;;A61K39/39;;A61P31/14;;A61P31/16;;A61P31/18;;C12N2770/20022;;C12N2770/20034;;C12N2740/16022;;C12N2740/16034;;C12N2760/16022;;C12N2760/16034;;C07K2319/00;;A61P31/14;;A61P31/16;;A61K39/145;;A61K39/215;;C07K14/005;;C07K2319/00;;C12N2760/16122;;C12N2760/16134;;C12N2770/20022;;C12N2770/20034,A61K39/00;;A61K39/12;;A61P31/14,,0,0,,,,PENDING
710,EP,A1,EP 4407033 A1,048-046-235-453-086,2024-07-31,2024,EP 22886021 A,2022-10-26,CN 202111247093 A;;CN 2022127682 W,2021-10-26,METHOD FOR PURIFYING SINGLE-STRANDED DNA,"A method for purifying single-stranded DNA is provided. The method can comprise: mixing a sample containing single-stranded DNA with a single-stranded DNA binding protein, and incubating for a first time period to obtain a first product, the first product containing a conjugate of the single-stranded DNA and the single-stranded DNA binding protein; purifying the first product by using affinity chromatography to obtain a second product; and purifying the second product to at least remove the single-stranded DNA binding protein to obtain a target product containing a purified single-stranded DNA. Also provided are a kit for purifying single-stranded DNA, said kit comprising a single-stranded DNA binding protein and a purification reagent; and a use of a single-stranded DNA binding protein in purifying single-stranded DNA.",NANJING GENSCRIPT BIOTECH CO LTD,CHEN JUAN;;YE LUMENG,,https://lens.org/048-046-235-453-086,Patent Application,yes,0,0,5,107-966-527-352-666;;047-969-194-887-775;;010-927-512-019-044;;179-805-700-383-218;;048-046-235-453-086,EP;;CN;;WO;;US,5,107-966-527-352-666;;047-969-194-887-775;;010-927-512-019-044;;179-805-700-383-218;;048-046-235-453-086,EP;;CN;;WO;;US,18,C07K1/22;;C07K2319/40;;C07K2319/80;;C12N15/101;;C07K14/195;;C12Q1/6804;;C12Q1/6806;;C07K14/195;;C12N15/101;;C12N15/1013,C12N15/63;;C07K1/22;;C07K19/00;;C12N15/62,,0,0,,,,PENDING
711,CA,A1,CA 3217687 A1,001-876-938-637-620,2022-11-17,2022,CA 3217687 A,2022-05-10,US 202163186872 P;;IB 2022054342 W,2021-05-11,METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY,The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;DE MONDELO MARIA MARQUEZ;;OLYSLAGER YUNSI;;QIU JUN;;ZUDAIRE UBANI ENRIQUE;;XU JEAN,,https://lens.org/001-876-938-637-620,Patent Application,no,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,,,0,0,,,,PENDING
712,LV,A,LV 15886 A,052-081-497-237-007,2024-10-20,2024,LV P2023000080 A,2023-08-30,LV P2023000080 A,2023-08-30,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,QIU YUHONG;;PATEL NITIN;;PACAUD LIDA;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;SLAUGHTER ANA RUTE DE ASCENSAO;;LONARDI CAROLINA,,https://lens.org/052-081-497-237-007,Patent Application,no,0,0,1,052-081-497-237-007,LV,1,052-081-497-237-007,LV,0,,A61K39/00,,0,0,,,,PENDING
713,WO,A1,WO 2025/046624 A1,145-096-829-313-779,2025-03-06,2025,IN 2024051573 W,2024-08-28,IN 202341057776 A,2023-08-29,A METHOD FOR MATING DISRUPTION OF INSECTS PESTS USING SEMIOCHEMICALS,"The present disclosure describes methods of using semiochemicals for insect pest control, and more specifically methods of using semiochemicals in agricultural fields for effectively disruptive mating in insect pests based on competitive attraction.",PHEROMONES BIOTECH LLP;;ATGC BIOTECH PRIVATE LTD,GORANTLA DR MRKANDEYA,,https://lens.org/145-096-829-313-779,Patent Application,yes,10,0,1,145-096-829-313-779,WO,1,145-096-829-313-779,WO,0,A01P19/00;;A01N37/02;;A01N31/02;;A01N35/02,A01N25/00;;A01N27/00;;A01N31/00;;A01N33/00;;A01N35/00,,0,0,,,,PENDING
714,WO,A1,WO 2024/097812 A1,170-348-415-052-200,2024-05-10,2024,US 2023/0078433 W,2023-11-02,US 202263382419 P,2022-11-04,THERAPY FOR TREATING BLADDER CANCER,"The present disclosure relates to methods of treating bladder cancer in a subject comprising intravesical administration of an effective amount of an anti-Trop-2 antibody drug conjugate (ADC) (e.g., sacituzumab govitecan) to the subject.",GILEAD SCIENCES INC,DORNAN CARRIE M;;SCHOLLER NATHALIE,,https://lens.org/170-348-415-052-200,Patent Application,yes,52,0,1,170-348-415-052-200,WO,1,170-348-415-052-200,WO,48,A61K47/68037;;A61K47/6861;;A61P35/00,A61K47/68;;A61P35/00,,10,9,152-785-797-223-628;;037-855-419-900-566;;094-231-888-233-470;;044-093-793-754-488;;037-864-263-908-59X;;108-319-687-734-327;;041-929-702-214-063;;069-523-146-059-141;;081-734-318-931-800,10.1007/s11095-008-9566-7;;pmc2440939;;18369709;;10.1016/j.eururo.2021.10.009;;34736796;;34838351;;10.1016/j.eururo.2021.11.008;;10.1136/jitc-2022-sitc2022.1217;;31208270;;pmc6748572;;10.1080/19420862.2019.1632115;;36208791;;10.1016/j.pharmthera.2022.108296;;10.1177/1756287211431976;;22295042;;pmc3263923;;23827737;;10.1016/j.eururo.2013.06.003;;19106140;;10.1093/nar/gkn1009;;pmc2647283,"SHEN ZANCONG ET AL: ""Intravesical Treatments of Bladder Cancer: Review"", ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, vol. 25, no. 7, 28 March 2008 (2008-03-28), Berlin/Heidelberg, pages 1500 - 1510, XP093129884, ISSN: 0724-8741, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s11095-008-9566-7.pdf> [retrieved on 20240212], DOI: 10.1007/s11095-008-9566-7;;CHOI WOONYOUNG ET AL: ""A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer"", EUROPEAN UROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 81, no. 2, 1 November 2021 (2021-11-01), pages 138 - 142, XP086938409, ISSN: 0302-2838, [retrieved on 20211101], DOI: 10.1016/J.EURURO.2021.10.009;;REIKE MORITZ J ET AL: ""Not ""If"", but ""When"" and ""How"": Testing Antibody-Drug Conjugates in Patients with Non-muscle-invasive Bladder Cancer"", EUROPEAN UROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 81, no. 2, 24 November 2021 (2021-11-24), pages 143 - 144, XP086938851, ISSN: 0302-2838, [retrieved on 20211124], DOI: 10.1016/J.EURURO.2021.11.008;;CHOU CHIH-CHIEN ET AL: ""Efficacy and additional mechanism of action of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, in preclinical models of non-muscle invasive bladder cancer"", REGULAR AND YOUNG INVESTIGATOR AWARD ABSTRACTS, 7 November 2022 (2022-11-07), pages A1260 - A1260, XP093128900, DOI: 10.1136/jitc-2022-SITC2022.1217;;GOLDENBERG DAVID M. ET AL: ""Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan"", MABS, vol. 11, no. 6, 18 August 2019 (2019-08-18), US, pages 987 - 995, XP055948531, ISSN: 1942-0862, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748572/pdf/kmab-11-06-1632115.pdf> [retrieved on 20240212], DOI: 10.1080/19420862.2019.1632115;;LIU XINLIN ET AL: ""Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer"", PHARMACOLOGY & THERAPEUTICS, vol. 239, 5 October 2022 (2022-10-05), GB, pages 108296, XP093129913, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2022.108296;;ANASTASIADIS, A.REIJKE, T. M.: ""Best practice in the treatment of non muscle invasive bladder cancer"", THERAPEUTIC ADVANCES IN UROLOGY, vol. 4, no. 1, 2012, pages 13 - 32;;BABJUK ET AL.: ""EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013"", EUROPEAN UROLOGY, vol. 64, no. 4, 2013, pages 639 - 653;;""NCBI Gene ID"", Database accession no. 4070;;BAKER ET AL., NUCLEIC ACIDS RES, vol. 37, no. 3, 2009, pages 693 - 701",PENDING
715,AR,A1,AR 130938 A1,110-736-589-800-764,2025-02-05,2025,AR P230102927 A,2023-11-01,US 202263421740 P,2022-11-02,TERAPIA CON CÉLULAS T CAR DIRIGIDAS A BCMA CONTRA EL MIELOMA MÚLTIPLE,"Un método para evaluar la capacidad de respuesta de un sujeto a un tratamiento que comprende células T que expresan un receptor de antígeno quimérico (CAR) dirigido a BCMA bivalente, que comprende administrar al sujeto las células T, y evaluar la capacidad de respuesta del sujeto al tratamiento basado en la duración del tiempo que el sujeto mantiene un estado negativo de enfermedad residual mínima (MRD). Reivindicación 1: Un método para evaluar la capacidad de respuesta de un sujeto a un tratamiento que comprende células T que expresan un receptor de antígeno quimérico (CAR) dirigido a BCMA bivalente, caracterizado porque comprende: (a) administrar al sujeto las células T; (b) medir la duración del tiempo que el sujeto mantiene un estado negativo de enfermedad residual mínima (MRD); y (c) evaluar la capacidad de respuesta del sujeto al tratamiento basado en que (i) el estado negativo para MRD se mantiene por menos de 6 meses; (ii) el estado negativo para MRD se mantiene durante al menos 6 meses y menos de 12 meses; o (iii) el estado negativo para MRD se mantiene durante al menos 12 meses; en donde el CAR dirigido a BCMA bivalente comprende un dominio de unión al antígeno extracelular que comprende un primer dominio VHH y un segundo dominio VHH, un dominio transmembrana, y un dominio de señalización intracelular, en donde el primer dominio VHH comprende una CDR1, una CDR2, y una CDR3 como se establece en el dominio VHH que comprende la secuencia de aminoácidos de la SEQ ID Nº 2, y el segundo dominio VHH comprende una CDR1, una CDR2, y una CDR3 como se expone en el dominio VHH que comprende la secuencia de aminoácidos de la SEQ ID Nº 4.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN CHANG;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,,https://lens.org/110-736-589-800-764,Patent Application,no,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,A61K35/17;;C07K16/28;;C12N5/10;;G01N33/50,,0,0,,,,PENDING
716,US,A1,US 2023/0263837 A1,033-012-730-810-343,2023-08-24,2023,US 202017764127 A,2020-09-28,EP 19382827 A;;EP 2020077145 W,2019-09-26,THERAPEUTIC EFFICACY BY PULMONARY DELIVERY OF LIVE ATTENUATED MYCOBACTERIA,"The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTB VAC strain having a i) PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.",UNIV ZARAGOZA,AGUILÓ JUAN IGNACIO;;MARTÍN MONTAÑES CARLOS;;TARANCÓN ÍÑIGUEZ RAQUEL;;MATA LOZANO ELENA;;URANGA MAÍZ SANTIAGO;;VANEVA MARINOVA DESSISLAVA,UNIVERSIDAD DE ZARAGOZA (2022-04-20),https://lens.org/033-012-730-810-343,Patent Application,yes,1,0,12,121-502-967-901-114;;092-107-940-695-779;;030-222-543-737-167;;138-597-426-269-074;;092-526-361-253-825;;042-484-781-613-894;;034-538-340-189-857;;144-833-816-145-244;;033-012-730-810-343;;015-121-441-353-182;;029-562-245-679-953;;070-725-490-247-388,JP;;AU;;KR;;CN;;EP;;WO;;US;;CA;;MX,12,121-502-967-901-114;;092-107-940-695-779;;030-222-543-737-167;;138-597-426-269-074;;092-526-361-253-825;;042-484-781-613-894;;034-538-340-189-857;;144-833-816-145-244;;033-012-730-810-343;;015-121-441-353-182;;029-562-245-679-953;;070-725-490-247-388,JP;;AU;;KR;;CN;;EP;;WO;;US;;CA;;MX,46,A61K39/04;;C07K14/35;;A61K2039/522;;A61K2039/54;;A61K2039/544;;A61K2039/58;;A61K2039/577;;A61K39/04;;A61P11/06;;A61P31/04;;A61P31/06;;C07K14/35;;A61K2039/522;;A61K2039/54;;A61K2039/544;;A61K2039/58;;A61K2039/577;;A61P11/06;;A61P37/08;;A61P31/06;;A61K35/74;;A61K2039/522;;A61K2039/544;;A61K2039/577;;A61K2039/58,A61K35/74;;A61P11/06;;A61P31/06;;A61P37/08,,2,2,161-888-147-537-180;;028-352-774-351-126,29302700;;pmc5859035;;10.1007/s00109-017-1614-5;;30903437;;pmc6626558;;10.1007/s12016-019-08733-0,"Zhang Y et al. Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. J Mol Med (Berl). 2018 Apr;96(3-4):249-263. doi: 10.1007/s (Year: 2018) (Year: 2018);;Capucilli P, Hill DA. Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications. Clin Rev Allergy Immunol. 2019 Aug;57(1):111-127. doi: 10.1007/s12016-019-08733-0. PMID: 30903437; PMCID: PMC6626558. (Year: 2019)",PENDING
717,BR,A2,BR 112023023269 A2,004-662-449-335-272,2024-01-30,2024,BR 112023023269 A,2022-05-10,IB 2022054342 W;;US 202163186872 P,2021-05-11,Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car),métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car). a presente invenção refere-se a métodos de identificação precoce e detecção de neurotoxicidade associadas à administração de terapia de células t receptoras de antígeno quimérico (car) para reduzir a ocorrência e/ou gravidade da neurotoxicidade associada ao tratamento.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,CAROLYN CHANG JACKSON;;ENRIQUE ZUDAIRE UBANI;;ERIN C LEE;;XU JEAN;;GOLDBERG JENNA;;QIU JUN;;KEVIN C DE BRAGANCA;;MARIA MARQUEZ DE MONDELO;;MUHAMMAD S AKRAM;;LENDVAI NIKOLETTA;;OLYSLAGER YUNSI,,https://lens.org/004-662-449-335-272,Patent Application,no,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,G01N33/569;;A61K39/00;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
718,CN,A,CN 117616279 A,062-253-462-273-201,2024-02-27,2024,CN 202280033168 A,2022-05-10,US 202163186872 P;;IB 2022054342 W,2021-05-11,Methods of minimizing neurotoxicity associated with chimeric antigen receptor (CAR) T cell therapy,"The present disclosure relates to methods of early identification and detection of neurotoxicity associated with administration of chimeric antigen receptor (CAR) T cell therapy, and remission strategies for reducing the onset and/or severity of treatment-associated neurotoxicity.",JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MOHAMMAD S;;DEBRAGANKA KEVIN C;;GOLDBERG JANNA;;JACKSON CAROLINE CHANG;;LEE EILEEN C;;LUNDVOY NICOLETTA;;DE MONDELLO MARIA MAX;;OSLAG YUANXI;;QIU JUN;;SUDERE UBANI ENRIQUE;;XU QIN,,https://lens.org/062-253-462-273-201,Patent Application,no,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,G01N33/569;;A61K39/00;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
719,AU,A1,AU 2022/272021 A1,098-809-968-502-38X,2023-11-30,2023,AU 2022/272021 A,2022-05-10,US 202163186872 P;;IB 2022054342 W,2021-05-11,METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY,The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;DE MONDELO MARIA MARQUEZ;;OLYSLAGER YUNSI;;QIU JUN;;ZUDAIRE UBANI ENRIQUE;;XU JEAN,,https://lens.org/098-809-968-502-38X,Patent Application,no,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,G01N33/569;;A61K39/00;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
720,AU,A1,AU 2023/373360 A1,171-747-812-698-325,2025-06-12,2025,AU 2023/373360 A,2023-11-01,US 202263421740 P;;US 2023/0078327 W,2022-11-02,BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA,"A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.",JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,,https://lens.org/171-747-812-698-325,Patent Application,no,0,0,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,0,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,A61K35/17;;C07K16/28;;C12N5/10,,0,0,,,,PENDING
721,WO,A1,WO 2022/238901 A1,188-049-220-689-221,2022-11-17,2022,IB 2022054342 W,2022-05-10,US 202163186872 P,2021-05-11,METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY,The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;DE MONDELO MARIA MARQUEZ;;OLYSLAGER YUNSI;;QIU JUN;;UBANI ENRIQUE ZUDAIRE;;XU JEAN,,https://lens.org/188-049-220-689-221,Patent Application,yes,12,3,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,A61K39/00;;G01N33/569;;G01N33/574;;G01N33/68,,28,27,070-476-692-044-314;;009-761-212-310-304;;012-513-023-188-616;;008-090-851-282-177;;064-827-877-029-000;;043-637-566-380-03X;;002-162-655-922-108;;057-288-329-014-840;;007-484-806-914-230;;045-476-680-279-398;;072-598-877-487-064;;042-563-381-682-300;;009-910-966-882-567;;088-604-414-954-219;;172-734-673-091-42X;;157-471-655-495-329;;035-004-059-767-061;;006-693-194-794-243;;076-996-049-789-031;;017-631-148-770-561;;045-476-680-279-398;;006-817-615-112-362;;045-476-680-279-398;;079-467-705-222-216;;064-539-659-027-844;;022-282-817-336-139;;041-496-072-219-490,31723825;;pmc6746032;;10.1097/hs9.0000000000000186;;10.1200/jco.2017.72.8519;;pmc5590803;;28715249;;32607727;;10.1007/s11912-020-00935-6;;26904385;;pmc4759707;;10.1002/psp4.12044;;34175021;;10.1016/s0140-6736(21)00933-8;;17311819;;10.1093/annonc/mdl443;;21292775;;pmc3710442;;10.1182/blood-2010-10-299487;;27870103;;10.1002/phar.1871;;23485231;;10.1016/j.ejca.2012.12.027;;pmc12180426;;10.1016/j.bbmt.2018.12.758;;30592986;;10.1056/nejmoa1707447;;pmc5882485;;29226797;;10.1158/2159-8290.cd-17-1319;;pmc6385599;;29880584;;10.1056/nejmoa1804980;;30501490;;10.1056/nejmoa2024850;;33626253;;10.1056/nejmoa1817226;;31042825;;pmc8202968;;10.3389/fimmu.2020.00888;;pmc7235422;;32477359;;11274017;;10.1093/clinchem/47.4.673;;pmc7292936;;32535732;;10.1007/s40290-020-00342-z;;10.1158/0008-5472.can-16-1373;;27879265;;pmc5334262;;pmc8938935;;10.1182/blood.2019002289;;31537529;;pmc12180426;;10.1016/j.bbmt.2018.12.758;;30592986;;30880998;;pmc6400118;;10.2147/tcrm.s150524;;pmc12180426;;10.1016/j.bbmt.2018.12.758;;30592986;;8527407;;10.1093/intimm/7.7.1093;;10.18632/oncotarget.25359;;29899820;;pmc5995247;;pmc3630268;;10.1158/1078-0432.ccr-12-2422;;23344265;;10.1084/jem.20041674;;pmc2212784;;15642740,"LUCRECIA YÁÑEZ; MIRIAM SÁNCHEZ-ESCAMILLA; MIGUEL-ANGEL PERALES: ""CAR T Cell Toxicity: Current Management and Future Directions"", HEMASPHERE, vol. 3, no. 2, 1 April 2019 (2019-04-01), pages 1 - 10, XP055763414, DOI: 10.1097/HS9.0000000000000186;;CAMERON J. TURTLE ET AL: ""Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib"", JOURNAL OF CLINICAL ONCOLOGY, 17 July 2017 (2017-07-17), US, pages - 15, XP055402565, ISSN: 0732-183X, DOI: 10.1200/JCO.2017.72.8519;;LANDRY KARA ET AL: ""Neurological Complications of CAR T Cell Therapy"", CURRENT ONCOLOGY REPORTS, CURRENT SCIENCE, GB, vol. 22, no. 8, 1 July 2020 (2020-07-01), XP037193756, ISSN: 1523-3790, [retrieved on 20200701], DOI: 10.1007/S11912-020-00935-6;;JONSSON F ET AL: ""A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use"", CPT: PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, vol. 4, no. 12, 20 November 2015 (2015-11-20), pages 711 - 719, XP055943324, ISSN: 2163-8306, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/psp4.12044> DOI: 10.1002/psp4.12044;;BERDEJA JESUS G ET AL: ""Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study"", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 398, no. 10297, 24 June 2021 (2021-06-24), pages 314 - 324, XP086703761, ISSN: 0140-6736, [retrieved on 20210624], DOI: 10.1016/S0140-6736(21)00933-8;;RODRIGUEZ-ABREU ET AL.: ""Epidemiology of Hematological Malignancies"", ANN. ONCOL., vol. 18, no. l, 2007, pages 3 - 8;;RAJKUMAR ET AL.: ""Consensus Recommendations for the Uniform Reporting of Clinical Trials: Report of the International Myeloma Workshop Consensus Panel 1"", BLOOD, vol. 117, no. 8, 2011, pages 4691 - 4695;;CHUNG, C.: ""Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy"", PHARMACOTHERAPY, vol. 37, no. 1, 2017, pages 129 - 143;;FERLAY ET AL.: ""Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012"", EUR. J. CANCER, vol. 49, no. 6, 2013, pages 1374 - 1403;;LEE ET AL.: ""ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells"", BIOL. BLOOD MARROW TRANSPLANT, vol. 25, no. 4, 2018, pages 625 - 638, XP055809268, DOI: 10.1016/j.bbmt.2018.12.758;;NEELAPU ET AL.: ""Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma"", N. ENGL. J. MED., vol. 377, 2017, pages 2531 - 2544, XP055547040, DOI: 10.1056/NEJMoa1707447;;SANTOMASSO ET AL.: ""Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia"", CANCER DISCOV., vol. 8, 2018, pages 958 - 971, XP055501499, DOI: 10.1158/2159-8290.CD-17-1319;;SCHUSTER ET AL.: ""Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B Cell Lymphoma"", N. ENGL. J. MED., vol. 380, no. 1, 2019, pages 45 - 56;;MUNSHI ET AL.: ""Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma"", N. ENGL. J. MED., vol. 384, 2021, pages 705 - 716;;RAJE ET AL.: ""Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma"", N. ENGL. J. MED., vol. 380, no. 18, 2019, pages 1726 - 1737, XP009516323, DOI: 10.1056/NEJMoa1817226;;CERRANO ET AL.: ""The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice"", FRONT. IMMUNOL., vol. 11, no. 888, 2020;;BRADWELL ET AL.: ""Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine"", CLIN. CHEM, vol. 47, no. 4, 2001, pages 673 - 80;;ATALFATIMA: ""IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy"", PHARMACEUTICAL MEDICINE, vol. 34, 2020, pages 223 - 231, XP055740687, DOI: 10.1007/s40290-020-00342-z;;WANG ET AL.: ""IL-6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer"", CANCER RESEARCH, vol. 77, no. 5, 2016, pages 1119 - 1126;;VALLURUPALLIBERLINER: ""Emapalumab for the Treatment of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis"", BLOOD, vol. 134, no. 21, 2019, pages 1783 - 1786, XP086697578, DOI: 10.1182/blood.2019002289;;LEE ET AL.: ""ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells"", BIOL. BLOOD MARROW TRANSPLANT., vol. 25, no. 4, 2019, pages 625 - 638, XP055809268, DOI: 10.1016/j.bbmt.2018.12.758;;RIEGLER ET AL.: ""Current Approaches in the Grading and Management of Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy"", THER. CLIN. RISKMANAG., vol. 15, 2019, pages 323 - 335;;LEE ET AL.: ""ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells"", BIOL. BLOOD MARROW TRANSPLANT, vol. 25, 2019, pages 625 - 638, XP055809268, DOI: 10.1016/j.bbmt.2018.12.758;;LEE ET AL., BIOL. BLOOD MARROW TRANSPLANT, vol. 25, 2019, pages 625 - 638;;GRAS ET AL.: ""BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes"", INTEMAT. IMMUNOL., vol. 7, 1995, pages 1093 - 1106, XP000971907;;BU ET AL.: ""Pre-Clinical Validation of B Cell Maturation Antigen (BCMA) as a Target for T Cell Immunotherapy of Multiple Myeloma"", ONCOTARGET, vol. 9, no. 40, 2018, pages 25764 - 25780, XP055729676, DOI: 10.18632/oncotarget.25359;;CARPENTER ET AL.: ""B-Cell Maturation Antigen is a Promising Target for Adoptive T-Cell Therapy of Multiple Myeloma"", CLIN. CANCER RES., vol. 19, no. 8, 2013, pages 2048 - 2460, XP002727959, DOI: 10.1158/1078-0432.CCR-12-2422;;KRUMBHOLZ ET AL.: ""BAFF is Produced by Astrocytes and Up-Regulated in Multiple Sclerosis Lesions and Primary Central Nervous System Lymphoma"", J. EXP. MED., vol. 201, no. 2, 2005, pages 195 - 200, XP003016441, DOI: 10.1084/jem.20041674",PENDING
722,WO,A1,WO 2025/193685 A1,007-338-271-717-170,2025-09-18,2025,US 2025/0019350 W,2025-03-11,US 202463564470 P,2024-03-12,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN;;DE ASCENSAO SLAUGHTER ANA;;LONARDI CAROLINA,,https://lens.org/007-338-271-717-170,Patent Application,yes,0,0,1,007-338-271-717-170,WO,1,007-338-271-717-170,WO,0,A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/02;;A61K2239/38,A61P35/02;;A61K40/11;;A61K40/31;;A61K40/42,,0,0,,,,PENDING
723,LT,A,LT 2023534 A,094-465-657-581-648,2024-12-10,2024,LT 2023534 A,2023-08-30,US 202363497185 P;;US 202363504184 P,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,,https://lens.org/094-465-657-581-648,Patent Application,no,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/12;;A61P35/02,,0,0,,,,ACTIVE
724,IE,A1,IE 20230360 A1,014-584-316-543-563,2025-09-10,2025,IE 20230360 A,2023-08-30,US 202363497185 P;;US 202363504184 P,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,NITIN PATEL;;LIDA PACAUD;;YUHONG QIU;;NIKOLETTA LENDVAI;;WILLIAM DERAEDT;;JORDAN MARK SCHECTER;;ANA RUTE DE ASCENSAO SLAUGHTER;;CAROLINA LONARDI,,https://lens.org/014-584-316-543-563,Patent Application,no,3,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/00;;A61K40/00,,0,0,,,,PENDING
725,US,A1,US 2024/0270831 A1,086-624-261-431-34X,2024-08-15,2024,US 202218569613 A,2022-03-03,CN 202110674660 A;;CN 2022078975 W,2021-06-17,CHIMERIC IMMUNOGLOBULIN,"A chimeric immunoglobulin is provided. It is obtained by fusing a first polypeptide and a second polypeptide, wherein the first polypeptide includes an IgG variable region located at the N terminal; and the second polypeptide includes an IgA CH2-CH3 region or an IgM CH3-CH4 region located at the C terminal. The immunoglobulin has higher titer, and when coated in a solid phase, it still has higher titer than that of an IgG monomer with the same valence, so it can be widely applied in the detection field.",FAPON BIOTECH INC,MENG YUAN;;ZHONG DONGMEI,,https://lens.org/086-624-261-431-34X,Patent Application,yes,0,0,13,113-576-845-520-42X;;181-828-913-805-14X;;187-646-515-688-727;;182-128-181-986-537;;075-572-083-345-99X;;148-857-099-532-461;;004-640-301-138-03X;;115-461-334-206-896;;114-641-496-399-928;;103-782-195-759-379;;013-570-352-704-690;;086-624-261-431-34X;;050-364-448-620-007,KR;;JP;;CN;;EP;;WO;;US;;CA;;MX;;BR,13,113-576-845-520-42X;;181-828-913-805-14X;;187-646-515-688-727;;182-128-181-986-537;;115-461-334-206-896;;148-857-099-532-461;;004-640-301-138-03X;;075-572-083-345-99X;;114-641-496-399-928;;103-782-195-759-379;;013-570-352-704-690;;086-624-261-431-34X;;050-364-448-620-007,KR;;JP;;CN;;EP;;WO;;US;;CA;;MX;;BR,8,C07K16/00;;C07K16/468;;G01N33/577;;G01N33/548;;G01N33/587;;G01N33/582;;C07K2317/31;;C07K2317/52;;C07K2317/56;;G01N33/54387;;C07K2317/52;;C07K2317/64;;C07K2317/24;;C07K16/205;;C07K16/1003;;C07K16/18;;C07K16/40;;G01N33/6854;;C07K16/468;;G01N33/577;;G01N33/54387;;C07K2317/31;;C07K2317/52;;C07K2317/56;;G01N33/54388;;C07K16/18;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/528;;C07K2317/53,C07K16/18;;G01N33/543,,0,0,,,,PENDING
726,US,A1,US 2021/0236605 A1,169-472-382-823-226,2021-08-05,2021,US 201917050036 A,2019-04-24,IB 2018000464 W;;IB 2019000297 W,2018-04-25,COMBINATIONS OF OSTEOPONTIN AND 2'-FUCOSYLLACTOSE FOR USE AS MEDICAMENTS,"A combination of osteopontin (OPN) and 2′-fucosyllactose (2-FL) is used in the prevention or the treatment of immunological diseases or disorders due to inflammatory factors secretion affecting a human or an animal subject. The said combination is useful, in particular, in the prevention or the treatment of diseases or disorders due cytokine secretion, e.g. INF-γ, IL-2, IL-4, IL-17, IL-6, IL-10, TGF-β, Tbet, GA-TA3 and NFkB and/or immunoglobulin secretion, e.g. IgE and Ig1.",HEALTH AND HAPPINESS H&H HONG KONG LTD,DUTHEY BÉATRICE;;LANE JONATHAN;;MALARD PATRICE;;ZE XIAOLEI,HEALTH AND HAPPINESS (H&H) HONG KONG LIMITED (2020-10-08),https://lens.org/169-472-382-823-226,Patent Application,yes,2,2,10,043-652-751-089-522;;097-724-674-113-654;;046-743-491-153-366;;007-917-738-769-377;;117-226-841-462-432;;130-315-584-394-621;;169-472-382-823-226;;077-017-677-135-885;;137-411-474-989-872;;033-719-176-953-775,AU;;KR;;CN;;EP;;WO;;SG;;US;;CA,10,043-652-751-089-522;;097-724-674-113-654;;046-743-491-153-366;;007-917-738-769-377;;117-226-841-462-432;;130-315-584-394-621;;169-472-382-823-226;;077-017-677-135-885;;137-411-474-989-872;;033-719-176-953-775,AU;;KR;;CN;;EP;;WO;;SG;;US;;CA,0,A61K31/702;;A61K38/17;;A61K38/18;;A61K38/19;;A61K45/06;;A61P17/00;;A61P37/02;;A61K38/19;;A61K31/702;;A61K45/06;;A61K2300/00;;A61P11/00;;A61P17/00;;A61P37/02;;A61K38/39;;A23L33/125;;A23L33/17;;A23L33/40;;A23V2002/00;;A61K31/702;;A61P37/06,A61K38/39;;A23L33/00;;A23L33/125;;A23L33/17;;A61K31/702;;A61P37/06,,0,0,,,,DISCONTINUED
727,WO,A1,WO 2024/097738 A1,174-309-951-520-606,2024-05-10,2024,US 2023/0078327 W,2023-11-01,US 202263421740 P,2022-11-02,BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA,"A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PACAUD LIDA;;AKRAM MUHAMMAD;;GENG DONG;;SCHECTER JORDAN;;JACKSON CAROLYN;;ZUDAIRE UBANI ENRIQUE;;MADDURI DEEPU,,https://lens.org/174-309-951-520-606,Patent Application,yes,2,1,9,047-730-643-869-253;;062-534-687-026-106;;153-388-751-374-284;;152-655-662-871-972;;171-747-812-698-325;;110-736-589-800-764;;050-228-838-896-205;;174-309-951-520-606;;067-268-901-672-946,KR;;AU;;AR;;EP;;IL;;WO;;US;;TW;;MX,9,047-730-643-869-253;;062-534-687-026-106;;152-655-662-871-972;;153-388-751-374-284;;171-747-812-698-325;;110-736-589-800-764;;067-268-901-672-946;;174-309-951-520-606;;050-228-838-896-205,KR;;AU;;AR;;IL;;EP;;WO;;US;;TW;;MX,23,A61P35/00;;C12Q1/6886;;A61K2239/28;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4215;;C12Q2600/106;;A61K2239/38;;C12Q2600/118;;A61K40/11;;A61K2239/48;;A61K40/31;;A61K2239/28;;C12Q1/6886;;A61P35/00;;C12Q1/6886;;A61K2239/48;;C12Q2600/118;;C12Q2600/106;;A61K2239/38;;A61P35/00;;A61K40/4215;;A61K40/11;;A61K40/31,C07K16/28;;A61K35/17;;C12N5/10,,0,0,,,,PENDING
728,JP,A,JP 2020536489 A,099-641-751-863-061,2020-12-17,2020,JP 2020508007 A,2018-08-16,GB 201713163 A;;GB 2018052335 W,2017-08-16,ＨＰＶワクチン,本発明は、複数の保存ペプチド配列またはそのバリアントを含むポリペプチドをコードする核酸であって、ここで、前述の保存配列が、１以上のＨＰＶ遺伝子型１６、１８、３１、５２、５３、および５８にわたって保存されており；前述のポリペプチドが、各ＨＰＶタンパク質Ｅ１、Ｅ２、Ｅ４、Ｅ５、Ｅ６、およびＥ７の保存ペプチド配列を含む、核酸；ならびに関連するワクチン、ウイルスベクター、処置、および予防に関する。【選択図】図１,オックスフォード ユニバーシティ イノベーション リミテッドＯＸＦＯＲＤ ＵＮＩＶＥＲＳＩＴＹ ＩＮＮＯＶＡＴＩＯＮ ＬＩＭＩＴＥＤ,ドレル，ルーシー;;ブライト，ジョシュア;;レイズ−サンドヴァル，アルトゥーロ,,https://lens.org/099-641-751-863-061,Patent Application,no,3,0,18,099-641-751-863-061;;185-752-333-125-970;;098-381-435-727-776;;137-537-944-304-297;;007-728-611-413-573;;102-206-352-397-083;;033-909-543-443-61X;;167-830-201-467-336;;048-687-079-178-157;;112-905-490-631-97X;;070-303-467-335-689;;185-500-069-019-35X;;004-314-440-303-513;;199-339-796-594-086;;039-950-588-666-860;;038-722-411-994-390;;144-778-649-133-502;;038-582-775-443-571,JP;;KR;;AU;;CN;;EP;;WO;;SG;;US;;CA;;MX;;GB,18,099-641-751-863-061;;185-752-333-125-970;;098-381-435-727-776;;137-537-944-304-297;;007-728-611-413-573;;102-206-352-397-083;;033-909-543-443-61X;;167-830-201-467-336;;048-687-079-178-157;;112-905-490-631-97X;;070-303-467-335-689;;185-500-069-019-35X;;004-314-440-303-513;;199-339-796-594-086;;039-950-588-666-860;;038-722-411-994-390;;144-778-649-133-502;;038-582-775-443-571,JP;;KR;;AU;;CN;;EP;;WO;;SG;;US;;CA;;MX;;GB,159,A61K39/12;;A61K2039/58;;A61K2039/70;;C12N2710/20034;;A61P31/20;;C12N15/62;;C07K14/005;;C12N7/00;;C12N15/86;;A61K39/12;;A61P31/20;;A61K2039/58;;A61K2039/70;;C12N2710/20034;;C12N2710/10043;;A61K39/12;;A61K39/39;;C07K14/005;;C07K2319/00;;C12N7/00;;C12N2710/20022;;C12N2710/20034,C12N15/37;;A61K31/7088;;A61K38/02;;A61K39/12;;A61K39/235;;A61K48/00;;A61P31/20;;A61P37/04;;C07K14/025;;C12N15/86;;C12N15/861,,2,0,,,"3 BIOTECH(2016)6:39, JPN6022041915, ISSN: 0005063840;;VACCINE(2017)VOL.27, PP.431-440, JPN6022041917, ISSN: 0005063841",ACTIVE
729,US,A1,US 2023/0256043 A1,187-293-379-530-181,2023-08-17,2023,US 202118015952 A,2021-07-13,GB 202010755 A;;GB 202103580 A;;GB 2021051799 W,2020-07-13,FORMULATION PRODUCT,"The present invention relates to the field of food technology and in particular, nutrient and bioactive rich plant formulations. Formulated products including nutrients and bioactives such as those provided by the Moringa plant are provided. In particular, coated or encapsulated food products having a spec release behaviour and a process for their production is described. The processes described enable food material, for example Moringa, to be used to provide nutrient dense foods that are more accessible and protected against loss of nutritional value. The resulting food products therefore allow better delivery of nutritional benefits to users.",THE UNIV COURT OF THE UNIV OF ABERDEEN;;NUTRIIGEN LTD,NEACSU MADALINA;;RUSSELL WENDY ROSLYN;;YOUNG NIGEL EDMOND;;ROWE ALAN MICHAEL;;THOMSON VICTOR,THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (2023-02-07);;NUTRIIGEN LTD (2024-09-05),https://lens.org/187-293-379-530-181,Patent Application,yes,0,0,10,187-293-379-530-181;;107-719-984-184-102;;057-761-894-866-772;;155-640-561-886-865;;022-161-533-498-987;;190-100-571-287-833;;039-638-022-376-657;;008-337-290-842-323;;174-305-599-616-570;;070-256-137-759-682,AU;;EP;;IL;;WO;;US;;CA;;GB,12,187-293-379-530-181;;107-719-984-184-102;;057-761-894-866-772;;155-640-561-886-865;;190-100-571-287-833;;022-161-533-498-987;;194-414-345-857-532;;046-516-130-905-657;;039-638-022-376-657;;008-337-290-842-323;;174-305-599-616-570;;070-256-137-759-682,AU;;EP;;IL;;WO;;US;;CA;;GB,0,A23P10/30;;A23L11/05;;A21D13/24;;A23L7/122;;A23L7/191;;A23P20/105;;A23P10/40;;A23L11/05;;A21D13/24;;A23L7/122;;A23L7/191;;A23P10/30;;A23P10/40;;A23P20/105;;A23L11/05;;A23P10/40;;A23P20/105;;A21D13/24;;A23L7/122;;A23L7/191;;A23P10/30;;A23L29/262;;A23L29/35;;A23L33/105;;A23P10/30;;A23L29/256;;A23L29/25;;A23P10/40;;A61K9/4833;;A61K9/4866;;A61K9/5036;;A61K9/5089;;A61K36/185;;A61K2236/17,A61K36/185;;A23L29/25;;A23L29/256;;A23L29/262;;A23L29/30;;A23L33/105;;A23P10/30;;A23P10/40;;A61K9/48;;A61K9/50,,1,1,015-429-900-597-540,10.15316/sjafs.2018.145,"Temiz et al., Encapsulation Methods and Use in Animal Nutrition, Selcuk J Agr Food Sci, 32 (3), 624-631 (Year: 2018)",PENDING
730,US,A1,US 2022/0002754 A1,068-196-984-893-037,2022-01-06,2022,US 201917289015 A,2019-10-22,CN 2019112449 W;;CN 201811275713 A,2018-10-30,USE OF NW_006883358.1 IN CHO CELL GENOME FOR STABLE EXPRESSION OF PROTEIN,"The invention provides use of NW_006883358.1 in a CHO cell genome for stable expression of a protein. A site for stable expression of a protein in the CHO cell genome is located at the 6874389th base of CHO cell gene NW_006883358.1; 5′NNNNNNNNNNNNNNNNNNNNNGG3′ within a range of 6874325-6874443 near the site, which can be identified by CRISPR/Cas9 technology, is a target sequence. In the present application, different protein genes are introduced to a fixed position in the CHO cell genome for stable expression.",UNIV JIANGNAN,CHEN YUN;;JIN JIAN;;LI HUAZHONG;;ZHOU SONGTAO;;DUAN ZUOYING;;GONG XIAOHAI,JIANGNAN UNIVERSITY (2021-04-26),https://lens.org/068-196-984-893-037,Patent Application,yes,2,0,4,115-499-325-197-362;;171-687-870-247-360;;068-196-984-893-037;;080-746-581-528-359,CN;;WO;;US,4,115-499-325-197-362;;171-687-870-247-360;;068-196-984-893-037;;080-746-581-528-359,CN;;WO;;US,31,C12N5/0682;;C12N15/85;;C12N15/907;;C12N2510/02;;C12N15/11;;C12N15/907;;C12N2740/16043;;C12N2310/20;;C12N15/85;;C12N15/907;;C12N2510/02,C12N15/90;;C12N15/85,,3,2,080-146-039-775-799;;016-496-609-486-606,10.1093/nar/gkx1268;;29267886;;pmc5814880;;25010559;;pmc4175060;;10.1016/j.ymeth.2014.06.014,"Jin, J. et al. CN107557390A machine translation. p. 1-4. 2018 (Year: 2018);;Maurice Labuhn et al., ""Refined sgRNA efficacy prediction improves large and small-scale CRISPR–Cas9 applications,"" Nucleic Acids Research, 2018, Vol. 46, No. 3 1375–1385 (February 16, 2018) (Year: 2018);;Ami M. Kabadi et al., ""Engineering Synthetic TALE and CRISPR/Cas9 Transcription Factors for Regulating Gene Expression,"" Methods 69(2): 188–197 (July 8, 2014) (Year: 2014)",PENDING
731,US,A1,US 2024/0263152 A1,191-720-662-778-981,2024-08-08,2024,US 202218565361 A,2022-06-01,CN 202110610098 A;;CN 202111602506 A;;CN 2022096683 W,2021-06-01,GLYCOSYLTRANSFERASE AND APPLICATION THEREOF,"A glycosyltransferase and an application thereof, the amino acid sequence of the glycosyltransferase being shown as in SEQ ID NO: 112 or an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 112. The glycosyltransferase of the present invention has high enzyme activity and good stability and, when used for the preparation of steviol glycosides, has a significant improvement in catalytic activity and significantly improved conversion rate compared to the parent glycosyltransferase, solving the problem of the high price of the glycosyl donor UDPG (and/or ADPG), and thereby reducing the reaction costs and facilitating industrial production.",ABIOCHEM BIOTECHNOLOGY CO LTD,WU YAN;;TIAN ZHENHUA;;WANG SHU;;ZHENG XIAOFU,ABIOCHEM BIOTECHNOLOGY (GROUP) CO. LTD (2023-11-29),https://lens.org/191-720-662-778-981,Patent Application,yes,0,0,5,028-781-854-519-289;;146-752-977-808-887;;191-720-662-778-981;;129-132-272-558-933;;123-321-285-416-859,JP;;EP;;WO;;US,8,123-321-285-416-859;;146-752-977-808-887;;191-720-662-778-981;;061-507-462-087-151;;090-636-819-672-453;;028-781-854-519-289;;138-256-086-499-504;;129-132-272-558-933,JP;;EP;;CN;;WO;;US,112,C12N15/70;;C40B40/08;;C07K14/415;;C12N9/1051;;C12P19/56;;C12N9/1062;;C12Y204/01013;;C12Y204/01122;;C12Y204/01017;;C12N9/1051;;C12N15/70;;C12P19/56;;C12Y204/01013,C12N9/10;;C12N15/70;;C12P19/56,,0,0,,,,PENDING
732,US,A1,US 2025/0002897 A1,047-969-194-887-775,2025-01-02,2025,US 202218704449 A,2022-10-26,CN 202111247093 A;;CN 2022127682 W,2021-10-26,METHOD FOR PURIFYING SINGLE-STRANDED DNA,"A method for purifying single-stranded DNA is provided. The method can comprise: mixing a sample containing single-stranded DNA with a single-stranded DNA binding protein, and incubating for a first time period to obtain a first product, the first product containing a conjugate of the single-stranded DNA and the single-stranded DNA binding protein; purifying the first product by using affinity chromatography to obtain a second product; and purifying the second product to at least remove the single-stranded DNA binding protein to obtain a target product containing a purified single-stranded DNA. Also provided are a kit for purifying single-stranded DNA, the kit comprising a single-stranded DNA binding protein and a purification reagent; and a use of a single-stranded DNA binding protein in purifying single-stranded DNA.",NANJING GENSCRIPT BIOTECH CO LTD,CHEN JUAN;;YE LUMENG,NANJING GENSCRIPT BIOTECH CO. LTD (2022-11-25),https://lens.org/047-969-194-887-775,Patent Application,yes,0,0,5,107-966-527-352-666;;047-969-194-887-775;;010-927-512-019-044;;179-805-700-383-218;;048-046-235-453-086,EP;;CN;;WO;;US,5,107-966-527-352-666;;047-969-194-887-775;;010-927-512-019-044;;179-805-700-383-218;;048-046-235-453-086,EP;;CN;;WO;;US,0,C07K1/22;;C07K2319/40;;C07K2319/80;;C12N15/101;;C07K14/195;;C12Q1/6804;;C12Q1/6806;;C07K14/195;;C12N15/101;;C12N15/1013,C12N15/10;;C07K14/195,,0,0,,,,PENDING
733,WO,A1,WO 2021/167906 A1,140-338-003-697-179,2021-08-26,2021,US 2021/0018244 W,2021-02-16,US 202062978666 P,2020-02-19,NUCLEIC ACID SEQUENCE DETECTION BY ENDONUCLEASE DIGESTION AND MASS SPECTROMETRY,"A method of nucleic acid analysis is described, the method including the steps of (a) providing a sample comprising a plurality of end-blocked polynucleotides derived from a biological source; (b) digesting at least some of the end-blocked polynucleotides with a nucleic acid-directed endonuclease that targets a sequence of interest to produce polynucleotide fragments that comprise the sequence of interest and a ligatable end generated by endonuclease cleavage; (c) ligating a moiety to the ligatable end to produce a moiety-target polynucleotide construct; and (d) detecting the moiety-target polynucleotide construct or a transcription or translation produce produced from the moiety-target polynucleotide construct using mass spectrometry. The moiety may be an adaptor sequence with a promoter for RNA polymerase. The moiety may be a chemical moiety that is highly amenable to flight and detection in a mass spectrometer.",CHAN ZUCKERBERG BIOHUB INC,CRAWFORD EMILY D,,https://lens.org/140-338-003-697-179,Patent Application,yes,4,0,2,140-338-003-697-179;;003-522-310-115-346,WO;;US,2,140-338-003-697-179;;003-522-310-115-346,WO;;US,0,C12Q1/6806;;C12Q1/6806,C12Q1/6872;;C12N9/22;;C12Q1/6855;;C12Q1/6865,,0,0,,,,PENDING
734,WO,A1,WO 2022/231286 A1,086-810-625-687-311,2022-11-03,2022,KR 2022005981 W,2022-04-27,KR 20210056810 A;;KR 20220051246 A,2021-04-30,CORD COMPRISING BIO-BASED COMPONENT AND METHOD FOR PREPARING SAME,"The present application relates to a hybrid cord comprising a bio-based nylon primarily-twisted yarn. According to the present application, provided is a hybrid cord which comprises a bio-based nylon primarily-twisted yarn having a higher modulus than chemically synthesized nylon, while also having elongation and fatigue resistance properties equivalent to or higher than a commercially required standard (that is, the standard of a cord comprising conventional chemically synthesized nylon primarily-twisted yarn).",KOLON INC,LEE MIN HO;;CHUNG IL;;JEON OK HWA;;YIM JONGHA;;LEE SUNG GYU,,https://lens.org/086-810-625-687-311,Patent Application,yes,13,1,7,169-704-789-324-525;;086-810-625-687-311;;065-079-155-492-664;;007-114-768-601-330;;057-984-147-964-123;;043-005-414-412-789;;101-935-485-560-159,JP;;EP;;WO;;US;;TW,9,169-704-789-324-525;;086-810-625-687-311;;144-797-882-608-301;;065-079-155-492-664;;007-114-768-601-330;;057-984-147-964-123;;126-471-365-614-508;;101-935-485-560-159;;043-005-414-412-789,KR;;JP;;EP;;CN;;WO;;US;;TW,0,D02G3/48;;D02J13/00;;D10B2331/02;;D10B2331/021;;D02G3/047;;D02G3/36;;D02G3/48;;D10B2331/021;;D10B2401/063;;D10B2505/022,D02G3/04;;D02G3/28;;D02G3/36;;D02G3/48;;D02J13/00,,5,0,,,"CASWELL PAUL J: ""TERRYL™ BIO-BASED NYLON: DEVELOPMENT, PRODUCTION AND GROWTH POTENTIAL"", CATHAY, INDUSTRIAL BIOTECH, 1 June 2013 (2013-06-01), pages 1 - 25, XP093224635;;INDORAMA: ""Empowering Safety and Performance"", INDORAMA VENTURES, 1 May 2019 (2019-05-01), pages 1 - 8, XP093303946;;CASWELL PAUL J: ""TERRYL™ BIO-BASED NYLON: DEVELOPMENT, PRODUCTION AND GROWTH POTENTIAL"", CATHAY, INDUSTRIAL BIOTECH, 1 June 2013 (2013-06-01), pages 1 - 25, XP093224635;;INDORAMA: ""Empowering Safety and Performance"", INDORAMA VENTURES, 1 May 2019 (2019-05-01), pages 1 - 8, XP093303946;;See also references of EP 4276229A4",PENDING
735,US,A1,US 2025/0052769 A1,181-904-037-813-319,2025-02-13,2025,US 202418787548 A,2024-07-29,US 202418787548 A;;US 202363516204 P,2023-07-28,MIMOTOPES OF ARA H 2 AND USES OF THE SAME TO DIAGNOSE PEANUT ALLERGIES,"Disclosed herein are compositions and methods for predicting or assessing the presence and/or severity of IgE-mediated peanut allergy in a subject using peptides and or mimotopes that bind as well or better than naturally occurring sequences. The disclosed methods and compositions may comprise one or more peptides or mimotopes of Ara h 2, specifically Epitope 3, or a portion thereof. In many embodiments, the peptides and mimotopes may comprise at least one DPY_P sequence, and in many cases the second proline, “P,” in the sequence may be hydroxylated (i.e. “h”) and may be represented by h. In many embodiments, substituting a P->h within the disclosed peptide and mimotope sequences may increase binding of IgE from the subject. In many embodiments, enhanced binding of IgE from a subject indicates that the subject suffers from an IgE-mediated peanut allergy.",UNIV COLORADO REGENTS,DRESKIN STEPHEN;;BRAUN-SCHEIN CATHERINE;;CHEN XUENI,THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (2023-10-18),https://lens.org/181-904-037-813-319,Patent Application,yes,0,0,1,181-904-037-813-319,US,1,181-904-037-813-319,US,0,G01N2800/24;;G01N33/6893;;C07K14/415;;G01N33/6854;;G01N33/6893;;G01N2800/24;;C07K14/415,G01N33/68;;C07K14/415,,0,0,,,,PENDING
736,US,A1,US 2024/0335493 A1,034-437-649-998-975,2024-10-10,2024,US 202418746153 A,2024-06-18,US 202418746153 A;;US 202017058432 A,2020-11-24,MUNG BEAN HULL EXTRACT WITH ANTIVIRAL EFFECT AND EXTRACTION METHOD THEREOF,"The present invention is a mung bean hull extract with antiviral effect, and the mung bean hull extract achieves antiviral effect by inhibiting α-glucosidase and neuraminidase. The present invention also relates to a method for extracting the mung bean hull extract with antiviral effect and applications of the extract obtained by the method.",CHEN HUI WEN;;KINGS GROUND BIOTECH CO LTD,CHEN HUI-WEN;;YU FENG-LING;;HUNG YING-NIEN;;PI CHIA-CHEN,KING'S GROUND BIOTECH CO. LTD (2024-06-11);;CHEN HUI-WEN (2024-06-11),https://lens.org/034-437-649-998-975,Patent Application,yes,0,0,2,036-382-977-042-371;;034-437-649-998-975,US,2,036-382-977-042-371;;034-437-649-998-975,US,0,A61K31/352;;A61P31/16;;A61K36/48;;A61K2236/31;;A61K2236/333;;A61K2236/51;;A61P31/16;;A61K31/352;;A61K36/48;;A61K2236/31;;A61K2236/333;;A61K2236/51,A61K36/48;;A61K31/352;;A61P31/16,,0,0,,,,ACTIVE
737,US,A1,US 2024/0043559 A1,062-878-470-627-663,2024-02-08,2024,US 202318491313 A,2023-10-20,CN 2021089233 W;;CN 2022088432 W,2021-04-23,ANTI-GPC3 ANTIBODIES AND METHODS OF USE,Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3.,SHANGHAI HENLIUS BIOTECH INC,ISSAFRAS HASSAN;;XU WENFENG;;JIANG WEI-DONG;;KIM HEUNGNAM,SHANGHAI HENLIUS BIOTECH INC (2021-05-25);;HENGENIX BIOTECH INC (2021-06-07),https://lens.org/062-878-470-627-663,Patent Application,yes,0,0,10,166-227-880-320-535;;124-375-271-060-142;;044-671-897-887-965;;156-199-452-797-152;;062-878-470-627-663;;190-796-499-035-073;;134-547-500-175-80X;;018-252-594-031-626;;109-351-151-634-252;;029-961-340-168-666,KR;;AU;;JP;;EP;;IL;;CN;;WO;;US;;CA;;BR,10,166-227-880-320-535;;124-375-271-060-142;;044-671-897-887-965;;156-199-452-797-152;;062-878-470-627-663;;190-796-499-035-073;;134-547-500-175-80X;;018-252-594-031-626;;109-351-151-634-252;;029-961-340-168-666,KR;;AU;;JP;;EP;;IL;;CN;;WO;;US;;CA;;BR,0,C07K16/303;;C07K2317/22;;C07K2317/569;;C07K2317/52;;C07K2317/64;;C07K2319/00;;C07K2317/24;;C07K2317/41;;C07K2317/33;;C07K2317/732;;A61P35/00;;A61K2039/505;;A61K2039/545;;C07K2317/72;;C07K16/303;;C07K2317/72;;C07K2317/732;;C07K2317/64;;C07K2317/33;;C07K2319/00;;C07K2317/24;;A61K2039/505;;C07K2317/22;;C07K2317/52;;C07K2317/41;;A61P35/00;;C07K2317/569;;A61K2039/545;;C07K16/303;;A61K47/6803;;C12N5/0636;;A61P35/00;;C07K2317/92;;C07K2317/569;;C07K2317/31;;C07K2317/72;;C07K2319/03;;A61K2039/505;;A61K2039/545;;A61K40/31;;A61K40/11;;A61P35/00;;A61K2239/13;;C07K16/303;;C07K2317/52;;C07K2317/565;;C07K2317/569;;A61K40/31,C07K16/30;;A61K39/00;;A61P35/00,,0,0,,,,DISCONTINUED
738,CN,A,CN 116179380 A,063-557-472-167-364,2023-05-30,2023,CN 202210949668 A,2022-08-09,CN 202210949668 A,2022-08-09,"Yarrowia lipolytica engineering bacterium WSMHP with high yield of pyruvic acid, construction method and application","The invention discloses a yarrowia lipolytica engineering bacterium with high yield of pyruvic acid as well as a construction method and application of the yarrowia lipolytica engineering bacterium WSMHP. According to the yarrowia lipolytica engineering bacterium WSMHP, an oxaloacetic acid transporter protein encoding gene Oac1p in a yarrowia lipolytica genome is knocked out, and meanwhile, a pyruvate decarboxylase encoding gene Pyc2 and a phosphoenolpyruvate carboxylation kinase encoding gene Pck1 are overexpressed. Compared with an original strain YW100-1 of the yersinia lipolytica, the yield of pyruvic acid is increased by 39.0% and reaches 168.9 g/L when glycerol is used as a unique carbon source, and an excellent strain is provided for industrial production of pyruvic acid.",UNIV ZHEJIANG TECHNOLOGY,YUAN WEI;;LI QINGQING;;LIU MENGZHU;;WANG SONGMAO;;LI LINGXIU;;DU YONGBAO;;WEI LITIAN;;SHI YUNA;;ZHANG YINJUN,,https://lens.org/063-557-472-167-364,Patent Application,no,4,0,2,080-043-918-543-781;;063-557-472-167-364,CN,2,080-043-918-543-781;;063-557-472-167-364,CN,0,C12N15/815;;C07K14/39;;C12N9/88;;C12N15/113;;C12P7/40;;C12N1/16;;C12Y401/01001;;C12Y401/01;;C12R2001/645;;C12N2310/20;;Y02E50/10,C12N1/19;;C12N15/113;;C12N15/31;;C12N15/60;;C12N15/81;;C12P7/40;;C12R1/645,,1,0,,,"SONGMAO WANG等: ""Engineering of Yarrowia lipolytica for producing pyruvate from glycerol"", 3 BIOTECH, 20 March 2022 (2022-03-20), pages 98",ACTIVE
739,WO,A1,WO 2022/156188 A1,030-716-289-152-867,2022-07-28,2022,CN 2021111152 W,2021-08-06,CN 202110087186 A,2021-01-22,METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR,"Provided is a method for producing a target DNA sequence and a cloning vector. The method includes the step of amplifying and extracting a DNA construct in a host cell, and a three-step thermostatic enzyme reaction step of protelomerase-IIS type restriction endonuclease and/or meganuclease-DNA exonuclease catalysis, wherein the construct is autonomously replicated and contains: (a) one or more IIS type restriction endonuclease and/or meganuclease recognition sequences; (b) the target DNA sequence; and (c) protelomerase recognition sequences at lateral wings of two ends of the target DNA sequence.",NANJING GENSCRIPT BIOTECH CO LTD,YE LUMENG;;SUN HAIYE;;GAO QIAN;;CHEN JUAN,,https://lens.org/030-716-289-152-867,Patent Application,yes,8,2,8,166-660-010-449-746;;030-716-289-152-867;;108-709-581-892-734;;046-176-019-162-711;;061-221-035-405-289;;090-184-033-672-625;;156-825-872-954-834;;057-243-983-475-722,JP;;KR;;CN;;EP;;IL;;WO;;US,8,166-660-010-449-746;;030-716-289-152-867;;046-176-019-162-711;;108-709-581-892-734;;061-221-035-405-289;;090-184-033-672-625;;156-825-872-954-834;;057-243-983-475-722,JP;;KR;;CN;;EP;;IL;;WO;;US,0,C12N15/66;;C12N15/85;;C12N15/70;;C12N2800/80;;C12N15/907;;C12N15/70;;C12N15/85;;C12N15/907;;C12Q2521/301;;C12N2800/80;;C12Q2521/313;;C12N15/66;;C12Q2521/319;;C12N15/66;;C12N15/85;;C12N15/70;;C12N9/22;;C12N9/1276;;C12N2800/80;;C12N9/1276;;C12N9/22;;C12N15/1003;;C12N15/63;;C12N2800/80,C12N15/63;;A61K48/00;;C12N15/10;;C12P19/34,,3,0,,,"ZHANG DIAN-BAO, ET AL.: ""Research progress in engineered nucleases for genome site-specific editing"", BASIC & CLINICAL MEDICINE, vol. 33, no. 12, 5 December 2013 (2013-12-05), pages 1634 - 1637, XP055952106, ISSN: 1001-6325;;SLAVCEV, ALTHOUGH, 2016;;See also references of EP 4274899A4",PENDING
740,EP,A1,EP 4592392 A1,069-618-988-060-335,2025-07-30,2025,EP 23867070 A,2023-06-30,CN 202211157754 A;;CN 2023104682 W,2022-09-22,NOVEL TUMOR DETECTION MARKER TAGME AND USE THEREOF,"Provided are a tumor detection marker TAGMe and use thereof. On the basis of analysis and research on a large number of clinical samples, novel DNA methylation tumor markers are obtained by separation. The markers are in a low methylation state in a normal tissue and in a high methylation state in a tumor sample, and show a significant difference in the methylation state in apatient with a tumor, and the difference is statistically significant. The markers have a more excellent effect when they are used in combination for detection. The tumor markers can be used as markers for diagnosis, screening, typing, detection, and prognosis of al clinical tumor, can also be used as novel molecules for clinical auxiliary diagnosis or prognosis of a tumor, or can be used for designing a diagnostic reagent and kit.",SHANGHAI EPIPROBE BIOTECHNOLOGY CO LTD,LI ZHENYAN;;DONG SHIHUA;;MAO ZHANRUI,,https://lens.org/069-618-988-060-335,Patent Application,yes,0,0,3,040-641-780-901-716;;069-618-988-060-335;;081-453-737-926-749,CN;;EP;;WO,3,040-641-780-901-716;;069-618-988-060-335;;081-453-737-926-749,CN;;EP;;WO,16,C12Q1/6886;;C12Q2600/154,C12N15/12;;C12N15/11;;C12Q1/6851;;C12Q1/6869;;C12Q1/6886,,0,0,,,,PENDING
741,EP,A1,EP 4393489 A1,085-187-906-404-359,2024-07-03,2024,EP 22849946 A,2022-07-29,KR 20210100261 A;;KR 2022011254 W,2021-07-29,NOVEL BENZENE DERIVATIVE AND IMMUNOSUPPRESSION-RELATED USE THEREOF,"The present invention relates to a novel benzene derivative and immunosuppressive-related use thereof. Specifically, it relates to a composition comprising a compound of Formula 1, its stereoisomer, solvate, hydrate, crystalline form, or pharmaceutically acceptable salt. The composition has preventive or therapeutic applications in immune disorders such as autoimmune diseases, transplant rejections, allergic diseases, and inflammatory conditions.",PROVIBIO CO LTD,PARK SEOK JU,,https://lens.org/085-187-906-404-359,Patent Application,yes,0,0,5,085-187-906-404-359;;082-851-124-699-686;;176-616-771-071-025;;048-105-736-991-226;;080-327-394-660-454,JP;;KR;;EP;;CN;;WO,5,048-105-736-991-226;;085-187-906-404-359;;176-616-771-071-025;;082-851-124-699-686;;080-327-394-660-454,JP;;KR;;EP;;CN;;WO,0,A61P37/00;;A61K31/44;;A61P37/06;;A61K31/166;;A61Q19/00;;A61K8/42;;A61K8/4926;;A61K8/49;;A23L33/10;;C07D213/81;;C07D231/56;;C07D303/36;;C07D213/82;;C07D217/26;;C07D237/24;;C07D233/64;;C07D241/24;;C07C233/65;;C07C311/16;;C07C233/66;;C07D213/81;;A61K31/44;;A61K31/166;;A61K31/472;;A61K31/47;;A61K31/50;;A61K31/4965;;A61P37/00;;A61P37/06;;A61P37/08;;A61P29/00;;C07D213/82;;C07D217/26;;C07D215/48;;C07D237/24;;C07D233/64;;C07D241/24;;C07D207/327;;C07C233/64;;C07C233/65;;C07C233/66;;C07C235/84;;C07C237/48;;C07C233/05;;C07C311/16;;C07C311/39;;C07C235/46;;C07C235/42;;C07C271/42;;A23L33/10;;A61K8/4926;;A61K8/42;;A61Q19/00;;C07C2601/14;;A23V2002/00;;A23V2200/324;;A23V2250/30,A61K31/166;;A61K31/18;;A61K31/197;;A61K31/222;;A61K31/381;;A61K31/416;;A61K31/44;;A61K31/5377;;A61P37/00;;A61P37/06,,0,0,,,,PENDING
742,WO,A1,WO 2021/001647 A1,165-176-117-894-136,2021-01-07,2021,GB 2020051575 W,2020-07-01,GB 201909439 A,2019-07-01,NOVEL CONSTRUCT,"The invention relates to an NHEJ or MMEJ detection construct, to NHEJ or MMEJ detection assays comprising said construct and to a method of screening for an NHEJ or MMEJ modulator comprising said construct.",ARTIOS PHARMA LTD,RAJENDRA EESON;;ROBINSON HELEN,,https://lens.org/165-176-117-894-136,Patent Application,yes,1,0,7,106-217-005-751-243;;165-176-117-894-136;;051-706-976-349-066;;120-714-427-113-30X;;023-544-810-916-046;;067-500-102-337-651;;006-734-384-099-469,JP;;CN;;EP;;WO;;US;;CA;;GB,7,106-217-005-751-243;;165-176-117-894-136;;051-706-976-349-066;;120-714-427-113-30X;;067-500-102-337-651;;023-544-810-916-046;;006-734-384-099-469,JP;;CN;;EP;;WO;;US;;CA;;GB,12,C12N15/1075;;C12Q1/6897;;C12N15/85;;C12N2800/10,C12N15/10,,5,5,086-013-000-514-224;;070-810-703-796-716;;006-899-343-498-610;;044-360-592-185-163;;064-176-089-355-124,10.1093/nar/gkv1349;;pmc4824085;;26657630;;10.1016/j.omtn.2018.03.010;;29858075;;pmc5992787;;pmc4385936;;25789972;;10.1038/cddis.2015.58;;pmc3493447;;23144625;;10.1371/journal.pgen.1003026;;pmc4992412;;27453047;;10.1016/j.molcel.2016.06.020,"KAJA KOSTYRKO ET AL: ""Assays for DNA double-strand break repair by microhomology-based end-joining repair mechanisms"", NUCLEIC ACIDS RESEARCH ADVANCE ACCESS, vol. 44, no. 6, 10 December 2015 (2015-12-10), GB, pages e56 - e56, XP055645754, ISSN: 0305-1048, DOI: 10.1093/nar/gkv1349;;MERT YANIK ET AL: ""Development of a Reporter System to Explore MMEJ in the Context of Replacing Large Genomic Fragments"", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 11, 1 June 2018 (2018-06-01), pages 407 - 415, XP055667005, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2018.03.010;;S SHARMA ET AL: ""Homology and enzymatic requirements of microhomology-dependent alternative end joining"", CELL DEATH & DISEASE, vol. 6, no. 3, 1 March 2015 (2015-03-01), pages e1697 - e1697, XP055666992, DOI: 10.1038/cddis.2015.58;;DIANA D. VILLARREAL ET AL: ""Microhomology Directs Diverse DNA Break Repair Pathways and Chromosomal Translocations"", PLOS GENETICS, vol. 8, no. 11, 8 November 2012 (2012-11-08), pages e1003026, XP055666983, ISSN: 1553-7390, DOI: 10.1371/journal.pgen.1003026;;WYATT ET AL., MOLECULAR CELL, vol. 63, no. 4, 2016, pages 662 - 673",PENDING
743,US,A1,US 2023/0151406 A1,003-522-310-115-346,2023-05-18,2023,US 202117797680 A,2021-02-16,US 202117797680 A;;US 202062978666 P;;US 2021/0018244 W,2020-02-19,NUCLEIC ACID SEQUENCE DETECTION BY ENDONUCLEASE DIGESTION AND MASS SPECTROMETRY,"A method of nucleic acid analysis is described, the method including the steps of (a) providing a sample comprising a plurality of end-blocked polynucleotides derived from a biological source; (b) digesting at least some of the end-blocked polynucleotides with a nucleic acid-directed endonuclease that targets a sequence of interest to produce polynucleotide fragments that comprise the sequence of interest and a ligatable end generated by endonuclease cleavage; (c) ligating a moiety to the ligatable end to produce a moiety-target polynucleotide construct; and (d) detecting the moiety-target polynucleotide construct or a transcription or translation produce produced from the moiety-target polynucleotide construct using mass spectrometry. The moiety may be an adaptor sequence with a promoter for RNA polymerase. The moiety may be a chemical moiety that is highly amenable to flight and detection in a mass spectrometer.",CHAN ZUCKERBERG BIOHUB INC,CRAWFORD EMILY D,CZ BIOHUB SF LLC (2023-01-27);;CHAN ZUCKERBERG BIOHUB INC (2021-03-18),https://lens.org/003-522-310-115-346,Patent Application,yes,4,0,2,140-338-003-697-179;;003-522-310-115-346,WO;;US,2,140-338-003-697-179;;003-522-310-115-346,WO;;US,0,C12Q1/6806;;C12Q1/6806,C12Q1/6806,,0,0,,,,PENDING
744,EP,A1,EP 4176893 A1,166-856-064-638-803,2023-05-10,2023,EP 21833302 A,2021-07-01,CN 202010623708 A;;CN 202110353488 A;;CN 2021103931 W,2020-07-01,CONSTRUCTION AND APPLICATION OF FUSION PROTEIN VACCINE PLATFORM,"The present invention relates to the construction and application of a fusion protein vaccine platform. The present invention provides a vaccine, comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope in the preparation of prophylactic or therapeutic compositions. The vaccine of the present invention can be produced by eukaryotic cell expression systems to prepare wild-type and various mutant antigen vaccines, and vaccination by means of subcutaneous/muscular or nasal or other routes can lead to a strong immune response to a body. The vaccine of the present invention can be used as a prophylactic or therapeutic vaccine.",INST BIOPHYSICS CAS,FU YANGXIN;;PENG HUA;;SUN SHIYU,,https://lens.org/166-856-064-638-803,Patent Application,yes,0,0,15,075-947-509-386-130;;150-114-855-501-754;;160-285-713-187-439;;101-157-007-488-115;;053-263-542-407-76X;;189-246-547-701-076;;084-242-920-933-217;;043-946-747-739-311;;166-856-064-638-803;;184-124-611-792-914;;096-862-123-045-201;;000-403-733-607-86X;;059-101-602-850-525;;176-058-390-840-296;;047-478-646-498-468,AU;;JP;;EP;;WO;;US;;CA;;PH,22,098-306-187-533-381;;075-947-509-386-130;;195-379-103-023-207;;150-114-855-501-754;;178-481-822-690-318;;160-285-713-187-439;;101-157-007-488-115;;053-263-542-407-76X;;184-124-611-792-914;;043-946-747-739-311;;139-413-996-810-413;;084-242-920-933-217;;166-856-064-638-803;;189-246-547-701-076;;096-862-123-045-201;;000-403-733-607-86X;;059-101-602-850-525;;176-058-390-840-296;;186-413-477-594-32X;;047-478-646-498-468;;182-069-930-001-612;;018-810-410-607-306,AU;;JP;;CN;;EP;;WO;;US;;CA;;PH,93,A61K39/12;;A61P31/12;;A61P35/00;;A61P31/04;;C07K14/555;;C12N15/62;;C07K2319/30;;A61K2039/6056;;C12N2730/10134;;C12N2770/20034;;A61K2039/605;;A61K2039/6031;;A61K2039/55505;;A61K2039/575;;A61P31/20;;A61P31/14;;A61K2039/543;;A61K39/001106;;C12N2760/16134;;C12N2710/16734;;C12N2710/16234;;C12N2710/16634;;C07K2317/52;;A61K39/39;;A61P31/12;;A61K9/0019;;A61K39/12;;A61K39/395;;A61K2039/6056;;A61K2039/6075;;A61K40/4204,A61K38/21;;A61K39/02;;A61K39/12;;A61K39/395;;A61P31/04;;A61P31/12;;A61P35/00;;C12N15/20;;C12N15/62,,0,0,,,,PENDING
745,KR,A,KR 20240026124 A,112-584-848-017-620,2024-02-27,2024,KR 20237038933 A,2022-05-10,US 202163186872 P;;IB 2022054342 W,2021-05-11,키메라 항원 수용체(CAR) T 세포 요법과 연관된 신경독성을 최소화하는 방법,본 개시내용은 키메라 항원 수용체(CAR) T 세포 요법의 투여와 연관된 신경독성의 조기 식별 및 검출의 방법 및 치료 연관된 신경독성의 발생 및/또는 중증도를 감소시키기 위한 완화 전략에 관한 것이다.,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;DE MONDELO MARIA MARQUEZ;;OLYSLAGER YUNSI;;QIU JUN;;ZUDAIRE UBANI ENRIQUE;;XU JEAN,,https://lens.org/112-584-848-017-620,Patent Application,no,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,G01N33/574;;A61K45/06;;A61P35/00;;G01N33/569;;G01N33/68,,0,0,,,,PENDING
746,US,A1,US 2025/0025539 A1,191-563-013-734-982,2025-01-23,2025,US 202418910526 A,2024-10-09,US 202418910526 A;;US 2024/0030129 W;;US 202363503190 P,2023-05-19,STABILIZED FORMULA OF CROTOXIN,"A highly stable acidifed formula of Crotoxin comprising saline and benzalkonium chloride, and optionally Thiamine, is disclosed that facilitates the therapeutic use of Crotoxin. Also disclosed is a method of preparing a highly stable formula of Crotoxin.",CELTIC BIOTECH LTD;;CELTIC BIOTECH LTD Q,REID PAUL,CELTIC BIOTECH LTD (2023-05-08),https://lens.org/191-563-013-734-982,Patent Application,yes,0,0,2,118-113-421-168-873;;191-563-013-734-982,WO;;US,2,118-113-421-168-873;;191-563-013-734-982,WO;;US,0,A61P21/00;;A61K38/465;;C12Y301/01004;;A61K9/0019;;A61K47/186;;A61K38/465;;A61K47/02;;A61K47/186;;C12Y301/01004,A61K38/46;;A61K47/02;;A61K47/18,,0,0,,,,PENDING
747,US,A1,US 2025/0269024 A1,093-517-015-489-773,2025-08-28,2025,US 202519045247 A,2025-02-04,US 202519045247 A;;US 202463549995 P,2024-02-05,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,AKRAM MUHAMMAD SHOAIB;;LENDVAI NIKOLETTA;;JETHAVA YOGESH;;SCHECTER JORDAN MARK;;DE BRAGANCA KEVIN,,https://lens.org/093-517-015-489-773,Patent Application,yes,0,0,2,093-517-015-489-773;;124-945-677-051-862,WO;;US,2,093-517-015-489-773;;124-945-677-051-862,WO;;US,0,A61K40/4215;;A61K40/11;;A61K40/31;;A61K2239/13;;A61K2239/38;;C07K16/241;;C07K16/245;;C07K16/248;;A61K39/3955;;A61P35/00;;A61K2239/48;;A61K31/675;;A61K31/216,A61K40/42;;A61K40/11;;A61K40/31;;A61P35/00;;C07K14/725;;C07K16/28,,0,0,,,,PENDING
748,CN,A,CN 113789276 A,002-021-448-671-677,2021-12-14,2021,CN 202111081824 A,2021-09-15,CN 202111081824 A,2021-09-15,Lactobacillus plantarum capable of producing beta-nicotinamide mononucleotide and application of lactobacillus plantarum,"The invention discloses lactobacillus plantarum capable of producing beta-nicotinamide mononucleotide and application of the lactobacillus plantarum, and belongs to the technical field of microbial fermentation. The lactobacillus plantarum is lactobacillus plantarum QCT009, and the registration number of the lactobacillus plantarum in the China General Microbiological Culture Collection Center is CGMCC NO.21881. The lactobacillus plantarum is applied to the preparation of beta-nicotinamide mononucleotide. The invention also discloses a method for preparing the beta-nicotinamide mononucleotide by using the lactobacillus plantarum QCT009. When the lactobacillus plantarum QCT009 provided by the invention is used for preparing the beta-nicotinamide mononucleotide, the yield of the beta-nicotinamide mononucleotide is higher than that of the beta-nicotinamide mononucleotide prepared by existing microbial fermentation, and the problem of low yield of the beta-nicotinamide mononucleotide prepared by the existing microbial fermentation is solved.",QIANCHONGTANG FUJIAN BIOTECHNOLOGY CO LTD,YANG ZITIAO,,https://lens.org/002-021-448-671-677,Patent Application,no,4,1,2,002-021-448-671-677;;029-759-734-120-893,CN,2,002-021-448-671-677;;029-759-734-120-893,CN,0,C12P19/30,C12N1/20;;C12P25/00;;C12R1/25,,1,0,,,"HIROSHI T AGUCHI等: ""Relative Activity of Pyridine Nucleotides to Nicotinic Acid as Niacin Nutriture in Lactobacillus plantarum ATCC 8014"", 《BIOSCI. BIOTECH. BIOCHEM》",ACTIVE
749,US,A1,US 2022/0346335 A1,072-316-540-120-20X,2022-11-03,2022,US 202217686729 A,2022-03-04,CN 202110471372 A,2021-04-29,MOLECULAR BREEDING METHOD FOR WHEAT FUSARIUM HEAD BLIGHT-RESISTANCE,"Disclosed is a molecular marker polymerization wheat breeding method for Fusarium head blight-resistance. The method uses an intermediate material for Fusarium head blight-resistance as a resistance source, and excellent varieties (strains) in a northern part of Huanghuai wheat production area as agronomic parents, and uses molecular marker-assisted selection and conventional breeding techniques. The molecular markers are a linked marker LJJT-1 of a Fusarium head blight-resistant gene Fhb1 and linked markers LJJ-2 and LJJ-3 of a Fusarium head blight-resistant gene Fhb2, so as to create a semi-winter Fusarium head blight-resistant breeding material with outstanding target traits and excellent comprehensive traits, which lays a material foundation for cultivating Fusarium head blight-resistant wheat varieties suitable for planting in the Huanghuai wheat production area.",CROP RES INST SHANDONG ACAD AGRICULTURAL SCIENCES;;JIANGSU LIXIAHE REGIONAL AGRICULTURAL RES INSTITUTE;;SHANDONG ACAD AGRICULTURAL SCIENCES,LIU JIANJUN;;HU WENJING;;LI HAOSHENG;;CHEN XUEYAN;;ZHAI SHENGNAN;;CAO XINYOU;;SONG JIANMIN;;GUO JUN;;LIU CHENG;;LIU AIFENG;;CHENG DUNGONG;;CHU XIUSHENG;;LI FAJI;;HAN RAN;;ZI YAN;;WANG XIAOLU,JIANGSU LIXIAHE REGIONAL AGRICULTURAL RESEARCH INSTITUTE (2022-03-03);;CROP RESEARCH INSTITUTE. SHANDONG ACADEMY OF AGRICULTURAL SCIENCES (2022-03-03);;SHANDONG ACADEMY OF AGRICULTURAL SCIENCES (2022-03-03),https://lens.org/072-316-540-120-20X,Patent Application,yes,2,2,3,040-372-546-606-855;;150-645-384-626-480;;072-316-540-120-20X,CN;;US,3,040-372-546-606-855;;150-645-384-626-480;;072-316-540-120-20X,CN;;US,6,A01H1/02;;A01H1/04;;C12Q1/6895;;C12Q2600/13;;C12Q2600/156;;A01H5/10;;A01H6/4678;;A01H1/045;;A01H1/045,A01H1/04,,1,1,119-966-138-390-760,pmc7080935;;32206506;;10.1007/s13205-020-2158-x,"Khan et al., 2020, Fusarium head blight in wheat: contemporary status and molecular approaches, 3 Biotech. 10:172, pp 1-17.",DISCONTINUED
750,WO,A1,WO 2025/063932 A1,148-400-517-170-118,2025-03-27,2025,TR 2024051083 W,2024-09-19,TR 2023011702 A,2023-09-20,A NON-TOXIC AND ENVIRONMENTALLY FRIENDLY ALTERNATIVE STAIN FOR HIGH SENSITIVITY DNA VISUALISATION SYSTEMS,"This invention relates to a new stain alternative that can be used as a nucleic acid stain, derived from the seeds of P. harmala, a plant with fluorescent properties, which is plant-based, non-harmful in terms of health, safe, inexpensive, environmentally friendly, and easy to produce.",ERCIYES UENIVERSITESI STRATEJI GELISTIRME DAIRE BASKANLIGI;;KAYSERI UENIVERSITESI STRATEJI GELISTIRME DAIRE BASKANLIGI,DUMAN FATIH;;CEYLAN AHMET;;KORKUSUZ ELIF;;KOCAKAYA ZEKIYE,,https://lens.org/148-400-517-170-118,Patent Application,yes,0,0,1,148-400-517-170-118,WO,1,148-400-517-170-118,WO,0,C09B61/00;;G01N2021/6439;;G01N33/52,C09B67/00;;G01N21/91,,2,1,061-020-343-123-880,10.1016/j.jphotobiol.2013.11.021;;24368411,"SARKAR SARITA; BHADRA KAKALI: ""Binding of alkaloid harmalol to DNA: Photophysical and calorimetric approach"", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, ELSEVIER SCIENCE S.A., BASEL., CH, vol. 130, 7 December 2013 (2013-12-07), CH , pages 272 - 280, XP028616345, ISSN: 1011-1344, DOI: 10.1016/j.jphotobiol.2013.11.021;;MIRAJ SEPIDEH: ""A review study of therapeutic effects of Peganum harmala"", DER PHARMACIA LETTRE, VOL. 8, NO. 13, SCHOLAR RESEARCH LIBRARY, 1 January 2016 (2016-01-01), pages 161 - 166, XP093295650, Retrieved from the Internet <URL:https://www.scholarsresearchlibrary.com/articles/a-review-study-of-therapeutic-effects-of-peganum-harmala.pdf>",PENDING
751,US,A1,US 2024/0368657 A1,157-416-210-386-654,2024-11-07,2024,US 202418748282 A,2024-06-20,CN 2022116876 W;;CN 2023116412 W,2022-09-02,INCLUSION BODY MEDIATED METHOD FOR DOUBLE-STRANDED RNA PRODUCING,"An inclusion body mediated method for double-stranded RNA producing. The method includes: transforming the vector to bacteria; culturing and inducing the bacteria expressed an inclusion body; and extracting the inclusion body by the sonication or high-pressure lysis of the collected bacteria, wherein the vector at least includes a nucleic acid sequence encoding a siRNA-binding polypeptide that corporate p19 protein with protein 1.",XIAOMO BIOTECH LTD,HUANG LINFENG;;HUANG PANPAN,XIAOMO BIOTECH LIMITED (2024-05-07);;XIAOMO (SHANGHAI) BIOTECH LIMITED (2024-12-20),https://lens.org/157-416-210-386-654,Patent Application,yes,0,0,4,017-288-410-149-688;;157-416-210-386-654;;166-315-748-696-041;;036-518-078-021-964,CN;;WO;;US,4,017-288-410-149-688;;157-416-210-386-654;;166-315-748-696-041;;036-518-078-021-964,CN;;WO;;US,0,C12N15/113;;C12N15/70;;C12N2310/14;;C12N2330/50;;C12N15/111;;C07K14/005;;C12N15/62;;C12N2770/38022;;C07K14/005;;C12N9/22;;C12N15/113;;C12N15/70;;C12N2310/14;;C12N2770/20022;;C12N2770/38022;;C12P19/34;;C12Y301/26003,C12P19/34;;C07K14/005;;C12N9/22;;C12N15/113;;C12N15/70,,0,0,,,,PENDING
752,US,A1,US 2023/0293679 A1,184-124-611-792-914,2023-09-21,2023,US 202118003872 A,2021-07-01,CN 202010623708 A;;CN 202110353488 A;;CN 2021103931 W,2020-07-01,CONSTRUCTION AND APPLICATION OF FUSION PROTEIN VACCINE PLATFORM,"The present invention relates to the construction and application of a fusion protein vaccine platform. The present invention provides a vaccine, comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope in the preparation of prophylactic or therapeutic compositions. The vaccine of the present invention can be produced by eukaryotic cell expression systems to prepare wild-type and various mutant antigen vaccines, and vaccination by means of subcutaneous/muscular or nasal or other routes can lead to a strong immune response to a body. The vaccine of the present invention can be used as a prophylactic or therapeutic vaccine.",INST BIOPHYSICS CAS,FU YANGXIN;;PENG HUA;;SUN SHIYU,INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES (2022-12-21),https://lens.org/184-124-611-792-914,Patent Application,yes,1,0,15,075-947-509-386-130;;150-114-855-501-754;;160-285-713-187-439;;101-157-007-488-115;;053-263-542-407-76X;;189-246-547-701-076;;084-242-920-933-217;;043-946-747-739-311;;166-856-064-638-803;;184-124-611-792-914;;096-862-123-045-201;;000-403-733-607-86X;;059-101-602-850-525;;176-058-390-840-296;;047-478-646-498-468,AU;;JP;;EP;;WO;;US;;CA;;PH,22,098-306-187-533-381;;075-947-509-386-130;;195-379-103-023-207;;150-114-855-501-754;;178-481-822-690-318;;160-285-713-187-439;;101-157-007-488-115;;053-263-542-407-76X;;184-124-611-792-914;;043-946-747-739-311;;139-413-996-810-413;;084-242-920-933-217;;166-856-064-638-803;;189-246-547-701-076;;096-862-123-045-201;;000-403-733-607-86X;;059-101-602-850-525;;176-058-390-840-296;;186-413-477-594-32X;;047-478-646-498-468;;182-069-930-001-612;;018-810-410-607-306,AU;;JP;;CN;;EP;;WO;;US;;CA;;PH,93,A61K39/12;;A61P31/12;;A61P35/00;;A61P31/04;;C07K14/555;;C12N15/62;;C07K2319/30;;A61K2039/6056;;C12N2730/10134;;C12N2770/20034;;A61K2039/605;;A61K2039/6031;;A61K2039/55505;;A61K2039/575;;A61P31/20;;A61P31/14;;A61K2039/543;;A61K39/001106;;C12N2760/16134;;C12N2710/16734;;C12N2710/16234;;C12N2710/16634;;C07K2317/52;;A61K39/39;;A61P31/12;;A61K9/0019;;A61K39/12;;A61K39/395;;A61K2039/6056;;A61K2039/6075;;A61K40/4204,A61K39/395;;A61K9/00;;A61K39/00;;A61K39/12;;A61P31/12,,0,0,,,,PENDING
753,US,A1,US 2024/0287569 A1,017-867-816-620-202,2024-08-29,2024,US 202418405235 A,2024-01-05,CN 202310159430 A,2023-02-23,"MYOGLOBIN AND EXPRESSION VECTOR AND EXPRESSION ENGINEERING BACTERIUM THEREOF, AND USE THEREOF","The present disclosure provides myoglobin (MB) and an expression vector and an expression engineering bacterium thereof, and use thereof, and relates to the technical field of genetic engineering. In the present disclosure, recombinant Escherichia coli strains with signal peptides Pel B and Omp A inserted under same conditions have an expression level of Sus scrofa myoglobin (SsMB) increased by 2.06 and 1.17 times, respectively, compared with an original expression strain of the SsMB. The signal peptides that can increase the expression level of the SsMB provide a new idea for research and application of improving the expression level of the SsMB.",UNIV ZHEJIANG;;NINGBO INNOVATION CENTER ZHEJIANG UNIV;;SHANGHAI INST FOR ADVANCED STUDY OF ZJU,CHEN WEI;;XIE LIANGHUA;;MENG YUNHE;;YOU KAIHAO;;ZHOU JINGWEN;;GUAN XIN,ZHEJIANG UNIVERSITY (2023-12-18);;SHANGHAI INSTITUTE FOR ADVANCED STUDY OF ZJU (2023-12-18);;NINGBO INNOVATION CENTER ZHEJIANG UNIVERSITY (2023-12-18),https://lens.org/017-867-816-620-202,Patent Application,yes,0,0,2,050-168-821-367-225;;017-867-816-620-202,CN;;US,2,050-168-821-367-225;;017-867-816-620-202,CN;;US,0,C12N15/70;;C12N15/67;;C07K14/805;;C12R2001/19;;Y02A50/30;;C12Y301/03001;;C12P21/02;;C12N9/88;;C12N15/70;;C12N9/16;;C12Y402/0201;;C12N9/16;;C12N9/88;;C12N15/70;;C12N2800/101;;C12P21/02;;C12Y301/03001;;C12Y402/0201,C12P21/02;;C12N9/16;;C12N9/88;;C12N15/70,,0,0,,,,PENDING
754,US,A1,US 2021/0196777 A1,193-281-942-178-471,2021-07-01,2021,US 201817058432 A,2018-05-31,CN 2018089229 W,2018-05-31,MUNG BEAN HULL EXTRACT WITH ANTIVIRAL EFFECT AND EXTRACTION METHOD THEREOF,"The present invention is a mung bean hull extract with antiviral effect, and the mung bean hull extract achieves antiviral effect by inhibiting α-glucosidase and neuraminidase. The present invention also relates to a method for extracting the mung bean hull extract with antiviral effect and applications of the extract obtained by the method.",CHEN HUI WEN;;KINGS GROUND BIOTECH CO LTD,CHEN HUI-WEN;;YU FENG-LING;;HUNG YING-NIEN;;PI CHIA-CHEN,KING'S GROUND BIOTECH CO. LTD (2020-11-24);;CHEN HUI-WEN (2020-11-25),https://lens.org/193-281-942-178-471,Patent Application,yes,0,0,4,076-590-992-348-827;;193-281-942-178-471;;117-423-582-958-363;;105-357-761-613-880,JP;;WO;;US,4,076-590-992-348-827;;193-281-942-178-471;;117-423-582-958-363;;105-357-761-613-880,JP;;WO;;US,0,A61P31/12;;A61P31/22;;A61K36/48;;A61K31/352;;A61P31/16;;A61K2236/00;;A61P31/16;;A61K31/352;;A61K36/48;;A61K2236/31;;A61K2236/333;;A61K2236/51,A61K36/48;;A61K31/352;;A61P31/16,,0,0,,,,DISCONTINUED
755,US,A1,US 2024/0009301 A1,195-139-328-544-158,2024-01-11,2024,US 202118265081 A,2021-12-03,EP 20211707 A;;EP 21164128 A;;EP 2021084132 W,2020-12-03,IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV,"The invention relates to an immunogenic composition for use as a medicament to prevent and/or treat a medical condition associated with a SARS-CoV infection, said composition comprising one or more bacteria of the human microbiota and/or immunogenic parts thereof, wherein said composition is capable of inducing acquired immunity to said infection. The invention further relates to isolated bacteria of the human microbiota that bind to a neutralising antibody that recognises the spike protein of SARS-CoV, preferably the spike protein of SARS-CoV2. In another aspect, the invention relates to an in vitro method for the diagnosis, prognosis, risk stratification and/or therapy management of a human subject with an increased risk of an adverse event associated with a medical condition associated with a SARS-CoV infection (preferably with SARS-CoV-2).",DEUTSCHES RHEUMA FORSCHUNGSZENTRUM BERLIN,KRUGLOV ANDREY,DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN (2023-06-05),https://lens.org/195-139-328-544-158,Patent Application,yes,0,1,4,177-602-220-068-048;;098-900-490-400-866;;195-139-328-544-158;;135-962-658-947-165,EP;;WO;;US;;CA,5,177-602-220-068-048;;116-222-870-247-489;;098-900-490-400-866;;195-139-328-544-158;;135-962-658-947-165,EP;;WO;;US;;CA,0,A61K39/12;;C12N2770/20011;;A61K39/09;;A61K39/092;;A61K2039/542;;A61K2039/521;;A61K2039/58;;A61P31/14;;Y02A50/30;;C07K16/1003;;A61P31/14;;A61K39/02;;A61K39/092;;A61K39/215;;A61K2039/521;;A61K2039/522;;A61K2039/542;;A61K2039/58;;A61K39/09;;C07K16/1003,A61K39/215;;A61K39/02;;A61K39/09;;A61P31/14,,0,0,,,,PENDING
756,US,A1,US 2020/0375880 A1,036-074-427-687-912,2020-12-03,2020,US 201716463956 A,2017-11-23,FR 1661486 A;;EP 2017080224 W,2016-11-25,PLANT EXTRACTS FROM THE TAGETES GENUS AND USES OF SAME,"An extract of plants from the Tagetes genus enriched with leontopodic acid B, a method for preparing the extract, a cosmetic composition, a nutraceutical composition, and a pharmaceutical composition, where the compositions includes, as the active agent, at least one extract of plants from the Tagetes genus. A method of using the extract as a drug for preventing and/or treating a neurodegenerative disease, including Alzheimer's disease. A cosmetic composition including the extract.",PLANT ADVANCED TECH PAT,GINGLINGER JEAN-FRANÇOIS;;DESLIS SIMON;;EMILE LÉNA,PLANT ADVANCED TECHNOLOGIES PAT (2017-12-14),https://lens.org/036-074-427-687-912,Patent Application,yes,0,1,4,036-074-427-687-912;;061-863-614-872-61X;;064-601-345-787-845;;084-810-222-247-853,WO;;US;;FR,4,036-074-427-687-912;;061-863-614-872-61X;;064-601-345-787-845;;084-810-222-247-853,WO;;US;;FR,0,C07C67/56;;A61K8/375;;A61K8/9789;;A61K36/28;;A61K2800/522;;A61P25/28;;A61Q19/00;;A61Q19/08;;A61K8/9789;;A01G22/60;;A01G31/00;;A61K8/375;;A61K31/202;;A61K36/28;;A61K2236/331;;A61Q19/08,A61K8/9789;;A01G22/60;;A01G31/00;;A61K8/37;;A61K31/202;;A61K36/28;;A61Q19/08,,0,0,,,,DISCONTINUED
757,US,A1,US 2025/0092412 A1,151-405-324-387-67X,2025-03-20,2025,US 202418825366 A,2024-09-05,CN 202311195940 A,2023-09-15,GBWOX3A GENE AND APPLICATION THEREOF IN PLANT TISSUE CULTURE,"A Ginkgo biloba wuschel-related homeobox 3A (GbWOX3A) gene and an application thereof in plant tissue culture are provided. The GbWOX3A gene is derived from a Ginkgo biloba embryo, the gene sequence of the GbWOX3A gene is SEQ ID NO: 1, and the amino acid sequence encoded by the GbWOX3A gene is SEQ ID NO: 2. An expression of the GbWOX3A gene in developing embryo of Ginkgo biloba and regenerating a callus has specificity, and transgenic function verification experiments prove that overexpression of the GbWOX3A gene can promote regeneration of adventitious buds during the plant tissue culture. Therefore, the GbWOX3A gene has important theoretical significance and application value in the plant tissue culture, and especially plays an important role in improving the regeneration efficiency of gymnosperms.",UNIV NANJING FORESTRY,FU FANGFANG;;XUE LIANGJIAO;;CAO FULIANG;;ZHAO ANQI;;XU WEI;;XU PINGJUN;;YANG XIAOMING;;MING MEILING,NANJING FORESTRY UNIVERSITY (2024-09-04),https://lens.org/151-405-324-387-67X,Patent Application,yes,0,0,4,149-552-117-102-051;;038-391-166-762-41X;;063-383-786-267-010;;151-405-324-387-67X,CN;;US,4,149-552-117-102-051;;038-391-166-762-41X;;063-383-786-267-010;;151-405-324-387-67X,CN;;US,0,C07K14/415;;C12N15/8261;;C12N15/8203;;Y02A40/146;;C12N15/8205;;C12N15/8262;;C07K14/415;;C12N15/8261;;A01H5/04;;C12N15/8205;;C12N15/8262,C12N15/82,,2,1,020-755-348-375-26X,10.1093/dnares/dsz020;;31580414;;pmc6796506,Qiu et al. DNA Research. 26(5). October. 423-431 (Year: 2019);;GenBank Accession No. FM882126.1. Nardmann et al. (Year: 2009),ACTIVE
758,EP,A1,EP 3816292 A1,169-371-170-481-698,2021-05-05,2021,EP 19830583 A,2019-07-03,CN 201810724563 A;;CN 2019094632 W,2018-07-04,METHOD OF OBTAINING MULTI-LEAF ALFALFA MATERIAL BY MEANS OF MSPALM1 ARTIFICIAL SITE-DIRECTED MUTANT,"Disclosed is a method for obtaining multileaflet Medicago sativa materials by means of MsPALM1 artificial site-directed mutants. The method comprises: selecting a target site from an exon region of a compound leaf developmental regulatory gene MsPALM1 of Medicago sativa and constructing a plant CRISPR/Cas9 editing recombinant vector MsCRISPR/Cas9::PALM1 and introducing the vector into Medicago sativa cells and regenerating into plants, cutting and repairing to cause a loss-of-function mutation in the MsPALM1 gene of Medicago sativa cells, and then screening the mutant plants by restriction endonuclease digestion and/or targeted deep sequencing of the target sites of the regenerated plantsgenome to obtain lines carrying four MsPALM1 allelic genes with simultaneous loss of function mutation. After phenotypic identification, it was confirmed that the compound leaves of the regenerated plants changed from three leaflets to five leaflets. The method can quickly obtain multileaflet Medicago sativa materials with a short breeding period and stable trait.",GUANGDONG SANJIE FORAGE BIOTECHNOLOGY CO LTD,CHEN HAITAO;;WANG WEN;;XIE XIONGPING;;QIU QIANG;;SHANG ZHANHUAN;;SU KEXIAN;;HE HUI,,https://lens.org/169-371-170-481-698,Patent Application,yes,0,0,9,028-881-695-080-78X;;096-561-844-852-776;;116-143-383-253-974;;103-461-120-771-667;;147-508-737-591-692;;169-371-170-481-698;;132-611-789-460-679;;187-419-949-833-776;;141-108-833-328-607,AU;;CN;;EP;;WO;;US;;CA,11,028-881-695-080-78X;;116-143-383-253-974;;103-461-120-771-667;;096-561-844-852-776;;085-095-259-783-55X;;147-508-737-591-692;;169-371-170-481-698;;132-611-789-460-679;;187-419-949-833-776;;141-108-833-328-607;;035-445-667-521-034,AU;;CN;;EP;;WO;;US;;CA,14,C07K14/415;;C12N15/8216;;C12N15/8261;;C07K14/415;;A01H6/544;;C12N15/8213;;C12N15/8216;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N15/8216,C12N15/29;;A01H5/12;;A01H6/54;;C12N15/82,,0,0,,,,PENDING
759,AR,A1,AR 132020 A1,022-372-803-593-395,2025-05-21,2025,AR P240100509 A,2024-02-29,US 202363497185 P;;US 202363504184 P;;US 2023/0031673 W,2023-04-19,TERAPIA DE CÉLULAS CAR-T DIRIGIDA A BCMA PARA MIELOMA MÚLTIPLE,"En la presente descripción se proporcionan métodos para tratar a un sujeto que tiene mieloma múltiple y han recibido uno a tres tratamientos previos. Se administran al sujeto infusiones de células T con receptor de antígeno quimérico (CAR) que comprenden un CAR capaz de unirse específicamente a un epítopo de BCMA. Reivindicación 1: Un método para tratar a un sujeto, que comprende administrar al sujeto una dosis de células T que comprenden un receptor de antígeno quimérico (CAR) que comprende: (a) un dominio de unión al antígeno extracelular capaz de unirse específicamente a un epítopo del antígeno de maduración de células B (BCMA), (b) un dominio transmembrana, y (c) un dominio de señalización intracelular, en donde el sujeto tiene mieloma múltiple, ha recibido una a tres líneas de terapia previas, que incluyen una terapia con un fármaco inmunomodulador (IMiD), y es refractario al IMiD.",LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,,https://lens.org/022-372-803-593-395,Patent Application,no,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K39/00;;A61P35/00;;C12Q1/6886,,0,0,,,,PENDING
760,BE,A1,BE 1031543 A1,019-533-216-095-750,2024-11-19,2024,BE 202305716 A,2023-08-30,US 202363497185 P;;US 202363504184 P,2023-04-19,Thérapie par cellule CAR-T ciblée par BCMA de Myélome Multiple,La présente invention concerne des procédés de traitement d’un sujet atteint d’un myélome multiple et ayant reçu un à trois traitements antérieurs. Des perfusions de récepteur antigénique chimérique (CAR)-lymphocytes T comprenant un CAR capable de se lier spécifiquement à un épitope de BCMA sont administrées au sujet.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,,https://lens.org/019-533-216-095-750,Patent Application,no,11,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61P35/00;;A61K39/00;;C07K14/725;;C07K16/28;;C12N5/0783,,54,27,050-959-366-576-084;;070-280-788-085-909;;149-205-978-448-517;;017-150-654-990-340;;002-264-966-090-625;;102-694-840-088-330;;063-086-322-407-483;;018-694-860-400-630;;035-100-608-588-913;;003-912-708-516-610;;003-931-599-928-408;;095-945-393-711-654;;060-578-906-283-340;;064-758-125-126-733;;035-747-206-252-883;;036-537-002-834-639;;117-599-617-388-110;;025-596-639-921-781;;009-034-724-212-694;;019-817-021-691-872;;032-942-121-304-562;;009-733-370-384-407;;043-910-215-326-984;;053-536-682-236-035;;012-550-665-370-447;;044-566-966-395-039;;109-462-744-640-609,8502296;;10.1038/363446a0;;10.1038/374168a0;;7877689;;10.2217/nnm.13.86;;23730699;;10.1126/science.3140379;;3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nbt0898-778;;9702779;;10.1038/346776a0;;2201923;;pmc39610;;8622939;;10.1073/pnas.93.8.3346;;10.1093/nar/27.22.4324;;pmc148712;;10536138;;10.1385/1-59259-922-2:123;;16082031;;10.1016/0022-2836(81)90321-1;;6271971;;6096211;;10.1016/0378-1119(84)90115-x;;10.1126/science.3039660;;3039660;;7460013;;10.1016/0092-8674(80)90558-9;;15385951;;10.1038/sj.gt.3302362;;3037341;;pmc365315;;10.1128/mcb.7.5.2031-2034.1987;;10.1128/mcb.7.5.2031;;25061170;;10.1182/blood-2014-06-578989;;pmc4110654;;10.4049/jimmunol.180.3.1309;;18209024;;21926977;;pmc3192229;;10.1038/nm.2446;;6994593;;10.1146/annurev.bb.09.060180.002343;;19561539;;pmc2747302;;10.1097/cji.0b013e3181ac6138;;10.1111/bjh.17888;;34622447;;pmc7861652;;33554050;;10.1097/hs9.0000000000000528;;pmc9818178;;36612152;;10.3390/cancers15010155;;33172403;;pmc7656738;;10.1186/s12885-020-07503-y;;10.1056/nejmoa1606038;;27557302;;10.2307/2337108,"HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 8;;GREENBERG ET AL., NATURE, vol. 374, 1995, pages 168 - 73;;HASSANZADEH-GHASSABEH ET AL., NANOMEDICINE (LOND, vol. 8, 2013, pages 1013 - 26;;KABAT ET AL.: ""Sequences of Immunological Interest"", vol. 7, 1991, NATIONAL INSTITUTE OF HEALTH, article ""Gene Transfer and Expression Protocols"";;HOLLIGER ET AL., NAT. BIOTECH., vol. 23, no. 9, 2005, pages 1 126 - 1129;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;OSBOURN ET AL., NAT. BIOTECHNOL, vol. 16, 1998, pages 778;;JOHNSTON, NATURE, vol. 346, 1990, pages 776 - 777;;NO ET AL., PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 3346 - 3351;;INDRA ET AL., NUC. ACID. RES., vol. 27, 1999, pages 4324 - 4327;;NUE. ACID. RES., vol. 28, 2000, pages e99;;KRAMERFUSSENEGGER, METHODS MOL. BIOL, vol. 308, 2005, pages 123 - 144;;""Fundamental Immunology"", 1993, RAVEN PRESS, pages: 353 - 363;;WIGLER ET AL., PROC. NATL. ACAD. SCI. ÉTATS-UNIS, vol. 77, 1980, pages 3567;;O'HARE ET AL., PROC. NATL. ACAD. SCI. ÉTATS-UNIS, vol. 78, 1981, pages 2072;;COLBERRE-GARAPIN ET AL., J. MOL. BIOL., vol. 150, 1981, pages 1;;SANTERRE ET AL., GENE, vol. 30, 1984, pages 147;;KENT ET AL., SCIENCE, vol. 237, 1987, pages 901 - 903;;WIGLER ET AL., CELL, IP., vol. 223, 1977;;SZYBALSKASZYBALSKI, PROC. NATL. ACAD. SCI. ÉTATS-UNIS, vol. 48, 1962, pages 2026;;LOWY ET AL., CELL, vol. 22, 1980, pages 817;;CONESE ET AL., GENE THERAPY, vol. 11, 2004, pages 1735 - 1742;;""Immunobiology"", 2001, GARLAND;;BRASH ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 2031 - 2034;;RESTIFO, BLOOD, vol. 124, no. 4, 2014, pages 476 - 77;;JOSHI ET AL., J. IMMUNOL., vol. 180, no. 3, 2008, pages 1309 - 15;;GATTINONI ET AL., NAT. MED., vol. 17, 2011, pages 1290 - 7;;FLYNN ET AL., CLIN. TRANSLAT. IMMUNOL., vol. 3, 2014, pages e20;;SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467;;KOCHENDERFER ET AL., J. IMMUNOTHERAPY, vol. 32, no. 7, 2009, pages 689 - 702;;HERMAN ET AL., J. IMMUNOLOGICAL METHODS, vol. 285, no. 1, 2004, pages 25 - 40;;VAN DE DONK, HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, vol. 2020, 2020, pages 248 - 58;;RODRIGUEZ-LOBATO ET AL., BR J HAEMATOL, vol. 196, 2022, pages 649 - 59;;YONG ET AL., BR J HAEMATOL, vol. 175, 2016, pages 252 - 64;;DHAKAL ET AL., CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, vol. 22, 2022, pages S167;;DHAKAL ET AL., HEMASPHERE, vol. 6, 2022, pages 790 - 1;;DIMOPOULOS ET AL., HEMASPHERE, vol. 5, 2021, pages e528;;DE ARRIBA DE LA FUENTE ET AL., CANCERS (BASEL, 2022, pages 15;;FONSECA ET AL., BMC CANCER, vol. 20, 2020, pages 1087;;BERDEJA ET AL., LANCET, vol. 398, 2021, pages 314 - 24;;MARTIN ET AL., J CLIN ONCOL, 2022, pages JC02200842;;LIN ET AL., J CLIN ONCOL, 2023;;VAN DE DONK ET AL., BLOOD, vol. 140, 2022, pages 7536 - 7;;EINSELE ET AL., AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING, 3 June 2022 (2022-06-03);;RAJKUMAR ET AL., BLOOD, vol. 117, 2011, pages 4691 - 5;;RICHARDSON ET AL., LANCET ONCOL, vol. 20, 2019, pages 781 - 94;;DIMOPOULOS ET AL., LANCET ONCOL, vol. 22, 2021, pages 801 - 12;;PALUMBO ET AL., N ENGL J MED, vol. 375, 2016, pages 754 - 66;;LEE ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 25, 2019, pages 625 - 38;;XU ET AL., STAT MED, vol. 36, 2017, pages 592 - 605;;ZUCKER ET AL., BIOMETRIKA, vol. 77, 1990, pages 853 - 64;;RODRIGUEZ-OTERO ET AL., N ENGL J MED, 2023;;COHEN ET AL., BLOOD CANCER J, vol. 12, 2022, pages 32",ACTIVE
761,FR,A1,FR 3147946 A1,175-281-899-286-318,2024-10-25,2024,FR 2309079 A,2023-08-30,US 202363497185 P;;US 202363504184 P,2023-04-19,Thérapie par cellule CAR-T ciblée par BCMA de Myélome Multiple,La présente invention concerne des procédés de traitement d’un sujet atteint d’un myélome multiple et ayant reçu un à trois traitements antérieurs. Des perfusions de récepteur antigénique chimérique (CAR)-lymphocytes T comprenant un CAR capable de se lier spécifiquement à un épitope de BCMA sont administrées au sujet.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN MARK;;DE ASCENSAO SLAUGHTER ANA RUTE;;LONARDI CAROLINA,,https://lens.org/175-281-899-286-318,Patent Application,no,0,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,0,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,A61K35/17;;A61P35/00,,0,0,,,,PENDING
762,US,A1,US 2022/0186239 A1,080-967-150-454-051,2022-06-16,2022,US 202117548597 A,2021-12-13,CN 202011465541 A,2020-12-14,"PEACH POLYGALACTURONASE-INHIBITING PROTEIN PpPGIP1 GENE, AND CLONING METHOD AND USE THEREOF","The present invention discloses a peach polygalacturonase-inhibiting protein PpPGIP1 gene, and a cloning method and use thereof. The peach polygalacturonase-inhibiting protein PpPGIP1 gene has a nucleotide sequence shown in SEQ ID NO: 1, and a protein encoded by the peach polygalacturonase-inhibiting protein PpPGIP1 gene has an amino acid sequence shown in SEQ ID NO: 2. The cloning method includes the following steps: (1) extracting total RNA from a peach, and subjecting the total RNA to reverse transcription to obtain cDNA, which serves as a template; (2) designing primers based on the PpPGIP1 gene sequence; and (3) Polymerase Chain Reaction (PCR) amplification: conducting PCR amplification to obtain a PpPGIP1 gene amplification product. As there is a protein-protein interaction relationship between PpPGIP1 and PpVIN2, the effective inhibition of the PpPGIP1 expression in peach can significantly reduce the activity of the acid invertase PpVIN2 and thus reduce the decomposition of sucrose.",UNIV NINGBO,SHAO XINGFENG;;WEI YINGYING;;MAO YIHUI;;CHEN YI;;JIANG SHU,NINGBO UNIVERSITY (2021-12-06),https://lens.org/080-967-150-454-051,Patent Application,yes,0,1,4,138-021-381-489-425;;080-967-150-454-051;;050-730-273-386-198;;146-399-693-206-177,CN;;US,4,138-021-381-489-425;;080-967-150-454-051;;050-730-273-386-198;;146-399-693-206-177,CN;;US,11,C07K14/415;;C12N15/8218;;C12N15/8218;;C12N15/8205,C12N15/82,,0,0,,,,ACTIVE
763,US,A1,US 2021/0269816 A1,187-419-949-833-776,2021-09-02,2021,US 201917257595 A,2019-07-03,CN 201810724563 A;;CN 2019094632 W,2018-07-04,Method of Obtaining Multileaflet Medicago Sativa Materials by Means of MsPALM1 Artificial Site-Directed Mutants,"Disclosed is a method for obtaining multileaflet Medicago sativa materials by means of MsPALM1 artificial site-directed mutants. The method comprises: selecting a target site from an exon region of a compound leaf developmental regulatory gene MsPALM1 of Medicago sativa and constructing a plant CRISPR/Cas9 editing recombinant vector MsCRISPR/Cas9::PALM1 and introducing the vector into Medicago sativa cells and regenerating into plants, cutting and repairing to cause a loss-of-function mutation in the MsPALM1 gene of Medicago sativa cells, and then screening the mutant plants by restriction endonuclease digestion and/or targeted deep sequencing of the target sites of the regenerated plants to obtain lines carrying four MsPALM1 allelic genes with simultaneous loss of function mutation. After phenotypic identification, it was confirmed that the compound leaves of the regenerated plants changed from three leaflets to five leaflets. The method can quickly obtain multileaflet Medicago sativa materials with a short breeding period and stable trait.",GUANGDONG SANJIE FORAGE BIOTECHNOLOGY CO LTD,CHEN HAITAO;;WANG WEN;;XIE XIONGPING;;QIU QIANG;;SHANG ZHANHUAN;;SU KEXIAN;;HE HUI,,https://lens.org/187-419-949-833-776,Patent Application,yes,0,0,9,028-881-695-080-78X;;096-561-844-852-776;;116-143-383-253-974;;103-461-120-771-667;;147-508-737-591-692;;169-371-170-481-698;;132-611-789-460-679;;187-419-949-833-776;;141-108-833-328-607,AU;;CN;;EP;;WO;;US;;CA,11,028-881-695-080-78X;;116-143-383-253-974;;103-461-120-771-667;;096-561-844-852-776;;085-095-259-783-55X;;147-508-737-591-692;;169-371-170-481-698;;132-611-789-460-679;;187-419-949-833-776;;141-108-833-328-607;;035-445-667-521-034,AU;;CN;;EP;;WO;;US;;CA,2,C07K14/415;;C12N15/8216;;C12N15/8261;;C07K14/415;;A01H6/544;;C12N15/8213;;C12N15/8216;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N15/8216,C12N15/82,,0,0,,,,DISCONTINUED
764,KR,A,KR 20210058277 A,021-902-797-026-050,2021-05-24,2021,KR 20190145533 A,2019-11-14,KR 20190145533 A,2019-11-14,Pyrrolopyrimidine pyrrolopyridine and indazole derivatives as therapeutic agents,"The present invention relates to: a compound selected from novel pyrrolopyrimidine, pyrrolopyridine and an indazole derivative having a protein kinase inhibitory activity, and a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof or a stereoisomer thereof; and a pharmaceutical composition for preventing, alleviating, or treating cancer, containing the compound. A compound according to the present invention has an excellent ability to inhibit the activation of Bcr-Abl tyrosine kinase and T315I-Bcr-Abl tyrosine kinase, which is a drug-resistant mutant species, but does not have an inhibitory activity against VEGFR2 protein kinase, and thus can greatly reduce drug resistance and side effects and be effectively used in the prevention, alleviation, or treatment of cancer, particularly blood cancer, especially chronic myeloid leukemia.",KOREA INST SCI & TECH,SIM TAE BO;;SHIN IN JAE;;NAM YUN JU;;DEBABRATA BHUNIA;;PARK CHAN JUNG;;HUR WOO YOUNG,,https://lens.org/021-902-797-026-050,Patent Application,no,5,3,3,018-034-434-581-105;;021-902-797-026-050;;056-005-201-584-722,KR;;WO,3,021-902-797-026-050;;018-034-434-581-105;;056-005-201-584-722,KR;;WO,0,A61K31/506;;A61K31/519;;A61P35/00;;A61P35/02;;C07D403/04;;C07D403/14;;C07D405/14;;C07D471/04;;C07D487/04;;C07D471/04;;A61K31/506;;A61K31/519;;A61P35/00;;C07D403/04;;C07D403/14;;C07D405/14;;C07D487/04,C07D471/04;;A61K31/506;;A61K31/519;;A61P35/00;;C07D403/04;;C07D403/14;;C07D405/14;;C07D487/04,,2,2,000-394-787-580-082;;149-250-002-775-711,23190221;;10.1056/nejmoa1205127;;pmc3777383;;10.1038/nbt0114-9a;;24406915,"Cortes JE et al., N. Engl. J. Med. 367:2075-2088, 2012;;Senior M., Nat. Biotech. 32(1):9-11, 2014",ACTIVE
765,US,A1,US 2024/0043558 A1,161-059-770-905-661,2024-02-08,2024,US 202318491160 A,2023-10-20,CN 2021089248 W;;CN 2022088436 W,2021-04-23,"ANTI-GPC3 ANTIBODIES, MULTISPECIFIC ANTIBODIES AND METHODS OF USE","Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3. The antibody derivative is a multispecific antibody that binds to GPC3 and an additional antigen, e.g., 4-1BB.",SHANGHAI HENLIUS BIOTECH INC,ISSAFRAS HASSAN;;XU WENFENG;;JIANG WEI-DONG;;KIM HEUNGNAM,SHANGHAI HENLIUS BIOTECH INC (2021-05-25);;HENGENIX BIOTECH INC (2021-06-07),https://lens.org/161-059-770-905-661,Patent Application,yes,0,0,10,098-657-741-526-109;;089-873-253-431-688;;160-794-598-650-007;;042-062-595-826-730;;123-092-151-894-445;;046-761-656-925-272;;148-233-667-813-355;;101-880-380-362-118;;155-187-119-558-145;;161-059-770-905-661,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA,10,098-657-741-526-109;;089-873-253-431-688;;160-794-598-650-007;;042-062-595-826-730;;123-092-151-894-445;;046-761-656-925-272;;148-233-667-813-355;;101-880-380-362-118;;155-187-119-558-145;;161-059-770-905-661,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA,0,A61P35/00;;C07K16/303;;C07K2317/569;;C07K2319/00;;C07K2317/52;;C07K2317/35;;C07K2317/732;;C07K2317/41;;C07K2317/73;;A61K2039/505;;C07K16/24;;C07K2317/31;;C07K2317/75;;C07K2317/92;;C07K16/28;;C07K16/46;;C07K2317/622;;A61P35/00;;C07K2317/569;;C07K2317/92;;C07K16/24;;C07K2317/52;;C07K2317/732;;C07K2317/75;;C07K2317/73;;C07K16/303;;C07K2317/35;;C07K2317/41;;A61K2039/505;;C07K2317/31;;C07K2319/00;;C07K16/303;;C07K16/2878;;A61P35/00;;C07K2317/31;;C07K2317/569;;C07K2317/73;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K2039/505;;C07K16/2878;;C07K16/303;;C07K2317/22;;C07K2317/24;;C07K2317/31;;C07K2317/569;;C07K2317/73;;C07K2317/732;;C07K2317/75;;C07K2317/92,C07K16/30;;A61P35/00;;C07K16/28,,0,0,,,,DISCONTINUED
766,CN,A,CN 120290394 A,019-140-278-175-02X,2025-07-11,2025,CN 202510469740 A,2025-04-15,CN 202510469740 A,2025-04-15,Immobilized microbial inoculum capable of degrading toluene as well as preparation method and application of immobilized microbial inoculum,"The invention relates to the technical field of toluene degradation treatment, and discloses an immobilized microbial inoculum capable of degrading toluene as well as a preparation method and application of the immobilized microbial inoculum. The preparation method comprises the following steps: adding a bacillus megatherium activated bacterium solution into a liquid culture medium, and adding nano carbon black powder to obtain carbon black immobilized bacteria; heating and stirring the carboxymethyl xylan zinc complex and the nano magnesium lithium silicate until the mixture is molten; after cooling, adding the nano carbon black immobilized bacteria to obtain a mixed solution; slowly dropwise adding the mixed solution into a calcium chloride solution to form embedded pellets; and washing to obtain the immobilized microbial inoculum. According to the immobilized microbial inoculum capable of degrading toluene and the preparation method and application thereof, a strain is embedded in CXY-Zn/nLMS gel and gradually released through gel beads, the biological activity of the strain is better maintained, meanwhile, carbon black of a porous structure provides a place for attachment and growth of the strain, the service life of the strain is prolonged, the degradation capacity of microorganisms is improved, and the immobilized microbial inoculum can be used for degrading toluene. The prepared immobilized microbial agent can be used for sewage treatment and soil improvement.",UNIV TIANJIN,JIN CHAO;;DENG YUXUAN;;LU FENGHAO;;NIU XIAOJUN;;LI WANRUI;;GUO JIALIN,,https://lens.org/019-140-278-175-02X,Patent Application,no,6,0,1,019-140-278-175-02X,CN,1,019-140-278-175-02X,CN,0,,C12N1/20;;B09C1/10;;C02F3/34;;C02F101/32;;C12N11/14;;C12R1/11,,1,0,,,"DHANYA VIJAYAN: ""Biodegradation of aromatic hydrocarbons using microbial adsorbed bioreactor"", 3 BIOTECH, 11 May 2020 (2020-05-11), pages 1 - 8",PENDING
767,EP,A1,EP 4337959 A1,103-135-023-473-12X,2024-03-20,2024,EP 22726177 A,2022-05-10,US 202163186872 P;;IB 2022054342 W,2021-05-11,METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY,,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD S;;DE BRAGANCA KEVIN C;;GOLDBERG JENNA;;JACKSON CAROLYN CHANG;;LEE ERIN C;;LENDVAI NIKOLETTA;;MARQUEZ DE MONDELO MARIA;;OLYSLAGER YUNSI;;QIU JUN;;ZUDAIRE UBANI ENRIQUE;;XU JEAN,,https://lens.org/103-135-023-473-12X,Patent Application,yes,0,0,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,13,004-662-449-335-272;;099-636-511-536-41X;;110-164-744-781-479;;112-584-848-017-620;;103-135-023-473-12X;;196-668-635-362-055;;098-809-968-502-38X;;159-393-295-167-461;;169-852-505-734-229;;188-049-220-689-221;;001-876-938-637-620;;182-214-796-170-834;;062-253-462-273-201,AU;;JP;;US;;TW;;CA;;BR;;MX;;KR;;AR;;IL;;EP;;CN;;WO,0,G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;G01N2800/52;;A61K39/0011;;A61K2039/545;;A61K35/17;;G01N33/57426;;A61K31/573;;A61K35/17;;A61K39/0011;;A61K2039/505;;A61K2039/545;;A61K45/06;;G01N33/56972;;G01N33/6863;;G01N33/6866;;G01N2800/52;;A61P35/00;;G01N33/57426;;G01N33/6866;;G01N33/6863;;G01N33/56972;;A61K45/06;;A61P35/00;;G01N2800/52;;A61K40/42;;A61K40/31;;A61K40/11;;A61P35/00;;A61K31/573;;A61K35/17;;A61K45/06;;A61K2039/505;;G01N33/6863;;G01N2800/52;;A61K39/0011,G01N33/569;;A61K39/00;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
768,WO,A1,WO 2024/220613 A1,040-637-016-777-80X,2024-10-24,2024,US 2024/0025116 W,2024-04-18,US 202363497185 P;;US 202363504184 P;;US 2023/0031673 W,2023-04-19,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subj ect.,LEGEND BIOTECH USA INC;;JANSSEN BIOTECH INC,PATEL NITIN;;PACAUD LIDA;;QIU YUHONG;;LENDVAI NIKOLETTA;;DERAEDT WILLIAM;;SCHECTER JORDAN;;DE ASCENSAO SLAUGHTER ANA;;LONARDI CAROLINA,,https://lens.org/040-637-016-777-80X,Patent Application,yes,2,0,16,182-093-526-282-600;;014-584-316-543-563;;166-572-954-876-606;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,16,182-093-526-282-600;;166-572-954-876-606;;014-584-316-543-563;;094-465-657-581-648;;059-449-957-041-476;;019-533-216-095-750;;012-834-079-213-873;;022-372-803-593-395;;040-637-016-777-80X;;036-468-946-847-588;;175-281-899-286-318;;131-064-784-313-331;;125-757-598-969-649;;179-806-961-014-503;;152-849-271-863-276;;019-415-909-270-876,BE;;NL;;AR;;IL;;WO;;US;;IE;;TW;;LT;;FR,23,C07K2319/03;;C07K16/2878;;A61K2039/5156;;A61K2039/804;;A61P35/00;;C07K14/7051;;C07K16/2896;;C12N5/0636;;C07K16/2866;;C07K2317/24;;C07K2317/569;;C07K2317/22;;A61K2039/505;;A61K2039/507;;A61K2039/55;;A61K2239/48;;C07K2319/33;;C07K14/70578;;A61K40/11;;A61K40/31;;A61K40/4215;;A61P35/00;;A61K2239/13;;A61K2239/21;;A61K2239/48;;A61K2239/22;;A61K2239/38;;A61K35/17;;A61K45/06;;C07K16/2878;;A61K40/11;;A61K40/31;;A61K40/4215;;A61K40/4232;;C07K14/7051;;C07K16/2875;;C07K2317/569,C07K16/28;;A61K35/17;;A61K39/00;;C07K14/725,,0,0,,,,PENDING
769,WO,A2,WO 2021/016079 A2,099-323-466-261-121,2021-01-28,2021,US 2020/0042529 W,2020-07-17,US 201962876435 P,2019-07-19,COMPOSITION AND METHODS OF TARGETING THE PRE-B CELL RECEPTOR FOR THE TREATMENT OF LEUKEMIAS AND LYMPHOMAS,"The present invention relates to antibodies that bind the pre-B cell receptor components VpreB and lambda-5, and compositions comprising such antibodies for use in diagnosing and eliminating pre-BCR-expressing leukemia and lymphoma cells.",PASCAL BIOSCIENCES US INC,GRAY PATRICK;;TJOELKER LARRY;;WOOD CHRISTI,,https://lens.org/099-323-466-261-121,Patent Application,yes,0,1,6,014-971-194-249-779;;050-132-162-931-050;;175-698-795-770-133;;150-974-331-340-03X;;099-323-466-261-121;;138-880-545-542-890,AU;;EP;;WO;;US;;CA,6,099-323-466-261-121;;050-132-162-931-050;;175-698-795-770-133;;150-974-331-340-03X;;138-880-545-542-890;;014-971-194-249-779,AU;;EP;;WO;;US;;CA,191,C07K16/2803;;A61P35/02;;C07K2317/30;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K45/06;;A61P35/02;;C07K16/2803;;C07K2317/31;;C07K2317/515;;C07K2317/565,C07K16/30,,0,0,,,,PENDING
770,US,A1,US 2022/0251610 A1,197-783-225-281-842,2022-08-11,2022,US 202217668859 A,2022-02-10,US 202217668859 A;;US 202163147816 P,2021-02-10,Prehydrolysate Fermentability in Biomass Pretreatment,"A method for pretreating lignocellulosic biomass to improve fermentability is disclosed. The method involves reacting lignocellulosic biomass with an acidic mixture while heating at a temperature from about 120° C. to about 200° C. to produce a prehydrolysate mixture. The acidic mixture includes a dilute acid and nucleophilic proteins, hydrolyzed amino acids or combinations thereof.",UNIV CINCINNATI,TU MAOBING;;ZHANG YU;;SHENG YEQUAN,UNIVERSITY OF CINCINNATI (2022-02-21),https://lens.org/197-783-225-281-842,Patent Application,yes,0,0,1,197-783-225-281-842,US,1,197-783-225-281-842,US,0,C12P7/10;;C12P2201/00;;C12P7/10;;C10L1/02;;C10L2200/0469;;C10L2290/26;;C12P2201/00,C12P7/10;;C10L1/02,,2,0,,,"Amit et al. Bioresour. Tech. 2015,pp 1-27.;;LUO et al., BIOTECH BIOFUELS, 2019, pp 12-51.",PENDING
771,WO,A1,WO 2022/117798 A1,135-962-658-947-165,2022-06-09,2022,EP 2021084132 W,2021-12-03,EP 21164128 A;;EP 20211707 A,2020-12-03,IMMUNOGENIC COMPOSITIONS FOR PRODUCING NEUTRALISING ANTIBODIES AGAINST SARS-COV,"The invention relates to an immunogenic composition for use as a medicament to prevent and/or treat a medical condition associated with a SARS-CoV infection, said composition comprising one or more bacteria of the human microbiota and/or immunogenic parts thereof, wherein said composition is capable of inducing acquired immunity to said infection. The invention further relates to isolated bacteria of the human microbiota that bind to a neutralising antibody that recognises the spike protein of SARS-CoV, preferably the spike protein of SARS-CoV2. In another aspect, the invention relates to an in vitro method for the diagnosis, prognosis, risk stratification and/or therapy management of a human subject with an increased risk of an adverse event associated with a medical condition associated with a SARS-CoV infection (preferably with SARS-CoV-2).",DEUTSCHES RHEUMA FORSCHUNGSZENTRUM BERLIN,KRUGLOV ANDREY,,https://lens.org/135-962-658-947-165,Patent Application,yes,4,0,4,177-602-220-068-048;;098-900-490-400-866;;195-139-328-544-158;;135-962-658-947-165,EP;;WO;;US;;CA,5,177-602-220-068-048;;116-222-870-247-489;;098-900-490-400-866;;195-139-328-544-158;;135-962-658-947-165,EP;;WO;;US;;CA,0,A61K39/12;;C12N2770/20011;;A61K39/09;;A61K39/092;;A61K2039/542;;A61K2039/521;;A61K2039/58;;A61P31/14;;Y02A50/30;;C07K16/1003;;A61P31/14;;A61K39/02;;A61K39/092;;A61K39/215;;A61K2039/521;;A61K2039/522;;A61K2039/542;;A61K2039/58;;A61K39/09;;C07K16/1003,A61K39/09;;A61K39/12;;A61K39/39;;A61P31/14;;C07K16/10,,23,10,011-255-032-933-205;;012-842-346-375-894;;027-174-881-360-743;;051-306-236-164-16X;;013-625-581-405-34X;;058-548-515-716-269;;059-613-353-592-383;;113-555-607-912-222;;113-555-607-912-222;;011-255-032-933-205,10.23736/s0026-4806.20.06570-2;;32255312;;pmc7358304;;10.3389/fmed.2020.00389;;32733907;;10.1038/s41538-020-00078-9;;33083549;;pmc7536434;;34608166;;10.1007/s10096-015-2491-x;;26385346;;10.1053/j.gastro.2020.05.048;;32442562;;pmc7237927;;10.3389/fmicb.2020.01840;;pmc7411080;;32849438;;29771684;;10.1172/jci97065;;pmc6063483;;pmc4294419;;25121750;;10.1016/j.chom.2014.07.003;;pmc4294419;;25121750;;10.1016/j.chom.2014.07.003;;10.23736/s0026-4806.20.06570-2;;32255312,"DI PIERRO FRANCESCO: ""A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2"", vol. 111, no. 3, 1 June 2020 (2020-06-01), IT, XP055830162, ISSN: 0026-4806, Retrieved from the Internet <URL:https://www.minervamedica.it/en/getfreepdf/cmR3RW4wQlZ1NU9GWjQzNVY3NzhYVDR5MmdNU2dBRTQrZmlKRDBZenRzWmRUY2lhaG02eG5NVG0wRE01RkF4Uw%3D%3D/R10Y2020N03A0281.pdf> DOI: 10.23736/S0026-4806.20.06570-2;;GABRIELLA D'ETTORRE ET AL: ""Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19"", FRONTIERS IN MEDICINE, vol. 7, 7 July 2020 (2020-07-07), XP055758279, DOI: 10.3389/fmed.2020.00389;;OLAIMAT AMIN N. ET AL: ""The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19"", vol. 4, no. 1, 1 December 2020 (2020-12-01), XP055830179, Retrieved from the Internet <URL:https://www.nature.com/articles/s41538-020-00078-9.pdf> DOI: 10.1038/s41538-020-00078-9;;MARCHISIO P ET AL: ""Streptococcus salivarius24SMB administered by nasal spray for the prevention of acute otitis media in otitis-prone children"", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, SPRINGER, WIESBADEN, DE, vol. 34, no. 12, 18 September 2015 (2015-09-18), pages 2377 - 2383, XP035893036, ISSN: 0934-9723, [retrieved on 20150918], DOI: 10.1007/S10096-015-2491-X;;ZUO TAO ET AL: ""Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization"", GASTROENTEROLOGY, ELSEVIER INC, US, vol. 159, no. 3, 20 May 2020 (2020-05-20), pages 944, XP086259055, ISSN: 0016-5085, [retrieved on 20200520], DOI: 10.1053/J.GASTRO.2020.05.048;;BAO LIRONG ET AL: ""Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection"", FRONTIERS IN MICROBIOLOGY, vol. 11, 31 July 2020 (2020-07-31), XP055830199, DOI: 10.3389/fmicb.2020.01840;;NINNEMANN JUSTUS ET AL: ""Induction of cross-reactive antibody responses against the RBD domain of the spike protein of SARS-CoV-2 by commensal microbiota"", BIORXIV, 8 August 2021 (2021-08-08), pages 1 - 27, XP055832001, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.08.08.455272v1.full.pdf> [retrieved on 20210813], DOI: 10.1101/2021.08.08.455272;;REN ET AL., J IMMUNOL, 2012;;MIAYUCHI ET AL., NATURE, 2020;;ROBAK ET AL., JCI, 2018;;ICHINOHE ET AL., PNAS, 2011;;SCHAUPP ET AL., CELL, 2020;;TRAMA ET AL., CELL HOST AND MICROBE, 2014;;TRAMA ET AL., CELL HOST & MICROBES, 2014;;DI PIERRO F ET AL., MINERVA MEDICA, vol. 111, no. 3, 1 July 2020 (2020-07-01);;D'ETTORRE G ET AL., FRONTIERS IN MEDICINE, vol. 7, 7 July 2020 (2020-07-07);;OLAIMAT AMIN N ET AL., SCIENCE OF FOOD, vol. 4, no. 1, 1 December 2020 (2020-12-01);;ZUO TAO ET AL., GASTROENTEROLOGY, vol. 159, no. 3, 20 May 2020 (2020-05-20);;BAO LIRONG ET AL., FRONTIERS IN MICROBIOLOGY, vol. 11, 31 July 2020 (2020-07-31);;MARCHISIO P ET AL., EUROPEAN J. CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol. 34, no. 12, 18 September 2015 (2015-09-18);;GOMES M ET AL., NAT COMMS, 2021;;GOMES ET AL., NAT COMMS, 2021;;BACHER ET AL., IMMUNITY, 2020",PENDING
772,WO,A1,WO 2025/060527 A1,183-276-481-729-170,2025-03-27,2025,CN 2024099005 W,2024-06-13,CN 202311240995 A,2023-09-22,"3'-SIALYLLACTOSE-PRODUCING ENGINEERED BACTERIUM, AND CONSTRUCTION METHOD AND APPLICATION THEREOF","An engineered bacterium producing 3' -sialyllactose and its construction methods and applications. The engineered bacterium has the ability to produce 3' -sialyllactose, and with exogenous UDP-N-acetylglucosamine 2-epimerase gene (neuC), exogenous sialic acid synthase gene (neuB), exogenous N-acetylneuraminate cytidylyltransferase gene (css) and exogenousα-2, 3-sialyltransferase gene (ST) in its genome or in the recombinant plasmid it carries. This engineered bacterium has a high ability to produce 3' -sialyllactose without need for antibiotics.",SYNAURA BIOTECHNOLOGY SHANGHAI CO LTD,WU YAN;;MA ZHENFENG;;TIAN ZHENHUA;;WANG SHU;;LI MIAO;;YAO FEI;;XU HONG;;LIU YUROU,,https://lens.org/183-276-481-729-170,Patent Application,yes,8,0,2,183-276-481-729-170;;053-974-857-368-380,CN;;WO,2,183-276-481-729-170;;053-974-857-368-380,CN;;WO,102,C12N9/90;;C12N9/1085;;C12N9/1241;;C12N9/1081;;C12N9/1205;;C12N9/1096;;C12N9/80;;C12N9/78;;C12N9/1229;;C12N9/88;;C12N9/2471;;C12N15/70;;C07K14/245;;C12P19/26;;C12Y501/03014;;C12Y205/01056;;C12Y207/07043;;C12Y207/01011;;C12Y206/01016;;C12Y305/01025;;C12Y305/99006;;C12Y207/04025;;C12Y207/0104;;C12Y401/03003;;C12Y207/0106;;C12Y501/03009;;C12Y302/01023;;C12N2800/101;;C12R2001/19;;C12N9/2402;;C12N9/90;;C12N9/1085;;C12N9/1241;;C12N9/1048;;C12N9/1205;;C12N9/1096;;C12N9/80;;C12N9/78;;C12N9/1229;;C12N9/88;;C12N1/20;;C07K14/245;;C12P19/26;;C12R2001/19;;C12Y501/03014;;C12Y205/01056;;C12Y204/00;;C12Y207/07043;;C12Y207/01011;;C12Y206/01016;;C12Y305/01025;;C12Y305/99006;;C12Y207/04025;;C12Y207/0104;;C12Y401/03003;;C12Y207/0106;;C12Y501/03009;;C12Y302/01023,C07K14/245;;C12N1/20;;C12N9/10;;C12N9/12;;C12N9/24;;C12N9/78;;C12N9/80;;C12N9/88;;C12N9/90;;C12N15/52;;C12P19/26,,2,0,,,"""NCBI"", Database accession no. WP 002874240. 1;;""GenBank"", Database accession no. WP 002874241.1",PENDING
773,US,A1,US 2025/0019706 A1,036-282-264-050-541,2025-01-16,2025,US 202418814161 A,2024-08-23,US 202418814161 A;;US 2023/0063245 W;;US 202263313423 P,2022-02-24,Deaminase-Based RNA Sensors,"RNA editing tools for use in systems designed to measure RNA in vivo and manipulate specific cell types are disclosed herein. An RNA sensor system comprising a) a single-stranded RNA (ssRNA) sensor comprising a stop codon and a payload; optionally wherein the ssRNA sensor further comprises a normalizing gene; and b) an adenosine deaminase acting on RNA (ADAR) deaminase; wherein the sensor is capable of binding to a ssRNA target to form a double-stranded RNA (dsRNA) duplex that becomes a substrate for the ADAR deaminase; wherein the substrate comprises a mispairing within the stop codon; and wherein the mispairing is editable by the ADAR deaminase, which editing can effectively remove the stop codon so as to enable translation and expression of the payload. A method of quantifying ribonucleic acid (RNA) levels using the RNA sensor system is also disclosed.",UNIV LELAND STANFORD JUNIOR,GAO XIAOJING;;KASENIIT KRISTJAN EERIK;;KATZ NOA;;KOLBER NATALIE S;;WOLFSBERG ERIC,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2023-02-28),https://lens.org/036-282-264-050-541,Patent Application,yes,2,0,8,166-033-735-076-200;;114-260-310-835-885;;106-878-808-204-698;;071-377-729-264-357;;036-282-264-050-541;;028-675-222-320-758;;139-985-278-983-022;;086-415-215-537-409,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US,8,071-377-729-264-357;;106-878-808-204-698;;114-260-310-835-885;;166-033-735-076-200;;036-282-264-050-541;;028-675-222-320-758;;139-985-278-983-022;;086-415-215-537-409,KR;;JP;;AU;;EP;;CN;;IL;;WO;;US,0,C12N15/1086;;C12N15/90;;C12N2800/90;;C12N15/85;;C12N15/82;;C12Q1/6813;;C12N15/1086;;C12N2800/90;;C12Q2521/301;;C12Q1/6813;;C12Q2521/539;;C12N15/82;;C12Q2563/107;;C12N15/85;;C12Q2525/301;;C12N15/90;;C12N15/90;;C12N9/78;;C12N15/1086;;C12N15/86;;C12Q1/6813;;C12N2310/531;;C12N2750/14143;;C12N2800/90;;C12Q2563/107;;C12Q2525/301;;C12Y305/04004;;C12N9/78;;C12N15/113;;C12N2310/531,C12N15/113;;C12N9/78,,4,4,128-656-551-694-461;;032-307-042-738-589;;056-257-755-400-64X;;024-228-413-515-611,10.1038/s41587-022-01493-x;;36198772;;10.1038/s41587-021-01068-2;;34711989;;26051678;;10.1016/j.biochi.2015.05.020;;10.1093/nar/gkx1114;;pmc5778536;;29228265,"Kaseniit et al. “Modular and programmable RNA sensing using ADAR editing in living cells” Nat. Biotech. (2022) 41: 482-487 . (bioRxiv preprint doi: https://doi.org/10.1101/2022.01.28.478207; this version posted January 29, 2022 (Year: 2022);;Zhao et al. “RNA-responsive elements for eukaryotic translational control” Nat. Biotech. (2022) 40: 539-545 (Year: 2022);;Daniel at al. “RNA editing of non-coding RNA and its role in gene regulation” Biochimie (2015) 117 :22-27. (Year: 2015);;Diaz de Arce et al. “Complete motif analysis of sequence requirements for translation initiation at non-AUG start codons” Nucleic Acids Research (2018) Vol. 46, No. 2: 985–994. (Year: 2018)",PENDING
774,US,A1,US 2020/0325535 A1,021-338-777-153-912,2020-10-15,2020,US 202016897052 A,2020-06-09,US 202016897052 A;;US 201414300453 A;;US 201314056636 A;;US 201213615183 A;;US 8068408 A;;US 6239108 P;;US 96753907 P;;US 96253007 P;;US 93111507 P;;US 92178707 P,2007-04-04,"Compositions, Devices, Systems, and Methods for Using a Nanopore","Devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore are provided. The devices and methods also determine (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.",UNIV CALIFORNIA,AKESON MARK A;;DEAMER DAVID W;;DUNBAR WILLIAM B;;LIEBERMAN KATE;;WILSON NOAH A,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-11-29),https://lens.org/021-338-777-153-912,Patent Application,yes,1,0,49,050-750-190-792-148;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;085-188-996-524-024;;172-840-139-122-539;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;110-967-876-084-674;;007-641-951-572-149;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;044-951-647-888-187;;192-696-239-263-373;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;082-548-722-396-405;;123-067-273-122-369;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;176-430-871-659-277,KR;;JP;;AU;;CN;;EP;;IL;;WO;;US;;CA,49,176-430-871-659-277;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;172-840-139-122-539;;085-188-996-524-024;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;007-641-951-572-149;;110-967-876-084-674;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;192-696-239-263-373;;044-951-647-888-187;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;123-067-273-122-369;;082-548-722-396-405;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;050-750-190-792-148,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA,0,C12Q1/6869;;G01N33/48721;;C25B3/29;;C12Q1/25;;G01N33/48721;;G01N33/573;;C25B3/29;;C12Q1/54;;C12Q1/6874;;G01N27/3278;;G01N27/4166;;C25B3/29;;C12Q1/6869;;G01N33/48721;;C12Q1/6874;;C12Q1/54;;G01N27/3278;;G01N27/4166,C12Q1/6874;;C25B3/29;;C12Q1/54;;C12Q1/6869;;G01N27/327;;G01N27/416;;G01N33/487,,0,0,,,,ACTIVE
775,US,A1,US 2022/0273809 A1,191-829-414-625-491,2022-09-01,2022,US 202017628382 A,2020-07-17,US 202017628382 A;;US 202062962632 P;;US 201962931578 P;;US 201962876261 P;;EP 2020070348 W,2019-07-19,AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER,The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.,GENMAB AS,JANMAAT MAARTEN;;PENCHEVA NORA;;BREIJ ESTHER CORNELIA WILHELMINA;;BOSHUIZEN JULIA;;PEEPER DANIEL SIMON;;FORSSMANN ULF;;AHMADI TAHAMTAN;;CASTRO PATRICIA GARRIDO,,https://lens.org/191-829-414-625-491,Patent Application,yes,1,0,3,191-829-414-625-491;;081-628-868-663-418;;134-584-043-502-766,EP;;WO;;US,274,005-944-002-831-650;;088-825-071-177-292;;191-829-414-625-491;;077-641-345-365-448;;055-693-640-711-792;;118-964-440-011-180;;113-907-992-013-106;;031-630-939-437-266;;176-524-535-590-247;;011-017-873-286-037;;108-708-181-749-248;;074-958-452-762-349;;049-134-930-455-506;;031-645-007-908-584;;183-122-337-393-914;;078-765-562-036-369;;054-762-117-103-047;;069-517-806-608-628;;049-190-114-691-179;;134-955-364-678-295;;092-839-742-428-85X;;143-461-547-532-594;;137-439-712-749-837;;122-644-288-456-59X;;020-633-922-837-794;;016-023-766-978-081;;015-802-990-532-179;;057-221-171-857-082;;026-744-838-469-175;;185-603-013-858-72X;;077-396-771-330-604;;174-631-020-211-157;;031-243-329-021-124;;116-189-271-417-448;;029-652-108-080-345;;024-352-610-560-217;;131-160-739-188-981;;114-171-545-309-260;;071-089-623-482-798;;119-736-198-079-33X;;091-729-346-635-79X;;174-253-976-461-972;;082-214-328-550-670;;171-940-164-109-389;;018-444-513-356-848;;069-041-348-565-905;;079-205-410-881-185;;145-057-489-903-948;;135-553-886-184-094;;145-492-380-916-426;;002-265-061-280-074;;016-069-129-450-691;;002-058-354-655-878;;162-223-027-902-809;;057-623-371-766-320;;161-405-306-346-201;;116-181-093-775-552;;085-357-718-490-13X;;050-632-540-760-780;;129-128-140-615-375;;154-327-037-132-47X;;034-014-081-502-935;;141-281-694-692-191;;128-575-396-857-392;;139-390-336-323-004;;037-232-668-630-412;;066-821-397-577-839;;089-194-259-206-022;;139-015-774-484-858;;081-628-868-663-418;;046-308-333-606-749;;117-663-566-551-013;;162-068-009-354-944;;166-881-777-377-994;;099-738-596-266-718;;085-455-540-050-450;;119-649-093-615-428;;117-751-314-954-65X;;196-237-606-393-325;;043-495-995-004-162;;121-531-669-007-571;;191-321-626-059-658;;091-378-463-072-752;;045-424-142-858-013;;178-156-883-737-336;;088-477-946-790-404;;041-751-601-684-095;;147-543-501-742-929;;123-072-555-896-174;;104-692-430-778-666;;158-932-708-577-324;;105-625-071-146-806;;042-800-380-924-597;;102-215-024-577-426;;039-986-776-041-109;;106-439-669-091-368;;022-598-559-472-55X;;186-132-977-744-266;;061-459-927-012-86X;;010-765-563-915-472;;014-267-676-037-307;;113-456-637-918-955;;101-436-445-895-994;;035-368-920-976-264;;031-031-013-921-586;;047-872-394-934-686;;010-531-190-973-247;;007-229-018-985-881;;016-773-784-325-976;;138-128-228-536-555;;127-075-162-855-952;;084-253-794-976-649;;134-825-111-554-504;;123-802-385-903-002;;184-360-550-410-234;;042-109-070-702-159;;100-393-590-498-473;;160-491-192-701-937;;107-305-688-804-733;;187-409-115-433-822;;074-190-176-455-354;;058-978-782-568-440;;148-512-109-743-403;;123-586-863-440-142;;102-244-717-491-505;;060-497-322-558-182;;001-317-549-363-901;;009-994-693-216-34X;;122-245-547-758-077;;051-147-426-323-162;;009-662-633-431-450;;179-443-711-437-255;;156-974-242-520-408;;031-852-865-053-561;;026-957-605-422-789;;147-077-304-300-069;;079-640-262-995-792;;155-237-583-986-162;;189-368-091-285-304;;040-120-116-419-717;;147-357-989-151-698;;001-941-945-141-752;;059-066-933-144-165;;083-010-674-546-019;;178-982-083-592-647;;050-250-573-229-044;;172-525-100-113-520;;170-242-677-437-332;;176-025-626-476-62X;;148-433-807-889-252;;079-746-536-347-30X;;032-517-419-154-678;;055-174-789-658-403;;026-247-665-776-013;;134-584-043-502-766;;122-216-965-584-257;;136-008-862-167-022;;033-009-784-613-321;;100-977-155-934-663;;034-377-288-985-578;;085-975-435-799-91X;;184-794-912-139-620;;024-714-933-679-971;;081-275-929-853-039;;121-277-968-926-091;;102-431-285-090-233;;036-304-159-516-703;;160-491-449-116-347;;068-692-267-436-311;;104-506-697-137-479;;165-040-602-436-320;;126-692-075-442-778;;113-204-360-280-846;;036-542-304-400-744;;052-233-672-909-262;;102-530-319-807-591;;073-844-022-478-645;;005-156-128-794-771;;113-344-559-275-352;;191-061-909-778-152;;136-542-853-306-887;;124-927-687-110-804;;149-651-655-872-815;;070-446-095-718-352;;078-736-130-215-504;;014-691-769-582-112;;114-701-496-932-624;;048-162-614-026-525;;117-775-369-020-324;;196-374-405-092-279;;044-029-844-512-352;;067-297-780-471-162;;198-250-903-991-662;;044-725-402-975-164;;053-686-630-909-879;;086-765-321-901-497;;121-289-321-445-615;;123-315-348-069-153;;023-550-333-423-185;;008-266-865-574-775;;120-005-985-431-028;;015-346-926-279-248;;036-098-086-472-521;;177-369-752-468-28X;;134-184-500-217-176;;190-243-574-790-723;;055-525-627-890-199;;124-677-258-837-571;;040-721-379-430-268;;170-973-628-819-675;;136-239-846-672-625;;099-204-602-438-699;;041-386-378-927-070;;010-900-365-092-419;;147-001-020-402-492;;199-088-309-459-060;;046-339-240-609-723;;032-407-504-213-815;;082-497-921-989-791;;088-761-878-168-856;;077-885-269-634-36X;;178-654-659-490-457;;049-808-112-957-609;;053-021-763-251-517;;004-587-467-387-984;;020-510-556-952-88X;;048-737-889-792-16X;;084-209-283-150-61X;;053-855-000-169-858;;100-765-752-018-298;;183-920-423-689-582;;133-305-531-135-60X;;067-619-212-346-143;;107-632-450-472-423;;177-701-931-877-494;;159-409-113-268-207;;066-197-585-717-02X;;084-634-178-581-167;;034-875-214-961-516;;083-916-165-384-630;;161-683-324-095-362;;162-954-352-948-471;;100-050-327-044-031;;131-822-751-248-57X;;147-111-148-769-725;;079-052-131-798-51X;;061-170-197-439-708;;048-454-338-919-937;;107-754-502-900-967;;147-748-498-993-725;;117-292-945-365-050;;097-559-801-410-330;;026-878-156-913-324;;040-682-114-559-147;;143-695-741-475-898;;064-258-255-046-917;;154-400-287-437-311;;132-888-127-266-238;;086-381-869-843-015;;054-476-496-648-196;;156-277-805-513-903;;152-118-716-008-469;;125-641-993-106-347;;065-881-828-873-84X;;125-345-272-919-800;;057-557-583-020-309;;131-244-138-012-137;;108-743-400-396-977;;112-137-505-113-501;;177-973-051-288-375;;004-233-995-505-325;;018-742-104-741-740;;108-311-297-755-548;;154-812-687-011-361,DE;;JP;;KR;;CN;;EP;;ES;;WO;;FI;;US;;SG;;TW;;DK,154,C07K16/2863;;C07K2317/76;;A61K2039/505;;C07K16/2818;;C07K16/2827;;C07K2317/565;;A61K47/68031;;A61K47/6843;;A61P35/00;;A61K47/02;;A61K2121/00;;A61K47/68031;;C07K16/2863,A61K47/68;;A61K47/02;;A61P35/00,,0,0,,,,PENDING
776,EP,A1,EP 3910062 A1,135-789-659-937-544,2021-11-17,2021,EP 19903304 A,2019-12-27,CN 201811619556 A;;CN 2019129359 W,2018-12-28,PICHIA PASTORIS MUTANT STRAIN FOR EXPRESSING EXOGENOUS GENE,"Provided is a Pichia pastoris mutant strain for expressing an exogenous gene. Specifically, provided is a Pichia pastoris mutant strain comprising, with respect to Pichia pastoris mutant strain GS115 or CICC32806, one or more of the following six mutations: BQ9382_C1-2260, EKK deletions at positions 308-310, a hypothetical protein; BQ9382_C1-3800, E129K, 60S ribosomal subunit assembly/exported protein LOCI; BQ9382 C1-5700, I312M, mitochondrial external NADH dehydrogenase, type II NAD(P)H:quinone oxidoreductase; BQ9382_C2-3950, Q145X, an essential protein having a binding partner Psrlp and used for completely activating a general stress response; BQ9382_C3-2220, E188K, a hypothetical protein; and BQ9382_C3-4370, W196X, orotidine 5\'-phosphate decarboxylase. The provided Pichia pastoris mutant strain is an effective commonly employed host for exogenous expression, and can efficiently express different proteins, especially phospholipase and lipase.",WILMAR SHANGHAI BIOTECHNOLOGY RES & DEV CT CO LTD,WU WEI;;DAI XIAOJUN;;CAO HAISHENG;;ZHOU MEIFENG;;NIU QIWEN,,https://lens.org/135-789-659-937-544,Patent Application,yes,0,0,10,174-317-804-960-572;;182-024-886-560-783;;145-970-296-750-084;;057-222-872-031-544;;018-618-229-657-499;;135-789-659-937-544;;147-273-776-370-282;;094-534-430-362-076;;033-671-302-470-185;;000-701-218-554-252,JP;;CN;;EP;;WO;;US,10,174-317-804-960-572;;182-024-886-560-783;;145-970-296-750-084;;057-222-872-031-544;;018-618-229-657-499;;135-789-659-937-544;;147-273-776-370-282;;094-534-430-362-076;;033-671-302-470-185;;000-701-218-554-252,JP;;CN;;EP;;WO;;US,17,C12N9/20;;C12Y301/01003;;C12N9/50;;C12N9/2437;;C12Y302/01004;;C12N9/2411;;C12N9/2465;;C12N9/18;;C12N1/16;;C12N15/815;;C11B3/003;;C11C3/10;;C11C3/10;;C12N9/20;;C12R2001/84;;C11B3/003;;A23K20/147;;A23K20/189;;A23L29/06;;A23L33/14;;A23L33/195;;C12Y106/0501;;C12Y401/01023;;C12N9/88;;C12N9/0036;;C12Y106/05;;C12N9/52;;C07K14/39;;C12N1/165;;C12N15/815;;C12N1/165;;C12R2001/84;;C12N9/16;;C12N15/815;;C12P7/649,C12N15/81;;C11B3/00;;C12N1/19,,0,0,,,,PENDING
777,US,A1,US 2021/0147803 A1,162-123-564-081-040,2021-05-20,2021,US 201917040661 A,2019-03-22,KR 20180033828 A;;KR 20190031875 A;;KR 2019003341 W,2018-03-23,METHOD FOR PRODUCING NATURAL KILLER CELLS,"The present disclosure relates to a method for producing natural killer (NK) cells. More specifically, the present disclosure relates to a method for producing NK cells, characterized in that peripheral blood mononuclear cells from which CD3-positive cells are removed are proliferated together with feeder cells, and the peripheral blood mononuclear cells are re-stimulated with feeder cells at the time of reaching a specific accumulated population doubling level. The present disclosure also relates to a method for producing NK cells, characterized in that NK cells are cultured under appropriate culture conditions by using a bioreactor. The production method according to the present disclosure has an advantage that NK cells having a high cell-killing ability and cell survival rate can be produced with high purity and at high efficiency in a short period of time by a clinically friendly method as compared with existing methods, thereby increasing the productivity of an NK cell therapy agent.",GREEN CROSS LAB CELL CORP,HWANG YU-KYEONG;;PAIK SANG;;HAN SEUNGRYEL;;LEE SANGHYUN;;LAM HYEONGJIN;;KIM JUYOUNG;;HAN MU RI;;NOH DONG IL,GREEN CROSS LAB CELL CORPORATION (2021-02-23);;GC CELL CORPORATION (2021-11-01),https://lens.org/162-123-564-081-040,Patent Application,yes,1,7,13,162-123-564-081-040;;000-901-632-420-280;;014-851-523-188-537;;086-818-452-318-919;;110-232-918-022-811;;086-333-195-199-406;;161-538-293-406-939;;097-334-172-716-734;;162-626-308-070-507;;155-397-611-333-736;;048-869-078-697-93X;;046-822-475-290-235;;168-397-706-352-085,KR;;JP;;AU;;IL;;EP;;CN;;US;;CA,14,162-123-564-081-040;;000-901-632-420-280;;014-851-523-188-537;;086-818-452-318-919;;110-232-918-022-811;;086-333-195-199-406;;085-250-219-827-05X;;161-538-293-406-939;;097-334-172-716-734;;162-626-308-070-507;;155-397-611-333-736;;048-869-078-697-93X;;046-822-475-290-235;;168-397-706-352-085,KR;;JP;;AU;;IL;;EP;;CN;;WO;;US;;CA,0,C12N5/0087;;C12N5/0646;;C12N2501/515;;C12N2501/2302;;C12N2501/2312;;C12N2501/2315;;C12N2501/2318;;C12N2501/2321;;C12N5/0087;;C12N5/0646;;C12N5/0646;;C12N2500/60;;C12N2501/2302;;C12N2501/2312;;C12N2501/2315;;C12N2501/2318;;C12N2501/2321;;C12N2501/515;;C12N2523/00;;C12N2527/00;;C12N5/0087;;A61K40/15;;C12N2506/115;;C12N5/0646;;C12N2500/02;;C12N2500/60;;C12N2501/2302;;C12N2501/2312;;C12N2501/2315;;C12N2501/2318;;C12N2501/2321;;C12N2501/998;;C12N2506/11;;C12N2527/00,C12N5/0783,,3,3,044-422-820-024-398;;003-874-715-292-454;;064-411-404-798-02X,10.1016/j.jcyt.2016.05.009;;27378344;;10.1007/10_2008_15;;19373453;;22475724;;10.1186/1479-5876-10-69;;pmc3402993,"Mock et al., Automated manufacturing of chimeric antigen receptor T cells for adoptive immunology using CliniMACs Prodigy, Cytotherapy, 18: 1002-1011. (Year: 2016);;Eibl, Regine, Sören Werner, and Dieter Eibl. ""Bag bioreactor based on wave-induced motion: characteristics and applications."" Disposable bioreactors: 55-87. (Year: 2009);;Somerville, Robert PT, et al. ""Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor."" Journal of translational medicine 10: 1-11. (Year: 2012)",PENDING
778,EP,A1,EP 4458861 A1,104-752-729-119-640,2024-11-06,2024,EP 22914863 A,2022-12-28,CN 202111639610 A;;CN 2022142626 W,2021-12-29,"ANTIBODY TARGETING CD3, MULTISPECIFIC ANTIBODY, AND USES THEREOF","An antibody targeting CD3 or an antigen-binding fragment thereof, which has a moderate ability to activate T cells and can effectively reduce cell factor release. A multispecific antibody targeting CD3 and other antigens, such as tumor-associated antigens and/or immune checkpoint molecules, which can significantly reduce cytokine release while ensuring efficient and specific killing of target cells, and has a significantly improved safety. The present invention also relates to uses of the antibody targeting CD3 or the antigen-binding fragment thereof, and the multispecific antibody or a composition comprising same in disease treatment.",SICHUAN HUIYU PHARMACEUTICAL CO LTD;;SICHUAN HUIYU SEACROSS PHARMACEUTICAL TECH CO LTD,HU YAN;;GUO SANYOU;;TENG YUMIN;;WEI TAO;;DING ZHAO,,https://lens.org/104-752-729-119-640,Patent Application,yes,0,0,5,104-752-729-119-640;;075-116-326-515-799;;155-578-974-619-226;;199-929-648-535-447;;173-295-306-216-707,JP;;EP;;CN;;WO;;US,5,104-752-729-119-640;;173-295-306-216-707;;155-578-974-619-226;;199-929-648-535-447;;075-116-326-515-799,JP;;EP;;CN;;WO;;US,176,A61P35/00;;C07K16/2809;;C07K2317/622;;C07K16/005;;C07K2317/56;;C07K2317/567;;C07K2317/33;;C07K2317/92;;C07K2317/52;;C07K16/18;;C07K2317/569;;C07K2317/22;;C07K2317/31;;C07K2317/24;;C07K16/2803;;C07K16/2887;;C07K16/30;;C07K16/32;;C07K16/28;;C07K2317/76;;C07K16/28;;C07K16/2803;;C07K16/2809;;C07K16/2887;;C07K16/30;;C07K16/32;;C07K2317/22;;C07K2317/24;;C07K2317/31;;C07K2317/569;;C07K2317/73;;C07K2317/92,C07K16/46;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
779,US,A1,US 2024/0352517 A1,065-346-627-779-414,2024-10-24,2024,US 202418637154 A,2024-04-16,US 202418637154 A;;US 202017098101 A;;US 202016897052 A;;US 201414300453 A;;US 201314056636 A;;US 201213615183 A;;US 8068408 A;;US 6239108 P;;US 96753907 P;;US 96253007 P;;US 93111507 P;;US 92178707 P,2007-04-04,"Compositions, Devices, Systems, and Methods for Using a Nanopore","Devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore are provided. The devices and methods also determine (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.",UNIV CALIFORNIA,AKESON MARK A;;CHEN ROGER JINTEH ARRIGO,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-12-11),https://lens.org/065-346-627-779-414,Patent Application,yes,1,0,49,050-750-190-792-148;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;085-188-996-524-024;;172-840-139-122-539;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;110-967-876-084-674;;007-641-951-572-149;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;044-951-647-888-187;;192-696-239-263-373;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;082-548-722-396-405;;123-067-273-122-369;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;176-430-871-659-277,KR;;JP;;AU;;CN;;EP;;IL;;WO;;US;;CA,49,176-430-871-659-277;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;172-840-139-122-539;;085-188-996-524-024;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;007-641-951-572-149;;110-967-876-084-674;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;192-696-239-263-373;;044-951-647-888-187;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;123-067-273-122-369;;082-548-722-396-405;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;050-750-190-792-148,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA,0,C12Q1/6869;;G01N33/48721;;C25B3/29;;C12Q1/25;;G01N33/48721;;G01N33/573;;C25B3/29;;C12Q1/54;;C12Q1/6874;;G01N27/3278;;G01N27/4166;;C25B3/29;;C12Q1/6869;;G01N33/48721;;C12Q1/6874;;C12Q1/54;;G01N27/3278;;G01N27/4166,C12Q1/6874;;C12Q1/54;;C12Q1/6869;;C25B3/29;;G01N27/327;;G01N27/416;;G01N33/487,,1,1,073-477-535-611-745,10.1073/pnas.93.24.13770;;8943010;;pmc19421,"Kasianowicz, J. J., et al. (1996). ""Characterization of individual polynucleotide molecules using a membrane channel."" 93: 13770-13773. (Year: 1996)",PENDING
780,US,A1,US 2022/0265708 A1,006-032-807-474-43X,2022-08-25,2022,US 201916961418 A,2019-01-10,US 201916961418 A;;US 201862721791 P;;US 201862690892 P;;US 201862687059 P;;US 201862678836 P;;US 201862659233 P;;US 201862659114 P;;US 201862626781 P;;US 201862622601 P;;US 201862616609 P;;US 201862616079 P;;US 2019/0013068 W,2018-01-11,Modified Cell Expansion and Uses Thereof,"The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.",INNOVATIVE CELLULAR THERAPEUTICS INC;;INNOVATIVE CELLULAR THERAPEUTICS CO LTD,XIAO LEI;;PU CHENGFEI;;CAO ZHIYUAN;;WU ZHAO;;MAO LI;;BI MAO,INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTD (2021-01-18);;INNOVATIVE CELLULAR THERAPEUTICS INC (2020-07-07);;INNOVATIVE CELLULAR THERAPEUTICS CO. LTD (2020-07-08),https://lens.org/006-032-807-474-43X,Patent Application,yes,1,1,11,125-810-468-287-586;;005-036-057-997-136;;079-201-824-272-218;;159-905-317-668-387;;006-032-807-474-43X;;104-312-497-094-333;;026-305-114-597-249;;021-836-660-601-330;;077-881-025-205-130;;026-532-938-710-427;;051-578-325-532-816,JP;;EP;;CN;;WO;;US;;CA,61,171-356-069-386-633;;164-009-299-682-067;;071-107-605-182-739;;159-905-317-668-387;;006-032-807-474-43X;;026-444-632-261-606;;021-836-660-601-330;;134-934-235-456-44X;;033-650-688-554-417;;026-532-938-710-427;;056-150-571-228-881;;088-406-296-247-806;;190-411-678-570-08X;;009-749-619-579-872;;002-659-153-862-233;;198-372-288-662-781;;189-135-018-324-760;;136-992-994-759-597;;026-305-114-597-249;;136-988-063-529-310;;128-770-369-551-068;;051-578-325-532-816;;098-277-382-565-581;;113-109-872-602-954;;006-410-039-368-882;;138-707-318-762-341;;023-486-460-209-479;;050-100-570-682-974;;103-943-305-099-805;;158-506-486-044-781;;021-942-395-136-421;;117-849-584-960-692;;189-806-006-721-835;;041-043-655-520-865;;125-810-468-287-586;;022-018-317-160-277;;014-154-271-138-766;;192-935-014-361-605;;037-974-001-419-566;;044-270-338-064-017;;165-634-834-795-662;;140-557-069-668-16X;;155-512-652-867-559;;090-223-763-358-020;;092-599-293-050-424;;139-467-891-485-152;;152-428-224-633-931;;076-707-203-630-43X;;077-881-025-205-130;;127-764-582-951-485;;011-525-121-427-678;;174-117-349-320-98X;;003-166-983-492-586;;106-397-250-187-632;;104-312-497-094-333;;039-870-960-272-324;;017-308-508-564-973;;184-978-330-903-832;;005-036-057-997-136;;040-667-879-569-659;;079-201-824-272-218,AU;;JP;;KR;;EP;;CN;;WO;;US;;SG;;CA,427,C12N2740/16043;;C12N5/0636;;C12N2510/00;;C07K14/7051;;C07K16/2803;;C07K16/3092;;A61K2039/507;;C07K2319/03;;C07K2319/33;;C07K2317/622;;C07K2317/70;;A61P35/00;;C07K16/28;;C07K16/2896;;C07K16/2878;;A61K2039/572;;A61K40/31;;A61K40/4202;;A61K40/4257;;A61K40/4211;;A61K40/11;;C12N5/0636;;C12N15/625;;C12N15/86;;C12N2740/15043;;A61K40/11;;A61K40/31;;A61K40/4202;;A61K40/4211;;A61K40/4257,A61K35/17;;C12N5/0783;;C12N15/62;;C12N15/86,,2,1,029-139-790-454-217,10.1038/nbt.2471;;23302931;;pmc6352981,"Hanada et al., 2013, Nat. Biotech. Vol. 31: 33-34;;Lindner et al., 2020, Sci. Adv. Vol. 6: 1-8",DISCONTINUED
781,US,A1,US 2024/0200130 A1,034-490-975-992-985,2024-06-20,2024,US 202418402501 A,2024-01-02,US 202418402501 A;;US 201916386472 A;;US 201862767633 P;;US 201862659073 P,2018-04-17,"HIGHLY SENSITIVE IN VITRO ASSAYS TO DEFINE SUBSTRATE PREFERENCES AND SITES OF NUCLEIC-ACID BINDING, MODIFYING, AND CLEAVING AGENTS","Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.",MASSACHUSETTS GEN HOSPITAL,JOUNG J KEITH;;PATTANAYAK VIKRAM;;PETRI KARL,THE GENERAL HOSPITAL CORPORATION (2019-10-08),https://lens.org/034-490-975-992-985,Patent Application,yes,1,0,17,106-505-241-885-303;;038-948-598-556-711;;034-490-975-992-985;;009-334-097-005-622;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;138-305-460-735-625;;165-552-951-053-124;;088-269-227-016-272;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,17,106-505-241-885-303;;038-948-598-556-711;;009-334-097-005-622;;034-490-975-992-985;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;088-269-227-016-272;;165-552-951-053-124;;138-305-460-735-625;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,0,C12N9/22;;C12Q1/6853;;C12Q1/6827;;C12Q1/6806;;C12N15/1058;;C12Q1/6874;;C12Y305/04005,C12Q1/6874;;C12N15/10,,0,0,,,,PENDING
782,US,A1,US 2021/0071248 A1,138-305-460-735-625,2021-03-11,2021,US 202016852257 A,2020-04-17,US 202016852257 A;;US 201916386472 A;;US 201862767633 P;;US 201862659073 P,2018-04-17,"HIGHLY SENSITIVE IN VITRO ASSAYS TO DEFINE SUBSTRATE PREFERENCES AND SITES OF NUCLEIC-ACID BINDING, MODIFYING, AND CLEAVING AGENTS","Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.",MASSACHUSETTS GEN HOSPITAL,JOUNG J KEITH;;PATTANAYAK VIKRAM;;PETRI KARL,THE GENERAL HOSPITAL CORPORATION (2019-10-08),https://lens.org/138-305-460-735-625,Patent Application,yes,0,6,17,106-505-241-885-303;;038-948-598-556-711;;034-490-975-992-985;;009-334-097-005-622;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;138-305-460-735-625;;165-552-951-053-124;;088-269-227-016-272;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,17,106-505-241-885-303;;038-948-598-556-711;;009-334-097-005-622;;034-490-975-992-985;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;088-269-227-016-272;;165-552-951-053-124;;138-305-460-735-625;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,131,C12N9/22;;C12Q1/6853;;C12Q1/6827;;C12Q1/6806;;C12N15/1058;;C12Q1/6874;;C12Y305/04005,C12Q1/6874;;C12N15/10,,1,0,,,"HighQu. (2016, July 26). Blunting and phosphorylation of DNA prior to Blunt-end ligation. https://www.lifescience.net/protocols/935/blunting-and-phosphorylation-of-dna-prior-to-blunt/ (Year: 2016)",ACTIVE
783,EP,A1,EP 4276171 A1,151-701-432-156-357,2023-11-15,2023,EP 21917051 A,2021-07-28,CN 202110006046 A;;CN 2021108983 W,2021-01-05,BACILLUS SUBTILIS GENETICALLY ENGINEERED BACTERIUM FOR PRODUCING TAGATOSE AND METHOD FOR PREPARING TAGATOSE,"Provided are a bacillus subtilis genetically engineered bacterium for producing tagatose and a method for preparing tagatose. The genetically engineered bacterium comprises constructing thermostable α-glucan phosphorylases, thermostable glucose phosphomutases, thermostable glucose phosphate isomerases, thermostable 6-tagatose phosphate epimerases, and thermostable 6-tagatose phosphate phosphatases which are independently expressed or coexpressed. The usage of the genetically engineered bacterium can effectively convert starch into tagatose. Compared with existing methods for producing tagatose, the method has advantages such as suitability for whole-cell recycling, high safety, high yield, simple production process, low cost, and easiness in large-scale preparation.",TIANGONG BIOTECHNOLOGY TIANJIN CO LTD,MA YANHE;;SHI TING;;LI YUNJIE;;HAN PINGPING;;LI YUAN,"TIANJIN YEAHE BIOTECHNOLOGY CO., LTD (2023-12-20)",https://lens.org/151-701-432-156-357,Patent Application,yes,0,0,8,157-536-505-221-968;;028-586-393-529-172;;168-236-901-338-249;;144-794-147-800-037;;151-701-432-156-357;;032-094-003-151-99X;;122-673-450-296-487;;022-327-661-025-698,JP;;KR;;CN;;EP;;WO;;US,8,157-536-505-221-968;;028-586-393-529-172;;168-236-901-338-249;;144-794-147-800-037;;151-701-432-156-357;;032-094-003-151-99X;;122-673-450-296-487;;022-327-661-025-698,JP;;KR;;CN;;EP;;WO;;US,32,C12N9/1051;;C12N9/90;;C12N9/92;;C12N9/16;;C12N15/75;;C12P19/02;;C12Y504/02002;;C12Y503/01009;;C12Y501/03;;C12N15/75;;C12P19/02;;C12P19/24;;C12Y204/01001;;C12Y501/03;;C12Y504/02002;;C12Y503/01009;;C12N9/1051;;C12N9/90;;C12N9/1205;;C12Y207/01101;;C12N15/52;;C12R2001/125;;C12N15/75;;C12P19/02;;C12P19/24;;C12N15/52;;C12N9/1051;;C12N9/92;;C12N9/90;;C12N9/16;;C12Y504/02002;;C12Y503/01009;;C12Y501/03;;C12Y204/01001;;C12N9/1051;;C12N9/16;;C12N9/90;;C12N11/00;;C12N15/75;;C12P19/02;;C12Y204/01001;;C12Y301/03;;C12Y501/03;;C12Y503/01009;;C12Y504/02002,C12N1/21;;C12N11/14;;C12N15/75;;C12P19/02;;C12R1/125,,0,0,,,,PENDING
784,US,A1,US 2024/0309392 A1,168-972-277-225-835,2024-09-19,2024,US 202418678690 A,2024-05-30,US 202418678690 A;;US 202117538322 A;;US 202016758649 A;;US 2018/0057904 W;;US 201862727000 P;;US 201762578658 P,2017-10-30,Plant promoter for transgene expression,"This disclosure concerns compositions and methods for promoting transcription of a nucleotide sequence in a plant or plant cell, employing a promoter from a GmCAB2 gene. Some embodiments relate to a promoter or a 5′ UTR from a GmCAB2 gene that functions in plants to promote transcription of operably linked nucleotide sequences. Other embodiments relate to a 3′ UTR or a terminator from a GmCAB2 gene that functions in plants to promote transcription of operably linked nucleotide sequences.",CORTEVA AGRISCIENCE LLC;;PIONEER HI BRED INT,SIDORENKO LYUDMILA;;LARSEN CORY M;;ANTHONY GENY;;SRIRAM SHREEDHARAN;;BUTLER HOLLY JEAN;;SIMS LYNNE E;;DIEHN SCOTT H;;RAUSCHER GILDA M;;RIPP KEVIN G;;MEYER KNUT,CORTEVA AGRISCIENCE LLC (2018-03-28);;PIONEER HI-BRED INTERNATIONAL INC (2018-09-20),https://lens.org/168-972-277-225-835,Patent Application,yes,1,0,2,009-315-856-765-822;;168-972-277-225-835,US,19,102-262-237-600-652;;168-972-277-225-835;;187-453-352-974-049;;056-310-915-256-14X;;182-272-543-495-951;;172-751-465-194-840;;081-062-855-466-095;;178-380-356-928-778;;096-073-140-925-057;;009-315-856-765-822;;123-580-309-263-954;;123-500-365-053-190;;142-250-239-054-790;;072-972-740-309-635;;177-770-521-090-671;;020-584-089-906-068;;117-814-366-176-47X;;113-739-956-331-625;;068-007-624-994-621,AR;;EP;;CN;;WO;;US;;TW;;CA;;BR,0,Y02A40/146;;C12N15/8223;;C12N15/8216;;C12N15/8223;;Y02A40/146;;C12N15/8216,C12N15/82,,2,1,014-504-988-317-216,10.1079/ivp2003477,Stahl et al. (2004) BMC Biotech 4:31;;Potenza et al. (2004) In Vitro Cell Dev Biol Plant 40:1-22,ACTIVE
785,US,A1,US 2022/0396642 A1,082-480-362-712-225,2022-12-15,2022,US 202017774786 A,2020-11-05,JP 2019203572 A;;JP 2019211881 A;;JP 2020041429 W,2019-11-08,METHOD FOR PRODUCING WATER-SOLUBLE POLYSACCHARIDES,"[Problem] An object is to obtain a water-soluble polysaccharide (mainly pectin) in a high yield under mild extraction conditions (temperature and pH) and also without using any special agent or extraction device, and to suppress the excessive degradation of the polysaccharide (reduction in the molecular weight of a neutral sugar side chain, demethyl esterification, and deacetylation).[Means for Solution] By adjusting the particle size of pulp dried with superheated steam of the beet pulp generated as a by-product in a step of producing sugar from sugar beet and using the resultant as a raw material, a water-soluble polysaccharide (mainly pectin) can be obtained in a high yield in a short time under mild extraction conditions, and also the excessive degradation of the water-soluble polysaccharide (reduction in the molecular weight of a neutral sugar side chain, demethyl esterification, and deacetylation) can be suppressed.",NIPPON BEET SUGAR MFG,ABE TATSUYA;;NAGURA TAIZO,NIPPON BEET SUGAR MANUFACTURING. CO. LTD (2022-05-10),https://lens.org/082-480-362-712-225,Patent Application,yes,0,1,6,041-147-569-495-057;;082-480-362-712-225;;054-944-683-760-655;;008-790-004-091-115;;007-925-370-147-659;;017-307-248-008-414,JP;;EP;;WO;;US,6,054-944-683-760-655;;082-480-362-712-225;;017-307-248-008-414;;041-147-569-495-057;;007-925-370-147-659;;008-790-004-091-115,JP;;EP;;WO;;US,0,A23L29/231;;A23L19/01;;A23L21/10;;A23L5/23;;A23L29/231;;A23V2002/00;;C08B37/0048,C08B37/00;;A23L5/20;;A23L29/231,,2,1,006-129-518-104-847,10.1016/j.carbpol.2006.04.014,"Kobyashi et al , Biosci. Biotech. Biochem., 1993, 57(6), 998-1000.;;Xu et al, Carbohydrate Polymers, 2007, 67, 56-65.",PENDING
786,KR,A,KR 20220150477 A,091-003-673-255-53X,2022-11-11,2022,KR 20210057233 A,2021-05-03,KR 20210057233 A,2021-05-03,METHOD FOR PURIFYING SOPHOROLIPID,"The present invention relates to a method for separating sophorolipids with improved physical properties such as specific odor, color, and viscosity from oxidized and lactone-type sophorolipid precipitates produced by culturing yeast of genus Candida, and purifying the sophorolipids. The method comprises the following steps: performing ultrafiltration; removing activated carbon and ethanol; and preparing an aqueous solution and adjusting the pH of the aqueous solution to pH 5 or more and less than pH 7.",MACROCARE TECH LTD,KIM MOO SUNG;;LEE SANG RIN;;KIM KYUNG CHUL,,https://lens.org/091-003-673-255-53X,Patent Application,no,0,0,6,187-408-903-954-966;;017-004-572-089-967;;191-190-992-532-727;;114-653-960-797-822;;153-738-115-687-789;;091-003-673-255-53X,KR;;EP;;WO;;US,6,187-408-903-954-966;;017-004-572-089-967;;114-653-960-797-822;;191-190-992-532-727;;153-738-115-687-789;;091-003-673-255-53X,KR;;EP;;WO;;US,0,C07H1/00;;C07H15/10;;C12P19/44;;C12R2001/72;;B01D61/146;;B01D2311/08;;B01D2311/18;;B01D2311/12;;B01D2311/2626;;C07H1/08;;C07H15/10;;C07H1/00;;C12P19/44;;C07B63/00;;C07H1/08,C07H15/10;;C07B63/00;;C07H1/00;;C12P19/44,,3,1,019-189-073-369-856,11334668;;10.1016/s0168-1656(01)00248-6,"J. Biotech., 2001, 87, 263-272;;Spectroscopy and Spectral Analysis, 2012, 32, 2171-2175;;IOP Conf. Ser.:Earth Environ. Sci., 2018, 146, 012071",ACTIVE
787,CN,A,CN 112005653 A,024-155-927-524-158,2020-12-01,2020,CN 202010937845 A,2020-09-08,CN 202010937845 A,2020-09-08,Method for promoting germination of mung bean seeds,"The invention discloses a method for promoting germination of mung bean seeds. The method for promoting germination of the mung bean seeds comprises the following steps: (1) carrying out molecular cluster structure change treatment on water initiated by mung bean seed water to obtain a water sample after water-gas-water two-phase circulation; and (2) carrying out water initiation on the mung beanseeds by using the treated water, and obtaining different germination rates of the mung bean seeds under different temperatures, different water addition amounts and different germination time environments. The method for germination of the mung bean seeds proves that the treated water is used for carrying out water initiation on the mung bean seeds, so that the germination rate of the mung bean seeds is improved; only one set of water treatment equipment (made of food-grade stainless steel) is needed, the cost is low; only the two-phase change of water exists, so that the method can be widelyapplied to the growth of the mung bean sprouts; and the method is further popularized to vegetable greenhouse irrigation and farmland crop irrigation, and seed germination is promoted.",UNIV HARBIN SCIENCE & TECH,HAN GUIHUA;;HONG JIAN,,https://lens.org/024-155-927-524-158,Patent Application,no,9,0,1,024-155-927-524-158,CN,1,024-155-927-524-158,CN,0,A01C1/00;;A01G31/00;;C02F1/00,A01C1/00;;A01G31/00;;C02F1/00,,1,0,,,"NIDHI SHUKLA等: ""“Hydro-Priming Methods for Initiation of Metabolic Process and Synchronization of Germination in Mung Bean (VignaRadiata L.) Seeds”"", 《J. CROP SCI. BIOTECH》",DISCONTINUED
788,US,A1,US 2024/0376540 A1,172-840-139-122-539,2024-11-14,2024,US 202418647857 A,2024-04-26,US 202418647857 A;;US 202017098101 A;;US 202016897052 A;;US 201414300453 A;;US 201314056636 A;;US 201213615183 A;;US 8068408 A;;US 6239108 P;;US 96753907 P;;US 96253007 P;;US 93111507 P;;US 92178707 P,2007-04-04,"Compositions, Devices, Systems, and Methods for Using a Nanopore","Devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore are provided. The devices and methods also determine (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.",UNIV CALIFORNIA,AKESON MARK A;;CHEN ROGER JINTEH ARRIGO,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-12-11),https://lens.org/172-840-139-122-539,Patent Application,yes,2,0,49,050-750-190-792-148;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;085-188-996-524-024;;172-840-139-122-539;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;110-967-876-084-674;;007-641-951-572-149;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;044-951-647-888-187;;192-696-239-263-373;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;082-548-722-396-405;;123-067-273-122-369;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;176-430-871-659-277,KR;;JP;;AU;;CN;;EP;;IL;;WO;;US;;CA,49,176-430-871-659-277;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;172-840-139-122-539;;085-188-996-524-024;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;007-641-951-572-149;;110-967-876-084-674;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;192-696-239-263-373;;044-951-647-888-187;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;123-067-273-122-369;;082-548-722-396-405;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;050-750-190-792-148,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA,0,C12Q1/6869;;G01N33/48721;;C25B3/29;;C12Q1/25;;G01N33/48721;;G01N33/573;;C25B3/29;;C12Q1/54;;C12Q1/6874;;G01N27/3278;;G01N27/4166;;C25B3/29;;C12Q1/6869;;G01N33/48721;;C12Q1/6874;;C12Q1/54;;G01N27/3278;;G01N27/4166,C12Q1/6874;;C12Q1/54;;C12Q1/6869;;C25B3/29;;G01N27/327;;G01N27/416;;G01N33/487,,0,0,,,,PENDING
789,WO,A1,WO 2022/074145 A1,098-808-811-611-452,2022-04-14,2022,EP 2021077761 W,2021-10-07,EP 20200810 A,2020-10-08,CASP8AP2 ANTAGONISTS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER,"The present invention provides the use of a CASP8AP2 antagonist in the prevention or treatment of cancer. Preferably, the antagonist reduces the viability of the cancer cells without significantly reducing the viability of normal cells in the subject to be treated. Further, methods of treatment and pharmaceutical compositions suitable in said methods are provided, as well.",UNIV FREIBURG ALBERT LUDWIGS;;DEUTSCHES KREBSFORSCH,DIEDERICHS SVEN;;MYACHEVA KSENIA,,https://lens.org/098-808-811-611-452,Patent Application,yes,4,0,4,160-155-156-352-300;;055-962-973-100-159;;054-676-359-612-521;;098-808-811-611-452,JP;;EP;;WO;;US,4,160-155-156-352-300;;055-962-973-100-159;;054-676-359-612-521;;098-808-811-611-452,JP;;EP;;WO;;US,141,C12N15/113;;C12N2310/11;;C12N2310/14;;C12N2310/20;;G01N33/5011;;C12N15/113;;A61K31/7088;;A61P35/00;;C12N2310/11;;C12N2310/14;;C12N2310/20;;G01N33/5011,C12N15/113;;A61K31/7088;;A61K31/713;;A61P35/00;;G01N33/68,,14,11,006-608-015-407-879;;012-406-610-377-178;;038-224-535-294-36X;;082-404-990-280-14X;;047-963-475-714-54X;;010-826-463-387-621;;135-022-099-010-877;;097-631-905-745-219;;006-234-066-686-923;;093-494-899-662-025;;149-242-662-481-217,22216762;;pmc3281783;;10.1186/1476-4598-11-1;;pmc9621094;;32910455;;10.1002/bit.27561;;pmc3302898;;10.1371/journal.pone.0032971;;22427918;;22648522;;pmc3423492;;10.1007/s00109-012-0920-1;;pmc4081087;;24875475;;10.1093/nar/gku480;;10.1016/j.jcrpr.2017.07.001;;25238250;;10.1371/journal.pone.0108032;;pmc4169604;;10.1038/19709;;10235259;;pmc2835096;;10.1038/mt.2008.205;;18813282;;29982332;;pmc7414524;;10.1093/bib/bby054;;10.1186/preaccept-1316450832143458;;10.1186/s13059-014-0554-4;;25476604;;pmc4290824,"AMANDA B HUMMON ET AL: ""Systems-wide RNAi analysis of CASP8AP2/FLASH shows transcriptional deregulation of the replication-dependent histone genes and extensive effects on the transcriptome of colorectal cancer cells"", MOLECULAR CANCER, vol. 11, no. 1, 4 January 2012 (2012-01-04), pages 1 - 22, XP021130809, ISSN: 1476-4598, DOI: 10.1186/1476-4598-11-1;;ABAANDOU LAURA ET AL: ""Knockout of the caspase 8-associated protein 2 gene improves recombinant protein expression in HEK293 cells through up-regulation of the cyclin-dependent kinase inhibitor 2A gene"", BIOTECHNOLOGY AND BIOENGINEERING, vol. 118, no. 1, 24 September 2020 (2020-09-24), pages 186 - 198, XP055877237, ISSN: 0006-3592, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/bit.27561> DOI: 10.1002/bit.27561;;CHEN SONG ET AL: ""FLASH Knockdown Sensitizes Cells To Fas-Mediated Apoptosis via Down-Regulation of the Anti-Apoptotic Proteins, MCL-1 and Cflip Short"", vol. 7, no. 3, E32971, 9 March 2012 (2012-03-09), pages 1 - 9, XP055784716, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302898/pdf/pone.0032971.pdf> DOI: 10.1371/journal.pone.0032971;;HA WON KIM ET AL: ""Stem cell-based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of infarcted heart function"", JOURNAL OF MOLECULAR MEDICINE, vol. 90, no. 9, 31 May 2012 (2012-05-31), pages 997 - 1010, XP035100571, ISSN: 1432-1440, DOI: 10.1007/S00109-012-0920-1;;HANNUS MICHAEL ET AL: ""siPools: highly complex but accurately defined siRNA pools eliminate off-target effects"", vol. 42, no. 12, 29 May 2014 (2014-05-29), GB, pages 8049 - 8061, XP055784968, ISSN: 0305-1048, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081087/pdf/gku480.pdf> DOI: 10.1093/nar/gku480;;HASSANPOUR ET AL., J. CANCER RES. PRACTICE, vol. 4, 2017, pages 127 - 129;;HUMMON ET AL., MOL. CANCER, vol. 11, 2012, pages 1 - 22;;MINAMIDA ET AL., PLOS ONE, vol. 9, 2014, pages el08032;;IMAI ET AL., NATURE, vol. 398, 1999, pages 777 - 785;;""Genbank"", Database accession no. NM_012115.4;;AARSTMA-RUS ET AL., MOLECULAR THERAPY, vol. 17, 2009, pages 548 - 553;;NAITO ET AL., FRONT. GENET., vol. 3, 2012, pages 1 - 7;;CHEN ET AL., BRIEFINGS IN BIOINFORMATICS, vol. 20, 2019, pages 1836 - 1852;;LI, W,XU, HXIAO, T ET AL.: ""MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens"", GENOME BIOL, vol. 15, 2014, pages 554, XP021208793, DOI: 10.1186/s13059-014-0554-4",PENDING
790,US,A1,US 2024/0254527 A1,157-536-505-221-968,2024-08-01,2024,US 202118260333 A,2021-07-28,CN 202110006046 A;;CN 2021108983 W,2021-01-05,BACILLUS SUBTILIS GENETICALLY ENGINEERED BACTERIUM FOR PRODUCING TAGATOSE AND METHOD FOR PREPARING TAGATOSE,"Provided are a Bacillus subtilis genetically engineered bacterium for producing tagatose and a method for preparing tagatose. The genetically engineered bacterium comprises constructing thermostable α-glucan phosphorylases, thermostable glucose phosphomutases, thermostable glucose phosphate isomerases, thermostable 6-tagatose phosphate epimerases, and thermostable 6-tagatose phosphate phosphatases which are independently expressed or co-expressed. The usage of the genetically engineered bacterium can effectively convert starch into tagatose. Compared with existing methods for producing tagatose, the method has advantages such as suitability for whole-cell recycling, high safety, high yield, simple production process, low cost, and easiness in large-scale preparation.",TIANJIN YEAHE BIOTECHNOLOGY CO LTD,MA YANHE;;SHI TING;;LI YUNJIE;;HAN PINGPING;;LI YUAN,TIANJIN YEAHE BIOTECHNOLOGY CO. LTD (2023-10-09);;TIANGONG BIOTECHNOLOGY (TIANJIN) CO. LTD (2023-07-27);;TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY CHINESE ACADEMY OF SCIENCES (2023-05-24),https://lens.org/157-536-505-221-968,Patent Application,yes,1,0,8,157-536-505-221-968;;028-586-393-529-172;;168-236-901-338-249;;144-794-147-800-037;;151-701-432-156-357;;032-094-003-151-99X;;122-673-450-296-487;;022-327-661-025-698,JP;;KR;;CN;;EP;;WO;;US,8,157-536-505-221-968;;028-586-393-529-172;;168-236-901-338-249;;144-794-147-800-037;;151-701-432-156-357;;032-094-003-151-99X;;122-673-450-296-487;;022-327-661-025-698,JP;;KR;;CN;;EP;;WO;;US,32,C12N9/1051;;C12N9/90;;C12N9/92;;C12N9/16;;C12N15/75;;C12P19/02;;C12Y504/02002;;C12Y503/01009;;C12Y501/03;;C12N15/75;;C12P19/02;;C12P19/24;;C12Y204/01001;;C12Y501/03;;C12Y504/02002;;C12Y503/01009;;C12N9/1051;;C12N9/90;;C12N9/1205;;C12Y207/01101;;C12N15/52;;C12R2001/125;;C12N15/75;;C12P19/02;;C12P19/24;;C12N15/52;;C12N9/1051;;C12N9/92;;C12N9/90;;C12N9/16;;C12Y504/02002;;C12Y503/01009;;C12Y501/03;;C12Y204/01001;;C12N9/1051;;C12N9/16;;C12N9/90;;C12N11/00;;C12N15/75;;C12P19/02;;C12Y204/01001;;C12Y301/03;;C12Y501/03;;C12Y503/01009;;C12Y504/02002,C12P19/02;;C12N9/10;;C12N9/16;;C12N9/90;;C12N11/00;;C12N15/75,,6,6,008-120-631-983-38X;;000-938-322-005-89X;;023-481-904-534-57X;;061-859-656-899-093;;132-695-844-930-786;;033-556-137-796-742,10.1126/science.282.5392.1315;;9812895;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.3.co;2-j;;10944397;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.0.co;2-s;;10.1128/jb.183.8.2405-2410.2001;;pmc95154;;11274097;;15029827;;10.1017/s0033583503003901;;10512619;;10.1021/bi990993h;;pmc4910044;;27305971;;10.1038/srep27943,"Broun et al., Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids. Science, 1998, Vol. 282: 1315-1317. (Year: 1998);;Devos et al., Practical limits of function prediction. Proteins: Structure, Function, and Genetics. 2000, Vol. 41: 98-107. (Year: 2000);;Seffernick et al., Melamine deaminase and Atrazine chlorohydrolase: 98 percent identical but functionally different. J. Bacteriol., 2001, Vol. 183 (8): 2405-2410. (Year: 2001);;Whisstock et al., Prediction of protein function from protein sequence. Q. Rev. Biophysics., 2003, Vol. 36 (3): 307-340. (Year: 2003);;Witkowski et al., Conversion of b-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with glutamine. Biochemistry, 1999, Vol. 38: 11643-11650. (Year: 1999);;Zhang et al., Multigene disruption in undomesticated Bacillus subtilis ATCC 6051a using the CRISPR/Cas9 system. Scientific Reports, 2016, 6:27943, pages 1-11 (Year: 2016)",PENDING
791,US,A1,US 2021/0180070 A1,032-283-908-865-340,2021-06-17,2021,US 201816771704 A,2018-12-13,US 201816771704 A;;US 201762597951 P;;US 2018/0065417 W,2017-12-13,TUNABLE TRANSCRIPTIONAL REGULATORS REPONSIVE TO ENVIRONMENTAL TRIGGERS,"This present patent application relates to a method for controlling a targeted gene expression with an environmental trigger useful for manufacturing a natural product or an analogue thereof biologically. In particular, the present invention discloses an expression system comprises a gene expressing for a fusion protein of elastin-like polypeptides (ELPs) and a transcription factor, wherein a targeted gene expression is regulated by the phase change of the fusion protein initiated by an environmental trigger, including changes of temperature, pH value, ionic strength or a combination thereof. The method, the expression system and their products are within the scope of this invention.",PURDUE RESEARCH FOUNDATION,SOLOMON KEVIN V;;HILLMAN ETHAN;;LEE KOK ZHI;;WANG YU HONG,PURDUE RESEARCH FOUNDATION (2018-12-12),https://lens.org/032-283-908-865-340,Patent Application,yes,0,0,3,112-088-667-686-988;;053-956-821-283-802;;032-283-908-865-340,WO;;US,3,112-088-667-686-988;;053-956-821-283-802;;032-283-908-865-340,WO;;US,19,C07K14/78;;C07K2319/23;;C07K2319/71;;C12N15/63;;C12N15/70;;C12N15/81;;C12P15/00;;C12N15/70;;C07K14/78;;C07K2319/23;;C07K2319/71;;C12N15/81,C12N15/70;;C07K14/78;;C12N15/81,,0,0,,,,ACTIVE
792,WO,A1,WO 2021/216447 A1,022-419-230-109-644,2021-10-28,2021,US 2021/0027960 W,2021-04-19,US 202063012415 P,2020-04-20,DEVICES AND METHODS FOR MULTIPLEXING CHEMICAL SYNTHESIS,"The present invention relates to the field of chemical synthesis. Specifically, the present invention relates to methods, materials, compositions, and devices for multiplexing chemical synthesis. In particular, the present invention provides novel methods, materials, compositions, and devices to synthesize plurality of chemical compounds, including but not limited to nucleic acids, peptides, saccharides, and phospholipids. Specifically, the present invention provides methods, materials, compositions, and devices to first form plurality of isolated wells on a solid substrate and then to carry out plurality of chemical reactions in the isolated wells, in parallel, and on the same substrate.",LC SCIENCES,ZHAO XIAOCHUAN;;ZHANG XIAOLIN,,https://lens.org/022-419-230-109-644,Patent Application,yes,4,0,4,068-393-580-709-603;;022-419-230-109-644;;152-194-123-155-812;;173-261-425-075-155,EP;;WO;;US,4,173-261-425-075-155;;022-419-230-109-644;;152-194-123-155-812;;068-393-580-709-603,EP;;WO;;US,0,C08F2/48;;B01J19/0046;;B01J2219/00585;;B01J2219/00623;;B01J2219/00664;;B01J2219/00675;;B01J2219/00711;;B01J2219/00621;;B01J2219/00668;;B01J2219/00722;;B01J2219/00725;;B01J2219/00599;;B01L3/5085;;B01L2200/12;;B01J2219/00608;;B01J2219/00612;;B01J2219/00632;;B33Y10/00;;B33Y30/00;;B01J19/0046;;B01J2219/00585;;B01J2219/00599;;B01J2219/00621;;B01J2219/00623;;B01J2219/00664;;B01J2219/00675;;B01J2219/00711;;B01J2219/00722,C08F2/00;;B01J19/00;;C08F2/44;;C08F2/48,,1,0,,,See also references of EP 4139368A4,PENDING
793,US,A1,US 2021/0155984 A1,106-505-241-885-303,2021-05-27,2021,US 202017107832 A,2020-11-30,US 202017107832 A;;US 201916386472 A;;US 201862767633 P;;US 201862659073 P,2018-04-17,"HIGHLY SENSITIVE IN VITRO ASSAYS TO DEFINE SUBSTRATE PREFERENCES AND SITES OF NUCLEIC-ACID BINDING, MODIFYING, AND CLEAVING AGENTS","Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.",MASSACHUSETTS GEN HOSPITAL,JOUNG J KEITH;;PATTANAYAK VIKRAM;;PETRI KARL;;SASAKI KANAE ESTHER,THE GENERAL HOSPITAL CORPORATION (2019-10-18),https://lens.org/106-505-241-885-303,Patent Application,yes,0,4,17,106-505-241-885-303;;038-948-598-556-711;;034-490-975-992-985;;009-334-097-005-622;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;138-305-460-735-625;;165-552-951-053-124;;088-269-227-016-272;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,17,106-505-241-885-303;;038-948-598-556-711;;009-334-097-005-622;;034-490-975-992-985;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;088-269-227-016-272;;165-552-951-053-124;;138-305-460-735-625;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,131,C12N9/22;;C12Q1/6853;;C12Q1/6827;;C12Q1/6806;;C12N15/1058;;C12Q1/6874;;C12Y305/04005,C12Q1/6874;;C12N15/10,,1,1,040-761-696-690-633,pmc3920298;;10.1002/0471140864.ps3001s73;;24510614,Cole NB. Site-specific protein labeling with SNAP-tags. Curr Protoc Protein Sci. 2013 Sep 24;73:30.1.1-30.1.16. doi: 10.1002/0471140864.ps3001s73. PMID: 24510614; PMCID: PMC3920298. (Year: 2013),ACTIVE
794,US,A1,US 2024/0309446 A1,101-769-113-634-224,2024-09-19,2024,US 202318502817 A,2023-11-06,US 202318502817 A;;US 202016852257 A;;US 201916386472 A;;US 201862767633 P;;US 201862659073 P,2018-04-17,"HIGHLY SENSITIVE IN VITRO ASSAYS TO DEFINE SUBSTRATE PREFERENCES AND SITES OF NUCLEIC-ACID BINDING, MODIFYING, AND CLEAVING AGENTS","Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.",MASSACHUSETTS GEN HOSPITAL,JOUNG J KEITH;;PATTANAYAK VIKRAM;;PETRI KARL;;GEHRKE JASON MICHAEL;;SASAKI KANAE ESTHER,THE GENERAL HOSPITAL CORPORATION (2019-10-08),https://lens.org/101-769-113-634-224,Patent Application,yes,2,0,17,106-505-241-885-303;;038-948-598-556-711;;034-490-975-992-985;;009-334-097-005-622;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;138-305-460-735-625;;165-552-951-053-124;;088-269-227-016-272;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,17,106-505-241-885-303;;038-948-598-556-711;;009-334-097-005-622;;034-490-975-992-985;;010-451-207-435-868;;015-220-222-555-917;;047-456-458-112-671;;088-269-227-016-272;;165-552-951-053-124;;138-305-460-735-625;;022-787-078-823-884;;101-769-113-634-224;;080-504-606-269-727;;136-581-224-188-664;;188-184-379-989-244;;190-501-545-031-428;;063-197-755-845-405,JP;;AU;;CN;;EP;;WO;;US;;CA,0,C12N9/22;;C12Q1/6853;;C12Q1/6827;;C12Q1/6806;;C12N15/1058;;C12Q1/6874;;C12Y305/04005,C12Q1/6874;;C12N15/10,,0,0,,,,PENDING
795,US,A1,US 2024/0002845 A1,055-962-973-100-159,2024-01-04,2024,US 202118031001 A,2021-10-07,EP 20200810 A;;EP 2021077761 W,2020-10-08,CASP8AP2 ANTAGONISTS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER,"The present invention provides the use of a CASP8AP2 antagonist in the prevention or treatment of cancer. Preferably, the antagonist reduces the viability of the cancer cells without significantly reducing the viability of normal cells in the subject to be treated. Further, methods of treatment and pharmaceutical compositions suitable in said methods are provided, as well.",UNIV FREIBURG ALBERT LUDWIGS;;DEUTSCHES KREBSFORSCH,DIEDERICHS SVEN;;MYACHEVA KSENIA,DEUTSCHES KREBSFORSCHUNGSZENTRUM (2023-05-10);;ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (2023-05-10),https://lens.org/055-962-973-100-159,Patent Application,yes,0,0,4,160-155-156-352-300;;055-962-973-100-159;;054-676-359-612-521;;098-808-811-611-452,JP;;EP;;WO;;US,4,160-155-156-352-300;;055-962-973-100-159;;054-676-359-612-521;;098-808-811-611-452,JP;;EP;;WO;;US,141,C12N15/113;;C12N2310/11;;C12N2310/14;;C12N2310/20;;G01N33/5011;;C12N15/113;;A61K31/7088;;A61P35/00;;C12N2310/11;;C12N2310/14;;C12N2310/20;;G01N33/5011,C12N15/113;;A61K31/7088;;A61P35/00;;G01N33/50,,0,0,,,,DISCONTINUED
796,US,A1,US 2022/0315629 A1,092-745-545-011-871,2022-10-06,2022,US 202217724342 A,2022-04-19,US 202217724342 A;;US 201916697685 A;;US 201715550323 A;;US 2016/0017267 W;;US 201562114217 P,2015-02-10,GRIFFITHSIN MUTANTS,"The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.",US HEALTH;;UNIV LOUISVILLE RES FOUND INC;;UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,O'KEEFE BARRY R;;MOULAEI TINOUSH;;PALMER KENNETH E;;ROHAN LISA C;;FUQUA JOSHUA L;;KRAMZER LINDSAY F,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (2017-11-22);;UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC (2017-12-01);;UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2018-01-19),https://lens.org/092-745-545-011-871,Patent Application,yes,1,0,15,087-347-806-817-773;;136-715-658-570-95X;;189-327-791-673-024;;062-677-871-221-399;;181-412-546-425-401;;121-055-785-769-202;;104-974-395-966-041;;138-801-735-495-038;;092-745-545-011-871;;129-370-651-376-420;;132-051-872-999-322;;011-285-026-241-111;;041-787-910-921-407;;049-606-282-354-725;;147-155-966-074-065,AU;;EP;;ES;;WO;;US;;LT;;CA,15,087-347-806-817-773;;136-715-658-570-95X;;189-327-791-673-024;;062-677-871-221-399;;181-412-546-425-401;;121-055-785-769-202;;104-974-395-966-041;;138-801-735-495-038;;092-745-545-011-871;;129-370-651-376-420;;132-051-872-999-322;;011-285-026-241-111;;041-787-910-921-407;;049-606-282-354-725;;147-155-966-074-065,AU;;EP;;ES;;WO;;US;;LT;;CA,18,A61K38/00;;C07K14/405;;A61K38/16;;A61K38/00;;C07K14/405;;A61K38/16,C07K14/405;;A61K38/16,,0,0,,,,ACTIVE
797,JP,A,JP 2021520205 A,040-060-630-385-159,2021-08-19,2021,JP 2020554242 A,2018-04-02,CN 2018081635 W,2018-04-02,機能的なＩｎｃＲＮＡをスクリーニングおよび同定するための方法,ペアのガイドＲＮＡを使用して、長鎖ノンコーディングＲＮＡのスプライスドナー部位またはスプライスアクセプター部位周辺の−５０ｂｐ〜＋７５ｂｐの範囲のゲノム配列を標的とする、ＣＲＩＳＰＲシステムによって長鎖ノンコーディングＲＮＡをスクリーニングまたは同定するためのハイスループット方法が提供される。【選択図】図５,北京大学ＰＥＫＩＮＧ ＵＮＩＶＥＲＳＩＴＹ;;博雅▲緝▼因（北京）生物科技有限公司ＥＤＩＧＥＮＥ ＢＩＯＴＥＣＨＮＯＬＯＧＹ ＩＮＣ．,ウェイ，ウェンシォン;;リゥ，イン;;ツァオ，ヂョンヂォン;;ワン，イーナン;;グォ，ユー;;ユェン，ポンフェイ,,https://lens.org/040-060-630-385-159,Patent Application,no,0,0,8,040-060-630-385-159;;052-416-420-583-608;;020-425-551-475-475;;135-215-365-282-084;;139-251-748-714-693;;079-205-766-526-395;;019-836-875-186-670;;061-243-350-498-777,JP;;EP;;CN;;WO;;US,8,040-060-630-385-159;;052-416-420-583-608;;139-251-748-714-693;;135-215-365-282-084;;020-425-551-475-475;;079-205-766-526-395;;019-836-875-186-670;;061-243-350-498-777,JP;;EP;;CN;;WO;;US,150,C12N15/113;;C12N2310/20;;C12N2330/31;;C12N2740/16043;;C12N2310/20;;C12N9/22;;C12N15/113;;C12N2330/31;;C12N2740/16043,C12N15/113;;C12N15/09;;C12N15/63;;C12N15/86;;C12Q1/02;;C12Q1/68;;C12Q1/6897;;C40B40/06,,2,0,,,"NATURE BIOTECH., vol. 34, JPN6021043854, 2016, pages 1279 - 1286, ISSN: 0004818749;;NATURE, vol. 539, JPN6021043855, 2016, pages 452 - 455, ISSN: 0004818750",ACTIVE
798,US,A1,US 2022/0275351 A1,137-111-641-867-107,2022-09-01,2022,US 202017762869 A,2020-09-25,CN 201910918850 A;;CN 2020117818 W,2019-09-26,Preparation of Glycosyltransferase UGT76G1 Mutant and Use Thereof,"Provided are a glycosyltransferase UGT76G1 mutant, an isolated polynucleotide, a carrier, a production method, and a composition and a kit for the glycosylation of substrates. Further provided are a method for increasing the catalytic activity of the glycosyltransferase UGT76G1 mutant, and a method for promoting the glycosylation of flavone compounds and the use thereof. The glycosyltransferase UGT76G1 mutant is subjected to mutations at positions corresponding to positions 87, 199, 204 or 379 of SEQ ID NO: 1, and significantly improves the transformation activity of substrates of the flavone compounds.",CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES,WANG YONG;;SUN YUWEI;;LIU ZHIFENG;;CHEN ZHUO;;LI JIANHUA;;LIU HAILI;;LV HUAJUN,CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES (2022-08-03),https://lens.org/137-111-641-867-107,Patent Application,yes,1,0,6,129-536-495-367-027;;137-111-641-867-107;;190-527-729-314-815;;177-535-775-912-743;;159-428-754-840-086;;144-517-217-424-108,EP;;CN;;WO;;US,6,129-536-495-367-027;;137-111-641-867-107;;144-517-217-424-108;;177-535-775-912-743;;159-428-754-840-086;;190-527-729-314-815,EP;;CN;;WO;;US,15,C12N9/1048;;C12N15/63;;C12N15/70;;C12P19/56;;C12N15/70;;C12N9/1051;;C12P17/162;;C12N9/1051,C12N9/10,,2,1,014-026-623-433-093,10.1016/j.xplc.2019.100004;;pmc7747997;;33404544,"C7EA09 (UniProt Database, 2009) (Year: 2009);;Liu et al. Structural Insights into the CatalyticMechanism of a Plant Diterpene Glycosyltransferase SrUGT76G1, Plant Communications 1, 100004, January 2020 (Year: 2020)",PENDING
799,US,A1,US 2025/0222414 A1,096-328-177-267-379,2025-07-10,2025,US 202318852687 A,2023-04-06,GB 202205582 A;;SE 2250464 A;;EP 2023059247 W,2022-04-14,A SOLUTION MANAGEMENT SYSTEM FOR BIOPROCESSING,"A solution management system (1) for bioprocessing, wherein each flow path formed between solution inlets (2) and solution outlets (9) of the system comprises one or more bend sections having an inner cross-sectional area and/or an inner cross-sectional geometry and/or a centre line radius varying along the length of the bend section. Various embodiments of the solution management system (1) provide for improved laminar fluid flow with a reduced pressure drop between the solution inlets (2) and solution outlets (9) therein.",CYTIVA SWEDEN AB,MARTELEUR KLAS;;ALRIKSSON JOHAN,,https://lens.org/096-328-177-267-379,Patent Application,yes,0,0,6,011-986-760-255-675;;138-161-796-104-675;;010-442-860-076-074;;039-279-171-368-958;;096-328-177-267-379;;181-004-290-130-243,KR;;JP;;CN;;EP;;WO;;US,7,181-004-290-130-243;;011-986-760-255-675;;039-279-171-368-958;;010-442-860-076-074;;131-399-790-435-137;;096-328-177-267-379;;138-161-796-104-675,JP;;KR;;CN;;EP;;WO;;US;;GB,0,B01F35/80;;F04B13/00;;F04B23/04;;B01F33/844;;B01F35/2202;;B01F35/211;;B01F35/2132;;B01F25/433;;B01F35/80;;B01F33/844;;B01F35/2202;;B01F35/211;;B01F35/2132;;B01F35/7176;;B01F35/214;;B01F35/7547;;B01F25/31;;F04B13/00;;F04B23/04;;B01F2025/917;;B01F2101/22;;B33Y80/00;;B01F35/7176;;B01F35/2131;;B01F35/2133;;B01F35/712;;B01F35/214;;B01F2101/44;;B01F2101/2202;;B01F35/213;;B01F35/2132;;B01F23/45,B01F23/45;;B01F35/21;;B01F35/213;;B01F35/214;;B01F35/71;;B01F101/00;;B01F101/44;;B33Y80/00,,0,0,,,,PENDING
800,EP,A1,EP 4538378 A1,069-433-987-213-124,2025-04-16,2025,EP 23823135 A,2023-06-13,CN 202210664659 A;;CN 2023099902 W,2022-06-13,WILD-TYPE-MUTANT ? PROTEIN SWITCHING EXPRESSION SYSTEM CAPABLE OF INCREASING EFFICIENCY OF PREPARING SCREENING-TAG-FREE PLASMID,"Provided is a precursor plasmid used for preparing a screening-tag-free plasmid, the precursor plasmid comprising: (1) a conditioned replication initiation site having a plasmid replication initiation capacity that is dependent on regulatory proteins, wherein the conditioned replication initiation site has a first replication initiation state in the presence of a first regulatory protein and a second replication initiation site in the presence of a second regulatory protein, and has a stronger ability to initiate plasmid replication in the second replication initiation state than in the first replication initiation state; 2) a first regulatory protein expression cassette expressing the first regulatory protein; 3) a sequence encoding a repressor protein; 4) a screened tag gene; 5) a target gene, or a cloning site for inserting the target gene; and 6) paired recombination sites. Also provided are a host cell suitable for the recombination of the precursor plasmid and the production of a screening-tag-free plasmid, and a method for large-scale production of the screening-tag-free plasmid.",NANJING GENSCRIPT BIOTECH CO LTD,ZHOU FAN;;ZHANG LU;;LI HONG,,https://lens.org/069-433-987-213-124,Patent Application,yes,0,0,4,064-883-772-084-026;;108-805-784-524-341;;099-056-732-310-595;;069-433-987-213-124,CN;;EP;;WO,4,064-883-772-084-026;;108-805-784-524-341;;099-056-732-310-595;;069-433-987-213-124,CN;;EP;;WO,20,C12N15/85;;C12N2800/101;;C12N2800/107;;C12N2820/002;;G01N33/5023;;C12N15/72;;C12Q1/6806,C12N15/64;;C12N5/10;;C12N15/63,,0,0,,,,PENDING
801,US,A1,US 2024/0124852 A1,080-432-247-107-485,2024-04-18,2024,US 202218554972 A,2022-04-13,CN 202110393844 A;;CN 2022086599 W,2021-04-13,"RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF","The present application discloses a recombinant Newcastle disease virus genome, a recombinant Newcastle disease virus rNDV-VEGF-Trap containing the genome and a preparation method therefor, a DNA molecule encoding the recombinant Newcastle disease virus genome, and a use of the genome and the recombinant Newcastle disease virus in the preparation of a drug for treating cancer. The recombinant Newcastle disease virus provided by the present application relates to inserting a coding gene of VEGF-Trap into the genome of the recombinant Newcastle disease virus, such that the recombinant Newcastle disease virus obtained therefrom is replicated with a strong replication capability, thereby killing host cancer cells; moreover, the recombinant Newcastle disease virus has reliable safety for non-cancer cells, and shows improved anti-tumor effect and oncolytic efficiency.",JIANGSU KANIONREAL BIOMEDICAL TECH CO LTD,XIAO WEI;;LI DESHAN;;LIU TIANYAN;;WANG ZHENZHONG;;CAO YUKAI;;LIU ZHIHANG;;YU DAN,JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO. LTD (2023-10-26);;JIANGSU KANION PHARMACEUTICAL CO. LTD (2024-10-23),https://lens.org/080-432-247-107-485,Patent Application,yes,0,0,5,006-493-884-763-587;;023-816-043-446-173;;012-816-507-737-325;;186-588-471-580-431;;080-432-247-107-485,JP;;CN;;WO;;US,5,012-816-507-737-325;;023-816-043-446-173;;006-493-884-763-587;;186-588-471-580-431;;080-432-247-107-485,JP;;CN;;WO;;US,5,C07K14/005;;C07K14/475;;C12N7/00;;C12N15/85;;A61K35/768;;A61K38/1866;;A61P35/00;;A61P35/02;;C12N2760/18121;;C12N2760/18122;;C12N2760/18132;;A61K35/768;;A61K38/18;;A61P35/00;;A61P35/02;;C07K14/115;;C07K14/435;;C12N7/00;;C12N15/85;;C12N2710/00;;C12N15/11;;C12N15/90;;C07K14/005;;A61K38/00;;C12N15/86;;A61P35/00;;A61K35/768;;A61K38/00;;C07K14/005;;C12N7/00;;C12N2760/18121;;C12N2760/18122;;C12N2760/18132,C12N7/00;;A61K35/768;;A61P35/00;;C07K14/005,,0,0,,,,PENDING
802,EP,A1,EP 4467571 A1,154-721-565-313-560,2024-11-27,2024,EP 23742866 A,2023-01-17,CN 202210068506 A;;CN 2023072510 W,2022-01-20,ANTI-CD3 AND ANTI-CD20 BISPECIFIC ANTIBODY AND USE THEREOF,"The present invention provides a bispecific antibody targeting CD3 and CD20 and a composition comprising same. Further provided are a nucleic acid molecule encoding the bispecific antibody of the present invention, a vector and a host cell for expressing the bispecific antibody of the present invention, and a therapeutic and diagnostic method and a use of the antibody of the present invention or an antigen-binding fragment thereof.",SHANGHAI JUNSHI BIOSCIENCES CO LTD,FENG HUI;;ZHOU YUEHUA;;LIU DANDAN;;LIU HONGCHUAN;;LI RUISHENG;;LIU HUI;;HE ZHIJUAN,,https://lens.org/154-721-565-313-560,Patent Application,yes,0,0,8,068-163-072-468-256;;154-721-565-313-560;;001-387-752-104-722;;192-560-464-968-393;;018-893-950-372-591;;140-374-611-392-385;;036-360-876-267-048;;037-390-109-342-768,JP;;AU;;KR;;EP;;CN;;WO;;US,8,068-163-072-468-256;;154-721-565-313-560;;001-387-752-104-722;;192-560-464-968-393;;018-893-950-372-591;;140-374-611-392-385;;036-360-876-267-048;;037-390-109-342-768,JP;;AU;;KR;;EP;;CN;;WO;;US,0,C07K16/2887;;C07K16/2809;;C12N15/85;;C12N5/0682;;A61P35/00;;A61P35/02;;G01N33/6872;;C07K2317/31;;C07K2317/56;;C07K2317/52;;C12N2510/00;;C12N2800/107;;A61K2039/505;;G01N2333/7051;;G01N2333/70596;;A61P35/00;;A61P35/02;;C07K16/2887;;C07K16/2809;;C07K2317/31;;C07K2317/94;;C07K2317/92;;C07K2317/73;;A61K2039/505;;G01N2333/7051;;G01N2333/70596;;G01N33/6872;;C07K16/2887;;C07K16/2809;;G01N33/6872;;A61P35/02;;C07K2317/52;;C07K2317/56;;C07K2317/31;;C07K2317/565;;A61K2039/505;;G01N2333/7051;;G01N2333/70596;;A61P35/00;;A61K2039/505;;C07K16/2809;;C07K16/2887;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/92;;C07K2317/94,C07K16/46;;A61K38/19;;A61K39/395;;A61P35/00;;C12N15/13,,0,0,,,,PENDING
803,US,A1,US 2021/0208080 A1,048-055-382-707-802,2021-07-08,2021,US 201917057737 A,2019-05-21,CN 201810491290 A;;CN 201810526541 A;;CN 2019087828 W,2018-05-21,CHEMILUMINESCENCE ANALYTICAL METHOD AND SYSTEM AND KIT USING SAME,"Disclosed is a chemiluminescence analytical method in the technical field of chemiluminescence. The present method broadens a detection range and indicates an HD-HOOK sample or a sample that is beyond the detection range by way of selecting two signal values from signal values that are read in multiple times, and simply and quickly calculates the concentration of an analyte during detection. Disclosed are a system using the chemiluminescence analytical method and a kit for the chemiluminescence analytical method.",BEYOND DIAGNOSTICS SHANGHAI CO LTD;;CHEMCLIN DIAGNOSTICS CO LTD,YANG YANG;;LIU YUHUI;;LI LIN,CHEMCLIN DIAGNOSTICS (SHANGHAI) CO. LTD (2020-11-30);;CHEMCLIN DIAGNOSTICS CO. LTD (2020-11-30),https://lens.org/048-055-382-707-802,Patent Application,yes,3,1,7,048-055-382-707-802;;144-007-397-123-07X;;177-142-307-147-043;;195-371-732-265-499;;015-548-298-126-907;;053-791-161-480-428;;185-021-273-829-634,JP;;EP;;WO;;US,11,048-055-382-707-802;;162-051-557-679-909;;144-007-397-123-07X;;177-142-307-147-043;;055-501-754-390-107;;099-980-800-360-804;;185-021-273-829-634;;195-371-732-265-499;;015-548-298-126-907;;053-791-161-480-428;;036-624-541-101-608,JP;;CN;;EP;;WO;;US,0,G01N21/76;;G01N33/582;;G01N33/5306;;G01N21/76;;G01N33/52,G01N21/76;;G01N33/52,,9,4,112-666-785-675-958;;011-513-768-562-709;;021-106-481-762-599;;043-561-408-336-537,10.1007/s00216-017-0791-y;;29247381;;10.1016/s0891-5849(99)00107-0;;10490282;;10.1021/ac00052a016;;1598850;;10.1002/bio.1170070202,"Balke T, Uelker U EP2790019A1 Machine Translation English (Year: 2014);;Bian Y, Liu C, She T, Wang M, Yan J, Wei D, Li H (12/15/5017) “Development of a light-initiated chemiluminescent assay for the quantitation of sIgE against egg white allergens based on component-resolved diagnosis”, Analytical and Bioanalytical Chemistry, 410, pages 1501-1510 (Year: 2018);;Wang H, Joseph JA (09/1999), ""Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader"", Free Radical Biology and Medicine, 27, 5/6 , pages 612-616. (Year: 1999);;EP2790019A1 - High dose hook detection - Google Patents - translation (Year: 2014);;Szekeres PG, Leong K, Day TA, Kingston AE, Karran EH (2008), “Development of Homogeneous 384-Well High-Throughput Screening Assays for Aβ1-40 and Aβ1-42 Using AlphaScreen™ Technology”, Journal of Biomolecular Screening, 13, 2, pages 101-111 (Year: 2008);;Motsenbocker M, Sugawara T, Shintani M, Masuya H, Ichimori Y, Kondo K. (1993) “Establishment of the Optically pumped Chemiluminescence Technique for Diagnostics”, Analytical Chemistry, 65, 4, pages 403-408. (Year: 1993);;Stanley (1992) “A Survey of More than 90 Comm. available Luminometers and Imaging Devices for Low-light Measruements of Chemiluminescence and Bioluminescence, Including Instruments for Manual, Automatic and Specialized Operation, for HPLC, LC, GLC and Microtitre Plates.”, J Biolum Chemilum 7, p 77-108 (Year: 1992);;Kiyokazu, N. Immunity nephelometry analyzing method 1994 JPH06109740A Machine translation, 14 pages (Year: 1994);;Balke T, Uelker U. High dose hook detection 2014 EP2790019A1 Machine translation, 13 pages (Year: 2014)",DISCONTINUED
804,US,A1,US 2024/0002454 A1,181-550-802-178-741,2024-01-04,2024,US 202218255108 A,2022-04-25,CN 202110516304 A;;CN 2022088907 W,2021-05-12,MOLECULAR PEPTIDE MUTANT,"The invention relates to a molecular peptide mutant, the amino acid sequence of which is as shown in SEQ ID NO: 1. In the invention, SpyCatcher is designed and modified to obtain a molecular peptide SpyCatcher-21 with stimulus response to pH on the basis of not affecting the formation of isopeptide bonds, and Pro is introduced into a key loop of the SpyCatcher-21 through analysis of the crystal structure to reduce the flexibility of the loop and obtain a mutant SpyCatcher-21_A82P, which can raise ligation efficiency with SpyTag. The SpyCatcher-21_A82P can be used to achieve double-enzyme catalysis according to objective needs by changing the pH of the environment to obtain different degrees of coupling, or obtain a three-enzyme coupled catalytic system through electrostatic interaction with a positively charged enzyme.",NANJING UNIVERSITY OF TECHNOLOGY,JIANG LING;;CHEN YAO;;ZHU LIYING;;LIU WEI;;CHEN XIANHAN;;CHEN XINYI,NANJING TECH UNIVERSITY (2023-04-12),https://lens.org/181-550-802-178-741,Patent Application,yes,0,0,4,092-772-209-737-79X;;012-115-610-892-057;;029-345-240-075-930;;181-550-802-178-741,CN;;WO;;US,4,012-115-610-892-057;;092-772-209-737-79X;;029-345-240-075-930;;181-550-802-178-741,CN;;WO;;US,1,C07K14/315;;C12N15/70;;Y02A50/30;;C12N15/70;;C07K14/315;;C07K14/315;;C12N15/70,C07K14/315;;C12N15/70,,0,0,,,,PENDING
805,US,A1,US 2021/0332417 A1,005-340-388-835-074,2021-10-28,2021,US 202016984878 A,2020-08-04,CN 202010346628 A,2020-04-27,"Molecular Marker For Identifying Sanxan Gum and Its Synthetic Strain, Preparation Method And Application Thereof","The present invention relates to microorganism identification, and more particularly to a molecular marker for identifying Sanxan gum and its synthetic strain, and preparation method and application thereof. The molecular marker is prepared by PCR amplification using genomic DNA of Sphingomonas sp. with deposit number CGMCC No. 1650 or CGMCC No. 19480 as a template for PCR amplification, and the primer 1 with nucleotide sequence shown in SEQ No. 5 and the primer 2 with nucleotide sequence shown in SEQ No. 6 as primers. The present invention overcomes the problems that three gums must be separated from each other by cloning and sequencing and other operations in a compound gum system containing Sanxan gum, gellan gum and welan gum which results in cumbersome steps.",HEBEI XINHE BIOCHEMICAL CO LTD,ZHANG YU;;ZHANG GUOPEI;;ZHANG SHAOHUA,HEBEI XINHE BIOCHEMICAL CO. LTD (2020-07-15),https://lens.org/005-340-388-835-074,Patent Application,yes,0,3,3,005-340-388-835-074;;142-480-409-501-615;;169-549-576-150-501,CN;;US,3,005-340-388-835-074;;142-480-409-501-615;;169-549-576-150-501,CN;;US,13,C12Q1/689;;C12Q1/686;;C12Q1/689;;C12Q2600/158;;Y02A50/30;;C12Q1/689,C12Q1/689,,0,0,,,,DISCONTINUED
806,EP,A1,EP 4001398 A1,089-655-535-755-781,2022-05-25,2022,EP 19938066 A,2019-07-16,BR 2019050275 W,2019-07-16,MODIFIED TRICHODERMA FUNGAL STRAIN FOR THE PRODUCTION OF AN ENZYME COCKTAIL,"The present invention relates to a novel strain of Trichoderma comprising genetic modifications that enable the improved production of an enzyme cocktail, involving at least upregulation of the transcription factor Xyr1 according to SEQ ID No. 1; disruption of the gene ACE1 according to SEQ ID No. 2; disruption of the gene SLP1 according to SEQ ID No. 3; and expression of the gene Cel3a from Rasamsonia emersonii according to SEQ ID No. 4.",CENTRO NAC DE PESQUISA EM ENERGIA E MATERIAIS,MURAKAMI MARIO TYAGO;;FONSECA LUCAS MIRANDA;;PARREIRAS LUCAS SALERA,,https://lens.org/089-655-535-755-781,Patent Application,yes,0,0,6,089-655-535-755-781;;053-959-224-468-191;;188-679-783-609-754;;013-430-817-625-112;;173-010-734-173-190;;192-397-948-716-03X,EP;;CN;;WO;;US;;BR,6,192-397-948-716-03X;;053-959-224-468-191;;188-679-783-609-754;;089-655-535-755-781;;173-010-734-173-190;;013-430-817-625-112,CN;;EP;;WO;;US;;BR,6,C12N15/80;;C07K14/37;;C12N9/2445;;C12N9/58;;C12R2001/645;;C12R2001/885;;C12Y302/01021;;C12Y304/21014;;C07K14/37;;C12N9/0008;;C12N9/2445;;C12N9/485;;C12N9/58;;C12N15/52;;C12Y102/04002;;C12Y302/01021;;C12Y304/15001;;C12Y304/23018,C12N1/15;;C12N15/63;;C12R1/885,,0,0,,,,PENDING
807,CN,A,CN 115093985 A,105-329-169-734-730,2022-09-23,2022,CN 202210456761 A,2022-04-24,CN 202210456761 A,2022-04-24,Bifidobacterium lactis as well as fermentation method and application thereof,"The invention provides a novel bifidobacterium lactis, the preservation number of the novel bifidobacterium lactis is CGMCC (China General Microbiological Culture Collection Center) No.24307, and the preservation date is January 14, 2022. The bifidobacterium lactis fermentation product provided by the invention contains amino acids, small peptides, polysaccharides, B vitamins and other components beneficial to skin care, can strengthen stratum corneum metabolism, remove cell free radicals, inhibit lipid peroxidation, activate body repair performance and inhibit cell tyrosinase activity, and has the functions of repairing, whitening and resisting oxidation. The product is also rich in lactic acid and sodium lactate, is a main water-soluble acid in natural moisturizing factors of a human body, has strong hygroscopicity, effectively enhances hydration of cuticles, and prevents moisture loss of skin; the lactic acid and the sodium lactate form a buffer solution which has good affinity to the skin and can adjust the pH value of the skin.",SHENZHEN DUOWEISHENG HEALTH FOOD CO LTD,ZHANG XUANHE;;ZHANG YIGAN,,https://lens.org/105-329-169-734-730,Patent Application,no,4,4,2,105-329-169-734-730;;024-826-124-827-934,CN,2,105-329-169-734-730;;024-826-124-827-934,CN,0,A61K8/99;;A61Q19/00;;C12N1/04;;C12N1/20;;Y02A50/30,C12N1/20;;A61K8/99;;A61Q19/00;;C12N1/04;;C12R1/01,,1,0,,,"CHANG-HO KANG等: ""Antioxidant activity and short-chain fatty acid production of lactic acid bacteria isolated from Korean individuals and fermented foods"", 3 BIOTECH",ACTIVE
808,WO,A1,WO 2023/111930 A1,193-580-006-167-411,2023-06-22,2023,IB 2022062286 W,2022-12-15,IT 202100031637 A,2021-12-17,POWDERS FOR INHALATION AND PRODUCTION PROCESS THEREOF,"Pharmaceutical compositions in the form of dry powder for inhalation comprising a local anesthetic such as procaine, chloroprocaine, lidocaine, prilocaine, mepivacaine, bupivacaine, etidocaine, ropivacaine, and tetracaine or salts and/or solvates thereof and a hydrophilic biocompatible polymer, in particular hyaluronates, are described. The compositions of the invention are useful for the treatment of the cough.",UNIV DEGLI STUDI DI PARMA;;UNIV DEGLI STUDI DI FIRENZE;;AZIENDA OSPEDALIERO UNIV CAREGGI,BETTINI RUGGERO;;BUTTINI FRANCESCA;;FONTANA GIOVANNI;;LAVORINI FEDERICO,,https://lens.org/193-580-006-167-411,Patent Application,yes,1,0,9,176-230-134-749-663;;038-132-217-555-263;;193-580-006-167-411;;022-221-027-524-46X;;105-631-792-066-495;;103-428-172-758-945;;023-746-963-070-980;;004-027-553-058-700;;194-749-375-482-588,AU;;JP;;KR;;CN;;EP;;WO;;US;;IT;;CA,9,176-230-134-749-663;;038-132-217-555-263;;193-580-006-167-411;;022-221-027-524-46X;;103-428-172-758-945;;023-746-963-070-980;;105-631-792-066-495;;004-027-553-058-700;;194-749-375-482-588,AU;;KR;;JP;;CN;;EP;;WO;;US;;IT;;CA,0,A61K9/1652;;A61K9/0075;;A61K31/167;;A61P11/14;;A61K9/00;;A61K31/245;;A61K31/445;;A61K9/0075;;A61K9/1652;;A61K31/167;;A61K31/245;;A61K31/445;;A61P11/14;;A61P11/14;;A61K9/0075;;A61K9/1652;;A61K9/1682;;A61K31/167,A61K9/00;;A61K9/16;;A61K31/167;;A61P11/14,,1,1,006-911-486-052-076,11326346;;10.1053/ajem.2001.21724,"UDEZUE ET AL: ""Lidocaine inhalation for cough suppression"", AMERICAN JOURNAL OF EMERGENCY MEDICINE, CENTRUM PHILADELPHIA, PA, US, vol. 19, no. 3, May 2001 (2001-05-01), pages 206 - 207, XP005744179, ISSN: 0735-6757, DOI: 10.1053/AJEM.2001.21724",PENDING
809,US,A1,US 2021/0189482 A1,141-138-405-721-426,2021-06-24,2021,US 202017098101 A,2020-11-13,US 202017098101 A;;US 202016897052 A;;US 201414300453 A;;US 201314056636 A;;US 201213615183 A;;US 8068408 A;;US 6239108 P;;US 96753907 P;;US 96253007 P;;US 93111507 P;;US 92178707 P,2007-04-04,"Compositions, Devices, Systems, and Methods for Using a Nanopore","Devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore are provided. The devices and methods also determine (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.",UNIV CALIFORNIA,AKESON MARK A;;DEAMER DAVID W;;DUNBAR WILLIAM B;;CHEN ROGER JINTEH ARRIGO;;WILSON NOAH A,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2012-11-30),https://lens.org/141-138-405-721-426,Patent Application,yes,5,2,49,050-750-190-792-148;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;085-188-996-524-024;;172-840-139-122-539;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;110-967-876-084-674;;007-641-951-572-149;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;044-951-647-888-187;;192-696-239-263-373;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;082-548-722-396-405;;123-067-273-122-369;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;176-430-871-659-277,KR;;JP;;AU;;CN;;EP;;IL;;WO;;US;;CA,49,176-430-871-659-277;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;172-840-139-122-539;;085-188-996-524-024;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;007-641-951-572-149;;110-967-876-084-674;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;192-696-239-263-373;;044-951-647-888-187;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;123-067-273-122-369;;082-548-722-396-405;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;050-750-190-792-148,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA,0,C12Q1/6869;;G01N33/48721;;C25B3/29;;C12Q1/25;;G01N33/48721;;G01N33/573;;C25B3/29;;C12Q1/54;;C12Q1/6874;;G01N27/3278;;G01N27/4166;;C25B3/29;;C12Q1/6869;;G01N33/48721;;C12Q1/6874;;C12Q1/54;;G01N27/3278;;G01N27/4166,C12Q1/6874;;C25B3/29;;C12Q1/54;;C12Q1/6869;;G01N27/327;;G01N27/416;;G01N33/487,,0,0,,,,ACTIVE
810,US,A1,US 2022/0288222 A1,046-541-277-799-777,2022-09-15,2022,US 202017633548 A,2020-08-19,KR 20190101351 A;;KR 2020011030 W,2019-08-19,USE OF IMMUNOCYTOKINE COMPRISING INTERFERON-BETA OR VARIANT THEREOF FOR TREATING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE CANCER,"The present invention relates to a use of a recombinant protein in which an interferon-beta protein and an antibody binding to a HER2 antigen are fused for the purpose of treating cancer patients of which the HER2 expression level is IHC 1+ or higher. The recombinant protein can exhibit efficacy better than conventional antibody therapeutic agents through cancer-specific anti-cancer immune responses in patients, thereby being used for more patients, and thus is effectively usable as a novel agent for treating cancer.",GENOPHARM INC,JEONG HAE MIN;;LEE JI SUN,GENOPHARM INC (2022-04-01),https://lens.org/046-541-277-799-777,Patent Application,yes,0,0,7,025-522-823-185-604;;119-060-156-315-296;;136-052-100-308-720;;026-702-424-089-070;;046-541-277-799-777;;026-333-594-591-935;;078-546-722-423-991,KR;;JP;;EP;;CN;;WO;;US,7,025-522-823-185-604;;119-060-156-315-296;;136-052-100-308-720;;026-702-424-089-070;;046-541-277-799-777;;026-333-594-591-935;;078-546-722-423-991,KR;;JP;;EP;;CN;;WO;;US,5,A61K47/6849;;A61K38/215;;A61P35/00;;G01N33/57492;;A61K38/215;;A61K47/6813;;A61K47/6855;;A61P35/00;;C07K14/565;;C07K16/32;;C07K2317/73;;C07K2319/01;;C07K14/565;;A61K38/00;;A61K47/6813;;A61K47/6851;;C07K16/32;;C07K2319/00;;G01N33/57492;;A61K47/6813;;A61K38/21;;A61K47/6851;;A61K2039/505;;A61P35/00;;C07K14/565;;C07K16/32;;C07K2319/01,A61K47/68;;A61K38/21;;A61P35/00;;C07K14/565;;C07K16/32,,0,0,,,,PENDING
811,US,A1,US 2022/0008392 A1,137-523-674-542-57X,2022-01-13,2022,US 201917293155 A,2019-11-13,US 201917293155 A;;US 201862767215 P;;EP 2019081145 W,2018-11-14,METHODS OF TREATING CANCER,"Methods of treating Mcl-1 dependent cancers are described herein. The methods can include determining whether the cancer is Bfl-1 positive, and administering an inhibitor of CDK9 to a patient if the cancer is Bfl-1 positive.",ASTRAZENECA AB,CIDADO JUSTIN;;BOIKO SCOTT;;DREW LISA,ASTRAZENECA PHARMACEUTICALS LP (2019-01-14);;ASTRAZENECA UK LIMITED (2019-01-15);;ASTRAZENECA AB (2019-01-21),https://lens.org/137-523-674-542-57X,Patent Application,yes,0,0,8,174-385-461-150-221;;137-987-857-715-387;;139-105-304-073-711;;137-523-674-542-57X;;030-031-417-713-63X;;183-018-765-950-377;;030-239-254-710-356;;198-055-974-186-691,JP;;CN;;EP;;WO;;US;;TW,8,174-385-461-150-221;;137-987-857-715-387;;139-105-304-073-711;;137-523-674-542-57X;;030-031-417-713-63X;;183-018-765-950-377;;030-239-254-710-356;;198-055-974-186-691,JP;;CN;;EP;;WO;;US;;TW,0,G01N33/57426;;A61K31/4162;;A61K31/4439;;A61K45/06;;G01N33/57407;;G01N2333/82;;G01N2800/52;;A61K31/4162;;A61K31/4439;;G01N33/57407;;G01N33/57426;;G01N2333/82;;G01N2800/52,A61K31/4162;;A61K31/4439;;G01N33/574,,3,2,073-919-282-849-426;;073-919-282-849-426,29269870;;pmc5740070;;10.1038/s41598-017-18368-w;;29269870;;pmc5740070;;10.1038/s41598-017-18368-w,"Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, Burns C, Ditzler SH, Dixon CP, Beirne E, Gillespie KC, Kleinman EF, Klinghoffer RA. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. (cont'd) (Year: 2017);;(cont'd from above)...Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007. doi: 10.1038/s41598-017-18368-w. (Year: 2017);;AstraZeneca IMED Biotech Unit “Innovative Medicines and Early Development Biotech Unit -Year 2017” (hereinafter “AstraZeneca”). (Year: 2017)",DISCONTINUED
812,US,A1,US 2021/0355182 A1,131-609-974-849-02X,2021-11-18,2021,US 202016997198 A,2020-08-19,KR 20200057108 A,2020-05-13,RECOMBINANT VECTOR AND METHOD FOR PRODUCING RECOMBINANT FIBROBLAST GROWTH FACTOR 19 USING THE SAME,"A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ΔssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state, due to when not utilizing tags such as an existing fusion partner there is no change in the amino acid, which is a problem generated in the removal process.",UNIV NAT CHONNAM IND FOUND;;KOREA INST OCEAN SCI & TECH,KIM GEUN JOONG;;CHOI HYE JI;;CHEONG DAE EUN;;YOO SU KYOUNG;;LEE DONG HYUN;;PARK JAE HONG;;LEE JUNG HYUN;;YIM HYUNG SOON;;AN YOUNG JUN;;LEE KYEONG WON,INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (2020-07-21);;KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY (2020-07-21),https://lens.org/131-609-974-849-02X,Patent Application,yes,1,0,3,062-679-987-031-158;;195-095-696-529-97X;;131-609-974-849-02X,KR;;US,3,062-679-987-031-158;;195-095-696-529-97X;;131-609-974-849-02X,KR;;US,33,C12Y503/04001;;A61K38/00;;C07K14/50;;C07K2319/60;;C12N9/90;;C07K14/50;;A61K38/00;;C12N9/90;;C12Y503/04001,C07K14/50;;A61K38/00;;C12N9/90,,2,2,004-015-718-620-67X;;157-542-500-057-477,pmc6797904;;10.3389/fbioe.2019.00248;;31681738;;10.2147/rrbc.s83483,"Khambhati et al. (Frontiers in Bioeng. Biotech.7(248): 1-16, 2019);;Mitra et al. (Research and Reports in Biochemistry 6: 57-65, 2016)",ACTIVE
813,US,A1,US 2024/0324602 A1,077-233-992-197-580,2024-10-03,2024,US 202418740972 A,2024-06-12,CN 2022116331 W,2022-08-31,METHOD FOR RNAI FUNGICIDE GENERATING AND THE RNAI FUNGICIDE THEREOF,"A method for RNAi fungicide generating and the RNAi fungicide thereof. The method includes culturing bacteria in multi-aperture culture plate to express siRNA-binding polypeptide; extracting the siRNA-binding polypeptide from the bacteria; generating a pro-siRNA library product according to the siRNA-binding polypeptide, screening at least one target gene from the pro-siRNA library product to generate RNAi fungicide.",XIAOMO BIOTECH LTD,HUANG LINFENG;;HUANG PANPAN;;REN YUTIAN;;LI SHANQIN,XIAOMO BIOTECH LIMITED (2024-05-07);;XIAOMO (SHANGHAI) BIOTECH LIMITED (2024-12-20),https://lens.org/077-233-992-197-580,Patent Application,yes,0,0,3,167-690-474-242-384;;137-870-011-132-787;;077-233-992-197-580,CN;;WO;;US,3,167-690-474-242-384;;137-870-011-132-787;;077-233-992-197-580,CN;;WO;;US,0,C12N15/113;;A01N63/60;;C12N2310/14;;C12N2320/12;;C12N2330/31;;A01P3/00;;A01N63/60;;A01P3/00;;C12N15/113;;C12N2310/14;;C12N2320/12;;C12N2330/31,A01N63/60;;A01P3/00;;C12N15/113,,0,0,,,,PENDING
814,US,A1,US 2024/0091731 A1,173-261-425-075-155,2024-03-21,2024,US 202117768066 A,2021-04-19,US 202117768066 A;;US 202063012415 P;;US 2021/0027960 W,2020-04-20,DEVICES AND METHODS FOR MULTIPLEXING CHEMICAL SYNTHESIS,"The present invention relates to the field of chemical synthesis. Specifically, the present invention relates to methods, materials, compositions, and devices for multiplexing chemical synthesis. In particular, the present invention provides novel methods, materials, compositions, and devices to synthesize plurality of chemical compounds, including but not limited to nucleic acids, peptides, saccharides, and phospholipids. Specifically, the present invention provides methods, materials, compositions, and devices to first form plurality of isolated wells on a solid substrate and then to carry out plurality of chemical reactions in the isolated wells, in parallel, and on the same substrate.",LC SCIENCES,ZHAO XIAOCHUAN;;ZHANG XIAOLIN,BOART LONGYEAR COMPANY (2023-09-01),https://lens.org/173-261-425-075-155,Patent Application,yes,2,0,4,068-393-580-709-603;;022-419-230-109-644;;152-194-123-155-812;;173-261-425-075-155,EP;;WO;;US,4,173-261-425-075-155;;022-419-230-109-644;;152-194-123-155-812;;068-393-580-709-603,EP;;WO;;US,0,C08F2/48;;B01J19/0046;;B01J2219/00585;;B01J2219/00623;;B01J2219/00664;;B01J2219/00675;;B01J2219/00711;;B01J2219/00621;;B01J2219/00668;;B01J2219/00722;;B01J2219/00725;;B01J2219/00599;;B01L3/5085;;B01L2200/12;;B01J2219/00608;;B01J2219/00612;;B01J2219/00632;;B33Y10/00;;B33Y30/00;;B01J19/0046;;B01J2219/00585;;B01J2219/00599;;B01J2219/00621;;B01J2219/00623;;B01J2219/00664;;B01J2219/00675;;B01J2219/00711;;B01J2219/00722,B01J19/00;;B33Y10/00;;B33Y30/00,,1,0,,,"Benz et al., Marrying chemistry with biology by combining on-chip solution-based combinatorial synthesis and cellular screening, Nature Communications, 2019, 10(2879), 1-10. (Year: 2019)",PENDING
815,WO,A1,WO 2024/154002 A1,035-837-012-884-347,2024-07-25,2024,IB 2024000031 W,2024-01-19,US 202363480575 P,2023-01-19,GLYCOSYLATED ANIMAL PROTEIN EXPRESSION IN PLANT CELLS,"A method for animal protein production in a plant cell is disclosed. The method comprises designing a DNA vector for expression of an animal gene; inserting the DNA vector into the plant cell; grow the cells in defined media under defined conditions. In certain embodiments, the protein will remain in the Endoplasmic reticulum preventing downstream glycan modification. The addition of H/KDEL fused to the C-Terminal CDS of the protein will keep the protein from moving out of the endoplasmic reticulum. In some embodiments, the protein will pass from the endoplasmic reticulum to the Golgi apparatus and undergo additional modifications. In some embodiments, the addition of a vacuole targeting signal peptide fused to the C-terminal CDS of the protein directs the protein to a vacuole. In certain embodiments, the protein is passed along the endoplasmic reticulum, the Golgi apparatus, and undergo further modifications in the apoplast.",ASTERIX FOODS LTD,EVEN DAN,,https://lens.org/035-837-012-884-347,Patent Application,yes,4,0,3,035-837-012-884-347;;024-133-025-341-806;;175-187-105-811-395,AU;;IL;;WO,3,024-133-025-341-806;;035-837-012-884-347;;175-187-105-811-395,AU;;IL;;WO,13,G01N33/5097;;G01N2440/38;;C07K2319/02;;C07K14/79;;C12N15/8257;;C12N15/8221,C07K14/47;;C07K19/00;;C12N5/04;;C12N5/10;;C12N15/12;;C12N15/82;;G01N33/68,,0,0,,,,PENDING
816,EP,A1,EP 3798616 A1,117-225-361-290-833,2021-03-31,2021,EP 19807781 A,2019-05-21,CN 201810491322 A;;CN 2019087829 W,2018-05-21,"CHEMICAL LUMINESCENCE ANALYSIS AND MEASUREMENT METHOD, SYSTEM USING SAME, AND KIT","A chemical luminescence immune analysis and measurement method, a system using the chemical luminescence immune analysis and measurement method, and a kit are disclosed. The method broadens a detection range and indicates an HD-HOOK sample or a sample that is beyond the detection range by way of selecting two signal values from signal values that are read in multiple times.",BEYOND DIAGNOSTICS SHANGHAI CO LTD;;CHEMCLIN DIAGNOSTICS CO LTD,YANG YANG;;ZHAO WEIGUO;;LIU YUHUI;;LI LIN,"CHEMCLIN DIAGNOSTICS (SHANGHAI) CO., LTD. (2022-02-16);;CHEMCLIN DIAGNOSTICS CO., LTD. (2022-02-16)",https://lens.org/117-225-361-290-833,Patent Application,yes,0,0,6,130-183-021-962-013;;180-480-333-908-643;;117-225-361-290-833;;120-445-954-803-06X;;191-635-388-883-589;;165-757-929-916-084,JP;;CN;;EP;;WO;;US,6,165-757-929-916-084;;180-480-333-908-643;;117-225-361-290-833;;120-445-954-803-06X;;191-635-388-883-589;;130-183-021-962-013,JP;;EP;;CN;;WO;;US,0,G01N21/76;;G01N33/53;;G01N33/582;;G01N21/76;;G01N33/53;;G01N33/557;;G01N21/76;;G01N33/53,G01N21/76,,0,0,,,,DISCONTINUED
817,EP,A1,EP 4039805 A1,144-517-217-424-108,2022-08-10,2022,EP 20869418 A,2020-09-25,CN 201910918850 A;;CN 2020117818 W,2019-09-26,PREPARATION OF GLYCOSYLTRANSFERASE UGT76G1 MUTANT AND USE THEREOF,"Provided are a glycosyltransferase UGT76G1 mutant, an isolated polynucleotide, a carrier, a production method, and a composition and a kit for the glycosylation of substrates. Further provided are a method for increasing the catalytic activity of the glycosyltransferase UGT76G1 mutant, and a method for promoting the glycosylation of flavone compounds and the use thereof. The glycosyltransferase UGT76G1 mutant is subjected to mutations at positions corresponding to positions 87, 199, 204 or 379 of SEQ ID NO: 1, and significantly improves the transformation activity of substrates of the flavone compounds.",CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES,WANG YONG;;SUN YUWEI;;LIU ZHIFENG;;CHEN ZHUO;;LI JIANHUA;;LIU HAILI;;LV HUAJUN,,https://lens.org/144-517-217-424-108,Patent Application,yes,0,0,6,129-536-495-367-027;;137-111-641-867-107;;190-527-729-314-815;;177-535-775-912-743;;159-428-754-840-086;;144-517-217-424-108,EP;;CN;;WO;;US,6,129-536-495-367-027;;137-111-641-867-107;;144-517-217-424-108;;177-535-775-912-743;;159-428-754-840-086;;190-527-729-314-815,EP;;CN;;WO;;US,15,C12N9/1048;;C12N15/63;;C12N15/70;;C12P19/56;;C12N9/1051;;C12N15/70;;C12P17/162;;C12N9/1051,C12N9/10;;C12N15/54;;C12N15/63;;C12P17/16,,0,0,,,,PENDING
818,US,A1,US 2021/0163560 A1,187-288-920-634-493,2021-06-03,2021,US 201816608706 A,2018-04-11,CN 201710302732 A;;CN 2018082669 W,2017-04-28,"HUMAN FGF21 MUTANT, PREPARATION METHOD AND USE THEREOF","The present disclosure relates to a human FGF21 mutant, a preparation method and a use thereof, and specifically relates to a human fibroblast growth factor 21 (FGF21) mutant, a gene encoding the same, and a method for preparing the mutant and a method of using the mutant for treating type 2 diabetes, obesity, dyslipidemia or metabolic disorders.",HEFEI INST PHYSICAL SCI CAS,WANG JUNFENG;;ZHAO HONGXIN;;ZHU LEI,HEIFEI ZHONGKE LONGWOOD BIOTECHNOLOGY CO. LTD (2022-08-05);;HEFEI INSTITUTES OF PHYSICAL SCIENCE CHINESE ACADEMY OF SCIENCES (2021-02-05),https://lens.org/187-288-920-634-493,Patent Application,yes,2,0,9,110-343-974-479-703;;187-288-920-634-493;;021-981-963-013-633;;047-314-527-003-791;;028-014-287-755-463;;174-986-291-769-163;;034-003-963-084-794;;131-594-295-844-615;;033-015-433-431-690,JP;;EP;;CN;;WO;;US,9,110-343-974-479-703;;187-288-920-634-493;;021-981-963-013-633;;174-986-291-769-163;;028-014-287-755-463;;047-314-527-003-791;;034-003-963-084-794;;131-594-295-844-615;;033-015-433-431-690,JP;;EP;;CN;;WO;;US,18,C07K14/50;;A61K38/00;;C07K14/50;;A61K38/00;;C07K14/50;;A61K38/00;;A61K38/1825,C07K14/50,,0,0,,,,ACTIVE
819,US,A1,US 2025/0041252 A1,004-027-553-058-700,2025-02-06,2025,US 202218718808 A,2022-12-15,IT 202100031637 A;;IB 2022062286 W,2021-12-17,POWDERS FOR INHALATION AND PRODUCTION PROCESS THEREOF,"Pharmaceutical compositions in the form of dry powder for inhalation comprising a local anesthetic such as procaine, chloroprocaine, lidocaine, prilocaine, mepivacaine, bupivacaine, etidocaine, ropivacaine, and tetracaine or salts and/or solvates thereof and a hydrophilic biocompatible polymer, in particular hyaluronates, are described. The compositions of the invention are useful for the treatment of the cough.",UNIV DEGLI STUDI DI PARMA;;UNIV DEGLI STUDI DI FIRENZE;;AZIENDA OSPEDALIERO UNIV CAREGGI;;UNIV DEGLI STUDI DI PARMA 50%;;UNIV DEGLI STUDI DI FIRENZE 25%;;AZIENDA OSPEDALIERO UNIV CAREGGI 25%,BETTINI RUGGERO;;BUTTINI FRANCESCA;;FONTANA GIOVANNI;;LAVORINI FEDERICO,UNIVERSITA' DEGLI STUDI DI FIRENZE (25%) (2024-06-03);;UNIVERSITA' DEGLI STUDI DI PARMA (50%) (2024-06-03);;AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (25%) (2024-06-03),https://lens.org/004-027-553-058-700,Patent Application,yes,0,0,9,176-230-134-749-663;;038-132-217-555-263;;193-580-006-167-411;;022-221-027-524-46X;;105-631-792-066-495;;103-428-172-758-945;;023-746-963-070-980;;004-027-553-058-700;;194-749-375-482-588,AU;;JP;;KR;;CN;;EP;;WO;;US;;IT;;CA,9,176-230-134-749-663;;038-132-217-555-263;;193-580-006-167-411;;022-221-027-524-46X;;103-428-172-758-945;;023-746-963-070-980;;105-631-792-066-495;;004-027-553-058-700;;194-749-375-482-588,AU;;KR;;JP;;CN;;EP;;WO;;US;;IT;;CA,0,A61K9/1652;;A61K9/0075;;A61K31/167;;A61P11/14;;A61K9/00;;A61K31/245;;A61K31/445;;A61K9/0075;;A61K9/1652;;A61K31/167;;A61K31/245;;A61K31/445;;A61P11/14;;A61P11/14;;A61K9/0075;;A61K9/1652;;A61K9/1682;;A61K31/167,A61K31/167;;A61K9/00;;A61K9/16;;A61P11/14,,0,0,,,,PENDING
820,US,A1,US 2021/0171973 A1,085-095-259-783-55X,2021-06-10,2021,US 202117141308 A,2021-01-05,US 202117141308 A;;CN 201810724563 A;;US 201917257595 A;;CN 2019094632 W,2018-07-04,Method of Obtaining Multileaflet Medicago Sativa Materials by Means of MsPALM1 Artificial Site-Directed Mutants,"Disclosed is a method for obtaining multileaflet Medicago sativa materials by means of MsPALM1 artificial site-directed mutants. The method comprises: selecting a target site from an exon region of a compound leaf developmental regulatory gene MsPALM1 of Medicago sativa and constructing a plant CRISPR/Cas9 editing recombinant vector MsCRISPR/Cas9::PALM1 and introducing the vector into Medicago sativa cells and regenerating into plants, cutting and repairing to cause a loss-of-function mutation in the MsPALM1 gene of Medicago sativa cells, and then screening the mutant plants by restriction endonuclease digestion and/or targeted deep sequencing of the target sites of the regenerated plants to obtain lines carrying four MsPALM1 allelic genes with simultaneous loss of function mutation. After phenotypic identification, it was confirmed that the compound leaves of the regenerated plants changed from three leaflets to five leaflets. The method can quickly obtain multileaflet Medicago sativa materials with a short breeding period and stable trait.",GUANGDONG SANJIE FORAGE BIOTECHNOLOGY CO LTD,CHEN HAITAO;;WANG WEN;;XIE XIONGPING;;QIU QIANG;;SHANG ZHANHUAN;;SU KEXIAN;;HE HUI,GUANGDONG SANJIE FORAGE BIOTECHNOLOGY CO. LTD (2020-12-22),https://lens.org/085-095-259-783-55X,Patent Application,yes,0,3,2,085-095-259-783-55X;;035-445-667-521-034,US,11,028-881-695-080-78X;;116-143-383-253-974;;103-461-120-771-667;;096-561-844-852-776;;085-095-259-783-55X;;147-508-737-591-692;;169-371-170-481-698;;132-611-789-460-679;;187-419-949-833-776;;141-108-833-328-607;;035-445-667-521-034,AU;;CN;;EP;;WO;;US;;CA,2,C12N15/8262;;C12N15/8213;;C12N2310/20;;C12N15/8213;;C12N15/8262,C12N15/82,,0,0,,,,ACTIVE
821,WO,A2,WO 2023/092128 A2,110-850-576-421-182,2023-05-25,2023,US 2022/0080254 W,2022-11-21,US 202163281872 P,2021-11-22,APTAMERS FOR THE REVERSIBLE INHIBITION OF DNA POLYMERASES,Described herein are methods and compositions for improved polymerase chain reaction (PCR). In one aspect the methods and compositions include improved aptamers to reversibly inhibit polymerase and exonuclease activity of the polymerase enzyme.,INTEGRATED DNA TECH INC;;RUPP SUSAN MARIE;;SHUBHAM SHAMBHAVI;;ROSE SCOTT;;CAGLE BRIANNA,RUPP SUSAN MARIE;;SHUBHAM SHAMBHAVI;;ROSE SCOTT;;CAGLE BRIANNA,,https://lens.org/110-850-576-421-182,Patent Application,yes,0,0,8,175-630-631-944-554;;022-288-857-052-891;;004-734-426-675-32X;;110-850-576-421-182;;098-858-215-163-572;;078-182-363-040-256;;075-616-129-828-455;;051-194-538-644-878,AU;;JP;;KR;;EP;;CN;;WO;;CA,8,175-630-631-944-554;;004-734-426-675-32X;;022-288-857-052-891;;110-850-576-421-182;;098-858-215-163-572;;078-182-363-040-256;;075-616-129-828-455;;051-194-538-644-878,JP;;AU;;KR;;EP;;CN;;WO;;CA,9,C12N15/115;;C12Q1/6848;;C12N9/1252;;C12Q1/686;;C12N15/115;;C12N9/1252;;C12Q1/6848;;C12Q1/686;;C12Q2525/205,C12N15/115;;C12N9/12;;C12Q1/6848,,2,1,017-216-732-209-839,10.1016/0196-8858(81)90046-4,"WANG ET AL., BIOTECH. ADV., vol. 37, 2019, pages 28 - 50;;SMITHWATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 4, 1981, pages 82 - 489",PENDING
822,EP,A1,EP 4019050 A1,078-546-722-423-991,2022-06-29,2022,EP 20853969 A,2020-08-19,KR 20190101351 A;;KR 2020011030 W,2019-08-19,USE OF IMMUNOCYTOKINE COMPRISING INTERFERON-BETA OR VARIANT THEREOF FOR TREATING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE CANCER,"The present invention relates to a use of a recombinant protein in which an interferon-beta protein and an antibody binding to a HER2 antigen are fused for the purpose of treating cancer patients of which the HER2 expression level is IHC 1+ or higher. The recombinant protein can exhibit efficacy better than conventional antibody therapeutic agents through cancerspecific anti-cancer immune responses in patients, thereby being used for more patients, and thus is effectively usable as a novel agent for treating cancer.",GENOPHARM INC,JEONG HAE MIN;;LEE JI SUN,,https://lens.org/078-546-722-423-991,Patent Application,yes,0,0,7,025-522-823-185-604;;119-060-156-315-296;;136-052-100-308-720;;026-702-424-089-070;;046-541-277-799-777;;026-333-594-591-935;;078-546-722-423-991,KR;;JP;;EP;;CN;;WO;;US,7,025-522-823-185-604;;119-060-156-315-296;;136-052-100-308-720;;026-702-424-089-070;;046-541-277-799-777;;026-333-594-591-935;;078-546-722-423-991,KR;;JP;;EP;;CN;;WO;;US,5,A61K47/6849;;A61K38/215;;A61P35/00;;G01N33/57492;;A61K38/215;;A61K47/6813;;A61K47/6855;;A61P35/00;;C07K14/565;;C07K16/32;;C07K2317/73;;C07K2319/01;;C07K14/565;;A61K38/00;;A61K47/6813;;A61K47/6851;;C07K16/32;;C07K2319/00;;G01N33/57492;;A61K47/6813;;A61K38/21;;A61K47/6851;;A61K2039/505;;A61P35/00;;C07K14/565;;C07K16/32;;C07K2319/01,A61K47/68;;A61K38/21;;A61K39/00;;A61P35/00;;C07K14/565;;C07K16/32,,0,0,,,,DISCONTINUED
823,EP,A1,EP 4083061 A1,006-655-751-386-094,2022-11-02,2022,EP 21171407 A,2021-04-30,EP 21171407 A,2021-04-30,FUSION PROTEINS AND USE THEREOF IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY,"There are disclosed fusion proteins comprising an anti-CD3 antibody and an autoantigen involved in autoimmune diseases, nucleic acid encoding the same, pharmaceutical composition comprising them and the use thereof for the treatment of autoimmune diseases and particularly of membranous nephropathy.",KILOMETRO ROSSO SPA,PERICO LUCA;;CASIRAGHI FEDERICA;;BENIGNI ARIELA;;REMUZZI GIUSEPPE,,https://lens.org/006-655-751-386-094,Patent Application,yes,2,0,5,143-237-748-502-619;;012-482-702-203-153;;005-164-869-865-506;;006-655-751-386-094;;150-616-133-101-564,EP;;CN;;WO;;US,5,143-237-748-502-619;;012-482-702-203-153;;005-164-869-865-506;;006-655-751-386-094;;150-616-133-101-564,EP;;CN;;WO;;US,16,C07K14/705;;C12N15/62;;A61P13/12;;C07K16/2809;;C07K2317/622;;C07K2319/21;;C07K14/4713;;C07K2319/33;;A61P13/12;;A61K38/00;;C07K14/705;;C07K16/2809;;C07K2317/622;;C07K2319/21;;C07K2319/33;;C12N15/86;;C12N2740/15043,C07K14/705;;A61K39/395;;A61P13/12;;C07K16/18;;C07K19/00;;C12N15/09;;C12N15/62,,25,22,012-474-208-722-046;;083-945-009-744-393;;004-440-694-419-118;;003-483-997-494-338;;028-625-702-042-165;;033-401-386-102-67X;;039-099-146-869-04X;;019-123-839-807-185;;078-511-847-986-499;;030-920-142-183-595;;005-410-206-287-929;;002-469-553-486-727;;128-489-443-275-838;;012-474-208-722-046;;003-483-997-494-338;;005-606-531-569-393;;004-440-694-419-118;;079-410-468-296-790;;083-945-009-744-393;;004-330-410-830-726;;010-342-021-874-640;;028-030-401-652-127,16213416;;10.1016/s1359-6446(05)03554-3;;10.1681/asn.2013121315;;pmc4310656;;25205735;;10.1056/nejmoa0810457;;pmc2762083;;19571279;;10.1016/j.pharmthera.2017.12.002;;29269044;;27373970;;10.1016/j.clim.2016.06.011;;pmc1447637;;10983209;;10.2105/ajph.90.9.1463;;29143151;;pmc5688039;;10.1007/s13317-017-0100-y;;25804280;;10.1681/asn.2014070640;;pmc4587688;;10.1681/asn.2016091022;;28487395;;pmc5576929;;10.1038/nrneph.2017.92;;28669992;;10.1126/scitranslmed.aav1648;;30842314;;pmc8201923;;pmc5343513;;27365313;;10.1126/science.aaf6756;;10.1007/s11912-019-0759-5;;30715609;;16213416;;10.1016/s1359-6446(05)03554-3;;10.1016/j.pharmthera.2017.12.002;;29269044;;10.1172/jci72270;;pmc4089468;;24892704;;10.1056/nejmoa0810457;;pmc2762083;;19571279;;10.1681/asn.2014050502;;pmc4310666;;25288605;;10.1681/asn.2013121315;;pmc4310656;;25205735;;25394321;;pmc4278759;;10.1056/nejmoa1409354;;25573986;;10.1182/blood-2014-02-555169;;26567246;;pmc4849812;;10.1681/asn.2014111061,"WOLF ET AL: ""BiTEs: bispecific antibody constructs with unique anti-tumor activity"", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 18, 15 September 2005 (2005-09-15), pages 1237 - 1244, XP005103829, ISSN: 1359-6446, DOI: 10.1016/S1359-6446(05)03554-3;;KAO LIYO ET AL: ""Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy"", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 26, no. 2, 1 February 2015 (2015-02-01), pages 291 - 301, XP009187063, ISSN: 1533-3450, [retrieved on 20140909], DOI: 10.1681/ASN.2013121315;;BECK ET AL: ""M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, no. 1, 2 July 2009 (2009-07-02), US, pages 11 - 21, XP055568290, ISSN: 0028-4793, DOI: 10.1056/NEJMoa0810457;;KRISHNAMURTHY ANURADHA ET AL: ""Bispecific antibodies for cancer therapy: A review"", PHARMACOLOGY & THERAPEUTICS, ELSEVIER, GB, vol. 185, 18 December 2017 (2017-12-18), pages 122 - 134, XP085376489, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2017.12.002;;DICKINSON BONNY L ED - HEDRICH CHRISTIAN: ""Unraveling the immunopathogenesis of glomerular disease"", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 169, 30 June 2016 (2016-06-30), pages 89 - 97, XP029675863, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2016.06.011;;""NCBI"", Database accession no. NP _031392.3;;WALSH SJRAU LM: ""Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States"", AM. J. PUBLIC HEALTH., vol. 90, no. 9, 2000, pages 1463 - 1466;;""Autoimmune Diseases"", NATL. INST. ENVIRON. HEALTH SCI.;;THE COST BURDEN OF AUTOIMMUNE DISEASE: THE LATEST FRONT IN THE WAR ON HEALTHCARE SPENDING, vol. 14;;DU FHMILLS EAMAO-DRAAYER Y: ""Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment"", AUTOIMMUN. HIGHLIGHTS., vol. 8, no. 1, 2017, pages 12;;RUGGENENTI PDEBIEC HRUGGIERO B ET AL.: ""Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy"", J. AM. SOC. NEPHROL. JASN., vol. 26, no. 10, 2015, pages 2545 - 2558;;VAN DEN BRAND JAJGRUGGENENTI PCHIANCA A ET AL.: ""Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy"", J. AM. SOC. NEPHROL. JASN., 2017;;RUGGENENTI PFERVENZA FCREMUZZI G: ""Treatment of membranous nephropathy: time for a paradigm shift"", NAT. REV. NEPHROL., 2017;;KANSAL RRICHARDSON NNEELI I ET AL.: ""Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus"", SCI. TRANSL. MED., vol. 11, 2019, pages 482;;ELLEBRECHT CTBHOJ VGNACE A ET AL.: ""Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease"", SCIENCE, vol. 353, no. 6295, 2016, pages 179 - 184, XP055434542, DOI: 10.1126/science.aaf6756;;DEMICHELIS-GOMEZ RPEREZ-SAMANO DBOURLON C: ""Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?"", CURR. ONCOL. REP., vol. 21, no. 2, 2019, pages 17, XP036719451, DOI: 10.1007/s11912-019-0759-5;;WOLF EHOFMEISTER RKUFER PSCHLERETH BBAEUERLE PA: ""BiTEs: bispecific antibody constructs with unique anti-tumor activity"", DRUG DISCOV. TODAY., vol. 10, no. 18, 2005, pages 1237 - 1244, XP005103829, DOI: 10.1016/S1359-6446(05)03554-3;;KRISHNAMURTHY AJIMENO A: ""Bispecific antibodies for cancer therapy: A review"", PHARMACOL. THER., vol. 185, 2018, pages 122 - 134, XP085376489, DOI: 10.1016/j.pharmthera.2017.12.002;;BECK LHSALANT DJ: ""Membranous nephropathy: from models to man"", J. CLIN. INVEST., vol. 124, no. 6, 2014, pages 2307 - 2314;;BECK LHBONEGIO RGBLAMBEAU G ET AL.: ""M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy"", N. ENGL. J. MED., vol. 361, no. 1, 2009, pages 11 - 21, XP055568290, DOI: 10.1056/NEJMoa0810457;;FRESQUET MJOWITT TAGUMMADOVA J ET AL.: ""Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy"", J. AM. SOC. NEPHROL. JASN., vol. 26, no. 2, 2015, pages 302 - 313, XP055224195, DOI: 10.1681/ASN.2014050502;;KAO LLAM VWALDMAN MGLASSOCK RJZHU Q: ""Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy"", J. AM. SOC. NEPHROL. JASN., vol. 26, no. 2, 2015, pages 291 - 301, XP009187063, DOI: 10.1681/ASN.2013121315;;TOMAS NMBECK LHMEYER-SCHWESINGER C ET AL.: ""Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy"", N. ENGL. J. MED., vol. 371, no. 24, 2014, pages 2277 - 2287, XP009181856, DOI: 10.1056/NEJMoa1409354;;MEI HEWIRRIES IFROLICH D ET AL.: ""A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow"", BLOOD, vol. 125, no. 11, 2015, pages 1739 - 1748;;SEITZ-POLSKI BDOLLA GPAYRE C ET AL.: ""Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy"", J. AM. SOC. NEPHROL., vol. 27, no. 5, 2016, pages 1517 - 1533, XP002800680, DOI: 10.1681/ASN.2014111061",DISCONTINUED
824,US,A1,US 2021/0071263 A1,012-298-096-481-718,2021-03-11,2021,US 202017013947 A,2020-09-08,CN 201810190175 A;;CN 2018086201 W,2018-03-08,"Tumor Biomarker and Application Thereof, and Tumor Detection Kit","Disclosed are a tumor biomarker and application thereof, and a tumor detection kit. Patients suffering from non-small cell lung cancer, containing an EML4-ALK or SLC34A2-ROS1 fusion gene, have a specific circular RNA in blood. The base sequences of the circular RNA are represented by SEQ ID NOS. 1-6. The circular RNA is associated with non-small cell lung cancer, stably and constantly exists in plasma samples, and has high specificity and effectiveness, and thus can be used as a biomarker for tumor detection. Reagents such as primers and probes for detecting the circular RNA can be used for preparing the tumor detection kit.",UNIV SICHUAN,PENG YONG;;WEI YUQUAN;;TAN SHUANGYAN;;WU KE,SICHUAN UNIVERSITY (2020-09-04),https://lens.org/012-298-096-481-718,Patent Application,yes,0,1,5,102-572-447-770-522;;102-893-168-881-18X;;091-182-649-245-936;;010-731-040-984-107;;012-298-096-481-718,CN;;WO;;US,5,102-572-447-770-522;;102-893-168-881-18X;;091-182-649-245-936;;010-731-040-984-107;;012-298-096-481-718,CN;;WO;;US,371,C12Q1/6886;;C12Q2600/112;;C12Q2600/118;;C12Q2600/178;;C12Q1/6886;;C12Q2600/156;;C12Q2600/178;;C12Q1/6886;;C12Q2600/156,C12Q1/6886,,0,0,,,,ACTIVE
825,US,A1,US 2024/0082205 A1,046-013-815-508-641,2024-03-14,2024,US 202118270071 A,2021-12-29,US 202118270071 A;;US 202063131638 P;;CN 2021142454 W,2020-12-29,USE OF PHTHALIDE COMPOUNDS IN TREATMENT OF MENINGIOMA,"The present invention relates to the use of compounds of formula (I) and formula (II) and/or pharmaceutically acceptable salts of the aforementioned compounds in the treatment of meningioma and the reduction of the recurrence rate of meningioma. In formulas (I) and (II), R1 is C1-C20 alkyl, C3-C10 cycloalkyl, C6-C20 aryl, C1-C20 alkoxy, C6-C20 aryloxy, or halogen; p is 0 to 3; R2 is H, C1-C20 alkyl, or C6-C20 aryl; and R3 is H, C1-C20 alkyl, C3-C10 cycloalkyl, or C6-C20 aryl.",EVERFRONT BIOTECH INC,LIN SHINN-ZONG;;CHIU TSUNG-LANG;;HARN HORNG-JYH;;CHIOU TZYY-WEN;;LEE JUI-HAO,EVERFRONT BIOTECH INC (2023-06-07),https://lens.org/046-013-815-508-641,Patent Application,yes,0,0,2,046-013-815-508-641;;151-813-315-210-824,WO;;US,2,046-013-815-508-641;;151-813-315-210-824,WO;;US,0,A61K31/343;;A61K31/192;;A61P35/00;;A61K31/222;;A61K31/7068;;A61K9/0019;;A61K45/06;;A61K31/365;;A61K31/235;;A61K31/17;;A61K31/4164;;A61K31/513;;A61P35/00;;A61K9/0024;;A61K31/222;;A61K31/343;;A61K45/06,A61K31/343;;A61K9/00;;A61K31/222;;A61K45/06;;A61P35/00,,0,0,,,,PENDING
826,EP,A1,EP 4471123 A1,058-708-552-290-770,2024-12-04,2024,EP 22923646 A,2022-12-29,CN 202210096134 A;;CN 2022143105 W,2022-01-26,METHOD FOR CONSTRUCTING THREONINE-PRODUCING ENGINEERED BACTERIUM,"The present invention provides a method for constructing a threonine-producing engineered bacterium. According to the present invention, a 2-methylcitrate synthase 1-inactivated strain (Corynebacterium) is applied to the production of threonine, and the production of threonine produced by the 2-methylcitrate synthase 1-inactivated strain is increased by about 42% compared with that produced by an unengineered strain. When the application of the 2-methylcitrate synthase 1-inactivated strain is further combined with enhanced expression of at least one of aspartate aminotransferase, aspartate kinase, homoserine dehydrogenase, threonine synthase, NAD kinase, fructose-1,6-bisphosphatase 2 and the like in the threonine synthesis pathway, the production of threonine is improved. The method provides a new way for large-scale production of threonine and has high application value.",LANGFANG MEIHUA BIOTECHNOLOGY DEV CO LTD,KANG PEI;;GONG WEIBO;;HE JUN;;LI YAN,,https://lens.org/058-708-552-290-770,Patent Application,yes,0,0,8,030-315-147-311-298;;046-778-799-837-027;;131-718-168-559-32X;;082-039-736-012-876;;162-730-837-943-940;;058-708-552-290-770;;039-829-946-529-117;;041-697-207-898-576,JP;;AU;;CN;;EP;;WO;;US;;MX,8,030-315-147-311-298;;046-778-799-837-027;;131-718-168-559-32X;;082-039-736-012-876;;162-730-837-943-940;;058-708-552-290-770;;039-829-946-529-117;;041-697-207-898-576,JP;;AU;;CN;;EP;;WO;;US;;MX,0,C12N9/1025;;C12N9/1096;;C12N9/1217;;C12N9/0006;;C12N9/88;;C12N9/1205;;C12N9/16;;C12N15/52;;C12N15/77;;C12P13/08;;C12Y203/03005;;C12Y207/02004;;C12Y206/01001;;C12Y101/01003;;C12Y402/03001;;C12Y207/01023;;C12Y301/03011;;C12N15/77;;C12N9/0004;;C12R2001/15;;C12N9/10;;C12P13/08;;C12N9/14;;C12N9/88;;C12N15/52;;C12N9/1096;;C12N9/1025;;C12N9/1217;;C12N9/0006;;C12N9/1205;;C12N9/16;;C12N9/1029;;C12P13/06;;C12R2001/15;;C12N9/0006;;C12N9/1025;;C12N9/1096;;C12N9/1205;;C12N9/1217;;C12N9/16;;C12N9/88;;C12N15/77;;C12P13/08;;C12Y101/01003;;C12Y203/03005;;C12Y206/01001;;C12Y207/01023;;C12Y207/02004;;C12Y301/03011;;C12Y402/03001,C12N1/21;;C12N15/63;;C12N15/77;;C12P13/08;;C12R1/15,,0,0,,,,PENDING
827,US,A1,US 2020/0399575 A1,189-828-978-091-599,2020-12-24,2020,US 202016893510 A,2020-06-05,DE 102019115147 A,2019-06-05,BIOCOMPATIBLE COMPOSITE ELEMENTS AND METHODS FOR PRODUCING,"A biocompatible composite element for a bioreactor is provided that includes an outer frame and an inner component. The outer frame is a polymeric material. The outer frame can be inseparably attached to a wall of the bioreactor. The inner component is a transparent material selected from a group consisting of glass, sapphire, and glass ceramic. The inner component is secured in the outer component in an inseparable hermetically tight manner. The inner component is configured for a spectral process control through the transparent material of the inner component.",SCHOTT AG,OTT CHRISTIAN;;HETTLER ROBERT;;STANGL CHRISTOPH;;BLÜMEL HELENA;;ECKER REINHARD,SCHOTT AG (2020-09-15),https://lens.org/189-828-978-091-599,Patent Application,yes,28,3,11,062-891-204-779-951;;074-429-346-062-265;;009-497-315-135-908;;125-712-720-966-021;;191-594-096-241-172;;190-502-243-622-905;;189-828-978-091-599;;191-077-271-939-151;;124-082-430-864-190;;021-430-658-621-148;;097-631-551-137-960,DE;;JP;;CN;;EP;;US,12,062-891-204-779-951;;125-712-720-966-021;;009-497-315-135-908;;074-429-346-062-265;;191-594-096-241-172;;190-502-243-622-905;;189-828-978-091-599;;191-077-271-939-151;;021-430-658-621-148;;144-519-678-671-223;;124-082-430-864-190;;097-631-551-137-960,DE;;JP;;EP;;CN;;US,0,C12M23/22;;C12M23/20;;C12M37/04;;C12M41/00;;C12M37/04;;C12M23/22;;C12M41/46;;C12M23/48;;C12M23/28;;B32B1/08;;B32B27/288;;B32B27/32;;B32B2307/412;;C08J7/08;;C08J2323/06;;C08J2371/10;;C12M23/02;;C12M23/22;;C12M23/46;;C12M23/06;;C12M31/02;;C12M37/04,C12M3/00;;B29C71/02;;B32B1/08;;B32B17/06;;B32B27/28;;B32B27/32;;C12M1/00,,1,0,,,"Damdar et al. (Proceedings of the ASME Symposium on Elevated Temperature Application of Materials for Fossil, Nuclear, and Petrochemical Industries March 25-27, 2014) (Year: 2014)",PENDING
828,WO,A1,WO 2021/139895 A1,162-534-289-705-272,2021-07-15,2021,EP 2020050528 W,2020-01-10,EP 2020050528 W,2020-01-10,METHODS OF PRODUCING LACTIC ACID FROM UNMODIFIED STARCH,"The technology provided herein relates to novel methods for producing lactic acid (L-lactic acid, D-lactic acid and D/L-Lactic acid) from starch containing material with extreme thermophilic bacterial cells belonging to the genus Caldicellulosiruptor, mutants thereof, isolated strains, microbial cultures, and microbial compositions. The novel methods are in particular suitable for the production of lactic acid from any carbon source, not limited to but especially useful for unmodified starch and/or starch-containing material.",BLUCON BIOTECH GMBH,SVETLICHNAYA TATIANA;;SVETLICHNY VITALY;;KRÄMER MARCO,,https://lens.org/162-534-289-705-272,Patent Application,yes,5,0,5,162-534-289-705-272;;173-452-266-945-046;;135-383-837-596-106;;099-194-556-971-380;;018-410-155-999-177,EP;;CN;;WO;;US,5,162-534-289-705-272;;173-452-266-945-046;;018-410-155-999-177;;099-194-556-971-380;;135-383-837-596-106,CN;;EP;;WO;;US,0,C12N1/22;;C12N1/205;;C12P7/56;;C12R2001/01;;Y02E50/10;;C12P7/56;;C12N1/205;;C12R2001/01,C12P7/56;;C12R1/01,,23,18,040-567-353-682-157;;020-598-308-998-773;;083-500-840-960-891;;042-289-974-588-628;;018-020-465-357-555;;018-020-465-357-555;;070-955-528-210-032;;100-275-023-475-753;;087-421-467-604-53X;;001-103-396-696-25X;;097-067-577-395-277;;046-476-956-410-577;;158-430-265-645-649;;006-719-136-734-034;;093-619-101-976-938;;074-488-197-260-232;;014-462-529-725-525;;019-979-499-270-526,10.1007/s002030050196;;10.1201/b19872-10;;17576217;;10.1111/j.1472-765x.2007.02137.x;;10.1016/s1389-1723(04)70230-3;;16233654;;10.1016/j.procbio.2004.01.045;;10.1016/j.procbio.2004.01.045;;10.1128/aem.72.1.269-275.2006;;16391053;;pmc1352207;;17884326;;10.1016/j.biotechadv.2007.07.004;;30388577;;10.1016/j.biortech.2018.10.043;;25937690;;pmc4409858;;10.1002/jctb.4627;;10.1002/1521-4095(200012)12:23<1841::aid-adma1841>3.0.co;2-e;;10.1111/j.1574-6976.1995.tb00168.x;;10.1016/j.ijhydene.2010.05.063;;10.1016/0378-1097(94)90481-2;;10.1111/j.1574-6968.1994.tb07043.x;;8076802;;10.1128/aem.53.4.832-838.1987;;16347327;;pmc203765;;18587891;;10.1002/bit.260331118;;pmc168907;;12824352;;10.1093/nar/gkg500;;10.1093/bioinformatics/17.12.1244;;11751241,"ZUZANA MLADENOVSKA ET AL: ""Isolation and characterization of Caldicellulosiruptor lactoaceticus sp. nov., an extremely thermophilic, cellulolytic, anaerobic bacterium"", ARCHIVES OF MICROBIOLOGY, vol. 163, no. 3, 1 March 1995 (1995-03-01), Berlin/Heidelberg, pages 223 - 230, XP055686487, ISSN: 0302-8933, DOI: 10.1007/BF00305357;;KARMAKAR R.BAN D.GHOSH: ""Comparative study of native and modified starches isolated from conventional and nonconventional sources"", INTERNATIONAL FOOD RESEARCH JOURNAL, vol. 21, no. 2, 2014, pages 597 - 602;;BHANWAR, S.GANGULI, A.: ""Amylase and galactosidase production on potato starch waste by Lactococcus lactis subsp. lactic isolated from pickled yam"", JOURNAL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, vol. 73, 2014, pages 324 - 330;;PANDA H.RAY R.: ""Part 1. Biochemistry & Biotechnology"", 2016, CRC PRESS, article ""Amylolytic Lactic Acid Bacteria Microbiology and Technological Interventions in Food Fermentations. In book: Fermented foods"";;JOHN, R.P.NAMPOOTHIRI, M.K.PANDEY, A.: ""Polyurethane foam as an inert carrier for the production of L(+) lactic acid by Lactobacillus casei under solid state fermentation"", LETTER IN APPLIED MICROBIOLOGY, vol. 44, 2007, pages 582 - 587;;NARITA, J.NAKAHARA, S.FUKUDA, H.KONDO, A.: ""Efficient production of L-(+)-lactic acid from raw starch by Streptococcus bovis 148"", JOURNAL OF BIOSCIENCE BIOENGINEERING, vol. 97, 2004, pages 423 - 425, XP002507572;;NAVEENA, B.J.ALTAF, MD.BHADRAYYA, K.MADHAVENDRA, S.S.REDDY, G.: ""Production of L(+) lactic acid by Lactobacillus amylophilus GV6 in semi-solid state fermentation using wheat bran"", FOOD TECHNOLOGY AND BIOTECHNOLOGY, vol. 42, 2004, pages 147 - 152;;NAVEENA, B.J.ALTAF, MD.BHADRAYYA, K.MADHAVENDRA, S.S.REDDY, G.: ""Direct fermentation of starch to L (+) lactic acid in SSF by Lactobacillus amylophilus GV6 using wheat bran as support and substrate medium optimization using RSM"", PROCESS BIOCHEMISTRY, vol. 40, 2005, pages 681 - 690, XP025306477, DOI: 10.1016/j.procbio.2004.01.045;;NARITA, J.OKANO, K.KITAO, T.ISHIDA, S.: ""Display of alpha-amylase on the surface of Lactobacillus casei cells by use of the PgsA anchor protein, and production of lactic acid from starch"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 72, 2006, pages 269 - 275, XP055312989, DOI: 10.1128/AEM.72.1.269-275.2006;;REDDY, G.MD. ALTAFNAVEENA, B.J.VENKATESHWAR, M.VIJAY, K.E.: ""Amylolytic bacterial lactic acid fermentation: A review"", BIOTECHNOLOGY ADVANCES, vol. 26, 2008, pages 22 - 34, XP022360243, DOI: 10.1016/j.biotechadv.2007.07.004;;WANG Y.CAI W.LUO J.QI B.WAN Y.: ""One step open fermentation for lactic acid production from inedible starchy biomass by thermophilic Bacillus coagulans IPE22"", BIORESOURCE TECHNOLOGY, vol. 272, 2019, pages 398 - 406;;SMERILLI M.NEUREITER, M.WURZ, ST.HAAS, C.FRUHAUF, S.FUCHS W.: ""Direct fermentation of potato starch and potato residues to lactic acid by Geobacillus stearothermophilus under non-sterile conditions"", CHEM TECHNOL BIOTECHNOL., vol. 90, 2014, pages 648 - 657;;DRUMRIGHT R.E.GRUBER PRHENTON DE: ""Polylactic acid technology"", ADV MATER, vol. 12, 2000, pages 1841 - 1846, XP000977276, DOI: 10.1002/1521-4095(200012)12:23<1841::AID-ADMA1841>3.3.CO;2-5;;NARAYANAN N.ROYCHOUDHURY P.SRIVASTAVA A.: ""L(+) Lactic acid fermentation and its product polymerization"", ELECTRON J BIOTECHNOL, vol. 7, 2004, pages 167 - 179;;DATTA RTSAI S.BONSIGNORE P.MOON S.FRANK J.: ""Technological and economic potential of poly(lactic acid) and lactic acid derivatives"", FEMS MICROBIOL REV, vol. 16, 1995, pages 221 - 231, XP002372479;;VAIDYAA.PANDEY RMUDLIAR S.SURESH KUMAR M.CHAKRABARTI T.DEVOTTA S.: ""roduction and recovery of lactic acid for polylactide-an overview"", CRIT REV ENVIRON SCI TECHNOL, vol. 35, 2005, pages 429 - 467;;MARS A.VEUSKEMS T.BUDDE M.VON DOEVEREN P.LIPIS STBAKKER R.DE VRIJECLAASEN P.: ""Biohydrogen production from untreated and hydrolyzed potato steam peels by the extreme thermophiles Caldicellulosiruptor saccharolyticus and Thermotoga neapolitana"", INTERNATIONAL JOURNAL OF HYDROGEN ENERGY, vol. 35, 2010, pages 7730 - 7737;;RAINEY FADONNISON AMJANSSEN PHSAUL DRODRIGO ABERGQUIST PLDANIEL RMSTACKEBRANDT EMORGAN HW: ""Description of Caldicellulosiruptor saccharolyticus gen. nov., sp. nov: an obligately anaerobic, extremely thermophilic, cellulolytic bacterium"", FEMS MICROBIOL LETT, vol. 120, 1994, pages 263 - 266, XP023916519, DOI: 10.1111/j.1574-6968.1994.tb07043.x;;SISSONS CHSHARROCK KRDANIEL RMMORGAN HW: ""Isolation of cellulolytic anaerobic extreme thermophiles from New Zealand thermal sites"", APPL ENVIRON MICROBIOL, vol. 53, 1987, pages 832 - 838;;DONNISON AMBROCKELSBY CMMORGAN HWDANIEL RM: ""The degradation of lignocellulosics by extremely thermophilic microorganisms"", BIOTECHNOL BIOENG, vol. 33, 1989, pages 1495 - 1499;;HUNGATE RE.: ""Methods in Microbiology"", 1969, ACADEMIC PRESS, article ""A roll tube method for cultivation of strict anaerobes"", pages: 118 - 132;;CHENNA RSUGAWARA HKOIKE TLOPEZ RGIBSON TJHIGGINS DGTHOMPSON JD: ""Multiple sequence alignment with the Clustal series of programs"", NUCLEIC ACIDS RES., vol. 13, 2003, pages 3497 - 3500, XP002316493, DOI: 10.1093/nar/gkg500;;KUMAR STAMURA KJAKOBSEN IBNEI M: ""MEGA2: molecular evolutionary genetics analysis software"", BIOINFORMATICS, vol. 17, 2001, pages 1244 - 1245",PENDING
829,CN,A,CN 112746021 A,082-496-308-082-601,2021-05-04,2021,CN 202011226275 A,2020-11-05,CN 202011226275 A,2020-11-05,"Penicillium oxalicum K10, chitinase produced by penicillium oxalicum K10 and method for preparing chitosan oligosaccharide by utilizing chitinase","The invention provides penicillium oxalicum K10, chitinase produced by the penicillium oxalicum K10, a method for preparing chitosan oligosaccharide by utilizing the chitinase, and a process for carrying out enzymolysis on colloid chitin by utilizing chitinase produced by penicillium oxalicum K10 to produce the chitosan oligosaccharide. According to the penicillium oxalicum K10, a penicillium oxalicum K10 strain is preserved in China Center for Type Culture Collection (Wuhan University) on October 6, 2020, and the preservation number is CCTCC NO: M 2020571.",LUOHE HEMIAOWANG BIOTECHNOLOGY CO LTD,ZHANG BINGZHONG;;KANG LIXIN,,https://lens.org/082-496-308-082-601,Patent Application,no,0,3,2,082-496-308-082-601;;075-084-361-071-077,CN,2,082-496-308-082-601;;075-084-361-071-077,CN,0,C12N9/2442;;C12P19/14;;C12P19/26;;C12Y302/01014,C12N1/14;;C12N9/42;;C12P19/14;;C12P19/26;;C12R1/80,,5,3,048-525-773-886-223;;048-525-773-886-223;;049-519-095-168-796,10.1007/s13205-013-0118-4;;28324456;;pmc3909569;;10.1007/s13205-013-0118-4;;28324456;;pmc3909569;;7765867;;10.1111/j.1472-765x.1995.tb00404.x,"PAREEK N: ""Enhanced production of chitin deacetylase by Penicillium oxalicum SAEM-51 through response surface optimization of fermentation conditions"", 《3 BIOTECH》;;PAREEK N: ""“Enhanced production of chitin deacetylase by Penicillium oxalicum SAEM-51 through response surface optimization of fermentation conditions"", 《3 BIOTECH》;;吴绵斌: ""绿色木霉合成几丁质酶条件的研究"", 《化学反应工程与工艺》;;J. RODRIGUEZ: ""Purification and properties of a chitinase from Penicillium oxalicurn autolysates"";;吴绵斌: ""绿色木霉合成几丁质酶条件的研究""",ACTIVE
830,WO,A1,WO 2022/056276 A1,029-031-611-870-182,2022-03-17,2022,US 2021/0049887 W,2021-09-10,US 202063077133 P;;US 202063077140 P,2020-09-11,IDENTIFICATION AND PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODIES,"A method of obtaining a nucleotide sequence, from an immunized genetically modified non-human mammal, encoding an immunoglobulin variable domain of an antibody specific for a particular antigen is disclosed. A method for making antibodies against a particular antigen is also disclosed.",REGENERON PHARMA,LIU YASHU;;GUO CHUNGUANG;;ZHANG QIAN;;LEVENKOVA NATASHA;;MURPHY ANDREW J;;OLSON WILLIAM,,https://lens.org/029-031-611-870-182,Patent Application,yes,110,0,9,078-928-283-609-308;;067-441-698-301-328;;008-752-601-483-275;;029-031-611-870-182;;015-876-474-831-430;;173-102-768-637-254;;114-558-411-848-708;;086-443-552-830-962;;100-566-358-000-661,KR;;JP;;AU;;EP;;IL;;WO;;US;;TW;;CA,10,015-876-474-831-430;;067-441-698-301-328;;029-031-611-870-182;;174-070-031-500-723;;173-102-768-637-254;;078-928-283-609-308;;114-558-411-848-708;;086-443-552-830-962;;100-566-358-000-661;;008-752-601-483-275,KR;;JP;;AU;;IL;;CN;;EP;;WO;;US;;TW;;CA,40,C07K16/00;;A01K2207/15;;A01K2217/072;;A01K2227/105;;A01K2267/01;;C07K16/2803;;C07K16/462;;C07K2317/10;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/92;;G16B15/30;;G16B35/20;;C12N15/1072;;A01K2207/15;;A01K2217/072;;A01K2227/105;;A01K2267/01;;C07K16/00;;C07K16/2803;;C07K16/462;;C07K2317/10;;C07K2317/21;;C07K2317/24;;C07K2317/56;;C07K2317/565;;C07K2317/92;;G16B15/30;;G16B35/20;;C07K16/00;;A01K2207/15;;A01K2217/072;;A01K2227/105;;A01K2267/01;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C12N15/1096;;C12Q1/6869;;C12Q2535/122;;G01N33/6848;;G01N33/6854;;G16B15/30;;G16B35/20;;C12N15/1072,C07K16/00;;A01K67/027;;C07K16/28;;C07K16/46;;C12Q1/6872;;G16B30/10,,43,22,077-652-050-910-393;;055-874-932-579-917;;005-345-480-489-517;;031-933-089-611-974;;095-050-980-581-957;;081-762-779-850-964;;059-038-435-839-492;;039-312-419-452-38X;;007-161-773-585-269;;039-384-864-129-401;;026-148-170-669-52X;;111-501-633-494-339;;021-612-452-406-271;;077-019-541-070-890;;045-155-508-723-808;;044-109-290-778-916;;039-488-184-734-209;;027-698-389-206-012;;008-952-075-770-544;;002-992-911-980-044;;083-013-935-834-670;;050-307-970-524-770,pmc10373632;;27184599;;10.1038/nrg.2016.49;;25461729;;10.1016/j.cbpa.2014.11.007;;10.1159/000049204;;11872956;;10.1073/pnas.82.2.488;;pmc397064;;3881765;;10.1006/bbrc.1999.1372;;10491297;;10683722;;10.2144/00282bm01;;11252783;;10.2144/01303bm04;;10.2144/00295bm09;;11084857;;1518797;;10.1093/protein/5.5.467;;9512562;;10.1093/nar/26.7.1848;;pmc147442;;8655519;;pmc178091;;10.1128/jb.178.11.3346-3349.1996;;8590473;;10.1007/bf00315788;;8850009;;10.1385/0-89603-332-5:229;;10.1017/cbo9780511596773.011;;10.1038/s42003-019-0551-y;;31428692;;pmc6689056;;10.1101/660472;;31311926;;pmc6635368;;10.1038/s41467-019-11049-4;;27362342;;10.1146/annurev-genom-083115-022413;;10.1136/archdischild-2013-304340;;pmc3841808;;23986538;;10.1002/cpmb.59;;pmc6020069;;29851291;;10.1038/nature10242;;21776081;;19224008;;pmc2643089;;29161012;;pmc6138622;;10.1021/acs.analchem.7b04747,"SARA GOODWIN ET AL: ""Coming of age: ten years of next-generation sequencing technologies"", NATURE REVIEWS GENETICS, vol. 17, no. 6, 17 May 2016 (2016-05-17), GB, pages 333 - 351, XP055544186, ISSN: 1471-0056, DOI: 10.1038/nrg.2016.49;;JASON J LAVINDER ET AL: ""Next-generation sequencing and protein mass spectrometry for the comprehensive analysis of human cellular and serum antibody repertoires"", CURRENT OPINION IN CHEMICAL BIOLOGY, VOL. 24, 1 February 2015 (2015-02-01), pages 112 - 120, XP055453470, Retrieved from the Internet <URL:https://ac.els-cdn.com/S1367593114001719/1-s2.0-S1367593114001719-main.pdf?_tid=8f1a8114-17ce-11e8-9b40-00000aacb362&acdnat=1519303837_f02441baca90214f5e2672db1cf72ca8> [retrieved on 20180222], DOI: 10.1016/j.cbpa.2014.11.007;;LEFRANC, M-P.: ""The Immunoglobulin FactsBook"", 23 May 2001, ACADEMIC PRESS;;LUCAS, J. ET AL.: ""Molecular Biology of B Cells"", 2015, ACADEMIC PRESS, article ""The Structure and Regulation of the Immunoglobulin Loci"";;CHRISTELE, M-J ET AL.: ""Nomenclature and Overview of the Mouse (Mus musculus and At s sp.) Immunoglobulin Kappa (IGK) Genes"", EXP CLIN LMMUNOGENET, vol. 18, 2001, pages 255 - 279, XP055617822;;SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;KUNKEL, PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492;;OLIGONUCLEOTIDE SYNTHESIS, 1984;;PERBAL: ""A Practical Guide To Molecular Cloning"", 1984;;""Immobilized Cells And Enzymes"", 1986, IRL PRESS;;""Current Protocols in Molecular Biology"", 1994, JOHN WILEY & SONS, INC.;;FUKUOKA ET AL., BIOCHEM . BIOPHYS. RES COMMUN., vol. 263, 1999, pages 357 - 360;;KIMMAAS, BIOTECH, vol. 28, 2000, pages 196 - 198;;PARIKHGUENGERICH, BIOTECH., vol. 24, no. 4, 1998, pages 28 - 431;;RAYNICKOLOFF, BIOTECH, vol. 13, 1992, pages 342 - 346;;WANG ET AL., BIOTECH, vol. 19, 1995, pages 556 - 559;;WANGMALCOLM, BIOTECH, vol. 26, 1999, pages 639 - 641;;HOGREFE, STRATEGIES, vol. 14, no. 3, 2001, pages 74 - 75;;ANGAGSCHUTZ, BIOTECH, vol. 30, 2001, pages 486 - 488;;WANGWILKINSON, BIOTECH, vol. 29, 2000, pages 976 - 978;;KANG ET AL., BIOTECH, vol. 20, 1996, pages 44 - 46;;OGELMCPHERSON, PROTEIN ENGINEER, vol. 5, 1992, pages 467 - 468;;KIRSCHJOLY, NUCL. ACIDS RES., vol. 26, 1998, pages 1848 - 1850;;RHEMHANCOCK, J. BACTERIOL., vol. 178, 1996, pages 3346 - 3349;;BOLESMIOGSA, CURR. GENET., vol. 28, 1995, pages 197 - 198;;BARRENTTINO ET AL., NUC. ACIDS. RES., vol. 22, 1993, pages 541 - 542;;TESSIERTHOMAS, METHS. MOLEC. BIOL., vol. 57, pages 229 - 237;;PONS ET AL., METH MOLEC BIOL., vol. 67, pages 209 - 218;;MURPHY, A.: ""Recombinant Antibodies for Immunotherapy"", 2009, CAMBRIDGE UNIVERSITY PRESS, article ""VelocImmune: Immunoglobulin Variable Region Humanized Mouse"", pages: 101 - 107;;DEKOSKY ET AL., NAT. MED., vol. 21, no. 1, 2015, pages 85 - 91;;GOLDSTEIN ET AL., COMMUN. BIOL., vol. 2, 2019, pages 304;;SINGH ET AL., NAT COMMUN., vol. 1, no. 1, 2019, pages 3120;;LEVY S.E.MYERS RM., AULLU. REV. GELLOM. HUM. GENET., vol. 17, 2016, pages 95 - 115;;BEHJATI S.TARPEY P.S., ARCH DIS CHILD PRACT FD, vol. 98, no. 6, 2013, pages 236 - 238;;ALEKSEYEV ET AL., ACADEMIC PATHOLOGY, vol. 5, 2018, pages 1 - 11;;RONAGHIKARAMOHAMEDPETTERSSONUHLENNYREN, ANAL. BIOCHEM., vol. 242, no. 1, 1 November 1996 (1996-11-01), pages 84 - 9;;SLATKOGARDNERAUSUBEL, CURR. PROTOC. MOL. BIOL., vol. 122, no. 1, 2018, pages e59;;ROTHBERG ET AL., NATURE, vol. 475, 2011, pages 348 - 352;;PITT, CLIN. BIOCHEM. REV., vol. 30, 2009, pages 19 - 34;;CHEN ET AL., ANAL CHEM., vol. 90, no. 1, 2018, pages 110 - 127;;MACDONALD ET AL., PROC. NATL. ACAD SCI USA;;""Remington's The Science and Practice of Pharmacy"", 2006, LIPPINCOTT, WILLIAMS & WILKINS;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS",PENDING
831,US,A1,US 2025/0154275 A1,037-390-109-342-768,2025-05-15,2025,US 202318832031 A,2023-01-17,CN 202210068506 A;;CN 2023072510 W,2022-01-20,ANTI-CD3 AND ANTI-CD20 BISPECIFIC ANTIBODY AND USE THEREOF,"The present invention provides a bispecific antibody targeting CD3 and CD20 and a composition comprising same. Further provided are a nucleic acid molecule encoding the bispecific antibody of the present invention, a vector and a host cell for expressing the bispecific antibody of the present invention, and a therapeutic and diagnostic method and a use of the antibody of the present invention or an antigen-binding fragment thereof.",SHANGHAI JUNSHI BIOSCIENCES CO LTD;;SUZHOU JUNMENG BIOSCIENCES CO LTD,FENG HUI;;ZHOU YUEHUA;;LIU DANDAN;;LIU HONGCHUAN;;LI RUISHENG;;LIU HUI;;HE ZHIJUAN,SHANGHAI JUNSHI BIOSCIENCES CO. LTD (2024-07-19),https://lens.org/037-390-109-342-768,Patent Application,yes,0,0,8,068-163-072-468-256;;154-721-565-313-560;;001-387-752-104-722;;192-560-464-968-393;;018-893-950-372-591;;140-374-611-392-385;;036-360-876-267-048;;037-390-109-342-768,JP;;AU;;KR;;EP;;CN;;WO;;US,8,068-163-072-468-256;;154-721-565-313-560;;001-387-752-104-722;;192-560-464-968-393;;018-893-950-372-591;;140-374-611-392-385;;036-360-876-267-048;;037-390-109-342-768,JP;;AU;;KR;;EP;;CN;;WO;;US,0,C07K16/2887;;C07K16/2809;;C12N15/85;;C12N5/0682;;A61P35/00;;A61P35/02;;G01N33/6872;;C07K2317/31;;C07K2317/56;;C07K2317/52;;C12N2510/00;;C12N2800/107;;A61K2039/505;;G01N2333/7051;;G01N2333/70596;;A61P35/00;;A61P35/02;;C07K16/2887;;C07K16/2809;;C07K2317/31;;C07K2317/94;;C07K2317/92;;C07K2317/73;;A61K2039/505;;G01N2333/7051;;G01N2333/70596;;G01N33/6872;;C07K16/2887;;C07K16/2809;;G01N33/6872;;A61P35/02;;C07K2317/52;;C07K2317/56;;C07K2317/31;;C07K2317/565;;A61K2039/505;;G01N2333/7051;;G01N2333/70596;;A61P35/00;;A61K2039/505;;C07K16/2809;;C07K16/2887;;C07K2317/24;;C07K2317/31;;C07K2317/73;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
832,WO,A1,WO 2021/136798 A1,160-924-424-624-119,2021-07-08,2021,EP 2020088013 W,2020-12-30,EP 20150132 A,2020-01-02,SINGLE-USE CELL CULTURE CONTAINER WITH ONE OR MORE IN-SITU ONLINE SENSORS,"Herein is reported a small volume bioreactor comprising a cultivation vessel and a reactor head plate, wherein the cultivation vessel has a working volume of from 20 ml to 350 ml and comprises two or more in-situ sensors, wherein the reactor head plate comprises an in-situ sensor port, wherein to the in-situ sensor port at least one in-situ glucose sensor and one in-situ pH sensor are connected.",HOFFMANN LA ROCHE;;HOFFMANN LA ROCHE,SCHWALD CHRISTIAN,,https://lens.org/160-924-424-624-119,Patent Application,yes,7,2,14,066-848-095-118-370;;160-924-424-624-119;;186-859-381-181-981;;000-009-526-384-581;;084-473-598-477-177;;047-622-422-039-557;;178-721-029-457-641;;101-342-441-990-700;;098-900-210-525-083;;181-092-048-242-100;;125-048-047-807-828;;076-330-973-867-874;;033-530-555-839-623;;011-559-407-511-838,KR;;JP;;AU;;EP;;CN;;ES;;IL;;WO;;US;;CA;;BR;;MX,14,066-848-095-118-370;;160-924-424-624-119;;186-859-381-181-981;;000-009-526-384-581;;084-473-598-477-177;;047-622-422-039-557;;178-721-029-457-641;;101-342-441-990-700;;098-900-210-525-083;;181-092-048-242-100;;125-048-047-807-828;;076-330-973-867-874;;033-530-555-839-623;;011-559-407-511-838,KR;;JP;;AU;;EP;;CN;;ES;;IL;;WO;;US;;CA;;BR;;MX,0,C12M23/28;;C12M41/34;;C12M41/26;;C12M29/06;;C12M23/08;;C12M23/38;;C12M23/08;;C12M29/06;;C12M41/34;;C12M41/26;;C12M23/38;;C12M23/28;;C12M41/26;;C12M41/30;;C12M41/34;;C12M27/20;;C12M23/28;;C12M23/08;;C12M23/28;;C12M23/38;;C12M27/02;;C12M29/06;;C12M29/20;;C12M41/26;;C12M41/38,C12M1/00;;C12M1/12;;C12M1/34,,2,1,042-264-585-563-311,23775295;;10.1002/bit.24978,"BAREITHER, R. ET AL., BIOTECHNOL. BIOENG., vol. 110, 2013, pages 3126 - 3138;;BAREITHER, R.POLLARD, D., BIOTECH. PROG., vol. 155, 2011, pages 217 - 224",PENDING
833,US,A1,US 2023/0277658 A1,047-607-459-286-863,2023-09-07,2023,US 202218054101 A,2022-11-09,US 202218054101 A;;US 202117272151 A;;US 2019/0048962 W;;US 201862725852 P,2018-08-31,COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING,"Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.",UNIV YALE,QUIJANO ELIAS;;RICCIARDI ADELE;;BAHAL RAMAN;;TURCHICK AUDREY;;ECONOMOS NICHOLAS;;SALTZMAN W MARK;;GLAZER PETER,YALE UNIVERSITY (2023-01-18),https://lens.org/047-607-459-286-863,Patent Application,yes,1,0,14,047-869-087-681-917;;130-724-254-214-71X;;047-607-459-286-863;;175-891-007-748-918;;095-921-277-633-285;;179-664-671-955-136;;073-974-112-626-803;;000-074-896-472-512;;180-028-239-482-34X;;056-490-626-099-505;;012-958-591-096-244;;183-659-918-270-63X;;133-998-684-032-729;;128-321-432-143-996,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;SG;;CA;;BR;;MX,14,047-869-087-681-917;;130-724-254-214-71X;;047-607-459-286-863;;175-891-007-748-918;;095-921-277-633-285;;179-664-671-955-136;;073-974-112-626-803;;000-074-896-472-512;;180-028-239-482-34X;;056-490-626-099-505;;012-958-591-096-244;;183-659-918-270-63X;;133-998-684-032-729;;128-321-432-143-996,JP;;AU;;KR;;CN;;EP;;IL;;WO;;US;;SG;;CA;;BR;;MX,0,C12N15/113;;C12N15/102;;C12N15/907;;C12N2310/20;;C12N2320/50;;C12N2310/152;;C12N2320/31;;C12N9/22;;C07K16/44;;A61K48/0008;;C12N15/87;;A01K2227/105;;A01K2267/0306;;A01K2227/105;;A01K2267/0306;;A61K48/0008;;C07K16/44;;C12N9/22;;C12N15/102;;C12N15/113;;C12N15/87;;C12N15/907;;C12N2310/152;;C12N2310/20;;C12N2320/31;;C12N2320/50;;C12N15/113;;C12N9/22;;C12N15/102;;C07K16/44;;A61K48/00;;A61P7/04;;C12N15/90;;C07K2317/24;;C07K2317/565;;C12N2310/20;;C12N2310/3181;;A61P7/00;;A61K9/5153;;A61K31/7088;;A61K35/28;;A61K38/14;;A61K38/465;;A61K39/39533;;A61K48/00;;A61K2039/545,A61K39/395;;A61K9/51;;A61K31/7088;;A61K35/28;;A61K38/14;;A61K38/46;;A61P7/00,,2,2,063-640-832-834-034;;005-004-812-299-918,10631780;;10.1016/s0167-7799(99)01398-0;;10.1126/science.290.5491.471;;11183771,"Skolnick et al, 2000, Trends in Biotech, vol. 18, pp-34-39 (Year: 2000);;Attwood, Science, vol. 290, pp. 471-473 (Year: 2000)",DISCONTINUED
834,CN,A,CN 112305221 A,182-114-130-891-477,2021-02-02,2021,CN 202011182562 A,2020-10-29,CN 202011182562 A,2020-10-29,Canine parvovirus detection kit and preparation method thereof,"The invention discloses a canine parvovirus detection kit, which comprises a test strip and a marking tube, the test strip comprises a sample pad, a reaction film and a water absorption pad, the reaction film is provided with a detection line and a quality control line which are mutually spaced, the detection line is closer to the sample pad than the quality control line, a first canine parvovirusmonoclonal antibody and a quality control antibody which are respectively labeled by fluorescent microspheres are loaded on the inner surface of the labeling tube, and the detection line is coated with a second canine parvovirus monoclonal antibody, the first canine parvovirus monoclonal antibody and the second canine parvovirus monoclonal antibody respectively recognize different epitopes of canine parvovirus, and the quality control line is coated with an antigen capable of being specifically combined with the quality control antibody.",HEALVET GUANGZHOU MEDICAL TECH CO LTD,REN BAOFENG;;WANG WEI;;DENG YANZHEN,,https://lens.org/182-114-130-891-477,Patent Application,no,16,4,1,182-114-130-891-477,CN,1,182-114-130-891-477,CN,0,G01N33/582;;G01N33/558;;G01N33/56983;;G01N33/577;;G01N33/585;;G01N2333/015;;G01N2469/10,G01N33/58;;G01N33/558;;G01N33/569;;G01N33/577,,1,1,030-315-958-189-361,10.1046/j.1439-0450.2000.00328.x;;10763385,"SINOVUS BIOTECH AB, ET AL.: ""A Comparative Study of a New Rapid and One-Step Test for the Detection of Parvovirus in Faeces from Dogs, Cats and Mink."", 《J. VET. MED.》",DISCONTINUED
835,US,A1,US 2022/0071981 A1,199-097-353-457-542,2022-03-10,2022,US 202117532123 A,2021-11-22,US 202117532123 A;;US 201916478651 A;;US 2018/0015918 W;;US 201762452069 P;;US 201762465283 P,2017-01-30,COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION,Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.,CHILDRENS HOSPITAL PHILADELPHIA;;UNIV PENNSYLVANIA;;COLD SPRING HARBOR LABORATORY,BLOBEL GERD;;GREVET JEREMY;;SHI JUNWEI;;VAKOC CHRISTOPHER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2021-03-30),https://lens.org/199-097-353-457-542,Patent Application,yes,8,1,8,032-970-325-134-313;;139-542-004-601-928;;159-929-971-597-92X;;094-444-847-302-715;;199-097-353-457-542;;057-778-767-081-922;;069-446-926-641-937;;040-655-169-352-043,EP;;WO;;US,8,159-929-971-597-92X;;139-542-004-601-928;;094-444-847-302-715;;040-655-169-352-043;;199-097-353-457-542;;057-778-767-081-922;;069-446-926-641-937;;032-970-325-134-313,EP;;WO;;US,20,A61K31/454;;A61K31/517;;A61P7/06;;A61K45/06;;A61K48/00;;C12N15/90;;C12N15/1137;;C12N2310/20;;A61P7/06;;A61K31/454;;A61K31/517;;A61K45/06;;C12N15/1137,A61K31/454;;A61K31/517;;A61P7/06;;C12N15/113,,7,5,077-407-466-521-149;;032-198-822-446-501;;022-373-218-179-470;;133-289-265-514-801;;087-933-724-280-628,19946423;;pmc2778829;;10.1155/2009/251915;;34713219;;pmc8525389;;10.3389/fgeed.2020.571239;;pmc4608240;;10.1182/blood-2015-06-649087;;26320100;;10.1126/science.1165409;;19056937;;10.1016/j.bmcl.2009.10.033;;19854648,"Kanelakis KC, Pyati J, Wagaman PC, Chuang JC, Yang Y, Shankley NP. Functional Characterization of the Canine Heme-Regulated eIF2alpha Kinase: Regulation of Protein Synthesis. Adv Hematol. 2009;2009:251915. doi: 10.1155/2009/251915. Epub 2009 Jun 22. PMID: 19946423; PMCID: PMC2778829. (Year: 2009);;Barbarani G, Labedz A, Ronchi AE. Beta-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies. Front Genome Ed. 2020 Dec 3;2:571239. doi: 10.3389/fgeed.2020.571239. PMID: 34713219; PMCID: PMC8525389. (Year: 2020);;National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 5280343, Quercetin. Retrieved August 14, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/Quercetin. (Year: 2024);;Renneville A, Van Galen P, Canver MC, McConkey M, Krill-Burger JM, Dorfman DM, Holson EB, Bernstein BE, Orkin SH, Bauer DE, Ebert BL. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015 Oct 15;126(16):1930-9. doi: 10.1182/blood-2015-06-649087. Epub 2015 Aug 28. PMID: 26320100 (Year: 2015);;Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008 Dec 19;322(5909):1839-42. doi: 10.1126/science.1165409. Epub 2008 Dec 4. (Year: 2008);;Chen JJ. Translational control by heme-regulated eIF2Î± kinase during erythropoiesis. Curr Opin Hematol. 2014 May;21(3):172-8. doi: 10.1097/MOH.0000000000000030. PMID: 24714526; PMCID: PMC4124034. (Year: 2014);;Rosen MD, et al. Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6548-51. doi: 10.1016/j.bmcl.2009.10.033. Epub 2009 Oct 13. (Year: 2009)",PENDING
836,WO,A1,WO 2023/198625 A1,039-279-171-368-958,2023-10-19,2023,EP 2023059247 W,2023-04-06,GB 202205582 A;;SE 2250464 A,2022-04-14,A SOLUTION MANAGEMENT SYSTEM FOR BIOPROCESSING,"A solution management system (1) for bioprocessing, wherein each flow path formed between solution inlets (2) and solution outlets (9) of the system comprises one or more bend sections having an inner cross-sectional area and/or an inner cross-sectional geometry and/or a centre line radius varying along the length of the bend section. Various embodiments of the solution management system (1) provide for improved laminar fluid flow with a reduced pressure drop between the solution inlets (2) and solution outlets (9) therein.",CYTIVA SWEDEN AB,MARTELEUR KLAS;;ALRIKSSON JOHAN,,https://lens.org/039-279-171-368-958,Patent Application,yes,8,0,6,011-986-760-255-675;;138-161-796-104-675;;010-442-860-076-074;;039-279-171-368-958;;096-328-177-267-379;;181-004-290-130-243,KR;;JP;;CN;;EP;;WO;;US,7,181-004-290-130-243;;011-986-760-255-675;;039-279-171-368-958;;010-442-860-076-074;;131-399-790-435-137;;096-328-177-267-379;;138-161-796-104-675,JP;;KR;;CN;;EP;;WO;;US;;GB,0,B01F35/80;;F04B13/00;;F04B23/04;;B01F33/844;;B01F35/2202;;B01F35/211;;B01F35/2132;;B01F25/433;;B01F35/80;;B01F33/844;;B01F35/2202;;B01F35/211;;B01F35/2132;;B01F35/7176;;B01F35/214;;B01F35/7547;;B01F25/31;;F04B13/00;;F04B23/04;;B01F2025/917;;B01F2101/22;;B33Y80/00;;B01F35/7176;;B01F35/2131;;B01F35/2133;;B01F35/712;;B01F35/214;;B01F2101/44;;B01F2101/2202;;B01F35/213;;B01F35/2132;;B01F23/45,B01F35/80;;C12M1/00;;F04B43/00,,0,0,,,,PENDING
837,US,A1,US 2020/0338642 A1,189-968-569-121-763,2020-10-29,2020,US 202016924408 A,2020-07-09,US 202016924408 A;;US 201715731498 A;;US 201662493109 P,2016-06-22,MECHANO-CHEMICAL DE-MIXING OF METAL ALLOYS AND MIXED MATERIALS,"A physical and chemical method is provided for de-mixing (e.g. extracting, separating, purifying and/or enriching) the metal constituents of an alloy or mixed material into different droplet or solid particle products that are highly enriched in the respective phases of the metal. The method involves for instance but is not limited to, shearing, separating and segregating metallic droplets and particles in a carrier fluid to form other droplets or particles that are each separately highly enriched in one of some, if not of all, of the constituent phases of the alloy or mixed material.",UNIV IOWA STATE RES FOUND INC,THUO MARTIN;;SPORRER JACOB;;FRANKIEWICZ CHRISTOPHE,IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC (2018-10-03),https://lens.org/189-968-569-121-763,Patent Application,yes,0,0,4,158-531-494-113-024;;189-968-569-121-763;;007-966-991-547-242;;153-121-841-235-701,US,4,158-531-494-113-024;;189-968-569-121-763;;007-966-991-547-242;;153-121-841-235-701,US,0,B22F9/30;;B22F9/02;;C01G3/02;;C01G19/02;;C22B1/005;;C22B7/00;;C22B7/005;;C22B30/06;;C22B59/00;;B22F9/30;;B22F9/02;;C01G3/02;;C01G19/02;;C22B1/005;;C22B7/00;;C22B7/005;;C22B30/06;;C22B59/00;;Y02P10/20,B22F9/30;;B22F9/02;;C01G3/02;;C01G19/02;;C22B1/00;;C22B7/00;;C22B30/06;;C22B59/00,,0,0,,,,ACTIVE
838,US,A1,US 2024/0077423 A1,033-848-898-754-234,2024-03-07,2024,US 202117795351 A,2021-03-21,CN 202110162555 A;;CN 2021080525 W,2021-02-05,A TRANSCRIPTIONAL REGULATOR SPECIFICALLY RESPONDING TO D-2-HYDROXYGLUTARATE AND APPLICATION THEREOF,A transcriptional regulator specifically responding to D-2-hydroxyglutarate (D-2-HG) and its application in the biological detection of D-2-HG. Wherein the transcriptional regulator is named DhdR and the nucleotide sequence is shown as SEQ ID NO: 1. The D-2-HG biosensors BD2HG-0 and BD2HG-1 are constructed using the transcriptional regulator DhdR and can detect biological samples containing D-2-HG.,UNIV SHANDONG,GAO CHAO;;XIAO DAN;;ZHANG WEN;;MA CUIQING;;XU PING,SHANDONG UNIVERSITY (2022-07-13),https://lens.org/033-848-898-754-234,Patent Application,yes,0,0,4,122-112-937-389-204;;002-196-167-272-842;;169-714-851-457-601;;033-848-898-754-234,CN;;WO;;US,4,122-112-937-389-204;;002-196-167-272-842;;169-714-851-457-601;;033-848-898-754-234,CN;;WO;;US,4,C07K14/195;;G01N21/763;;C07K14/195;;C12N15/70;;C07K14/195;;C07K2319/21;;C12N15/70;;G01N21/6486;;G01N21/763,G01N21/64;;C07K14/195;;C12N15/70;;G01N21/76,,0,0,,,,PENDING
839,US,A1,US 2023/0008335 A1,034-230-916-393-826,2023-01-12,2023,US 202217811302 A,2022-07-07,CN 202110774093 A,2021-07-08,"OLIGOPEPTIDE WITH ANTI-INFLAMMATORY ACTIVITY, PREPARATION METHOD, AND APPLICATION THEREOF","An oligopeptide with anti-inflammatory activity, a preparation method, and an application thereof are provided, belonging to the field of biotechnology. An amino acid sequence of the oligopeptide is shown as SEQ ID NO:1. The preparation method includes: digesting a wheat germ protein through a simulated gastrointestinal tract to obtain protein digestion products; separating the protein digestion products by ultrafiltration membranes to obtain components I (>3 kDa), II (1˜3 kDa), and III (<1 kDa), screening the components to obtain III as an anti-inflammatory active component, and finally identifying the oligopeptide by LC-MS/MS polypeptide. The oligopeptide has strong anti-inflammatory activity, is derived from the wheat germ protein, has the characteristics of safety, high efficiency, simple preparation method, good repeatability, has broad prospects in food, medicine, and other fields, and can be applied to preparations of medicines or functional foods for preventing and treating enteritis.",UNIV NANJING FINANCE & ECONOMICS;;UNIV NANJING CHINESE MEDICINE,WANG FANG;;SHEN XINCHUN;;FANG YONG;;WENG ZEBIN,NANJING UNIVERSITY OF FINANCE AND ECONOMICS (2022-07-06);;NANJING UNIVERSITY OF CHINESE MEDICINE (2022-07-06),https://lens.org/034-230-916-393-826,Patent Application,yes,1,0,4,180-251-795-205-142;;102-231-824-914-582;;079-993-065-477-201;;034-230-916-393-826,CN;;US,4,180-251-795-205-142;;102-231-824-914-582;;079-993-065-477-201;;034-230-916-393-826,CN;;US,0,C07K14/415;;A23L33/18;;A23V2002/00;;A61K8/645;;A61K38/00;;A61P1/00;;C12P21/06;;A61P29/00;;A23L33/18;;A61K8/645;;A61K38/00;;A61K2800/10;;A61Q19/00;;C07K14/415;;A23L33/18;;A23L33/40;;A23V2002/00;;A61K8/645;;A61K38/00;;A61P29/00;;A61Q19/00,C07K14/415;;A23L33/00;;A23L33/18;;A61K8/64;;A61P29/00;;A61Q19/00,,1,1,007-903-614-823-784,10.1016/s0899-9007(96)00000-8;;8862535,"Conner et al. Inflammation, Free Radicals, and Antioxidants. Nutrition. 1996; 12: 274-277. (Year: 1996)",ACTIVE
840,US,A1,US 2024/0270824 A1,047-634-752-254-063,2024-08-15,2024,US 202418405405 A,2024-01-05,CN 202310117896 A,2023-02-15,"HEMOGLOBIN (Hb) RECOMBINANT EXPRESSION VECTOR AND RECOMBINANT ENGINEERING BACTERIUM, AND PREPARATION METHOD AND USE THEREOF","The present disclosure provides a gene expression cassette encoding hemoglobin (Hb) and use thereof, and relates to the technical field of genetic engineering. In the present disclosure, a recombinant Escherichia coli strain with signal peptides Pel B, Pho A, and Omp A inserted under same conditions has an expression level of leghemoglobin (LegH) increased by 3.01, 1.25, and 1.22 times, respectively, compared with an original LegH expressing strain. The present disclosure provides signal peptides that can increase the expression level of the LegH, and provide a new idea for research and application of improving the expression level of the LegH.",UNIV ZHEJIANG;;NINGBO INNOVATION CENTER ZHEJIANG UNIV;;SHANGHAI INST FOR ADVANCED STUDY OF ZJU,CHEN WEI;;XIE LIANGHUA;;MENG YUNHE;;YOU KAIHAO,ZHEJIANG UNIVERSITY (2023-12-18);;SHANGHAI INSTITUTE FOR ADVANCED STUDY OF ZJU (2023-12-18);;NINGBO INNOVATION CENTER ZHEJIANG UNIVERSITY (2023-12-18),https://lens.org/047-634-752-254-063,Patent Application,yes,0,0,2,167-888-599-488-023;;047-634-752-254-063,CN;;US,2,167-888-599-488-023;;047-634-752-254-063,CN;;US,0,C07K14/805;;C12N15/70;;C07K2319/02;;C12R2001/19;;Y02A50/30;;C07K14/805;;C12N15/70;;C12N1/205;;C12N1/205;;C12R2001/19;;C07K14/805;;C12N15/70;;C12N2500/34,C07K14/805;;C12N1/20;;C12N15/70;;C12R1/19,,0,0,,,,PENDING
841,WO,A1,WO 2023/021529 A1,104-413-695-704-166,2023-02-23,2023,IN 2022050743 W,2022-08-17,IN 202121037256 A,2021-08-17,IMPROVED ENZYMATIC SYNTHESIS OF SITAGLIPTIN OR ITS SALTS THEREOF,"The present invention discloses an improved enzymatic synthesis of Sitalgiptin or its pharmaceutically acceptable salts in good yield and purity. The present invention provides novel intermediate (R)- 3-Acetamido-4-(2,4,5-Trifluorophenyl) butanoic acid (5).",FERMENTA BIOTECH LTD,DATLA ANUPAMA;;NAGRE PRASHANT;;TAMORE JAGDISH;;WADHAVANE SACHIN;;MURALIDHARAN KRISHNA;;TRIVIKRAM SREENATH,,https://lens.org/104-413-695-704-166,Patent Application,yes,3,0,1,104-413-695-704-166,WO,1,104-413-695-704-166,WO,0,C12N9/20;;C07C233/47;;C12Y301/01003,C07C27/20;;C12N9/10,,0,0,,,,PENDING
842,US,A1,US 2021/0403507 A1,069-029-341-867-212,2021-12-30,2021,US 202016896196 A,2020-06-08,CN 202010413944 A,2020-05-15,PEPTIDE PROBE FOR RECOGNITION OF G-QUADRUPLEX AND USE THEREOF IN DETECTION OF G-QUADRUPLEX IN CELL,"A polypeptide probe, including: from two to four G4-binding domains, and one or more linkers disposed between every two G4-binding domains. Each G4-binding domain includes a specific motif including a sequence of amino acids(SEQ ID NO: 1)PGHLKGREIGMWY.",CHANGZHI MEDICAL COLLEGE,TAN ZHENG;;ZHENG KEWEI;;ZHENG JINPING,CHANGZHI MEDICAL COLLEGE (2020-04-05),https://lens.org/069-029-341-867-212,Patent Application,yes,1,3,4,172-295-651-516-771;;069-029-341-867-212;;151-791-162-012-055;;002-253-922-234-574,CN;;US,4,172-295-651-516-771;;069-029-341-867-212;;151-791-162-012-055;;002-253-922-234-574,CN;;US,70,C07K14/00;;C12Q1/6869;;C07K14/00;;C07K7/06;;C07K14/00;;C07K14/47;;C07K2319/80;;C07K2319/85;;C12Q1/68;;C12Q1/6869;;C12Q2565/133,C07K7/06;;C12Q1/6869,,1,1,085-519-227-719-584,30678288;;pmc6384609;;10.3390/molecules24030396,"Sun et al. Developing Novel G-Quadruplex Ligands: From Interaction with Nucleic Acids to Interfering with Nucleic Acid-Protein Interaction. Molecules. 2019, Volume 24, 396, 29 pages. (Year: 2019)",ACTIVE
843,US,A1,US 2021/0102222 A1,169-726-827-703-006,2021-04-08,2021,US 202017127210 A,2020-12-18,US 202017127210 A;;US 201514947476 A;;US 98388807 A;;US 85902506 P;;US 85941706 P;;US 96782007 P,2006-11-13,METHOD OF INACTIVATING A GLUCOCORTICOID RECEPTOR GENE IN AN ISOLATED CELL,"Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.",SANGAMO THERAPEUTICS INC;;HOPE CITY,REIK ANDREAS;;JENSEN MICHAEL;;HOLMES MICHAEL C;;GREGORY PHILIP D;;ANDO DALE,SANGAMO THERAPEUTICS INC (2008-03-06);;CITY OF HOPE (2008-03-15),https://lens.org/169-726-827-703-006,Patent Application,yes,3,0,19,117-240-959-346-737;;190-104-228-352-835;;194-357-694-480-608;;178-138-104-348-704;;015-606-319-468-74X;;173-863-507-816-584;;051-721-362-345-832;;138-189-736-474-863;;169-726-827-703-006;;058-950-451-343-859;;057-016-649-242-173;;121-441-722-791-571;;139-963-992-074-240;;109-173-577-906-287;;065-517-712-087-061;;138-012-939-720-215;;106-160-651-463-735;;080-501-111-459-170;;063-554-115-944-731,JP;;AU;;EP;;WO;;HK;;US;;CA,19,117-240-959-346-737;;190-104-228-352-835;;194-357-694-480-608;;178-138-104-348-704;;173-863-507-816-584;;015-606-319-468-74X;;051-721-362-345-832;;138-189-736-474-863;;169-726-827-703-006;;121-441-722-791-571;;058-950-451-343-859;;139-963-992-074-240;;057-016-649-242-173;;065-517-712-087-061;;109-173-577-906-287;;138-012-939-720-215;;106-160-651-463-735;;080-501-111-459-170;;063-554-115-944-731,JP;;AU;;EP;;WO;;HK;;US;;CA,57,C12N15/62;;A61P9/12;;A61P11/06;;A61P29/00;;A61P35/00;;A61P37/06;;C07K14/721;;C12N15/86;;C07K14/721;;C12N9/22;;C12N15/62;;C12N2710/10043;;C12N2740/15043;;G01N33/743;;G01N2333/723,C12N15/86;;C07K14/72;;C12N9/22;;C12N15/62;;G01N33/74,,15,13,024-030-751-108-011;;033-213-362-758-06X;;058-408-457-243-963;;024-025-307-018-216;;007-306-230-249-511;;164-012-515-125-60X;;033-208-287-874-821;;048-969-795-207-882;;127-060-172-423-713;;009-403-109-750-651;;015-688-002-889-580;;075-487-220-451-62X;;114-072-738-105-375,10494832;;pmc4033837;;10.1515/bc.1999.103;;pmc110700;;10954606;;10.1093/nar/28.17.3361;;10.1128/mcb.21.1.289-297.2001;;pmc88802;;11113203;;10.1038/nbt1125;;16082368;;17763826;;10.1007/s00018-007-7206-8;;pmc2921987;;10.1073/pnas.0800940105;;pmc2299223;;18359850;;18500334;;pmc2674762;;10.1038/nbt1409;;18784746;;10.1038/gt.2008.145;;pmc2747807;;19064913;;pmc2604940;;10.1073/pnas.0810475105;;10.1007/s11248-009-9323-7;;19821047;;pmc2810328;;20111598;;10.1371/journal.pone.0008870;;20717154;;10.1038/nrg2842;;10.1016/s0021-9258(18)99192-1;;2037566,"Chandrasegaran (Biol. Chem., 1999, Vol. 380, pg 841-848);;Smith (Nucleic Acids Research 2000, Vol. 28, No. 17, pg 3361-3369);;Bibikova (MCB, Jan. 2001, Vol. 21, No. 1, pg 289-297);;Porteus (Nature Biotech., 2005, Vol. 23, No. 8, pg 967- 973);;Wu (Cell Mol. Lif Science, 2007, Vol. 64, 2933-2944);;Santiago (PNAS, April 2008, Vol. 105, No. 15, pg 5809-5814);;Doyon (Nature Biotech., June 2008, Vol. 26, No. 6, pg 702-708);;Perez (Nature Biotech., July 2008, Vol. 26, No. 6, pg 808-816);;Carroll (Gene Therapy, Sept. 11, 2008, Vol. 15, pg 1463-1468);;Beumer (PNAS, Dec. 16, 2008, Vol. 105, No. 50, pg 19821-19826);;Geurts (Science, July 24, 2009, Vol. 325, No. 5939, pg 433-435, and Supplemental Materials associated therewith);;Remy (Transgenic Res. Published online Sept 26, 2009, Vol. 19, pg 363-371);;Mashimo (PLoS ONE, Jan. 2010, Vol. 5, No. 1, e8870, pg 1-7);;Urnov (Nature Reviews Genetics, Sept. 2010, Vol. 11, pg 636-646);;Alksnis (J. Biol. Chem., 1991, Vol. 266, No. 16, pg 10078-10085)",ACTIVE
844,US,A1,US 2024/0301503 A1,168-298-545-264-303,2024-09-12,2024,US 202218573338 A,2022-06-22,KR 20210080807 A;;KR 20220076394 A;;KR 2022008902 W,2021-06-22,"NOVEL BIOMARKER FOR DIAGNOSING AND PREDICTING METASTASIS OR PROGNOSIS OF VARIOUS CANCERS, AND USE","The present invention relates to a novel biomarker for diagnosing cancer, and a use thereof. STC1, a novel biomarker for diagnosing or predicting the prognosis of cancer according to the present invention, was found to be related to poor prognosis of cancer patients according to the expression level, and was found to be overexpressed in various cancer cell lines. In addition, STC1 was found to be a biomarker related to the proliferation, invasion, and migration (metastasis) of cancer cells. In addition, it was found that STC1 is detected in the serum or urine of bladder cancer patients, and can be effectively used for diagnosing and predicting the prognosis of bladder cancer by identifying differences in expression according to the patient's clinical stage.",UNIV DONG A RES FOUND FOR IND ACAD COOP,LEEM SUN-HEE;;MUN JEONG-YEON;;JEONG MI-SO;;KIM MIN-HYE;;YANG GI-EUN,DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION (2023-07-05),https://lens.org/168-298-545-264-303,Patent Application,yes,0,0,2,131-800-778-195-79X;;168-298-545-264-303,WO;;US,4,131-800-778-195-79X;;016-640-197-810-812;;168-298-545-264-303;;066-156-396-768-054,KR;;WO;;US,4,C12Q1/6886;;C12Q1/6809;;C12Q1/6809;;C12Q1/6886;;C12Q2600/112;;C12Q2600/118;;C12Q2600/136;;C12Q2600/158;;G01N2333/00;;G01N2333/575,C12Q1/6886;;C12Q1/6809,,0,0,,,,PENDING
845,EP,A1,EP 4342908 A1,181-828-913-805-14X,2024-03-27,2024,EP 22823813 A,2022-03-03,CN 202110674660 A;;CN 2022078975 W,2021-06-17,CHIMERIC IMMUNOGLOBULIN,"A chimeric immunoglobulin is provided. It is obtained by fusing a first polypeptide and a second polypeptide, wherein the first polypeptide includes an IgG variable region located at the N terminal; and the second polypeptide includes an IgA CH2-CH3 region or an IgM CH3-CH4 region located at the C terminal. The immunoglobulin has higher titer, and when coated in a solid phase, it still has higher titer than that of an IgG monomer with the same valence, so it can be widely applied in the detection field.",FAPON BIOTECH INC,MENG YUAN;;ZHONG DONGMEI,,https://lens.org/181-828-913-805-14X,Patent Application,yes,0,0,13,113-576-845-520-42X;;181-828-913-805-14X;;187-646-515-688-727;;182-128-181-986-537;;075-572-083-345-99X;;148-857-099-532-461;;004-640-301-138-03X;;115-461-334-206-896;;114-641-496-399-928;;103-782-195-759-379;;013-570-352-704-690;;086-624-261-431-34X;;050-364-448-620-007,KR;;JP;;CN;;EP;;WO;;US;;CA;;MX;;BR,13,113-576-845-520-42X;;181-828-913-805-14X;;187-646-515-688-727;;182-128-181-986-537;;115-461-334-206-896;;148-857-099-532-461;;004-640-301-138-03X;;075-572-083-345-99X;;114-641-496-399-928;;103-782-195-759-379;;013-570-352-704-690;;086-624-261-431-34X;;050-364-448-620-007,KR;;JP;;CN;;EP;;WO;;US;;CA;;MX;;BR,8,C07K16/00;;C07K16/468;;G01N33/577;;G01N33/548;;G01N33/587;;G01N33/582;;C07K2317/31;;C07K2317/52;;C07K2317/56;;G01N33/54387;;C07K2317/52;;C07K2317/64;;C07K2317/24;;C07K16/205;;C07K16/1003;;C07K16/18;;C07K16/40;;G01N33/6854;;C07K16/468;;G01N33/577;;G01N33/54387;;C07K2317/31;;C07K2317/52;;C07K2317/56;;G01N33/54388;;C07K16/18;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/528;;C07K2317/53,C07K16/00;;C12P21/08,,0,0,,,,PENDING
846,WO,A1,WO 2021/144721 A1,155-787-941-848-269,2021-07-22,2021,IB 2021050238 W,2021-01-14,IT 202000000634 A,2020-01-15,GRAPE SEED EXTRACTS FOR USE IN THE PREVENTION OR REDUCTION OF STRESS,"Disclosed are compositions comprising grape seed extracts, in particular extracts with a proanthocyanidin content exceeding 95% by weight and a catechin and epicatechin content ≥ 5% and ≤ 15% by weight, which are useful to prevent or reduce the perception of stress symptoms, in particular the perception of stress among the male population.",INDENA SPA,RIVA ANTONELLA;;RONCHI MASSIMO;;PETRANGOLINI GIOVANNA;;MORAZZONI PAOLO,,https://lens.org/155-787-941-848-269,Patent Application,yes,1,0,9,123-326-621-474-269;;180-860-413-007-196;;003-269-525-147-808;;082-471-753-931-260;;038-071-005-525-285;;033-813-260-984-364;;139-207-013-617-640;;181-839-572-312-577;;155-787-941-848-269,AU;;JP;;CN;;EP;;WO;;US;;CA;;IT;;BR,9,123-326-621-474-269;;180-860-413-007-196;;038-071-005-525-285;;003-269-525-147-808;;082-471-753-931-260;;033-813-260-984-364;;139-207-013-617-640;;181-839-572-312-577;;155-787-941-848-269,JP;;AU;;CN;;EP;;WO;;US;;CA;;IT;;BR,0,A61K36/87;;A61P43/00;;A61P25/22;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2054;;A61K9/2813;;A61K9/282;;A61K9/286;;A61K9/2866;;A61K31/353;;A61K36/87,A61K36/87;;A61P43/00,,2,1,020-842-934-348-905,24171039;;pmc3792515;;10.1155/2013/313142,"DATABASE WPI Week 200816, Derwent World Patents Index; AN 2008-C15943, XP002800171;;GIANNI BELCARO ET AL: ""Grape Seed Procyanidins in Pre- and Mild Hypertension: A Registry Study"", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2013, 1 January 2013 (2013-01-01), US, pages 1 - 5, XP055726331, ISSN: 1741-427X, DOI: 10.1155/2013/313142",PENDING
847,US,A1,US 2022/0386624 A1,061-905-246-197-608,2022-12-08,2022,US 202217887538 A,2022-08-15,US 202217887538 A,2022-08-15,STRAIN OF PSEUDOMONAS AERUGINOSA 9# AND APPLICATIONS THEREOF,"A strain of Pseudomonas aeruginosa 9 # and its applications are disclosed, which relates to the technical field of microorganisms. The deposit number of the Pseudomonas aeruginosa 9 # of the disclosure is CCTCC NO: M 2021178. The strain of Pseudomonas aeruginosa 9 # can inhibit the growth of the Ustilaginodea vixens strain YY7850, which is the first instance that the Pseudomonas aeruginosa strain has been found to antagonize the pathogen of rice false smut. In view of the ability of strain 9 # to inhibit the pathogen of rice false smut, the strain has the potential to be developed into a biocontrol bacterium of rice false smut.",CHINA NAT RICE RES INST,LIN XIAOYAN;;CHEN MINGXUE;;CAO ZHAOYUN;;YANG HUAN,,https://lens.org/061-905-246-197-608,Patent Application,yes,1,0,1,061-905-246-197-608,US,1,061-905-246-197-608,US,0,A01P3/00;;A01N63/27;;C12N1/205;;C12R2001/385;;A01N63/27;;A01P3/00;;C12N1/205;;C12R2001/385,A01N63/27;;A01P3/00;;C12N1/20,,4,2,019-434-112-366-698;;082-411-127-813-334,10.1016/j.scitotenv.2016.06.121;;27341110;;pmc4296558;;22549165,"Lin et al., ""Characterization of cadmium-resistant bacteria and their potential for reducing accumulation of cadmium in rice grains"", Sci. Total Environ. 569-570:97-104, 2016 (Year: 2016);;LB AGAR, LENNOX, 2011, 1 page (Year: 2011);;LaBauve et al., ""Growth and Laboratory Maintenance of Pseudomonas aeruginosa"", Curr. Protoc. Microbiol. Author Manuscript, PubMed Central 2015, 11 pages (Year: 2015);;Manidipa et al., ""Pseudomonads: Potential Biocontrol agents of Rice Diseases"", Res. J. Agricultrure and Forestry Sci. 1:19-25, 2013 (Year: 2013)",DISCONTINUED
848,US,A1,US 2021/0054387 A1,011-805-271-425-607,2021-02-25,2021,US 202016745983 A,2020-01-17,TW 108129823 A,2019-08-21,RECOMBINANT CANDIDA CELL AND PREPARATION PROCESS AND USE THEREOF,"Disclosed herein is a process for producing a recombinant Candida cell, which involves genetically engineering a parent Candida cell using a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas)(CRISPR/Cas) system. A recombinant Candida cell obtained using the process and a method for producing D-lactic acid from a biomass using the recombinant Candida cell are also disclosed.",FAR EASTERN NEW CENTURY CORP,WANG CHU-CHIN;;CHUANG YU-CHUAN;;SHIH SHU-YIN;;JHANG YI-CYUN,FAR EASTERN NEW CENTURY CORPORATION (2019-12-23),https://lens.org/011-805-271-425-607,Patent Application,yes,2,0,6,121-752-646-180-485;;184-212-857-587-718;;010-373-105-805-791;;050-982-541-666-665;;042-705-005-696-11X;;011-805-271-425-607,CN;;US;;TW,6,121-752-646-180-485;;042-705-005-696-11X;;010-373-105-805-791;;050-982-541-666-665;;011-805-271-425-607;;184-212-857-587-718,CN;;US;;TW,27,C12N15/905;;C12N9/0006;;C12P7/56;;C12Y101/01028;;C12N9/22;;C12N15/1137;;C12N15/815;;C12N2310/20;;C12P7/56;;C12Y401/01001;;C12N15/81;;C12N1/165;;C12N9/22;;C12N2310/20;;C12R2001/72,C12N15/81;;C12N9/22;;C12R1/72,,2,2,000-901-574-147-174;;018-988-071-129-810,34150504;;10.1016/j.meteno.2015.03.001;;pmc8193243;;10.1016/j.meteno.2017.08.002;;pmc5699526;;29188185,"Stovicek et al., ""CRISPR–Cas system enables fast and simple genome editing of industrial Saccharomyces cerevisiae strains"", Metab. Eng. Commun. 2:13-22, 2015 (Year: 2015);;Ozaki et al., ""Metabolic engineering of Schizosaccharomyces pombe via CRISPR-Cas9 genome editing for lactic acid production from glucose and cellobiose"", Metab. Eng. Commun. 5:60-67, 2017 (Year: 2017)",ACTIVE
849,US,A1,US 2022/0259270 A1,013-430-817-625-112,2022-08-18,2022,US 201917626877 A,2019-07-16,BR 2019050275 W,2019-07-16,MODIFIED TRICHODERMA FUNGAL STRAIN FOR THE PRODUCTION OF AN ENZYME COCKTAIL,"The present invention relates to a novel strain of Trichoderma comprising genetic modifications that enable the improved production of an enzyme cocktail, involving at least upregulation of the transcription factor Xyr1 according to SEQ ID No. 1; disruption of the gene ACE1 according to SEQ ID No. 2; disruption of the gene SLP1 according to SEQ ID No. 3; and expression of the gene Cel3a from Rasamsonia emersonii according to SEQ ID No. 4.",CENTRO NAC DE PESQUISA EM ENERGIA E MATERIAIS,MURAKAMI MARIO TYAGO;;FONSECA LUCAS MIRANDA;;PARREIRAS LUCAS SALERA,CENTRO NACIONAL DE PESQUISA EM ENERGIA E MATERIAIS (2022-05-16),https://lens.org/013-430-817-625-112,Patent Application,yes,1,0,6,089-655-535-755-781;;053-959-224-468-191;;188-679-783-609-754;;013-430-817-625-112;;173-010-734-173-190;;192-397-948-716-03X,EP;;CN;;WO;;US;;BR,6,192-397-948-716-03X;;053-959-224-468-191;;188-679-783-609-754;;089-655-535-755-781;;173-010-734-173-190;;013-430-817-625-112,CN;;EP;;WO;;US;;BR,6,C12R2001/885;;C12N15/80;;C07K14/37;;C12N9/58;;C12Y302/01021;;C12Y304/21014;;C12N9/2445;;C12R2001/645;;C07K14/37;;C12N9/0008;;C12N9/2445;;C12N9/485;;C12N9/58;;C12N15/52;;C12Y102/04002;;C12Y302/01021;;C12Y304/15001;;C12Y304/23018,C07K14/37;;C12N9/02;;C12N9/42;;C12N9/48;;C12N9/58;;C12N15/52,,10,3,099-148-434-391-858;;054-791-873-080-816;;054-964-895-195-342,26309247;;pmc4550459;;10.1371/journal.pone.0134723;;10.1007/s00253-021-11578-3;;34581845;;pmc5289010;;28184245;;10.1186/s13068-017-0717-0,"Landowski et al. “Enabling Low Cost Biopharmaceuticals: A Systematic Approach to Delete Proteases from a Well-Known Protein Production Host Trichoderma reesei”, PLoS ONE, 2015, Vol. 10, Issue 8, article e0134723; 28 pages. (Year: 2015);;Murray et al. “Expression in Trichoderma reesei and characterization of a thermostable family 3 β-glucosidase from the moderately thermophilic fungus Talaromyces emersonii”, Protein Expression and Purification, 2004, Vol. 38, Issue 2, pp.248-257. (Year: 2004);;Dwyer et al. “Recombinant production and characterisation of two chitinases from Rasamsonia emersonii, and assessment of their potential industrial applicability”, Applied Microbiology and Biotechnology, 2021, Vol. 105, pp.7769-7783. (Year: 2021);;GenBank 01 reference corresponding to accession number XP006966092, identified in GenBank on February 5, 2020 (Year: 2020);;GenBank 02 reference corresponding to accession number Q9P8W3.1, deposited in GenBank on May 29, 2024 (Year: 2024);;GenBank 03 reference corresponding to accession number XP006968395, deposited in GenBank on February 5, 2020 (Year: 2020);;GenBank 04 reference corresponding to accession number AAL69548, deposited in GenBank on July 10, 2003 (Year: 2003);;GenBank 05 reference corresponding to accession number XP006961768, deposited in GenBank on February 5, 2020 (Year: 2020);;GenBank 06 corresponding to accession number ABB59678, deposited in GenBank on October 2, 2006 (Year: 2006);;Ellilä et al. “Development of a low‑cost cellulase production process using Trichoderma reesei for Brazilian biorefineries”, Biotechnology for Biofuels, 2017, Vol. 10, article 30, 17 pages. (Year: 2017)",PENDING
850,WO,A1,WO 2022/133169 A1,014-535-507-589-707,2022-06-23,2022,US 2021/0063955 W,2021-12-17,US 202063127587 P,2020-12-18,CHIMERIC ANTIGEN RECEPTOR SYSTEMS WITH ADAPTABLE RECEPTOR SPECIFICITY,"The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.",CENTURY THERAPEUTICS INC,CARTON JILL;;NASO MICHAEL;;BORGES LUIS;;WHEELER JOHN;;DEVANEY ANDREW,,https://lens.org/014-535-507-589-707,Patent Application,yes,58,10,12,156-039-287-935-335;;179-158-186-278-467;;014-535-507-589-707;;013-293-744-591-485;;141-129-558-977-073;;095-106-707-288-012;;020-918-687-866-155;;080-968-873-079-608;;071-291-212-316-081;;062-134-665-901-640;;181-455-017-299-470;;162-332-945-485-701,JP;;AU;;AR;;CN;;EP;;WO;;US;;TW;;CA,12,162-332-945-485-701;;156-039-287-935-335;;014-535-507-589-707;;013-293-744-591-485;;141-129-558-977-073;;095-106-707-288-012;;020-918-687-866-155;;080-968-873-079-608;;071-291-212-316-081;;062-134-665-901-640;;181-455-017-299-470;;179-158-186-278-467,JP;;AU;;AR;;CN;;EP;;WO;;US;;TW;;CA,134,C07K16/18;;C07K16/30;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C07K2318/20;;A61P35/00;;C07K16/4208;;C07K14/7051;;C12N5/0636;;A61K40/4204;;A61K40/11;;A61K40/31;;C12N5/0636;;A61K40/11;;A61K40/31;;A61K40/4204,A61K39/00;;C07K16/18;;A61P35/00;;C07K14/705;;C07K16/30;;C07K16/42,,79,68,003-837-445-050-486;;113-898-797-372-224;;002-300-365-861-303;;065-543-615-775-304;;002-085-591-832-640;;049-612-970-455-301;;112-204-849-270-508;;020-302-793-258-828;;010-988-316-803-877;;021-251-297-626-440;;031-933-089-611-974;;026-851-425-535-342;;000-127-360-200-507;;076-607-506-177-849;;095-050-980-581-957;;081-762-779-850-964;;000-515-321-238-769;;059-038-435-839-492;;039-312-419-452-38X;;007-161-773-585-269;;039-384-864-129-401;;026-148-170-669-52X;;111-501-633-494-339;;021-612-452-406-271;;054-401-517-825-598;;012-582-448-101-431;;024-842-043-504-041;;021-205-310-526-974;;082-981-051-785-035;;077-532-829-551-519;;001-490-044-769-438;;005-218-993-322-382;;062-583-333-788-366;;034-882-216-262-941;;004-696-362-732-238;;037-746-277-847-997;;032-330-914-541-050;;059-783-224-775-628;;079-426-588-945-333;;007-202-397-793-299;;017-432-145-660-664;;143-567-630-855-189;;133-425-852-251-552;;087-629-857-628-134;;013-323-148-570-367;;040-573-961-841-570;;094-857-606-776-915;;001-431-119-334-376;;004-806-965-782-319;;015-639-251-167-350;;022-700-685-856-667;;009-073-833-235-053;;075-924-048-888-91X;;005-256-565-741-692;;072-366-322-919-406;;032-026-264-382-468;;004-212-749-090-555;;048-533-982-202-633;;044-907-186-843-585;;020-703-580-582-672;;004-701-796-869-470;;092-475-980-877-170;;107-273-667-679-802;;005-058-719-114-708;;061-912-118-293-713;;083-323-576-454-468;;027-088-607-245-004;;000-878-298-781-810,33007850;;10.3390/ijms21197222;;pmc7582510;;pmc7345059;;32481667;;10.3390/antib9020019;;pmc7419675;;10.3389/fonc.2020.01362;;32850436;;25450000;;10.1016/j.jim.2014.10.009;;22722836;;10.1038/nature11155;;30553519;;10.1016/j.ddtec.2018.10.005;;10.1002/j.1460-2075.1985.tb03694.x;;3924594;;pmc554253;;pmc347216;;6294651;;10.1073/pnas.79.22.6777;;2985280;;10.1016/s0092-8674(85)80025-8;;10.1128/jvi.63.4.1651-1660.1989;;pmc248413;;2538648;;10.1073/pnas.82.2.488;;pmc397064;;3881765;;10.1016/0092-8674(84)90039-4;;6231105;;2426350;;10.4049/jimmunol.137.4.1097;;pmc43728;;8171039;;10.1073/pnas.91.9.4086;;10.1006/bbrc.1999.1372;;10491297;;10683722;;10.2144/00282bm01;;10343905;;10.2144/99264st03;;11252783;;10.2144/01303bm04;;10.2144/00295bm09;;11084857;;1518797;;10.1093/protein/5.5.467;;9512562;;10.1093/nar/26.7.1848;;pmc147442;;8655519;;pmc178091;;10.1128/jb.178.11.3346-3349.1996;;8590473;;10.1007/bf00315788;;8850009;;10.1385/0-89603-332-5:229;;11162109;;10.1006/jmbi.2000.4265;;12204693;;10.1016/s1074-5521(02)00187-4;;15208403;;10.1093/protein/gzh053;;10.1038/nbt1127;;16211069;;10.1016/j.tibtech.2005.07.007;;16054718;;16151406;;10.1038/nbt1142;;10.1016/j.copbio.2006.10.003;;17055245;;10.1097/01.mol.0000252612.21602.e3;;17095910;;10.1385/1-59745-187-8:95;;17041261;;17643280;;10.1016/j.copbio.2007.04.010;;10.1074/jbc.m109.063305;;10.2210/pdb3l9j/pdb;;20179326;;pmc2852948;;pmc6259850;;10.3390/molecules16032467;;21407148;;18339624;;pmc3259661;;10.1074/jbc.m709987200;;10.1016/j.cell.2006.07.024;;16904174;;10.1016/j.cell.2008.03.028;;18423197;;pmc2615249;;21135032;;10.1093/intimm/dxq458;;20516640;;10.1172/jci42027;;pmc2898602;;10.1016/j.stem.2010.06.002;;pmc2917234;;20621045;;10.1371/journal.pone.0011373;;20617191;;pmc2894062;;9224705;;10.1016/s0014-5793(97)00475-4;;17141798;;10.1016/j.jim.2006.10.006;;10.1016/j.tibtech.2003.08.007;;14573361;;2499928;;10.1126/science.2499928;;10.1016/0092-8674(83)90344-6;;6678608;;pmc253118;;2831375;;10.1128/jvi.62.4.1120-1124.1988;;10.1182/blood.v82.3.845.845;;8393352;;10.1182/blood.v82.3.845.bloodjournal823845;;6438633;;10.1073/pnas.81.22.7161;;pmc392097;;10.1128/mcb.6.2.716;;3466023;;10.1128/mcb.6.2.716-718.1986;;pmc367564;;pmc3109217;;10.1016/j.coi.2011.03.008;;21530212;;10.4161/hv.7.0.14574;;21266849;;10.1128/mcb.5.5.1188-1190.1985;;pmc366838;;2987679;;10.1128/mcb.5.5.1188;;4705382;;10.1016/0042-6822(73)90341-3;;pmc367891;;3670292;;10.1128/mcb.7.8.2745;;10.1128/mcb.7.8.2745-2752.1987;;10.1128/mcb.10.2.689;;pmc360867;;2105458;;10.1128/mcb.10.2.689-695.1990;;pmc299564;;10.1073/pnas.84.23.8463;;2446324;;10.1038/327070a0;;10.1073/pnas.87.24.9568;;2175906;;pmc55213;;10.1016/s0021-9258(18)61209-8;;3558345;;10.1073/pnas.87.9.3410;;pmc53910;;2333290;;10.1016/0169-409x(93)90057-b;;10.1016/0076-6879(87)49054-x;;3320679;;10.1182/blood-2005-12-4827;;16569767;;17855550;;pmc2169009;;10.1128/jvi.00476-07;;1835892;;10.1182/blood.v78.12.3232.3232;;10.1002/ar.10039;;11788941;;10.1002/ar.10039.abs,"SUTHERLAND ASHLEY R. ET AL: ""Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting"", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 19, 30 September 2020 (2020-09-30), pages 7222, XP055888376, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582510/pdf/ijms-21-07222.pdf> DOI: 10.3390/ijms21197222;;STANOVA ALIYA K. ET AL: ""Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy"", ANTIBODIES, vol. 9, no. 2, 28 May 2020 (2020-05-28), pages 19, XP055853734, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345059/pdf/antibodies-09-00019.pdf> DOI: 10.3390/antib9020019;;VAN DER SCHANS JORT J. ET AL: ""Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment"", FRONTIERS IN ONCOLOGY, vol. 10, 5 August 2020 (2020-08-05), XP055793125, DOI: 10.3389/fonc.2020.01362;;GENE ROBERT W. ET AL: ""High affinity anti-Internalin B VHH antibody fragments isolated from naturally and artificially immunized repertoires"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 416, 8 November 2014 (2014-11-08), NL, pages 29 - 39, XP055902219, ISSN: 0022-1759, DOI: 10.1016/j.jim.2014.10.009;;BARANOVA EKATERINA ET AL: ""SbsB structure and lattice reconstruction unveil Ca2+ triggered S-layer assembly"", NATURE, vol. 487, no. 7405, 10 June 2012 (2012-06-10), London, pages 119 - 122, XP055576237, ISSN: 0028-0836, DOI: 10.1038/nature11155;;RICHARDS DANIEL A ED - PRABHU SAILETA: ""Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery"", DRUG DISCOVERY TODAY: TECHNOLOGIES, vol. 30, 8 November 2018 (2018-11-08), pages 35 - 46, XP085556181, ISSN: 1740-6749, DOI: 10.1016/J.DDTEC.2018.10.005;;DIJKEMA ET AL., EMBO J, vol. 4, 1985, pages 761;;GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6777;;BOSHART ET AL., CELL, vol. 41, 1985, pages 521;;JANG ET AL., J. VIROL., vol. 63, 1989, pages 1651 - 1660;;SAMBROOKFRITSCHMANIATIS: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;KUNKEL, PROC. NATL. ACAD. SCI. USA, vol. 1, 2, 1985, pages 488 - 492;;MEUER, S. C. ET AL., CELL, vol. 36, 1984, pages 897 - 906;;YANG, S. Y. ET AL., J. IMMUNOL., vol. 137, 1986, pages 1097 - 1100;;PERALES ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 4086 - 4090;;FUKUOKA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 263, 1999, pages 357 - 360;;KIMMAAS, BIOTECH, vol. 28, 2000, pages 196 - 198;;PARIKHGUENGERICH, BIOTECH, vol. 24, no. 4, 1998, pages 28 - 431;;RAYNICKOLOFF, BIOTECH, vol. 13, 1992, pages 342 - 346;;WANG ET AL., BIOTECH, vol. 19, 1995, pages 556 - 559;;WANGMALCOLM, BIOTECH, vol. 26, 1999, pages 680 - 682;;XUGONG, BIOTECH, vol. 26, pages 639 - 641;;HOGREFE, STRATEGIES, vol. 3, 2001, pages 74 - 75;;ANGAGSCHUTZ, BIOTECH, vol. 30, 2001, pages 486 - 488;;WANGWILKINSON, BIOTECH, vol. 29, 2000, pages 976 - 978;;KANG ET AL., BIOTECH, vol. 20, 1996, pages 44 - 46;;OGELMCPHERSON, PROTEIN ENGINEER, vol. 5, 1992, pages 467 - 468;;KIRSCHJOLY, NUCL. ACIDS. RES., vol. 26, 1998, pages 1848 - 1850;;RHEMHANCOCK, J. BACTERIOL., vol. 178, 1996, pages 3346 - 3349;;BOLESMIOGSA, CURR. GENET., vol. 28, 1995, pages 197 - 198;;BARRENTTINO ET AL., NUC. ACIDS. RES., vol. 22, 1993, pages 541 - 542;;TESSIERTHOMAS, METHS. MOLEC. BIOL., vol. 57, pages 229 - 237;;PONS ET AL., METH. MOLEC. BIOL., vol. 67, pages 209 - 218;;WORN APLUCKTHUN A, J MOL BIOL, vol. 305, 2001, pages 989 - 1010;;XU L ET AL., CHEM BIOL, vol. 9, 2002, pages 933 - 42;;WIKMAN M ET AL., PROTEIN ENG DES SEL, vol. 17, 2004, pages 455 - 62;;BINZ H ET AL., NAT BIOLECHNOL, vol. 23, 2005, pages 1257 - 68;;HEY T ET AL., TRENDS BIOTECHNOL, vol. 23, 2005, pages 514 - 522;;HOLLIGER PHUDSON P, NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 36;;GILL DDAMLE N, CURR OPIN BIOTECH, vol. 17, 2006, pages 653 - 8;;KOIDE AKOIDE S, METHODS MOL BIOL, vol. 352, 2007, pages 95 - 109;;SKERRA, CURRENT OPIN. IN BIOTECH., vol. 18, 2007, pages 295 - 304;;BYLA P ET AL., J BIOL CHEM, vol. 285, 2010, pages 12096;;ZOLLER F ET AL., MOLECULES, vol. 16, 2011, pages 2467 - 85;;WYPYCH ET AL., JBC, vol. 283, no. 23, 2008, pages 16194 - 16205;;TAKAHASHI, KYAMANAKA, S, CELL, vol. 126, no. 4, 2006, pages 663 - 76;;HANNA ET AL., CELL, vol. 133, 2008, pages 250 - 264;;WADA ET AL., INT. IMMUNOL., vol. 23, 2011, pages 65 - 74;;WATARAI ET AL., J. CLIN. INVEST., vol. 120, 2010, pages 2610 - 2618;;STAERK ET AL., CELL STEM CELL, vol. 7, 2010, pages 20 - 24;;BROWN ET AL., PLOS ONE, vol. 5, 2010, pages e11373;;ILIADES, P. ET AL., FEBS LETT, vol. 409, 1997, pages 437 - 441;;STONE, E. ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 318, 2007, pages 88 - 94;;HOLT, L. J. ET AL., TRENDS BIOTECHNOL, vol. 21, no. 11, 2003, pages 484 - 490;;WILSON ET AL., SCIENCE, vol. 244, no. 4910, 1989, pages 1342 - 1344;;MANN ET AL., CELL, vol. 33, 1983, pages 153;;MARKOWITZ ET AL., J. VIROL., vol. 62, 1988, pages 1120;;KUO ET AL., BLOOD, vol. 82, 1993, pages 845;;POTTER ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 81, 1984, pages 7161 - 7165;;TUR-KASPA ET AL., MOL. CELL BIOL., vol. 6, 1986, pages 716 - 718;;SARDESAI, N. Y.WEINER, D. B., CURRENT OPINION IN IMMUNOTHERAPY, vol. 23, 2011, pages 421 - 9;;FERRARO, B ET AL., HUMAN VACCINES, vol. 7, 2011, pages 120 - 127;;GHOSHB ACHHAWAT, LIVER DISEASES, TARGETED DIAGNOSIS AND THERAPY USING SPECIFIC RECEPTORS AND LIGANDS, 1991, pages 87 - 104;;GOPAL, T. V., MOL CELL BIOL, vol. 5, no. 5, May 1985 (1985-05-01), pages 1188 - 90;;GRAHAMVAN DER EB, VIROLOGY, vol. 52, 1973, pages 456 - 467;;CHENOKAYAMA, MOL. CELL BIOL., vol. 7, no. 8, 1987, pages 2745 - 2752;;RIPPE ET AL., MOL. CELL BIOL., vol. 10, 1990, pages 689 - 695;;FECHHEIMER ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 84, 1987, pages 8463 - 8467;;KLEIN ET AL., NATURE, vol. 327, 1987, pages 70 - 73;;YANG ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 87, 1990, pages 9568 - 9572;;WUWU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432;;WAGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, no. 9, 1990, pages 3410 - 3414;;WUWU, ADV. DRUG DELIVERY REV., vol. 12, 1993, pages 159 - 167;;NICOLAU ET AL., METHODS ENZYMOL., vol. 149, pages 157 - 176;;CORNISH ET AL., BLOOD, vol. 108, no. 2, 2006, pages 600 - 8;;BAZDARSIEG, JOURNAL OF VIROLOGY, vol. 81, no. 22, 2007, pages 12670 - 12674;;BATTALIA ET AL., IMMUNOLOGY, vol. 139, no. 1, 2013, pages 109 - 120;;HOSHINO ET AL., BLOOD, vol. 78, no. 12, 15 December 1991 (1991-12-15), pages 3232 - 40;;VITALE ET AL., THE ANATOMICAL RECORD, vol. 266, 2002, pages 87 - 92",PENDING
851,US,A1,US 2025/0250596 A1,105-000-353-693-891,2025-08-07,2025,US 202519186223 A,2025-04-22,US 202519186223 A;;US 202418435544 A;;US 202318179136 A;;US 202117530018 A;;US 202016997133 A;;US 201916287290 A;;US 201715787448 A;;US 201715445254 A;;US 201662413240 P;;US 201662336989 P;;US 201662302421 P,2016-03-02,METHODS FOR MAKING L-GLUFOSINATE,"Methods for the production of L-glufosinate (also known as phosphinothricin or (S)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic acid) are provided. The methods comprise a two-step process. The first step involves the oxidative deamination of D-glufosinate to PPO (2-oxo-4-(hydroxy(methyl)phosphinoyl)butyric acid). The second step involves the specific amination of PPO to L-glufosinate, using an amine group from one or more amine donors. By combining these two reactions, the proportion of L-glufosinate in a mixture of L-glufosinate and D-glufosinate can be substantially increased.",BASF SE,GREEN BRIAN MICHAEL;;GRADLEY MICHELLE LORRAINE,,https://lens.org/105-000-353-693-891,Patent Application,yes,7,0,50,191-960-178-895-556;;188-821-078-453-39X;;128-741-073-692-627;;072-120-846-807-739;;079-451-275-847-948;;174-912-614-103-584;;150-560-041-708-457;;192-256-179-448-325;;121-177-098-155-714;;010-220-668-665-318;;137-113-662-103-80X;;050-129-446-551-511;;162-735-676-470-38X;;053-554-868-262-839;;135-857-407-442-918;;055-400-257-723-633;;105-000-353-693-891;;187-913-651-884-806;;049-050-039-452-48X;;011-529-487-142-210;;047-294-799-569-080;;094-842-189-447-990;;031-004-586-864-853;;166-300-856-661-338;;077-302-689-284-258;;109-715-344-761-260;;041-656-413-400-192;;041-053-729-809-995;;187-121-024-424-856;;149-377-308-906-102;;099-565-244-988-028;;049-981-277-662-541;;007-269-710-394-072;;068-070-946-459-471;;100-055-091-225-612;;024-819-766-416-808;;003-309-128-401-343;;191-617-296-003-717;;117-987-291-522-336;;132-953-658-265-793;;123-837-520-674-143;;163-556-002-914-91X;;122-288-205-293-230;;116-320-366-508-343;;167-887-766-319-928;;123-400-874-824-661;;166-684-618-963-694;;119-191-536-234-439;;099-620-055-364-637;;077-416-658-949-785,JP;;AU;;CL;;US;;CA;;MX;;BR;;KR;;EP;;CN;;IL;;ZA;;WO;;MA,51,191-960-178-895-556;;188-821-078-453-39X;;128-741-073-692-627;;079-451-275-847-948;;072-120-846-807-739;;150-560-041-708-457;;174-912-614-103-584;;192-256-179-448-325;;121-177-098-155-714;;010-220-668-665-318;;137-113-662-103-80X;;050-129-446-551-511;;162-735-676-470-38X;;053-554-868-262-839;;135-857-407-442-918;;055-400-257-723-633;;105-000-353-693-891;;187-913-651-884-806;;049-050-039-452-48X;;011-529-487-142-210;;047-294-799-569-080;;094-842-189-447-990;;031-004-586-864-853;;166-300-856-661-338;;077-302-689-284-258;;109-715-344-761-260;;041-656-413-400-192;;041-053-729-809-995;;187-121-024-424-856;;149-377-308-906-102;;099-565-244-988-028;;049-981-277-662-541;;007-269-710-394-072;;068-070-946-459-471;;024-819-766-416-808;;100-055-091-225-612;;003-309-128-401-343;;191-617-296-003-717;;117-987-291-522-336;;132-953-658-265-793;;123-837-520-674-143;;163-556-002-914-91X;;016-844-205-835-759;;122-288-205-293-230;;167-887-766-319-928;;116-320-366-508-343;;123-400-874-824-661;;166-684-618-963-694;;119-191-536-234-439;;099-620-055-364-637;;077-416-658-949-785,JP;;AU;;CL;;US;;CA;;MX;;BR;;KR;;AR;;EP;;CN;;IL;;ZA;;WO;;MA,0,C12P13/04;;C12P9/00;;C12P41/00;;C12N9/0024;;C12Y104/03003;;C12P41/00;;C12P9/00;;C12P13/04;;A01N57/20;;C12Y104/03003;;C12Y206/01019;;C12N9/10;;C12Y206/01019;;C12P9/00;;C12P13/04;;A01N57/18;;C12Y104/03003;;A01N57/20;;C12N1/20;;C12P13/02;;A01N25/30;;C12P41/00;;A01N25/30;;A01N57/20;;C12N1/20;;C12N9/10;;C12P13/02;;C12P13/04;;C12P41/00;;C12Y104/03003;;C12Y206/01019;;C12P41/00;;C12P9/00;;C12P13/04;;A01N25/30;;A01N57/20;;C12P13/02;;C12Y104/03003;;C12Y206/01019;;C12N1/20;;C12N9/10,C12P13/02;;A01N25/30;;A01N57/20;;C12N1/20;;C12N9/10;;C12P9/00;;C12P13/04;;C12P41/00,,1,1,034-182-105-502-474,21397351;;10.1016/j.tibtech.2011.01.010,"Pollegioni et al., New biotech applications from evolved D-amino acid oxidases. Trends in Biotechnol., 2011, Vol. 29(6): 276-283. (Year: 2011)",PENDING
852,US,A1,US 2021/0254010 A1,050-095-265-105-237,2021-08-19,2021,US 201916973220 A,2019-05-31,US 201916973220 A;;US 201862684854 P;;US 2019/0034789 W,2018-06-14,Isolation of Mesenchymal Stromal Cells,"Methods for isolating mesenchymal stromal cells from umbilical cord blood. The methods include providing a blood collection bag having raw umbilical cord blood contained therein, draining the umbilical cord blood from the blood collection bag, introducing a cell detachment solution into the blood collection bag to dissociate mesenchymal stromal cells adhered to the bag surface, thereby forming a mesenchymal stromal cell enriched fluid, and voiding the mesenchymal stromal cell enriched fluid into a collection apparatus for further processing and culturing.",ABRAHAM J AND PHYLLIS KATZ CORD BLOOD FOUND,LAUGHLIN MARY;;DO JEONG-SU;;VAN'T HOF WOUTER,ABRAHAM J AND PHYLLIS KATZ CORD BLOOD FOUNDATION (2020-11-18),https://lens.org/050-095-265-105-237,Patent Application,yes,2,0,5,110-079-639-035-419;;190-139-279-900-758;;126-548-586-805-087;;028-068-625-311-827;;050-095-265-105-237,EP;;WO;;US;;CA,5,110-079-639-035-419;;190-139-279-900-758;;126-548-586-805-087;;028-068-625-311-827;;050-095-265-105-237,EP;;WO;;US;;CA,0,C12N5/0665;;C12N5/0665;;B01D21/262;;B01D2251/70;;B01D2251/90;;C12N2500/84;;C12N2502/1157,C12N5/0775;;B01D21/26,,0,0,,,,DISCONTINUED
853,US,A1,US 2023/0265136 A1,145-187-503-289-135,2023-08-24,2023,US 202218063499 A,2022-12-08,CN 202210176623 A,2022-02-24,USE OF CNPY3 PROTEIN AS TARGET FOR TREATING OF DENGUE FEVER,"A use of a canopy fibroblast growth factor signaling regulator 3 (CNPY3) protein as a target for treating of dengue fever is provided belongs to the technical field of antiviral drugs. An important host protein CNPY3 related to dengue virus infection is identified. A host gene is significantly down-regulated in blood of dengue patients and in dengue virus (DENV) infected dendritic cells and THP-1 cells. Its expression is negatively correlated with the progression of dengue disease and positively correlated with the expression of most Toll-like receptors. Down-regulation of the host gene inhibits the production of IFN-β and the expression of ISGs in THP-1 cells, promoting DENV-2 infection. Up-regulation of the host gene expression in Vero and HEK 293T cells inhibits DENV-2 infection. It indicates that CNPY3 participates in an innate immune response signaling pathway, has the effect of anti-dengue virus, and is a potential therapeutic target for dengue fever.",UNIV ARMY MEDICAL,LI JINTAO;;DING XIAOYAN;;ZHOU YUXIN;;HE JIUXIANG;;ZHOU XIAOYANG;;QIU MINYUE,ARMY MEDICAL UNIVERSITY (2022-12-07),https://lens.org/145-187-503-289-135,Patent Application,yes,0,0,3,037-439-962-093-265;;041-396-475-401-475;;145-187-503-289-135,CN;;WO;;US,3,037-439-962-093-265;;041-396-475-401-475;;145-187-503-289-135,CN;;WO;;US,0,C07K14/47;;A61K38/00;;A61K48/005;;A61P31/14;;A61P31/14;;A61K38/00;;C07K14/47;;Y02A50/30;;C07K14/47;;A61K38/00;;A61P31/14,C07K14/47;;A61P31/14,,0,0,,,,PENDING
854,US,A1,US 2023/0045199 A1,030-199-232-128-572,2023-02-09,2023,US 202017786147 A,2020-12-23,US 202017786147 A;;US 201962952653 P;;US 2020/0066779 W,2019-12-23,COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION,Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.,CHILDRENS HOSPITAL PHILADELPHIA;;UNIV PENNSYLVANIA,BLOBEL GERD;;PESLAK SCOTT;;SHI JUNWEI,THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (2020-12-02);;THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2021-06-17),https://lens.org/030-199-232-128-572,Patent Application,yes,1,0,2,030-199-232-128-572;;170-988-995-340-051,WO;;US,2,030-199-232-128-572;;170-988-995-340-051,WO;;US,12,A61P7/06;;A61K31/454;;A61K31/713;;C12N15/1137;;C12N2310/20;;C12Y301/03016;;C12N2310/20;;A61P7/06;;A61K31/454;;A61K31/713;;C12N15/1137;;C12N2320/31,C12N15/113;;A61K31/454;;A61K31/713;;A61P7/06,,8,7,014-723-756-409-429;;037-687-051-633-518;;113-614-190-992-905;;010-137-131-903-585;;107-703-011-822-474;;048-680-369-923-133;;043-875-130-123-896,10.1016/j.ajpath.2011.01.041;;pmc3081176;;21514445;;10.1007/978-1-4939-7299-9_7;;29127681;;10.1023/b:drug.0000011792.13160.b0;;14739664;;27544028;;10.1016/j.bbrc.2016.08.090;;10.1016/j.toxlet.2013.02.011;;23454832;;10.1182/blood-2015-09-667923;;26679864;;pmc4797024;;10.1182/blood-2010-11-319137;;pmc3148160;;21536862,"Chen et al., 2011, The American Journal of Pathology, Vol. 178, No. 5, pg. 2333-2343 (Year: 2011);;Cui and Engel, 2017, Gene and Cell Therapies for Beta-Globinopathies, Advances in Experimental Medicine and Biology 1013, Chapter 7, pg. 177-202 (Year: 2017);;Le et al., 2004, Investigational New Drugs, 22: 159-167 (Year: 2004);;Wu et al., 2016, Biochemical and Biophysical Research Communications, 478, pg. 1179-1184 (Year: 2016);;Zhou et al., 2013, Toxicology Letters, (2013) 194-201 (Year: 2013);;Swingle et al., 2007, Methods in Molecular Biology, Volume 365: Protein Phosphatase Protocols, Chapter 3, pg. 23-38 (Year: 2007);;Dulmovits et al., 2016, Blood, Vol. 127, No. 11, pg. 1481-1492 (Year: 2016);;Meiler et al., 2011, Blood, Vol. 118, No. 4, pg. 1109-1112; Fig. 1A (Year: 2011)",PENDING
855,US,A1,US 2022/0298587 A1,051-706-976-349-066,2022-09-22,2022,US 202017597091 A,2020-07-01,GB 201909439 A;;GB 2020051575 W,2019-07-01,NOVEL CONSTRUCT,"The invention relates to an NHEJ or MMEJ detection construct, to NHEJ or MMEJ detection assays comprising said construct and to a method of screening for an NHEJ or MMEJ modulator comprising said construct.",ARTIOS PHARMA LTD,RAJENDRA EESON;;ROBINSON HELEN,ARTIOS PHARMA LIMITED (2022-09-14),https://lens.org/051-706-976-349-066,Patent Application,yes,0,0,7,106-217-005-751-243;;165-176-117-894-136;;051-706-976-349-066;;120-714-427-113-30X;;023-544-810-916-046;;067-500-102-337-651;;006-734-384-099-469,JP;;CN;;EP;;WO;;US;;CA;;GB,7,106-217-005-751-243;;165-176-117-894-136;;051-706-976-349-066;;120-714-427-113-30X;;067-500-102-337-651;;023-544-810-916-046;;006-734-384-099-469,JP;;CN;;EP;;WO;;US;;CA;;GB,12,C12N15/1075;;C12Q1/6897;;C12N15/85;;C12N2800/10,C12Q1/6897;;C12N15/85,,0,0,,,,PENDING
856,US,A1,US 2021/0130758 A1,144-519-678-671-223,2021-05-06,2021,US 202016994744 A,2020-08-17,US 202016994744 A;;DE 102019115147 A;;US 202016893510 A,2019-06-05,BIOCOMPATIBLE COMPOSITE ELEMENTS AND METHODS FOR PRODUCING,"A biocompatible composite element for a bioreactor is provided that includes an outer frame and an inner component. The outer frame is a polymeric material. The outer frame can be inseparably attached to a wall of the bioreactor. The inner component is a transparent material selected from a group consisting of glass, sapphire, and glass ceramic. The inner component is secured in the outer component in an inseparable hermetically tight manner. The inner component is configured for a spectral process control through the transparent material of the inner component.",SCHOTT AG,OTT CHRISTIAN;;HETTLER ROBERT;;STANGL CHRISTOPH;;BLÜMEL HELENA;;ECKER REINHARD,SCHOTT AG (2020-09-15),https://lens.org/144-519-678-671-223,Patent Application,yes,4,1,1,144-519-678-671-223,US,12,062-891-204-779-951;;125-712-720-966-021;;009-497-315-135-908;;074-429-346-062-265;;191-594-096-241-172;;190-502-243-622-905;;189-828-978-091-599;;191-077-271-939-151;;021-430-658-621-148;;144-519-678-671-223;;124-082-430-864-190;;097-631-551-137-960,DE;;JP;;EP;;CN;;US,0,C12M23/22;;C12M23/28;;C12M23/48;;C12M37/04;;C12M41/46;;C12M23/06;;C12M23/28;;C12M23/22,C12M1/12;;C12M1/00,,0,0,,,,PENDING
857,EP,A1,EP 4484574 A1,077-067-622-317-257,2025-01-01,2025,EP 22927705 A,2022-02-24,CN 2022077609 W,2022-02-24,SINGLE-CELL TRANSCRIPTOME SEQUENCING METHOD AND USE THEREOF,"The present invention provides a single-cell transcriptome sequencing method and use thereof. The method comprises: preparing a single-cell suspension with a test cell sample, then fixing cells with a fixative solution; and using a reverse transcription primer to perform an in-situ reverse transcription reaction on RNA of the fixed single cell to synthesize a first cDNA strand.",UNIV ZHEJIANG,WANG YONGCHENG;;XU ZIYE;;WANG YUTING,,https://lens.org/077-067-622-317-257,Patent Application,yes,0,0,5,077-067-622-317-257;;181-710-450-303-739;;082-986-295-359-561;;094-387-394-353-131;;129-791-233-406-813,JP;;AU;;EP;;WO;;US,5,077-067-622-317-257;;181-710-450-303-739;;082-986-295-359-561;;094-387-394-353-131;;129-791-233-406-813,JP;;AU;;EP;;WO;;US,0,C12Q1/6806;;C12Q1/6869;;C12Q1/6806;;C12Q1/6869,C12Q1/6869;;C12Q1/6806;;C40B50/06,,0,0,,,,PENDING
858,US,A1,US 2022/0142216 A1,175-832-067-596-792,2022-05-12,2022,US 202017434235 A,2020-02-26,US 202017434235 A;;US 201962810556 P;;US 2020/0019864 W,2019-02-26,Novel Mogrosides and Uses of the Same,"Mogrosides containing non-glucose glycosides are provided herein. Compositions, including consumables comprising the novel mogrosides described herein, are also provided.",COCA COLA CO,PRAKASH INDRA;;MA GIL;;MERCOGLIANDO CHRISTOPHER;;PETROVIC GORAN,THE COCA-COLA COMPANY (2019-02-27),https://lens.org/175-832-067-596-792,Patent Application,yes,5,2,13,162-146-090-721-756;;175-832-067-596-792;;066-586-536-760-602;;116-056-033-303-104;;064-741-852-812-819;;167-889-705-237-581;;048-914-471-640-710;;195-605-097-264-639;;188-238-130-015-744;;124-390-936-267-718;;043-024-916-738-141;;017-799-826-141-078;;033-880-105-639-552,KR;;JP;;AU;;CN;;EP;;WO;;US;;SG;;CA;;BR;;MX,13,162-146-090-721-756;;175-832-067-596-792;;066-586-536-760-602;;116-056-033-303-104;;064-741-852-812-819;;167-889-705-237-581;;048-914-471-640-710;;195-605-097-264-639;;188-238-130-015-744;;124-390-936-267-718;;043-024-916-738-141;;017-799-826-141-078;;033-880-105-639-552,KR;;JP;;AU;;CN;;EP;;WO;;US;;SG;;CA;;BR;;MX,0,C07H15/24;;A23L2/60;;C07J17/005;;C07H15/24;;C07J17/005;;A23L2/38;;A23L2/52;;C07G3/00;;A23L2/60;;A23L27/36;;A23L2/60;;A23V2002/00;;C07J17/005,A23L27/30;;A23L2/60;;C07J17/00,,1,1,002-745-531-785-564,29191092;;10.1080/09168451.2017.1387514,"Hikaru, Plant-derived isoprenoid sweeteners: recent progress in biosynthesis gene discovery and perspectives on microbial production, Biosci, Biotech. and Biochem,, 2018, 82, 6, 927-934 (Year: 2018)",PENDING
859,EP,A1,EP 4484958 A1,083-964-076-326-486,2025-01-01,2025,EP 23182541 A,2023-06-29,EP 23182541 A,2023-06-29,TARGETED PROTEOMICS FOR MONITORING AUTOPHAGY,"The invention relates to a peptide mix comprising peptides for use in monitoring autophagy, the peptides being derived from proteins involved in autophagy.",UNIV OF FRIBOURG,The designation of the inventor has not yet been filed,,https://lens.org/083-964-076-326-486,Patent Application,yes,1,0,1,083-964-076-326-486,EP,2,133-286-749-449-440;;083-964-076-326-486,EP;;WO,99,G01N33/6848;;G01N2458/15;;G01N2510/00,G01N33/68,,8,8,044-020-875-247-933;;040-086-288-073-672;;078-349-780-033-390;;009-949-102-765-118;;116-956-094-710-778;;045-322-977-932-798;;036-600-152-884-841;;171-167-453-063-000,28712572;;pmc5526835;;10.1016/j.cub.2017.06.021;;34663331;;pmc8524881;;10.1186/s12935-021-02249-4;;25311616;;pmc4258159;;10.1021/pr500714a;;36635405;;pmc9838376;;10.1038/s41576-022-00562-w;;34152791;;10.1146/annurev-cellbio-120219-035530;;pmc8563709;;10.1038/s41419-021-04121-9;;34728604;;pmc8526019;;33183148;;10.1080/15548627.2020.1847461;;pmc9797988;;10.1083/jcb.202108144;;36574265,"JOACHIM JUSTIN ET AL: ""Centriolar Satellites Control GABARAP Ubiquitination and GABARAP-Mediated Autophagy"", CURRENT BIOLOGY, CURRENT SCIENCE, GB, vol. 27, no. 14, 14 July 2017 (2017-07-14), pages 2123, XP085254315, ISSN: 0960-9822, DOI: 10.1016/J.CUB.2017.06.021;;SUN RUI-JIE ET AL: ""Quantitative LC-MS/MS uncovers the regulatory role of autophagy in immune thrombocytopenia"", CANCER CELL INTERNATIONAL, vol. 21, no. 1, 18 October 2021 (2021-10-18), pages 1 - 10, XP093102955, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s12935-021-02249-4/fulltext.html> DOI: 10.1186/s12935-021-02249-4;;ALAYEV ANYA ET AL: ""Phosphoproteomics Reveals Resveratrol-Dependent Inhibition of Akt/mTORC1/S6K1 Signaling"", JOURNAL OF PROTEOME RESEARCH, vol. 13, no. 12, 29 October 2014 (2014-10-29), pages 5734 - 5742, XP093103238, ISSN: 1535-3893, DOI: 10.1021/pr500714a;;H. YAMAMOTOS. ZHANGN. MIZUSHIMA: ""Autophagy genes in biology and disease"", NAT REV GENET 10.1038/S41576-022-00562-W, 2023, pages 1 - 19;;T. LAMARKT. JOHANSEN: ""Mechanisms of Selective Autophagy"", ANNU REV CELL DEV BIOL, vol. 37, 2021, pages 143 - 169;;M. BORDIR. DE CEGLIB. TESTAR. A. NIXONA. BALLABIOF. CECCONI: ""A gene toolbox for monitoring autophagy transcription"", CELL DEATH DIS, vol. 12, 2021, pages 1044;;D. SIVA SANKARJ. DENGJEL: ""Protein complexes and neighborhoods driving autophagy"", AUTOPHAGY, vol. 17, 2021, pages 2689 - 2705;;J. ZHOUN. L. RASMUSSENH. L. OLSVIKV. AKIMOVZ. HUG. EVJENS. KAESER-PEBERNARDD. S. SANKARC. ROUBATYP. VERLHAC: ""TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1"", J CELL BIOL, 2023, pages 222",DISCONTINUED
860,WO,A1,WO 2021/261837 A1,091-639-030-766-671,2021-12-30,2021,KR 2021007589 W,2021-06-17,KR 20200077383 A,2020-06-24,ORAL PHARMACEUTICAL COMPOSITION COMPRISING NAFAMOSTAT MESYLATE AS ACTIVE INGREDIENT,"The present invention relates to an oral pharmaceutical composition comprising nafamostat mesylate as an active ingredient, a method for preparing same, and a method for preventing or treating coronavirus disease (COVID-19) using same. The composition according to one aspect is an antiviral oral pharmaceutical composition that has a preventive or therapeutic effect on coronavirus disease (COVID-19), is easy to administer, and can be safely used without side effects even when taken for a long time.",NEWGLAB PHARMA CO LTD,HAN SIN YOUNG;;YOON HYUNG YOUNG;;KIM JOO EUN;;HYUN CHANG KEUN,,https://lens.org/091-639-030-766-671,Patent Application,yes,3,2,2,091-639-030-766-671;;035-842-446-345-320,KR;;WO,2,091-639-030-766-671;;035-842-446-345-320,KR;;WO,0,A61K9/48;;A61K31/24;;A61K47/12;;A61K47/36;;A61P31/14;;A61K9/4866;;A61K9/4858;;A61K31/24;;A61K47/12;;A61K47/36;;A61P31/14,A61K9/48;;A61K31/24;;A61K47/12;;A61K47/36;;A61P31/14,,2,1,021-467-850-440-610,10.3390/v12060629;;32532094;;pmc7354595,"YAMAMOTO MIZUKI, KISO MAKI, SAKAI-TAGAWA YUKO, IWATSUKI-HORIMOTO KIYOKO, IMAI MASAKI, TAKEDA MAKOTO, KINOSHITA NORIKO, OHMAGARI NO: ""The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner"", VIRUSES, vol. 12, no. 6, pages 629, XP055832268, DOI: 10.3390/v12060629;;ANONYMOUS: ""Ensysce, a California Based Biotech Company With a Mission to Solve the Opioid Crisis, Exploring a Treatment for COVID-19"", BUSINESSWIRE, 15 April 2020 (2020-04-15), XP055882901, Retrieved from the Internet <URL:https://www.businesswire.com/news/home/20200415005156/en/Ensysce-a-California-Based-Biotech-Company-With-a-Mission-to-Solve-the-Opioid-Crisis-Exploring-a-Treatment-for-COVID-19.>",PENDING
861,EP,A2,EP 4566671 A2,047-478-646-498-468,2025-06-11,2025,EP 25168339 A,2021-07-01,EP 21833302 A;;CN 2021103931 W;;CN 202010623708 A;;CN 202110353488 A,2020-07-01,CONSTRUCTION AND APPLICATION OF FUSION PROTEIN VACCINE PLATFORM,"The present invention relates to the construction and application of a fusion protein vaccine platform. The present invention provides a vaccine, comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope in the preparation of prophylactic or therapeutic compositions. The vaccine of the present invention can be produced by eukaryotic cell expression systems to prepare wild-type and various mutant antigen vaccines, and vaccination by means of subcutaneous/muscular or nasal or other routes can lead to a strong immune response to a body. The vaccine of the present invention can be used as a prophylactic or therapeutic vaccine.",INST BIOPHYSICS CAS,FU YANGXIN;;PENG HUA;;SUN SHIYU,,https://lens.org/047-478-646-498-468,Patent Application,yes,0,0,15,075-947-509-386-130;;150-114-855-501-754;;160-285-713-187-439;;101-157-007-488-115;;053-263-542-407-76X;;189-246-547-701-076;;084-242-920-933-217;;043-946-747-739-311;;166-856-064-638-803;;184-124-611-792-914;;096-862-123-045-201;;000-403-733-607-86X;;059-101-602-850-525;;176-058-390-840-296;;047-478-646-498-468,AU;;JP;;EP;;WO;;US;;CA;;PH,22,098-306-187-533-381;;075-947-509-386-130;;195-379-103-023-207;;150-114-855-501-754;;178-481-822-690-318;;160-285-713-187-439;;101-157-007-488-115;;053-263-542-407-76X;;184-124-611-792-914;;043-946-747-739-311;;139-413-996-810-413;;084-242-920-933-217;;166-856-064-638-803;;189-246-547-701-076;;096-862-123-045-201;;000-403-733-607-86X;;059-101-602-850-525;;176-058-390-840-296;;186-413-477-594-32X;;047-478-646-498-468;;182-069-930-001-612;;018-810-410-607-306,AU;;JP;;CN;;EP;;WO;;US;;CA;;PH,93,A61K39/12;;A61P31/12;;A61P35/00;;A61P31/04;;C07K14/555;;C12N15/62;;C07K2319/30;;A61K2039/6056;;C12N2730/10134;;C12N2770/20034;;A61K2039/605;;A61K2039/6031;;A61K2039/55505;;A61K2039/575;;A61P31/20;;A61P31/14;;A61K2039/543;;A61K39/001106;;C12N2760/16134;;C12N2710/16734;;C12N2710/16234;;C12N2710/16634;;C07K2317/52;;A61K39/39;;A61P31/12;;A61K9/0019;;A61K39/12;;A61K39/395;;A61K2039/6056;;A61K2039/6075;;A61K40/4204,A61P31/12,,24,23,126-661-760-630-820;;001-930-156-678-836;;006-953-345-221-222;;034-094-810-007-33X;;002-010-592-900-67X;;053-880-836-837-46X;;056-406-054-524-97X;;018-867-320-652-143;;020-517-379-296-464;;101-283-830-576-100;;003-946-932-157-208;;011-483-806-642-730;;041-253-656-315-658;;107-485-591-498-873;;032-575-326-752-543;;152-636-436-238-534;;040-491-508-558-671;;018-404-118-505-501;;033-996-471-769-896;;027-171-822-693-034;;032-454-095-831-699;;150-899-611-085-363;;016-722-289-911-388,29599078;;10.1016/s2468-1253(18)30056-6;;10.1016/s0140-6736(15)61412-x;;26231459;;10.3410/f.731220250.793569875;;pmc5605509;;28919117;;10.1016/s0140-6736(17)32154-2;;29955068;;pmc7097467;;10.1038/s41572-018-0006-7;;29955060;;10.1038/s41572-018-0002-y;;10.1586/14760584.2013.824709;;24024871;;25766291;;10.1016/j.chom.2015.02.012;;pmc4362519;;33024307;;10.1038/s41579-020-00459-7;;pmc7537588;;32227757;;10.1056/nejmp2005630;;10.1016/j.cell.2020.07.012;;32730807;;pmc7366990;;21862310;;10.1016/j.copbio.2011.06.012;;pmc3216605;;22355641;;10.1038/srep00124;;10.1038/nri2155;;17703228;;16979566;;10.1016/j.immuni.2006.08.008;;10.1586/14760584.7.3.373;;18393607;;15723812;;10.1016/j.immuni.2005.01.005;;11207245;;10.4049/jimmunol.166.5.2961;;10.1182/blood.v99.9.3263;;11964292;;14502286;;10.1038/ni978;;10.4049/jimmunol.176.8.4682;;16585561;;22184405;;10.1182/blood-2011-06-363564;;11698286;;10.1182/blood.v98.10.3022;;10.1002/eji.201040523;;21061437;;10.1016/s1074-7613(01)00126-1;;11336691,"WHO W.: ""Global hepatitis report 2017 [J]."", GENEVA: WORLD HEALTH ORGANIZATION, 2017;;RAZAVI-SHEARER DGAMKRELIDZE I, NGUYEN M H ET AL.: ""Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study [J]."", THE LANCET GASTROENTEROLOGY & HEPATOLOGY, vol. 3, no. 6, 2018, pages 383 - 403;;SCHWEITZER AHORN JMIKOLAJCZYK R T ET AL.: ""Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 [J]."", THE LANCET, vol. 386, no. 10003, 2015, pages 1546 - 55;;VOS TABAJOBIR A AABATE K H ET AL.: ""Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [J]."", THE LANCET, vol. 390, no. 10100, 2017, pages 1211 - 59;;KRAMMER FSMITH G J DFOUCHIER R A M ET AL.: ""Influenza [J"", NATURE REVIEWS DISEASE PRIMERS, vol. 4, no. 1, 2018, pages 3;;HANNOUN C.: ""The evolving history of influenza viruses and influenza vaccines [J]."", EXPERT REVIEW OF VACCINES, vol. 12, no. 9, 2013, pages 1085 - 94;;HOUSER KSUBBARAO K.: ""Influenza vaccines: challenges and solutions [J]."", CELL HOST & MICROBE, vol. 17, no. 3, 2015, pages 295 - 300, XP029145223, DOI: 10.1016/j.chom.2015.02.012;;HU BGUO HZHOU P ET AL.: ""Characteristics of SARS-CoV-2 and COVID-19 [J]."", NATURE REVIEWS MICROBIOLOGY, 2020, pages 1 - 14;;LURIE NSAVILLE MHATCHETT R ET AL.: ""Developing Covid-19 vaccines at pandemic speed [J]."", NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, no. 21, 2020, pages 1969 - 73;;LI QWU JNIE J ET AL.: ""The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity [J]."", CELL, vol. 182, no. 5, 2020, pages 1284 - 94;;KONTERMANN R E: ""Strategies for extended serum half-life of protein therapeutics [J"", CURRENT OPINION IN BIOTECHNOLOGY, vol. 22, no. 6, 2011, pages 868 - 76, XP028397475, DOI: 10.1016/j.copbio.2011.06.012;;MEKHAIEL D NCZAJKOWSKY D MANDERSEN J T ET AL.: ""Polymeric human Fc-fusion proteins with modified effector functions [J]."", SCIENTIFIC REPORTS, vol. 1, no. 1, 2011, pages 1 - 11, XP002708372, DOI: 10.1038/srep00124;;ROOPENIAN D CAKILESH S.: ""FcRn: the neonatal Fc receptor comes of age [J]."", NATURE REVIEWS IMMUNOLOGY, vol. 7, no. 9, 2007, pages 715 - 25;;VILCEK J.: ""Fifty years of interferon research: aiming at a moving target [J]."", IMMUNITY, vol. 25, no. 3, 2006, pages 343 - 8;;BRACCI LLA SORSA VBELARDELLI F ET AL.: ""Type I interferons as vaccine adjuvants against infectious diseases and cancer [J]."", EXPERT REVIEW OF VACCINES, vol. 7, no. 3, 2008, pages 373 - 81;;HAHM BTRIFILO M JZUNIGA E I ET AL.: ""Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling [J"", IMMUNITY, vol. 22, no. 2, 2005, pages 247 - 57;;ITO TAMAKAWA RINABA M ET AL.: ""Differential regulation of human blood dendritic cell subsets by IFNs [J]."", THE JOURNAL OF IMMUNOLOGY, vol. 166, no. 5, 2001, pages 2961 - 9, XP002971753;;MONTOYA MSCHIAVONI GMATTEI F ET AL.: ""Type I interferons produced by dendritic cells promote their phenotypic and functional activation [J"", BLOOD, vol. 99, no. 9, 2002, pages 3263 - 71;;LE BON AETCHART NROSSMANN C ET AL.: ""Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon [J]."", NATURE IMMUNOLOGY, vol. 4, no. 10, 2003, pages 1009 - 15, XP037924575, DOI: 10.1038/ni978;;LE BON ADURAND VKAMPHUIS E ET AL.: ""Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming [J]."", THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 8, 2006, pages 4682 - 9, XP002516827;;SPADARO FLAPENTA CDONATI S ET AL.: ""IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing [J]."", BLOOD, THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 119, no. 6, 2012, pages 1407 - 17, XP086694233, DOI: 10.1182/blood-2011-06-363564;;PARLATO SSANTINI S MLAPENTA C ET AL.: ""Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities [J"", BLOOD, THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 98, no. 10, 2001, pages 3022 - 9;;ROUZAUT AGARASA STEIJEIRA A ET AL.: ""Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α [J]."", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 40, no. 11, 2010, pages 3054 - 63, XP071224635, DOI: 10.1002/eji.201040523;;LE BON ASCHIAVONI GD'AGOSTINO G ET AL.: ""Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo [J]."", IMMUNITY, vol. 14, no. 4, 2001, pages 461 - 70, XP001008314, DOI: 10.1016/S1074-7613(01)00126-1",PENDING
862,US,A1,US 2023/0152312 A1,006-768-607-901-507,2023-05-18,2023,US 202117911959 A,2021-02-12,US 202117911959 A;;US 202062977133 P;;US 202063014088 P;;US 2021/0018015 W,2020-02-14,DEVICES AND METHODS FOR TREATING ISCHAEMIA AND ACUTE RESPIRATORY DISTRESS SYNDROMES,"Devices and methods for conducting lateral flow immunochromatographic assays may be used, in some aspects, to measure the level of glutathione-S-transferase pi in a biological fluid collected from a human subject suspected of having had a stroke in order to determine whether the subject has had a stroke or to aid in the selection and administration of a treatment for the suspected stroke. In other aspects, such devices may be used to diagnose, monitor, and/or treat acute respiratory distress syndromes (ARDS), such as the novel coronavirus designated COVID-19.",GALAXY CCRO INC,PIKE IAN HUGO;;ELDER TERRY;;LAROCHE MAXIME;;STANKOV MILOVAN,GALAXY CCRO INC (2020-05-20),https://lens.org/006-768-607-901-507,Patent Application,yes,0,0,10,092-278-693-102-820;;046-892-427-788-999;;096-234-066-942-792;;082-989-433-160-731;;055-759-962-500-508;;108-284-913-604-276;;175-448-431-310-265;;006-768-607-901-507;;140-292-981-576-326;;025-174-544-727-257,JP;;AU;;EP;;WO;;US;;CA;;MX;;BR,10,092-278-693-102-820;;046-892-427-788-999;;082-989-433-160-731;;096-234-066-942-792;;055-759-962-500-508;;108-284-913-604-276;;175-448-431-310-265;;006-768-607-901-507;;025-174-544-727-257;;140-292-981-576-326,JP;;AU;;EP;;WO;;US;;CA;;MX;;BR,1,G01N33/54388;;G01N2333/91177;;G01N2800/2871;;G01N33/573;;G01N33/54388;;G01N2333/91177;;G01N2800/125;;G01N2800/2871;;G01N2800/52,G01N33/543,,0,0,,,,PENDING
863,US,A1,US 2025/0179569 A1,082-986-295-359-561,2025-06-05,2025,US 202218840834 A,2022-02-24,CN 2022077609 W,2022-02-24,SINGLE-CELL TRANSCRIPTOME SEQUENCING METHOD AND USE THEREOF,"The present invention provides a single-cell transcriptome sequencing method and use thereof. The method comprises: preparing a single-cell suspension with a test cell sample, then fixing cells with a fixative solution; and using a reverse transcription primer to perform an in-situ reverse transcription reaction on RNA of the fixed single cell to synthesize a first cDNA strand.",UNIV ZHEJIANG,WANG YONGCHENG;;XU ZIYE;;WANG YUTING,ZHEJIANG UNIVERSITY (2024-08-12),https://lens.org/082-986-295-359-561,Patent Application,yes,0,0,5,077-067-622-317-257;;181-710-450-303-739;;082-986-295-359-561;;094-387-394-353-131;;129-791-233-406-813,JP;;AU;;EP;;WO;;US,5,077-067-622-317-257;;181-710-450-303-739;;082-986-295-359-561;;094-387-394-353-131;;129-791-233-406-813,JP;;AU;;EP;;WO;;US,0,C12Q1/6806;;C12Q1/6869;;C12Q1/6806;;C12Q1/6869,C12Q1/6869;;C12Q1/6806,,0,0,,,,PENDING
864,US,A1,US 2023/0270128 A1,053-724-494-600-096,2023-08-31,2023,US 202118040592 A,2021-08-06,NL 2026242 A;;NL 2021050497 W,2020-08-07,OLEOGEL,"The invention provides a method for producing an oleogel, the method comprising a mixing stage, a cross-linking stage and optionally a drying stage; wherein the mixing stage comprises mixing starting materials to provide a starting mixture, wherein the starting materials comprise (i) a hydrocolloid, (ii) a protein, (iii) one or more of a fat and an oil, and (iv) water, wherein the protein is a vegetable based protein and wherein the one or more of the fat the oil is a vegetable based; wherein the cross-linking stage comprises cross-linking the hydrocolloid and the protein in the starting mixture, to provide a cross-linked structure; and wherein the optional drying stage comprises drying the cross-linked structure to provide a further processed cross-linked structure; wherein the oleogel comprises the cross-linked structure or wherein the oleogel comprises the further processed cross-linked structure, wherein the oleogel comprises a total amount of fat and oil relative to a total amount of the oleogel in the range of 20-90 wt. %.",BFLIKE B V,CAMILLERI MICHAEL;;HOOGLAND OSCAR JAN;;FRANKEN WOUTER MATTHIJS,BFLIKE B.V (2023-02-14),https://lens.org/053-724-494-600-096,Patent Application,yes,2,1,10,021-938-917-169-764;;188-490-202-491-876;;089-172-391-885-571;;075-542-647-584-48X;;002-019-016-362-245;;165-036-740-055-049;;137-524-662-889-423;;054-035-211-075-192;;053-724-494-600-096;;145-113-787-532-050,NL;;AU;;CN;;EP;;WO;;US;;CA;;BR;;MX,10,188-490-202-491-876;;021-938-917-169-764;;089-172-391-885-571;;002-019-016-362-245;;075-542-647-584-48X;;165-036-740-055-049;;137-524-662-889-423;;054-035-211-075-192;;053-724-494-600-096;;145-113-787-532-050,NL;;AU;;CN;;EP;;WO;;US;;CA;;BR;;MX,0,A23D7/0053;;A23D9/007;;A23D9/02;;A23J3/227;;A23L29/20;;A23L13/426;;A23J3/14;;A23J3/16;;A23L29/272;;A23L29/272;;A23D7/0053;;A23D7/04;;A23J3/14;;A23J3/16;;A23J3/227,A23D7/04;;A23D7/005;;A23J3/14;;A23J3/16;;A23J3/22;;A23L29/269,,1,0,,,"What is gellan gum E418 high acyl vs low acyl?. Gellan Gum from CINOGEL BIOTECH. (2020, May 18). https://www.cinogel.com/p/gellan-gum.html",PENDING
865,EP,A1,EP 4454647 A1,097-900-480-003-799,2024-10-30,2024,EP 22909620 A,2022-11-21,CN 202111599362 A;;CN 2022133165 W,2021-12-24,"USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS","The present invention relates to the use of a class of 1,4-dihydro-naphthyridine derivatives in the treatment of tumors.",NEURODAWN PHARMACEUTICAL CO LTD,ZHANG ZHENGPING;;LI FULONG;;WANG LEI;;CHEN RONG;;YANG WEIDONG;;FANG FANG;;AN WENJI;;HUA YAO;;FENG LIN,,https://lens.org/097-900-480-003-799,Patent Application,yes,0,0,14,001-806-387-318-442;;050-234-879-924-541;;079-038-442-484-007;;171-100-647-150-19X;;005-917-555-698-913;;050-302-961-299-281;;032-448-315-746-488;;023-546-700-846-808;;098-793-023-218-458;;074-195-052-448-120;;182-103-815-541-193;;142-370-216-206-276;;166-956-136-472-477;;097-900-480-003-799,JP;;AU;;KR;;IL;;CN;;EP;;ZA;;WO;;US;;CA;;MX,14,001-806-387-318-442;;050-234-879-924-541;;079-038-442-484-007;;171-100-647-150-19X;;005-917-555-698-913;;050-302-961-299-281;;032-448-315-746-488;;023-546-700-846-808;;098-793-023-218-458;;074-195-052-448-120;;182-103-815-541-193;;142-370-216-206-276;;166-956-136-472-477;;097-900-480-003-799,JP;;AU;;KR;;IL;;CN;;EP;;ZA;;WO;;US;;CA;;MX,0,A61K31/4375;;A61P35/00;;Y02P20/55;;A61P35/00;;A61K31/4375;;A61K31/495;;A61K31/4375;;Y02P20/55;;A61P35/00;;A61K31/4375;;A61P35/00;;A61P35/00;;A61K31/4188;;A61K31/4745,A61K31/4375;;A61P35/00,,0,0,,,,PENDING
866,WO,A2,WO 2021/163608 A2,096-234-066-942-792,2021-08-19,2021,US 2021/0018015 W,2021-02-12,US 202062977133 P;;US 202063014088 P,2020-02-14,DEVICES AND METHODS FOR TREATING ISCHAEMIA AND ACUTE RESPIRATORY DISTRESS SYNDROMES,"Devices and methods for conducting lateral flow immunochromatographic assays may be used, in some aspects, to measure the level of glutathione-S-transferase pi in a biological fluid collected from a human subject suspected of having had a stroke in order to determine whether the subject has had a stroke or to aid in the selection and administration of a treatment for the suspected stroke. In other aspects, such devices may be used to diagnose, monitor, and/or treat acute respiratory distress syndromes (ARDS), such as the novel coronavirus designated COVID-19.",GALAXY CCRO INC,PIKE IAN HUGO;;ELDER TERRY;;LAROCHE MAXIME;;STANKOV MILOVAN,,https://lens.org/096-234-066-942-792,Patent Application,yes,0,1,10,092-278-693-102-820;;046-892-427-788-999;;096-234-066-942-792;;082-989-433-160-731;;055-759-962-500-508;;108-284-913-604-276;;175-448-431-310-265;;006-768-607-901-507;;140-292-981-576-326;;025-174-544-727-257,JP;;AU;;EP;;WO;;US;;CA;;MX;;BR,10,092-278-693-102-820;;046-892-427-788-999;;082-989-433-160-731;;096-234-066-942-792;;055-759-962-500-508;;108-284-913-604-276;;175-448-431-310-265;;006-768-607-901-507;;025-174-544-727-257;;140-292-981-576-326,JP;;AU;;EP;;WO;;US;;CA;;MX;;BR,1,G01N33/54388;;G01N2333/91177;;G01N2800/2871;;G01N33/573;;G01N33/54388;;G01N2333/91177;;G01N2800/125;;G01N2800/2871;;G01N2800/52,,,0,0,,,,PENDING
867,KR,A,KR 20220078026 A,126-015-727-429-897,2022-06-10,2022,KR 20200167098 A,2020-12-03,KR 20200167098 A,2020-12-03,Culture Reactor Of Microbe For Wastewater Treatment And Cultivation Method Using thereof,"본 발명은 본 발명은 오폐수 처리용 미생물 배양장치 및 이를 이용한 배양방법에 관한 것으로, 보다 상세하게는 일측에는 원수가 공급되는 원수 유입구(111)가 구비되고 타측에는 처리수가 배출되는 처리수 유출구(112)가 마련된 소정 형상을 갖는 반응조 본체부(100); 상기 반응조 본체부(100) 내부 공간에 위치하는 격벽(200); 및 상기 반응조 본체부(100) 내부 공간에 구비되는 교반기(300);를 포함하는 것을 특징으로 하는 오폐수 처리용 미생물 배양장치 및 이를 이용한 배양방법에 관한 것이다.",GS ENGINEERING & CONSTR CORP,BAE HYO KWAN;;PARK JI HYE;;HWANG KWANG HYUN,,https://lens.org/126-015-727-429-897,Patent Application,no,4,0,2,025-804-401-579-617;;126-015-727-429-897,KR,2,025-804-401-579-617;;126-015-727-429-897,KR,0,Y02W10/10;;C12M23/02;;C02F3/307;;C02F3/34;;C12M23/34;;C12M27/06;;C12M41/14,C12M1/00;;C02F3/30;;C02F3/34;;C12M1/06,,1,0,,,"Ji. Evolution of microbial dynamics with the introduction of real seawater portions in a low-strength feeding anammox process. Applied microbial biotech. 2020.4.17. 104, 5593-5604 1부.*",ACTIVE
868,EP,A1,EP 3775167 A1,143-340-198-972-952,2021-02-17,2021,EP 19784760 A,2019-04-12,CN 2018082945 W;;CN 2019082407 W,2018-04-13,METHODS OF CANCER TREATMENT USING TUMOR ANTIGEN-SPECIFIC T CELLS,,SYZ CELL THERAPY CO;;HRYZ SHENZHEN BIOTECH CO,ZHOU XIANGJUN;;HAN YANYAN;;CHEN XIHE;;LIANG XIAOLING,HRYZ (GUANGZHOU) BIOTECH CO. (2024-04-24);;HRYZ (SHANGHAI) BIOTECH CO. (2024-04-24);;HRYZ (SHENZHEN) BIOTECH CO. (2024-04-17),https://lens.org/143-340-198-972-952,Patent Application,yes,0,0,12,142-512-893-472-898;;085-061-142-708-761;;060-234-697-897-813;;125-263-638-446-835;;136-094-778-040-866;;154-837-340-135-753;;043-770-532-229-406;;143-340-198-972-952;;019-060-423-993-476;;174-770-146-791-660;;183-350-322-722-003;;001-402-106-933-609,CN;;EP;;WO;;US;;TW,12,136-094-778-040-866;;085-061-142-708-761;;125-263-638-446-835;;060-234-697-897-813;;142-512-893-472-898;;043-770-532-229-406;;154-837-340-135-753;;143-340-198-972-952;;019-060-423-993-476;;174-770-146-791-660;;001-402-106-933-609;;183-350-322-722-003,EP;;CN;;WO;;US;;TW,0,A61P35/00;;A61K2039/70;;A61K2039/892;;C12N2710/20034;;A61K39/12;;A61K2039/585;;A61K2039/572;;C12N5/0636;;A61K40/19;;A61K40/24;;A61K40/4201;;A61K40/4208;;A61K40/4205;;A61K40/4239;;A61K40/4241;;A61K40/424;;A61K40/4243;;A61K40/4246;;A61K40/4257;;A61K40/4266;;A61K40/4268;;A61K40/4269;;A61K40/428;;A61K40/46;;A61K40/11;;A61P35/00;;C12N5/0636;;C12N2501/24;;C12N2501/515;;C12N2502/1121;;A61K40/11;;A61K40/19;;A61K40/24;;A61K40/46;;A61K40/424;;A61K40/428;;A61K40/4201;;A61K40/4205;;A61K40/4208;;A61K40/4239;;A61K40/4241;;A61K40/4243;;A61K40/4246;;A61K40/4257;;A61K40/4266;;A61K40/4268;;A61K40/4269,C12N5/0783;;A61K39/00;;A61P35/00;;C12N5/0784,,0,0,,,,PENDING
869,EP,A1,EP 3775166 A1,117-774-595-707-648,2021-02-17,2021,EP 19777370 A,2019-03-29,CN 2018081338 W;;CN 2019080535 W,2018-03-30,IMPROVED MULTIPLE ANTIGEN SPECIFIC CELL THERAPY METHODS,,SYZ CELL THERAPY CO;;HRYZ SHENZHEN BIOTECH CO,ZHOU XIANGJUN;;MA YIFAN;;HAN YANYAN;;LI JIN;;TANG LONGQING;;LIU JUNYUN;;WU DONGYUN,HRYZ (GUANGZHOU) BIOTECH CO. (2024-04-24);;HRYZ (SHANGHAI) BIOTECH CO. (2024-04-24);;HRYZ (SHENZHEN) BIOTECH CO. (2024-04-17),https://lens.org/117-774-595-707-648,Patent Application,yes,0,0,11,092-320-721-683-930;;132-745-231-780-431;;026-588-736-866-282;;135-963-907-201-650;;101-244-219-228-548;;079-281-313-963-650;;012-457-852-091-295;;101-032-611-807-507;;117-774-595-707-648;;141-043-866-374-322;;164-130-071-692-394,CN;;EP;;WO;;US;;TW,11,135-963-907-201-650;;132-745-231-780-431;;026-588-736-866-282;;164-130-071-692-394;;101-244-219-228-548;;079-281-313-963-650;;012-457-852-091-295;;101-032-611-807-507;;117-774-595-707-648;;141-043-866-374-322;;092-320-721-683-930,CN;;EP;;WO;;US;;TW,0,A61P35/00;;C12N2502/1121;;C12N5/0638;;C12N2501/24;;C12N2501/2302;;C12N2501/2307;;C12N2501/2315;;C12N2501/2321;;C12N2501/02;;C12N2501/2304;;C12N2501/22;;C12N5/0639;;C12N2501/998;;C12N2502/1114;;A61K2239/31;;A61K2239/53;;A61K2239/50;;A61K40/19;;A61K40/24;;A61K40/4201;;A61K40/11;;A61P35/00;;C12N5/0638;;C12N2501/02;;C12N2501/2302;;C12N2501/2307;;C12N2501/2315;;C12N2501/2321;;C12N2501/24;;C12N2501/50;;C12N2501/515;;C12N2501/999;;C12N2502/1121;;A61K2239/50;;C12N5/0639;;A61K2239/31;;A61K2239/53;;A61K40/11;;A61K40/19;;A61K40/24;;A61K40/4201,C12N5/0783;;A61K35/17;;A61K38/17;;A61P35/00;;C12N5/0784,,0,0,,,,PENDING
870,EP,A1,EP 3775168 A1,151-524-367-480-067,2021-02-17,2021,EP 19785434 A,2019-04-12,CN 2018082947 W;;CN 2019082408 W,2018-04-13,METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS,,SYZ CELL THERAPY CO;;HRYZ SHENZHEN BIOTECH CO,ZHOU XIANGJUN;;HAN YANYAN;;LIANG XIAOLING;;CHEN XIHE,HRYZ (GUANGZHOU) BIOTECH CO. (2024-04-24);;HRYZ (SHANGHAI) BIOTECH CO. (2024-04-24);;HRYZ (SHENZHEN) BIOTECH CO. (2024-04-17),https://lens.org/151-524-367-480-067,Patent Application,yes,0,0,24,064-127-335-550-005;;098-024-760-020-189;;112-734-642-470-615;;090-664-234-368-091;;058-585-996-883-211;;199-750-217-830-006;;184-643-577-143-99X;;033-063-266-997-086;;104-428-092-862-634;;154-200-707-531-78X;;129-898-448-930-233;;136-946-107-200-061;;181-618-624-081-856;;114-833-978-821-622;;049-952-292-599-269;;126-310-407-583-037;;061-228-658-868-898;;183-363-343-868-469;;113-749-567-615-682;;151-524-367-480-067;;184-296-920-214-852;;123-821-228-992-105;;151-219-208-360-569;;032-183-008-237-623,JP;;KR;;CN;;EP;;WO;;US;;TW,24,064-127-335-550-005;;098-024-760-020-189;;112-734-642-470-615;;090-664-234-368-091;;058-585-996-883-211;;199-750-217-830-006;;184-643-577-143-99X;;033-063-266-997-086;;104-428-092-862-634;;154-200-707-531-78X;;129-898-448-930-233;;136-946-107-200-061;;181-618-624-081-856;;114-833-978-821-622;;049-952-292-599-269;;126-310-407-583-037;;061-228-658-868-898;;183-363-343-868-469;;113-749-567-615-682;;151-524-367-480-067;;184-296-920-214-852;;123-821-228-992-105;;151-219-208-360-569;;032-183-008-237-623,JP;;KR;;CN;;EP;;WO;;US;;TW,293,C07K14/7051;;C12N5/0636;;A61P35/00;;C12N2510/00;;C07K14/4702;;C12N5/0639;;A61K40/32;;A61K40/19;;A61K40/24;;A61K40/4201;;A61K40/4208;;A61K40/4205;;A61K40/4232;;A61K40/4239;;A61K40/4241;;A61K40/424;;A61K40/4243;;A61K40/4246;;A61K40/4266;;A61K40/4268;;A61K40/4269;;A61K40/46;;A61K40/11;;A61K38/00;;A61P35/00;;C07K14/7051;;A61K39/12;;C12N2710/20034;;C07K16/2809;;C07K16/2818;;C12N5/0639;;C12N5/0636;;A61K40/32;;A61K40/19;;A61K40/24;;A61K40/4201;;A61K40/4208;;A61K40/4205;;A61K40/4232;;A61K40/4239;;A61K40/4241;;A61K40/424;;A61K40/4243;;A61K40/4246;;A61K40/4266;;A61K40/4268;;A61K40/4269;;A61K40/46;;A61K40/11;;C07K14/7051;;C12Q1/6816;;C12N5/0636;;A61P35/00;;C12N2501/998;;C12N2502/11;;C07K16/2809;;C07K16/30;;A61K35/17;;A61P35/00;;A61K38/00;;C07K14/7051;;C12N5/0636;;C12N5/0639;;C12N2502/1114;;C12N2502/1121;;C12P21/02;;A61K40/11;;A61K40/19;;A61K40/24;;A61K40/32;;A61K40/46;;A61K40/424;;A61K40/4201;;A61K40/4205;;A61K40/4208;;A61K40/4232;;A61K40/4239;;A61K40/4241;;A61K40/4243;;A61K40/4246;;A61K40/4266;;A61K40/4268;;A61K40/4269,C12N5/0783;;A61K38/17;;A61P35/00;;C12N5/0784;;C12N5/0786,,0,0,,,,PENDING
871,US,A1,US 2023/0067480 A1,169-595-014-120-21X,2023-03-02,2023,US 202017790484 A,2020-12-30,CN 2019129957 W;;CN 2020141501 W,2019-12-30,METHOD FOR TREATING USHER SYNDROME AND COMPOSITION THEREOF,"Provided is a method for targeted editing of target RNA containing a G to A mutation in a USH2A gene transcript based on LEAPER technology, comprising: introducing a construct of an adenosine deaminase recruiting RNA (arRNA) for editing the target RNA or a construct encoding said arRNA into a cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to the target RNA, and wherein the arRNA is capable of recruiting adenosine deaminase acting on RNA (ADAR), so that the target adenosine in the target RNA is deaminated, thereby performing in vivo editing of the base from A to I on RNA safely and effectively, repairing a pathogenic mutation site, and achieving the purpose of treating disease such as Usher syndrome.",EDIGENE THERAPEUTICS BEIJING INC,LIU NENGYIN;;YI ZEXUAN;;YUAN PENGFEI;;ZHAO YANXIA;;TANG GANGBIN,,https://lens.org/169-595-014-120-21X,Patent Application,yes,0,0,18,067-496-159-929-78X;;054-371-145-982-634;;063-838-202-080-868;;198-898-423-807-688;;169-595-014-120-21X;;193-021-580-763-807;;184-542-667-972-799;;058-872-265-645-561;;165-053-687-577-909;;146-958-174-186-838;;179-036-253-160-149;;117-947-036-265-188;;041-232-121-491-273;;161-752-870-687-687;;031-193-361-231-495;;066-306-087-055-887;;040-907-038-893-649;;100-706-969-312-332,JP;;AU;;US;;TW;;CA;;CO;;EC;;PH;;MX;;BR;;PE;;CR;;KR;;IL;;EP;;CN;;WO,18,067-496-159-929-78X;;054-371-145-982-634;;063-838-202-080-868;;198-898-423-807-688;;169-595-014-120-21X;;058-872-265-645-561;;184-542-667-972-799;;193-021-580-763-807;;165-053-687-577-909;;146-958-174-186-838;;179-036-253-160-149;;117-947-036-265-188;;041-232-121-491-273;;161-752-870-687-687;;031-193-361-231-495;;066-306-087-055-887;;040-907-038-893-649;;100-706-969-312-332,JP;;AU;;US;;TW;;CA;;CO;;EC;;PH;;MX;;BR;;PE;;CR;;KR;;EP;;IL;;CN;;WO,35,C12N15/113;;C12N15/102;;C12N2750/14143;;C12N2310/20;;A61K31/7105;;A61K31/7115;;A61K48/00;;C12N15/11;;C12N15/113;;C12N15/1137;;C12N15/102;;A61K48/00;;A61K31/7115;;A61P43/00;;A61P43/00;;A61K48/00;;C12N15/102;;C12N15/11;;C12N15/86;;C12N2750/14141,C12N15/10;;A61K48/00;;A61P43/00;;C12N15/11;;C12N15/86,,0,0,,,,PENDING
872,US,A1,US 2022/0054527 A1,085-484-423-630-694,2022-02-24,2022,US 202117518415 A,2021-11-03,US 202117518415 A;;US 202117167428 A;;US 201615234177 A;;US 201562205031 P,2015-08-14,METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND,"Provided are implants and a glycolytic dependent compound for use in enhancing toxicity of the glycolytic dependent compound towards a cell, tissue and/or organ e.g., a diseased cell, tissue and/or organ, wherein the implant and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.",ETHICON INC;;OMRIX BIOPHARMACEUTICALS LTD,GALLOWAY JAMES;;BYK-TENNENBAUM TAMARA;;ILAN EREZ;;WEISSMAN LIOR;;DORON SIVAN;;MONTIA EVE;;SCHMITZ NIELS-DERREK,ETHICON INC (2022-07-22);;OMRIX BIOPHARMACEUTICALS LTD (2022-07-24),https://lens.org/085-484-423-630-694,Patent Application,yes,1,0,1,085-484-423-630-694,US,19,096-339-675-624-336;;085-484-423-630-694;;114-502-137-823-221;;147-502-782-973-721;;163-720-456-675-177;;141-424-354-718-522;;063-736-669-633-393;;134-924-965-093-194;;086-270-016-251-745;;124-695-559-146-319;;093-106-451-455-151;;073-217-608-923-109;;187-789-126-526-722;;119-180-104-743-340;;056-104-694-341-617;;088-080-996-626-180;;128-215-341-965-370;;030-129-652-031-255;;048-042-219-075-46X,AU;;RU;;CN;;EP;;ES;;WO;;HK;;US;;MA,0,A61K31/717;;A61K31/704;;A61K31/717;;A61K31/704;;A61L2400/04;;A61L24/0015;;A61L15/28;;A61L24/08;;A61L15/44;;A61L24/0042,A61K31/717;;A61K31/704;;A61L15/28;;A61L15/44;;A61L24/00;;A61L24/08,,2,1,080-698-365-863-140,10.1038/sj.onc.1209597;;16892078,Pelicano et al. Oncogene. 2006; 25: 4633-4646. (Year: 2006);;Mohan et al. 3 Biotech. 2021; 11:15; 13 pages. (Year: 2021),PENDING
873,KR,A,KR 20220141138 A,018-486-143-121-106,2022-10-19,2022,KR 20210047312 A,2021-04-12,KR 20210047312 A,2021-04-12,JMA-1 3- Production method for 3-Hydroxypropionic acid with Kluyveromyces marxianus JMA-1,"The present invention relates to a method for producing 3-hydroxypropionic acid using a Kluyveromyces marxianus JMA-1 strain, and vectors and hosts capable of effectively expressing 3-hydroxypropionic acid were discovered. Through the same, the present invention is able to efficiently induce the expression of 3-hydroxy propionic acid from a Kluyveromyces marxianus strain.",KNU INDUSTRY COOPERATION FOUND,HA SUK JIN;;KANG KYOUNG GON;;PARK JAE BUM;;KWON DEOK HO,,https://lens.org/018-486-143-121-106,Patent Application,no,2,0,2,052-203-501-106-492;;018-486-143-121-106,KR,2,052-203-501-106-492;;018-486-143-121-106,KR,18,C12N15/815;;C12N9/0008;;C12N9/93;;C12P7/52;;C12Y102/01075;;C12Y604/01002,C12N15/81;;C12N9/00;;C12N9/02;;C12P7/52,,3,1,002-501-684-304-994,10.1007/s13205-017-0985-1;;28955646;;pmc5612877,"2019 한국생물공학회 춘계학술발표대회 및 국제심포지엄 [초록집], 2019.04., P0241. p. 337.*;;한국생물공학회 추계학술발표대회 및 국제심포지엄 [초록집], 2019.04., P0114. p. 254.*;;3 Biotech, 2017, 7:349.*",ACTIVE
874,US,A1,US 2024/0318216 A1,162-735-075-933-545,2024-09-26,2024,US 202418733787 A,2024-06-04,US 202418733787 A;;EP 15184968 A;;US 202117323737 A;;US 201815758653 A;;EP 2016071420 W,2015-09-12,Production of Human Milk Oligosaccharides in Microbial Hosts with Engineered Import/Export,"The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.",CHR HANSEN HMO GMBH,JENNEWEIN STEFAN;;WARTENBERG DIRK,CHR. HANSEN A/S (2025-01-07),https://lens.org/162-735-075-933-545,Patent Application,yes,0,0,34,125-468-710-010-841;;103-831-434-837-951;;109-676-485-744-860;;188-458-429-824-444;;105-687-920-648-653;;134-089-508-568-899;;168-242-704-506-793;;148-829-670-849-76X;;175-561-674-072-905;;092-241-673-167-601;;027-869-240-326-044;;097-882-370-938-191;;151-931-374-768-833;;054-775-309-640-165;;106-346-999-979-252;;062-295-690-741-025;;145-108-262-879-485;;144-801-902-777-989;;122-056-138-717-765;;053-340-470-488-762;;130-829-663-570-222;;144-804-018-184-30X;;087-054-605-698-73X;;162-735-075-933-545;;089-346-927-934-94X;;088-687-893-874-975;;145-436-052-013-213;;138-131-019-107-17X;;115-215-357-658-349;;107-199-060-546-314;;102-945-553-890-463;;066-710-624-112-010;;193-747-822-745-154;;045-010-182-877-737,KR;;JP;;AU;;RU;;CN;;EP;;WO;;US;;NZ;;MX;;PH;;BR,34,125-468-710-010-841;;103-831-434-837-951;;109-676-485-744-860;;188-458-429-824-444;;105-687-920-648-653;;134-089-508-568-899;;168-242-704-506-793;;148-829-670-849-76X;;175-561-674-072-905;;092-241-673-167-601;;027-869-240-326-044;;097-882-370-938-191;;151-931-374-768-833;;054-775-309-640-165;;106-346-999-979-252;;062-295-690-741-025;;145-108-262-879-485;;144-801-902-777-989;;122-056-138-717-765;;053-340-470-488-762;;130-829-663-570-222;;144-804-018-184-30X;;087-054-605-698-73X;;162-735-075-933-545;;089-346-927-934-94X;;088-687-893-874-975;;145-436-052-013-213;;138-131-019-107-17X;;115-215-357-658-349;;107-199-060-546-314;;102-945-553-890-463;;066-710-624-112-010;;193-747-822-745-154;;045-010-182-877-737,KR;;JP;;AU;;RU;;CN;;EP;;WO;;US;;NZ;;MX;;PH;;BR,0,C12P19/18;;C12N9/1051;;C12Y204/01146;;C07K14/245;;C12N9/1051;;C12P19/04;;C12P19/18;;C12N15/70;;C07K14/195;;C12Y204/01146;;C12N15/67;;C12N15/70;;C12N9/1051;;C12P19/18;;C12Y204/01146;;C12P19/18;;C12N9/1051;;C12N15/70;;C12Y204/01146,C12P19/18;;C12N9/10;;C12N15/70,,0,0,,,,PENDING
875,US,A1,US 2025/0223326 A1,024-895-761-932-947,2025-07-10,2025,US 202318853878 A,2023-05-10,EP 22305688 A;;EP 2023062497 W,2022-05-10,SYNCITIN-1 FUSION PROTEINS AND USES THEREOF FOR CARGO DELIVERY INTO TARGET CELLS,"The inventors developed a new system to modify tropism of syncytins, envelope proteins, which can be used to functionalize particles such as virus particle or more particularly viral-like particles (VLPs), and used for gene transfer or other applications. In particular, they created a fusion protein containing the Syncytin-1 (SYN) signal sequence (SS), a targeting moiety (either natural or engineered), the SYN protein and a flexible linker between SYN and the targeting moiety to enhance transduction of the cell type expressing the receptor or the antigen targeted by the targeting moiety, for instance hematopoietic stem progenitor cells (HSPCs). The inventors demonstrated that the fusion strategy allows modification of syncytin tropism towards different receptors in order to target f the desired cell type. The system is adaptable to other desired antigens to retarget the fusion protein to a specific cell type.",INST NAT SANTE RECH MED;;ASSIST PUBLIQUE HOPITAUX PARIS APHP;;FOND IMAGINE;;UNIV PARIS CITE,MICCIO ANNARITA;;VON JOEST MATHIEU,UNIVERSITÉ PARIS CITÉ (2024-10-21);;FONDATION IMAGINE (2024-10-21);;INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (2024-10-21);;ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (2024-10-21),https://lens.org/024-895-761-932-947,Patent Application,yes,0,0,4,024-895-761-932-947;;133-279-129-501-812;;146-111-610-512-094;;042-338-154-585-892,JP;;EP;;WO;;US,4,024-895-761-932-947;;133-279-129-501-812;;146-111-610-512-094;;042-338-154-585-892,JP;;EP;;WO;;US,0,C07K14/005;;A61K38/00;;C07K2319/00;;C07K2319/33;;C07K2319/02;;A61P7/00;;A61P7/06;;C12N2740/16022;;C12N2740/16023;;C12N2740/16043;;C12N2740/16045;;C12N15/86;;C07K2317/622;;C07K16/2896;;C07K14/605;;C07K14/475;;A61K48/0041;;A61K2039/55555;;C07K14/4702;;C07K16/26;;C07K16/2812;;C07K16/2815;;C07K16/2896;;C07K16/40;;C07K2317/622;;C07K2319/02;;C07K2319/33;;C12N7/00;;C12N15/625;;C12N2740/16022;;C12N2740/16023;;C12N2740/16042;;C12N2740/16051;;C12N2740/16211,C07K14/47;;C07K16/26;;C07K16/28;;C07K16/40;;C12N7/00;;C12N15/62,,0,0,,,,PENDING
876,WO,A1,WO 2023/217904 A1,146-111-610-512-094,2023-11-16,2023,EP 2023062497 W,2023-05-10,EP 22305688 A,2022-05-10,SYNCITIN-1 FUSION PROTEINS AND USES THEREOF FOR CARGO DELIVERY INTO TARGET CELLS,"The inventors developed a new system to modify tropism of syncytins, envelope proteins, which can be used to functionalize particles such as virus particle or more particularly viral- like particles (VLPs), and used for gene transfer or other applications. In particular, they created a fusion protein containing the Syncytin-1 (SYN) signal sequence (SS), a targeting moiety (either natural or engineered), the SYN protein and a flexible linker between SYN and the targeting moiety to enhance transduction of the cell type expressing the receptor or the antigen targeted by the targeting moiety, for instance hematopoietic stem progenitor cells (HSPCs). The inventors demonstrated that the fusion strategy allows modification of syncytin tropism towards different receptors in order to target the desired cell type. The system is adaptable to other desired antigens to retarget the fusion protein to a specific cell type.",INST NAT SANTE RECH MED;;ASSIST PUBLIQUE HOPITAUX PARIS APHP;;FOND IMAGINE;;UNIV PARIS CITE,MICCIO ANNARITA;;VON JOEST MATHIEU,,https://lens.org/146-111-610-512-094,Patent Application,yes,52,1,4,024-895-761-932-947;;133-279-129-501-812;;146-111-610-512-094;;042-338-154-585-892,JP;;EP;;WO;;US,4,024-895-761-932-947;;133-279-129-501-812;;146-111-610-512-094;;042-338-154-585-892,JP;;EP;;WO;;US,41,C07K14/005;;A61K38/00;;C07K2319/00;;C07K2319/33;;C07K2319/02;;A61P7/00;;A61P7/06;;C12N2740/16022;;C12N2740/16023;;C12N2740/16043;;C12N2740/16045;;C12N15/86;;C07K2317/622;;C07K16/2896;;C07K14/605;;C07K14/475;;A61K48/0041;;A61K2039/55555;;C07K14/4702;;C07K16/26;;C07K16/2812;;C07K16/2815;;C07K16/2896;;C07K16/40;;C07K2317/622;;C07K2319/02;;C07K2319/33;;C12N7/00;;C12N15/625;;C12N2740/16022;;C12N2740/16023;;C12N2740/16042;;C12N2740/16051;;C12N2740/16211,C07K14/005;;A61K38/00;;A61K47/64;;A61P7/00;;A61P7/06;;C07K14/475;;C07K14/605;;C07K16/28;;C07K19/00;;C12N15/86,,109,89,015-189-942-638-515;;115-288-571-467-41X;;053-898-205-880-571;;002-467-504-102-329;;028-268-819-520-789;;010-061-122-557-993;;005-466-829-280-590;;005-018-889-537-520;;032-728-154-591-070;;058-570-767-655-942;;006-612-691-199-587;;053-898-205-880-571;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;030-607-398-087-475;;032-746-280-247-35X;;077-779-211-707-723;;051-940-176-386-905;;074-817-300-512-106;;013-323-148-570-367;;106-753-778-592-300;;008-959-745-114-899;;074-103-961-593-279;;105-016-972-918-515;;029-609-193-470-845;;043-303-207-686-862;;084-196-662-298-606;;032-112-713-585-254;;010-174-813-792-598;;095-279-733-802-586;;082-981-051-785-035;;183-488-865-778-013;;148-045-503-004-692;;050-659-379-690-674;;011-914-335-483-578;;025-988-764-969-787;;065-880-567-615-193;;009-010-603-169-806;;104-219-196-921-271;;091-900-184-005-767;;027-244-305-589-508;;059-460-465-480-226;;036-531-598-073-297;;025-338-998-858-401;;042-184-594-482-564;;040-955-040-669-669;;003-165-604-276-708;;115-537-265-566-748;;001-207-151-979-32X;;090-178-151-392-850;;036-531-598-073-297;;049-648-157-796-669;;002-386-081-652-091;;150-712-225-748-613;;042-924-537-342-013;;009-706-440-465-939;;027-105-520-524-520;;084-033-279-775-370;;084-243-600-334-05X;;050-576-388-403-055;;010-425-788-978-502;;001-293-592-612-48X;;036-893-292-975-894;;075-377-470-782-838;;005-604-457-702-74X;;009-050-947-857-887;;001-191-489-068-327;;002-193-473-352-839;;023-008-904-514-014;;055-552-440-386-041;;026-144-786-904-542;;069-210-062-763-687;;037-382-005-727-153;;009-369-502-752-411;;032-088-427-310-025;;003-782-474-116-362;;075-542-159-434-634;;116-344-233-947-429;;005-870-580-519-686;;030-854-616-839-830;;014-007-758-100-073;;077-490-006-534-280;;008-063-717-836-542;;174-479-393-787-067;;083-299-759-722-333;;043-368-544-937-826;;035-630-546-020-975;;042-070-058-794-120,pmc3828447;;24255580;;10.3978/j.issn.1000-9604.2013.10.06;;10.21203/rs.3.rs-227071/v1;;10.1186/s12977-021-00558-0;;34158079;;pmc8220723;;pmc1524976;;16820059;;10.1186/1742-4690-3-41;;17080327;;10.1007/s10495-006-0329-9;;10383156;;pmc7019722;;10.3390/jcm9010068;;31888091;;29377003;;10.1038/nchembio.2565;;pmc6035732;;pmc8431961;;10.1126/science.abg6155;;34413232;;10.1016/0022-2836(70)90057-4;;5420325;;17617614;;10.4049/jimmunol.179.2.1210;;10.1128/jvi.74.7.3321-3329.2000;;pmc111833;;10708449;;pmc1524976;;16820059;;10.1186/1742-4690-3-41;;3713831;;10.1038/321522a0;;10.1038/332323a0;;3127726;;10.1016/0959-440x(92)90091-k;;10.1073/pnas.81.21.6851;;6436822;;pmc392030;;1560545;;pmc241093;;10.1128/jvi.66.5.3230-3235.1992;;10.1016/0076-6879(83)92046-3;;6190069;;10.1073/pnas.77.7.4216;;6933469;;pmc349802;;2677748;;10.1038/341544a0;;10.1016/j.tibtech.2003.08.007;;14573361;;10.1038/256495a0;;1172191;;10.1016/j.cbpa.2009.04.627;;19501012;;9255793;;10.1038/nbt0897-772;;10.1038/nbt962;;15097997;;10.1038/nature02740;;15241406;;11929862;;10.1074/jbc.m109788200;;10.1038/6172;;10052354;;10.1110/ps.0203102;;12021449;;pmc2373628;;10.1038/nbt860;;12923547;;pmc41526;;10.1073/pnas.92.14.6404;;7541540;;10.1016/j.tibtech.2005.07.007;;16054718;;15011780;;10571020;;10.1016/s0925-4439(99)00055-1;;10.1002/ijc.1300;;11391627;;10954529;;pmc116340;;10.1128/jvi.74.18.8307-8315.2000;;7884882;;10.1128/jvi.69.4.2366-2377.1995;;pmc188909;;pmc113972;;10.1128/jvi.75.2.759-771.2001;;11134289;;10.1128/mmbr.67.2.226-237.2003;;12794191;;pmc156468;;10.1128/jvi.67.5.2787-2798.1993;;8474175;;pmc237603;;10.1128/jvi.68.5.3232-3242.1994;;pmc236814;;8151785;;9380714;;pmc23491;;10.1073/pnas.94.20.10803;;10.1016/0042-6822(90)90341-n;;1699349;;10.1038/sj.gt.3301292;;11083469;;pmc484202;;15249598;;10.1093/nar/gnh105;;10.1101/pdb.prot067546;;22194265;;10.1371/journal.pone.0028314;;pmc3227654;;22140574;;23688724;;10.1016/j.jbiotec.2013.05.001;;22553333;;10.1128/jvi.07164-11;;pmc3416305;;10.1038/sj.gt.3300768;;9930301;;10.1016/j.jviromet.2006.05.006;;16797087;;10.1038/sj.gt.3301292;;11083469;;7823872;;10.1016/s0091-679x(08)60600-7;;1316479;;10.1128/jvi.66.6.3725-3732.1992;;pmc241157;;10.1002/j.1460-2075.1985.tb03680.x;;pmc554239;;4006902;;10.1073/pnas.93.3.1156;;8577732;;pmc40048;;pmc3177186;;10.1093/nar/gkr815;;pmc3177181;;10.1093/nar/gkr407;;21727090;;10.1093/nar/gkr739;;21576234;;10.1126/science.1207773;;21700836;;pmc3489282;;21131970;;10.1038/nmeth.1539;;17603476;;10.1038/nbt1317;;20051983;;10.1038/nsmb.1710;;pmc2850169;;10.1534/genetics.111.131433;;pmc3176093;;21828278;;12033941;;10.1021/bi020095c;;10.1093/bioinformatics/btn331;;pmc2732218;;18586699;;27096362;;10.1038/nature17945;;10.1038/nmeth.4038;;27798611;;pmc5557288;;10.1038/nature17946;;27096365;;pmc4873371;;29160308;;pmc5726555;;10.1038/nature24644;;10.1126/sciadv.aao4774;;28875174;;pmc5576876;;pmc6535181;;10.1038/s41576-018-0059-1;;30341440;;30323312;;10.1038/s41556-020-00620-7;;33420494;;10.1038/s41586-019-1711-4;;31634902;;pmc6907074;;pmc3368803;;22446836;;10.1038/nchembio.922;;pmc3110149;;21406691;;10.1126/scisignal.2001449;;pmc4289409;;10.1038/nbt.3081;;25357182;;25231175;;10.1038/gt.2014.80;;pmc4817938;;10.1038/mtna.2013.17;;23653154;;18077339;;10.1073/pnas.0707873105;;pmc2154466;;25787982;;pmc5527709;;10.1007/s13346-012-0099-6;;10.4049/jimmunol.165.8.4676;;11035111;;pmc5861771;;10.3389/fmicb.2018.00462;;29593697;;pmc3404425;;22463386;;10.1089/hum.2012.020;;10.1515/bc.2006.137;;16895482;;15269105;;10.1095/biolreprod.104.033340;;10.1101/816223;;15585113;;10.1089/hum.2004.15.976;;pmc9482878;;10.1038/s41434-022-00315-8;;35194185;;10.1172/jci118732;;pmc507370;;8675688;;22474615;;pmc3312399;;10.1101/cshperspect.a007781,"MO HONGBO ET AL: ""Human endogenous retroviral syncytin exerts inhibitory effect on invasive phenotype of B16F10 melanoma cells."", CHINESE JOURNAL OF CANCER RESEARCH, 1 October 2013 (2013-10-01), CN, pages 556 - 564, XP055973979, ISSN: 1000-9604, DOI: 10.3978/j.issn.1000-9604.2013.10.06;;STAFL KRYSTOF ET AL: ""Heterologous avian system for quantitative analysis of Syncytin-1 interaction with ASCT2 receptor"", RETROVIROLOGY, vol. 18, no. 1, 22 June 2021 (2021-06-22), XP093064854, DOI: 10.1186/s12977-021-00558-0;;CHEYNET VALÉRIE ET AL: ""Identification of the hASCT2-binding domain of the Env ERVWE1/syncytin-1 fusogenic glycoprotein"", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 3, no. 1, 4 July 2006 (2006-07-04), pages 41, XP021019151, ISSN: 1742-4690, DOI: 10.1186/1742-4690-3-41;;INA KNERR ET AL: ""Fusiogenic endogenous-retroviral syncytin-1 exerts anti-apoptotic functions in staurosporine-challenged CHO cells"", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, vol. 12, no. 1, 31 October 2006 (2006-10-31), pages 37 - 43, XP019463718, ISSN: 1573-675X;;ERBEN ULRIKE ET AL: ""Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells"", CANCER RESEARCH, vol. 59, no. 12, 15 June 1999 (1999-06-15), 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas, pages 2924 - 2930, XP055974164, ISSN: 0008-5472;;OLSEN CATHRINE ELISABETH ET AL: ""Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization"", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 1, 26 December 2019 (2019-12-26), pages 68, XP055864658, DOI: 10.3390/jcm9010068;;ZENAN L CHANG ET AL: ""Rewiring T-cell responses to soluble factors with chimeric antigen receptors"", NATURE CHEMICAL BIOLOGY, vol. 14, no. 3, 29 January 2018 (2018-01-29), New York, pages 317 - 324, XP055594731, ISSN: 1552-4450, DOI: 10.1038/nchembio.2565;;SEGEL MLASH BSONG JLADHA ALIU CCJIN XMEKHEDOV SLMACRAE RKKOONIN EVZHANG F.: ""Mammalian retrovirus-like protein PEG 10 packages its own mRNA and can be pseudotyped for mRNA delivery"", SCIENCE, vol. 373, no. 6557, 20 August 2021 (2021-08-20), pages 882 - 889, XP055919110, DOI: 10.1126/science.abg6155;;NEEDLEMANSAUL B.WUNSCHCHRISTIAN D.: ""A general method applicable to the search for similarities in the amino acid sequence of two proteins"", JOURNAL OF MOLECULAR BIOLOGY, vol. 48, no. 3, 1970, pages 443 - 53;;ANTONY JMELLESTAD KKHAMMOND RIMAIZUMI KMALLET FWARREN KGPOWER C.: ""The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: a role for endoplasmic reticulum chaperones in astrocytes"", J IMMUNOL., vol. 179, no. 2, 15 July 2007 (2007-07-15), pages 1210 - 24, XP055283181, DOI: 10.4049/jimmunol.179.2.1210;;COSSET FL.: ""An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor"", J VIROL., vol. 74, 2000, pages 3321 - 3329, XP000946327, DOI: 10.1128/JVI.74.7.3321-3329.2000;;CHEYNET VORIOL GMALLET F.: ""Identification of the hASCT2-binding domain of the Env ERIlWEllsyncytin-1 fusogenic glycoprotein"", RETROVIROLOGY, vol. 3, 4 July 2006 (2006-07-04), pages 41;;HUNTER, R. J.L. R. WHITE: ""Sequences of Proteins of Immunological Interest"", 1987, US DEPARTMENT OF HEALTH AND HUMAN SERVICES;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;ROYER ET AL., J. VIROL., vol. 66, 1992, pages 3230 - 3235;;MULLER, METH. ENZYMOL., vol. 92, 1983, pages 589 - 601;;URLAUB, G.CHASIN, L. A.: ""Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity"", PROC NATL ACAD SCI U S A, vol. 77, 1980, pages 4216 - 4220, XP008004784, DOI: 10.1073/pnas.77.7.4216;;WARD ET AL., NATURE, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 6;;HOLT ET AL., TRENDS BIOTECHNOL., vol. 21, no. 11, 2003, pages 484 - 490;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;GEBAUERSKERRA, CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 245;;NORD ET AL., NAT. BIOTECHNOL., vol. 15, 1997, pages 772 - 777;;BINZ ET AL., NAT. BIOTECHNOL., vol. 22, 2004, pages 575 - 582;;PANCER ET AL., NATURE, vol. 430, 2004, pages 174 - 180;;PANNI ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 21666 - 21674;;SCHNEIDER, NAT. BIOTECHNOL., vol. 17, 1999, pages 170 - 175;;LEGENDRE ET AL., PROTEIN SCI., vol. 11, 2002, pages 1506 - 1518;;STOOP ET AL., NAT. BIOTECHNOL., vol. 21, 2003, pages 1063 - 1068;;VITA ET AL., PNAS, vol. 92, 1995, pages 6404 - 6408;;STEMMER ET AL., PROTEIN SCAFFOLDS AND USES THEREOF;;HEY ET AL.: ""Artificial, Non-Antibody Binding Proteins for Pharmaceutical and Industrial Applications"", TRENDS IN BIOTECHNOLOGY, vol. 23, no. 10, October 2005 (2005-10-01), pages 514 - 522, XP055867373, DOI: 10.1016/j.tibtech.2005.07.007;;ACRES ET AL., CURR OPIN MOL THER, vol. 6, February 2004 (2004-02-01), pages 40 - 7;;TAYLOR-PAPADIMITRIOU ET AL., BIOCHIM BIOPHYS ACTA, vol. 1455, no. 2-3, 8 October 1999 (1999-10-08), pages 301 - 13;;EMENS ET AL., CANCER BIOL THER., vol. 2, July 2003 (2003-07-01), pages 161 - 8;;OHSHIMA ET AL., INT J CANCER., vol. 93, no. 1, 1 July 2001 (2001-07-01), pages 91 - 6;;ORTS-GILG, K. NATTE ET AL., JOURNAL OF NANOPARTICLE RESEARCH, vol. 13, no. 4, 2011, pages 1593 - 1604;;MANGEOT ET AL., JOURNAL OF VIROLOGY, vol. 71, no. 18, 2000, pages 8307 - 8315;;CARRIERE ET AL., J. VIROL., vol. 69, 1995, pages 2366 - 2377;;WILK ET AL., J. VIROL., vol. 75, 2001, pages 759 - 77130;;CHAZALGERLIER, MICROBIOL. MOLEC. BIOL. REV., vol. 67, 2003, pages 226 - 237;;HONGBOULANGER, J, VIROL., vol. 67, 1993, pages 2787 - 2798;;SPEARMAN ET AL., J. VIROL., vol. 68, 1994, pages 3232 - 3242;;SHARMA ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 10803 - 10808;;GUIBINGUA ET AL., MOLECULAR THERAPY, vol. 5, no. 5, 2002, pages 538 - 546;;RASMUSSEN ET AL., VIROLOGY, vol. 178, no. 2, 1990, pages 435 - 451;;NEGRE ET AL., GENE THERAPY, vol. 7, 2000, pages 1613 - 1623;;MANGEOT ET AL., NUCLEIC ACIDS RESEARCH, vol. 32, no. 12, 2004, pages e102;;SAENZ ET AL., COLD SPRING HARB PROTOC, vol. 1, 2012, pages 118 - 123;;JALAGUIER ET AL., PLOSONE, vol. 6, no. 11, 2011, pages e28314;;CERVERA ET AL., J BIOTECHNOL, vol. 166, no. 4, pages 152 - 165;;TANG ET AL., JOURNAL OF VIROLOGY, vol. 86, no. 14, 2012, pages 7662 - 7676;;OLSEN, GENE THER, vol. 5, no. l 1, 1998, pages 1481 - 1487;;MSELLI-LAKHAL, J VIROL METHODS, vol. 136, no. 1-2, 2006, pages 177 - 184;;CAMPILLO ET AL., PMID: 16979784 (COMPUTATION ANALYSIS), 2006;;PASTUZYN ET AL., PMID: 29328916 (ARC), 2018;;ASHLEY ET AL., PMID: 2932891 S (ARC), 2018;;ABED ET AL., PMID: 30951545, vol. 10, 2019;;NEGRE, GENE THER, vol. 7, 2000, pages 1613 - 1623;;YEE ET AL., METHODS CELL BIOL, vol. 43, 1994, pages 99 - 112;;TAKAHARA ET AL., JOURNAL OF VIROLOGY, vol. 66, no. 6, June 1992 (1992-06-01), pages 3725 - 32;;F. WAGNER ET AL., EMBO JOURNAL, vol. 4, no. 3, 1985, pages 663 - 666;;KIM, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 1156 - 1160;;""Chemical Warfare Agents"", 1992, ACADEMIC PRESS;;HOCKEMEYER ET AL., NATURE BIOTECH., vol. 29, 2011, pages 143 - 734;;MOSCOU ET AL., SCIENCE, vol. 326, 2009, pages 3501 - 12;;CERMAK ET AL., NUCL. ACIDS RES., vol. 39, 2011, pages e82;;WOOD ET AL., SCIENCE, vol. 333, 2011, pages 307;;DOYON ET AL., NATURE METHODS, vol. 8, 2010, pages 74 - 79;;SZCZEPEK ET AL., NATURE BIOTECH., vol. 25, 2007, pages 786 - 793;;GUO ET AL., J. MOL. BIOL., vol. 200, 2010, pages 96;;HUERTAS, P., NAT. STRUCT. MOL. BIOL., vol. 17, 2010, pages 11 - 16;;CARROLL ET AL., GENETICS SOCIETY OF AMERICA, vol. 188, 2011, pages 773 - 782;;SERA, BIOCHEMISTRY, vol. 41, 2002, pages 7074 - 7081;;LIU, BIOINFORMATICS, vol. 24, 2008, pages 1850 - 1857;;BITINAITE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 10570 - 5;;""Genbank"", Database accession no. GL669193765;;FONFARA, I. ET AL.: ""The CRISPR-associated DNA-cleaving enzyme Cpfl also processes precursor CRISPR RNA"", NATURE 28, vol. 532, no. 7600, 2016, pages 517 - 21, XP055349049, DOI: 10.1038/nature17945;;HESS GTFRESARD LHAN KLEE CHLI ACIMPRICH KAMONTGOMERY SBBASSIK MC: ""Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells"", NAT METHODS, vol. 13, no. 12, 2016, pages 1036 - 1042, XP055832741, DOI: 10.1038/nmeth.4038;;KOMOR, A.C. ET AL.: ""Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage"", NATURE, vol. 533, 2016, pages 420 - 424, XP055968803, DOI: 10.1038/nature17946;;GAUDELLI, N.M. ET AL.: ""Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage"", NATURE, vol. 551, 2017, pages 464 - 471;;KOMOR, A.C. ET AL.: ""Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity"", SCIENCE ADVANCES, vol. 3, 2017, pages eaao4774, XP055453964, DOI: 10.1126/sciadv.aao4774;;REES, H. A. ET AL.: ""Base editing: precision chemistry on the genome and transcriptome of living cells."", NAT REV GENET., vol. 19, no. 12, December 2018 (2018-12-01), pages 770 - 788;;NAKAMURA, M.GAO, Y.DOMINGUEZ, A.A. ET AL.: ""CRISPR technologies for precise epigenome editing"", NAT CELL BIOL, vol. 23, 2021, pages 11 - 22, XP037330797, DOI: 10.1038/s41556-020-00620-7;;ANZALONE, ANDREW IL; RANDOLPH, PEYTON B.; DAVIS, JESSIE R.; SOUSA, ALEXANDER A.; KOBLAN, LUKE W.; LEVY, JONATHAN M.; CHEN, PETER J: ""Search-and-replace genome editing without double-strand breaks or donor DNA"", NATURE., vol. 576, no. 7785, 21 October 2019 (2019-10-21), pages 149 - 157, XP037926823, DOI: 10.1038/s41586-019-1711-4;;MIYAMOTO T. ET AL.: ""Rapid and Orthogonal Logic Gating with a Gibberellin-induced Dimerization System"", NAT CHEM BIOL., vol. 8, no. 5, 2012, pages 465 - 470, XP055221911, DOI: 10.1038/nchembio.922;;LIANG F. S. ET AL.: ""Engineering the ABA plant stress pathway for regulation of induced proximity"", SCI SIGNAL., vol. 4, no. 164, 2011, pages rs2, XP009535150, DOI: 10.1126/scisignal.2001449;;C. G. A THOMAS: ""Medical Microbiology"", 1983, BAILLIERE TINDALL;;ZURIS ET AL., NAT BIOTECHNOL, vol. 33, no. 1, 2015, pages 73 - 80;;JOHNSTON ET AL., GENE THER, vol. 21, no. 12, 2014, pages 1008 - 1020;;FENARD ET AL., MOLECULAR THERAPY NUCLEIC ACIDS, vol. 2, 2013, pages e90;;ANASTASOV ET AL.: ""Lentiviral vectors and exosomes as gene and protein delivery tools"", METHODS IN MOLECULAR BIOLOGY, vol. 1448, 2016, pages 49 - 61;;""Ensembl"", Database accession no. ENSG00000049130;;""Ensembl database"", Database accession no. ENSG00000112164;;MANGENEY, M. ET AL.: ""Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins"", PROC NATL ACAD SCI U S A, vol. 104, 2007, pages 20534 - 20539, XP002633415, DOI: 10.1073/PNAS.0707873105;;SWAMINATHAN, S. K. ET AL.: ""Identification and characterization of a novel scFv recognizing human and mouse CD133"", DRUG DELIV TRANSL RES, vol. 3, 2013, pages 143 - 151, XP055309678, DOI: 10.1007/s13346-012-0099-6;;KOLM-LITTY, V. ET AL.: ""Human monoclonal antibodies isolated from type I diabetes patients define multiple epitopes in the protein tyrosine phosphatase-like IA-2 antigen"", J IMMUNOL, vol. 165, 2000, pages 4676 - 4684;;GRANDI, N.TRAMONTANO, E.: ""HERV Envelope Proteins: Physiological Role and Pathogenic Potential in Cancer and Autoimmunity"", FRONT MICROBIOL, vol. 9, 2018, pages 462, XP055940354, DOI: 10.3389/fmicb.2018.00462;;VERHOEYEN, E. ET AL.: ""Stem cell factor-displaying simian immunodeficiency viral vectors together with a low conditioning regimen allow for long-term engraftment of gene-marked autologous hematopoietic stem cells in macaques"", HUM GENE THER, vol. 23, 2012, pages 754 - 768, XP055946189, DOI: 10.1089/hum.2012.020;;DREWLO, S.LEYTING, S.KOKOZIDOU, M.MALLET, F.POTGENS, A. J. G.: ""C-Terminal truncations of syncytin-1 (ERVWE1 envelope) that increase its fusogenicity"", BIOL CHEM, vol. 387, 2006, pages 1113 - 1120;;CHANG, C.CHEN, P.-T.CHANG, G.-D.HUANG, C.-J.CHEN, H.: ""Functional characterization of the placental fusogenic membrane protein syncytin"", BIOL REPROD, vol. 71, 2004, pages 1956 - 1962, XP002371324, DOI: 10.1095/biolreprod.104.033340;;COQUIN, Y.FERRAND, M.SEYE, A.MENU, L.GALY, A., SYNCYTINS ENABLE NOVEL POSSIBILITIES TO TRANSDUCE HUMAN OR MOUSE PRIMARY B CELLS AND TO ACHIEVE WELL-TOLERATED IN VIVO GENE TRANSFER, 2019, Retrieved from the Internet <URL:http://biorxiv.org/lookup/doi/10.1101/816223>;;LOGAN, A. C. ET AL.: ""Factors influencing the titer and infectivity of lentiviral vectors"", HUM GENE THER, vol. 15, 2004, pages 976 - 988, XP055046446, DOI: 10.1089/hum.2004.15.976;;CORRE, G. ET AL.: ""Lentiviral standards to determine the sensitivity of assays that quantify lentiviral vector copy numbers and genomic insertion sites in cells"", GENE THER, vol. 29, 2022, pages 536 - 543;;AANSTOOT, H. J. ET AL.: ""Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes"", J CLIN INVEST, vol. 97, 1996, pages 2772 - 2783, XP009155084;;ROEP, B. O.PEAKMAN, M.: ""Antigen targets of type 1 diabetes autoimmunity"", COLD SPRING HARB PERSPECT MED, vol. 2, 2012, pages a007781",PENDING
877,US,A1,US 2025/0241804 A1,077-258-386-244-130,2025-07-31,2025,US 202318858128 A,2023-04-17,US 202318858128 A;;US 202263332443 P;;US 2023/0018821 W,2022-04-19,SUBSTRATES TREATED WITH SOLUTIONS CONTAINING CYCLODEXTRINS FOR IMPARTING ODOR CONTROL TO MATERIALS USED IN ABSORBENT PRODUCTS,"Solutions containing cyclodextrins for imparting odor control to materials used in absorbent products and associated products and methods. The solutions containing cyclodextrins for imparting odor control to materials used in absorbent products contain an optional polar organic solvent, water, cyclodextrin, and one or more odor-controlling compounds. The solutions can be used to uniformly apply a homogeneous solution of a cyclodextrin complex onto a solid surface whereby the cyclodextrin complex precipitates in situ on the solid surface. The cyclodextrin complex precipitates deposited from these solutions rapidly release odor-masking scents when hydrated with urine and can be deposited on substrates more effectively than cyclodextrin complexes in solid form.",RAYONIER ADVANCED MAT INC,CHMIELEWSKI HARRY;;MURGUIA TINA;;PEACH MIKE;;BHATTACHARYA PRIYANKA;;SHINALL SUSAN;;FENN LARISSA,,https://lens.org/077-258-386-244-130,Patent Application,yes,0,0,8,170-141-899-350-475;;077-258-386-244-130;;060-208-706-706-136;;054-766-911-391-785;;155-607-351-457-97X;;131-253-609-096-002;;185-076-591-976-224;;090-561-130-953-622,JP;;EP;;CN;;WO;;US;;CO,8,170-141-899-350-475;;077-258-386-244-130;;060-208-706-706-136;;054-766-911-391-785;;155-607-351-457-97X;;131-253-609-096-002;;185-076-591-976-224;;090-561-130-953-622,JP;;EP;;CN;;WO;;US;;CO,0,A23L33/21;;A61F13/8405;;A61F2013/8408;;A61F13/8405;;A61F2013/8435,A61F13/84,,0,0,,,,PENDING
878,WO,A1,WO 2025/038442 A1,137-904-011-333-565,2025-02-20,2025,US 2024/0041697 W,2024-08-09,US 202363532157 P,2023-08-11,ANTI-IL-5 ANTIBODIES AND USES THEREOF,"The invention provides novel anti-IL-5 proteins, antibodies and IL-5 binding fragments thereof, which inhibit association of IL-5 with IL-5 receptor and are suitable for administration to a human or feline subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-5 protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-5-related disorders.",INVETX INC,BRONDYK WILLIAM;;SEVIGNY LEILA,,https://lens.org/137-904-011-333-565,Patent Application,yes,4,0,2,137-904-011-333-565;;039-555-180-842-605,WO;;US,2,137-904-011-333-565;;039-555-180-842-605,WO;;US,128,C07K2317/565;;C07K16/244;;C07K2317/76;;C07K2317/24;;C07K2317/92;;A61K2039/552;;C07K16/244;;C07K2317/92;;C07K2317/76;;C07K2317/24,C07K16/24;;A61K39/00,,0,0,,,,PENDING
879,WO,A1,WO 2020/201131 A1,197-567-217-115-485,2020-10-08,2020,EP 2020058800 W,2020-03-27,EP 19305413 A,2019-03-29,NEW MARKERS FOR DISCRIMINATING JUVENILE IDIOPATHIC ARTHRITIS (JIA) AND SEPTIC ARTHRITIS (SA),"The invention relates to a use of a compound selected in the group consisting of (i) a compound for detecting CD141+conventional dendritic cells (cDC), (ii) a compound for detecting CD123+ plasmacytoid dendritic cells (pDC), (iii) a compound for detecting CD303+ plasmacytoid dendritic cells (pDC), and mixtures thereof, and preferably additionally a compound for detecting PDL2 on said subsets of dendritic cells or mixtures thereof and/or on CD1c+ cDC cells, in particular CD14+ InfDC cells, for determining, in a subject affected by a juvenile arthritic form, if the juvenile arthritic form is a juvenile inflammatory arthritis (JIA) or is a septic arthritis (SA). The invention also relates to in vitro methods methods for discriminating juvenile idiopathic arthritis (JIA) and septic arthritis (SA) in a subject affected by juvenile arthritis form, combinations of compounds and kits dedicated to said in vitro methods.",UNIV MONTPELLIER;;CT HOSPITALIER UNIVERSITAIRE MONTPELLIER;;INST NAT SANTE RECH MED,LOUIS-PLENCE PASCALE;;CREN MAILYS;;JEZIORSKI ERIC,,https://lens.org/197-567-217-115-485,Patent Application,yes,1,0,2,197-567-217-115-485;;154-684-233-342-568,EP;;WO,2,197-567-217-115-485;;154-684-233-342-568,EP;;WO,0,G01N33/564,G01N33/564,,12,9,001-656-805-438-949;;117-369-592-778-003;;080-041-717-176-277;;081-973-323-695-847;;016-974-240-768-243;;070-563-119-781-261;;019-272-456-968-319;;009-332-364-238-318;;045-047-797-370-034,28241879;;10.1186/s13023-017-0586-4;;pmc5329952;;10.4078/jrd.2017.24.3.131;;10.3389/fimmu.2017.01935;;29358940;;pmc5766641;;pmc2882837;;20479115;;10.1084/jem.20100348;;26444869;;pmc4596870;;10.1371/journal.pone.0139867;;pmc3012272;;21218014;;10.3345/kjp.2010.53.11.931;;10.1136/archdischild-2016-310594;;27655660;;10.1136/archdischild-2014-307490;;25732253;;27348712;;10.1038/nmeth.3901,"LAURA AOUST ET AL: ""Time to diagnosis in juvenile idiopathic arthritis: a french perspective"", ORPHANET JOURNAL OF RARE DISEASES, vol. 12, no. 1, 28 February 2017 (2017-02-28), XP055603887, DOI: 10.1186/s13023-017-0586-4;;YOUNG DAE KIM ET AL: ""Differential Diagnosis of Juvenile Idiopathic Arthritis"", JOURNAL OF RHEUMATIC DISEASES, vol. 24, no. 3, 1 January 2017 (2017-01-01), pages 131, XP055603895, ISSN: 2093-940X, DOI: 10.4078/jrd.2017.24.3.131;;MEYER MELISSA: ""Tumors Interrupt IRF8-Mediated Dendritic Cell Development to Overcome Immune Surveillance"", 15 May 2018 (2018-05-15), St Louis Missouri, XP055604570, Retrieved from the Internet <URL:https://media.proquest.com/media/pq/classic/doc/4325591423/fmt/ai/rep/NPDF?hl=&cit:auth=Meyer,+Melissa+A.&cit:title=Tumors+Interrupt+IRF8-Mediated+Dendritic+Cell+Development+to+Overcome+Immune+Surveillance&cit:pub=ProQuest+Dissertations+and+Theses&cit:vol=&cit:iss=&cit:pg=&cit:date=2018&ic=true&cit:> [retrieved on 20190711], DOI: 10.7936/K7J67GB6;;PATTY SACHAMITR ET AL: ""Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141+ Subset"", FRONTIERS IN IMMUNOLOGY, vol. 8, 8 January 2018 (2018-01-08), XP055604577, DOI: 10.3389/fimmu.2017.01935;;A. BACHEM ET AL: ""Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells"", TRENDS IN IMMUNOLOGY, vol. 28, no. 2, 17 May 2010 (2010-05-17), pages 45 - 1281, XP055128162, ISSN: 1471-4906, DOI: 10.1084/jem.20100348;;ANNE-MARIT SPONAAS ET AL: ""PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy"", PLOS ONE, vol. 10, no. 10, 7 October 2015 (2015-10-07), pages e0139867, XP055604587, DOI: 10.1371/journal.pone.0139867;;KI HWAN KIM ET AL: ""Juvenile idiopathic arthritis: Diagnosis and differential diagnosis"", KOREAN JOURNAL OF PEDIATRICS, vol. 53, no. 11, 1 January 2010 (2010-01-01), pages 931, XP055603892, ISSN: 1738-1061, DOI: 10.3345/kjp.2010.53.11.931;;CAROLINE GAMSE: ""Distinguishing Septic Arthritis from Juvenile Idiopathic Arthritis at Initial Presentation"", 23 May 2017 (2017-05-23), XP055604684, Retrieved from the Internet <URL:https://www.medpagetoday.com/resource-centers/focus-on-pediatric-rheumatology/distinguishing-septic-arthritis-juvenile-idiopathic-arthritis-initial-presentation/726> [retrieved on 20190711];;CAMILLE AUPIAIS ET AL: ""Arthritis in children: comparison of clinical and biological characteristics of septic arthritis and juvenile idiopathic arthritis"", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 102, no. 4, 21 September 2016 (2016-09-21), GB, pages 316 - 322, XP055603872, ISSN: 0003-9888, DOI: 10.1136/archdischild-2016-310594;;AUPIAIS C ET AL., ARCH DIS CHILD., vol. 100, no. 8, 2015, pages 742 - 747;;VILLANI ET AL., SCIENCE, vol. 356, 2017, pages 283;;TYANOVA S ET AL., NAT METHODS., vol. 13, no. 9, 2016, pages 731 - 740",PENDING
880,US,A1,US 2021/0277436 A1,145-436-052-013-213,2021-09-09,2021,US 202117323769 A,2021-05-18,US 202117323769 A;;EP 15184968 A;;US 201815758653 A;;EP 2016071420 W,2015-09-12,PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES IN MICROBIAL HOSTS WITH ENGINEERED IMPORT / EXPORT,"The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.",JENNEWEIN BIOTECHNOLOGIE GMBH,JENNEWEIN STEFAN;;WARTENBERG DIRK,CHR. HANSEN A/S (2025-01-07);;CHR. HANSEN HMO GMBH (2021-05-04),https://lens.org/145-436-052-013-213,Patent Application,yes,0,2,34,125-468-710-010-841;;103-831-434-837-951;;109-676-485-744-860;;188-458-429-824-444;;105-687-920-648-653;;134-089-508-568-899;;168-242-704-506-793;;148-829-670-849-76X;;175-561-674-072-905;;092-241-673-167-601;;027-869-240-326-044;;097-882-370-938-191;;151-931-374-768-833;;054-775-309-640-165;;106-346-999-979-252;;062-295-690-741-025;;145-108-262-879-485;;144-801-902-777-989;;122-056-138-717-765;;053-340-470-488-762;;130-829-663-570-222;;144-804-018-184-30X;;087-054-605-698-73X;;162-735-075-933-545;;089-346-927-934-94X;;088-687-893-874-975;;145-436-052-013-213;;138-131-019-107-17X;;115-215-357-658-349;;107-199-060-546-314;;102-945-553-890-463;;066-710-624-112-010;;193-747-822-745-154;;045-010-182-877-737,KR;;JP;;AU;;RU;;CN;;EP;;WO;;US;;NZ;;MX;;PH;;BR,34,125-468-710-010-841;;103-831-434-837-951;;109-676-485-744-860;;188-458-429-824-444;;105-687-920-648-653;;134-089-508-568-899;;168-242-704-506-793;;148-829-670-849-76X;;175-561-674-072-905;;092-241-673-167-601;;027-869-240-326-044;;097-882-370-938-191;;151-931-374-768-833;;054-775-309-640-165;;106-346-999-979-252;;062-295-690-741-025;;145-108-262-879-485;;144-801-902-777-989;;122-056-138-717-765;;053-340-470-488-762;;130-829-663-570-222;;144-804-018-184-30X;;087-054-605-698-73X;;162-735-075-933-545;;089-346-927-934-94X;;088-687-893-874-975;;145-436-052-013-213;;138-131-019-107-17X;;115-215-357-658-349;;107-199-060-546-314;;102-945-553-890-463;;066-710-624-112-010;;193-747-822-745-154;;045-010-182-877-737,KR;;JP;;AU;;RU;;CN;;EP;;WO;;US;;NZ;;MX;;PH;;BR,102,C12P19/18;;C12N9/1051;;C12Y204/01146;;C07K14/245;;C12N9/1051;;C12P19/04;;C12P19/18;;C12N15/70;;C07K14/195;;C12Y204/01146;;C12N15/67;;C12N15/70;;C12N9/1051;;C12P19/18;;C12Y204/01146;;C12P19/18;;C12N9/1051;;C12N15/70;;C12Y204/01146,C12P19/18;;C12N9/10;;C12N15/70,,0,0,,,,ACTIVE
881,CN,A,CN 112011526 A,049-851-130-861-639,2020-12-01,2020,CN 202010809269 A,2020-08-12,CN 202010809269 A,2020-08-12,Xylanase PaXynA with low-temperature activity and coding gene and application thereof,"The invention relates to xylanase PaXynA with low-temperature activity and a coding gene and application thereof. The protein has xylanase activity, and the amino acid sequence of the protein has at least 99% consistency with SEQ ID NO: 2. The xylanase PaXynA disclosed by the invention has good low-temperature adaptability.",BIOTECHNOLOGY RES INST CAAS,LIN MIN;;ZHANG WEI;;LI JIANG;;GAO RUYU;;ZHOU ZHENGFU;;LU WEI;;KE XIUBIN,,https://lens.org/049-851-130-861-639,Patent Application,no,2,0,2,049-851-130-861-639;;148-266-066-050-226,CN,2,049-851-130-861-639;;148-266-066-050-226,CN,0,C12N9/2482;;C12N15/70;;C12P19/02;;C12P19/14,C12N9/42;;C12N1/21;;C12N15/56;;C12N15/70;;C12P19/02;;C12P19/14;;C12R1/19,,2,1,050-870-729-009-054,10.1007/s13205-016-0457-z;;pmc4929084;;28330222,"HILLOL CHAKDAR: ""Bacterial xylanases: biology to biotechnology"", 《BIOTECH》;;OLIVIA J. RICKMAN等: ""Xylanolytic psychrotrophs from andosolic sedge fens and moss heaths in Iceland"", 《BIORXIV》",ACTIVE
882,US,A1,US 2024/0342103 A1,006-028-572-576-615,2024-10-17,2024,US 202218251185 A,2022-11-25,CN 202211315441 A;;CN 2022134412 W,2022-10-26,NANOCOMPOSITE AND PREPARATION METHOD AND USE THEREOF,"The present disclosure provides a nanocomposite and a preparation method and use thereof. In the present disclosure, the nanocomposite is wrapped with Prussian blue nanoparticles (PB) using a platelet membrane (PM) as a shell; and a surface of the PM is modified with an aptamer of cancer cells and horseradish peroxidase (HRP). An ability of platelets (PLTs) to specifically target cancer cells and inflammatory sites can effectively enhance the accumulation of nanoparticles at tumor sites, and help PB better achieve a desirable photothermal therapy (PTT) under near-infrared light irradiation. In addition, hydrogen peroxide is highly expressed in the tumor microenvironment; the HRP modified on a surface of the nanocomposite can decompose the hydrogen peroxide to generate oxygen bubbles, which drive active transport of the nanocomposite, thereby enhancing the accumulation in cancer cells. Modification with the aptamer of cancer cells on a platelet membrane surface enhances cancer cell targeting.",QILU UNIV OF TECHNOLOGY SHANDONG ACADEMY OF SCIENCES,GUO YINGSHU;;LI WENXIN,QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES) (2023-03-23),https://lens.org/006-028-572-576-615,Patent Application,yes,0,0,3,178-952-205-664-710;;054-519-015-142-918;;006-028-572-576-615,CN;;WO;;US,3,054-519-015-142-918;;178-952-205-664-710;;006-028-572-576-615,CN;;WO;;US,0,A61K38/44;;A61K47/64;;A61K41/00;;A61K47/54;;A61K47/69;;A61P35/00;;A61P35/00;;A61K9/5068,A61K9/50;;A61P35/00,,0,0,,,,PENDING
883,WO,A1,WO 2022/168106 A1,195-632-189-250-377,2022-08-11,2022,IN 2021050456 W,2021-05-13,IN 202121005152 A,2021-02-06,CHEMO-ENZYMATIC PROCESS FOR SYNTHESIS OF MOLNUPIRAVIR,"Disclosed herein is a process for synthesis of Molnupiravir from cytidine of using a lipase for esterification reaction. The process comprises of reacting compound of formula II with acetone in presence of sulphuric acid to obtain compound of formula III; enzymatically converting compound of Formula III to compound of Formula IV, and Hydroxyaminating Formula IV using Hydroxyl amine sulphate or hydrochloride followed by deprotection to obtain compound of formula I",FERMENTA BIOTECH LTD,DATLA ANUPAMA;;NAGRE PRASHANT;;TAMORE JAGDISH;;PRABHU MANOJKUMAR SADANAND;;TRIVIKRAM SREENATH,,https://lens.org/195-632-189-250-377,Patent Application,yes,1,0,1,195-632-189-250-377,WO,1,195-632-189-250-377,WO,0,A61P31/12;;C12P19/40,A61K31/00;;A61K31/7068;;A61P31/12;;C07H19/067,,2,2,049-527-829-363-17X;;102-520-561-448-33X,10.1039/d0cc05944g;;10.26434/chemrxiv.12931445;;33030468;;34963891;;10.26434/chemrxiv.13472373;;10.1021/acscentsci.1c00608;;pmc8704035,"N. VASUDEVAN ET AL.: ""A concise route to MK -4482 (EIDD-2801) from cytidin e"", CHEM. COMMUN., vol. 56, 2 October 2020 (2020-10-02), pages 13363 - 13364, XP055950766, DOI: https://doi.org/10.1039/DOCC05944G;;BENKOVICS TAMAS, MCINTOSH JOHN A, SILVERMAN STEVEN M, KONG JONGROCK, MALIGRES PETER, ITOH TETSUJI, YANG HAO, HUFFMAN MARK A, VERMA: ""Evolving to an Ideal Synthesis of Molnupiravir, an Investigational Treatment for COVID19"", CHEMRXIV, 23 December 2020 (2020-12-23), Cambridge, pages 1 - 5, XP055959886, DOI: 10.26434/chemrxiv.13472373.v1",PENDING
884,US,A1,US 2025/0230202 A1,173-239-152-351-749,2025-07-17,2025,US 202418411600 A,2024-01-12,US 202418411600 A,2024-01-12,USE OF PROMYELOCYTIC LEUKEMIA 1 (PML-1) PROTEIN IN PREPARATION OF DRUG FOR INHIBITING CYTOKINE STORM,"The present disclosure provides use of a promyelocytic leukemia 1 (PML-1) protein in preparation of a drug for inhibiting a cytokine storm, and belongs to the technical field of biomedicine. The present disclosure further provides use of a PML-1 protein and/or a product expressing the PML-1 protein in preparation of a drug for inhibiting a cytokine storm. In the present disclosure, the PML-1 protein and/or the product expressing the PML-1 protein can significantly inhibit the expression of proteins TAB1, TAK1, and p-TAK1 and inhibit inflammatory cytokines TNF-α, IL-1β, MIP-1α, IL-6, IL-8, and MCP-1 in an inflammatory signaling pathway, thereby inhibiting the cytokine storm. The PML-1 protein can be directly used for the treatment of inflammations and related diseases. Compared with traditional chemical anti-inflammatory drugs, the protein shows more significant curative effect, stronger specificity, lower toxicity, smaller side effects, and clearer biological functions, exhibiting broad application prospects.",CHENGDU FUDAI BIOMEDICAL CO LTD,SHEN FUBING;;SHEN DAI;;LIU MENGLING,CHENGDU FUDAI BIOMEDICAL CO. LTD (2024-01-08),https://lens.org/173-239-152-351-749,Patent Application,yes,0,0,1,173-239-152-351-749,US,1,173-239-152-351-749,US,0,C12N2740/15043;;A61K38/00;;C12N15/86;;A61P29/00;;C07K14/435;;C07K14/435;;C12N15/86;;A61K38/00;;C12N2740/15043;;A61P29/00,C07K14/435;;A61K38/00;;A61P29/00;;C12N15/86,,0,0,,,,PENDING
885,EP,A1,EP 4047018 A1,182-962-898-594-797,2022-08-24,2022,EP 22152931 A,2021-04-19,CN 202010357134 A;;EP 21796353 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND VEGF, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",DANSHENG PHARMACEUTICAL TECH SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING,"SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. (2023-05-03)",https://lens.org/182-962-898-594-797,Patent Application,yes,19,0,32,028-846-487-920-111;;001-087-470-491-846;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,182,C07K16/2818;;C07K16/22;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;C07K16/468;;A61P35/00;;A61P35/02;;A61P29/00;;A61P37/02;;A61P27/02;;A61P11/06;;A61P19/02;;A61P17/06;;A61P17/00;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C07K2317/76;;C07K2317/24;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/46;;C07K2317/64;;C07K2317/55;;C07K2317/515;;C07K16/2818;;C07K16/22;;C07K2317/24;;C07K2317/92;;C07K2317/94;;C07K2317/76;;A61K2039/505;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;A61K2039/505;;C07K16/22;;C07K16/2803;;C07K16/2863;;C07K16/2878;;C07K16/468;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/55;;C07K2317/76;;C07K2317/92;;C07K2317/94,C07K16/22;;A61K39/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/28;;C07K16/32;;C07K16/46,,19,17,045-279-754-888-717;;019-028-085-291-892;;004-097-259-326-739;;145-295-183-351-742;;003-613-117-343-797;;022-648-069-840-113;;033-951-567-552-932;;031-719-370-148-435;;008-411-420-307-533;;079-845-525-923-31X;;018-454-440-471-739;;052-515-652-666-158;;151-255-362-741-675;;027-360-429-703-956;;019-537-469-767-795;;018-905-882-624-966;;015-746-288-084-78X,31028837;;10.1016/j.pharmthera.2019.04.006;;10.1155/2012/980250;;pmc3312285;;22474489;;10.1038/icb.2014.93;;pmc4445461;;25367186;;20016854;;10.1016/s0022-2836(03)00526-6;;12818205;;10.1074/jbc.m500815200;;15757893;;pmc4848005;;10.1080/15384047.2015.1121344;;26671532;;10.1038/nbt0297-159;;9035142;;10.1038/nbt1345;;17934452;;10.1080/19420862.2015.1007826;;25611120;;pmc4623437;;24463572;;10.1038/nbt.2797;;10.1038/nbt0798-677;;9661204;;10.1074/jbc.m110.117382;;20400508;;pmc2885242;;pmc3585358;;23468998;;10.1371/journal.pone.0057479;;10.1016/j.critrevonc.2007.04.011;;17624800;;28986820;;pmc5777978;;10.1007/s13238-017-0473-8;;10.1158/1535-7163.mct-19-0608;;31974274,"SUURS FRANS V ET AL: ""A review of bispecific antibodies and antibody constructs in oncology and clinical challenges"", PHARMACOLOGY & THERAPEUTICS, ELSEVIER, GB, vol. 201, 24 April 2019 (2019-04-24), pages 103 - 119, XP085764019, ISSN: 0163-7258, [retrieved on 20190424], DOI: 10.1016/J.PHARMTHERA.2019.04.006;;AHMAD Z AYEAP S KALI A M ET AL.: ""scFv antibody: principles and clinical application[J"", CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, vol. 2012, 2012, pages 980250;;HUEHLS A MCOUPET T ASENTMAN C L: ""Bispecific T-cell engagers for cancer immunotherapy[J"", IMMUNOLOGY AND CELL BIOLOGY, vol. 93, no. 3, 2015, pages 290 - 296, XP055537601, DOI: 10.1038/icb.2014.93;;WU C: ""Diabodies: molecular engineering and therapeutic applications[J"", DRUG NEWS PERSPECT, vol. 22, no. 8, 2009, pages 453;;KIPRIYANOV S M, MOLDENHAUER G, BRAUNAGEL M: ""Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies[J"", JOURNAL OF MOLECULAR BIOLOGY, vol. 330, no. 1, 2003, pages 99 - 111, XP004445110, DOI: 10.1016/S0022-2836(03)00526-6;;LU DZHANG HKOO H ET AL.: ""A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity[J"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 20, 2005, pages 19665 - 19672, XP002516978, DOI: 10.1074/JBC.M500815200;;CHEN ZXIE WACHEAMPONG D O ET AL.: ""A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity[J"", CANCER BIOLOGY & THERAPY, vol. 17, no. 2, 2016, pages 139 - 150, XP055544048, DOI: 10.1080/15384047.2015.1121344;;COLOMA M JMORRISON S L: ""Design and production of novel tetravalent bispecific antibodies[J"", NATURE BIOTECHNOLOGY, vol. 15, no. 2, 1997, pages 159, XP000647731, DOI: 10.1038/nbt0297-159;;WU CYING HGRINNELL C ET AL.: ""Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin[J"", NATURE BIOTECHNOLOGY, vol. 25, no. 11, 2007, pages 1290;;MAZOR YOGANESYAN VYANG C ET AL.: ""MAbs"", vol. 9, 2017, TAYLOR & FRANCIS, article ""Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies[C"", pages: 1010 - 1020;;LEWIS S MWU XPUSTILNIK A ET AL.: ""Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface[J"", NATURE BIOTECHNOLOGY, vol. 32, no. 2, 2014, pages 191, XP055240003, DOI: 10.1038/nbt.2797;;MERCHANT A MZHU ZYUAN J Q ET AL.: ""An efficient route to human bispecific IgG[J"", NATURE BIOTECHNOLOGY, vol. 16, no. 7, 1998, pages 677, XP002141015, DOI: 10.1038/nbt0798-677;;GUNASEKARAN KPENTONY MSHEN M ET AL.: ""Enhancing antibody Fc heterodimer formation through electrostatic steering effects applications to bispecific molecules and monovalent IgG[J"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 25, 2010, pages 19637 - 19646, XP055546816, DOI: 10.1074/jbc.M110.117382;;SAMPEI ZIGAWA TSOEDA T ET AL.: ""Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity[J"", PLOS ONE, vol. 8, no. 2, 2013, pages e57479, XP055553036, DOI: 10.1371/journal.pone.0057479;;KABAT ET AL., NIH PUBL.NO.91-3242, vol. I, 1991, pages 647 - 669;;SAMBROOK, J.RITSCH, E.F.MANIAIS, T.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;MAGDELAINE-BEUZELIN CKAAS QWEHBI V ET AL.: ""Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment[J"", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 64, no. 3, 2007, pages 210 - 225, XP022344458, DOI: 10.1016/j.critrevonc.2007.04.011;;WANG XMATHIEU MBREZSKI R J: ""IgG Fc engineering to modulate antibody effector functions[J"", PROTEIN & CELL, vol. 9, no. 1, 2018, pages 63 - 73, XP055457296, DOI: 10.1007/s13238-017-0473-8;;HO SKXU ZTHAKUR A ET AL.: ""Epitope and Fc-mediated Crosslinking, but not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity[J"", MOLECULAR CANCER THERAPEUTICS, 2020, pages 1040 - 1051",ACTIVE
886,EP,A1,EP 3770251 A1,162-626-308-070-507,2021-01-27,2021,EP 19770939 A,2019-03-22,KR 20180033828 A;;KR 20190031875 A;;KR 2019003341 W,2018-03-23,METHOD FOR PRODUCING NATURAL KILLER CELLS,"The present disclosure relates to a method for producing natural killer (NK) cells. More specifically, the present disclosure relates to a method for producing NK cells, characterized in that peripheral blood mononuclear cells from which CD3-positive cells are removed are proliferated together with feeder cells, and the peripheral blood mononuclear cells are re-stimulated with feeder cells at the time of reaching a specific accumulated population doubling level. The present disclosure also relates to a method for producing NK cells, characterized in that NK cells are cultured under appropriate culture conditions by using a bioreactor. The production method according to the present disclosure has an advantage that NK cells having a high cell-killing ability and cell survival rate can be produced with high purity and at high efficiency in a short period of time by a clinically friendly method as compared with existing methods, thereby increasing the productivity of an NK cell therapy agent.",GREEN CROSS LAB CELL CORP,HWANG YU-KYEONG;;PAIK SANG HOON;;HAN SEUNGRYEL;;LEE SANGHYUN;;LAM HYEONGJIN;;KIM JUYOUNG;;HAN MU RI;;NOH DONG IL,GC CELL CORPORATION (2022-06-08),https://lens.org/162-626-308-070-507,Patent Application,yes,0,0,13,162-123-564-081-040;;000-901-632-420-280;;014-851-523-188-537;;086-818-452-318-919;;110-232-918-022-811;;086-333-195-199-406;;161-538-293-406-939;;097-334-172-716-734;;162-626-308-070-507;;155-397-611-333-736;;048-869-078-697-93X;;046-822-475-290-235;;168-397-706-352-085,KR;;JP;;AU;;IL;;EP;;CN;;US;;CA,14,162-123-564-081-040;;000-901-632-420-280;;014-851-523-188-537;;086-818-452-318-919;;110-232-918-022-811;;086-333-195-199-406;;085-250-219-827-05X;;161-538-293-406-939;;097-334-172-716-734;;162-626-308-070-507;;155-397-611-333-736;;048-869-078-697-93X;;046-822-475-290-235;;168-397-706-352-085,KR;;JP;;AU;;IL;;EP;;CN;;WO;;US;;CA,0,C12N5/0087;;C12N5/0646;;C12N2501/515;;C12N2501/2302;;C12N2501/2312;;C12N2501/2315;;C12N2501/2318;;C12N2501/2321;;C12N5/0087;;C12N5/0646;;C12N5/0646;;C12N2500/60;;C12N2501/2302;;C12N2501/2312;;C12N2501/2315;;C12N2501/2318;;C12N2501/2321;;C12N2501/515;;C12N2523/00;;C12N2527/00;;C12N5/0087;;A61K40/15;;C12N2506/115;;C12N5/0646;;C12N2500/02;;C12N2500/60;;C12N2501/2302;;C12N2501/2312;;C12N2501/2315;;C12N2501/2318;;C12N2501/2321;;C12N2501/998;;C12N2506/11;;C12N2527/00,C12N5/0783,,0,0,,,,PENDING
887,EP,A1,EP 4086346 A1,066-306-087-055-887,2022-11-09,2022,EP 20909536 A,2020-12-30,CN 2019129957 W;;CN 2020141501 W,2019-12-30,METHOD FOR TREATING USHER SYNDROME AND COMPOSITION THEREOF,"Provided is a method for targeted editing of target RNA containing a G to A mutation in a USH2A gene transcript based on LEAPER technology, comprising: introducing a construct of an adenosine deaminase recruiting RNA (arRNA) for editing the target RNA or a construct encoding said arRNA into a cell, wherein the arRNA comprises a complementary RNA sequence that hybridizes to the target RNA, and wherein the arRNA is capable of recruiting adenosine deaminase acting on RNA (ADAR), so that the target adenosine in the target RNA is deaminated, thereby performing in vivo editing of the base from A to I on RNA safely and effectively, repairing a pathogenic mutation site, and achieving the purpose of treating disease such as Usher syndrome.",EDIGENE THERAPEUTICS BEIJING INC,LIU NENGYIN;;YI ZEXUAN;;YUAN PENGFEI;;ZHAO YANXIA;;TANG GANGBIN,,https://lens.org/066-306-087-055-887,Patent Application,yes,0,0,18,067-496-159-929-78X;;054-371-145-982-634;;063-838-202-080-868;;198-898-423-807-688;;169-595-014-120-21X;;193-021-580-763-807;;184-542-667-972-799;;058-872-265-645-561;;165-053-687-577-909;;146-958-174-186-838;;179-036-253-160-149;;117-947-036-265-188;;041-232-121-491-273;;161-752-870-687-687;;031-193-361-231-495;;066-306-087-055-887;;040-907-038-893-649;;100-706-969-312-332,JP;;AU;;US;;TW;;CA;;CO;;EC;;PH;;MX;;BR;;PE;;CR;;KR;;IL;;EP;;CN;;WO,18,067-496-159-929-78X;;054-371-145-982-634;;063-838-202-080-868;;198-898-423-807-688;;169-595-014-120-21X;;058-872-265-645-561;;184-542-667-972-799;;193-021-580-763-807;;165-053-687-577-909;;146-958-174-186-838;;179-036-253-160-149;;117-947-036-265-188;;041-232-121-491-273;;161-752-870-687-687;;031-193-361-231-495;;066-306-087-055-887;;040-907-038-893-649;;100-706-969-312-332,JP;;AU;;US;;TW;;CA;;CO;;EC;;PH;;MX;;BR;;PE;;CR;;KR;;EP;;IL;;CN;;WO,35,C12N15/113;;C12N15/102;;C12N2750/14143;;C12N2310/20;;A61K31/7105;;A61K31/7115;;A61K48/00;;C12N15/11;;C12N15/113;;C12N15/1137;;C12N15/102;;A61K48/00;;A61K31/7115;;A61P43/00;;A61P43/00;;A61K48/00;;C12N15/102;;C12N15/11;;C12N15/86;;C12N2750/14141,C12N15/113;;A61K31/7115;;A61K48/00;;C12N15/11,,0,0,,,,DISCONTINUED
888,EP,A1,EP 4063387 A1,032-964-433-688-646,2022-09-28,2022,EP 20889117 A,2020-11-20,CN 201911155025 A;;CN 2020130511 W,2019-11-22,PSMA ANTIBODY AND USE THEREOF,"The present disclosure relates to an antibody fragment specifically binding to PSMA, particularly to a single-chain Fv (scFv), a bispecific antibody containing the scFv, and a chimeric antigen receptor (CAR) and the preparation and the use thereof.",NANTONG YICHEN BIOPHARMA CO LTD,WANG FENG;;ZHENG HUAYANG;;ZHANG YUHAN,YICHEN THERAPEUTICS LIMITED (2023-10-18),https://lens.org/032-964-433-688-646,Patent Application,yes,0,1,6,007-082-640-777-448;;032-964-433-688-646;;189-354-159-848-883;;156-875-360-205-771;;117-787-499-555-835;;025-464-498-792-175,EP;;CN;;WO;;US,6,007-082-640-777-448;;032-964-433-688-646;;189-354-159-848-883;;156-875-360-205-771;;117-787-499-555-835;;025-464-498-792-175,EP;;CN;;WO;;US,68,C07K2317/622;;C07K2317/92;;C07K2317/565;;C07K2317/31;;C07K16/2809;;C07K16/3069;;A61K2039/505;;C07K2317/73;;C07K2317/90;;G01N33/57434;;C07K16/2809;;C07K16/30;;C07K2317/31;;C07K2317/56,C07K16/28;;A61K39/395;;C07K16/30;;C12P21/04,,0,0,,,,PENDING
889,US,A1,US 2024/0209395 A1,177-388-057-136-594,2024-06-27,2024,US 202218557159 A,2022-04-08,CN 202110455720 A;;CN 202110761757 A;;CN 2022085852 W,2021-04-26,MYELOID-SPECIFIC PROMOTER AND USE THEREOF,"Provided are a myeloid-specific promoter and a use thereof. The myeloid-specific promoter includes a nucleic acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The myeloid-specific promoter shows specificity to myeloid tissues. It initiates a gene expression with high efficiency in myeloid cells, but with relative low efficiency in non-myeloid cells. As such, the myeloid-specific promoter regulates the specific expression of a gene in myeloid tissues. The myeloid-specific promoter and the CYBB gene are inserted into a lentiviral vector, and the constructed lentiviral expression vector shows specificity to myeloid tissues and can effectively restore the expression of gp91-phox protein and restore the generation function of ROS, which is of great significance for CGD treatment.",BEIJING MEIKANG GENO IMMUNE BIOTECHNOLOGY CO LTD,CHANG LUNG-JI;;YUAN HAOKUN;;ZHANG RUI,BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO. LTD (2023-07-17),https://lens.org/177-388-057-136-594,Patent Application,yes,0,0,7,177-388-057-136-594;;042-400-657-948-821;;151-791-130-080-213;;114-840-860-784-470;;075-896-824-103-105;;172-622-003-639-488;;043-739-753-209-585,JP;;EP;;CN;;WO;;US,7,177-388-057-136-594;;042-400-657-948-821;;151-791-130-080-213;;075-896-824-103-105;;114-840-860-784-470;;172-622-003-639-488;;043-739-753-209-585,JP;;EP;;CN;;WO;;US,5,C07K14/47;;C12N15/86;;C12N7/00;;C12N5/0647;;A61K38/17;;A61P37/02;;C12N2510/00;;C12N2740/15043;;C12N2740/15021;;C12N5/0645;;C12N9/0036;;C12Y106/03001;;C12N15/86;;C12N5/0642;;C12N5/0645;;C12N2501/125;;C12N2501/145;;C12N2501/2306;;C12N2501/22;;C12N2501/727;;C12N2740/16043;;A61K48/005;;A61K48/0058;;A61K38/00;;C12N2501/26;;C12N2506/11;;C12N2510/00;;A61K48/0058;;C07K14/47;;C12N5/0647;;C12N5/10;;C12N15/86;;C12N2510/00;;C12N2740/15021;;C12N2740/15043;;C12N5/0645,C12N15/86;;A61K48/00;;C07K14/47;;C12N5/0789;;C12N5/10,,0,0,,,,PENDING
890,EP,A1,EP 4050028 A1,068-970-806-027-857,2022-08-31,2022,EP 22152936 A,2021-04-19,CN 202010357134 A;;EP 21796353 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/TGF-BETA, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",DANSHENG PHARMACEUTICAL TECH SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING,"SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. (2023-05-03)",https://lens.org/068-970-806-027-857,Patent Application,yes,19,0,32,028-846-487-920-111;;001-087-470-491-846;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,182,C07K16/2818;;C07K16/22;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;C07K16/468;;A61P35/00;;A61P35/02;;A61P29/00;;A61P37/02;;A61P27/02;;A61P11/06;;A61P19/02;;A61P17/06;;A61P17/00;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C07K2317/76;;C07K2317/24;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/46;;C07K2317/64;;C07K2317/55;;C07K2317/515;;C07K16/2818;;C07K16/22;;C07K2317/24;;C07K2317/92;;C07K2317/94;;C07K2317/76;;A61K2039/505;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;A61K2039/505;;C07K16/22;;C07K16/2803;;C07K16/2863;;C07K16/2878;;C07K16/468;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/55;;C07K2317/76;;C07K2317/92;;C07K2317/94,C07K16/22;;A61K39/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/28;;C07K16/32;;C07K16/46,,17,15,019-028-085-291-892;;004-097-259-326-739;;003-613-117-343-797;;022-648-069-840-113;;033-951-567-552-932;;031-719-370-148-435;;008-411-420-307-533;;079-845-525-923-31X;;018-454-440-471-739;;052-515-652-666-158;;151-255-362-741-675;;027-360-429-703-956;;019-537-469-767-795;;018-905-882-624-966;;015-746-288-084-78X,10.1155/2012/980250;;pmc3312285;;22474489;;10.1038/icb.2014.93;;pmc4445461;;25367186;;10.1016/s0022-2836(03)00526-6;;12818205;;10.1074/jbc.m500815200;;15757893;;pmc4848005;;10.1080/15384047.2015.1121344;;26671532;;10.1038/nbt0297-159;;9035142;;10.1038/nbt1345;;17934452;;10.1080/19420862.2015.1007826;;25611120;;pmc4623437;;24463572;;10.1038/nbt.2797;;10.1038/nbt0798-677;;9661204;;10.1074/jbc.m110.117382;;20400508;;pmc2885242;;pmc3585358;;23468998;;10.1371/journal.pone.0057479;;10.1016/j.critrevonc.2007.04.011;;17624800;;28986820;;pmc5777978;;10.1007/s13238-017-0473-8;;10.1158/1535-7163.mct-19-0608;;31974274,"AHMAD Z AYEAP S KALI A M ET AL.: ""scFv antibody: principles and clinical application[J"", CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, vol. 2012, 2012, pages 980250;;HUEHLS A MCOUPET T ASENTMAN C L: ""Bispecific T-cell engagers for cancer immunotherapy[J"", IMMUNOLOGY AND CELL BIOLOGY, vol. 93, no. 3, 2015, pages 290 - 296, XP055537601, DOI: 10.1038/icb.2014.93;;KIPRIYANOV S MMOLDENHAUER Q BRAUNAGEL M ET AL.: ""Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies[J"", JOURNAL OF MOLECULAR BIOLOGY, vol. 330, no. 1, 2003, pages 99 - 111, XP004445110, DOI: 10.1016/S0022-2836(03)00526-6;;LU DZHANG HKOO H ET AL.: ""A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity[J]."", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 20, 2005, pages 19665 - 19672, XP002516978, DOI: 10.1074/JBC.M500815200;;CHEN ZXIE WACHEAMPONG D O ET AL.: ""A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity[J"", CANCER BIOLOGY & THERAPY, vol. 17, no. 2, 2016, pages 139 - 150, XP055544048, DOI: 10.1080/15384047.2015.1121344;;COLOMA M JMORRISON S L: ""Design and production of novel tetravalent bispecific antibodies[J"", NATURE BIOTECHNOLOGY, vol. 15, no. 2, 1997, pages 159, XP000647731, DOI: 10.1038/nbt0297-159;;WU CYING H ET AL., NATURE BIOTECHNOLOGY, vol. 25, no. 11, 2007, pages 1290;;MAZOR YOGANESYAN VYANG C ET AL.: ""MAbs"", vol. 9, 2017, TAYLOR & FRANCIS, article ""Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies[C"", pages: 1010 - 1020;;LEWIS S MWU XPUSTILNIK A ET AL.: ""Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface[J"", NATURE BIOTECHNOLOGY, vol. 32, no. 2, 2014, pages 191, XP055240003, DOI: 10.1038/nbt.2797;;MERCHANT A MZHU ZYUAN J Q ET AL.: ""An efficient route to human bispecific IgG[J"", NATURE BIOTECHNOLOGY, vol. 16, no. 7, 1998, pages 677, XP002141015, DOI: 10.1038/nbt0798-677;;GUNASEKARAN KPENTONY MSHEN M ET AL.: ""Enhancing antibody Fc heterodimer formation through electrostatic steering effects applications to bispecific molecules and monovalent IgG[J"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 25, 2010, pages 19637 - 19646, XP055546816, DOI: 10.1074/jbc.M110.117382;;SAMPEI ZIGAWA TSOEDA T ET AL.: ""Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity[J"", PLOS ONE, vol. 8, no. 2, 2013, pages e57479, XP055553036, DOI: 10.1371/journal.pone.0057479;;KABAT ET AL.: ""NIH Publ."", vol. I, 1991, pages: 647 - 669;;SAMBROOK, J.FRITSCH, E.F.MANIAIS, T: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;MAGDELAINE-BEUZELIN CKAAS QWEHBI V ET AL.: ""Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment[J"", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 64, no. 3, 2007, pages 210 - 225, XP022344458, DOI: 10.1016/j.critrevonc.2007.04.011;;WANG XMATHIEU MBREZSKI R J: ""IgG Fc engineering to modulate antibody effector functions[J"", PROTEIN & CELL, vol. 9, no. 1, 2018, pages 63 - 73, XP055457296, DOI: 10.1007/s13238-017-0473-8;;HO SKXU ZTHAKUR A ET AL.: ""Epitope and Fc-mediated Crosslinking, but not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity[J"", MOLECULAR CANCER THERAPEUTICS, 2020, pages 1040 - 1051",DISCONTINUED
891,US,A1,US 2022/0259330 A1,139-061-991-882-171,2022-08-18,2022,US 202117617516 A,2021-04-19,CN 202010357134 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING;;ZHU YUNXIA,SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO. LTD (2021-12-03),https://lens.org/139-061-991-882-171,Patent Application,yes,5,0,32,028-846-487-920-111;;001-087-470-491-846;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,153,C07K16/2818;;C07K16/22;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;C07K16/468;;A61P35/00;;A61P35/02;;A61P29/00;;A61P37/02;;A61P27/02;;A61P11/06;;A61P19/02;;A61P17/06;;A61P17/00;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C07K2317/76;;C07K2317/24;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/46;;C07K2317/64;;C07K2317/55;;C07K2317/515;;C07K16/2818;;C07K16/22;;C07K2317/24;;C07K2317/92;;C07K2317/94;;C07K2317/76;;A61K2039/505;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;A61K2039/505;;C07K16/22;;C07K16/2803;;C07K16/2863;;C07K16/2878;;C07K16/468;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/55;;C07K2317/76;;C07K2317/92;;C07K2317/94,C07K16/46;;C07K16/22;;C07K16/28,,2,1,159-938-939-206-17X,10.1074/jbc.m114.600973;;25568323;;pmc4342462,"WO2020138487-English Translation_02JUL2020 (Year: 2020);;Silva, et. al, J Biol Chem, 2015, 290, 5462-5469 (Year: 2015)",PENDING
892,US,A1,US 2022/0127361 A1,066-304-956-211-919,2022-04-28,2022,US 202217571975 A,2022-01-10,US 202217571975 A;;CN 202010357134 A;;US 202117617516 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/TGF-beta, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING;;ZHU YUNXIA,DANSHENG PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO. LTD (2022-03-22);;SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO. LTD (2023-03-17),https://lens.org/066-304-956-211-919,Patent Application,yes,0,0,3,066-304-956-211-919;;159-316-266-245-468;;056-137-166-567-875,US,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,153,A61P35/00;;C07K16/22;;C07K16/2818;;C07K16/34;;C07K2317/31;;C07K2317/35;;C07K16/2818;;A61K2039/505;;A61P35/00;;C07K16/22;;C07K16/2803;;C07K2317/31;;C07K2317/35;;C07K2317/76;;C07K2317/92,C07K16/28;;A61P35/00;;C07K16/22,,0,0,,,,PENDING
893,EP,A1,EP 4559317 A1,163-520-232-167-206,2025-05-28,2025,EP 23730569 A,2023-03-16,ES 202230258 A;;IB 2023000138 W,2022-03-23,POSTBIOTIC FOOD ADDITIVE,"A postbiotic food additive for foodstuffs obtained from cereal flour, comprising a mixture of lysates of probiotic micro-organisms, lysates from cultures of the following microorganisms: Bacillus licheniformis, Bacillus pumilus, Bacillus subtilis, 2 Bifidobacterium animalis subsp. lactis, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus delbrueckii subsp. bulgaricus, Lacticaseibacillus casei, Lactobacillus plantarum, Lactobacillus reuteri, Lacticaseibacillus rhamnosus, Saccharomyces cerevisiae, and Streptococcus thermophilus.",IGEN BIOLAB GROUP AG,GUARDIA ALBA MARÍA JESÚS,SIGNIFER S.L. (2025-08-27);;IGEN BIOLAB S.L. (2025-07-30),https://lens.org/163-520-232-167-206,Patent Application,yes,0,0,5,116-966-367-128-660;;163-520-232-167-206;;011-308-991-493-205;;002-744-792-542-451;;003-939-446-755-477,EP;;ES;;WO;;FR,5,116-966-367-128-660;;163-520-232-167-206;;003-939-446-755-477;;002-744-792-542-451;;011-308-991-493-205,EP;;ES;;WO;;FR,0,A21D2/267;;A21D2/268;;A21D2/362;;A23L33/135;;A23L33/14;;A23L33/195;;A21D13/045;;A23L33/135;;A23L7/104,A21D2/26;;A21D2/36;;A21D13/045;;A23L33/135;;A23L33/14;;A23L33/195,,0,0,,,,PENDING
894,US,A1,US 2022/0127362 A1,056-137-166-567-875,2022-04-28,2022,US 202217572039 A,2022-01-10,CN 202010357134 A;;US 202117617516 A;;US 202217572039 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/LAG-3, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING;;ZHU YUNXIA,DANSHENG PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO. LTD (2022-03-22);;SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO. LTD (2021-12-03),https://lens.org/056-137-166-567-875,Patent Application,yes,0,0,3,066-304-956-211-919;;159-316-266-245-468;;056-137-166-567-875,US,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,153,A61P35/00;;C07K16/22;;C07K16/2818;;C07K16/34;;C07K2317/31;;C07K2317/35;;C07K16/2818;;A61K2039/505;;A61P35/00;;C07K16/22;;C07K16/2803;;C07K2317/31;;C07K2317/35;;C07K2317/76;;C07K2317/92,C07K16/28,,0,0,,,,DISCONTINUED
895,CN,A,CN 118510801 A,051-936-905-648-150,2024-08-16,2024,CN 202280073251 A,2022-11-03,US 202163275471 P;;CN 2021128578 W;;US 2022/0079216 W,2021-11-04,BCMA-targeted CAR-T cell therapy for multiple myeloma,"Provided herein are methods of treating subjects afflicted with multiple myeloma and having been subjected to previous treatment with limited treatment selection. An infusion of a chimeric antigen receptor (CAR)-T cell comprising an anti-BCMA CAR comprising a polypeptide is administered to a subject. In certain embodiments, the dosage of CAR-T cells administered to the subject is from 1.0 * 105 to 5.0 * 106 CAR-T cells per kilogram of mass of the subject. Therapeutic methods effectively obtain and maintain trace residual disease-negative conditions as well as other beneficial clinical outcomes associated with efficacy and safety.",JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,AKRAM MOHAMMAD;;DEBRAGANKA KEVIN;;FAN XIAOHU;;GENG DONG;;NESHEIWAT TONJA;;PACAUD LYDIA;;SCHECHTER JORDAN;;VASOS HELEN;;SUDERE UBANI ENRIQUE,,https://lens.org/051-936-905-648-150,Patent Application,no,0,0,10,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,11,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;190-956-049-117-32X;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61P35/00;;C07K14/7051;;C07K16/2878;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C12N2510/00;;C07K14/70578;;A61K2239/38;;A61K2239/31;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K35/17;;C12N2510/00;;C07K2317/76;;C07K2317/565;;C07K2317/24;;A61K31/167;;A61K39/3955;;C07K2319/02;;C07K2317/569;;C07K2319/03;;A61K38/1774;;A61K2039/545;;C07K16/2878;;C07K2319/33;;A61K31/7076;;A61K2039/54;;A61K2039/505;;C07K14/70517;;C07K14/70578;;A61K31/138;;A61K31/675;;A61K2039/5156;;A61P35/00;;C07K14/7051;;C07K16/2866;;A61K2239/38;;A61K2239/48;;A61K2239/31;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K45/06;;C07K14/7051;;C07K16/2878;;A61K2239/13;;A61K2239/48;;A61K2239/38;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C12N2510/00;;A61K40/31;;A61K40/4215;;C12N5/0636;;A61P35/00;;A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/1774;;A61K39/3955;;A61K2039/505;;A61K2039/5156;;A61K2039/54;;A61K2039/545;;C07K14/7051;;C07K14/70517;;C07K16/2866;;C07K16/2878;;C07K2317/24;;C07K2317/565;;C07K2317/569;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C07K2319/33,C07K16/28;;A61K39/00;;A61P35/00;;C07K14/705;;C07K14/725;;C12N5/0783,,0,0,,,,PENDING
896,AU,A1,AU 2022/381186 A1,097-242-378-138-900,2024-05-16,2024,AU 2022/381186 A,2022-11-03,CN 2021128578 W;;US 202163275471 P;;US 2022/0079216 W,2021-11-04,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 10",JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD;;DEBRAGANCA KEVIN;;FAN XIAOHU;;GENG DONG;;NESHEIWAT TONIA;;PACAUD LIDA;;SCHECTER JORDAN;;VARSOS HELEN;;ZUDAIRE UBANI ENRIQUE,,https://lens.org/097-242-378-138-900,Patent Application,no,0,0,10,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,11,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;190-956-049-117-32X;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61P35/00;;C07K14/7051;;C07K16/2878;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C12N2510/00;;C07K14/70578;;A61K2239/38;;A61K2239/31;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K35/17;;C12N2510/00;;C07K2317/76;;C07K2317/565;;C07K2317/24;;A61K31/167;;A61K39/3955;;C07K2319/02;;C07K2317/569;;C07K2319/03;;A61K38/1774;;A61K2039/545;;C07K16/2878;;C07K2319/33;;A61K31/7076;;A61K2039/54;;A61K2039/505;;C07K14/70517;;C07K14/70578;;A61K31/138;;A61K31/675;;A61K2039/5156;;A61P35/00;;C07K14/7051;;C07K16/2866;;A61K2239/38;;A61K2239/48;;A61K2239/31;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K45/06;;C07K14/7051;;C07K16/2878;;A61K2239/13;;A61K2239/48;;A61K2239/38;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C12N2510/00;;A61K40/31;;A61K40/4215;;C12N5/0636;;A61P35/00;;A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/1774;;A61K39/3955;;A61K2039/505;;A61K2039/5156;;A61K2039/54;;A61K2039/545;;C07K14/7051;;C07K14/70517;;C07K16/2866;;C07K16/2878;;C07K2317/24;;C07K2317/565;;C07K2317/569;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C07K2319/33,C07K16/28;;A61K39/00;;A61P35/00;;C07K14/705;;C07K14/725;;C12N5/0783,,0,0,,,,PENDING
897,KR,A,KR 20240158888 A,133-293-779-545-13X,2024-11-05,2024,KR 20247028096 A,2023-02-27,US 202263314968 P;;US 2023/0063352 W,2022-02-28,다발성 골수종을 위한 BCMA를 표적으로 하는 CAR-T 세포 요법,"본 출원은 실타캡타진 오토류셀 현탁액으로 다발성 골수종을 앓고 있는 대상체를 치료하는 방법을 제공한다. 본 출원은 실타캡타진 오토류셀 현탁액을 함유한 완제 의약품, 실타캡타진 오토류셀 현탁액의 사용 설명서 및 실타캡타진 오토류셀 현탁액을 함유한 완제 의약품을 판매하기 위한 방법을 더 제공한다.",JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC;;NANJING LEGEND BIOTECH CO LTD,FAN XIAOHU;;SCHECTER JORDAN;;PACAUD LIDA;;HIRSCHMANN MICHAEL,,https://lens.org/133-293-779-545-13X,Patent Application,no,0,0,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,0,A61K2239/38;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/11;;A61P35/00;;A61K2239/48;;A61K2239/38;;A61K40/31;;A61K40/4215;;A61K40/11;;A61K31/675;;A61P35/00;;A61K45/06;;A61K31/52;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215,A61K39/00;;A61P35/00,,0,0,,,,PENDING
898,CN,A,CN 118574849 A,148-151-119-350-717,2024-08-30,2024,CN 202280083099 A,2022-12-15,CN 2021139277 W;;CN 2022139295 W,2021-12-17,Anti-OX40 antibodies and methods of use,Antibodies and antibody derivatives that bind to OX40 and methods of using the same are provided. The antibody or the antibody derivative comprises a single-domain antibody which is combined with OX40.,SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,XU WENFENG;;DONG CHEN;;LIN PEIHUA;;JIANG WEIDONG,,https://lens.org/148-151-119-350-717,Patent Application,no,0,0,9,087-418-480-810-664;;099-129-899-739-590;;122-063-982-942-285;;053-109-437-256-036;;143-056-010-797-550;;040-294-361-943-678;;166-116-846-187-767;;057-425-438-174-753;;148-151-119-350-717,JP;;AU;;KR;;EP;;CN;;WO;;ZA;;US;;CA,9,087-418-480-810-664;;143-056-010-797-550;;122-063-982-942-285;;053-109-437-256-036;;099-129-899-739-590;;057-425-438-174-753;;166-116-846-187-767;;040-294-361-943-678;;148-151-119-350-717,JP;;KR;;AU;;EP;;CN;;WO;;ZA;;US;;CA,0,A61P35/00;;C07K16/2878;;C07K2317/569;;C07K2317/92;;C07K2317/24;;C07K2317/33;;C07K2317/75;;A61K2039/505;;C07K16/2878;;C07K14/7051;;C12N5/0636;;A61K47/6803;;A61K47/6849;;A61P35/00;;C07K2317/31;;C07K2317/569;;C07K2317/24;;C07K2317/52;;C07K2317/75;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K2039/505;;C07K16/2878;;C07K2317/35;;C07K2317/52;;C07K2317/565;;C07K2317/569,C07K16/28;;A61K39/395;;A61P35/00;;C12N5/10;;C12N15/85,,0,0,,,,PENDING
899,CN,A,CN 118900698 A,193-197-827-593-598,2024-11-05,2024,CN 202380022977 A,2023-02-27,US 202263314968 P;;US 2023/0063352 W,2022-02-28,BCMA-targeted CAR-T cell therapy for multiple myeloma,"The present application provides methods of treating a subject suffering from multiple myeloma with a suspension of chidamidyl olarenide. The present application also provides a pharmaceutical product containing the suspension of the chidazino-olarenide, an instruction for use of the suspension of the chidazino-olarenide, and a method for selling a pharmaceutical product containing a suspension of the chidazino-olarenide.",JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,FAN XIAOHU;;SCHECHTER JORDAN;;PACAUD LYDIA;;HIRSCHMANN MICHAEL,,https://lens.org/193-197-827-593-598,Patent Application,no,0,0,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,0,A61K2239/38;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/11;;A61P35/00;;A61K2239/48;;A61K2239/38;;A61K40/31;;A61K40/4215;;A61K40/11;;A61K31/675;;A61P35/00;;A61K45/06;;A61K31/52;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215,A61K39/00,,0,0,,,,PENDING
900,US,A1,US 2023/0414512 A1,190-680-814-648-351,2023-12-28,2023,US 202318199832 A,2023-05-19,US 202318199832 A;;US 202117163911 A;;US 201916429816 A;;US 201715619253 A;;US 201414259010 A;;US 201313858677 A;;US 74223511 A;;US 2010/0033942 W;;US 17605709 P,2009-05-06,Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same,"Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.",LABORATORY SKIN CARE INC,MANSOURI ZAHRA,LABORATORY SKIN CARE INC (2011-03-09),https://lens.org/190-680-814-648-351,Patent Application,yes,1,0,59,178-469-795-220-262;;147-949-801-170-141;;159-802-180-637-165;;009-445-595-607-185;;074-556-930-243-833;;080-493-524-237-093;;021-273-209-996-036;;157-767-464-784-788;;042-752-375-061-72X;;036-011-340-088-898;;118-485-476-166-08X;;159-271-967-503-697;;080-086-761-960-156;;066-058-966-131-188;;134-920-437-858-597;;003-708-878-777-743;;156-065-274-546-698;;000-543-238-280-913;;081-549-549-208-404;;163-494-687-323-280;;026-702-110-576-044;;013-004-192-391-43X;;161-500-734-103-789;;039-331-257-634-706;;022-777-897-486-43X;;109-990-690-145-846;;131-233-927-776-857;;172-451-734-202-593;;134-525-923-284-517;;018-728-102-500-432;;107-798-587-574-607;;052-421-146-028-498;;161-275-798-086-203;;135-981-504-391-698;;064-743-228-282-18X;;123-195-419-530-995;;173-975-279-093-682;;171-247-286-226-721;;034-471-439-388-035;;185-052-120-788-853;;080-908-791-759-592;;093-840-682-587-991;;082-802-764-998-886;;033-345-912-088-887;;129-321-413-137-220;;139-108-498-423-524;;089-279-441-427-086;;054-305-879-143-690;;001-251-036-208-632;;158-508-945-575-485;;163-187-779-220-692;;137-758-407-654-207;;069-321-035-942-710;;003-738-330-175-541;;130-075-267-453-149;;174-930-265-092-66X;;074-904-306-283-362;;103-247-963-447-542;;190-680-814-648-351,AU;;JP;;CL;;EA;;US;;TW;;CA;;BR;;MX;;KR;;MY;;EP;;ES;;IL;;CN;;WO;;ZA;;SG;;NZ,59,178-469-795-220-262;;147-949-801-170-141;;159-802-180-637-165;;009-445-595-607-185;;074-556-930-243-833;;080-493-524-237-093;;021-273-209-996-036;;157-767-464-784-788;;042-752-375-061-72X;;036-011-340-088-898;;118-485-476-166-08X;;159-271-967-503-697;;080-086-761-960-156;;066-058-966-131-188;;134-920-437-858-597;;003-708-878-777-743;;156-065-274-546-698;;000-543-238-280-913;;081-549-549-208-404;;163-494-687-323-280;;026-702-110-576-044;;013-004-192-391-43X;;161-500-734-103-789;;039-331-257-634-706;;022-777-897-486-43X;;109-990-690-145-846;;131-233-927-776-857;;172-451-734-202-593;;134-525-923-284-517;;018-728-102-500-432;;064-743-228-282-18X;;052-421-146-028-498;;161-275-798-086-203;;135-981-504-391-698;;107-798-587-574-607;;123-195-419-530-995;;173-975-279-093-682;;171-247-286-226-721;;034-471-439-388-035;;185-052-120-788-853;;080-908-791-759-592;;093-840-682-587-991;;082-802-764-998-886;;033-345-912-088-887;;129-321-413-137-220;;139-108-498-423-524;;089-279-441-427-086;;054-305-879-143-690;;001-251-036-208-632;;158-508-945-575-485;;163-187-779-220-692;;137-758-407-654-207;;069-321-035-942-710;;003-738-330-175-541;;130-075-267-453-149;;174-930-265-092-66X;;074-904-306-283-362;;103-247-963-447-542;;190-680-814-648-351,AU;;JP;;CL;;EA;;US;;TW;;CA;;BR;;MX;;KR;;MY;;EP;;ES;;IL;;CN;;WO;;ZA;;SG;;NZ,0,A61K9/0014;;A61K9/10;;A61K9/1694;;A61K31/353;;A61K31/355;;A61K31/525;;A61K47/6921;;A61K47/6923;;A61K9/1611;;Y10T428/2982;;A61K31/235;;A61K31/60;;A61K38/385;;A61K38/40;;A61P23/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P9/00;;A61K9/1611;;A61K47/6923;;A61P31/12;;A61K9/0014;;A61P33/00;;A61K9/10;;A61P35/00;;A61K9/1694;;A61P9/00;;A61K31/353;;A61P25/00;;A61K31/525;;A61P25/06;;A61K31/235;;A61P23/00;;A61K31/355;;A61P25/04;;A61K38/385;;A61P29/00;;A61K38/40;;A61P31/04;;A61K47/6921;;A61P31/10;;A61K31/60;;A61P25/08;;A61K2300/00;;A61K47/6923;;A61K47/6921;;A61K9/0014;;A61K9/10;;A61K9/1611;;A61K9/1694;;A61K31/235;;A61K31/353;;A61K31/355;;A61K31/525;;A61K31/60;;Y10T428/2982;;A61K9/0014;;A61K9/10;;A61K9/1694;;A61K31/353;;A61K31/355;;A61K31/525;;A61K47/6921;;A61K47/6923;;A61K9/1611;;A61K31/235;;A61K31/60;;A61K38/385;;A61K38/40,A61K9/16;;A61K9/00;;A61K9/10;;A61K31/235;;A61K31/353;;A61K31/355;;A61K31/525;;A61K31/60;;A61K38/38;;A61K38/40;;A61K47/69,,0,0,,,,PENDING
901,US,A1,US 2021/0277435 A1,106-346-999-979-252,2021-09-09,2021,US 202117323737 A,2021-05-18,US 202117323737 A;;EP 15184968 A;;US 201815758653 A;;EP 2016071420 W,2015-09-12,PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES IN MICROBIAL HOSTS WITH ENGINEERED IMPORT / EXPORT,"The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.",JENNEWEIN BIOTECHNOLOGIE GMBH,JENNEWEIN STEFAN;;WARTENBERG DIRK,CHR. HANSEN A/S (2025-01-07);;CHR. HANSEN HMO GMBH (2021-05-04),https://lens.org/106-346-999-979-252,Patent Application,yes,0,0,34,125-468-710-010-841;;103-831-434-837-951;;109-676-485-744-860;;188-458-429-824-444;;105-687-920-648-653;;134-089-508-568-899;;168-242-704-506-793;;148-829-670-849-76X;;175-561-674-072-905;;092-241-673-167-601;;027-869-240-326-044;;097-882-370-938-191;;151-931-374-768-833;;054-775-309-640-165;;106-346-999-979-252;;062-295-690-741-025;;145-108-262-879-485;;144-801-902-777-989;;122-056-138-717-765;;053-340-470-488-762;;130-829-663-570-222;;144-804-018-184-30X;;087-054-605-698-73X;;162-735-075-933-545;;089-346-927-934-94X;;088-687-893-874-975;;145-436-052-013-213;;138-131-019-107-17X;;115-215-357-658-349;;107-199-060-546-314;;102-945-553-890-463;;066-710-624-112-010;;193-747-822-745-154;;045-010-182-877-737,KR;;JP;;AU;;RU;;CN;;EP;;WO;;US;;NZ;;MX;;PH;;BR,34,125-468-710-010-841;;103-831-434-837-951;;109-676-485-744-860;;188-458-429-824-444;;105-687-920-648-653;;134-089-508-568-899;;168-242-704-506-793;;148-829-670-849-76X;;175-561-674-072-905;;092-241-673-167-601;;027-869-240-326-044;;097-882-370-938-191;;151-931-374-768-833;;054-775-309-640-165;;106-346-999-979-252;;062-295-690-741-025;;145-108-262-879-485;;144-801-902-777-989;;122-056-138-717-765;;053-340-470-488-762;;130-829-663-570-222;;144-804-018-184-30X;;087-054-605-698-73X;;162-735-075-933-545;;089-346-927-934-94X;;088-687-893-874-975;;145-436-052-013-213;;138-131-019-107-17X;;115-215-357-658-349;;107-199-060-546-314;;102-945-553-890-463;;066-710-624-112-010;;193-747-822-745-154;;045-010-182-877-737,KR;;JP;;AU;;RU;;CN;;EP;;WO;;US;;NZ;;MX;;PH;;BR,102,C12P19/18;;C12N9/1051;;C12Y204/01146;;C07K14/245;;C12N9/1051;;C12P19/04;;C12P19/18;;C12N15/70;;C07K14/195;;C12Y204/01146;;C12N15/67;;C12N15/70;;C12N9/1051;;C12P19/18;;C12Y204/01146;;C12P19/18;;C12N9/1051;;C12N15/70;;C12Y204/01146,C12P19/18;;C12N9/10;;C12N15/70,,0,0,,,,ACTIVE
902,US,A1,US 2024/0132538 A1,173-464-693-373-36X,2024-04-25,2024,US 202017768461 A,2020-11-20,GB 201917046 A;;EP 2020082966 W,2019-11-22,PROTEIN PURIFICATION USING A SPLIT INTEIN SYSTEM,"The present invention relates to protein purification, primarily in the chromatographic field. More closely, the invention relates to affinity chromatography using a split intein system with an improved C-intein tag and N-intein ligand, wherein the target protein may be purified as a tag-less end product with a native N-terminus.",CYTIVA BIOPROCESS R & D AB,SEVINSKY CHRISTOPHER JAMES;;LUNDBACK PETER;;OHMAN JOHAN;;GROSSMANN GREGORY;;DINN SEAN R,CYTIVA BIOPROCESS R&D AB (2020-01-08),https://lens.org/173-464-693-373-36X,Patent Application,yes,4,1,11,094-242-097-463-513;;069-789-422-714-586;;173-464-693-373-36X;;007-049-379-733-403;;090-827-703-208-941;;024-085-509-740-586;;012-861-983-652-296;;181-831-176-898-952;;040-254-007-780-822;;168-925-783-887-725;;110-016-891-293-462,KR;;JP;;EP;;CN;;WO;;US;;CA;;GB,11,090-827-703-208-941;;024-085-509-740-586;;007-049-379-733-403;;173-464-693-373-36X;;069-789-422-714-586;;094-242-097-463-513;;012-861-983-652-296;;040-254-007-780-822;;181-831-176-898-952;;168-925-783-887-725;;110-016-891-293-462,KR;;JP;;CN;;EP;;WO;;US;;CA;;GB,5,C12N9/1252;;C07K2319/92;;C07K14/545;;C07K1/22;;C12N9/1252;;C07K1/22;;C07K14/545;;C07K2319/92;;C07K1/22;;C07K14/195;;C07K17/10;;C07K2319/92,C07K1/22;;C07K14/195;;C07K17/10,,2,1,103-936-784-342-378,10.1002/pro.5560070106;;9514260;;pmc2143824,"Strancar et al. Advances in Biochem. Engineer./Biotech., 2002, vol. 76, 49-85 (Year: 2002);;Pietrokovski Protein Science, 1998, 7, 64-71 (Year: 1998)",PENDING
903,US,A1,US 2021/0220276 A1,156-065-274-546-698,2021-07-22,2021,US 202117163911 A,2021-02-01,US 202117163911 A;;US 201916429816 A;;US 201715619253 A;;US 201414259010 A;;US 201313858677 A;;US 74223511 A;;US 2010/0033942 W;;US 17605709 P,2009-05-06,Methods of Treating Skin,"Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.",LABORATORY SKIN CARE INC,MANSOURI ZAHRA,LABORATORY SKIN CARE INC (2011-03-09),https://lens.org/156-065-274-546-698,Patent Application,yes,3,0,59,178-469-795-220-262;;147-949-801-170-141;;159-802-180-637-165;;009-445-595-607-185;;074-556-930-243-833;;080-493-524-237-093;;021-273-209-996-036;;157-767-464-784-788;;042-752-375-061-72X;;036-011-340-088-898;;118-485-476-166-08X;;159-271-967-503-697;;080-086-761-960-156;;066-058-966-131-188;;134-920-437-858-597;;003-708-878-777-743;;156-065-274-546-698;;000-543-238-280-913;;081-549-549-208-404;;163-494-687-323-280;;026-702-110-576-044;;013-004-192-391-43X;;161-500-734-103-789;;039-331-257-634-706;;022-777-897-486-43X;;109-990-690-145-846;;131-233-927-776-857;;172-451-734-202-593;;134-525-923-284-517;;018-728-102-500-432;;107-798-587-574-607;;052-421-146-028-498;;161-275-798-086-203;;135-981-504-391-698;;064-743-228-282-18X;;123-195-419-530-995;;173-975-279-093-682;;171-247-286-226-721;;034-471-439-388-035;;185-052-120-788-853;;080-908-791-759-592;;093-840-682-587-991;;082-802-764-998-886;;033-345-912-088-887;;129-321-413-137-220;;139-108-498-423-524;;089-279-441-427-086;;054-305-879-143-690;;001-251-036-208-632;;158-508-945-575-485;;163-187-779-220-692;;137-758-407-654-207;;069-321-035-942-710;;003-738-330-175-541;;130-075-267-453-149;;174-930-265-092-66X;;074-904-306-283-362;;103-247-963-447-542;;190-680-814-648-351,AU;;JP;;CL;;EA;;US;;TW;;CA;;BR;;MX;;KR;;MY;;EP;;ES;;IL;;CN;;WO;;ZA;;SG;;NZ,59,178-469-795-220-262;;147-949-801-170-141;;159-802-180-637-165;;009-445-595-607-185;;074-556-930-243-833;;080-493-524-237-093;;021-273-209-996-036;;157-767-464-784-788;;042-752-375-061-72X;;036-011-340-088-898;;118-485-476-166-08X;;159-271-967-503-697;;080-086-761-960-156;;066-058-966-131-188;;134-920-437-858-597;;003-708-878-777-743;;156-065-274-546-698;;000-543-238-280-913;;081-549-549-208-404;;163-494-687-323-280;;026-702-110-576-044;;013-004-192-391-43X;;161-500-734-103-789;;039-331-257-634-706;;022-777-897-486-43X;;109-990-690-145-846;;131-233-927-776-857;;172-451-734-202-593;;134-525-923-284-517;;018-728-102-500-432;;064-743-228-282-18X;;052-421-146-028-498;;161-275-798-086-203;;135-981-504-391-698;;107-798-587-574-607;;123-195-419-530-995;;173-975-279-093-682;;171-247-286-226-721;;034-471-439-388-035;;185-052-120-788-853;;080-908-791-759-592;;093-840-682-587-991;;082-802-764-998-886;;033-345-912-088-887;;129-321-413-137-220;;139-108-498-423-524;;089-279-441-427-086;;054-305-879-143-690;;001-251-036-208-632;;158-508-945-575-485;;163-187-779-220-692;;137-758-407-654-207;;069-321-035-942-710;;003-738-330-175-541;;130-075-267-453-149;;174-930-265-092-66X;;074-904-306-283-362;;103-247-963-447-542;;190-680-814-648-351,AU;;JP;;CL;;EA;;US;;TW;;CA;;BR;;MX;;KR;;MY;;EP;;ES;;IL;;CN;;WO;;ZA;;SG;;NZ,0,A61K9/0014;;A61K9/10;;A61K9/1694;;A61K31/353;;A61K31/355;;A61K31/525;;A61K47/6921;;A61K47/6923;;A61K9/1611;;Y10T428/2982;;A61K31/235;;A61K31/60;;A61K38/385;;A61K38/40;;A61P23/00;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/08;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P33/00;;A61P35/00;;A61P9/00;;A61K9/1611;;A61K47/6923;;A61P31/12;;A61K9/0014;;A61P33/00;;A61K9/10;;A61P35/00;;A61K9/1694;;A61P9/00;;A61K31/353;;A61P25/00;;A61K31/525;;A61P25/06;;A61K31/235;;A61P23/00;;A61K31/355;;A61P25/04;;A61K38/385;;A61P29/00;;A61K38/40;;A61P31/04;;A61K47/6921;;A61P31/10;;A61K31/60;;A61P25/08;;A61K2300/00;;A61K47/6923;;A61K47/6921;;A61K9/0014;;A61K9/10;;A61K9/1611;;A61K9/1694;;A61K31/235;;A61K31/353;;A61K31/355;;A61K31/525;;A61K31/60;;Y10T428/2982;;A61K9/0014;;A61K9/10;;A61K9/1694;;A61K31/353;;A61K31/355;;A61K31/525;;A61K47/6921;;A61K47/6923;;A61K9/1611;;A61K31/235;;A61K31/60;;A61K38/385;;A61K38/40,A61K9/16;;A61K9/00;;A61K9/10;;A61K31/235;;A61K31/353;;A61K31/355;;A61K31/525;;A61K31/60;;A61K38/38;;A61K38/40;;A61K47/69,,0,0,,,,DISCONTINUED
904,EP,A1,EP 3985097 A1,087-990-146-151-357,2022-04-20,2022,EP 20201696 A,2020-10-14,EP 20201696 A,2020-10-14,A METHOD AND SYSTEM FOR CONFIGURING AND/OR SETUP OF A DOWNSTREAM PROCESS FOR PROCESSING A BIOMASS,"The invention relates to a computer-implemented method for configuring and/or setup and/or controlling of a downstream process for processing a biomass, comprising:receiving at least one measurement value of at least one feature of an upstream process by which the biomass to be processed in the downstream process has been obtained;determining at least one downstream process parameter based on the received at least one measurement value.The invention further relates to a computer-program product and a system for configuring and/or setup and/or controlling of a downstream process, a method and a system for processing a biomass.",SARTORIUS STEDIM BIOTECH GMBH,LEUPOLD MARCO;;ESPACHS ALEXANDRE;;HUSEMANN BERNWARD;;RODENBERG MICHAEL;;MATUSZCZYK JENS;;KAMPMANN MARKUS,,https://lens.org/087-990-146-151-357,Patent Application,yes,3,4,6,098-094-354-039-945;;040-500-263-079-825;;087-990-146-151-357;;141-442-005-021-726;;188-796-177-440-373;;027-265-913-313-372,JP;;CN;;EP;;WO;;US,6,098-094-354-039-945;;040-500-263-079-825;;087-990-146-151-357;;141-442-005-021-726;;188-796-177-440-373;;027-265-913-313-372,JP;;CN;;EP;;WO;;US,0,C12M41/48;;C12M47/02;;C12M47/10;;C12M41/48;;C12M33/14;;C12M41/46;;C12M47/02;;C12M47/10,C12M1/36;;C12M1/00,,1,1,103-778-860-580-044,28955024;;10.3390/bioengineering1040188,"PETRA GRONEMEYER ET AL: ""Trends in upstream and downstream process development for antibody manufacturing"", BIOENGINEERING (BASEL, SWITZERLAND) 08 MAY 2017, vol. 1, no. 4, 1 October 2014 (2014-10-01), pages 188 - 212, XP055461223, ISSN: 2306-5354, DOI: 10.3390/bioengineering1040188",DISCONTINUED
905,EP,A1,EP 3851852 A1,136-716-001-685-212,2021-07-21,2021,EP 20152470 A,2020-01-17,EP 20152470 A,2020-01-17,METHOD FOR SEPARATION OF SPERM WITH UNDAMAGED INTACT HEADS FROM SPERM WITH DAMAGED HEADS AND SOMATIC CELLS,"The present invention provides a method of separation of sperm cells with undamaged intact heads from sperm cells with damaged heads and/or somatic cells and/or cell debris in a cell sample obtained from an animal, comprising the steps of:- providing an anti-CD46 antibody bound to a carrier and/or to a tag;- contacting the cell sample with the anti-CD46 antibody bound to the carrier and/or to the tag in order to bind CD46 presenting cells and/or cell debris from the cell sample to the anti-CD46 antibody;- removing the CD46 presenting cells bound via the anti-CD46 antibody to the carrier and/or to the tag to obtain a cell sample free of CD46 presenting cells, wherein CD46 presenting cells include sperm cells with damaged heads, somatic cells and cell debris.This technology is designed to separate sperm with undamaged intact heads to be further used in assisted reproduction, medicine (in particular breeding programs and veterinary medicine), storage purpose, and research.",BIOTECHNOLOGICKY USTAV AV CR V V I;;PRIMECELL ADVANCED THERAPY A S;;CESKA ZEMEDELSKA UNIVERZITA V PRAZE,KOMRSKOVA KATERINA;;POSTLEROVA PAVLA;;FROLIKOVA MICHAELA;;ZAHRADNICEK MICHAL;;POSPISILOVA VERONIKA;;FOROSTYAK SERHIY;;SIMONIK ONDREJ,,https://lens.org/136-716-001-685-212,Patent Application,yes,1,0,9,136-716-001-685-212;;100-386-182-361-624;;194-387-718-803-510;;124-094-752-342-051;;007-464-600-262-726;;023-550-091-713-648;;184-195-718-910-800;;176-006-073-997-287;;029-915-042-159-676,EP;;ES;;WO;;CZ;;PL,9,136-716-001-685-212;;100-386-182-361-624;;194-387-718-803-510;;007-464-600-262-726;;124-094-752-342-051;;023-550-091-713-648;;184-195-718-910-800;;176-006-073-997-287;;029-915-042-159-676,EP;;ES;;WO;;CZ;;PL,1,B01D57/00;;C12N5/061;;G01N33/689;;G01N33/5005,G01N33/50;;G01N33/68,,4,4,002-078-942-036-844;;069-674-671-972-834;;018-130-802-499-587;;035-914-307-350-12X,25232015;;10.1095/biolreprod.114.121897;;10.1016/j.cryobiol.2011.08.001;;21884688;;10.1016/j.theriogenology.2005.09.010;;16242762;;18042631;;10.1530/rep-07-0363,"J. F. ODHIAMBO ET AL: ""Increased Conception Rates in Beef Cattle Inseminated with Nanopurified Bull Semen"", BIOLOGY OF REPRODUCTION, vol. 91, no. 4, 17 September 2014 (2014-09-17), US, pages 97 - 97, XP055239594, ISSN: 0006-3363, DOI: 10.1095/biolreprod.114.121897;;MARTÍNEZ-SOTO JUAN CARLOS ET AL: ""Assessment of two thawing processes of cryopreserved human sperm in pellets"", CRYOBIOLOGY, ACADEMIC PRESS INC, US, vol. 63, no. 3, 23 August 2011 (2011-08-23), pages 131 - 136, XP028597748, ISSN: 0011-2240, DOI: 10.1016/J.CRYOBIOL.2011.08.001;;SILVA P F N ET AL: ""Detection of damage in mammalian sperm cells"", THERIOGENOLOGY, LOS ALTOS, CA, US, vol. 65, no. 5, 15 March 2006 (2006-03-15), pages 958 - 978, XP027930357, ISSN: 0093-691X, [retrieved on 20060315];;PETER M JOHNSON ET AL: ""Rapid sperm acrosome reaction in the absence of acrosomal CD46 expression in promiscuous field mice (Apodemus)"", JOURNALS OF REPRODUCTION & FERTILITY, vol. 134, no. 6, 1 December 2007 (2007-12-01), GB, pages 739 - 747, XP055708907, ISSN: 1470-1626, DOI: 10.1530/REP-07-0363",DISCONTINUED
906,EP,A1,EP 4050031 A1,064-733-099-755-411,2022-08-31,2022,EP 22152938 A,2021-04-19,CN 202010357134 A;;EP 21796353 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1/LAG-3, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",DANSHENG PHARMACEUTICAL TECH SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING,,https://lens.org/064-733-099-755-411,Patent Application,yes,19,0,32,028-846-487-920-111;;001-087-470-491-846;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,182,C07K16/2818;;C07K16/22;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;C07K16/468;;A61P35/00;;A61P35/02;;A61P29/00;;A61P37/02;;A61P27/02;;A61P11/06;;A61P19/02;;A61P17/06;;A61P17/00;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C07K2317/76;;C07K2317/24;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/46;;C07K2317/64;;C07K2317/55;;C07K2317/515;;C07K16/2818;;C07K16/22;;C07K2317/24;;C07K2317/92;;C07K2317/94;;C07K2317/76;;A61K2039/505;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;A61K2039/505;;C07K16/22;;C07K16/2803;;C07K16/2863;;C07K16/2878;;C07K16/468;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/55;;C07K2317/76;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/22;;C07K16/32;;C07K16/46,,17,16,019-028-085-291-892;;004-097-259-326-739;;145-295-183-351-742;;003-613-117-343-797;;022-648-069-840-113;;033-951-567-552-932;;031-719-370-148-435;;008-411-420-307-533;;079-845-525-923-31X;;018-454-440-471-739;;052-515-652-666-158;;151-255-362-741-675;;027-360-429-703-956;;019-537-469-767-795;;018-905-882-624-966;;015-746-288-084-78X,10.1155/2012/980250;;pmc3312285;;22474489;;10.1038/icb.2014.93;;pmc4445461;;25367186;;20016854;;10.1016/s0022-2836(03)00526-6;;12818205;;10.1074/jbc.m500815200;;15757893;;pmc4848005;;10.1080/15384047.2015.1121344;;26671532;;10.1038/nbt0297-159;;9035142;;10.1038/nbt1345;;17934452;;10.1080/19420862.2015.1007826;;25611120;;pmc4623437;;24463572;;10.1038/nbt.2797;;10.1038/nbt0798-677;;9661204;;10.1074/jbc.m110.117382;;20400508;;pmc2885242;;pmc3585358;;23468998;;10.1371/journal.pone.0057479;;10.1016/j.critrevonc.2007.04.011;;17624800;;28986820;;pmc5777978;;10.1007/s13238-017-0473-8;;10.1158/1535-7163.mct-19-0608;;31974274,"AHMAD Z AYEAP S KALI A M ET AL.: ""scFv antibody: principles and clinical application"", CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, vol. 2012, 2012, pages 980250;;HUEHLS A MCOUPET T ASENTMAN C L: ""Bispecific T-cell engagers for cancer immunotherapy"", IMMUNOLOGY AND CELL BIOLOGY, vol. 93, no. 3, 2015, pages 290 - 296, XP055537601, DOI: 10.1038/icb.2014.93;;WU C.: ""Diabodies: molecular engineering and therapeutic applications"", DRUG NEWS PERSPECT, vol. 22, no. 8, 2009, pages 453;;KIPRIYANOV S MMOLDENHAUER QBRAUNAGEL M ET AL.: ""Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies"", JOURNAL OF MOLECULAR BIOLOGY, vol. 330, no. 1, 2003, pages 99 - 111, XP004445110, DOI: 10.1016/S0022-2836(03)00526-6;;LU DZHANG HKOO H ET AL.: ""A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 20, 2005, pages 19665 - 19672, XP002516978, DOI: 10.1074/JBC.M500815200;;CHEN ZXIE WACHEAMPONG D O ET AL.: ""A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity"", CANCER BIOLOGY & THERAPY, vol. 17, no. 2, 2016, pages 139 - 150, XP055544048, DOI: 10.1080/15384047.2015.1121344;;COLOMA M JMORRISON S L: ""Design and production of novel tetravalent bispecific antibodies"", NATURE BIOTECHNOLOGY, vol. 15, no. 2, 1997, pages 159, XP000647731, DOI: 10.1038/nbt0297-159;;WU CYING HGRINNELL C ET AL.: ""Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin"", NATURE BIOTECHNOLOGY, vol. 25, no. 11, 2007, pages 1290;;MAZOR YOGANESYAN VYANG C ET AL.: ""MAbs"", vol. 9, 2017, TAYLOR & FRANCIS, article ""Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies"", pages: 1010 - 1020;;LEWIS S MWU XPUSTILNIK A ET AL.: ""Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface"", NATURE BIOTECHNOLOGY, vol. 32, no. 2, 2014, pages 191, XP055240003, DOI: 10.1038/nbt.2797;;MERCHANT A MZHU ZYUAN J Q ET AL.: ""An efficient route to human bispecific IgG"", NATURE BIOTECHNOLOGY, vol. 16, no. 7, 1998, pages 677, XP002141015, DOI: 10.1038/nbt0798-677;;GUNASEKARAN KPENTONY MSHEN M ET AL.: ""Enhancing antibody Fc heterodimer formation through electrostatic steering effects applications to bispecific molecules and monovalent IgG"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 25, 2010, pages 19637 - 19646, XP055546816, DOI: 10.1074/jbc.M110.117382;;SAMPEI ZIGAWA TSOEDA T ET AL.: ""Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity"", PLOS ONE, vol. 8, no. 2, 2013, pages e57479, XP055553036, DOI: 10.1371/journal.pone.0057479;;SAMBROOK, J.FRITSCH, E.F.MANIAIS, T.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;MAGDELAINE-BEUZELIN CKAAS QWEHBI V ET AL.: ""Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment"", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 64, no. 3, 2007, pages 210 - 225, XP022344458, DOI: 10.1016/j.critrevonc.2007.04.011;;WANG XMATHIEU MBREZSKI R J: ""IgG Fc engineering to modulate antibody effector functions"", PROTEIN & CELL, vol. 9, no. 1, 2018, pages 63 - 73, XP055457296, DOI: 10.1007/s13238-017-0473-8;;HO SKXU ZTHAKUR A ET AL.: ""Epitope and Fc-mediated Crosslinking, but not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity"", MOLECULAR CANCER THERAPEUTICS, 2020, pages 1040 - 1051",DISCONTINUED
907,WO,A1,WO 2024/076963 A1,187-445-712-722-452,2024-04-11,2024,US 2023/0075797 W,2023-10-03,US 202263412640 P,2022-10-03,MICRO MAGNETIC RESONANCE RELAXOMETRY (MRR) FOR RAPID AND NON-INVASIVE DETECTION OF IPSC QUALITY AND DIFFERENTIATION,Method and system wherein induced pluripotent stem cells quality and differentiation are evaluated using T2 magnetic resonance relaxometry.,MASSACHUSETTS INST TECHNOLOGY;;UNIV NANYANG TECH;;SINGAPORE MIT ALLIANCE FOR RESEARCH & TECH CENTRE,HAN JONGYOON;;CHEW SING YIAN;;ROXBY DANIEL;;TAN ZU YAO;;NGUYEN TAN DAI,,https://lens.org/187-445-712-722-452,Patent Application,yes,4,0,2,052-460-593-190-835;;187-445-712-722-452,EP;;WO,2,052-460-593-190-835;;187-445-712-722-452,EP;;WO,0,G01N24/08;;G01R33/448;;G01R33/302;;C12N5/0696,G01N24/08;;C12N5/0735;;G01R33/30;;G01R33/44,,77,75,131-577-709-511-577;;005-142-901-798-335;;054-930-251-134-67X;;018-308-188-924-023;;131-577-709-511-577;;108-115-558-006-53X;;019-552-941-957-628;;032-330-914-541-050;;069-539-843-224-348;;020-259-222-288-432;;005-988-360-304-951;;117-939-434-528-924;;013-027-154-735-205;;051-076-348-265-423;;098-796-003-876-780;;005-338-383-180-74X;;041-090-591-143-58X;;016-717-939-052-938;;017-795-649-372-482;;089-569-125-352-022;;093-762-071-774-471;;066-953-362-513-397;;061-795-402-997-726;;013-601-754-197-432;;023-586-825-005-70X;;022-627-474-410-448;;010-078-668-603-972;;010-078-668-603-972;;122-591-853-158-880;;037-217-807-286-581;;005-142-901-798-335;;131-577-709-511-577;;072-680-484-262-203;;069-431-848-562-19X;;009-689-749-320-840;;042-598-876-652-904;;028-753-463-043-510;;083-595-947-050-534;;029-062-382-070-860;;025-409-034-770-03X;;084-997-621-274-034;;093-259-390-824-845;;034-423-372-666-144;;054-217-002-229-199;;099-110-553-842-099;;074-104-297-913-696;;081-006-516-241-16X;;131-553-448-178-908;;174-409-815-032-614;;180-203-106-259-801;;120-967-953-208-259;;121-324-596-648-594;;000-206-212-878-071;;041-622-842-124-880;;029-466-076-013-914;;001-631-562-265-359;;065-975-178-367-546;;116-397-715-666-995;;104-191-403-693-856;;069-423-037-568-723;;019-483-751-968-709;;134-466-147-405-517;;061-481-109-480-216;;039-237-776-093-314;;071-913-411-712-750;;016-880-392-817-756;;131-577-709-511-577;;019-007-654-892-493;;034-487-815-877-307;;124-247-920-232-359;;034-449-651-497-385;;086-355-859-769-342;;115-096-060-154-626;;113-146-599-112-200;;031-327-623-356-679,36988042;;pmc10184698;;10.1101/2022.06.01.494362;;10.1093/stcltm/szad014;;34608158;;10.1038/s41514-020-00049-0;;pmc7536436;;33083002;;pmc4469967;;10.1038/srep11425;;26081638;;23020427;;10.1063/1.4754296;;36988042;;pmc10184698;;10.1101/2022.06.01.494362;;10.1093/stcltm/szad014;;17411174;;10.1063/1.2712940;;10.1016/j.jmr.2008.02.019;;18374613;;10.1016/j.cell.2006.07.024;;16904174;;33007237;;10.1016/j.stem.2020.09.014;;10.1016/j.reth.2020.06.002;;33490319;;pmc7794047;;pmc8641078;;34515419;;10.1002/sctm.21-0239;;pmc9426776;;36051285;;10.3389/fcvm.2022.950829;;34522725;;10.1016/j.reth.2021.08.005;;pmc8427225;;10.1182/blood.2022017296;;36112961;;36808132;;10.1038/s41467-023-36408-0;;pmc9941131;;10.1136/jitc-2020-sitc2020.0380;;31245451;;pmc6581851;;10.1016/j.reth.2019.05.006;;10.1038/cr.2012.171;;pmc3541652;;23229514;;pmc3189018;;21949375;;10.1073/pnas.1108077108;;22028197;;10.1002/stem.767;;33959917;;10.1007/7651_2021_399;;10.1038/s12276-018-0054-9;;pmc5938022;;29674624;;10.1038/ncomms4449;;24622388;;10.1038/ncomms7626;;pmc4375778;;25806427;;pmc7595118;;10.1038/s41598-020-73656-2;;33116175;;10.1038/nrc3034;;21390058;;10.1016/j.stemcr.2015.01.006;;pmc4375796;;25684226;;10.1016/j.stemcr.2015.01.006;;pmc4375796;;25684226;;10.5772/54400;;10.1038/nm.3622;;25173428;;34608158;;10.1038/s41514-020-00049-0;;pmc7536436;;33083002;;36988042;;pmc10184698;;10.1101/2022.06.01.494362;;10.1093/stcltm/szad014;;34675308;;pmc8531323;;10.1038/s41598-021-00305-7;;pmc4340884;;10.1371/journal.pone.0118307;;25714340;;10.1016/j.cub.2010.11.049;;pmc3034649;;21167714;;10.2217/rme-2018-0095;;30205750;;30082899;;10.1038/s41592-018-0074-3;;pmc7650268;;32883317;;10.1186/s13041-020-00662-w;;34321477;;10.1038/s41467-021-24868-1;;pmc8319125;;pmc4839185;;26321202;;10.1016/j.stem.2015.08.003;;10.1038/s41418-020-00664-0;;33184465;;pmc8027637;;10.1101/713651;;35018826;;10.1089/scd.2021.0255;;10.1371/journal.pone.0037342;;pmc3355139;;22615985;;25347300;;10.1371/journal.pone.0110496;;pmc4210199;;32978066;;10.1016/j.jcyt.2020.07.009;;pmc4503445;;26176961;;10.1371/journal.pone.0132480;;10.1089/ten.tec.2013.0725;;25036750;;pmc4346545;;10.1007/s10735-020-09926-0;;33179120;;pmc7790792;;10.3390/antiox11050865;;pmc9137504;;35624729;;35014607;;pmc8752087;;10.7554/elife.73456;;10.3389/fimmu.2022.816282;;pmc8983924;;35401569;;10.1196/annals.1297.063;;15247045;;pmc6893074;;31587993;;10.1016/j.stemcr.2019.09.002;;pmc4870095;;10.1111/nyas.13008;;26890363;;34858857;;pmc8631356;;10.3389/fonc.2021.778492;;10.1002/cam4.4761;;pmc9582687;;35460205;;pmc3108097;;20420524;;10.1146/annurev.nutr.012809.104804;;10.1039/c3mt00347g;;24549403;;10.1182/blood.2021013472;;35994752;;28163381;;pmc5281535;;10.3164/jcbn.16-70;;10.1042/bj20061840;;17233627;;pmc1874234;;33727584;;10.1038/s41598-021-85387-z;;pmc7971025;;10.1016/s0021-9258(19)76437-0;;3654617;;pmc2717717;;18835072;;10.1016/j.blre.2008.08.001;;10.1007/s00394-011-0256-6;;22009264;;31892083;;10.1016/j.talanta.2019.120503;;36988042;;pmc10184698;;10.1101/2022.06.01.494362;;10.1093/stcltm/szad014;;30599084;;10.1002/stem.2967;;pmc7193162;;32053740;;10.1002/2211-5463.12811;;10.1016/j.reth.2019.05.002;;31890764;;pmc6933472;;21439131;;10.3727/096368910x564085;;pmc5634865;;29017529;;10.1186/s13287-017-0679-y;;pmc7444229;;10.1177/0963689719896559;;32166974;;pmc7069952;;10.1038/s41419-020-2383-6;;32170107;;22736480;;10.1002/cbic.201200202,"THAMARATH SMITHA SURENDRAN ET AL: ""Rapid and Live-cell Detection of Senescence in Mesenchymal Stem Cells by Micro Magnetic Resonance Relaxometry"", BIORXIV, 2 June 2022 (2022-06-02), pages 1 - 32, XP093066218, DOI: 10.1101/2022.06.01.494362;;TAN JEROME ET AL: ""Title of abstract: Label-free assessment of differentiation efficiency in iPSCderived Spinal Cord Progenitor Cells via Magnetic Resonance Relaxometry (MRR)"", 14TH STEM CELL SOCIETY SINGAPORE SYMPOSIUM 2022, 6 October 2022 (2022-10-06), pages 1 - 2, XP093113142, Retrieved from the Internet <URL:https://dr.ntu.edu.sg/bitstream/10356/163335/3/Jerome%20Abstract%20Stem%20Cell%20Society%20Singapore(1).pdf> [retrieved on 20231218];;PENG, W.K. ET AL.: ""Molecular phenotyping of oxidative stress in diabetes mellitus with point-of-care NMR system"", NP.IAGING AND MECHANISMS OF DISEASE,, vol. 6, no. 1, 2020, pages 1 - 12;;FOOK KONG, T. ET AL.: ""Enhancing malaria diagnosis through microfluidic cell enrichment and magnetic resonance relaxometry detection"", SCIENTIFIC REPORTS, vol. 5, no. 1, 2015, pages 1 - 12, XP055408509, DOI: 10.1038/srep11425;;PENG, W.K. ET AL.: ""Development of miniaturized, portable magnetic resonance relaxometry system for point-of-care medical diagnosis"", REVIEW OF SCIENTIFIC INSTRUMENTS, vol. 83, no. 9, 2012, pages 095115, XP012162672, DOI: 10.1063/1.4754296;;THAMARATH, S.S. ET AL.: ""Rapid and Live-cell Detection of Senescence in Mesenchymal Stem Cells by Micro Magnetic Resonance Relaxometry"", BIORXIV DOI.ORG/10.1101/2022.06.01.494362, 2022;;TAKEDA K: ""A highly integrated FPGA-based nuclear magnetic resonance spectrometer"", REV SCI INSTRUM, vol. 78, no. 3, 2007, pages 033103, XP012103816, DOI: 10.1063/1.2712940;;TAKEDA K: ""OPENCORE NMR: open-source core modules for implementing an integrated FPGA-based NMR spectrometer"", JOURNAL OF MAGNETIC RESONANCE, vol. 192, no. 2, 2008, pages 218 - 229, XP022684284, DOI: 10.1016/j.jmr.2008.02.019;;K. TAKAHASHIS. YAMANAKA: ""Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors"", CELL, vol. 126, no. 4, August 2006 (2006-08-01), pages 663 - 676;;S. YAMANAKA: ""Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges"", CELL STEM CELL, vol. 27, no. 4, October 2020 (2020-10-01), pages 523 - 531, XP086279810, DOI: 10.1016/j.stem.2020.09.014;;J. TAKAHASHI: ""iPS cell-based therapy for Parkinson's disease: A Kyoto trial"", REGEN. THER., vol. 13, March 2020 (2020-03-01), pages 18 - 22;;I. W. CARASL. R. COLLINSA. A. CREASEY: ""A Stem Cell Journey in Ophthalmology: From the Bench to the Clinic"", STEM CELLS TRANSL. MED., vol. 10, no. 12, December 2021 (2021-12-01), pages 1581 - 1587;;S. MIYAGAWA ET AL.: ""Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy"", FRONT. CARDIOVASC. MED., vol. 9, August 2022 (2022-08-01), pages 950829;;K. SUGAI ET AL.: ""First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: Study protocol"", REGEN. THER., vol. 18, December 2021 (2021-12-01), pages 321 - 333;;N. SUGIMOTO ET AL.: ""iPLATl: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study"", BLOOD, vol. 140, no. 22, December 2022 (2022-12-01), pages 2398 - 2402;;K. ABE ET AL.: ""Engraftment of allogeneic iPS cell-derived cartilage organoid in a primate model of articular cartilage defect"", NAT. COMMUN., vol. 14, no. 1, February 2023 (2023-02-01);;D. HONG ET AL.: ""380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors"", J. IMMUNOTHER. CANCER, vol. 8, November 2020 (2020-11-01);;N. NAGOSHIO. TSUJIM. NAKAMURAH. OKANO: ""Cell therapy for spinal cord injury using induced pluripotent stem cells"", REGEN. THER., vol. 11, June 2019 (2019-06-01), pages 75 - 80;;M. NAKAMURAH. OKANO: ""Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells"", CELL RES., vol. 23, no. 1, January 2013 (2013-01-01);;S. NORI ET AL.: ""Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice"", PROC. NATL. ACAD. SCI., vol. 108, no. 40, October 2011 (2011-10-01), pages 16825 - 16830, XP055057521, DOI: 10.1073/pnas.1108077108;;A. YASUDA ET AL.: ""Significance of Remyelination by Neural Stem/Progenitor Cells Transplanted into the Injured Spinal Cord"", STEM CELLS, vol. 29, no. 12, 2011, pages 1983 - 1994;;S. H. TAYWINANTOZ. J. KHONGY. H. KOHS. Y. NG: ""Methods in Molecular Biology"", 2021, SPRINGER US, article ""Generation of Cortical, Dopaminergic, Motor, and Sensory Neurons from Human Pluripotent Stem Cells"";;J. E. SHIN ET AL.: ""Brain and spinal cord injury repair by implantation of human neural progenitor cells seeded onto polymer scaffolds"", EXP. MOL. MED, vol. 50, no. 4, April 2018 (2018-04-01), pages 39;;Q. QU ET AL.: ""High-efficiency motor neuron differentiation from human pluripotent stem cells and the function of Islet-1"", NAT. COMMUN., vol. 5, no. 1, March 2014 (2014-03-01);;Z.-W. DU ET AL.: ""Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells"", NAT. COMMUN., vol. 6, no. 1, 1 March 2015 (2015-03-01);;N. BALAFKAN ET AL.: ""A method for differentiating human induced pluripotent stem cells toward functional cardiomyocytes in 96-well microplates"", SCI. REP., vol. 10, no. 1, October 2020 (2020-10-01);;U. BEN-DAVIDN. BENVENISTY: ""The tumorigenicity of human embryonic and induced pluripotent stem cells"", NAT. REV. CANCER, vol. 11, no. 4, April 2011 (2011-04-01), pages 268 - 277, XP055099905, DOI: 10.1038/nrc3034;;S. NORI ET AL.: ""Term Safety Issues of iPSC-Based Cell Therapy in a Spinal Cord Injury Model: Oncogenic Transformation with Epithelial-Mesenchymal Transition"", STEM CELL REP., vol. 4, no. 3, March 2015 (2015-03-01), pages 360 - 373;;S. NORI ET AL.: ""Long-Term Safety Issues of iPSC-Based Cell Therapy in a Spinal Cord Injury Model: Oncogenic Transformation with Epithelial-Mesenchymal Transition"", STEM CELL REP., vol. 4, no. 3, March 2015 (2015-03-01), pages 360 - 373;;J. CARLOSA. L.: ""Pluripotent Stem Cells"", 2013, INTECH, article ""Safety Assessment of Reprogrammed Cells Prior to Clinical Applications: Potential Approaches to Eliminate Teratoma Formation"";;W. K. PENG ET AL.: ""Micromagnetic resonance relaxometry for rapid label-free malaria diagnosis"", NAT. MED., vol. 20, no. 9, September 2014 (2014-09-01), pages 1069 - 1073;;W. K. PENGL. CHENB. O. BOEHMJ. HANT. P. LOH: ""Molecular phenotyping of oxidative stress in diabetes mellitus with point-of-care NMR system"", NPJ AGING MECH. DIS., vol. 6, no. 1, October 2020 (2020-10-01);;S. S. THAMARATH ET AL.: ""Rapid and Live-cell Detection of Senescence in Mesenchymal Stem Cells by Micro Magnetic Resonance Relaxometry"", BIOPHYSICS, June 2022 (2022-06-01);;M. S. PETRONEK ET AL.: ""Quantum chemical insight into the effects of the local electron environment on T2*-based MRI"", SCI. REP., vol. 11, no. 1, October 2021 (2021-10-01), pages 20817;;GARITAONANDIA, I. ET AL.: ""Increased risk of genetic and epigenetic instability in human embryonic stem cells associated with specific culture conditions"", PLOS ONE, vol. 10, no. 2, 2015, pages 18307;;RUIZ, S. ET AL.: ""A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity"", CURRENT BIOLOGY, vol. 21, no. 1, 2011, pages 45 - 52, XP027587142;;SULLIVAN, S. ET AL.: ""Quality control guidelines for clinical-grade human induced pluripotent stem cell lines"", REGENERATIVE MEDICINE, vol. 13, no. 7, 2018, pages 859 - 866;;H. KUMAMARU ET AL.: ""Generation and post-injury integration of human spinal cord neural stem cells"", NAT. METHODS, vol. 15, no. 9, September 2018 (2018-09-01);;K. KAJIKAWA ET AL.: ""Cell therapy for spinal cord injury by using human iPSC-derived region-specific neural progenitor cells"", MOL. BRAIN, vol. 13, no. 1, December 2020 (2020-12-01), pages 120, XP093000781, DOI: 10.1186/s13041-020-00662-w;;T. QIANT. M. HEASTERA. R. HOUGHTALINGK. SUNK. SAMIMIM. C. SKALA: ""Label-free imaging for quality control of cardiomyocyte differentiation"", NAT. COMMUN., vol. 12, no. 1, December 2021 (2021-12-01), pages 4580;;S.-Y. NG ET AL.: ""Genome-wide RNA-Seq of Human Motor Neurons Implicates Selective ER Stress Activation in Spinal Muscular Atrophy"", CELL STEM CELL, vol. 17, no. 5, November 2015 (2015-11-01), pages 569 - 584;;J.-H. HOR ET AL.: ""ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation"", CELL DEATH DIFFER., vol. 28, no. 4, April 2021 (2021-04-01);;L. HAN ET AL.: ""Distinctive Clinical and Pathologic Features of Immature Teratomas Arising from Induced Pluripotent Stem Cell-Derived Beta Cell Injection in a Diabetes Patient"", STEM CELLS DEV., vol. 31, no. 5-6, March 2022 (2022-03-01), pages 97 - 101;;T. KURODA ET AL.: ""Highly Sensitive In Vitro Methods for Detection of Residual Undifferentiated Cells in Retinal Pigment Epithelial Cells Derived from Human iPS Cells"", PLOS ONE, vol. 7, no. 5, May 2012 (2012-05-01), pages e37342, XP055382467, DOI: 10.1371/journal.pone.0037342;;K. TANOS. YASUDAT. KURODAH. SAITOA. UMEZAWAY. SATO: ""A Novel In Vitro Method for Detecting Undifferentiated Human Pluripotent Stem Cells as Impurities in Cell Therapy Products Using a Highly Efficient Culture System"", PLOS ONE, vol. 9, no. 10, October 2014 (2014-10-01), pages e110496, XP055485499, DOI: 10.1371/journal.pone.0110496;;T. WATANABE ET AL.: ""Multisite studies for validation and improvement of a highly efficient culture assay for detection of undifferentiated human pluripotent stem cells intermingled in cell therapy products"", CYTOTHERAPY, vol. 23, no. 2, February 2021 (2021-02-01), pages 176 - 183;;C. SONG ET AL.: ""Use of Ferritin Expression, Regulated by Neural Cell-Specific Promoters in Human Adipose Tissue-Derived Mesenchymal Stem Cells, to Monitor Differentiation with Magnetic Resonance Imaging In Vitro"", PLOS ONE, vol. 10, no. 7, July 2015 (2015-07-01), pages e0132480;;D. LU ET AL.: ""Accelerated Neuronal Differentiation Toward Motor Neuron Lineage from Human Embryonic Stem Cell Line (H9"", TISSUE ENG. PART C METHODS, vol. 21, no. 3, March 2015 (2015-03-01), pages 242 - 252;;F. ZHANG ET AL.: ""Transferrin improved the generation of cardiomyocyte from human pluripotent stem cells for myocardial infarction repair"", J. MOL. HISTOL., vol. 52, no. 1, February 2021 (2021-02-01), pages 87 - 99, XP037331881, DOI: 10.1007/s10735-020-09926-0;;W. J. CHENG. P. KUNGJ. P. GNANA-PRAKASAM: ""Role of Iron in Aging Related Diseases"", ANTIOXIDANTS, vol. 11, no. 5, April 2022 (2022-04-01), pages 865;;T. SATOJ. S. SHAPIROH.-C. CHANGR. A. MILLERH. ARDEHALI: ""Aging is associated with increased brain iron through cortex-derived hepcidin expression"", ELIFE, vol. 11, January 2022 (2022-01-01), pages e73456;;S. KUVIBIDILAR. P. WARRIERB. SURENDRA BALIGA: ""An overview of the role of iron in T cell activation"", J. TRACE ELEM. EXP. MED., vol. 16, no. 4, 2003, pages 219 - 225;;S. NIY. YUANY. KUANGAND X. LI: ""Iron Metabolism and Immune Regulation"", FRONT. IMMUNOL., vol. 13, 2022;;D. W. KILLILEAS. L. WONGH. S. CAHAYAH. ATAMNAB. N. AMES: ""Iron Accumulation during Cellular Senescence"", ANN. N. Y. ACAD. SCI., vol. 1019, no. 1, June 2004 (2004-06-01), pages 365 - 367, XP071399764, DOI: 10.1196/annals.1297.063;;A. COZZI ET AL.: ""Stem Cell Modeling of Neuroferritinopathy Reveals Iron as a Determinant of Senescence and Ferroptosis during Neuronal Aging"", STEM CELL REP., vol. 13, no. 5, November 2019 (2019-11-01), pages 832 - 846;;D. H. MANZN. L. BLANCHETTEB. T. PAULF. M. TORTIS. V. TORTI: ""Iron and cancer: recent insights"", ANN. N. Y. ACAD. SCI., vol. 1368, no. 1, March 2016 (2016-03-01), pages 149 - 161;;Q. GUO ET AL.: ""The Role of Iron in Cancer Progression"", FRONT. ONCOL., vol. 11, 2021;;T. BASAKR. K. KANWAR: ""Iron imbalance in cancer: Intersection of deficiency and overload"", CANCER MED., vol. 11, no. 20, 2022, pages 3837 - 3853;;M. WESSLING-RESNICK: ""Iron Homeostasis and the Inflammatory Response"", ANNU. REV. NUTR., vol. 30, August 2010 (2010-08-01), pages 105 - 122, XP055213495, DOI: 10.1146/annurev.nutr.012809.104804;;D. B. KELLE. PRETORIUS: ""Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells"", METALLOMICS, vol. 6, no. 4, April 2014 (2014-04-01), pages 748 - 773;;O. MARQUESG. WEISSM. U. MUCKENTHALER: ""The role of iron in chronic inflammatory diseases: from mechanisms to treatment options in anemia of inflammation"", BLOOD, vol. 140, no. 19, November 2022 (2022-11-01), pages 2011 - 2023;;T. HIRAYAMAH. NAGASAWA: ""Chemical tools for detecting Fe ions"", J. CLIN. BIOCHEM. NUTR., vol. 60, no. 1, January 2017 (2017-01-01), pages 39 - 48;;M. TENOPOULOUT. KURZP.-T. DOULIASD. GALARISU. T. BRUNK: ""Does the calcein-AM method assay the total cellular ''labile iron pool'' or only a fraction of it?"", BIOCHEM. J., vol. 403, April 2007 (2007-04-01), pages 261 - 266;;U. ABBASIS. ABBINAA. GILLV. BHAGATJ. N. KIZHAKKEDATHU: ""A facile colorimetric method for the quantification of labile iron pool and total iron in cells and tissue specimens"", SCI. REP., vol. 11, March 2021 (2021-03-01), pages 6008;;J. S. ROHRERM. S. JOOE. DARTYGED. E. SAYERSA. FONTAINEE. C. THEIL: ""Stabilization of iron in a ferrous form by ferritin. A study using dispersive and conventional x-ray absorption spectroscopy."", J. BIOL. CHEM., vol. 262, no. 28, October 1987 (1987-10-01), pages 13385 - 13387;;M. A. KNOVICHJ. A. STOREYL. G. COFFMANS. V. TORTI: ""Ferritin for the Clinician"", BLOOD REV., vol. 23, no. 3, May 2009 (2009-05-01), pages 95 - 104, XP026068914, DOI: 10.1016/j.blre.2008.08.001;;V. FIORITOS. GENINATTI CRICHL. SILENGOF. ALTRUDAS. AIMEE. TOLOSANO: ""Assessment of iron absorption in mice by ICP-MS measurements of (57)Fe levels"", EARR. J. NUTR., vol. 51, no. 7, October 2012 (2012-10-01), pages 783 - 789, XP035116825, DOI: 10.1007/s00394-011-0256-6;;B. ANS. Z. CANS. BAKIRDERE: ""Traceable and accurate quantification of iron in seawater using isotope dilution calibration strategies by triple quadrupole ICP-MS/MS: Characterization measurements of iron in a candidate seawater CRM"", TALANTA, vol. 209, March 2020 (2020-03-01), pages 120503;;S. S. THAMARATH ET AL.: ""Rapid and Live-Cell Detection of Senescence in Mesenchymal Stem Cells by Micro Magnetic Resonance Relaxometry"", STEM CELLS TRANSL. MED., March 2023 (2023-03-01), pages szad014;;Z. HAN ET AL.: ""Iron Homeostasis Determines Fate of Human Pluripotent Stem Cells Via Glycerophospholipids-Epigenetic Circuit"", STEM CELLS, vol. 37, no. 4, April 2019 (2019-04-01), pages 489 - 503;;Z. HAN ET AL.: ""Iron overload inhibits self-renewal of human pluripotent stem cells via DNA damage and generation of reactive oxygen species"", FEBS OPEN BIO, vol. 10, no. 5, May 2020 (2020-05-01), pages 726 - 733;;K. KANIE ET AL.: ""Effect of mechanical vibration stress in cell culture on human induced pluripotent stem cells"", REGEN. THER., vol. 12, December 2019 (2019-12-01), pages 27 - 35, XP093052873, DOI: 10.1016/j.reth.2019.05.002;;Y. ZHOU ET AL.: ""Characterization of Human Umbilical Cord Lining-Derived Epithelial Cells and Transplantation Potential"", CELL TRANSPLANT., vol. 20, no. 11-12, December 2011 (2011-12-01), pages 1827 - 1841, XP055652944, DOI: 10.3727/096368910X564085;;R. SALEHH. M. REZA: ""Short review on human umbilical cord lining epithelial cells and their potential clinical applications"", STEM CELL RES. THER., vol. 8, no. 1, October 2017 (2017-10-01), pages 222;;R. H. G. LIMJ. X. K. LIEWA. WEEJ. MASILAMANIS. K. Y. CHANGT. T. PHAN: ""Safety Evaluation of Human Cord-Lining Epithelial Stem Cells Transplantation for Liver Regeneration in a Porcine Model"", CELL TRANSPLANT., vol. 29, 2020, pages 963689719896559;;WINANTOZ. J. KHONGB.-S. SOHY. FANS.-Y. NG: ""Organoid cultures of MELAS neural cells reveal hyperactive Notch signaling that impacts neurodevelopment"", CELL DEATH DIS., vol. 11, no. 3, March 2020 (2020-03-01);;Y. WEIZ. AYDINY. ZHANGZ. LIUM. GUO: ""A Turn-on Fluorescent Sensor for Imaging Labile Fe3+ in Live Neuronal Cells at Subcellular Resolution"", CHEMBIOCHEM, vol. 13, no. 11, July 2012 (2012-07-01), pages 1569 - 1573",PENDING
908,US,A1,US 2025/0032444 A1,065-286-685-824-082,2025-01-30,2025,US 202218714605 A,2022-11-30,FI 20216228 A;;FI 20225643 A;;FI 2022050801 W,2021-11-30,Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (PCpEV),"The present invention is directed to 4-methylumbelliferone (hymecromone) or a derivative thereof for use in the treatment of major depressive disorder, mood disorders, anxiety-related disorders and depression associated with diseases or drug treatments including Alzheimer's disease, HIV associated neurocognitive disorders (HAND), psoriasis, chronic fatigue syndrome, Parkinson's disease, Long COVID syndrome and drug treatment regimens with IFN-alpha or vitamin A analogues, promoted by pathogenic extracellular vesicles, wherein 4-methylumbelliferone inhibits hyaluronic acid (HA) synthases and block the incorporation of HA and/or low molecular weight cleavage products into said extracellular vesicles. The present invention is also directed to a method for monitoring the efficacy of the treatment and delivery of therapeutic cargo to cells incorporating pEV by means of HA-binding receptors. The present invention further provides an in vitro screening method for identifying further inhibitors of HA synthases.",EVEXYS BIOTECH OY,BAUR ANDREAS;;YLÖSMÄKI ERKKO,EVEXYS BIOTECH OY (2024-05-23),https://lens.org/065-286-685-824-082,Patent Application,yes,0,0,3,180-849-692-150-659;;065-286-685-824-082;;021-514-207-221-055,EP;;WO;;US,3,180-849-692-150-659;;065-286-685-824-082;;021-514-207-221-055,EP;;WO;;US,0,A61K31/352;;A61P25/24;;A61K35/00;;G01N33/6896;;G01N2333/91102;;G01N2800/52;;G01N2500/10;;A61K31/352;;A61K35/00;;G01N33/6896;;G01N2333/91102;;G01N2500/10;;G01N2800/52,A61K31/352;;A61K35/00;;G01N33/68,,0,0,,,,PENDING
909,US,A1,US 2021/0380944 A1,032-162-682-866-98X,2021-12-09,2021,US 202117396487 A,2021-08-06,US 202117396487 A;;US 201916557316 A;;EP 2019070125 W;;US 201862703654 P,2018-07-26,THERAPEUTIC PREPARATIONS OF GAMMA-DELTA T CELLS AND NATURAL KILLER CELLS AND METHODS FOR MAKING AND USING THEM,"Provided are methods of making innate immune cell compositions containing gamma.delta (γδ) T cells and/or Natural Killer (NK) cells, and the resulting compositions and related products of manufacture and kits for use in cancer and infectious disease therapy. The methods provided herein permit tailoring of the relative amounts of gamma.delta (γδ) T cells and Natural Killer (NK) cells in the compositions. for cellular therapies against a wide variety of cancers and infectious diseases. The resulting compositions can further be used to generate compositions containing either NK cells alone or gamma.delta T cells alone, for immune cellular therapies. The compositions provided herein also can be genetically altered: the gamma delta T cells and Natural Killer cells are modified to express chimeric antigen receptors (CARs) or exogenous T cell receptors (TCRs), which can be used to target any cell surface molecule either directly or indirectly, e.g., a marker on a cancer cell or an infected cell.",OSPEDALE PEDIATRICO BAMBINO GESÙ,QUINTARELLI CONCETTA;;DE ANGELIS BIAGIO;;LOCATELLI FRANCO,OSPEDALE PEDIATRICO BAMBINO GESÙ (OPBG) (2019-09-05),https://lens.org/032-162-682-866-98X,Patent Application,yes,0,0,2,032-162-682-866-98X;;139-503-410-942-443,US,15,050-549-728-685-826;;034-965-381-986-859;;046-316-560-299-216;;163-849-663-345-768;;043-745-968-093-728;;171-802-681-224-814;;014-963-061-270-953;;076-537-000-420-679;;129-516-926-713-000;;129-876-630-346-968;;032-162-682-866-98X;;139-503-410-942-443;;025-839-535-158-789;;112-495-119-797-01X;;072-510-631-088-742,JP;;KR;;AU;;CN;;EP;;WO;;SG;;US;;CA,1,A61P35/00;;A61P35/02;;A01K2207/12;;A01K2227/105;;A01K2267/0331;;C07K16/2803;;C07K16/2806;;C07K2319/03;;C07K14/7051;;C12N5/0646;;C12N5/0636;;C12N2510/00;;C12N2501/2302;;C12N2501/2315;;C12N2501/53;;C12N5/0087;;A61K2239/47;;A61K2239/31;;A61K2239/48;;A61K2239/38;;A61K40/15;;A61K40/4217;;A61K40/4258;;A61K40/4211;;A61K40/11;;A61K40/31;;C12N5/0646;;C12N5/0636;;C12N5/0037;;C12N2501/998;;A61K45/06;;A61P35/02;;C12N2501/2302;;C12N2501/2315;;A61P35/00;;A61K2239/47;;A61K2239/31;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/15;;A61K40/31;;A61K40/4211;;A61K40/4217;;A61K40/4258,C12N5/0783;;A61K35/17;;A61K45/06;;A61P35/00;;A61P35/02;;C12N5/00,,9,4,029-647-133-396-708;;119-848-279-676-618;;005-502-095-093-731;;010-232-252-655-51X,10.1038/mt.2014.104;;24895997;;pmc4435582;;10.1016/j.jcyt.2013.05.014;;23993299;;10.1182/blood.v96.12.3827;;11090067;;10.1182/blood.v96.12.3827.h8003827_3827_3837;;10.3109/10428194.2011.634048;;pmc3491067;;22023526,"Siegers and Lamb (Molecular Therapy, 2014, 22(8): 1416-1422) (Year: 2014);;Schumm et al (Cytotherapy, 2013, 15: 1253-1258) (Year: 2013);;Lopez et al (Blood, 2000, 96(2): 3827-3837) (Year: 2000);;Miltenyi Biotech (2015, 3 pages) (Year: 2015);;Miltenyi Biotech CliniMACs TCR alpha/beta Product Line (2021, 3 pages) (Year: 2021);;Boisssel et al (Leuk. Lymphoma, 2012, 53(5): 958-965) (Year: 2012);;Capsomidis et al (Molec. Ther., 2/2018, 262(2): 354-365) (Year: 2018);;Koepsell et al (Transfusion, 2013, 53: 404-410) (Year: 2013);;Van Acker et al (J. Hematol. & Oncol. 2016, 9:101: 1-13) (Year: 2016)",PENDING
910,EP,A1,EP 3798317 A1,120-709-831-505-19X,2021-03-31,2021,EP 20195846 A,2008-04-04,US 92178707 P;;US 93111507 P;;US 96253007 P;;US 96753907 P;;EP 08727306 A;;US 2008/0004467 W;;US 6239108 P,2007-04-04,"COMPOSITIONS, DEVICES, SYSTEMS, AND METHODS FOR USING A NANOPORE","The invention herein disclosed provides for devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore. The devices and methods are also used to determine rapidly (∼ >50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.",UNIV CALIFORNIA,AKESON MARK A;;DEAMER DAVID W;;DUNBAR WILLIAM B;;BENNER SEICO;;CHEN ROGER JINTEH ARRIGO;;WILSON NOAH A;;LIEBERMAN KATE;;ABU-SHUMAYS ROBIN;;HURT NICHOLAS;;BRANTON DANIEL,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2024-01-03),https://lens.org/120-709-831-505-19X,Patent Application,yes,34,0,49,050-750-190-792-148;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;085-188-996-524-024;;172-840-139-122-539;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;110-967-876-084-674;;007-641-951-572-149;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;044-951-647-888-187;;192-696-239-263-373;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;082-548-722-396-405;;123-067-273-122-369;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;176-430-871-659-277,KR;;JP;;AU;;CN;;EP;;IL;;WO;;US;;CA,49,176-430-871-659-277;;138-165-236-190-155;;146-499-599-991-461;;014-613-785-022-533;;160-430-942-926-192;;103-188-606-784-906;;171-274-449-097-076;;187-773-736-669-951;;087-399-139-203-480;;172-840-139-122-539;;085-188-996-524-024;;001-601-687-726-393;;045-884-642-162-896;;065-346-627-779-414;;122-937-646-667-696;;021-773-940-935-188;;007-641-951-572-149;;110-967-876-084-674;;143-633-631-741-936;;042-683-265-636-821;;028-006-470-291-142;;038-055-592-922-284;;003-244-243-784-437;;153-470-023-927-373;;195-969-471-261-17X;;158-456-995-433-053;;030-019-644-371-05X;;036-146-177-576-653;;120-709-831-505-19X;;112-392-292-520-223;;192-696-239-263-373;;044-951-647-888-187;;147-017-416-182-461;;021-338-777-153-912;;122-197-094-319-35X;;031-022-549-023-034;;141-138-405-721-426;;068-980-186-262-897;;188-464-636-890-226;;127-604-820-017-311;;123-067-273-122-369;;082-548-722-396-405;;194-860-957-651-834;;178-884-920-806-19X;;031-909-238-807-939;;088-715-067-359-483;;040-935-091-770-718;;066-044-316-006-353;;050-750-190-792-148,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA,0,C12Q1/6869;;G01N33/48721;;C25B3/29;;C12Q1/25;;G01N33/48721;;G01N33/573;;C25B3/29;;C12Q1/54;;C12Q1/6874;;G01N27/3278;;G01N27/4166;;C25B3/29;;C12Q1/6869;;G01N33/48721;;C12Q1/6874;;C12Q1/54;;G01N27/3278;;G01N27/4166,C12Q1/68;;C25B3/29;;G01N33/487,,25,20,006-559-985-093-956;;083-026-804-644-431;;073-477-535-611-745;;018-924-643-168-303;;068-798-547-570-852;;043-488-428-934-552;;078-312-516-928-137;;081-376-983-952-92X;;031-982-825-878-521;;014-065-259-226-128;;020-068-178-416-246;;015-405-576-155-188;;035-198-512-614-863;;027-792-210-134-567;;020-013-008-687-707;;036-928-668-575-379;;121-636-791-461-218;;034-211-481-478-172;;006-559-985-093-956;;063-687-361-818-238,18654412;;pmc2507869;;10.1038/nnano.2007.344;;24496266;;10.1016/j.snb.2012.11.027;;pmc3564666;;10.1073/pnas.93.24.13770;;8943010;;pmc19421;;10.1038/313402a0;;2578624;;16339375;;10.1101/gr.3770505;;10.1016/j.tibtech.2006.10.005;;17055093;;10.1016/0076-6879(87)52057-2;;3657585;;10.1073/pnas.94.6.2150;;9122163;;pmc20056;;9521923;;10.1101/gr.8.3.195;;pmc38202;;10.1073/pnas.93.20.10614;;8855227;;11231558;;10.1038/85696;;12582251;;pmc150236;;10.1093/nar/gkg218;;10.1038/nature04268;;pmc1356566;;16284617;;pmc1865524;;16902131;;10.1126/science.1130105;;17339846;;10.1038/nmeth1021;;pmc1302674;;10.1016/s0006-3495(03)74913-3;;12547778;;10.1016/s0006-3495(03)75042-5;;pmc1302803;;12668445;;10.1038/nature01405;;12540915;;18654412;;pmc2507869;;10.1038/nnano.2007.344;;1100841;;10.1016/0022-2836(75)90213-2,"SEICO BENNER ET AL: ""Sequence-specific detection of individual DNA polymerase complexes in real time using a nanopore"", NATURE NANOTECHNOLOGY, vol. 2, no. 11, 28 October 2007 (2007-10-28), pages 718 - 724, XP055055941, ISSN: 1748-3387, DOI: 10.1038/nnano.2007.344;;JUNGSUK KIM ET AL: ""Detecting single-abasic residues within a DNA strand immobilized in a biological nanopore using an integrated CMOS sensor"", SENSORS AND ACTUATORS B: CHEMICAL, vol. 177, 1 February 2013 (2013-02-01), pages 1075 - 1082, XP055137142, ISSN: 0925-4005, DOI: 10.1016/j.snb.2012.11.027;;KASIANOWICZ ET AL., PROC. NATL. ACAD. SCI. USA., vol. 93, 1996, pages 13770 - 13773;;KASHIMA ET AL., NATURE, vol. 313, 1985, pages 402 - 404;;SAMBROOK ET AL.: ""Molecular Cloning. A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY;;ANDERSONYOUNG: ""Nucleic Acid Hybridisation. A Practical Approach"", 1985, IRL PRESS, article ""Quantitative Filter Hybridisation"", pages: 73 - 111;;METZKER, GENOME RES., vol. 15, 2005, pages 1767 - 1776;;RHEEBURNS, TIBS, vol. 24, 2006, pages 580 - 586;;WAHLBERGER, METHODS ENZYMOL., vol. 152, 1987, pages 507 - 511;;""Nucleic Acid Hybridisation: A Practical Approach"", 1985, IRL PRESS;;HELLER ET AL., PROC. NATL. ACAD. SCI., vol. 94, 1997, pages 2150 - 2155;;MEYERS: ""Molecular Biology and Biotechnology"", 1995, WILEY VCH, pages: 856 - 853;;GORDON, GENOME RES., vol. 8, 1998, pages 195 - 202;;SCHENA ET AL., PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 10614 - 10619;;VERCOUTERE ET AL., NAT. BIOTECHNOL, vol. 19, no. 3, 2001, pages 248 - 252;;VERCOUTERE ET AL., NUCLEIC ACIDS RESEARCH, vol. 31, 2003, pages 1311 - 1318;;ABBONDANZIERI ET AL., NATURE, vol. 438, no. 7067, 2005, pages 460 - 465;;GREENLEAFBLOCK, SCIENCE, vol. 313, no. 5788, 2006, pages 801;;HORNBLOWER ET AL., NATURE METH., vol. 4, 2007, pages 315 - 317;;WINTERS-HILT ET AL., BIOPHYS. J., vol. 84, no. 2, 2003, pages 967 - 976;;BATES ET AL., BIOPHYSICAL JOURNAL, vol. 84, 2003, pages 2366 - 2372;;BUSTAMANTE ET AL., NATURE, vol. 421, 2003, pages 423 - 427;;BENNER ET AL., NATURE NANOTECHNOLOGY, vol. 2, 2007, pages 718 - 724;;SANGERCOULSON, J. MOL. BIOL., vol. 94, 1975, pages 441 - 448;;SMITH ET AL., PROTEIN ENGINEERING, vol. 5, 1992, pages 35 - 51",ACTIVE
911,WO,A1,WO 2022/229434 A1,143-237-748-502-619,2022-11-03,2022,EP 2022061573 W,2022-04-29,EP 21171407 A,2021-04-30,FUSION PROTEINS AND USE THEREOF IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY,"There are disclosed fusion proteins comprising an anti-CD3 antibody and an autoantigen involved in autoimmune diseases, nucleic acid encoding the same, pharmaceutical composition comprising them and the use thereof for the treatment of autoimmune diseases and particularly of membranous nephropathy.",KILOMETRO ROSSO SPA,PERICO LUCA;;CASIRAGHI FEDERICA;;BENIGNI ARIELA;;REMUZZI GIUSEPPE,,https://lens.org/143-237-748-502-619,Patent Application,yes,2,0,5,143-237-748-502-619;;012-482-702-203-153;;005-164-869-865-506;;006-655-751-386-094;;150-616-133-101-564,EP;;CN;;WO;;US,5,143-237-748-502-619;;012-482-702-203-153;;005-164-869-865-506;;006-655-751-386-094;;150-616-133-101-564,EP;;CN;;WO;;US,16,C07K14/705;;C12N15/62;;A61P13/12;;C07K16/2809;;C07K2317/622;;C07K2319/21;;C07K14/4713;;C07K2319/33;;A61P13/12;;A61K38/00;;C07K14/705;;C07K16/2809;;C07K2317/622;;C07K2319/21;;C07K2319/33;;C12N15/86;;C12N2740/15043,C07K14/705;;A61K39/395;;A61P13/12;;C07K14/47;;C07K16/18;;C07K16/28;;C07K19/00;;C12N15/09;;C12N15/62,,18,17,012-474-208-722-046;;083-945-009-744-393;;004-440-694-419-118;;003-483-997-494-338;;028-625-702-042-165;;033-401-386-102-67X;;039-099-146-869-04X;;078-511-847-986-499;;005-410-206-287-929;;002-469-553-486-727;;012-474-208-722-046;;004-440-694-419-118;;083-945-009-744-393;;004-330-410-830-726;;019-123-839-807-185;;010-342-021-874-640;;143-937-154-458-291,16213416;;10.1016/s1359-6446(05)03554-3;;10.1681/asn.2013121315;;pmc4310656;;25205735;;10.1056/nejmoa0810457;;pmc2762083;;19571279;;10.1016/j.pharmthera.2017.12.002;;29269044;;27373970;;10.1016/j.clim.2016.06.011;;pmc1447637;;10983209;;10.2105/ajph.90.9.1463;;29143151;;pmc5688039;;10.1007/s13317-017-0100-y;;10.1681/asn.2016091022;;28487395;;pmc5576929;;10.1126/scitranslmed.aav1648;;30842314;;pmc8201923;;pmc5343513;;27365313;;10.1126/science.aaf6756;;16213416;;10.1016/s1359-6446(05)03554-3;;10.1056/nejmoa0810457;;pmc2762083;;19571279;;10.1681/asn.2013121315;;pmc4310656;;25205735;;25394321;;pmc4278759;;10.1056/nejmoa1409354;;25804280;;10.1681/asn.2014070640;;pmc4587688;;25573986;;10.1182/blood-2014-02-555169;;pmc508480;;9389740;;10.1172/jci119822,"WOLF ET AL: ""BiTEs: bispecific antibody constructs with unique anti-tumor activity"", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 18, 15 September 2005 (2005-09-15), pages 1237 - 1244, XP005103829, ISSN: 1359-6446, DOI: 10.1016/S1359-6446(05)03554-3;;KAO LIYO ET AL: ""Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy"", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 26, no. 2, 1 February 2015 (2015-02-01), pages 291 - 301, XP009187063, ISSN: 1533-3450, [retrieved on 20140909], DOI: 10.1681/ASN.2013121315;;BECK ET AL: ""M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, no. 1, 2 July 2009 (2009-07-02), US, pages 11 - 21, XP055568290, ISSN: 0028-4793, DOI: 10.1056/NEJMoa0810457;;KRISHNAMURTHY ANURADHA ET AL: ""Bispecific antibodies for cancer therapy: A review"", PHARMACOLOGY & THERAPEUTICS, ELSEVIER, GB, vol. 185, 18 December 2017 (2017-12-18), pages 122 - 134, XP085376489, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2017.12.002;;DICKINSON BONNY L ED - HEDRICH CHRISTIAN: ""Unraveling the immunopathogenesis of glomerular disease"", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 169, 30 June 2016 (2016-06-30), pages 89 - 97, XP029675863, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2016.06.011;;WALSH SJRAU LM: ""Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States"", AM. J. PUBLIC HEALTH, vol. 90, no. 9, 2000, pages 1463 - 1466;;""Autoimmune Diseases"", NATL. INST. ENVIRON. HEALTH SCI.;;DU FHMILLS EAMAO-DRAAYER Y: ""Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment"", AUTOIMMUN. HIGHLIGHTS, vol. 8, no. 1, 2017, pages 12;;VAN DEN BRAND JAJG, RUGGENENTI P, CHIANCA A: ""Safety of Tituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropthy"", J. AM. SOC. NEPHROL. JASN., 2017;;KANSAL RRICHARDSON NNEELI I ET AL.: ""Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus"", SCI. TRANSL. MED., vol. 11, 2019, pages 482;;ELLEBRECHT CTBHOJ VGNACE A ET AL.: ""Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease"", SCIENCE, vol. 353, no. 6295, 2016, pages 179 - 184, XP055434542, DOI: 10.1126/science.aaf6756;;WOLF EHOFMEISTER RKUFER PSCHLERETH BBAEUERLE PA: ""BiTEs: bispecific antibody constructs with unique anti-tumor activity"", DRUG DISCOV. TODAY., vol. 10, no. 18, 2005, pages 1237 - 1244, XP005103829, DOI: 10.1016/S1359-6446(05)03554-3;;BECK LHBONEGIO RGBLAMBEAU G ET AL.: ""M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy"", N. ENGL. J. MED., vol. 361, no. 1, 2009, pages 11 - 21, XP055568290, DOI: 10.1056/NEJMoa0810457;;KAO LLAM VWALDMAN MGLASSOCK RJZHU Q: ""Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy"", J. AM. SOC. NEPHROL. JASN., vol. 26, no. 2, 2015, pages 291 - 301, XP009187063, DOI: 10.1681/ASN.2013121315;;TOMAS NMBECK LHMEYER-SCHWESINGER C ET AL.: ""Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy"", N. ENGL. J. MED., vol. 371, no. 24, 2014, pages 2277 - 2287, XP009181856, DOI: 10.1056/NEJMoa1409354;;RUGGENENTI PDEBIEC HRUGGIERO B ET AL.: ""Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy"", J. AM., vol. 26, no. 10, 2015, pages 2545 - 2558;;MEI HEWIRRIES IFROLICH D ET AL.: ""A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow"", BLOOD, vol. 125, no. 11, 2015, pages 1739 - 1748;;SCHULTZE JLMICHALAK SSEAMON MJ ET AL.: ""CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy"", J. CLIN. INVEST., vol. 100, no. 11, 1997, pages 2757 - 2765, XP002217478, DOI: 10.1172/JCI119822",PENDING
912,WO,A1,WO 2025/071427 A1,178-590-561-268-591,2025-04-03,2025,RS 2023000015 W,2023-09-26,RS 2023000015 W,2023-09-26,APPARATUS WITH INTEGRATED ELECTRODES FOR ELECTRICAL MONITORING OF CELL CULTURES,"The invention is a device, shown in Fig 1., comprising at least one well with integrated electrodes, layers forming plates and at least two integrated electrodes positioned in at least two different planes inside the well, for electrical measurements of in vitro culture of biological constructs such as cells layer, 3D tissue constructs or organoids. The apparatus comprises at least one well with at least two integrated electrodes with at least one suspended electrode of the at least two electrodes integrated into the well at different planes, or with the plurality of suspended electrodes realized on multiple suspended layers in different combinations, Fig 4., The invention is a measurement instrument, capable for electrical measurements of in vitro culture of biological construct.",CHERRY BIOTECH SAS;;BIOSENSE INSTITUTE RESEARCH INSTITUTE FOR INFORMATION TECH IN BIOSYSTEMS,DE PADUA HOMS CORBERA ANTONI;;DUBOURG GEORGES LOUIS MARC;;CHELAKKARAN PRABHAKARAN DIVYASREE;;RADONIC VASA;;BIRGERMAJER SLOBODAN,,https://lens.org/178-590-561-268-591,Patent Application,yes,1,0,1,178-590-561-268-591,WO,1,178-590-561-268-591,WO,0,C12M35/02;;C12M23/12;;C12M21/08;;C12M41/00;;B01L3/5085;;B01L2300/0645;;B01L2300/0887;;B01L2300/0851;;B01L2300/0858,G01N27/00;;C12M1/00;;C12M1/34,,1,1,035-178-895-124-934,19568672;;10.1039/b820596e;;pmc2818679,"KATHERINE MUSICK, DAVID KHATAMI, BRUCE C. WHEELER: ""Three-dimensional micro-electrode array for recording dissociated neuronal cultures"", LAB ON A CHIP, ROYAL SOCIETY OF CHEMISTRY, vol. 9, no. 14, 1 January 2009 (2009-01-01), pages 2036, XP055031481, ISSN: 14730197, DOI: 10.1039/b820596e",PENDING
913,US,A1,US 2022/0411530 A1,189-354-159-848-883,2022-12-29,2022,US 202017778422 A,2020-11-20,CN 201911155025 A;;CN 2020130511 W,2019-11-22,PSMA Antibody and Use Thereof,"The present disclosure relates to an antibody fragment specifically binding to PSMA, particularly to a single-chain Fv (scfv), a bispecific antibody containing the scFv, and a chimeric antigen receptor (CAR) and the preparation and the use thereof.",NANTONG YICHEN BIOPHARMA CO LTD,WANG FENG;;ZHENG HUAYANG;;ZHANG YUHAN,NANTONG YICHEN BIOPHARMA. CO. LTD (2021-08-31);;YICHEN THERAPEUTICS LIMITED (2023-08-02),https://lens.org/189-354-159-848-883,Patent Application,yes,0,1,6,007-082-640-777-448;;032-964-433-688-646;;189-354-159-848-883;;156-875-360-205-771;;117-787-499-555-835;;025-464-498-792-175,EP;;CN;;WO;;US,6,007-082-640-777-448;;032-964-433-688-646;;189-354-159-848-883;;156-875-360-205-771;;117-787-499-555-835;;025-464-498-792-175,EP;;CN;;WO;;US,68,C07K2317/622;;C07K2317/92;;C07K2317/565;;C07K2317/31;;C07K16/2809;;C07K16/3069;;A61K2039/505;;C07K2317/73;;C07K2317/90;;G01N33/57434;;C07K16/2809;;C07K16/30;;C07K2317/31;;C07K2317/56,C07K16/30;;C07K16/28,,0,0,,,,PENDING
914,US,A1,US 2025/0092425 A1,128-513-793-572-338,2025-03-20,2025,US 202418417394 A,2024-01-19,CN 202311212976 A,2023-09-19,"FgTad2-FgTad3-Ame1 EDITING ENZYME SYSTEM, EDITING TOOL, AND EDITING METHOD","The present disclosure belongs to the technical field of gene editing, and specifically provides a FgTad2-FgTad3-Amel editing enzyme system, an editing tool, and an editing method. In the present disclosure, the system is a ternary complex composed of three genes (proteins), FgTAD2, FgTAD3, and AME1, and can catalyze A-to-I editing on mRNAs. Extensive A-to-I mRNA editing can be detected by expressing the AME1 gene in vegetative stage of Fusarium graminearum. Transforming the FgTad2-FgTad3-Ame1 editing enzyme system into Saccharomyces cerevisiae, Escherichia coli, and human cells to allow expression can produce A-to-I mRNA editing. This indicates that a Fusarium graminearum-derived A-to-I mRNA editing system is active and broadly adaptable, and has a great potential to be developed as a gene editing tool in different organisms.",UNIV NORTHWEST A&F,LIU HUIQUAN;;FENG CHANJING;;DU YANFEI;;XIN KAIYUN;;ZOU JINGWEN;;WANG QINHU;;JIANG CONG,NORTHWEST A&F UNIVERSITY (2024-01-16),https://lens.org/128-513-793-572-338,Patent Application,yes,0,0,2,066-110-533-679-282;;128-513-793-572-338,CN;;US,2,066-110-533-679-282;;128-513-793-572-338,CN;;US,0,C12N9/78;;C07K14/37;;C12N15/70;;C12N15/81;;C12N15/85;;C12N15/1024;;C12Y305/04;;C12R2001/865;;C12R2001/19;;C12N2800/107;;C12N9/22;;C12N9/78;;C12N15/85;;C12N15/11;;C12Y305/04;;C12N15/90;;C12N2310/20;;C12N2310/20;;C12N9/22;;C12N9/78;;C12N15/11;;C12N15/85;;C12N15/90;;C12Y305/04,C12N15/90;;C12N9/22;;C12N9/78;;C12N15/11;;C12N15/85,,0,0,,,,PENDING
915,US,A1,US 2021/0309733 A1,119-133-139-600-946,2021-10-07,2021,US 202117216660 A,2021-03-29,US 202117216660 A;;US 2021/0021402 W;;US 202063088971 P;;US 202063072716 P;;US 202063027128 P;;US 202062986751 P,2020-03-08,METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY,"The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.",HUMANIGEN INC,DURRANT CAMERON;;CHAPPELL DALE,HUMANIGEN INC (2021-04-07),https://lens.org/119-133-139-600-946,Patent Application,yes,0,4,12,111-915-979-409-664;;144-632-442-132-172;;074-359-018-107-953;;077-687-908-355-467;;182-108-635-350-915;;178-078-151-728-409;;006-336-344-087-750;;074-707-913-431-862;;115-889-297-133-372;;002-484-367-491-288;;067-605-204-292-547;;119-133-139-600-946,JP;;AU;;KR;;IL;;EP;;CN;;WO;;US;;CA;;MX;;BR,17,111-915-979-409-664;;144-632-442-132-172;;026-632-286-251-007;;182-108-635-350-915;;178-078-151-728-409;;074-707-913-431-862;;006-336-344-087-750;;163-041-693-578-050;;113-722-365-387-183;;176-849-424-365-229;;002-484-367-491-288;;119-133-139-600-946;;067-605-204-292-547;;074-359-018-107-953;;077-687-908-355-467;;115-889-297-133-372;;028-923-096-621-866,JP;;KR;;AU;;IL;;EP;;CN;;WO;;US;;TW;;CA;;MX;;BR,0,A61K31/706;;A61P11/00;;A61P29/00;;C07K16/243;;A61K2039/505;;A61K2039/55;;A61K39/3955;;C07K2317/76;;A61K31/706;;C07K2317/76;;A61K39/3955;;A61K2039/505;;A61P29/00;;A61K2039/55;;C07K16/243;;A61P11/00;;C07K16/243;;A61K31/513;;A61K45/06;;A61K31/14;;C07K2317/24;;C07K2317/76;;A61K2039/505;;A61K2039/55;;C07K16/243;;A61K31/706;;A61P29/00;;A61P11/00;;A61K39/3955,C07K16/24;;A61K31/706;;A61K39/395;;A61P11/00;;A61P29/00,,0,0,,,,DISCONTINUED
916,IT,A1,IT 202100006290 A1,102-973-103-449-775,2022-09-16,2022,IT 202100006290 A,2021-03-16,IT 202100006290 A,2021-03-16,UNA MASCHERA FACCIALE INDOSSABILE E CONFIGURATA PER FILTRARE L’ARIA INALATA DA UN UTENTE,,U EARTH BIOTECH LTD;;U EARTH BIOTECH LTD;;U EARTH BIOTECH LTD,MAGGIO ELISABETTA,,https://lens.org/102-973-103-449-775,Patent Application,no,8,0,2,102-973-103-449-775;;123-550-504-350-618,WO;;IT,2,102-973-103-449-775;;123-550-504-350-618,WO;;IT,0,A62B23/025;;A41D13/113;;A41D13/1192,A62B/,,2,0,,,"ANONYMOUS: ""The U-Mask's Bio Layer kills harmful bacteria - DesignWanted"", 21 October 2020 (2020-10-21), pages 1 - 15, XP055862132, Retrieved from the Internet <URL:https://designwanted.com/design/u-mask-model-2-u-earth/> [retrieved on 20211116];;TAHSINASTECH: ""Unboxing the F1 mask (U mask model 2). Best mask in 2020? (Not sponsored)"", 6 October 2020 (2020-10-06), XP055862102, Retrieved from the Internet <URL:https://www.youtube.com/watch?v=KCM47gt_Ss8> [retrieved on 20211116]",PENDING
917,CA,A1,CA 3237341 A1,122-927-463-136-607,2023-05-11,2023,CA 3237341 A,2022-11-03,CN 2021128578 W;;US 202163275471 P;;US 2022/0079216 W,2021-11-04,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.",NANJING LEGEND BIOTECH CO LTD;;JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD;;DEBRAGANCA KEVIN;;FAN XIAOHU;;GENG DONG;;NESHEIWAT TONIA;;PACAUD LIDA;;SCHECTER JORDAN;;VARSOS HELEN;;ZUDAIRE UBANI ENRIQUE,,https://lens.org/122-927-463-136-607,Patent Application,no,0,0,10,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,11,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;190-956-049-117-32X;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61P35/00;;C07K14/7051;;C07K16/2878;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C12N2510/00;;C07K14/70578;;A61K2239/38;;A61K2239/31;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K35/17;;C12N2510/00;;C07K2317/76;;C07K2317/565;;C07K2317/24;;A61K31/167;;A61K39/3955;;C07K2319/02;;C07K2317/569;;C07K2319/03;;A61K38/1774;;A61K2039/545;;C07K16/2878;;C07K2319/33;;A61K31/7076;;A61K2039/54;;A61K2039/505;;C07K14/70517;;C07K14/70578;;A61K31/138;;A61K31/675;;A61K2039/5156;;A61P35/00;;C07K14/7051;;C07K16/2866;;A61K2239/38;;A61K2239/48;;A61K2239/31;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K45/06;;C07K14/7051;;C07K16/2878;;A61K2239/13;;A61K2239/48;;A61K2239/38;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C12N2510/00;;A61K40/31;;A61K40/4215;;C12N5/0636;;A61P35/00;;A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/1774;;A61K39/3955;;A61K2039/505;;A61K2039/5156;;A61K2039/54;;A61K2039/545;;C07K14/7051;;C07K14/70517;;C07K16/2866;;C07K16/2878;;C07K2317/24;;C07K2317/565;;C07K2317/569;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C07K2319/33,C07K16/28;;A61K39/00;;A61P35/00;;C07K14/705;;C07K14/725;;C12N5/0783,,0,0,,,,PENDING
918,CN,A,CN 114761433 A,002-581-973-633-754,2022-07-15,2022,CN 202080085731 A,2020-12-09,CN 201911266831 A;;CN 2020134775 W,2019-12-11,Anti-Claudin18.2 monoclonal antibody as well as preparation method and application thereof,"The invention relates to an anti-Claudin18.2 monoclonal antibody and application of the anti-Claudin18.2 monoclonal antibody. The invention relates to an antibody, a nucleic acid molecule for coding the antibody, an expression vector for expressing the antibody, a host cell and a pharmaceutical composition containing the antibody. The antibody is independently used or is combined with an anti-Her2 antibody and/or IL15 and other medicaments to prepare anti-cancer medicaments.",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,HONG XUEJIAO;;LIU JUNLI;;HE HONGLIN;;LI CHAOQUN;;XU XU;;JIANG WEIDONG,,https://lens.org/002-581-973-633-754,Patent Application,no,4,2,3,002-581-973-633-754;;070-517-879-876-733;;040-863-116-953-300,CN;;WO,3,002-581-973-633-754;;040-863-116-953-300;;070-517-879-876-733,CN;;WO,0,C07K16/00;;A61K39/395;;C07K16/28;;A61P35/00,C07K16/28;;A61K39/395;;A61P35/00;;C12N15/13,,0,0,,,,ACTIVE
919,CN,A,CN 117224689 A,099-087-372-757-837,2023-12-15,2023,CN 202311527171 A,2023-11-16,CN 202311527171 A,2023-11-16,Use of combination of anti-HER2 antibody and chemotherapeutic agent in treatment of gastric cancer,"The present invention relates to methods and uses of an anti-HER2 antibody combination in combination with a chemotherapeutic agent for the treatment of gastric cancer. The methods and uses are that trastuzumab, a second anti-HER2 antibody and a chemotherapeutic agent are combined to treat HER2-positive advanced gastric cancer, and compared with an existing HER2-positive advanced gastric cancer first-line treatment regimen, the trastuzumab, the second anti-HER2 antibody and the chemotherapeutic agent (XELOX) combined treatment method prolongs the progression-free lifetime (PFS) and/or the overall lifetime (OS) of a patient.",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,WANG QINGYU;;YANG FUTANG;;CHENG JIANCHENG;;QIU WENTING,,https://lens.org/099-087-372-757-837,Patent Application,no,11,1,3,099-087-372-757-837;;164-426-284-338-690;;186-212-531-311-263,CN;;WO,3,099-087-372-757-837;;164-426-284-338-690;;186-212-531-311-263,CN;;WO,0,A61K31/513;;A61K31/555;;A61K31/7068;;A61K33/243;;A61K39/395;;A61K45/06;;A61P1/00;;A61P35/00;;A61P35/04;;C07K16/32,A61K45/06;;A61K31/513;;A61K31/555;;A61K31/7068;;A61K33/243;;A61K39/395;;A61P1/00;;A61P35/00;;A61P35/04;;C07K16/32,,1,1,016-547-098-154-868,10.4049/jimmunol.167.1.257;;11418657,"WILLIAMS, GS: ""Unequal VH gene rearrangement frequency within the large VH7183 gene family is not due to recombination signal sequence variation, and mapping of the genes shows a bias of rearrangement based on chromosomal location"", J. IMMUNOL., vol. 167, pages 257 - 263, XP055304513, DOI: 10.4049/jimmunol.167.1.257",ACTIVE
920,WO,A2,WO 2023/164695 A2,085-892-216-597-556,2023-08-31,2023,US 2023/0063352 W,2023-02-27,US 202263314968 P,2022-02-28,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.",JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,FAN XIAOHU;;SCHECTER JORDAN;;PACAUD LIDA;;HIRSCHMANN MICHAEL,,https://lens.org/085-892-216-597-556,Patent Application,yes,16,3,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,17,A61K2239/38;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/11;;A61P35/00;;A61K2239/48;;A61K2239/38;;A61K40/31;;A61K40/4215;;A61K40/11;;A61K31/675;;A61P35/00;;A61K45/06;;A61K31/52;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215,A61K39/00,,36,22,050-959-366-576-084;;070-280-788-085-909;;149-205-978-448-517;;017-150-654-990-340;;002-264-966-090-625;;102-694-840-088-330;;035-100-608-588-913;;003-912-708-516-610;;019-206-191-830-81X;;090-530-046-937-847;;003-931-599-928-408;;095-945-393-711-654;;060-578-906-283-340;;064-758-125-126-733;;035-747-206-252-883;;063-086-322-407-483;;036-537-002-834-639;;025-596-639-921-781;;009-034-724-212-694;;019-817-021-691-872;;032-942-121-304-562;;045-476-680-279-398,8502296;;10.1038/363446a0;;10.1038/374168a0;;7877689;;10.2217/nnm.13.86;;23730699;;10.1126/science.3140379;;3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nbt0898-778;;9702779;;10.1093/nar/27.22.4324;;pmc148712;;10536138;;10.1385/1-59259-922-2:123;;16082031;;10.1073/pnas.77.6.3567;;pmc349658;;6251468;;7017722;;10.1073/pnas.78.4.2072;;pmc319285;;10.1016/0022-2836(81)90321-1;;6271971;;6096211;;10.1016/0378-1119(84)90115-x;;10.1126/science.3039660;;3039660;;7460013;;10.1016/0092-8674(80)90558-9;;15385951;;10.1038/sj.gt.3302362;;10.1038/346776a0;;2201923;;3037341;;pmc365315;;10.1128/mcb.7.5.2031-2034.1987;;10.1128/mcb.7.5.2031;;10.4049/jimmunol.180.3.1309;;18209024;;21926977;;pmc3192229;;10.1038/nm.2446;;6994593;;10.1146/annurev.bb.09.060180.002343;;19561539;;pmc2747302;;10.1097/cji.0b013e3181ac6138;;pmc12180426;;10.1016/j.bbmt.2018.12.758;;30592986,"HAMERS-CASTERMAN ET AL., NATURE, vol. 363, 1993, pages 446 - 8;;GREENBERG ET AL., NATURE, vol. 374, 1995, pages 168 - 73;;HASSANZADEH-GHASSABEH ET AL., NANOMEDICINE, vol. 8, 2013, pages 1013 - 26;;KABAT ET AL.: ""Gene Transfer and Expression Protocols"", 1991, NATIONAL INSTITUTE OF HEALTH, BETHESDA;;HOLLIGER ET AL., NAT. BIOTECH., vol. 23, no. 9, 2005, pages 1 126 - 1129;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;OSBOURN ET AL., NAT. BIOTECHNOL, vol. 16, 1998, pages 778;;NO ET AL., PROC. NATL. ACAD. SCI., vol. 185, 1996, pages 3346 - 3351;;INDRA ET AL., NUC. ACID. RES., vol. 27, 1999, pages 4324 - 4327;;NUC. ACID. RES., vol. 28, 2000, pages e99;;KRAMERFUSSENEGGER, METHODS MOL. BIOL, vol. 308, 2005, pages 123 - 144;;""Fundamental Immunology"", 1993, RAVEN PRESS, pages: 353 - 363;;WIGLER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 3567;;O'HARE ET AL., PROC., vol. 78, 1981, pages 1527;;MULLIGANBERG, PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 2072;;COLBERRE-GARAPIN ET AL., J. MOL. BIOL., vol. 150, 1981, pages 1;;SANTERRE ET AL., GENE, vol. 30, 1984, pages 147;;KENT ET AL., SCIENCE, vol. 237, 1987, pages 901 - 903;;WIGLER ET AL., CELL, IP, 1977, pages 223;;SRYBALSKASRYBALSKI, PROC. NATL. ACAD. SCI. USA, vol. 48, 1962, pages 2026;;LOWY ET AL., CELL, vol. 22, 1980, pages 817;;CONESE ET AL., GENE THERAPY, vol. 11, 2004, pages 1735 - 1742;;""Immunobiology"", 2001, GARLAND PUBLISHING;;JOHNSTON, NATURE, vol. 346, 1990, pages 776 - 777;;BRASH ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 2031 - 2034;;LEE ET AL., BLOOD, vol. 4, 2014, pages 476 - 77;;JOSHI ET AL., J. IMMUNOL, vol. 180, no. 3, 2008, pages 1309 - 15;;GATTINONI ET AL., NAT. MED, vol. 17, 2011, pages 1290 - 7;;FLYNN ET AL., CLIN. TRANSLAT. IMMUNOL, vol. 3, no. 2014, pages e20;;SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467;;KOCHENDERFER ET AL., J. IMMUNOTHERAPY, vol. 32, no. 7, 2009, pages 689 - 702;;HERMAN ET AL., J. IMMUNOLOGICAL METHODS, vol. 285, no. 1, 2004, pages 25 - 40;;LEE DWSANTOMASSO BDLOCKE FL ET AL.: ""ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells"", BIOL BLOOD MARROW TRANSPLANT, vol. 25, 2019, pages 625 - 638, XP055809268, DOI: 10.1016/j.bbmt.2018.12.758;;NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS, vol. 5, 2017, pages 0;;NDC, vol. 57894, no. 1, pages 11 - 01",PENDING
921,US,A1,US 2024/0209087 A1,150-616-133-101-564,2024-06-27,2024,US 202218556691 A,2022-04-29,EP 21171407 A;;EP 2022061573 W,2021-04-30,FUSION PROTEINS AND USE THEREOF IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY,"There are disclosed fusion proteins comprising an anti-CD3 antibody and an autoantigen involved in autoimmune diseases, nucleic acid encoding the same, pharmaceutical composition comprising them and the use thereof for the treatment of autoimmune diseases and particularly of membranous nephropathy.",KILOMETRO ROSSO SPA,PERICO LUCA;;CASIRAGHI FEDERICA;;BENIGNI ARIELA;;REMUZZI GIUSEPPE,KILOMETRO ROSSO SPA (2023-10-17),https://lens.org/150-616-133-101-564,Patent Application,yes,0,0,5,143-237-748-502-619;;012-482-702-203-153;;005-164-869-865-506;;006-655-751-386-094;;150-616-133-101-564,EP;;CN;;WO;;US,5,143-237-748-502-619;;012-482-702-203-153;;005-164-869-865-506;;006-655-751-386-094;;150-616-133-101-564,EP;;CN;;WO;;US,16,C07K14/705;;C12N15/62;;A61P13/12;;C07K16/2809;;C07K2317/622;;C07K2319/21;;C07K14/4713;;C07K2319/33;;A61P13/12;;A61K38/00;;C07K14/705;;C07K16/2809;;C07K2317/622;;C07K2319/21;;C07K2319/33;;C12N15/86;;C12N2740/15043,C07K16/28;;A61K38/00;;A61P13/12;;C07K14/705;;C12N15/86,,0,0,,,,PENDING
922,WO,A1,WO 2023/099818 A1,180-849-692-150-659,2023-06-08,2023,FI 2022050801 W,2022-11-30,FI 20216228 A;;FI 20225643 A,2021-11-30,PREVENTION AND TREATMENT OF DEPRESSIVE DISORDERS AND CONDITIONS PROMOTED BY PROTEASE CONTAINING PLASMA EXTRACELLULAR VESICLES (PCPEV),"The present invention is directed to 4-methylumbelliferone (hymecromone) or a derivative thereof for use in the treatment of major depressive disorder, mood disorders, anxiety-related disorders and depression associated with diseases or drug treatments including Alzheimer's disease, HIV associated neurocognitive disorders (HAND), psoriasis, chronic fatigue syndrome, Parkinson's disease, Long COVID syndrome and drug treatment regimens with IFN-alpha or vitamin A analogues, promoted by pathogenic extracellular vesicles, wherein 4-methylumbelliferone inhibits hyaluronic acid (HA) synthases and block the incorporation of HA and/or low molecular weight cleavage products into said extracellular vesicles. The present invention is also directed to a method for monitoring the efficacy of the treatment and delivery of therapeutic cargo to cells incorporating pEV by means of HA-binding receptors. The present invention further provides an in vitro screening method for identifying further inhibitors of HA synthases.",EVEXYS BIOTECH OY,BAUR ANDREAS;;YLÖSMÄKI ERKKO,,https://lens.org/180-849-692-150-659,Patent Application,yes,5,2,3,180-849-692-150-659;;065-286-685-824-082;;021-514-207-221-055,EP;;WO;;US,3,180-849-692-150-659;;065-286-685-824-082;;021-514-207-221-055,EP;;WO;;US,0,A61K31/352;;A61P25/24;;A61K35/00;;G01N33/6896;;G01N2333/91102;;G01N2800/52;;G01N2500/10;;A61K31/352;;A61K35/00;;G01N33/6896;;G01N2333/91102;;G01N2500/10;;G01N2800/52,A61K31/352;;A61K35/00;;A61K48/00;;A61P25/24;;G01N33/50,,6,6,033-568-844-493-909;;039-942-376-668-67X;;073-152-045-825-665;;020-970-243-983-375;;084-525-238-501-841;;022-981-422-843-294,32563935;;10.1016/j.psyneuen.2020.104767;;23517722;;10.1016/j.bmc.2013.02.017;;26541745;;pmc4753080;;10.1016/j.addr.2015.10.017;;10.1016/j.ebiom.2016.03.004;;pmc4856776;;27211553;;pmc2192324;;10.1084/jem.183.3.1161;;8642258;;8177317;;10.1038/369120a0,"YANG MI ET AL: ""7, 8-Dihydroxy-4-methylcoumarin reverses depression model-induced depression-like behaviors and alteration of dendritic spines in the mood circuits"", PSYCHONEUROENDOCRINOLOGY, OXFORD, GB, vol. 119, 8 June 2020 (2020-06-08), XP086239455, ISSN: 0306-4530, [retrieved on 20200608], DOI: 10.1016/J.PSYNEUEN.2020.104767;;PATIL PRAVIN O ET AL: ""A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease"", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 9, 27 February 2013 (2013-02-27), pages 2434 - 2450, XP028545178, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2013.02.017;;JIURONG LIANG ET AL: ""Hyaluronan as a therapeutic target in human diseases"", ADVANCED DRUG DELIVERY REVIEWS, vol. 97, 1 February 2016 (2016-02-01), Amsterdam , NL, pages 186 - 203, XP055609747, ISSN: 0169-409X, DOI: 10.1016/j.addr.2015.10.017;;LEE,J.HSCHIERER,SBLUME,KDINDORF,JWITTKI,SXIANG,WOSTALECKI,CKOLIHA,NWILD,SSCHULER,G: ""HIV-Nef and ADAM17-Containing Plasma Extracellular Vesicles Induce and Correlate with Immune Pathogenesis in Chronic HIV Infection"", EBIOMEDICINE, vol. 6, 2016, pages 103 - 113;;RAPOSO,G., NIJMAN,H.W., STOORVOGEL,W., LIEJENDEKKER,R., HARDING,C.V., MELIEF,C.J., GEUZE,H.: ""B lymphocytes secrete antigen-presenting vesicles"", J. EXP. MED., vol. 183, 1996, pages 1161 - 1172, XP002060486, DOI: 10.1084/jem.183.3.1161;;TULP,AVERWOERD,DDOBBERSTEIN,BPLOEGH,H.LPIETERS,J: ""Isolation and characterization of the intracellular MHC class II compartment"", NATURE, vol. 369, 1994, pages 120 - 126, XP002085383, DOI: 10.1038/369120a0",PENDING
923,WO,A1,WO 2022/228086 A1,042-400-657-948-821,2022-11-03,2022,CN 2022085852 W,2022-04-08,CN 202110455720 A;;CN 202110761757 A,2021-04-26,MYELOID-SPECIFIC PROMOTER AND USE THEREOF,"Provided are a myeloid-specific promoter and a use thereof. The myeloid-specific promoter includes a nucleic acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The myeloid-specific promoter shows specificity to myeloid tissues. It initiates a gene expression with high efficiency in myeloid cells, but with relative low efficiency in non-myeloid cells. As such, the myeloid-specific promoter regulates the specific expression of a gene in myeloid tissues. The myeloid-specific promoter and the CYBB gene are inserted into a lentiviral vector, and the constructed lentiviral expression vector shows specificity to myeloid tissues and can effectively restore the expression of gp91-phox protein and restore the generation function of ROS, which is of great significance for CGD treatment.",BEIJING MEIKANG GENO IMMUNE BIOTECHNOLOGY CO LTD,CHANG LUNG-JI;;YUAN HAOKUN;;ZHANG RUI,,https://lens.org/042-400-657-948-821,Patent Application,yes,6,0,7,177-388-057-136-594;;042-400-657-948-821;;151-791-130-080-213;;114-840-860-784-470;;075-896-824-103-105;;172-622-003-639-488;;043-739-753-209-585,JP;;EP;;CN;;WO;;US,7,177-388-057-136-594;;042-400-657-948-821;;151-791-130-080-213;;075-896-824-103-105;;114-840-860-784-470;;172-622-003-639-488;;043-739-753-209-585,JP;;EP;;CN;;WO;;US,5,C07K14/47;;C12N15/86;;C12N7/00;;C12N5/0647;;A61K38/17;;A61P37/02;;C12N2510/00;;C12N2740/15043;;C12N2740/15021;;C12N5/0645;;C12N9/0036;;C12Y106/03001;;C12N15/86;;C12N5/0642;;C12N5/0645;;C12N2501/125;;C12N2501/145;;C12N2501/2306;;C12N2501/22;;C12N2501/727;;C12N2740/16043;;A61K48/005;;A61K48/0058;;A61K38/00;;C12N2501/26;;C12N2506/11;;C12N2510/00;;A61K48/0058;;C07K14/47;;C12N5/0647;;C12N5/10;;C12N15/86;;C12N2510/00;;C12N2740/15021;;C12N2740/15043;;C12N5/0645,C12N15/113;;A61K38/17;;C12N5/10;;C12N7/01;;C12N15/12;;C12N15/867,,1,1,012-767-037-090-791,17583472;;10.1016/j.ygeno.2007.04.010,"O'REILLY, D. , GREAVES, D.R.: ""Cell-type-specific expression of the human CD68 gene is associated with changes in Pol II phosphorylation and short-range intrachromosomal gene looping"", GENOMICS, vol. 90, no. 3, 1 August 2007 (2007-08-01), US , pages 407 - 415, XP022182855, ISSN: 0888-7543, DOI: 10.1016/j.ygeno.2007.04.010",PENDING
924,IT,A1,IT 202200008435 A1,119-439-061-812-069,2023-10-28,2023,IT 202200008435 A,2022-04-28,IT 202200008435 A,2022-04-28,MACCHINA PER L’EROGAZIONE DI UNA BEVANDA AD INFUSIONE E SERBATOIO,,LELIT S R L,TOCK DANIEL,,https://lens.org/119-439-061-812-069,Patent Application,no,3,0,4,055-853-160-482-45X;;119-439-061-812-069;;110-611-853-967-071;;060-089-142-108-720,AU;;EP;;WO;;IT,4,055-853-160-482-45X;;119-439-061-812-069;;060-089-142-108-720;;110-611-853-967-071,AU;;EP;;WO;;IT,0,A47J31/60;;A47J31/368,A47J/,,1,1,058-013-303-564-135,10.4172/2155-9821.1000322,"SCHAGES, J. ET AL.: ""the influence of Technical and microbiological Parameters on the Hygienic Quality of Coffee from fully Automated Coffee machines"", J BIOPROCESS BIOTECH, vol. 8.324, 2018, pages 2",PENDING
925,AU,A1,AU 2023/223523 A1,010-214-405-071-840,2024-09-26,2024,AU 2023/223523 A,2023-02-27,US 202263314968 P;;US 2023/0063352 W,2022-02-28,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.",JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,FAN XIAOHU;;SCHECTER JORDAN;;PACAUD LIDA;;HIRSCHMANN MICHAEL,,https://lens.org/010-214-405-071-840,Patent Application,no,0,0,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,0,A61K2239/38;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/11;;A61P35/00;;A61K2239/48;;A61K2239/38;;A61K40/31;;A61K40/4215;;A61K40/11;;A61K31/675;;A61P35/00;;A61K45/06;;A61K31/52;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215,A61K39/00,,0,0,,,,PENDING
926,EP,A1,EP 4426737 A1,103-660-410-952-820,2024-09-11,2024,EP 22817497 A,2022-11-03,CN 2021128578 W;;US 202163275471 P;;US 2022/0079216 W,2021-11-04,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,,JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,AKRAM MUHAMMAD;;DEBRAGANCA KEVIN;;FAN XIAOHU;;GENG DONG;;NESHEIWAT TONIA;;PACAUD LIDA;;SCHECTER JORDAN;;VARSOS HELEN;;ZUDAIRE UBANI ENRIQUE,,https://lens.org/103-660-410-952-820,Patent Application,yes,0,0,10,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,11,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;190-956-049-117-32X;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61P35/00;;C07K14/7051;;C07K16/2878;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C12N2510/00;;C07K14/70578;;A61K2239/38;;A61K2239/31;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K35/17;;C12N2510/00;;C07K2317/76;;C07K2317/565;;C07K2317/24;;A61K31/167;;A61K39/3955;;C07K2319/02;;C07K2317/569;;C07K2319/03;;A61K38/1774;;A61K2039/545;;C07K16/2878;;C07K2319/33;;A61K31/7076;;A61K2039/54;;A61K2039/505;;C07K14/70517;;C07K14/70578;;A61K31/138;;A61K31/675;;A61K2039/5156;;A61P35/00;;C07K14/7051;;C07K16/2866;;A61K2239/38;;A61K2239/48;;A61K2239/31;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K45/06;;C07K14/7051;;C07K16/2878;;A61K2239/13;;A61K2239/48;;A61K2239/38;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C12N2510/00;;A61K40/31;;A61K40/4215;;C12N5/0636;;A61P35/00;;A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/1774;;A61K39/3955;;A61K2039/505;;A61K2039/5156;;A61K2039/54;;A61K2039/545;;C07K14/7051;;C07K14/70517;;C07K16/2866;;C07K16/2878;;C07K2317/24;;C07K2317/565;;C07K2317/569;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C07K2319/33,C07K16/28;;A61K39/00;;A61P35/00;;C07K14/705;;C07K14/725;;C12N5/0783,,0,0,,,,PENDING
927,US,A1,US 2022/0137054 A1,151-749-580-070-224,2022-05-05,2022,US 202017434225 A,2020-03-04,EP 19305252 A;;EP 2020055649 W,2019-03-05,NEW BIOMARKERS AND BIOTARGETS IN RENAL CELL CARCINOMA,"Renal Cell Carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and has a worldwide mortality. However, mortality rates have barely improved over the last 20 years. Novel biomarkers and biomarkers are thus urgently required for this cancer. The inventors have devised a strategy to produce mouse cancer cell lines of progressively enhanced aggressiveness and specialization. The mouse renal cancer cell line RENCA was serially passaged in vivo using multiple implantation strategies designed to replicate different aspects of primary tumour growth and metastasis. Transcriptomic and epigenomic data has been acquired for the derived cell lines and primary analyses have been performed. The inventors then selected plurality of genes with no reported role in RCC which were upregulated in their specialized cell lines, and checked their relevance in patient data and clinical samples. This approach contributes to identify 4 serum biomarkers, namely IL-34, SAA2, PONL1 and CFB that are suitable for predicting survival time in patients suffering from RCC. The inventors also validated that the 4 proteins are also biotargets for the treatment of RCC.",INST NAT SANTE RECH MED;;UNIV BORDEAUX;;CENTRE NAT RECH SCIENT;;UNIV COTE D'AZUR;;UNIV LIVERPOOL,BIKFALVI ANDREAS;;COOLEY LINDSAY;;SOULEYREAU WILFRIED;;PAGES GILLES;;FALCIANI FRANCESCO;;DUFIES MAEVA;;CLARKE KIM,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (2021-11-26);;INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (2021-11-26);;UNIVERSITÉ COTE D'AZUR (2021-11-26);;UNIVERSITY OF LIVERPOOL (2021-11-26);;UNIVERSITÉ DE BORDEAUX (2021-11-26),https://lens.org/151-749-580-070-224,Patent Application,yes,2,0,5,151-749-580-070-224;;081-890-604-697-458;;005-106-355-594-213;;152-532-376-633-789;;034-427-197-304-581,EP;;ES;;WO;;US,5,151-749-580-070-224;;081-890-604-697-458;;005-106-355-594-213;;152-532-376-633-789;;034-427-197-304-581,EP;;ES;;WO;;US,4,G01N33/57438;;G01N33/6869;;G01N2333/54;;C12N2320/30;;C12Q1/6886;;C12Q2600/106;;C12Q2600/118;;C12Q2600/158;;G01N33/57438;;G01N33/6869,G01N33/574;;C12Q1/6886;;G01N33/68,,5,4,073-615-701-020-16X;;111-751-126-569-959;;006-628-740-449-754;;011-128-698-477-11X,10.1002/pmic.201400382;;26177823;;10.1021/pr5002719;;25057901;;pmc5907910;;10.1124/pr.117.014944;;29669750;;pmc4997553;;10.1038/bjc.2016.230;;27490806,"Tao et al., J Am Heart Assoc, 6:e004911, pages 1-11. (Year: 2017);;Kim et al, Proteomics, 15: 3116-3125. (Year: 2015);;Lee et al, J Proteome Res, 13:4878-4888. (Year: 2014);;Shergalis et al, (Phamacol Rev, July 2018, 70:412-445. (Year: 2018);;Greef et al., British J Cancer, 115:505-516. (Year: 2016)",DISCONTINUED
928,EP,A1,EP 4349989 A1,146-752-977-808-887,2024-04-10,2024,EP 22815324 A,2022-06-01,CN 202110610098 A;;CN 202111602506 A;;CN 2022096683 W,2021-06-01,GLYCOSYLTRANSFERASE AND APPLICATION THEREOF,"A glycosyltransferase and an application thereof, the amino acid sequence of the glycosyltransferase being shown as in SEQ ID NO: 112 or an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 112. The glycosyltransferase of the present invention has high enzyme activity and good stability and, when used for the preparation of steviol glycosides, has a significant improvement in catalytic activity and significantly improved conversion rate compared to the parent glycosyltransferase, solving the problem of the high price of the glycosyl donor UDPG (and/or ADPG), and thereby reducing the reaction costs and facilitating industrial production.",ABIOCHEM BIOTECHNOLOGY CO LTD,WU YAN;;TIAN ZHENHUA;;WANG SHU;;ZHENG XIAOFU,"ABIOCHEM BIOTECHNOLOGY (GROUP) CO., LTD. (2024-11-27)",https://lens.org/146-752-977-808-887,Patent Application,yes,0,0,5,028-781-854-519-289;;146-752-977-808-887;;191-720-662-778-981;;129-132-272-558-933;;123-321-285-416-859,JP;;EP;;WO;;US,8,123-321-285-416-859;;146-752-977-808-887;;191-720-662-778-981;;061-507-462-087-151;;090-636-819-672-453;;028-781-854-519-289;;138-256-086-499-504;;129-132-272-558-933,JP;;EP;;CN;;WO;;US,112,C12N15/70;;C40B40/08;;C07K14/415;;C12N9/1051;;C12P19/56;;C12N9/1062;;C12Y204/01013;;C12Y204/01122;;C12Y204/01017;;C12N9/1051;;C12N15/70;;C12P19/56;;C12Y204/01013,C12N15/63;;C12N9/10;;C12P19/00,,0,0,,,,PENDING
929,CN,A,CN 118974096 A,069-790-004-678-779,2024-11-15,2024,CN 202380023997 A,2023-03-24,CN 2022082932 W;;CN 2023083531 W,2022-03-25,Anti-MSLN antibodies and methods of use,"The present disclosure relates to antibodies and antibody derivatives that bind to MSLN and methods of use thereof. In certain embodiments, the antibodies or antibody derivatives disclosed herein include single domain antibodies that bind to MSLN.",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,LIN PEIHUA;;JIANG WEIDONG;;XU WENFENG;;ISAFRAS HASSAN;;ZENG QILING;;WANG JINTANG,,https://lens.org/069-790-004-678-779,Patent Application,no,0,0,8,155-273-038-468-106;;006-110-092-876-646;;122-780-320-335-111;;069-790-004-678-779;;088-252-158-794-191;;050-360-227-986-533;;165-220-232-596-076;;079-220-963-270-910,AU;;JP;;KR;;CN;;EP;;WO;;ZA;;US,8,155-273-038-468-106;;006-110-092-876-646;;122-780-320-335-111;;069-790-004-678-779;;088-252-158-794-191;;050-360-227-986-533;;165-220-232-596-076;;079-220-963-270-910,AU;;JP;;KR;;CN;;EP;;WO;;ZA;;US,0,A61P35/00;;C07K16/30;;C07K2317/22;;C07K2317/569;;C07K2317/732;;C07K2317/33;;C07K16/30;;C07K14/7051;;A61P35/00;;C07K2317/24;;C07K2317/31;;C07K2317/569;;C07K2317/92;;C07K2317/52;;A61K2039/505;;A61P35/00;;C07K16/30;;C07K2317/52;;C07K2317/565;;C07K2317/569;;C07K2317/732,C07K16/30;;A61K39/395;;A61P35/00;;C12N15/00;;C12N15/13,,0,0,,,,PENDING
930,CN,A,CN 118987199 A,090-703-315-287-25X,2024-11-22,2024,CN 202410853932 A,2020-07-17,CN 201910683287 A;;CN 202080053981 A;;CN 2020102678 W,2019-07-26,Methods and compositions against anti-CD73 antibodies and variants,"The present invention relates generally to methods and compositions directed against anti-CD73 antibodies and variants, and specifically provides anti-CD73 antibodies, variants, and antigen-binding fragments thereof, which bind to human CD73 with high affinity and inhibit the enzymatic activity of CD73, and optionally induce CD73 internalization. Isolated nucleic acid molecules encoding the anti-CD73 antibodies, variants, and antigen-binding fragments thereof, and related expression vectors, and host cells are also provided. Methods of making anti-CD73 antibodies, variants, and antigen-binding fragments thereof are provided. Related pharmaceutical compositions and methods of treating subjects using these pharmaceutical compositions are also provided.",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,JIANG WEIDONG;;CHEN YIYING;;ZENG QILING,,https://lens.org/090-703-315-287-25X,Patent Application,no,0,0,12,160-483-046-270-446;;071-887-199-099-592;;160-045-486-560-48X;;001-240-566-756-026;;024-793-347-718-534;;195-839-029-827-884;;147-200-644-628-846;;010-825-117-153-553;;148-278-980-868-431;;076-406-490-073-066;;164-756-256-334-467;;090-703-315-287-25X,JP;;CN;;EP;;WO;;US;;CA;;BR,12,160-483-046-270-446;;071-887-199-099-592;;024-793-347-718-534;;001-240-566-756-026;;160-045-486-560-48X;;195-839-029-827-884;;147-200-644-628-846;;010-825-117-153-553;;148-278-980-868-431;;076-406-490-073-066;;164-756-256-334-467;;090-703-315-287-25X,JP;;CN;;EP;;WO;;US;;CA;;BR,0,C07K16/2896;;C07K16/40;;A61P35/00;;C07K2317/56;;C07K2317/92;;C07K2317/76;;C07K2317/565;;A61K39/3955;;A61K45/06;;A61K47/6849;;C07K2317/31;;C07K2317/33;;C07K2317/52;;C07K2317/55;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K2317/55;;C07K2317/92;;A61K2039/505;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/33;;A61K47/6849;;A61P35/00;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K2317/31;;C07K2317/33;;C07K2317/565;;C07K2317/77;;G01N33/57492,A61K39/395;;A61K45/06;;A61K47/68;;A61P35/00;;C07K16/28;;C07K16/40,,0,0,,,,PENDING
931,US,A1,US 2023/0270786 A1,139-905-003-719-748,2023-08-31,2023,US 202318175347 A,2023-02-27,US 202318175347 A;;US 202263314968 P,2022-02-28,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,"Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.",JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,FAN XIAOHU;;SCHECTER JORDAN;;PACAUD LIDA;;HIRSCHMANN MICHAEL,NANJING LEGEND BIOTECH CO. LTD (2023-03-29);;JANSSEN RESEARCH & DEVELOPMENT LLC (2023-03-09);;JANSSEN BIOTECH INC (2023-03-10);;LEGEND BIOTECH USA INC (2023-03-29),https://lens.org/139-905-003-719-748,Patent Application,yes,0,2,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,0,A61K2239/38;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/11;;A61P35/00;;A61K2239/48;;A61K2239/38;;A61K40/31;;A61K40/4215;;A61K40/11;;A61K31/675;;A61P35/00;;A61K45/06;;A61K31/52;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215,A61K35/17;;A61K31/52;;A61K31/675;;A61K45/06;;A61P35/00,,0,0,,,,PENDING
932,JP,A,JP 2021102587 A,066-234-503-449-528,2021-07-15,2021,JP 2019235259 A,2019-12-25,JP 2019235259 A,2019-12-25,COGNITIVE FUNCTION IMPROVING COMPOSITION,"To provide a novel composition for maintaining, enhancing or improving cognitive functions.SOLUTION: The present invention provides a composition for maintaining, enhancing or improving cognitive functions, comprising a hop oxidation reaction product and a whey protein enzyme degradation product as active ingredients. The cognitive functions include a memory function (for example, a spatial memory function, a working memory function). The composition can be provided as a food composition and can be also provided in a unit package form per meal.SELECTED DRAWING: None",KIRIN HOLDINGS CO LTD,ANO YASUHISA,,https://lens.org/066-234-503-449-528,Patent Application,no,4,0,2,001-483-570-237-241;;066-234-503-449-528,JP,2,001-483-570-237-241;;066-234-503-449-528,JP,1,,A61K36/185;;A23L33/105;;A23L33/18;;A23L33/19;;A61K31/122;;A61K35/20;;A61K38/01;;A61K38/05;;A61K38/07;;A61P25/28,,2,1,055-589-905-627-60X,31198106;;10.1080/09168451.2019.1630254,"SCIENTIFIC REP., vol. 8, no. 15372, JPN6023052580, 2018, pages 1 - 10, ISSN: 0005379259;;BIOSCI BIOTECH BIOCHEM., vol. 83, no. 10, JPN6023052581, 2019, pages 1937 - 1945, ISSN: 0005379258",ACTIVE
933,KR,A,KR 20240117530 A,051-745-550-105-277,2024-08-01,2024,KR 20247015027 A,2022-11-03,CN 2021128578 W;;US 202163275471 P;;US 2022/0079216 W,2021-11-04,다발성 골수종을 위한 BCMA를 표적으로 하는 CAR-T 세포 요법,"본 명세서는 다발성 골수종을 앓고 있고 사전 치료를 받았으며 치료 옵션이 제한적인 대상체를 치료하는 방법을 제공한다. 폴리펩티드를 함유하는 항BCMA CAR을 포함하는 키메라 항원 수용체(CAR)-T세포의 주입이 대상체에게 투여된다. 일부 실시예에서, 대상체에게 투여되는 CAR-T세포의 용량은 1.0 × 105 내지 5.0 × 106개의 CAR-T세포/kg 대상체 질량이다. 치료 방법은 미세 잔존 질환 음성 상태 뿐만 아니라 효능 및 안전성과 관련된 기타 유익한 임상 결과를 효과적으로 획득하고 유지한다.",JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC;;NANJING LEGEND BIOTECH CO LTD,AKRAM MUHAMMAD;;DEBRAGANCA KEVIN;;FAN XIAOHU;;GENG DONG;;NESHEIWAT TONIA;;PACAUD LIDA;;SCHECTER JORDAN;;VARSOS HELEN;;ZUDAIRE UBANI ENRIQUE,,https://lens.org/051-745-550-105-277,Patent Application,no,0,0,10,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,11,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;190-956-049-117-32X;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61P35/00;;C07K14/7051;;C07K16/2878;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C12N2510/00;;C07K14/70578;;A61K2239/38;;A61K2239/31;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K35/17;;C12N2510/00;;C07K2317/76;;C07K2317/565;;C07K2317/24;;A61K31/167;;A61K39/3955;;C07K2319/02;;C07K2317/569;;C07K2319/03;;A61K38/1774;;A61K2039/545;;C07K16/2878;;C07K2319/33;;A61K31/7076;;A61K2039/54;;A61K2039/505;;C07K14/70517;;C07K14/70578;;A61K31/138;;A61K31/675;;A61K2039/5156;;A61P35/00;;C07K14/7051;;C07K16/2866;;A61K2239/38;;A61K2239/48;;A61K2239/31;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K45/06;;C07K14/7051;;C07K16/2878;;A61K2239/13;;A61K2239/48;;A61K2239/38;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C12N2510/00;;A61K40/31;;A61K40/4215;;C12N5/0636;;A61P35/00;;A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/1774;;A61K39/3955;;A61K2039/505;;A61K2039/5156;;A61K2039/54;;A61K2039/545;;C07K14/7051;;C07K14/70517;;C07K16/2866;;C07K16/2878;;C07K2317/24;;C07K2317/565;;C07K2317/569;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C07K2319/33,A61K39/00;;A61K45/06;;C07K14/725;;C07K16/28;;C12N5/0783,,0,0,,,,PENDING
934,CN,A,CN 118488965 A,191-511-664-213-334,2024-08-13,2024,CN 202280083103 A,2022-12-15,CN 2021139273 W;;CN 2022139288 W,2021-12-17,"Anti-OX40 antibodies, multispecific antibodies and methods of use thereof","Antibodies and antibody derivatives that bind to OX40 and methods of using the same are provided. In certain embodiments, the antibodies or antibody derivatives disclosed herein comprise a single domain antibody that binds to OX40. In certain embodiments, the antibody derivatives are multispecific antibodies that bind to OX40 and additional antigens (e.g., CTLA4).",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,XU WENFENG;;DONG CHEN;;LIN PEIHUA;;JIANG WEIDONG;;ZHANG RENKUAN,,https://lens.org/191-511-664-213-334,Patent Application,no,0,0,9,119-832-798-561-402;;172-140-383-939-965;;062-343-488-604-186;;177-240-991-123-118;;186-186-272-604-056;;001-750-278-069-301;;078-891-104-867-20X;;191-511-664-213-334;;068-416-227-222-182,KR;;AU;;JP;;EP;;CN;;ZA;;WO;;US;;CA,9,119-832-798-561-402;;172-140-383-939-965;;062-343-488-604-186;;177-240-991-123-118;;186-186-272-604-056;;001-750-278-069-301;;078-891-104-867-20X;;191-511-664-213-334;;068-416-227-222-182,KR;;AU;;JP;;EP;;CN;;ZA;;WO;;US;;CA,0,C07K16/46;;A61P35/00;;C07K16/2878;;C07K2317/30;;C07K16/2818;;C07K2317/569;;C07K2317/92;;C07K2317/24;;C07K2317/75;;A61K2039/505;;C07K16/2878;;C07K16/2818;;C07K14/7051;;A61K47/6803;;A61P35/00;;C07K2317/24;;C07K2317/31;;C07K2317/569;;C07K2317/52;;C07K2317/76;;C07K2317/622;;C07K2317/92;;A61K2039/505;;A61P35/00;;C07K16/2818;;C07K16/2878;;C07K2317/24;;C07K2317/31;;C07K2317/569;;C07K2317/92,C07K16/28;;A61K39/00;;A61P35/00;;C07K16/46;;C12N15/00,,0,0,,,,PENDING
935,EP,A2,EP 4486372 A2,068-128-085-899-852,2025-01-08,2025,EP 23714942 A,2023-02-27,US 202263314968 P;;US 2023/0063352 W,2022-02-28,BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA,,JANSSEN BIOTECH INC;;NANJING LEGEND BIOTECH CO LTD;;LEGEND BIOTECH USA INC,FAN XIAOHU;;SCHECTER JORDAN;;PACAUD LIDA;;HIRSCHMANN MICHAEL,,https://lens.org/068-128-085-899-852,Patent Application,yes,0,0,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,9,139-905-003-719-748;;115-781-384-858-158;;010-214-405-071-840;;085-892-216-597-556;;068-128-085-899-852;;165-920-842-992-84X;;095-867-535-040-569;;133-293-779-545-13X;;193-197-827-593-598,AU;;JP;;KR;;EP;;CN;;WO;;US;;MX,0,A61K2239/38;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/11;;A61P35/00;;A61K2239/48;;A61K2239/38;;A61K40/31;;A61K40/4215;;A61K40/11;;A61K31/675;;A61P35/00;;A61K45/06;;A61K31/52;;A61K2239/38;;A61K2239/48;;A61K40/11;;A61K40/31;;A61K40/4215,A61K39/00,,0,0,,,,PENDING
936,EP,A1,EP 3967711 A1,001-087-470-491-846,2022-03-16,2022,EP 21796353 A,2021-04-19,CN 2021088153 W;;CN 202010357134 A,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING;;ZHU YUNXIA,,https://lens.org/001-087-470-491-846,Patent Application,yes,0,1,32,028-846-487-920-111;;001-087-470-491-846;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,153,C07K16/2818;;C07K16/22;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;C07K16/468;;A61P35/00;;A61P35/02;;A61P29/00;;A61P37/02;;A61P27/02;;A61P11/06;;A61P19/02;;A61P17/06;;A61P17/00;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C07K2317/76;;C07K2317/24;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;C07K16/46;;C07K2317/64;;C07K2317/55;;C07K2317/515;;C07K16/2818;;C07K16/22;;C07K2317/24;;C07K2317/92;;C07K2317/94;;C07K2317/76;;A61K2039/505;;C07K16/32;;C07K16/2803;;C07K16/2878;;C07K16/2863;;A61K2039/505;;C07K16/22;;C07K16/2803;;C07K16/2863;;C07K16/2878;;C07K16/468;;C07K2317/24;;C07K2317/31;;C07K2317/35;;C07K2317/51;;C07K2317/515;;C07K2317/55;;C07K2317/76;;C07K2317/92;;C07K2317/94,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/46,,0,0,,,,PENDING
937,US,A1,US 2021/0393739 A1,108-012-501-046-125,2021-12-23,2021,US 202117321002 A,2021-05-14,US 2011/0040979 W;;US 202117321002 A;;US 201916291390 A;;US 201615004372 A;;US 201213717349 A;;US 35598710 P,2010-06-17,THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN,"The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.",UNIV NEW YORK,GOLD LESLIE I;;MICHALAK MAREK,CALREGEN INC (2012-12-11);;NEW YORK UNIVERSITY (2010-07-11),https://lens.org/108-012-501-046-125,Patent Application,yes,1,1,19,024-058-296-199-701;;110-461-162-565-646;;092-167-299-847-283;;061-185-557-495-589;;001-042-169-367-10X;;169-948-844-101-377;;146-584-201-476-547;;148-129-742-676-814;;168-543-106-543-235;;056-369-171-956-317;;081-336-307-406-847;;033-473-334-424-039;;016-026-805-832-311;;163-116-288-032-269;;108-012-501-046-125;;119-641-303-529-071;;134-927-682-333-761;;170-139-052-611-171;;040-066-721-699-425,EP;;WO;;US;;CA,19,024-058-296-199-701;;110-461-162-565-646;;092-167-299-847-283;;061-185-557-495-589;;001-042-169-367-10X;;169-948-844-101-377;;146-584-201-476-547;;148-129-742-676-814;;168-543-106-543-235;;056-369-171-956-317;;081-336-307-406-847;;033-473-334-424-039;;016-026-805-832-311;;163-116-288-032-269;;108-012-501-046-125;;119-641-303-529-071;;134-927-682-333-761;;170-139-052-611-171;;040-066-721-699-425,EP;;WO;;US;;CA,9,A61K38/1738;;A61K8/0208;;A61K8/64;;A61K2800/91;;A61P17/00;;A61P17/02;;A61P19/00;;A61Q19/08;;A61K38/1738;;A61K8/0208;;A61K8/64;;A61K8/735;;A61K2800/91;;A61Q7/00;;A61Q19/08,A61K38/17;;A61K8/02;;A61K8/64;;A61K8/73;;A61Q7/00;;A61Q19/08,,4,3,025-448-110-533-75X;;089-128-147-061-45X;;164-598-044-767-964,10.1083/jcb.131.5.1351;;8522595;;pmc2120639;;10.1084/jem.188.12.2349;;9858521;;pmc2212424;;10.1634/stemcells.22-4-544;;15277700,"Ren St-Arnaud,Constitutive Expression of Calreticulin in Osteoblasts Inhibits MineralizationThe Journal of Cell Biology, Volume 131, Number 5, December 1995 1351-1359.;;By Sandra E. Pike, Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth, The Journal of Experimental Medicine • Volume 188, Number 12, December 21, 1998 2349–235.;;Vera Matrosova, Hyaluronic Acid Facilitates the Recovery of Hematopoiesis following 5- Fluorouracil Administration, Stem Cells · February 2004.;;National Cancer Institute, NCI, ""Bone Tissue"" accessed on 9/21/2022.",ACTIVE
938,US,A1,US 2022/0127360 A1,159-316-266-245-468,2022-04-28,2022,US 202217571894 A,2022-01-10,CN 202010357134 A;;US 202117617516 A;;US 202217571894 A;;CN 2021088153 W,2020-04-29,"TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND VEGF, PREPARATION METHOD THEREFOR, AND USE THEREOF","Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.",SUNSHINE GUOJIAN PHARMACEUTICAL SHANGHAI CO LTD,ZHAO JIE;;HUANG HAOMIN;;ZHU ZHENPING;;ZHU YUNXIA,DANSHENG PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO. LTD (2022-03-22);;SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO. LTD (2023-03-17),https://lens.org/159-316-266-245-468,Patent Application,yes,0,0,3,066-304-956-211-919;;159-316-266-245-468;;056-137-166-567-875,US,35,028-846-487-920-111;;001-087-470-491-846;;159-316-266-245-468;;064-733-099-755-411;;149-785-875-164-726;;059-342-688-302-446;;158-361-048-511-867;;001-090-387-725-83X;;170-805-682-980-256;;035-516-113-384-600;;138-122-276-019-977;;013-814-869-642-62X;;056-137-166-567-875;;066-304-956-211-919;;094-713-984-989-202;;180-826-319-624-818;;142-631-863-988-49X;;182-962-898-594-797;;168-360-810-488-127;;068-970-806-027-857;;138-178-084-992-791;;169-536-104-730-919;;046-795-130-097-359;;160-230-904-354-158;;180-240-538-575-456;;022-947-213-872-217;;139-061-991-882-171;;149-888-896-923-404;;071-623-061-763-068;;148-601-564-885-133;;107-375-308-846-485;;194-372-847-965-290;;160-369-437-265-223;;006-904-465-353-069;;086-868-513-724-327,JP;;EP;;CN;;ES;;WO;;US;;TW,153,A61P35/00;;C07K16/22;;C07K16/2818;;C07K16/34;;C07K2317/31;;C07K2317/35;;C07K16/2818;;A61K2039/505;;A61P35/00;;C07K16/22;;C07K16/2803;;C07K2317/31;;C07K2317/35;;C07K2317/76;;C07K2317/92,C07K16/28;;A61P35/00;;C07K16/22,,0,0,,,,PENDING
939,US,A1,US 2021/0107984 A1,168-353-395-612-702,2021-04-15,2021,US 202017131946 A,2020-12-23,US 202017131946 A;;FR 1455177 A;;US 201615316074 A;;FR 2015051498 W,2014-06-06,Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes,"The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.",UNIV LILLE;;CENTRE NAT RECH SCIENT;;ROUSSY INST GUSTAVE;;CELLVAX;;UNIV PARIS SACLAY,DELHEM NADIRA;;BUSSON PIERRE;;MORALES OLIVIER;;BARJON CLEMENT;;MRIZAK DHAFER;;LHUILLIER CLAIRE;;MUSTAPHA RAMI,,https://lens.org/168-353-395-612-702,Patent Application,yes,3,0,27,019-653-864-360-985;;087-290-159-771-566;;089-663-369-978-858;;029-004-407-965-754;;116-425-197-785-040;;162-284-726-798-800;;062-858-606-314-781;;157-684-330-244-483;;166-571-811-814-104;;168-353-395-612-702;;152-480-860-907-313;;132-199-320-613-242;;160-198-336-957-737;;137-423-275-762-833;;062-636-479-364-108;;078-454-332-088-931;;075-474-161-281-946;;106-514-317-411-732;;143-298-757-162-563;;195-068-196-177-820;;148-738-609-265-77X;;160-982-312-896-959;;136-015-462-645-334;;172-301-094-783-989;;090-777-191-804-615;;129-077-453-681-261;;062-826-162-999-612,JP;;HU;;US;;SI;;LT;;CA;;PT;;HR;;CN;;EP;;ES;;WO;;FR,27,019-653-864-360-985;;087-290-159-771-566;;089-663-369-978-858;;029-004-407-965-754;;116-425-197-785-040;;162-284-726-798-800;;062-858-606-314-781;;157-684-330-244-483;;166-571-811-814-104;;168-353-395-612-702;;152-480-860-907-313;;132-199-320-613-242;;160-198-336-957-737;;137-423-275-762-833;;062-636-479-364-108;;078-454-332-088-931;;075-474-161-281-946;;106-514-317-411-732;;143-298-757-162-563;;195-068-196-177-820;;148-738-609-265-77X;;160-982-312-896-959;;136-015-462-645-334;;172-301-094-783-989;;090-777-191-804-615;;129-077-453-681-261;;062-826-162-999-612,JP;;HU;;US;;SI;;LT;;CA;;PT;;HR;;CN;;EP;;ES;;WO;;FR,17,C07K16/18;;C07K16/3092;;C07K2317/34;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K2317/34;;C07K2317/56;;C07K2317/565;;C07K2317/76;;A61P35/00;;A61P35/02;;A61P43/00;;C07K16/2851;;C07K16/3084;;A61K2039/505;;C07K2317/34;;C07K2317/56;;C07K2317/565;;C07K2317/76;;C07K16/3092;;C07K16/18;;A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/2851;;C07K16/30,C07K16/28;;A61K39/395;;A61K45/06;;C07K16/18;;C07K16/30,,6,5,027-880-661-246-429;;032-427-821-815-367;;087-523-165-177-47X;;005-251-111-154-677;;079-786-804-592-093,14596803;;10.1016/j.jmb.2003.09.054;;18974080;;10.1093/protein/gzn058;;10.4049/jimmunol.173.12.7358;;15585860;;10.1038/s41577-019-0126-7;;30718829;;31544850;;pmc6784186;;10.3390/antib8030044,"Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. 2003 Nov 14;334(1): 103-18. (Year: 2003);;Lloyd et al., Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel. 2009 Mar;22(3):159-68. (Year: 2009);;Goel et al., Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response. J Immunol. 2004 Dec 15; 173(12):7358-67. (Year: 2004);;Kanyavuz et al., Breaking the law: unconventional strategies for antibody diversification. Nat Rev Immunol. 2019 Jun; 19(6):355-368. (Year: 2019);;Almagro et al. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies 2019, 8(3), 44. (Year: 2019);;BMC-Infectious Agents and Cancer Submission Guidelines and Eiditorial policies, pages 1-56. 11/13/2024 (Year: 2024)",PENDING
940,WO,A1,WO 2023/122296 A1,066-253-194-919-779,2023-06-29,2023,US 2022/0053858 W,2022-12-22,US 202163292985 P,2021-12-22,METHOD FOR CONDUCTING UNIFORM REACTIONS,"Systems and methods for conducting surface-mediated chemical and/or biochemical reactions within an enclosed chamber are disclosed. Systems and methods of the present disclosure may be used in conducting hybridization reactions of biopolymers. In some examples, an improved method for mixing thin films of solutions in a hybridization chamber includes altering the direction of mixing at least once over the course of a reaction. In some examples, an improved method for mixing thin films of solutions in a hybridization chamber includes altering the speed of mixing at least once over the course of a reaction. In some examples, an improved method for mixing thin films of solutions in a hybridization chamber includes altering the speed of mixing and the direction of mixing at least once over the course of a reaction.",SOMALOGIC OPERATING CO INC,CLEVELAND JASON PAUL;;MONSERUD JON;;VANT-HULL BARRY PATRICK JOHN;;KISLUKHIN ALEX,,https://lens.org/066-253-194-919-779,Patent Application,yes,6,0,6,054-314-118-812-911;;037-973-815-122-206;;170-821-305-544-168;;066-253-194-919-779;;119-243-644-990-049;;024-398-732-902-397,JP;;EP;;WO;;US;;CA,6,054-314-118-812-911;;037-973-815-122-206;;170-821-305-544-168;;066-253-194-919-779;;119-243-644-990-049;;024-398-732-902-397,JP;;EP;;WO;;US;;CA,0,B01L2300/0822;;B01L2300/0819;;B01L9/523;;B01L2400/0409;;B01L2300/1827;;B01L7/52;;C12M23/48;;B01L3/50851;;B01L7/52;;B01L9/523;;B01L2300/0663;;B01L2300/0829;;B01L2300/18;;B01L2400/0403,B01L1/02;;B01L7/00;;B01L9/00;;C12M1/00;;C12M1/02;;C12M3/00;;C12M3/04,,2,1,060-065-125-323-879,9447593;;10.1038/nbt0198-49,"GOLD ET AL., PLOS ONE, vol. 5, no. 12, December 2010 (2010-12-01), pages 5005;;TYAGI, NAT. BIOTECH. J, vol. 6, 1998, pages 49 53",PENDING
941,CN,A,CN 115993422 A,140-055-804-706-557,2023-04-21,2023,CN 202111224459 A,2021-10-19,CN 202111224459 A,2021-10-19,Assay of polysorbate esters,"The invention relates to determination of polysorbate, in particular to a method for detecting and analyzing polysorbate in a biological agent, especially a protein solution. The method comprises the following steps: (1) providing a sample containing polysorbate; (2) treating the sample to obtain a treated sample portion 1 and a treated sample portion 2 wherein the treated sample portion 1 is free of the polysorbate esters and the treated sample portion 2 comprises the polysorbate esters; and (3) detecting the treated sample part 2 to determine the presence or amount of the polysorbate.",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,WANG LINLIN;;WANG HONGYA;;PAN LINGYUAN;;ZHANG LEI;;ZHANG ZHONGLI,,https://lens.org/140-055-804-706-557,Patent Application,no,0,0,1,140-055-804-706-557,CN,1,140-055-804-706-557,CN,0,,G01N30/88,,0,0,,,,PENDING
942,US,A1,US 2022/0154196 A1,085-848-723-257-443,2022-05-19,2022,US 202117512614 A,2021-10-27,US 202117512614 A;;US 202016921495 A;;US 201962875752 P,2019-07-18,NOVEL INTERGENIC SEQUENCE REGIONS AND USES THEREOF,"The invention provides recombinant DNA molecules comprising novel synthetic Intergenic Sequence Regions for use in plants to reduce the interaction of a first transgene expression cassette on a second transgene cassette when inserted between the first transgene cassette and second transgene cassette. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the novel synthetic Intergenic Sequence Regions. The invention also provides methods to reduce the interaction between transgene expression cassettes using the novel synthetic Intergenic Sequence Regions.",MONSANTO TECHNOLOGY LLC,DAVIS IAN W,,https://lens.org/085-848-723-257-443,Patent Application,yes,1,0,27,066-508-118-501-794;;193-078-894-716-672;;098-778-986-479-09X;;110-539-956-979-59X;;180-124-871-098-35X;;158-106-692-243-690;;005-904-187-175-576;;102-088-623-826-683;;101-208-795-609-244;;089-587-709-945-832;;193-496-763-806-223;;073-630-287-957-779;;192-983-305-618-315;;148-063-107-919-769;;000-945-912-192-07X;;054-945-223-429-368;;150-044-124-871-208;;009-522-736-299-822;;085-848-723-257-443;;165-469-334-681-136;;039-294-782-002-07X;;021-711-711-909-900;;125-242-367-238-774;;103-267-796-660-829;;132-574-219-433-484;;001-143-471-743-607;;176-064-552-490-294,JP;;AU;;CL;;US;;CA;;CO;;BR;;MX;;CR;;KR;;AR;;CN;;EP;;WO;;UY,27,066-508-118-501-794;;193-078-894-716-672;;098-778-986-479-09X;;110-539-956-979-59X;;180-124-871-098-35X;;158-106-692-243-690;;005-904-187-175-576;;102-088-623-826-683;;101-208-795-609-244;;089-587-709-945-832;;193-496-763-806-223;;073-630-287-957-779;;192-983-305-618-315;;148-063-107-919-769;;000-945-912-192-07X;;054-945-223-429-368;;150-044-124-871-208;;009-522-736-299-822;;085-848-723-257-443;;165-469-334-681-136;;039-294-782-002-07X;;021-711-711-909-900;;125-242-367-238-774;;103-267-796-660-829;;132-574-219-433-484;;001-143-471-743-607;;176-064-552-490-294,JP;;AU;;CL;;US;;CA;;CO;;BR;;MX;;CR;;KR;;AR;;CN;;EP;;WO;;UY,28,C12N15/113;;C12N15/8216;;A23L7/10;;C12N15/8216;;Y02A40/146;;C12N15/8216;;A01H5/00;;C12N15/8216,C12N15/82,,2,2,010-310-884-912-327;;004-185-521-828-946,10.1111/j.1467-7652.2009.00416.x;;19490507;;10.3390/genes12091422;;pmc8470105;;34573404,Gudynaite-Savitch et al. (2009) Plant Biotech J 7:742-85;;Kurbidaeva & Purugganan (2021) “Insulators in Plants: Progress and Open Questions” Genes 12(9):1422,ACTIVE
943,IL,A,IL 312602 A,046-405-151-994-28X,2024-07-01,2024,IL 31260224 A,2024-05-02,CN 2021128578 W;;US 202163275471 P;;US 2022/0079216 W,2021-11-04,Bcma-targeted car-t cell therapy for multiple myeloma,,JANSSEN BIOTECH INC;;LEGEND BIOTECH USA INC;;NANJING LEGEND BIOTECH CO LTD,,,https://lens.org/046-405-151-994-28X,Patent Application,no,0,0,10,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,11,046-405-151-994-28X;;051-745-550-105-277;;097-242-378-138-900;;051-936-905-648-150;;122-927-463-136-607;;190-956-049-117-32X;;129-619-639-379-662;;103-660-410-952-820;;085-078-924-588-697;;019-636-185-472-251;;023-530-181-610-759,KR;;AU;;JP;;IL;;CN;;EP;;WO;;US;;CA;;MX,0,A61P35/00;;C07K14/7051;;C07K16/2878;;C07K2317/569;;C07K2319/03;;C07K2319/33;;C12N2510/00;;C07K14/70578;;A61K2239/38;;A61K2239/31;;A61K2239/48;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K35/17;;C12N2510/00;;C07K2317/76;;C07K2317/565;;C07K2317/24;;A61K31/167;;A61K39/3955;;C07K2319/02;;C07K2317/569;;C07K2319/03;;A61K38/1774;;A61K2039/545;;C07K16/2878;;C07K2319/33;;A61K31/7076;;A61K2039/54;;A61K2039/505;;C07K14/70517;;C07K14/70578;;A61K31/138;;A61K31/675;;A61K2039/5156;;A61P35/00;;C07K14/7051;;C07K16/2866;;A61K2239/38;;A61K2239/48;;A61K2239/31;;A61K40/31;;A61K40/4215;;A61K40/4211;;A61K40/11;;A61K45/06;;C07K14/7051;;C07K16/2878;;A61K2239/13;;A61K2239/48;;A61K2239/38;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C12N2510/00;;A61K40/31;;A61K40/4215;;C12N5/0636;;A61P35/00;;A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/1774;;A61K39/3955;;A61K2039/505;;A61K2039/5156;;A61K2039/54;;A61K2039/545;;C07K14/7051;;C07K14/70517;;C07K16/2866;;C07K16/2878;;C07K2317/24;;C07K2317/565;;C07K2317/569;;C07K2317/76;;C07K2319/02;;C07K2319/03;;C07K2319/33,A61K31/138;;A61K31/167;;A61K31/675;;A61K31/7076;;A61K35/17;;A61K38/17;;A61K39/00;;A61K39/395;;A61P35/00;;C07K14/705;;C07K14/725;;C07K16/28,,0,0,,,,PENDING
944,WO,A1,WO 2022/256623 A1,122-826-607-208-110,2022-12-08,2022,US 2022/0032117 W,2022-06-03,US 202163197195 P,2021-06-04,E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION,"Described herein are fusion protein(s), e.g., fusion protein(s) comprising: i) a cereblon protein, e.g., a human cereblon protein, and ii) a Proximity Labeling Enzyme. Also described are polynucleotide sequence(s) encoding the fusion protein(s), vector(s) comprising the polynucleotide sequence(s), and cells transformed with the vector(s). Also described herein are methods of using the fusion protein(s), polynucleotide sequence(s), vector(s), and cell(s).",MONTE ROSA THERAPEUTICS INC,SADOK AMINE;;BONENFANT DEBORA,,https://lens.org/122-826-607-208-110,Patent Application,yes,3,4,3,194-480-115-273-30X;;122-826-607-208-110;;178-952-195-966-765,EP;;WO;;US,3,194-480-115-273-30X;;122-826-607-208-110;;178-952-195-966-765,EP;;WO;;US,71,C12Q2521/501;;G01N2500/00;;C12Q1/00;;C07K2319/00;;C12N9/104;;C07K2319/60;;C12Y603/04015;;C12N9/93;;C07K14/705;;C12Q1/48;;G01N33/6848,C12Q1/00;;C12N9/10,,28,23,017-980-893-846-250;;000-948-345-083-793;;015-689-854-506-556;;033-274-563-088-022;;025-757-799-244-024;;056-446-956-829-517;;064-508-752-607-307;;000-948-345-083-793;;111-220-988-737-159;;054-865-800-319-303;;031-631-846-535-099;;015-675-003-936-139;;029-586-387-309-225;;092-760-851-706-263;;098-485-729-406-325;;002-977-923-548-309;;090-678-964-562-942;;022-476-605-537-313;;044-424-420-872-100;;028-373-705-126-470;;017-216-732-209-839;;056-201-471-905-934;;036-568-628-778-765,pmc4587326;;25900982;;10.1074/mcp.m114.045658;;26912792;;10.1091/mbc.e15-12-0844;;pmc4831873;;34046695;;10.1007/s00018-021-03856-0;;pmc8159249;;10.1177/2472555220965528;;pmc8013866;;33143537;;25108355;;10.1038/nsmb.2874;;30125270;;pmc6126969;;10.1038/nbt.4201;;10.1110/ps.04911804;;pmc2286582;;15459338;;26912792;;10.1091/mbc.e15-12-0844;;pmc4831873;;pmc5886736;;29400715;;10.1038/nmeth.4601;;10.7554/elife.54983;;32391793;;pmc7302878;;29654266;;10.1038/s41375-018-0106-0;;pmc6035154;;pmc1622771;;10.1073/pnas.0606979103;;17005721;;10.1080/10409238.2017.1304354;;28402189;;6307823;;10.1016/0378-1119(83)90107-5;;pmc6721553;;31366153;;10.3390/cells8080796;;10.1016/s0021-9258(19)84611-2;;2808334;;pmc221863;;10.1128/jb.132.1.349-351.1977;;334731;;6350817;;10.1016/0076-6879(83)01026-5;;2004116;;10.1016/0304-4157(91)90013-m;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/0196-8858(81)90046-4;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.5772/52301,"COYAUD ETIENNE ET AL: ""BioID-based Identification of Skp Cullin F-box (SCF)[beta]-TrCP1/2 E3 Ligase Substrates[S]"", MOLECULAR & CELLULAR PROTEOMICS, 1 July 2015 (2015-07-01), United States, pages 1781 - 1795, XP055960692, Retrieved from the Internet <URL:https://www.mcponline.org/action/showPdf?pii=S1535-9476(20)32848-6> [retrieved on 20220913], DOI: 10.1074/mcp.M114.045658;;DAE IN KIM ET AL: ""An improved smaller biotin ligase for BioID proximity labeling"", MOLECULAR BIOLOGY OF THE CELL, vol. 27, no. 8, 15 April 2016 (2016-04-15), US, pages 1188 - 1196, XP055763337, ISSN: 1059-1524, DOI: 10.1091/mbc.E15-12-0844;;LOW TECK YEW ET AL: ""Recent progress in mass spectrometry-based strategies for elucidating protein-protein interactions"", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 78, no. 13, 27 May 2021 (2021-05-27), pages 5325 - 5339, XP037499030, ISSN: 1420-682X, [retrieved on 20210527], DOI: 10.1007/S00018-021-03856-0;;ISHIDA ET AL.: ""E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones"", SLAS DISCOVERY, vol. 26, no. 4, 2021, pages 484 - 502, XP055799419, DOI: 10.1177/2472555220965528;;""UniProt"", Database accession no. Q96SW2;;CHAMBERLAIN ET AL., NAT. STRUCT. MOL. BIOL., vol. 21, 2014, pages 803 - 9;;BRANON ET AL.: ""Efficient Proximity Labeling in Living Cells and Organisms with TurboID"", NATURE BIOTECHNOLOGY, 2018;;CHOI-RHEE ET AL.: ""Promiscuous Protein Biotinylation by Escherichia coli biotin protein ligase"", PROTEIN SCIENCE, vol. 13, no. 11, 2004, pages 3043 - 50, XP055069906, DOI: 10.1110/ps.04911804;;KIM ET AL.: ""an improved smaller biotin ligase for BioID proximity labeling"", MOL. BIOL. CELL, vol. 27, 2016, pages 1188 - 96, XP055763337, DOI: 10.1091/mbc.E15-12-0844;;RAMANATHAN ET AL.: ""RNA-protein interaction detection in living cells"", NAT. METHODS, vol. 15, 2018, pages 207 - 12;;KIDO ET AL.: ""AirID, a novel proximity biotinylation enzyme, for analysis of protein-protein interactions"", ELIFE, vol. 9, 2020, pages e54983, XP055898500, DOI: 10.7554/eLife.54983;;MILONE ET AL.: ""Clinical Use of Lentiviral Vectors"", LEUKEMIA, vol. 32, 2018, pages 1529 - 41, XP036541149, DOI: 10.1038/s41375-018-0106-0;;WU ET AL.: ""piggyback is a Flexible and Highly Active Transposon as Compared to Sleeping Beauty, Tol2, and Mosl in Mammalian Cells"", PNAS, vol. 103, no. 41, 2006, pages 15008 - 13;;HUDECEK ET AL.: ""Going Non-Viral: the Sleeping Beauty Transposon System Breaks on Through to the Clinical Side"", CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 52, no. 4, 2017, pages 355 - 380, XP055541375, DOI: 10.1080/10409238.2017.1304354;;SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory Manual"", 2001;;KRIEGLER: ""Gene Transfer and Expression: A Laboratory Manual"", vol. 182, 1990, article ""Guide to Protein Purification"";;""Current Protocols in Molecular Biology"", 2010;;PALVA ET AL., GENE, vol. 22, 1983, pages 229 - 235;;KALLUNKI ET AL.: ""How to Choose the Right Inducible Gene Expression System for Mammalian Studies?"", CELLS, vol. 8, 2019, pages 796, XP055870170, DOI: 10.3390/cells8080796;;COLLEY ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 17619 - 22;;MORRISON, J. BACTERIOL., vol. 132, 1977, pages 349 - 351;;CLARK-CURTISSCURTISS ET AL.: ""Methods in Enzymology"", vol. 101, 1983, pages: 347 - 362;;GARCIA-BUSTOS ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1071, 1991, pages 83 - 101;;SMITH, T. F.M. S. WATERMAN, J MOL BIOL, vol. 147, 1981, pages 195 - 7;;SMITHWATERMAN, ADVANCES IN APPLIED MATHEMATICS, 1981, pages 482 - 489;;SCHWARZDAYHOF: ""Atlas of Protein Sequence and Structure"", 1979, pages: 353 - 358;;ALTSCHUL, S. F.W. GISH ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10;;YANG ET AL.: ""Culture Conditions and Types of Growth Media for Mammalian cells"", INTECH",PENDING
945,CN,A,CN 119968393 A,198-016-526-025-980,2025-05-09,2025,CN 202380066024 A,2023-09-21,CN 2022120415 W;;CN 2023120292 W,2022-09-22,Anti-B7H3 antibodies and methods of use,"The present disclosure relates to antibodies and antibody derivatives that bind to B7H3 (also known as CD276) and methods of use thereof. In certain embodiments, the antibodies or antibody derivatives disclosed herein include single domain antibodies that bind to B7H3.",SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC;;SHANGHAI HENLIUS BIOTECH INC,ZHANG RENKUAN;;XU WENFENG;;JIANG WEIDONG;;ISAFRAS HASSAN;;XUE JIE;;LIN PEIHUA,,https://lens.org/198-016-526-025-980,Patent Application,no,0,0,6,198-016-526-025-980;;144-573-773-696-119;;170-790-055-210-464;;033-208-476-576-508;;098-394-752-656-775;;105-895-279-393-398,KR;;AU;;CN;;EP;;WO;;US,6,198-016-526-025-980;;144-573-773-696-119;;170-790-055-210-464;;033-208-476-576-508;;098-394-752-656-775;;105-895-279-393-398,KR;;AU;;CN;;EP;;WO;;US,0,A61P35/00;;C07K16/2827;;C07K2317/22;;C07K2317/569;;C07K2317/92;;C07K2317/732;;A61K2039/505;;C07K16/2827;;A61P35/00;;C07K2317/41;;C07K2317/52;;C07K2317/567;;C07K2317/33;;C07K2317/31;;C07K2317/569;;C07K2317/734;;C07K2317/92;;A61K2039/505;;A61P35/00;;A61K2039/505;;C07K16/2827;;C07K2317/569;;C07K2317/732;;C07K2317/92,C07K16/28;;A61K39/395;;A61P35/00;;C07K19/00;;C12N5/00;;C12N15/11;;C12N15/63;;G01N33/574,,0,0,,,,PENDING
946,CA,A1,CA 3236106 A1,004-716-189-645-434,2023-05-11,2023,CA 3236106 A,2022-11-07,US 202163277049 P;;US 202163277052 P;;US 202263404008 P;;US 202263404068 P;;EP 2022081018 W,2021-11-08,"MODIFIED ARENAVIRUS PARTICLES EXPRESSING MUTANT KRAS, MUTATED CANCER DRIVER GENE, OR TUMOR-ASSOCIATED ANTIGEN AS CANCER IMMUNOTHERAPIES","The invention relates to genetically modified arenaviruses suitable for the treatment of neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus, wherein the arenavirus has been engineered to include a nucleotide sequence encoding one or more antigenic fragment(s) of mutant KRAS alone or to further include a nucleotide sequence encoding one or more antigenic fragment(s) of a mutated cancer driver gene (e.g., a mutant TP53) or a tumor-associated antigen.",HOOKIPA BIOTECH GMBH,LAUTERBACH HENNING;;LAMPERT JORG CHRISTOPH;;HABBEDDINE MOHAMED;;RAGUZ JOSIPA;;SCHIPPERS TIMO;;SCHMIDT SARAH;;AHMADI-ERBER SARAH;;ROSSKOPF SANDRA;;ORLINGER KLAUS;;MATUSHANSKY IGOR,,https://lens.org/004-716-189-645-434,Patent Application,no,0,0,10,103-519-475-955-19X;;178-788-164-289-78X;;052-568-170-458-996;;179-546-761-356-607;;171-151-549-057-290;;086-368-721-283-019;;120-093-345-538-284;;059-971-160-605-66X;;187-454-184-826-139;;004-716-189-645-434,KR;;JP;;AU;;IL;;EP;;WO;;US;;TW;;CA;;MX,12,103-519-475-955-19X;;178-788-164-289-78X;;052-568-170-458-996;;179-546-761-356-607;;171-151-549-057-290;;194-552-670-755-375;;059-971-160-605-66X;;120-093-345-538-284;;086-368-721-283-019;;187-454-184-826-139;;004-716-189-645-434;;013-204-177-665-558,KR;;JP;;AU;;AR;;CN;;IL;;EP;;WO;;US;;TW;;CA;;MX,0,C12N7/00;;A61P35/00;;C07K14/4748;;A61K2039/5256;;A61K2039/572;;C12N2710/16234;;A61K39/12;;A61P31/20;;A61K2039/53;;C12N2760/10043;;C12N2760/10021;;C12N2760/10022;;A61P35/00;;C12N2710/16234;;C12N2760/10021;;C12N2760/10043;;C07K14/4748;;C12N2760/10022;;A61K39/12;;A61P31/20;;A61K2039/5256;;A61K2039/572;;A61K2039/53;;C12N7/00;;C12N7/00;;C12N15/86;;C07K14/4748;;A61K39/12;;A61P35/00;;C12N2760/10021;;C12N2760/10022;;C12N2710/16234;;C12N2760/10041;;A61K2039/53;;A61K2039/5256;;A61K2039/572;;A61K39/001164;;A61K2039/5258;;A61K2039/575;;C12N7/00;;C12N9/14;;C12N15/86;;C12N2760/10022;;C12N2760/10023;;C12N2760/10034;;C12N2760/10043;;C12N2760/10052;;C12N2760/10062;;C12Y306/05002,A61K39/00;;C07K14/00;;C12N7/00,,0,0,,,,PENDING
947,WO,A1,WO 2021/216665 A1,005-266-227-668-073,2021-10-28,2021,US 2021/0028335 W,2021-04-21,US 202063013553 P,2020-04-22,COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF,"The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).",ANIMA BIOTECH INC,SHEPPARD DAVID WILLIAM;;TIERNEY JASON PAUL;;MANDABI AVIAD;;SCHMIDT WOLFGANG;;LEVANTO STEFANO;;HAMBLIN JULIE NICOLE;;BULL RICHARD JAMES;;ALROY IRIS;;MANSOUR WISSAM;;KLEPFISH MOTY;;WANG YAODE;;LI HAITANG,,https://lens.org/005-266-227-668-073,Patent Application,yes,3,3,12,117-444-468-756-760;;073-798-184-832-411;;125-405-970-428-330;;165-961-343-345-710;;053-478-826-047-063;;172-647-686-394-942;;088-239-755-103-188;;126-601-689-357-643;;143-465-483-431-812;;005-266-227-668-073;;128-023-916-088-860;;036-932-284-454-588,JP;;AU;;IL;;CN;;EP;;WO;;US;;CA,12,117-444-468-756-760;;125-405-970-428-330;;053-478-826-047-063;;165-961-343-345-710;;073-798-184-832-411;;088-239-755-103-188;;126-601-689-357-643;;143-465-483-431-812;;005-266-227-668-073;;172-647-686-394-942;;128-023-916-088-860;;036-932-284-454-588,JP;;AU;;CN;;IL;;EP;;WO;;US;;CA,0,A61P1/16;;A61P9/00;;A61P11/00;;A61P17/00;;A61P13/12;;A61P19/04;;A61P37/00;;A61P37/06;;A61P43/00;;C07D401/14;;C07D403/12;;C07D403/14;;C07D401/12;;C07D491/048;;C07D471/04;;C07D209/14;;C07D417/12;;C07D413/12;;C07D498/04;;C07D487/08;;C07D487/10;;C07D235/14;;C07D495/04;;A61P1/16;;A61P37/00;;C07D471/04;;C07D209/14;;C07D495/04;;C07D401/12;;A61P13/12;;C07D403/14;;A61P37/06;;C07D487/08;;A61P11/00;;C07D403/12;;A61P17/00;;C07D413/12;;C07D401/14;;C07D235/14;;C07D498/04;;A61P19/04;;C07D417/12;;A61P9/00;;C07D491/048;;A61P43/00;;C07D487/10;;C07D401/12;;C07D403/12;;C07D413/12;;C07D417/12;;C07D471/04;;C07D487/04;;C07D487/08;;C07D487/10;;C07D491/048;;C07D498/04,C07D401/14;;A61K31/395;;A61K31/42;;A61K31/425;;A61P1/16;;A61P9/00;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/04;;A61P37/00;;A61P37/06;;A61P43/00;;C07D401/02;;C07D401/06;;C07D403/02;;C07D403/12;;C07D403/14;;C07D413/14;;C07D471/02;;C07D471/12;;C07D487/02;;C07D491/02;;C07D498/02;;C07D513/04,,6,1,011-538-500-126-114,10.1042/bj20110033;;21906027,"DATABASE REGISTRY 9 July 2015 (2015-07-09), ANONYMOUS : ""1H-Benzimidazole, 2-[[4-(6-methyl-4-pyrimidinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)"", XP055868628, retrieved from STN Database accession no. 1798001-22-5;;DATABASE REGISTRY 18 December 2019 (2019-12-18), ANONYMOUS : "" Pyrido[3,2-d]pyrimidine, 4-[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)"", XP055868637, retrieved from STN Database accession no. 2393415-65-9;;DATABASE REGISTRY 18 December 2019 (2019-12-18), ANONYMOUS : ""3-Pyridinemethanol, 4-[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME) "", XP055868640, retrieved from STN Database accession no. 2393131-54-7;;DI RUOMIN, WU XIANGQI, CHANG ZAI, ZHAO XIA, FENG QIUTING, LU SHUANGSHUANG, LUAN QING, HEMMINGS BRIANA, LI XINLI, YANG ZHONGZHOU: ""S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt."", BIOCHEMICAL JOURNAL, vol. 441, no. 1, 1 January 2012 (2012-01-01), pages 199 - 207, XP009531964, ISSN: 0264-6021, DOI: 10.1042/BJ20110033;;DATABASE REGISTRY 28 May 2019 (2019-05-28), ANONYMOUS : ""- Methanone, [4-(1H-indol-2-ylmethyl)-1-piperazinyl]-3-pyridinyl- (CA INDEX NAME)"", XP055868645, retrieved from STN Database accession no. 2318894-41-4;;See also references of EP 4139291A4",PENDING
948,US,A1,US 2020/0317791 A1,002-073-123-604-980,2020-10-08,2020,US 202016839179 A,2020-04-03,US 202016839179 A;;US 201962829282 P,2019-04-04,Anti-HLA-C Antibodies and Uses Thereof,"Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.",JANSSEN BIOTECH INC,EBERWINE RYAN;;FOURIE ANNE;;KIM PAUL H;;MANTHEY CARL L;;ZHOU HONG,,https://lens.org/002-073-123-604-980,Patent Application,yes,0,1,7,055-024-185-146-454;;064-442-534-302-856;;031-358-944-850-32X;;186-200-632-956-580;;002-073-123-604-980;;108-723-421-937-324;;114-951-225-907-146,JP;;AU;;EP;;WO;;US;;MA,7,055-024-185-146-454;;064-442-534-302-856;;031-358-944-850-32X;;186-200-632-956-580;;002-073-123-604-980;;108-723-421-937-324;;114-951-225-907-146,JP;;AU;;EP;;WO;;US;;MA,226,C07K16/2833;;A61K38/00;;C07K2317/21;;C07K2317/76;;C07K2317/92;;C07K16/2833;;A61K38/00;;C07K2317/24;;C07K2317/565,C07K16/28,,0,0,,,,ACTIVE
949,EP,A1,EP 4581642 A1,001-458-923-514-36X,2025-07-09,2025,EP 23768346 A,2023-08-31,US 202263374528 P;;IB 2023058604 W,2022-09-02,PATIENT TRAINER MIRROR TO CORRECTLY POSITIONING AN INFUSION DEVICE,,JANSSEN BIOTECH INC,MELLINGER JUSTIN;;WALSH RYAN T;;QUINLAN JOHN,,https://lens.org/001-458-923-514-36X,Patent Application,yes,0,0,2,138-234-412-584-070;;001-458-923-514-36X,EP;;WO,2,138-234-412-584-070;;001-458-923-514-36X,EP;;WO,0,G16H40/63;;G16H50/20;;G16H30/40;;G16H20/17,G16H30/40;;G16H40/63;;G16H50/20,,0,0,,,,PENDING
950,CO,A2,CO 2023005374 A2,014-486-829-569-022,2023-05-19,2023,CO 2023005374 A,2023-04-27,EP 2021079560 W;;EP 20020492 A;;EP 20203887 A,2020-10-25,Medios y métodos para producir conjugados de ligador-anticuerpo,"La presente invención se refiere a un método para generar un conjugado de anticuerpo-carga útil por medio de una transglutaminasa microbiana (MTG). El método comprende un paso de conjugar un ligador que comprende la estructura (mostrada en la dirección N -> C) (Sp1)-RK-(Sp2)-B-(Sp3) o (Sp1)-B-(Sp2)-RK-(Sp3) a un residuo de Gln comprendido en un anticuerpo, en donde (Sp1) es un separador químico o está ausente; (Sp2) es un separador químico o está ausente; (Sp3) es un separador químico o está ausente; R es arginina o un derivado de arginina o un mimético de arginina; K es lisina o un derivado de lisina o un mimético de lisina; B es una porción de enlace o una carga útil; y en donde el ligador está conjugado al residuo de Gln comprendido en el anticuerpo a través de una amina primaria comprendida en la cadena lateral del residuo de lisina, el derivado de lisina o el mimético de lisina. Además, la invención se refiere a conjugados de ligador-anticuerpo, conjugados fármaco-anticuerpo y construcciones de ligador que comprenden un motivo RK.",ARARIS BIOTECH AG,SPYCHER PHILIPP;;PROBST PHILIPP;;ATTINGER-TOLLER ISABELLA;;BERTRAND ROMAIN;;STARK RAMONA;;GRABULOVSKI DRAGAN,,https://lens.org/014-486-829-569-022,Patent Application,no,0,0,15,078-664-669-508-036;;069-293-812-522-361;;076-426-624-632-483;;143-825-660-051-463;;021-264-849-183-16X;;038-377-355-128-863;;084-765-098-633-633;;086-316-633-041-314;;006-536-244-420-719;;014-486-829-569-022;;022-260-662-394-184;;000-666-705-873-583;;003-673-174-047-673;;163-224-561-797-878;;002-914-105-994-106,JP;;AU;;KR;;CL;;IL;;EP;;WO;;US;;CO;;CA;;MX;;PE,16,078-664-669-508-036;;038-377-355-128-863;;143-825-660-051-463;;076-426-624-632-483;;021-264-849-183-16X;;069-293-812-522-361;;084-765-098-633-633;;086-316-633-041-314;;006-536-244-420-719;;014-486-829-569-022;;022-260-662-394-184;;000-666-705-873-583;;003-673-174-047-673;;101-966-211-221-696;;163-224-561-797-878;;002-914-105-994-106,AU;;JP;;CL;;US;;CO;;CA;;MX;;PE;;KR;;IL;;CN;;EP;;WO,0,A61K47/6803;;A61K47/6889;;A61K47/65;;A61P35/00;;A61K47/6855;;A61K47/6849;;C07K2317/524;;C07K16/2803;;C07K16/32;;A61K47/68033;;A61K47/68037;;A61K47/68031;;A61K47/6803;;C07K2317/524;;A61K47/65;;A61K47/6889;;C07K16/32;;A61P35/00;;A61K47/6855;;C07K16/2803;;A61K47/6849;;A61K47/6889;;A61K47/65;;A61K47/6849;;A61K47/6855;;A61P35/00;;C07K16/2803;;C07K16/32;;C07K2317/524;;A61K47/68031;;A61K47/68033;;A61K47/68035;;A61K47/68037;;A61K47/6889;;A61P35/00;;C12N9/1044;;C12Y203/02013;;A61K47/6803;;A61K47/68031;;A61K47/68033;;A61K47/68037,A61K47/68;;A61K47/65;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
951,EP,A1,EP 4445135 A1,014-160-253-216-004,2024-10-16,2024,EP 22830521 A,2022-12-06,EP 21212578 A;;EP 2022084542 W,2021-12-06,ISOLATION AND DIAGNOSTICS OF FETAL CELLS,,ARCEDI BIOTECH APS,SINGH RIPUDAMAN;;JENSEN PALLE SCHELDE,,https://lens.org/014-160-253-216-004,Patent Application,yes,0,0,3,114-571-824-701-348;;001-606-404-778-816;;014-160-253-216-004,EP;;WO;;US,3,114-571-824-701-348;;001-606-404-778-816;;014-160-253-216-004,EP;;WO;;US,0,G01N33/5091;;C12N5/0605;;G01N33/5094;;G01N2800/38;;G01N33/56966;;G01N33/6863;;G01N33/6872,G01N33/50;;C12N5/073,,0,0,,,,PENDING
952,MX,A,MX 2022004965 A,009-712-628-967-560,2022-11-07,2022,MX 2022004965 A,2020-10-30,JP 2019199095 A;;JP 2020040763 W,2019-10-31,INSULIN RESISTANCE INHIBITOR FOR RUMINANT ANIMALS.,"This insulin resistance inhibitor for ruminant animals is characterized by containing cashew nut shell oil, heat-treated cashew nut shell oil, anacardic acid, cardanol and/or cardol.",SDS BIOTECH CORP,HIKITA CHIE,,https://lens.org/009-712-628-967-560,Patent Application,no,0,0,15,181-705-586-847-501;;008-076-642-421-504;;195-232-884-251-82X;;198-102-767-860-531;;009-712-628-967-560;;028-907-705-721-919;;064-897-319-828-397;;085-766-641-861-736;;189-581-760-090-903;;182-688-646-396-576;;067-847-979-164-526;;040-946-485-782-707;;050-945-021-065-273;;187-344-165-991-65X;;156-457-347-081-653,KR;;AU;;JP;;AR;;CN;;EP;;WO;;US;;CA;;MX;;BR,15,181-705-586-847-501;;008-076-642-421-504;;195-232-884-251-82X;;198-102-767-860-531;;009-712-628-967-560;;028-907-705-721-919;;064-897-319-828-397;;085-766-641-861-736;;189-581-760-090-903;;182-688-646-396-576;;067-847-979-164-526;;040-946-485-782-707;;050-945-021-065-273;;187-344-165-991-65X;;156-457-347-081-653,KR;;AU;;JP;;AR;;CN;;EP;;WO;;US;;CA;;MX;;BR,0,A23K10/30;;A23K20/10;;A23K20/158;;A23K50/10;;A61K31/05;;A61K31/60;;A61K36/22;;A61P3/10;;A61P5/50;;A23K10/37;;A61P3/10;;A61K31/60;;A61K36/22;;A23K50/10;;A61K31/05;;A23K20/111;;A23K20/163;;Y02P60/87;;A23K10/30;;A61K36/22;;A61K31/60;;A61K31/05;;A61P3/10;;A23K10/37;;A23K20/158;;A23K50/10;;A61K2300/00;;A61P3/10;;A61K31/05;;A61K31/60;;A61K36/22,A61K31/60;;A23K10/37;;A23K20/158;;A23K50/10;;A61K31/05;;A61K36/22;;A61P3/10,,0,0,,,,PENDING
953,EP,A1,EP 4142806 A1,009-119-344-759-922,2023-03-08,2023,EP 20725990 A,2020-04-30,EP 2020061735 W,2020-04-30,VISUALIZATION OF HER2 EXPRESSION IN HUMAN PATIENTS,,HOBER BIOTECH AB,HOBER SOPHIA;;GAROUSI JAVAD;;TOLMACHEV VLADIMIR;;OLGA BRAGINA;;LINDBO SARAH;;CHERNOV VLADIMIR,,https://lens.org/009-119-344-759-922,Patent Application,yes,0,0,6,144-849-279-377-205;;084-170-559-886-770;;009-119-344-759-922;;153-873-140-210-685;;132-639-666-417-528;;083-228-737-642-748,CN;;EP;;WO;;US,6,009-119-344-759-922;;084-170-559-886-770;;083-228-737-642-748;;153-873-140-210-685;;132-639-666-417-528;;144-849-279-377-205,EP;;CN;;WO;;US,0,A61K51/088;;A61K51/08;;A61K51/08;;A61K51/088,A61K51/08,,0,0,,,,PENDING
954,BR,A2,BR 112022006734 A2,008-310-968-871-09X,2022-09-06,2022,BR 112022006734 A,2020-10-09,EP 2020078478 W;;US 201962913126 P,2019-10-09,MODULADORES ATF6 E USOS DOS MESMOS,"MODULADORES ATF6 E USOS DOS MESMOS. A presente invenção refere-se a compostos como moduladores para Fator de Transcrição de Ativação 6 (ATF6). Os compostos podem localizar o uso como agentes terapêuticos para o tratamento de doenças ou distúrbios mediados por ATF6 e podem localizar o uso particular no tratamento de infecção viral, doença neurodegenerativa, doença vascular, ou câncer.",PRAXIS BIOTECH LLC,BRAHMAM PUJALA;;BALAJI DASHRATH SATHE;;POOJA THAKRAL;;SEBASTIAN BERNALES;;GONZALO ANDRÉS URETA DÍAZ;;SEBASTIAN BELMAR,,https://lens.org/008-310-968-871-09X,Patent Application,no,0,0,15,003-728-442-303-393;;008-310-968-871-09X;;079-510-551-360-069;;186-786-293-043-808;;003-859-571-108-72X;;058-292-337-481-236;;076-368-438-102-945;;097-386-764-301-81X;;139-613-791-656-519;;058-610-369-469-654;;072-657-209-120-803;;118-784-808-873-195;;091-855-385-965-799;;097-866-366-563-85X;;004-112-807-354-857,AU;;KR;;JP;;CL;;IL;;CN;;EP;;WO;;US;;CA;;BR;;MX,15,003-728-442-303-393;;008-310-968-871-09X;;079-510-551-360-069;;186-786-293-043-808;;003-859-571-108-72X;;058-292-337-481-236;;076-368-438-102-945;;097-386-764-301-81X;;139-613-791-656-519;;058-610-369-469-654;;072-657-209-120-803;;118-784-808-873-195;;091-855-385-965-799;;097-866-366-563-85X;;004-112-807-354-857,AU;;KR;;JP;;CL;;IL;;CN;;EP;;WO;;US;;CA;;BR;;MX,0,C07D413/14;;C07D417/14;;A61P25/28;;A61P35/00;;A61P3/10;;C07D413/14;;A61P3/10;;A61P35/00;;A61P25/28;;C07D417/14;;C07D413/14;;A61K31/422;;A61K31/427;;A61K31/497;;A61P35/00;;A61P25/00;;A61P9/00;;A61P3/10;;C07D417/14;;C07D413/14,C07D413/14;;A61K31/42;;A61K31/433;;A61P3/10;;A61P25/28;;A61P35/00;;C07D417/14,,0,0,,,,DISCONTINUED
955,CA,A1,CA 3207011 A1,014-815-989-870-329,2022-08-11,2022,CA 3207011 A,2022-02-08,GB 202101726 A;;EP 2022053022 W,2021-02-08,METHOD OF DELIVERING MRNA IN VIVO,"The present invention concerns an in vivo method for introducing a naked mRNA molecule into the cytosol of a cell(s) in a subject, by the use of photochemical internalization, wherein the photosensitising agent is a sulphonated meso-tetraphenyl chlorin, sulfonated tetraphenylporphine or a di- or tetrasulfonated aluminium phthalocyanine used in an amount of 0.000001-0.001 µg and the cells(s) are contacted with the mRNA molecule and photosensitising agent for 30 seconds to 10 minutes before irradiation of the cell(s). The method may be used to express a polypeptide in the subject. The method is also directed to pharmaceutical compositions containing the photosensitising agents and the mRNA and uses of the molecules in therapy, e.g. to treat or prevent cancer or an infection.",PCI BIOTECH AS,HOGSET ANDERS,,https://lens.org/014-815-989-870-329,Patent Application,no,0,0,9,080-805-228-802-633;;185-297-251-295-931;;164-287-699-679-924;;014-815-989-870-329;;112-533-985-854-951;;027-846-338-249-137;;193-438-766-600-946;;108-446-849-645-549;;144-422-268-858-22X,AU;;KR;;JP;;EP;;CN;;WO;;US;;CA;;GB,9,080-805-228-802-633;;185-297-251-295-931;;164-287-699-679-924;;014-815-989-870-329;;112-533-985-854-951;;027-846-338-249-137;;193-438-766-600-946;;108-446-849-645-549;;144-422-268-858-22X,AU;;KR;;JP;;EP;;CN;;WO;;US;;CA;;GB,0,A61K31/7105;;A61P31/00;;A61K41/0071;;A61K41/0071;;A61K31/7105;;A61P35/00;;A61P31/00;;A61K41/0071;;A61K48/0016,,,0,0,,,,PENDING
956,MX,A,MX 2024002010 A,013-062-976-295-185,2024-04-18,2024,MX 2024002010 A,2022-08-17,EP 21191940 A;;EP 2022073016 W,2021-08-18,THERAPEUTIC PAPILLOMA VIRUS VACCINES.,"The present invention relates to a nucleic acid comprising or consisting of nucleic acid sequences encoding papilloma virus proteins E1, E6, and E7; wherein said nucleic acid molecule encodes a single polyprotein.",SIRION BIOTECH GMBH,WAGNER RALF;;JORDAN INGO;;SANDIG VOLKER;;HOLST PETER JOHANNES;;THIRION CHRISTIAN;;PERTL CORDULA;;KARLAS ALEXANDER;;RAHBÆK BOILESEN DITTE;;NECKERMANN PATRICK;;ASBACH BENEDIKT,,https://lens.org/013-062-976-295-185,Patent Application,no,0,0,10,154-171-730-360-86X;;158-143-283-076-329;;109-573-916-926-200;;013-062-976-295-185;;064-962-223-478-458;;053-989-345-044-78X;;077-325-029-641-08X;;041-944-406-550-658;;079-496-011-222-345;;050-320-374-871-983,KR;;AU;;JP;;EP;;CN;;WO;;US;;CA;;MX,10,079-496-011-222-345;;158-143-283-076-329;;109-573-916-926-200;;013-062-976-295-185;;064-962-223-478-458;;053-989-345-044-78X;;077-325-029-641-08X;;041-944-406-550-658;;154-171-730-360-86X;;050-320-374-871-983,KR;;AU;;JP;;CN;;EP;;WO;;US;;CA;;MX,0,A61K39/12;;C07K14/005;;A61K2039/5256;;A61K2039/53;;A61K2039/585;;A61K2039/70;;C12N2710/10343;;C12N2710/20022;;C12N2710/20034;;A61P31/20;;A61P35/00;;C07K14/005;;C12N15/86;;A61K39/12;;A61P31/20;;A61P35/00;;C12N2710/20022;;C12N2710/20034;;C12N2710/10343;;A61K2039/53;;A61K2039/585;;A61P37/04;;A61P35/00;;A61K39/295;;A61K2039/5256;;A61K2039/53;;A61K2039/585;;A61K2039/70;;C07K14/005;;C12N2710/10343;;C12N2710/20022;;C12N2710/20034,A61K39/12;;A61P31/20;;A61P35/00;;C07K14/005,,0,0,,,,PENDING
957,EP,A1,EP 3760230 A1,011-403-300-926-557,2021-01-06,2021,EP 20180279 A,2006-12-28,US 75488905 P;;EP 17156111 A;;EP 12174197 A;;EP 06846836 A;;US 2006/0062674 W,2005-12-29,"HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES","A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.",JANSSEN BIOTECH INC,BENSON JACQUELINE;;CARTON JILL;;CUNNINGHAM MARK;;ORLOVSKY YEVGENIYA I;;RAUCHENBERGER ROBERT;;SWEET RAYMOND,,https://lens.org/011-403-300-926-557,Patent Application,yes,158,0,116,031-112-586-287-310;;071-926-699-560-540;;183-837-113-928-827;;032-398-848-148-381;;075-780-579-067-547;;022-854-521-720-730;;022-932-247-274-213;;143-732-617-526-328;;196-577-772-340-246;;043-946-668-781-538;;053-507-242-810-07X;;192-296-582-473-615;;082-188-312-694-673;;129-708-038-260-783;;019-040-367-987-806;;062-613-412-087-511;;048-840-209-413-337;;083-544-035-705-526;;147-347-595-307-785;;051-522-805-567-070;;123-882-496-672-393;;189-558-485-396-661;;072-641-288-695-261;;016-305-337-797-165;;095-995-449-007-144;;159-780-553-917-510;;074-256-142-615-654;;003-369-624-458-597;;063-098-198-716-542;;056-541-694-562-925;;031-538-841-986-900;;075-836-061-540-803;;184-063-470-558-801;;033-974-963-437-858;;073-407-483-190-42X;;076-026-558-398-357;;068-162-432-178-785;;023-816-394-099-599;;096-681-329-918-271;;189-477-169-941-643;;121-077-408-456-857;;127-406-045-529-721;;050-689-293-590-32X;;101-028-291-011-304;;116-659-629-786-672;;051-885-521-320-300;;021-027-412-171-757;;169-165-352-949-602;;113-314-171-997-271;;148-982-212-186-189;;078-459-661-246-286;;053-927-128-641-20X;;109-719-669-181-887;;165-048-872-093-58X;;075-529-909-058-214;;100-250-939-756-669;;051-124-784-954-851;;147-575-870-615-307;;091-293-617-806-972;;013-694-427-784-811;;115-969-597-822-698;;039-587-836-665-047;;037-671-171-399-643;;052-274-214-196-69X;;062-368-508-359-116;;027-716-182-582-009;;122-670-880-913-955;;167-639-305-594-035;;169-700-441-535-999;;118-431-677-799-584;;131-149-486-276-862;;043-617-561-434-600;;116-615-321-894-429;;005-027-194-918-241;;179-040-635-340-411;;074-270-871-233-091;;065-026-127-668-731;;108-356-860-796-146;;066-829-803-528-896;;179-652-438-311-82X;;168-398-335-926-346;;065-884-082-605-016;;067-459-167-290-469;;145-358-317-916-522;;071-761-037-595-864;;096-230-740-052-663;;116-811-355-290-349;;071-642-885-279-520;;172-550-284-313-264;;042-870-148-517-894;;065-019-251-149-95X;;147-174-741-796-941;;141-015-689-845-075;;198-862-785-781-265;;154-793-270-299-549;;039-171-278-977-628;;145-621-326-287-399;;059-459-736-252-594;;063-112-978-089-760;;196-468-713-988-883;;001-348-757-534-957;;024-893-038-904-825;;188-148-908-963-085;;171-914-300-155-955;;007-988-926-055-492;;035-562-590-967-136;;168-619-515-446-979;;011-403-300-926-557;;164-992-532-289-143;;094-115-802-166-679;;089-937-722-861-569;;084-153-342-026-708;;025-582-060-120-224;;068-122-966-190-993;;132-978-581-993-899;;027-249-964-034-656,JP;;EA;;CY;;HU;;SI;;LT;;CA;;MX;;HR;;PL;;MY;;EP;;CN;;WO;;ZA;;HK;;NZ;;NI;;SV;;NL;;AU;;LU;;US;;NO;;EC;;BR;;PT;;CR;;KR;;IL;;ES;;GT;;SG;;HN;;UA;;RS;;DK,116,031-112-586-287-310;;071-926-699-560-540;;183-837-113-928-827;;032-398-848-148-381;;075-780-579-067-547;;022-854-521-720-730;;022-932-247-274-213;;143-732-617-526-328;;196-577-772-340-246;;043-946-668-781-538;;053-507-242-810-07X;;192-296-582-473-615;;082-188-312-694-673;;129-708-038-260-783;;019-040-367-987-806;;062-613-412-087-511;;048-840-209-413-337;;083-544-035-705-526;;147-347-595-307-785;;051-522-805-567-070;;123-882-496-672-393;;189-558-485-396-661;;072-641-288-695-261;;016-305-337-797-165;;095-995-449-007-144;;159-780-553-917-510;;074-256-142-615-654;;003-369-624-458-597;;063-098-198-716-542;;075-836-061-540-803;;056-541-694-562-925;;031-538-841-986-900;;184-063-470-558-801;;033-974-963-437-858;;073-407-483-190-42X;;076-026-558-398-357;;068-162-432-178-785;;023-816-394-099-599;;096-681-329-918-271;;189-477-169-941-643;;121-077-408-456-857;;127-406-045-529-721;;050-689-293-590-32X;;101-028-291-011-304;;116-659-629-786-672;;051-885-521-320-300;;021-027-412-171-757;;169-165-352-949-602;;113-314-171-997-271;;148-982-212-186-189;;078-459-661-246-286;;053-927-128-641-20X;;109-719-669-181-887;;165-048-872-093-58X;;075-529-909-058-214;;100-250-939-756-669;;051-124-784-954-851;;147-575-870-615-307;;091-293-617-806-972;;013-694-427-784-811;;115-969-597-822-698;;039-587-836-665-047;;037-671-171-399-643;;052-274-214-196-69X;;062-368-508-359-116;;027-716-182-582-009;;122-670-880-913-955;;167-639-305-594-035;;169-700-441-535-999;;118-431-677-799-584;;131-149-486-276-862;;043-617-561-434-600;;116-615-321-894-429;;005-027-194-918-241;;179-040-635-340-411;;074-270-871-233-091;;065-026-127-668-731;;108-356-860-796-146;;066-829-803-528-896;;179-652-438-311-82X;;168-398-335-926-346;;065-884-082-605-016;;067-459-167-290-469;;145-358-317-916-522;;071-761-037-595-864;;096-230-740-052-663;;116-811-355-290-349;;071-642-885-279-520;;172-550-284-313-264;;042-870-148-517-894;;065-019-251-149-95X;;147-174-741-796-941;;141-015-689-845-075;;198-862-785-781-265;;154-793-270-299-549;;039-171-278-977-628;;145-621-326-287-399;;059-459-736-252-594;;063-112-978-089-760;;196-468-713-988-883;;001-348-757-534-957;;024-893-038-904-825;;188-148-908-963-085;;171-914-300-155-955;;007-988-926-055-492;;035-562-590-967-136;;168-619-515-446-979;;011-403-300-926-557;;164-992-532-289-143;;094-115-802-166-679;;089-937-722-861-569;;084-153-342-026-708;;025-582-060-120-224;;068-122-966-190-993;;132-978-581-993-899;;027-249-964-034-656,JP;;EA;;CY;;HU;;SI;;LT;;CA;;MX;;HR;;PL;;MY;;EP;;CN;;WO;;ZA;;HK;;NZ;;NI;;SV;;NL;;AU;;LU;;US;;NO;;EC;;BR;;PT;;CR;;KR;;IL;;ES;;GT;;SG;;HN;;UA;;RS;;DK,147,A61J1/00;;A61K39/395;;A61P37/00;;C07K16/24;;C07K16/42;;C12N5/10;;C12N15/63;;A61K9/0019;;A61K9/08;;A61K39/3955;;A61K47/183;;A61K47/26;;A61K2039/505;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P17/06;;A61P17/08;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;C07K16/244;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/565;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K2319/00;;C07K2319/30;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2319/30;;C07K2317/34;;C07K2317/52;;C07K2317/76;;C07K16/244;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/06;;A61P17/08;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P9/00;;C07K16/18;;C07K16/00;;A61K39/395;;G01N33/567;;A61K9/0019;;A61K9/08;;A61K39/3955;;A61K47/183;;A61K47/26;;C07K16/24;;C07K2317/76;;C07K2317/34;;C07K2317/52;;A61K2039/505;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2319/30;;C07K16/244;;A61K9/0019;;A61K9/08;;A61K39/3955;;A61K47/26,A61K39/395;;A61K39/00;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P17/06;;A61P17/08;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/02;;C07K16/24;;G01N33/567,,54,41,031-063-853-127-197;;037-711-371-585-567;;049-134-753-209-354;;018-694-084-068-187;;079-239-484-562-537;;010-156-725-160-700;;034-345-578-106-977;;008-488-627-612-805;;006-574-964-805-278;;042-204-626-457-327;;045-094-249-115-990;;069-144-826-896-138;;009-483-512-107-343;;005-257-289-507-991;;070-318-112-524-781;;033-196-732-268-796;;025-341-111-050-549;;054-570-775-551-531;;021-433-356-315-640;;001-945-201-684-525;;046-475-261-047-666;;051-933-738-521-473;;038-314-889-849-800;;021-301-666-722-431;;044-081-857-951-31X;;004-330-044-304-645;;079-955-239-615-671;;074-932-950-939-666;;085-191-504-989-317;;119-057-543-305-576;;041-591-849-635-094;;055-627-091-352-479;;109-335-162-634-020;;154-374-780-007-386;;015-227-671-156-374;;047-137-602-401-446;;083-491-402-733-347;;009-472-949-586-873;;048-807-766-092-463;;074-431-159-672-271;;001-299-917-854-389,10.1002/j.1460-2075.1991.tb04932.x;;1834458;;pmc453097;;3724461;;10.1016/0076-6879(86)21019-8;;10.1016/0022-2836(87)90412-8;;3681981;;2471267;;10.1126/science.2471267;;7698489;;10.1042/bst0220940;;9336846;;10.1002/pro.5560061018;;pmc2143560;;10.1385/1-59259-240-6:001;;11968478;;pmc256472;;10.1128/jvi.45.2.773-781.1983;;6300434;;3713831;;10.1038/321522a0;;10.1038/332323a0;;3127726;;10.1126/science.2451287;;2451287;;10.4049/jimmunol.151.5.2623;;8360482;;1350088;;10.1073/pnas.89.10.4285;;pmc49066;;2153136;;10.1016/s0021-9258(19)40049-5;;10.1038/6179;;10052355;;10.1007/978-3-642-60234-4_5;;10394717;;10335391;;10.1007/978-1-4615-4729-7_11;;10.1007/978-94-011-5298-3_5;;9738962;;10.1023/a:1006029617949;;8595138;;10.1016/s0167-7799(00)89016-2;;pmc157595;;7480334;;10.1104/pp.109.2.341;;10.1016/0022-2836(92)90457-u;;1569578;;10.1126/science.2185544;;2185544;;10.1021/bc00029a006;;7849070;;10.1126/science.1549776;;1549776;;1515467;;10.1021/bc00014a009;;10.1002/(sici)1097-0290(19971120)56:4<456::aid-bit11>3.0.co;2-a;;10.1002/(sici)1097-0290(19971120)56:4<456::aid-bit11>3.3.co;2-n;;18642248;;1657617;;10.1002/eji.1830211134;;1716486;;10.1016/1043-4666(90)90011-h;;10.1016/0006-291x(86)91157-5;;3729942;;2445655;;10.1089/hyb.1987.6.489;;10.1016/0022-1759(87)90367-x;;3805735;;2158862;;10.1016/0092-8674(90)90815-v;;8055960;;10.1111/j.1432-1033.1994.tb19059.x;;pmc52963;;1660140;;10.1073/pnas.88.23.10535;;pmc2119031;;10.1084/jem.174.6.1483;;1660525;;8278368;;pmc42917;;10.1073/pnas.91.1.215;;10.1016/1043-4666(94)90049-3;;7893970;;10.1002/eji.1830240916;;8088324;;10.1038/337525a0;;2536900;;8878440;;10.1172/jci118989;;pmc507628;;16354186;;10.1111/j.0022-202x.2005.23935.x,"TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;SURESH, METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901;;CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WHITELAM ET AL., BIOCHEM. SOC. TRANS., vol. 22, 1994, pages 940 - 944;;KUMARAN ET AL., PROTEIN SCI., vol. 6, no. 10, 1997, pages 2233 - 2241;;HOOGENBOOM HR.: ""Methods in Molecular Biology"", vol. 178, 2002, article ""Overview of antibody phage-display technology and its applications"", pages: 1 - 37;;SPRAGUE ET AL., J. VIROL., vol. 45, 1983, pages 773 - 781;;JONES ET AL., NATURE, vol. 321, 1986, pages 522;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 4285;;ENGELMANN, H. ET AL., J. BIOL. CHEM., vol. 265, 1990, pages 1531 - 1536;;UMANA ET AL., NATURE BIOTECHNOLOGY, vol. 17, February 1999 (1999-02-01), pages 176 - 180;;CRAMER ET AL., CURR. TOP. MICROBOL. IMMUNOL., vol. 240, 1999, pages 95 - 118;;HOOD ET AL., ADV. EXP. MED. BIOL., vol. 464, 1999, pages 127 - 147;;CONRAD ET AL., PLANT MOL. BIOL., vol. 38, 1998, pages 101 - 109;;FISCHER ET AL., BIOTECHNOL. APPL. BIOCHEM., vol. 30, October 1999 (1999-10-01), pages 99 - 108;;MA ET AL., TRENDS BIOTECHNOL., vol. 13, 1995, pages 522 - 7;;MA ET AL., PLANT PHYSIOL., vol. 109, 1995, pages 341 - 6;;BERZOFSKY ET AL.: ""Fundamental Immunology"", 1984, RAVEN PRESS, article ""Antibody-Antigen Interactions"";;SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 - 904;;MARRACK ET AL., SCIENCE, vol. 248, 1990, pages 705 - 711;;WERLEN ET AL., BIOCONJUGATE CHENZ., vol. 5, 1994, pages 411 - 417;;DE VOS ET AL., SCIENCE, vol. 255, 1992, pages 306 - 312;;ITOH ET AL., BIOORG. CHEM., vol. 24, no. 1, 1996, pages 59 - 68;;FISCH ET AL., BIOCONJUGATE CHEM., vol. 3, 1992, pages 147 - 153;;CAPELLAS ET AL., BIOTECHNOL. BIOENG., vol. 56, no. 4, 1997, pages 456 - 463;;NURSING: ""Health Professional's Drug Guide"", 2001, PRENTICE-HALL, INC, pages: 1137 - 1136;;BIGLIARDI ET AL., J. INVEST. DERMATOL, 2000;;LESSLAUER ET AL., EUR. J. IMMUNOL., vol. 21, 1991, pages 2883 - 2886;;""The Merck Manual"", 1992, MERCK & COMPANY;;MOLLER, A. ET AL., CYTOKINE, vol. 2, no. 3, 1990, pages 162 - 169;;""Remington: The Science & Practice of Pharmacy"", 1995, WILLIAMS & WILLIAMS;;""Physician's Desk Reference"", 1998, APPLETON AND LANGE;;""Merck Manual"", 1972, MERCK & COMPANY;;LIANG ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 137, 1986, pages 847 - 854;;BRINGMAN ET AL., HYBRIDOMA, vol. 6, 1987, pages 489 - 507;;HIRAI ET AL., J. IMMUNOL. METH., vol. 96, 1987, pages 57 - 62;;LOETSCHER ET AL., CELL, vol. 61, 1990, pages 351 - 359;;CORCORAN ET AL., EUR. J. BIOCHEM., vol. 223, 1994, pages 831 - 840;;ASHKENAZI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 10535 - 10539;;PEPPEL ET AL., J. EXP. MED., vol. 174, 1991, pages 1483 - 1489;;KOLLS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 215 - 219;;BUTLER ET AL., CYTOKINE, vol. 6, no. 6, 1994, pages 616 - 623;;BAKER ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 2040 - 2048;;CAPON ET AL., NATURE, vol. 337, 1989, pages 525 - 531;;JUNGINGER ET AL.: ""Remington's Pharmaceutical Sciences"", 1994, MARCEL DEKKER, INC., pages: 59 - 90;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;WRONE-SMITH ET AL.: ""Dermal injection of immunocytes induces psoriasis"", J. CLIN. INVEST., vol. 98, 1996, pages 1878 - 1887, XP002188300, DOI: 10.1172/JCI118989;;GOTLIEB ET AL., J.EXP.MED, 1986;;WRAIGHT ET AL., J. INVEST. DERMATOL, 1997;;JONGH ET AL., J. INVEST DERMATOL, vol. 125, 2005, pages 1163 - 1173",PENDING
958,US,A1,US 2024/0270870 A1,008-216-444-202-02X,2024-08-15,2024,US 202418631269 A,2024-04-10,US 202418631269 A;;US 202217895295 A;;US 202163237663 P,2021-08-27,Anti-PSMA Antibodies And Uses Thereof,"Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.",JANSSEN BIOTECH INC,GOLDBERG SHALOM;;KLEIN DONNA;;KOHLI NEERAJ;;MCDEVITT THERESA MARIE;;ORCUTT STEVEN J,,https://lens.org/008-216-444-202-02X,Patent Application,yes,0,0,16,017-820-319-003-045;;090-047-607-590-266;;100-115-673-111-14X;;037-113-374-893-741;;066-704-578-317-910;;083-829-692-268-484;;001-656-855-954-028;;159-765-089-574-474;;031-644-199-983-129;;169-436-263-663-145;;089-107-203-093-200;;008-216-444-202-02X;;056-423-985-692-933;;059-609-520-625-17X;;059-928-349-906-673;;165-111-796-272-509,JP;;AU;;CL;;US;;CO;;CA;;MX;;PE;;KR;;IL;;EP;;CN;;WO;;DO,28,054-059-068-778-94X;;016-049-294-798-853;;037-113-374-893-741;;083-829-692-268-484;;066-704-578-317-910;;030-076-762-983-410;;001-656-855-954-028;;089-107-203-093-200;;048-375-900-342-480;;180-488-126-763-679;;169-436-263-663-145;;056-423-985-692-933;;059-609-520-625-17X;;001-686-803-003-551;;059-928-349-906-673;;165-111-796-272-509;;061-903-405-102-727;;149-789-805-326-820;;015-610-312-139-11X;;017-820-319-003-045;;090-047-607-590-266;;100-115-673-111-14X;;006-023-341-936-772;;159-765-089-574-474;;126-821-372-673-730;;031-644-199-983-129;;008-216-444-202-02X;;129-923-293-184-038,JP;;AU;;CL;;US;;TW;;CO;;CA;;MX;;PE;;KR;;AR;;EP;;CN;;IL;;WO;;UY;;DO,0,A61P35/00;;C07K16/3069;;C07K2317/565;;C07K2317/56;;C07K2317/10;;C07K2317/92;;C07K2317/94;;C07K2317/622;;C07K2317/31;;C07K2317/52;;C07K2317/55;;A61K47/6869;;A61K51/1096;;A61K51/1072;;A61K47/68031;;A61K47/68037;;A61P35/00;;C07K16/3069;;C07K2317/92;;C07K2317/51;;C07K2317/55;;C07K2317/10;;C07K2317/565;;A61K47/68037;;C07K2317/52;;A61K51/1096;;A61K47/68031;;C07K2317/31;;A61P35/04;;A61K51/1072;;C07K2317/94;;C07K2317/56;;A61K47/6869;;C07K2317/72;;C07K2317/622;;C07K16/3069;;A61P35/04;;A61K47/6869;;A61K47/68031;;A61K47/68037;;C07K2317/72;;C07K2317/92;;A61K2039/505;;A61K47/6869;;A61P35/04;;C07K16/3069;;C07K2317/51;;C07K2317/56;;C07K2317/72;;C07K2317/94;;A61K47/68031;;A61K47/68037;;A61P35/00,C07K16/30;;A61K47/68;;A61P35/04,,0,0,,,,PENDING
959,CA,A1,CA 3216498 A1,014-275-308-108-343,2022-11-24,2022,CA 3216498 A,2022-05-17,US 202163189852 P;;US 202163242976 P;;CA 2022050777 W,2021-05-18,APPLICATIONS OF GHR-106 MONOCLONAL ANTIBODY AS A GNRH ANTAGONIST,"GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fragment thereof can be used to control ovulation, terminate ectopic pregnancy, and/or treat reproductive disorders or conditions in mammalian subjects.",VANCOUVER BIOTECH LTD,LEE CHI-YU GREGORY,,https://lens.org/014-275-308-108-343,Patent Application,no,0,0,7,024-864-894-153-582;;096-897-000-609-572;;012-779-658-914-130;;007-254-336-593-52X;;014-275-308-108-343;;141-160-556-261-202;;101-528-345-336-632,JP;;EP;;WO;;US;;TW;;CA,8,024-864-894-153-582;;096-897-000-609-572;;012-779-658-914-130;;007-254-336-593-52X;;014-275-308-108-343;;065-559-934-302-877;;141-160-556-261-202;;101-528-345-336-632,JP;;EP;;CN;;WO;;US;;TW;;CA,14,A61P15/00;;A61P5/24;;A61P5/04;;C07K2317/24;;C07K2317/92;;C07K2317/33;;C07K2317/76;;A61K2039/505;;C07K16/2869;;C07K2317/34;;A61K39/395;;A61P5/24;;A61K2039/505;;A61K2039/545;;C07K16/2869;;C07K2317/24;;C07K2317/33;;C07K2317/52;;C07K2317/565;;C07K2317/76,A61K39/395;;A61P5/04;;A61P5/24;;A61P15/00;;C07K16/28,,0,0,,,,PENDING
960,AU,A1,AU 2019/379858 A1,011-827-411-706-580,2021-05-20,2021,AU 2019/379858 A,2019-11-13,US 201862760782 P;;IB 2019059766 W,2018-11-13,Control of trace metals during production of anti-CD38 antibodies,"The disclosure relates to methods to control trace metals during production of anti-CD38 antibodies, drug substances and drug products generated using the methods, and uses of the generated drug substances and drug products.",JANSSEN BIOTECH INC,LARMORE NICOLE;;RAMANATHAN BALASUBRAMANIAN;;YEAGER RICHARD,,https://lens.org/011-827-411-706-580,Patent Application,no,0,1,26,118-200-509-045-97X;;003-248-758-203-601;;104-554-509-303-254;;088-478-514-911-262;;054-321-999-379-18X;;026-574-073-050-620;;134-901-304-563-29X;;038-074-181-492-746;;041-315-879-668-304;;024-736-452-346-41X;;026-807-715-299-765;;011-827-411-706-580;;151-795-792-095-084;;061-933-223-546-180;;109-365-419-434-356;;000-379-491-608-984;;049-308-820-760-371;;002-051-254-811-384;;127-603-262-717-473;;066-032-938-519-921;;191-569-029-073-119;;188-902-845-150-336;;187-523-822-522-508;;142-674-981-560-670;;121-593-127-976-603;;048-174-140-339-295,AU;;JP;;EA;;US;;TW;;CA;;MX;;BR;;KR;;EP;;CN;;ES;;IL;;WO;;SG;;MA,26,118-200-509-045-97X;;003-248-758-203-601;;104-554-509-303-254;;088-478-514-911-262;;054-321-999-379-18X;;026-574-073-050-620;;134-901-304-563-29X;;038-074-181-492-746;;041-315-879-668-304;;024-736-452-346-41X;;026-807-715-299-765;;011-827-411-706-580;;151-795-792-095-084;;061-933-223-546-180;;109-365-419-434-356;;000-379-491-608-984;;049-308-820-760-371;;002-051-254-811-384;;127-603-262-717-473;;066-032-938-519-921;;191-569-029-073-119;;188-902-845-150-336;;187-523-822-522-508;;142-674-981-560-670;;121-593-127-976-603;;048-174-140-339-295,AU;;JP;;EA;;US;;TW;;CA;;MX;;BR;;KR;;EP;;CN;;ES;;IL;;WO;;SG;;MA,0,C07K16/2896;;C12Y302/01035;;C07K2317/41;;C07K2317/21;;C07K2317/14;;C07K1/14;;C07K16/065;;C07K16/2896;;C07K2317/14;;C07K2317/21;;C07K2317/41;;C12Y302/01035;;C07K16/2896;;C12N15/85;;C12Y603/01002;;C07K2317/56;;C07K2317/14;;C07K2317/21;;C07K2317/41;;C12N2500/10;;A61K2039/505;;C07K16/2896;;C12Y302/01035;;C07K1/14;;C07K16/065,C12N15/13;;A61K39/395;;C07K16/00;;C07K16/28;;C12P21/08,,0,0,,,,ACTIVE
961,BR,A2,BR 112023016680 A2,007-360-777-237-060,2023-11-14,2023,BR 112023016680 A,2022-02-22,IB 2022051540 W;;US 202163151924 P,2021-02-22,Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina,"terapias de combinação com anti-corpos anti-cd38 e parp ou inibidores de receptor de adenosina. esta invenção refere-se a métodos e composições para o tratamento de uma doença mediante administração de uma terapia de combinação que compreende um anticorpo anti-cd38 e um inibidor de poli-adp ribose polimerase (parpi); um anticorpo anti-cd38 e um antagonista do receptor de adenosina; ou um anticorpo anti-cd38, um parpi e um antagonista do receptor de adenosina a um indivíduo (por exemplo, um paciente humano) em necessidade dos mesmos.",JANSSEN BIOTECH INC,DIANA ALVAREZ ARIAS,,https://lens.org/007-360-777-237-060,Patent Application,no,0,0,11,151-860-028-572-760;;152-333-441-931-255;;038-189-271-652-707;;130-671-844-749-451;;007-360-777-237-060;;067-096-993-396-281;;187-654-969-025-223;;095-383-738-274-823;;021-150-588-485-227;;024-007-346-432-63X;;164-747-205-119-113,JP;;AU;;KR;;EP;;CN;;WO;;US;;CA;;BR;;MX,11,151-860-028-572-760;;152-333-441-931-255;;007-360-777-237-060;;038-189-271-652-707;;130-671-844-749-451;;067-096-993-396-281;;187-654-969-025-223;;095-383-738-274-823;;021-150-588-485-227;;024-007-346-432-63X;;164-747-205-119-113,JP;;AU;;KR;;EP;;CN;;WO;;US;;CA;;BR;;MX,0,C07K16/2896;;C07K2317/21;;C07K2317/52;;C07K2317/75;;C07K2317/76;;A61K2039/505;;A61P35/00;;C07K16/40;;A01K2217/075;;A01K2227/105;;A01K2217/072;;A01K2207/15;;C07K16/2896;;A61K39/395;;A61K31/4439;;A61K31/502;;A61K31/5025;;A61K31/55;;A61P35/00;;C07K2317/21;;C07K2317/52;;C07K2317/75;;C07K2317/76;;A61K2039/505;;A01K2217/075;;A01K2227/105;;A61P35/00;;A61K31/4439;;A61K31/502;;A61K31/5025;;A61K31/55;;C07K16/2818,C07K16/28;;A01K67/027;;A61K39/00;;A61P35/00;;C07K16/40,,0,0,,,,DISCONTINUED
962,WO,A2,WO 2023/086580 A2,005-576-972-368-496,2023-05-19,2023,US 2022/0049719 W,2022-11-11,US 202163279094 P;;US 202163282264 P;;US 202263299749 P;;US 202263317980 P;;US 202263321915 P;;US 202263336476 P;;US 202263375050 P,2021-11-13,MULTICYCLIC COMPOUNDS,"Compounds of Formulae (I), (II) and (III), including pharmaceutically acceptable salts are described herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions a disease or disorder that can be treated with a KOR agonist and/or MOR agonist. Compounds described herein, along with pharmaceutically acceptable salts and compositions thereof, can be used to alleviate at least one symptom of the disease or disorder described herein.",ATLEE BIOTECH INC,SOLOMON ATLEE,,https://lens.org/005-576-972-368-496,Patent Application,yes,0,2,7,059-653-051-759-105;;180-519-419-296-401;;069-888-694-442-290;;117-182-154-861-149;;005-576-972-368-496;;127-404-684-955-728;;020-654-461-414-467,JP;;EP;;IL;;WO;;US;;CA,7,059-653-051-759-105;;180-519-419-296-401;;069-888-694-442-290;;117-182-154-861-149;;005-576-972-368-496;;127-404-684-955-728;;020-654-461-414-467,JP;;EP;;IL;;WO;;US;;CA,0,A61K31/366;;C07D307/40;;C07D407/04;;A61P1/00;;A61K31/341;;A61K31/341;;C07D307/40;;A61P1/00;;A61K31/366;;C07D407/04;;A61K31/341;;A61K31/343;;A61K31/366;;C07D307/54;;C07D405/04;;C07D493/08,C07D311/76;;A61K31/366,,0,0,,,,PENDING
963,AU,A1,AU 2020/268951 A1,012-608-948-599-70X,2021-11-18,2021,AU 2020/268951 A,2020-05-01,US 201962843073 P;;IB 2020054157 W,2019-05-03,Low temperature vials and vial assemblies,"Vials and vial assemblies for storing a medicament in low temperature environments are provided. In one exemplary embodiment, a vial is provided that includes a base portion and a finish portion. The finish portion has an outer surface and an inner surface, in which the inner surface defines a channel that is configured to receive a first portion of a deformable sealing member. The finish portion on the outer surface thereof includes a surface feature that is configured to engage with a second portion of the deformable sealing member. The surface feature is configured to remain engaged with the second portion of the deformable sealing member when the deformable sealing member contracts from a first configuration to a second configuration, thereby maintaining a seal between the finish portion and the deformable sealing member.",JANSSEN BIOTECH INC,FOLTA CHRISTOPHER M;;ASSELTA ROGER P,,https://lens.org/012-608-948-599-70X,Patent Application,no,0,0,11,094-943-905-931-613;;097-550-034-014-802;;062-613-774-280-28X;;030-642-872-440-234;;070-948-883-894-947;;012-608-948-599-70X;;023-041-554-464-620;;072-137-423-943-203;;170-278-058-677-489;;048-580-097-498-453;;142-305-695-976-25X,JP;;KR;;AU;;IL;;CN;;EP;;WO;;US;;CA;;BR;;MX,11,097-550-034-014-802;;030-642-872-440-234;;062-613-774-280-28X;;142-305-695-976-25X;;070-948-883-894-947;;012-608-948-599-70X;;023-041-554-464-620;;072-137-423-943-203;;170-278-058-677-489;;048-580-097-498-453;;094-943-905-931-613,JP;;KR;;AU;;IL;;CN;;EP;;WO;;US;;CA;;MX;;BR,0,A61J1/06;;A61J1/14;;B65D51/002;;A61J1/06;;B65D51/002;;A61J1/14;;A61J1/065;;A61J1/14;;A61J1/1412;;A61J1/1468;;B65D51/002;;A61J1/1468;;A61J1/065;;A61J1/1406;;A61J1/1412;;B65D51/002,A61J1/06;;A61J1/14;;B65D51/00,,0,0,,,,PENDING
964,US,A1,US 2024/0376476 A1,006-393-091-520-712,2024-11-14,2024,US 202318196080 A,2023-05-11,US 202318196080 A,2023-05-11,NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF,"The present disclosure relates to the technical field of biotechnology, and discloses a nucleic acid targeting proprotein convertase subtilisin/kexin 9 and uses thereof. The nucleic acid provided by the present disclosure can effectively inhibit the expression of PCSK9, thereby being capable of treating and/or preventing hyperlipidemia related diseases.",SYNERK BIOTECH LTD,JIANG WEIWEN;;YU DONG;;TANG JIMMY XIBAI,SYNERK BIOTECH LIMITED (2023-07-20),https://lens.org/006-393-091-520-712,Patent Application,yes,0,0,1,006-393-091-520-712,US,1,006-393-091-520-712,US,0,A61K47/549;;C12N15/1137;;C12N2310/14;;C12Y304/21061;;C12N9/6454;;C12N2310/315;;C12N2310/321;;C12N2310/322;;C12N2310/351;;C12N15/1137;;C12N2310/14;;A61K47/549;;C12Y304/21061,C12N15/113;;A61K47/54,,0,0,,,,PENDING
965,WO,A1,WO 2021/209893 A1,011-800-875-934-602,2021-10-21,2021,IB 2021053035 W,2021-04-13,US 202063009623 P;;US 202063014277 P,2020-04-14,"PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMIN OP YRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF","Provided herein are pharmaceutical compositions for oral administration comprising N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)pirimidine- 2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient; and a combination of (i) a cellulose derivative and (ii) a sugar or polyol as diluents. The disclosed compositions are characterized by improved manufacturability, while maintaining the pharmaceutical benefits of minimizing the effect according to changes in pH environment in the stomach, possessing excellent stability, and exhibiting good bioavailability.",JANSSEN BIOTECH INC,MAXIMILIEN JACQUELINE;;RAJAN GOPAL,,https://lens.org/011-800-875-934-602,Patent Application,yes,9,3,19,041-037-449-598-548;;197-045-295-688-969;;064-784-124-018-334;;082-556-655-910-485;;096-363-727-363-992;;129-921-169-640-674;;176-428-407-903-800;;116-434-204-845-342;;017-515-249-626-093;;030-986-218-840-048;;005-984-782-773-928;;028-222-513-085-047;;041-070-091-204-245;;035-097-240-568-206;;011-800-875-934-602;;152-356-958-696-819;;150-943-909-931-396;;120-065-775-269-784;;044-140-402-079-710,AU;;JP;;US;;TW;;CA;;PH;;MX;;BR;;KR;;IL;;EP;;CN;;WO;;UY,20,041-037-449-598-548;;197-045-295-688-969;;064-784-124-018-334;;082-556-655-910-485;;096-363-727-363-992;;005-984-782-773-928;;017-515-249-626-093;;116-434-204-845-342;;176-428-407-903-800;;129-921-169-640-674;;030-986-218-840-048;;000-692-463-361-516;;028-222-513-085-047;;041-070-091-204-245;;035-097-240-568-206;;120-065-775-269-784;;152-356-958-696-819;;044-140-402-079-710;;150-943-909-931-396;;011-800-875-934-602,AU;;JP;;US;;TW;;CA;;PH;;MX;;BR;;KR;;AR;;IL;;EP;;CN;;WO;;UY,0,A61K9/2018;;A61K9/2054;;A61K31/5377;;A61P35/00;;A61K9/284;;C07B2200/13;;A61P35/00;;A61K9/0053;;A61K9/2054;;A61K9/2009;;A61K31/5377;;A61K9/2018;;A61K9/2054;;A61K9/2018;;A61K9/2009;;A61K31/5377;;A61P35/00;;A61K9/0053;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/284;;A61K31/5377;;C07B2200/13,A61K9/20;;A61K31/5377;;A61P35/00,,0,0,,,,PENDING
966,WO,A1,WO 2021/211924 A1,018-594-726-923-467,2021-10-21,2021,US 2021/0027605 W,2021-04-16,US 202063010935 P,2020-04-16,TREATMENT OF ATOPIC DERMATITIS,Symptoms of atopic dermatitis in a human subject are reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.,JANSSEN BIOTECH INC,ZHUANG YANLI;;SRIVASTAVA BHASKAR;;KEEFE KAREN;;PARATKAR SWAROOPA;;RANDAZZO BRUCE;;MUNOZ ERNESTO;;SIMARD JOHN,,https://lens.org/018-594-726-923-467,Patent Application,yes,8,0,1,018-594-726-923-467,WO,1,018-594-726-923-467,WO,22,C07K16/245;;A61K2039/505;;A61P37/08,A61P37/08;;A61K39/00;;C07K16/24,,25,15,049-246-977-894-035;;030-448-608-769-680;;058-230-743-211-879;;030-607-398-087-475;;010-916-105-450-247;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;060-301-220-665-473;;038-386-043-927-169;;037-793-298-361-285;;035-637-602-968-261;;116-577-424-924-059;;005-663-818-775-064;;019-098-047-918-31X,pmc5438978;;10.3389/fphar.2017.00278;;28588486;;20685078;;pmc2965562;;10.1016/j.jclinepi.2010.04.011;;10.1111/j.1610-0387.2007.06609.x;;18190558;;10.1073/pnas.81.21.6851;;6436822;;pmc392030;;1368267;;10.1038/nbt0792-779;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;1507232;;10.1016/0022-2836(92)90639-2;;10.1073/pnas.0502680102;;pmc1187972;;16087878;;10.1016/0022-1759(94)00326-r;;7730665;;27690741;;10.1056/nejmoa1610020;;19067703;;10.1111/j.1365-2133.2008.08941.x;;10.1016/j.jaad.2020.04.104;;32344071;;10.1111/j.1365-2230.1994.tb01167.x;;8033378;;10.1001/archderm.140.12.1513;;15611432,"ANONYMOUS: ""A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov"", 30 July 2019 (2019-07-30), pages 1 - 11, XP055817587, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/study/NCT03496974> [retrieved on 20210624];;GABRIELE FENINI ET AL: ""Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases"", FRONTIERS IN PHARMACOLOGY, vol. 8, 22 May 2017 (2017-05-22), XP055647731, DOI: 10.3389/fphar.2017.00278;;RIEGER ET AL.: ""Glossary of Genetics: Classical and Molecular"", 1991, SPRINGER-VERLAG;;BARBAS ET AL., PROC NAT. ACAD. SCI. USA, vol. 91, 1994, pages 3809 - 3813;;""Stedman's Medical Dictionary"", 2000, LIPPINCOTT, WILLIAMS & WILKINS;;HANIFIN JM ET AL., EXP DERMATOL, vol. 1-3, no. 1, 2001, pages 11 - 18;;AUSUBEL ET AL.: ""Handbook of Therapeutic Abs"", 2007, GREENE PUBLISHING AND WILEY-INTERSCIENCE;;CELLA D ET AL., J CLIN EPIDEMIOL, vol. 63, no. 11, 2010, pages 1179 - 1194;;SCHMITT ET AL.: ""Determinants of treatment goals and satisfaction of patients with atopic eczema"", J DTSCH DERMATOL GES, vol. 6, no. 6, 2008, pages 458 - 465;;JAMES ET AL.: ""Andrews' Diseases of the Skin: Clinical Dermatology - Expert Consult"", 2011, SAUNDERS;;GODING: ""MAbs: Principles and Practice"", 1986, ACADEMIC PRESS, pages: 59 - 103;;MORRISON ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 81, 1984, pages 6851;;NEUBERGER ET AL., NATURE, vol. 314, 1984, pages 452;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 2004;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605;;DRABER ET AL., J. IMMUNOL. METHODS, vol. 181, 1995, pages 37;;SIMPSON ELBIEBER TGUTTMAN-YASSKY E ET AL.: ""Two phase 3 trials of dupilumab versus placebo in atopic dermatitis"", N ENGL J MED, vol. 375, no. 24, 2016, pages 2335 - 2348;;DAWN ET AL.: ""Itch characteristics in atopic dermatitis: results of a web-based questionnaire"", BR J DERMATOL, vol. 160, no. 3, 2009, pages 642 - 644;;SIMPSON ET AL.: ""When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council"", J AM ACAD DERMATOL, no. 4, October 2017 (2017-10-01), pages 623 - 633, XP085202070, DOI: 10.1016/j.jaad.2017.06.042;;SIMPSON E ET AL., J AM ACAD DERMATOL, vol. 83, no. 3, 2020, pages 839 - 846;;HRQOLFINLAY AYKHAN GK, CLIN EXPERI DERMATOL, vol. 19, no. 3, 1994, pages 210 - 216;;CHARMAN CR ET AL., ARCH DERMATOL, vol. 140, no. 12, 2004, pages 1513 - 1519",PENDING
967,AR,A1,AR 116173 A1,024-219-063-658-799,2021-04-07,2021,AR P190101401 A,2019-05-24,US 201862676099 P,2018-05-24,AGENTES DE UNIÓN A PSMA Y USOS DE ESTOS,"La presente se refiere a anticuerpos uniéndose específicamente a PSMA o PSMA y CD3, polinucleótidos que codifican los anticuerpos o fragmentos, y métodos para elaborar y usar lo anterior.",JANSSEN BIOTECH INC,,,https://lens.org/024-219-063-658-799,Patent Application,no,0,0,29,037-940-118-998-279;;073-204-226-214-179;;105-555-299-341-826;;173-842-309-810-074;;142-289-218-265-87X;;135-378-097-791-021;;188-929-740-828-235;;081-471-546-542-717;;055-358-077-418-926;;054-056-391-712-103;;189-008-176-341-687;;060-183-077-008-344;;136-291-018-066-898;;084-393-832-157-033;;129-509-673-993-829;;191-210-548-329-365;;097-050-077-103-214;;089-275-632-481-984;;113-154-333-497-086;;011-109-347-104-027;;144-018-212-554-230;;073-283-616-659-032;;062-964-163-485-862;;148-046-180-949-767;;014-762-144-149-883;;058-605-122-694-554;;032-341-588-307-448;;101-023-161-430-882;;024-219-063-658-799,JP;;EA;;CA;;MX;;CN;;EP;;WO;;JO;;MA;;NI;;AU;;CL;;US;;TW;;EC;;PH;;BR;;PE;;CR;;KR;;AR;;IL;;SG;;UY;;DO,29,037-940-118-998-279;;073-204-226-214-179;;105-555-299-341-826;;173-842-309-810-074;;142-289-218-265-87X;;135-378-097-791-021;;188-929-740-828-235;;081-471-546-542-717;;055-358-077-418-926;;054-056-391-712-103;;189-008-176-341-687;;060-183-077-008-344;;136-291-018-066-898;;084-393-832-157-033;;129-509-673-993-829;;191-210-548-329-365;;097-050-077-103-214;;089-275-632-481-984;;113-154-333-497-086;;011-109-347-104-027;;144-018-212-554-230;;073-283-616-659-032;;062-964-163-485-862;;148-046-180-949-767;;014-762-144-149-883;;058-605-122-694-554;;032-341-588-307-448;;101-023-161-430-882;;024-219-063-658-799,JP;;EA;;CA;;MX;;CN;;EP;;WO;;JO;;MA;;NI;;AU;;CL;;US;;TW;;EC;;PH;;BR;;PE;;CR;;KR;;AR;;IL;;SG;;UY;;DO,0,C07K16/3069;;A61K2039/505;;C07K2317/31;;C07K16/2809;;C07K16/3069;;C07K2317/92;;C07K2317/31;;C07K16/2809;;C07K2317/515;;C07K2317/76;;A61K2039/505;;C07K2317/21;;C07K2317/565;;C07K16/3069;;C07K16/2809;;A61P35/00;;C07K2317/92;;C07K2317/31;;C07K2317/565;;A61K2039/505;;C07K16/2809;;C07K16/3069;;C07K2317/21;;C07K2317/31;;C07K2317/515;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;C07K16/30,,0,0,,,,DISCONTINUED
968,WO,A2,WO 2022/247833 A2,027-480-224-908-145,2022-12-01,2022,CN 2022094749 W,2022-05-24,CN 202111500433 A;;CN 202111503790 A;;CN 202110592489 A;;CN 202111667275 A,2021-05-28,"COMPOSITION, KIT, METHOD, AND USE THEREOF FOR DETECTING SARS-COV-2 MUTATION SITES","The present invention relates to the field of molecular biology detection, specifically to detection of SARS-CoV-2, and more specifically to detection of major mutation sites of SARS-CoV-2 variants. Further provided are a kit comprising a composition, a use of the composition, and a method for detecting and genotyping of SARS-CoV-2 variants. By using the composition in the present invention, major mutations of the novel coronavirus variants can be identified, and preliminary screening and confirmation of variant types are performed by site-combination detection, so that different mutation sites can be treated differently, thereby leading to more effective treatment and prevention. The composition of the present invention, in combination with a fluorescent probe method, can be used to detect multiple targets simultaneously, with advantages of a low cost, a high throughput, a simple operation and a short usage time.",SANSURE BIOTECH INC,DAI LIZHONG;;TAN DEYONG;;LIU JIA;;DENG ZHONGPING;;SUN QINGZHI;;WU KANG;;CHENG XING;;REN XIAOMEI;;GAO TANGJIE;;GUO XINWU,,https://lens.org/027-480-224-908-145,Patent Application,yes,0,1,3,027-480-224-908-145;;199-624-002-877-758;;089-972-155-819-711,EP;;WO,9,088-260-018-634-727;;050-306-035-802-771;;056-940-957-610-705;;199-624-002-877-758;;089-972-155-819-711;;156-115-203-971-18X;;027-480-224-908-145;;046-711-025-012-308;;179-213-564-764-18X,CN;;EP;;WO,72,C12Q1/701;;C12Q1/70;;C12Q2600/156;;C12Q2600/16,C12Q1/70,,2,2,056-201-471-905-934;;028-862-168-091-90X,2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917,"ALTSCHUL ET AL., MOL BIOL, vol. 215, no. 3, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, no. 17, 1997, pages 3389 - 402",PENDING
969,CA,A1,CA 3136811 A1,024-089-920-925-423,2020-10-22,2020,CA 3136811 A,2020-04-16,US 201962834932 P;;US 201962842893 P;;US 2020/0028414 W,2019-04-16,ALKYL-TPP COMPOUNDS FOR MITOCHONDRIA TARGETING AND ANTI-CANCER TREATMENTS,"Alkyl-tripheny!phosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the adherent ""bulk"" of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently inhibits mitochondrial oxygen consumption rate, while simultaneously shifting cell metabolism toward the glycolytic pathway. This shift to a strict metabolic dependency on glycolysis may be used to eradicate the residual glycolytic CSC population, by using additional metabolic stressors. For example, d-TPP may be combined with a glycolytic inhibitor or an OXPHOS inhibitor, through co-administration or sequential administration, to treat cancer and eradicate CSCs.",LUNELLA BIOTECH INC,SOTGIA FEDERICA;;LISANTI MICHAEL P,,https://lens.org/024-089-920-925-423,Patent Application,no,0,0,11,089-269-864-099-10X;;109-044-210-375-01X;;021-383-762-508-98X;;049-451-653-290-895;;096-925-090-178-31X;;085-834-442-780-652;;139-884-985-972-709;;024-089-920-925-423;;170-081-261-226-000;;061-020-155-815-919;;016-183-207-687-731,JP;;KR;;CN;;EP;;WO;;US;;SG;;CA,11,089-269-864-099-10X;;109-044-210-375-01X;;021-383-762-508-98X;;049-451-653-290-895;;096-925-090-178-31X;;085-834-442-780-652;;139-884-985-972-709;;024-089-920-925-423;;170-081-261-226-000;;061-020-155-815-919;;016-183-207-687-731,JP;;KR;;CN;;EP;;WO;;US;;SG;;CA,0,A61P35/00;;A61K31/66;;A61K31/375;;A61K31/7004;;A61K31/65;;A61K31/609;;A61K31/4375;;A61K31/7052;;A61K31/7048;;A61P35/02;;A61K45/06;;A61K31/662;;A61K31/375;;A61K31/7004;;A61K31/65;;A61K31/167;;A61K31/4375;;A61K31/7052;;A61K31/7048;;A61K31/609;;A61K45/06;;A61P35/00;;A61K2300/00;;A61K31/167;;A61K31/375;;A61K31/4375;;A61K31/65;;A61K31/66;;A61K31/7004;;A61K31/7048;;A61K31/7052,A61K31/66;;A61P35/00;;C07F9/54,,0,0,,,,PENDING
970,EP,A1,EP 3950648 A1,030-638-050-775-826,2022-02-09,2022,EP 19922172 A,2019-03-27,ES 2019070206 W,2019-03-27,FERTILISING COMPOSITION WHICH INCLUDES A PLANT-ASSIMILABLE PHOSPHORUS AND CALCIUM POTENTIATOR AND USE THEREOF,"The invention provides a fertilising composition which includes a plant-assimilable phosphorus and calcium potentiator, said assimilable phosphorus potentiator being glyceric acid, a combination of said fertilising composition together with other fertilisers and/or biostimulants, as well as its use in the form of a hydrosoluble powder, granulate or liquid prior dissolution in water for direct application by fertigation or foliar application.",FERTINAGRO BIOTECH SL,ATARES REAL SERGIO;;ROMERO LOPEZ JOAQUÍN;;SALAET MADORRAN IGNASI;;FERRER GINES MARÍA;;CABALLERO MOLADA MARCOS;;YANCE CHAVEZ TULA DEL CARMEN;;FUERTES DOÑATE CARLOS,,https://lens.org/030-638-050-775-826,Patent Application,yes,0,0,14,046-896-429-727-266;;030-638-050-775-826;;156-557-766-071-677;;049-079-551-907-227;;179-083-073-171-109;;078-610-733-051-859;;102-368-136-738-295;;173-366-576-211-223;;110-507-970-915-334;;183-738-794-234-244;;003-938-113-887-952;;149-233-075-393-533;;127-817-510-442-207;;199-176-481-496-568,AU;;JP;;CN;;EP;;WO;;US;;CA;;BR;;MX,14,046-896-429-727-266;;030-638-050-775-826;;156-557-766-071-677;;049-079-551-907-227;;179-083-073-171-109;;078-610-733-051-859;;102-368-136-738-295;;173-366-576-211-223;;110-507-970-915-334;;183-738-794-234-244;;003-938-113-887-952;;149-233-075-393-533;;127-817-510-442-207;;199-176-481-496-568,AU;;JP;;CN;;EP;;WO;;US;;CA;;BR;;MX,0,C05D9/02;;C05F11/02;;C05G5/10;;C05G5/23;;C05F11/00;;A01P21/00;;A01N37/36;;C05G5/23;;C05G5/10;;C05F11/02;;C05F11/10,C05G1/00,,0,0,,,,PENDING
971,US,A1,US 2024/0141055 A1,023-979-006-267-543,2024-05-02,2024,US 202318216074 A,2023-06-29,US 202318216074 A;;US 202016878209 A;;US 201916382645 A;;US 201715596609 A;;US 201514790144 A;;US 201313835518 A;;US 201261611332 P,2012-03-15,Human Anti-CD27 Antibodies,"Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.",JANSSEN BIOTECH INC,CHEN JOHN;;FRANSSON JOHAN;;FURSOV NATALIE;;HAMEL DAMON;;MALIA THOMAS;;OBMOLOVA GALINA;;ORT TATIANA;;RYCYZYN MICHAEL;;SCULLY MICHAEL;;SWEET RAYMOND;;TEPLYAKOV ALEXEY;;WHEELER JOHN;;ALMAGRO JUAN CARLOS,,https://lens.org/023-979-006-267-543,Patent Application,yes,0,0,54,067-865-597-257-750;;191-313-117-655-080;;063-790-622-065-55X;;179-465-774-004-913;;182-790-721-921-555;;013-008-259-994-269;;159-034-398-498-568;;182-095-453-504-004;;018-955-355-319-519;;099-049-876-232-519;;116-629-868-657-256;;046-491-917-788-302;;023-979-006-267-543;;008-372-971-949-162;;153-261-336-314-892;;034-975-669-971-225;;171-691-520-691-826;;163-071-350-364-613;;067-066-733-752-115;;082-278-757-560-730;;029-029-048-847-772;;006-030-283-293-005;;132-390-909-816-427;;007-918-981-864-248;;087-322-404-316-641;;037-155-697-486-281;;001-573-205-994-681;;028-982-601-763-858;;148-065-178-002-367;;103-552-340-709-850;;013-147-755-325-38X;;028-740-219-093-249;;026-209-390-672-882;;008-241-793-893-652;;198-830-174-517-135;;029-553-155-631-310;;154-090-749-039-561;;163-860-152-165-113;;001-234-370-681-148;;051-612-816-360-832;;150-597-189-088-804;;049-769-706-838-720;;119-029-511-016-245;;199-006-879-467-298;;166-266-694-110-413;;009-354-451-133-01X;;003-134-122-277-52X;;071-310-189-243-144;;128-441-209-886-945;;115-335-907-797-375;;007-112-912-767-193;;121-449-956-688-792;;058-928-615-538-169;;143-688-937-797-463,JP;;EA;;CA;;MX;;MY;;EP;;CN;;WO;;ZA;;HK;;NZ;;JO;;AU;;CL;;US;;TW;;CO;;EC;;BR;;PH;;PE;;CR;;KR;;AR;;GT;;SG;;UA;;UY,54,067-865-597-257-750;;191-313-117-655-080;;063-790-622-065-55X;;179-465-774-004-913;;182-790-721-921-555;;013-008-259-994-269;;159-034-398-498-568;;182-095-453-504-004;;018-955-355-319-519;;099-049-876-232-519;;116-629-868-657-256;;046-491-917-788-302;;023-979-006-267-543;;008-372-971-949-162;;153-261-336-314-892;;034-975-669-971-225;;171-691-520-691-826;;163-071-350-364-613;;067-066-733-752-115;;082-278-757-560-730;;029-029-048-847-772;;006-030-283-293-005;;132-390-909-816-427;;007-918-981-864-248;;087-322-404-316-641;;037-155-697-486-281;;001-573-205-994-681;;028-982-601-763-858;;148-065-178-002-367;;103-552-340-709-850;;013-147-755-325-38X;;028-740-219-093-249;;026-209-390-672-882;;008-241-793-893-652;;198-830-174-517-135;;029-553-155-631-310;;154-090-749-039-561;;163-860-152-165-113;;001-234-370-681-148;;051-612-816-360-832;;150-597-189-088-804;;049-769-706-838-720;;119-029-511-016-245;;199-006-879-467-298;;166-266-694-110-413;;009-354-451-133-01X;;003-134-122-277-52X;;071-310-189-243-144;;128-441-209-886-945;;115-335-907-797-375;;007-112-912-767-193;;121-449-956-688-792;;058-928-615-538-169;;143-688-937-797-463,JP;;EA;;CA;;MX;;MY;;EP;;CN;;WO;;ZA;;HK;;NZ;;JO;;AU;;CL;;US;;TW;;CO;;EC;;BR;;PH;;PE;;CR;;KR;;AR;;GT;;SG;;UA;;UY,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/2878;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P31/00;;A61P33/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07K16/2896;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/73;;C07K2317/76;;C07K2317/92;;C07K16/2878,C07K16/28,,0,0,,,,PENDING
972,US,A1,US 2024/0010718 A1,029-411-673-240-308,2024-01-11,2024,US 202318327577 A,2023-06-01,US 202318327577 A;;US 202016880118 A;;US 201962851968 P;;US 201962896205 P,2019-05-23,METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA,"A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).",JANSSEN BIOTECH INC,GERMINARO MATTHEW;;O'BRIEN CHRISTOPHER;;PERRIGOUE JACQUELINE,,https://lens.org/029-411-673-240-308,Patent Application,yes,0,0,15,175-693-795-113-421;;195-454-565-502-947;;053-126-616-610-090;;025-070-738-244-126;;120-740-166-404-289;;007-252-751-463-432;;163-651-284-663-164;;029-411-673-240-308;;085-112-442-560-647;;055-539-771-820-66X;;163-290-496-838-260;;078-788-454-642-400;;172-810-136-486-321;;081-477-636-612-704;;049-066-275-729-811,AU;;JP;;KR;;EP;;IL;;CN;;WO;;US;;CA;;MX;;BR,16,195-454-565-502-947;;175-693-795-113-421;;007-252-751-463-432;;025-070-738-244-126;;120-740-166-404-289;;053-126-616-610-090;;163-651-284-663-164;;029-411-673-240-308;;085-112-442-560-647;;055-539-771-820-66X;;081-477-636-612-704;;078-788-454-642-400;;172-810-136-486-321;;163-290-496-838-260;;046-042-218-513-509;;049-066-275-729-811,AU;;JP;;KR;;EP;;IL;;CN;;EA;;WO;;US;;CA;;MX;;BR,0,A61P1/04;;A61P29/00;;A61K9/0019;;C07K2317/76;;C07K2317/21;;C07K16/244;;C07K16/241;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K47/26;;A61K9/08;;C07K16/244;;C07K2317/31;;A61K2039/507;;C07K2317/565;;C07K16/241;;C07K2317/76;;C07K2317/21;;A61P29/00;;A61K2039/505;;A61P1/04;;A61K2039/545;;A61K9/0019;;C07K16/244;;C07K16/241;;A61K9/0019;;A61K47/22;;A61K47/26;;A61P1/00;;A61P29/00;;C07K2317/21;;C07K2317/76;;A61K2039/505;;A61K2039/507;;A61K2039/545;;A61K2039/54;;C07K16/244;;C07K16/241;;A61K9/0019;;A61P1/04;;C07K2317/31;;C07K2317/565;;A61K2039/545;;A61K2039/507;;C07K2317/76;;A61P29/00;;A61K39/395,C07K16/24;;A61K9/00;;A61K39/395;;A61P1/04;;A61P29/00,,0,0,,,,PENDING
973,AR,A1,AR 126899 A1,030-076-762-983-410,2023-11-29,2023,AR P220102317 A,2022-08-26,US 202163237663 P;;US 202063277245 P;;US 202063339784 P,2020-05-09,RADIOCONJUGADOS ANTI-PSMA Y USOS DE ESTOS,"En la presente descripción se describen anticuerpos o fragmentos de unión al antígeno de estos que se unen al antígeno prostático específico de membrana (PSMA), polinucleótidos, vectores, células huésped, radioconjugados, conjugados anticuerpo-fármaco y métodos para tratar el cáncer usando los mismos. Reivindicación 1: Un radioinmunoconjugado de la fórmula: (1) o (2) en donde: M⁺ es un ion radiometálico, en donde M⁺ se selecciona del grupo que consiste en actinio-225 (²²⁵Ac), indio-111 (¹¹¹In), radio-223 (²³³Ra), bismuto-213 (²¹³Bi), plomo-212 (²¹²Pb(II) y/o ²¹²Pb(IV)), terbio-149 (¹⁴⁹Tb), terbio-152 (¹⁵²Tb), terbio-155 (¹⁵⁵Tb), fermio-255 (²⁵⁵Fm), torio-227 (²²⁷Th), torio-226 (²²⁶Th⁴⁺), astatina-211 (²¹¹At), cerio-134 (¹³⁴Ce), neodimio-144 (¹⁴⁴Nd), lantano-132 (¹³²La), lantano-135 (¹³⁵La) y uranio-230 (²³⁰U); y mAb es un anticuerpo o fragmento de unión al antígeno que se une a PSMA. Reivindicación 15: Una composición farmacéutica que comprende el radioinmunoconjugado de la reivindicación 1, y un portador farmacéuticamente aceptable. Reivindicación 19: Un método para detectar un cáncer que expresa PSMA en un sujeto comprende poner en contacto la muestra del sujeto con un radioinmunoconjugado de la reivindicación 1.",JANSSEN BIOTECH INC,GOLDBERG SHALOM;;KLEIN DONNA;;KOHLI NEERAJ;;MDEVITT THERESA MARIE;;ORCUTT STEVEN J,,https://lens.org/030-076-762-983-410,Patent Application,no,0,0,1,030-076-762-983-410,AR,28,054-059-068-778-94X;;016-049-294-798-853;;037-113-374-893-741;;083-829-692-268-484;;066-704-578-317-910;;030-076-762-983-410;;001-656-855-954-028;;089-107-203-093-200;;048-375-900-342-480;;180-488-126-763-679;;169-436-263-663-145;;056-423-985-692-933;;059-609-520-625-17X;;001-686-803-003-551;;059-928-349-906-673;;165-111-796-272-509;;061-903-405-102-727;;149-789-805-326-820;;015-610-312-139-11X;;017-820-319-003-045;;090-047-607-590-266;;100-115-673-111-14X;;006-023-341-936-772;;159-765-089-574-474;;126-821-372-673-730;;031-644-199-983-129;;008-216-444-202-02X;;129-923-293-184-038,JP;;AU;;CL;;US;;TW;;CO;;CA;;MX;;PE;;KR;;AR;;EP;;CN;;IL;;WO;;UY;;DO,0,,C07K16/28;;A61K51/10;;A61P35/00,,0,0,,,,PENDING
974,CN,A,CN 119894915 A,026-674-786-497-80X,2025-04-25,2025,CN 202380067189 A,2023-09-21,US 202263376579 P;;IB 2023059349 W,2022-09-21,Novel stable nucleoside phosphate and analogs thereof,"The present disclosure includes oligonucleotide and nucleic acid compositions having a stable phosphate moiety. Formula (Ia) and Formula (Ib) wherein: X is selected from the group consisting of a 3-to 5-membered cycloalkyl group,-CHCH-, a 3-to 5-membered heterocycle, and-CH3CH3-. # imgabs0 #",JANSSEN BIOTECH INC,PUHAVIC MARKO;;KIM YOUHAN;;RAMSISAN MOHAN;;DESJARLAIS RENEE;;LUTHER FREDERIK H,,https://lens.org/026-674-786-497-80X,Patent Application,no,0,0,4,020-865-374-730-349;;143-535-142-405-537;;026-674-786-497-80X;;189-860-594-570-793,IL;;EP;;CN;;WO,4,020-865-374-730-349;;143-535-142-405-537;;026-674-786-497-80X;;189-860-594-570-793,IL;;EP;;CN;;WO,0,C07H19/06;;C07H19/16;;A61P43/00;;C07F9/65586;;C07F9/6512;;C07F9/6561;;C07H19/06;;C07F9/6561;;C07F9/6512;;A61P43/00;;C07H19/16;;C07F9/65586,C07H19/06;;A61P43/00;;C07F9/38;;C07H19/16,,0,0,,,,PENDING
975,CL,A1,CL 2022002766 A1,023-296-252-103-306,2023-04-21,2023,CL 2022002766 A,2022-10-06,US 202063007118 P;;US 202063026387 P,2020-04-08,Anticuerpos anti-phf-pau y sus usos.,"Se describen anticuerpos monoclonales anti-PHF-tau y fragmentos de unión al antígeno de estos. Además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatías.",JANSSEN BIOTECH INC,LUO JINQUAN;;MERCKEN MARC;;VAN KOLEN KRISTOF;;GANESAN RAJKUMAR;;SINGH SANJAYA;;VENKATARAMANI SATHYADEVI;;LA PORTE SHERRY;;NANJUNDA RUPESH;;JAIPRASART PHARAVEE,,https://lens.org/023-296-252-103-306,Patent Application,no,0,0,20,040-015-797-645-087;;026-610-575-810-445;;075-724-111-088-880;;162-267-759-188-596;;027-296-514-629-857;;023-296-252-103-306;;095-289-458-013-61X;;052-149-433-186-595;;145-279-072-179-476;;022-710-037-919-091;;095-476-353-315-279;;115-083-393-943-938;;160-760-037-844-236;;150-399-980-552-974;;070-069-245-969-94X;;015-708-120-628-555;;069-366-355-247-791;;158-251-477-163-541;;086-150-435-480-474;;119-578-611-317-565,AU;;JP;;CL;;US;;TW;;CA;;CO;;EC;;MX;;BR;;PH;;PE;;CR;;KR;;EP;;IL;;CN;;WO;;DO,21,040-015-797-645-087;;026-610-575-810-445;;075-724-111-088-880;;162-267-759-188-596;;027-296-514-629-857;;023-296-252-103-306;;095-289-458-013-61X;;052-149-433-186-595;;145-279-072-179-476;;022-710-037-919-091;;095-476-353-315-279;;115-083-393-943-938;;086-150-435-480-474;;170-939-859-407-863;;150-399-980-552-974;;070-069-245-969-94X;;015-708-120-628-555;;069-366-355-247-791;;158-251-477-163-541;;119-578-611-317-565;;160-760-037-844-236,AU;;JP;;CL;;US;;TW;;CA;;CO;;EC;;MX;;BR;;PH;;PE;;CR;;KR;;AR;;EP;;IL;;CN;;WO;;DO,0,C07K16/18;;C07K2317/24;;C07K2317/92;;C07K2317/34;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/92;;C07K2317/34;;A61P25/28;;A61K2039/505;;C07K16/18;;A61P25/28;;G01N33/6896;;C07K2317/24;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/56;;C12N15/63;;G01N33/6896,A61K39/00;;A61K9/00;;A61K39/395,,0,0,,,,PENDING
976,EP,A1,EP 4440571 A1,021-514-207-221-055,2024-10-09,2024,EP 22826669 A,2022-11-30,FI 20216228 A;;FI 20225643 A;;FI 2022050801 W,2021-11-30,PREVENTION AND TREATMENT OF DEPRESSIVE DISORDERS AND CONDITIONS PROMOTED BY PROTEASE CONTAINING PLASMA EXTRACELLULAR VESICLES (PCPEV),,EVEXYS BIOTECH OY,BAUR ANDREAS;;YLÖSMÄKI ERKKO,,https://lens.org/021-514-207-221-055,Patent Application,yes,0,0,3,180-849-692-150-659;;065-286-685-824-082;;021-514-207-221-055,EP;;WO;;US,3,180-849-692-150-659;;065-286-685-824-082;;021-514-207-221-055,EP;;WO;;US,0,A61K31/352;;A61P25/24;;A61K35/00;;G01N33/6896;;G01N2333/91102;;G01N2800/52;;G01N2500/10;;A61K31/352;;A61K35/00;;G01N33/6896;;G01N2333/91102;;G01N2500/10;;G01N2800/52,A61K31/352;;A61K35/00;;A61K48/00;;A61P25/24;;G01N33/50,,0,0,,,,PENDING
977,CN,A,CN 119072469 A,023-274-497-358-270,2024-12-03,2024,CN 202380032595 A,2023-03-23,US 202263325360 P;;IB 2023052886 W,2022-03-30,2-[(2-oxo-4-phenyl-2h-chromene-7-yl) oxy] propanamide derivatives,"Disclosed are 2-[(2-oxo-4-phenyl-2H-chromene-7-yl) oxy] propanamide derivatives, in which at least one of R1 to R4 contains an amino group, and methods for preparing the same. These derivatives can be used to target and eliminate cancer stem cells, and can be used as therapeutic agents for the treatment of cancer, including reducing the likelihood of tumor recurrence and metastasis and/or preventing tumor recurrence and metastasis. The compounds disclosed herein have demonstrated to inhibit tumor cell spherogenic ability, migration, and stemness-related signaling in cancer stem cells. These properties result from selective inhibition of mitochondrial transcription against mitochondrial RNA polymerase (POLRMT) in cancer cells. # imgabs0 #",LUNELLA BIOTECH INC,LISANTI MICHAEL P;;SOTGIA FEDERICA;;CANGUES METSA JOS ¨;;DI PISA FILIPPO,,https://lens.org/023-274-497-358-270,Patent Application,no,0,0,9,084-415-709-414-553;;131-305-051-690-601;;061-848-771-755-964;;133-834-463-528-367;;023-274-497-358-270;;127-208-684-315-052;;127-060-036-758-340;;179-289-982-659-842;;028-395-491-019-844,KR;;JP;;AU;;IL;;CN;;EP;;WO;;US;;MX,9,084-415-709-414-553;;131-305-051-690-601;;061-848-771-755-964;;133-834-463-528-367;;023-274-497-358-270;;127-060-036-758-340;;127-208-684-315-052;;179-289-982-659-842;;028-395-491-019-844,KR;;JP;;AU;;IL;;CN;;EP;;WO;;US;;MX,0,A61P35/00;;C07D405/12;;A61K45/06;;C07D311/18;;C07D405/12;;A61K31/453;;A61K31/37;;A61K31/4025;;A61P35/00;;A61P35/04;;C07D311/18;;A61P35/04;;A61K31/37;;A61K31/4025;;A61K31/453;;C07D311/18;;C07D405/12,C07D311/16;;A61K31/37;;A61K31/4025;;A61K31/453;;A61P35/00;;C07D405/12,,0,0,,,,PENDING
978,CN,A,CN 113396221 A,018-326-731-300-845,2021-09-14,2021,CN 202080009763 A,2020-01-14,US 201962793933 P;;IB 2020050267 W,2019-01-18,Beta-GALACTOSIDASE ALPHA PEPTIDE AS A NON-ANTIBIOTIC SELECTION MARKER AND USES THEREOF,"Provided herein are methods of using a nucleic acid construct as a selectable marker. The nucleic acid construct comprises an isolated beta-galactosidase expression cassette comprising a nucleic acid sequence encoding the amino-terminal fragment of beta- galactosidase operably linked to a promoter. Also provided are isolated vectors comprising the beta-galactosidase expression cassette, methods of generating the isolated vector, and kits comprising the isolated vector.",JANSSEN BIOTECH INC,PERRY WILLIAM,,https://lens.org/018-326-731-300-845,Patent Application,no,1,0,13,168-429-052-538-019;;018-326-731-300-845;;134-245-756-413-740;;049-938-828-293-233;;199-898-244-653-106;;110-572-910-947-984;;053-472-054-207-196;;083-204-710-025-663;;077-020-155-480-064;;139-081-963-793-17X;;026-878-222-976-121;;019-288-844-628-232;;192-526-458-011-828,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA;;BR;;MX,13,168-429-052-538-019;;018-326-731-300-845;;134-245-756-413-740;;049-938-828-293-233;;199-898-244-653-106;;110-572-910-947-984;;053-472-054-207-196;;083-204-710-025-663;;077-020-155-480-064;;139-081-963-793-17X;;026-878-222-976-121;;019-288-844-628-232;;192-526-458-011-828,JP;;KR;;AU;;CN;;EP;;IL;;WO;;US;;CA;;BR;;MX,0,C12N15/63;;C12N15/72;;C12N2800/101;;C12N2820/55;;C12N2800/102;;C12N9/2471;;C12N9/1241;;C12N9/1241;;C12N9/2471;;C12N15/63;;C12N15/72;;C12N2800/101;;C12N2800/102;;C12N2820/55;;C12N15/65;;C12N9/2402;;C12N15/72;;C12N15/81;;C12Y302/01023;;C12N2800/101;;C12N2800/102;;C12N9/2471;;C12N15/65;;C12N15/72;;C12N15/81;;C12N2800/101;;C12N2800/102;;C12N2820/55;;C12Y302/01023,C12N15/63;;C12N9/12;;C12N9/38;;C12N15/52;;C12N15/72,,4,1,003-694-928-260-036,9767582;;10.1046/j.1365-2958.1998.01012.x,"DAVID SUMMERS: ""Timing, self-control and a sense of direction are the secrets of multicopy plasmid stability"", 《MOLECULAR MICROBIOLOGY》, vol. 29, no. 5, 31 December 1998 (1998-12-31);;JIAMIAO LU等: ""The Extragenic Spacer Length Between the 5′ and 3′ Ends of the Transgene Expression Cassette Affects Transgene Silencing From Plasmid-based Vectors"", 《MOLECULAR THERAPY》, vol. 20, no. 11, 8 May 2012 (2012-05-08), pages 2114 - 2115;;KOTARO NISHIYAMA等: ""Development of a reporter peptide that catalytically produces a fluorescent signal through a-complementation"", 《PROTEIN SCIENCE》, vol. 24, 4 March 2015 (2015-03-04), pages 599 - 603;;JENS STAAL等: ""Engineering a Minimal Cloning Vector from a pUC18 Plasmid Backbone with an Extended Multiple Cloning Site"", 《PREPRINTS》, 15 October 2018 (2018-10-15), pages 1 - 9",PENDING
979,CL,A1,CL 2024001016 A1,017-684-630-648-045,2024-10-04,2024,CL 2024001016 A,2024-04-04,US 201662364811 P,2016-07-20,"Anticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas.","En la presente invención, se proporcionan anticuerpos que se unen de manera específica a GPRC5D. Además, se describen los polinucleótidos relacionados capaces de codificar los anticuerpos específicos de GPRC5D o de unión al antígeno proporcionados, células que expresan los anticuerpos o fragmentos de unión al antígeno proporcionados, así como los vectores asociados y los anticuerpos o fragmentos de unión al antígeno marcados de forma detectable. Además, se describen los métodos para usar los anticuerpos proporcionados. Por ejemplo, los anticuerpos proporcionados podrían usarse para diagnosticar, tratar o monitorear la progresión, la regresión o la estabilidad del cáncer que expresa GPRC5D; para determinar si un paciente debe recibir o no tratamiento para cáncer; o para determinar si un sujeto sufre de un cáncer que expresa GPRC5D o no y, así, podría ser susceptible de tratamiento con un agente terapéutico anticáncer específico de GPRC5D, tal como los anticuerpos multiespecíficos contra GPRC5D y CD3 descritos en la presente descripción.",JANSSEN BIOTECH INC,RICARDO ATTAR;;DIANA CHIN;;SUZANNE EDAVETTAL;;FRANCOIS GAUDET;;YINGZHE LI;;LEOPOLDO LUISTRO;;NATHAN MAJEWSKI;;MARK MENDONCA;;KONDANDARAM PILLARISETTI;;ALEXEY TEPLYAKOV;;MARK TORNETTA,,https://lens.org/017-684-630-648-045,Patent Application,no,0,0,57,172-603-071-433-824;;035-082-935-460-363;;132-996-527-684-218;;165-871-253-589-683;;077-734-334-777-79X;;073-061-187-391-555;;006-497-319-460-418;;018-833-303-326-965;;046-286-521-290-556;;172-935-937-449-132;;059-763-570-339-687;;037-965-024-103-818;;068-014-316-722-937;;058-003-221-128-664;;125-268-384-709-182;;012-015-208-636-671;;141-176-431-029-545;;032-884-416-201-023;;110-022-512-023-958;;004-916-285-639-890;;190-586-549-673-159;;139-487-661-805-091;;017-389-730-030-697;;017-684-630-648-045;;085-842-846-007-519;;006-020-903-868-457;;008-534-626-058-376;;167-589-457-882-412;;143-086-406-073-011;;131-916-560-972-490;;179-717-691-664-340;;158-709-073-296-278;;121-854-528-000-751;;187-715-875-938-60X;;180-314-390-781-841;;137-817-032-339-397;;110-314-672-013-681;;050-925-067-976-090;;176-894-213-144-066;;188-033-329-217-58X;;145-926-282-541-97X;;077-332-502-922-764;;153-091-760-875-26X;;031-728-792-792-911;;145-680-876-159-578;;191-999-963-306-161;;066-912-783-456-932;;160-769-176-805-06X;;063-205-792-156-69X;;061-582-820-924-694;;068-232-211-469-723;;070-158-303-614-94X;;194-727-468-573-692;;098-004-752-450-287;;042-120-992-201-702;;145-261-294-409-382;;135-879-465-632-039,JP;;EA;;CA;;MX;;EP;;CN;;WO;;ZA;;NI;;MA;;AU;;CL;;US;;TW;;CO;;EC;;BR;;PH;;PE;;CR;;KR;;AR;;IL;;SG;;UY;;IN,57,172-603-071-433-824;;035-082-935-460-363;;132-996-527-684-218;;165-871-253-589-683;;077-734-334-777-79X;;073-061-187-391-555;;006-497-319-460-418;;018-833-303-326-965;;046-286-521-290-556;;172-935-937-449-132;;059-763-570-339-687;;037-965-024-103-818;;068-014-316-722-937;;058-003-221-128-664;;125-268-384-709-182;;012-015-208-636-671;;141-176-431-029-545;;032-884-416-201-023;;110-022-512-023-958;;004-916-285-639-890;;190-586-549-673-159;;139-487-661-805-091;;017-389-730-030-697;;017-684-630-648-045;;085-842-846-007-519;;006-020-903-868-457;;008-534-626-058-376;;167-589-457-882-412;;143-086-406-073-011;;131-916-560-972-490;;179-717-691-664-340;;158-709-073-296-278;;121-854-528-000-751;;187-715-875-938-60X;;180-314-390-781-841;;137-817-032-339-397;;110-314-672-013-681;;050-925-067-976-090;;176-894-213-144-066;;188-033-329-217-58X;;145-926-282-541-97X;;077-332-502-922-764;;153-091-760-875-26X;;031-728-792-792-911;;145-680-876-159-578;;191-999-963-306-161;;066-912-783-456-932;;160-769-176-805-06X;;063-205-792-156-69X;;061-582-820-924-694;;068-232-211-469-723;;070-158-303-614-94X;;194-727-468-573-692;;098-004-752-450-287;;042-120-992-201-702;;145-261-294-409-382;;135-879-465-632-039,JP;;EA;;CA;;MX;;EP;;CN;;WO;;ZA;;NI;;MA;;AU;;CL;;US;;TW;;CO;;EC;;BR;;PH;;PE;;CR;;KR;;AR;;IL;;SG;;UY;;IN,0,C07K16/28;;C07K16/2809;;A61K39/3955;;A61K45/06;;A61P35/00;;C07K2317/56;;C07K2317/565;;C07K2317/31;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C12R2001/91;;A61K2039/505;;A61K2239/31;;A61K2239/38;;A61K2239/46;;A61K40/10;;A61K40/4202;;C07K16/28;;C07K16/2809;;A61K2039/505;;C07K2317/31;;C07K2317/21;;C07K2317/565;;C07K2317/33;;C07K2317/734;;C07K2317/732;;C07K2317/76;;C07K2317/94;;C07K2317/92;;A61K2239/38;;A61K2239/31;;A61K2239/46;;A61K40/10;;A61K40/4202;;C07K16/2809;;C07K2317/21;;C07K2317/31;;C07K2317/33;;C07K2317/76;;A61K2039/505;;C07K16/28;;C07K2317/92;;A61P35/00;;A61P35/02;;Y02A50/30;;A61K2239/46;;A61K2239/38;;A61K2239/31;;A61K40/10;;A61K40/4202;;C07K16/28;;C07K2317/732;;C07K2317/31;;C07K2317/33;;C07K2317/92;;C07K2317/94;;C07K2317/76;;C07K2317/21;;C07K2317/565;;A61K2039/505;;A61P35/02;;A61P35/00;;C07K16/2809;;C07K2317/734;;A61K39/0011;;A61P35/00;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/31;;C07K2317/732;;C07K2317/565;;C07K2317/92;;C07K16/28;;A61P35/02;;C07K2317/31;;C07K2317/33;;C07K16/2809;;C07K2317/76;;C07K2317/21;;A61K2239/38;;A61K2239/31;;A61K2239/46;;A61K39/0011;;A61K40/10;;A61K40/4202;;A61K2039/505;;C07K16/28;;C07K2317/565;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2317/94,A61K39/395;;A61P35/02,,0,0,,,,PENDING
980,CA,A1,CA 3229430 A1,020-045-453-655-515,2023-02-23,2023,CA 3229430 A,2022-08-12,US 202163233343 P;;US 202263322273 P;;US 2022/0074891 W,2021-08-16,ANTI-VEGFR1 ANTIBODIES AND THEIR USES,"Disclosed herein are antibodies or antigen binding fragments thereof that bind vascular endothelial growth factor receptor 1 (VEGFR1), polynucleotides, vectors, host cells and methods of treating chronic kidney disease using the same.",JANSSEN BIOTECH INC,BREYER MATTHEW D;;GONZALEZ VILLALOBOS ROMER A;;LI JINGJUN;;RUTKOSKI THOMAS J;;SWANSON RONALD V;;ZHENG GANG;;ZHENG SONGMAO;;ZHENG XIRONG,,https://lens.org/020-045-453-655-515,Patent Application,no,0,0,15,103-314-919-859-512;;056-935-041-532-181;;174-434-302-366-63X;;055-342-519-286-494;;093-392-495-736-078;;190-671-692-624-882;;036-820-477-520-16X;;179-547-277-299-326;;048-009-440-770-23X;;005-511-477-267-519;;098-886-963-587-707;;101-694-334-828-061;;020-045-453-655-515;;144-127-196-264-374;;000-115-036-940-96X,JP;;AU;;CL;;US;;TW;;CO;;CA;;MX;;KR;;IL;;EP;;CN;;WO;;UY,17,008-828-215-821-65X;;112-874-322-849-073;;103-314-919-859-512;;056-935-041-532-181;;174-434-302-366-63X;;055-342-519-286-494;;093-392-495-736-078;;190-671-692-624-882;;036-820-477-520-16X;;179-547-277-299-326;;048-009-440-770-23X;;005-511-477-267-519;;098-886-963-587-707;;101-694-334-828-061;;020-045-453-655-515;;144-127-196-264-374;;000-115-036-940-96X,JP;;AU;;CL;;US;;TW;;CO;;CA;;MX;;KR;;AR;;CN;;IL;;EP;;WO;;UY,0,C07K16/2863;;A61K47/6849;;A61K47/6801;;A61P13/12;;C07K2317/34;;C07K2317/92;;C07K2317/565;;C07K2317/56;;C07K2317/52;;A61K2039/505;;A61P13/12;;C07K16/2863;;C07K2317/34;;C07K2317/76;;C07K2317/622;;C07K2317/52;;C07K2317/71;;C07K2317/21;;C07K2317/33;;C07K2317/94;;C07K2317/70;;C07K2317/92;;A61P13/12;;C07K2317/33;;C07K2317/70;;C07K2317/94;;C07K2317/21;;C07K2317/622;;C07K2317/92;;C07K2317/34;;C07K2317/71;;C07K16/2863;;C07K2317/52;;C07K2317/76;;C07K16/2863;;A61P13/12;;C07K2317/76;;C07K2317/52;;C07K2317/622;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P13/12;;A61K2039/505;;C07K16/2863;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/76;;C07K2317/92,C07K16/28;;A61P13/12;;C07K16/22,,0,0,,,,PENDING
981,WO,A1,WO 2025/046493 A1,023-614-419-869-25X,2025-03-06,2025,IB 2024058377 W,2024-08-28,US 202363579643 P,2023-08-30,BIOENGINEERED IMMUNOMODULATORY FUSION PROTEIN COMPOSITIONS,"Provided herein are, inter alia, materials and methods for bioengineered immunomodulatory fusion proteins and uses thereof for modulating immune responses, as well as improving a response of a subject in need therefore, such as to a vaccine, or treating a disease or disorder, such as cancer or a pathogen infection.",JANSSEN BIOTECH INC,TAMOT NINKKA;;HARVILLA PAUL BYRON,,https://lens.org/023-614-419-869-25X,Patent Application,yes,4,0,1,023-614-419-869-25X,WO,1,023-614-419-869-25X,WO,50,C07K14/705;;A61K38/00;;A61P35/00,C07K14/705;;A61K38/00;;A61P35/00;;C12N5/0784,,3,3,062-592-870-238-313;;073-971-680-632-124;;115-077-253-428-394,22804572;;10.3109/08830185.2012.703272;;pmc3815466;;10.1016/j.vaccine.2009.09.055;;19786146;;pmc2784276;;25052763;;pmc4269809;;10.1038/mi.2014.59,"KORNBLUTH, RICHARD S. ET AL.: ""Design of CD40 agonists and their use in growing B cells for cancer immunotherapy"", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 31, no. 4, 17 July 2012 (published online), pages 279 - 288, XP009179456, DOI: 10.3109/08830185.2012.703272;;THACKER, ERIN E. ET AL.: ""A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo"", VACCINE, vol. 27, 26 September 2009 (published online), pages 7116 - 7124, XP026734135, DOI: 10.1016/j.vaccine.2009.09.055;;FAN, X ET AL.: ""Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes"", MUCOSAL IMMUNOLOGY, vol. 8, no. 1, 23 July 2014 (published online), pages 211 - 220, XP055331190, DOI: 10.1038/mi.2014.59",PENDING
982,EP,A1,EP 3840726 A1,019-331-063-618-155,2021-06-30,2021,EP 19852009 A,2019-08-22,US 201862721884 P;;IB 2019057079 W,2018-08-23,LIPASE DEGRADATION RESISTANT SURFACTANTS FOR USE IN LARGE MOLECULE THERAPEUTIC FORMULATIONS,,JANSSEN BIOTECH INC,LABRENZ STEVEN;;STAHL PATRICK,,https://lens.org/019-331-063-618-155,Patent Application,yes,0,0,16,058-778-460-307-102;;116-532-553-903-730;;092-879-799-323-385;;009-687-640-590-768;;065-818-705-398-469;;085-571-998-500-052;;155-780-277-943-222;;037-203-290-726-857;;060-770-676-475-565;;179-392-367-559-706;;028-324-242-935-229;;055-751-950-645-789;;019-331-063-618-155;;197-328-154-734-765;;165-799-747-840-459;;064-291-799-759-469,KR;;EP;;ES;;CN;;IL;;WO;;US;;MA,16,058-778-460-307-102;;116-532-553-903-730;;092-879-799-323-385;;009-687-640-590-768;;065-818-705-398-469;;085-571-998-500-052;;155-780-277-943-222;;037-203-290-726-857;;060-770-676-475-565;;028-324-242-935-229;;179-392-367-559-706;;055-751-950-645-789;;019-331-063-618-155;;197-328-154-734-765;;165-799-747-840-459;;064-291-799-759-469,KR;;EP;;ES;;CN;;IL;;WO;;US;;MA,0,A61K31/25;;A61K38/465;;C12Y301/01001;;A61K47/10;;A61K39/39591;;A61K9/0019;;A61K47/183;;A61K47/26;;A61K31/25;;A61K38/465;;C12Y301/01001;;A61K9/08;;A61K47/10;;A61K47/26;;A61K38/465;;A61K39/39591;;C12Y301/01001;;A61K31/25;;C12Y301/01001;;A61K38/465,A61K9/08;;A61K39/395;;A61K39/44,,0,0,,,,ACTIVE
983,MX,A,MX 2023004606 A,022-260-662-394-184,2023-05-08,2023,MX 2023004606 A,2021-10-25,EP 20020492 A;;EP 20203887 A;;EP 2021079560 W,2020-10-25,MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES.,"The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker comprising the structure (shown in N -> C direction) (Sp<sub>1</sub>)-RK-(Sp<sub>2</sub>)-B-(Sp<sub>3</sub>) or (Sp<sub>1</sub>)- B-(Sp<sub>2</sub>)-RK-(Sp<sub>3</sub>) to a Gin residue comprised in an antibody, wherein (Sp<sub>1</sub>) is a chemical spacer or is absent; (Sp<sub>2</sub>) is a chemical spacer or is absent; (Sp<sub>3</sub>) is a chemical spacer or is absent; R is arginine or an arginine derivative or an arginine mimetic; K is lysine or a lysine derivative or a lysine mimetic; B is a linking moiety or a payload; and wherein the linker is conjugated to the Gln residue comprised in the antibody via a primary amine comprised in the side chain of the lysine residue, the lysine derivative or the lysine mimetic. Further, the invention relates to antibody-linker conjugates, antibody-drug conjugates and linker constructs comprising an RK motif.",ARARIS BIOTECH AG,ATTINGER-TOLLER ISABELLA;;GRABULOVSKI DRAGAN;;BERTRAND ROMAIN;;SPYCHER PHILIPP;;PROBST PHILIPP;;STARK RAMONA,,https://lens.org/022-260-662-394-184,Patent Application,no,0,0,15,078-664-669-508-036;;069-293-812-522-361;;076-426-624-632-483;;143-825-660-051-463;;021-264-849-183-16X;;038-377-355-128-863;;084-765-098-633-633;;086-316-633-041-314;;006-536-244-420-719;;014-486-829-569-022;;022-260-662-394-184;;000-666-705-873-583;;003-673-174-047-673;;163-224-561-797-878;;002-914-105-994-106,JP;;AU;;KR;;CL;;IL;;EP;;WO;;US;;CO;;CA;;MX;;PE,16,078-664-669-508-036;;038-377-355-128-863;;143-825-660-051-463;;076-426-624-632-483;;021-264-849-183-16X;;069-293-812-522-361;;084-765-098-633-633;;086-316-633-041-314;;006-536-244-420-719;;014-486-829-569-022;;022-260-662-394-184;;000-666-705-873-583;;003-673-174-047-673;;101-966-211-221-696;;163-224-561-797-878;;002-914-105-994-106,AU;;JP;;CL;;US;;CO;;CA;;MX;;PE;;KR;;IL;;CN;;EP;;WO,0,A61K47/6803;;A61K47/6889;;A61K47/65;;A61P35/00;;A61K47/6855;;A61K47/6849;;C07K2317/524;;C07K16/2803;;C07K16/32;;A61K47/68033;;A61K47/68037;;A61K47/68031;;A61K47/6803;;C07K2317/524;;A61K47/65;;A61K47/6889;;C07K16/32;;A61P35/00;;A61K47/6855;;C07K16/2803;;A61K47/6849;;A61K47/6889;;A61K47/65;;A61K47/6849;;A61K47/6855;;A61P35/00;;C07K16/2803;;C07K16/32;;C07K2317/524;;A61K47/68031;;A61K47/68033;;A61K47/68035;;A61K47/68037;;A61K47/6889;;A61P35/00;;C12N9/1044;;C12Y203/02013;;A61K47/6803;;A61K47/68031;;A61K47/68033;;A61K47/68037,A61K47/68;;A61K47/65;;A61P35/00;;C07K16/28,,0,0,,,,PENDING
984,KR,A,KR 20230156094 A,019-015-728-927-223,2023-11-13,2023,KR 20237034184 A,2022-03-07,US 202163158552 P;;IB 2022052009 W,2021-03-09,EGFR-활성화 돌연변이가 결여된 암의 치료,본 발명은 적어도 하나의 EGFR-활성화 돌연변이를 결여하는 종양을 갖는 암을 갖는 대상체의 치료에 관한 것이다.,JANSSEN BIOTECH INC,HENLEY BENJAMIN J;;MOORES SHERI L,,https://lens.org/019-015-728-927-223,Patent Application,no,0,0,13,062-026-193-662-320;;019-015-728-927-223;;001-028-147-333-469;;148-361-083-401-193;;128-980-472-503-844;;065-888-676-843-124;;120-024-561-909-220;;155-380-693-431-741;;163-151-157-409-007;;185-350-897-947-898;;176-085-364-153-728;;089-615-932-064-38X;;129-570-197-535-917,KR;;AU;;JP;;CN;;IL;;CL;;EP;;WO;;US;;CA;;BR;;MX,14,062-026-193-662-320;;019-015-728-927-223;;001-028-147-333-469;;185-350-897-947-898;;148-361-083-401-193;;128-980-472-503-844;;065-888-676-843-124;;120-024-561-909-220;;155-380-693-431-741;;163-151-157-409-007;;106-325-203-713-668;;176-085-364-153-728;;129-570-197-535-917;;089-615-932-064-38X,KR;;AU;;JP;;CN;;CL;;IL;;EP;;WO;;US;;CA;;BR;;MX,42,C07K16/2863;;C07K2317/31;;C07K2317/565;;C07K2317/71;;C07K2317/72;;C07K2317/73;;A61K39/3955;;A61K2039/505;;A61K2039/585;;A61P35/00;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C07K16/2863;;C07K2317/565;;C07K2317/71;;C07K2317/73;;C12Q2600/156;;C07K2317/92;;A61K39/3955;;C07K2317/72;;C07K2317/31;;A61K2039/505;;A61K2039/585;;A61P35/00;;A61K2039/54;;C12Q2600/106;;C07K2317/52;;A61P11/00;;A61K2039/545;;A61K39/39558;;A61K45/06;;C12Q1/6886;;C07K16/2863;;A61P35/00;;C12Q1/6886;;C07K2317/31;;C07K2317/565;;C07K2317/71;;C07K2317/72;;C07K2317/73;;A61K2039/505;;A61K2039/585;;C12Q2600/106;;C12Q2600/156;;A61P11/00;;A61P35/00;;A61K39/39558;;A61K45/06;;A61K2039/505;;A61K2039/54;;A61K2039/545;;C07K16/2863;;C07K2317/31;;C07K2317/52;;C07K2317/71;;C07K2317/92,C07K16/28;;A61K39/00;;A61P35/00;;C12Q1/6886,,0,0,,,,PENDING
985,CN,A,CN 117512069 A,029-525-162-208-782,2024-02-06,2024,CN 202311674732 A,2023-12-07,CN 202311674732 A,2023-12-07,Nucleic acid detection method,"The invention belongs to the field of molecular biological detection, particularly relates to a nucleic acid detection method, and more particularly relates to a method for rapidly extracting and detecting nucleic acid. The invention provides a nucleic acid detection method which comprises the following steps: S1, mixing a to-be-detected sample with a direct diffusion preservation solution, and performing ultrasonic treatment to obtain a sample nucleic acid solution; s2, adding the sample nucleic acid solution obtained in the step S1 into an amplification reaction solution to obtain a mixed solution; s3, carrying out amplification reaction by utilizing the mixed solution and detecting nucleic acid; the direct diffusion preserving fluid comprises a protective agent, a nuclease inhibitor, a surfactant, a buffer system and a bacteriostatic agent. By using the method provided by the invention, the whole detection process is simple, the influence in the process is small, and the detection time is short.",SANSURE BIOTECH INC,DAI LIZHONG;;SUN QINGZHI;;TAN DEYONG;;XU SIYAO;;WANG JIAN;;GUO JUN;;JI BOZHI;;WU KANG;;LIU JIA;;YANG JIANHUA,,https://lens.org/029-525-162-208-782,Patent Application,no,10,2,1,029-525-162-208-782,CN,5,145-830-638-132-979;;029-525-162-208-782;;171-012-390-525-100;;049-945-664-948-066;;098-540-428-728-848,CN;;EP;;WO;;US,0,C12Q1/6806;;C12Q1/686;;C12Q1/701,C12Q1/6806;;C12Q1/686;;C12Q1/70;;C12R1/93,,0,0,,,,PENDING
986,KR,A,KR 20240159657 A,029-147-619-626-912,2024-11-05,2024,KR 20247022421 A,2023-05-25,CN 202310476403 A;;CN 2023096273 W,2023-04-27,VVN001을 함유하는 안과 조성물,"본 출원은 VVN001을 함유하는 안과 조성물을 제공하는 바, 상기 안과 조성물은 활성물질과 안과 부형제를 포함하고, 여기서, 상기 활성물질은 식 I로 표시되는 나트륨염 및 식 I의 유리상태의 산 중의 적어도 하나로부터 선택되며, 상기 안과 조성물은 활성물질에 의해 T 세포가 매개하는 염증 반응을 억제함으로써, 안구 염증 반응을 감소시킨다. 나아가, 본 출원은 낮은 농도의 pH 완충제 농도를 선택하여, pH 완충제 농도가 눈물의 완충 능력에 매칭되도록 하여, 눈물 친화적이며 편한 느낌이 강하게 하고, 또한 본 출원의 활성물질의 평균체류시간을 증가시키는 동시에 본 출원의 식 I로 표시되는 활성물질의 생체이용률을 향상시킨다. JPEGpct00024.jpg3380 식 I",VIVAVISION BIOTECH LTD,XIA ERNING;;HAN QIAO;;SHEN WANG;;LU YANGQINGQIN;;GAO HONGYAN,,https://lens.org/029-147-619-626-912,Patent Application,no,0,0,8,042-699-123-344-432;;135-102-838-858-485;;162-311-594-725-773;;029-147-619-626-912;;042-678-497-640-727;;077-417-151-001-615;;177-612-268-517-059;;133-448-369-859-80X,JP;;KR;;AU;;CN;;IL;;WO;;TW,8,042-699-123-344-432;;135-102-838-858-485;;162-311-594-725-773;;029-147-619-626-912;;042-678-497-640-727;;077-417-151-001-615;;177-612-268-517-059;;133-448-369-859-80X,JP;;KR;;AU;;CN;;IL;;WO;;TW,0,A61K9/0048;;A61K9/08;;A61K31/662;;A61K47/10;;A61K47/02;;A61K47/18;;A61K47/26;;A61P27/02;;A61P29/00;;A61K31/662;;A61P29/00;;A61K47/10;;A61K47/02;;A61K9/00;;A61K47/26;;A61K47/36;;A61K31/66;;A61K47/16;;A61P27/02;;A61K47/18;;A61K9/08;;A61K31/662;;A61K9/0048;;A61K47/02;;A61P27/02,A61K31/662;;A61K9/00;;A61K47/02;;A61P27/02,,0,0,,,,PENDING
987,US,A1,US 2024/0125798 A1,030-151-477-565-524,2024-04-18,2024,US 202118278121 A,2021-11-17,KR 20210024914 A;;KR 20210158188 A;;KR 2021016860 W,2021-02-24,"METHOD FOR SCREENING FUNCTIONAL MATERIAL PALLIATIVE OF ALLERGY, ATOPY, AND ITCHINESS",A method for screening a functional material according to the present invention comprises steps of: treating a linker material-coated substrate with a capture protein; treating the capture protein-treated substrate with a functional material candidate; treating the functional material candidate-treated substrate with biotin-conjugated IgE; and treating the biotin-bound IgE-treated substrate with fluorescently labeled streptavidin.,SHEBAH BIOTECH INC,CHO YONG-WAN;;LIM HYE-WON;;JE HAN-WOOL;;KIM YOUNG-BIN;;KYEONG GYU-RI;;KIM YOUNG-SOOK,SHEBAH BIOTECH INC (2023-08-11),https://lens.org/030-151-477-565-524,Patent Application,yes,0,0,2,109-958-750-992-933;;030-151-477-565-524,WO;;US,4,141-922-574-393-792;;109-958-750-992-933;;030-151-477-565-524;;091-403-029-129-017,KR;;WO;;US,0,G01N33/68;;G01N33/582;;G01N33/5008;;G01N33/6854;;G01N33/566;;G01N33/5008;;G01N33/582;;G01N33/6854,G01N33/68;;G01N33/50;;G01N33/58,,0,0,,,,PENDING
988,IL,A,IL 303555 A,024-700-804-183-307,2023-07-01,2023,IL 30355523 A,2023-06-08,IL 30355523 A,2023-06-08,A system for 3d cultivation of plant cells and methods of use,,PLURI BIOTECH LTD,LIOR RAVIV;;ERAN BEN ELIEZER,,https://lens.org/024-700-804-183-307,Patent Application,no,0,0,8,182-012-253-999-624;;024-700-804-183-307;;164-354-727-401-936;;091-335-380-773-959;;091-623-883-888-906;;025-074-454-997-52X;;012-885-303-917-331;;118-135-690-176-959,KR;;AU;;IL;;CN;;WO;;US,8,182-012-253-999-624;;024-700-804-183-307;;164-354-727-401-936;;091-335-380-773-959;;091-623-883-888-906;;025-074-454-997-52X;;012-885-303-917-331;;118-135-690-176-959,KR;;AU;;IL;;CN;;WO;;US,0,C12N5/0062;;C12N5/04;;A01H4/002;;A01H4/001;;C12M25/18;;C12M27/14;;C12M27/02;;C12M33/00;;C12N5/04;;C12M47/00;;C12M41/34;;C12M29/10;;C12M41/00;;C12N5/0062;;C12M33/00;;C12M27/02;;C12M29/00;;A01H4/002;;C12M41/48;;C12M23/04;;C12M25/18;;C12M27/02;;C12M29/14;;C12M35/04;;C12M41/12;;C12M41/26;;C12M41/32;;C12M41/34;;C12N5/04;;C12N2513/00,,,0,0,,,,PENDING
989,GB,A,GB 2619840 A,030-516-683-230-767,2023-12-20,2023,GB 202314075 A,2019-08-09,GB 202314075 A;;GB 202309104 A,2019-08-09,Medicament delivery device,"The device comprises a laryngeal mask having a patient-contacting surface configured to fit against a patient at an area surrounding the patient’s laryngeal inlet, a delivery tube (16, figure 3C) having interior wall surfaces defining a medicament channel and a gas channel and an epiglottis-holding ridge 99. In use, the ridge touches and bends the patient’s epiglottis so it is retracted away from patient-contacting surface.",ONY BIOTECH INC,COREY COMMAROTO;;KATE ACKERMAN,,https://lens.org/030-516-683-230-767,Patent Application,no,5,0,3,042-017-990-245-300;;030-516-683-230-767;;096-400-605-924-392,GB,3,042-017-990-245-300;;030-516-683-230-767;;096-400-605-924-392,GB,0,A61M16/0409;;A61M16/0477;;A61M16/0816;;A61M16/0445;;A61M16/0409;;A61M16/0486,A61M16/04,,0,0,,,,ACTIVE
990,CN,A,CN 114862767 A,030-118-483-349-559,2022-08-05,2022,CN 202210388085 A,2022-04-13,CN 202210388085 A,2022-04-13,Abnormal sample suction detection method,"The invention is applicable to the technical field of in-vitro detection, and provides a sample suction anomaly detection method, which comprises the following steps: acquiring a to-be-detected hydraulic curve when a sampling needle sucks a sample; obtaining a first sample suction state through the negative pulse area of the hydraulic curve to be measured; acquiring a second sample suction state based on the jitter wave area and the jitter wave number of the hydraulic curve to be measured; when the first sample suction state or the second sample suction state is abnormal, abnormal processing is carried out, and an alarm prompt is given; wherein if the first sample suction state is abnormal, the sampling needle is in a needle blocking state; if the second sample suction state is abnormal, the sampling needle is in an empty suction state. According to the invention, the accuracy of the test result of the analyzer can be improved.",GENRUI BIOTECH INC,LIN GUIWEN;;FAN ZANHUI,,https://lens.org/030-118-483-349-559,Patent Application,no,3,0,2,030-118-483-349-559;;110-289-159-308-364,CN,2,030-118-483-349-559;;110-289-159-308-364,CN,0,G06T7/0012;;G06T7/62;;G06T2207/30024,G06T7/00;;G06T7/62,,1,0,,,"李延斌等: ""全自动生化分析仪的分类、结构和选购"", 《中国医疗器械信息》, vol. 14, no. 3, 15 March 2008 (2008-03-15), pages 34 - 40",ACTIVE
991,EP,A1,EP 4314286 A1,029-988-201-374-240,2024-02-07,2024,EP 22789458 A,2022-08-08,CN 202110901455 A;;CN 202111294356 A;;CN 202210098137 A;;CN 202210143116 A;;CN 2022110828 W,2021-08-06,"COMPOSITIONS FOR LIQUEFYING A VISCOUS BIOLOGICAL SAMPLE, COMBINATION PRODUCTS, LIQUEFYING AGENTS, AND KITS THEREOF, AND METHODS AND APPLICATION THEREOF",,SANSURE BIOTECH INC,DAI LIZHONG;;DENG ZHONGPING;;CHEN SHIYAO;;DENG YONG;;LIU JIA,,https://lens.org/029-988-201-374-240,Patent Application,yes,0,0,3,029-988-201-374-240;;000-760-283-684-299;;096-598-390-329-102,EP;;WO;;US,9,002-080-375-644-431;;000-760-283-684-299;;144-362-510-994-19X;;041-173-534-281-082;;035-176-540-239-119;;029-988-201-374-240;;155-998-968-218-101;;096-598-390-329-102;;017-979-807-796-325,CN;;EP;;WO;;US,0,C12Q1/6806;;C12N15/1006;;C12Q1/6806;;C12Q1/6851,C12N15/10;;C12Q1/6806,,0,0,,,,PENDING
992,EP,A1,EP 3873523 A1,034-034-605-711-358,2021-09-08,2021,EP 19874869 A,2019-10-25,US 201862751019 P;;IB 2019059178 W,2018-10-26,TYPE I INTERFERON SIGNATURES AND METHODS OF USE,,JANSSEN BIOTECH INC,CESARONI MATTEO;;CHEVRIER MARC;;JORDAN JARRAT;;SCHREITER JESSICA,,https://lens.org/034-034-605-711-358,Patent Application,yes,0,0,13,053-088-083-997-24X;;175-874-179-450-929;;001-878-633-888-874;;115-372-234-281-560;;054-293-647-264-105;;161-726-706-965-527;;123-694-414-536-489;;034-034-605-711-358;;165-838-187-980-398;;173-850-075-278-790;;155-081-949-813-111;;184-194-950-522-621;;164-549-894-215-137,JP;;KR;;EA;;CN;;IL;;EP;;WO;;US;;CA;;MA,13,053-088-083-997-24X;;175-874-179-450-929;;001-878-633-888-874;;115-372-234-281-560;;054-293-647-264-105;;161-726-706-965-527;;123-694-414-536-489;;034-034-605-711-358;;165-838-187-980-398;;173-850-075-278-790;;155-081-949-813-111;;184-194-950-522-621;;164-549-894-215-137,JP;;KR;;EA;;CN;;IL;;EP;;WO;;US;;CA;;MA,30,C12Q1/6883;;C12Q1/6886;;C12Q2600/106;;C12Q2600/158;;C07K16/249;;A61P37/06;;A61K2039/505;;A61K2039/54;;A61K2039/545;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K2039/54;;A61K2039/545;;A61P37/06;;C07K14/56;;C07K16/249;;C07K2317/565;;C07K2317/76;;C07K2317/94;;C12Q1/6809;;C12Q1/6883;;C12Q1/6886;;C12Q2539/00;;C12Q2545/114;;C12Q2600/106;;C12Q2600/158;;C12Q1/6883;;A61P37/06;;C07K16/249;;C12Q2600/158;;C12Q2600/106;;C07K2317/565;;C07K2317/76;;C07K2317/94;;A61K2039/505;;A61K2039/545;;A61K2039/54;;C07K14/56;;C12Q1/6809;;C12Q2545/114;;C12Q2539/00;;C07K2317/565;;G16H50/30;;G16H20/10,A61K39/395;;A61K38/21;;C07K16/24;;C12Q1/68,,0,0,,,,PENDING
993,CN,A,CN 118043897 A,026-762-224-664-16X,2024-05-14,2024,CN 202280065956 A,2022-08-31,US 202217707813 A;;US 2022/0075785 W;;US 202163250909 P,2021-09-30,Personalized medical and therapy platform,"Apparatuses, systems, methods, and computer program products are disclosed for managing development and therapy supply chains in delivering personalized medical therapy. In some aspects, a Unified Configuration System (UCS) for an enterprise software platform is described that enables various benefit-related parties of the personalized medical development and treatment supply chain and facilitates creation and management of independent configurations of their supply chain management software for the enterprise software platform.",JANSSEN BIOTECH INC,DUNN JAMES A;;HAN CHONG;;YAGIRO GEORGE G;;RAYDOBLE ANDREW;;SOUTHWICK ROBERT J;;ZHANG DANLU;;JONES ERIC M;;LAI ANTHONY,,https://lens.org/026-762-224-664-16X,Patent Application,no,0,0,6,026-762-224-664-16X;;041-265-697-715-146;;049-268-312-651-132;;058-995-105-134-041;;095-418-076-554-697;;116-722-106-348-373,CN;;EP;;WO;;US,6,026-762-224-664-16X;;041-265-697-715-146;;049-268-312-651-132;;058-995-105-134-041;;095-418-076-554-697;;116-722-106-348-373,CN;;EP;;WO;;US,0,G06F8/71;;G16H10/60;;G16H40/20;;G16H20/10;;G16H10/60;;G16H20/10;;G06F8/71,G16H10/60;;G16H20/60,,0,0,,,,PENDING
994,EP,A1,EP 4551232 A1,026-199-683-146-177,2025-05-14,2025,EP 23834331 A,2023-06-26,US 202263358194 P;;CA 2023050884 W,2022-07-04,METABOLOMIC IMPROVEMENTS USING RESISTANT STARCH SUPPLEMENTATION,,MCPHARMA BIOTECH INC,MCLAREN DEREK;;MCLAREN EARL,,https://lens.org/026-199-683-146-177,Patent Application,yes,0,0,6,184-806-628-141-948;;131-278-038-812-116;;026-199-683-146-177;;093-850-585-427-135;;138-730-267-283-53X;;043-802-718-666-122,KR;;JP;;AU;;EP;;WO;;MX,6,184-806-628-141-948;;131-278-038-812-116;;026-199-683-146-177;;093-850-585-427-135;;138-730-267-283-53X;;043-802-718-666-122,KR;;JP;;AU;;EP;;WO;;MX,0,A61K31/718;;A61K31/718;;A61P3/00,A61K31/718;;A61P3/00;;A61P25/16;;A61P25/28,,0,0,,,,PENDING
995,EP,A1,EP 4198517 A1,027-544-488-618-416,2023-06-21,2023,EP 21216007 A,2021-12-20,EP 21216007 A,2021-12-20,POINT-OF-CARE REAL-TIME QUANTITATIVE PCR TEST DEVICE,"Point-of-Care Real-time Quantitative PCR-Testvorrichtung, qPCR, mit einem Gehäuse, einem im Gehäuse angeordneten Testmodul (12) zur Aufnahme einer Testprobe und einem mit dem Testmodul (12) verbundene Steuermodul (14), wobei das Steuermodul (14) ausgebildet ist zur Steuerung des Testmoduls (12) zur Durchführung eines qPCR-Tests und Bestimmung eines Testergebnisses, und einem Übertragungsmodul (16), wobei das Übertragungsmodul (16) ausgebildet ist das Testergebnis und/oder Statusinformation der qPCR-Testvorrichtung an mindestens einen Empfänger zu übertragen.",PROCOMCURE BIOTECH GMBH,ÖNDER KAMIL,,https://lens.org/027-544-488-618-416,Patent Application,yes,4,0,4,078-934-079-910-33X;;019-949-309-040-205;;027-544-488-618-416;;182-803-934-938-510,DE;;AT;;EP;;WO,4,182-803-934-938-510;;019-949-309-040-205;;027-544-488-618-416;;078-934-079-910-33X,DE;;AT;;EP;;WO,0,G16H10/40;;C12Q1/686;;C12Q2545/10;;C12Q2561/113;;G16H40/63;;G16H40/67;;G16H50/80;;H04L63/0428;;H04L67/025;;G01N35/00871;;B01L7/52;;C12Q1/6851;;C12Q1/686;;G16H40/67,G01N35/00;;B01L7/00;;C12Q1/6851;;C12Q1/686;;G16H40/67,,0,0,,,,PENDING
996,WO,A1,WO 2025/067633 A1,040-274-472-734-379,2025-04-03,2025,EP 2023076494 W,2023-09-26,EP 2023076494 W,2023-09-26,PHARMACEUTICAL COMPOSITIONS COMPRISING AMINOPEPTIDASE AND DIPEPTIDYLPEPTIDASE POLYPEPTIDES AND USES THEREOF,The present disclosure relates to compositions comprising polypeptides with peptidase activity that are aminopeptidase (AP) and dipeptidylpeptidase (DPP) polypeptides which are useful for degradation of disease-promoting peptides such as gluten-immunogenic peptides. The formulation of the compositions protects the peptidases from acidic conditions in the stomach when administered orally. The compositions described herein are useful in medical applications such as in the treatment of gluten-related disorders including celiac disease (CeD) and non-celiac gluten sensitivity (NCGS) as well as other diseases that may profit from a gluten-free diet (GFD).,AMYRA BIOTECH AG,TSCHOLLAR WERNER;;MOURABIT SULAYMAN,,https://lens.org/040-274-472-734-379,Patent Application,yes,3,0,2,040-274-472-734-379;;124-166-838-897-357,WO,2,040-274-472-734-379;;124-166-838-897-357,WO,3,A61K38/4813;;A61K38/168;;A61K36/899;;A61K36/88;;A61K9/1652;;A61P1/00;;A61P37/00;;A61K36/062;;A61K9/146;;A61K9/5036;;A61K9/5026;;A61K9/1635,A61K38/48;;A61K9/16;;A61K9/28;;A61K9/48;;A61K31/722;;A61K31/732;;A61K31/734;;A61K33/08;;A61K36/06;;A61K36/062;;A61K36/88;;A61K36/899;;A61K38/16;;A61P1/00;;A61P37/00,,27,16,099-094-164-156-59X;;057-807-581-529-979;;010-320-675-722-163;;051-183-689-567-757;;059-248-976-174-118;;013-239-934-007-115;;029-598-192-816-532;;065-803-748-708-701;;002-557-922-988-838;;004-493-288-413-529;;095-568-868-610-865;;129-860-125-183-401;;125-800-814-333-700;;037-547-948-051-868;;099-592-496-651-046;;032-728-154-591-070,36678923;;pmc9861284;;10.3390/pharmaceutics15010295;;10.1088/1742-6596/2579/1/012006;;10.1016/j.smim.2015.11.001;;26603490;;10.1021/pr050173t;;pmc1343496;;16212427;;10.1126/sciadv.aaw7756;;31457091;;pmc6685723;;10.4049/jimmunol.1601693;;pmc5426360;;28373482;;10.1111/apt.16075;;32981131;;pmc7780203;;10.1111/jgh.13705;;28244667;;10.1177/2050640615578388;;25922675;;pmc4406911;;24077239;;10.3390/nu5103839;;pmc3820047;;10.1038/ajg.2013.97;;23567359;;pmc8724473;;10.1007/s12551-021-00856-z;;35047092;;10.14309/ctg.0000000000000411;;34613954;;pmc8500619;;20012198;;10.1007/s10620-009-1076-x;;16487408;;10.1111/j.1365-2982.2006.00759.x;;10.1016/0022-2836(70)90057-4;;5420325,"LAURO MARIA ROSARIA ET AL: ""Eudraguard Natural and Protect: New ""Food Grade"" Matrices for the Delivery of an Extract from Sorbus domestica L. Leaves Active on the [alpha]-Glucosidase Enzyme"", PHARMACEUTICS, vol. 15, no. 1, 16 January 2023 (2023-01-16), CH, pages 295, XP093145932, ISSN: 1999-4923, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861284/pdf/pharmaceutics-15-00295.pdf> DOI: 10.3390/pharmaceutics15010295;;RIZZO S ET AL: ""Food-grade polymers: A new vision in the controlled release of bioactive substances"", JOURNAL OF PHYSICS: CONFERENCE SERIES, INSTITUTE OF PHYSICS PUBLISHING, GB, vol. 2579, no. 1, 1 August 2023 (2023-08-01), XP020477643, ISSN: 1742-6588, [retrieved on 20230801], DOI: 10.1088/1742-6596/2579/1/012006;;BAILEY, A. J. ET AL., PHILOS. TRANS. R. SOC. LOND. B. BIOL. SCI., vol. 357, 2002, pages 133 - 142;;SHARMA, N. ET AL., FRONT. NUTR., vol. 7, 2020, pages 6;;STAMNAES, J.SOLLID, L. M., SEMIN. IMMUNOL., vol. 27, 2015, pages 343 - 352;;SHAN, L. ET AL., J. PROTEOME RES., vol. 4, 2005, pages 1732 - 1741;;GOEL, G. ET AL., SCI. ADV., vol. 5, 2019, pages eaaw7756;;JABRI, B.SOLLID, L. M., J. IMMUNOL. BALTIM. MD, vol. 198, 1950, pages 3005 - 3014;;SINGH, P. ET AL., CLIN. GASTROENTEROL. HEPATOL., vol. 16, pages 823 - 836;;SILVESTER, J. A. ET AL., ALIMENT. PHARMACOL. THER., vol. 52, 2020, pages 1469 - 1479;;GIBSON, P. R.SKODJE, G. I.LUNDIN, K. E. A., J. GASTROENTEROL. HEPATOL., vol. 32, no. 1, 2017, pages 86 - 89;;BIESIEKIERSKI, J. R.IVEN, J., UNITED EUR. GASTROENTEROL. J., vol. 3, 2015, pages 160 - 165;;CATASSI, C. ET AL., NUTRIENTS, vol. 5, 2013, pages 3839 - 3853;;BOETTCHER, E.CROWE, S. E., AM. J. GASTROENTEROL., vol. 108, 2013, pages 728 - 736;;NEMTEANU, R ET AL., INT. J. MOL. SCI., vol. 23, 2022;;MACHADO, M. V., INT. J. MOL. SCI., 2023, pages 24;;SIEGEL, M. ET AL., CHEM. BIOL., vol. 13, 2006, pages 649 - 658;;HERRERA, M. G.DODERO, V. I., BIOPHYS. REV., vol. 13, 2021, pages 1147 - 1154;;HERRERA, M. G. ET AL., MOL. NUTR. FOOD RES., vol. 65, 2021, pages 2100200;;MONACHESI, C. ET AL., CLIN. TRANSL. GASTROENTEROL., 2021, pages 12;;SANAKA, M.YAMAMOTO, T.KUYAMA, Y., DIG. DIS. SCI., vol. 55, 2010, pages 2431 - 2440;;KOZIOLEK, M. ET AL., UNDERST. CHALL. -RULE--5 COMPD., vol. 101, 2016, pages 75 - 88;;SCHULZE, K., NEUROGASTROENTEROL. MOTIL., vol. 18, 2006, pages 172 - 183;;SMITHWATERMAN, ADS APP. MATH., vol. 2, 1981, pages 482;;NEDDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSONLIPMAN, PROC. NATL ACAD. SCI. USA, vol. 88, 1988, pages 2444;;GAPBESTFITFASTABLAST PBLAST NTFASTA, WISCONSIN GENETICS SOFTWARE PACKAGE, GENETICS COMPUTER GROUP",PENDING
997,US,A1,US 2024/0180944 A1,041-811-426-584-32X,2024-06-06,2024,US 202418442204 A,2024-02-15,US 202418442204 A;;US 202117282212 A;;US 2019/0054231 W;;US 201862740137 P;;US 201862750559 P;;US 201962788187 P,2018-10-02,AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGS,"This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).",LUNELLA BIOTECH INC,SOTGIA FEDERICA;;LISANTI MICHAEL P,LUNELLA BIOTECH INC (2019-10-21),https://lens.org/041-811-426-584-32X,Patent Application,yes,0,0,31,003-968-636-675-999;;018-210-564-483-765;;123-911-516-366-300;;174-303-639-255-097;;153-603-893-458-327;;178-810-556-945-633;;091-698-265-892-605;;022-309-688-506-791;;106-524-963-605-143;;178-832-710-625-687;;109-843-867-574-516;;195-756-799-811-869;;191-605-723-416-594;;066-512-720-902-314;;028-317-938-427-331;;087-982-702-336-433;;161-265-072-146-239;;191-950-135-640-474;;003-091-150-649-020;;021-772-175-615-296;;024-846-852-844-087;;004-130-002-375-561;;003-542-174-443-887;;052-686-709-005-366;;041-811-426-584-32X;;064-392-906-184-377;;004-219-746-568-156;;068-635-059-709-206;;185-617-429-189-600;;019-011-856-056-081;;042-257-727-563-857,JP;;AU;;CL;;US;;CA;;EC;;CO;;PH;;BR;;MX;;PE;;CU;;CR;;KR;;CN;;IL;;EP;;WO;;ZA;;SG;;DO,31,003-968-636-675-999;;018-210-564-483-765;;123-911-516-366-300;;174-303-639-255-097;;153-603-893-458-327;;178-810-556-945-633;;091-698-265-892-605;;022-309-688-506-791;;106-524-963-605-143;;178-832-710-625-687;;109-843-867-574-516;;195-756-799-811-869;;191-605-723-416-594;;087-982-702-336-433;;028-317-938-427-331;;066-512-720-902-314;;161-265-072-146-239;;191-950-135-640-474;;021-772-175-615-296;;003-091-150-649-020;;024-846-852-844-087;;004-130-002-375-561;;042-257-727-563-857;;052-686-709-005-366;;041-811-426-584-32X;;064-392-906-184-377;;004-219-746-568-156;;185-617-429-189-600;;068-635-059-709-206;;019-011-856-056-081;;003-542-174-443-887,JP;;AU;;CL;;US;;CA;;EC;;CO;;PH;;BR;;MX;;PE;;CU;;CR;;KR;;CN;;IL;;EP;;WO;;ZA;;SG;;DO,0,A61K31/7048;;A61K31/7052;;A61P39/00;;A61K31/65;;A61K31/7048;;A61K31/7052;;A61P39/00;;A61K31/7052;;A61K31/7048;;A61K45/06;;A61P39/00;;A61P43/00;;A61K31/7048;;A61K31/7052;;A61K45/06,A61K31/7048;;A61K31/7052;;A61K45/06,,0,0,,,,ACTIVE
998,WO,A1,WO 2022/248531 A1,044-423-375-737-596,2022-12-01,2022,EP 2022064157 W,2022-05-25,EP 21175997 A;;EP 21193308 A,2021-05-26,VACCINATION TARGETING INTRACELLULAR PATHOGENS,"Provided are novel fusion polypeptides comprising a B-cell epitope-rich region, which comprises at least one fragment of at least one surface exposed protein from an intracellular pathogen, and a T-cell epitope-rich region, which comprises at least 2 densely arranged groups of T-cell epitope hotspots comprising at least one CTL inducing amino acid sequence, where the epitope hotspots are derived from at least two non-identical proteins of said intracellular pathogen. Also disclosed are nucleic acids and vectors encoding the fusion polypeptides and pharmaceutical means and methods based on the fusion polypeptides, nucleic acids and vectors.",EVAXION BIOTECH AS,SØRENSEN ANDERS BUNDGAARD;;VINDAHL KRINGELUM JENS;;GARDE CHRISTIAN;;TROLLE THOMAS;;KLAUSEN MICHAEL SCHANTZ;;THYGESEN CHRISTIAN;;PERSSON GRY;;GRØNLUND JESPER TRANHOLM,,https://lens.org/044-423-375-737-596,Patent Application,yes,15,0,2,044-423-375-737-596;;052-640-799-590-760,EP;;WO,2,044-423-375-737-596;;052-640-799-590-760,EP;;WO,43,C07K2319/33;;C07K2319/74;;A61K39/12;;C07K2319/00;;C07K14/005;;C07K14/195;;C07K14/705;;C07K14/521;;C12N2770/20022;;C12N2770/20034;;A61K2039/53;;A61P31/14;;A61K2039/55505;;A61K2039/545;;A61K2039/575,C07K14/195;;A61K39/02;;A61K39/12;;C07K14/005;;C07K14/52;;C07K14/705,,16,10,124-792-427-015-83X;;060-736-061-836-038;;039-522-056-746-762;;047-830-556-898-310;;077-091-167-341-553;;091-642-755-062-396;;005-547-673-002-053;;082-142-090-930-138;;095-009-613-240-195;;013-324-909-836-938,10.1016/j.micpath.2020.104236;;pmc7196559;;32376359;;10.1080/07391102.2020.1756411;;32295479;;pmc7196925;;pmc7492789;;32938504;;10.1186/s40249-020-00752-w;;32882432;;pmc7462568;;10.1016/j.meegid.2020.104517;;pmc4494225;;26344110;;10.3390/vaccines1030225;;pmc3109246;;10.1007/s11095-011-0407-8;;21424159;;16115700;;10.1016/j.vaccine.2005.07.074;;9327522;;10.1006/smim.1997.0083;;9143702;;10.1146/annurev.immunol.15.1.617;;pmc7578095;;10.1038/s41590-020-0778-2;;32839612,"KALITA PARISMITA ET AL: ""Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2"", MICROBIAL PATHOGENESIS, ACADEMIC PRESS LIMITED, NEW YORK, NY, US, vol. 145, 4 May 2020 (2020-05-04), XP086183220, ISSN: 0882-4010, [retrieved on 20200504], DOI: 10.1016/J.MICPATH.2020.104236;;ENAYATKHANI MARYAM ET AL: ""Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study"", JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, vol. 39, no. 8, 24 May 2021 (2021-05-24), US, pages 2857 - 2872, XP055827090, ISSN: 0739-1102, DOI: 10.1080/07391102.2020.1756411;;MUHAMMAD TAHIR UL QAMAR ET AL: ""Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2"", INFECTIOUS DISEASES OF POVERTY, BIOMED CENTRAL LTD, LONDON, UK, vol. 9, no. 1, 16 September 2020 (2020-09-16), pages 1 - 14, XP021281812, DOI: 10.1186/S40249-020-00752-W;;AKHAND MST RUBAIAT NAZNEEN ET AL: ""Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine"", INFECTION , GENETICS AND EVOLUTION, ELSEVIER, AMSTERDAM, NL, vol. 85, 1 September 2020 (2020-09-01), XP086352743, ISSN: 1567-1348, [retrieved on 20200901], DOI: 10.1016/J.MEEGID.2020.104517;;THYGESEN, CHRISTIAN B. ET AL.: ""Efficient Generative Modelling of Protein Structure Fragments using a Deep Markov Model"", INTERNATIONAL CONFERENCE ON MACHINE LEARNING, 2021;;WILLIAMS J.A., VACCINES (BASEL, vol. 1, no. 3, September 2013 (2013-09-01), pages 225 - 249;;VAN GAAL EVB ET AL., PHARM RES., vol. 28, no. 7, 2011, pages 1707 - 172;;JOHNSON ET AL., VACCINE, vol. 24, no. 3, 2006, pages 293 - 303;;""the subunit and adjuvant approach"", 1995, PLENUM PRESS;;ROBINSONTORRES, SEMINARS IN IMMUNOL, vol. 9, 1997, pages 271 - 283;;DONNELLY ET AL., ANNU REV IMMUNOL, vol. 15, 1997, pages 617 - 648;;""Remington's Pharmaceutical Sciences"", 1991, MACK PUB. CO.;;THYGESEN, CHRISTIAN B. ET AL.: ""Efficient Generative Modelling of Protein Structure Fragments using a Deep Markov Model."", INTERNATIONAL CONFERENCE ON MACHINE LEARNING, 2021;;JURTZ V ET AL., THE JOURNAL OF IMMUNOLOGY, 2017, pages ji1700893;;REYNISSON ET AL., NUCLEIC ACIDS RESEARCH, May 2020 (2020-05-01);;BAILEY ET AL., NATURE IMMUNOLOGY, vol. 21, no. 11, 2020, pages 1327 - 1335",PENDING
999,KR,A,KR 20230074775 A,042-848-449-000-417,2023-05-31,2023,KR 20237013901 A,2021-09-23,EP 20197898 A;;EP 2021076193 W,2020-09-23,바이러스 벡터의 효능 증가를 위한 화합물,"본 발명은 환자에서 바이러스 벡터(백신 및 유전자 치료요법에 사용됨)에 대한 바람직하지 않은 중화 항체의 제거를 위한 화합물을 제공한다. 화합물은 불활성 생물중합체 스캐폴드 및 적어도 화학식 P ( - S - P )(n-1)의 제1의 펩타이드 n-머 및 화학식 P ( - S - P)(n-1)의 제2의 펩타이드 n-머를 포함하고, 여기서, 각각의 발생에 대해 독립적으로, P는 2 내지 13개 아미노산의 서열 길이를 지닌 펩타이드이고 S는 비-펩타이드 스페이서이고, 여기서, 각각의 펩타이드 n-머에 대해 독립적으로, n은 적어도 1의 정수이고, 여기서 펩타이드 n-머 각각은 생물중합체 스캐폴드에 결합된다. 각각의 발생에 대해 독립적으로, P는 바이러스 벡터의 캡시드 단백질 서열의 적어도 6개 아미노산 길이를 갖는 서열 단편을 포함하는 아미노산 서열을 갖는다. 또한, 화합물을 포함하는 약제학적 조성물뿐만 아니라 개체내 존재하는 하나 이상의 항체를 제거하는 방법 및 백신 또는 유전자 치료요법 조성물을 사용한 치료에 대한 바람직하지 않은 면역 반응을 억제하는 방법이 제공된다.",ABLEVIA BIOTECH GMBH,SMRZKA OSKAR;;WANKO BETTINA,,https://lens.org/042-848-449-000-417,Patent Application,no,0,0,12,021-929-980-693-898;;138-308-537-704-135;;112-226-942-085-347;;167-948-731-470-704;;056-236-650-896-295;;186-564-251-984-42X;;129-184-165-537-605;;120-522-023-432-762;;118-770-553-366-409;;042-848-449-000-417;;040-635-442-392-68X;;145-114-805-471-971,JP;;AU;;KR;;EP;;IL;;CN;;WO;;US;;CA;;MX;;BR,12,138-308-537-704-135;;040-635-442-392-68X;;112-226-942-085-347;;056-236-650-896-295;;167-948-731-470-704;;186-564-251-984-42X;;120-522-023-432-762;;021-929-980-693-898;;118-770-553-366-409;;129-184-165-537-605;;145-114-805-471-971;;042-848-449-000-417,JP;;AU;;KR;;IL;;EP;;CN;;WO;;US;;CA;;MX;;BR,4380,A61P37/06;;A61K2039/575;;C12N2710/10334;;C12N2750/14134;;A61K47/6835;;A61K47/6811;;A61K47/644;;A61K47/64;;A61K47/643;;C07K14/005;;C12N2710/10322;;C12N2750/14122;;A61K47/644;;C07K14/005;;A61P37/06;;A61K47/64;;A61K47/643;;C12N2750/14122;;A61K47/6835;;A61K2039/575;;C12N2710/10322;;C12N2750/14134;;C12N2710/10334;;A61K47/6811;;C07K17/06;;C07K14/005;;C07K7/64;;A61K47/644;;A61K47/6811;;A61K47/6849;;A61K47/643;;A61P37/06;;C12N2710/10334;;C12N2750/14134;;C12N2710/10322;;C12N2750/14122;;A61K47/643;;A61K47/644;;A61K47/6849;;A61K39/235;;A61K2039/505,C07K17/06;;A61K47/64;;A61K47/68;;A61P37/06;;C07K7/64;;C07K14/005,,0,0,,,,PENDING
1000,US,A1,US 2024/0327869 A1,042-657-476-151-884,2024-10-03,2024,US 202418744565 A,2024-06-14,US 202418744565 A;;US 202016934970 A;;US 201962877577 P;;US 201962877561 P;;US 201962877551 P;;US 201962877540 P;;US 201962877532 P;;US 201962877524 P;;US 201962877516 P;;US 201962877508 P,2019-07-23,SYNTHETIC GENETIC ELEMENTS FOR BIOMANUFACTURE,"Recombinant constructs, cells and means for improved production of Adeno-Associated Viruses (AAVs) are described. Also described are methods of using the constructs and cells to produce recombinant AAVs.",JANSSEN BIOTECH INC,PERRY III WILLIAM LLOYD;;TOMKOWICZ BRIAN,JANSSEN RESEARCH & DEVELOPMENT LLC (2021-05-03);;JANSSEN BIOTECH INC (2021-05-12),https://lens.org/042-657-476-151-884,Patent Application,yes,0,0,15,086-778-343-858-867;;056-603-363-566-463;;020-037-853-125-871;;186-574-804-897-772;;026-087-708-935-759;;023-711-818-220-364;;128-212-102-676-797;;042-657-476-151-884;;189-116-246-031-114;;027-608-792-841-647;;087-591-503-517-399;;062-740-516-744-186;;045-392-911-114-163;;147-503-235-466-506;;087-676-717-905-525,JP;;AU;;CN;;EP;;IL;;WO;;US;;TW;;CA,16,086-778-343-858-867;;056-603-363-566-463;;027-608-792-841-647;;189-116-246-031-114;;026-087-708-935-759;;023-711-818-220-364;;042-657-476-151-884;;128-212-102-676-797;;186-574-804-897-772;;020-037-853-125-871;;087-591-503-517-399;;062-740-516-744-186;;045-392-911-114-163;;036-225-809-718-767;;147-503-235-466-506;;087-676-717-905-525,JP;;AU;;AR;;CN;;EP;;IL;;WO;;US;;TW;;CA,0,C07K14/005;;C12N15/86;;C12N9/14;;C12N9/22;;C12N2750/14122;;C12N2750/14143;;C12N2750/14152;;C12N2710/10343;;C12N2800/30;;C12N2830/42;;C12N15/86;;C07K14/005;;C12N2750/14143;;C12N9/22;;C12N2800/30;;C12N2710/10343;;C12N2750/14122;;C12N2830/42;;C12N2750/14152;;C12N9/14;;C12N9/22;;C12N2750/14152;;C12N2750/14151;;C12N2750/14121;;C12N2830/40;;C12N15/86;;C07K14/005;;C12N2830/36;;C12N2800/30;;C12N2830/50;;C12N2750/14143;;C12N2800/50;;C12N2750/14122;;C12N7/00;;C12N9/14;;C12N2710/10343;;C12N2830/42;;C12N7/00;;C12N15/86;;C12N2750/14121;;C12N2750/14151;;C12N2800/50;;C12N2830/36;;C12N2830/40;;C12N2830/42;;C12N2830/50,C12N15/86;;C12N7/00,,0,0,,,,PENDING
